clinical_feature	cancer_color	cancer_type	data_type	description	patient_sample	Default_value
ADJUVANT_CHEMO	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Adjuvant Chemotherapy	Patient	
ADJUVANT_TX	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Adjuvant treatment.	Patient	
AGE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	Age at which a condition or disease was first diagnosed.	Patient	
CANCER_TYPE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Cancer Type	Sample	Breast Cancer ; Invasive Breast Carcinoma ; Breast Sarcoma ; Breast Invasive Ductal Carcinoma ; Breast Invasive Carcinoma, NOS ; Breast Cancer, NOS ; Skin Cancer, Non-Melanoma
CANCER_TYPE_DETAILED	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Cancer Type Detailed	Sample	Adenoid Cystic Breast Cancer ; Benign Phyllodes Tumor of the Breast ; Borderline Phyllodes Tumor of the Breast ; Malignant Phyllodes Tumor of the Breast ; Infiltrating Ductal Carcinoma ; Ductal Carcinoma In Situ (DCIS) ; Mucinous Carcinoma ; Infiltrating Tubular Carcinoma ; Mixed Carcinoma ; Infiltrating Lobular Carcinoma ; Medullary Breast Carcinoma ; Invasive Breast Carcinoma ; Breast Invasive Ductal Carcinoma ; Breast Mixed Ductal and Lobular Carcinoma ; Breast Invasive Cancer, NOS ; Breast Invasive Lobular Carcinoma ; Breast Invasive Carcinoma, NOS ; Breast ; Breast Invasive Mixed Mucinous Carcinoma ; Metaplastic Breast Cancer ; Breast Invasive Carcinoma ; Breast Neoplasm, NOS ; Breast Invasive Carcinosarcoma, NOS ; Juvenile Secretory Carcinoma of the Breast ; Invasive Breast Cancer ; Breast Ductal Carcinoma In Situ ; Paget Disease of the Nipple ; Basal Cell Carcinoma ; Solid Papillary Carcinoma of the Breast ; Breast Angiosarcoma ; Breast Invasive Carcinoma (NOS)
ER_STATUS_BY_IHC	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	breast carcinoma progesterone receptor status	Sample ; Patient	Negative ; Positive ; Indeterminate
FOLLOWUP_YEARS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	Followup in years	Patient	
FUSION_STATUS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Yes/No indicator of fusion status	Sample	YES
GENOMIC_ALTERATIONS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	Number of genomic alterations	Sample	15 ; 31 ; 33 ; 19 ; 18 ; 25 ; 20 ; 29 ; 9 ; 14 ; 16
IHC_HER2	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	IHC-HER2	Sample ; Patient	Negative ; HR-/HER2- ; HR+/HER2- ; ND ; HER2+ ; equivocal ; Equivocal ; Positive ; Indeterminate
LOCAL_REGIONAL_RECURRENCE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Local Regional Recurrence	Patient	
METASTATIC_SITE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	The anatomic location to which the cancer has spread.	Sample	Lung ; Liver ; Lymph Node ; Soft Tissue ; Heart ; Retroperitoneum ; Chest Wall ; Bone ; Brain ; Ovary ; Pleura ; Adrenal Gland ; Axilla ; Pelvis ; Bone NOS ; Parasternal Mass ; Neck ; Skin ; Uterus ; Scalp ; Cervix ; Peritoneum ; Mediastinum ; Pericardium ; Back ; Stomach ; Epidural ; Fallopian Tube ; Pterygoid Palatine Tissue ; Appendix ; Bladder ; Epidural Mass ; Upper Tract ; Adnexa or Endomterium ; Retroperitenium ; Pleural Fluid ; Colon ; Ipsilateral Breast ; Rib ; Bowel ; Vertebrate ; Spine ; Small Bowel ; Contralateral Breast ; Mediastinal Mass ; Peritoneal Fluid ; Iliac Bone ; Ascites Fluid ; Orbit ; Trachea ; CSF ; Sternum ; Spine (bone) ; Buttock ; Omentum ; Lymph node ; Femur ; Spleen ; Esophagus ; Right Neck ; Cerebellum ; Bone (Femur) ; Orbit - Right ; Intercostal space ; Scapula ; Uterus/Cervix ; Soft tissue, Posterior Left Shoulder ; Groin ; Sacral Mass ; Spine (Bone) ; Abdomen ; Brain and Leptomeninges ; Orbital Floor ; Abdominal Wall ; Humerus ; Transverse Colon ; Pleural Fliud ; Thigh ; Bone|Liver ; Other, specify ; Lung|Bone|Liver|Other, specify
METASTATIC_TUMOR_INDICATOR	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Distant metastasis present ind2	Sample ; Patient	No ; Yes ; NO ; YES
MUTATION_COUNT	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	Mutation Count	Sample	11 ; 23 ; 22 ; 12 ; 19 ; 15 ; 21 ; 18 ; 7 ; 6 ; 16 ; 14 ; 4 ; 10 ; 68 ; 8 ; 3 ; 25 ; 1 ; 13 ; 75 ; 29 ; 59 ; 48 ; 31 ; 51 ; 44 ; 26 ; 9 ; 114 ; 37 ; 28 ; 20 ; 57 ; 76 ; 129 ; 54 ; 104 ; 39 ; 52 ; 27 ; 151 ; 62 ; 102 ; 63 ; 24 ; 65 ; 41 ; 30 ; 50 ; 17 ; 42 ; 36 ; 53 ; 47 ; 101 ; 40 ; 35 ; 234 ; 160 ; 88 ; 58 ; 49 ; 249 ; 940 ; 113 ; 56 ; 92 ; 81 ; 150 ; 33 ; 105 ; 167 ; 165 ; 370 ; 82 ; 108 ; 475 ; 120 ; 69 ; 67 ; 389 ; 131 ; 5 ; 34 ; 147 ; 121 ; 32 ; 38 ; 80 ; 45 ; 232 ; 206 ; 73 ; 43 ; 60 ; 248 ; 100 ; 46 ; 2 ; 74 ; 117 ; 177 ; 112 ; 163 ; 93 ; 782 ; 155 ; 61 ; 72 ; 84 ; 64 ; 107 ; 143 ; 135 ; 348 ; 157 ; 310 ; 99 ; 95 ; 87 ; 698 ; 83 ; 115 ; 66 ; 79 ; 511 ; 127 ; 139 ; 144 ; 103 ; 132 ; 123 ; 122 ; 189 ; 180 ; 305 ; 247 ; 71 ; 78 ; 128 ; 309 ; 86 ; 77 ; 176 ; 90 ; 7908 ; 97 ; 352 ; 383 ; 125 ; 146 ; 800 ; 106 ; 110 ; 655 ; 164 ; 148 ; 1002 ; 126 ; 96 ; 119 ; 85 ; 262 ; 89 ; 140 ; 188 ; 317 ; 91 ; 198 ; 94 ; 456 ; 236 ; 465 ; 133 ; 346 ; 118 ; 172 ; 137 ; 230 ; 179 ; 109 ; 156 ; 223 ; 98 ; 161 ; 70 ; 201 ; 141 ; 284 ; 55 ; 168 ; 174 ; 185 ; 238 ; 447 ; 116 ; 170 ; 314 ; 142 ; 203 ; 192 ; 334 ; 326 ; 718 ; 240 ; 145 ; 233 ; 178 ; 154 ; 1222 ; 275 ; 306 ; 149 ; 372 ; 303 ; 773 ; 124 ; 153 ; 186 ; 220 ; 184 ; 217 ; 243 ; 224 ; 287 ; 402 ; 386 ; 187 ; 175 ; 269 ; 194 ; 313 ; 342 ; 196 ; 183 ; 210 ; 1312 ; 601 ; 111 ; 162 ; 138 ; 221 ; 543 ; 682 ; 290 ; 704 ; 548 ; 3427 ; 130 ; 505 ; 215 ; 282 ; 281 ; 486 ; 270 ; 362 ; 190 ; 989 ; 915 ; 357 ; 4280 ; 1994 ; 557 ; 1073 ; 216 ; 136 ; 556 ; 670 ; 253 ; 1044 ; 258 ; 599 ; 3860 ; 388 ; 861 ; 1086 ; 1136 ; 239 ; 209 ; 250 ; 1053 ; 347 ; 166 ; 885 ; 676 ; 817 ; 1078 ; 181 ; 211 ; 770 ; 604 ; 208 ; 591 ; 459 ; 271 ; 134 ; 212 ; 300 ; 195 ; 227 ; 173 ; 1095 ; 4259 ; 400 ; 5399 ; 1117 ; 288 ; 754 ; 826 ; 276 ; 159 ; 171 ; 256 ; 219 ; 332 ; 832 ; 1251 ; 422 ; 312 ; 633 ; 191 ; 689 ; 785 ; 971 ; 797 ; 813 ; 3080 ; 366 ; 365 ; 3879 ; 436 ; 193
MYB_MYBL1_FUSION	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Description of MYB or MYBL1 fusions identified.	Sample	MYB-NFIB Fusion ; Negative
MYB_NFIB_CNA	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	MYB-NFIB Fusion Gene Copy Number Alterations	Sample	9q13-q34.2 loss ; 17q21-q25.1 gain; 17p13.3-p11.2 loss ; 12q12-q14.1 loss ; 17q21-q25.1 gain
MYB_NFIB_FISH	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	MYB-NFIB FISH.	Sample	Negative ; Positive
MYB_NFIB_NONSYNONYMOUS_COUNT	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Count of non-synonymous mutations in MYB-NFIB Fusion Gene	Sample	11 ; 22 ; 23 ; 10 ; 9 ; 18 ; 14 ; 19 ; 6 ; 7
MYB_NFIB_REARRANGEMENT	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	MYB-NFIB Rearrangement Description	Patient	
NEOADJUVANT_CHEMO	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Neoadjuvant Chemotherapy.	Patient	
ONCOTREE_CODE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Oncotree Code	Sample	ACBC ; BPT ; BLPT ; MPT ; IDC ; DCIS ; IMMC ; BRCA ; ILC ; MDLC ; BRCANOS ; BRCNOS ; BREAST ; MBC ; BNNOS ; CSNOS ; JSCB ; PD ; BCC ; SPC ; PBS
OVERALL_PATIENT_HISTOLOGY	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Overall Patient Histology	Patient	
PLATFORM	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Platform.	Sample	WES
PRIMARY_SITE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Text term to describe the organ sub-division in an individual with cancer.	Sample	Breast ; Breast NOS ; Right Upper Outer Quadrant ; Right Lower Outer Quadrant ; Left Upper Outer Quadrant|Left ; Left Lower Outer Quadrant ; Left ; Right Upper Outer Quadrant|Right ; Right Upper Inner Quadrant|Right ; Left Lower Inner Quadrant ; Right ; Left Lower Outer Quadrant|Left ; Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant|Left ; Left Lower Inner Quadrant|Left Lower Outer Quadrant|Left ; Right Upper Inner Quadrant|Right Lower Inner Quadrant|Right ; Left Upper Inner Quadrant ; Right Upper Inner Quadrant|Right Upper Outer Quadrant|Right ; Right Upper Inner Quadrant|Right Upper Outer Quadrant|Right Lower Inner Quadrant|Right Lower Outer Quadrant|Right ; Left Upper Inner Quadrant|Left ; Right Upper Inner Quadrant ; Left Upper Outer Quadrant ; Right Upper Inner Quadrant|Right Lower Inner Quadrant ; Left Lower Inner Quadrant|Left ; Left Upper Inner Quadrant|Left Upper Outer Quadrant ; Right Lower Outer Quadrant|Right ; Right Lower Inner Quadrant ; Right|Right Upper Inner Quadrant ; Left Upper Outer Quadrant|Left Lower Outer Quadrant|Left ; Left Upper Outer Quadrant|Left Lower Outer Quadrant ; Right Upper Inner Quadrant|Right Upper Outer Quadrant ; Left Upper Inner Quadrant|Left Lower Inner Quadrant ; Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant ; Right Lower Inner Quadrant|Right Lower Outer Quadrant ; Left|Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant ; Right Upper Outer Quadrant|Right Lower Outer Quadrant ; Right Upper Outer Quadrant|Right Lower Inner Quadrant|Right Lower Outer Quadrant ; Left Lower Inner Quadrant|Left Lower Outer Quadrant ; Right|Right Upper Outer Quadrant ; Left|Left Upper Outer Quadrant ; Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left ; Left Upper Inner Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant|Left ; Left|Left Upper Inner Quadrant ; Right|Right Lower Inner Quadrant ; Right Lower Inner Quadrant|Right Lower Outer Quadrant|Right
PR_STATUS_BY_IHC	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Breast carcinoma progesterone receptor status	Sample ; Patient	Negative ; Positive ; Indeterminate
RADIATION_THERAPY	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Radiation Therapy.	Patient	
SAMPLE_COUNT	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Number of Samples Per Patient	Patient	
SAMPLE_TYPE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	The type of sample (i.e., normal, primary, met, recurrence).	Sample	Primary ; Metastasis ; Unknown
SEX	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Sex	Patient	
SOMATIC_STATUS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Somatic Status	Sample	Matched ; Unmatched ; UnMatched
STUDY	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Study.	Patient	
TIME_TO_MET_MONTHS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	Time to metastasis (months).	Patient	
TMB_NONSYNONYMOUS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	NUMBER	TMB (nonsynonymous)	Sample	0.366666667 ; 0.766666667 ; 0.733333333 ; 0.4 ; 0.566666667 ; 0.466666667 ; 0.7 ; 0.6 ; 0.233333333 ; 0.2 ; 0.533333333333 ; 0.233333333333 ; 0.466666666667 ; 0.133333333333 ; 0.366666666667 ; 0.333333333333 ; 2.26666666667 ; 0.266666666667 ; 0.1 ; 0.833333333333 ; 0.0333333333333 ; 2.53333333333 ; 0.433333333333 ; 0.966666666667 ; 1.96666666667 ; 1.6 ; 0.666666666667 ; 0.566666666667 ; 1.03333333333 ; 0.5 ; 1.7 ; 1.46666666667 ; 0.9 ; 0.3 ; 3.8 ; 1.26666666667 ; 0.766666666667 ; 1.86666666667 ; 1.93333333333 ; 2.5 ; 4.26666666667 ; 0.933333333333 ; 1.83333333333 ; 3.5 ; 1.3 ; 1.73333333333 ; 0.866666666667 ; 5.06666666667 ; 2.06666666667 ; 3.33333333333 ; 2.1 ; 0.8 ; 2.2 ; 1.4 ; 1.0 ; 1.76666666667 ; 0.733333333333 ; 1.56666666667 ; 3.36666666667 ; 1.36666666667 ; 1.2 ; 1.23333333333 ; 7.8 ; 1.8 ; 5.333333333 ; 2.933333333 ; 1.033333333 ; 1.933333333 ; 0.533333333 ; 1.633333333 ; 8.266666667 ; 31.36666667 ; 2.066666667 ; 3.733333333 ; 1.866666667 ; 3.066666667 ; 2.7 ; 1.366666667 ; 1.166666667 ; 5 ; 1.1 ; 3.466666667 ; 5.533333333 ; 5.5 ; 4.3 ; 0.966666667 ; 12.2 ; 2.733333333 ; 3.033333333 ; 0.833333333 ; 1.733333333 ; 3.533333333 ; 15.86666667 ; 4 ; 2.166666667 ; 2.3 ; 0.933333333 ; 12.96666667 ; 1 ; 4.333333333 ; 0.666666667 ; 1.566666667 ; 0.166666667 ; 0.433333333 ; 1.133333333 ; 0 ; 0.866666667 ; 4.9 ; 1.9 ; 1.066666667 ; 1.266666667 ; 2.666666667 ; 2.233333333 ; 2.766666667 ; 1.5 ; 7.7 ; 1.333333333 ; 1.466666667 ; 6.866666667 ; 2.433333333 ; 1.666666667 ; 2 ; 0.133333333 ; 3.333333333 ; 1.533333333 ; 0.066666667 ; 2.466666667 ; 3.9 ; 0.333333333 ; 0.033333333 ; 5.933333333 ; 5.4 ; 1.233333333 ; 3.1 ; 2.533333333 ; 26.03333333 ; 5.166666667 ; 2.033333333 ; 2.4 ; 2.8 ; 2.133333333 ; 4.766666667 ; 4.5 ; 11.6 ; 5.233333333 ; 10.33333333 ; 1.433333333 ; 4.466666667 ; 4.366666667 ; 3.166666667 ; 2.9 ; 23.36666667 ; 4.033333333 ; 3.433333333 ; 3.833333333 ; 2.266666667 ; 3.4 ; 2.633333333 ; 17.03333333 ; 4.233333333 ; 4.666666667 ; 4.8 ; 0.166666666667 ; 0.0666666666667 ; 0.633333333333 ; 1.1091553006 ; 2.2183106012 ; 3.32746590179 ; 7.76408710418 ; 0.0 ; 8.87324240478 ; 12.2007083066 ; 3.45879237993 ; 6.65493180359 ; 4.43662120239 ; 5.54577650299 ; 6.91758475987 ; 9.78719697615 ; 0.978719697615 ; 1.95743939523 ; 8.80847727853 ; 3.91487879046 ; 2.93615909284 ; 7.82975758092 ; 5.87231818569 ; 6.8510378833 ; 11.7446363714 ; 4.89359848807 ; 24.4679924404 ; 8.64698094984 ; 4.32349047492 ; 2.59409428495 ; 1.72939618997 ; 0.864698094984 ; 7.78228285485 ; 6.05288666489 ; 5.1881885699 ; 10.3763771398 ; 21.6174523746 ; 3.16666666667 ; 3.46666666667 ; 3.6 ; 3.43333333333 ; 1.13333333333 ; 1.33333333333 ; 1.16666666667 ; 2.73333333333 ; 4.4 ; 3.76666666667 ; 4.1 ; 3.06666666667 ; 4.06666666667 ; 3.56666666667 ; 6.3 ; 6.0 ; 10.1666666667 ; 8.23333333333 ; 1.53333333333 ; 2.76666666667 ; 2.46666666667 ; 4.03333333333 ; 2.6 ; 1.66666666667 ; 10.3333333333 ; 2.56666666667 ; 5.83333333333 ; 2.13333333333 ; 3.0 ; 264.633333333 ; 3.26666666667 ; 11.7666666667 ; 12.8 ; 4.2 ; 4.93333333333 ; 1.63333333333 ; 26.7666666667 ; 2.63333333333 ; 4.36666666667 ; 3.23333333333 ; 2.23333333333 ; 2.96666666667 ; 2.93333333333 ; 11.6333333333 ; 2.43333333333 ; 3.66666666667 ; 5.2 ; 22.0 ; 5.46666666667 ; 33.5666666667 ; 4.23333333333 ; 3.2 ; 2.03333333333 ; 3.53333333333 ; 4.16666666667 ; 2.83333333333 ; 8.73333333333 ; 1.06666666667 ; 3.03333333333 ; 6.63333333333 ; 5.13333333333 ; 15.4 ; 3.83333333333 ; 7.93333333333 ; 15.7 ; 4.43333333333 ; 5.3 ; 11.6666666667 ; 1.43333333333 ; 2.33333333333 ; 3.7 ; 2.0 ; 3.93333333333 ; 5.76666666667 ; 4.56666666667 ; 2.16666666667 ; 3.13333333333 ; 7.6 ; 6.26666666667 ; 3.63333333333 ; 5.23333333333 ; 4.86666666667 ; 6.23333333333 ; 7.4 ; 3.96666666667 ; 5.43333333333 ; 2.66666666667 ; 6.73333333333 ; 4.66666666667 ; 9.4 ; 5.56666666667 ; 2.86666666667 ; 5.8 ; 6.13333333333 ; 8.0 ; 4.83333333333 ; 14.8333333333 ; 1.71332918708 ; 15.5281742084 ; 9.98239770538 ; 8.56664593538 ; 19.5743939523 ; 0.266666667 ; 0.633333333 ; 2.366666667 ; 3.266666667 ; 4.266666667 ; 3.966666667 ; 3.366666667 ; 5.666666667 ; 10.5 ; 3 ; 6.833333333 ; 1.833333333 ; 1.766666667 ; 7.764087104 ; 4.436621202 ; 3.91487879 ; 6.654931804 ; 5.18818857 ; 5.545776503 ; 9.511679045 ; 8.64698095 ; 36.60212492 ; 15.52817421 ; 1.109155301 ; 5.872318186 ; 3.45879238 ; 2.218310601 ; 28.83803782 ; 12.20070831 ; 8.873242405 ; 9.982397705 ; 4.323490475 ; 3.327465902 ; 7.829757581 ; 19.57439395 ; 2.594094285 ; 4.893598488 ; 11.09155301 ; 1.957439395 ; 7.782282855 ; 6.851037883 ; 8.808477279 ; 0.978719698 ; 2.936159093 ; 6.91758476 ; 0.864698095 ; 17.74648481 ; 6.052886665 ; 13.30986361 ; 21.07395071 ; 17.2939619 ; 29.94719312 ; 43.25705672 ; 10.76591667 ; 14.41901891 ; 23.29226131 ; 46.58452263 ; 31.12913142 ; 26.42543184 ; 16.63732951 ; 29.36159093 ; 14.68079546 ; 9.787196976 ; 21.61745237 ; 32.85852761 ; 11.74463637 ; 25.44671214 ; 24.46799244 ; 20.55311365 ; 27.40415153 ; 16.63823486 ; 15.65951516 ; 1.72939619 ; 43.0636667 ; 12.10577333 ; 15.56456571 ; 17.61695456 ; 13.70207577 ; 14.69986761 ; 11.24107523 ; 18.59567425 ; 28.38287123 ; 36.31731999 ; 10.37637714 ; 45.02110609 ; 22.51055305 ; 39.77611237 ; 12.97047142 ; 23.48927274 ; 25.07624475 ; 18.15865999 ; 19.02335809 ; 13.83516952 ; 19.88805618 ; 16.4292638 ; 31.99382951 ; 25.94094285 ; 23.34684856 ; 22.48215047 ; 34.5879238 ; 33.7232257 ; 69.1758476 ; 3.73333333333 ; 3.86666666667 ; 6.43333333333 ; 6.1 ; 11.1 ; 4.96666666667 ; 3.3 ; 10.93333333 ; 24.06666667 ; 5.6 ; 6.633333333 ; 7.966666667 ; 2.966666667 ; 3.566666667 ; 7.766666667 ; 6.066666667 ; 3.233333333 ; 5.1 ; 2.566666667 ; 5.866666667 ; 4.133333333 ; 2.333333333 ; 7.833333333 ; 3.133333333 ; 40.7 ; 1.966666667 ; 9.1 ; 10.13333333 ; 5.133333333 ; 12.4666666667 ; 10.1333333333 ; 25.9333333333 ; 6.83333333333 ; 5.63333333333 ; 4.0 ; 5.33333333333 ; 6.2 ; 7.46666666667 ; 6.33333333333 ; 7.96666666667 ; 2.36666666667 ; 7.3 ; 8.06666666667 ; 7.66666666667 ; 9.63333333333 ; 13.5 ; 6.96666666667 ; 13.1 ; 5.16666666667 ; 6.16666666667 ; 9.16666666667 ; 6.5 ; 4.73333333333 ; 10.4333333333 ; 11.4666666667 ; 7.26666666667 ; 6.7 ; 7.13333333333 ; 4.13333333333 ; 9.03333333333 ; 44.0 ; 20.3333333333 ; 6.06666666667 ; 4.6 ; 5.36666666667 ; 5.26666666667 ; 7.43333333333 ; 8.2 ; 7.566666667 ; 4.166666667 ; 2.833333333 ; 18.36666667 ; 3.933333333 ; 23.23333333 ; 3.633333333 ; 10 ; 4.633333333 ; 4.066666667 ; 24.2 ; 18.96666667 ; 117.1333333 ; 17.46666667 ; 24.4 ; 5.266666667 ; 7.433333333 ; 9.766666667 ; 9.533333333 ; 2.866666667 ; 16.76666667 ; 3.766666667 ; 3.666666667 ; 9.2 ; 23.8 ; 4.566666667 ; 6.366666667 ; 34.03333333 ; 31.43333333 ; 5.733333333 ; 12.26666667 ; 147.1 ; 69.7 ; 8.766666667 ; 36.56666667 ; 10.8 ; 4.7 ; 18.76666667 ; 23.33333333 ; 11.3 ; 8.6 ; 35.83333333 ; 7.366666667 ; 6.9 ; 7.166666667 ; 8.633333333 ; 19.96666667 ; 128.4333333 ; 5.033333333 ; 4.966666667 ; 12.93333333 ; 5.566666667 ; 28.66666667 ; 36.16666667 ; 37.86666667 ; 6.966666667 ; 8.333333333 ; 9.633333333 ; 6.233333333 ; 12.36666667 ; 35.13333333 ; 11.56666667 ; 29.56666667 ; 5.466666667 ; 6.766666667 ; 22.46666667 ; 27.16666667 ; 35.93333333 ; 6.033333333 ; 7.033333333 ; 25.66666667 ; 20.16666667 ; 8.1 ; 6.933333333 ; 6.6 ; 4.866666667 ; 19.7 ; 2.615035408 ; 1.307517704 ; 5.230070815 ; 6.537588519 ; 3.922553111 ; 9.152623927 ; 10.46014163 ; 14.38269474 ; 18.30524785 ; 11.76765933 ; 7.845106223 ; 16.99773015 ; 27.45787178 ; 13.07517704 ; 28.76538948 ; 15.69021245 ; 36.61049571 ; 20.92028326 ; 30.07290719 ; 23.53531867 ; 33.9954603 ; 26.15035408 ; 31.38042489 ; 22.22780096 ; 19.61276556 ; 52.30070815 ; 60.14581437 ; 39.22553111 ; 24.84283637 ; 104.6014163 ; 40.53304882 ; 45.76311963 ; 15.26666667 ; 9.066666667 ; 4.433333333 ; 7.1 ; 6.133333333 ; 3.866666667 ; 10.6 ; 10.1 ; 6 ; 7.2 ; 6.166666667 ; 6.533333333 ; 5.766666667 ; 8.033333333 ; 36.93333333 ; 142.6666667 ; 27.13333333 ; 180.8333333 ; 37.36666667 ; 5.066666667 ; 9.6 ; 25.26666667 ; 4.533333333 ; 27.96666667 ; 9.3 ; 4.833333333 ; 5.433333333 ; 14.66666667 ; 7.633333333 ; 11.03333333 ; 28 ; 5.7 ; 7.933333333 ; 41.83333333 ; 14.26666667 ; 4.733333333 ; 10.43333333 ; 21.36666667 ; 6.4 ; 7.266666667 ; 23.1 ; 5.966666667 ; 26.6 ; 32.36666667 ; 26.63333333 ; 6.8 ; 103.0666667 ; 11.23333333 ; 12.3 ; 130.3 ; 14.56666667 ; 13.06666667
TUMOR_SIZE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Tumor size.	Sample	40 ; 35 ; 25 ; 45 ; 17 ; 22 ; 15 ; 20 ; 23 ; 24 ; 180 ; 140 ; 120 ; 63 ; 650 ; 90 ; 67 ; 80 ; 95 ; 28 ; 48 ; 190 ; 50 ; 44 ; 32 ; 220 ; 200 ; 1.5 ; 1.3 ; 2.1 ; 3.1 ; 1.8 ; 1.4 ; 1.1 ; 0.9 ; 2.3 ; 1.7 ; 1.6 ; 2.2 ; 3.2 ; 2.7 ; 7 ; 0.7 ; 9 ; 2.5 ; 3.5 ; 4 ; 1.9 ; 5 ; 4.5 ; 6 ; 1.2 ; 2.8 ; 8.4 ; 4.1 ; 2 ; 0 ; 3.8 ; 10 ; 31 ; 65 ; 29 ; 34 ; 16 ; 21 ; 19 ; 36 ; 33 ; 18 ; 12 ; 13 ; 14 ; 55 ; 30 ; 39 ; 70 ; 27 ; 150 ; 60 ; 26 ; 38 ; 52 ; 3 ; 46 ; 11 ; 53 ; 47 ; 43 ; 42 ; 57 ; 100 ; 37 ; 8 ; 160 ; 84 ; 130 ; 5.5 ; 62 ; 1 ; 49 ; 99 ; 68 ; 41 ; 75 ; 51 ; 61 ; 79 ; 71 ; 22.5 ; 17.9 ; 14.5 ; 12.8 ; 18.5 ; 15.5 ; 21.5 ; 16.9 ; 24.4 ; 12.5 ; 40.3 ; 11.8 ; 32.6 ; 17.2 ; 13.8 ; 15.7 ; 182 ; 85 ; 18.3 ; 21.6 ; 28.5 ; 16.2 ; 15.2 ; 31.1 ; 14.3 ; 12.6 ; 25.1 ; 17.6 ; 2.12 ; 21.3 ; 22.32 ; 17.7 ; 15.47 ; 24.15 ; 20.5 ; 69 ; 88 ; 13.6 ; 66 ; 20.8 ; 27.3 ; 21.1 ; 22.8 ; 25.2 ; 26.7 ; 8.9 ; 19.1 ; 11.4 ; 14.9 ; 20.33 ; 17.06 ; 18.95 ; 31.7 ; 21.87 ; 24.6 ; 24.05 ; 17.3 ; 21.4 ; 19.5 ; 58
TUMOR_STAGE	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Tumor stage.	Sample	II ; I ; Stage IIA ; Stage III ; Stage IIB ; Stage IIIA ; Stage IIIB ; Stage IA ; Stage IIIC ; T3 ; T2 ; T1 ; TX ; T4 ; 2 ; 1 ; 4 ; 3 ; 0
TYPE_OF_SURGERY	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	Type of Surgery.	Sample	Breast Conservation/Mastectomy ; Mastectomy ; Breast Conservation
VITAL_STATUS	HotPink	Adenoid Cystic Carcinoma of the Breast (MSK, J Pathol. 2015)	STRING	The survival state of the person.	Patient	
ETHNICITY	HotPink	Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)	STRING	The text for reporting information about ethnicity.	Patient	
HISTOLOGICAL_DIAGNOSIS	HotPink	Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)	STRING	Text term for the structural pattern of cancer cells used to define a microscopic diagnosis.	Patient	
MEAN_COVERAGE	HotPink	Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)	NUMBER	Mean Coverage (x)	Sample	50 ; 64 ; 68 ; 69 ; 61 ; 58 ; 74 ; 60 ; 79 ; 52 ; 73 ; 57 ; 71 ; 72 ; 54 ; 89 ; 75
NUM_SOMATIC_MUTATION	HotPink	Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)	NUMBER	Total Number of Somatic Mutations	Sample	16 ; 7 ; 14 ; 19 ; 4 ; 11 ; 12 ; 68 ; 10 ; 8 ; 3 ; 22 ; 18 ; 25 ; 1
SURGERY	HotPink	Breast Fibroepithelial Tumors (Duke-NUS, Nat Genet 2015)	STRING	Surgery.	Patient	
COUNTRY	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	Country of procurement.	Patient	
ER_STATUS	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	ER Status	Sample	Negative ; Positive ; +ve ; -ve ; Performed but Not Available ; Not Performed ; Indeterminate ; Unk/ND ; Positive low
GRADE	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness.	Sample	III ; II ; I ; 2 ; 3 ; 1
HER2_AMPLIFICATION_STATUS	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	HER2 Amplification Status	Sample	Yes ; No
HER2_STATUS	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	HER2 Status	Sample	Negative ; Positive ; -ve ; +ve ; Equivocal
MENOPAUSE_STATUS	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	Text term to signify the status of a woman's menopause, the permanent cessation of menses, usually defined by 6 to 12 months of amenorrhea.	Patient	
NONSILENT_RATE	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	NUMBER	Nonsilent Mutation Rate	Sample	2.62 ; 0.44 ; 0.61 ; 1 ; 2.07 ; 0.72 ; 0.87 ; 0.68 ; 1.56 ; 0.37 ; 0.51 ; 0.67 ; 1.05 ; 0.54 ; 1.64 ; 1.47 ; 0.35 ; 4 ; 1.32 ; 0.85 ; 0.62 ; 2.24 ; 1.54 ; 2.02 ; 2.61 ; 0.55 ; 0.94 ; 4.46 ; 0.79 ; 0.49 ; 0.47 ; 0.98 ; 1.85 ; 0.34 ; 0.96 ; 0.31 ; 3.63 ; 0.43 ; 0.82 ; 1.41 ; 0.95 ; 0.8 ; 0.41 ; 5.25 ; 2.19 ; 3.57 ; 2.27 ; 2.35 ; 0.58 ; 1.52 ; 1.06 ; 0.99 ; 1.26 ; 0.52 ; 0.65 ; 0.75 ; 1.89 ; 0.78 ; 0.84 ; 1.62 ; 3.45 ; 0.38 ; 1.22 ; 1.42 ; 0.92 ; 1.28 ; 0.6 ; 0.71 ; 1.74 ; 1.73 ; 8.05 ; 0.91 ; 1.92
PLOIDY	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	NUMBER	Ploidy.	Sample	1.95 ; 2.16 ; 2.01 ; 1.99 ; 1.88 ; 3.24 ; 3.87 ; 3.98 ; 2.04 ; 1.97 ; 3.83 ; 2.12 ; 2.28 ; 1.75 ; 1.92 ; 3.59 ; 3.25 ; 2.09 ; 4.05 ; 3.21 ; 3.81 ; 2.08 ; 2.03 ; 3.96 ; 1.66 ; 1.85 ; 2.1 ; 2.13 ; 2.21 ; 2.05 ; 1.63 ; 1.94 ; 2.27 ; 2.07 ; 2.31 ; 3.12 ; 2.18 ; 2.06 ; 1.9 ; 2.67 ; 1.91 ; 3.44 ; 1.98 ; 3.88 ; 1.79 ; 2 ; 1.89 ; 3.08 ; 3.78 ; 4.17 ; 3.75 ; 3.53 ; 1.96 ; 1.01 ; 3.04 ; 3.56 ; 2.93 ; 3.69 ; 3.79 ; 1.86
PR_STATUS	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	PR Status	Sample	Negative ; Positive ; +ve ; -ve ; Indeterminate ; Performed but Not Available ; Not Performed ; Unk/ND
PURITY	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	NUMBER	Purity	Sample	0.27 ; 0.23 ; 0.52 ; 0.7 ; 0.28 ; 0.43 ; 0.73 ; 0.22 ; 0.6 ; 0.33 ; 0.36 ; 0.8 ; 0.76 ; 0.61 ; 0.72 ; 0.29 ; 0.3 ; 0.82 ; 0.2 ; 0.34 ; 0.79 ; 0.54 ; 0.71 ; 0.25 ; 0.19 ; 0.47 ; 0.62 ; 0.67 ; 0.59 ; 0.44 ; 0.31 ; 0.58 ; 0.5 ; 0.26 ; 0.42 ; 0.56 ; 0.14 ; 0.63 ; 0.68 ; 0.35 ; 0.37 ; 0.89 ; 0.39 ; 0.66 ; 0.65 ; 0.64 ; 0.4 ; 0.53 ; 0.55
SILENT_RATE	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	NUMBER	Silent Mutation Rate	Sample	0.72 ; 0.21 ; 0.17 ; 0.14 ; 0.54 ; 0.13 ; 0.24 ; 0.68 ; 0.1 ; 0.035 ; 0.067 ; 0.34 ; 0.38 ; 0.28 ; 1.09 ; 0.43 ; 0.76 ; 0.59 ; 0.73 ; 0.034 ; 0.31 ; 1.15 ; 0.27 ; 0.82 ; 0.07 ; 1.41 ; 0.11 ; 0.51 ; 0.45 ; 0.2 ; 1.85 ; 0.66 ; 1.27 ; 0.48 ; 0.068 ; 0.9 ; 0.41 ; 0.62 ; 1.47 ; 0.39 ; 0.57 ; 0.58 ; 0.3 ; 0.069 ; 2.43
STAGE	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	Stage	Patient	
SUBTYPE	HotPink	Breast Invasive Carcinoma (Broad, Nature 2012)	STRING	Subtype	Patient	
STUDY_ID	HotPink	Metastatic Breast Cancer (INSERM, PLoS Med 2016)	STRING	Study ID	Patient	
BEST_RESPONSE_TO_THERAPY	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Best Response to Therapy	Patient	
BLOCK_ACCESSION	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	block accession	Patient	
COMMENTS	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Comments.	Patient	
FRACTION_GENOME_ALTERED	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	NUMBER	Fraction Genome Altered	Sample	0.1565 ; 0.2533 ; 0.6218 ; 0.1038 ; 0.3070 ; 0.0364 ; 0.2324 ; 0.2287 ; 0.3847 ; 0.5632 ; 0.1807 ; 0.3038 ; 0.2584 ; 0.3508 ; 0.0664 ; 0.1848 ; 0.3939 ; 0.6389 ; 0.2638 ; 0.6420 ; 0.0433 ; 0.0935 ; 0.0967 ; 0.4888 ; 0.3328 ; 0.5693 ; 0.2282 ; 0.6115 ; 0.1014 ; 0.6313 ; 0.2450 ; 0.2425 ; 0.1328 ; 0.2393 ; 0.0197 ; 0.4175 ; 0.2707 ; 0.1541 ; 0.2331 ; 0.6065 ; 0.0496 ; 0.2071 ; 0.0804 ; 0.1357 ; 0.5070 ; 0.2437 ; 0.2659 ; 0.1077 ; 0.1658 ; 0.0918 ; 0.0781 ; 0.1066 ; 0.4439 ; 0.2606 ; 0.3178 ; 0.5257 ; 0.4827 ; 0.0633 ; 0.4419 ; 0.4294 ; 0.0561 ; 0.1511 ; 0.4225 ; 0.4912 ; 0.2116 ; 0.2344 ; 0.5444 ; 0.3489 ; 0 ; 0.0021 ; 0.0070 ; 0.1644 ; 0.1675 ; 0.5319 ; 0.3956 ; 0.0795 ; 0.2517 ; 0.2728 ; 0.0010 ; 0.4713 ; 0.0271 ; 0.4940 ; 0.2644 ; 0.1904 ; 0.3594 ; 0.2975 ; 0.0867 ; 0.2110 ; 0.3599 ; 0.5844 ; 0.4611 ; 0.2160 ; 0.6769 ; 0.3498 ; 0.1604 ; 0.1220 ; 0.0619 ; 0.1389 ; 0.2804 ; 0.3300 ; 0.0181 ; 0.1924 ; 0.5023 ; 0.3117 ; 0.4096 ; 0.3805 ; 0.4682 ; 0.4717 ; 0.1235 ; 0.0772 ; 0.1594 ; 0.0173 ; 0.3030 ; 0.1957 ; 0.0370 ; 0.0453 ; 0.1401 ; 0.2277 ; 0.0625 ; 0.2094 ; 0.0001 ; 0.2771 ; 0.0192 ; 0.0923 ; 0.5665 ; 0.2479 ; 0.2730 ; 0.1299 ; 0.0238 ; 0.0847 ; 0.1088 ; 0.3919 ; 0.1363 ; 0.3904 ; 0.1261 ; 0.0188 ; 0.1956 ; 0.0071 ; 0.5572 ; 0.2187 ; 0.0373 ; 0.2249 ; 0.3217 ; 0.2509 ; 0.2083 ; 0.3056 ; 0.1287 ; 0.2928 ; 0.5149 ; 0.0028 ; 0.7093 ; 0.1696 ; 0.4260 ; 0.0366 ; 0.1391 ; 0.2652 ; 0.3344 ; 0.5659 ; 0.1210 ; 0.5131 ; 0.2544 ; 0.2498 ; 0.3202 ; 0.4590 ; 0.2521 ; 0.6256 ; 0.2668 ; 0.1471 ; 0.4476 ; 0.3347 ; 0.6571 ; 0.2246 ; 0.3013 ; 0.0110 ; 0.4821 ; 0.3500 ; 0.5945 ; 0.2404 ; 0.3121 ; 0.2589 ; 0.3777 ; 0.2458 ; 0.4510 ; 0.3431 ; 0.3467 ; 0.2773 ; 0.3074 ; 0.3684 ; 0.4453 ; 0.0143 ; 0.1217 ; 0.4931 ; 0.1060 ; 0.4926 ; 0.2748 ; 0.4027 ; 0.6867 ; 0.3140 ; 0.3756 ; 0.2901 ; 0.2414 ; 0.7005 ; 0.3227 ; 0.2811 ; 0.4029 ; 0.4956 ; 0.7094 ; 0.1027 ; 0.3465 ; 0.1555 ; 0.0763 ; 0.2176 ; 0.0340 ; 0.2981 ; 0.0119 ; 0.9463 ; 0.6407 ; 0.4163 ; 0.3928 ; 0.4696 ; 0.4622 ; 0.0288 ; 0.7015 ; 0.7399 ; 0.4274 ; 0.6731 ; 0.0950 ; 0.7824 ; 0.6170 ; 0.4434 ; 0.4998 ; 0.6513 ; 0.7563 ; 0.5222 ; 0.5356 ; 0.4533 ; 0.7810 ; 0.5313 ; 0.7061 ; 0.6677 ; 0.4668 ; 0.4340 ; 0.5025 ; 0.2146 ; 0.0853 ; 0.3822 ; 0.6310 ; 0.6214 ; 0.6936 ; 0.0237 ; 0.1548 ; 0.3991 ; 0.7327 ; 0.3834 ; 0.5981 ; 0.8535 ; 0.5979 ; 0.8331 ; 0.5386 ; 0.0109 ; 0.5144 ; 0.7700 ; 0.3136 ; 0.7041 ; 0.0901 ; 0.0000 ; 0.5152 ; 0.3686 ; 0.4407 ; 0.5378 ; 0.4552 ; 0.6191 ; 0.5381 ; 0.5402 ; 0.4834 ; 0.0895 ; 0.4875 ; 0.4237 ; 0.4452 ; 0.9025 ; 0.4681 ; 0.0657 ; 0.4982 ; 0.5101 ; 0.6161 ; 0.4262 ; 0.3435 ; 0.3953 ; 0.2605 ; 0.6060 ; 0.0710 ; 0.4856 ; 0.0027 ; 0.2303 ; 0.4432 ; 0.5742 ; 0.0848 ; 0.7127 ; 0.3320 ; 0.2263 ; 0.6710 ; 0.4764 ; 0.3468 ; 0.2665 ; 0.0291 ; 0.5383 ; 0.4189 ; 0.4950 ; 0.1791 ; 0.3518 ; 0.1673 ; 0.4491 ; 0.2866 ; 0.4276 ; 0.2130 ; 0.1868 ; 0.7158 ; 0.2907 ; 0.4417 ; 0.2609 ; 0.4975 ; 0.2434 ; 0.3591 ; 0.1065 ; 0.3250 ; 0.0591 ; 0.3619 ; 0.2545 ; 0.6527 ; 0.2783 ; 0.5033 ; 0.5527 ; 0.3844 ; 0.2446 ; 0.6450 ; 0.3997 ; 0.3454 ; 0.5728 ; 0.4871 ; 0.2213 ; 0.0491 ; 0.3390 ; 0.5399 ; 0.2237 ; 0.1253 ; 0.6304 ; 0.6096 ; 0.3385 ; 0.4088 ; 0.2311 ; 0.2697 ; 0.5081 ; 0.2977 ; 0.2233 ; 0.3556 ; 0.2475 ; 0.4986 ; 0.2736 ; 0.3800 ; 0.6421 ; 0.2357 ; 0.4388 ; 0.6024 ; 0.6652 ; 0.0305 ; 0.6192 ; 0.0603 ; 0.1399 ; 0.1179 ; 0.1698 ; 0.1132 ; 0.1516 ; 0.1771 ; 0.0892 ; 0.2325 ; 0.2619 ; 0.4882 ; 0.1988 ; 0.0836 ; 0.2309 ; 0.1143 ; 0.0134 ; 0.3174 ; 0.0493 ; 0.3395 ; 0.2833 ; 0.0924 ; 0.1221 ; 0.0627 ; 0.3296 ; 0.1867 ; 0.1308 ; 0.2724 ; 0.3029 ; 0.0531 ; 0.5843 ; 0.0845 ; 0.1767 ; 0.2171 ; 0.2837 ; 0.1891 ; 0.1036 ; 0.2284 ; 0.1229 ; 0.2568 ; 0.0595 ; 0.1153 ; 0.1161 ; 0.0729 ; 0.3425 ; 0.4003 ; 0.1316 ; 0.0982 ; 0.2922 ; 0.5678 ; 0.1522 ; 0.1108 ; 0.1319 ; 0.3132 ; 0.0724 ; 0.2656 ; 0.2086 ; 0.1967 ; 0.1110 ; 0.5175 ; 0.5078 ; 0.1470 ; 0.1281 ; 0.0056 ; 0.8633 ; 0.2365 ; 0.2305 ; 0.3681 ; 0.3068 ; 0.3623 ; 0.2741 ; 0.1043 ; 0.0790 ; 0.1630 ; 0.1734 ; 0.1178 ; 0.4013 ; 0.6142 ; 0.3585 ; 0.2512 ; 0.1198 ; 0.2206 ; 0.1372 ; 0.0870 ; 0.1535 ; 0.1154 ; 0.1025 ; 0.0862 ; 0.5876 ; 0.3270 ; 0.0661 ; 0.2496 ; 0.2451 ; 0.4705 ; 0.0741 ; 0.1520 ; 0.2386 ; 0.0928 ; 0.2134 ; 0.1003 ; 0.1567 ; 0.1353 ; 0.2474 ; 0.1789 ; 0.4600 ; 0.0945 ; 0.7708 ; 0.3042 ; 0.2136 ; 0.6103 ; 0.2875 ; 0.1612 ; 0.2830 ; 0.1819 ; 0.2758 ; 0.0864 ; 0.6502 ; 0.6432 ; 0.2105 ; 0.1054 ; 0.2863 ; 0.4219 ; 0.1923 ; 0.5104 ; 0.0930 ; 0.0703 ; 0.1170 ; 0.3321 ; 0.1429 ; 0.1633 ; 0.3072 ; 0.0264 ; 0.5374 ; 0.1710 ; 0.0004 ; 0.1049 ; 0.5805 ; 0.1949 ; 0.4504 ; 0.3332 ; 0.5133 ; 0.2092 ; 0.1617 ; 0.3076 ; 0.0851 ; 0.4849 ; 0.2941 ; 0.0817 ; 0.3367 ; 0.2882 ; 0.1378 ; 0.2156 ; 0.1214 ; 0.2853 ; 0.2342 ; 0.0936 ; 0.0180 ; 0.6741 ; 0.1009 ; 0.4653 ; 0.3749 ; 0.1678 ; 0.1869 ; 0.1591 ; 0.2622 ; 0.1608 ; 0.1927 ; 0.1997 ; 0.2195 ; 0.1622 ; 0.0606 ; 0.0838 ; 0.0207 ; 0.0719 ; 0.3048 ; 0.2630 ; 0.1460 ; 0.0757 ; 0.2329 ; 0.1483 ; 0.0053 ; 0.2579 ; 0.0490 ; 0.1835 ; 0.4779 ; 0.1942 ; 0.3826 ; 0.0482 ; 0.1347 ; 0.2998 ; 0.1888 ; 0.1498 ; 0.1094 ; 0.2935 ; 0.1936 ; 0.3571 ; 0.0269 ; 0.0302 ; 0.0002 ; 0.1381 ; 0.4632 ; 0.3799 ; 0.3537 ; 0.4298 ; 0.3127 ; 0.2358 ; 0.5814 ; 0.6033 ; 0.0787 ; 0.6182 ; 0.3453 ; 0.3607 ; 0.0827 ; 0.4345 ; 0.3215 ; 0.6621 ; 0.5461 ; 0.7671 ; 0.5363 ; 0.9470 ; 0.2607 ; 0.3924 ; 0.5648 ; 0.4203 ; 0.2534 ; 0.1794 ; 0.5528 ; 0.2209 ; 0.3154 ; 0.3672 ; 0.6388 ; 0.3856 ; 0.2207 ; 0.3303 ; 0.2489 ; 0.5337 ; 0.2109 ; 0.3023 ; 0.4427 ; 0.2300 ; 0.3929 ; 0.3307 ; 0.3083 ; 0.0756 ; 0.7056 ; 0.1121 ; 0.2643 ; 0.2215 ; 0.5584 ; 0.3914 ; 0.6549 ; 0.5927 ; 0.7074 ; 0.3639 ; 0.4588 ; 0.4787 ; 0.8203 ; 0.1231 ; 0.2398 ; 0.6614 ; 0.5338 ; 0.6372 ; 0.5434 ; 0.0683 ; 0.3867 ; 0.4981 ; 0.2338 ; 0.4565 ; 0.6977 ; 0.5959 ; 0.4749 ; 0.3816 ; 0.1205 ; 0.4832 ; 0.2947 ; 0.3773 ; 0.3265 ; 0.3796 ; 0.6855 ; 0.2818 ; 0.2787 ; 0.2493 ; 0.1509 ; 0.5521 ; 0.1201 ; 0.2488 ; 0.1275 ; 0.3875 ; 0.3859 ; 0.8185 ; 0.1890 ; 0.4255 ; 0.2328 ; 0.2904 ; 0.1500 ; 0.1667 ; 0.3045 ; 0.3503 ; 0.1333 ; 0.5344 ; 0.3504 ; 0.2971 ; 0.3587 ; 0.2376 ; 0.5116 ; 0.4360 ; 0.7348 ; 0.2502 ; 0.3133 ; 0.4767 ; 0.1946 ; 0.1145 ; 0.2774 ; 0.3490 ; 0.1055 ; 0.0338 ; 0.4249 ; 0.2442 ; 0.2679 ; 0.5755 ; 0.4961 ; 0.9462 ; 0.3632 ; 0.9971 ; 0.4715 ; 0.4385 ; 0.0222 ; 0.5273 ; 0.2258 ; 0.0908 ; 0.1545 ; 0.1001 ; 0.6267 ; 0.5352 ; 0.0641 ; 0.1298 ; 0.2346 ; 0.1457 ; 0.6832 ; 0.5787 ; 0.4675 ; 0.0542 ; 0.1163 ; 0.3066 ; 0.0005 ; 0.4859 ; 0.1150 ; 0.4147 ; 0.1074 ; 0.1035 ; 0.3513 ; 0.1273 ; 0.5293 ; 0.5026 ; 0.1086 ; 0.1817 ; 0.5575 ; 0.2858 ; 0.2323 ; 0.3942 ; 0.3918 ; 0.8977 ; 0.4140 ; 0.2687 ; 0.2212 ; 0.0008 ; 0.2015 ; 0.0969 ; 0.3313 ; 0.5518 ; 0.3999 ; 0.6055 ; 0.4239 ; 0.1485 ; 0.1756 ; 0.1531 ; 0.1071 ; 0.1189 ; 0.4302 ; 0.3264 ; 0.2363 ; 0.3373 ; 0.3177 ; 0.2490 ; 0.2219 ; 0.6589 ; 0.3921 ; 0.4019 ; 0.5448 ; 0.5029 ; 0.1676 ; 0.4509 ; 0.3295 ; 0.2038 ; 0.4579 ; 0.2005 ; 0.3426 ; 0.1579 ; 0.1106 ; 0.0332 ; 0.1587 ; 0.6640 ; 0.3412 ; 0.3411 ; 0.2168 ; 0.1646 ; 0.2671 ; 0.0713 ; 0.5036 ; 0.3845 ; 0.6718 ; 0.0162 ; 0.2369 ; 0.6568 ; 0.0082 ; 0.1268 ; 0.2689 ; 0.1605 ; 0.5135 ; 0.5180 ; 0.3198 ; 0.3238 ; 0.3564 ; 0.5880 ; 0.5299 ; 0.2254 ; 0.4187 ; 0.2019 ; 0.1661 ; 0.3008 ; 0.7389 ; 0.1640 ; 0.3573 ; 0.2448 ; 0.3667 ; 0.4688 ; 0.6207 ; 0.3900 ; 0.4374 ; 0.4906 ; 0.3656 ; 0.6736 ; 0.1263 ; 0.4267 ; 0.2815 ; 0.8612 ; 0.2170 ; 0.0566 ; 0.1480 ; 0.6723 ; 0.1533 ; 0.3525 ; 0.5466 ; 0.3387 ; 0.2173 ; 0.9465 ; 0.0342 ; 0.3797 ; 0.3139 ; 0.3560 ; 0.3854 ; 0.5329 ; 0.3094 ; 0.6120 ; 0.6698 ; 0.1084 ; 0.4824 ; 0.0458 ; 0.1113 ; 0.2982 ; 0.2527 ; 0.0485 ; 0.3549 ; 0.3774 ; 0.2631 ; 0.1180 ; 0.3813 ; 0.5139 ; 0.1685 ; 0.4490 ; 0.4112 ; 0.0515 ; 0.1288 ; 0.4586 ; 0.1645 ; 0.0944 ; 0.3391 ; 0.1072 ; 0.5605 ; 0.1889 ; 0.4015 ; 0.0779 ; 0.1846 ; 0.2459 ; 0.7276 ; 0.4243 ; 0.4230 ; 0.1313 ; 0.0132 ; 0.4963 ; 0.0874 ; 0.1230 ; 0.3954 ; 0.1040 ; 0.0970 ; 0.3226 ; 0.3326 ; 0.3172 ; 0.2577 ; 0.4507 ; 0.3827 ; 0.0886 ; 0.6044 ; 0.2996 ; 0.2262 ; 0.5125 ; 0.4068 ; 0.6107 ; 0.4291 ; 0.2557 ; 0.0506 ; 0.1701 ; 0.1635 ; 0.3124 ; 0.2412 ; 0.2295 ; 0.4323 ; 0.8768 ; 0.1039 ; 0.1011 ; 0.3765 ; 0.0345 ; 0.7006 ; 0.4018 ; 0.1266 ; 0.0676 ; 0.0644 ; 0.0078 ; 0.1777 ; 0.9022 ; 0.3884 ; 0.4637 ; 0.5930 ; 0.6261 ; 0.2439 ; 0.2396 ; 0.4697 ; 0.2559 ; 0.0919 ; 0.3026 ; 0.3329 ; 0.1758 ; 0.4664 ; 0.1908 ; 0.1508 ; 0.2122 ; 0.1413 ; 0.2286 ; 0.4130 ; 0.1934 ; 0.2932 ; 0.1815 ; 0.0055 ; 0.0649 ; 0.0343 ; 0.1024 ; 0.0011 ; 0.0024 ; 0.0788 ; 0.5576 ; 0.4456 ; 0.6891 ; 0.6367 ; 0.5093 ; 0.5712 ; 0.3189 ; 0.4238 ; 0.4139 ; 0.5238 ; 0.5938 ; 0.2236 ; 0.2244 ; 0.4178 ; 0.4822 ; 0.1496 ; 0.5082 ; 0.5975 ; 0.4748 ; 0.5073 ; 0.6449 ; 0.6540 ; 0.7120 ; 0.2526 ; 0.2440 ; 0.1436 ; 0.1651 ; 0.1810 ; 0.1537 ; 0.3382 ; 0.5769 ; 0.4742 ; 0.4517 ; 0.4188 ; 0.2302 ; 0.0497 ; 0.3501 ; 0.3394 ; 0.2647 ; 0.2769 ; 0.4736 ; 0.5655 ; 0.0550 ; 0.1954 ; 0.3341 ; 0.1920 ; 0.4218 ; 0.6893 ; 0.1127 ; 0.4728 ; 0.5060 ; 0.1279 ; 0.5508 ; 0.3874 ; 0.4862 ; 0.4473 ; 0.1840 ; 0.1454 ; 0.3545 ; 0.5799 ; 0.2247 ; 0.2471 ; 0.4257 ; 0.3310 ; 0.6342 ; 0.4935 ; 0.6384 ; 0.2379 ; 0.2976 ; 0.4628 ; 0.4073 ; 0.0186 ; 0.2339 ; 0.5447 ; 0.5158 ; 0.6402 ; 0.1598 ; 0.4072 ; 0.4617 ; 0.5865 ; 0.3414 ; 0.2706 ; 0.0526 ; 0.1870 ; 0.0564 ; 0.4235 ; 0.6230 ; 0.5771 ; 0.7763 ; 0.1625 ; 0.1507 ; 0.9194 ; 0.3903 ; 0.3660 ; 0.4999 ; 0.1680 ; 0.8133 ; 0.2889 ; 0.5848 ; 0.0537 ; 0.3962 ; 0.3374 ; 0.2511 ; 0.5412 ; 0.3958 ; 0.3666 ; 0.3057 ; 0.5143 ; 0.3841 ; 0.4386 ; 0.5249 ; 0.3721 ; 0.5080 ; 0.4169 ; 0.4660 ; 0.4437 ; 0.0203 ; 0.2375 ; 0.3375 ; 0.5264 ; 0.4899 ; 0.6458 ; 0.3186 ; 0.4201 ; 0.5783 ; 0.2522 ; 0.4195 ; 0.2052 ; 0.1491 ; 0.3223 ; 0.5314 ; 0.6241 ; 0.1900 ; 0.6598 ; 0.0294 ; 0.3197 ; 0.2573 ; 0.3067 ; 0.4683 ; 0.4661 ; 0.3598 ; 0.3401 ; 0.5807 ; 0.3479 ; 0.6661 ; 0.5382 ; 0.3047 ; 0.3618 ; 0.3569 ; 0.3363 ; 0.0567 ; 0.2726 ; 0.3409 ; 0.4320 ; 0.6379 ; 0.5476 ; 0.1486 ; 0.3738 ; 0.2735 ; 0.3729 ; 0.5372 ; 0.2850 ; 0.4577 ; 0.4550 ; 0.6346 ; 0.2592 ; 0.2827 ; 0.7049 ; 0.1978 ; 0.0067 ; 0.1751 ; 0.3445 ; 0.6873 ; 0.4501 ; 0.6962 ; 0.2909 ; 0.4593 ; 0.4466 ; 0.5083 ; 0.2817 ; 0.1932 ; 0.2292 ; 0.2591 ; 0.2939 ; 0.0445 ; 0.1852 ; 0.6140 ; 0.2042 ; 0.3836 ; 0.4282 ; 0.3100 ; 0.3148 ; 0.3742 ; 0.1693 ; 0.4412 ; 0.4179 ; 0.3910 ; 0.4304 ; 0.1879 ; 0.2484 ; 0.3331 ; 0.4275 ; 0.1725 ; 0.3379 ; 0.0652 ; 0.0846 ; 0.5220 ; 0.7681 ; 0.2112 ; 0.3922 ; 0.6550 ; 0.2010 ; 0.0605 ; 0.0579 ; 0.0466 ; 0.1858 ; 0.5128 ; 0.7993 ; 0.5130 ; 0.2961 ; 0.2570 ; 0.5590 ; 0.3835 ; 0.3327 ; 0.3965 ; 0.4414 ; 0.1674 ; 0.0953 ; 0.3823 ; 0.4794 ; 0.5976 ; 0.4185 ; 0.3049 ; 0.4465 ; 0.5113 ; 0.4801 ; 0.4252 ; 0.3433 ; 0.3293 ; 0.5462 ; 0.7917 ; 0.3528 ; 0.5138 ; 0.2883 ; 0.4714 ; 0.5658 ; 0.5015 ; 0.2405 ; 0.6768 ; 0.7118 ; 0.7599 ; 0.3665 ; 0.2714 ; 0.1894 ; 0.4409 ; 0.5300 ; 0.3635 ; 0.3162 ; 0.6611 ; 0.3689 ; 0.6503 ; 0.1059 ; 0.7011 ; 0.3935 ; 0.1482 ; 0.3539 ; 0.4858 ; 0.5134 ; 0.6858 ; 0.4545 ; 0.5743 ; 0.5948 ; 0.3886 ; 0.2121 ; 0.5163 ; 0.1917 ; 0.2248 ; 0.2064 ; 0.3898 ; 0.6942 ; 0.2279 ; 0.1373 ; 0.5631 ; 0.2432 ; 0.3546 ; 0.8231 ; 0.7237 ; 0.1280 ; 0.5241 ; 0.2272 ; 0.0507 ; 0.9131 ; 0.4110 ; 0.1203 ; 0.7518 ; 0.4335 ; 0.3995 ; 0.3734 ; 0.4892 ; 0.3601 ; 0.7802 ; 0.2335 ; 0.5140 ; 0.0460 ; 0.4064 ; 0.7231 ; 0.1947 ; 0.6119 ; 0.2878 ; 0.2072 ; 0.4381 ; 0.3897 ; 0.4303 ; 0.3153 ; 0.7164 ; 0.1878 ; 0.8165 ; 0.3949 ; 0.3014 ; 0.6920 ; 0.4394 ; 0.1557 ; 0.2917 ; 0.1686 ; 0.5691 ; 0.2756 ; 0.3727 ; 0.8488 ; 0.5816 ; 0.1818 ; 0.0634 ; 0.3876 ; 0.8423 ; 0.1811 ; 0.3448 ; 0.1495 ; 0.1412 ; 0.3625 ; 0.2381 ; 0.2926 ; 0.2214 ; 0.8288 ; 0.7216 ; 0.1812 ; 0.2330 ; 0.0501 ; 0.2472 ; 0.1911 ; 0.3661 ; 0.4155 ; 0.5736 ; 0.4352 ; 0.3583 ; 0.2712 ; 0.3304 ; 0.0732 ; 0.1062 ; 0.3130 ; 0.1475 ; 0.1720 ; 0.2470 ; 0.6308 ; 0.5272 ; 0.6394 ; 0.3436 ; 0.4720 ; 0.3371 ; 0.2691 ; 0.3403 ; 0.1096 ; 0.1058 ; 0.4009 ; 0.2031 ; 0.7186 ; 0.6232 ; 0.5652 ; 0.5898 ; 0.3185 ; 0.3971 ; 0.5231 ; 0.4063 ; 0.5453 ; 0.5196 ; 0.2633 ; 0.2223 ; 0.3019 ; 0.1239 ; 0.1131 ; 0.4424 ; 0.5954 ; 0.2762 ; 0.3937 ; 0.3021 ; 0.3175 ; 0.3702 ; 0.6123 ; 0.4815 ; 0.0630 ; 0.7996 ; 0.2473 ; 0.1833 ; 0.3386 ; 0.4780 ; 0.3336 ; 0.3925 ; 0.3015 ; 0.5847 ; 0.2563 ; 0.2478 ; 0.6300 ; 0.4086 ; 0.2035 ; 0.1073 ; 0.3739 ; 0.3181 ; 0.5640 ; 0.5732 ; 0.1348 ; 0.1166 ; 0.2141 ; 0.3555 ; 0.0057 ; 0.4761 ; 0.9389 ; 0.2285 ; 0.0171 ; 0.2449 ; 0.3406 ; 0.5907 ; 0.5858 ; 0.5955 ; 0.5757 ; 0.5019 ; 0.2884 ; 0.2101 ; 0.2288 ; 0.5672 ; 0.0759 ; 0.6916 ; 0.2394 ; 0.6783 ; 0.1951 ; 0.6146 ; 0.3668 ; 0.6082 ; 0.2079 ; 0.3934 ; 0.4156 ; 0.2925 ; 0.2401 ; 0.5275 ; 0.0240 ; 0.5030 ; 0.5965 ; 0.3170 ; 0.2753 ; 0.3404 ; 0.2345 ; 0.1785 ; 0.3393 ; 0.1305 ; 0.6084 ; 0.4174 ; 0.6185 ; 0.5193 ; 0.2316 ; 0.0287 ; 0.2985 ; 0.4802 ; 0.6025 ; 0.4158 ; 0.1609 ; 0.5115 ; 0.3407 ; 0.4823 ; 0.6496 ; 0.4332 ; 0.6183 ; 0.2795 ; 0.6619 ; 0.5268 ; 0.8258 ; 0.3567 ; 0.3881 ; 0.3693 ; 0.0880 ; 0.0706 ; 0.1832 ; 0.2114 ; 0.0250 ; 0.8613 ; 0.3872 ; 0.1538 ; 0.5499 ; 0.4544 ; 0.8038 ; 0.4723 ; 0.1410 ; 0.1692 ; 0.0504 ; 0.0764 ; 0.2999 ; 0.4123 ; 0.4244 ; 0.4812 ; 0.4327 ; 0.3478 ; 0.0830 ; 0.1464 ; 0.6869 ; 0.1254 ; 0.2564 ; 0.2513 ; 0.3720 ; 0.2886 ; 0.5393 ; 0.5552 ; 0.0511 ; 0.7026 ; 0.1017 ; 0.3752 ; 0.7528 ; 0.7364 ; 0.2469 ; 0.4699 ; 0.2066 ; 0.1752 ; 0.4137 ; 0.0943 ; 0.0668 ; 0.0974 ; 0.2395 ; 0.6355 ; 0.0304 ; 0.5353 ; 0.0960 ; 0.5560 ; 0.4482 ; 0.6399 ; 0.4919 ; 0.6495 ; 0.5324 ; 0.2149 ; 0.0955 ; 0.1755 ; 0.2988 ; 0.2599 ; 0.4941 ; 0.1871 ; 0.2468 ; 0.1284 ; 0.2174 ; 0.6953 ; 0.2418 ; 0.0026 ; 0.3917 ; 0.3851 ; 0.1984 ; 0.4708 ; 0.1218 ; 0.4458 ; 0.4934 ; 0.6276 ; 0.5800 ; 0.5701 ; 0.5013 ; 0.3421 ; 0.3974 ; 0.2315 ; 0.4101 ; 0.2616 ; 0.0642 ; 0.3461 ; 0.3753 ; 0.1551 ; 0.1747 ; 0.8131 ; 0.2899 ; 0.4958 ; 0.3679 ; 0.2043 ; 0.0003 ; 0.3588 ; 0.3801 ; 0.0516 ; 0.2128 ; 0.1070 ; 0.3241 ; 0.2371 ; 0.3062 ; 0.6099 ; 0.3346 ; 0.8650 ; 0.3378 ; 0.4363 ; 0.1082 ; 0.2547 ; 0.0280 ; 0.3906 ; 0.4326 ; 0.6812 ; 0.1926 ; 0.0801 ; 0.1371 ; 0.7568 ; 0.4880 ; 0.7475 ; 0.5418 ; 0.5105 ; 0.5567 ; 0.0587 ; 0.1886 ; 0.5216 ; 0.5664 ; 0.4106 ; 0.2129 ; 0.3973 ; 0.2230 ; 0.4841 ; 0.0157 ; 0.4642 ; 0.2676 ; 0.2245 ; 0.6202 ; 0.2519 ; 0.1716 ; 0.0467 ; 0.2869 ; 0.5789 ; 0.3838 ; 0.1860 ; 0.3840 ; 0.4568 ; 0.6945 ; 0.3168 ; 0.1757 ; 0.5076 ; 0.4543 ; 0.4200 ; 0.5770 ; 0.3469 ; 0.3644 ; 0.0527 ; 0.4339 ; 0.3211 ; 0.1492 ; 0.0372 ; 0.2566 ; 0.5321 ; 0.3035 ; 0.8500 ; 0.1671 ; 0.5248 ; 0.3004 ; 0.6534 ; 0.2731 ; 0.1529 ; 0.0185 ; 0.4301 ; 0.9385 ; 0.6725 ; 0.6117 ; 0.6057 ; 0.2859 ; 0.5680 ; 0.3111 ; 0.0929 ; 0.3911 ; 0.1527 ; 0.2800 ; 0.6223 ; 0.2571 ; 0.6414 ; 0.8935 ; 0.1192 ; 0.2520 ; 0.2460 ; 0.0196 ; 0.4167 ; 0.0897 ; 0.0581 ; 0.5294 ; 0.0258 ; 0.1845 ; 0.2226 ; 0.1602 ; 0.2281 ; 0.5854 ; 0.5836 ; 0.3580 ; 0.4804 ; 0.4367 ; 0.3511 ; 0.7312 ; 0.3405 ; 0.6624 ; 0.5957 ; 0.5751 ; 0.2823 ; 0.5198 ; 0.0915 ; 0.3536 ; 0.9839 ; 0.2060 ; 0.1320 ; 0.3943 ; 0.5142 ; 0.3757 ; 0.8829 ; 0.4777 ; 0.1290 ; 0.5179 ; 0.3036 ; 0.4578 ; 0.0560 ; 0.5643 ; 0.4311 ; 0.6917 ; 0.4576 ; 0.2984 ; 0.6773 ; 0.5642 ; 0.2242 ; 0.0061 ; 0.6029 ; 0.3092 ; 0.6630 ; 0.9594 ; 0.6249 ; 0.7337 ; 0.7263 ; 0.3892 ; 0.1837 ; 0.6625 ; 0.3353 ; 0.0932 ; 0.2028 ; 0.4467 ; 0.5762 ; 0.7051 ; 0.0208 ; 0.2104 ; 0.4428 ; 0.2636 ; 0.5568 ; 0.6089 ; 0.0996 ; 0.6220 ; 0.4817 ; 0.1026 ; 0.7942 ; 0.2717 ; 0.0992 ; 0.5983 ; 0.1142 ; 0.0775 ; 0.3416 ; 0.5120 ; 0.6539 ; 0.2389 ; 0.1340 ; 0.1322 ; 0.3163 ; 0.5616 ; 0.0428 ; 0.0512 ; 0.4922 ; 0.4597 ; 0.5200 ; 0.2234 ; 0.3122 ; 0.3244 ; 0.1432 ; 0.1729 ; 0.2380 ; 0.3160 ; 0.0301 ; 0.4390 ; 0.5667 ; 0.3358 ; 0.0114 ; 0.5210 ; 0.4991 ; 0.4264 ; 0.5679 ; 0.1137 ; 0.2742 ; 0.3690 ; 0.6243 ; 0.0738 ; 0.1057 ; 0.4043 ; 0.9650 ; 0.2515 ; 0.1723 ; 0.5237 ; 0.5856 ; 0.2250 ; 0.0156 ; 0.0131 ; 0.3901 ; 0.4433 ; 0.1728 ; 0.2661 ; 0.5651 ; 0.7723 ; 0.3459 ; 0.4119 ; 0.6255 ; 0.6970 ; 0.8638 ; 0.2733 ; 0.0434 ; 0.0339 ; 0.0463 ; 0.1332 ; 0.6101 ; 0.3297 ; 0.8333 ; 0.0559 ; 0.0251 ; 0.3440 ; 0.6282 ; 0.3458 ; 0.3206 ; 0.0578 ; 0.0727 ; 0.5159 ; 0.3380 ; 0.2775 ; 0.4099 ; 0.1252 ; 0.7735 ; 0.3338 ; 0.1950 ; 0.3966 ; 0.4670 ; 0.0390 ; 0.2699 ; 0.4100 ; 0.5480 ; 0.1982 ; 0.3605 ; 0.0049 ; 0.3337 ; 0.0698 ; 0.3612 ; 0.5031 ; 0.3305 ; 0.2097 ; 0.5225 ; 0.0681 ; 0.3251 ; 0.5802 ; 0.0066 ; 0.1090 ; 0.1128 ; 0.2612 ; 0.1056 ; 0.6378 ; 0.7036 ; 0.1255 ; 0.3398 ; 0.5796 ; 0.5741 ; 0.6062 ; 0.0199 ; 0.0454 ; 0.1970 ; 0.0439 ; 0.6231 ; 0.5387 ; 0.3166 ; 0.2721 ; 1.0000 ; 0.3520 ; 0.1877 ; 0.1730 ; 0.0961 ; 0.3437 ; 0.6016 ; 0.3446 ; 0.5850 ; 0.1136 ; 0.6273 ; 0.3106 ; 0.0396 ; 0.0484 ; 0.4618 ; 0.5420 ; 0.3318 ; 0.3451 ; 0.2781 ; 0.4266 ; 0.3658 ; 0.1034 ; 0.1613 ; 0.2476 ; 0.7300 ; 0.0471 ; 0.3559 ; 0.0913 ; 0.2298 ; 0.6246 ; 0.8609 ; 0.1829 ; 0.1177 ; 0.2698 ; 0.0645 ; 0.8296 ; 0.1853 ; 0.6642 ; 0.0612 ; 0.8922 ; 0.1975 ; 0.9642 ; 0.1561 ; 0.5258 ; 0.1706 ; 0.4398 ; 0.6730 ; 0.2807 ; 0.6515 ; 0.2593 ; 0.2683 ; 0.1202 ; 0.2767 ; 0.3673 ; 0.3286 ; 0.3728 ; 0.7351 ; 0.0814 ; 0.2873 ; 0.4108 ; 0.7040 ; 0.4542 ; 0.2962 ; 0.2150 ; 0.6919 ; 0.6037 ; 0.2879 ; 0.1184 ; 0.2540 ; 0.2791 ; 0.0705 ; 0.6206 ; 0.2778 ; 0.2854 ; 0.1116 ; 0.5496 ; 0.1451 ; 0.0789 ; 0.1005 ; 0.3471 ; 0.2870 ; 0.9158 ; 0.0553 ; 0.4181 ; 0.0060 ; 0.1433 ; 0.3043 ; 0.3361 ; 0.3817 ; 0.1119 ; 0.5176 ; 0.2871 ; 0.4224 ; 0.5904 ; 0.5547 ; 0.0336 ; 0.7286 ; 0.1283 ; 0.0263 ; 0.0159 ; 0.0400 ; 0.0069 ; 0.1903 ; 0.5405 ; 0.6293 ; 0.4737 ; 0.1787 ; 0.1556 ; 0.6987 ; 0.2653 ; 0.2495 ; 0.0881 ; 0.0486 ; 0.0265 ; 0.1623 ; 0.9299 ; 0.4650 ; 0.5147 ; 0.2313 ; 0.1928 ; 0.3399 ; 0.1151 ; 0.6008 ; 0.0007 ; 0.4028 ; 0.2634 ; 0.5545 ; 0.1237 ; 0.0800 ; 0.4030 ; 0.3550 ; 0.2217 ; 0.1013 ; 0.6918 ; 0.7790 ; 0.0530 ; 0.5662 ; 0.6467 ; 0.1101 ; 0.2189 ; 0.2949 ; 0.4581 ; 0.2085 ; 0.6211 ; 0.4497 ; 0.0455 ; 0.0639 ; 0.2819 ; 0.2989 ; 0.0916 ; 0.3155 ; 0.4060 ; 0.6001 ; 0.9350 ; 0.6765 ; 0.5887 ; 0.3883 ; 0.1490 ; 0.0374 ; 0.2444 ; 0.2549 ; 0.1959 ; 0.1739 ; 0.2583 ; 0.0990 ; 0.4904 ; 0.3649 ; 0.4485 ; 0.0988 ; 0.1679 ; 0.4598 ; 0.5004 ; 0.0680 ; 0.2070 ; 0.1000 ; 0.4116 ; 0.1489 ; 0.2124 ; 0.5934 ; 0.2915 ; 0.9202 ; 0.3771 ; 0.2855 ; 0.5505 ; 0.7008 ; 0.0309 ; 0.3064 ; 0.0430 ; 0.5371 ; 0.5281 ; 0.8505 ; 0.3994 ; 0.5558 ; 0.2127 ; 0.1856 ; 0.0316 ; 0.1339 ; 0.2751 ; 0.6573 ; 0.9084 ; 0.6805 ; 0.1996 ; 0.8249 ; 0.3278 ; 0.9239 ; 0.2651 ; 0.3457 ; 0.4855 ; 0.4342 ; 0.2266 ; 0.2542 ; 0.2538 ; 0.1616 ; 0.5206 ; 0.6006 ; 0.5897 ; 0.1233 ; 0.3871 ; 0.3280 ; 0.1547 ; 0.2430 ; 0.4711 ; 0.2424 ; 0.0201 ; 0.0556 ; 0.0241 ; 0.1251 ; 0.0794 ; 0.0655 ; 0.3108 ; 0.4587 ; 0.3120 ; 0.0708 ; 0.1338 ; 0.1719 ; 0.4775 ; 0.0524 ; 0.3309 ; 0.3626 ; 0.1167 ; 0.2740 ; 0.4319 ; 0.3267 ; 0.3242 ; 0.5390 ; 0.3262 ; 0.0547 ; 0.2076 ; 0.0198 ; 0.6102 ; 0.3705 ; 0.3147 ; 0.3763 ; 0.1103 ; 0.6976 ; 0.2703 ; 0.8338 ; 0.4236 ; 0.0583 ; 0.0046 ; 0.9386 ; 0.7776 ; 0.0939 ; 0.3532 ; 0.2794 ; 0.2198 ; 0.3372 ; 0.2062 ; 0.5039 ; 0.3703 ; 0.2068 ; 0.0545 ; 0.3218 ; 0.0777 ; 0.5918 ; 0.0629 ; 0.1769 ; 0.2523 ; 0.3574 ; 0.4299 ; 0.1849 ; 0.4462 ; 0.2075 ; 0.5543 ; 0.0981 ; 0.4927 ; 0.5874 ; 0.4401 ; 0.0972 ; 0.1321 ; 0.0190 ; 0.0948 ; 0.0546 ; 0.5234 ; 0.4117 ; 0.5373 ; 0.7283 ; 0.4515 ; 0.7439 ; 0.2422 ; 0.1352 ; 0.0036 ; 0.0267 ; 0.4223 ; 0.2805 ; 0.0742 ; 0.1207 ; 0.2900 ; 0.3747 ; 0.0776 ; 0.0855 ; 0.2539 ; 0.7370 ; 0.7117 ; 0.1238 ; 0.4184 ; 0.5008 ; 0.2427 ; 0.0508 ; 0.5441 ; 0.3915 ; 0.3450 ; 0.3384 ; 0.1955 ; 0.1503 ; 0.0737 ; 0.6531 ; 0.0025 ; 0.2433 ; 0.6756 ; 0.2896 ; 0.5666 ; 0.8067 ; 0.5219 ; 0.5878 ; 0.1953 ; 0.1702 ; 0.1974 ; 0.0118 ; 0.0421 ; 0.1905 ; 0.6690 ; 0.7705 ; 0.5840 ; 0.0525 ; 0.5221 ; 0.5581 ; 0.6169 ; 0.2253 ; 0.1874 ; 0.1958 ; 0.1805 ; 0.1326 ; 0.2018 ; 0.0834 ; 0.1493 ; 0.0750 ; 0.3462 ; 0.1293 ; 0.0383 ; 0.6200 ; 0.2148 ; 0.6593 ; 0.3977 ; 0.1966 ; 0.4601 ; 0.4148 ; 0.3495 ; 0.1786 ; 0.4572 ; 0.6665 ; 0.2238 ; 0.2806 ; 0.6843 ; 0.4125 ; 0.1487 ; 0.0195 ; 0.6519 ; 0.0261 ; 0.0823 ; 0.4351 ; 0.5690 ; 0.5677 ; 0.6318 ; 0.6743 ; 0.0934 ; 0.1276 ; 0.6960 ; 0.3792 ; 0.0548 ; 0.1753 ; 0.7376 ; 0.8528 ; 0.0753 ; 0.3712 ; 0.4144 ; 0.0622 ; 0.2565 ; 0.4395 ; 0.3497 ; 0.0875 ; 0.3781 ; 0.1656 ; 0.1408 ; 0.1075 ; 0.1649 ; 0.2803 ; 0.1915 ; 0.0252 ; 0.1343 ; 0.1983 ; 0.1061 ; 0.3744 ; 0.0857 ; 0.2041 ; 0.0998 ; 0.2273 ; 0.1614 ; 0.2115 ; 0.0723 ; 0.4034 ; 0.1211 ; 0.2650 ; 0.0882 ; 0.0225 ; 0.0382 ; 0.0205 ; 0.0369 ; 0.4608 ; 0.1219 ; 0.0429 ; 0.2677 ; 0.2649 ; 0.3289 ; 0.1446 ; 0.0137 ; 0.1227 ; 0.6821 ; 0.6459 ; 0.5254 ; 0.4842 ; 0.3784 ; 0.1568 ; 0.0829 ; 0.7142 ; 0.3034 ; 0.5792 ; 0.3427 ; 0.6104 ; 0.4151 ; 0.2829 ; 0.1120 ; 0.0626 ; 0.0770 ; 0.0679 ; 0.0150 ; 0.3167 ; 0.3142 ; 0.2304 ; 0.0448 ; 0.0816 ; 0.1249 ; 0.2340 ; 0.1172 ; 0.1636 ; 0.0586 ; 0.0761 ; 0.4232 ; 0.0745 ; 0.3724 ; 0.3552 ; 0.1042 ; 0.0740 ; 0.3803 ; 0.1697 ; 0.1525 ; 0.0438 ; 0.0832 ; 0.0468 ; 0.4463 ; 0.2312 ; 0.2240 ; 0.0249 ; 0.2877 ; 0.0062 ; 0.4078 ; 0.0809 ; 0.2202 ; 0.0686 ; 0.2709 ; 0.0965 ; 0.0009 ; 0.0736 ; 0.0728 ; 0.1139 ; 0.0577 ; 0.0394 ; 0.1222 ; 0.4810 ; 0.1781 ; 0.4890 ; 0.2179 ; 0.0206 ; 0.0843 ; 0.0230 ; 0.0211 ; 0.5551 ; 0.0450 ; 0.1259 ; 0.3354 ; 0.0015 ; 0.0303 ; 0.3150 ; 0.2506 ; 0.2144 ; 0.3481 ; 0.1575 ; 0.3006 ; 0.0371 ; 0.3760 ; 0.0410 ; 0.0755 ; 0.2504 ; 0.2378 ; 0.1240 ; 0.3905 ; 0.0125 ; 0.4226 ; 0.7181 ; 0.4474 ; 0.0334 ; 0.4204 ; 0.1277 ; 0.5544 ; 0.5697 ; 0.5100 ; 0.3870 ; 0.0762 ; 0.1409 ; 0.2314 ; 0.3578 ; 0.3984 ; 0.0565 ; 0.0876 ; 0.3597 ; 0.0419 ; 0.3334 ; 0.1256 ; 0.4261 ; 0.3775 ; 0.0018 ; 0.0912 ; 0.3171 ; 0.2916 ; 0.1171 ; 0.7305 ; 0.1738 ; 0.2666 ; 0.4673 ; 0.1694 ; 0.2385 ; 0.4644 ; 0.0212 ; 0.2898 ; 0.6164 ; 0.0065 ; 0.3704 ; 0.3885 ; 0.1031 ; 0.4477 ; 0.5170 ; 0.1323 ; 0.1169 ; 0.4164 ; 0.0064 ; 0.0714 ; 0.2188 ; 0.1659 ; 0.0608 ; 0.1447 ; 0.2667 ; 0.1662 ; 0.2535 ; 0.2186 ; 0.3330 ; 0.5964 ; 0.5879 ; 0.5360 ; 0.4814 ; 0.6349 ; 0.2755 ; 0.2093 ; 0.0042 ; 0.5127 ; 0.6839 ; 0.7067 ; 0.3053 ; 0.7140 ; 0.1952 ; 0.1257 ; 0.0602 ; 0.1504 ; 0.0035 ; 0.2106 ; 0.0079 ; 0.4914 ; 0.3196 ; 0.4048 ; 0.2203 ; 0.2306 ; 0.1434 ; 0.3086 ; 0.3824 ; 0.2604 ; 0.0997 ; 0.4864 ; 0.5781 ; 0.3352 ; 0.4495 ; 0.2435 ; 0.3370 ; 0.2888 ; 0.7457 ; 0.5064 ; 0.2351 ; 0.0023 ; 0.5168 ; 0.3129 ; 0.1032 ; 0.1012 ; 0.0440 ; 0.4324 ; 0.1497 ; 0.2402 ; 0.1505 ; 0.3085 ; 0.3986 ; 0.4994 ; 0.4415 ; 0.1654 ; 0.0783 ; 0.0978 ; 0.0038 ; 0.3315 ; 0.1715 ; 0.2768 ; 0.0214 ; 0.5079 ; 0.2765 ; 0.0031 ; 0.2016 ; 0.1524 ; 0.1476 ; 0.2397 ; 0.2797 ; 0.0013 ; 0.1624 ; 0.3302 ; 0.4724 ; 0.4680 ; 0.1140 ; 0.4263 ; 0.2974 ; 0.1147 ; 0.2050 ; 0.3159 ; 0.2986 ; 0.0849 ; 0.2383 ; 0.3410 ; 0.1876 ; 0.2406 ; 0.0966 ; 0.1717 ; 0.6233 ; 0.2349 ; 0.0701 ; 0.0331 ; 0.0734 ; 0.0044 ; 0.1943 ; 0.2098 ; 0.0076 ; 0.5156 ; 0.2507 ; 0.2321 ; 0.1285 ; 0.3709 ; 0.0329 ; 0.2322 ; 0.6121 ; 0.5020 ; 0.0963 ; 0.2259 ; 0.2426 ; 0.3360 ; 0.4694 ; 0.1749 ; 0.7492 ; 0.2078 ; 0.2364 ; 0.2682 ; 0.1182 ; 0.0478 ; 0.0538 ; 0.2529 ; 0.4719 ; 0.2390 ; 0.0473 ; 0.2627 ; 0.6686 ; 0.1468 ; 0.2120 ; 0.1388 ; 0.4575 ; 0.1053 ; 0.0568 ; 0.2680 ; 0.4307 ; 0.1264 ; 0.4546 ; 0.2095 ; 0.3722 ; 0.6086 ; 0.3669 ; 0.0032 ; 0.2708 ; 0.0413 ; 0.4634 ; 0.5432 ; 0.3079 ; 0.2994 ; 0.1909 ; 0.3863 ; 0.2601 ; 0.2727 ; 0.0352 ; 0.0358 ; 0.3340 ; 0.1200 ; 0.1971 ; 0.2861 ; 0.5342 ; 0.0399 ; 0.4214 ; 0.4359 ; 0.2845 ; 0.0146 ; 0.2997 ; 0.0047 ; 0.1759 ; 0.4368 ; 0.1270 ; 0.4525 ; 0.0037 ; 0.3152 ; 0.4953 ; 0.2528 ; 0.2069 ; 0.4566 ; 0.3932 ; 0.2980 ; 0.3182 ; 0.4344 ; 0.5849 ; 0.0147 ; 0.5151 ; 0.3524 ; 0.2844 ; 0.0299 ; 0.1518 ; 0.1045 ; 0.4627 ; 0.1990 ; 0.0153 ; 0.1325 ; 0.3538 ; 0.0149 ; 0.1560 ; 0.2008 ; 0.0087 ; 0.1677 ; 0.2359 ; 0.2621 ; 0.2801 ; 0.1228 ; 0.4036 ; 0.0160 ; 0.2022 ; 0.0259 ; 0.0423 ; 0.5230 ; 0.4676 ; 0.2835 ; 0.4918 ; 0.6280 ; 0.2099 ; 0.8709 ; 0.1989 ; 0.2026 ; 0.3474 ; 0.6636 ; 0.0292 ; 0.1961 ; 0.4309 ; 0.3683 ; 0.4120 ; 0.1376 ; 0.0979 ; 0.0051 ; 0.4562 ; 0.2532 ; 0.0427 ; 0.2480 ; 0.4669 ; 0.0589 ; 0.8403 ; 0.4626 ; 0.2169 ; 0.6981 ; 0.0878 ; 0.5141 ; 0.1590 ; 0.6227 ; 0.2006 ; 0.2096 ; 0.0624 ; 0.2319 ; 0.3534 ; 0.1740 ; 0.3510 ; 0.2785 ; 0.4624 ; 0.3245 ; 0.2353 ; 0.2953 ; 0.4820 ; 0.0805 ; 0.3891 ; 0.5868 ; 0.2400 ; 0.2862 ; 0.2029 ; 0.7750 ; 0.7128 ; 0.5269 ; 0.5707 ; 0.2126 ; 0.2810 ; 0.5430 ; 0.1722 ; 0.3051 ; 0.2923 ; 0.2693 ; 0.5970 ; 0.0246 ; 0.2159 ; 0.5793 ; 0.2268 ; 0.2615 ; 0.5203 ; 0.4480 ; 0.0307 ; 0.1244 ; 0.5760 ; 0.2391 ; 0.2637 ; 0.1761 ; 0.2658 ; 0.6574 ; 0.2360 ; 0.2987 ; 0.2004 ; 0.1774 ; 0.6168 ; 0.6577 ; 0.1421 ; 0.4896 ; 0.1400 ; 0.2809 ; 0.0039 ; 0.0826 ; 0.3819 ; 0.1945 ; 0.1286 ; 0.4286 ; 0.2228 ; 0.1895 ; 0.5277 ; 0.3920 ; 0.3054 ; 0.2750 ; 0.0102 ; 0.0133 ; 0.6610 ; 0.0401 ; 0.5398 ; 0.2014 ; 0.6626 ; 0.2874 ; 0.3642 ; 0.1863 ; 0.2645 ; 0.6114 ; 0.2623 ; 0.5998 ; 0.4050 ; 0.2463 ; 0.3755 ; 0.3487 ; 0.4379 ; 0.2646 ; 0.2745 ; 0.0909 ; 0.0685 ; 0.3983 ; 0.4954 ; 0.0904 ; 0.4229 ; 0.4529 ; 0.5577 ; 0.1670 ; 0.3199 ; 0.5233 ; 0.0574 ; 0.1782 ; 0.2688 ; 0.0380 ; 0.4567 ; 0.2790 ; 0.5615 ; 0.1813 ; 0.1416 ; 0.2280 ; 0.7523 ; 0.1406 ; 0.5289 ; 0.1300 ; 0.6948 ; 0.0730 ; 0.0112 ; 0.0651 ; 0.6036 ; 0.0145 ; 0.6647 ; 0.3025 ; 0.3858 ; 0.3779 ; 0.2789 ; 0.3193 ; 0.8687 ; 0.2705 ; 0.0942 ; 0.2590 ; 0.4750 ; 0.5202 ; 0.3060 ; 0.0029 ; 0.0127 ; 0.0219 ; 0.5223 ; 0.0444 ; 0.3254 ; 0.1866 ; 0.1776 ; 0.1519 ; 0.3842 ; 0.3077 ; 0.7845 ; 0.0359 ; 0.8010 ; 0.5446 ; 0.1558 ; 0.2597 ; 0.5056 ; 0.7222 ; 0.9606 ; 0.5297 ; 0.3878 ; 0.5745 ; 0.8529 ; 0.6408 ; 0.0048 ; 0.6563 ; 0.3183 ; 0.1129 ; 0.1828 ; 0.2832 ; 0.0355 ; 0.3633 ; 0.0030 ; 0.1726 ; 0.0813 ; 0.2891 ; 0.2117 ; 0.1814 ; 0.2518 ; 0.6794 ; 0.3839 ; 0.2757 ; 0.6153 ; 0.0432 ; 0.3515 ; 0.5839 ; 0.7013 ; 0.1940 ; 0.4850 ; 0.3849 ; 0.4247 ; 0.6156 ; 0.1016 ; 0.1050 ; 0.3314 ; 0.0786 ; 0.2719 ; 0.4205 ; 0.2828 ; 0.2702 ; 0.0068 ; 0.0077 ; 0.2770 ; 0.1215 ; 0.3429 ; 0.0596 ; 0.1836 ; 0.4530 ; 0.7224 ; 0.0014 ; 0.1405 ; 0.2162 ; 0.2764 ; 0.1513 ; 0.2193 ; 0.0333 ; 0.4041 ; 0.3544 ; 0.2135 ; 0.4745 ; 0.1993 ; 0.7368 ; 0.1973 ; 0.1291 ; 0.2467 ; 0.4416 ; 0.3444 ; 0.2231 ; 0.5365 ; 0.3216 ; 0.2334 ; 0.5724 ; 0.5777 ; 0.4619 ; 0.4594 ; 0.6204 ; 0.2635 ; 0.2927 ; 0.0554 ; 0.3101 ; 0.0034 ; 0.0858 ; 0.4084 ; 0.0315 ; 0.5301 ; 0.0947 ; 0.1185 ; 0.2903 ; 0.2133 ; 0.2155 ; 0.3923 ; 0.6620 ; 0.4659 ; 0.1015 ; 0.1801 ; 0.0872 ; 0.5972 ; 0.1068 ; 0.5821 ; 0.0058 ; 0.0417 ; 0.0431 ; 0.1370 ; 0.1672 ; 0.1292 ; 0.0760 ; 0.6357 ; 0.0033 ; 0.4338 ; 0.3192 ; 0.1844 ; 0.4610 ; 0.1123 ; 0.3558 ; 0.3356 ; 0.0964 ; 0.5685 ; 0.5424 ; 0.0095 ; 0.6181 ; 0.4684 ; 0.2438 ; 0.0293 ; 0.6391 ; 0.1987 ; 0.1842 ; 0.0245 ; 0.0407 ; 0.4591 ; 0.5565 ; 0.0320 ; 0.5995 ; 0.0006 ; 0.2192 ; 0.0243 ; 0.0019 ; 0.0442 ; 0.2912 ; 0.3365 ; 0.2464 ; 0.6472 ; 0.4121 ; 0.1803 ; 0.0346 ; 0.2461 ; 0.1583 ; 0.4065 ; 0.4909 ; 0.6470 ; 0.0059 ; 0.1099 ; 0.2143 ; 0.7555 ; 0.6052 ; 0.5267 ; 0.2347 ; 0.2165 ; 0.0080 ; 0.0803 ; 0.4870 ; 0.6846 ; 0.0091 ; 0.1397 ; 0.2077 ; 0.2024 ; 0.2569 ; 0.1795 ; 0.2744 ; 0.2419 ; 0.2289 ; 0.1144 ; 0.0365 ; 0.6802 ; 0.3700 ; 0.2204 ; 0.1159 ; 0.4759 ; 0.3512 ; 0.3247 ; 0.2293 ; 0.1797 ; 0.5247 ; 0.1648 ; 0.5754 ; 0.3024 ; 0.6151 ; 0.3663 ; 0.2581 ; 0.2839 ; 0.5359 ; 0.0397 ; 0.2920 ; 0.6986 ; 0.3770 ; 0.4851 ; 0.2048 ; 0.3581 ; 0.2113 ; 0.1784 ; 0.2152 ; 0.3081 ; 0.2227 ; 0.0470 ; 0.1820 ; 0.4532 ; 0.1174 ; 0.2628 ; 0.3735 ; 0.5587 ; 0.3475 ; 0.1631 ; 0.1100 ; 0.5819 ; 0.4481 ; 0.5148 ; 0.0799 ; 0.0377 ; 0.6144 ; 0.1317 ; 0.3156 ; 0.6455 ; 0.4004 ; 0.0022 ; 0.3492 ; 0.6490 ; 0.0569 ; 0.3540 ; 0.3271 ; 0.2211 ; 0.3902 ; 0.0563 ; 0.0873 ; 0.5051 ; 0.2260 ; 0.4001 ; 0.4879 ; 0.0124 ; 0.2831 ; 0.4549 ; 0.0532 ; 0.4161 ; 0.0959 ; 0.2362 ; 0.0831 ; 0.0418 ; 0.2931 ; 0.6483 ; 0.1115 ; 0.2142 ; 0.0529 ; 0.0475 ; 0.3782 ; 0.3652 ; 0.1419 ; 0.3887 ; 0.2936 ; 0.1798 ; 0.1267 ; 0.1714 ; 0.4524 ; 0.0272 ; 0.1194 ; 0.0615 ; 0.5288 ; 0.3188 ; 0.0274 ; 0.4868 ; 0.1092 ; 0.1265 ; 0.3463 ; 0.2001 ; 0.4421 ; 0.1183 ; 0.1297 ; 0.0139 ; 0.1539 ; 0.3402 ; 0.3195 ; 0.3531 ; 0.3312 ; 0.7482 ; 0.2675 ; 0.4596 ; 0.4996 ; 0.2548 ; 0.4758 ; 0.2102 ; 0.6819 ; 0.0239 ; 0.2505 ; 0.6247 ; 0.0854 ; 0.4049 ; 0.0105 ; 0.0802 ; 0.6504 ; 0.5901 ; 0.7930 ; 0.7249 ; 0.9487 ; 0.4075 ; 0.4762 ; 0.6312 ; 0.6877 ; 0.8618 ; 0.0856 ; 0.9395 ; 0.2857 ; 0.9013 ; 0.7764 ; 0.7807 ; 0.6982 ; 0.7075 ; 0.7618 ; 0.1864 ; 0.6085 ; 0.5414 ; 0.6590 ; 0.2270 ; 0.1477 ; 0.7260 ; 0.4171 ; 0.6315 ; 0.2216 ; 0.1770 ; 0.1444 ; 0.1754 ; 0.6834 ; 0.3959 ; 0.4499 ; 0.0090 ; 0.4183 ; 0.4392 ; 0.2560 ; 0.6118 ; 0.3272 ; 0.1426 ; 0.3791 ; 0.4387 ; 0.4348 ; 0.3282 ; 0.1311 ; 0.1991 ; 0.1872 ; 0.4429 ; 0.5086 ; 0.5103 ; 0.3530 ; 0.2178 ; 0.5888 ; 0.3853 ; 0.3284 ; 0.1657 ; 0.2530 ; 0.2241 ; 0.1204 ; 0.2455 ; 0.1384 ; 0.2825 ; 0.5535 ; 0.4472 ; 0.6184 ; 0.5703 ; 0.7354 ; 0.1887 ; 0.4836 ; 0.2578 ; 0.2294 ; 0.3933 ; 0.0323 ; 0.3455 ; 0.0540 ; 0.3895 ; 0.6245 ; 0.3359 ; 0.1390 ; 0.0379 ; 0.2183 ; 0.1224 ; 0.2600 ; 0.1655 ; 0.3979 ; 0.0662 ; 0.5533 ; 0.5005 ; 0.0416 ; 0.0628 ; 0.0696 ; 0.1663 ; 0.2049 ; 0.1465 ; 0.2175 ; 0.1699 ; 0.8102 ; 0.9247 ; 0.2950 ; 0.1463 ; 0.4924 ; 0.2003 ; 0.1711 ; 0.2684 ; 0.5469 ; 0.0922 ; 0.0135 ; 0.1458 ; 0.3758 ; 0.2913 ; 0.1336 ; 0.2626 ; 0.2715 ; 0.1592 ; 0.3087 ; 0.3780 ; 0.1306 ; 0.0514 ; 0.1597 ; 0.0692 ; 0.2553 ; 0.2163 ; 0.4494 ; 0.2822 ; 0.3572 ; 0.4206 ; 0.1404 ; 0.1652 ; 0.4686 ; 0.1469 ; 0.2632 ; 0.3890 ; 0.5784 ; 0.2084 ; 0.4010 ; 0.4054 ; 0.0224 ; 0.4535 ; 0.1621 ; 0.4925 ; 0.4059 ; 0.5596 ; 0.1392 ; 0.4800 ; 0.1695 ; 0.4639 ; 0.7676 ; 0.1570 ; 0.3862 ; 0.3566 ; 0.5058 ; 0.0182 ; 0.5209 ; 0.5419 ; 0.2033 ; 0.6039 ; 0.4604 ; 0.2377 ; 0.6126 ; 0.6781 ; 0.8802 ; 0.5478 ; 0.3037 ; 0.4897 ; 0.1705 ; 0.2044 ; 0.5947 ; 0.3261 ; 0.3018 ; 0.7838 ; 0.6582 ; 0.6364 ; 0.7894 ; 0.3213 ; 0.0962 ; 0.5278 ; 0.8781 ; 0.8846 ; 0.5657 ; 0.0985 ; 0.3281 ; 0.6927 ; 0.5583 ; 0.8305 ; 0.8514 ; 0.7978 ; 0.8791 ; 0.8670 ; 0.3482 ; 0.4122 ; 0.8477 ; 0.4874 ; 0.7241 ; 0.4182 ; 0.8139 ; 0.5422 ; 0.6434 ; 0.8320 ; 0.8391 ; 0.7053 ; 0.7702 ; 0.3103 ; 0.4872 ; 0.6694 ; 0.1653 ; 0.3443 ; 0.4620 ; 0.5706 ; 0.6329 ; 0.6125 ; 0.4067 ; 0.5687 ; 0.2959 ; 0.3716 ; 0.3818 ; 0.0488 ; 0.6900 ; 0.4450 ; 0.7001 ; 0.7821 ; 0.4308 ; 0.2002 ; 0.2554 ; 0.0092 ; 0.6644 ; 0.1627 ; 0.2575 ; 0.0850 ; 0.1862 ; 0.4559 ; 0.3308 ; 0.6187 ; 0.2256 ; 0.7393 ; 0.5339 ; 0.4373 ; 0.6606 ; 0.4948 ; 0.3809 ; 0.6888 ; 0.2586 ; 0.3987 ; 0.4757 ; 0.3820 ; 0.7997 ; 0.3596 ; 0.6303 ; 0.0236 ; 0.3785 ; 0.7774 ; 0.8243 ; 0.3003 ; 0.2040 ; 0.3449 ; 0.2366 ; 0.5204 ; 0.8082 ; 0.7459 ; 0.7509 ; 0.7972 ; 0.6400 ; 0.2990 ; 0.6090 ; 0.7883 ; 0.7226 ; 0.6035 ; 0.8140 ; 0.8336 ; 0.6643 ; 0.6871 ; 0.5725 ; 0.7762 ; 0.4551 ; 0.1499 ; 0.6078 ; 0.3882 ; 0.4242 ; 0.1135 ; 0.2541 ; 0.5109 ; 0.3466 ; 0.1834 ; 0.2940 ; 0.6517 ; 0.7952 ; 0.3707 ; 0.8407 ; 0.2964 ; 0.2017 ; 0.8146 ; 0.6499 ; 0.3825 ; 0.5001 ; 0.2372 ; 0.2639 ; 0.6288 ; 0.8353 ; 0.4154 ; 0.1526 ; 0.5772 ; 0.6833 ; 0.8048 ; 0.1552 ; 0.4808 ; 0.4256 ; 0.0123 ; 0.8379 ; 0.8627 ; 0.2151 ; 0.5240 ; 0.5641 ; 0.5709 ; 0.8631 ; 0.8090 ; 0.1368 ; 0.4221 ; 0.5016 ; 0.6558 ; 0.2291 ; 0.0999 ; 0.0905 ; 0.2166 ; 0.8573 ; 0.7113 ; 0.8681 ; 0.7613 ; 0.7741 ; 0.4792 ; 0.7785 ; 0.7577 ; 0.7633 ; 0.8172 ; 0.6592 ; 0.8032 ; 0.7692 ; 0.8558 ; 0.8442 ; 0.7936 ; 0.7859 ; 0.6395 ; 0.4051 ; 0.3249 ; 0.6212 ; 0.1430 ; 0.7951 ; 0.5729 ; 0.8615 ; 0.7747 ; 0.7927 ; 0.3725 ; 0.3114 ; 0.7064 ; 0.4602 ; 0.7430 ; 0.0669 ; 0.2531 ; 0.3350 ; 0.0949 ; 0.4228 ; 0.0549 ; 0.3948 ; 0.2788 ; 0.6433 ; 0.3717 ; 0.4648 ; 0.2734 ; 0.6995 ; 0.5072 ; 0.5245 ; 0.1456 ; 0.5862 ; 0.6993 ; 0.5566 ; 0.4731 ; 0.5077 ; 0.6201 ; 0.4693 ; 0.6853 ; 0.8301 ; 0.2384 ; 0.3837 ; 0.6418 ; 0.6734 ; 0.6537 ; 0.4176 ; 0.4687 ; 0.3230 ; 0.0678 ; 0.8790 ; 0.3428 ; 0.6026 ; 0.5645 ; 0.5853 ; 0.2261 ; 0.6356 ; 0.6180 ; 0.4921 ; 0.6632 ; 0.8204 ; 0.5479 ; 0.3864 ; 0.0725 ; 0.6188 ; 0.4092 ; 0.2232 ; 0.4915 ; 0.9228 ; 0.4843 ; 0.0938 ; 0.1854 ; 0.1574 ; 0.2021 ; 0.0984 ; 0.2516 ; 0.5065 ; 0.2670 ; 0.0275 ; 0.5900 ; 0.5638 ; 0.1117 ; 0.1329 ; 0.3579 ; 0.1223 ; 0.3754 ; 0.1051 ; 0.1216 ; 0.5445 ; 0.4752 ; 0.0716 ; 0.0443 ; 0.0767 ; 0.4806 ; 0.5550 ; 0.1367 ; 0.1157 ; 0.0325 ; 0.0451 ; 0.1708 ; 0.5715 ; 0.0894 ; 0.6939 ; 0.0052 ; 0.3733 ; 0.0040 ; 0.7743 ; 0.5960 ; 0.6816 ; 0.4149 ; 0.5066 ; 0.4656 ; 0.3151 ; 0.7932 ; 0.0837 ; 0.3713 ; 0.0273 ; 0.0911 ; 0.1517 ; 0.3616 ; 0.5284 ; 0.5906 ; 0.2012 ; 0.1282 ; 0.5951 ; 0.0368 ; 0.1778 ; 0.0570 ; 0.5530 ; 0.7465 ; 0.0041 ; 0.4698 ; 0.6208 ; 0.0489 ; 0.0684 ; 0.4145 ; 0.4799 ; 0.3000 ; 0.1994 ; 0.4090 ; 0.1883 ; 0.4895 ; 0.1324 ; 0.1912 ; 0.0989 ; 0.5613 ; 0.2153 ; 0.0598 ; 0.6020 ; 0.1632 ; 0.3715 ; 0.6645 ; 0.5937 ; 0.6347 ; 0.4614 ; 0.0215 ; 0.1742 ; 0.1481 ; 0.0535 ; 0.1839 ; 0.4194 ; 0.2373 ; 0.1111 ; 0.1209 ; 0.2481 ; 0.2933 ; 0.0120 ; 0.6392 ; 0.1764 ; 0.7787 ; 0.5340 ; 0.0702 ; 0.0798 ; 0.4133 ; 0.0328 ; 0.1344 ; 0.1393 ; 0.0045 ; 0.2749 ; 0.7412 ; 0.1356 ; 0.1821 ; 0.3460 ; 0.5875 ; 0.5014 ; 0.3125 ; 0.0452 ; 0.3342 ; 0.1639 ; 0.5776 ; 0.3009
GENE_PANEL	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Gene panel.	Sample	IMPACT341 ; IMPACT468 ; IMPACT410 ; WES
MONTHS_ON_STUDY	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	NUMBER	months on study	Patient	
MONTHS_ON_TREATMENT	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	NUMBER	Months on Treatment	Patient	
OTHER_PATIENT_ID	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Legacy DMP patient identifier (DMPnnnn)	Patient	
PATIENT_STUDY_ID	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	patient study id	Patient	
PIK3CA_MUTATION	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	PIK3CA mutation is present.	Sample	YES ; NO
REASON_FOR_TX_DISCONTINUATION	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	reason for tx discontinuation	Patient	
SAMPLE_CLASS	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	The sample classification (i.e., tumor, cellline, xenograph).	Sample	Tumor ; Primary Resection ; Biopsy 1 ; Biopsy 2 ; Biopsy 3 ; Biopsy 4 ; cfDNA ; Xenograft
SAMPLE_ORIGIN	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Sample origin	Sample	FFPE
SNAPSHOT_MUTATIONS	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	snapshot mutations	Sample	Not detected ; NE ; PTEN loss/p110a gain (unconfirmed) ; PIK3CA_pE545K ; PIK3CA_pE542K ; PIK3CA_pH1047R
STATUS	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Status.	Patient	
STUDY_ARM	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	study arm	Patient	
THERAPY	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	therapy	Patient	
TREATMENT_BEST_RESPONSE	HotPink	Breast Cancer (MSK, NPJ Breast Cancer 2019)	STRING	Treatment best response	Patient	
ER	HotPink	Juvenile Papillomatosis and Breast Cancer (MSK,J Pathol. 2015)	STRING	ER	Sample	+
HER2	HotPink	Juvenile Papillomatosis and Breast Cancer (MSK,J Pathol. 2015)	STRING	HER2	Sample	-
DX_PSTAGE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Diagnosis P Stage	Patient	
HISTOLOGY	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Histology	Patient	
MSI_COMMENT	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	MSI Comment	Sample	MICROSATELLITE STABLE (MSS). See MSI note below. ; MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below. ; MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below. ; MICROSATELLITE INSTABILITY-INDETERMINATE. This result is for investigational use only. See MSI note below.
MSI_SCORE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	MSI Score	Sample	1.68 ; 3.96 ; 0.4 ; 0.89 ; 1.33 ; 0.23 ; 1.62 ; 0 ; 0.48 ; 0.49 ; 0.7 ; 0.25 ; 0.17 ; 0.08 ; 2.68 ; 0.59 ; 1.01 ; 1.17 ; 1.37 ; 1.9 ; 0.93 ; 0.09 ; 2.44 ; 0.79 ; 0.58 ; 1.25 ; 2.51 ; 0.42 ; 5.09 ; 0.36 ; 0.37 ; 0.26 ; 0.34 ; 0.07 ; 0.1 ; 0.2 ; 0.9 ; 0.71 ; 1.07 ; 0.16 ; 0.27 ; 6.23 ; 0.14 ; 0.3 ; 1.86 ; 0.47 ; 2.26 ; 4.37 ; 0.22 ; 3.37 ; 0.18 ; 3.43 ; 0.24 ; 0.76 ; 0.91 ; 1.39 ; 1.77 ; 0.78 ; 5.53 ; 0.45 ; 0.62 ; 0.32 ; 0.51 ; 1.36 ; 1.52 ; 2.07 ; 1.57 ; 1.2 ; 0.06 ; 1.22 ; 1.03 ; 1.21 ; 0.97 ; 0.13 ; 2.23 ; 1.11 ; 2.41 ; 1.61 ; 4.3 ; 1.04 ; 2.49 ; 2.69 ; 1.02 ; 1.85 ; 0.57 ; 3.42 ; 0.99 ; 0.8 ; 1.58 ; 1.53 ; 0.56 ; 0.74 ; 1.16 ; 0.38 ; 1.64 ; 3.99 ; 0.73 ; 1.13 ; 1.41 ; 5.43 ; 1.51 ; 0.05 ; 0.28 ; 2.55 ; -1 ; 18.54 ; 1.15 ; 0.64 ; 0.11 ; 0.68 ; 18.84 ; 2.5 ; 1.08 ; 1.6 ; 1.27 ; 0.63 ; 1.23 ; 0.52 ; 1.12 ; 0.88 ; 1.45 ; 0.19 ; 0.65 ; 0.21 ; 1.3 ; 3.09 ; 0.29 ; 0.33 ; 0.54 ; 3.22 ; 2.13 ; 0.66 ; 1 ; 1.43 ; 0.41 ; 2.45 ; 5.7 ; 0.35 ; 1.98 ; 1.32 ; 2.05 ; 1.87 ; 0.39 ; 1.84 ; 1.4 ; 0.72 ; 0.84 ; 1.05 ; 3.14 ; 8.44 ; 3.12 ; 2.6 ; 0.94 ; 16.68 ; 2.93 ; 2.04 ; 1.96 ; 0.55 ; 1.56 ; 1.79 ; 1.65 ; 5.97 ; 0.61 ; 4.97 ; 2.27 ; 1.34 ; 1.46 ; 3.89 ; 0.31 ; 1.49 ; 0.69 ; 0.82 ; 1.42 ; 1.09 ; 16.88 ; 2.86 ; 0.87 ; 0.15 ; 2.58 ; 1.48 ; 1.7 ; 0.83 ; 0.53 ; 0.44 ; 0.77 ; 2.03 ; 2.1 ; 1.44 ; 3.17 ; 2 ; 2.09 ; 0.67 ; 1.59 ; 1.54 ; 2.12 ; 3.32 ; 0.5 ; 1.92 ; 3.62 ; 2.35 ; 2.43 ; 2.97 ; 3.68 ; 3.73 ; 18.38 ; 3.52 ; 3.33 ; 1.31 ; 2.16 ; 0.6 ; 0.12 ; 1.83 ; 4.36 ; 0.81 ; 1.55 ; 0.95 ; 14.52 ; 1.24 ; 2.99 ; 1.38 ; 0.98 ; 1.06 ; 1.66 ; 4.83 ; 2.02 ; 1.35 ; 1.88 ; 2.31 ; 2.75 ; 2.57 ; 2.36 ; 0.85 ; 4.96 ; 3.9 ; 2.87 ; 6.85 ; 0.43 ; 2.4 ; 4.55 ; 3 ; 2.15 ; 3.04 ; 1.63 ; 4.35 ; 2.08 ; 1.71 ; 5.65 ; 3.85 ; 2.8 ; 3.55 ; 2.22 ; 1.97 ; 3.29 ; 0.86 ; 0.75 ; 2.28 ; 2.29 ; 3.51 ; 1.18 ; 2.33 ; 2.48 ; 2.46 ; 3.76 ; 1.91 ; 0.96 ; 3.91 ; 3.7 ; 3.88 ; 3.93 ; 1.14 ; 3.05 ; 1.72 ; 5.04 ; 3.11 ; 3.01 ; 1.26 ; 2.59 ; 1.28 ; 2.89 ; 2.47 ; 2.78 ; 0.92 ; 3.25 ; 3.44 ; 2.2 ; 1.29 ; 3.06 ; 1.74 ; 3.92 ; 2.17 ; 1.89 ; 1.81 ; 3.5 ; 1.82 ; 3.6 ; 2.21 ; 3.47 ; 5.03 ; 3.69 ; 4.7 ; 2.81 ; 2.9 ; 1.47 ; 1.75 ; 2.54 ; 3.3 ; 3.28 ; 4.4 ; 3.21 ; 1.5 ; 0.46 ; 1.1 ; 4.2 ; 3.02 ; 2.01 ; 1.73 ; 3.98 ; 3.18 ; 2.64 ; 1.99 ; 3.26 ; 1.78 ; 3.27 ; 4.79 ; 2.73
MSI_TYPE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	MSI Type	Sample	Stable ; Indeterminate ; Do not report ; Instable
OS_MONTHS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	Overall survival in months since date of sequencing. If patient died before sequencing overall survival in months is set to '0'. If patient is alive and last contact date is before date of sequencing, overall survival in months is set to 'NA'	Patient	
OS_STATUS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Overall patient survival status.	Patient	
PFS_MONTHS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	Progress Free Survival (Months)	Patient	
PFS_STATUS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Progression Free Status	Patient	
RACE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	The text for reporting information about race.	Patient	
REASON_STOP	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Reason Stop	Patient	
RELIGION	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Religion	Patient	
SAMPLE_COVERAGE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	Sample coverage	Sample	799 ; 2610 ; 407 ; 887 ; 1057 ; 850 ; 667 ; 446 ; 842 ; 336 ; 389 ; 674 ; 633 ; 1049 ; 234 ; 549 ; 782 ; 902 ; 445 ; 750 ; 476 ; 477 ; 186 ; 520 ; 274 ; 451 ; 737 ; 541 ; 506 ; 405 ; 670 ; 172 ; 433 ; 565 ; 510 ; 669 ; 283 ; 344 ; 556 ; 618 ; 352 ; 188 ; 778 ; 395 ; 502 ; 508 ; 163 ; 797 ; 767 ; 260 ; 772 ; 501 ; 440 ; 402 ; 762 ; 749 ; 960 ; 738 ; 906 ; 1131 ; 535 ; 834 ; 691 ; 1115 ; 922 ; 678 ; 871 ; 704 ; 952 ; 729 ; 714 ; 831 ; 919 ; 851 ; 621 ; 1062 ; 733 ; 908 ; 989 ; 610 ; 1121 ; 765 ; 693 ; 769 ; 999 ; 1043 ; 627 ; 1012 ; 435 ; 760 ; 660 ; 725 ; 828 ; 796 ; 681 ; 1091 ; 994 ; 297 ; 1094 ; 662 ; 844 ; 432 ; 776 ; 526 ; 746 ; 938 ; 970 ; 878 ; 874 ; 664 ; 900 ; 785 ; 741 ; 415 ; 400 ; 413 ; 652 ; 536 ; 781 ; 563 ; 635 ; 211 ; 416 ; 815 ; 739 ; 625 ; 544 ; 697 ; 953 ; 803 ; 425 ; 801 ; 471 ; 592 ; 686 ; 626 ; 671 ; 475 ; 281 ; 928 ; 1008 ; 293 ; 240 ; 1154 ; 1165 ; 840 ; 1259 ; 1031 ; 680 ; 619 ; 757 ; 811 ; 673 ; 468 ; 310 ; 483 ; 452 ; 504 ; 720
SAMPLE_STATUS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Sample Status	Sample	pre-tx
SO_COMMENTS	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Sign-out comments	Sample	Note: Low tumor content (approximately 20% or less). Negative results should be interpreted with caution.    Note: Assessment of the copy number profile is limited by increased background noise. ; Note: The RAD51B, TSHR and DICER1 copy number losses fall slightly below the cut off criteria for deletion. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 8q. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 1q.          Note: The MYC copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clini ; Note: The FGFR1 copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated.        Note: Low sequencing depth of coverage of 172X, negative results should ; Note: The AXIN2 copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: Low tumor content (approximately 20% or less). Negative results should be interpreted with caution. ; Note: The ERBB2 and RARA copy number gains fall slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution. ; Note: The HOXB13 copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: The FYN and ROS1 copy number gains fall slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: The ERBB2 copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by FISH has been performed ; Note: The PRKAR1A,  SOX9, RARA and H3F3B copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated.      Note: Low tumor content (approximately 20% or le ; minor contamination normal ; Note: The PIK3CA copy number gain falls slightly below the cut off criteria for amplification. Confirmatory testing by an alternate method is suggested, if clinically indicated. ; Note: The ERBB2 p.A37T mutation frequency suggests that the mutation occurs on the amplified allele ; Note: A comparison of variant frequencies suggests the PIK3CA p.E545K mutation is subclonal.    Note: The ERBB2  p.S310F suggests that the mutation occurs on the amplified allele ; Note: The copy number profile is suggestive of an intragenic gain of CDK12 exons7-14. ; Note: Copy number profile is suggestive of a fragmented genome.. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome 1q. Note: Copy number profile is suggestive of broad copy number loss on Chromosome 17q21-25, 6q and 7q. Note: Copy number profile is suggestive of intragenic gain of CDK12 ex ; Note: Copy number profile is suggestive of a fragmented genome. ; Note: The FLCN copy number profile is suggestive of an amplification of exons 4-8 and intragenic deletion of exons 9-14. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arms 8q and 16p. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 1p32-34. ; Note: Copy number profile is suggestive of broad copy number losses on Chromosome arms 5p13, 9p21-24, 12q24, 17p, 17q11, and 17q21-25. Note: Copy number profile is suggestive of broad copy number gains on Chromosome arms 1q and 5q32-35. ; Note: Copy number profile is suggestive of broad copy number loss on Chromosome arms 11q14-24 (including ATM and KMT2A), 16q (including CDH1), and 17p (including TP53). Note: Copy number profile is suggestive of broad copy number gain on Chromosome 1q31-4 ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 21q. ; Note: The copy number profile from the MSK-IMPACT assay and an allele specific copy number analysis by FACETS is consistent with a fragmented genome. See M17-16643 for HER2 FISH analysis performed on a different tissue block from the same specimen. ; Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 8q21-24, including MYC. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 17q including ERBB2. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosomes arm 1q32-44. ; Note: Copy number profile is suggestive of broad copy number gain on Chromosome arms 8q and 17q22-25. Note: Copy number profile is suggestive of broad copy number loss on Chromosome arms 3p13-21.1 (including BAP1), 6q15-23, 9p (including CDKN2A and CDKN2B ; Note: Copy number profile is suggestive of multiple chromosome level losses.
TMB	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	Total number of mutations divided by the length of the total genomic target region captured (mutations/Mbs)	Sample	1.1 ; 2.2 ; 3.3 ; 7.8 ; 8.9 ; 12.3 ; 3.5 ; 6.7 ; 4.5 ; 5.6 ; 0 ; 7 ; 1 ; 2 ; 3.9 ; 3 ; 7.9 ; 9.8 ; 5.9 ; 11.8 ; 4.9 ; 6.9 ; 24.6 ; 8.8 ; 4.4 ; 2.6 ; 1.8 ; 0.9 ; 6.1 ; 5.3 ; 10.5 ; 21.9
TUMOR_PURITY	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	NUMBER	Tumor Purity	Sample	50 ; 60 ; 70 ; 75 ; 30 ; 40 ; 35 ; 20 ; 90 ; 80 ; 10 ; 85 ; 65 ; 95 ; 100
TX_LINE	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Treatment Line	Patient	
TX_LOCATION	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Treatment Location	Patient	
TX_REG	HotPink	MAPK on resistance to anti-HER2 therapy for breast cancer (MSK, Nat Commun. 2022)	STRING	Treatment Regimen	Patient	
APOBEC_SIGNATURE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Enriched APOBEC signature	Patient	
CANCER TYPE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Cancer type	Sample	Breast Cancer
CD3_TILS_COUNTS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	CD3+ cell counts	Patient	
CD3_TILS_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	CD3 tumor-infiltrating lymphocytes (TILS) status.	Patient	
CHROMOSOME_INSTABILITY_INDEX_CIN_	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Chromosome instability index as genome wide measure for copy number alterations	Patient	
CIBERSORT_ABSOLUTE_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Level of immune cells inferred from mRNA using the CIBERSORT algorithm	Patient	
ERBB2_GENE_AMPLIFIED	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Significant gene copy number amplification; based on GISTIC2 calls: thresholded == 2 & continuous > 1	Patient	
ERBB2_PROTEOGENOMIC_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Proteogenomic ERBB2 status: gene copy amflification and outlier protein expression	Patient	
ERBB2_UPDATED_CLINICAL_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Updated clinical ERRB2 status (central IHC for 68 tumors)	Patient	
ER_UPDATED_CLINICAL_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Updated clinical ER status (central IHC for 68 tumors)	Patient	
ESTIMATE_IMMUNE_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Level of immune infiltration inferred from mRNA using the ESTIMATE algorithm	Patient	
ESTIMATE_STROMAL_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Level of stromal cells inferred from mRNA using the ESTIMATE algorithm	Patient	
ESTIMATE_TUMORPURITY	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Tumor purity inferred from mRNA using the ESTIMATE algorithm	Patient	
ISCHEMIA_TIME_IN_MINUTES	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Ischemia time in minutes	Sample	0 ; 1 ; 6 ; 8 ; 4 ; 9 ; 10 ; 15 ; 24 ; 12 ; 21 ; 29 ; 30 ; 11 ; 28 ; 20 ; 19 ; 13 ; 22 ; 16 ; 17 ; 14 ; 7 ; 5 ; 18 ; 26 ; 25
NMF_CLUSTER	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	NMF-based multi-omics subtype	Sample	Basal-I ; HER2-I ; LumA-I ; LumB-I
NMF_CLUSTER_MEMBERSHIP_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Cluster Membership score indicating the representiveness of a tumor in its cluster	Sample	1 ; 0.672 ; 0.782 ; 0.958 ; 0.825 ; 0.734 ; 0.55 ; 0.508 ; 0.915 ; 0.913 ; 0.551 ; 0.555 ; 0.409 ; 0.816 ; 0.854 ; 0.634 ; 0.938 ; 0.99 ; 0.6 ; 0.559 ; 0.93 ; 0.791 ; 0.65 ; 0.779 ; 0.586 ; 0.781 ; 0.535 ; 0.607 ; 0.786 ; 0.683 ; 0.898 ; 0.598 ; 0.771 ; 0.863 ; 0.826 ; 0.333 ; 0.604 ; 0.824 ; 0.577 ; 0.799 ; 0.446 ; 0.569 ; 0.423 ; 0.784 ; 0.383 ; 0.776 ; 0.811 ; 0.648 ; 0.814 ; 0.872 ; 0.72 ; 0.941 ; 0.937 ; 0.75 ; 0.962 ; 0.658 ; 0.637 ; 0.414 ; 0.957 ; 0.903 ; 0.934 ; 0.738 ; 0.588 ; 0.78 ; 0.572 ; 0.632 ; 0.606 ; 0.726 ; 0.978 ; 0.638 ; 0.485 ; 0.862 ; 0.418 ; 0.744 ; 0.809 ; 0.641 ; 0.623 ; 0.91 ; 0.79 ; 0.795 ; 0.472 ; 0.484 ; 0.767 ; 0.618 ; 0.871 ; 0.988 ; 0.828 ; 0.849 ; 0.43 ; 0.533 ; 0.612 ; 0.837 ; 0.371 ; 0.615 ; 0.578 ; 0.69 ; 0.757 ; 0.539 ; 0.711 ; 0.728 ; 0.609 ; 0.481 ; 0.536 ; 0.443 ; 0.392 ; 0.402
NUMBER_OF_NON_SYNONYMOUS_MUTATIONS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Total number of somatic mutations (non-synonymous) in the sample	Patient	
ONCOTREE CODE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Oncotree code	Sample	BRCA
PAM50	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	PAM50 classification	Sample	Basal ; Her2 ; LumA ; LumB ; Normal-like
PR_CLINICAL_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Initial clinical PR status	Patient	
STEMNESS_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Stem cell-like phenotype score	Patient	
TMT_CHANNEL	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	TMT10 reporter ion channel	Sample	127C ; 128C ; 129N ; 127N ; 130C ; 128N ; 126 ; 130N ; 129C ; 130C|127N ; 129C|130C ; 128C|129C|130N ; 126|129N ; 129C|126 ; 127C|130C ; 129C|128C
TMT_PLEX	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	TMT10 plex number	Sample	13 ; 12 ; 2 ; 16 ; 17 ; 1 ; 7 ; 9 ; 3 ; 6 ; 5 ; 11 ; 10 ; 8 ; 4 ; 6|17 ; 2|5 ; 10|12|17 ; 3|11 ; 11|16 ; 8|16 ; 3|17
TNBC_UPDATED_CLINICAL_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Triple Negative Breast Cancer (TNBC) status; based on PG ERBB2, updated clinical ER status; initial clinical PR status	Patient	
TOP2A_GENE_AMPLIFIED	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Significant gene copy number amplification; based on GISTIC2 calls: thresholded == 2 & continuous > 1	Patient	
TOP2A_PROTEOGENOMIC_STATUS	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	STRING	Proteogenomic TOP2A status: gene copy amflification and outlier protein expression	Patient	
XCELL_IMMUNE_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Level of immune cells inferred from mRNA using the xCell algorithm	Patient	
XCELL_STROMAL_SCORE	HotPink	Proteogenomic landscape of breast cancer (CPTAC, Cell 2020)	NUMBER	Level of stromal cells inferred from mRNA using the xCell algorithm	Patient	
DISEASE_STATUS	HotPink	Breast Cancer (HTAN, 2022)	STRING	Disease Status	Patient	
PATIENT_GRADE	HotPink	Breast Cancer (HTAN, 2022)	STRING	Patient Tumor Grade	Patient	
SAMPLE_COLLECTION_METHOD	HotPink	Breast Cancer (HTAN, 2022)	STRING	Sample Collection Method	Sample	Surgical Resection ; Biopsy
SPECIMEN_PRESERVATION_TYPE	HotPink	Breast Cancer (HTAN, 2022)	STRING	The method used for preparing the tissue for examination and study.	Sample	Formalin ; Dimidoester
SPECIMEN_SITE	HotPink	Breast Cancer (HTAN, 2022)	STRING	Specimen Site	Sample	Breast NOS ; Liver ; Bone NOS
SPECIMEN_TYPE	HotPink	Breast Cancer (HTAN, 2022)	STRING	The broad cancer phenotype and site information values for a sample to be processed.	Sample	Tissue NOS
TIME_TO_LAST_FOLLOWUP	HotPink	Breast Cancer (HTAN, 2022)	NUMBER	Time to last followup.	Patient	
ABERRANT_CELL_FRACTION	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	NUMBER	Aberrant Cell Fraction	Sample	0.7 ; 0.77 ; 0.72 ; 0.56 ; 0.5 ; 0.71 ; 0.48 ; 0.6 ; 0.43 ; 0.36 ; 0.84 ; 0.61 ; 0.59 ; 0.81 ; 0.54 ; 0.55 ; 0.53 ; 0.46 ; 0.57 ; 0.67 ; 0.58 ; 0.25 ; 0.47 ; 0.37 ; 0.73 ; 0.62 ; 0.63 ; 0.75 ; 0.64 ; 0.3 ; 0.68 ; 0.74 ; 0.49 ; 0.8 ; 0.65 ; 0.42 ; 0.51 ; 0.45 ; 0.83 ; 0.32 ; 0.41 ; 0.76 ; 0.33 ; 0.35 ; 0.52
HISTOPATHOLOGY	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	STRING	Histopathology	Patient	
MITOTIC_COUNT	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	NUMBER	Mitotic Count	Sample	1 ; 6 ; 53 ; 7 ; 40 ; 19 ; 2 ; 18 ; 21 ; 27 ; 13 ; 3 ; 5 ; 20 ; 14 ; 11 ; 110 ; 48 ; 17 ; 28 ; 8 ; 22 ; 46 ; 9 ; 72 ; 32 ; 33 ; 4 ; 31 ; 26 ; 30 ; 36 ; 24 ; 23 ; 16 ; 90 ; 0 ; 58 ; 10
MITOTIC_SCORE	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	STRING	Mitotic Score	Sample	1 ; 3 ; 2
PLEOMORPHISM_SCORE	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	STRING	Pleomorphism Score	Sample	2 ; 3 ; 1
TUBULE_SCORE	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	STRING	Tubule Score	Sample	3 ; 2 ; 1
TUMOR_PLOIDY	HotPink	Breast Invasive Carcinoma (Sanger, Nature 2012)	STRING	Tumor Ploidy	Sample	
CN_CLUSTER	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	CN cluster.	Sample	3 ; 1 ; 4 ; 2 ; 5
CONVERTED_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Converted Stage	Sample	No_Conversion ; Stage IIA ; Stage IIIA ; Stage I ; Stage IIB ; Stage IIIC ; Stage IV ; Stage IIIB ; Stage
INTEGRATED_CLUSTERS_NO_EXP	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Integrated Clusters (no exp)	Sample	2 ; 1 ; 3 ; 5 ; 4
INTEGRATED_CLUSTERS_UNSUP_EXP	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Integrated Clusters (unsup exp)	Sample	2 ; 1 ; 4 ; 3 ; 5
INTEGRATED_CLUSTERS_WITH_PAM50	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Integrated Clusters (with PAM50)	Sample	2 ; 3 ; 1 ; 4
METASTASIS	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Metastasis.	Patient	
METASTASIS_CODED	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Metastasis-Coded	Sample	Positive ; Negative
METHYLATION_CLUSTER	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Methylation cluster.	Sample	5 ; 4 ; 2 ; 3 ; 1
MIRNA_CLUSTER	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	MICRNA cluster	Sample	3 ; 5 ; 4 ; 6 ; 2 ; 1 ; 7
NODES	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Node	Sample	N3 ; N0 ; N2 ; N1
NODE_CODED	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Node-Coded	Sample	Positive ; Negative
PAM50_SUBTYPE	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	PAM50 subtype	Sample	Basal-like ; HER2-enriched ; Luminal A ; Luminal B ; Normal-like ; LuminalB ; Basal ; LuminalA ; Her2 ; Normal ; Other
RPPA_CLUSTER	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	RPPA Cluster.	Sample	Basal ; X ; LumA/B ; ReacII ; ReacI ; Her2 ; LumA
SIGCLUST_INTRINSIC_MRNA	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	SigClust Intrinsic mRNA	Sample	-13 ; -5 ; -2 ; -1 ; -11 ; 0 ; -12 ; -10 ; -9 ; -3 ; -4 ; -8 ; -7 ; -6
SIGCLUST_UNSUPERVISED_MRNA	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	SigClust Unsupervised mRNA	Sample	0 ; -6 ; -12 ; -11 ; -8 ; -10 ; -5 ; -1 ; -3 ; -9 ; -4 ; -7 ; -2
SURVIVAL_DATA_FORM	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Survival Data Form	Sample	followup ; enrollment
TUMOR_T1_CODED	HotPink	Breast Invasive Carcinoma (TCGA, Nature 2012)	STRING	Tumor--T1 Coded	Sample	T_Other ; T1
DFS_EVENT	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Disease Free Event	Patient	
DFS_MONTHS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Disease free (months) since initial treatment.	Patient	
ER_PCT_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	ER Percent Positivity of the Primary Tumor	Sample	70 ; 0 ; 90 ; 50 ; 80 ; 60 ; 95 ; 100 ; 91 ; 75 ; 1 ; 97 ; 30 ; 65 ; 89 ; 85 ; 86 ; 40 ; 44 ; 1 (weak intensity) ; 5 ; 99 ; 10 ; 98 ; 25 ; 31 ; 87 ; 74 ; 79 ; 96 ; 3 ; 18 ; 93 ; 81 ; 35 ; 84 ; 94 ; 20 ; 9 ; 78 ; 4 ; 42 ; 30-60 ; 14 ; >60 ; 51 ; 77 ; 62 ; 88 ; 29 ; 72 ; 66 ; 57 ; 39 ; 2 ; 11 ; 22 ; 23 ; 13 ; 5 (weak intensity) ; 15 ; 41 ; 67 ; 3 (weak intensity)
ER_STATUS_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	ER Status of the Primary Tumor	Sample	Positive ; Negative ; Unk/ND
HER2_FISH	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 FISH Status of the Sample that Underwent Sequencing.	Sample	Negative ; Positive ; Unk/ND ; Test Failure ; Equivocal ; Negative (outside)
HER2_FISH_RATIO	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 FISH Ratio Value of the Sample that Underwent Sequencing.	Sample	0.24 ; 1.2 ; 1 ; 2 (CN 4.8) ; 4 ; 2.9 ; 1.1 ; 4.0, CN 9.7 ; 1.7 ; 0.88 ; 2.3 ; Not done ; 1.23 ; 2.5 ; 1.4 ; 1.8 (CN 7.5) ; 0.75 ; 4.5 ; 1.5 ; 1.3 ; 3.2 (Heterogenous) ; 1.7 (CN 6.2) ; 0.9 ; 2 (CN 6.4) ; 8.4 ; 6.3 ; 1.6 ; 7 ; Not done (decalcified) ; 2.1 (CN 4.1) ; 1.02 ; 2.6 ; 2.2 ; 3.4 (CN 7.2) ; 2.1 ; 0.74 ; 1.28 ; 3.4 ; 0.94 ; 0.7 ; 1.2 (CN 2.4) ; 0.8 ; 1.9 (CN 4.3) ; 2 ; 3.3 ; 3.29 ; 4.3 (CN 14.3) ; 1.21 ; 6.9 ; 1.37 ; 3.9 ; 2.1 (Heterogenous) ; 3.7 ; 3.6 ; 1.24 ; 16.4 ; 1.8 (CN 5.3) ; 1.3 (OSH, CN 2.0) ; 1.6 (CN 6.6) ; 1.46 ; 2.5 (CN 3) ; 1.3 (OSH CN 4.2) ; 16.6 ; 1.42 ; 1.4 (CN 4.8) ; 4.9 ; 1.9 (CN 4.2) ; 2.4 (heterogenous) ; 3.2 ; 2 (CN 4.6) ; 1.9 ; 0 ; 2.1 (CN 3.7) ; 1.8 ; 2.5 (CN 4.6) ; 1.18 ; 1.39 ; 2.4 (CN 5.9) ; 4.8 ; 1.4 (CN 3.0) (same sample OSH 2.3) ; 1.53 ; 5.4 ; 4.4 ; 1.81
HER2_FISH_RATIO_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 FISH Ratio of the Primary Tumor	Sample	0.7 ; 6.4 ; 1.8 ; 1.2 ; 1 ; 1.4 ; 1.8, MSK failed ; 2.72 ; 0.81 ; 6.5 ; 1.1 ; 2.2 ; 4.1 ; 7.2 ; 0.84 ; 2.8 ; 3.5 ; 1.9 ; 1.7 ; 1.3 ; 1.28 ; 1.33 ; 11.3 ; 7.4 ; 1.43 ; 1.24 ; 1.27 ; 1.6 ; 4 ; 1.15 ; 1.7 (CN 6.2) ; 1.18 ; 1.31 ; 8.9 ; 4.5 ; 2 ; 1.37 ; 5.6 ; 3.3 ; 7 ; 2.3 ; 6.1 ; 6.6 ; 0.6 ; 0.9 ; 2.6 ; 2.7 ; 6.81 ; 6.7 ; 2.5 ; 8.7 ; 2.4 ; 8.6 ; 4.6 ; 4.54 ; 1.7 (Outside: 2.4) ; 6.3 ; 1.4, 1.9 ; 5.02 ; 1.17 ; 5.54 ; 1.13 ; 6 ; 1.9 (CN 4.3) ; 1.5 ; 1.14 ; 11.8 ; 1.91 ; 6.2 ; 3.4 ; 3 ; 8.3 ; 5.11 ; 1.21 ; 2.9 ; 2.1 ; 13.96 ; 4.8 ; 3.6 ; 1.8 (CN 5.3) ; 1.8 (CN 5.6) ; 1.6 (CN 6.6) ; 4.2 ; 1.09 ; 2.1 (CN 6) ; 7.3 ; 1.56 ; 16.6 ; 1.42 ; 1.4 (CN 4.8) ; 1.38 ; 1.77 ; 5.1 ; 1.35 ; 3.2 ; 0.5 ; 1.11 ; 1.23 ; 1.12 ; 4.9 ; 2.4 (heterogenous) ; 2 (CN 4.6) ; 1.69 ; 2.3 (CN 5.4) ; 2.4 (CN 5.9) ; 1.46 ; 1.53 ; 0.8 ; 1.04 ; 4.4 ; 1.34 ; 1.81 ; 1.16
HER2_FISH_STATUS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 FISH Status of the Primary Tumor as per Pathology Report and ASCO/CAP 2013 guideline.	Sample ; Patient	Negative ; Unk/ND ; Positive ; Equivocal ; Indeterminate
HER2_IHC_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 IHC Status of Primary Tumor	Sample	Negative ; Positive ; Unk/ND ; Equivocal ; UNk/ND
HER2_IHC_SCORE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 IHC Value of the Sample that Underwent Sequencing.	Sample ; Patient	0-1+ ; 0+ ; 2+ ; 3+ ; 1+ ; 1-2+ ; 3+ (outside) ; 1+ (focal) ; 2+ (focal) ; 1+ (outside 3+) ; 2-3+ ; 3+ (heterogenous 70-80% pos) ; 1-2+ (outside 3+) ; 2 ; 1 ; 3 ; 0
HER2_IHC_STATUS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 IHC Status of the Sample that Underwent Sequencing.	Sample	Negative ; Equivocal ; Positive ; Unk/ND
HER2_IHC_VALUE_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	HER2 IHC Value of the Primary Tumor	Sample	1+ ; 0-1+ ; 0+ ; 3+ ; 2+ ; 1-2+ ; 3+ (2+ outside) ; 1+ (focal) ; 2+ (3+ outside) ; 1+ (3+ outside)
HER2_STATUS_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall HER2 status of the primary tumor.	Patient	
HR_STATUS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall HR Status of the Sample that Underwent Sequencing.	Sample	Positive ; Negative ; Unk/ND
INVASIVE_CARCINOMA_DX_AGE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Invasive Carcinoma Diagnosis Age	Sample	37 ; 43 ; 38 ; 49 ; 60 ; 41 ; 48 ; 64 ; 53 ; 50 ; 52 ; 46 ; 42 ; 39 ; 61 ; 51 ; 69 ; 36 ; 62 ; 70 ; 63 ; 32 ; 67 ; 55 ; 31 ; 58 ; 33 ; 47 ; 66 ; 54 ; 45 ; 56 ; 40 ; 44 ; 34 ; 59 ; 25 ; 65 ; 29 ; 57 ; 73 ; 80 ; 71 ; 74 ; 27 ; 72 ; 79 ; 76 ; 35 ; 68 ; 30 ; 28 ; 78 ; 77 ; 26 ; 87 ; 75 ; 23 ; 83 ; 81 ; 91 ; 88 ; 82 ; 84 ; 24 ; 85
INVASIVE_CARCINOMA_DX_TIME	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Time to Diagnosis Invasive Carcinoma	Sample	444.87 ; 516.48 ; 449.8 ; 513.68 ; 458.36 ; 592.96 ; 518.55 ; 591.12 ; 722.37 ; 487.73 ; 580.33 ; 764.61 ; 635.82 ; 601.81 ; 620.56 ; 556.51 ; 506.61 ; 463.09 ; 488.55 ; 549.38 ; 735.69 ; 734.57 ; 551.58 ; 617.11 ; 604.05 ; 833.95 ; 434.74 ; 745.16 ; 720.69 ; 444.77 ; 576.78 ; 846.55 ; 610 ; 753.03 ; 386.74 ; 805.99 ; 658.45 ; 374.14 ; 590.2 ; 697.37 ; 397.47 ; 561.02 ; 796.05 ; 559.93 ; 558.13 ; 647.11 ; 611.78 ; 541.68 ; 507.76 ; 547.2 ; 800.3 ; 458.68 ; 565.07 ; 628.36 ; 674.38 ; 662.11 ; 637.04 ; 700.36 ; 429.21 ; 760.66 ; 606.32 ; 480.23 ; 727.96 ; 526.64 ; 457.11 ; 761.41 ; 717.63 ; 626.22 ; 392.5 ; 492.04 ; 659.77 ; 480.99 ; 633.22 ; 409.44 ; 504.21 ; 510.23 ; 452.93 ; 825.43 ; 711.68 ; 522.01 ; 302.2 ; 570.53 ; 719.74 ; 622.5 ; 632.2 ; 643.65 ; 561.97 ; 640.95 ; 802.53 ; 410.43 ; 570.2 ; 438.16 ; 479.41 ; 651.38 ; 491.22 ; 795.03 ; 460.46 ; 461.68 ; 676.25 ; 783.45 ; 598.91 ; 645.26 ; 512.6 ; 405.03 ; 581.12 ; 579.44 ; 395.13 ; 554.28 ; 605.3 ; 654.61 ; 466.15 ; 443.95 ; 556.15 ; 612.11 ; 347.14 ; 564.51 ; 655.3 ; 668.95 ; 636.02 ; 585.39 ; 397.01 ; 776.61 ; 629.54 ; 427.8 ; 578.49 ; 368.98 ; 702.83 ; 393.65 ; 603.88 ; 410.46 ; 682.99 ; 873.59 ; 499.7 ; 642.3 ; 492.27 ; 709.74 ; 429.44 ; 958.19 ; 484.34 ; 649.38 ; 672.37 ; 618.91 ; 852.93 ; 563.68 ; 524.87 ; 612.83 ; 684.84 ; 597.14 ; 578.39 ; 561.35 ; 777.01 ; 740.66 ; 554.21 ; 519.51 ; 375.43 ; 615.23 ; 525.86 ; 434.97 ; 604.31 ; 765.72 ; 889.7 ; 569.8 ; 562.8 ; 653.22 ; 604.61 ; 550.95 ; 615.1 ; 590.63 ; 574.44 ; 579.08 ; 322.7 ; 762.99 ; 403.36 ; 530.43 ; 454.38 ; 691.68 ; 536.74 ; 599.18 ; 864.28 ; 548.65 ; 644.97 ; 615.69 ; 745.03 ; 532.43 ; 679.24 ; 646.94 ; 871.68 ; 480.39 ; 757.43 ; 676.78 ; 625.66 ; 466.48 ; 764.97 ; 638.03 ; 662.99 ; 571.38 ; 542.6 ; 533.75 ; 799.7 ; 709.77 ; 639.47 ; 687.73 ; 609.08 ; 710.23 ; 949.7 ; 478.72 ; 628.91 ; 661.84 ; 839.64 ; 802.89 ; 682.47 ; 614.21 ; 465.43 ; 399.8 ; 407.24 ; 502.37 ; 916.41 ; 805.46 ; 418.62 ; 699.44 ; 692.7 ; 507.8 ; 572.17 ; 441.74 ; 661.09 ; 565.2 ; 586.12 ; 731.05 ; 503.68 ; 458.19 ; 798.62 ; 521.51 ; 791.68 ; 558.49 ; 691.18 ; 697.63 ; 532.3 ; 409.14 ; 629.08 ; 548.62 ; 454.97 ; 806.22 ; 691.35 ; 684.97 ; 703.62 ; 508.88 ; 782.63 ; 437.3 ; 775.13 ; 518.72 ; 434.61 ; 619.64 ; 568.62 ; 478.68 ; 685.69 ; 741.22 ; 651.02 ; 816.28 ; 450.36 ; 448.16 ; 702.2 ; 411.51 ; 473.13 ; 460.36 ; 814.31 ; 512.24 ; 693.62 ; 647.07 ; 566.38 ; 539.18 ; 444.34 ; 480.59 ; 582.57 ; 363.42 ; 361.68 ; 848.78 ; 461.12 ; 962.8 ; 494.87 ; 533.42 ; 488.91 ; 602.57 ; 826.88 ; 709.64 ; 570.79 ; 578.88 ; 781.64 ; 351.38 ; 393.88 ; 563.22 ; 696.58 ; 382.8 ; 676.58 ; 578.85 ; 678.36 ; 738.55 ; 487.83 ; 665.86 ; 653.32 ; 633.09 ; 486.18 ; 558.36 ; 757.76 ; 575.92 ; 650.72 ; 494.01 ; 721.15 ; 712.5 ; 748.22 ; 466.64 ; 793.62 ; 720.76 ; 720.26 ; 845.43 ; 530.46 ; 695 ; 502.27 ; 792.43 ; 911.55 ; 722.11 ; 417.17 ; 804.67 ; 669.7 ; 340.56 ; 624.28 ; 442.86 ; 701.35 ; 533.95 ; 614.01 ; 456.81 ; 674.44 ; 320.69 ; 577.04 ; 732.34 ; 714.38 ; 541.48 ; 514.8 ; 494.93 ; 624.57 ; 530.95 ; 550.36 ; 410.36 ; 395.03 ; 586.88 ; 767.66 ; 610.2 ; 573.85 ; 765.36 ; 554.61 ; 703.49 ; 847.86 ; 557.04 ; 676.91 ; 575.26 ; 628.95 ; 442.7 ; 675.49 ; 491.32 ; 675.03 ; 639.61 ; 482.66 ; 574.28 ; 641.88 ; 387.11 ; 799.24 ; 866.84 ; 610.69 ; 501.05 ; 581.05 ; 621.28 ; 396.18 ; 303.82 ; 479.38 ; 672.11 ; 609.67 ; 487.47 ; 615.59 ; 879.84 ; 629.8 ; 608.72 ; 336.48 ; 574.87 ; 684.47 ; 388.91 ; 664.18 ; 608.98 ; 588.32 ; 622.86 ; 711.94 ; 543.49 ; 592.93 ; 461.05 ; 549.9 ; 555.92 ; 520.76 ; 511.22 ; 612.7 ; 515.59 ; 646.48 ; 739.08 ; 559.74 ; 656.74 ; 375.26 ; 618.09 ; 443.55 ; 526.91 ; 963.85 ; 520.33 ; 688.68 ; 454.7 ; 364.08 ; 458.22 ; 496.88 ; 483.03 ; 321.81 ; 735.63 ; 512.99 ; 833.06 ; 441.61 ; 638.98 ; 738.98 ; 597.43 ; 554.41 ; 725.16 ; 716.58 ; 546.41 ; 480.69 ; 415.39 ; 631.38 ; 877.7 ; 781.74 ; 688.82 ; 669.64 ; 886.51 ; 497.43 ; 376.84 ; 649.61 ; 621.51 ; 736.94 ; 408.42 ; 375.92 ; 515.66 ; 698.65 ; 800.66 ; 397.4 ; 680.1 ; 559.44 ; 759.57 ; 524.51 ; 599.47 ; 606.68 ; 758.59 ; 503.91 ; 545.3 ; 463.68 ; 561.91 ; 472.6 ; 606.91 ; 678.59 ; 667.63 ; 541.05 ; 585.79 ; 497.8 ; 381.81 ; 688.75 ; 639.87 ; 735.49 ; 513.75 ; 590.3 ; 644.7 ; 686.64 ; 584.28 ; 562.11 ; 601.78 ; 587.17 ; 519.57 ; 386.71 ; 542.96 ; 626.15 ; 621.15 ; 814.34 ; 745.1 ; 726.05 ; 798.95 ; 395.66 ; 573.36 ; 499.38 ; 465.26 ; 735.13 ; 480.82 ; 587.86 ; 626.48 ; 664.28 ; 713.19 ; 577.4 ; 462.93 ; 654.51 ; 787.04 ; 612.37 ; 696.32 ; 727.6 ; 570.03 ; 571.32 ; 633.62 ; 778.45 ; 758.49 ; 698.45 ; 350.49 ; 934.87 ; 486.55 ; 692.73 ; 871.32 ; 709.51 ; 693.75 ; 384.7 ; 839.9 ; 386.81 ; 385.43 ; 574.24 ; 509.24 ; 836.74 ; 502.76 ; 555 ; 497.34 ; 681.32 ; 739.24 ; 721.91 ; 665.16 ; 546.78 ; 728.62 ; 533.19 ; 857.53 ; 801.02 ; 774.54 ; 420.39 ; 492.11 ; 335.23 ; 555.03 ; 600.13 ; 418.98 ; 622.53 ; 646.41 ; 576.91 ; 508.39 ; 750.03 ; 825.26 ; 605.13 ; 766.64 ; 681.41 ; 417.76 ; 582.07 ; 765.33 ; 659.31 ; 722.99 ; 671.25 ; 427.6 ; 768.16 ; 340.59 ; 540.92 ; 490.07 ; 469.87 ; 927.2 ; 437.01 ; 677.43 ; 517.93 ; 517.43 ; 496.68 ; 472.2 ; 767.53 ; 709.7 ; 542.01 ; 566.61 ; 430.39 ; 917.83 ; 763.49 ; 734.84 ; 699.77 ; 681.61 ; 677.4 ; 729.84 ; 586.64 ; 632.27 ; 437.11 ; 559.38 ; 462.24 ; 655.66 ; 672.17 ; 640.82 ; 790.69 ; 453.45 ; 847.37 ; 653.26 ; 676.71 ; 841.74 ; 693.29 ; 451.61 ; 645.43 ; 335.49 ; 506.97 ; 777.17 ; 618.78 ; 655.16 ; 421.02 ; 571.74 ; 445.46 ; 520.43 ; 612.93 ; 643.39 ; 405 ; 383.68 ; 417.27 ; 811.35 ; 555.56 ; 375.03 ; 500.59 ; 808.45 ; 425.49 ; 497.4 ; 715.49 ; 715.69 ; 469.34 ; 669.54 ; 519.77 ; 591.51 ; 705 ; 687.17 ; 644.47 ; 610.89 ; 477.63 ; 659.87 ; 647.57 ; 634.64 ; 762.93 ; 392.04 ; 604.24 ; 768.78 ; 629.31 ; 491.91 ; 475.07 ; 547.47 ; 487.89 ; 492.66 ; 632.66 ; 667.6 ; 700.26 ; 754.77 ; 507.96 ; 460.39 ; 476.02 ; 494.84 ; 463.98 ; 413.72 ; 739.11 ; 522.93 ; 361.05 ; 418.68 ; 359.01 ; 857.01 ; 418.65 ; 724.77 ; 695.66 ; 481.81 ; 771.02 ; 666.78 ; 552.7 ; 641.78 ; 814.51 ; 320.53 ; 648.06 ; 556.28 ; 558.09 ; 536.61 ; 537.04 ; 713.62 ; 632.76 ; 631.12 ; 789.34 ; 690.66 ; 501.28 ; 805.82 ; 650.95 ; 337.8 ; 314.01 ; 701.15 ; 767.7 ; 428.52 ; 1045.1 ; 734.51 ; 763.75 ; 535.13 ; 462.99 ; 598.85 ; 787.76 ; 529.01 ; 501.41 ; 632.14 ; 493.82 ; 760.07 ; 493.03 ; 675.89 ; 511.84 ; 520.26 ; 477.53 ; 632.93 ; 748.26 ; 531.41 ; 627.37 ; 489.54 ; 680.2 ; 664.31 ; 453.39 ; 687.37 ; 781.22 ; 806.32 ; 386.18 ; 782.14 ; 542.93 ; 592.57 ; 880.79 ; 396.05 ; 496.81 ; 544.28 ; 497.86 ; 651.94 ; 728.06 ; 858.29 ; 758.72 ; 711.74 ; 781.81 ; 619.93 ; 476.97 ; 566.97 ; 583.22 ; 698.55 ; 448.09 ; 676.12 ; 598.98 ; 487.99 ; 882.89 ; 447.7 ; 470.03 ; 762.14 ; 781.97 ; 933.65 ; 601.45 ; 463.65 ; 727.8 ; 630.99 ; 538.36 ; 658.26 ; 547.63 ; 518.16 ; 951.94 ; 803.98 ; 597.83 ; 731.12 ; 360.1 ; 550.72 ; 582.86 ; 660.36 ; 547.83 ; 624.24 ; 431.81 ; 503.13 ; 359.74 ; 901.38 ; 751.84 ; 373.26 ; 448.49 ; 793.72 ; 567.04 ; 639.24 ; 473.95 ; 581.09 ; 613.68 ; 531.91 ; 782.47 ; 639.97 ; 675.56 ; 809.7 ; 772.63 ; 622.01 ; 843.62 ; 754.93 ; 271.51 ; 680.86 ; 654.24 ; 652.04 ; 348.68 ; 374.05 ; 678.45 ; 644.51 ; 672.99 ; 644.87 ; 384.77 ; 561.18 ; 420.59 ; 642.43 ; 492.17 ; 422.34 ; 575.49 ; 482.11 ; 816.64 ; 612.24 ; 874.93 ; 373.19 ; 673.95 ; 459.28 ; 842.47 ; 753.78 ; 354.08 ; 500.46 ; 680.56 ; 504.67 ; 576.74 ; 680.49 ; 605.53 ; 477.27 ; 368.68 ; 562.37 ; 692.17 ; 596.68 ; 831.45 ; 653.85 ; 439.74 ; 491.38 ; 490 ; 837.04 ; 337.4 ; 558.32 ; 372.8 ; 392.24 ; 674.14 ; 752.3 ; 826.51 ; 513.91 ; 362.96 ; 818.98 ; 690.72 ; 494.54 ; 653.03 ; 609.54 ; 920.2 ; 660.16 ; 830.07 ; 673.09 ; 699.28 ; 500 ; 605.33 ; 705.95 ; 533.36 ; 592.7 ; 629.11 ; 607.11 ; 681.97 ; 623.22 ; 604.64 ; 566.35 ; 558.85 ; 660.2 ; 565.86 ; 780.36 ; 555.86 ; 1002.2 ; 566.74 ; 685.76 ; 760.72 ; 488.98 ; 700.43 ; 432.07 ; 731.84 ; 817.14 ; 494.34 ; 551.22 ; 613.26 ; 489.9 ; 636.68 ; 371.32 ; 710.2 ; 450 ; 433.59 ; 630.69 ; 715.43 ; 642.01 ; 518.59 ; 600.72 ; 586.84 ; 484.57 ; 643.98 ; 692.63 ; 575.95 ; 669.31 ; 727.99 ; 848.26 ; 619.05 ; 788.16 ; 445.23 ; 638.45 ; 977.24 ; 785.79 ; 475.26 ; 777.7 ; 932.17 ; 472.07 ; 819.41 ; 457.47 ; 801.32 ; 774.08 ; 565.69 ; 444.47 ; 497.66 ; 541.45 ; 872.11 ; 456.78 ; 925.23 ; 607.43 ; 672.7 ; 520.53 ; 569.38 ; 452.24 ; 408.75 ; 446.94 ; 586.91 ; 743.42 ; 600.16 ; 607.93 ; 528.98 ; 672.07 ; 840.66 ; 436.45 ; 564.05 ; 536.15 ; 436.55 ; 576.22 ; 950 ; 665.1 ; 779.14 ; 862.17 ; 878.39 ; 597.01 ; 537.4 ; 539.21 ; 658.65 ; 803.85 ; 780.66 ; 551.25 ; 703.72 ; 409.47 ; 466.28 ; 470.95 ; 662.17 ; 769.57 ; 635 ; 612.17 ; 781.51 ; 737.43 ; 450.79 ; 612.8 ; 639.64 ; 516.02 ; 487.01 ; 751.61 ; 578.62 ; 641.05 ; 477.89 ; 705.36 ; 574.97 ; 598.55 ; 843.39 ; 758.85 ; 362.5 ; 417.57 ; 679.77 ; 593.49 ; 801.35 ; 402.96 ; 719.14 ; 743.19 ; 492.4 ; 803.75 ; 569.61 ; 322.04 ; 800.76 ; 649.28 ; 704.51 ; 712.99 ; 683.91 ; 421.05 ; 800.07 ; 349.8 ; 613.91 ; 694.54 ; 657.73 ; 789.77 ; 795.43 ; 710.1 ; 637.83 ; 693.45 ; 809.38 ; 650.56 ; 432.34 ; 485.1 ; 627.27 ; 567.66 ; 746.48 ; 689.41 ; 675.07 ; 758.26 ; 567.27 ; 613.03 ; 428.75 ; 432.27 ; 640.56 ; 570.16 ; 718.91 ; 717.07 ; 652.37 ; 570.76 ; 700.2 ; 744.8 ; 615.56 ; 716.32 ; 484.8 ; 634.44 ; 767.2 ; 652.43 ; 656.78 ; 707.01 ; 593.36 ; 389.61 ; 577.99 ; 623.75 ; 573.82 ; 770.23 ; 664.64 ; 421.74 ; 714.51 ; 949.31 ; 556.84 ; 538.78 ; 1092.47 ; 650.49 ; 571.45 ; 672.43 ; 587.93 ; 505 ; 601.32 ; 674.7 ; 491.35 ; 399.41 ; 626.05 ; 497.96 ; 402.4 ; 550.16 ; 534.7 ; 562.86 ; 445.95 ; 704.21 ; 663.09 ; 778.85 ; 664.77 ; 817.8 ; 808.22 ; 929.01 ; 553.49 ; 623.95 ; 600.89 ; 540.72 ; 462.14 ; 750.07 ; 599.57 ; 718.49 ; 951.97 ; 520.36 ; 489.44 ; 708.78 ; 615.89 ; 741.97 ; 401.32 ; 498.85 ; 593.75 ; 473.32 ; 605.66 ; 725.07 ; 577.24 ; 592.4 ; 616.38 ; 403.39 ; 532.89 ; 722.4 ; 813.59 ; 670.26 ; 528.26 ; 787.7 ; 869.38 ; 793.52 ; 408.68 ; 583.62 ; 767.73 ; 812.93 ; 435.46 ; 605.43 ; 707.17 ; 544.84 ; 370.79 ; 741.15 ; 534.41 ; 733.98 ; 838.75 ; 400.76 ; 659.14 ; 661.41 ; 483.65 ; 703.98 ; 1053.39 ; 553.75 ; 750.79 ; 634.47 ; 750.43 ; 574.54 ; 687.24 ; 735.72 ; 627.17 ; 919.38 ; 690.1 ; 555.79 ; 563.06 ; 540.43 ; 472.01 ; 586.78 ; 450.46 ; 328.62 ; 760.56 ; 681.25 ; 699.87 ; 671.74 ; 646.15 ; 723.06 ; 591.25 ; 808.72 ; 420.72 ; 444.93 ; 602.93 ; 496.12 ; 507.34 ; 928.45 ; 746.71 ; 552.11 ; 580.46 ; 478.42 ; 990.13 ; 467.11 ; 580.16 ; 540.66 ; 642.63 ; 730.92 ; 705.26 ; 767.01 ; 836.58 ; 927.04 ; 704.61 ; 687.5 ; 951.32 ; 724.21 ; 1013.32 ; 907.53 ; 416.81 ; 779.44 ; 462.89 ; 432.17 ; 638.88 ; 430.53 ; 799.01 ; 725.3 ; 738.19 ; 421.12 ; 698.32 ; 378.75 ; 865.07 ; 643.59 ; 473.09 ; 678.06 ; 593.29 ; 631.18 ; 849.24 ; 698.06 ; 796.64 ; 726.32 ; 586.18 ; 877.57 ; 589.93 ; 841.64 ; 468.59 ; 721.61 ; 663.32 ; 702.73 ; 828.52 ; 717.11 ; 544.01 ; 633.32 ; 699.8 ; 894.84 ; 425.76 ; 671.18 ; 554.9 ; 839.38 ; 423.75 ; 768.09 ; 491.88 ; 542.76 ; 536.18 ; 389.05 ; 570.43 ; 625.63 ; 346.18 ; 584.7 ; 605.99 ; 915.82 ; 517.01 ; 567.83 ; 552.37 ; 581.25 ; 802.66 ; 593.88 ; 691.71 ; 794.31 ; 670.95 ; 933.72 ; 624.84 ; 631.74 ; 431.25 ; 723.36 ; 387.27 ; 540.23 ; 390.95 ; 472.96 ; 444.51 ; 662.73 ; 532.76 ; 492.01 ; 685.79 ; 595.26 ; 496.28 ; 704.08 ; 517.8 ; 485.66 ; 726.74 ; 651.15 ; 666.81 ; 428.78 ; 881.05 ; 497.04 ; 607.53 ; 621.58 ; 457.73 ; 707.76 ; 508.65 ; 571.22 ; 645.72 ; 697.53 ; 738.75 ; 699.61 ; 846.71 ; 792.57 ; 813.45 ; 779.93 ; 429.8 ; 677.04 ; 787.66 ; 688.32 ; 917.99 ; 728.19 ; 303.03 ; 516.74 ; 528.59 ; 939.01 ; 699.31 ; 493.45 ; 425.33 ; 832.01 ; 555.89 ; 846.88 ; 942.04 ; 693.91 ; 884.31 ; 522.66 ; 716.12 ; 452.76 ; 762.01 ; 793.19 ; 478.59 ; 661.71 ; 740.03 ; 790.13 ; 498.82 ; 758.39 ; 658.78 ; 665.56 ; 954.44 ; 744.77 ; 477.99 ; 792.3 ; 820.56 ; 428.06 ; 951.74 ; 818.03 ; 843.78 ; 447.11 ; 778.32 ; 667.76 ; 820.36 ; 761.35 ; 550.13 ; 472.34 ; 655.23 ; 878.06 ; 816.18 ; 568.65 ; 588.45 ; 723.75 ; 935.33 ; 361.71 ; 637.99 ; 945.13 ; 802.99 ; 495.95 ; 870.76 ; 612.07 ; 580.23 ; 813.65 ; 605.16 ; 825.3 ; 733.09 ; 637.66 ; 618.72 ; 607.76 ; 563.75 ; 647.2 ; 666.35 ; 686.18 ; 649.08 ; 786.35 ; 772.93 ; 463.03 ; 475.2 ; 571.64 ; 551.09 ; 738.65 ; 543.36 ; 606.45 ; 581.74 ; 585.13 ; 498.36 ; 691.12 ; 452.5 ; 653.29 ; 438.19 ; 753.95 ; 910.56 ; 917.17 ; 605.56 ; 368.82 ; 795.89 ; 864.64 ; 772.83 ; 867.6 ; 698.03 ; 922.8 ; 544.77 ; 780.76 ; 785.66 ; 742.99 ; 568.49 ; 373.52 ; 908.65 ; 644.21 ; 728.03 ; 888.55 ; 768.72 ; 556.55 ; 506.78 ; 904.77 ; 399.24 ; 967.73 ; 934.31 ; 613.45 ; 585.07 ; 619.28 ; 649.64 ; 673.26 ; 652.6 ; 569.74 ; 904.84 ; 749.57 ; 536.51 ; 760.26 ; 737.07 ; 626.88 ; 478.75 ; 705.72 ; 555.07 ; 743.06 ; 589.97 ; 814.38 ; 771.81 ; 542.3 ; 531.74 ; 615.82 ; 536.55 ; 903.52 ; 569.9 ; 811.48 ; 798.32 ; 576.88 ; 858.62 ; 453.49 ; 704.64 ; 454.34 ; 785.56 ; 752.93 ; 551.61 ; 761.81 ; 876.94 ; 413.91 ; 610.23 ; 647.34 ; 994.31 ; 511.41 ; 679.7 ; 718.52 ; 609.34 ; 575.13 ; 551.97 ; 719.28 ; 637.86 ; 545.36 ; 393.85 ; 706.48 ; 754.64 ; 909.24 ; 798.09 ; 577.57 ; 562.96 ; 375.72 ; 490.72 ; 928.82 ; 503.78 ; 969.97 ; 677.63 ; 286.68 ; 757.2 ; 369.67 ; 587.37 ; 479.7 ; 757.24 ; 747.93 ; 581.61 ; 498.42 ; 548.03 ; 863.78 ; 630.79 ; 580.3 ; 558.39 ; 539.44 ; 676.51 ; 744.51 ; 455.69 ; 633.52 ; 506.58 ; 656.35 ; 849.61 ; 959.18 ; 635.33 ; 505.3 ; 795.53 ; 695.86 ; 505.36 ; 810.26 ; 693.85 ; 444.7 ; 862.24 ; 594.7 ; 807.11 ; 468.75 ; 737.53 ; 731.64 ; 673.03 ; 714.21 ; 898.16 ; 832.53 ; 614.84 ; 544.08 ; 639.38 ; 654.05 ; 571.09 ; 500.53 ; 480.86 ; 660.03 ; 707.66 ; 772.37 ; 621.84 ; 865.3 ; 592.14 ; 698.26 ; 632.86 ; 870.13 ; 593.06 ; 780.26 ; 769.14 ; 733.52 ; 352.3 ; 892.96 ; 578.19 ; 286.71 ; 587.73 ; 611.51 ; 537.83 ; 621.74 ; 567.2 ; 553.55 ; 887.07 ; 793.45 ; 848.82 ; 855.03 ; 837.01 ; 357.8 ; 539.24 ; 740.49 ; 644.54 ; 693.26 ; 918.36 ; 488.42 ; 502.4 ; 847.96 ; 608.26 ; 588.68 ; 969.77 ; 849.7 ; 458.09 ; 991.45 ; 755.39 ; 697.11 ; 559.8 ; 659.44 ; 677.89 ; 600.03 ; 781.61 ; 925.76 ; 829.28 ; 917.34 ; 623.98 ; 567.4 ; 801.58 ; 927.89 ; 720.92 ; 1025.39 ; 658.68 ; 630.03 ; 724.01 ; 695.16 ; 934.84 ; 1011.61 ; 645.59 ; 646.38 ; 819.44 ; 789.08 ; 822.6 ; 794.61 ; 885.56 ; 690.56 ; 578.13 ; 711.22 ; 458.82 ; 623.49 ; 672.57 ; 813.52 ; 757.89 ; 850.89 ; 457.3 ; 867.89 ; 318.06 ; 803.16 ; 941.94 ; 627.34 ; 640.76 ; 585.26 ; 527.6 ; 869.34 ; 698.85 ; 830.56 ; 519.67 ; 565.1 ; 584.77 ; 821.94 ; 789.51 ; 499.11 ; 690.53 ; 646.78 ; 684.41 ; 344.67 ; 655.76 ; 840.86 ; 615.49 ; 768.55 ; 635.46 ; 871.12 ; 618.59 ; 450.63 ; 564.24 ; 699.67 ; 621.78 ; 897.73 ; 780.33 ; 777.99 ; 736.41 ; 528.65 ; 903.32 ; 633.98 ; 510.46 ; 609.7 ; 674.64 ; 586.15 ; 624.34 ; 762.17 ; 566.68 ; 784.54 ; 742.6 ; 302.86 ; 872.8 ; 377.2 ; 753.52 ; 544.38 ; 793.85 ; 571.25 ; 923.39 ; 530.79 ; 787.8 ; 564.8 ; 735.53 ; 827.53 ; 687.86 ; 879.64 ; 895.53 ; 657.37 ; 742.57 ; 806.41 ; 732.07 ; 903.42 ; 608.36 ; 554.05 ; 781.91 ; 683.95 ; 563.32 ; 785.1 ; 748.42 ; 544.97 ; 711.64 ; 578.55 ; 821.61 ; 764.84 ; 807.7
LAST_CONTACT_DAYS_TO	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Time of the last follow up in days (reference: date of birth).	Patient	
LATERALITY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	For tumors in paired organs, designates the side on which the cancer originates.	Patient	
MENOPAUSAL_STATUS_AT_DIAGNOSIS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Menopausal Status At Diagnosis	Patient	
METASTATIC_DZ_FUP	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Indicate metastatic disease at last followup.	Patient	
METASTATIC_RECURRENCE_TIME_MONTHS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Months between diagnosis of the primary tumor and metastatic recurrence.	Patient	
M_STAGE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	M Stage	Patient	
NGS_SAMPLE_COLLECTION_TIME	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	NGS Sample Collection Time Period	Sample	445 ; 517 ; 534 ; 618 ; 489 ; 593 ; 744 ; 761 ; 825 ; 881 ; 567 ; 604 ; 581 ; 765 ; 746 ; 692 ; 723 ; 633 ; 563 ; 578 ; 500 ; 538 ; 576 ; 788 ; 736 ; 627 ; 626 ; 790 ; 875 ; 637 ; 834 ; 480 ; 854 ; 838 ; 836 ; 608 ; 850 ; 615 ; 754 ; 391 ; 815 ; 819 ; 404 ; 398 ; 590 ; 728 ; 621 ; 898 ; 895 ; 726 ; 640 ; 718 ; 755 ; 612 ; 564 ; 591 ; 609 ; 605 ; 575 ; 800 ; 459 ; 565 ; 630 ; 682 ; 671 ; 735 ; 700 ; 762 ; 619 ; 488 ; 729 ; 532 ; 537 ; 504 ; 523 ; 763 ; 724 ; 644 ; 393 ; 492 ; 660 ; 482 ; 634 ; 471 ; 603 ; 556 ; 508 ; 528 ; 303 ; 628 ; 623 ; 720 ; 670 ; 772 ; 571 ; 791 ; 803 ; 411 ; 455 ; 487 ; 666 ; 507 ; 506 ; 677 ; 823 ; 690 ; 648 ; 543 ; 454 ; 583 ; 622 ; 707 ; 413 ; 554 ; 606 ; 681 ; 698 ; 655 ; 467 ; 553 ; 468 ; 743 ; 701 ; 348 ; 405 ; 725 ; 669 ; 636 ; 654 ; 587 ; 805 ; 873 ; 552 ; 884 ; 369 ; 704 ; 415 ; 683 ; 573 ; 600 ; 649 ; 431 ; 1003 ; 652 ; 721 ; 673 ; 717 ; 919 ; 853 ; 802 ; 820 ; 635 ; 561 ; 777 ; 741 ; 804 ; 625 ; 452 ; 857 ; 891 ; 818 ; 687 ; 653 ; 596 ; 520 ; 645 ; 579 ; 323 ; 768 ; 447 ; 693 ; 586 ; 715 ; 909 ; 661 ; 617 ; 745 ; 597 ; 680 ; 647 ; 872 ; 495 ; 486 ; 757 ; 679 ; 748 ; 786 ; 470 ; 639 ; 835 ; 672 ; 535 ; 812 ; 747 ; 771 ; 688 ; 610 ; 975 ; 479 ; 629 ; 848 ; 418 ; 558 ; 916 ; 792 ; 808 ; 774 ; 787 ; 706 ; 607 ; 572 ; 443 ; 810 ; 509 ; 799 ; 656 ; 594 ; 691 ; 712 ; 789 ; 662 ; 549 ; 806 ; 732 ; 826 ; 783 ; 494 ; 519 ; 435 ; 646 ; 514 ; 760 ; 816 ; 501 ; 433 ; 513 ; 589 ; 695 ; 624 ; 372 ; 387 ; 849 ; 978 ; 963 ; 847 ; 842 ; 659 ; 651 ; 613 ; 832 ; 798 ; 696 ; 811 ; 357 ; 394 ; 731 ; 399 ; 864 ; 699 ; 710 ; 560 ; 584 ; 616 ; 827 ; 714 ; 824 ; 473 ; 938 ; 929 ; 793 ; 935 ; 862 ; 807 ; 828 ; 346 ; 674 ; 545 ; 536 ; 676 ; 541 ; 664 ; 531 ; 557 ; 769 ; 750 ; 767 ; 868 ; 675 ; 702 ; 632 ; 524 ; 484 ; 439 ; 813 ; 859 ; 396 ; 440 ; 305 ; 716 ; 778 ; 924 ; 420 ; 441 ; 389 ; 900 ; 739 ; 544 ; 462 ; 658 ; 521 ; 512 ; 751 ; 516 ; 667 ; 780 ; 795 ; 602 ; 432 ; 527 ; 964 ; 546 ; 336 ; 322 ; 547 ; 833 ; 860 ; 540 ; 740 ; 444 ; 887 ; 498 ; 511 ; 709 ; 409 ; 385 ; 559 ; 905 ; 582 ; 474 ; 689 ; 785 ; 642 ; 499 ; 796 ; 641 ; 730 ; 614 ; 958 ; 550 ; 665 ; 503 ; 493 ; 466 ; 844 ; 948 ; 758 ; 580 ; 478 ; 738 ; 759 ; 350 ; 858 ; 694 ; 463 ; 840 ; 412 ; 685 ; 574 ; 631 ; 779 ; 863 ; 548 ; 776 ; 491 ; 663 ; 367 ; 668 ; 650 ; 568 ; 899 ; 713 ; 423 ; 770 ; 708 ; 437 ; 345 ; 490 ; 472 ; 937 ; 477 ; 539 ; 595 ; 1023 ; 801 ; 845 ; 395 ; 408 ; 866 ; 406 ; 456 ; 515 ; 989 ; 421 ; 414 ; 542 ; 809 ; 426 ; 497 ; 910 ; 392 ; 496 ; 817 ; 686 ; 465 ; 525 ; 373 ; 427 ; 457 ; 885 ; 773 ; 814 ; 829 ; 321 ; 657 ; 368 ; 794 ; 1046 ; 893 ; 529 ; 880 ; 585 ; 505 ; 734 ; 453 ; 781 ; 883 ; 397 ; 719 ; 782 ; 620 ; 510 ; 483 ; 917 ; 984 ; 997 ; 742 ; 953 ; 678 ; 598 ; 360 ; 384 ; 901 ; 588 ; 867 ; 475 ; 332 ; 381 ; 533 ; 933 ; 374 ; 843 ; 388 ; 370 ; 903 ; 338 ; 752 ; 363 ; 522 ; 993 ; 611 ; 920 ; 831 ; 705 ; 566 ; 1041 ; 764 ; 869 ; 378 ; 434 ; 643 ; 485 ; 697 ; 851 ; 599 ; 638 ; 1011 ; 784 ; 932 ; 458 ; 775 ; 592 ; 913 ; 925 ; 570 ; 601 ; 889 ; 562 ; 951 ; 878 ; 551 ; 855 ; 797 ; 877 ; 969 ; 417 ; 822 ; 342 ; 970 ; 429 ; 766 ; 912 ; 949 ; 1093 ; 400 ; 403 ; 469 ; 711 ; 451 ; 727 ; 555 ; 448 ; 983 ; 753 ; 1055 ; 971 ; 334 ; 343 ; 424 ; 837 ; 928 ; 1014 ; 861 ; 380 ; 996 ; 722 ; 886 ; 896 ; 839 ; 430 ; 569 ; 1026 ; 530 ; 940 ; 944 ; 365 ; 955 ; 821 ; 954 ; 879 ; 939 ; 1047 ; 737 ; 464 ; 918 ; 907 ; 906 ; 684 ; 995 ; 577 ; 377 ; 930 ; 288 ; 749 ; 856 ; 960 ; 733 ; 830 ; 481 ; 353 ; 888 ; 359 ; 460 ; 926 ; 1013 ; 852 ; 319 ; 943 ; 871 ; 347 ; 307 ; 874 ; 379 ; 756 ; 904
N_STAGE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	N Stage	Patient	
OVERALL_HER2_STATUS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall HER2 Status of the Sample that Underwent Sequencing.	Sample	Negative ; Positive ; Unk/ND ; Equivocal
OVERALL_HER2_STATUS_PATIENT	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall patient tumor HER2 status based on the reivew of the primary and metastatic tumors and the clinical history.	Patient	
OVERALL_HR_STATUS_PATIENT	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall patient tumor hormone receptor status based on the reivew of the primary and metastatic tumors and the clinical history.	Patient	
OVERALL_RECEPTOR_STATUS_PATIENT	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall patient tumor receptor subtype based on the reivew of the primary and metastatic tumors and the clinical history. 	Patient	
OVERALL_TUMOR_GRADE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Overall Primary Tumor Histological Grade.	Sample	II  Intermediate Grade (Moderately Differentiated) ; III High Grade (Poorly Differentiated) ; I  Low Grade (Well Differentiated) ; Unknown
PRIMARY_NUCLEAR_GRADE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Primary Nuclear Grade	Sample	III (High) ; II (Intermediate) ; Unknown ; I (Low) ; I (low)
PRIOR_BREAST_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Prior Breast Primary	Sample	No ; Synchronous Bilateral ; Yes
PRIOR_LOCAL_RECURRENCE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Prior Local Recurrence	Patient	
PR_PCT_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	PR Percent Positivity of the Primary Tumor	Sample	22 ; 0 ; 30 ; 50 ; 60 ; 90 ; 70 ; 95 ; 80 ; 100 ; 85 ; 99 ; 3 (weak intensity) ; 5 ; 1 ; 65 ; 73 ; 21 ; 10 ; 40 ; 20 ; 23 ; 75 ; 15 ; 82 ; 3 ; 25 ; 69 ; 24 ; 98 ; 52 ; 11 ; 59 ; 96 ; 86 ; 74 ; 92 ; 94 ; 91 ; 81 ; 34 ; 4 ; 47 ; >60 ; 43 ; 2 ; 62 ; 35 ; 18 ; 31 ; 33 ; 41 ; 56 ; 89 ; 77 ; 6 ; 49 ; 45 ; <5 ; 28 ; 48 ; 93 ; 37 ; 8 ; 87 ; 36 ; 16 ; 32 ; 61 ; 97
PR_STATUS_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	PR Status of the Primary Tumor	Sample	Positive ; Negative ; Unk/ND
RECEPTOR_STATUS_PRIMARY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Receptor Status of the Primary Tumor	Sample	HR+/HER2- ; Triple Negative ; HR+/HER2+ ; HR+/HER2_Unknown ; HR+/HER2_Equivocal ; Unk/ND ; HR-/HER2+ ; HR-/HER2- ; HR-/HER2_Unknown ; HR-/HER2_Equivocal
SAMPLE_SITE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Sample Site	Sample	Treatment Naive Primary ; Liver ; Breast ; Post-Treatment Primary ; Chest Wall ; Lung ; Brain ; Lymph Node ; Bone ; Post-Neo Primary ; Local Recurrence/Breast ; Soft Tissue ; Ovary ; Uterus ; Skin ; Pleura ; Peritoneum ; Pericardium ; Local Recurrence/Lymph Node ; Epidural Mass ; Bowel ; Stomach ; Appendix ; Bladder/Ureter ; Lymph node ; Parotid ; Orbit ; Trachea ; Local Recurrence ; Spleen ; Esophegus
STAGE_AT_DIAGNOSIS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Stage At Diagnosis	Sample	IV ; IIA ; IB ; IA ; IIIA ; IIIC ; IIB ; IIIB ; unk
TIME_TO_DEATH_MONTHS	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	NUMBER	Time To Death (Months)	Patient	
TUMOR_SAMPLE_HISTOLOGY	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Tumor Sample Histology	Sample	Breast Invasive Ductal Carcinoma ; Breast Mixed Ductal and Lobular Carcinoma ; Breast Invasive Lobular Carcinoma ; Breast Invasive Carcinoma, NOS ; Breast Invasive Mixed Mucinous Carcinoma ; Breast Undifferentiated Carcinoma ; Breast Metaplastic Carcinoma ; Breast Invasive Myoepithelial Carcinoma ; Breast Invasive Carcinosarcoma ; Tubular Carcinoma ; Breast Adenoid Cystic Carcinoma
TUMOR_TISSUE_ORIGIN	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	Tumor Tissue of Origin of the Sequnced Tumor.	Sample	Breast
T_STAGE	HotPink	Breast Cancer (MSK, Cancer Cell 2018)	STRING	T Stage	Patient	
ALPELISIB_DOSE	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Alpelisib Dose (mg)	Patient	
ALPELISIB_SCHEDULING	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Alpelisib Scheduling	Patient	
BREAST_CANCER_SUBTYPE	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Breast Cancer Subtype	Patient	
CLINICAL_BENEFIT	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Clinical Benefit	Patient	
ENDOCRINE_THERAPY	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Endocrine Therapy	Patient	
MEASURABLE_DISEASE	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Measurable Disease	Patient	
OFF_STUDY_REASON	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Off Study Reason	Patient	
PATIENT_DISPLAY_NAME	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Patient Display Name	Patient	
PIK3CA_MUT_PRE_TREATMENT_TUMOR	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	PIK3CA Pre Treatment Tumor Mutation	Patient	
PIK3CA_PRE_TREATMENT_TUMOR	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	PIK3CA Pre Treatment Tumor	Patient	
RECIST_RESPONSE	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	NUMBER	Best RECIST Response	Patient	
SAMPLE_COLLECTION_TIMEPOINT	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Sample Collection Time	Sample	pre-treatment ; post-treatment ; on-treatment
SEQUENCING_PLATFORM	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Tumor Sequencing Platform	Sample	Sequenom ; GUARDANT ; Failed ; MSK-IMPACT ; Foundation
TREATMENT_ARM	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	STRING	Treatment Arm	Patient	
WEEKS_ON_STUDY	HotPink	Breast Cancer (MSK, Nature Cancer 2020)	NUMBER	Weeks on Study	Patient	
CENTER	HotPink	Breast Cancer (SMC 2018)	STRING	Center of sequencing	Patient	
COHORT	HotPink	Breast Cancer (SMC 2018)	STRING	Cohort	Patient	
CYT_SCORE	HotPink	Breast Cancer (SMC 2018)	NUMBER	Cytolytic Activity Score	Sample	11.65587835 ; 61.07734523 ; 11.32946601 ; 5.988873016 ; 6.635088545 ; 12.22376374 ; 18.37942872 ; 6.531531214 ; 10.87578963 ; 3.107812736 ; 4.173631512 ; 0.969948452 ; 13.6511538 ; 23.92983076 ; 5.40684751 ; 8.397309093 ; 6.207431031 ; 17.81248158 ; 11.99947499 ; 13.9044741 ; 12.41317445 ; 3.166528067 ; 4.428182471 ; 7.121404356 ; 1.608664042 ; 15.56099611 ; 1.767710384 ; 16.06974798 ; 2.511374126 ; 6.13908788 ; 2.658683885 ; 19.61536133 ; 12.23147579 ; 12.07445237 ; 5.63505102 ; 5.048999901 ; 19.21193379 ; 20.95642622 ; 2.993325909 ; 3.788799282 ; 1.551450934 ; 6.345833279 ; 28.1967374 ; 17.92877018 ; 22.44930288 ; 2.666720833 ; 8.169632795 ; 12.09462691 ; 9.191082635 ; 5.319962406 ; 24.85146475 ; 32.81156656 ; 25.62811737 ; 3.144709844 ; 14.03122945 ; 4.033088147 ; 3.361249768 ; 14.55244997 ; 3.363881686 ; 4.351068834 ; 7.12240128 ; 2.210972637 ; 8.520176055 ; 15.89213642 ; 14.5556793 ; 10.8402583 ; 5.191338941 ; 23.15651096 ; 9.785192895 ; 6.516977827 ; 2.459268184 ; 3.679252642 ; 11.40545484 ; 19.70427619 ; 0.264952826 ; 3.715992465 ; 1.618023486 ; 4.16449 ; 6.321930085 ; 6.935214488 ; 0.14 ; 1.08 ; 18.03926551 ; 10.91296477 ; 1.434782213 ; 30.06033932 ; 5.065964864 ; 0.105830052 ; 7.89722103 ; 38.91545837 ; 24.852014 ; 4.487983957 ; 5.373890583 ; 0.632771681 ; 13.4771028 ; 4.672654492 ; 12.5824163 ; 1.433631752 ; 6.051396533 ; 7.890145753 ; 0.33763886 ; 7.44908048 ; 7.566042559 ; 1.645904007 ; 4.583579387 ; 5.392012611 ; 4.178420754 ; 5.615051202 ; 2.128097742 ; 27.77383121 ; 4.686683262 ; 3.05995098 ; 6.791237001 ; 50.41132016 ; 13.54467054 ; 2.219594558 ; 17.85763142 ; 13.34164907 ; 30.06456053 ; 53.40613261 ; 5.043153775 ; 9.48372817 ; 4.29036129 ; 5.753033982 ; 8.691202448 ; 3.978844053 ; 6.064948475 ; 14.78549627 ; 1.894069692 ; 5.707363665 ; 8.620812027 ; 1.711782696 ; 1.74198163 ; 3.985599077 ; 7.905744747 ; 0.997246208 ; 5.525667381 ; 3.593744565 ; 7.809897567 ; 3.095044426 ; 2.537242598 ; 0.972728122 ; 14.48830563 ; 1.910157062 ; 9.929994965 ; 8.064192458 ; 7.013401457 ; 4.887698845 ; 2.019900988 ; 1.838124044 ; 3.127906648 ; 2.429485542 ; 5.442499426 ; 6.948856021 ; 17.43124494 ; 4.976102893 ; 63.52414895 ; 6.922138398 ; 14.50875598 ; 19.24128374 ; 2.25166605 ; 6.691621627 ; 73.43173565 ; 4.405995915 ; 9.174213863 ; 4.73894503 ; 36.13813498 ; 17.31991917 ; 2.746998362 ; 12.6736735
HISTOLOGY_SUBTYPE	HotPink	Breast Cancer (SMC 2018)	STRING	Histology of the Cancer Subtype	Patient	
IHC_SUBTYPE	HotPink	Breast Cancer (SMC 2018)	STRING	Immunohistochemistry Subtype	Sample	ER+ ; TN ; ER+HER2+ ; UA ; HER2+
INITIAL_TNM_STAGE	HotPink	Breast Cancer (SMC 2018)	STRING	TNM Stage	Sample	3A ; 2A ; 3C ; 2B ; 1A ; 4 ; 1B
MUTATION_BURDEN	HotPink	Breast Cancer (SMC 2018)	NUMBER	Mutation Burden	Sample	1.30103 ; 0.69897 ; 1.54407 ; 1.75587 ; 1.44716 ; 1.34242 ; 1.11394 ; 1.32222 ; 0.90309 ; 1.07918 ; 0.95424 ; 1.14613 ; 1.6721 ; 1.53148 ; 1.27875 ; 1.85126 ; 1.80618 ; 1.23045 ; 1.64345 ; 1.17609 ; 2.03743 ; 1.49136 ; 0.60206 ; 1.73239 ; 1.85733 ; 1.99564 ; 1.39794 ; 2.15229 ; 1.51851 ; 2.10721 ; 1.70757 ; 1.95904 ; 1.78533 ; 1.4624 ; 1.92428 ; 1.38021 ; 2.07555 ; 2.00432 ; 1.81291 ; 2.07188 ; 2.23045 ; 1.6902 ; 1.50515 ; 2.49969 ; 2.15534 ; 1.81954 ; 1.41497 ; 1.74819 ; 1 ; 1.61278 ; 1.25527 ; 1.57978 ; 0.47712 ; 0.8451 ; 1.72428 ; 1.83251 ; 2.05308 ; 0.77815 ; 1.36173 ; 1.69897 ; 1.68124 ; 1.04139 ; 1.86332 ; 1.5682 ; 1.91908 ; 1.95424 ; 1.90849 ; 1.43136 ; 1.20412 ; 2.14613 ; 1.59106 ; 1.62325 ; 1.79239 ; 1.63347 ; 1.76343 ; 0
SUBTYPE_CONSENSUS	HotPink	Breast Cancer (SMC 2018)	STRING	Subtype Consensus	Sample	ER+ ; TN ; ER+HER2+ ; HER2+
TREATMENT_CHEMOTHERAPY	HotPink	Breast Cancer (SMC 2018)	STRING	Chemotherapy(Yes/No)	Patient	
AGE_AT_SEQ_REPORTED_YEARS	HotPink	Metastatic Breast Cancer (MSK, Cancer Discovery 2022)	NUMBER	Age (in years) at which sequencing was reported	Sample	45 ; 62 ; 63 ; 48 ; 51 ; 61 ; 55 ; 57 ; 46 ; 53 ; 71 ; 73 ; 74 ; 77 ; 72 ; 70 ; 33 ; 34 ; 75 ; 76 ; 67 ; 54 ; 52 ; 50 ; 59 ; 42 ; 44 ; 40 ; 38 ; 56 ; 41 ; 58 ; 35 ; 49 ; 84 ; 60 ; 68 ; 37 ; 65 ; 66 ; 39 ; 47 ; 69 ; 82 ; 43 ; 79 ; 81 ; 83 ; 64 ; 36 ; 80 ; 78 ; 31 ; 86 ; 85 ; 30 ; 87 ; 88 ; 29 ; 32 ; 21
AGE_CURRENT	HotPink	Metastatic Breast Cancer (MSK, Cancer Discovery 2022)	NUMBER	Patient Current Age	Patient	
TUMOR_SITE	HotPink	Metaplastic Breast Cancer (MSK,NPJ Breast Cancer 2021)	STRING	Tumor Site	Patient	
TUMOR_SIZE_CM	HotPink	Metaplastic Breast Cancer (MSK,NPJ Breast Cancer 2021)	NUMBER	Tumor size (cm)	Sample	3.0 ; 1.1 ; 1.4 ; 1.6 ; 2.1 ; 2.9 ; 2.5 ; 5.8 ; 5.2 ; 2.3 ; 1.7 ; 4.5 ; 3.9 ; 3.1 ; 2.2 ; 3
ANGIOLYMPHATIC_INVASION	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Presence of angiolymphatic invasion.	Patient	
CLIN_M_STAGE	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Patient	
CLIN_N_STAGE	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Patient	
EST_TUMOR_CELLULARITY	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Estimated tumor cellularity.	Sample	Moderate ; High ; Low
HISTOLOGICAL_TYPE	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Histological Type	Patient	
IHC_BASAL	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	Basal carcinoma by immunohistochemistry for EGFR and CK5/6	Sample	EGFR-ve/low and/or CK5/6-ve/low ; EGFR+ve and/or CK5/6+ve
IHC_CK5_6	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	IHC_CK5/6	Sample	Negative ; Positive ; Positive low
IHC_EGFR	HotPink	Breast Invasive Carcinoma (British Columbia, Nature 2012)	STRING	IHC_EGFR	Sample	Negative ; Positive ; Positive low
ARCHER	HotPink	Non-CDH1 Invasive Lobular Carcinoma (MSK, 2023)	STRING	Whether or not a supplemental MSK-ARCHER test was performed on the sample in addition to the MSK-IMPACT test.	Sample	NO
INSTITUTE	HotPink	Non-CDH1 Invasive Lobular Carcinoma (MSK, 2023)	STRING	Institute Source	Sample	MSKCC
PAIEN_DISPLAY_NAME	HotPink	Non-CDH1 Invasive Lobular Carcinoma (MSK, 2023)	STRING	Patient Display Name	Patient	
SAMPLE_DISPLAY_NAMW=E	HotPink	Non-CDH1 Invasive Lobular Carcinoma (MSK, 2023)	STRING	Sample Display Name	Sample	P-0000820-T02-IM3 ; P-0003591-T01-IM5 ; P-0004023-T01-IM3 ; P-0004023-T02-IM5 ; P-0005526-T01-IM5 ; P-0005968-T01-IM5 ; P-0007759-T01-IM5 ; P-0008952-T01-IM5 ; P-0009325-T02-IM5 ; P-0010869-T01-IM5 ; P-0011400-T01-IM5 ; P-0014406-T01-IM6 ; P-0017113-T01-IM6 ; P-0019191-T01-IM6 ; P-0019864-T01-IM6 ; P-0024899-T01-IM6 ; P-0024979-T01-IM6 ; P-0025335-T01-IM6 ; P-0026032-T01-IM6 ; P-0026113-T01-IM6 ; P-0026615-T01-IM6 ; P-0031517-T01-IM6 ; P-0034517-T01-IM6 ; P-0034891-T01-IM6 ; P-0056185-T02-IM6
SEQUENCING_TYPE	HotPink	Breast Cancer Xenografts (British Columbia, Nature 2015)	STRING	Sequencing Type	Sample	Targeted ; Whole Genome
ADJ_XRT	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Status of adjuvant radiation therapy. Adjuvant therapy is therapy received after surgery. 	Patient	
AGE_AT_DIAGNOSIS_GROUP	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient's age at the time of primary diagnosis with breast cancer grouped into 5 year intervals.	Patient	
ANY_THERAPY_2YRS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: Since your diagnosis with metastatic breast cancer, have you been on any of your cancer therapies for more than 2 years?	Patient	
BXCEP17_COPY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Copy number of CEP17 in the pathology report. This is the number of copies of the CEP17 gene seen in the sample, which is used to calculate the HER2/CEP17 ratio. Having multiple copies of a gene means that the tumor's DNA has many consecutive repetitions of the region that codes for a given gene. Having multiple extra copies of a gene is also described as an amplification, while losing copies of a gene is described as a deletion. 	Sample	UNKNOWN ; 3.38 ; 1.8 ; 2.6 ; 1.79 ; 2.16 ; 1.95 ; NOT DONE ; 2.7 ; 3.7 ; 2 ; 1.13 ; 1.68 ; 3.2 ; 1.9 ; 3.1 ; 3.6 ; 1.85 ; 73 ; 1.65 ; 3.8 ; 1.7 ; 2.4 ; 2.57 ; 3.12 ; 3.13 ; 2.5 ; 2.1 ; 2.8 ; 2.12 ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; NOT_DONE ; N/A_BLOOD_SAMPLE ; 2.65 ; 2.88 ; 2.2 ; 2.45
BXHER2_COPY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Copy number of HER2 in the pathology report. This is the number of copies of the HER2 gene seen in the sample, which is used to calculate the HER2/CEP17 ratio. Having multiple copies of a gene means that the tumor's DNA has many consecutive repetitions of the region that codes for a given gene. Having multiple extra copies of a gene is also described as an amplification, while losing copies of a gene is described as a deletion. 	Sample	UNKNOWN ; 2.09 ; 16.8 ; 13.63 ; 2.3 ; 3 ; 1.9 ; 2.2 ; 22.75 ; 2.26 ; 2.78 ; 2.6 ; NOT DONE ; 1.88 ; 6.1 ; 4.13 ; 2.08 ; 3.6 ; 4.4 ; 6.8 ; 1.5 ; 2.68 ; 1.8 ; 3.2 ; 78 ; 3.65 ; 4.2 ; 1.1 ; 3.5 ; 4.7 ; 5.52 ; 4.25 ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; NOT_DONE ; N/A_BLOOD_SAMPLE ; 6.55 ; 5.45 ; 6.2 ; 3.99 ; 2.5
BXHER2_RATIO	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Ratio of HER2/CEP17 in the pathology report. This is one component of the Flourescence In Situ Hybridization (FISH) test. This ratio is used to determine if the HER2 gene is overexpressed, relative to the CEP17 protein, which acts as a baseline measurement. HER2/CEP17 ratios >2.2 indicate a HER2 Positive tumor.	Sample	UNKNOWN ; 1.1 ; 1.37 ; 3.4 ; 7 ; 1.7 ; 4 ; 1.14 ; 1 ; 1.2 ; 1.4 ; 9.48 ; 1.3 ; 1.29 ; 1.33 ; NOT DONE ; 0.69 ; 1.65 ; 3.67 ; 1.24 ; 5.1 ; 3.2 ; 0.7 ; 15.8 ; 2.2 ; 0.8 ; 1.45 ; 1.94 ; 2.21 ; 1.54 ; 2.9 ; 0.9 ; 1.15 ; 1.83 ; 1.8 ; 1.05 ; 1.5 ; 1.07 ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; NOT_DONE ; N/A_BLOOD_SAMPLE ; 1.38 ; 2.5 ; 1.89 ; 1.9 ; 0.71 ; 1.55 ; 1.47 ; 1.63
BX_DCIS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Notes if Ductal Carcinoma In Situ was reported in the pathology report	Sample	YES ; NO ; N/A_BLOOD_SAMPLE
BX_ER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Estrogen Receptor (ER) status reported in the pathology report	Sample	POSITIVE ; UNKNOWN ; NEGATIVE ; NOT DONE ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; N/A_BLOOD_SAMPLE
BX_GRADE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Sample grade reported in the pathology report 	Sample	UNKNOWN ; II INTERMEDIATE GRADE (MODERATELY DIFFERENTIATED) ; III HIGH GRADE (POORLY DIFFERENTIATED) ; NOT DONE ; I-II ; I LOW GRADE (WELL DIFFERENTIATED) ; II-III ; NOT_FOUND_IN_RECORD ; N/A_BLOOD_SAMPLE
BX_HER2FISH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 Flourescence In Situ Hyrbridization (FISH) results in the pathology report. This is most commonly performed on tumor samples with a HER2 Immunohistochemistry (IHC) score of 2+, or equivocal. This is an additional test that aims to measure whether or not the HER2 gene is overexpressed in a tumor sample.	Sample	UNKNOWN ; NEGATIVE ; NOT DONE ; POSITIVE ; EQUIVOCAL ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; NOT_DONE ; N/A_BLOOD_SAMPLE
BX_HER2IHC	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 Immunohistochemistry (IHC) results in the pathology report. This test involves staining tissue samples and looking at them under a microscope to determine if the HER2 protein is overexpressed in the sample. Results can be reported as 0+, 1+, 2+, or 3+. 0+ and 1+ indicate a HER2 negative tumor, 2+ is considered equivocal and may require further testing, and 3+ indicates a HER2 Positive tumor.	Sample	UNKNOWN ; 0 ; 1+ ; NOT DONE ; 3+ ; 2+ ; EQUIVOCAL ; 1+ - 2+ ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; NOT_DONE ; N/A_BLOOD_SAMPLE ; 1+-2+
BX_HER2OVERALL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 status reported in the pathology report	Sample	UNKNOWN ; NEGATIVE ; NOT DONE ; POSITIVE ; EQUIVOCAL ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; N/A_BLOOD_SAMPLE
BX_HISTOLOGY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	The sample's histology reported in the pathology report (IDC = Invasive Ductal Carcinoma, ILC = Invasive Lobular Carcinoma).	Sample	ADENOCARCINOMA ; IDC ; MIXED IDLC ; ILC ; CARCINOMA NOS ; DCIS ; MIXED_IDLC ; CARCINOMA ; N/A_BLOOD_SAMPLE
BX_KI67	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	The percentage of Ki67 reported in the pathology report	Sample	UNKNOWN ; 19.30% ; 10% ; 52% ; 20% ; 94% ; 31% ; 50% ; 12% ; 60% ; 25% ; >90% ; 28% ; 40% ; 88% ; 4% ; POSITIVE ; 9% ; 14% ; 70% ; NOT DONE ; 45% ; 82% ; 30% ; 15% ; 0 ; 74.50% ; 93% ; 43% ; 5% ; 27% ; 8% ; NOT_FOUND_IN_RECORD ; 19.3 ; 0.1 ; 0.2 ; 0.52 ; 0.4 ; 0.04 ; NOT_DONE ; HIGH ; 94 ; N/A_BLOOD_SAMPLE ; 70%_(HIGH) ; 31 ; 10 ; 0.5 ; 12 ; 60 ; 40 ; 0.45 ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; 0.25 ; 74.5 ; >90 ; 93 ; 0.82 ; 0.3 ; 89 ; 0.12 ; 70 ; 28 ; 0.09 ; 20 ; 0.88 ; 43 ; 5 ; 27 ; 0.15 ; 8 ; 26
BX_LCIS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Notes if Lobular Carcinoma In Situ was reported in the pathology report	Sample	NO ; YES ; N/A_BLOOD_SAMPLE
BX_LOCATION	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	The location in the body where the biopsy or surgery was performed	Sample	BONE ; BREAST ; LIVER ; AXILLARY LYMPH NODE ; LUNG ; CHEST WALL ; OMENTUM ; REGIONAL LYMPH NODE ; AXILLA ; SOFT TISSUE ; BRAIN-CNS ; FALLOPIAN TUBE ; PLEURA ; BRAIN ; BONE MARROW ; CERVICAL LYMPH NODE ; PLEURAL FLUID ; BREAST SKIN ; BLOOD ; LYMPH NODE REGIONAL ; LYMPH NODE DISTANT ; GASTRIC BODY ; ASCENDING COLON
BX_NOTES	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Additional information regarding the sample	Sample	LYMPHOVASCULAR INVASION PRESENT ; ALL HISTOLOGY RESIDUAL ; LYMPHOVASCULAR AND PERINEURAL INVOLVEMENT PRESENT ; LOCATED AT 6:00 ; LOCATED AT 3:00 ; LOCATED AT 6:30 ; PERINEURAL INVASION PRESENT ; TREATMENT EFFECT OBSERVED ; LYMPHATIC INVASION PRESENT ; PERINEURAL TUMOR INVASION PRESENT ; 13/15 AXILLARY LN+ FOR MET CARCINOMA ; EXTENSIVE LYMPHATIC INVASION PRESENT ; LYMPHOVASCUALR INVASION PRESENT ; LYMPHATIC INVASION PRESENT; ER/PR CANNOT BE INTERPRETED ; LYMPH-VASCULAR INVASION PRESENT ; ANGIOLYMPHATIC INVASION PRESENT ; 40% TREATMENT EFFECT ; SUPRACLAVICULAR LN ; LOCATED AT 4:00 ; LOCATED AT 1:00 ; RIGHT INNER QUADRANT ; LOBULAR CANCERIZATION PRSENT ; LOCATION DETAILS: AXILLA ; EQUIVOCAL FISH TEST AND POSITIVE IHC SCORE SUGGESTIVE OF HETEROGENEITY AND CLONAL DIFFERENCES ; SUBTYPE: MUCINOUS ADENOCARCINOMA ; HER2 IHC POSITIVE; HER2 FISH RESULT NEGATIVE ; INVASIVE MICROPAPILLARY CARCINOMA ; LOCATED AT 3:00; LYMPHATIC INVASION PRESENT ; LOCATED AT 11:00 ; TESTING PERFORMED ON DIFFERENT SAMPLE
BX_PERCENT_ER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Percentage of Estrogen Receptor (ER) reported in the pathology report. A value of >= 1% indicates an ER Positive tumor.	Sample	UNKNOWN ; 0% ; NOT DONE ; 95% ; 90% ; 60% ; 99% ; 30% ; 40% ; 5% ; 50% ; 87% ; 79% ; 80% ; 100% ; 85% ; 98% ; 71.50% ; 70% ; >90% ; > 95% ; <1% ; >95% ; >75% ; 75% ; 93% ; 92% ; 97% ; 74% ; 0 ; 98.80% ; 88% ; >70% ; 57% ; 55% ; 50-60% ; 3% ; 71-80% ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; 95 ; 90 ; 0.56 ; 60 ; 99 ; 30 ; 40 ; 100 ; 71.5 ; 5 ; 50 ; 97 ; N/A_BLOOD_SAMPLE ; 0.4 ; 87 ; >90 ; 79 ; 80 ; >95 ; 70 ; 74 ; 85 ; 98.8 ; <1 ; 98 ; 0.95 ; 0.7 ; >75 ; 88 ; 0.05 ; 0.75 ; 93 ; >70 ; 57 ; 55 ; 1 ; 50-60 ; 0.5 ; 3 ; 0.9 ; 92 ; 71-80 ; 96
BX_PERCENT_PR	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Progesterone Receptor (PR) percentage reported in the pathology report. A value of >=1% indicates a PR Positive tumor.	Sample	UNKNOWN ; 0% ; 100% ; 90% ; 97% ; 75% ; 98% ; 80% ; NOT DONE ; 30% ; 63% ; 53% ; 50% ; 95% ; 1% ; 85% ; 15% ; 69% ; 79.60% ; 13% ; 5% ; 20% ; 4% ; 16% ; <1% ; >90% ; 26-75% ; 65% ; 3-5% ; 10% ; 40% ; 60-70% ; 88% ; 21% ; 72.80% ; 92% ; 70% ; 34% ; <5% ; 60% ; >75% ; 25% ; 70-75% ; 99% ; 71-90% ; >80% ; NOT_FOUND_IN_RECORD ; 0 ; 100 ; 90 ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; 97 ; 2 ; 0.17 ; 75 ; 98 ; 50 ; 79.6 ; 5 ; 13 ; 80 ; N/A_BLOOD_SAMPLE ; 30 ; 63 ; <1 ; 53 ; 1 ; >90 ; 20 ; 95 ; 21 ; 85 ; 72.8 ; 0.5 ; 92 ; 0.16 ; 26-75 ; 0.65 ; 0.05 ; 70 ; 10 ; 69 ; 15 ; 4 ; 3-5 ; 34 ; <5 ; 65 ; 0.1 ; 60 ; >75 ; 0.9 ; 0.4 ; 60-70 ; 88 ; 25 ; 70-75 ; 99 ; 0.95 ; 71-90 ; >80 ; 96
BX_PR	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Progesterone Receptor (PR) status as reported in the pathology report 	Sample	POSITIVE ; UNKNOWN ; NEGATIVE ; NOT DONE ; NOT_FOUND_IN_RECORD ; TESTING_PERFORMED_ON_DIFFERENT_SAMPLE ; N/A_BLOOD_SAMPLE
BX_SIDEDNESS_BREAST	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Left or right sidedness for breast procedures	Sample	LEFT ; RIGHT ; N/A_BLOOD_SAMPLE
BX_TIME_DAYS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	NUMBER	Sample collection time in days from primary diagnosis 	Sample	0 ; 8 ; 10 ; 26 ; 114 ; 16 ; 161 ; 639 ; 3629 ; 17 ; 1525 ; 263 ; 39 ; 512 ; 25 ; 28 ; 110 ; 4031 ; 1 ; 293 ; 1721 ; 3 ; 132 ; 23 ; 40 ; 230 ; 254 ; 936 ; 34 ; 6189 ; 11213 ; 271 ; 908 ; 199 ; 106 ; 4 ; 37 ; 2071 ; 1211 ; 166 ; 143 ; 170 ; 21 ; 6 ; 68 ; 43 ; 38 ; 41 ; 120 ; 45 ; 14 ; 9 ; 467 ; 386 ; 236 ; 15 ; 940 ; 64 ; 3549 ; 1407 ; 3113 ; 400 ; 18 ; 338 ; 44 ; 29 ; 647 ; 30 ; 65 ; 149 ; 652 ; 1842 ; 198 ; 147 ; 57 ; -8 ; 55 ; 42 ; 482 ; 20 ; 12 ; 27 ; 854 ; -3 ; 1235 ; -1 ; 2920 ; 4204 ; 7693 ; 214 ; 232 ; 3764 ; 3257 ; 46 ; 32 ; 12426 ; 186 ; 153 ; 2544 ; 334 ; 48 ; 858 ; 1011 ; 1533 ; 11484 ; 13 ; 1768 ; 1688 ; 6180 ; 1413 ; 1682 ; 5161 ; 1463 ; 1641 ; 7110 ; 2759 ; 160 ; 7265 ; 47 ; 2681 ; 182 ; 7678 ; 70 ; 1189 ; 215 ; 930 ; 1196 ; 5010 ; 7 ; 93 ; 360 ; 5200 ; 3178 ; 3200 ; 194 ; 6470 ; 1325 ; 5244 ; 1835 ; 201 ; 154 ; 3227 ; 4557 ; 2271 ; 3503 ; 2015 ; 2282 ; 2689 ; 1067 ; 3920 ; 1060 ; 350 ; 410 ; 213 ; -21 ; 798 ; 805 ; 5070 ; 500 ; 7902 ; 1587 ; 3582 ; 1700 ; 827 ; 2531 ; 9180 ; 1092 ; 7989 ; 3419 ; 4658 ; 5288 ; 5754 ; 5017 ; 50 ; 2563 ; 3058 ; 2258 ; 519 ; 60 ; 33 ; 325 ; 1715 ; 516 ; 165 ; 481 ; 2585 ; 310 ; 4878 ; 2093 ; 1650 ; 3612 ; 31 ; 211 ; 56 ; 146 ; 2127 ; 22 ; 1888 ; 945 ; 1106 ; 19 ; 2795 ; 4328 ; 217 ; 459
BX_TYPE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	The procedure performed to obtain the sample	Sample	FNA ; CORE ; LUMPECTOMY ; MASTECTOMY ; PUNCH ; OTHER ; EXCISION ; WEDGE ; RE-EXCISION ; DISSECTION ; RESECTION ; UNKNOWN ; BILATERAL SALPINGO-OOPHERECTOMY ; N/A_BLOOD_SAMPLE ; LOBECTOMY ; NOT_FOUND_IN_RECORD ; BILATERAL_SALPINGO_OOPHERECTOMY
CALC_MET_SETTING	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated variable to classify if samples were taken while the patient had metastatic disease, or prior to metastatic disease. Samples taken less than 4 months prior to the diagnosis of metastatic disease are classified as METASTATIC DISEASE PRESENT	Sample	METASTATIC DISEASE PRESENT ; NO METASTATIC DISEASE PRESENT ; UNKNOWN ; METASTATIC_DISEASE_PRESENT ; NO_METASTATIC_DISEASE_PRESENT ; ABSTRACTION_PENDING ; NOT_FOUND_IN_RECORD
CALC_TIME_TO_METS_DX_DAYS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	NUMBER	Calculated elapsed time, in days, between the patient's primary diagnosis with breast cancer and diagnosis with metastatic breast cancer as reported in the medical record	Patient	
CALC_TIME_TO_METS_DX_MONTHS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	NUMBER	Calculated elapsed time, in months, between patient's primary diagnosis with breast cancer and diagnosis with metastatic breast cancer as reported in the medical record	Patient	
CALC_TREATMENT_NAIVE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated variable that is set to YES if a sample was taken prior to the start of any medical therapy	Sample	YES ; NO ; UNKNOWN ; ABSTRACTION_PENDING ; INCONCLUSIVE
DX_CEP17_COPY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Copy number of CEP17 in diagnostic sample. This is the number of copies of the CEP17 gene seen in the sample, which is used to calculate the HER2/CEP17 ratio. Having multiple copies of a gene means that the tumor's DNA has many consecutive repetitions of the region that codes for a given gene. Having multiple extra copies of a gene is also described as an amplification, while losing copies of a gene is described as a deletion. 	Patient	
DX_ER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Estrogen Receptor (ER) status of diagnostic sample	Patient	
DX_GRADE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Grade of diagnostic sample	Patient	
DX_HER2FISH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 Flourescence In Situ Hyrbridization (FISH) results in diagnostic sample. This is most commonly performed on tumor samples with a HER2 Immunohistochemistry (IHC) score of 2+, or equivocal. This is an additional test that aims to measure whether or not the HER2 gene is overexpressed in a tumor sample.	Patient	
DX_HER2IHC	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 Immunohistochemistry (IHC) results of diagnostic sample. This test involves staining tissue samples and looking at them under a microscope to determine if the HER2 protein is overexpressed in the sample. Results can be reported as 0+, 1+, 2+, or 3+. 0+ and 1+ indicate a HER2 negative tumor, 2+ is considered equivocal and may require further testing, and 3+ indicates a HER2 Positive tumor.	Patient	
DX_HER2OVERALL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	HER2 status of diagnostic sample	Patient	
DX_HER2_COPY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Copy number of HER2 in diagnostic sample. This is the number of copies of the HER2 gene seen in the sample, which is used to calculate the HER2/CEP17 ratio. Having multiple copies of a gene means that the tumor's DNA has many consecutive repetitions of the region that codes for a given gene. Having multiple extra copies of a gene is also described as an amplification, while losing copies of a gene is described as a deletion. 	Patient	
DX_HER2_RATIO	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Ratio of HER2/CEP17 in diagnostic sample. This is one component of the Flourescence In Situ Hybridization (FISH) test. This ratio is used to determine if the HER2 gene is overexpressed, relative to the CEP17 protein, which acts as a baseline measurement. HER2/CEP17 ratios >2.2 indicate a HER2 Positive tumor.	Patient	
DX_HISTOLOGY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Histology of diagnostic sample	Patient	
DX_LOCATION	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Location in the body of initial breast cancer diagnosis 	Patient	
DX_PERCENT_ER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Percentage of Estrogen Receptor (ER) reported in diagnostic sample. A value of >= 1% indicates an ER Positive tumor .	Patient	
DX_PERCENT_PR	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Progesterone Receptor (PR) percentage reported in diagnostic sample. A value of >=1% indicates a PR Positive tumor.	Patient	
DX_PR	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Progesterone Receptor (PR) status of diagnostic sample	Patient	
DX_SIDEDNESS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Left or right sidedness of diagnostic sample	Patient	
DX_STAGE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	American Joint Committee on Cancer (AJCC) Summary Stage at Diagnosis. Using the AJCC method, a breast cancer is characterized by the size of the tumor (T), the number of lymph nodes it has spread to (N), and whether or not it has metastatsized (M). Together, the T, N, and M values are used to determine the Summary stage, e.g. Stage I, Stage II, Stage III, Stage IV 	Patient	
DX_TYPE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Type of procedure used to obtain diagnostic sample	Patient	
EVER_METS_SITES	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	All locations in the body where breast cancer spread at any point in the patient's treatment	Patient	
GERMLINE_MUTKNOWN_BRCA1	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Reported germline BRCA1 mutation	Patient	
GERMLINE_MUTKNOWN_BRCA2	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Reported germline BRCA2 mutation	Patient	
GERMLINE_MUTKNOWN_PALB2	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Reported germline PALB2 mutation	Patient	
HER2_STATUS_REPORTED	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: At any time, was your breast cancer found to be HER2 positive (HER2+)?	Patient	
HISPANIC	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: Do you consider yourself Hispanic, Latino/a or Spanish?	Patient	
HORMONE_RECEPTOR_STATUS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: At any time, was your breast cancer found to be hormone receptor positive (HR+, ER+ and/or PR+)?	Patient	
INFLAMMATORY_STATUS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: At any time, were you diagnosed with inflammatory breast cancer?	Patient	
METS_SITES_AT_DX	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	All locations in the body where breast cancer spread at the time of diagnosis with metastatic breast cancer.	Patient	
METS_SITES_AT_METS_ABST_ADRENAL_GLAND	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to adrenal gland noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_ASCITES	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to ascites noted during the patient's course of treatment. Ascites is the accumulation of fluid in the abdominal cavity.	Patient	
METS_SITES_AT_METS_ABST_BONE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to bone noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_BRAIN_CNS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to brain or central nervous system noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_CHEST_WALL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to chest wall noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_DIST_LYMPH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to distant lymph nodes noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_INTRA_ABDOMINAL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to intraabdominal area noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_LIVER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to liver noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_LUNG	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to lung noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_OVARY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to ovary noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_PLEURAL_EFFUSION	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to pleural effusion noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_REG_LYMPH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to regional lymph nodes noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_SKIN	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to skin noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_SOFT_TISSUE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to soft tissue noted during the patient's course of treatment	Patient	
METS_SITES_AT_METS_ABST_UNKNOWN	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastases unknown or not reported during patient's course of treatment. This is set to YES if metastatic sites could not be determined from available medical records.	Patient	
METS_SITES_AT_METS_DX_ADRENAL_GLAND	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to adrenal gland noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_ASCITES	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to ascites noted at time of diagnosis with metastatic disease. Ascites is the accumulation of fluid in the abdominal cavity. 	Patient	
METS_SITES_AT_METS_DX_BONE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to bone noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_BRAIN_CNS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to Brain or Central Nervous System noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_CHEST_WALL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to chest wall noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_DIST_LYMPH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to distant lymph nodes noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_INTRA_ABDOMINAL	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to intraabdominal area noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_LIVER	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to liver noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_LUNG	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to lung noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_OVARY	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to ovary noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_PLEURAL_EFFUSION	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to pleural effusion noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_REG_LYMPH	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to regional lymph nodes noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_SKIN	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to skin noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_SOFT_TISSUE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastasis to soft tissue noted at time of diagnosis with metastatic disease	Patient	
METS_SITES_AT_METS_DX_UNKNOWN	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Metastatic sites unknown or not reported at time of diagnosis with metastatic disease. This is set to YES if metastatic sites could not be determined from available medical records.	Patient	
N_STAGE_REPORTED	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	American Joint Committee on Cancer (AJCC) Summary Stage at Diagnosis. Using the AJCC method, a breast cancer is characterized by the size of the tumor (T), the number of lymph nodes it has spread to (N), and whether or not it has metastatsized (M). Together, the T, N, and M values are used to determine the Summary stage, e.g. Stage I, Stage II, Stage III, Stage IV	Patient	
PATIENT_NOTES	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Additional notes about patient's clinical history	Patient	
RACE_CATEGORIZED	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: What is your race (select all that apply)? Infrequent responses have been categorized as Other for confidentiality. 	Patient	
SAMPLE_TIMEPOINT	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Sample sequential timepoint (T1 = timepoint 1, T2 = timepoint 2, etc.)	Sample	MBCProject_GvHkH2Hk_T1 ; MBCProject_GvHkH2Hk_T2 ; MBCProject_N4srsKsr_T1 ; MBCProject_N4srsKsr_T2 ; MBCProject_4MF1FlFQ_T1 ; MBCProject_4MF1FlFQ_T3 ; MBCProject_wAiri7fp_T1 ; MBCProject_K7f6fdUz_T2 ; MBCProject_xBfJfri9_T1 ; MBCProject_xBfJfri9_T3B ; MBCProject_gKsRsqTR_T1 ; MBCProject_QbiZiytx_T2 ; MBCProject_QbiZiytx_T1 ; MBCProject_VrsMsqTb_T1 ; MBCProject_57iLiJIl_T1 ; MBCProject_ErfKfJt0_T1 ; MBCProject_K0UDUnFE_T1 ; MBCProject_RKf1frsr_T3 ; MBCProject_RKf1frsr_T2 ; MBCProject_RKf1frsr_T1 ; MBCProject_wKuZuQS1_T3 ; MBCProject_kwS1CXSR_T1 ; MBCProject_O8u9SjuW_T1 ; MBCProject_7of5i3hp_T1 ; MBCProject_VbfASefz_T1 ; MBCProject_4DIpSBFV_T1 ; MBCProject_gotjfgf0_T2 ; MBCProject_gotjfgf0_T1 ; MBCProject_bvHXCoTY_T1 ; MBCProject_9JI1fwuX_T1 ; MBCProject_ZdudUNFZ_T1 ; MBCProject_3jhES9fq_T2 ; MBCProject_3LI1TNs3_T1 ; MBCProject_4OIOfAt9_T2 ; MBCProject_7XFmtytw_T3 ; MBCProject_74CYIyHw_T1 ; MBCProject_1ps2hZH8_T1 ; MBCProject_rmSBIguN_T1C ; MBCProject_rmSBIguN_T1A ; MBCProject_KphMt4F9_T1 ; MBCProject_KphMt4F9_T2 ; MBCProject_zyt5TKFB_T1A ; MBCProject_zyt5TKFB_T1B ; MBCProject_JGCBTpH1_T1 ; MBCProject_bAi0Slsx_T2 ; MBCProject_GouMi0U1_T1 ; MBCProject_DxibF0hM_T2 ; MBCProject_P2CMUEiX_T1 ; MBCProject_JBh5TjcM_T1 ; MBCProject_kduys9h5_T1 ; MBCProject_kduys9h5_T2 ; MBCProject_d5CbUNTb_T2 ; MBCProject_d5CbUNTb_T1 ; MBCProject_BOHWtZT8_T1 ; MBCProject_BOHWtZT8_T2 ; MBCProject_epUYsdCE_T1 ; MBCProject_kAFQF3t6_T1 ; MBCProject_5jSPs9fl_T3 ; MBCProject_PASlTyTy_T1 ; MBCProject_pMcWcrtZ_T2 ; MBCProject_rJHBiKTl_T1 ; MBCProject_AqtYu0IW_T2 ; MBCProject_AqtYu0IW_T1 ; MBCProject_PXcjFYIo_T1 ; MBCProject_PXcjFYIo_T2 ; MBCProject_99CdCOHm_T1B_2 ; MBCProject_VQfmS0fK_T1 ; MBCProject_VQfmS0fK_T2 ; MBCProject_gjhMuoha_T1 ; MBCProject_PzUBH7I3_T1 ; MBCProject_PzUBH7I3_T2 ; MBCProject_PzUBH7I3_T3 ; MBCProject_Y7fYC1iG_T1 ; MBCProject_7VFnIqfw_T1 ; MBCProject_ePi1smiM_T3 ; MBCProject_ePi1smiM_T1B ; MBCProject_ePi1smiM_T1C ; MBCProject_ePi1smiM_T1D ; MBCProject_ePi1smiM_T2 ; MBCProject_7JtRIPI2_T1 ; MBCProject_7JtRIPI2_T2 ; MBCProject_1qhlIasw_T1 ; MBCProject_4vC6Fgio_T1 ; MBCProject_NDIbs9i6_T1 ; MBCProject_ZPHRs3Uw_T1 ; MBCProject_BVHET8iq_T1 ; MBCProject_KGs1fxH2_T1A ; MBCProject_KGs1fxH2_T1B ; MBCProject_KGs1fxH2_T1K ; MBCProject_3MUnT7Ty_T1 ; MBCProject_mrhKt1Ue_T1 ; MBCProject_kRC3tlcA_T1 ; MBCProject_lXCmTEuv_T1 ; MBCProject_jEhBHrS2_T1 ; MBCProject_27uAugT4_T1 ; MBCProject_p1CQTdIg_T1 ; MBCProject_70CxiQFk_T1 ; MBCProject_DDUmIZuW_T1 ; MBCProject_7OcOivcV_T1 ; MBCProject_LvS2IvIy_T1 ; MBCProject_EBTBIGFy_T1 ; MBCProject_j2F2sQC0_T1 ; MBCProject_nZHYc4Ie_T1 ; MBCProject_43UpSwhz_T1 ; MBCProject_2pt4t9cA_T2 ; MBCProject_yZSnSluK_T1 ; MBCProject_qmu6TYto_T1 ; MBCProject_qmu6TYto_T2 ; MBCProject_Jeu1F5cz_T1 ; MBCProject_pktAIxFb_T2 ; MBCProject_pktAIxFb_T1 ; MBCProject_eXSVsxUm_T2 ; MBCProject_eXSVsxUm_T1 ; MBCProject_rMHPsbIq_T1 ; MBCProject_bpunhmim_T2 ; MBCProject_LVSjf8h7_T1A ; MBCProject_XmiOUMSm_T1 ; MBCProject_kzuMSZIW_T1 ; MBCProject_BVCVuGhl_T1 ; MBCProject_pyhbI1H5_T3 ; MBCProject_brTys8Hl_T2 ; MBCProject_Y8H6SghO_T2 ; MBCProject_lQtMtjFR_T1 ; MBCProject_lQtMtjFR_T2 ; MBCProject_LDCbC8t9_T1 ; MBCProject_2ViLiZS8_T1 ; MBCProject_2kS5fYc1_T1 ; MBCProject_GKu6TliY_T2 ; MBCProject_wKuwTYhK_T1 ; MBCProject_JKTZhEUe_T1 ; MBCProject_OwuoTVhg_T1 ; MBCProject_oqupfDu7_T1 ; MBCProject_oqupfDu7_T2B ; MBCProject_MYuoCmI7_T1 ; MBCProject_rvULI3TV_T1 ; MBCProject_goSDCjUM_T1 ; MBCProject_RJf1h2Sp_T1 ; MBCProject_BvsPhwI1_T2 ; MBCProject_gdIlF4hG_T1 ; MBCProject_6vTVHzur_T1 ; MBCProject_6vTVHzur_T3 ; MBCProject_0aTBfPcG_T1 ; MBCProject_e4SaTnIW_T1 ; MBCProject_e4SaTnIW_T2 ; MBCProject_e4SaTnIW_T4 ; MBCProject_XVHkUVTb_T1 ; MBCProject_7wCjtKIW_T3 ; MBCProject_mrIQIdsx_T3 ; MBCProject_mrIQIdsx_T1 ; MBCProject_mrIQIdsx_T2 ; MBCProject_LPHKFauY_T1 ; MBCProject_MlheH1iY_T1 ; MBCProject_wzCxuoio_T1 ; MBCProject_6QhZF6ur_T1 ; MBCProject_DximH6Cn_T1 ; MBCProject_briXiduE_T1 ; MBCProject_k4hlFwFg_T1 ; MBCProject_k4hlFwFg_T2 ; MBCProject_gASyuQSl_T2 ; MBCProject_gASyuQSl_T0A ; MBCProject_gASyuQSl_T0B ; MBCProject_gASyuQSl_T0C ; MBCProject_W2CQswiv_T1 ; MBCProject_6JhKimhv_T1 ; MBCProject_ZeTySaU3_T2 ; MBCProject_oZT8clio_T1 ; MBCProject_3vhkhAcY_T1 ; MBCProject_nwIeUoSD_T1 ; MBCProject_GpizsQiW_T1 ; MBCProject_Y7iLIOU0_T1 ; MBCProject_Y7iLIOU0_T1A ; MBCProject_Gxhdtafa_T1 ; MBCProject_glf3CWFa_T1 ; MBCProject_YNTyfDfq_T1B ; MBCProject_EWubi6hd_T1 ; MBCProject_7AC8CoUL_T1 ; MBCProject_QNs8uGhM_T1 ; MBCProject_WYHpfXf1_T1 ; MBCProject_WYHpfXf1_T2 ; MBCProject_2WCGcxuk_T4 ; MBCProject_AwukckTD_T1 ; MBCProject_zatdFvhp_T2 ; MBCProject_W5ceiLi0_T1 ; MBCProject_MmSBTJtJ_T1 ; MBCProject_jmfDfEs8_T1 ; MBCProject_x4cLHdhw_T1 ; MBCProject_x4cLHdhw_T2 ; MBCProject_x4cLHdhw_T3 ; MBCProject_PkTDsOSa_T1 ; MBCProject_PkTDsOSa_T1A ; MBCProject_nkU3hDhB_T1A ; MBCProject_nkU3hDhB_T1B ; MBCProject_nkU3hDhB_T2 ; MBCProject_6zfRF2fl_T2 ; MBCProject_m9SNc1Iq_T1 ; MBCProject_beTYUZij_T1 ; MBCProject_JpCASlSG_T2 ; MBCProject_kQTqIOSP_T2 ; MBCProject_mMhdcrh5_T1 ; MBCProject_NzHBsOtg_T1 ; MBCProject_EkHAIECZ_T1 ; MBCProject_W4FBsLSx_T1 ; MBCProject_W4FBsLSx_T2 ; MBCProject_W4FBsLSx_T3 ; MBCProject_lGCMIGT0_T1A ; MBCProject_lGCMIGT0_T1B ; MBCProject_JGcLUJiA_T2 ; MBCProject_JGcLUJiA_T4 ; MBCProject_JGcLUJiA_T5 ; MBCProject_5vTpUpCv_T1 ; MBCProject_Ali6SAHL_T1 ; MBCProject_9RtxtGUO_T1 ; MBCProject_nEcXsyfj_T2 ; MBCProject_8bfWIQu1_T1 ; MBCProject_8bfWIQu1_T2 ; MBCProject_B7f5hRfD_T0 ; MBCProject_B7f5hRfD_T1 ; MBCProject_AzCnt3sL_T1 ; MBCProject_LnHAS5T0_T1 ; MBCProject_oNI6SXtq_T2 ; MBCProject_2Wf9hPtA_T2 ; MBCProject_xlhkS5CG_T1 ; MBCProject_m1fOs2FL_T1 ; MBCProject_QJFdf8hQ_T2 ; MBCProject_ygcMFgCR_T1A ; MBCProject_ygcMFgCR_T1B ; MBCProject_ygcMFgCR_T1C ; MBCProject_W9hmcWcz_T1 ; MBCProject_5gHasou8_T1 ; MBCProject_5gHasou8_T2 ; MBCProject_DWTkcWCW_T1 ; MBCProject_qQSACYuv_T1 ; MBCProject_lqSlSztO_T2 ; MBCProject_AJF3tVc8_T1 ; MBCProject_6Yt3czsW_T1 ; MBCProject_lJflt3UR_T1 ; MBCProject_y2F3IgIE_T1 ; MBCProject_xBfJfri9_T2 ; MBCProject_xBfJfri9_T3A ; MBCProject_2pt4t9cA_T1 ; MBCProject_VrsMsqTb_T2 ; MBCProject_wKuZuQS1_T2 ; MBCProject_4DIpSBFV_T2 ; MBCProject_qyf8tJUa_T1 ; MBCProject_PltxioCD_BLOOD_P ; MBCProject_3jhES9fq_T1 ; MBCProject_7XFmtytw_T2 ; MBCProject_dPIxCpiZ_T1 ; MBCProject_dPIxCpiZ_T2 ; MBCProject_rmSBIguN_T1_A ; MBCProject_rmSBIguN_T1_C ; MBCProject_1efxSxuz_BLOOD_P ; MBCProject_8juyTguN_BLOOD_P ; MBCProject_nVtEHZi1_BLOOD_P ; MBCProject_R3UpTWFr_T3 ; MBCProject_pwswieUY_BLOOD_P ; MBCProject_MvhNc7Cd_T1 ; MBCProject_nrI4FWfZ_BLOOD_P ; MBCProject_4pfxtQc0_BLOOD_P ; MBCProject_BOHWtZT8_T3 ; MBCProject_GMuyflik_BLOOD_P ; MBCProject_lQtMtjFR_T3 ; MBCProject_9oHNUZUE_BLOOD_P ; MBCProject_MNHjCeCY_BLOOD_P ; MBCProject_odSqHlhG_BLOOD_P ; MBCProject_odSqHlhG_T7 ; MBCProject_DBi1S1cl_BLOOD_P ; MBCProject_rLt0uZhz_BLOOD_P ; MBCProject_LYtpINtB_BLOOD_P ; MBCProject_ZbTlfDcK_BLOOD_P ; MBCProject_WPHlSPTB_BLOOD_P ; MBCProject_axtmcztr_BLOOD_P ; MBCProject_bBIxhQUD_BLOOD_P ; MBCProject_N2HMfxSz_BLOOD_P ; MBCProject_7lC9TJT0_BLOOD_P ; MBCProject_A2TwSMcO_BLOOD_P ; MBCProject_0jUXcgsJ_BLOOD_P ; MBCProject_JYf4UmC7_BLOOD_P ; MBCProject_GjsDCOfR_T1 ; MBCProject_7oIotZSe_T1 ; MBCProject_kNiBiwtL_T2 ; MBCProject_pMcWcrtZ_T1 ; MBCProject_MBIOSgIG_BLOOD_P ; MBCProject_5Rc8S6Iz_BLOOD_P ; MBCProject_xoHAF6s8_T1 ; MBCProject_xoHAF6s8_T2 ; MBCProject_7OTls3Cz_BLOOD_P ; MBCProject_AmUotWsr_BLOOD_P ; MBCProject_JqfQclUP_BLOOD_P ; MBCProject_kPcWtWUk_BLOOD_P ; MBCProject_wlTjfwfB_BLOOD_P ; MBCProject_mrIDsjij_BLOOD_P ; MBCProject_BvsPhwI1_BLOOD_P ; MBCProject_zafPHNuX_BLOOD_P ; MBCProject_BztkUKtA_BLOOD_P ; MBCProject_07t2uAFn_BLOOD_P ; MBCProject_l8UGfecE_BLOOD_P ; MBCProject_OwCgI7fY_BLOOD_P ; MBCProject_XgHGHMUm_BLOOD_P ; MBCProject_lBSVSqup_BLOOD_P ; MBCProject_eQULU6Ug_BLOOD_P ; MBCProject_nYsGsgf7_BLOOD_P ; MBCProject_YXcpfacz_BLOOD_P ; MBCProject_JBcJhKtB_BLOOD_P ; MBCProject_lvCYUbiZ_BLOOD_P ; MBCProject_Mqu7Tacm_BLOOD_P ; MBCProject_DNckSWc3_BLOOD_P ; MBCProject_5wS3unim_BLOOD_P ; MBCProject_W4FBsLSx_BLOOD_P ; MBCProject_x3Tef5t3_BLOOD_P ; MBCProject_LlHlUas0_BLOOD_P ; MBCProject_jWt4f1So_BLOOD_P ; MBCProject_g1hacEF1_T1 ; MBCProject_e4SaTnIW_T3 ; MBCProject_m9uaInfr_BLOOD_P ; MBCProject_kjf7TNhM_BLOOD_P ; MBCProject_kQhvcOSQ_BLOOD_P ; MBCProject_qOFXIAux_BLOOD_P ; MBCProject_jWTAt6t6_BLOOD_P ; MBCProject_knuPtacD_BLOOD_P ; MBCProject_ZgTbHMhN_BLOOD_P ; MBCProject_1mFRTZu0_BLOOD_P ; MBCProject_GeurS8S6_BLOOD_P ; MBCProject_mlhYclhy_BLOOD_P ; MBCProject_eEtEC7IB_T2 ; MBCProject_W7HMcZI4_BLOOD_P ; MBCProject_W7HMcZI4_T1 ; MBCProject_W7HMcZI4_T2 ; MBCProject_W7HMcZI4_T3 ; MBCProject_W7HMcZI4_T4 ; MBCProject_JXUNUQI8_BLOOD_P ; MBCProject_53FkFziE_BLOOD_P ; MBCProject_VkSgSghO_BLOOD_P ; MBCProject_nEcXsyfj_BLOOD_P ; MBCProject_l5S6FdFR_BLOOD_P ; MBCProject_1JSQupur_BLOOD_P ; MBCProject_K9frSgTN_BLOOD_P ; MBCProject_9EHmUJIO_BLOOD_P ; MBCProject_D7U7SNiz_BLOOD_P ; MBCProject_NQIMHkTd_BLOOD_P ; MBCProject_3ehYUAsz_BLOOD_P ; MBCProject_69SPhYf2_BLOOD_P ; MBCProject_eAFkF0s8_BLOOD_P ; MBCProject_oAsLszt0_T1 ; MBCProject_rAs1s0F8_BLOOD_P ; MBCProject_rAs1s0F8_T1 ; MBCProject_4ViNTZSe_T1 ; MBCProject_yWS4imiO_BLOOD_P ; MBCProject_W2CQswiv_BLOOD_P ; MBCProject_nBfYHRSQ_BLOOD_P ; MBCProject_QGI0fOhX_BLOOD_P ; MBCProject_25TAUefB_BLOOD_P ; MBCProject_5gCKFQfm_BLOOD_P ; MBCProject_WzU1HEsr_T2 ; MBCProject_N4HEIRId_BLOOD_P ; MBCProject_4zcacDSB_BLOOD_P ; MBCProject_8YF9FlFx_BLOOD_P ; MBCProject_pzSJS7s4_BLOOD_P ; MBCProject_JxsQiWI9_T3 ; MBCProject_LDH0iycR_T1 ; MBCProject_YEFnulFd_T1 ; MBCProject_YEFnulFd_T2 ; MBCProject_bDH0sbix_T2 ; MBCProject_XWtLC4UZ_BLOOD_P ; MBCProject_G4s2c4fv_BLOOD_P ; MBCProject_ELtvf4UO_BLOOD_P ; MBCProject_nMHqU2Hx_BLOOD_P ; MBCProject_kwseuaHX_BLOOD_P ; MBCProject_l9HwF2io_BLOOD_P ; MBCProject_92frH4SX_T1 ; MBCProject_yNfLhMIW_BLOOD_P ; MBCProject_83Urs6H0_BLOOD_P ; MBCProject_wGFQuEcy_BLOOD_P ; MBCProject_PNursEUY_BLOOD_P ; MBCProject_ELU6IJh0_BLOOD_P ; MBCProject_JwiAIYSe_BLOOD_P ; MBCProject_AgF4uvCq_BLOOD_P ; MBCProject_rYSXcxcV_T1 ; MBCProject_wzUlU9hX_BLOOD_P ; MBCProject_oeubIAFD_T1 ; MBCProject_o5cqTwTa_BLOOD_P ; MBCProject_AesAugs2_BLOOD_P ; MBCProject_GOfliRi4_BLOOD_P ; MBCProject_ewHohEi6_T1 ; MBCProject_gxU5FJhl_BLOOD_P ; MBCProject_7XhrFPT1_T1 ; MBCProject_86HMf8FA_T2
SURGERY_AT_DX	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Surgery performed within 6 months of diagnosis	Patient	
TRIPLE_NEG_STATUS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Patient-reported response to the question: At any time, was your breast cancer found to be triple negative (e.g. NOT ER+, PR+, or HER2+)?	Patient	
T_STAGE_REPORTED	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	American Joint Committee on Cancer (AJCC) Summary Stage at Diagnosis. Using the AJCC method, a breast cancer is characterized by the size of the tumor (T), the number of lymph nodes it has spread to (N), and whether or not it has metastatsized (M). Together, the T, N, and M values are used to determine the Summary stage, e.g. Stage I, Stage II, Stage III, Stage IV	Patient	
X2YR_AIS	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on an aromatase inhibitors for more than 2 years.	Patient	
X2YR_ALKYLATING_AGENT	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on an alkylating agent for more than 2 years.	Patient	
X2YR_ANTHRACYCLINE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on an anthracycline for more than 2 years.	Patient	
X2YR_ANTIHER2	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on anti-HER2 therapy for more than 2 years.	Patient	
X2YR_CAPECITABINE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on capecitabine for more than 2 years.	Patient	
X2YR_CDK46	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on a CDK4/6 inhibitor for more than 2 years.	Patient	
X2YR_FULVESTRANT	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on fulvestrant for more than 2 years.	Patient	
X2YR_TAMOXIFEN	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on tamoxifen for more than 2 years.	Patient	
X2YR_TAXANE	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on a taxane for more than 2 years.	Patient	
X2YR_VEGF_INHIBITOR	HotPink	The Metastatic Breast Cancer Project (Archived, 2020)	STRING	Calculated based on patient-reported response to the question:  If [you have been on any therapies for more than two years], please list the cancer therapies you have been on for more than 2 years, if you know their names. Listed as TRUE if patients reported being on a VEGF inhibitor for more than 2 years.	Patient	
AGE_AT_DIAGNOSIS	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient's age at the time of primary diagnosis with breast cancer grouped into 5 year intervals.	Patient	
ANYTIME_CANCER_LOC_ASCITES	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Ascites	Patient	
ANYTIME_CANCER_LOC_AXILLARY_LYMPH_NODE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Axillary lymph node (lymph nodes in the armpit)	Patient	
ANYTIME_CANCER_LOC_BONE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Bone	Patient	
ANYTIME_CANCER_LOC_BRAIN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Brain	Patient	
ANYTIME_CANCER_LOC_BREAST	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Breast	Patient	
ANYTIME_CANCER_LOC_CHEST_WALL	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Chest Wall	Patient	
ANYTIME_CANCER_LOC_LIVER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Liver	Patient	
ANYTIME_CANCER_LOC_LUNG	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Lung	Patient	
ANYTIME_CANCER_LOC_OTHER_LYMPH_NODE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Lymph nodes anywhere other than the axilla/armpit	Patient	
ANYTIME_CANCER_LOC_OVARY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Ovary	Patient	
ANYTIME_CANCER_LOC_PLEURAL_EFFUSION	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Pleural Effusion	Patient	
ANYTIME_CANCER_LOC_SKIN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: Please select all of the places in your body that metastatic breast cancer has been found at any time (select all that apply). Listed as TRUE if patient selected Skin	Patient	
CANCER_IDENTIFICATION_IDC	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: At any time since your original diagnosis of breast cancer was it identified as any of the following (select all that apply)? Listed as TRUE if patient selected Invasive Ductal Carcinoma (IDC)	Patient	
CANCER_IDENTIFICATION_ILC	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: At any time since your original diagnosis of breast cancer was it identified as any of the following (select all that apply)? Listed as TRUE if patient selected Invasive Lobular Carcinoma (ILC)	Patient	
CANCER_IDENTIFICATION_MIDLC	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: At any time since your original diagnosis of breast cancer was it identified as any of the following (select all that apply)? Listed as TRUE if patient selected Mixed Invasive Ductal/Lobular Carcinoma	Patient	
CANCER_IDENTIFICATION_RARE_SUBTYPE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: At any time since your original diagnosis of breast cancer was it identified as any of the following (select all that apply)? Listed as TRUE if patient selected Other Rare Subtypes	Patient	
DCIS_SX_BX	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Whether DCIS was present in surgical biopsy	Patient	
DIAGNOSED_BY_SCREENING	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Whether patient was diagnosed by screening	Patient	
DIAGNOSIS_CANCER_BONE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Bone	Patient	
DIAGNOSIS_CANCER_LOC_ASCITES	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Ascites	Patient	
DIAGNOSIS_CANCER_LOC_AXILLARY_LN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Axillary lymph node (lymph nodes in the armpit)	Patient	
DIAGNOSIS_CANCER_LOC_BRAIN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Brain	Patient	
DIAGNOSIS_CANCER_LOC_BREAST	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Breast	Patient	
DIAGNOSIS_CANCER_LOC_CHEST_WALL	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Chest Wall	Patient	
DIAGNOSIS_CANCER_LOC_LIVER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Liver	Patient	
DIAGNOSIS_CANCER_LOC_LUNG	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Lung	Patient	
DIAGNOSIS_CANCER_LOC_OTHER_LN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Lymph nodes anywhere other than the axilla/armpit	Patient	
DIAGNOSIS_CANCER_LOC_OVARY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Ovary	Patient	
DIAGNOSIS_CANCER_LOC_PLEURAL_EFFUSION	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Pleural Effusion	Patient	
DIAGNOSIS_CANCER_LOC_SKIN	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient reported response to the question: When you were first diagnosed with metastatic breast cancer, where were all of the places in your body where it was detected (select all that apply)? Listed as TRUE if patient selected Skin	Patient	
DX_BREASTFEEDING	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Whether the patient's initial breast cancer was diagnosed while breast feeding	Patient	
DX_CEP17_COPY_NUMBER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Copy nubmer of CEP17 in diagnostic sample	Patient	
DX_HER2_COPY_NUMBER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Copy number of HER2 in diagnostic sample	Patient	
DX_PREGNANT	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Whether the patient's initial breast cancer was diagnosed during pregnancy	Patient	
HER2_POSITIVE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	 Patient-reported response to the question: At any time, was your breast cancer found to be HER2 positive (HER2+)?	Patient	
HR_POSITIVE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	 Patient-reported response to the question: At any time, was your breast cancer found to be hormone receptor positive (HR+, ER+ and/or PR+)?	Patient	
INFLAMMATORY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	 Patient-reported response to the question: At any time, were you diagnosed with inflammatory breast cancer?	Patient	
LCIS_SX_BX	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Whether LCIS was present in surgical biopsy	Patient	
LOCAL_REGIONAL_RECURRENCE_LOCATION	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient's location of breast cancer at diagnosis of local regional recurrence	Patient	
MENOPAUSAL_STATUS_DX	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Menopausal status of patient at initial diagnosis	Patient	
METS_SITES_AT_METS_ABST	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	All locations in the body where breast cancer spread at any point in the patient's treatment	Patient	
METS_SITES_AT_METS_DX	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	All locations in the body where breast cancer spread at the time of diagnosis with metastatic breast cancer.	Patient	
PT_NOTES	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Additional notable information about  patient not mentioned in previous fields.	Patient	
RACE_CATEGORY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Patient-reported response to the question: What is your race (select all that apply)? Infrequent responses have been categorized as Other for confidentiality.	Patient	
SX_CEP17_COPY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 CEP17 Copy Number of Surgical Biopsy	Patient	
SX_ER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	ER Status of Surgical Biopsy	Patient	
SX_GRADE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Grade of Surgical Biopsy	Patient	
SX_HER2FISH	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 FISH Status of Surgical Biopsy	Patient	
SX_HER2IHC	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 IHC Status of Surgical Biopsy	Patient	
SX_HER2OVERALL	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 Overall Status of Surgical Biopsy	Patient	
SX_HER2_COPY	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 Copy Number of Surgical Biopsy	Patient	
SX_HER2_RATIO	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	HER2 Ratio of Surgical Biopsy	Patient	
SX_PERCENT_ER	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	ER Percentage of Surgical Biopsy	Patient	
SX_PERCENT_PR	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	PR Percentage of Surgical Biopsy	Patient	
SX_PR	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	PR Status of Surgical Biopsy	Patient	
SX_STAGE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	Stage of surgical biopsy as recorded in medical record	Patient	
THERAPIES	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	 Patient-reported response to the question: Since your diagnosis with metastatic breast cancer, have you been on any of your cancer therapies for more than 2 years?	Patient	
TRIPLE_NEGATIVE	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	STRING	 Patient-reported response to the question: At any time, was your breast cancer found to be triple negative (e.g. NOT ER+, PR+, or HER2+)?	Patient	
TUMOR_FRACTION	HotPink	The Metastatic Breast Cancer Project (Provisional, December 2021)	NUMBER	Tumor fraction value derived from Ultra Low Pass Whole Genome Sequencing (ULP-WGS) performed on cell-free DNA (cfDNA) from blood samples.	Sample	0.2992 ; 0.2985 ; 0.07889 ; 0.1094 ; 0.1458 ; 0.05484 ; 0.08272 ; 0.27 ; 0.09148 ; 0.6382 ; 0.4004 ; 0.08137 ; 0.4282 ; 0.2379 ; 0.06543 ; 0.255 ; 0.4932 ; 0.2252 ; 0.1972 ; 0.07212 ; 0.1429 ; 0.1634 ; 0.1076 ; 0.08131 ; 0.3765 ; 0.2698 ; 0.3895 ; 0.1386 ; 0.1792 ; 0.06182 ; 0.1284 ; 0.0682 ; 0.2896 ; 0.05773 ; 0.3131 ; 0.05178 ; 0.07764 ; 0.1104 ; 0.2777 ; 0.4222 ; 0.07604 ; 0.1639 ; 0.336 ; 0.06191 ; 0.1063 ; 0.05234 ; 0.2018 ; 0.1363 ; 0.3213 ; 0.1685 ; 0.05103 ; 0.4415 ; 0.3388 ; 0.05365 ; 0.2369 ; 0.2928 ; 0.06483 ; 0.07667 ; 0.08566 ; 0.06811 ; 0.05009 ; 0.1036 ; 0.2079 ; 0.1618 ; 0.06479 ; 0.3112 ; 0.4071 ; 0.09866 ; 0.05518 ; 0.2108 ; 0.07329 ; 0.1498 ; 0.06245 ; 0.08217 ; 0.05679 ; 0.2681 ; 0.1596 ; 0.502 ; 0.3017 ; 0.2964 ; 0.05409 ; 0.2262 ; 0.05815 ; 0.0957 ; 0.05072 ; 0.05163 ; 0.2558 ; 0.277 ; 0.1265 ; 0.3045 ; 0.439 ; 0.05876 ; 0.05225 ; 0.1438 ; 0.1416 ; 0.4101 ; 0.2557 ; 0.3321 ; 0.05766 ; 0.1506 ; 0.3144 ; 0.05247 ; 0.3769
AJCC_METASTASIS_PATHOLOGIC_PM	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Code to represent the defined absence or presence of distant spread or metastases (M) to locations via vascular channels or lymphatics beyond the regional lymph nodes, using criteria established by the American Joint Committee on Cancer (AJCC).	Patient	
AJCC_NODES_PATHOLOGIC_PN	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	Patient	
AJCC_PATHOLOGIC_TUMOR_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The extent of a cancer, especially whether the disease has spread from the original site to other parts of the body based on AJCC staging criteria.	Patient	
AJCC_STAGING_EDITION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The version or edition of the American Joint Committee on Cancer Cancer Staging Handbooks, a publication by the group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.	Patient	
AJCC_TUMOR_PATHOLOGIC_PT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC).	Patient	
BRACHYTHERAPY_TOTAL_DOSE_POINT_A	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Brachytherapy first reference point administered total dose	Patient	
CENT17_COPY_NUMBER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Fluorescence in situ hybridization diagnostic procedure chromosome 17 signal result range	Patient ; Sample	1.1 ; 1.9 ; 4 ; 2.9 ; 160 ; 51 ; 2.98 ; 2.08 ; 2.13 ; 1.8 ; 2 ; 2.2 ; 2.5 ; 1.57 ; 49 ; 74 ; 3 ; 2.3 ; 2.8 ; 2.7 ; 46 ; 1.93 ; 3.7 ; 1.5 ; 4.43 ; 1.45 ; 1.4 ; 3.33 ; polisomy ; 1.7 ; 3.2 ; 5 ; 125 ; 3.1 ; 118 ; 1.67 ; 1.73 ; 2.38 ; 54 ; 35 ; 2.65
CLINICAL_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Stage group determined from clinical information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for cancer.	Patient	
CLIN_T_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Extent of the primary cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Patient	
DAYS_TO_COLLECTION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Days to sample collection.	Sample	1416 ; 4330 ; 4242 ; 4137 ; 4106 ; 4103 ; 4230 ; 3879 ; 109 ; 122 ; 120 ; 94 ; 100 ; 88 ; 1240 ; 344 ; 372 ; 198 ; 937 ; 315 ; 338 ; 310 ; 229 ; 69 ; 832 ; 2604 ; 1553 ; 147 ; 617 ; 156 ; 2781 ; 4536 ; 4537 ; 4343 ; 3752 ; 3840 ; 4147 ; 3091 ; 5230 ; 4301 ; 3871 ; 4456 ; 4420 ; 4460 ; 4670 ; 4574 ; 4572 ; 4753 ; 4838 ; 4876 ; 121 ; 116 ; 52 ; 272 ; 211 ; 194 ; 232 ; 201 ; 230 ; 238 ; 203 ; 215 ; 263 ; 226 ; 261 ; 264 ; 243 ; 273 ; 292 ; 212 ; 250 ; 295 ; 938 ; 883 ; 368 ; 1325 ; 912 ; 465 ; 213 ; 590 ; 214 ; 51 ; 155 ; 123 ; 528 ; 764 ; 1648 ; 1581 ; 1267 ; 1091 ; 967 ; 1932 ; 932 ; 679 ; 854 ; 707 ; 423 ; 416 ; 548 ; 581 ; 909 ; 988 ; 63 ; 66 ; 42 ; 37 ; 1030 ; 469 ; 444 ; 550 ; 526 ; 928 ; 1142 ; 919 ; 525 ; 325 ; 249 ; 604 ; 224 ; 220 ; 569 ; 112 ; 44 ; 84 ; 829 ; 335 ; 5041 ; 197 ; 218 ; 251 ; 188 ; 170 ; 169 ; 417 ; 359 ; 136 ; 2998 ; 1051 ; 31 ; 30 ; 21 ; 64 ; 45 ; 53 ; 850 ; 2634 ; 86 ; 62 ; 260 ; 173 ; 141 ; 225 ; 275 ; 282 ; 189 ; 193 ; 158 ; 162 ; 164 ; 144 ; 102 ; 103 ; 76 ; 135 ; 98 ; 104 ; 93 ; 252 ; 65 ; 80 ; 58 ; 77 ; 478 ; 5538 ; 5893 ; 5392 ; 399 ; 2815 ; 176 ; 38 ; 39 ; 1246 ; 56 ; 48 ; 59 ; 183 ; 2441 ; 161 ; 79 ; 40 ; 54 ; 3641 ; 2325 ; 2275 ; 2245 ; 2219 ; 2213 ; 2161 ; 1913 ; 1812 ; 1786 ; 1763 ; 1720 ; 1717 ; 1673 ; 1629 ; 1611 ; 1405 ; 1381 ; 1225 ; 3740 ; 5418 ; 163 ; 435 ; 32 ; 49 ; 41 ; 1238 ; 2927 ; 223 ; 143 ; 142 ; 134 ; 125 ; 168 ; 204 ; 166 ; 132 ; 83 ; 75 ; 50 ; 68 ; 43 ; 2429 ; 101 ; 576 ; 1904 ; 1517 ; 1074 ; 133 ; 99 ; 1833 ; 2051 ; 3755 ; 1340 ; 1315 ; 1339 ; 1490 ; 1372 ; 1464 ; 2109 ; 2464 ; 2436 ; 108 ; 1661 ; 513 ; 486 ; 449 ; 447 ; 4665 ; 1910 ; 6583 ; 1644 ; 1820 ; 2144 ; 2723 ; 2228 ; 2606 ; 91 ; 160 ; 106 ; 1382 ; 986 ; 219 ; 174 ; 299 ; 700 ; 78 ; 1590 ; 97 ; 245 ; 2164 ; 4248 ; 401 ; 146 ; 1015 ; 2979 ; 778 ; 3080 ; 2709 ; 2191 ; 61 ; 67 ; 1506 ; 796 ; 182 ; 3110 ; 2198 ; 3355 ; 2089 ; 184 ; 114 ; 233 ; 1779 ; 1627 ; 306 ; 1148 ; 1143 ; 703 ; 845 ; 87 ; 1954 ; 1610 ; 1935 ; 1563 ; 2467 ; 2677 ; 312 ; 1500 ; 1480 ; 418 ; 505 ; 899 ; 60 ; 567 ; 210 ; 149 ; 159 ; 127 ; 110 ; 639 ; 1871 ; 414 ; 129 ; 140 ; 36 ; 1541 ; 73 ; 1378 ; 1415 ; 1357 ; 1407 ; 2858 ; 2411 ; 2066 ; 154 ; 328 ; 498 ; 85 ; 499 ; 616 ; 131 ; 47 ; 29 ; 826 ; 755 ; 771 ; 561 ; 421 ; 343 ; 279 ; 70 ; 254 ; 595 ; 429 ; 441 ; 1715 ; 1645 ; 981 ; 560 ; 259 ; 128 ; 952 ; 107 ; 237 ; 152 ; 244 ; 350 ; 71 ; 289 ; 74 ; 605 ; 285 ; 139 ; 55 ; 507 ; 869 ; 1493 ; 468 ; 436 ; 191 ; 921 ; 477 ; 231 ; 185 ; 157 ; 126 ; 181 ; 3599 ; 3772 ; 1026 ; 1022 ; 35 ; 1320 ; 1259 ; 742 ; 105 ; 278 ; 216 ; 240 ; 148 ; 92 ; 187 ; 22 ; 656 ; 2928 ; 3020 ; 1316 ; 720 ; 384 ; 167 ; 241 ; 1184 ; 941 ; 759 ; 1276 ; 667 ; 1003 ; 1518 ; 1033 ; 880 ; 453 ; 302 ; 394 ; 180 ; 698 ; 637 ; 606 ; 575 ; 788 ; 484 ; 422 ; 1733 ; 819 ; 2767 ; 2036 ; 363 ; 1153 ; 333 ; 728 ; 769 ; 34 ; 33 ; 2694 ; 2414 ; 587 ; 995 ; 1328 ; 308 ; 2623 ; 2260 ; 1979 ; 1390 ; 756 ; 2546 ; 2445 ; 2310 ; 1911 ; 1274 ; 1204 ; 614 ; 2696 ; 2331 ; 2038 ; 1862 ; 674 ; 358 ; 545 ; 119 ; 27 ; 743 ; 676 ; 28 ; 57 ; 1608 ; 1031 ; 668 ; 554 ; 748 ; 177 ; 1207 ; 118 ; 5305 ; 7820 ; 7362 ; 6372 ; 6687 ; 6664 ; 6660 ; 6475 ; 5557 ; 5836 ; 5350 ; 4754 ; 5073 ; 3278 ; 4565 ; 5238 ; 364 ; 552 ; 946 ; 352 ; 962 ; 1591 ; 1931 ; 644 ; 2456 ; 258 ; 1178 ; 1522 ; 1863 ; 1011 ; 1477 ; 1332 ; 1828 ; 5724 ; 7492 ; 6869 ; 6755 ; 1071 ; 1401 ; 1391 ; 1266 ; 1080 ; 1094 ; 293 ; 301 ; 745 ; 206 ; 583 ; 542 ; 1088 ; 739 ; 549 ; 672 ; 470 ; 1672 ; 1305 ; 1399 ; 1164 ; 1115 ; 1057 ; 958 ; 2348 ; 2597 ; 1317 ; 1513 ; 1337 ; 1177 ; 1083 ; 268 ; 303 ; 280 ; 395 ; 2512 ; 1512 ; 1535 ; 1567 ; 1716 ; 1888 ; 1976 ; 2239 ; 6336 ; 6279 ; 6286 ; 6035 ; 5890 ; 7858 ; 5047 ; 7290 ; 5165 ; 1098 ; 968 ; 190 ; 346 ; 2233 ; 673 ; 572 ; 329 ; 321 ; 205 ; 691 ; 884 ; 1633 ; 2289 ; 2395 ; 2413 ; 5606 ; 5531 ; 4664 ; 4476 ; 5294 ; 5179 ; 5323 ; 5600 ; 906 ; 724 ; 1414 ; 1596 ; 3254 ; 3213 ; 3193 ; 3033 ; 2960 ; 2915 ; 2365 ; 2086 ; 1822 ; 365 ; 3403 ; 6002 ; 1171 ; 1495 ; 715 ; 596 ; 1155 ; 1065 ; 801 ; 1697 ; 2850 ; 1924 ; 1630 ; 1552 ; 2030 ; 1574 ; 1533 ; 670 ; 2793 ; 1948 ; 1578 ; 1017 ; 1549 ; 2141 ; 2301 ; 5388 ; 6821 ; 5113 ; 5243 ; 761 ; 1223 ; 798 ; 1135 ; 1217 ; 1197 ; 1170 ; 1344 ; 1338 ; 1130 ; 997 ; 541 ; 815 ; 89 ; 221 ; 1096 ; 1064 ; 910 ; 792 ; 652 ; 519 ; 461 ; 434 ; 393 ; 360 ; 269 ; 247 ; 2368 ; 1162 ; 891 ; 454 ; 1044 ; 16 ; 3948 ; 4011 ; 2669 ; 3629 ; 3374 ; 2639 ; 3417 ; 3571 ; 2695 ; 2737 ; 2697 ; 3621 ; 965 ; 960 ; 827 ; 722 ; 716 ; 597 ; 506 ; 475 ; 457 ; 426 ; 387 ; 357 ; 287 ; 1939 ; 1744 ; 1528 ; 1463 ; 1471 ; 1450 ; 1424 ; 1331 ; 1233 ; 1157 ; 1140 ; 1085 ; 1008 ; 413 ; 1167 ; 1084 ; 1335 ; 1248 ; 972 ; 267 ; 975 ; 773 ; 675 ; 309 ; 2527 ; 1268 ; 783 ; 729
DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Time interval from the last day on which a person is known to be alive to the date of initial pathologic diagnosis, represented as a calculated number of days.	Patient	
DAYS_TO_PATIENT_PROGRESSION_FREE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	days_to_patient_progression_free	Patient	
DAYS_TO_SPECIMEN_COLLECTION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Days to sample procurement.	Sample	
DAYS_TO_TUMOR_PROGRESSION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	days_to_tumor_progression	Patient	
DFS_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Disease free status since initial diagnosis	Patient	
DISEASE_CODE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Disease code	Patient ; Sample	FPPP
ER_POSITIVITY_SCALE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Positive finding estrogen receptor other measurement scale text	Patient ; Sample	Strong ; 10-75% ; >75% ; H-Score ; H-SCORE ; Allred Score 8 ; Allred Score 7 ; 0 ; Allred score = 7 ; Allred score = 0 ; Allred score = 8 ; Allred score = 5 ; 7 ; Two-tier ; 8 ; H score ; Allred Score = 7 ; >10% ; Allred score 5 ; Allred score 8 ; Allred score 7 (per outside facility) ; Allred score 7 ; 230 ; Allred ; 80 ; 120 ; 180 ; 250 ; 190 ; 205 ; Intensity=Strong ; Intensity=moderate ; Allred Score 6 ; Allred Score 5 ; Allred Score ; allred score = 8 ; Strong using Weak, Moderate and Strong ; 288 fmol/mg ; Moderate using the scale of Weak, Moderate, Strong ; Moderate using scale of Weak, Moderate, Strong ; STRONG ; allred scrore = 8 ; allred score = 0 ; 49 fmol/mg protein ; allred score = 7 ; Allred score = 2 ; H Score
ER_POSITIVITY_SCALE_USED	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast carcinoma immunohistochemistry er pos finding scale	Patient ; Sample	3 Point Scale ; 4 Point Scale
ER_STATUS_IHC_PERCENT_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	progesterone receptor level cell percent category	Patient ; Sample	90-99% ; <10% ; 70-79% ; 80-89% ; 50-59% ; 40-49% ; 10-19% ; 30-39% ; 20-29% ; 60-69%
EXTRANODAL_INVOLVEMENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Indicator that identifies whether a patient with malignant lymphoma has lymphomatous involvement of an extranodal site.	Patient	
FIRST_SURGICAL_PROCEDURE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Surgical procedure purpose other text	Patient ; Sample	Total mastectomy with left sentinel lymph node biospy ; Segmental mastectomy ; bilateral total mastectomies with right sentinel node biopsy ; Patey's Surgery ; Right Total Mastectomy and Sentinel Node Biopsy ; Right total mastectomy with lymph node left axillary lymph node excision ; Left segmental mastectomy with axillary lymph node dissection ; Total Mastectomy ; Bilateral Mastectomy ; Total mastectomy ; Bilateral skin sparing Mastectomy and Bilateral breast reconstruction with tissue expanders. ; segmental mastectomy ; Fine Needle aspiration biopsy ; excisional biopsy ; Excisional biopsy ; Wide local excision ; Modified radical mastectomy with left breast biopsy ; total mastectomy ; Wide re-excisional biopsy ; total mastectomy and sentinel node biopsy ; right segmental mastectomy ; needle localized segmental mastectomy ; biopsy ; Wide Local Excision ; right segmental mastectomy witrh axillary node dissection ; Right segmental mastectomy with sentinel lymph node and axillary lymph node biopsy ; Left segmental mastectomy with level 1 and level 2 axillary dissection ; Right segmental mastectomy ; Left segmental mastectomy with left axillary lymph node dissection ; total mastectomy with rigth axillary lymph node and sentinel lymph node dissection ; segmental mastectomy with excision of mass on chest wall and axillary node dissection ; segmental mastectomy with axillary lymph node dissection ; needle directed right breast biopsy with left segmental mastectomy with axillary lymph node dissection ; localized segmental mastectomy with axillary node dissection ; Partial mastectomy ; partial left mastectomy ; Surgical Resection ; Mastectomy ; Surgical resection ; TOTAL MASTECTOMY ; Modified Radical Masectomy ; Pateys surgery ; Excision ; Partial Mastectomy ; breast conserving therapy ; Excisional biospy ; Total mastectomy with retromammary lymph node excision ; Segmental mastectomy with sentinel lymph node biopsy ; Segmental mastectomy with sentinel node biopsy ; Total mastectomy with sentinel lymoh node biopsy ; Total mastectomy with sentinel lymph node biopsy ; segmental mastectomy with right sentinel lymph node biopsy ; partial mastectomy ; total mastectomy with sentinel lymph node biopsy with tissue reconstruction ; left segmental mastectomy with axillary sentinel lymph node biopsy ; left segmental mastectomy with sentinel node dissection ; segmental mastectomy with sentinel lymph node biopsy ; right total mastectomy with sentinel lymph node dissection right reconstruction with TRAMP ; Segmental mastectomy with left axillary lymph node dissection ; segmental mastectomy with sentinel lymph node biopsy and wire localization ; Segmental mastectomy with sentinel axillary lymph node biopsy
FORM_COMPLETION_DATE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Form completion date	Patient	
HER2_AND_CENT17_CELLS_COUNT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	HER2 neu and centromere 17 copy number analysis input total number count	Patient ; Sample	60 ; 20 ; 279 ; 389 ; 30 ; 40 ; 330 ; 229 ; 228 ; 569 ; 556 ; 197 ; 561 ; 403 ; 371 ; 200 ; 65 ; 167
HER2_AND_CENT17_SCALE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 and centromere 17 positive finding other measurement scale text	Patient ; Sample	Vysis AutoVysion System ; HER2 amplification - negative
HER2_CENT17_COUNTED_CELLS_COUNT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	HER2 neu and centromere 17 copy number metastatic breast carcinoma analysis input total number count	Patient	
HER2_CENT17_RATIO	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	HER2 neu chromosone 17 signal ratio value	Patient ; Sample	1.05 ; 1 ; 1.2 ; 1.1 ; 1.6 ; 0.92 ; 16.3 ; 1.5 ; 1.21 ; 2.6 ; 1.9 ; 7.1 ; 1.4 ; 1.03 ; 0.42 ; 1.15 ; 3 ; 3.8 ; 15.12 ; 1.3 ; 4.8 ; 2.2 ; 0.9 ; 1.04 ; 1.7 ; 2.7 ; 1.29 ; 1.65 ; 1.02 ; 1.18 ; 3.2 ; 1.08 ; 1.46 ; 1.11 ; 1.07 ; 1.16 ; 4.05 ; 1.06 ; 1.12 ; 1.32 ; 0.97 ; 1.09 ; 1.33 ; 7 ; 1.22 ; 1.8 ; 1.14 ; 1.41 ; 1.17 ; 0.5 ; 11 ; 2.1 ; 1.13 ; 0.99 ; 0.93 ; 1.23 ; 1.69 ; 1.19 ; 3.4 ; 1.25 ; 1.31 ; 2.83 ; 4.7
HER2_COPY_NUMBER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 neu breast carcinoma copy analysis input total number	Patient ; Sample	1.1 ; 1.8 ; 4.6 ; 3.2 ; 185 ; 816 ; 3.43 ; 2.2 ; 2.58 ; 1.9 ; 5.8 ; 3.3 ; 3.8 ; 2.8 ; 2.5 ; 2.6 ; 5 ; 2 ; >6 ; 52 ; 114 ; 3 ; 2.4 ; 79 ; not amplified ; 2.23 ; 15 ; 1.67 ; 4.7 ; 1.62 ; 1.57 ; 3.53 ; 1 ; <4.0 ; >6.0 ; 6.4 ; 2.3 ; 21 ; 132 ; 145 ; 1.73 ; 1.85 ; 2.81 ; 2.83 ; 172 ; 118 ; 1.66 ; 4.5 ; 5.65 ; 12.45
HER2_FISH_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 erbb pos finding fluorescence in situ hybridization calculation method text	Patient ; Sample	PathVysion HER-2 DNA Probe Kit ; PathVysion ; PathVysion HER-2 DNA probe kit. ; Path Vysion HER-2 DNA probe kit ; PathVysion Her-2 DNA ; Pathvysion HER-2 DNA Probe Kit ; ratio > 2.2 is positive ; >=2.0 Positive ; Enumerate 60 tumor cells; ratio HER2/Centromer 17 >= 2.1 is amplified ; Enumerate 60 tumor cells; ratio HER2/Centromere 17 >= 2.1 is amplified ; Pathvysion HER2 DNA Probe Kit ; Enumerate 60 tumor cells; Ratio of HER2/Centromere 17 >=2.1 is amplified ; Enumerate 60 tumor cells; ratio of HER2/Centromere 17 >= 2.1 is amplified ; Enumerate 60 tumor cells; ratio of HER2/Centromere >=2.1 is amplified ; Path Vysion HER2 DNA Probe Kit ; >2.2 Positive ; Positive >2.2 ; PathVision HER2 DNA Probe Kit
HER2_IHC_PERCENT_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 erbb pos finding cell percent category	Patient ; Sample	<10% ; 30-39% ; 10-19% ; 90-99% ; 70-79% ; 40-49% ; 50-59% ; 20-29% ; 60-69% ; 80-89%
HER2_POSITIVITY_METHOD_TEXT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 erbb method calculation method text	Patient ; Sample	Hecep Test TM DAKO ; Hercep Test  TM Dako ; DAKO Hercep Test TM ; Hercep Test TM DAKO ; 3+ Positive ; dextran coated charcoal ; + or - ; HerceptTest TM Dako ; Venten ; HercepTest TM Dako ; Dako Hercept Test ; DAKOHercepTest TM
HER2_POSITIVITY_SCALE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pos finding HER2 erbb2 other measurement scale text	Patient ; Sample	Hercep Test  TM Dako ; FISH ; Dako ; 0 ; CISH ; ACIS ; 10-75%
HISTOLOGICAL_SUBTYPE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text to describe a tumor's histologic subtype or mixed diagnosis that is different from previously specified options.	Patient	
HISTORY_NEOADJUVANT_TRTYN	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text term to describe the patient's history of neoadjuvant treatment and the kind of treament given prior to resection of the tumor.	Patient	
HISTORY_OTHER_MALIGNANCY	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text term to describe the patient's history of prior cancer diagnosis and the spatial location of any previous cancer occurrence.	Patient	
ICD_10	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	10th revision of the International Statistical Classification of Diseases and Related Health Problems.	Patient	
ICD_O_3_HISTOLOGY	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._A system of numbered categories for representation of data.	Patient	
ICD_O_3_SITE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The third edition of the International Classification of Diseases for Oncology, published in 2000, used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms._The description of an anatomical region or of a body part._Named locations of, or within, the body._A system of numbered categories for representation of data.	Patient	
IHC_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	IHC Score	Patient ; Sample	1 ; 3 ; 2 ; 0 ; 4
INFORMED_CONSENT_VERIFIED	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Informed consent verified	Patient	
INITIAL_PATHOLOGIC_DX_YEAR	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Numeric value to represent the year of an individual's initial pathologic diagnosis of cancer.	Patient	
IS_FFPE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	If the sample is from FFPE	Sample	NO
LONGEST_DIMENSION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Longest dimension of the sample measured in millimeters	Sample	
LYMPH_NODES_EXAMINED	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	the yes/no/unknown indicator whether a lymph node assessment was performed at the primary presentation of disease.	Patient	
LYMPH_NODES_EXAMINED_HE_COUNT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Numeric value to signify the count of positive lymph nodes identified through hematoxylin and eosin (H&E) staining light microscopy.	Patient	
LYMPH_NODES_EXAMINED_IHC_COUNT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Numeric value to signify the count of positive lymph nodes identified through keratin immunohistochemistry (IHC) staining method,	Patient	
LYMPH_NODE_EXAMINED_COUNT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	The total number of lymph nodes removed and pathologically assessed for disease.	Patient	
MARGIN_STATUS_REEXCISION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast cancer surgery margin status	Patient ; Sample	Close ; Negative ; Positive
METASTATIC_SITE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic Site Other	Patient ; Sample	Abdomen ; axilaary node negative but intrammary node positive ; Skin ; skin ; Ovary
METASTATIC_SITE_PATIENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The anatomic location to which the cancer has spread.	Patient	
METHOD_OF_INITIAL_SAMPLE_PROCUREMENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text name of the procedure to secure the tissue used for the original pathologic diagnosis.	Patient	
METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text to describe a method used to secure tissue for an original pathologic diagnosis that is different from other identified methods.	Patient	
METHOD_OF_SAMPLE_PROCUREMENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text name of the procedure to secure the tissue used for the original pathologic diagnosis.	Sample	
MICROMET_DETECTION_BY_IHC	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Cytokeratin immunohistochemistry staining method micrometastasis indicator	Patient ; Sample	NO ; YES
NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Yes/No/Unknown indicator to identify whether a patient has had a new tumor event after initial treatment.	Patient ; Sample	NO ; YES
NTE_CENT17_HER2_OTHER_SCALE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma pos finding other scale measurement text	Patient	
NTE_CENT_17_HER2_RATIO	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Metastatic breast carcinoma HER2 neu chromosone 17 signal ratio value	Patient ; Sample	2.47 ; 1.09
NTE_CENT_17_SIGNAL_NUMBER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma fluorescence in situ hybridization diagnostic proc centromere 17 signal result range	Patient	
NTE_ER_IHC_INTENSITY_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma immunohistochemistry er pos cell score	Patient ; Sample	3
NTE_ER_POSITIVITY_DEFINE_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma estrogen receptor detection method text	Patient	
NTE_ER_POSITIVITY_OTHER_SCALE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pos finding metastatic breast carcinoma estrogen receptor other measuremenet scale text	Patient	
NTE_ER_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma estrogen receptor status	Patient ; Sample	Positive ; Negative
NTE_ER_STATUS_IHC_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma estrogen receptor level cell percent category	Patient	
NTE_HER2_FISH_DEFINE_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma HER2 erbb pos finding fluorescence in situ hybridization calculation method text	Patient	
NTE_HER2_FISH_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma lab proc HER2 neu in situ hybridization outcome type	Patient ; Sample	Negative
NTE_HER2_POSITIVITY_IHC_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma erbb2 immunohistochemistry level result	Patient ; Sample	2+ ; 1+
NTE_HER2_POSITIVITY_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma HER2 erbb method calculation method text	Patient	
NTE_HER2_POSITIVITY_OTHER_SCALE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma pos finding HER2 erbb2 other measure scale text	Patient	
NTE_HER2_SIGNAL_NUMBER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	HER2 neu metastatic breast carcinoma copy analysis input total number	Patient	
NTE_HER2_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma lab proc HER2 neu immunohistochemistry receptor status	Patient ; Sample	Negative
NTE_HER2_STATUS_IHC_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma HER2 erbb pos finding cell percent category	Patient	
NTE_PR_IHC_INTENSITY_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Metastatic breast carcinoma immunohistochemistry pr pos cell score	Patient ; Sample	1
NTE_PR_POSITIVITY_DEFINE_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma progesterone receptor detection method text	Patient	
NTE_PR_POSITIVITY_OTHER_SCALE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma pos finding progesterone receptor other measure scale text	Patient	
NTE_PR_STATUS_BY_IHC	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma progesterone receptor status	Patient ; Sample	Negative ; Positive
NTE_PR_STATUS_IHC_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic breast carcinoma progesterone receptor level cell percent category	Patient	
OCT_EMBEDDED	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Oct embedded	Sample	TRUE ; FALSE
OTHER_METHOD_OF_SAMPLE_PROCUREMENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The type of procedure or method used to collect the specimen.	Sample	
OTHER_SAMPLE_ID	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Legacy DMP sample identifier (DMPnnnn)	Sample	5fa9998b-deff-493e-8a8e-dc2422192a48 ; 9d501ca9-f50d-45fc-bcc3-fee15f9771cd ; aa1037f4-1414-4e05-b11a-c558a23b7e62 ; 2190d984-3941-41d4-b6de-d0aa76f3570d ; 73af0f78-cc37-43ff-8f46-524a9ba80eda ; 29ac24fb-0065-47f8-b044-f4a66fad2394 ; 50463a25-4292-4bc7-926a-341493e68242 ; f754aa5f-49c8-4e8b-a1fe-f370f807499a ; f2a49aa7-b756-4eaa-a6fd-00f56c7e7851 ; bed56886-f4fe-4917-b32a-18b3d3f47c24 ; f0471d79-d107-4809-976e-fe5b231f0e9d ; fa3f34b7-5f69-41f8-9384-42af0260d7ec ; e3118dbe-9f93-45b0-81d3-2e64f06b7c74 ; fc3fe505-f138-426f-87d3-c7ae138be02d ; caa51a8b-eadc-4d87-b0f8-f6ffc17723b5 ; c2f00c0c-9ad9-4c1d-912c-52eacedcba12 ; 1624f434-259b-4782-afe1-7ac3d13d7807 ; 0dfe13f0-e1f5-4f7e-95b5-e88f9d9e920a ; 71e87611-903b-4b9d-a506-87e58914dc81 ; 3596c171-86d4-48ae-80a5-847c874d4860 ; 159debac-79e0-4727-940c-020e120f8347 ; 81243c1f-affa-4985-ba0e-1f19db52db73 ; e957973b-0b41-484f-9f16-a112bed3107e ; 6a1c2fdb-18ce-40ec-af79-191b489f39a7 ; f4544809-7b92-40bc-b121-0db70c8af314 ; b8718131-47af-4eec-b601-12fa3969ca44 ; 82df814f-5c83-413f-99f5-153aed79161c ; 76f4bdbc-58c8-4424-865b-c6531d908dc3 ; 15c2deaa-1162-4ee8-b698-179bfd67a78d ; 26b0cf7a-584f-46e5-8f83-b6b5f7d542ba ; 09191482-34de-4130-afbe-dd47d481d539 ; 0cc10a1e-a90a-4c55-87a2-a74d47474a4a ; 11678ad0-81ae-4420-8976-52f99c5d7d5d ; ca44a8bf-428e-48b5-ae58-614f9a3e0fd8 ; bea52276-596c-479e-981d-ca9132742098 ; f713031b-b8ee-4195-91b1-ac9cf63d76a4 ; 14193a12-5601-4f0c-90aa-ecd24d6ac41b ; e5c171ac-f700-439c-9e44-6cfed2c9cea7 ; 5cd62b0e-902e-492c-843d-5d8aa6964dc5 ; e5a9fa79-2d0f-4cda-9fea-baab86f78b8e ; 7e598a8a-9fb8-4c2d-94e7-ae1921addcd1 ; 1fc22273-7e02-4193-9fbb-476e0eab6afb ; 3ad0093a-e57a-450a-b0ef-942c9b67a586 ; a0e467f8-79c1-499e-b881-669b4bd55b8c ; 3de73049-e6e7-4ed7-be98-bf174fd37c89 ; 33f49b4e-924e-4590-8afa-e17403602137 ; f0785dc2-a43e-4b59-a21c-ab55c490d441 ; 72367269-4151-4e1f-8636-ff91396ba46c ; 6adbf536-e89b-4148-8ed6-9b9117f78c64 ; cf2b65de-c6a1-4ebc-a62a-c652ce17d2d0 ; ae08dbd6-548a-469c-ba12-b6a87515bce7 ; 0fc347ae-7ad9-4987-887a-d37fe871d6c2 ; f2eac3ac-cb30-4d6d-a85a-4ea1ad3e7301 ; e11024c2-709d-4e47-a9f3-45894a27f2bb ; ca263104-9c70-4b9f-95d1-7a886587eebd ; 6e7092aa-e92c-4d9b-8ed1-f8c32f39fe80 ; 781d285c-5b2a-4d42-b35e-3840d954070b ; ed00a16b-6b8e-44e4-998a-ae4dcca5a93c ; 4584c7e2-8011-4231-a5e6-26a264f6d1b1 ; 940d64bd-8c96-476f-84f9-678d1ed3500f ; 3182e60d-be44-4f03-ba0c-431e0c1f1d5e ; 50111388-1058-413a-ac2a-3fd4f84091aa ; 0d7511fd-b57f-4bba-abc2-38b24ba4a15a ; f642ec37-b771-4b55-a133-a54f3b54ac99 ; 9bd5963e-d8f4-4eed-b32b-2eedb00db268 ; 8d84c9f4-6f19-42a6-9f55-8b4ccafc6117 ; 5a4c0145-86eb-40ae-9983-adb13652a9a2 ; eae4c66c-03a5-4663-a484-a01612602409 ; b32287fb-5ff5-4f5f-a9dc-0c0d514351b4 ; c6ba5d28-97b4-4f07-b91c-997b286dff03 ; 80265a56-75ca-479d-b92b-4fdaeb18ed17 ; bdc13064-e554-4a1e-9037-03187bcb3507 ; aa5103b4-c25d-4ca4-847b-a1ece4c14aff ; f5678056-2dc2-4f1c-87e9-4fba6c78b460 ; a56aa062-cc7f-4ceb-96d6-2a6c251fc9b5 ; 6bbd477d-699c-4988-a27b-0c3233b595eb ; 118fd65d-0b94-4663-a2a3-1f53b278711b ; 24153fe0-2c47-456a-b344-874a0e28de4d ; 5854b639-f677-4ee3-9d68-61b1cdd5a647 ; 91657171-7e5e-4a81-9201-d0b2d5806c04 ; 644c9a14-09da-4382-a6d1-dce67f25a4ff ; bfd30c90-9b30-4e7b-96f5-1f1b2ce23f04 ; d728c743-10a6-4ac4-8725-61c0d2980057 ; ca459603-f477-4ff4-9d47-902b3cbad196 ; af9f631b-2857-48e2-8d77-34f66c1c6149 ; 2556d93d-9252-4248-a044-91deaa7f02df ; 3e2102ac-0d18-4cf5-8617-863245e21b3f ; bf42e8ce-cd3e-46c8-92f9-ea5cda443a6f ; 1e20ead6-a07f-4f0d-962a-a3a240722fb6 ; f66358d4-9319-4c23-983d-ab5056daacf1 ; f4d51ca6-89a6-4571-ae8d-0fad7dde4452 ; 6bfd7e43-77e4-4666-9b28-c5d4cdcd6ad7 ; c5181ae5-bd05-459f-920d-26bd31bd9088 ; 62d2a36e-feb1-4084-8111-7ea38a4e3049 ; 58d073a2-68b8-4f48-ba5e-020258abef71 ; 00a59c97-91b4-413e-8d9e-674753997221 ; 5b62628a-b301-4d60-9213-396e3fc5a3ed ; 5e429dd7-787c-4e7d-b672-b000b7b57929 ; e70a8d1b-f29d-412f-8c90-85862a2b75ad ; 0c61c676-2a72-4dbe-8dcb-284bd112570c ; e2da00f3-fdb9-4ab4-964a-6828568e2e6e ; de6d4267-c1cb-4761-a539-5f83368735af ; 09b414c4-a314-43c5-823a-d91442b6b02b ; cef6023a-2fbf-44ee-a9b3-df78707bd85a ; 26f9a1ab-fa60-47f3-ac29-96acaa68fb4a ; e57574e4-7e01-4e61-bd29-ee4ec63dddd6 ; 50a70e24-2ce8-43fd-87d7-eab2c1fa9a86 ; 28e05d2f-0559-425a-accf-d5b4c1152548 ; e2ef6df2-c375-4c59-ae1b-c8cca22a8387 ; b41b1f04-226e-466c-b5e1-f61e45ad3210 ; 142d082f-444c-4384-97c0-bbc78e228470 ; 684196da-0213-497f-b239-7b5e76b01d0e ; 9f55d963-2c1d-4886-980e-edff099babf5 ; 8ba7248f-69cd-4b16-8900-ad2feec2eab8 ; 22ebe36e-3c42-4ca0-a624-c4219074bab9 ; ac0612f6-3d84-44d5-a224-6cbe65531505 ; f2b7091e-ed85-4546-8f11-307154153d31 ; bbe1e6e5-7c52-44aa-940e-104f07751e11 ; 7a3b5790-35c8-473a-b952-bb603aca5aa1 ; c5eb7bf2-fc4a-497e-ace9-c715fea47e5b ; 174435cc-64d1-4d33-953c-1ada5df46ecd ; 3d164bd9-7416-47af-a102-29954e3efe2c ; bf055644-7bca-43b6-8f5a-e21c42f7cf88 ; 50c357b1-a9fc-44e4-9a7b-937e6d74e081 ; da9dc40b-0350-4b8c-8a7a-15100d5aeb90 ; 9f52ae8b-7fe7-441c-9fb6-c55a9bd1a0d0 ; 0bc7a0cb-2a16-4f63-8188-39fd4c20b8b3 ; b8e11365-4360-4db7-bfe8-a8da3ca4819b ; e216aa55-98fc-4d0d-a24e-cfa05778f973 ; d5d86fc3-a720-43b7-8125-160f3af04de0 ; 438152c8-2d26-4b35-9f68-a4b6c473916e ; ae5c9a58-e3ae-420f-8f72-1e4ffdd3df24 ; 4068463b-8568-4bdb-8db0-19390ec0c7f8 ; 5faa442d-a995-48aa-a52c-a7efe6f56cab ; 7fb4bff6-4385-4503-9016-f9b620af3f8c ; bc220c5a-7255-40be-9c68-2997f0b0d319 ; 3b675bbd-b18e-4b72-b3c3-30527a9c157a ; be145e7b-25ee-409a-8c9c-5e17c9b6c5aa ; a63690bb-5761-47d7-854e-7be44d9b0b3a ; e92843db-568c-496a-bb91-b377b38e252b ; 92058c44-a484-4e08-b1fe-dfe2f03a0aa1 ; c236908e-4814-409b-9fcc-2bedf60aa168 ; cc937913-802f-48cd-a490-e6b90f007c5d ; cc07e1f1-e1e7-4335-ab8b-b7bebef1669f ; 3c2bed9f-2ab5-4623-b631-99e394d7723d ; 0c30cd0e-a2d2-42b0-9ca9-8297de64e4a8 ; fb0b2d84-d982-4d3a-9803-36420f2e7e46 ; 558c43ad-12ad-42dd-94b2-80a607465fcb ; 92b16015-e552-48e3-a095-0197b99b52a8 ; ea78a749-5aee-44e6-9592-b2e20eeb7ff9 ; 061e539b-4cde-4e37-bbcf-30937ce689c9 ; 60cfca96-802d-4a36-8c14-fc0bed308bc3 ; 990eab72-718f-4d71-aa03-892fdfdfa365 ; 652c3b39-d1cb-42e8-98e1-2acb0011bd50 ; f5675b71-ed1b-4fdb-be07-d627dc98ed88 ; a6b12e25-7b2d-460c-876f-02a75a82d7d2 ; 7893162b-3d19-4c54-86ee-aa4884d84e8a ; 8fa798fe-f032-4d77-b362-06261db78e6d ; ae28fd1e-2445-47ad-8c01-1b47d6396694 ; 63963cdd-909a-47d8-bae5-965aa9d1cb99 ; 70d8df1b-251c-4b3d-9de8-c20facd4cad8 ; b4402906-2bfa-4b75-b479-4e660556fbe5 ; 989450c7-cf32-4ed9-a74e-259a9be428ac ; 41af42ec-7521-4783-916e-2c982eef0f98 ; e5053de2-2a3b-4559-a166-35df5386d644 ; 086eac10-6ea8-4cc4-a6e5-91f051e50c54 ; 633ef184-2257-4cbd-90e8-64e92d91abb2 ; 93324982-7cfa-477c-88a0-b6eef61f6ca2 ; a582257d-4bf7-416b-a465-29a3220bc8c3 ; ef5821f3-677a-4bd3-9d99-d9cdd533cdb5 ; b58f47b2-c3ce-49a2-9bd2-f4c2cbda734c ; 4fbe5e67-d18a-48d5-bd88-19a2f4c01c8d ; a9d130f4-84e6-4f3c-982f-69971b5b7a46 ; 48c16c0d-085f-4266-b729-13bfd7aa9dab ; c216cce6-3e13-466e-942d-348f9f803ab2 ; eadfbcf9-0058-4021-8dde-7296d441e42f ; 92f1452b-54af-408f-98a8-cd76191f472b ; 4c7ed667-0015-48e5-a262-cabd54a35244 ; b462982a-4dd0-425e-bce3-0eb8f5527264 ; 8d122839-4167-48b2-9f3a-7ff7c3f134d8 ; 0ca24149-4cc4-4ad1-b448-4cc33fef851e ; 7adf414b-c3f7-4e2c-aa80-81d3edd9764e ; 27c9fa1c-e5e1-40d3-8d25-81f10d27d984 ; 9f6511cf-f17a-48b9-8e58-9c251bd5e8f4 ; 8d9f2037-1c1f-4c73-a993-dc4c2aa67d30 ; dd38ba60-656a-46f7-b22b-bcee3b6d2f19 ; d490330a-de38-478f-9504-a69260ab3967 ; d7e3b628-d5fd-4e79-9c4a-6409330fb8a7 ; a28d9c46-4774-4167-8c1e-ee95436c7b2e ; 723e0934-327e-46f2-94f0-20a65da1ea0e ; fbf64fdd-6787-4647-b0cd-860acc8abce6 ; eee3738e-89d5-41be-8f9d-564e46b4e065 ; 4c6bdfb2-3438-4216-b76d-d87c386bfa96 ; 9ae58006-9650-4494-991a-6ee217331740 ; 55a21e0c-e8a7-43bf-8b28-0e06211114d7 ; 529056f9-7bdf-4675-bff7-a82abddf5734 ; a3ac21e2-b92b-4597-a870-8444ddc6b4d6 ; cb5043e3-c1c1-4b06-9135-1aada484ba4b ; 43993e01-588a-40de-80ec-72c1a66fe70b ; 9eaa7f15-8a97-4a49-9e93-b5790a1fade0 ; d19fe184-84a8-4a49-a4d4-75891670da4d ; d2d7f976-2330-47aa-b1b3-947b3182b0b0 ; ca0d78dc-c860-4835-ad07-052f176804a4 ; c1adf54e-8248-4b44-a9a1-e883fcc4f702 ; 409b906a-5e2c-4ce6-bc85-20a59fa383f4 ; 6d129f34-7de2-4f8a-b150-e6111c5845cc ; c3927b5c-d641-45e5-87ea-9cc18c7ec85e ; 0f0cca8e-770c-45df-a6cc-466cc9328637 ; 3f1e9bda-addf-4e24-a92f-123085bf40bc ; 0d7c1a37-5da1-4257-a118-b7d0717f23da ; 147a9822-8704-4a7f-b856-9a659f4717b3 ; 55e28aaf-8025-4b46-97d3-96cdf512a609 ; 9ff0477c-10cd-47d6-8d0d-4e763ea185a8 ; 2c619641-7849-4837-ab92-0da80342b3e9 ; 9d657232-b6b4-4100-833c-5f94059a9ba7 ; 8da9c00e-1ec3-4657-9511-a2a00b8961cb ; d8b4969f-428d-4bf3-bbd8-883c72e8a934 ; d6023f30-0d07-4839-98d1-0b22b366cc51 ; 0edccd9b-72e9-4c69-899e-4bba4dbacb40 ; f0cf4acd-6b09-4538-b58c-e86c623b6c71 ; 7de9f347-2a8b-4647-bd46-011d74fc48fc ; e2b02d95-df95-48ad-b26f-3eb15201969d ; 31a140ce-bcb7-46b4-8105-626c9db1e183 ; 9cbd4bd6-244b-4274-a230-a7bd02e79571 ; c7f97f19-47ae-48d3-a90a-0162d3975747 ; c9ec05fa-5548-4fe3-8c09-a32c9e599d90 ; f773ae1d-0ad9-42dd-9675-c8b7287fec85 ; 5754d368-87b9-40e5-9a56-bd48ad9a80e3 ; dcc31bf1-9890-4fb1-9677-b5fb77e1fc37 ; 146bd11a-e66a-4d8d-990a-9f1199cdf255 ; d12bd5fd-838e-491b-8949-6a22f78194ad ; 9ff22b6b-ec23-41f5-a887-a59da1639858 ; 7f15f76b-305d-43f7-8d02-34cd0f76340e ; d79df987-e362-43f5-acbd-b19522bace7d ; 3cf5c205-2a3b-4f17-8e56-2078e88f615c ; 17cdb451-9b35-4aab-8bc2-b4a64ef3e3b4 ; 49bfd2cc-fddd-4376-8e53-8008ca075779 ; bc641d07-e041-403a-aa3a-e76279a8a1d1 ; a00cc4fb-6852-4869-89a7-f9f2fc941ccc ; 5cdd3886-898b-4861-a748-d4164ce14a07 ; 0d5c5f1c-d20e-480c-a89b-8feba01caf96 ; 8cf391f9-d743-408f-8891-2c49db90907c ; 30d31924-b87c-4065-a437-00d6033f2979 ; a92b6d90-f7b4-4b17-b56b-b2fb7103b55f ; f9029956-e7fb-447a-9b6a-ea3dd2acadf4 ; 87676c70-e2ad-4103-8bc0-3d3c1e40a790 ; 002997ef-3b93-443a-80a3-bae63e129d99 ; 112649f5-133d-4c45-a66f-4fe9a70bd5b7 ; b692cb10-ff2f-456b-a2c0-706b608d4e7e ; 67d804d7-b6a5-4a70-92cd-f93195d928a4 ; ec76e770-ba6b-4294-a992-993183640ff8 ; 6b1bb382-0103-4207-a0e8-871aa6aae81c ; 7423f6fa-4f31-46b1-a391-b5fc45833c2b ; ae72a901-e7b7-41cf-8eeb-2a7fb51e14f0 ; 51e96168-f2d8-4827-9910-66264b410b4c ; c6f8aca1-259f-48ab-a470-a1afecb8a2a9 ; 02ec11f4-1d26-4d2f-babe-d576ebfff1c7 ; bf8eb507-a277-4f3a-a605-313cd37f18b4 ; 91202959-0b44-43ba-961c-58c9de842d76 ; eb2de640-6c2a-4c8a-87c3-80f9fbdc3d9b ; 57e65074-4dc7-4f55-9638-8d123702305c ; eda0ff5c-84cf-44cb-888f-0aab17441dfa ; 9864f875-05af-4336-b532-a283e4dfeed6 ; 4a299407-b9dc-4500-b6b1-27a474ab4c4a ; 317b72a8-0332-4db8-b9d1-9a26d9907a24 ; 01aeb34a-75e4-446d-97ae-6e32c47158ad ; de71b625-2b73-43a7-9bc0-89d6a13d0d52 ; 5da663cd-e223-41ec-8b2f-796c141ec677 ; 4bdb6c69-67b3-406b-9ac6-9cca2c15f52f ; 7a3cd962-7512-4797-864a-cf374b5cb385 ; 17f2ecdd-59bb-4251-a1b3-2e0a461ea070 ; 0190a751-0a1f-4911-b5dd-26964b7fa5a5 ; 7e9145f7-ccff-4132-b2b7-9b992eebebf4 ; e11babda-c07c-4406-85ed-0b1d45985017 ; b7542984-1410-45e6-b936-8333ff902eb4 ; be694dea-a16a-4841-9588-89bba1b37dc6 ; 9e163b4c-d624-4c71-9d68-8f002aee6fec ; 29ba933a-c5f0-4637-b741-ee9739f02cd2 ; d4371446-8326-4e35-9e86-d8a48393efae ; 4f69c5f3-4e8c-4b71-a5fe-3179412c17e6 ; 6fe6d586-3b5d-4cd4-acb8-5691936441b9 ; b10e80e2-6ded-42f8-beab-b436e0286be1 ; 0f6ed829-a59b-48b7-a2ca-3aa9db40e4c2 ; e1c492c0-cf81-445d-8aa2-a8e8068ead1d ; e61781e7-6c4e-4a6f-8f8d-22896b1243ca ; dc85267a-0ce1-439e-9ecf-e5a13ad06f26 ; 3944bcd6-1a95-4297-8cf3-7e7d38b9390e ; 4a21e922-a294-43f0-89cb-862dabed4f8c ; FABFEC99-220B-4A94-A8FE-01DFD71487F6 ; 7E2ED541-38EE-473F-AC5D-3CAE6F5D9A56 ; 62D4D442-98A0-4540-B22A-4ACF1FBFC40B ; 891365B0-3BB1-4F7C-B351-6191B18EE9D7 ; D32E480B-D1EE-4BAE-AF15-8B5B94C1CC8A ; D92B4202-25D2-40B1-A704-C6BCA0EB5BC3 ; DE8AE7A3-D96B-4B54-9373-8E63F3AC926B ; 7E728799-4C12-451A-AFA9-0B26996F5736 ; 5D7A6563-6E74-48CB-A6A9-6D860759DDAC ; 6AB6C7D7-A0B5-4830-94A3-F16BC11EF953 ; E53D7A9A-3DB0-4A24-8DC1-6DC80428CD24 ; D6F5C34A-0F5C-4AED-977A-74A1E5D50915 ; 2B62733A-FCBD-46B9-B2BE-9397C563E3BD ; 9EBE5223-7566-4026-83AE-812283A8AAEB ; C18A3E05-F8EE-454C-89B2-5659045BA68E ; C6514DEB-3214-4CEB-8DB6-46DACA13911F ; 66760E17-251D-4981-BB02-82C29B315080 ; 1BE16830-BC94-422F-B925-26A772F1ED58 ; 6407B3AB-D159-4700-8E6B-D460411643AC ; 70C927BD-AB54-4E15-8521-5E3A5035DEA5 ; E46B29B9-C697-4739-B292-398674A5ADB9 ; FD735DC5-2EC3-43BD-B1B1-8FA811BE0633 ; 22FF97E9-F168-48BB-9B61-6F50ABA08D27 ; 3F9D6A98-182C-4297-85C5-02CE3B1A3500 ; A189A276-126A-4357-8AEA-9AC6A791A1C5 ; E4F422A0-1142-4BF2-B848-B681295B370E ; 9F55D4C8-5E41-4FFE-B819-1D8BFD06927B ; 571468B9-6FB4-40C6-8830-1FFAD5419B60 ; 6CB73E8A-B788-4EFC-B60E-F33424FC93DE ; 5FCE29D3-4250-4696-B691-D4BC953C21CD ; 07C938AD-70F7-418F-B6C9-EC6E4B1DAE66 ; ED47A919-BE85-4D06-AEE3-87B6485498CC ; 57557C6C-4927-449B-976E-127C0916763B ; 25DE243D-F03E-496B-B5F0-3DD8E61303FE ; 554CD9E3-7BF0-4D5B-A389-D258A8F46073 ; D6E981EE-1AFC-4F84-A3BE-E87E0D1460CD ; B0763E0D-56A7-4953-AD36-C3B218C059B3 ; DAEC3A82-E1F5-4D6F-87DD-90853E48BF29 ; 9439BB31-588C-433B-A7A5-787D8B496F57 ; 8E391BEC-541C-49DC-A0A8-5ECE5F268F1F ; 08F10BB1-6DD4-4F36-86A3-1801F9762187 ; A3AFBB9F-F611-4BF7-A7F7-8DB59022F66F ; 2FA19AF2-6FA0-4164-A0BB-8524D6085D80 ; FCA8DA49-849B-4790-A956-DB7EE97C39E9 ; 930B82A6-A039-4F8F-8487-B0ABB4FE7ABA ; CA3A64DA-CEBC-4451-AD48-5FDB6B9C26CC ; CD8AC496-CD1B-426F-8E17-8F15BA8E94D1 ; 3BC62725-AD6D-4685-BC50-0F1127363D90 ; 8318A9A4-E78E-4DB8-97C7-2CC733D0C512 ; 401D075C-D443-4592-8C03-E675CAAD2B50 ; 8BA93AD6-932D-42C9-8268-DDDA46802057 ; 025EAC6D-539E-4E43-A6F7-4A2D2DEF571D ; 112C8CDD-A187-4D9F-8C71-400848804D32 ; 05BF18CD-2346-4EF9-B6DF-58AA8A67E8A5 ; 96E71B7B-D32B-48BC-858D-20F7C8B7812D ; 122305ED-CA1E-431F-A332-0AC3409CDED2 ; 796DF715-916F-46E4-9DA1-E19C94958E07 ; 4949D427-3B3C-408D-8035-C884BB41E41C ; C685196B-C3CF-49FA-AAE4-F6CCBE04779F ; FC56BE13-C3DD-4DD9-8C34-DC6C7F9D1E16 ; B85BE663-EDBA-4E1E-A10C-D0297744A0E9 ; 8D65B4EE-183B-4767-9091-DEC23A17AF93 ; 42C7E92B-6820-4562-9E32-A424A99A6CBA ; 2A5F4696-6E02-4FE9-B66D-8C2AE93B7C2F ; 668220CE-7E03-4CCF-99F9-99127DDF9806 ; 5D1CB65A-7798-455D-8100-25871CEC5A47 ; FB635F1D-5EE1-4E58-86EA-B1AADA2DE4BA ; 061F9BB8-09F5-4788-B39D-35138A3AA019 ; 143FC27D-E119-48FF-A5EA-BD6AAFC0404E ; 50BD5C91-6557-4456-92D3-AE40CF7A8B9D ; D22E0F16-8D28-467D-AB10-2DD72F7EAB42 ; 9BC1887E-B3ED-4732-B8BC-EF4F4EA59258 ; 7D3DEA42-F18F-4CF6-973D-EA2BAE39BA38 ; 5AE24B78-4C64-4A08-BD13-3D58182215AD ; 2868849C-2BA4-42DE-AEF2-028BF68F4CB3 ; 075393F6-0404-410E-9FD5-7C2C63D3FA84 ; 1F617C60-D09C-4DE3-9973-CF655BEA3046 ; 4EE0389F-33EC-4A69-BC02-1C458D812CB2 ; 70E344F1-A29C-42C7-9FE8-DA9219D45158 ; 083F4985-57C0-4931-BA8A-00F565430DA9 ; 314E66DF-0ADC-4B7F-98E0-A32929192C71 ; ECE8AB6E-9A67-440A-8F3E-C80F3820474F ; 7153D60A-43D2-4A9A-BD8D-C15CD0BD9D75 ; 405B2B8F-7E2E-4D80-89BE-299DA48374EF ; 06239773-A7E3-4262-9B5F-0105E3B1467A ; 27E8B056-063F-4742-A591-B98FB9A948A5 ; 549F03A5-3F91-4975-9EEB-AA062264A602 ; 0B6EE423-04A5-4426-B397-9669FEAE4C44 ; 153D5E35-20A4-40F8-901A-D7208FA2D3D8 ; 66E4ECF2-AF70-46C8-BE47-783E8E3EDECD ; B599719F-F028-45EB-8464-ECF9AD60179F ; 6FAE8A0E-A96A-4895-B40D-C1EB491F0F3E ; A14E7E3D-0593-4D69-B17B-E79DFB065A0F ; 3447BDBF-5177-451E-BB93-736153EA76A9 ; C9E12D18-6092-499F-92AE-6FD6B16F2ACD ; FED3A891-21BE-4196-B9EF-0BF7C8F976AA ; 281F2BE7-7FB2-46F2-9A4A-033DB48329A1 ; 659EE487-4309-4D68-A9BC-9079EE87E4A9 ; 91D2288C-0D88-4A49-A0E4-0A7D2A95CCC6 ; 9D306F32-10BF-4EF7-AC97-91DC07D8EB4A ; 0A1F4A81-38C6-407A-A33B-716A0F9A6B4D ; DA7FE5E0-6AE0-47F0-9B32-FB6B80C4BE38 ; 6B746708-F6EF-45CD-B877-AFA1949D1D78 ; CAA2D510-9024-4D7D-B0EF-80FA4BE1E2EE ; EA7490BF-06AC-43E0-BB61-A2756D027836 ; 38F37F0C-75D2-4A56-B62A-9472A9C3AE13 ; 5012E9C0-A0F3-4F57-8840-FEE059DFE671 ; 4C932085-E46B-4544-A32C-C38B2BAC837A ; 6961FFFE-50B4-4296-8390-196B6070F739 ; EFDDCF44-AC69-436A-BA29-261E8DC6AD55 ; E852C16B-CD36-4551-8CC5-8B59719CA987 ; 287B037A-C32A-49F0-BED6-7674D2E26574 ; CDE5B270-BEC9-40D4-9C59-29F93EF08293 ; 51FB2284-4C63-49D7-9E38-C7D213AB43A6 ; 3374057F-4159-464C-B6C3-276BB12A8902 ; 8518E829-4248-4F12-B32F-F4019F7BA4E2 ; 9E1C48C2-CE8E-4256-8CB2-31B12C523C66 ; 312A82EE-9236-4282-B5EB-EE6063BABF5A ; CEE987EF-2EB6-4CDD-8094-331DE8EC38CA ; 2CF478D5-5400-4724-BF36-89BF1DF26284 ; BA0B6F0B-4E90-40B5-A47B-44ED4EB5DDE2 ; A896CC6D-91D8-4C63-B9C6-2B049E88B8B3 ; 4B4DDC10-5B37-42D2-BBF8-B0CAC95AE1B3 ; B22A4ADB-8D8A-490A-A6F4-CC091B41F56F ; A172DB3E-B6D5-4153-ADEC-9E772D6C1971 ; E0630A0D-D4AA-4C20-87EA-441EA60E6CFE ; E3A1436E-8E38-4CB9-A913-0A50512DB5B3 ; EFEA8F6E-FB7D-42F5-ABCA-3FF47DA3C062 ; 0201CF15-D073-447F-B96E-ECA0800B8CFF ; 5C016B5F-9E0B-4B33-90A0-D8B833DE27D3 ; 6A6B6B80-65C6-413D-94ED-07F13E48D62C ; 74EC0A11-F4F7-4F19-93F9-48674394A885 ; 817DA1B7-E485-496B-B593-2F8422545C6F ; E958EA52-21BC-43CE-9A24-72ACDA04E48D ; 03EB5BA8-0307-49B0-AA05-003007D79107 ; 040438CF-A4BA-4F06-B562-73C79738F53E ; 87845B6D-D3A0-43BF-82CF-A9429759E353 ; DA67ED79-947D-4F49-B1EE-B26B184693CA ; EFE1592D-EF98-40DF-B31E-545BAEF69207 ; 3440B3EB-511E-4904-873D-7A05D88FE879 ; 2C9BB39C-A023-4B44-B8CD-A454E8B60B28 ; 79A531B5-1BF5-442B-BEF7-72B9FC628F5F ; E7BB0755-D706-480D-989D-108B3E817973 ; D36BAC7B-872B-44A8-8C7F-8CB850B49603 ; 076736E4-6B47-40F4-BBD6-3868DFD1B9C5 ; 4C42EC4C-0EBD-41FF-8758-1E6A69CF7EB3 ; EE6B71D0-3596-4669-B138-AF822C2C3C6B ; CC10FEB5-CED7-4C1E-B429-C4AC77236765 ; 8C8D4BD4-3AA9-4AD1-9715-2376EE540A0C ; 764A5732-0B44-4CBE-93F2-7B84FD7D81A1 ; 38CFB491-3A6F-41C7-88B1-62BD97DBA0C5 ; E2EF5D26-F3EE-4F1F-9553-9239548B57D2 ; CEC6AD5E-A8D3-43CD-8A74-2199899F2422 ; E943BA18-21BE-49EC-8D2A-CFAD16E37FA0 ; 2969174B-856A-4BA1-97C3-9038891CF24F ; AD9E6197-47AC-454C-9C33-1988E9B66611 ; C677F76A-9A14-455B-B53B-1DE5CD448678 ; FFFBF817-1853-4783-B3E3-D05261CF2CD8 ; 5B55C210-049A-4835-AC3B-BBA70C72973B ; A4C6B7C7-739F-42E9-A9E0-9B59F1503F16 ; 9F40B937-E6C0-4259-BC0A-5FDCC6549B46 ; A86DD3FC-DE1F-4089-8AD1-95C683F9951F ; 87AAE20E-C532-4D73-AAB6-88BEFC3A2E6F ; DC2E6E86-4A3D-4F9B-BA04-6C0CBAEF94A0 ; 723A715F-02AA-4708-BB61-84A36792EC83 ; 0C7A94A8-4802-4CAA-B59A-6013CE8B3170 ; B9EEEAF9-5A04-4F93-B2FB-897377BD57F4 ; 049340E0-5AC8-4E7F-9C92-971B1200ABAE ; 29D94E70-4462-4FF5-AA91-75D7A412083F ; 3E936C86-FBB5-415D-A657-F96FE5565E34 ; 151A1187-E07E-4B76-B2D2-2DA133B9116B ; D7DC97C6-5819-48EE-99DB-E34F117AB1A3 ; ECE822AF-EA84-419B-99F1-6CE53E4C1E8A ; D5DE71C5-B810-426D-A1F9-7F7FF07B775F ; DA53D0EB-95FD-466A-A7AA-6251CB4CE408 ; 2678D877-E48E-48E3-95C1-65ECCE46308E ; CF5FDA71-8FBA-43FC-91F3-E4BAA36571DD ; 97AD1ECF-7643-461F-B9A2-1AC953825895 ; 2B7230C7-0182-4417-9861-03672629D98D ; 3DC0BC4F-6863-4297-8915-F29E1AA25D26 ; 9E1E6F69-AECE-4672-A059-D27AF0352C84 ; 1DBB21BE-290D-4C22-A6DA-9EB4A0C41EDF ; B280103F-8732-4EE4-9E61-357A9CB3A0A9 ; C26F4FCF-BB96-46BA-80DF-C8F3B926A296 ; 0039A298-3369-4DA5-9BFD-19792E9632BE ; 99095138-B471-48D0-AED9-DD8AFC8DED68 ; 8718F7F1-A95D-4245-9B00-6C061B69A1C6 ; CB7C50BF-C1DF-4B2D-939D-CBE1A4B7B667 ; BC4EF13B-1AB7-4929-953D-45592691394F ; 3D137341-F9A3-4CF0-8F26-ACAD49FA113E ; 5AEEF496-2885-42D7-802E-319B76BBE215 ; A76BC38A-9EEF-4E6C-B021-F940FF5137B8 ; EF196594-35DC-4BA9-8BEB-1EFE72D59E6A ; DA3319A2-F906-495C-B0DE-38CB8672E28F ; 8E324F79-8FBF-4D12-94D2-7B5A978425FC ; CC3A7053-34F6-412F-85B8-DE4C8B481D7E ; E5C7EA3C-3AAA-4409-B10B-372F2F8E30F6 ; 31E39E5F-AF9C-4F34-B065-8363CF9DF39C ; 2B8C960A-3E9A-49BF-8329-7D322DA90326 ; 1889A2AF-AE25-41EC-8A6D-0EC5C5B852CB ; 796B90A8-99D6-4102-81A0-96C6954E9F26 ; 61DB743A-627F-4666-B958-2542DBF3F320 ; 9DE14345-B948-4929-AAD7-8ABC4E2D35BA ; 155DAECE-CD56-4A90-9EE9-2C291C871BFF ; CE4833CA-7926-4C85-9A2D-1DEF273D4F77 ; 0849AA2E-A846-4DE6-8BA3-EB916DC13F35 ; E8811C84-1822-40CB-BA64-10939E29CD35 ; 4D7F3615-8DA4-4702-A84F-EFD533311291 ; B8348B74-69A1-43B1-A7F5-3AB429378EBB ; 3C8913CA-BC61-415B-9C6F-12295328022C ; 34E08E44-8C58-48BD-B682-1EDE7BAEAD3C ; 27BC9F32-2419-4E24-97A1-4136E7BE5A39 ; 1317942A-EF03-4ED9-B418-40A27AA3D6EC ; 31E5BC10-074B-4BB2-92F9-D9217C0EFC3B ; 65842833-68A7-4EFD-A781-19B5DC6BD257 ; D189E6C5-830E-4624-9DF4-CEF3301D0FBC ; 5A1BB598-9A38-452A-9599-365501038A88 ; 569DC2BF-8078-4330-AFAC-F3FF65903249 ; 842AED9A-EF31-404A-B93A-FB8F5FAA0467 ; E6142F96-4B9B-4691-8E7D-47D36BBDF37F ; 0DCB8872-8B48-4100-8AD4-4C89A0D3B9ED ; 25B35473-484C-4908-AE47-B6E6ED2DFB99 ; 468B4AB5-9750-4685-A967-184DA2CFCDB4 ; 62246534-B42C-4D81-B09E-792E55E3CB9A ; C53140B8-0058-4BB2-BE77-5121CD0E5B95 ; 4320C739-978F-4EBF-85C6-23D4735A38C1 ; C7F909CB-2D45-4B58-90BA-180C10E78723 ; 6F1FC322-359B-49FD-AC0D-CC7626F52604 ; 25B06E67-6D9E-4051-87CA-76E1F110B418 ; D763EDF9-B6F2-4814-B263-180ACED12DA2 ; 7091B5BC-E61D-464D-8931-58D9DBEC8CD5 ; 2895FE68-6AD0-4E50-AF50-CEC91436DDD9 ; 32915A08-0985-4232-BB08-A4B0850CB11C ; 4DDA3F93-216C-41D5-B1C0-85EE571D7759 ; 86DE89EF-D62D-4146-BC8A-E138C9EF7555 ; 5D3AF3D2-F86B-4FC5-A56E-381F82B84CD0 ; 4D088B92-CCB7-44FE-A582-F1D9034CD643 ; BFB67AE4-DCFE-4002-8F5A-35DBEC269889 ; 9970C93C-8A6C-4E05-9D2F-4B6BDF087A98 ; 96C72A6B-A6C2-4965-BE92-0910312689F3 ; 7231D76B-0AA1-4614-BDAA-84411618C8C0 ; F472B29C-F85A-422E-8446-453468AB9CC9 ; 98193DAB-86D9-456C-B67F-E3350327A609 ; B8E8E280-C3EA-4757-BB41-1611C95DC868 ; 75E9AD4A-AE3E-4331-9C35-0CE639ED3009 ; A6C10459-25FB-486D-A027-D17F1941B5AE ; BFC636BB-4E93-4E8B-BCC3-C98CF820E6E7 ; CB914F76-BE58-463E-B9DF-C7CB2811BD3C ; B1379238-CFFE-492C-ACAA-F8F0B0F733FF ; 8B7229CB-2578-4A81-8463-407DF893B47C ; C32E8A89-BC6B-4E8A-8719-4509412B5729 ; 8063E0BE-03EA-4A66-8592-DBB2D9F49045 ; 8A384D0C-BE3C-4A35-8B57-2C48DE743EBE ; E24E7C7E-1CD5-4C45-B50C-A731F894CDBE ; 88BFA581-96C7-4D12-B76A-630F44087833 ; ACC34A68-41A6-4C75-8F69-C0CE8727D7E7 ; 421AF19A-AE32-44B3-B91F-FED6A9B99DE1 ; AD431126-BE1F-483F-9333-FA30B2354F43 ; 43623706-5604-4F3D-8746-9BFA0B92C0A9 ; 1422B157-EEC7-460E-96C8-9121847D283B ; 197B76A1-A09A-4659-83AA-2C14FD1023A9 ; 0050D7C9-ECE9-4B6C-8023-1FF2EFCB3C9C ; E355913A-6E4C-4D63-8A53-8BE4C5B003B8 ; 2A532346-0008-4AF8-99BC-D709585DA1D6 ; 685B5DF4-0620-40E2-AA09-0DD736BB5E2B ; 8434F4A2-0EAD-40F6-9B63-9C958A3FB812 ; A31DEC9B-3626-4CB0-8265-1425D5CE1C1E ; 371EE0D6-5C89-4D9E-B57B-D22A0B86987E ; 2BD0E061-F49D-4F0C-A76D-1A647860E0D0 ; 097B9DD5-5617-48BA-8600-EC5A99C75A42 ; 4B35717E-B682-4B39-A5EF-5C9C037E6304 ; B13AB974-E4A4-4926-BD17-17A1E9CA7CE6 ; B884AF8F-FF0C-4CAC-9A26-F4F27B35F8E7 ; 0E20BD04-FDC5-4DBF-B132-5E4562E59413 ; 71CA5ED1-C8D8-4B05-AAA1-C4051976FE1C ; D91EC6E8-CDEA-41B8-A88E-252586D3B9AE ; 1152AD19-6FB1-4DFE-AF73-B74323A47AC7 ; 863804BA-7FCD-49CE-A544-5A98EB3F2857 ; 533D59AB-89CB-485F-934D-F22D8B602EE3 ; 11B582C7-95BF-4A07-8996-EF4D0D4F897E ; 64149D95-1EC6-47EB-985B-0F67252D7F26 ; CB389C7A-50D4-4F2D-9C5C-C1FFF17E442A ; ACC566D9-9CFE-4DEB-B1A0-F04B5A0449F5 ; 9C531ED5-E501-4CBF-9977-202DC1C5E623 ; 6B4D9AE9-5776-4EFA-86AC-3772B179D59F ; A56EE32F-1975-400F-A09E-A747383C9A46 ; A1953616-E244-4A52-B283-2E39D58F2C9A ; F2F2B11F-A4EB-4260-B2B6-822544ADAD60 ; 27DAC66A-E5AC-41B4-95E6-4A9F209261EE ; 4530D39F-1A96-46B3-9964-CBA7C03AD9C9 ; 0692591C-B717-4D4E-B3CE-EA1620EB127E ; 0DE093D5-C752-4E93-A783-EC262B3A3780 ; 081947CF-1635-4A57-9903-0C405EAD6D84 ; 93CE6743-424B-4A1E-8748-E11756399B2B ; 515600AA-A11B-4630-B88D-C59082ED1684 ; d3c85f76-56ed-4f64-9edb-9cdf80526e33 ; 7fd5702e-2d7b-4b79-b2d8-5ca4ca33cf65 ; ace39ef3-1b5e-4ad2-a20d-62957e524281 ; 69886602-a4f1-4ad4-ba56-a0e031c2e295 ; 9dc315ce-3b76-4754-b103-2c2580cde4ab ; f2deda2c-63c8-4b4f-a725-381f00298cd0 ; 1a9f7284-9770-4936-9fa4-500698184680 ; 5c28c3b3-1dfe-46ac-83f6-dd5cdb47d813 ; e8cb34ed-67cb-48b7-83cd-621a1224e781 ; 36cafcfc-cc5e-4203-b018-c2c949e24c12 ; 600df455-fdf4-4955-8d65-236b7b112693 ; 3ee32152-2834-4137-a6e8-254f3cca6b6e ; bdcd6720-fcbf-4c64-8703-b8932472ad19 ; 7fa91f3b-34db-41ba-8447-d745eebac2db ; 7b80a02f-c065-4ec2-95fc-05baf0aa3926 ; d1224e18-6c94-45f7-afb0-d4321150cc8f ; 504ec583-0496-4d64-bcc9-aa52868cc9f2 ; dac9090c-fae9-4d99-b5d7-fc3c8b6a201a ; 993d2cba-b4f8-4a46-994b-b97bb9f10d34 ; 750932d7-0e9d-44e0-bc5a-6031ca4b0448 ; ce2a0734-ea41-4e2c-87dd-516f6e5b83d6 ; 685fa2ea-3dff-450a-8ea6-e97dfe9000a4 ; f411d1ba-697f-4759-afb1-89eaa56e6da7 ; 0d2e50fa-daef-45a3-97b2-5d71ab03cfbf ; e7008896-7348-4b14-a443-d9da1352c80e ; e5bfc024-9ee5-4e37-97ee-45e695489f8d ; 2d80cd9e-8906-4fc9-9645-b3c137d71dc7 ; b16578d4-4d04-430d-8f9c-168ec0288cf1 ; 5d1a5545-6934-41e5-b41b-8e0ee88e6ec6 ; 74fcf73e-30a7-446d-9066-07d2e29ac78f ; 050ec96b-f110-429e-a138-4a41b38a24ae ; 24eaa7eb-502d-4c9a-b390-507b51c53f96 ; 90b93fd6-b94d-4a98-ad7d-dba3428cbb25 ; 3b3eab6c-c039-4c2b-ae4c-18b043d3d810 ; 0dba8c12-0f21-4489-8639-47c156ddfa5f ; 0b2e3720-4a7e-44cd-9e38-7d883f559c1c ; 8e464b23-588b-4d8d-a094-03efeb76789c ; 1964addf-c524-4c72-b596-009235bad133 ; b1de1587-febd-4e50-99ac-eb3dcb23033a ; f4f60d69-6c0d-4a73-90fa-ee369de95fdd ; ea93b70f-c0b6-4063-86a8-cac7d5d99c77 ; 298e1da3-0691-4675-931e-4a36f2ca858d ; 6d462341-cb4a-47bf-8c1b-2ffd6cf5e9ed ; 4c54a99b-a820-4602-9b39-deaca98034a5 ; c385c7fc-0e3e-4fc8-87c1-6db442e5606f ; 3de1ba17-00fc-462f-92a4-096e8112fd89 ; 4ab5f84d-7ba2-49e2-862b-48ff8cff3c34 ; 32b46b33-43d1-4663-bebd-f31673f18a16 ; 5af3de3e-4376-41ab-ae28-4ea9a95dce2d ; 5ebda262-2b64-4495-afec-38d3fa616d9a ; f26df76e-66bc-4e25-8a27-41b6147dc67b ; 8b5c7e4d-a220-4499-9e38-7deacc1776a2 ; 7b2cc917-cd91-486b-bb9b-4c57cf4e86e0 ; a36231aa-f304-4bbf-aa86-b9547916c097 ; 2223917e-5ff9-4726-99be-c73b19522265 ; cc620a1f-7955-43f8-aa30-12e244f89f1b ; 582b2af4-08e5-44d8-996d-d00db1e98413 ; 035ceab2-5468-41d5-9adf-f669225be543 ; 250c0ab4-ef0f-4340-a86d-628b98f8acca ; 0856c285-b57f-47ac-be8b-865dc2ddb58f ; ac9318f5-9e1f-4340-8da6-3815fff8bff5 ; b9140410-1ed1-4012-9637-412b7c688d68 ; 084b2d8f-96a8-41f1-844d-20004cd665e7 ; 6871927f-1488-4366-8545-439557a377aa ; 6d1ce13f-530e-433f-b2a3-f30793b0b003 ; 03115606-c46f-40ef-a95f-cdc1c174797d ; 6f8b48ba-ef24-4d33-a0c3-bc900a6c8cd2 ; 3ed5e5ce-12c3-4d15-9414-0b76f874e43c ; 8df411bb-1d82-4470-84ff-e2d335698d42 ; af859133-ccf5-4157-a260-738c9583c17b ; 5a9087b1-d001-4fcc-b061-f59e7026e711 ; 600a6f89-e714-4258-b4e7-33240123bfc6 ; 7d53f59e-5ae6-4325-9054-c9b1eac7983d ; e315f3f0-664e-47fb-9f3a-c55b3eda826a ; ea748969-579b-43dd-b2cd-1b0ac46b64ea ; 35f3fabc-9939-43a2-8491-c3813a970d13 ; d9e29db0-558c-4bd5-aa94-15d5d57110b1 ; 95c533d3-798c-4aca-8f38-dc4825f254b5 ; b09dcf83-93a7-466b-9414-12896ac7749c ; 1c0714ec-70a9-4902-bd98-8b0fb002c084 ; fe23a254-a0a4-452c-a2ba-685f66738a86 ; 5b9560c4-0632-479a-835f-67d373e59206 ; 108f6aeb-833e-45a1-81fc-4b0b8e3c7163 ; 9d772786-6ac9-4e52-9899-023ffa7247d2 ; ca92f9ad-c58e-41e9-a621-13bab969e94e ; 6408cd12-8623-4205-a757-bd6777a040f6 ; d09d5a48-2dc0-4d0f-8b20-d1f11a08143b ; 8046edc0-e5f9-42ec-85f2-6cc66596633f ; a19fbcc1-a781-4496-97ed-487aa83aae29 ; 05507d2c-3dea-4554-8f06-039fd555309a ; 7f00169e-2572-4158-a453-ccec33cd2159 ; 481cdbff-1f84-4508-ad9f-21a61009d68a ; ce3c01d9-e8c7-4bd6-84f9-741f38b07267 ; 6093f268-1c3f-4fec-bde7-fc3721ecaf8e ; e4dee88b-58d0-4953-ad4a-a2df876f3c95 ; e17e273d-6f53-4419-9f0c-1e4e667c5257 ; 6dd4870f-1ec2-484b-8703-6397d8e67daa ; 5dfab1d0-fed6-47b2-a47d-402e088361ad ; abff5667-7ef4-46c1-ad34-ceabc27e7992 ; 7cd3890a-bac7-42d0-a615-4b0f862200b8 ; ea7fb858-c17b-40d4-9a22-cbd9da614b65 ; 80105f2a-438a-4d44-947d-3f5a50d6cab0 ; 28d6a08d-f73d-4981-882c-aac092fdebb9 ; df545b98-f81f-4e0d-a714-90b406f2a238 ; 673cf36a-0405-4671-a76b-f0607d56beaf ; aa1e0129-d008-4648-8098-24f1981bc386 ; 12ece355-f1d0-446c-84e9-0aed3e6d29f8 ; 72439e36-3c17-4a90-b3e1-8f6ccfd3dcd4 ; 0d9139aa-d829-4ac9-8a65-822dcf79971c ; bd7e34c8-d477-4caf-a44d-aa9a3a4bf7d4 ; 63792ecf-4f55-4eb5-bfbc-78accb4f104a ; 5c703f38-38a5-4543-a964-88cf1d5ba2f1 ; a7e04cc7-3f4c-4986-a336-8083e5653754 ; bf0f55ac-2f35-4f8b-a1d9-c4e283fc7365 ; c8e05740-9d67-4e06-a30f-4298b6523a5a ; 2a3e4dbb-aaff-4b14-bbed-f2d7cf0f8fa3 ; a03cd506-47aa-4333-a9a4-fa1a6815ac75 ; 269af1ab-d92d-42da-bb6b-91929fab99f0 ; 059a543a-4408-4c82-96ef-eae1cc126763 ; 32ed93a7-250a-4fd4-81a8-6d94a6bc9f33 ; 02a0a874-6d4e-4e56-8d74-7952c912fed2 ; 0126489d-c12a-4651-8700-d7090732d7ab ; 7bd968be-14ae-4a63-96d5-814d16072818 ; 0dd8e6c7-9b41-4489-924f-bddf7d189eb3 ; 960d194f-fe39-42a0-831d-5c031cf93544 ; 8deb20df-b01a-40d8-a398-5dbb14786792 ; a09a99f9-33e3-45d5-bfc2-f57ce149a527 ; c6d8d136-3bd3-49d2-8305-3377240a1ce7 ; 9ae522c2-0fbf-493c-b3c7-a6ccd685c787 ; 860baf5b-abcf-4014-8b4b-d0a4b0d15c51 ; b6fe1d5a-f1c0-470d-bf49-b5a13157d2c6 ; 57aff09f-0e97-4e65-a227-3dc7a8516367 ; 1d8f72b7-8596-40e8-afdf-244dd897758c ; 4a7e95e4-58b5-4e96-a029-98f294b3cd54 ; cbf66244-42c8-4df6-aca7-932e77bb5e0e ; 2e4b5ba3-ccc8-40f6-80ac-edaea1685204 ; b2905a3f-810b-4e74-af5c-42d513d91746 ; 439d2ec5-1059-4556-b886-60b42b6db1d7 ; d78ecfd3-1a99-47e6-bb5f-a13c57148a76 ; 27b748ba-fef9-4eaa-96b6-a8ad31b5c478 ; 2f2d2e05-c6ea-4f29-8bed-040bd9c46911 ; c7da9758-e55a-4ed7-984f-cd86e2f6ea20 ; 181ff04b-8315-4069-a4cc-e102796ecde4 ; 071f43e9-e416-453b-a519-c197c5aaf1d1 ; a4910543-8bfd-4cd9-9eab-cf16aead9537 ; 78feb5be-f9d1-4cc6-baba-274136b9487c ; 76c09917-15f9-4908-ab22-ea1401abcb3b ; 199c6271-b0af-489c-99b8-fc76e7e66cf2 ; 46fecdc9-9d0d-41cd-811a-28731f0b7f92 ; 1be0c409-dd2c-4d82-80c4-2a71ec4d17d4 ; a919faa8-0df6-4a94-b12d-46d99df6f26d ; 4f5e142f-d936-469d-abaa-37baf6f045af ; f93c9b46-b07e-4a5f-9b3e-d7cebe34ebed ; cf11642a-eb96-4b37-b914-371c71f8e0ca ; 0bbcc10c-ff75-433b-a58b-7915d27eb7d6 ; 0c12ea89-eeb4-4865-91eb-10cf75884c21 ; efbff161-d65a-4009-8e95-50d7f6cae435 ; c6e14fab-a2a2-4102-8b70-2865757d2f48 ; 0c8df249-80de-4675-93e5-d06ad8ea3001 ; 09d6f42c-5e9f-4adc-bd8c-e5dca597fc01 ; 47436ce0-438f-475b-ac0d-1972d0c5285e ; ca3c9a05-88b7-4d99-abd5-fc557e3929a0 ; 14423610-4958-43f4-9a75-1a61c1293024 ; 2bf07767-58bd-4eb8-a0ff-434a9fdf5c8e ; 43f2cdb0-e5f0-4586-808a-fc0ef3313aa0 ; ef8c35b3-bdab-4a7e-b5ab-a0a99f4db803 ; e405d22f-86a6-4141-ae74-7098d0fdedfd ; 81bebbeb-bdb8-43f4-8113-b8f53425b725 ; 95f2fd0c-9121-47bf-b2c1-dd9ed667a146 ; 4c3d691c-fdf7-46e3-977e-68500c4ac358 ; 9ef8142a-8627-4dcf-8c87-15b1bc2bfea2 ; 74f23f3b-989c-441b-8715-505378d175e3 ; 75103265-c66d-4bd9-8ecf-cfcf66402918 ; 476b6ab5-f108-4280-9d53-7eb75fe17e4a ; 6b1c8010-d4fe-40e7-8e09-7a7dbdde6616 ; 183a47b2-1b00-4a72-adeb-f35b55692ee1 ; 832b8766-0e59-4ad4-b4c9-1e39b2ce4fb1 ; 052e361c-9cf7-4a92-a77d-f3d70f9dec0b ; 5c031f2a-0e98-4ab4-b8c5-3a296fda419d ; 7877c9a9-2002-4d6d-9ca4-f200c1ac00e7 ; 2ee13ed0-cb80-4375-a329-91ff9904bb7c ; e6ff00d4-c0aa-417e-acec-ae4727ae63b0 ; 02c8bf84-4816-49a9-b5d1-0edebb8627c7 ; ef48e806-e31c-4a11-afe8-dcc232357329 ; ba869eea-6e25-4afb-a0ad-73fda57a1d88 ; f76e87a9-4a50-48b4-9527-eac98c38800e ; 3490858a-b2ef-4700-91ea-5e71c71cff67 ; 69dbb2ae-3f19-4c29-9c24-810ae60312f3 ; c144ae50-ed29-4e27-bbee-fa81e79ac7db ; 6c05cfbf-4858-45d1-b5b8-d943a542d196 ; 05415f21-4c6d-4cf4-924c-9c1eb769e696 ; 392933ed-ca0e-458d-b0b1-6ccfe71df1c3 ; 00f81e98-e5c3-43b2-9757-f769ec17f3f8 ; 8e666196-bf9d-4b71-9c66-ee9272b671a5 ; 118021a5-6601-40a5-aef3-53c7fa4ed007 ; 63aa7e64-3d7c-43e8-87fa-f52855faed80 ; 6292ad22-cf2f-4e72-a95d-2441d667a147 ; 0a43ad98-2671-4701-9e5d-35ad63e8ad50 ; ddee0b07-2771-40c7-bdda-c1100958f0d8 ; 630613d2-682f-4a1a-b1fa-95320fb9a9b7 ; 008dafdd-a3d1-4801-8c0a-8714e2b58e48 ; 834d2e25-da72-413b-bb0e-3beb24d46472 ; 7ec2c455-d90f-4cd5-9bbb-aedbf21eca00 ; 357e1eca-0f5c-49d6-b437-0ed0afe3b178 ; 270be245-2239-4e96-a917-79cca40868ba ; b98aa84f-5144-4062-badc-32e89368d684 ; 973ee776-e287-4568-a43d-7b16cc0094a9 ; 18bb30b2-6018-45af-9393-f7a8ea40fa04 ; 31532d08-cb6e-40fa-9dfe-d2c6d037dcb1 ; fc1f0ad4-8412-4143-8ebf-fa6592f396e9 ; 3f6f1066-37f9-464d-872a-f1390eb36f6e ; 8137ffee-bb4f-4e5f-b831-acfc9c5585a8 ; 992d3519-cd51-4f48-880c-81fef52be1bf ; d1991ebd-1cd1-4c2d-ac99-2a6ecd3f90f1 ; 5423b7f8-d2bb-47c8-9af8-3d3e1276888c ; c1898b32-a9c5-410b-a197-572b2a6a2d7a ; 1acae6e0-3100-4de8-a436-e15cdbe1322b ; ffb838b0-db61-4dc9-aadc-41562f677f54 ; a99e45da-6933-4300-9c8a-e9d0f9e9c825 ; 662cc11c-da31-4e31-8e77-46011b38ea96 ; dcf7829e-abaa-435f-b41d-a2bcfde5d66a ; 4c70c0b1-1566-4e39-9dec-5050f62cd0a8 ; a7e71eac-1768-4fc2-8eba-1576d22e0f43 ; 1142b1cf-ebf3-485b-aae2-dcf4d8793212 ; 93a3fc8a-1b50-4da3-9dbb-cf9f582fc22e ; b2921c9d-c655-46f3-86e5-2fc2bed1ed33 ; 69bfa6ce-ed46-4321-a107-347c49d68951 ; 4a7c76a9-c3a2-4b57-a57a-de055152dcf8 ; 19193b8f-1e1b-448c-b934-93f25e60d45b ; 7ea6d404-9d2c-4b69-ac8b-d9ccd2d6cc65 ; 8835b20e-9343-4266-a356-e0343c657130 ; 989c2df5-5183-4daa-a8da-fc9ab18a437c ; 38ac0df0-950e-4c55-9f8a-96fd3f837ee6 ; 2fd1998c-1ea4-42eb-84b9-db352da9cf25 ; 08044da0-8cb7-4bf7-bbb6-b80be4fddd8c ; 9ec60572-39e4-4a0d-b157-cf0ec726fb1d ; dbd8fda0-bdf2-40f0-80b6-daef5ebf9c97 ; 289f5433-4834-401f-9361-efc8e883e630 ; 710257f0-ac05-4fee-b6a3-9c48ecc65b0e ; c0c04ba3-7fdf-47f3-8750-a487639a76df ; c59fa5bd-0b6d-41d5-83ef-7766f0241d70 ; 8da89b04-df25-4ed7-9d9a-e6c9478784e7 ; 46b0a695-f283-4623-a78b-954753e8ee62 ; 7909743a-2bde-48c3-8254-3fbd57ac2e33 ; 9113cf96-0feb-4e13-b1d5-0ddd12c2cab7 ; c0819744-0dad-4597-b9ac-9117497418a8 ; 759a1619-0432-4988-8a6f-5a0ef0956f87 ; e240d339-c042-42dc-b97a-d1effcac44b7 ; c90925f3-2126-478f-b0d4-f3b2c50cfbf9 ; eeb8b594-1bba-4af3-be80-682e261965b4 ; 36ccb542-78a6-4960-8d49-fa02e08fd36f ; bbf837cc-d336-45bc-9024-a018a667f8ec ; f05204c8-8301-4117-b826-b5fa194d28d2 ; dd8ebcff-9598-45db-b762-7ef446159e52 ; d3263082-946d-4420-8a63-8d67eeee09c5 ; e8eda441-d2d9-4708-bb9c-21f7da4e3094 ; 2399b5a8-f089-4a62-b75a-e6c0bd909846 ; e8ff608
PATHOLOGY_REPORT_FILE_NAME	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pathology Report File Name	Sample	TCGA-AR-A1AR.747FB91B-F523-4FA0-91DD-6014EF55643D.pdf ; TCGA-BH-A1EO.A2B755DD-00C4-4349-8E11-C1196EBC91D3.pdf ; TCGA-BH-A1ES.9B2253AB-2C41-4E7A-9178-B690FFD9FF78.pdf ; TCGA-BH-A1ET.E66D3DF8-1605-4EFD-AAFA-74F82366FD16.pdf ; TCGA-BH-A1EU.FF6BC87F-029E-4565-A35A-6FB968F8EABA.pdf ; TCGA-BH-A1EV.16DEA43F-4A61-44E3-854F-6B6575B45628.pdf ; TCGA-BH-A1EW.56EFCA58-2328-4C5C-9618-981447E76B12.pdf ; TCGA-BH-A1F0.E2EE2397-0F8A-4A71-9B3C-0007F7D00500.pdf ; TCGA-C8-A1HF.40B07BB9-2CDB-463A-8773-771017E73DBC.pdf ; TCGA-C8-A1HG.0813A175-83ED-4F6E-AD7D-FB4135CFF34C.pdf ; TCGA-C8-A1HI.04EF4A48-80E1-4567-BB61-2B542F715266.pdf ; TCGA-C8-A1HL.ACA6B606-681C-427F-8923-77BAA7390795.pdf ; TCGA-C8-A1HM.4DAF6DB8-5429-4B39-B103-D4317166D05B.pdf ; TCGA-C8-A1HN.4C7445ED-B346-4DD7-8AFA-2E95E65364BF.pdf ; TCGA-E2-A14N.C972EC08-E1AE-4FCB-B8A1-15000306CDE7.pdf ; TCGA-E2-A15I.FE41053B-16F4-46B0-B243-571F4D5A1665.pdf ; TCGA-A2-A1FV.074223E9-5E1C-47E8-BE40-1C4442CAE9F0.pdf ; TCGA-A2-A1FW.849E9FA7-3420-427B-A310-3346CFA9F0CC.pdf ; TCGA-A2-A1FX.EAFC71A1-D6FC-46EA-BC47-D054C497D705.pdf ; TCGA-A2-A1G0.DA82E751-09C3-466E-A63A-38368D8A2C7C.pdf ; TCGA-A2-A1G1.E2E6CA22-AFE4-4B8F-90AC-32639687A590.pdf ; TCGA-A2-A1G4.5AD3B697-F097-496C-978B-F73BDA5394A7.pdf ; TCGA-A2-A1G6.02B4C31E-38F0-4AF3-8DAD-527D5F27C11A.pdf ; TCGA-A7-A13G.50782829-35B6-4A61-A3CE-F105A31EDB42.pdf ; TCGA-AO-A1KO.15FB8CBD-85EF-45BE-8065-9F4E922D457E.pdf ; TCGA-AO-A1KP.467172CC-6EA1-435D-BDC1-D65FBF8EA0E8.pdf ; TCGA-AO-A1KQ.EB5199BA-6164-4CFB-AFAA-B41544B83103.pdf ; TCGA-AO-A1KS.0FB93D92-81F6-4241-9094-4AABF70E6A0F.pdf ; TCGA-AO-A1KT.D9432167-0F2E-4377-9DB4-EA4E59A6C9B9.pdf ; TCGA-AQ-A1H2.1B5FA34B-E3B4-4D4B-AF0A-1C90016CC532.pdf ; TCGA-AQ-A1H3.6EB1A616-E99C-4AF6-9C0A-0FDC521A79CD.pdf ; TCGA-B6-A1KC.E1FDF8EB-9D75-4629-9C78-6019DAF8190E.pdf ; TCGA-B6-A1KF.40EE8416-9DD8-457D-94AC-A871B5C62873.pdf ; TCGA-B6-A1KN.72996825-1FFA-4C51-8DB0-DA74BCB595EB.pdf ; TCGA-BH-A1EN.809F294F-8C48-4719-866B-7169FB1CE24D.pdf ; TCGA-BH-A1EX.FA86A743-EA67-4554-ABA2-BB8C1DBDB0B1.pdf ; TCGA-BH-A1EY.2ED10396-96FF-4705-93AE-82FB9A80EC28.pdf ; TCGA-BH-A1F2.FA781D93-C180-4453-BF95-B2D01B6CDB5C.pdf ; TCGA-BH-A1F5.F70DE761-F081-4F4C-AD22-9A166CF78CA8.pdf ; TCGA-BH-A1F6.7E9B0BE7-121E-423F-AA37-445BA922FC13.pdf ; TCGA-BH-A1F8.BAA6AA92-69C5-454B-A550-246E7DB1EBE3.pdf ; TCGA-BH-A1FB.C5D116FF-3193-48A0-B69C-D98831D9976A.pdf ; TCGA-BH-A1FC.7B1B31D2-0CC5-4EE6-8AF3-16DF726BE13F.pdf ; TCGA-BH-A1FD.9F838476-4DF1-44D6-989F-33A1D490424B.pdf ; TCGA-BH-A1FE.098BAFB4-94D0-4FC8-B938-D8A410BD8FC1.pdf ; TCGA-BH-A1FG.49927626-EB84-4A79-8073-67818722123A.pdf ; TCGA-BH-A1FH.501C3E1B-573B-4A5A-A0ED-3CD15432E6FF.pdf ; TCGA-BH-A1FJ.8169BE67-03C8-4F4D-9A60-200705B795AE.pdf ; TCGA-BH-A1FL.032B81C5-F936-448E-A352-C186DF160B7C.pdf ; TCGA-BH-A1FM.DA6A0EC9-6E20-4E4A-9B7F-A32EFF7627AD.pdf ; TCGA-BH-A1FN.26F47A4F-B501-4C33-9D49-2039E98DBF26.pdf ; TCGA-BH-A1FR.B6E6765F-14BC-4D3D-9266-EF8065354070.pdf ; TCGA-C8-A1HE.DDB31719-1D2F-4502-B80E-544B684DC16F.pdf ; TCGA-C8-A1HJ.11F98715-1482-4D7D-9102-E362634806A7.pdf ; TCGA-C8-A1HK.4D1B4A09-FB4E-45EC-895B-2941D18AED18.pdf ; TCGA-C8-A1HO.24B1FA5C-7D84-4CE5-B094-2358ECE73C10.pdf ; TCGA-D8-A1J8.E8E799F8-158D-4AEC-8F86-D40F132C071C.pdf ; TCGA-D8-A1J9.D80E9389-AAD8-4EEB-9DE0-5DE57B5E5F6B.pdf ; TCGA-D8-A1JA.51A2B7B5-0CDD-427D-BC82-5498810B2641.pdf ; TCGA-D8-A1JB.27376503-A55C-4905-A885-632440EFCED2.pdf ; TCGA-D8-A1JC.B4DB830F-BFA4-47F5-94C7-D95984315866.pdf ; TCGA-D8-A1JD.332880ED-FE4E-4EE4-9E96-0A61BFCCA27E.pdf ; TCGA-D8-A1JE.746C603E-FB1F-40D7-BEAF-20ACE27D6C21.pdf ; TCGA-D8-A1JF.03724E51-8430-414F-B483-2CB92D6A878F.pdf ; TCGA-D8-A1JG.E1907A10-207B-41F1-8B8B-24D5B551BD05.pdf ; TCGA-D8-A1JH.49C79E09-2F69-4089-BFB1-53197DA09A46.pdf ; TCGA-D8-A1JI.EF2DC6FB-F026-4025-B148-DF07194914AB.pdf ; TCGA-D8-A1JK.1841FEE0-EC36-4EC4-8B5E-6D340C80735B.pdf ; TCGA-D8-A1JL.156DF753-DB3A-4934-9618-1E18CE46C845.pdf ; TCGA-D8-A1JM.947954F1-4CBA-42D3-99B2-6BE6E44E5239.pdf ; TCGA-D8-A1JN.021DF0B3-A535-4AD4-9545-1B9A7BC3E1E6.pdf ; TCGA-D8-A1JP.1B61F1C1-8B19-4D9C-B6B9-87EEE350A472.pdf ; TCGA-D8-A1JS.0EA57ABF-E3DA-4862-BAB8-A6E36408AC42.pdf ; TCGA-D8-A1JT.72AF26A2-FAD0-42FD-A63C-6E8E2597B84E.pdf ; TCGA-D8-A1JU.B5074D1A-C617-414F-B349-6096F59E122D.pdf ; TCGA-E2-A1IE.95443906-A63B-4E07-8C4A-ED0A918B88F8.pdf ; TCGA-E2-A1IH.12DAEBF2-CDBF-4D90-9C74-2A2AEF1E8433.pdf ; TCGA-E2-A1IN.CC0B1145-B242-45BD-A946-B14BA5A9E923.pdf ; TCGA-E2-A1L6.F23523C7-B6E9-4205-BD36-D76E9EE9C453.pdf ; TCGA-E2-A1L8.9AA68C63-2C14-430A-85C0-5A92F7FCCD36.pdf ; TCGA-E2-A1L9.97B6C43B-4C7D-49FC-BA49-00D2DF41827D.pdf ; TCGA-EW-A1IW.D4194F52-3E15-4105-9A1A-1326CF128BF8.pdf ; TCGA-EW-A1IY.7C003A4F-DC30-43D0-AC61-ACE6BA118BEE.pdf ; TCGA-EW-A1IZ.F5EF4698-364C-4A5B-A8EC-1CF231BEEF31.pdf ; TCGA-EW-A1J1.E8B860F6-F3FD-4FDF-B467-8988646C2F00.pdf ; TCGA-EW-A1J2.0046FACA-9E90-4BA9-B216-258A2A7A2EC6.pdf ; TCGA-EW-A1J3.79C0D757-50BE-4375-AF69-E577629EE0CA.pdf ; TCGA-EW-A1J5.D92CABBE-8D7E-41E5-B702-9ED07E94E5C4.pdf ; TCGA-EW-A1J6.F282122D-C129-4A8B-9A49-78D5267C37CA.pdf ; TCGA-A1-A0SB.BEC7EEA9-6DEA-4402-A3A1-07EF33D58174.pdf ; TCGA-A1-A0SF.1617B36B-4EFB-445E-95BC-E63B129AAAE7.pdf ; TCGA-A1-A0SG.89A67051-898A-4E2A-A874-E0165F274E63.pdf ; TCGA-A1-A0SI.4CD6BDB7-9629-41C6-8514-7661E3D33A66.pdf ; TCGA-A1-A0SN.D0269758-EFAE-4EBA-8CCF-4A6CF4D4B35A.pdf ; TCGA-A1-A0SQ.92EE56BF-AAA0-438E-9244-780DBB2D9835.pdf ; TCGA-AO-A1KR.FF188295-E139-4AEE-8EE8-364536F2BBE8.pdf ; TCGA-E2-A1IF.9E2EF2C8-A60D-443D-99B6-205B7053175A.pdf ; TCGA-E2-A1IG.ECD02213-B048-4776-B09B-982FE1260F80.pdf ; TCGA-E2-A1II.4F2A288E-8162-4579-BCD2-0FF31B0EEB3C.pdf ; TCGA-E2-A1IJ.35F7D0D1-BA21-4135-B444-6B10EAF66F25.pdf ; TCGA-E2-A1IK.FE54D4DC-C35E-44D2-B8B5-0B631AE0F89D.pdf ; TCGA-E2-A1IO.A9D36308-DAEF-48B9-A4EC-6B9B24EE3DC2.pdf ; TCGA-E2-A1L7.E78526AB-D72D-4407-B7E1-2255BB5B2F68.pdf ; TCGA-E2-A1LA.8F401B38-8D91-4F75-ADE5-52521EAA7DFE.pdf ; TCGA-E2-A1LB.A868EC86-9CB6-445E-B961-5D4C57263548.pdf ; TCGA-E2-A1LL.3327975F-94BE-460E-9900-E063340927BE.pdf ; TCGA-E9-A1N6.910A4342-BBC1-47AE-9316-695B0CD0375D.pdf ; TCGA-E9-A1N8.4F15F8D6-9F34-4A61-A006-E5E7A2E68207.pdf ; TCGA-E9-A1NA.595BB256-2F3D-493A-AA90-022BE0CC995F.pdf ; TCGA-E9-A1ND.AC26EE69-27D8-4523-917A-68573F5F614E.pdf ; TCGA-EW-A1IX.3CF4FC36-70EF-4EA3-874C-4A514FCDB717.pdf ; TCGA-EW-A1OV.88E39E13-8ADC-481A-992E-610B3BEBCBD4.pdf ; TCGA-EW-A1OW.2153CBCE-6DA9-4E0F-9F41-B9F08FD50647.pdf ; TCGA-EW-A1OX.4C40B309-3178-4E7E-A987-47698E5E364B.pdf ; TCGA-EW-A1OY.76358109-41A0-4D5C-8894-F6A63A925961.pdf ; TCGA-EW-A1OZ.42DE8E2C-395D-4E9B-B7BC-6A0B2F9BD7CE.pdf ; TCGA-EW-A1P0.F9FB00C3-9F86-40AC-A5E8-08712CD5002B.pdf ; TCGA-EW-A1P3.042304AE-706A-4033-A97F-3765A6AEC649.pdf ; TCGA-EW-A1P4.70C8D54A-9698-4275-BD96-A6EF2E26474B.pdf ; TCGA-EW-A1P5.82771A56-81CA-4414-949F-EFBCAE1C98D4.pdf ; TCGA-EW-A1P6.6FEAD496-58BA-42DC-A3F2-2F380EEB1588.pdf ; TCGA-EW-A1P7.8F35E936-E4DD-4E35-BD9B-6CB7974E2765.pdf ; TCGA-EW-A1P8.6CB5A0ED-5569-4FDC-B651-758BFC6B59D8.pdf ; TCGA-EW-A1PA.A68B2364-89DA-4DC7-9AA7-A08BBCC85025.pdf ; TCGA-EW-A1PB.B3B6DE56-F40C-40BF-B6B3-2BC10F695F16.pdf ; TCGA-EW-A1PD.B6D80CA9-F4DA-4DFB-80BF-08BEE17142BD.pdf ; TCGA-EW-A1PE.F59530A5-7370-4E77-9099-9F38B25A38EB.pdf ; TCGA-EW-A1PF.0D24479F-2F86-43AC-AAB1-83AAD99542C4.pdf ; TCGA-EW-A1PG.6197798C-6F04-470E-BA91-922548E2DFAF.pdf ; TCGA-A2-A1FZ.F93E326D-F4E0-4000-8A67-AA19C4D3637A.pdf ; TCGA-BH-A1FU.58B02C83-2AF7-4978-A3F7-A8B9E0D914A1.pdf ; TCGA-D8-A1X5.449F70F0-DFE1-40F9-879D-43283CFAF525.pdf ; TCGA-D8-A1XA.9320030D-5E19-4BEE-99DA-366B6762DED1.pdf ; TCGA-D8-A1XB.B7367E27-2A40-4E8F-8975-D5665E6506D9.pdf ; TCGA-D8-A1XC.E5D2E429-C41C-47E2-96CB-F3B6F412499B.pdf ; TCGA-D8-A1XD.D5614445-4EBF-4050-8FC6-D34D5CAADD82.pdf ; TCGA-D8-A1XF.FCBB54EB-6FBF-4DC4-B4D5-DB533687FA58.pdf ; TCGA-D8-A1XG.AA869507-1B46-4812-8EC5-A4E01C588E6E.pdf ; TCGA-E2-A1IL.E0CCE6AD-38A6-446C-ACF7-358C1DFC59F8.pdf ; TCGA-E2-A1IP.021D6868-16EA-4D55-9784-46A0F85C50C8.pdf ; TCGA-E2-A1IU.ACE20EC5-2822-4F50-949E-E194C59F0FCD.pdf ; TCGA-E2-A1LH.DAB174BB-862D-49BE-9BA4-9C11C4489305.pdf ; TCGA-E2-A1LK.6CC4E6EF-6664-448E-933E-FFA9117C7ABF.pdf ; TCGA-E9-A1N5.224A51C8-8EEB-424C-AD88-44C4321050EA.pdf ; TCGA-E9-A1N9.39D6D1DE-2CAE-470F-836B-926242F46E67.pdf ; TCGA-E9-A1NF.740CF6E1-C742-47DC-8057-9D73AF4D6171.pdf ; TCGA-E9-A1NH.A6248687-C0C0-4DEF-9D92-196CBDB5CBDE.pdf ; TCGA-E9-A1NI.3F4F5A98-F6EA-46D5-95E8-6797D419328A.pdf ; TCGA-E9-A1R2.5B9C0E4A-3958-4ECF-B8B2-E758E04E7722.pdf ; TCGA-E9-A1R4.AA095896-8217-4BEE-97EC-BC79F5C395BA.pdf ; TCGA-E9-A1R6.8A865E33-082A-454F-A6DF-89E994206E65.pdf ; TCGA-E9-A1RA.26140CA5-AF22-47DD-BE48-C3C7DE07E5DB.pdf ; TCGA-E9-A1RG.59D84893-8946-4C5C-A338-3E33A1F7DE00.pdf ; TCGA-EW-A1P1.AE0C51EF-017E-4F53-968C-804110F9A7E6.pdf ; TCGA-AQ-A0Y5.5BC01981-366E-44EC-A986-087DB7904E5C.pdf ; TCGA-B6-A1KI.C2711492-0BDD-487E-9C9B-CEF20BBE57C3.pdf ; TCGA-BH-A201.6AE92F6F-E29D-43B6-AF1E-F15720C1AAE8.pdf ; TCGA-BH-A202.57323AE5-3EFE-4492-8522-D9A6DB3F1BE0.pdf ; TCGA-D8-A1JJ.3F1DA529-4967-462D-8966-E634D66EB3E1.pdf ; TCGA-D8-A1X6.880A4D38-40C5-46C3-8EE7-36539DD64773.pdf ; TCGA-D8-A1X7.D3EA3547-7E53-442E-A957-B2DD7EBAFBB9.pdf ; TCGA-D8-A1X8.5F1C3B85-5E5C-428B-8779-3A5878DCE1F2.pdf ; TCGA-D8-A1XJ.EEA126DE-A667-4373-9DC5-96B55E4ABF07.pdf ; TCGA-D8-A1XK.B3DB4F9E-C91B-4913-93E8-F18FF22CBA7C.pdf ; TCGA-D8-A1XL.762963FB-3D8C-4616-8C8C-0CD3E45FD243.pdf ; TCGA-D8-A1XM.7E48315C-3717-40DB-8773-71D070AFC47B.pdf ; TCGA-D8-A1XO.9AAB53EC-89A0-4878-BB9D-D96BC56B54C4.pdf ; TCGA-D8-A1XQ.33B6269D-1D59-4184-A786-2BEB73F6D3A8.pdf ; TCGA-D8-A1XR.D9A0E659-99BC-4704-AC85-E63098BA731D.pdf ; TCGA-D8-A1XS.6C97C157-05A0-45CE-91E9-3DC8946EFEDE.pdf ; TCGA-D8-A1XT.99050E48-8DFE-4405-B8D8-7649CE2C9CFF.pdf ; TCGA-D8-A1XU.845F8FCF-CF3C-4CEF-B673-A57DE626939C.pdf ; TCGA-D8-A1XV.D3AC6B8A-CC8F-475C-BD2E-A869BD07D94C.pdf ; TCGA-D8-A1XW.BD71F606-58BC-46B9-8A03-CB25D5BECA96.pdf ; TCGA-D8-A1XY.9D1EDFE8-FA4E-4F6C-99E9-1FEB12175D6C.pdf ; TCGA-D8-A1XZ.1D6EE39C-DE75-4595-943A-CF53873F96BF.pdf ; TCGA-D8-A1Y0.53ED4388-8CD2-4925-81A9-9C4792C83566.pdf ; TCGA-D8-A1Y1.1B198706-8844-452A-8F5B-8880A239717C.pdf ; TCGA-E2-A1LG.08A790DE-B01D-4140-BB1C-B4844291D71E.pdf ; TCGA-E9-A1N4.64B91C7E-E6D8-4952-B49F-0F5D57332994.pdf ; TCGA-E9-A1NE.CF6E29A2-FAE6-45BB-B625-33877887A89E.pdf ; TCGA-E9-A1NG.73953A70-DAC0-443A-AC04-28BDA8D5F673.pdf ; TCGA-E9-A1R3.BE186852-8596-4CDB-B5C4-AA5838C15B5F.pdf ; TCGA-E9-A1R5.141B770B-22DD-4C87-AFF7-04D85FC9C74A.pdf ; TCGA-E9-A1R7.FA19C3C4-E13B-464B-84CC-3AF7E83D5B9C.pdf ; TCGA-EW-A1PH.2E77693B-FAAD-4CCC-BD4F-3D2470C25143.pdf ; TCGA-AC-A23E.C976ACED-7FF8-4287-9D68-C6FD17895FC0.pdf ; TCGA-AC-A23H.A7C7D409-D086-4A9B-8C8F-E7E231D5891D.pdf ; TCGA-BH-A204.531B1E8E-9936-42E0-B49B-39C61DD4E943.pdf ; TCGA-BH-A208.4F943D12-E769-45F3-86BE-75193786DD4E.pdf ; TCGA-BH-A209.E28150CE-E9B6-4C3F-B867-F9A75E2648DC.pdf ; TCGA-D8-A1X9.E69CF3E3-4799-4892-87E9-4291B14A1B9C.pdf ; TCGA-D8-A1Y2.4ACD42D6-9520-4DC6-BB40-9187A4D49981.pdf ; TCGA-D8-A1Y3.E8D4229D-5049-4991-BDE0-AFC2CBC1827E.pdf ; TCGA-E2-A1LI.B3A319BE-2230-43E2-91E5-A3B3C76B85BA.pdf ; TCGA-E2-A1LS.A514658A-FB29-4AA0-9451-2A960B3720C1.pdf ; TCGA-E9-A1N3.4F50E811-0743-440B-9094-6BA0F40BD734.pdf ; TCGA-E9-A1NC.AA1B707B-4DE8-4E0D-87CA-601760F4A6CF.pdf ; TCGA-E9-A1RB.3BE8EA29-3C5F-4339-9CE7-98994B545848.pdf ; TCGA-E9-A1RC.D10A419F-B161-4998-97DE-45DF70F4E212.pdf ; TCGA-E9-A1RD.EDDEB48B-B712-40B0-9DE5-9F5B5791AF4D.pdf ; TCGA-E9-A1RE.80831A1A-95BD-4ECD-B7D9-6DDCD5313B25.pdf ; TCGA-E9-A1RF.50F3690C-2082-4590-A923-656C5F226FAE.pdf ; TCGA-E9-A226.7C8F01DC-9CD9-4D61-9032-BC9F28A687EE.pdf ; TCGA-E9-A227.13CA22BB-5EA5-46C9-82D3-77867122D1B4.pdf ; TCGA-E9-A228.B0E8F3C1-E996-4E70-9630-AC95AF6E4EDC.pdf ; TCGA-E9-A229.15FA41AE-3A0F-4112-828B-EE8687A6F158.pdf ; TCGA-E9-A22A.BC3061B7-9C99-4270-84EE-B1306FA01AE2.pdf ; TCGA-E9-A22B.FC896EB8-1CEC-46A0-82E1-E3FBFAAB69F1.pdf ; TCGA-E9-A22D.ED60F792-A71B-4BAE-A536-5FF6D8C3DEAA.pdf ; TCGA-E9-A22E.7788E7FD-B5A3-4B22-83CA-EA3FB5E826FC.pdf ; TCGA-E9-A22G.E34F4BF0-A0C3-4C72-8E3A-F319D4CDDD5D.pdf ; TCGA-E9-A22H.672E4D81-DA47-495C-A58B-BD2B4FEA2380.pdf ; TCGA-A2-A25B.FCE29F34-5D13-4A21-A950-A8577C957C10.pdf ; TCGA-A2-A25C.1D4CA1BA-B534-4CEA-ABA5-EF9B31694204.pdf ; TCGA-A2-A25E.B81555D4-78D9-4235-AABE-F852CA6F15B5.pdf ; TCGA-A2-A25F.AC60F5BB-9371-4F69-BAA0-099AD7FC2A0B.pdf ; TCGA-A7-A26E.EA830A26-3DF5-4731-AD0A-F20A61D58817.pdf ; TCGA-A7-A26F.46A75AD3-BAD1-4A16-873E-0099BD10FA8C.pdf ; TCGA-A7-A26G.6BE810A6-3D30-4F75-89B7-00C866553165.pdf ; TCGA-A7-A26H.1159E2EF-6407-4D90-8ED6-7AB04CF4FB32.pdf ; TCGA-A7-A26I.CCE33A95-774E-4242-B2A1-05FF002ED1D9.pdf ; TCGA-A7-A26J.5CC0C09F-70F6-458A-B8E6-18BDC074BE74.pdf ; TCGA-AC-A23C.926E93B6-EF7C-4F13-824D-13D08B7F7938.pdf ; TCGA-AR-A24H.C373F2EE-C601-4E17-8E2D-D9BC6AC0301A.pdf ; TCGA-AR-A24K.BC7B3577-CA6C-41AD-98E2-89D357D29D37.pdf ; TCGA-AR-A24L.BF82AD23-B40E-459F-83EC-590D392664FD.pdf ; TCGA-AR-A24M.56DFBCCE-A9D9-4F08-AC7E-33998F3439B2.pdf ; TCGA-AR-A24N.AAF32BB7-716A-4C0E-AE7E-04F6A5BF5628.pdf ; TCGA-AR-A24O.887F0E3A-DC70-4CD4-AAAF-3C613195D895.pdf ; TCGA-AR-A24P.0BF7CB67-49F1-42EA-8B41-988BD7E0DE61.pdf ; TCGA-AR-A24Q.CCE8E855-2582-4214-B9B1-25F0431065CB.pdf ; TCGA-AR-A24R.C3259BD1-1A2A-40C4-A106-FA2EF0201811.pdf ; TCGA-AR-A24S.C0A8A457-8790-4745-BD5D-AFBE55254A1C.pdf ; TCGA-AR-A24T.226031B3-D9C2-4343-B3F7-4E0C36B901E7.pdf ; TCGA-AR-A24U.B481795F-C52C-4FCE-827A-07991C7A7C2E.pdf ; TCGA-AR-A24V.468CD293-C9F7-43C6-A40A-18FCDD22F6AA.pdf ; TCGA-AR-A24W.0F2464F7-4108-4700-B2EC-17BC6C432D42.pdf ; TCGA-AR-A24X.B537A19C-C7E8-42EB-BA3F-673417F3A9BA.pdf ; TCGA-AR-A24Z.AD07F611-0EEA-4890-A02C-6DA3F5F57C45.pdf ; TCGA-AR-A250.16BE833B-E17B-4B8A-9D71-B0D83D73D9DE.pdf ; TCGA-AR-A251.F5B17108-8904-48E7-9B3D-182F0EA388B7.pdf ; TCGA-AR-A252.8C52C92F-26CA-4E72-BE47-CA2ED1746785.pdf ; TCGA-AR-A254.C026CFCE-1A82-446D-AC78-8CF4788FD9EB.pdf ; TCGA-AR-A255.492DDF00-858B-4420-A43F-4FED2DF61C15.pdf ; TCGA-AR-A256.0FDC2801-71F8-4D45-BFF1-89445E621A41.pdf ; TCGA-BH-A203.3EBBE51B-6D17-4A77-AAE1-E0424CEA56DB.pdf ; TCGA-C8-A278.4F3E197A-9731-427C-A2AB-2D506A1C717B.pdf ; TCGA-C8-A27A.4CC1413A-5D03-4BE4-91E5-80B578CE7DFA.pdf ; TCGA-C8-A27B.CD43BA31-A5C6-4C0C-AA07-3171332776CC.pdf ; TCGA-E9-A1QZ.864BB34A-1008-480C-A3B5-A2C616E95C49.pdf ; TCGA-E9-A1RH.FA93BDAA-B56E-4217-9022-4EBE6009FCF7.pdf ; TCGA-E9-A1RI.91303D10-CC36-47CF-BF14-E1DCE0157D1C.pdf ; TCGA-E9-A243.742A4812-9EB1-4348-996E-3F1AD7FA3E5D.pdf ; TCGA-E9-A244.4158FEAB-066B-4500-8FD2-3F197438DFB5.pdf ; TCGA-E9-A247.61E73960-32B0-413E-AF1D-2EF4582293B3.pdf ; TCGA-E9-A248.8950E632-451D-4436-9AA2-740CB08237E8.pdf ; TCGA-E9-A249.6272ED78-501A-4055-8C87-430F46F518AA.pdf ; TCGA-E9-A24A.392524F7-B570-4047-A439-71FC15642DC8.pdf ; TCGA-A2-A259.33569E07-D7BF-491B-A352-CEEA81556800.pdf ; TCGA-A2-A25A.3971CA42-F1B0-4D85-9AD3-210B98E76A9C.pdf ; TCGA-A2-A25D.BE63B06A-E3E0-4E00-9B9F-5E7DE8852E07.pdf ; TCGA-BH-A28Q.9D040C65-C225-4D41-BA4C-6BB21EC1CD32.pdf ; TCGA-C8-A26V.929AB6C9-58B0-4E37-A2B4-9FC1F9099437.pdf ; TCGA-C8-A26W.0F1DC8BC-5987-4C50-9A34-79FFC1D2BA30.pdf ; TCGA-C8-A26X.8C845114-BBC6-45F2-9135-7E8298E24422.pdf ; TCGA-C8-A26Y.B660432A-A67B-40CC-89F8-80648DB8AE98.pdf ; TCGA-C8-A26Z.5E21E07E-BD5F-4AC7-985A-178416D756E2.pdf ; TCGA-C8-A273.EAB9E75C-2795-4D83-9806-5019DC14256E.pdf ; TCGA-C8-A274.A7FAA4F2-1846-48CF-9FB5-15E98430F6CE.pdf ; TCGA-C8-A275.BDE9E2A9-09E9-49BC-AFBE-BD32916972DC.pdf ; TCGA-D8-A27E.36F6CB19-17FE-47FA-BFCA-3846578C028B.pdf ; TCGA-D8-A27F.976C6F9E-DDCB-42F4-BD2C-A4D715396B47.pdf ; TCGA-D8-A27G.F8B8EEB1-0603-4181-9BD3-209143024EF8.pdf ; TCGA-D8-A27H.52D7E980-806C-499D-9DB9-40E1D651D9EB.pdf ; TCGA-D8-A27I.FAB622C2-3E45-4E72-AA36-9530BB830993.pdf ; TCGA-D8-A27K.6B2ADF84-5CEA-430A-87DD-5C2EC24C6E90.pdf ; TCGA-D8-A27L.1281F503-C256-4DFF-A3BD-BD5E51CE4249.pdf ; TCGA-D8-A27M.85045216-10EC-473C-96A9-268E71D2B566.pdf ; TCGA-D8-A27N.69007BC0-E1DF-4E68-BA6A-352F6A12F233.pdf ; TCGA-D8-A27P.ACC0A0E7-218F-4112-AC74-9F5D5A512DD3.pdf ; TCGA-D8-A27R.5E997487-9A03-4723-B1E6-FA0B557D8FDF.pdf ; TCGA-D8-A27T.15237FF6-A56E-4E05-B81D-B87E91B59917.pdf ; TCGA-D8-A27W.292571E3-D500-4337-B435-834B504F3109.pdf ; TCGA-E9-A1R0.DD0ADC20-2059-435E-9EB4-351C87D7CBEB.pdf ; TCGA-E9-A245.5F2A52E5-2844-4242-8CE4-A87DF9D9C97B.pdf ; TCGA-E9-A295.A23D86FF-CCA9-42B2-B6AE-9E365AAC03C8.pdf ; TCGA-GI-A2C8.4AABCBD1-DF12-45E1-9307-21D6CB0894A9.pdf ; TCGA-AC-A2B8.3D878253-22B3-4A53-AE54-C0D95E085DB1.pdf ; TCGA-AC-A2FB.F6CFE506-16BA-475A-A81F-1AC4B2EFE24A.pdf ; TCGA-AC-A2FF.E6897E14-465A-486A-A6AD-FCFED21629F2.pdf ; TCGA-AC-A2FG.C1ABCD83-40EA-4FF7-BEB6-69679589E8E7.pdf ; TCGA-D8-A27V.E5011BD1-E1DE-4A47-BF3C-66BA1E0B84DC.pdf ; TCGA-EW-A2FS.F273B11F-D3CE-4619-BEC2-15C110567503.pdf ; TCGA-EW-A2FV.335BFEB5-6356-43A3-896D-50BF3830B59E.pdf ; TCGA-EW-A2FW.0487E2B3-C03F-43A0-ABCB-B2BDBE0FF47E.pdf ; TCGA-AC-A2FK.1CF3FA64-EAE6-4A18-9B51-F5980A885371.pdf ; TCGA-AC-A2FO.5A7EB73F-E681-46CC-B2D6-C87EEAB0AC99.pdf ; TCGA-AR-A2LE.95DC80AB-C070-4613-8C11-A124AEDF9754.pdf ; TCGA-AR-A2LK.73FFBADB-37C0-4F17-8C95-F8DC94EF1AD3.pdf ; TCGA-AR-A2LL.B2314041-3E85-4E3F-8924-39FC285B08B2.pdf ; TCGA-AR-A2LM.F868DC95-23CA-4DFC-BAA3-FBF5BF6F45A9.pdf ; TCGA-E9-A2JS.1DFFCBD1-962D-4E9B-BEE1-726CABE3AA95.pdf ; TCGA-GM-A2DD.E7B75FEC-1706-42C1-8906-B17FE4440161.pdf ; TCGA-GM-A2DF.CA6B733A-6030-422C-9DE9-B9718CBB2FDC.pdf ; TCGA-GM-A2DH.C3243207-2190-4435-9AA9-39E3B913E316.pdf ; TCGA-GM-A2DK.FBD7BD94-2870-431D-A519-DAF72A97845F.pdf ; TCGA-GM-A2DM.18D46E96-4E16-4736-AACF-C6BF8AEC9368.pdf ; TCGA-GM-A2DN.8829274B-EB82-4155-A458-CF9F0E60B36E.pdf ; TCGA-AC-A2QH.C2A0E948-2B9E-4E49-90C4-57CE4C4A95B3.pdf ; TCGA-AR-A2LH.4E3FDA72-93E1-4961-B1DE-5BFDAC7E947D.pdf ; TCGA-AR-A2LN.128D4F7D-017D-459F-9664-AF509AE4555E.pdf ; TCGA-AR-A2LO.E5B6771D-450A-49AD-AEBC-7FC056BFCDBE.pdf ; TCGA-AR-A2LQ.C3537961-4636-4BD1-BC89-892580B36E43.pdf ; TCGA-AR-A2LR.C310F4EC-D8B1-45C4-8D55-705A9EE35902.pdf ; TCGA-B6-A2IU.EE769039-220E-4158-8999-09F17AFB4C46.pdf ; TCGA-BH-A2L8.B232BEE4-8579-4E26-B45C-8A5BFC0CEDBD.pdf ; TCGA-E9-A2JT.C70325C1-54EB-41BF-B77C-D92FADA8D23E.pdf ; TCGA-GM-A2D9.C690925E-38A2-48BC-8E2B-4EA383E27FE2.pdf ; TCGA-GM-A2DA.F3CD8E6E-B02F-4D5D-B895-6DF063F61603.pdf ; TCGA-GM-A2DB.5A315635-886B-459E-AF5D-079F66E859F0.pdf ; TCGA-GM-A2DC.48CB011B-074A-424B-B2D2-E8A2397CF02E.pdf ; TCGA-GM-A2DI.D437E9FF-5C09-4FD6-BB0B-0881CD4C50D7.pdf ; TCGA-GM-A2DL.8CF4E53E-924F-4DC6-8748-BC8A1F7D5662.pdf ; TCGA-GM-A2DO.100E842E-0ADD-4E58-B31B-0C67DC175787.pdf ; TCGA-HN-A2NL.CC1EE9E0-BC1A-46ED-A262-7A2B9CC8BBB1.pdf ; TCGA-AC-A2FE.F694CBD6-880D-40C7-AB17-D0AD02B7F06B.pdf ; TCGA-AC-A2FM.83BA3E82-E8E4-4A70-ADEE-A1360940EECE.pdf ; TCGA-AC-A2QI.5CF85AF1-D227-430C-99CD-C2A524CFFA29.pdf ; TCGA-AC-A2QJ.E422C6E8-084F-42B8-84E7-4EF387F098C7.pdf ; TCGA-AC-A3BB.4D864947-076C-4A66-940D-682E75E525A2.pdf ; TCGA-AR-A2LJ.5411AC07-09E4-40C3-844F-2DFAA216D947.pdf ; TCGA-BH-A0B6.06602AD0-AC4D-4674-B4B0-2D207C3E78DC.pdf ; TCGA-E2-A1LE.42E3E8C1-D18A-4457-B2F0-FE49F4C027D7.pdf ; TCGA-E2-A2P5.85E91C9F-9F61-4A25-B4D9-1BCBC7108F5E.pdf ; TCGA-E2-A2P6.E6A21CE6-841D-4D9B-A563-80B9BAF6E682.pdf ; TCGA-A2-A3KC.593AF241-8F84-4BA0-8878-7C1CE72A460B.pdf ; TCGA-A2-A3KD.3E4717BA-E9AE-45F9-9696-F8928D9FCECC.pdf ; TCGA-A7-A3IZ.90F83655-038B-412C-91BD-84CC3A4201D4.pdf ; TCGA-A7-A3J0.A5AED5F0-A144-4615-AF78-539B8523D15F.pdf ; TCGA-A7-A3J1.D8EFFB62-6A23-4033-8144-24B751DECB08.pdf ; TCGA-AC-A23G.810663DD-1718-4FD6-B9C2-77B4C091B3F1.pdf ; TCGA-AC-A3HN.F0308FC8-D8B4-487F-A072-05E66D01842A.pdf ; TCGA-C8-A3M8.25CD89AC-052F-4B9F-AE1C-B0824A7A5145.pdf ; TCGA-E2-A3DX.3B7CA8ED-58E2-4609-BE41-46525D3732E7.pdf ; TCGA-E9-A3HO.3EFA8B1E-0FDB-49A4-95FC-4C9C9B15B61A.pdf ; TCGA-A7-A2KD.3C301346-4594-4071-A754-04F8B3BE894C.pdf ; TCGA-A7-A3IY.63F5F3D8-6393-4DA7-BB74-7D587199D7FD.pdf ; TCGA-AC-A2BK.3E54B0CE-8863-4728-BC95-A47C1869F52A.pdf ; TCGA-AC-A2BM.9F00B6F4-EE91-4A18-B533-127E39EF8554.pdf ; TCGA-AC-A3OD.9F7E2B98-29E7-465F-AE12-33D78FDFD71A.pdf ; TCGA-B6-A0I1.1E498731-FE74-493E-A330-477643800305.pdf ; TCGA-C8-A3M7.953ADB1E-77C9-4721-B624-F9CCF040575F.pdf ; TCGA-E9-A3Q9.FE3E1376-1527-42C0-8F5F-8849D0F2743B.pdf ; TCGA-EW-A1PC.4A0524B4-2A0B-4442-91B6-0E2FEA90CBC6.pdf ; TCGA-EW-A2FR.792A24F5-065E-4001-97F6-3F9BA121C65D.pdf ; TCGA-GI-A2C9.ADDE6090-5278-42D5-8E89-E0AB630A4C06.pdf ; TCGA-GM-A3NY.1659798C-9B6A-4DF9-A5B6-79AD2194DF11.pdf ; TCGA-A2-A0CK.B065FC65-CD33-4878-AE2C-7E8C04F5ECAB.pdf ; TCGA-A2-A0CO.8C440009-E05E-4046-96AB-BAB211CB7D02.pdf ; TCGA-A2-A0CR.A3167E2D-3588-41D4-99AA-6DCB660D55A4.pdf ; TCGA-A7-A13H.642B4B50-E227-4484-904E-E629F7F9DBC1.pdf ; TCGA-A7-A3RF.4AF67A51-97C1-4D58-9E60-03FDFFACD38A.pdf ; TCGA-AC-A3EH.3094774B-B764-4D60-BFF3-48FEF39F4BEA.pdf ; TCGA-AC-A3QQ.07833A91-F827-4708-AECC-728C708F8E2D.pdf ; TCGA-AC-A3TM.87DB9AD3-7640-4A78-B401-D5562D03BA76.pdf ; TCGA-AC-A3TN.1A0D203A-BC4B-441F-97F6-D1FF7E959262.pdf ; TCGA-AC-A3W5.CA0CD57E-DA92-463E-A004-D554825A22D6.pdf ; TCGA-AC-A3W6.B52E150F-5B34-482A-84E7-1739B9AC09B7.pdf ; TCGA-AC-A3W7.3B77A3E1-AB8F-47B2-A5CC-A3B593A055CE.pdf ; TCGA-AR-A1AM.10C43124-3C21-443C-8268-23BF8A4D317E.pdf ; TCGA-BH-A28O.12A869FC-7578-4506-BB23-7C25597834EA.pdf ; TCGA-E2-A14U.7E0F430B-B96B-49B1-B4C1-88C1F3A855A7.pdf ; TCGA-E9-A3QA.1F02AA5F-67B1-4BAF-A3A9-CA20BCD7FBAF.pdf ; TCGA-EW-A3U0.8652E026-9C4D-4AB6-AADE-29DA3345892E.pdf ; TCGA-GM-A3NW.00C6FB2B-A1C9-4310-B178-740313565A32.pdf ; TCGA-A2-A0EP.F76120C1-B2B2-46EE-AAE1-57B05D258ED1.pdf ; TCGA-A2-A3XS.DD5295D4-3896-4AA5-AF75-30AEA45D1652.pdf ; TCGA-A2-A3XT.A614B6B7-256F-4148-8941-6145B2D9B8B5.pdf ; TCGA-A2-A3XU.5018EC57-96C6-4D63-B708-45559B4D8527.pdf ; TCGA-AC-A3QP.14E2FC4E-7205-4929-81B5-7FF3006F08AD.pdf ; TCGA-AC-A3YJ.0F890724-8554-4B2B-B4EC-6B9B24C757D8.pdf ; TCGA-E9-A3X8.00058FFD-35E6-4891-8B01-DAB3AE9EBF78.pdf ; TCGA-GM-A3XL.E8583D11-D6F7-41AC-8CD5-53437CBD8820.pdf ; TCGA-GM-A3XN.E9A88E5B-4F50-4683-9C65-56CFCB15405E.pdf ; TCGA-JL-A3YX.25782EF0-8786-446E-ADBA-21F489844237.pdf ; TCGA-A2-A3XV.405B9D03-6200-4DFA-A7D1-C622D3A48AEA.pdf ; TCGA-A2-A3XW.A4621FE7-E898-40BA-B45E-3DC9EF607F37.pdf ; TCGA-A2-A3XX.770EEADF-19CD-4AB9-A7FA-1A05EE17984C.pdf ; TCGA-A2-A3XY.EC1BB6E8-6897-4E70-80A6-5A4E4B9C4E1F.pdf ; TCGA-A2-A3XZ.A7B6FCF6-1B81-40B5-AD92-54681CBC8FE0.pdf ; TCGA-A2-A3Y0.0FEAEEBA-A72C-4207-AC21-6AF5B5ED1AFC.pdf ; TCGA-AC-A3YI.52CEF542-0F5B-4660-8746-2CF4A27B214E.pdf ; TCGA-B6-A3ZX.B3CFFF02-89AA-43AE-B19B-BEE6817AA997.pdf ; TCGA-B6-A400.AF83CCA2-3AA4-4933-B6AD-9C11DF501DDD.pdf ; TCGA-B6-A401.D76CF03A-54CD-4769-87AA-466473F41FC7.pdf ; TCGA-B6-A402.9BC704DE-0914-49F1-80F9-36CFE52B8484.pdf ; TCGA-B6-A40B.CB2E56BC-16AC-4BFE-AB6C-2FC7E48943BB.pdf ; TCGA-B6-A40C.87B150CC-1C5D-42D5-9951-9157A81316D5.pdf ; TCGA-D8-A3Z6.A8F63D86-37DF-472E-AF29-FB734EAB7E5C.pdf ; TCGA-JL-A3YW.476488A9-3708-4B11-854A-C91B583C7804.pdf ; TCGA-A7-A425.F969E3E4-0053-44E9-85BC-BEFDBD62C512.pdf ; TCGA-A7-A426.B644AEB6-7D46-4D4D-BA00-D42BCDDCB164.pdf ; TCGA-B6-A408.F5A14797-6676-4331-9424-D8B820008924.pdf ; TCGA-B6-A409.CC77BA51-CE5A-4839-A27A-DD8F389A2733.pdf ; TCGA-BH-A42T.3FFD87C3-1E75-4A8E-AA26-BF7995E42245.pdf ; TCGA-BH-A42U.25F791D8-27D6-4DC6-8D96-5D5CF68A5F13.pdf ; TCGA-BH-A42V.5BB5CEFD-CC07-4451-A774-25FB146067C7.pdf ; TCGA-D8-A3Z5.B16B3335-492B-471B-AEFE-2350EA558BFC.pdf ; TCGA-EW-A3E8.E4ECB8AA-0ECC-47A5-B940-045A2C3D9A1A.pdf ; TCGA-EW-A423.0BB6CAC8-CE26-461F-A9FE-46E28E96A368.pdf ; TCGA-EW-A424.EE644ADF-639E-450A-92E6-2A6F1BAD561F.pdf ; TCGA-GM-A3XG.E76B5204-99E5-42D0-AE7E-ED5525796CCB.pdf ; TCGA-LL-A440.5577BE88-72ED-43E5-9BB1-83D56C2EA346.pdf ; TCGA-LL-A441.1FFDD2E3-02D5-4C38-B6E9-1261EB57835A.pdf ; TCGA-LL-A442.389044F0-9D90-4639-8C42-C1A6EA816442.pdf ; TCGA-A2-A4RW.C1D4D6BB-AF86-4208-A729-C61365941217.pdf ; TCGA-A2-A4RX.CA88491F-5572-4B0D-8E3D-D536E3CE5069.pdf ; TCGA-A2-A4RY.2D6815B5-7704-4D67-93D1-78EDD924F131.pdf ; TCGA-A2-A4S0.0118D9AE-B923-4EEF-BBBC-82D559763FF9.pdf ; TCGA-A2-A4S1.041580F0-700A-4A47-83A6-207ED267E844.pdf ; TCGA-A2-A4S2.4A5630FF-0ADC-4E69-B22A-02F1F34F61F9.pdf ; TCGA-A2-A4S3.351D8E38-6E04-4F54-8CB1-975AEB7DB552.pdf ; TCGA-A7-A4SA.2649764C-9566-49DB-B8E9-B4B86DBB763C.pdf ; TCGA-A7-A4SB.03B39A59-0068-4276-8340-7B97A1395E68.pdf ; TCGA-A7-A4SC.5E14E7CA-3417-4379-8EE3-7F00D6D4A02B.pdf ; TCGA-A7-A4SD.563D1ED2-1A8B-4D90-BD42-AC3790D04913.pdf ; TCGA-A7-A4SE.C0C49D41-AA66-435B-9312-FAD8E2DC3305.pdf ; TCGA-A7-A4SF.C1B1FAA6-EB15-43BB-B3A3-D11511C76060.pdf ; TCGA-AQ-A54N.9BF0E34A-F78C-4BFD-AC4C-926FA1D60342.pdf ; TCGA-AQ-A54O.B3884493-D0D2-445C-B9BB-BC475021EBA4.pdf ; TCGA-D8-A4Z1.D77DF136-6F63-48B7-8187-6F8F98CC1F44.pdf ; TCGA-E9-A54X.BCDA7E7B-396B-4809-A0B3-2BC2C22DC908.pdf ; TCGA-E9-A54Y.3F43AE57-0EB8-4F40-980F-6E2C8C2B3A74.pdf ; TCGA-GM-A4E0.DB0291E6-E371-40F8-BDB3-0F85F015B3DE.pdf ; TCGA-LL-A50Y.C3BD4B5F-0FB9-4B22-B8FE-9D689660B5E9.pdf ; TCGA-LQ-A4E4.C13D16C9-BAC7-4CA4-B062-D925466F9E2B.pdf ; TCGA-MS-A51U.58D54D1A-3A8D-40DD-A643-846CAF242494.pdf ; TCGA-A7-A56D.D564A7FB-4F0A-4589-AB32-A6CD8B547219.pdf ; TCGA-AC-A5EI.C0F7848A-DD0B-47B2-956F-A24D597D70BC.pdf ; TCGA-AR-A5QM.4C3E3E5B-E24E-447B-A688-68D6EBE15A9F.pdf ; TCGA-BH-A5IZ.52B5D974-2653-44CA-937D-5467EE39938B.pdf ; TCGA-BH-A5J0.80DA141E-2752-4464-8D23-06DC7E9B05FE.pdf ; TCGA-E9-A5FK.D346F4E5-4E4A-4161-96FB-7B8ABBB17128.pdf ; TCGA-E9-A5FL.72186F5B-9F97-428C-8E06-9240E17E88DD.pdf ; TCGA-HN-A2OB.32AE5A1A-703B-43C3-948A-719A90DDACC5.pdf ; TCGA-OK-A5Q2.8F2F2141-EC62-4321-B799-054D32FEBA87.pdf ; TCGA-OL-A5D6.AD80BBA3-DA8E-4DFB-BDA1-FFDC131E9740.pdf ; TCGA-OL-A5D7.A8980EE8-52DE-4DA5-84DD-F8E86EBF6A9B.pdf ; TCGA-OL-A5D8.FD496AFB-43EF-41D8-850F-E57DD53C185C.pdf ; TCGA-OL-A5DA.5049C91E-F4BB-4AA7-BE64-837168189379.pdf ; TCGA-PE-A5DC.8693580D-FCB3-4943-9C2F-5F3DABFB5AF0.pdf ; TCGA-PE-A5DD.7A2719FC-1CA2-4D58-9EF7-594926D1FF66.pdf ; TCGA-PE-A5DE.6D2FA4DD-285F-4815-9494-76B297FA04AF.pdf ; TCGA-A7-A5ZV.FA5CF5A2-F44A-4303-9200-32250FAEF374.pdf ; TCGA-AC-A5EH.C49EB2B9-A19F-43FC-9A77-18BBB43F5B10.pdf ; TCGA-AC-A5XU.D61D4CCC-2AB5-4268-AEB7-C8928E0AF964.pdf ; TCGA-AR-A5QN.A9015F6A-F6BB-4AC8-B681-099232A6DFAC.pdf ; TCGA-AR-A5QP.F2409024-D848-4B02-A371-92BEA1105EC4.pdf ; TCGA-AR-A5QQ.511282C5-02AC-4105-8B52-5BBEC8B45D22.pdf ; TCGA-E9-A5UO.6C698240-6557-4F96-BF56-60792693920F.pdf ; TCGA-E9-A5UP.B50AB6D5-3010-450E-9CCE-E9BFA0202736.pdf ; TCGA-GM-A5PV.A616A83A-8D19-4085-B430-1AF80D4F9642.pdf ; TCGA-GM-A5PX.E49FAC55-434A-429B-8E61-C5E0FBD7C15C.pdf ; TCGA-LL-A5YM.B169A5B5-27CD-48A6-A8D7-C14D3824A20A.pdf ; TCGA-LL-A5YN.4D4811FB-5BF1-4574-975B-1740602E43D8.pdf ; TCGA-LL-A5YO.C5C5D704-2558-4D4B-937B-33BD91132882.pdf ; TCGA-LL-A5YP.B6B4DCFE-F044-44D6-BB90-EF71E6981E82.pdf ; TCGA-OL-A5RU.7507AC79-4C8E-4393-92B9-BFA6BEB492D0.pdf ; TCGA-OL-A5RV.0CA74400-1596-4C14-AF02-4F5169D61942.pdf ; TCGA-OL-A5RW.86B06754-B000-4F8B-9037-95E7A0BD4D20.pdf ; TCGA-OL-A5RX.9536A134-A44C-4698-A525-DEEE7FACD144.pdf ; TCGA-OL-A5RY.C8297152-7551-49A1-8C9D-6B411391AC77.pdf ; TCGA-OL-A5RZ.927C0D4A-327A-4168-80C7-151A4B865CC9.pdf ; TCGA-OL-A5S0.EDF80CFD-4115-48E9-BF76-DDE957A97AEB.pdf ; TCGA-A7-A5ZW.A56585F9-9651-472B-BF53-C708A686EB7D.pdf ; TCGA-A7-A5ZX.A8834D03-81F5-43BC-A4AB-F215C89CB095.pdf ; TCGA-AC-A5XS.C4F259BA-7C00-4326-ACB2-924C4AE33E87.pdf ; TCGA-AC-A62X.6BB72835-1002-4B35-9304-495E12A30905.pdf ; TCGA-AC-A62Y.83BCCC3C-0384-45CD-84B4-67E2EDE822EE.pdf ; TCGA-E2-A56Z.83AAF7BF-131D-4044-AD3B-670B838A23D6.pdf ; TCGA-E2-A570.803922CD-3D37-47DC-8BDC-EF8F4779685A.pdf ; TCGA-E2-A573.14EB270E-0AAB-4C12-8D71-ED79076C2E93.pdf ; TCGA-E2-A574.F3FAB505-03FF-4FAA-ABB6-96AD20F47871.pdf ; TCGA-LL-A5YL.17B51CA5-E325-4EA0-AFED-C6D0FD5A40EF.pdf ; TCGA-OL-A66H.3D84D02A-42B1-42E1-84FB-E9AE9381ABB4.pdf ; TCGA-OL-A66I.800346FC-BC14-4A33-B10C-84224D908481.pdf ; TCGA-OL-A66J.D5DE4BB3-81AC-44CB-9336-060F324C7A2F.pdf ; TCGA-OL-A66K.8A19AA55-9B1F-4325-B730-068F928F1C13.pdf ; TCGA-AC-A62V.BBA96852-E70C-4D37-A185-611F568BE90C.pdf ; TCGA-E2-A572.5CED2FBF-42DB-4D17-95C0-DEAE27BBFD02.pdf ; TCGA-E2-A576.967CCAA8-5BC6-4744-BD9A-3DFEF9EF4F27.pdf ; TCGA-E9-A6HE.649E6215-36F9-4BEB-9EE9-683E4FC75C42.pdf ; TCGA-LD-A66U.5FF5CE63-2A8F-4117-A384-A57EED6473D8.pdf ; TCGA-LL-A6FP.D318A0F0-38B2-4DFA-8326-E362603AAC5E.pdf ; TCGA-LL-A6FQ.5C3D9179-7434-4776-A2FF-68CEA0149C68.pdf ; TCGA-LL-A6FR.B18B184D-B7F1-4C4D-8DA2-D5ECF49749F6.pdf ; TCGA-OL-A66L.B8C192A7-E530-4301-B4D3-FF528A230260.pdf ; TCGA-OL-A66N.CDB6A529-DE8B-48F6-A569-D07251D139C3.pdf ; TCGA-OL-A66O.60ACE33B-BEE2-4A49-85F0-1364D245FCA9.pdf ; TCGA-OL-A66P.979468F0-6B4A-4759-9CA2-7BA1D1441BC2.pdf ; TCGA-AC-A6IX.3EE7548C-464D-4FC0-B1E2-2F6461C4A2A1.pdf ; TCGA-BH-A6R9.1DB8FAFB-FC4A-4401-8316-30FB5352335D.pdf ; TCGA-D8-A73X.9B227A4E-6237-4C95-B640-E64AFF0CC5F4.pdf ; TCGA-EW-A6SA.9C971870-BA92-4E0C-9861-31C56B7E7D64.pdf ; TCGA-EW-A6SB.6EEF1F11-603E-4196-91AB-724BBEE20CE7.pdf ; TCGA-EW-A6SC.315A77B4-1A2E-468D-9E44-FF0B07697943.pdf ; TCGA-LL-A73Z.D9FE314C-61F4-4E4D-BB29-4B681C2A8A10.pdf ; TCGA-LL-A740.3AD4AA3C-5F68-43D1-B578-07AB574D4DE3.pdf ; TCGA-S3-A6ZF.7B53A0D4-E13E-4573-B0A2-BB55AE54BD62.pdf ; TCGA-S3-A6ZG.47D02B80-47DA-4135-A288-21077C5947A9.pdf ; TCGA-S3-A6ZH.030860D0-66DF-46FF-95A3-2AE4852D5C19.pdf ; TCGA-A7-A6VV.C26EAF0E-202B-4F3E-9E59-3395A1BFCAB8.pdf ; TCGA-A7-A6VW.BE19CEFA-7A66-480C-BEC0-AF52F4C8A04C.pdf ; TCGA-A7-A6VX.80EDDCAC-B87B-47E6-A48C-F166D227DA6C.pdf ; TCGA-A7-A6VY.BB85F844-C710-41D5-8620-E246DC9D2C6A.pdf ; TCGA-AC-A6IV.5B978086-7443-4721-854B-877CE0FC10C0.pdf ; TCGA-AC-A6IW.302E69E0-39F0-4CDB-97F9-A6CDDB3D7233.pdf ; TCGA-AC-A6NO.A81EB5E0-305E-4657-94AD-0922CD1D79C6.pdf ; TCGA-BH-A6R8.BF07FF13-D7EE-40E1-9729-8F9CCBD1534F.pdf ; TCGA-D8-A73U.7BA4658F-3343-4176-BDCD-620A1001A032.pdf ; TCGA-EW-A6S9.4FC32F17-7A4D-4FF6-A710-FFFBC610CB56.pdf ; TCGA-EW-A6SD.9FB40DC5-BED9-420E-B334-4D0BE8B8BCF5.pdf ; TCGA-LD-A74U.CA6A13D4-DD80-4424-B5F3-654EE31263AE.pdf ; TCGA-LL-A73Y.9A8F7726-D97C-44DE-B72F-6BF0FC2078F8.pdf ; TCGA-OL-A6VO.961547D2-F235-47E9-9A6D-D286758E332E.pdf ; TCGA-OL-A6VR.217745AA-6C5A-46C5-AC04-1C6581A96A04.pdf ; TCGA-V7-A7HQ.82B46073-10CE-4D05-9421-6308E3FAD1AD.pdf ; TCGA-AC-A7VB.53881871-C36B-4622-BFC6-4DA3635D7B26.pdf ; TCGA-AC-A7VC.A1681334-684E-41E0-B3FA-EFFE1E5A8B7F.pdf ; TCGA-AQ-A7U7.2B30A85F-7A5F-46E4-BE22-28C902D5DFA3.pdf ; TCGA-BH-A8FZ.A2B05D26-AC8E-4439-B32C-B48537D20836.pdf ; TCGA-BH-A8G0.22134EA5-5ED5-47B8-9A33-01E59E58B54C.pdf ; TCGA-D8-A73W.359DB5F2-BD23-42E1-B316-9D908DBACD78.pdf ; TCGA-LD-A7W5.ADBA741B-AABF-4A33-A61F-C10EE555D175.pdf ; TCGA-LD-A7W6.859561F6-3113-45C8-8FBE-718BF860B582.pdf ; TCGA-LL-A7SZ.3FA5FACA-8A6B-4F42-A557-3B69866859E7.pdf ; TCGA-LL-A7T0.5540DD9C-FA3F-48B6-8243-414616816A76.pdf ; TCGA-AC-A8OP.F4F5C477-30BB-41EE-B188-B20DE019F30A.pdf ; TCGA-BH-A8FY.BC78EC6E-73C6-4234-9369-9A5586CD1A69.pdf ; TCGA-C8-A8HP.581088D6-9F9C-4572-B61D-BAF0F6C79B2F.pdf ; TCGA-C8-A8HQ.37FA6CD0-E789-44EA-AD78-C195CBB1EDE3.pdf ; TCGA-C8-A8HR.CA1E5192-ABB0-45E6-8547-2BA2B035238C.pdf ; TCGA-LL-A8F5.79A10C4B-1B5F-47BB-99EA-E694FB341696.pdf ; TCGA-PL-A8LZ.436F3280-98C7-4FA9-BD6F-1B02CAF1D262.pdf ; TCGA-W8-A86G.A5433CA5-1DCC-4711-9B3B-6478AE7B5FAA.pdf ; TCGA-XX-A899.EA8A0A91-7A83-4EC9-B7A0-0C3300D1FD14.pdf ; TCGA-XX-A89A.5D85E578-64B4-4238-922E-802B8ED87800.pdf ; TCGA-3C-AAAU.0CD23E1B-3FA3-4A43-AE6E-C8E7B51252F8.pdf ; TCGA-3C-AALI.84E6A935-1A49-4BC1-9669-3DEA161CF6FC.pdf ; TCGA-3C-AALJ.265E5A9A-64FD-4B86-89BC-5E89F253C118.pdf ; TCGA-3C-AALK.F43B01E6-E1DB-44B1-8003-93870606346A.pdf ; TCGA-4H-AAAK.8894688F-7167-48A1-BB1B-FC219B7675C2.pdf ; TCGA-5L-AAT0.F9B6971F-23C0-465F-BFEC-778BF228A1AE.pdf ; TCGA-5L-AAT1.B5CA42BB-9514-42C6-9FB0-C8889C1DC51A.pdf ; TCGA-5T-A9QA.2DB5519B-B36D-4616-94F3-601A01185F22.pdf ; TCGA-AC-A4ZE.6931CAAE-6DFE-4A61-84D5-4EC804C2F2C6.pdf ; TCGA-AC-A8OQ.FFA6F9F3-71C1-4AF9-B9F7-0466550EBC90.pdf ; TCGA-AC-A8OR.1E706FF8-F42C-4FC6-8976-BEB4213BD730.pdf ; TCGA-AC-A8OS.EEF4E8C6-6D80-4C6A-BFC6-E529692088C1.pdf ; TCGA-BH-AB28.3A87B5EE-D1AE-4D28-8F7A-3898AD4E0796.pdf ; TCGA-C8-A9FZ.23B3BAED-E281-4A1D-AB78-51D8D62466FF.pdf ; TCGA-E2-A9RU.E28607CD-0847-46F4-8E69-2D1DC80DE56F.pdf ; TCGA-LD-A9QF.E8601979-AE05-4E4D-BB39-6B9C5E67D050.pdf ; TCGA-LL-A9Q3.2697F2B6-725C-438F-B4D3-3E32DEF86FD6.pdf ; TCGA-OL-A6VQ.17C74789-D7B0-4291-A2AC-7A72C5DC58EE.pdf ; TCGA-OL-A97C.1582865E-9294-4D78-8B16-92FB70381D15.pdf ; TCGA-PL-A8LV.D35DBECD-5241-4562-85CC-2822BB338279.pdf ; TCGA-PL-A8LX.E6DD0840-4D71-4EEC-B559-F6BFC9E7E68B.pdf ; TCGA-PL-A8LY.8C97B391-96B4-468D-AAA3-24E196DE03CA.pdf ; TCGA-S3-AA0Z.6EC48BF8-C9AE-4B53-9DF4-850A5BAC6A6E.pdf ; TCGA-S3-AA10.6A981CB0-F551-48B1-AB91-5D5585A7F282.pdf ; TCGA-S3-AA11.B6605B1A-264D-46EF-BB6F-AD5EBE1B34DB.pdf ; TCGA-S3-AA12.9F96B0B1-2B88-49AE-8D3C-9FED70F1D950.pdf ; TCGA-S3-AA14.F4B87B89-A066-4BE9-88C9-60C7FB5BF373.pdf ; TCGA-S3-AA15.DD2B9E47-8C67-4599-B0B6-0D30DE727B55.pdf ; TCGA-S3-AA17.D7E24E6B-797F-4FC9-B0FB-794C4D379091.pdf ; TCGA-UL-AAZ6.1AD1E3C4-0D7C-447B-B330-0245F9159FCC.pdf ; TCGA-UU-A93S.821ED144-DF12-4E49-ADC7-27FA5E422B83.pdf ; TCGA-WT-AB41.FDB00212-9782-4ACE-AD59-019384297A2F.pdf ; TCGA-WT-AB44.B7EB0E0B-46C5-43C0-A78D-FB094290765A.pdf ; TCGA-Z7-A8R5.7726F7AA-88A8-4DD6-B322-6FC68893E0D2.pdf ; TCGA-Z7-A8R6.9A5C8EDF-9243-4F55-9036-A400CF3F4CC1.pdf ; TCGA-A2-A0CX.28AFD5DD-B607-4837-819F-688C9218ED06.pdf ; TCGA-A2-A0D0.D8B44020-EC34-4788-B7FB-790B9C12D886.pdf ; TCGA-A2
PATHOLOGY_REPORT_UUID	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pathology report uuid	Sample	747FB91B-F523-4FA0-91DD-6014EF55643D ; A2B755DD-00C4-4349-8E11-C1196EBC91D3 ; 9B2253AB-2C41-4E7A-9178-B690FFD9FF78 ; E66D3DF8-1605-4EFD-AAFA-74F82366FD16 ; FF6BC87F-029E-4565-A35A-6FB968F8EABA ; 16DEA43F-4A61-44E3-854F-6B6575B45628 ; 56EFCA58-2328-4C5C-9618-981447E76B12 ; E2EE2397-0F8A-4A71-9B3C-0007F7D00500 ; 40B07BB9-2CDB-463A-8773-771017E73DBC ; 0813A175-83ED-4F6E-AD7D-FB4135CFF34C ; 04EF4A48-80E1-4567-BB61-2B542F715266 ; ACA6B606-681C-427F-8923-77BAA7390795 ; 4DAF6DB8-5429-4B39-B103-D4317166D05B ; 4C7445ED-B346-4DD7-8AFA-2E95E65364BF ; C972EC08-E1AE-4FCB-B8A1-15000306CDE7 ; FE41053B-16F4-46B0-B243-571F4D5A1665 ; 074223E9-5E1C-47E8-BE40-1C4442CAE9F0 ; 849E9FA7-3420-427B-A310-3346CFA9F0CC ; EAFC71A1-D6FC-46EA-BC47-D054C497D705 ; DA82E751-09C3-466E-A63A-38368D8A2C7C ; E2E6CA22-AFE4-4B8F-90AC-32639687A590 ; 5AD3B697-F097-496C-978B-F73BDA5394A7 ; 02B4C31E-38F0-4AF3-8DAD-527D5F27C11A ; 50782829-35B6-4A61-A3CE-F105A31EDB42 ; 15FB8CBD-85EF-45BE-8065-9F4E922D457E ; 467172CC-6EA1-435D-BDC1-D65FBF8EA0E8 ; EB5199BA-6164-4CFB-AFAA-B41544B83103 ; 0FB93D92-81F6-4241-9094-4AABF70E6A0F ; D9432167-0F2E-4377-9DB4-EA4E59A6C9B9 ; 1B5FA34B-E3B4-4D4B-AF0A-1C90016CC532 ; 6EB1A616-E99C-4AF6-9C0A-0FDC521A79CD ; E1FDF8EB-9D75-4629-9C78-6019DAF8190E ; 40EE8416-9DD8-457D-94AC-A871B5C62873 ; 72996825-1FFA-4C51-8DB0-DA74BCB595EB ; 809F294F-8C48-4719-866B-7169FB1CE24D ; FA86A743-EA67-4554-ABA2-BB8C1DBDB0B1 ; 2ED10396-96FF-4705-93AE-82FB9A80EC28 ; FA781D93-C180-4453-BF95-B2D01B6CDB5C ; F70DE761-F081-4F4C-AD22-9A166CF78CA8 ; 7E9B0BE7-121E-423F-AA37-445BA922FC13 ; BAA6AA92-69C5-454B-A550-246E7DB1EBE3 ; C5D116FF-3193-48A0-B69C-D98831D9976A ; 7B1B31D2-0CC5-4EE6-8AF3-16DF726BE13F ; 9F838476-4DF1-44D6-989F-33A1D490424B ; 098BAFB4-94D0-4FC8-B938-D8A410BD8FC1 ; 49927626-EB84-4A79-8073-67818722123A ; 501C3E1B-573B-4A5A-A0ED-3CD15432E6FF ; 8169BE67-03C8-4F4D-9A60-200705B795AE ; 032B81C5-F936-448E-A352-C186DF160B7C ; DA6A0EC9-6E20-4E4A-9B7F-A32EFF7627AD ; 26F47A4F-B501-4C33-9D49-2039E98DBF26 ; B6E6765F-14BC-4D3D-9266-EF8065354070 ; DDB31719-1D2F-4502-B80E-544B684DC16F ; 11F98715-1482-4D7D-9102-E362634806A7 ; 4D1B4A09-FB4E-45EC-895B-2941D18AED18 ; 24B1FA5C-7D84-4CE5-B094-2358ECE73C10 ; E8E799F8-158D-4AEC-8F86-D40F132C071C ; D80E9389-AAD8-4EEB-9DE0-5DE57B5E5F6B ; 51A2B7B5-0CDD-427D-BC82-5498810B2641 ; 27376503-A55C-4905-A885-632440EFCED2 ; B4DB830F-BFA4-47F5-94C7-D95984315866 ; 332880ED-FE4E-4EE4-9E96-0A61BFCCA27E ; 746C603E-FB1F-40D7-BEAF-20ACE27D6C21 ; 03724E51-8430-414F-B483-2CB92D6A878F ; E1907A10-207B-41F1-8B8B-24D5B551BD05 ; 49C79E09-2F69-4089-BFB1-53197DA09A46 ; EF2DC6FB-F026-4025-B148-DF07194914AB ; 1841FEE0-EC36-4EC4-8B5E-6D340C80735B ; 156DF753-DB3A-4934-9618-1E18CE46C845 ; 947954F1-4CBA-42D3-99B2-6BE6E44E5239 ; 021DF0B3-A535-4AD4-9545-1B9A7BC3E1E6 ; 1B61F1C1-8B19-4D9C-B6B9-87EEE350A472 ; 0EA57ABF-E3DA-4862-BAB8-A6E36408AC42 ; 72AF26A2-FAD0-42FD-A63C-6E8E2597B84E ; B5074D1A-C617-414F-B349-6096F59E122D ; 95443906-A63B-4E07-8C4A-ED0A918B88F8 ; 12DAEBF2-CDBF-4D90-9C74-2A2AEF1E8433 ; CC0B1145-B242-45BD-A946-B14BA5A9E923 ; F23523C7-B6E9-4205-BD36-D76E9EE9C453 ; 9AA68C63-2C14-430A-85C0-5A92F7FCCD36 ; 97B6C43B-4C7D-49FC-BA49-00D2DF41827D ; D4194F52-3E15-4105-9A1A-1326CF128BF8 ; 7C003A4F-DC30-43D0-AC61-ACE6BA118BEE ; F5EF4698-364C-4A5B-A8EC-1CF231BEEF31 ; E8B860F6-F3FD-4FDF-B467-8988646C2F00 ; 0046FACA-9E90-4BA9-B216-258A2A7A2EC6 ; 79C0D757-50BE-4375-AF69-E577629EE0CA ; D92CABBE-8D7E-41E5-B702-9ED07E94E5C4 ; F282122D-C129-4A8B-9A49-78D5267C37CA ; BEC7EEA9-6DEA-4402-A3A1-07EF33D58174 ; 1617B36B-4EFB-445E-95BC-E63B129AAAE7 ; 89A67051-898A-4E2A-A874-E0165F274E63 ; 4CD6BDB7-9629-41C6-8514-7661E3D33A66 ; D0269758-EFAE-4EBA-8CCF-4A6CF4D4B35A ; 92EE56BF-AAA0-438E-9244-780DBB2D9835 ; FF188295-E139-4AEE-8EE8-364536F2BBE8 ; 9E2EF2C8-A60D-443D-99B6-205B7053175A ; ECD02213-B048-4776-B09B-982FE1260F80 ; 4F2A288E-8162-4579-BCD2-0FF31B0EEB3C ; 35F7D0D1-BA21-4135-B444-6B10EAF66F25 ; FE54D4DC-C35E-44D2-B8B5-0B631AE0F89D ; A9D36308-DAEF-48B9-A4EC-6B9B24EE3DC2 ; E78526AB-D72D-4407-B7E1-2255BB5B2F68 ; 8F401B38-8D91-4F75-ADE5-52521EAA7DFE ; A868EC86-9CB6-445E-B961-5D4C57263548 ; 3327975F-94BE-460E-9900-E063340927BE ; 910A4342-BBC1-47AE-9316-695B0CD0375D ; 4F15F8D6-9F34-4A61-A006-E5E7A2E68207 ; 595BB256-2F3D-493A-AA90-022BE0CC995F ; AC26EE69-27D8-4523-917A-68573F5F614E ; 3CF4FC36-70EF-4EA3-874C-4A514FCDB717 ; 88E39E13-8ADC-481A-992E-610B3BEBCBD4 ; 2153CBCE-6DA9-4E0F-9F41-B9F08FD50647 ; 4C40B309-3178-4E7E-A987-47698E5E364B ; 76358109-41A0-4D5C-8894-F6A63A925961 ; 42DE8E2C-395D-4E9B-B7BC-6A0B2F9BD7CE ; F9FB00C3-9F86-40AC-A5E8-08712CD5002B ; 042304AE-706A-4033-A97F-3765A6AEC649 ; 70C8D54A-9698-4275-BD96-A6EF2E26474B ; 82771A56-81CA-4414-949F-EFBCAE1C98D4 ; 6FEAD496-58BA-42DC-A3F2-2F380EEB1588 ; 8F35E936-E4DD-4E35-BD9B-6CB7974E2765 ; 6CB5A0ED-5569-4FDC-B651-758BFC6B59D8 ; A68B2364-89DA-4DC7-9AA7-A08BBCC85025 ; B3B6DE56-F40C-40BF-B6B3-2BC10F695F16 ; B6D80CA9-F4DA-4DFB-80BF-08BEE17142BD ; F59530A5-7370-4E77-9099-9F38B25A38EB ; 0D24479F-2F86-43AC-AAB1-83AAD99542C4 ; 6197798C-6F04-470E-BA91-922548E2DFAF ; F93E326D-F4E0-4000-8A67-AA19C4D3637A ; 58B02C83-2AF7-4978-A3F7-A8B9E0D914A1 ; 449F70F0-DFE1-40F9-879D-43283CFAF525 ; 9320030D-5E19-4BEE-99DA-366B6762DED1 ; B7367E27-2A40-4E8F-8975-D5665E6506D9 ; E5D2E429-C41C-47E2-96CB-F3B6F412499B ; D5614445-4EBF-4050-8FC6-D34D5CAADD82 ; FCBB54EB-6FBF-4DC4-B4D5-DB533687FA58 ; AA869507-1B46-4812-8EC5-A4E01C588E6E ; E0CCE6AD-38A6-446C-ACF7-358C1DFC59F8 ; 021D6868-16EA-4D55-9784-46A0F85C50C8 ; ACE20EC5-2822-4F50-949E-E194C59F0FCD ; DAB174BB-862D-49BE-9BA4-9C11C4489305 ; 6CC4E6EF-6664-448E-933E-FFA9117C7ABF ; 224A51C8-8EEB-424C-AD88-44C4321050EA ; 39D6D1DE-2CAE-470F-836B-926242F46E67 ; 740CF6E1-C742-47DC-8057-9D73AF4D6171 ; A6248687-C0C0-4DEF-9D92-196CBDB5CBDE ; 3F4F5A98-F6EA-46D5-95E8-6797D419328A ; 5B9C0E4A-3958-4ECF-B8B2-E758E04E7722 ; AA095896-8217-4BEE-97EC-BC79F5C395BA ; 8A865E33-082A-454F-A6DF-89E994206E65 ; 26140CA5-AF22-47DD-BE48-C3C7DE07E5DB ; 59D84893-8946-4C5C-A338-3E33A1F7DE00 ; AE0C51EF-017E-4F53-968C-804110F9A7E6 ; 5BC01981-366E-44EC-A986-087DB7904E5C ; C2711492-0BDD-487E-9C9B-CEF20BBE57C3 ; 6AE92F6F-E29D-43B6-AF1E-F15720C1AAE8 ; 57323AE5-3EFE-4492-8522-D9A6DB3F1BE0 ; 3F1DA529-4967-462D-8966-E634D66EB3E1 ; 880A4D38-40C5-46C3-8EE7-36539DD64773 ; D3EA3547-7E53-442E-A957-B2DD7EBAFBB9 ; 5F1C3B85-5E5C-428B-8779-3A5878DCE1F2 ; EEA126DE-A667-4373-9DC5-96B55E4ABF07 ; B3DB4F9E-C91B-4913-93E8-F18FF22CBA7C ; 762963FB-3D8C-4616-8C8C-0CD3E45FD243 ; 7E48315C-3717-40DB-8773-71D070AFC47B ; 9AAB53EC-89A0-4878-BB9D-D96BC56B54C4 ; 33B6269D-1D59-4184-A786-2BEB73F6D3A8 ; D9A0E659-99BC-4704-AC85-E63098BA731D ; 6C97C157-05A0-45CE-91E9-3DC8946EFEDE ; 99050E48-8DFE-4405-B8D8-7649CE2C9CFF ; 845F8FCF-CF3C-4CEF-B673-A57DE626939C ; D3AC6B8A-CC8F-475C-BD2E-A869BD07D94C ; BD71F606-58BC-46B9-8A03-CB25D5BECA96 ; 9D1EDFE8-FA4E-4F6C-99E9-1FEB12175D6C ; 1D6EE39C-DE75-4595-943A-CF53873F96BF ; 53ED4388-8CD2-4925-81A9-9C4792C83566 ; 1B198706-8844-452A-8F5B-8880A239717C ; 08A790DE-B01D-4140-BB1C-B4844291D71E ; 64B91C7E-E6D8-4952-B49F-0F5D57332994 ; CF6E29A2-FAE6-45BB-B625-33877887A89E ; 73953A70-DAC0-443A-AC04-28BDA8D5F673 ; BE186852-8596-4CDB-B5C4-AA5838C15B5F ; 141B770B-22DD-4C87-AFF7-04D85FC9C74A ; FA19C3C4-E13B-464B-84CC-3AF7E83D5B9C ; 2E77693B-FAAD-4CCC-BD4F-3D2470C25143 ; C976ACED-7FF8-4287-9D68-C6FD17895FC0 ; A7C7D409-D086-4A9B-8C8F-E7E231D5891D ; 531B1E8E-9936-42E0-B49B-39C61DD4E943 ; 4F943D12-E769-45F3-86BE-75193786DD4E ; E28150CE-E9B6-4C3F-B867-F9A75E2648DC ; E69CF3E3-4799-4892-87E9-4291B14A1B9C ; 4ACD42D6-9520-4DC6-BB40-9187A4D49981 ; E8D4229D-5049-4991-BDE0-AFC2CBC1827E ; B3A319BE-2230-43E2-91E5-A3B3C76B85BA ; A514658A-FB29-4AA0-9451-2A960B3720C1 ; 4F50E811-0743-440B-9094-6BA0F40BD734 ; AA1B707B-4DE8-4E0D-87CA-601760F4A6CF ; 3BE8EA29-3C5F-4339-9CE7-98994B545848 ; D10A419F-B161-4998-97DE-45DF70F4E212 ; EDDEB48B-B712-40B0-9DE5-9F5B5791AF4D ; 80831A1A-95BD-4ECD-B7D9-6DDCD5313B25 ; 50F3690C-2082-4590-A923-656C5F226FAE ; 7C8F01DC-9CD9-4D61-9032-BC9F28A687EE ; 13CA22BB-5EA5-46C9-82D3-77867122D1B4 ; B0E8F3C1-E996-4E70-9630-AC95AF6E4EDC ; 15FA41AE-3A0F-4112-828B-EE8687A6F158 ; BC3061B7-9C99-4270-84EE-B1306FA01AE2 ; FC896EB8-1CEC-46A0-82E1-E3FBFAAB69F1 ; ED60F792-A71B-4BAE-A536-5FF6D8C3DEAA ; 7788E7FD-B5A3-4B22-83CA-EA3FB5E826FC ; E34F4BF0-A0C3-4C72-8E3A-F319D4CDDD5D ; 672E4D81-DA47-495C-A58B-BD2B4FEA2380 ; FCE29F34-5D13-4A21-A950-A8577C957C10 ; 1D4CA1BA-B534-4CEA-ABA5-EF9B31694204 ; B81555D4-78D9-4235-AABE-F852CA6F15B5 ; AC60F5BB-9371-4F69-BAA0-099AD7FC2A0B ; EA830A26-3DF5-4731-AD0A-F20A61D58817 ; 46A75AD3-BAD1-4A16-873E-0099BD10FA8C ; 6BE810A6-3D30-4F75-89B7-00C866553165 ; 1159E2EF-6407-4D90-8ED6-7AB04CF4FB32 ; CCE33A95-774E-4242-B2A1-05FF002ED1D9 ; 5CC0C09F-70F6-458A-B8E6-18BDC074BE74 ; 926E93B6-EF7C-4F13-824D-13D08B7F7938 ; C373F2EE-C601-4E17-8E2D-D9BC6AC0301A ; BC7B3577-CA6C-41AD-98E2-89D357D29D37 ; BF82AD23-B40E-459F-83EC-590D392664FD ; 56DFBCCE-A9D9-4F08-AC7E-33998F3439B2 ; AAF32BB7-716A-4C0E-AE7E-04F6A5BF5628 ; 887F0E3A-DC70-4CD4-AAAF-3C613195D895 ; 0BF7CB67-49F1-42EA-8B41-988BD7E0DE61 ; CCE8E855-2582-4214-B9B1-25F0431065CB ; C3259BD1-1A2A-40C4-A106-FA2EF0201811 ; C0A8A457-8790-4745-BD5D-AFBE55254A1C ; 226031B3-D9C2-4343-B3F7-4E0C36B901E7 ; B481795F-C52C-4FCE-827A-07991C7A7C2E ; 468CD293-C9F7-43C6-A40A-18FCDD22F6AA ; 0F2464F7-4108-4700-B2EC-17BC6C432D42 ; B537A19C-C7E8-42EB-BA3F-673417F3A9BA ; AD07F611-0EEA-4890-A02C-6DA3F5F57C45 ; 16BE833B-E17B-4B8A-9D71-B0D83D73D9DE ; F5B17108-8904-48E7-9B3D-182F0EA388B7 ; 8C52C92F-26CA-4E72-BE47-CA2ED1746785 ; C026CFCE-1A82-446D-AC78-8CF4788FD9EB ; 492DDF00-858B-4420-A43F-4FED2DF61C15 ; 0FDC2801-71F8-4D45-BFF1-89445E621A41 ; 3EBBE51B-6D17-4A77-AAE1-E0424CEA56DB ; 4F3E197A-9731-427C-A2AB-2D506A1C717B ; 4CC1413A-5D03-4BE4-91E5-80B578CE7DFA ; CD43BA31-A5C6-4C0C-AA07-3171332776CC ; 864BB34A-1008-480C-A3B5-A2C616E95C49 ; FA93BDAA-B56E-4217-9022-4EBE6009FCF7 ; 91303D10-CC36-47CF-BF14-E1DCE0157D1C ; 742A4812-9EB1-4348-996E-3F1AD7FA3E5D ; 4158FEAB-066B-4500-8FD2-3F197438DFB5 ; 61E73960-32B0-413E-AF1D-2EF4582293B3 ; 8950E632-451D-4436-9AA2-740CB08237E8 ; 6272ED78-501A-4055-8C87-430F46F518AA ; 392524F7-B570-4047-A439-71FC15642DC8 ; 33569E07-D7BF-491B-A352-CEEA81556800 ; 3971CA42-F1B0-4D85-9AD3-210B98E76A9C ; BE63B06A-E3E0-4E00-9B9F-5E7DE8852E07 ; 9D040C65-C225-4D41-BA4C-6BB21EC1CD32 ; 929AB6C9-58B0-4E37-A2B4-9FC1F9099437 ; 0F1DC8BC-5987-4C50-9A34-79FFC1D2BA30 ; 8C845114-BBC6-45F2-9135-7E8298E24422 ; B660432A-A67B-40CC-89F8-80648DB8AE98 ; 5E21E07E-BD5F-4AC7-985A-178416D756E2 ; EAB9E75C-2795-4D83-9806-5019DC14256E ; A7FAA4F2-1846-48CF-9FB5-15E98430F6CE ; BDE9E2A9-09E9-49BC-AFBE-BD32916972DC ; 36F6CB19-17FE-47FA-BFCA-3846578C028B ; 976C6F9E-DDCB-42F4-BD2C-A4D715396B47 ; F8B8EEB1-0603-4181-9BD3-209143024EF8 ; 52D7E980-806C-499D-9DB9-40E1D651D9EB ; FAB622C2-3E45-4E72-AA36-9530BB830993 ; 6B2ADF84-5CEA-430A-87DD-5C2EC24C6E90 ; 1281F503-C256-4DFF-A3BD-BD5E51CE4249 ; 85045216-10EC-473C-96A9-268E71D2B566 ; 69007BC0-E1DF-4E68-BA6A-352F6A12F233 ; ACC0A0E7-218F-4112-AC74-9F5D5A512DD3 ; 5E997487-9A03-4723-B1E6-FA0B557D8FDF ; 15237FF6-A56E-4E05-B81D-B87E91B59917 ; 292571E3-D500-4337-B435-834B504F3109 ; DD0ADC20-2059-435E-9EB4-351C87D7CBEB ; 5F2A52E5-2844-4242-8CE4-A87DF9D9C97B ; A23D86FF-CCA9-42B2-B6AE-9E365AAC03C8 ; 4AABCBD1-DF12-45E1-9307-21D6CB0894A9 ; 3D878253-22B3-4A53-AE54-C0D95E085DB1 ; F6CFE506-16BA-475A-A81F-1AC4B2EFE24A ; E6897E14-465A-486A-A6AD-FCFED21629F2 ; C1ABCD83-40EA-4FF7-BEB6-69679589E8E7 ; E5011BD1-E1DE-4A47-BF3C-66BA1E0B84DC ; F273B11F-D3CE-4619-BEC2-15C110567503 ; 335BFEB5-6356-43A3-896D-50BF3830B59E ; 0487E2B3-C03F-43A0-ABCB-B2BDBE0FF47E ; 1CF3FA64-EAE6-4A18-9B51-F5980A885371 ; 5A7EB73F-E681-46CC-B2D6-C87EEAB0AC99 ; 95DC80AB-C070-4613-8C11-A124AEDF9754 ; 73FFBADB-37C0-4F17-8C95-F8DC94EF1AD3 ; B2314041-3E85-4E3F-8924-39FC285B08B2 ; F868DC95-23CA-4DFC-BAA3-FBF5BF6F45A9 ; 1DFFCBD1-962D-4E9B-BEE1-726CABE3AA95 ; E7B75FEC-1706-42C1-8906-B17FE4440161 ; CA6B733A-6030-422C-9DE9-B9718CBB2FDC ; C3243207-2190-4435-9AA9-39E3B913E316 ; FBD7BD94-2870-431D-A519-DAF72A97845F ; 18D46E96-4E16-4736-AACF-C6BF8AEC9368 ; 8829274B-EB82-4155-A458-CF9F0E60B36E ; C2A0E948-2B9E-4E49-90C4-57CE4C4A95B3 ; 4E3FDA72-93E1-4961-B1DE-5BFDAC7E947D ; 128D4F7D-017D-459F-9664-AF509AE4555E ; E5B6771D-450A-49AD-AEBC-7FC056BFCDBE ; C3537961-4636-4BD1-BC89-892580B36E43 ; C310F4EC-D8B1-45C4-8D55-705A9EE35902 ; EE769039-220E-4158-8999-09F17AFB4C46 ; B232BEE4-8579-4E26-B45C-8A5BFC0CEDBD ; C70325C1-54EB-41BF-B77C-D92FADA8D23E ; C690925E-38A2-48BC-8E2B-4EA383E27FE2 ; F3CD8E6E-B02F-4D5D-B895-6DF063F61603 ; 5A315635-886B-459E-AF5D-079F66E859F0 ; 48CB011B-074A-424B-B2D2-E8A2397CF02E ; D437E9FF-5C09-4FD6-BB0B-0881CD4C50D7 ; 8CF4E53E-924F-4DC6-8748-BC8A1F7D5662 ; 100E842E-0ADD-4E58-B31B-0C67DC175787 ; CC1EE9E0-BC1A-46ED-A262-7A2B9CC8BBB1 ; F694CBD6-880D-40C7-AB17-D0AD02B7F06B ; 83BA3E82-E8E4-4A70-ADEE-A1360940EECE ; 5CF85AF1-D227-430C-99CD-C2A524CFFA29 ; E422C6E8-084F-42B8-84E7-4EF387F098C7 ; 4D864947-076C-4A66-940D-682E75E525A2 ; 5411AC07-09E4-40C3-844F-2DFAA216D947 ; 06602AD0-AC4D-4674-B4B0-2D207C3E78DC ; 42E3E8C1-D18A-4457-B2F0-FE49F4C027D7 ; 85E91C9F-9F61-4A25-B4D9-1BCBC7108F5E ; E6A21CE6-841D-4D9B-A563-80B9BAF6E682 ; 593AF241-8F84-4BA0-8878-7C1CE72A460B ; 3E4717BA-E9AE-45F9-9696-F8928D9FCECC ; 90F83655-038B-412C-91BD-84CC3A4201D4 ; A5AED5F0-A144-4615-AF78-539B8523D15F ; D8EFFB62-6A23-4033-8144-24B751DECB08 ; 810663DD-1718-4FD6-B9C2-77B4C091B3F1 ; F0308FC8-D8B4-487F-A072-05E66D01842A ; 25CD89AC-052F-4B9F-AE1C-B0824A7A5145 ; 3B7CA8ED-58E2-4609-BE41-46525D3732E7 ; 3EFA8B1E-0FDB-49A4-95FC-4C9C9B15B61A ; 3C301346-4594-4071-A754-04F8B3BE894C ; 63F5F3D8-6393-4DA7-BB74-7D587199D7FD ; 3E54B0CE-8863-4728-BC95-A47C1869F52A ; 9F00B6F4-EE91-4A18-B533-127E39EF8554 ; 9F7E2B98-29E7-465F-AE12-33D78FDFD71A ; 1E498731-FE74-493E-A330-477643800305 ; 953ADB1E-77C9-4721-B624-F9CCF040575F ; FE3E1376-1527-42C0-8F5F-8849D0F2743B ; 4A0524B4-2A0B-4442-91B6-0E2FEA90CBC6 ; 792A24F5-065E-4001-97F6-3F9BA121C65D ; ADDE6090-5278-42D5-8E89-E0AB630A4C06 ; 1659798C-9B6A-4DF9-A5B6-79AD2194DF11 ; B065FC65-CD33-4878-AE2C-7E8C04F5ECAB ; 8C440009-E05E-4046-96AB-BAB211CB7D02 ; A3167E2D-3588-41D4-99AA-6DCB660D55A4 ; 642B4B50-E227-4484-904E-E629F7F9DBC1 ; 4AF67A51-97C1-4D58-9E60-03FDFFACD38A ; 3094774B-B764-4D60-BFF3-48FEF39F4BEA ; 07833A91-F827-4708-AECC-728C708F8E2D ; 87DB9AD3-7640-4A78-B401-D5562D03BA76 ; 1A0D203A-BC4B-441F-97F6-D1FF7E959262 ; CA0CD57E-DA92-463E-A004-D554825A22D6 ; B52E150F-5B34-482A-84E7-1739B9AC09B7 ; 3B77A3E1-AB8F-47B2-A5CC-A3B593A055CE ; 10C43124-3C21-443C-8268-23BF8A4D317E ; 12A869FC-7578-4506-BB23-7C25597834EA ; 7E0F430B-B96B-49B1-B4C1-88C1F3A855A7 ; 1F02AA5F-67B1-4BAF-A3A9-CA20BCD7FBAF ; 8652E026-9C4D-4AB6-AADE-29DA3345892E ; 00C6FB2B-A1C9-4310-B178-740313565A32 ; F76120C1-B2B2-46EE-AAE1-57B05D258ED1 ; DD5295D4-3896-4AA5-AF75-30AEA45D1652 ; A614B6B7-256F-4148-8941-6145B2D9B8B5 ; 5018EC57-96C6-4D63-B708-45559B4D8527 ; 14E2FC4E-7205-4929-81B5-7FF3006F08AD ; 0F890724-8554-4B2B-B4EC-6B9B24C757D8 ; 00058FFD-35E6-4891-8B01-DAB3AE9EBF78 ; E8583D11-D6F7-41AC-8CD5-53437CBD8820 ; E9A88E5B-4F50-4683-9C65-56CFCB15405E ; 25782EF0-8786-446E-ADBA-21F489844237 ; 405B9D03-6200-4DFA-A7D1-C622D3A48AEA ; A4621FE7-E898-40BA-B45E-3DC9EF607F37 ; 770EEADF-19CD-4AB9-A7FA-1A05EE17984C ; EC1BB6E8-6897-4E70-80A6-5A4E4B9C4E1F ; A7B6FCF6-1B81-40B5-AD92-54681CBC8FE0 ; 0FEAEEBA-A72C-4207-AC21-6AF5B5ED1AFC ; 52CEF542-0F5B-4660-8746-2CF4A27B214E ; B3CFFF02-89AA-43AE-B19B-BEE6817AA997 ; AF83CCA2-3AA4-4933-B6AD-9C11DF501DDD ; D76CF03A-54CD-4769-87AA-466473F41FC7 ; 9BC704DE-0914-49F1-80F9-36CFE52B8484 ; CB2E56BC-16AC-4BFE-AB6C-2FC7E48943BB ; 87B150CC-1C5D-42D5-9951-9157A81316D5 ; A8F63D86-37DF-472E-AF29-FB734EAB7E5C ; 476488A9-3708-4B11-854A-C91B583C7804 ; F969E3E4-0053-44E9-85BC-BEFDBD62C512 ; B644AEB6-7D46-4D4D-BA00-D42BCDDCB164 ; F5A14797-6676-4331-9424-D8B820008924 ; CC77BA51-CE5A-4839-A27A-DD8F389A2733 ; 3FFD87C3-1E75-4A8E-AA26-BF7995E42245 ; 25F791D8-27D6-4DC6-8D96-5D5CF68A5F13 ; 5BB5CEFD-CC07-4451-A774-25FB146067C7 ; B16B3335-492B-471B-AEFE-2350EA558BFC ; E4ECB8AA-0ECC-47A5-B940-045A2C3D9A1A ; 0BB6CAC8-CE26-461F-A9FE-46E28E96A368 ; EE644ADF-639E-450A-92E6-2A6F1BAD561F ; E76B5204-99E5-42D0-AE7E-ED5525796CCB ; 5577BE88-72ED-43E5-9BB1-83D56C2EA346 ; 1FFDD2E3-02D5-4C38-B6E9-1261EB57835A ; 389044F0-9D90-4639-8C42-C1A6EA816442 ; C1D4D6BB-AF86-4208-A729-C61365941217 ; CA88491F-5572-4B0D-8E3D-D536E3CE5069 ; 2D6815B5-7704-4D67-93D1-78EDD924F131 ; 0118D9AE-B923-4EEF-BBBC-82D559763FF9 ; 041580F0-700A-4A47-83A6-207ED267E844 ; 4A5630FF-0ADC-4E69-B22A-02F1F34F61F9 ; 351D8E38-6E04-4F54-8CB1-975AEB7DB552 ; 2649764C-9566-49DB-B8E9-B4B86DBB763C ; 03B39A59-0068-4276-8340-7B97A1395E68 ; 5E14E7CA-3417-4379-8EE3-7F00D6D4A02B ; 563D1ED2-1A8B-4D90-BD42-AC3790D04913 ; C0C49D41-AA66-435B-9312-FAD8E2DC3305 ; C1B1FAA6-EB15-43BB-B3A3-D11511C76060 ; 9BF0E34A-F78C-4BFD-AC4C-926FA1D60342 ; B3884493-D0D2-445C-B9BB-BC475021EBA4 ; D77DF136-6F63-48B7-8187-6F8F98CC1F44 ; BCDA7E7B-396B-4809-A0B3-2BC2C22DC908 ; 3F43AE57-0EB8-4F40-980F-6E2C8C2B3A74 ; DB0291E6-E371-40F8-BDB3-0F85F015B3DE ; C3BD4B5F-0FB9-4B22-B8FE-9D689660B5E9 ; C13D16C9-BAC7-4CA4-B062-D925466F9E2B ; 58D54D1A-3A8D-40DD-A643-846CAF242494 ; D564A7FB-4F0A-4589-AB32-A6CD8B547219 ; C0F7848A-DD0B-47B2-956F-A24D597D70BC ; 4C3E3E5B-E24E-447B-A688-68D6EBE15A9F ; 52B5D974-2653-44CA-937D-5467EE39938B ; 80DA141E-2752-4464-8D23-06DC7E9B05FE ; D346F4E5-4E4A-4161-96FB-7B8ABBB17128 ; 72186F5B-9F97-428C-8E06-9240E17E88DD ; 32AE5A1A-703B-43C3-948A-719A90DDACC5 ; 8F2F2141-EC62-4321-B799-054D32FEBA87 ; AD80BBA3-DA8E-4DFB-BDA1-FFDC131E9740 ; A8980EE8-52DE-4DA5-84DD-F8E86EBF6A9B ; FD496AFB-43EF-41D8-850F-E57DD53C185C ; 5049C91E-F4BB-4AA7-BE64-837168189379 ; 8693580D-FCB3-4943-9C2F-5F3DABFB5AF0 ; 7A2719FC-1CA2-4D58-9EF7-594926D1FF66 ; 6D2FA4DD-285F-4815-9494-76B297FA04AF ; FA5CF5A2-F44A-4303-9200-32250FAEF374 ; C49EB2B9-A19F-43FC-9A77-18BBB43F5B10 ; D61D4CCC-2AB5-4268-AEB7-C8928E0AF964 ; A9015F6A-F6BB-4AC8-B681-099232A6DFAC ; F2409024-D848-4B02-A371-92BEA1105EC4 ; 511282C5-02AC-4105-8B52-5BBEC8B45D22 ; 6C698240-6557-4F96-BF56-60792693920F ; B50AB6D5-3010-450E-9CCE-E9BFA0202736 ; A616A83A-8D19-4085-B430-1AF80D4F9642 ; E49FAC55-434A-429B-8E61-C5E0FBD7C15C ; B169A5B5-27CD-48A6-A8D7-C14D3824A20A ; 4D4811FB-5BF1-4574-975B-1740602E43D8 ; C5C5D704-2558-4D4B-937B-33BD91132882 ; B6B4DCFE-F044-44D6-BB90-EF71E6981E82 ; 7507AC79-4C8E-4393-92B9-BFA6BEB492D0 ; 0CA74400-1596-4C14-AF02-4F5169D61942 ; 86B06754-B000-4F8B-9037-95E7A0BD4D20 ; 9536A134-A44C-4698-A525-DEEE7FACD144 ; C8297152-7551-49A1-8C9D-6B411391AC77 ; 927C0D4A-327A-4168-80C7-151A4B865CC9 ; EDF80CFD-4115-48E9-BF76-DDE957A97AEB ; A56585F9-9651-472B-BF53-C708A686EB7D ; A8834D03-81F5-43BC-A4AB-F215C89CB095 ; C4F259BA-7C00-4326-ACB2-924C4AE33E87 ; 6BB72835-1002-4B35-9304-495E12A30905 ; 83BCCC3C-0384-45CD-84B4-67E2EDE822EE ; 83AAF7BF-131D-4044-AD3B-670B838A23D6 ; 803922CD-3D37-47DC-8BDC-EF8F4779685A ; 14EB270E-0AAB-4C12-8D71-ED79076C2E93 ; F3FAB505-03FF-4FAA-ABB6-96AD20F47871 ; 17B51CA5-E325-4EA0-AFED-C6D0FD5A40EF ; 3D84D02A-42B1-42E1-84FB-E9AE9381ABB4 ; 800346FC-BC14-4A33-B10C-84224D908481 ; D5DE4BB3-81AC-44CB-9336-060F324C7A2F ; 8A19AA55-9B1F-4325-B730-068F928F1C13 ; BBA96852-E70C-4D37-A185-611F568BE90C ; 5CED2FBF-42DB-4D17-95C0-DEAE27BBFD02 ; 967CCAA8-5BC6-4744-BD9A-3DFEF9EF4F27 ; 649E6215-36F9-4BEB-9EE9-683E4FC75C42 ; 5FF5CE63-2A8F-4117-A384-A57EED6473D8 ; D318A0F0-38B2-4DFA-8326-E362603AAC5E ; 5C3D9179-7434-4776-A2FF-68CEA0149C68 ; B18B184D-B7F1-4C4D-8DA2-D5ECF49749F6 ; B8C192A7-E530-4301-B4D3-FF528A230260 ; CDB6A529-DE8B-48F6-A569-D07251D139C3 ; 60ACE33B-BEE2-4A49-85F0-1364D245FCA9 ; 979468F0-6B4A-4759-9CA2-7BA1D1441BC2 ; 3EE7548C-464D-4FC0-B1E2-2F6461C4A2A1 ; 1DB8FAFB-FC4A-4401-8316-30FB5352335D ; 9B227A4E-6237-4C95-B640-E64AFF0CC5F4 ; 9C971870-BA92-4E0C-9861-31C56B7E7D64 ; 6EEF1F11-603E-4196-91AB-724BBEE20CE7 ; 315A77B4-1A2E-468D-9E44-FF0B07697943 ; D9FE314C-61F4-4E4D-BB29-4B681C2A8A10 ; 3AD4AA3C-5F68-43D1-B578-07AB574D4DE3 ; 7B53A0D4-E13E-4573-B0A2-BB55AE54BD62 ; 47D02B80-47DA-4135-A288-21077C5947A9 ; 030860D0-66DF-46FF-95A3-2AE4852D5C19 ; C26EAF0E-202B-4F3E-9E59-3395A1BFCAB8 ; BE19CEFA-7A66-480C-BEC0-AF52F4C8A04C ; 80EDDCAC-B87B-47E6-A48C-F166D227DA6C ; BB85F844-C710-41D5-8620-E246DC9D2C6A ; 5B978086-7443-4721-854B-877CE0FC10C0 ; 302E69E0-39F0-4CDB-97F9-A6CDDB3D7233 ; A81EB5E0-305E-4657-94AD-0922CD1D79C6 ; BF07FF13-D7EE-40E1-9729-8F9CCBD1534F ; 7BA4658F-3343-4176-BDCD-620A1001A032 ; 4FC32F17-7A4D-4FF6-A710-FFFBC610CB56 ; 9FB40DC5-BED9-420E-B334-4D0BE8B8BCF5 ; CA6A13D4-DD80-4424-B5F3-654EE31263AE ; 9A8F7726-D97C-44DE-B72F-6BF0FC2078F8 ; 961547D2-F235-47E9-9A6D-D286758E332E ; 217745AA-6C5A-46C5-AC04-1C6581A96A04 ; 82B46073-10CE-4D05-9421-6308E3FAD1AD ; 53881871-C36B-4622-BFC6-4DA3635D7B26 ; A1681334-684E-41E0-B3FA-EFFE1E5A8B7F ; 2B30A85F-7A5F-46E4-BE22-28C902D5DFA3 ; A2B05D26-AC8E-4439-B32C-B48537D20836 ; 22134EA5-5ED5-47B8-9A33-01E59E58B54C ; 359DB5F2-BD23-42E1-B316-9D908DBACD78 ; ADBA741B-AABF-4A33-A61F-C10EE555D175 ; 859561F6-3113-45C8-8FBE-718BF860B582 ; 3FA5FACA-8A6B-4F42-A557-3B69866859E7 ; 5540DD9C-FA3F-48B6-8243-414616816A76 ; F4F5C477-30BB-41EE-B188-B20DE019F30A ; BC78EC6E-73C6-4234-9369-9A5586CD1A69 ; 581088D6-9F9C-4572-B61D-BAF0F6C79B2F ; 37FA6CD0-E789-44EA-AD78-C195CBB1EDE3 ; CA1E5192-ABB0-45E6-8547-2BA2B035238C ; 79A10C4B-1B5F-47BB-99EA-E694FB341696 ; 436F3280-98C7-4FA9-BD6F-1B02CAF1D262 ; A5433CA5-1DCC-4711-9B3B-6478AE7B5FAA ; EA8A0A91-7A83-4EC9-B7A0-0C3300D1FD14 ; 5D85E578-64B4-4238-922E-802B8ED87800 ; 0CD23E1B-3FA3-4A43-AE6E-C8E7B51252F8 ; 84E6A935-1A49-4BC1-9669-3DEA161CF6FC ; 265E5A9A-64FD-4B86-89BC-5E89F253C118 ; F43B01E6-E1DB-44B1-8003-93870606346A ; 8894688F-7167-48A1-BB1B-FC219B7675C2 ; F9B6971F-23C0-465F-BFEC-778BF228A1AE ; B5CA42BB-9514-42C6-9FB0-C8889C1DC51A ; 2DB5519B-B36D-4616-94F3-601A01185F22 ; 6931CAAE-6DFE-4A61-84D5-4EC804C2F2C6 ; FFA6F9F3-71C1-4AF9-B9F7-0466550EBC90 ; 1E706FF8-F42C-4FC6-8976-BEB4213BD730 ; EEF4E8C6-6D80-4C6A-BFC6-E529692088C1 ; 3A87B5EE-D1AE-4D28-8F7A-3898AD4E0796 ; 23B3BAED-E281-4A1D-AB78-51D8D62466FF ; E28607CD-0847-46F4-8E69-2D1DC80DE56F ; E8601979-AE05-4E4D-BB39-6B9C5E67D050 ; 2697F2B6-725C-438F-B4D3-3E32DEF86FD6 ; 17C74789-D7B0-4291-A2AC-7A72C5DC58EE ; 1582865E-9294-4D78-8B16-92FB70381D15 ; D35DBECD-5241-4562-85CC-2822BB338279 ; E6DD0840-4D71-4EEC-B559-F6BFC9E7E68B ; 8C97B391-96B4-468D-AAA3-24E196DE03CA ; 6EC48BF8-C9AE-4B53-9DF4-850A5BAC6A6E ; 6A981CB0-F551-48B1-AB91-5D5585A7F282 ; B6605B1A-264D-46EF-BB6F-AD5EBE1B34DB ; 9F96B0B1-2B88-49AE-8D3C-9FED70F1D950 ; F4B87B89-A066-4BE9-88C9-60C7FB5BF373 ; DD2B9E47-8C67-4599-B0B6-0D30DE727B55 ; D7E24E6B-797F-4FC9-B0FB-794C4D379091 ; 1AD1E3C4-0D7C-447B-B330-0245F9159FCC ; 821ED144-DF12-4E49-ADC7-27FA5E422B83 ; FDB00212-9782-4ACE-AD59-019384297A2F ; B7EB0E0B-46C5-43C0-A78D-FB094290765A ; 7726F7AA-88A8-4DD6-B322-6FC68893E0D2 ; 9A5C8EDF-9243-4F55-9036-A400CF3F4CC1 ; 28AFD5DD-B607-4837-819F-688C9218ED06 ; D8B44020-EC34-4788-B7FB-790B9C12D886 ; 990F5885-8EDD-42A2-AEFE-9DEE3E95A0B1 ; DEB67EB8-155C-4ACF-B3D4-595E4CBE2E5C ; 8A853D7F-979F-4112-9659-1FDE84EF5102 ; 2BE28F5D-2DBB-476F-9AFF-6B2103ECF0CE ; F70DA7E5-2AB3-487F-8B2C-72EEE91E58E0 ; 019F390D-7479-4CDC-8C82-45A27910E782 ; 511CB4C5-FCEE-4EC4-98A4-4DD32ECA83C3 ; 43D912CD-BD3C-4E69-B28B-AB2E173C0BC2 ; 2F0333BC-E9BB-4903-B3E2-8AE241DDDF84 ; EB9B8904-F6CC-451F-8628-50CC71F1F7C3 ; AADFAF8B-92B8-4292-96A3-912D55EB9C31 ; B6B7939C-63AF-4B52-B494-AA09A9C03871 ; 5D888D65-685F-4598-884F-AD057DE5FD1D ; A314FB55-F20A-4485-965D-D7894D070A16 ; 738B601A-24D8-4261-B000-198648213070 ; 5664F531-9D45-4302-A455-63E46B5EDD26 ; 956F45E5-A8C6-4A4A-9D1F-D31912180584 ; DD669244-34D8-4725-A52C-F3AAF59852F9 ; 81ADDBAB-C02F-4DA8-9429-76293FB42E42 ; F24A752C-1AAE-4C70-B6D4-DD0E8C89D9AA ; D1456192-83E7-4FC8-B783-90D615830156 ; 5DA3A8E1-7EE6-45EC-89EC-69423E2B866B ; 2243F29C-191C-4D33-8483-09BB3AD36598 ; 5D93AE27-79A0-4809-AE7C-54814CED0851 ; 9ECA4450-A550-44DE-B2E5-FD1CFF02A9FE ; 6C7D956E-1247-4663-9ED5-D406AE6E2959 ; C39563FD-CD7F-47C6-A257-5CB70A01C67C ; DD558354-3BF1-4037-881E-011E6BFC0987 ; DE25BF82-5F7A-489B-BFC1-9386C44E7D62 ; 3E967C4F-B916-4A80-A9A1-A5E94F02322C ; AF0A2220-DEEC-44C8-B15C-B6442D5B7517 ; 6A49B3F9-6B43-4D74-A28B-C83BFE61EC7B ; 64F84FF4-A477-4E1E-B4BB-E5614517229E ; D4E86E20-B75E-4CDA-83F2-22C481D4B9E8 ; 6D2212CE-C80F-4545-A895-3F1B6E4C6DB6 ; 2261B407-340D-4BB3-94BC-F06096FBDA80 ; 6E136F3D-A6E1-4541-AA4B-65BC5872DE06 ; 683AAF99-3B91-4501-B701-C3A4E8439647 ; 6DCA5C2C-F28A-409D-9623-24AB748FB4E7 ; 33188769-D86E-41AD-A74D-31A7C2DD08B7 ; F2077079-D683-4D18-94B9-84C760674AF6 ; C1D59BA7-FC3E-46EA-B095-3B6DF42892B0 ; BC0E0F93-B183-44E8-B551-EA463B2FBCE4 ; 7DB1F816-A55F-449A-8DF9-6724B5100CA1 ; 5780D50C-5BF0-4392-BC9B-894D1369866A ; CA911D90-5DDA-49F1-993F-68FCA77A8558 ; DA7BD84B-C00E-40A0-9AE2-33FCE7995696 ; 549E825B-F206-4FF9-835B-2FBE51C7B831 ; FECA34F6-CEF7-4A6D-AA7E-F88542EAF6F7 ; 93D66EAD-B7D3-4688-8EC9-75C4380619D9 ; 9DCF000D-D996-49A6-950A-0CD1E90CC6C7 ; 85288EC6-0BDC-4955-8B88-1DEECBF0E235 ; 41A41A7F-E4DD-4D3A-B97D-B4657CA211E1 ; 91BFC77A-E56F-49F0-A294-A5EE9F266FB6 ; 34499A83-DFCE-4DB8-BAA0-A7590AF8BC07 ; 5A6E0F10-758E-4DC1-A5C7-57D5DF9B25EF ; 5D439E4F-F1B7-41F7-BF1D-1F6E93D6427D ; 1E002C47-CEC6-491C-9E67-B289687D5B66 ; C4A1A482-6AE5-4807-BA05-C73AC0898546 ; C55B6F4B-1248-4FBF-83C2-B0A1B33DEA03 ; 2728DB14-66D5-4E67-B9B6-63D93DBF509C ; 56C24ABB-CF1D-447F-A5A8-B762C4B01566 ; EBBF2A70-2773-40FA-823A-E608ABFEF591 ; F5A97F05-4B5C-4B10-BF10-5DDE7D412BCF ; 46C0AB7B-82FC-4D06-9F26-22AEC8BEEDA7 ; 5E615F92-6FD0-48C7-AC37-78526974BCFC ; C616E97C-8352-4FED-9E83-558318216FB6 ; B73AF7B0-EED3-413C-B249-C97F27E4EA1C ; F72703A2-2C57-459A-9015-94BD3D302491 ; DF890966-D14E-4EDF-B6E3-E10E40BA5B5D ; 3BC6CE69-2641-4B6D-85DF-E8FE838015D0 ; 25F8F043-2CD0-4344-9B4A-5BBB691B5BF9 ; E306BE26-0358-4BE4-AEF6-AD42CC0DA020 ; 8612388B-3680-4BD8-986C-E7ABE9F92F91 ; 1F6200B4-B53B-4E9F-B01B-12D2C0D4270E ; 76734A82-9137-4DA4-871E-D4EC1BC33831 ; 8C2B719A-D45A-4DF3-BA61-908A2E1F6D1D ; 6E2365F3-0875-4949-8409-7E26BBCDE700 ; 12683FCC-4828-4D9A-9B35-E4B7295CC417 ; 20F4DBD9-02FA-4FFD-AEF5-234910D31263 ; 0E27F140-3D60-4027-A370-68127564DE38 ; 0D1ACC76-910E-4243-A229-5F76B5A3299A ; 59163BD6-41E8-4489-81F0-036484447886 ; 5AEE90E0-A9A1-4944-AD6A-2675764D869D ; FE9C56C4-B6D4-4054-A58C-13642370052E ; 0BFAB667-8B40-46AE-A224-535573E268C7 ; 06905BD3-4D17-4625-8631-46CA81D1B47B ; 00C75246-4343-490D-9782-E6C0068C77B2 ; 7C877EE0-B4BC-4B17-94AB-81B67C7B6DB3 ; 16DE55CE-076E-43D3-84BD-332A79B95EFD ; 0E4B0EA9-14D1-4A82-814D-51CC2B9BA2B5 ; 726B60CA-1B1C-440D-82FA-A4C978C4D484 ; 24D42292-B875-4FAF-8C3A-9834414C3A01 ; 7D84A145-19AF-48D0-A5D9-F5724068CB26 ; F114D078-5F03-47F8-82AE-B8A21C2F9D31 ; E4F7064C-9D81-49B5-9992-898155B3F11E ; 2972AB07-2C29-43B8-96DA-1386C5E248EB ; DAB9A2B8-FCE7-4FF4-BAC4-4D2A04D7A43B ; 964DFAC8-91EC-4C0E-B499-3ED5F2D70096 ; D503E73D-8B94-46A0-A24F-93069A56DC7D ; CB780DE7-E98C-4F7E-9487-8F25FE80DC21 ; 57153075-9055-4D7E-9CD6-9167D165E860 ; 5DFA7970-3F68-4FC3-B2BA-5A42E866ECC3 ; B0DE3388-7826-40D3-ADEE-0B25FE201F4A ; 454CB5E9-3778-4666-9CED-913E08CB3615 ; 61BC91AE-CD06-432D-BCBA-6FAE2209C610 ; 60569C8B-7209-4A3F-A177-F337085E9146 ; A5D94D02-5423-4055-96E3-B5AA5799DC02 ; E9D3FFF1-5FB2-4F17-9C1D-D9775E3CC5AC ; 2A62DD22-EFE6-48CD-8BE6-59B08168F78A ; 5B82545F-2636-4A8A-88DD-1B387DE678FF ; 61462D57-DF98-4F89-BAEF-E8156A47E2DD ; 8FE77EF7-C83A-431F-B3BA-D93B5ECC70AF ; DC5B662B-1ADD-4D6E-A6E3-3EF8B922BC71 ; E20AC0FF-43C4-49EA-9E33-764E553933B7 ; 1ED901DF-BCDC-44C8-A7DF-AB895ECA0952 ; FD75D315-EED7-4350-A890-8FB94648E9FC ; AC2E3DDC-3AF6-45F0-8269-E9DA68F4367A ; 1E7788D8-B5FC-473A-8A10-79910443799A ; FC0C1BF3-74C3-4DFC-B9B5-2FD1728E287A ; 0D293DF8-374D-4681-9B2A-ACC98601AA25 ; 5B867CB6-F94D-435D-83E3-0ADB814B8077 ; AF12859A-D67A-488D-8BC2-ED28698F2ACA ; E0B04FB6-9500-4786-B6D9-303165EF9090 ; 6443B16E-E6D9-4A1D-B950-BEEC7BAEDBBE ; E4D30B42-383A-40BF-BB91-511A90227655 ; 26C566AF-C710-4856-AC21-83D73370EA84 ; 1304FB17-A20A-4EBC-9CC8-1554808AC1F6 ; 6FB7A794-C3E7-4501-A844-CF65B9C3D32C ; 045B2852-E1FF-4376-8F39-60FC940224D0 ; A3CB59DE-5893-4FA2-B4D5-EDA612480E76 ; 7189A8A8-EB8B-4795-B7FE-725CCC4B7FA7 ; 3E8F2012-A457-4358-9C8B-23292374A743 ; F124155D-6131-47F6-8320-46A41AB125D3 ; 9B4BA15D-A071-4213-AD2C-075A04ED48CD ; 5F5FF3CA-2DBB-4DE1-9190-1FE36E2B5ACB ; 049A2CA6-951A-452F-963A-F54FE87ECA31 ; 6B53F577-5EB6-4AF5-9773-3654D3432BE4 ; 3CD1D537-29E4-479B-99FA-26D27E192948 ; 338D5387-0CFB-4D91-944F-1F054C21C769 ; 03BD8920-CA01-4818-BBD7-925DDD3F6908 ; 0CC079D3-EB90-47B5-B554-599A67C9E12A ; 6C520037-2A9B-41CB-8362-97FFCA2AA6E2 ; 8CC70CDC-01EC-4E2B-84C1-F1C946602CCE ; 08519263-5ADD-4BA3-9BC6-C737ACA7DFE4 ; D779EEF8-C83C-4CCA-A140-9BF15DCF14AE ; D5EF8C37-811E-42B7-84E5-E6ED71217971 ; DB0B1C9D-6B94-46EF-A84E-3D912E08B7FD ; 29C262B5-D49D-4125-9661-19033A8EC6A8 ; 846851BE-3D24-46F0-A6BE-CEB22C7D0F62 ; 5EFC16F4-7FC7-479E-93F7-AEDC2D350A22 ; CE2FF4D3-B82C-4435-AE1C-3E2E6F104271 ; 4022B2EB-04C3-43F6-9D2C-1A47D80EF6EE ; 03C7A677-C223-47D6-869E-E6C3250B0C08 ; 1E3F3136-6D86-4470-85AA-55B11C9E24CD ; 71CEC5F6-16E5-46E1-A91B-B5E0F699B231 ; CA834E5F-30DC-46CF-AF33-AD11226FC09E ; FA43414D-3757-43CC-8949-77F82DF4FA4D ; 2D3D759B-D06A-4FC6-855A-5E9F83ADBED9 ; E958CD3C-EE14-4CE1-B55C-7830E320F6AE ; 291884D2-FDFD-4C98-BA19-1A0824ABB68F ; 55F3F917-E441-4C10-A3E3-0645A4E8374E ; CFC4801B-04BD-4FFC-911A-7B88E2FA4B49 ; 8AABC46F-03C7-4FBF-AC20-2C862E303A8B ; DFCA9C6E-710E-4645-9CFC-A908AAD583F3 ; 4379DEE0-F7CB-4A73-8828-21EA0AA830F5 ; F3BAF04C-35EE-450F-BFA8-E9DFE9F984FD ; 4A86A028-C56D-455E-A5CD-47D8A34B5734 ; 267F1EFD-AB89-4124-B803-00CC0E8E9CD2 ; 9B3F0B22-8442-4720-A21B-7EF12CBCD2CE ; 6C91D49C-9738-4A4F-A480-E71CD8EE5268 ; 0ED7357E-662C-4D65-82ED-29739919068F ; CE70DD1E-BCA4-4F89-AA5B-D90FE18A36FF ; 739E1733-3540-4E82-AC91-F511105DABD5 ; CE32A294-10FC-4DBA-A779-FAEEBE677D38 ; C6B0D463-9389-4BAE-93CA-3EE4717D20EC ; B8664381-386A-44A2-AC3B-D69A4980A8EA ; 79DAEAE5-A177-40E0-9BFC-54DC9F544764 ; C9AD69EB-506A-4442-B1C2-C8F09B519CB2 ; A76A272F-675E-4E56-8761-96B71419A012 ; 1F35A542-2795-4B1F-A846-7097B442C2D9 ; 8AC7EF1D-53EB-466B-9C45-A6A7E9DB9CCD ; FDF38AA6-DC65-4043-8277-71BAE47902B1 ; 42649B9A-29D4-4D05-A78C-AC801792ADEB ; 7D5763F7-7284-4AF5-BBFC-5D8B5CB7F495 ; 2F102533-4B6B-4411-9080-3697ED3099EA ; 161A2735-C3CF-466D-AE21-C6A2C987BB1E ; BD2AE048-BE93-4421-AD3E-BE6F9646484F ; FF7212E5-9A44-4659-B3B9-3EF2DB7A9E6D ; 2E8A1816-E963-4063-B2F0-6289514084A5 ; 6C202D3E-5670-4B63-82A2-9EE7AC385089 ; A1F0FEB5-6FEF-4FF7-AA1E-8EAAE551138B ; E8A43FF3-3D98-45EE-9567-6EED4DA38274 ; 15CAD156-1E40-4C83-B3ED-484964FE407F ; D58E5D64-B5B9-4487-8E46-225AE3617C14 ; 468411B5-1719-46B4-835D-E469D6AEFF12 ; EB9B6625-6674-4665-9BEE-D4DFD9366A02 ; C2976F78-89AF-4461-8D22-BFEBC0504722 ; 3023C34B-CF59-43EA-9241-33B738D19B05 ; 3A38A97C-2CBB-4802-9528-A4BBD62AEA4A ; 5607C6CE-21D5-495E-9174-85F1E2E0CB9D ; 0429FA9A-AD19-424C-94ED-1A902119E559 ; F2B21F52-74F4-44C5-9991-60EBCC4E43A6 ; D1B30DA1-FF63-4FC7-AB8B-818331EE6D72 ; BAEB6705-FCDC-4B40-B1CB-D926B8287F92 ; A6E2735B-AAD3-48D7-8289-306257CB5B6F ; 11E1BCE2-F246-4930-A97C-A14B34BCF840 ; EB00527B-1E37-420E-85E4-10063DB4BC1C ; 142F03FE-5B60-416D-8DCD-EC34DB5495DB ; A3CDF051-4162-47EC-BE8A-1519A5564518 ; 7F75F15A-2476-4FFD-97B3-313F06568E21 ; 53DD68D0-C2BE-4EC2-907E-3F1F11D31052 ; 1E3F22FC-3D82-4911-9C97-8CB87A3D131C ; F04188AB-51CE-4AA1-B72C-399BE7863235 ; E4CBDC29-63E2-4CF0-B02F-16CA9C69F26E ; 975989FE-8785-42C1-8551-53661B7B16A1 ; 891F4C63-8207-4CB8-AB59-A970CC6F1A1A ; 29EDE507-90BA-4ABE-B3EF-559EBA4CCD56 ; A997FF30-F112-48BE-8FF1-15F8266A5E62 ; C956B4B1-99E6-4823-886A-FA8FCD1E3E4D ; 94CF5704-1BE7-4CCC-870E-FB8527AC47E8 ; 93292768-8C20-4551-8CA8-44AE0FFB487E ; CC7D1177-1638-4A80-A3AA-266ADC260EC9 ; 584E15EE-1C80-4507-8AD3-558DF06DBDF3 ; C7476B2B-0040-4013-8D30-06935E3FB897 ; 71291A56-C2DB-4EB9-8223-DD7563CBBDC9 ; 575F2EFD-2D8B-4140-9FCB-D8CB9EC14D09 ; 8C4FEB77-99B6-4C73-9751-508953A874DC ; E57B4989-102F-44FD-8FB2-0627143FA904 ; CFF567FC-8867-4CA4-85AE-81A7D30095E7 ; 1FB1255E-D9EC-4FE9-BE96-F81271FCCFB6 ; 0C0EEC9F-A715-4769-B58C-99D06C3C91F3 ; 13302EC6-6511-42FE-AA8B-C875B5384FFE ; 4F047F5B-EF3A-4590-8E7A-D90A52860324 ; 6104F94F-BA8F-4435-A839-E1FEA6EFFDF3 ; 01992912-611F-4AA8-8570-B062CBCCAF70 ; 8169AA00-E396-4A3E-A91C-F67B1F0B8E3E ; 1E8B978E-3D1B-46E8-80EE-3A11EE571CEC ; BC75790C-FBC7-4897-B228-762245C48740 ; 161E2817-7DB2-46F8-BFEB-256DBBEFE633 ; 8401DFCF-8793-461A-B17E-E6584CE2423B ; 63F76DB5-8433-4EFE-9054-6C04F065DF2D ; 8E6902A6-A673-46CC-9AEB-3A71EF11099F ; 6F5EBE67-0A25-4B20-A1F6-9CE6C4FF4096 ; 7546B7FB-1976-4994-AFB7-6270382D44D7 ; 0DCD80E1-173E-4A1B-BDD8-74C7D12C1313 ; 5B685F7F-917D-41BA-A7AB-D0E15D457BC5 ; 7B1E6EEB-3B61-4CE8-B695-ED11C2EF169F ; 377F7050-F900-4345-A326-568F00050BC3 ; 383EC600-FBF3-4F91-8FAC-41E3DDE6589E ; 6643B290-5D7A-4649-B57D-47A5BA4E8D31 ; 3671D46F-6D69-42DA-9830-24F67EB8B0B6 ; E1A92F92-1DD2-4E33-9C16-3FD0371D1431 ; 6061FCA5-A113-4985-905D-E17020F6933E ; 6535D911-D718-4794-9D5E-6E06553464FF ; E9231B3
PATH_MARGIN	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text descriptor of the conclusive results following examination of tissue margin(s) for the presence of disease.	Patient	
PHARMACEUTICAL_TX_ADJUVANT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Indicator to signify whether or not whether the patient had adjuvant/post-operative pharmaceutical therapy.	Patient	
PRIMARY_SITE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	A text description of an 'other' originating or primary anatomic site of the disease/condition under investigation or review.	Patient	
PRIMARY_SITE_PATIENT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text term to describe the organ sub-division in an individual with cancer.	Patient	
PROJECT_CODE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Project code	Patient ; Sample	TCGA
PROSPECTIVE_COLLECTION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text indicator for the time frame of tissue procurement, indicating that the tissue was procured in parallel to the project.	Patient	
PR_POSITIVITY_DEFINE_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pgr detection method text	Patient ; Sample	manual counting ; H-Score 190 ; H-Score 160 ; H-SCORE 0 ; H-Score 290 ; H-Score 0 ; H-Score 140 ; H-SCORE 250 ; H-SCORE 150 ; H-SCORE 280 ; H-Score 70 ; H-SCORE 7 ; Image Analysis ; Allred score 0+0 = 0 ; Allred score 5+3 = 8 ; Allred score 2+3 = 5 ; Allred score 2+2 = 4 ; Immunohistochemistry ; IHC ; IMAGE ANALYSIS ; Allred score = 8 ; Allred score 4+3 = 7 ; Allred score 5+2 = 7 ; Allred score 3 + 2 = 5 ; image cytometry ; Allred score 0+0=0 ; Allred score 7 per outside facility report ; Allred score 5+3=8 ; Allred score 5+3= 8 ; Allred score 3+3=6 ; dextran coated charcoal ; Allred score 3+2=5 ; %IHC ; Allred 5 = 2+3 ; Allred 8 = 5+3 ; Allred 0 = 0+0 ; Allred (Biocare) ; allred score 5 +3 = 8 ; allred score 5+3+8 ; allred score 4+2=6 ; allred score 3 + 3 = 6 ; allred score 2+2 = 4 ; allred score 4 + 3 = 7 ; allred score 5 + 3 = 8 ; H-SCORE 245 ; H-SCORE 140 ; H-SCORE 1 ; H-SCORE 120 ; H-SCORE 162 ; H-SCORE 15 ; PR Negative H-Score 0 ; H-Score 260 ; H-Score-230
PR_POSITIVITY_IHC_INTENSITY_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast carcinoma immunohistochemistry pos cell score	Patient ; Sample	1+ ; 3+ ; 0 ; 2+ ; 4+
PR_POSITIVITY_SCALE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Pos finding progesterone receptor other measurement scale text	Patient ; Sample	Strong ; 10-75% ; >75% ; <10% ; H-Score ; H-SCORE ; Allred Score 4 ; Allred Score 5 ; Allred Score 7 ; Allred Score 8 ; 0 ; Allred score = 8 ; Allred score = 0 ; Allred score = 5 ; Allred score = 4 ; 7 ; Two-tier ; 8 ; H score ; Allred score = 2 ; Allred score = 7 ; Allred Score 6 ; >10% ; Allred Score 3 ; Allred score 5 ; Allred score 0 ; Allred score 7 per outside facility report ; Allred score 8 ; Allred score 6 ; Allred ; 110 ; 10 ; 230 ; 120 ; Intensity=Strong ; Intensity=weak ; Allread Score 8 ; Allred Score ; allred score = 8 ; Strong using Weak, Moderate and Strong ; 70 fmol/mg ; Strong, using scale of Weak, Moderate and Strong ; MODERATE ; allred score = 6 ; allred score = 4 ; allred score = 7 ; allred score =  8
PR_POSITIVITY_SCALE_USED	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast carcinoma immunohistochemistry progesterone receptor pos finding scale	Patient ; Sample	3 Point Scale ; 4 Point Scale
PR_STATUS_IHC_PERCENT_POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Progesterone receptor level cell percent category	Patient ; Sample	90-99% ; 70-79% ; <10% ; 20-29% ; 60-69% ; 50-59% ; 40-49% ; 30-39% ; 80-89% ; 10-19%
RADIATION_TREATMENT_ADJUVANT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	A yes/no indicator that asks whether the patient started adjuvant postoperative radiotherapy.	Patient	
RETROSPECTIVE_COLLECTION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text indicator for the time frame of tissue procurement, indicating that the tissue was obtained and stored prior to the initiation of the project.	Patient	
SAMPLE_INITIAL_WEIGHT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Sample Initial Weight	Sample	250 ; 100 ; 220 ; 590 ; 410 ; 600 ; 550 ; 180 ; 460 ; 300 ; 490 ; 980 ; 680 ; 280 ; 440 ; 150 ; 640 ; 360 ; 730 ; 710 ; 770 ; 120 ; 580 ; 540 ; 420 ; 200 ; 210 ; 30 ; 20 ; 80 ; 140 ; 290 ; 230 ; 90 ; 130 ; 430 ; 190 ; 260 ; 110 ; 1070 ; 380 ; 310 ; 350 ; 400 ; 270 ; 450 ; 40 ; 50 ; 170 ; 70 ; 160 ; 60 ; 320 ; 740 ; 240 ; 340 ; 370 ; 620 ; 390 ; 470 ; 330 ; 510 ; 650 ; 500 ; 840 ; 1250 ; 700 ; 520 ; 480 ; 990 ; 630 ; 900 ; 670 ; 1300 ; 1100 ; 1460 ; 1650 ; 1270 ; 800 ; 780 ; 158 ; 970 ; 750 ; 560 ; 690 ; 950 ; 850 ; 5 ; 10 ; 1550 ; 920 ; 1180 ; 960 ; 1390 ; 1500 ; 940 ; 530 ; 570 ; 1350 ; 830 ; 610 ; 2190 ; 760 ; 890 ; 1760 ; 910 ; 1740 ; 1020 ; 720 ; 1170 ; 1530 ; 1080 ; 1710 ; 810 ; 1130 ; 1050 ; 1360
SAMPLE_TYPE_ID	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Sample type id	Sample	1 ; 6
SHORTEST_DIMENSION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	Shortest Dimension	Sample	
SITE_OF_TUMOR_TISSUE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Text term that describes the anatomic site of the tumor or disease.	Patient	
SPECIMEN_CURRENT_WEIGHT	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The weight of the specimen.	Sample	
SPECIMEN_FREEZING_METHOD	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The method used to freeze the tissue after removal from the patient.	Sample	
SPECIMEN_SECOND_LONGEST_DIMENSION	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	NUMBER	The second longest dimension of the specimen.	Sample	
STAGE_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Stage Other	Patient	
STAGING_SYSTEM	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Staging System.	Patient	
STAGING_SYSTEM_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Staging System Other	Patient ; Sample	SLN and non-SLN biopsy ; Sentinel lymph node dissection ; Sentinel Lymph node biopsy and one non-sentinel lymph node biopsy ; Sentinel lymph node biopsy x 2 and 1 non-sentinel lymph node biopsy ; Sentinel lymph node biopsy and non-sentinel lymph node biopsy ; Sentinel lymph node and axillary lymph node biopsy ; sentinel LN and one non sentinel LN ; Sentinel lymph node and non-sentinel lymph node biopsy ; SN+1 non sentinel node ; sentinel + non sentinel ; mastectomy with TLND ; Pateys surgery ; SLN AND NON-SLN BX ; Sentinel lymph node biopsy plus non-sentinel lymph node biopsy ; Sentinel lymph node plus Level I and Level II lymph nodes ; FNA plus axillary lymph node dissection
SURGERY_FOR_POSITIVE_MARGINS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast carcinoma primary surgical procedure name	Patient ; Sample	Mastectomy NOS ; Other ; Modified radical mastectomy ; Lumpectomy
SURGERY_FOR_POSITIVE_MARGINS_OTHER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast neoplasm other surgical procedure descriptive text	Patient ; Sample	Re-excision of the inferior margin ; Re-Excision of Superior Margin ; Left breast reexcision ; Reexcision ; Skin excision ; Margin resection ; Re-excision of original lumpectomy site ; Right Breast Reexcision ; Right Breast reexcision ; surgical resection ; Reexcision of segmental mastectomy
SURGICAL_PROCEDURE_FIRST	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Breast carcinoma surgical procedure name	Patient ; Sample	Modified Radical Mastectomy ; Simple Mastectomy ; Lumpectomy ; Other
TIME_BETWEEN_CLAMPING_AND_FREEZING	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Time between clamping and freezing	Sample	
TIME_BETWEEN_EXCISION_AND_FREEZING	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Time between excision and freezing	Sample	
TISSUE_SOURCE_SITE	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	A Tissue Source Site collects samples (tissue, cell, or blood) and cliincal metadata which are then sent to tha Biospecimen Core Resource.	Patient ; Sample	LQ ; A2 ; A7 ; D8 ; AC ; BH ; C8 ; AN ; B6 ; E2 ; GM ; A1 ; AR ; EW ; AQ ; E9 ; AO ; GI ; MS ; LL ; A8 ; JL ; HN ; OL ; Columbia University ; Proteogenex, Inc. ; University of Sao Paulo ; Holy Cross ; UCSF ; Walter Reed ; Christiana Healthcare ; Indivumed ; International Genomics Consortium ; Cureline ; MSKCC ; UNC ; Mayo ; Duke ; University of Pittsburgh ; ILSBio ; Greater Poland Cancer Center ; Roswell Park ; Asterand ; University of Miami ; ABS - IUPUI ; MD Anderson ; Ontario Institute for Cancer Research (OICR) ; ABS - Research Metrics Pakistan ; Hartford Hospital ; Candler ; Gundersen Lutheran Health System ; University of Minnesota ; Mount Sinai School of Medicine ; University of Chicago ; Fox Chase ; Institute of Human Virology Nigeria ; Albert Einstein Medical Center ; Boston Medical Center ; Mary Bird Perkins Cancer Center - Our Lady of the Lake ; Medical College of Georgia ; Greenville Health System ; University of Kansas ; Spectrum Health ; John Wayne Cancer Center
TUMOR_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	The state or condition of an individual's neoplasm at a particular point in time.	Patient	
VIAL_NUMBER	HotPink	Breast Invasive Carcinoma (TCGA, Firehose Legacy)	STRING	Vial number	Sample	A ; B
DAYS_TO_BIRTH	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	NUMBER	Time interval from a person's date of birth to the date of initial pathologic diagnosis, represented as a calculated number of days.	Patient	
DAYS_TO_DEATH	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	NUMBER	Time interval from a person's date of death to the date of initial pathologic diagnosis, represented as a calculated number of days.	Patient	
DAYS_TO_LAST_FOLLOWUP	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	NUMBER	Time interval from the date of last followup to the date of initial pathologic diagnosis, represented as a calculated number of days.	Patient	
NTE_ER_STATUS_IHC__POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	STRING	Metastatic breast carcinoma estrogen receptor level cell percent category	Sample	70-79% ; 90-99% ; <10%
NTE_HER2_STATUS_IHC__POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	STRING	Metastatic breast carcinoma HER2 erbb pos finding cell percent category	Sample	<10%
NTE_PR_STATUS_IHC__POSITIVE	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	STRING	Metastatic breast carcinoma progesterone receptor level cell percent category	Sample	<10%
TUMOR_TISSUE_SITE	HotPink	Breast Invasive Carcinoma (TCGA, Cell 2015)	STRING	Text term that describes the anatomic site of the tumor or disease.	Sample	Breast
BREAST_SURGERY	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Type of Breast Surgery	Patient	
CELLULARITY	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Tumor Content	Patient	
CHEMOTHERAPY	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Chemotherapy.	Patient	
CLAUDIN_SUBTYPE	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Pam50 + Claudin-low subtype	Patient	
ER_IHC	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	ER status measured by IHC	Patient	
HER2_SNP6	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	HER2 status measured by SNP6	Patient	
HORMONE_THERAPY	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Hormone Therapy	Patient	
INFERRED_MENOPAUSAL_STATE	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Inferred Menopausal State	Patient	
INTCLUST	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Integrative Cluster	Patient	
LYMPH_NODES_EXAMINED_POSITIVE	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Number of lymphnodes positive	Patient	
NPI	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	NUMBER	Nottingham prognostic index	Patient	
RADIO_THERAPY	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Radio Therapy	Patient	
RFS_MONTHS	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	NUMBER	Time until last follow-up or relapse (in months)	Patient	
RFS_STATUS	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	Relapse Free Status (Recurred = cases where there was loco-regional relapse, distant relapse or death-specific death)	Patient	
THREEGENE	HotPink	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	STRING	3-Gene classifier subtype	Patient	
ANEUPLOIDY_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	Aneuploidy Score	Sample	19 ; 22 ; 13 ; 4 ; 7 ; 3 ; 14 ; 0 ; 11 ; 10 ; 2 ; 15 ; 24 ; 16 ; 18 ; 9 ; 5 ; 21 ; 6 ; 17 ; 8 ; 25 ; 20 ; 26 ; 23 ; 34 ; 31 ; 12 ; 29 ; 27 ; 28 ; 1 ; 33 ; 30 ; 35 ; 32
BUFFA_HYPOXIA_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	mRNA based Buffa Hypoxia Score	Patient	
CANCER_TYPE_ACRONYM	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Text field to hold cancer type acronym used by TCGA PanCanAtlas.	Patient	
DAYS_LAST_FOLLOWUP	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	Time interval from the date of last followup to the date of initial pathologic diagnosis, represented as a calculated number of days..	Patient	
DSS_MONTHS	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	The time period (months) usually begins at the time of diagnosis or at the start of treatment and ends at the time of death.	Patient	
DSS_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	The time period usually begins at the time of diagnosis or at the start of treatment and ends at the time of death.	Patient	
GENETIC_ANCESTRY_LABEL	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Genetic ancestries were determined using five different methods as described in Carrot-Zhang et al (2020). These consensus calls were created based on the ancestral population that received the majority of assignments for each patient.	Patient	
IN_PANCANPATHWAYS_FREEZE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Patient Part of PanCan Pathway Analysis	Patient	
MSI_SCORE_MANTIS	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	MSI Score reported by MANTIS. The suggested thresholds are MSI: >0.6, Indeterminate: 0.4-0.6 and MSS: <0.4.	Sample	0.3319 ; 0.3449 ; 0.3266 ; 0.3218 ; 0.3411 ; 0.3208 ; 0.3379 ; 0.2829 ; 0.2898 ; 0.4042 ; 0.311 ; 0.4765 ; 0.292 ; 0.2902 ; 0.259 ; 0.3423 ; 0.3308 ; 0.2779 ; 0.2921 ; 0.2911 ; 0.3046 ; 0.2846 ; 0.3005 ; 0.2887 ; 0.294 ; 0.289 ; 0.2769 ; 0.2774 ; 0.293 ; 0.3074 ; 0.2896 ; 0.2823 ; 0.273 ; 0.2894 ; 0.2975 ; 0.2726 ; 0.2932 ; 0.2981 ; 0.2792 ; 0.2663 ; 0.3096 ; 0.2684 ; 0.2742 ; 0.2747 ; 0.2711 ; 0.2606 ; 0.2756 ; 0.2627 ; 0.272 ; 0.2644 ; 0.2529 ; 0.2854 ; 0.2729 ; 0.3283 ; 0.2504 ; 0.2822 ; 0.3273 ; 0.261 ; 0.2844 ; 0.3032 ; 0.2874 ; 0.2956 ; 0.2804 ; 0.2795 ; 0.2768 ; 0.3164 ; 0.2828 ; 0.3097 ; 0.2978 ; 0.3038 ; 0.2793 ; 0.3031 ; 0.3072 ; 0.2855 ; 0.2746 ; 0.3021 ; 0.2845 ; 0.2988 ; 0.3819 ; 0.3028 ; 0.3077 ; 0.3009 ; 0.3124 ; 0.3305 ; 0.3239 ; 0.3362 ; 0.3368 ; 0.2954 ; 0.3082 ; 0.3052 ; 0.3222 ; 0.314 ; 0.333 ; 0.3265 ; 0.3314 ; 0.2961 ; 0.3169 ; 0.3073 ; 0.3179 ; 0.2941 ; 0.2963 ; 0.3153 ; 0.2994 ; 0.3062 ; 0.2918 ; 0.3083 ; 0.2929 ; 0.302 ; 0.2957 ; 0.3033 ; 0.2652 ; 0.281 ; 0.2301 ; 0.2683 ; 0.2619 ; 0.2908 ; 0.298 ; 0.3088 ; 0.321 ; 0.28 ; 0.2762 ; 0.2833 ; 0.3293 ; 0.3251 ; 0.301 ; 0.3156 ; 0.3412 ; 0.3212 ; 0.2964 ; 0.2958 ; 0.2891 ; 0.3081 ; 0.3006 ; 0.2899 ; 0.3188 ; 0.3243 ; 0.313 ; 0.2912 ; 0.2967 ; 0.2904 ; 0.3488 ; 0.3487 ; 0.355 ; 0.3463 ; 0.2642 ; 0.2424 ; 0.3039 ; 0.3035 ; 0.2516 ; 0.2916 ; 0.2615 ; 0.2632 ; 0.2674 ; 0.2806 ; 0.2648 ; 0.267 ; 0.2543 ; 0.2604 ; 0.2784 ; 0.2736 ; 0.2569 ; 0.2776 ; 0.2673 ; 0.2679 ; 0.2971 ; 0.2869 ; 0.2628 ; 0.2701 ; 0.2483 ; 0.2715 ; 0.2599 ; 0.2653 ; 0.2634 ; 0.2544 ; 0.2613 ; 0.271 ; 0.26 ; 0.2989 ; 0.2501 ; 0.266 ; 0.251 ; 0.2517 ; 0.277 ; 0.2734 ; 0.2626 ; 0.2589 ; 0.2437 ; 0.2556 ; 0.2753 ; 0.256 ; 0.2659 ; 0.2422 ; 0.275 ; 0.2519 ; 0.2927 ; 0.2681 ; 0.282 ; 0.2656 ; 0.2509 ; 0.2478 ; 0.7713 ; 0.2575 ; 0.2664 ; 0.2617 ; 0.2919 ; 0.217 ; 0.2865 ; 0.2601 ; 0.3232 ; 0.3013 ; 0.3158 ; 0.3604 ; 0.3186 ; 0.3286 ; 0.322 ; 0.3255 ; 0.3114 ; 0.3027 ; 0.3517 ; 0.3177 ; 0.3069 ; 0.3178 ; 0.3295 ; 0.2907 ; 0.2962 ; 0.2972 ; 0.3129 ; 0.3054 ; 0.3194 ; 0.3228 ; 0.3196 ; 0.3095 ; 0.2942 ; 0.3111 ; 0.3203 ; 0.3059 ; 0.3584 ; 0.3234 ; 0.2991 ; 0.3393 ; 0.3474 ; 0.3363 ; 0.331 ; 0.3405 ; 0.3371 ; 0.3014 ; 0.3364 ; 0.3115 ; 0.3361 ; 0.2731 ; 0.2695 ; 0.2375 ; 0.2812 ; 0.2757 ; 0.252 ; 0.8283 ; 0.2944 ; 0.2819 ; 0.3047 ; 0.2735 ; 0.2694 ; 0.2848 ; 0.3094 ; 0.3024 ; 0.2554 ; 0.3358 ; 0.3678 ; 0.2826 ; 0.2641 ; 0.3135 ; 0.3185 ; 0.2982 ; 0.3016 ; 0.2638 ; 0.2649 ; 0.239 ; 0.2568 ; 0.2639 ; 0.288 ; 0.2752 ; 0.2727 ; 0.2595 ; 0.2677 ; 0.2592 ; 0.2721 ; 0.2755 ; 0.2799 ; 0.2537 ; 0.3181 ; 0.3857 ; 0.2771 ; 0.3132 ; 0.2725 ; 0.3223 ; 0.2922 ; 0.3351 ; 0.3339 ; 0.2685 ; 0.2782 ; 0.3277 ; 0.306 ; 0.3378 ; 0.2926 ; 0.3192 ; 0.3145 ; 0.2818 ; 0.2857 ; 0.2872 ; 0.2892 ; 0.2842 ; 0.2984 ; 0.2682 ; 0.2992 ; 0.2878 ; 0.2496 ; 0.2497 ; 0.283 ; 0.2662 ; 0.2816 ; 0.2861 ; 0.2618 ; 0.2572 ; 0.2995 ; 0.3624 ; 0.3085 ; 0.3199 ; 0.3066 ; 0.3187 ; 0.3262 ; 0.3299 ; 0.3522 ; 0.3249 ; 0.3456 ; 0.3138 ; 0.3248 ; 0.3918 ; 0.3301 ; 0.3337 ; 0.3554 ; 0.3281 ; 0.3291 ; 0.3501 ; 0.3504 ; 0.3011 ; 0.3086 ; 0.3271 ; 0.2864 ; 0.2847 ; 0.3064 ; 0.3312 ; 0.2924 ; 0.3078 ; 0.3139 ; 0.2998 ; 0.2733 ; 0.2882 ; 0.2676 ; 0.278 ; 0.269 ; 0.2791 ; 0.3045 ; 0.2716 ; 0.2945 ; 0.2565 ; 0.2985 ; 0.2781 ; 0.264 ; 0.2783 ; 0.2897 ; 0.2802 ; 0.2622 ; 0.2843 ; 0.2875 ; 0.2824 ; 0.2808 ; 0.263 ; 0.2987 ; 0.2706 ; 0.3311 ; 0.3198 ; 0.3202 ; 0.3137 ; 0.3369 ; 0.3349 ; 0.3131 ; 0.3125 ; 0.2948 ; 0.2977 ; 0.284 ; 0.2952 ; 0.2849 ; 0.2667 ; 0.265 ; 0.2803 ; 0.2567 ; 0.2723 ; 0.2513 ; 0.2827 ; 0.2558 ; 0.2584 ; 0.2933 ; 0.2597 ; 0.2495 ; 0.2835 ; 0.3007 ; 0.2837 ; 0.279 ; 0.2654 ; 0.2675 ; 0.2522 ; 0.2815 ; 0.2724 ; 0.2596 ; 0.2507 ; 0.2493 ; 0.2743 ; 0.2722 ; 0.2546 ; 0.2461 ; 0.2885 ; 0.2585 ; 0.2539 ; 0.2635 ; 0.393 ; 0.2732 ; 0.2482 ; 0.2969 ; 0.2759 ; 0.2787 ; 0.2688 ; 0.2777 ; 0.3023 ; 0.7737 ; 0.2518 ; 0.2534 ; 0.2602 ; 0.2851 ; 0.2785 ; 0.2594 ; 0.3256 ; 0.2593 ; 0.2553 ; 0.2931 ; 0.3148 ; 0.2616 ; 0.3331 ; 0.3214 ; 0.3071 ; 0.3189 ; 0.326 ; 0.305 ; 0.3365 ; 0.4703 ; 0.3396 ; 0.3445 ; 0.29 ; 0.2668 ; 0.2744 ; 0.3141 ; 0.2965 ; 0.3711 ; 0.3017 ; 0.2876 ; 0.3109 ; 0.3586 ; 0.332 ; 0.3253 ; 0.3117 ; 0.2834 ; 0.2814 ; 0.2718 ; 0.2886 ; 0.2745 ; 0.287 ; 0.2636 ; 0.2714 ; 0.2797 ; 0.3348 ; 0.2608 ; 0.3679 ; 0.3767 ; 0.2758 ; 0.3394 ; 0.3101 ; 0.3403 ; 0.3 ; 0.2953 ; 0.3104 ; 0.394 ; 0.2895 ; 0.3167 ; 0.3121 ; 0.3233 ; 0.2838 ; 0.2879 ; 0.2934 ; 0.4316 ; 0.31 ; 0.324 ; 0.3658 ; 0.348 ; 0.3268 ; 0.3136 ; 0.3022 ; 0.3527 ; 0.3103 ; 0.3315 ; 0.4299 ; 0.2839 ; 0.4478 ; 0.3887 ; 0.3219 ; 0.327 ; 0.6238 ; 0.3143 ; 0.3015 ; 0.6331 ; 0.3401 ; 0.2853 ; 0.295 ; 0.312 ; 0.4692 ; 0.3123 ; 0.2936 ; 0.3201 ; 0.3162 ; 0.2925 ; 0.3289 ; 0.3195 ; 0.2559 ; 0.2906 ; 0.2796 ; 0.2884 ; 0.2603 ; 0.253 ; 0.2697 ; 0.2551 ; 0.2705 ; 0.2691 ; 0.2863 ; 0.2772 ; 0.2856 ; 0.2761 ; 0.2831 ; 0.2713 ; 0.2514 ; 0.2645 ; 0.3328 ; 0.3128 ; 0.3225 ; 0.4355 ; 0.3479 ; 0.3354 ; 0.3113 ; 0.329 ; 0.33 ; 0.3296 ; 0.3061 ; 0.3573 ; 0.4091 ; 0.3313 ; 0.2955 ; 0.3341 ; 0.3525 ; 0.3386 ; 0.3674 ; 0.361 ; 0.3531 ; 0.3642 ; 0.3721 ; 0.3237 ; 0.3399 ; 0.3235 ; 0.3184 ; 0.2805 ; 0.2873 ; 0.3146 ; 0.3151 ; 0.3563 ; 0.3227 ; 0.315 ; 0.3053 ; 0.3168 ; 0.2913 ; 0.3466 ; 0.3174 ; 0.3058 ; 0.3205 ; 0.3505 ; 0.3246 ; 0.3325 ; 0.3157 ; 0.4072 ; 0.3397 ; 0.3063 ; 0.3557 ; 0.3905 ; 0.339 ; 0.3216 ; 0.3161 ; 0.2903 ; 0.2997 ; 0.3043 ; 0.3408 ; 0.3778 ; 0.5417 ; 0.3332 ; 0.3472 ; 0.3521 ; 0.3465 ; 0.3431 ; 0.3252 ; 0.335 ; 0.3383 ; 0.3686 ; 0.3663 ; 0.3418 ; 0.2905 ; 0.3338 ; 0.3458 ; 0.3435 ; 0.3424 ; 0.3447 ; 0.3107 ; 0.3191 ; 0.3056 ; 0.299 ; 0.3306 ; 0.2914 ; 0.296 ; 0.2859 ; 0.2809 ; 0.2788 ; 0.3496 ; 0.3065 ; 0.3019 ; 0.3459 ; 0.3334 ; 0.3317 ; 0.304 ; 0.2801 ; 0.2939 ; 0.3564 ; 0.3469 ; 0.3539 ; 0.3583 ; 0.3448 ; 0.3272 ; 0.3499 ; 0.35 ; 0.2937 ; 0.2858 ; 0.3041 ; 0.328 ; 0.2986 ; 0.3036 ; 0.3357 ; 0.3475 ; 0.3342 ; 0.3236 ; 0.3535 ; 0.3793 ; 0.336 ; 0.3453 ; 0.3512 ; 0.3461 ; 0.3284 ; 0.3316 ; 0.341 ; 0.3335 ; 0.3254 ; 0.3562 ; 0.3439 ; 0.3366 ; 0.3434
MSI_SENSOR_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	MSI Score reported by MSIsensor. The suggested thresholds are MSI: >10, Indeterminate: 4-10 and MSS: <10.	Sample	0.55 ; 0.74 ; 0.31 ; 0.03 ; 0.01 ; 0 ; 0.46 ; 0.2 ; 0.02 ; 0.36 ; 0.63 ; 0.37 ; 1.02 ; 0.12 ; 0.57 ; 2.84 ; 0.26 ; 0.18 ; 1.12 ; 0.77 ; 1.39 ; 0.04 ; 0.05 ; 0.1 ; 0.13 ; 0.39 ; 0.07 ; 0.27 ; 1.11 ; 0.06 ; 0.32 ; 0.41 ; 1.96 ; 0.35 ; 0.86 ; 0.08 ; 0.11 ; 0.64 ; 0.24 ; 0.59 ; 1.59 ; 0.28 ; 1.48 ; 0.51 ; 0.14 ; 0.17 ; 0.29 ; 0.47 ; 1.2 ; 0.84 ; 0.21 ; 0.89 ; 0.3 ; 0.61 ; 0.98 ; 1.75 ; 0.38 ; 0.16 ; 0.6 ; 1.68 ; 1.26 ; 0.34 ; 1.1 ; 2.07 ; 4.87 ; 3.15 ; 1.3 ; 0.68 ; 0.91 ; 1.31 ; 0.72 ; 0.85 ; 1.23 ; 0.54 ; 0.87 ; 1.69 ; 0.25 ; 0.95 ; 1.74 ; 0.43 ; 1.33 ; 3.2 ; 0.97 ; 2.61 ; 0.45 ; 1.21 ; 0.49 ; 1 ; 0.19 ; 0.5 ; 1.22 ; 0.42 ; 0.62 ; 0.94 ; 0.52 ; 26.38 ; 0.22 ; 0.09 ; 0.66 ; 1.54 ; 0.92 ; 0.75 ; 1.25 ; 32.92 ; 2.5 ; 1.15 ; 0.67 ; 0.56 ; 0.53 ; 0.73 ; 1.04 ; 0.23 ; 0.88 ; 1.24 ; 0.15 ; 0.96 ; 1.34 ; 2.42 ; 1.03 ; 1.8 ; 1.38 ; 1.08 ; 0.78 ; 1.19 ; 0.58 ; 1.35 ; 0.79 ; 0.69 ; 1.18 ; 1.28 ; 1.71 ; 1.07 ; 1.63 ; 1.79 ; 1.78 ; 4.53 ; 1.05 ; 0.82 ; 2.69 ; 0.93 ; 1.45 ; 0.99 ; 0.48 ; 0.7 ; 0.4 ; 8.53 ; 1.06 ; 0.33 ; 26.46 ; 1.55 ; 0.44 ; 1.53 ; 0.81 ; 0.65 ; 0.8 ; 3.02 ; 4.8 ; 1.09 ; 1.82 ; 0.83 ; 13.12 ; 16.36 ; 6.24 ; 1.46 ; 1.89 ; 1.27 ; 2.89 ; 2.8 ; 2.68 ; 2.08 ; 2.28 ; 0.76 ; 1.16 ; 2.11 ; 1.64 ; 3.51 ; 0.71 ; 8.42 ; 1.86 ; 1.98 ; 3.86 ; 2.02 ; 4.09 ; 1.49 ; 2.05 ; 0.9
PATH_M_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Code to represent the defined absence or presence of distant spread or metastases (M) to locations via vascular channels or lymphatics beyond the regional lymph nodes, using criteria established by the American Joint Committee on Cancer (AJCC).	Patient	
PATH_N_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	Patient	
PATH_T_STAGE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC).	Patient	
PERSON_NEOPLASM_CANCER_STATUS	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Person neoplasm cancer status.	Patient	
PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Primary lymph node presentation assessment.	Patient	
PRIOR_DX	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Prior diagnosis.	Patient	
RAGNUM_HYPOXIA_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	mRNA based Ragnum Hypoxia Score	Patient	
TISSUE_PROSPECTIVE_COLLECTION_INDICATOR	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Tissue prospective collection indicator.	Sample	No ; Yes
TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Tissue retrospective collection indicator.	Sample	Yes ; No
TISSUE_SOURCE_SITE_CODE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Tissue Source Site Code	Sample	3C ; 4H ; 5L ; 5T ; A1 ; A2 ; A7 ; A8 ; AC ; AN ; AO ; AQ ; AR ; B6 ; BH ; C8 ; D8 ; E2 ; E9 ; EW ; GI ; GM ; HN ; JL ; LD ; LL ; LQ ; MS ; OK ; OL ; PE ; PL ; S3 ; UL ; UU ; V7 ; W8 ; WT ; XX ; Z7
TUMOR_TYPE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	STRING	Tumor Type	Sample	Infiltrating Lobular Carcinoma ; Infiltrating Ductal Carcinoma ; Other ; Mixed Histology (NOS) ; Mucinous Carcinoma ; Metaplastic Carcinoma ; Infiltrating Carcinoma (NOS) ; Medullary Carcinoma ; Breast Invasive Carcinoma
WEIGHT	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	Weight measured in kilograms.	Patient	
WINTER_HYPOXIA_SCORE	HotPink	Breast Invasive Carcinoma (TCGA, PanCancer Atlas)	NUMBER	mRNA based Winter Hypoxia Score	Patient	
PED_IND	LightBlue	High-Grade Serous Ovarian Cancer (MSK, NPJ Genome Med 2021)	STRING	Indication on whether this case is a pediatric patient or not	Patient	
ACGH_DATA	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	ACGH Data.	Sample	Yes
COMPLETE_DATA	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Complete data.	Sample	No ; Yes
MRNA_DATA	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	MRNA data.	Sample	Yes
PLATINUM_STATUS	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Platinum status.	Patient	
PRIMARY_THERAPY_OUTCOME_SUCCESS	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Primary therapy outhcome success.	Patient	
SEQUENCED	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Sequenced.	Sample	No ; Yes
TUMOR_RESIDUAL_DISEASE	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Tumor residual disease.	Sample	No Macroscopic disease ; 1-10 mm ; >20mm ; 11-20 mm
TUMOR_STAGE_2009	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011)	STRING	Tumor stage 2009.	Sample	IIIB ; IIIC ; IIC ; IV ; IIB ; IIA ; IIIA
YEAR_OF_DIAGNOSIS	LightBlue	Small Cell Carcinoma of the Ovary (MSK, Nat Genet 2014)	NUMBER	Year of Diagnosis	Patient	
ECOG_SCORE	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	NUMBER	The functional level of the patient based on the Zubrod performance scale.	Patient	
JEWISH_RELIGION_HERITAGE_INDICATOR	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	Text names for Jewish heritage categories for a patient/participant on a clinical trial.	Patient	
KARNOFSKY_PERFORMANCE_SCORE	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Score from the Karnofsky Performance status scale, representing the functional capabilities of a person.	Patient	
LYMPHOVASCULAR_INVASION_INDICATOR	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	Lymphovascular invasion indicator	Patient	
PERFORMANCE_STATUS_TIMING	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	A timepoint in reference to a patient's therapy in which a performance status assessment is conducted.	Patient	
RESIDUAL_TUMOR	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	Text terms to describe the status of a tissue margin following surgical resection.	Patient	
TREATMENT_OUTCOME_FIRST_COURSE	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	Text term for the measure of success of outcome after primary treatment (surgery and adjuvant therapies).	Patient	
VASCULAR_INVASION_INDICATOR	LightBlue	Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)	STRING	Vascular invasion indicator	Patient	
CONSENSUS_HR_STATUS	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Consensus HR Status	Patient	
CONSENSUS_SIGNATURE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Consensus Signature	Patient	
GYN_DIAGNOSIS_CHEMO_INTENT_DESCRIPTION	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Gyn Diagnosis Chemo Intent Description	Patient	
GYN_DIAGNOSIS_HISTOLOGY	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Gyn Diagnosis Histology	Patient	
MYRIAD_GIS_SCORE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	NUMBER	Myriad GIS Score	Patient	
MYRIAD_SIGNATURE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Myriad Signature	Patient	
PATH_SLIDE_EXISTS	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Path Slide Exists	Sample	YES ; NO
PATIENT_AGE_AT_DIAGNOSIS	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	NUMBER	Patient Age At Diagnosis	Patient	
PATIENT_ISABL_ID	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Patient Isabl ID	Patient	
PROCEDURE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Procedure	Sample	S1 ; S2 ; S3
PROCEDURE_TYPE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Procedure Type	Sample	Primary Debulking ; Interval Debulking ; Laparoscopic Biopsy ; Secondary Debulking
TUMOR_MEGASITE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Tumor Megasite	Sample	Non-Adnexa ; Adnexa ; Ascites
TUMOR_SITE_SAMPLE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Tumor Site	Sample	Omentum ; Peritoneum ; Right Upper Quadrant ; Left Adnexa ; Bowel ; Right Adnexa ; Other ; Ascites ; Pelvic Peritoneum ; Adnexa ; Left Upper Quadrant
TUMOR_SUBSITE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Tumor Subsite	Sample	Infracolic Omentum ; Pelvic Peritoneum ; Right Upper Quadrant ; Left Adnexa ; Sigmoid Colon ; Right Adnexa ; Left Renal Lymph Node ; Lymph Node ; Right Ovary ; Bowel ; Right Diaphragm ; Left Ovary ; Liver ; Rectum ; Omentum ; Left Infrarenal Lymph Node ; Cecum ; Peritoneal Nodule ; Ascites ; Peritoneal Nodules ; Colon ; Anterior Abdominal Wall ; Right Fallopian Tube ; Adrenal Gland ; Pelvic Peritoneum and Infracolic Omentum ; Undesignated Tumor ; Large Bowel Transverse Colon ; Soft Tissue Thoracic Diaphragm ; Ovaries ; Pelvic Peritoneum and Ascites ; Left Abdomen Diaphragm ; Splenic Capsule ; Cul de Sac ; Left Adnexa and Pelvic Peritoneum
TUMOR_SUPERSITE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	Tumor Supersite	Sample	Omentum ; Peritoneum ; Upper Quadrant ; Adnexa ; Bowel ; Other ; Ascites
WGS_SIGNATURE	LightBlue	Ovarian Cancer - MSK SPECTRUM (MSK, Nature 2022)	STRING	WGS Signature	Patient	
clinicalAttributeId	dedicatedColor	name_x	datatype	description_x	patientAttribute	value
BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	Bone marrow leukemic percentage.	Patient	
CYTOGENETICS	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	Cytogenetics.	Patient ; Sample	46,xy,del(20)(q12)[2]/46,xy[18] ; 46,xx ; 46,xy,t(3;3)(q25;q27)[8]/46,xy[12] ; 46,xy,del(3)(q26q27)[15]/46,xy[5] ; 46,xx,t(3;9)(p13;q22)[10]/46,xx[10] ; 46,xx[20] ; 46,xy[20] ; 45,xx,del(5)(q13q33),inc[2]/46,xx[2] ; complex ; 45,xy,-7[2]/46,xy[18] ; 47,xy,+8[16]/46,xy[2] ; 47,xx,+8[20] ; 45,xx,dic(5;17)(q13;p11.2),add(7)(q11.2),der(16)t(1;16)(p22;q24),inc[cp9]/46,xx[11] ; 46,xy[21] ; 46,xx[8] ; 46,xx,t(7;12)(q11.2;p13)[20] ; 45,xy,-7[19]/46,xy[1] ; 46,xx[20]trisomy8onfish ; 46,xx[22] ; 46,xy,-7,+mar[3]/46,xy[7] ; 46,xy[16] ; 47,xy,+14[9] ; 46,xy[11] ; 46,xy[24] ; 47,xy,+11[7]/46,xy[13] ; 46,xx,del(5)(q12q34),add(5)(q13),-7,del(15)(q?),add(15)(q23),+add(16)(q12 ; 46,xy,del(9)(q13q33)[4]/46,xy[11] ; 46,xx[21] ; 46,xx,del(5)(q11;q34),del(13)(q;q?)[20] ; 46,xx,del(5)(q14q34)[12]/46,xx,del(5)(q),del(20)(q12)[5]/46,xx[3] ; 45,x,-y[15]/46,xy[5] ; 46,xx,del(5)(q13q33~34)[5]/46,xx[15] ; 46,xx,del(5)(q13q34)[17]/47,xx,+8[3] ; 45,xy,-20[2]/46,xy[18] ; 45,x,-y[18] ; 46,xx,t(3;6)(p24;p12)[19]/46,xx[1] ; 45,xy,-7[1]/47,xy,+8[1]/46,xy[18] ; 45,xy,dic(5;17)(q11;p11)order(5)t(5;17)(q13;q11),-17[3]/46,xy,idem,+8[5]/44,xy,-4,ad ; 45,x,-y[19]/46,xy[3] ; 46,x,-y,+15[2]/46,xy[18] ; 46,xx[31] ; 46,xx[30] ; 46,xy[32] ; 47,xy,+8[9]/46,xy,del(20)(q11q13)/46,xy[11] ; 46,xy,del(20)(q11q13)[3]/46,xy[17] ; 47,xy,+8[18]/46,xy[4] ; 46,xy,del(3)(p11p14)[20] ; 45,x,-y[3]/46,xy[29] ; 47,xy,+8[10]/46,xy[10] ; 46,xy[13] ; 46,xx[25] ; 46,xx,del(5)(q21q33)[18]/46,xx[2] ; 46,xy,del(5)(q13-14q34)[15]/46,xy[6] ; 46,xy[25] ; 46,xx[27] ; 47,xx,der(2)t(2;11)(q37;p15),+8,r(11)[26] ; 47,xx,-9,+mar1,+mar2[3]/48,xx,idem,+20[16]/46,xx[1] ; 46,xx[29] ; 46,xy[7] ; 45,xx,-7[10]/46,xx[12] ; 47,xx,+11[14]/46,xx[6] ; 45,x,-y[9]/46,xy[11] ; 45,x,-y[4]/46,xy[16] ; 45,xy,der(14;21)(q10;q10) ; 46,xy[23] ; 46,xy,del(5)(q13q33)[11]/46,xy[9] ; 46,xx,del(20)(q12)[20] ; 46,xy,9ph ; 46,xy,del(9)(q12),del(11)(q21q24)[5]/46,xy[15] ; 46,xy,add(1)(p33),del(20)(q12)[17]/47,xy,idem,+21[3]/46,xy[1] ; 46,xy,del(20)(q12)[19]/46,xy[1] ; 45,x,-y[3]/46,xy[17] ; 46,xy ; 46,xx,del(5)(q14q34),del(8)(q21q23)[6]/44-45,xx,idem,-7,+15,-16,-19,-22,-22,+1-3mar[3]/44,xx,idem,add(17)(q25),+mar[2],+mar[2]/88-96,xx,idem*2[2]/46,xx[7] ; 46,xx,del(5)(q13q33)[3]/46,xx[19] ; 45,xx,der(4)del(4)(p13p15)del(4)(q23q26)der(5;17)(p10;q10)[11]/46,xx[9] ; 46,xy,del(20)(q12)[13]/46,xy[7] ; 45,xy,del(3)(p12p26),-12[4]/45,xy,idem,add(10)(p12),-13,add(19)(q13),+r[5]/46-47,xy,idem,+del(3)(p),-20,+22,+r[cp8]/46,xy[3] ; 46,xx,del(9)(q21q33),del(11)(q14q25)[14]/46,xx[6] ; 46,xy,add(3)(p1?)ordel(3)(p14p21)[8]/46,xy[12] ; 46,xx,del(5)(q14q34)[3]/46,xx[18] ; 43,x,-y,del(5)(q14q35),t(6;7)(p24;q21),del(12)(p12p11),-14,add(17)(q24),-19[10]/46,xy[10] ; 46,xy,i(8)(q10)[9]/46,xy[11] ; 45,x,-y[10]/46,xy,del(20)(q12)[7]/46,xy[3] ; 46,xx,der(20)t(20;21)(q12;q3),+8[12]/46,xx[8] ; 46,xy[22] ; 93<4n>,xxxx,-1,-1,add(3)(p11)*2,add(5)(q31)*2,-12,add(20)(q12)*2,der(22)t(1;22)(p21;q12)*2,+r(?)*2,+mar[20] ; 46,xy,del(20)(q11.2)[16]/46,xy[4] ; 51,xy,+y,+8,+9,+13,+21[7]/46,xy[21] ; 46,xy,+8 ; 46,xx[10] ; 46,xy,+der(1)t(1;7)(p13;p11.2),-7,del(20)(q11.2)[22]/46,xy[4] ; 46,xy[29] ; 46,xx,inv(10)(p13q11.2)[25]/45,xx,inv(10)(p13q11.2),-18[5] ; 46,xx,del(9)(q11)[2]/46,xx[28] ; 47,xx,-4,der(5)t(5;?)(q11.2;?),del(11)(q14.1),der(20)t(1;20)(q23;p13),+2mar[13]/47,xx,-4,der(5)t(5;?)(q11.2;?),del(11)(q14.1),-20,+3mar[11]/46,xx,-4,der(5)t(5;?)q11.2;?),del(11)(q14.1),-20,+2mar[4]/46,xx[2] ; 46,xy,-4,-5,-7,del(12)(p11.2),-20,-22,+5mar[1]/92,xxyy,-4*2,-5*2,-7*2,del(12)(p11.2)*2,-20,*2,-22,*2,+10mar[1]/46,xy,t(5;15)(q15;p11.1)[1]/46,xy[16] ; 46,xy[31] ; 46,xy,del(20)(q11.2)[16]/46,xy[8] ; 45,x,-y[4]/46,xy[27] ; 46,xy,+1,der(1;7)(q10;p10)[14] ; 47,xy,+8[2]/46,xy[12] ; 46,xy,del(20)(q11.2)[26] ; 45,xx,del(5)(q15q33),der(15;22)(q10;q10)[20]/45,xx,der(15;22)(q10;q10)[9]/46,xx,+8,der(15;22)(q10;q10)[6] ; 46,xy,del(5)(q13q31)[27]/46,xy[3] ; 45,y,add(x)(q26),del(1)(q24),add(2)(p23),-4,del(5)(q13q31),-6,add(7)(p15),+8,del(11)(p11.2),-12,-13,+14,-15,add(17)(q23),add(19)(q13.3),+2mar[18]/46,y,add(x)(q26),-4,del(5)(q13q31),+8,-13,+mar[14]/46,xy[2] ; 45,xy,-5,add(15)(p11.1),-17,-21,+2mar[31]/90,xxyy,-5,-5,add(15)(p11.1)*2,-17,-17,-21,-21,+4mar[3]/46,xy[1] ; 46,xy[30] ; 44,xy,-3,del(5)(q15q33),-7,add(17)(p11.2),add(19)(p13),-20,-22,+2mar[7]/86,xxyy,+x,-3,-3,del(5)(q15q33),+del(5)(q15q33),-6,-6,-7,-7,-14,add(17)(p11.2)*2,+18,add(19)(p13)*2,-20,-20,-22,-22,+3mar[1] ; 46,xy[12] ; 46,xy[26] ; 46,xy[28] ; 47,xy,+8[25]/46,xy[2] ; 46,xx[18] ; 46,xy[19] ; 46,xx[16] ; 45,xy,del(5)(q23),-7,add(10)(p13),add(13)(p11.2),-18,-20,+2mar[14]/44,xy,del(5)(q23),-7,add(10)(p13),add(13)(p11.2),-18,-20,+mar[10]/43,xy,del(5)(q23),-7,add(10)(p13),add(13)(p11.2),-18,-20[2] ; 46,xy,der(7)t(1;7)(q23;p15)[23]/46,xy[3] ; 45,xy,add(1)(p36.3),der(3;5)(q10;p10),add(6)(p23),-13,+add(15)(p11.2),add(20)(q13.3)[17]/44,xy,add(1)(p36.3),der(3;5)(q10;p10),add(6)(p23),-13,add(20)(q13.3)[9]/46,xy[2] ; 46,xy[8] ; 46,x,t(x;19)(p11.2;q13.1)[5]/46,xx,del(x)(q13)[1]/47,xx,+x[1]/46,xx[17] ; 46,xy,del(13)(q22)[9]/46,xy[6] ; 47,xx,+8[30] ; 43,xy,del(2)(q32),-5,-6,-7,+8,-10,-12,-15,-18,-21,+4mar[28]/46,xy[2] ; 47,xy,+8[2]/46,xy[28] ; 46,xy,del(11)(q21)[13]/47,xy,idem,+8[1]/45,x,-y[4]/46,xy[13] ; 46,xy,+1,der(1;7)(q10;p10)[9]/46,xy[1] ; 46,xy,del(5)(q13q31)[11]/92,xxyy,del(5)(q13q31)*2[1]/46,xy[24] ; 46,xx,+1,der(1;12)(q10;q10)[31]/47,xx,+1,+del(1)(p10),der(1;12)(q10;q10)[1] ; 50,xy,-5,+8,+9,add(11)(q21),add(12)(p11.2),-18,+19,+22,+2mar[22]/46,xy[2] ; 47,xx,+8[1]/47,xx,del(2)(p21),+8[1]/46,xx[20] ; 45,x,-y[5]/46,xy[6] ; 46,xy,+1,der(1;7)(q10;p10)[32]/46,xy[1] ; 47,xy,+8[33]/46,xy[2] ; 46,xx,t(2;3)(p23;q27)[32] ; 45,xx,-5[1]/44,xx,-5,-17[1]/44,xx,-14,-17[1]/46,xx[16] ; 46,xx[26] ; 47,xy,+21[15]/46,xy[11] ; 46,xx,der(17)t(1;17)(q23;q25)[5]/46,xx,der(9)t(1;9)(q23;q34)[1]/46,xx,der(19)t(1;19)(q23;p13)[1]/46,xx[19] ; 47,xy,der(1)t(1;?)(p31;?),-5,+2mar[18]/47,xy,der(1)t(1;?)(p31;?),-5,del(7)(q23),-8,+3mar[4]/47,xy,der(1)t(1;?)(p31;?),-5,add(11)(q23),+2mar[3]/47,xy,-5,+2mar[2] ; 46,xy,del(9)(p21)[5]/46,xy[21] ; 47,xy,+8[12]/46,xy[14] ; 46,xx[32] ; 46,xy,dup(1)(q23q32)[33]/46,xy[2] ; 46,xy,-5,-7,add(8)(q24.3),-21,+3mar[31]/46,xy[4] ; 46,xx,del(3)(p13),-5,+8,-18,-21,+2mar[1]/45,xx,idem,-8[1]/46,xx[18] ; 50,xy,+8,+9,+10,+21[1]/49,xy,idem,-10[1]/49,xy,idem,-22[1]/46,xy[27] ; 46,xy[1] ; 41~46,xx,del(5)(q14q34),-7,der(7;15)(p10;q10),+8,-9,add(13)(p11.2),-18,-20,-21,+1-2mar[cp17]/46,xx[3] ; 45,xy,-7[18]/46,xy[4] ; 43,xy,del(3)(p13),-5,-9,add(11)(p15),add(14)(q32),add(16)(p13.1),-17,add(18)(p11.2),add(19)(p13.3),add(21)(p11.1)[10]/46,xy[3] ; 43,xy,der(5;17)(p10;q10),-7,-18,add(21)(p11.1)[29]/44,xy,der(5;17)(p10;q10),-7,+8,-18,add(21)(p11.1)[1]/45,xy,der(5;17)(p10;q10),-7,+8,add(21)(p11.1)[1]/47,xy,+1,der(5;17)(p10;q10),-7,+8,+9,add(21)(p11.1)[1]/46,xy[1] ; 46,xy,dup(1)(q21q32)[5]/46,xy[25] ; 46,xx[33] ; 45,xy,add(5)(q13),-7,-10,del(12)(p12),del(16)(p12),add(18)(q23),add(19)(p13.3),add(21)(p11.1),+mar[13]/44,xy,add(5),add(5)(q13),-7,-10,-12,-21,+2mar[4]/46,xy[1] ; 46,xy,del(20)(q11.2)[31] ; 45,x,-y[3]/46,xy[27] ; 46,xx,del(5)(q15q31)[14]/46,xx[17] ; 45,x,-y[8]/46,xy[22] ; 46,xy,t(1;14;3)(p22;q11.2;p21)[11]/46,xy[10] ; 46,xx[5] ; 47,xy,t(1;20)(q23;q11.2),+der(20)t(1;20)[28]/46,xy,t(9;22)(q34;q11.2),-20[18] ; 46,xy,-7,+mar[27]/46,xy,-7,+14,der(14;14)(q10;q10),+mar[3]/47,xy,-7,+9,+mar[1] ; 47,xy,+8[14]/46,xy[1] ; 46,xx,del(5)(q22q33)[9]/46,xx,idem,del(12)(p12)[11] ; 46,xy,del(5)(q13),-7,+11,del(12)(p12),add(17)(p12)[4]/46,xy,del(5)(q13),-7,+der(8)t(8;14)(p11.2;q11.2),+11,del(12)(p12),-14,add(17)(p12)[14]/46,xy,der(3)t(3;?)(q26;?),del(5)(q13),+i(8)(q10),+11,del(12)(p12),add(14)(p13),add(17)(p12),-18/46,xy[1] ; 47,xy,+11 ; 46,xy,div(1) ; 46,xy,del(1)(p)[5]/46,xy[14] ; 45,x,-y[20]/46,xy,idem,add(9)(q)[1] ; 46,xy,-x,-y,dup(1)(q11;q23),+10,+5[6]/46,x,-y,-y,dup(1)(q11;q23),+8[5] ; 46,xx,del(5)(q13q33)[18] ; 46,xx,inv(3)(q21;q26)[6]/46,xx[14] ; 46,xx,t(15;18)(q26;q21)[7]/46,xx[12] ; 46,xy,+mar,-17[1]/46,xy[21] ; 46,xx,del(5)(q13q31)[3]/46,xx[20] ; 46,xy,del(20)(q11)[18]/46,xy[2] ; 47,xy,+mar[5]/46,xy[19] ; 44,xx,del(4)(p),del(5)(q13q33),der(7q),+8,add(10)(p),add(13)(p),-14,der(17q),-18,-20[22] ; 47,xy,+15[1]/46,xy[20] ; 45,xx,-7[19]/47,xx,+8[1] ; 45,xx,-7[13] ; 46,xy,del(5)(q13q33)[1]/46,xy[19] ; 45,xx,-7[20] ; 46-48,xy,del(3)(p21),del(5)(q13q33),add(6)(p21),del(15)(q12),del(16)(q13),add(17)(q25),+20[12]/46,xy[1] ; 44,xx,der(3;7)(q13;q21),-5,-7,+8,add(9)(q34),-12,add(14)(p11),add(17)(p11)[17]/46,xx[3] ; 44,xx,-2,-3,der(4)t(3;4)(p21;p14?),del(5)(q13q33),-6,der(7),add(12)(p11)[13]/43,xx,idem,der(7)[7]/46,xx[1] ; 46,xx,add(2)(p),del(5)(q13q33)[13]/45,xx,idem,-22/45,xx,idem,der(6) ; 46,xy,t(10;11)(q22;q23)[20] ; 46,xx,del(12)(p12?)[4]/45,xx,idem,-7[2]/46,xx,idem,-7,+8[9]/46,xx,idem,-7,+x[5]/48,xxx,+x,idem,-7,+8,+22[2] ; 46,xy,del(11)(q22q23)[11]/45,x,-y,-y,del(11)(q22q23)[7] ; 42,xy,der(5),-7,+8,der(9)t(9;12)(q22;q13),-12,add(14)(p11),add(15)(p11)*2,-16,der(19),-21[19] ; 46,xy,del(13)(q)[2]/46,xy[18] ; 45,x,-y[3]/45,xy,-7[1]/46,xy[16] ; 44-46,xy,der(2;5;2;7),t(2;6)(q23;?),der(3;17)(p;?),del(5)(q13q33),-7,t(19;20),t(21;21)(q10;q10),+21[24] ; 45,xy,-7[10]/45,xy,-7,add(18)(p11)[10] ; 46,xy,del(11)(q14)[10]/46,xy,del(11)(q14),del(20)(q13.2),der(21)[1] ; 44,xy,-5,-7,-17,+mar[6]/43,xy,-5,-7,-13,-15,-17,+mar,+mar[4]/46,xy[22] ; 47,xx,+mar[5]/46,xx[15] ; 45,xx,-5[3]/46,xx[17] ; 47,xy,+mar[3]/46,x,-y[2]/46,xy[17] ; 46,xy,del(1)(q) ; 46,xy,del(12)(p)[1]/46,xy[21] ; 47,xy,+17[1]/46,xy[19] ; 50,xx,+4mar[1]/46,xx[20] ; 46,xy,inv(3)(p21q29),-3,del(5)(q13q33),add(7)(q22),+8,-12,-14,+mar,+mar[21] ; 46,xx,inv(9)(p11q13)[21] ; 46,xy,-7,+mar[19]/46,xy[1] ; 46,xy,del(2)(p13q4),del(5)(q13q33),add(17)(p11),del(20)(q11)[20]/46,xy[1] ; 47,xy,+8[5]/46,xy[17] ; 46,xx,del(2)(p13)[8]/46,xx,idem,der(5)[11]/46,xx[2] ; 46,xx[23] ; 46,xx,del(5)(q22;q33)[11]/46,xx[9] ; 46,xx,+mar2[1]/45,x,-x,+mar1[1]/46,xx[19] ; 45,x,-y[4]/46,xy,t(2;21)(q23q22)[10]/46,xy,del(5)(q31q33)[2]/46,xy[4] ; 46,xy[18]/46,xy,del(13)[1]/46,xy,ver_nderung(12)[1] ; 44,xy,del(5)(q22q33),-7,-13[14]/45,xy,del(5)(q22q33),del(7)(p),-13[1]/44,xy,idem,del(11)(q23)[10]/44,xy,idem,add(1)(p),del(11)(q23)[8]/44,xy,idem,del(11)(q23),dup(20p11.2)[5]/44,xy,del(5)(q22q33),-7,-13,+mar[6] ; 46,xx,del(20)(q11)[18]/46,xx,idem,der(8)[2] ; 46,xx[19] ; 46,xy,del(7)(q22)[4]/46,xy,idem,der(4p)[3]/46,xy,idem,del(11)(q)[1]/46,xy[13] ; 47,xy,+8[9]/48,xy,+8,+21[1]/46,xy[10] ; 45,xy,-22[2]/46,xy[19] ; 47,xx,t(1;11)(q31;q25),del(7)(q32),+8[2]/47,xx,+7[1]/46,xx[19] ; 47,xy,+8[3]/46,xy[17] ; 45,x,-y,-y[3]/46,xy,del(3)(q)[1]/46,xy,t(1;7)[1]/46,xy,del(11)(q)[1]/46,xy,del(15)(q)[1]/46,xy[14] ; 46,xy,add(5)(p11),add(19(?q13)[2]/44/46,idem,der(9p),add(15)(q2?),-15,add(16)(p13),-18,der(21q)(1/3x)[18] ; 46,xy,del(5)(q13q33)[9]/45,xy,idem,-21[2]/47,xy,idem,+8[10]/46,xy,idem,+8,-21[1] ; 46,xy,del(13)(q)[1]/46,xy,del(11)(q)[1]/47,xy,+8[1]/46,xy[15] ; 46,xx,del(15)(q)[20] ; 46,xx,+1,der(1;7)(q10;q10)[18]/46,xx[3] ; 46,xy,del(1)(q?),inv(3)(q21;q26)[7]/46,xy[13] ; 46,xy,del(20)(q11)[6] ; 46,xx,del(14)(q)[1]/46,xx[20] ; 46,xy,t(15;17)?[1]/46,xy,del(9)(q)[1]/46,xy[18] ; 46,xy,inv(9)(p11;q13)[1]/47,idem,+8[19]einzelaberrationen:12p-,13q- ; 46,xy,del(8)(p)[1]/46,xy,del(9)(q)[1]/46,xy,del(9)(q),+21[1]/46,xy[17] ; 46,xy,del(11)(q21)[15] ; 46,xy,inv(9)(p11q13)[7]/45,xy,-5,-7,inv(9)(p11q13),add(12)(p),del(20)(q11),+mar[12]/46,xy,idem,+mar[2] ; 46,xy[20]/einzelaberrationen:46,idem,del(11)(q23)[1]/46,idem,del(20)(q11)[1] ; 45,x,-y[4] ; 47,xy,+8[1]/45,xy,-5[1]/46,xy,-5,+8[2] ; 45,xy,-7 ; 46,xy,del(20)(q)[3]/46,xy[17] ; 46,xx,del(5)(q13;q33)[5]/47,xx,+8[12] ; 45,x,-y,del(5)(q14q34)[17] ; 44,xy,der(1)t(1;9),der(3)t(3;5),+del(3)(q11),der(4)t(4;12),der(4;12),-7,der(8)t(1;8),der(9)t(9;12),-10,der(19)t(10;19),der(20)t(7;20),-21,+mar,inc[19]/46,xy[4] ; 46,xy,t(3;8)(q267;q34)[49]/46,xy[15] ; 45-46,xy,-5,-8,add(9)(p),-17,+2-4mar[18] ; 46,xy,del(20)(q11)[6]/46,xy[16] ; 51,xy,+1,del(5)(q13q33),+6,+11,+22,+22[16]/52,xy,idem,+15[5]/46,xy,der(9)? ; 46,xx,del(5)(q13q33)[1]/46,xx,idem,add(18)(q)[4] ; 46,xx,-8,+mar[2]/46,xx[21] ; 45,x,-y,add(18)(p)[4]/46,xy,45.idem,+der(1;14)(q11;q11),-14[17] ; 44,xx,-2,+der(2)t(2;6),der(2,6,7),del(5)(q12),-6,der(6),-7,der(7),del(12)(p11),-17,-18[21] ; 47,xx,+8[17]/46,xx[2] ; 46,xy,add(5)(p)[5]/46,xy,idem,der(8;12),t(8;12)(q11;q11),del(12)(p11)[2]/46,xy,idem,add(1)(p)[2]/46,xy[13] ; 45,x,-y,del(5)(q22q33),del(19),add(20)(q)[17]/44,xy,idem,-18[5] ; 46,xy,del(7)(q22)[22] ; 45,xy,add(2)(q),del(3)(q),der(5q),del(7)(q22),-13,der(17)[7]/46,xy[15] ; 45,xy,der(6)ins(6;19)(p23;?)t(6;9)(p25;?),der(7)t(5;7)(p14;q22),+8,del(17)(p12),-19[9]/46,xy[1] ; 45,xy,-7[15]/46,xy[13] ; 46,xy,del(7)(q31)[2]/46,xy[20] ; 46,xx,inv(9)(p11q12)[17] ; 47,xx,+19[17] ; 45,xy,del(5)(q),-7,del(12)(p),add(17),del(20)(q)[10]/46,xy[12] ; 46,xy,del(20)(q11)[5]/46,xy[14] ; 46,xx,del(7)(q22)[11]/46,xx,idem,add(13)(q)[2] ; 47,xy,+13[10]/46,xy[12] ; 45,x,-y,del(2)(p23),der(3)t(3;5)(p13;?),der(5)t(3;5)(p21;q13)[2]/44,x,-y,-y,del(2)(p23),der(3)t(3;5)(p13;?),-5[7]/46,xy[11] ; 47,xy,+8[5]/49,xy,+8,+21,+22[3]/46,xy[14] ; 46,xy,del(5)(q11q33)[17]/45,xy,sl,-7[22]/47,xy,sdl1,+mar[15]/45,xy,sdl2,-9[7]/46,xy,sdl3,add(11)(q)[4] ; 47,xx,+8[27]/47,xx,idem,+8[22] ; 47,xy,add(8)(q11)[18]/46,xy[5] ; 45,xy,-7[18]/46,xy,dup(1)(q34q25) ; 45,x,-y[14]/46,xy[6] ; 47,xyy,+y[1]/45,x,-y,-y[2]/46,xy[20] ; 48,xy,+8,+19[3]/46,xy[23] ; 45,x,-y[21] ; 45,xy,-7,inv(9)(p13q22)c,del(20)(q12q13)[9]/46,xy,idem,+21[4]/46,xy,inv(9)(q13q21)c[11] ; 46,xy,del(20)(q11)[14]/46,xy,idem,del(12)(p11)[5]/46,xy[4] ; 46,xy,del(16)(q) ; 45,xx,-2,der(2)del(2)(p?)t(2;7;5)(p;p11;q21),-5,-7,+der(7)t(5;7)(p11;q21)[12]/45,xx,idem,der(17)[3]/46,xx[9] ; 44-48,xy,del(1)(p32),der(3q),del(5)(q14q33),del(7)(q22),-7,+8,add(9)(q34),-13,-20,+1-4mar[16]/46,xy[6] ; 46,xy,del(7)(q)[1]/46,xy[20] ; 45,x,-y,del(20)(q)[23] ; 47,xx,+8 ; 47,xy,+8[8]/46,xy[17] ; 46,xy,+1,der(1;7)(q10,p10)[6+3]/46,xy[16+3] ; 47,xy,-3,der(5)t(3;5)(q13;q12),+der(5)t(3;5)(q13;q12),+8,del(12)(p12p13),der(13)ins(13;5)(q14;q34q35)[9]/46,xy[13] ; 47,xy,+8[23] ; 46,xx,del(5)(q14q33)[15]/46,xx[7] ; 46,xx[24] ; 46,xx,del(5)(q13q33)[25] ; 46,xx,t(3;21)(q26;q22)[23+6] ; 44,xy,t(5;2)(q11),-13,-18,-20 ; 46,xx,t(3;3)(q21;q26),del(7)(q11.1)[15] ; 46,xx,del(5)(q14q33)[13]/46,xx[17] ; 45,x,-y ; 46,xx,del(5)(q14q33)[11]/46,xx,idem,del(20)(q11)[2] ; 46,xx,asxl-1undrunx-1mutation[13] ; 46,xy,-7 ; keinezelleninteilung,cd34pbfish:49%5q- ; 46,xx,inv(3)(q21q26)[15]/46,xx[2]hyper,t(1;17)(del(10)(q)der(7)(t(3;12) ; 46,xx,del(20) ; 47,xx,+8[5]/46,xx[17] ; 46,xy,-x0ry,-3,del(5)(q)(14q33),+del(5)(q)(14q33),-9,del(12p11),-13,-17,add(19)(p),+1-3mar9 ; 47,xy,+8,del(12)(p11)[4]/47,xy,idem,del(7)(q11.3)[18]/46,xy[1] ; 46,xx,del(5)(q22q33),del(6)(q23),del(20)(q13)[22] ; 45,xy,der(12)t(12;17)(p13;q11),-17[23]/47,xy,+13[3]/46,xy[4] ; 46,xy,del(5)(q31)[10]/46,xy[2] ; 47,xy,+8[17]/46,xy[6] ; 46,xx,t(3;3),-7[8]/46,xx,del(12)()[2] ; 42-45,xy,add(1)(p32),der(5)t(1;5)(p32;q31),der(9)t(5;9;7;?),-10,der(17)t(7;17;17;?),-18,der(22)t(?17;22)(q21;p11),-22,+2-4mar[21]/46,xy[2] ; 46,xx,del(5)(q14q33)[2]/45,xx,idem,-2,der(7)t(7;?)(q22;2),i(11)(q10),add(16)(q22),-18,+mar[11]/46,xx,idem,der(2)t(2;11)(p13;q13),-3,der(7)t(7;?)(q22;?),i(11)(q10),+11,+mar[9] ; 45,xy,-y[6]/46,xy[17] ; 45,xy,-7[9]/46,xy[13] ; 47,xx,+8[22]/46,xx[1] ; 46,xy[6] ; 46,xx,del(9)(q22)[3]/46,xx[14] ; 46,xy,der(9)[4]/46,xy[15]/46,xy,einzelaberrationen(11)[2] ; 46,xy,del(5)(q14q34)[9]/46,xy[4] ; 47,xy,+8[13]/46,xy[13] ; 45,xx,-7[20]/46,xx[5] ; 46,xy[27] ; 46,xx[15] ; 45,xx,t(3;3)(q21;q26),-7[18]/46,xx[3] ; 45,x,-y[6]/46,xy[20] ; 46,xx,del(5)(q13q34)[18]/46,xx[3] ; 46,xx[34] ; 46,xy,dup(1)(q11q32)[3]/46,xy[25] ; 46,xy,inv(9)(p12q13)[25] ; 47,xx,del(3)(q25),+mar[2]/46,xx[9] ; 45,xy,-7[4]/46,xy[17] ; 46,xy,dup(21)(q21q22.3)[13]/47,xy,add(21)(q22.3),+mar[10]/46,xy[2] ; 47~55,xy,del(4)(q11q21),-5,add(7)(q22),del(7)(p15),+8,add(9)(q34),-13,-18,del(20)(q11.2~13.1),-21,+22,+mar1,+mar2,+4-8mar3,inc[22] ; 46,xy,del(12)(p11.2p13)[20] ; 46,xy,-7,-21,+mar1,+mar2[20] ; 46,xx,der(11)t(1;11)(q11;p13),del(5)(q13q31),inv(7)(p13q32),del(12)(q23),add(13)(p11.1),add(13)(p11.1),del(16)(p?),del(16)(p?),-17,-18,+mar1,+mar2,+mar3[10] ; 46,xy[14] ; 46,x,idic(x)(q13),del(12)(q15q22)[17] ; 46,xy[17] ; 46,xy,del(5)(q15q31)[16]/46,xy[1] ; 46,xy,del(17)(q25)[7]/46,xy[16] ; 46,xy,-7,del(12)(p11.2),+mar[15]/46,xy,del(12)(11.2)[3] ; 45,x,-y,del(20)(q12)[12]/46,xy[3] ; 43~46,xy,-5,-7,add(7)(q32~36),-12,-14,-16,del(17)(p11.2),+r,+1-4mar[5]/46,xy[19] ; 46,xx[13] ; 46,xy,t(3;5)(q25;q34)[15] ; 46,xy,+mar[2]/46,xy[18] ; 45,xy,del(1)(p),del(3)(q),-5,der(8)t(1;8)(p32;q24),del(11)(q23),del(12)(q15),+mar[3]/46,xy[17] ; 46,xy,del(4)(q22q24)[17]/45,x,-y[3] ; 46,xy,del(20)(q?)[9]/46,xy[16] ; 45,x,-y[16]/46,xy[3] ; 47,xy,+8[20] ; 46,xx,der(14)t(1;14)(q11;p11?)[14]/46,xx[6] ; 47,xx,+21[26] ; 47,xx,+19[11]/46,xx[10] ; 46,xx,del(20)(q?)[2]/46,xx,idem,der(1)t(1;2)(p36;p21?),del(20)(q?)[19] ; 46,xx,del(5)(q13q31?)[17]/46,xx,idem,del(6)(q21)[3] ; 46,xy,del(5)(q13q31?)[11]/46,xy[9] ; 45,x,-y[25] ; 47,xx,+8[6]/46,xx[14] ; 46,xy,del(20)(q?)[23] ; 46,xx,t(4;12)(qp?)[12]/46,xx[2] ; 45,x,-y[18]/46,xy[2] ; 48,xy,+13,+19[20] ; 45,x,-y[20] ; 47,xy,+y[12]/45,x,-y[6]/46,xy[4] ; 47,xy,+8[15]/46,xy[5] ; 46,xy,77~158<4n>xy[9]/46,xy[18] ; 47,xx,del(5)(q31q33),+8[3]/48,xx,+8,+9[4]/48,xx,del(5)(q31q33),+8,+9[2]/46,xx[11] ; 46,x,i(x)(q10),del(17)(q22q23.3)[7]/46,xx[13] ; 178~182<7n>,xxxxxxxyyyyyy...[24] ; 46,xy[15] ; 47,xy,del(5)(q31),+mar[5]/46,xx,+x[15] ; 46,x,-y[4]/46,xy[16] ; 47,xy,+8[6]/47,xy,del(7)(q32),+8[7]/46,xy[7] ; 46,xy[5] ; 46,xx,del(20)(q13.1)[7]/46,xx[16] ; 47,xy,+15[10]/46,xy[10] ; 47,xy,+mar[3]/46,xy[17] ; 46,xy,del(5)(q31q35)[6]/46,xy[17] ; 90,xxxx,-6,-7,-8,-11,+21,+22[5]/46,xx,del(7)(q23),del(20(q13.1)[3]/45,xx,-7[5]/45,xx,-7,del(7)(q32),del(11)(q32),-17[12] ; 46,xy[10] ; 47,xy,+mar[5]/46,xy[15] ; 46,xy,-10,+mar[5]/46,xy[10] ; 47,xy,mar[6]/48,xy,+8,+mar[4]/51,xy,del(4)(?q35),+8,+10,+11,+21,+mar[cp8] ; 44,xx,-13,-7[4]/46,xx[15] ; 47,xx,t(4;11)(q27;q32),+mar[4]/46,xx[16] ; 47,xy,+8[12]/46,xy[8] ; 45,x,-y[17]/46,xy[3] ; 45,xx,-7[1] ; 44,xx,del(5)(q31),der(5)t(5;8)(p15;q13),add(17)(p13),-18,-20,-21,der(21)dup(21)(q21),+mar[18]/46,xx[2] ; 47,xy,+8[18]/46,xy[2] ; 46,xy,i(17)(q10)[5]/46,xy[15] ; 47,xx,+8[7]/46,xx[1] ; 47,xy,+8[10]/46,xy[4] ; 46,xx[12] ; 46,xy,del(3)(p21),del(5)(q13q31)[18]/46,xy[2] ; 47,xy,+8[19]/46,xy[1] ; 44,xy,-3,-5,der(7)t(2;7)(q13;q11,2)-11,-12,+2mar[21]/90-92,xxyy,idem[5]/46,xy[1] ; 46,xx,t(2;3)(p15;q26)[15]/46,xx[5] ; 46,xx[14] ; 41-45,x,-x,-4,del(5)(q13),-6,add(11)(q24),-15,+r,+2-3mar[cp14]/46,xx[6] ; 46,xx[45] ; 45,x,-y[5]/46,xx,+x[10] ; 47,xy,+21[16]/46,xy[4] ; 46,xx,del(5)(q13q31)[15]/46,xx[5] ; 46,xx,del(5)(q13q31)[2]/46,xx[13] ; 46,xy,del(5)(q23q33)[10]/46,xy[10] ; 47,xy,+8[14]/46,xy[6] ; 46,xx[6] ; 46,xy,del(20)(q12)[3]/46,xy[7] ; 47,xy,+8[2]/46,xy[18] ; 47,xxyc[15].klinefelter ; 46,xx,del(11)(q23)[16]/46,xx[4] ; complexkaryotype ; 46,xy,del(9)(q13q22)[4]/46,xy[8] ; 45,x,-y[9] ; 46,xx,del(5)(q13q31)[4]/46,xx[6] ; 46,xy,del(5)(q),del(15)(q21.1)[20] ; 46,xx[11] ; 47,xy,+8[3]/46,xy[27] ; 45,xx,-5,del(7)(q22q32),+8,add(12)(p13),-22[18]/46,xx[2] ; 46,xy[18] ; 45,x,-y[7]/46,xy[10] ; 46,xx,ins(1;?)(q21;?),del(5)(q13q31)[20] ; 46,xx,del(5)(q13q31)[12]/46,xx[8] ; 45,x,-y[16]/46,xy[4] ; 47,xy,+13[6]/46,xy[12] ; 46,xy,del(5)(q13q31)[1]/45,xy,sl,-7[4]/46,xy[2] ; 46,x,idic(x)(q13)[5]/46,xx[35] ; 47,xy,+19[8]/46,xy[12] ; 47,xx,+8[3]/46,xx[7] ; 45,x,-y[5]/46,xy,del(5)(?q13q31)[2]/46,xy[13] ; 47,xy,+8[5]/46,xy[15] ; 47,xx,+15[3]/46,xx[17] ; 46,xx,del(5)(q13q33)[12]/46,xx[8] ; 44-45,xy,-5,der(6)del(6)(?q13q15)t(6;15)(p25;p13),-15,-18,+mar[cp10]/46,xy[4] ; 45,x,-y[16]/46,xy[14] ; 46,xy,del(20)(q11.2)[7]/48,xy,sl,+8,+mar[4]/46,xy[9] ; 46,xx,del(5)(?q22q33)[12]/46,xx[2] ; 44,xy,ins(7;?)(p11;?),-15,add(17)(?p13),-18,-18,+mar[cp10] ; 47,xy,+8[17]/46,xy[3] ; 45,xy,-7[16]/46,xy[1] ; 47,xy,+8[6]/46,xy[14] ; 46,xx,del(5)(q31;q31)[11]/46,xx[9] ; 46,x,-y[10]/46,xy[10] ; 46,xx,del(5)(q13q31)[16]/46,xx[4] ; 46,xx,del(5)(?q21q34)[18]/46,xx[2] ; 46,xy,del(4)(q23-25),-5,-7,i(8)(q10),-12,-16,+2mar[16]/46,xy[4] ; 44,xx,del(5)(q15q31),-12,-18,-20,+mar[cp8]/46,xx[5] ; 47,xx,+xc[20] ; 46,xx,del(5)(q13q31)[18]/46,xx[2] ; 44,xy,del(5)(q13q31),-7,del(12)(p11.2),t(13;14)(p10;p10),-19,+mar[12]/43,xy,-5,-7,del(12)(p11.2),t(13;14)(p10;p10),-19,+mar[8] ; 47,xx,+8[18]/46,xx[2] ; 45,x,-y[12]/46,xy[8] ; 43-45,xy,-6,-13,-15,-17,+2mar[cp9]/46,xy[3] ; 45,xx,del(5)(q13q33),-7,-17,+mar[19]/46,xx[1] ; 45,x,-y[19]/46,xy[1] ; 46,xx,del(20)(q11)[9]/46,xx[11] ; 47,xx,+8[17]/46,xx[3] ; 46,xy,del(20)(q11.2q13.1)[17]/46,xy[3] ; 43-44,xy,-7,-10,add(13)(p10),add(16)(q22),del(17)(p11.2),-18,-19,-20,i(21)(q10),+3mar[cp7]/46,xy[9] ; 44,xx,-7,-12,-16,-22,+mar,+der(?)t(?;12)(?;q13)[14]/46,xx[6] ; 46,xy,del(20)(q11.2)[4]/46,xy[16] ; 46,x,idic(x)(q13)[6]/46,xx[14] ; 45,xy,-2,t(5;7;?)(q13;p21;?),-10,del(11)(q14),del(12)(q13),del(13)(q12q21),-17,-18,del(20)(q11.2),add(22)(p11.2),+3mar[14]/46,xy[6] ; 46,xy,t(3;3)(q21;q26)[16]/46,xy,idem,add(14)(p11)[4] ; 46,xx,del(11)(q21)[13]/46,xx[7] ; 46,x,-x,t(3;?)(p21;?),-5,add(6)(p24),+mar1,+mar2[18] ; 43,xx,del(2)(q21q32?),-5,del(7)(q21),add(15)(p11.2),-16,-17,add(20)(q11.2)[8]/44,xx,idem,+mar[6]/46,xx[6] ; 46,xy,-3,del(5)(q13q33),+8,inv(12)(p13q24.1),-13[6]/46,xy[14] ; 45,xx,-7[14]/45,xx,idem,inv(8)(p32q12)[6] ; 46,xx,del(5)(q12q32),add(13)(p13),-13,-20,+mar1*2[9]/47,xx,idem,+mar2[4]/46,xx[7] ; 44~45,xx,del(5)(q13q33),del(7)(q22),+8,-14,-17,-18,+mar[cp20] ; 46,xy,r(1),del(5)(q31q35),del(7)(q22q34),-17,add(21)(p11.1),+mar[15]/46,xy[5] ; 46,xx,del(20q11.2)[14]/46,xx[6] ; 46,xx,del(5)(q14q23) ; 46,xy,20 ; 46,xx,deletion12p- ; 47,xy,+8 ; 41-48,xy,del(5)(q11),+8,dic(9;12)(p23;p13),-18,-20,-22,add(22)(q13).+mar1x3cp20 ; 46,xx,del(5)(q21q34) ; 46,xx,del(5)(q) ; 46,xx,del(5)(q14q34) ; 46,xx,del(11)(q) ; 46,xy,-7,+t(1:7)(p11;p11) ; 45,xy,e ; 42-45,xy,del(1)(p35),add(3)q(11),add(4)(p13),-5,add(6)t(6;9)(p22;q21),-7,-9,-12,+mar[cp17] ; 46,xx,5q31,7q31,cen8 ; 46,xy,add(7)(q21)11/46,xy5 ; 46,xy,del(3)(q13q24)[6]/46,xy[9] ; 46,xx,del(5) ; 45,xy,-7,del(20)(q12q13)[18]/46,xy[2] ; 46,xy,del(5)(q13q33) ; 45,xx,t(3;21)(q26;q22),-7 ; 46,xy,-7,del(12)(p) ; 45,xx,-72/46,xx19 ; 45,xx,-7 ; 46,xx,del(5)(q11.2q33.3)[20]/45,xx,del(3)(q21),del(5)(q11.2q33.3),del(5)(q11.2q13.3),-7,add(9)(p13)[5]/46,xx[3] ; 47,xx,del(6)(q15q23),+15[16]/46,xx[4] ; 46,xx,del(5)(q12q33)[1]/46,xx[2] ; 45,x,-y,add(13)(q34),-16,add(17)(p13),+mar[13]/46,xy[7] ; 46,xy,del(20)(q11.2)[12] ; 47,xy,+11[2]/46,xy[21] ; 46,xy,-20,+mar[7]/47,xy,-20,+mar*2[13] ; 47,xy,+8[13]/46,xy[7] ; 45-46,xx,del(5)(q13q33),del(7)(q22)[2],-11[17],i(11)[10][17],add(18)(q23),add(20)(q13)[17][cp18] ; 46,xx,t(3;6)(q23;p22.2)[2]/46,xx[18] ; 46,xx,del(5)(q13q32)[5]/46,xx[15] ; 46,xy,del(5)(q22q33)[9]/46,xy[11] ; 45,x,-x[18]/46,xx[2] ; 45,x,-x,-4,del(5)(q13q33),-7,add(8)(p11),der(9)t(4;9)(q11;p24),add(12)(p13),del(12)(p13),-14,+mar1,+mar2,+mar3[cp10] ; 46,xx,del(5)(q13q33)[3]/46,xx[17] ; 47,xy,+8,del(12)(p13)[20] ; 46,xy,del(9)(q13q32)[13]/46,xy[7] ; 47,xx,del(5)(q22q35),+mar[2] ; 46,xx,t(2;3)(p23;q26)[13]/46,xx[7] ; 46,xx,-5,-6,+mar1,+mar2[15]/46,xx[5] ; 47,xy,+8[4]/47,xy,sl,dup(1)(q21q32)[15]/46,xy[1] ; 73-78,xyy,+1,-5,-7,+13,+13,+15,+17,+19,-20,+21,+mar1,+mar2,+mar3[3]/46,xy[17] ; 47,xy,+21[13]/46,xy[7] ; 46,xx,add(9)(p24)[20] ; 46,xy,del(20)(q11.2)[20] ; 46,xx,del(5)(q15q33.3)[3]/46,xx[1] ; 46,xx,del(5)(q13q33)[6]/47,xx,+8[1]/46,xx[15] ; 44,xx,t(2;6;3)(p13;q16;q26),del(6)(p21),del(5)(q14q33),der(12)t(12;22)(p11;q11),der(13)t(13;13)(q22;p11),-22[22] ; +8(fish) ; 46,xx,del(5)(q13.3q33.1)[20]/46,xx[2] ; 45,x,-y[3]/46,xy[19] ; 43~44,xx,-3,del(5)(q22q33),-7,-21,+mar[cp7] ; 46,xx,del(5)(q13q33)[14]/46,xx[8] ; 45,xx,dic(3;7)(p11;p11?),del(5)(q13.1q33.3)[3]/44,xx,idem,der(12)t(12;15)(p11.1;q11.1),-15[9]/46,xx[1] ; 47,xy,+8[12] ; 86~92,xxyy[7]/46,xy[15] ; 79~87,xxxx,der(?)r(?;12;17),del(5)(q13),der(9)t(9;22)(q21;?),der(11)t(11;14)(q12;q11),der(12)t(12;18)(q;p?),der(17)t(12;17)(q;?),ins(22;9)(q;q?)cp[22] ; 47,xy,+8[2]/46,xy[11] ; 46,xx[3] ; 47,xx,+8[1]/46,xx[12] ; 46,xx,del(5)(q13q33)[1]/46,xx[21] ; 47,xy,+8[2]/46,xy[16] ; 46,xx,del(5)(q22q33)[5]/46,xx[5] ; 45,x,-y[6]/46,xy[21] ; 46,xy,der(1)[3]/42-45,xy[8]/46,xy[15] ; 44,xy,der(3)t(3;18)(p11-12;q11),del(59(q12q35),-7,-18,der(21)t(3;21)(p21;q21)[15]/46,xy[3] ; 46,xy,inv(3)(p11q11.2)[25] ; 46,xx,del(5)(q13-14q35)[4]/44-47,xx,-3,del(5)(q13-14q35),-8,-11,-15,der(17),-20,+4-5mar[cp16] ; 44,xx ; 46,xy,del(7)(q11)[1]/46,xy,del(7)(q11),der(11)t(3;11)(q26-27;q23)inv(11)(p15q22)[2]/46,xy[17] ; 46,xx,+8[2]/46,xx[23] ; 44-45,xy,der(5)t(4;5)(?;p14)t(5;22)(q11-12;q11),der(7)t(7;17)(q21;q24),-13,der(16)t(5;13;16)(?;q21;q23),der(16)t(16;?)(p13;?),del(16)(q22),der(17)t(17;?)(q24;?),del(20)(q12),-22,der(+)t(?;4),+mar[10]/46xy[1] ; 46,xx,del(5)(q13q33)[24]/46,xx[2] ; 46,xx,del(5)(q13q33)[18]/46,xx[6] ; 46,xx[28] ; 46,xx,inv(3)(p12q13)[26] ; 46,xy,der(7)t(1;7)(q10;p10),del(12)(p?)[25]/46,xy[5] ; 46,xx,del(5)(q13q33)[12]/46,xx[15] ; 46,xy,+19[2]/46,xy[25] ; 44-48,xy,t(3;4)(p13;q13),del(5)(q23-31;q33),t(8;12)(p22;q24),der(12),add(17)(p13),+21,+21,+21,+1-2mar[cp8]/44-47,xy,t(3;4)(p13;q13),-5,t(8;12)(p22;q24),der(12),+21,+21,+21,+mar[cp3]/46,xy[1] ; 45,x,-y[26] ; 46,xy,del(20)[3]/46,xy[18] ; 46,xx,del(5)(q13q33)[14]/46,xx[13] ; 52,xx,+1,del(5)(q13q33),+6,+8,+11,+14[19]/46,xx[1] ; 46,xy,del(5)(q13q33)[13]/46,xy[9] ; 45,xy,-7,del(20)(q12)[25]/46,xy[1] ; 46,xy,del(7)(q22)[6]/46,xy[20] ; 46,xx,del(5)(q13q33) ; 46,xx,del(5)(q21)[23]/46,xx[3] ; 46,xx,del(5)(q13q33)[5]/46,xx[18] ; 46,xx,del(5)(q13q33)[16]/46,xx[10] ; 46,xy,del(5)(q13q33)[14]/46,xy[13] ; 46,xy,del(20)(q11.2)[22] ; 46,xy,del(5)(q13q33),+8[14]/46,xy[11] ; 42~47,xy,add(2)(p23),del(3)(q21),-5,-7,+8,-9,del(11)(q13),-1,+1-5mar,inc[cp17] ; 46,xx,+8[3]/46,xx[23] ; 46,xy,t(1;21)(q23;q11.2),-7[25] ; 46,xy,der(12)[5]/46,xy[23] ; 46,xy,del(20)(q13.1)[7]/46,xy[18] ; 46,xy,t(2;13)(q35;q14)c[27] ; 45,x,-y[13]/44,x,-y,-7[7]/46,xy[1] ; 46,xx,del(5)(q13q34)[7]/47,xx,del(5)(q13q34),+8,del(12)(p13)[4]/51,xx,del(5)(q13q34),+8,+8,del(12)(p13),+del(12),+14,+18[5]/46,xx[8] ; 46,xx,+8[21]/46,xx[4] ; 46,xy,add(12)(q24)[25] ; 46,xy[9] ; 46,xy,-5,add(7)(q22),add(17)(p11.2)[2]/46,xy,idem,+11,-12,+mar[3]/43,xy,idem,-4,del(15)(q15),-19,add(21)(q21),+mar[4]/42,xy,sdl2,del(15)[11]/46,xy[3] ; 46,xy,del(11)(q13)[24] ; 46,xy,del(5))(q13q31)[8]/45,xy,idem,-y[3]/45,x,-y[3]/46,xy[7] ; 46,xx,i(17)(q10)[20]/46,xx[5] ; 45,xy,-5,del(7)(q?)[4]/44,xy,idem,t(14;17)[5]/43,xy,idem,-12,t(14;17)[3]/43,xy,idem,del(3)(q?),-12,t(14;17)[2]/46,xy[11] ; 45,x,-y[22]/46,xy[6] ; 45,xy,add(1)(p?),-5,+8,der(13;14)(q10;q10),-18,+21[19]/46,xy[8] ; 46,xy,del(5)(q2q3?)[25] ; 46,xy,del(5)(q13q31),del(11)(q13q23)[16]/46,xy[9] ; 47,xy,+8[13]/46,xy[12] ; 46,xx,del(5)(q13q33)[16]/46,xx[9] ; 46,xy,del(3)(p11),del/46,xy,5)(q13q31),+8[6]/47,xy,idem,add(7)(q21)[8]/45,xy,-16,del(17)(p11.2),-18,+mar1[4]/44,xy,-11,-16,del(17)(p11.2),-18,+mar2[3]/46,xy[3] ; 45,xy,-7[12]/46,xy[13] ; 47,xy,+8[18]/46,xy[16] ; 44,xy,-6,-7,add(12)(q24),add(12)(q24),-15,add(19)(p13),add(20)(q13),+mar1[4]/44,xy,idem,-13,-14,+mar2,+mar3[5]/46,xy[14] ; 46,xy,+8[2]/46,xy[23] ; 47,xx,-7,+21,+mar[20]/47,xx,-7,+21,+22[4]/46,xx[1] ; 46,xx,add(11)(q23)[17]/46,xx[9] ; 46,xy,+8[18]/46,xy[7] ; 46,xx,del(12)(q15q24)[20]/45,xx,idem,-20[3]/46,xx[2] ; 46,xy[4] ; 46,xy,del(20)(q)[1]/46,xy[24] ; 46,xx,del(5)(q13q33)[15]/45,xx,idem,-7[2]/46,xx[5] ; 42-45,xy,-2,-5,-6,-9,add(13)(p11.1),add(14)(p11.1),add(15)(p11.1),-16,-18,-20,del(20)(q11.2)+3-6mar[cp23]/46,xy[1] ; 45,xy,der(1)add(1)(p11?)del(1)(p11?),-7,add(10)(q26?),-16,+mar[10]/44,xy,der(1)add(1)(p11?)del(1)(p11?),-7,add(10)(q26?),-16[11]/46,xy[5] ; 46,xy,t(2:11)(p21:q23) ; 45,x[2]/46,xx[33] ; 46,xy,inv(9)(p11q11)[25] ; 47,xx,+mar ; 46,xx,del(5)(q13q33)[15]/46,xx,idem,del(12)(p12)[2]/46,xx[14] ; 47,xy,+8[20]/46,xy[6] ; 45,x,-x[11]/46,xx[14] ; 44,xx,-5,-7,mar[18]/46,xx[7] ; 46,xy,del(11)(q22),del(20)(q12)[16]/46,xy,add(4)(q35),del(11)(q22),del(20)(q12)[9] ; 46,xx,del(11) ; 43,xx,-5,del(7)(q11),+8,-12,-16,-20,inc[cp16]/46,xx[9] ; 46,xx,del(5)(q13q33)[17]/46,xx[9] ; 46,xx,del(5)(q12q33)[25] ; 46,xx,t(3;21)(q26:q22)[27] ; 46,xy,+y[27] ; 45,xx,-7[25] ; 46-47,xx,-3,-5,+8,-17,+3,mar[9]/46,xx[17] ; 46,x,-y ; 45,xy,-7,del(11)(q13)[10]/46,xy,idem,+mar[4]/47,xy,idem,+8,+mar[2]/46,xy[9] ; 45,x,-y[5]/46,xy[20] ; 44,xy,del(1)(q21),add(3)(q29),del(3)(p13),del(5)(q15;q33),-6,add(10)(q26),-15,add(17)(p13)[25]/46,xy[2] ; 46,xy,+8[8]/46,xy[19] ; 46,xx,+1,der(1;7)(q10;p10)[8]/43,xx,del(5)(q13q31),-7,del(12)(q13),-16,der(19;21)(p10;q10)[9]/46,xx[8] ; 44,xx,der(5)t(5;17)(q;q?),del(7)(q11),-15,-17[24] ; 47,xx,+8[25] ; 46,xx,-7,+8,+9,del(12)(12)(p13),-16,add(17)(p13)[22]/47,xx,idem,+21[4] ; 46,xy,del(20)(q11.2)[24]/47,xy,del(20)(q11.2),+8[1] ; 46,xx,der(7)(p?)add(7)(q?),inv(9)(p11q13)c[6]/46,xx,inv(9)(p11q13)c[16] ; 46,xx,+8[20]/46,xx[5] ; 45,xy,-7[19]/47,xy,idem,inv(3)(p21p26)[11]/46,xy[3] ; 45,xy,-7[14]/46,xy[7] ; 45-47,x,idic(x)(q11.2),del(5)(q13),+9,add(17)(q21),-18,+21,+mar[cp20]/46,xx[1] ; 45,x,-y[8]/46,xy[12] ; 46,xy,t(1;3)(p36;q21)[20] ; 46,xx,del(5)(q13q31)[10] ; 46,xx,+mar[21] ; 46,xy,del(15)(q),-7 ; 46,xy,del(20)(q11.2)[9]/46,xy[2] ; 46,xx,del(4)(q25q31)[16]/46,xx,del(5)(q13q31)[2]/46,xx[2] ; 46,xx,del(5)(q13q33)[16]/46,xx[4] ; 45,x,-y[10]/46,xy[10] ; 45,xy,-7[10]/46,xy[6] ; 45,x,-y[4]/46,xy[22] ; 46,xx,t(9;11)(p21;q23)[20] ; 44,xx,-5,-7,add(19)(q?)[2]/44,xx,idem,1dmin[5]/46,xx[6] ; 46,xy,del(5)(q?)[5]/56,xy,idem,+1,+2,+6,+9,+11,+13,add(15)(p),+19,+21,+22,+22[15] ; 46,xx,t(5;22)(q31;q13)[5]/46,xx[15] ; 46,xx,t(14:18) ; 46,xx,+4[5]/46,xx[14] ; 47,xy,+8[12]/46,xy[3] ; 46,xx,idic(x)(q13)[7]/47,xx,idic(x)(q13)*2[4]/46,xx[10] ; 47,xy,+mar[4]/45,x,-y[2]/46,xy[12] ; 46,xx,del(5)(q13q31)[4]/46,xx[8] ; 46,xx,del(5)(q13q33)[12]/46,xx[2] ; 45-49,xx,add(1)(p36),del(5)(q22q35),-7,-13,-14,-18,+3-9mar[15]/46,xx[1] ; 46,xy,del(13)(q12q14)[10]/46,xy[2] ; 45,x,-y,add(18)(q?)[15] ; 46,xy,t(1:7)(p36.1;q11.2) ; 46,xy,del(20)(q11.2)[11]/46,xy[9] ; 45-46,xy,add(3)(p),-5,-7,-16,+18,add(19)(8p),del(20)(q),-22,+1-2mar[cp8]/46,xy[16] ; 46,xx,del(5)(q12q35)[14]/46,xx[6] ; 46~47,xx,-5,-7,del(12)(p13),-13,-13,-14,-17,+6-8mar[cp4]/46~47,xx,-5,-7,del(12)(p13),-13,-13,add(14)(q32),-17,+5-6mar[cp4]/46,xx[4] ; 46,xx,+22[2]/46,xx[14] ; 46,xx,del(5)(q)[9]/46,xx[3] ; 46,xx,del(11)(q22)[8]/46,xx[12] ; 46,xy,del(16)(q22)[4]/46,xy[16] ; 46,xy,+8[10]/46,xy[10] ; 45,x,-y[5]/46,x,-y,+15[7]/46,xy[9] ; 46,xx,del(5)(q)[5]/46,xx,inv(3)(q),del(5)(q13),del(7)(q)[2]/51,xx,inv(3)(q),del(5)(q),del(7)(q),+5mar[8]/53,xx,inv(3)(q),del(5)(q),+6,del(7)(q),+6mar[2]/46,xx[2] ; 46,xx,inv(9)(p11q12) ; 46,xy,del(1)(p35),del(5)(q31),-18[14]/46,xy[6] ; 45,x,-y[4]/46,x,-y,+9[5]/46,xy[14] ; 45,xx,del(5)(q13q31)[4]/37~50,xx,idem,add(2)(q37),add(3)(p2),-8,add(8)(q22),-11,del(11)(q13),del(11)(q23),-12,der(12)t(12;17)(p13;q11),-16,-17,-17,+1-4mar[cp16] ; 46,x,-y[15]/46,xy[5] ; 43,xy,-7,add(9)(q13),-17,-19,add(19)(p13),-21,+mar[2]/43,xy,del(1)(p33),-7,add(9)(q13),add(17)(p11.2),-19,add(19)(p13),-21[8]/46,xy[1] ; 46,xx,del(5)(q13q31)[8]/46,xx[12] ; 46,xx,del(5)(q13q31)[20] ; 46,xx,del(5)(q13;q33)[8]/47,xx,+8[2] ; 46,xy,del(20)(q11)[7]/45,xy,idem,+8[4] ; 46,x,idic(x)(q11.3)[12] ; 46,xx,der(20)del(p12)del(q12)[11] ; 46,xy,-7,+21 ; 46,xx,add(17)(q),add(19)(p)[4]/46,xx[16] ; 46,xy,del(3)(q13.2)[5]/46,xy,del(3)(q21q25)[2]/46,xy,i(17)(q10)[2]/46,xy[5] ; 46,xy,+8,+13,mar ; 46,xy,inv(9)(p11q13)[20] ; 46,xy,del(20) ; 46,xx,del(20)(q13)[2]/46,xx[23] ; 46,xx,del(20)(q13.1)[10]/46,xx[1] ; 46,xy,-7[6]/46,xy[19] ; 45~47,xx,add(3)(p13),del(5)(?q22q35),-6,-9,+1-3mar[cp13]/46,xx[1] ; 46,xy,del(1)(p3)[15]/46,xy[10] ; 46,xx,t(11;19)(q23;p13)[20] ; 46,xy,add(3)(q26)[21] ; 45,x,-y[11]/46,xy[9] ; 46,xy,del(20)(q11.2q13.1)[5]/46,xy[9] ; 47,xy,+8,i(17)(q10)[7]/46,xy[3] ; 44,xx,-7,-18[11] ; 44,xy,-9,-18,-21,+mar[12] ; 46,xx,del(5)(q12q33)[15]/46,xx[5] ; 46,_xy,_der(1)t(1;5)(p21;p15),_+2,_del(2)(p14),_der(2)t(1;2)(p21;p14)t(2;20)(q12;?),_-5,_dic(13;21)(p13;p13),_der(15)t(1;15)(p31;p13),_dic(2;20)(?;p13)t(1;2)(p31;?),_+mar[25] ; 45,_xy,_dic(5;7)(q12;?q22)[13]/45,_idem,_dic(4;11)(p16;q24)dup(11)(q14q24)[3]/50,_x,_-y,_dic(1;8)(p12;q22)t(1;2)(p12;?p12)t(2;8)(?p25;q24),_der(1)t(1;4)(p13;q21),_der(2)t(2;19)(p12;?q13),_+3,_der(4)t(x;4)(q23;q34),_der(9)t(1;9)(p32;p21),_+der(9)t(9;16)(p2 ; 42-43,xy,der(4)t(4;12)(q32;q12)del(12)(q14q22),del(5)(q12q35),-7,-12,-13,-14,-16,-17,del(17)(p11),ins(18;7)(q22;?),der(19)t(7;19)(?;13),der(20)t(16;20)(?;q12)t(7;16)(p14;?),-22,ider(22)(q10)t(6;22)(?;q13)t(6;22)(q22;q13),+mar[24]/46,xy[2] ; 45,xy,der(5)t(5;7)(q11;p14),der(7)t(5;7)(q;q21),-13,-17,-20,add(22)(p11),+2mar,dmin(20)[9]/46,xy[6] ; 46,xx,del(5)(q14q34)[4]/46;idem,del(12)(p12p13)[2]/46,idem,t(x;17)(p21;q12)[2]/46,xx,t(1;5;10)(q21;q12;q21),del(12)(p12p13)[cp13]/46,xx[3] ; 45,xy,del(5)(q14q34),ins(15;7)(q21;q21q31),t(7;15)(q35;q21),-20,der(21)t(20;21)(?;p11)[10]/45,xy,idem,t(1;10;7;3)(q21;q22;q31;q26)[8]/46,xy[2] ; 39-44,x,-y,der(5)t(5;17)(q12;q12
DNA_INDEX	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	DNA index.	Sample	0.52 ; 0.59 ; 0.75 ; 0.76 ; 0.53 ; 0.74 ; 0.69 ; 0.56 ; 0.529 ; 0.839 ; 0.54 ; 0.752 ; 0.598 in 11%; 84% hyperdiploid peak ; 0.551 in 50% ; 0.516 ; 0.577 ; 0.525 ; 0.544 ; 0.571 in 32%; 66% hyperdiploid peak ; 0.607 in 37%; 58% hyperdiploid peak ; 1.184; no sign of hypodiploid clone ; 0.631 in 54%; 41% hyperdiploid peak ; 0.5752 ; 0.5335 ; 0.7742 ; 0.7745 ; 0.791 in 58%; 37% hyperdiploid peak ; 0.5076 ; 0.69 and a hyperdiploid clone ; 0.62 and a hyperdiploid clone ; 0.55 ; 0.65 ; 0.77
FOCAL_LESIONS_AT_RELAPSE	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	Focal Lesions At Relapse	Sample	IKZF2,TP53,RB1,SMAD2 ; NRAS,CDKN2A/B ; IKZF2,PAG1,VPREB1 ; NF1,PAG1, not sequenced ; ANKRD11,UPD (21p)
KNOWN_MOLECULAR_CLASSIFIER	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	Known Molecular Classifier	Patient	
PROTOCOL	LightSalmon	Hypodiploid Acute Lymphoid Leukemia (St Jude, Nat Genet 2013)	STRING	Protocol.	Patient	
AGE_AT_PROCUREMENT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Age At Procurement Of The Submitted Specimen	Sample	73 ; 74 ; 69 ; 70 ; 59 ; 71 ; 27 ; 31 ; 60 ; 61 ; 77 ; 65 ; 66 ; 67 ; 55 ; 72 ; 53 ; 18 ; 50 ; 81 ; 14 ; 36 ; 24 ; 64 ; 33 ; 57 ; 83 ; 7 ; 58 ; 79 ; 56 ; 41 ; 22 ; 5 ; 62 ; 8 ; 78 ; 42 ; 51 ; 38 ; 37 ; 32 ; 47 ; 30 ; 52 ; 54 ; 63 ; 75 ; 40 ; 35 ; 68 ; 39 ; 86 ; 48 ; 21 ; 20 ; 80 ; 17 ; 46 ; 44 ; 10 ; 85 ; 34 ; 23 ; 45 ; 49 ; 84 ; 26 ; 76 ; 82 ; 25 ; 29 ; 43 ; 16 ; 12 ; 3 ; 87 ; 2
BM_BLAST_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Bone marrow blast percentage.	Sample ; Patient	94 ; 95 ; 80 ; 87 ; 90 ; 91 ; 97 ; 92 ; 93 ; 40 ; 75 ; 83 ; 85 ; 70 ; 72 ; 68 ; 88 ; 36 ; 81 ; 34 ; 65 ; 77.5 ; 46 ; 50 ; 76 ; 71 ; 60 ; 73 ; 55 ; 0.5 ; 30 ; 62 ; 18 ; 7 ; 82 ; 28 ; 41 ; 64 ; 84 ; 21 ; 6 ; 51 ; 17 ; 49.4 ; 32 ; 66 ; 29 ; 25 ; 59.3 ; 20 ; 52 ; 54 ; 37 ; 22 ; 10 ; 12 ; 13 ; 67 ; 39 ; 25.9 ; 45 ; 78 ; 8 ; 3 ; 5 ; 54.8 ; 0.4 ; 74 ; 96 ; 4 ; 86.1 ; 42 ; 56 ; 69 ; 79 ; 1 ; 33 ; 9 ; 51.5 ; 15 ; 24 ; 2 ; 58 ; 35 ; 86 ; 53.74 ; 93.2 ; 0 ; 27 ; 89.6 ; 23 ; 98 ; 19 ; 91.8 ; 57 ; 71.5 ; 78.3 ; 63 ; 1.5 ; 59.5 ; 44 ; 3.5 ; 42.5 ; 26 ; 48 ; 26.3 ; 47 ; 88.5
BRAF_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	BRAF mutation	Sample	G596R ; Negative ; p.G469A, MAF 7%
CAUSE_OF_DEATH_SOURCE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Source of patient death reason	Patient	
CEBPA_BIALLELIC_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	CEBPA Biallelic Mutation	Sample	No ; Yes
CEBPA_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	CEBPA mutation.	Sample	Negative ; No Mutation info: RAF: 10-20% ; 1031?1032 ins AAC; MAF 50% ; p.D107fs*; MAF ~50% ; p.V119?M120insV; MAF 30% ; Double mutation ; Q305?Q312del RNVETQ; MAF: 50% ; p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50% ; c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50% ; Double positive ; Double positive: p.Ser17Profs*99 and p.Lys313dup ; Triple positive ; L81fs*72; MAF 92% ; p.P23fs*81; MAF 41% ; p.N307_V308ins; MAF 50% ; A111FS*56; MAF 48% ; Y181*; MAF 15% ; p.K313_V314insK; MAF 50% ; p.G96fs*12; MAF ~50% ; p.E10K; MAF 26.7% ; c.117delC; MAF 27.2% ; p.A66fs; MAF 37.3% ; p.R142fs*19; MAF 52% ; p.Gln41fs; MAF 4% ; p.K90fs; MAF 39.1% ; Foundation; M1fs*60; MAF 34% ; p.S28fs*81; MAF 28% ; p.K298Q; MAF 25% ; p.E163*; MAF 39% ; p.E163*; MAF 40% ; p.A240fs*83 (7 bp insertion with frameshift); MAF 19% ; p.R343fs*79; MAF 40% ; c.68dup; MAF 21% ; p.T98fs*10 ; MAF 40% ; p.N321D; MAF 20% ; p.R35fs*125; MAF 50% ; p.Ala40fs; MAF 20.3% ; p.Q311*; MAF 15% ; p.I68fs; MAF 50% ; No ; Yes ; Unknown ; NO ; YES
CREATININE_LEVEL_PRERESECTION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Hematology serum creatinine laboratory result value in mg dl	Sample	0.79 ; 1.04 ; 1.68 ; 0.67 ; 0.82 ; 0.86 ; 0.92 ; 0.85 ; 0.69 ; 0.8 ; 0.66 ; 1 ; 1.8 ; 0.9 ; 1.06 ; 1.6 ; 1.63 ; 1.48 ; 0.74 ; 0.83 ; 0.88 ; 1.18 ; 0.93 ; 0.63 ; 0.91 ; 1.03 ; 1.08 ; 0.96 ; 1.54 ; 1.05 ; 0.62 ; 0.84 ; 0.48 ; 0.5 ; 0.81 ; 2.48 ; 1.12 ; 0.41 ; 0.75 ; 0.68 ; 0.64 ; 1.01 ; 0.59 ; 1.13 ; 0.97 ; 0.6 ; 0.35 ; 0.7 ; 0.49 ; 0.61 ; 0.53 ; 0.58 ; 0.94 ; 0.77 ; 0.95 ; 0.56 ; 0.89 ; 1.37 ; 1.85 ; 0.65 ; 0.3 ; 1.44 ; 0.51 ; 0.71 ; 0.87 ; 1.22 ; 1.14 ; 1.66 ; 0.73 ; 0.44 ; 1.3 ; 0.72 ; 1.09 ; 0.78 ; 0.57 ; 1.02 ; 0.46 ; 1.27 ; 1.83 ; 0.52 ; 1.1 ; 1.24 ; 1.65 ; 1.61 ; 1.21 ; 1.07 ; 1.26 ; 0.76 ; 1.72 ; 0.54 ; 1.4 ; 1.17 ; 0.98 ; 1.33 ; 1.45 ; 0.21 ; 0.47 ; 0.24 ; 0.31 ; 0.55 ; 1.49 ; 0.99 ; 1.51 ; 2.67 ; 1.43 ; 1.57 ; 1.25 ; 4.22 ; 1.28 ; 1.2 ; 1.23 ; 1.52 ; 2.11 ; 1.87 ; 1.62 ; 1.19 ; 2.62 ; 1.16 ; 1.41 ; 1.5
CUMULATIVE_TREATMENT_REGIMENS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Chemotherapy treatment regimens for the Disease instance	Sample	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit) ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Cytarabine, Methotrexate ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine ; 7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib ; Decitabine|Quizartinib|Mitoxantrone ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate ; 7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC ; Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine ; 5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; Azacitidine ; 7+3 (Cytarabine, Idarubicin)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Sorafenib|Clofarabine|Clofarabine, Cytarabine ; 3+7 (Cytarabine, Daunorubicin) ; Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone) ; Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Et ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib) ; 7+3 (Cytarabine, Idarubicin)|HiDAC ; Decitabine ; 7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone) ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide ; ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide ; ATRA, Arsenic Trioxide|Idarubicin ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC ; Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1  ; Azacitidine|Decitabine ; 7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab) ; Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine ; 7+3 (Cytarabine, Idarubicin) ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; Azacitidine, Lenalidomide ; HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide ; Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI ; 7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ; Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit) ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG) ; Azacitidine, Lenalidomide|Temozolomide, Vorinostat ; Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG ; 7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; Decitabine, Midostaurin ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|Crenolanib ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040 ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06) ; Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine ; HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine ; HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan,  ; ATRA, Arsenic Trioxide ; Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine ; 7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide ; FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide ; Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin ; Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; 7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib ; 7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC ; FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone) ; S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine ; SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI ; 7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide ; Hydroxyurea ; Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924 ; 7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide ; AG-221 ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine ; Bevacizumab ; E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523 ; Fludarabine, Melphalan|Azacitidine ; Fludarabine, Melphalan|Lenalidomide|Decitabine ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine ; HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine ; 7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI ; Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate ; Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; CPX-351 (Liposomal Cytarabine + Daunorubicin) ; 7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin) ; 3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine ; ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea ; Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine ; 5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine ; SWOG S1203 (7+3 +/- Vorinostat) ; Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ; MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A ; Hydroxyurea|Azacitidine, MLN4924 ; Azacitidine|Sorafenib|Decitabine, Midostaurin ; 7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ; Decitabine|Busulfan, Cyclophosphamide ; Azacitidine|Decitabine|Clofarabine ; AG-221|Azacitidine|Decitabine ; 3+7 (Cytarabine, Daunorubicin)|Azacitidine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY) ; ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin) ; Fludarabine, Melphalan|Idarubicin and Cytarabine ; Azacitidine, MLN4924 ; 3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin) ; HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine ; Fludarabine, Melphalan|Azacitidine, Lenalidomide ; ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine) ; 7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide ; 3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin ; 7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine ; Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine ; HiDAC|SWOG S1203 (7+3 +/- Vorinostat) ; APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide ; 7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, ; 3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide ; Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI ; AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG ; Ruxolitinib|Imatinib|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|Cytarabine ; 3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide ; Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat ; Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; Azacitidine|Decitabine, Midostaurin ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide ; Cyclophosphamide, Fludarabine, TBI|Azacitidine|Venetoclax (ABT-199) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162) ; Decitabine, ABT-199|Hydroxyurea ; HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; AG-221|Decitabine ; AG-221|Hydroxyurea ; Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate ; Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea ; Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC ; FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199) ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine ; Azacitidine|Venetoclax (ABT-199), Azacitidine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide|Transplant ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine ; 7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine) ; FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16 ; AG-221|Azacitidine|Clofarabine ; 7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib ; 7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab ; 7+3 (Cytarabine, Idarubicin) plus Crenolanib ; HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI ; ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide ; AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide ; Vincristine, Dexamethasone ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF) ; Ruxolitinib|Hydroxyurea ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor) ; FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin ; R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone) ; 7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|Fludarabine, Cyclophosphamide, TBI |Venetoclax (ABT-199) ; Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone) ; Azacitidine|Venetoclax (ABT-199) ; AG-120|Decitabine ; Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|MiDAC ; 7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide ; 3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG ; Lenalidomide|Azacitidine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone ; Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib ; HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI ; HiDAC|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation) ; Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin) plus Sorafenib ; HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; Bortezomib|3+7 (Cytarabine, Daunorubicin)|MiDAC|Fludarabine, Cytarabine ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea ; Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide ; 3+7 (Cytarabine, Daunorubicin)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF) ; Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) ; HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG) ; Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin ; Lenalidomide|Decitabine ; Decitabine|Hydroxyurea ; HiDAC|3+7 (Cytarabine, Daunorubicin) ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Busulfan, Cyclophosphamide ; HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea ; FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate ; Azacitidine|Momelotinib ; ADE (Cytarabine, Daunorubicin & Etoposide) ; ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine ; 5+2 (Cytarabine, Idarubicin)|Decitabine ; Vidaza|Rituximab|Decitabine ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib ; SGN-CD33A ; 7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Decitabine|Busulfan, Cyclophosphamide ; Radiation ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide ; AG-221|Azacitidine, SGN-CD33A ; Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib ; Hydroxyurea|Decitabine ; Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|Hydroxyurea ; Azacitidine, Sorafenib|Decitabine, Midostaurin ; 7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation) ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim) ; HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib ; HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib ; 5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine ; 7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG ; HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ; Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin) ; 7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea ; AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine ; ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin) ; Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin ; HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea ; CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea ; Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin ; Ruxolitinib ; Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide ; Vidaza|Decitabine|Fludarabine, Cytarabine ; Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine ; AG-120|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC ; AG-221|Azacitidine|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|IDAC ; Azacitidine|Decitabine|Hydroxyurea|V212 ; 7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim) ; Vidaza ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine ; Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib ; 7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI ; Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib ; 7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI ; Lenalidomide|3+7 (Cytarabine, Daunorubicin) ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Radiation|Busulfan, Cyclophosphamide ; Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU ; Ruxolitinib|Hydroxyurea|Decitabine ; Vidaza|7+3 (Cytarabine, Idarubicin)|Azacitidine ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine ; Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide ; Fludarabine, Melphalan|Azacitidine|Sorafenib ; HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib ; 3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea ; HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone) ; 7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine ; HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin) ; HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide) ; HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; GCLAC (GCSF, Clofarabine & Cytarabine) ; Vidaza|Fludarabine, Melphalan|HiDAC ; FLX925|7+3 (Cytarabine, Idarubicin) ; Cytarabine|Decitabine ; Azacitidine|Fludarabine, Melphalan, ATG ; 7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ; Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|Azacitidine, Midostaurin|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924 ; SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide ; Vidaza|Decitabine ; Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib ; 7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone ; Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib ; Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea ; Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine ; Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine ; S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|CLAG (Cladribine, Cytarabine, Filgrastim) ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC ; Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC ; 7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide ; 7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea ; MiDAC|FLAG-IDA plus Midostaurin|7+3 (Cytarabine, Idarubicin) plus Dasatinib ; 7+3 (Cytarabine, Idarubicin)|Decitabine ; Cytarabine|Idarubicin and Cytarabine ; 7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine ; ATRA, Idarubicin ; HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide ; Cytarabine ; Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib ; Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate ; 7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab ; Vidaza, BI836858 (anti-CD33) ; GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI ; Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) ; AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor) ; Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC ; ATRA, Arsenic Trioxide, Idarubicin ; Dasatinib ; 7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI ; Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin) ; Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib ; Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine ; 7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate ; ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Azacitidine|Azacitidine, Lenalidomide|Decitabine|Hydroxyurea|Etoposide, Mitoxantrone ; 7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine ; 7+3 (Cytarabine, Idarubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine ; Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin ; Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone,
CUMULATIVE_TREATMENT_REGIMEN_COUNT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Unique number of chemotherapy treatment regiments for the Disease instance	Sample	3 ; 4 ; 5 ; 6 ; 0 ; 1 ; 2 ; 8 ; 13 ; 9 ; 7
CUMULATIVE_TREATMENT_STAGES	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Number of unique treatment stages for the disease instance	Sample	Consolidation | Induction | Experimental ; Consolidation | Induction | Experimental | Re-induction ; Consolidation | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Induction ; Allogeneic - Sibling | Induction | Experimental ; Salvage | Consolidation | Induction | Experimental | Supportive/Palliative Care ; Induction | Experimental | Supportive/Palliative Care ; Consolidation | Induction | Experimental | CNS | Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling | Consolidation | Induction | Re-induction ; Consolidation | Induction | Allogeneic - Matched Unrelated Donor ; Salvage | Induction | Experimental | Re-induction ; Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care ; Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling | Consolidation | Induction ; Supportive/Palliative Care ; Consolidation | Salvage | Induction | Experimental | Re-induction ; Induction ; Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Intensification | Re-induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Salvage | Induction | Re-induction ; Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Salvage | Unknown | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor ; Consolidation | Salvage | Induction | Re-induction | Maintenance ; Hypomethylating/Low Dose Cytarabine | Induction ; Induction | Re-induction ; Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor ; Induction | Maintenance ; Allogeneic - Sibling | Consolidation | Unknown | Induction ; Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Unknown | Induction | Re-induction ; Induction | Symptom Control ; Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Induction | Re-induction ; Induction | Intensification ; Salvage | Induction | Re-induction ; Salvage ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Experimental | Re-induction ; Allogeneic - Sibling | Consolidation | Salvage | Induction | Re-induction ; Allogeneic - Sibling | Consolidation | Salvage | Unknown | Induction | Re-induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Consolidation | Salvage | Induction | Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor ; Consolidation | Salvage | Induction | Experimental | Allogeneic - Matched Unrelated Donor ; Consolidation | Induction | Re-induction | Maintenance ; Induction | Experimental ; Consolidation | Salvage | Induction | Experimental ; Hypomethylating/Low Dose Cytarabine ; Consolidation | Salvage | Induction ; Hypomethylating/Low Dose Cytarabine | Salvage | Unknown | Induction | Experimental | Re-induction ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Induction ; Induction | Experimental | Re-induction | Supportive/Palliative Care ; Consolidation | Salvage | Induction | Re-induction | Post-Transplant Relapse | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Induction | Experimental | Maintenance ; Allogeneic - Sibling | Induction | Re-induction ; Hypomethylating/Low Dose Cytarabine | Salvage | Induction ; Allogeneic - Sibling | Salvage | Induction | Re-induction | Symptom Control ; Allogeneic - Sibling | Induction ; Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance | Re-induction ; Salvage | Induction | Experimental ; Hypomethylating/Low Dose Cytarabine | Induction | Re-induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction ; Salvage | Experimental ; Salvage | Induction | Re-induction | Symptom Control ; Salvage | Unknown | Induction | Maintenance ; Allogeneic - Sibling | Consolidation | Salvage | Induction ; Consolidation | Induction | Supportive/Palliative Care ; Unknown ; Induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Induction | Allogeneic - Mismatched Unrelated Donor ; Allogeneic - Sibling | Consolidation | Induction | Maintenance | Re-induction ; Induction | Intensification | Re-induction ; Allogeneic - Sibling | Salvage | Re-induction | Supportive/Palliative Care ; Consolidation | Induction | Maintenance ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Unknown | Induction ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Post-Transplant Relapse ; Allogeneic - Sibling | Induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Induction | Re-induction | Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental ; Consolidation | Salvage | Induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine | Salvage | Consolidation | Induction ; Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor ; Induction | Supportive/Palliative Care ; Induction | Experimental | Re-induction ; Hypomethylating/Low Dose Cytarabine | Experimental ; Salvage | Induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Re-induction ; Induction | Allogeneic - Mismatched Unrelated Donor ; Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor ; Consolidation | Induction | CNS | Re-induction | Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Maintenance ; Unknown | Induction ; Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental ; Salvage | Consolidation | Induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Experimental | Allogeneic - Child ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction ; Induction | CNS | Re-induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Experimental | Double Umbilical Cord Blood Transplant (DUCBT) ; Unknown | Supportive/Palliative Care ; Experimental | Supportive/Palliative Care ; Experimental ; Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | CNS | Re-induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction | Re-induction ; Salvage | Experimental | Supportive/Palliative Care ; Consolidation | Salvage | Experimental ; Hypomethylating/Low Dose Cytarabine | Induction | Supportive/Palliative Care ; Induction | Re-induction | Supportive/Palliative Care ; Consolidation | Induction | CNS | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Unknown | Experimental ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental ; Consolidation | Induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Induction | Experimental | Maintenance ; Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction ; Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Experimental | Re-induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Allogeneic - Matched Unrelated Donor ; Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction | Maintenance ; Consolidation | Experimental ; Hypomethylating/Low Dose Cytarabine | Experimental | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction ; Hypomethylating/Low Dose Cytarabine | Maintenance ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Child ; Hypomethylating/Low Dose Cytarabine | Induction | Re-induction | Supportive/Palliative Care ; Induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Hypomethylating/Low Dose Cytarabine | Induction | Experimental ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction ; Hypomethylating/Low Dose Cytarabine | Consolidation | Salvage | Induction ; Allogeneic - Sibling | Consolidation | Induction | Experimental ; Allogeneic - Sibling | Consolidation | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Salvage | Induction | Experimental | Intensification | Re-induction ; Induction | Experimental | Re-induction | Maintenance ; Consolidation | Induction | CNS ; Induction | CNS ; Consolidation | Maintenance ; Consolidation | Unknown | Induction | Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction ; Hypomethylating/Low Dose Cytarabine | Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling | Induction | Experimental | Re-induction | Post-Transplant Relapse ; Allogeneic - Sibling | Consolidation | Unknown | Induction | Experimental | Post-Transplant Relapse | Supportive/Palliative Care ; Consolidation | Induction | Allogeneic - Child | Maintenance ; Consolidation | Induction | Re-induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Experimental | Maintenance | Supportive/Palliative Care ; Consolidation | Induction | Experimental | Maintenance ; Salvage | Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine | Consolidation | Experimental ; Consolidation | Salvage | Induction | Double Umbilical Cord Blood Transplant (DUCBT) ; Consolidation | Induction | Allogeneic - Mismatched Unrelated Donor | Supportive/Palliative Care ; Symptom Control | Supportive/Palliative Care ; Induction | Frontline | Re-induction ; Salvage | Induction | Symptom Control ; Induction | Allogeneic - Mismatched Unrelated Donor | Re-induction ; Induction | Allogeneic - Mismatched Unrelated Donor | Experimental | Re-induction ; Allogeneic - Sibling | Hypomethylating/Low Dose Cytarabine | Consolidation | Induction | Re-induction | Supportive/Palliative Care ; Allogeneic - Sibling | Salvage | Induction | Re-induction | Supportive/Palliative Care ; Induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor ; Re-induction ; Unknown | Allogeneic - Matched Unrelated Donor ; Unknown | Induction | Re-induction ; Hypomethylating/Low Dose Cytarabine | Experimental | Supportive/Palliative Care ; Consolidation | Unknown | Induction ; Induction | Re-induction | Maintenance | Supportive/Palliative Care ; Salvage | Induction | Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling | Consolidation | Induction | Experimental | CNS | Re-induction ; Salvage | Induction | Experimental | Re-induction | Maintenance ; Consolidation | Induction | Allogeneic - Child ; Unknown | Induction | Re-induction | Allogeneic - Matched Unrelated Donor ; Induction | Double Umbilical Cord Blood Transplant (DUCBT) | Maintenance ; Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Re-induction ; Consolidation|Induction|Supportive/Palliative Care ; Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor ; Induction|Experimental|Supportive/Palliative Care ; Consolidation|Induction|Experimental ; Consolidation|Induction|Experimental|Re-induction ; Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care ; Allogeneic - Sibling|Induction|Experimental ; Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Unknown|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Salvage|Induction|Re-induction|Supportive/Palliative Care ; Allogeneic - Sibling|Consolidation|Induction|Re-induction ; Salvage|Experimental|Maintenance|Re-induction ; Consolidation|Induction|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care ; Consolidation|Salvage|Induction|Re-induction|Maintenance ; Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling|Consolidation|Induction ; Consolidation|Induction ; Unknown|Induction|Re-induction ; Hypomethylating/Low Dose Cytarabine|Salvage|Induction ; Induction|Maintenance|Symptom Control ; Consolidation|Salvage|Unknown|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Induction|Maintenance ; Maintenance ; Induction|Experimental|Re-induction|Maintenance ; Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Induction ; Induction|Re-induction ; Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction ; Consolidation|Induction|Re-induction ; Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction ; Induction|Re-induction|Allogeneic - Matched Unrelated Donor ; Induction|Intensification ; Hypomethylating/Low Dose Cytarabine|Maintenance ; Salvage|Induction|Experimental|Re-induction ; Salvage|Induction|Re-induction ; Maintenance|Supportive/Palliative Care ; Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction ; Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction ; Consolidation|Salvage|Induction|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Re-induction|Maintenance ; Induction|Experimental ; Consolidation|Salvage|Induction ; Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction ; Induction|Experimental|Re-induction|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance ; Allogeneic - Sibling|Induction|Re-induction ; Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control ; Allogeneic - Sibling|Induction ; Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction ; Salvage|Induction|Experimental ; Hypomethylating/Low Dose Cytarabine|Induction|Re-induction ; Salvage|Experimental ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction ; Salvage|Induction|Re-induction|Symptom Control ; Salvage|Unknown|Induction|Maintenance ; Allogeneic - Sibling|Consolidation|Salvage|Induction ; Maintenance|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Induction|Allogeneic - Mismatched Unrelated Donor ; Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction ; Induction|Intensification|Re-induction ; Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care ; Consolidation|Induction|Maintenance ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Unknown|Induction ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse ; Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Re-induction|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental ; Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Induction ; Consolidation|Salvage|Induction|Experimental ; Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor ; Induction|Supportive/Palliative Care ; Induction|Experimental|Re-induction ; Induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Experimental ; Salvage|Induction ; Re-induction|Allogeneic - Matched Unrelated Donor ; Induction|Allogeneic - Mismatched Unrelated Donor ; Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction ; Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance ; Unknown|Induction ; Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental ; Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction ; Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child ; Consolidation|Induction|Maintenance|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction ; Induction|CNS|Re-induction ; Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental ; Induction|Maintenance|Re-induction ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Experimental|Double Umbilical Cord Blood Transplant (DUCBT) ; Unknown|Supportive/Palliative Care ; Experimental|Supportive/Palliative Care ; Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Salvage|Experimental|Supportive/Palliative Care ; Consolidation|Salvage|Experimental ; Hypomethylating/Low Dose Cytarabine|Unknown|Experimental ; Induction|Re-induction|Supportive/Palliative Care ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental ; Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Induction|Experimental|Maintenance ; Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction ; Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor ; Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction ; Consolidation|Experimental ; Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child ; Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care ; Induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction ; Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance ; Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction ; Allogeneic - Sibling|Consolidation|Induction|Maintenance ; Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction ; Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction ; Allogeneic - Sibling|Salvage|Induction|Re-induction ; Consolidation|Induction|Allogeneic - Child|CNS|Re-induction ; Induction|CNS ; Consolidation|Maintenance ; Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT) ; Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care ; Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse ; Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Maintenance|Supportive/Palliative Care ; Consolidation|Salvage|Induction|Re-induction|Maintenance|Supportive/Palliative Care ; Consolidation|Induction|Allogeneic - Child|Maintenance ; Consolidation|Salvage|Unknown|Induction|Maintenance|Re-induction|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Experimental|Re-induction ; Consolidation|Induction|Experimental|Maintenance ; Induction|Experimental|Maintenance|Supportive/Palliative Care ; Salvage|Supportive/Palliative Care ; Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental ; Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT) ; Salvage|Induction|Experimental|Maintenance ; Salvage|Induction|Experimental|Frontline|Re-induction ; Symptom Control|Supportive/Palliative Care ; Induction|Frontline|Maintenance ; Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance ; Salvage|Induction|Symptom Control ; Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction ; Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care ; Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care ; Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Unknown|Allogeneic - Matched Unrelated Donor ; Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care ; Allogeneic - Sibling|Induction|Maintenance ; Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance ; Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care ; Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Maintenance ; Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor ; Induction|Re-induction|Maintenance|Supportive/Palliative Care ; Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction ; Salvage|Induction|Experimental|Re-induction|Maintenance ; Consolidation|Induction|Allogeneic - Child ; Salvage|Induction|Maintenance ; Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance ; Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor ; Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction ; Salvage|Induction|Supportive/Palliative Care ; Induction|Frontline|Re-induction|Allogeneic - Matched Unrelated Donor ; Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance ; Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care ; Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Salvage|Maintenance|Supportive/Palliative Care ; Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction ; Allogeneic - Sibling|Induction|Re-induction|Maintenance ; Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Salvage|Consolidation|Induction ; Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor ; Induction|Experimental|Re-Induction ; Haploidentical - Parent|Consolidation|Induction|Re-induction ; Salvage|Induction|Maintenance|Re-induction ; Induction|Intensification|Allogeneic - Matched Unrelated Donor ; Consolidation|Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor ; Consolidation|Induction|Maintenance|Allogeneic - Matched Unrelated Donor ; Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor
CUMULATIVE_TREATMENT_STAGE_COUNT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Number of Treatment Stages for the Disease instance	Sample	3 ; 4 ; 5 ; 2 ; 0 ; 1 ; 8 ; 7 ; 6
CUMULATIVE_TREATMENT_TYPES	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	The unique treatment types for the Disease instance	Sample ; Patient	Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Intrathecal ; Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Bone Marrow Transplant | Intrathecal | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Bone Marrow Transplant ; Supportive/Palliative Care ; Standard Chemotherapy ; DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s) | Intrathecal ; DLI | Standard Chemotherapy | Bone Marrow Transplant ; DLI | Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care ; Standard Chemotherapy | Supportive/Palliative Care ; Standard Chemotherapy | Bone Marrow Transplant | Intrathecal ; Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Bone Marrow Transplant | Supportive/Palliative Care ; Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other ; Standard Chemotherapy | Targeted Therapy - Other ; Unknown ; Standard Chemotherapy | Unknown | Bone Marrow Transplant ; Other ; Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Other ; Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other ; Standard Chemotherapy | Supportive/Palliative Care | Intrathecal ; Standard Chemotherapy | Unknown ; Standard Chemotherapy | Other ; Supportive/Palliative Care | Targeted Therapy - Other ; Targeted Therapy - Other ; Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s) | Targeted Therapy - Other ; Standard Chemotherapy | Targeted Therapy - Other | Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy | Targeted Therapy - Other | Intrathecal ; DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Other ; Standard Chemotherapy | Intrathecal | Other ; Standard Chemotherapy | Bone Marrow Transplant | Other ; DLI | Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s) ; Targeted Therapy - Kinase Inhibitor(s) ; Supportive/Palliative Care | Other
CUMULATIVE_TREATMENT_TYPE_COUNT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	The unique number of treatment types for the Disease instance	Sample ; Patient	2 ; 3 ; 4 ; 0 ; 1 ; 5
CURRENT_REGIMEN	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	The most current treatment	Sample	AC220 (Ambit) ; Hydroxyurea ; FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin) ; MiDAC ; Sorafenib ; Busulfan, Cyclophosphamide ; Quizartinib ; Etoposide, Mitoxantrone ; Mitoxantrone ; Fludarabine, Melphalan ; Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation) ; NONE ; Azacitidine ; Cytarabine ; 3+7 (Cytarabine, Daunorubicin) ; Donor Lymphocyte Infusion ; MEC (Cytarabine, Etoposide, Mitoxantrone) ; Decitabine ; COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib) ; HiDAC ; Busulfan, Fludarabine ; Cladribine ; Idarubicin ; Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation) ; COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab) ; Crenolanib ; 7+3 (Cytarabine, Idarubicin) ; GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) ; Azacitidine, Lenalidomide ; Dasatinib ; Azacitidine, Gemtuzumab ; Stanford Protocol 9153 (TLI, ATG) ; Temozolomide, Vorinostat ; Fludarabine, Melphalan, ATG ; Decitabine, Midostaurin ; Decitabine, Sirolimus ; ATRA, Arsenic Trioxide ; Fludarabine, BCNU, Melphalan ; GCLAC (GCSF, Clofarabine & Cytarabine) ; S0919 Trial (Pravastatin, Idarubicin, Cytarabine) ; Fludarabine, Cyclophosphamide, TBI ; Fludarabine, TBI ; AG-221 ; Bevacizumab ; Clofarabine, Cyclophosphamide, Etoposide ; Cyclophosphamide, Fludarabine, TBI ; Etoposide, TBI ; CPX-351 (Liposomal Cytarabine + Daunorubicin) ; CLAG (Cladribine, Cytarabine, Filgrastim) ; Decitabine, Hydroxyurea ; 5+2 (Cytarabine, Idarubicin) ; Fludarabine ; SWOG S1203 (7+3 +/- Vorinostat) ; Trametinib ; SGN-CD33A ; Azacitidine, MLN4924 ; Stanford Protocol 9022 (BU/CY) ; FLAG (Fludarabine, High-dose Cytarabine, G-CSF) ; Cyclophosphamide, TBI ; HAM (Cytarabine, Mitoxantrone) ; Ponatinib ; CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim) ; Bu/Cy/TBI ; Busulfan, Cyclophosphamide, Thymoglobulin ; Bu/Cy/ATG ; APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin) ; MEC, Lenalidomide ; R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine) ; Azacitidine, Sorafenib ; Fludarabine, Melphalan, TBI ; Fludarabine, Melphalan, TBI, ATG ; Ruxolitinib ; Binimetinib (MEK162) ; Decitabine, ABT-199 ; Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG) ; Venetoclax (ABT-199), Azacitidine ; Clofarabine, Cytarabine ; Transplant ; TBI, VP-16 ; Rituximab ; 7+3 (Cytarabine, Idarubicin) plus Crenolanib ; Fludarabine, Cyclophosphamide, Thiotepa, TBI ; ATRA, 6-MP, Methotrexate ; Vincristine, Dexamethasone ; Incyte trial (azacitidine and JAK 1 inhibitor) ; Etoposide ; R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone) ; Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501) ; Venetoclax (ABT-199) ; AG-120 ; Fludarabine, Melphalan, ATG, Methotrexate ; 7+3 (Cytarabine, Idarubicin) plus Sorafenib ; Fludarabine, Cytarabine ; Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG) ; ADE (Cytarabine, Daunorubicin & Etoposide) ; Radiation ; Cyclophosphamide ; Methotrexate, Mercaptopurine, Tretinoin ; IDAC ; Vidaza ; Paclitaxel ; anti-CD33 ; RVD (Bortezomib, Dexamethasone, Lenalidomide) ; FLX925 ; ALRN-6924 ; Sunitinib ; FLAG-IDA plus Midostaurin ; Etoposide, Cytarabine ; ATRA, Idarubicin ; Lenalidomide ; Fludarabine, Cyclophosphamide, TBI, Rituximab ; Vidaza, BI836858 (anti-CD33) ; ATRA, Arsenic Trioxide, Idarubicin ; Midostaurin ; Cyclophoshamide, TBI, ATG ; Azacitidine, Itacitinib ; Cytarabine, Mitoxantrone ; Unknown ; Ibrutinib ; Cytarabine, OXi4503 ; Decitabine, Ruxolitinib ; IMGN779 (Immunogen Trial) ; Idarubicin and Cytarabine ; Enasidenib ; Decitabine, Venetoclax ; HIDAC + Sorafenib ; Velcade ; Decitabine, MGB453 ; Azacitidine, Trametinib ; 3+4 (Cytarabine, Idarubicin) ; SY-1425 (Tamibarotene) plus Daratumumab ; Entospletinib ; Azacitidine, BI 836858 (anti-CD33) ; Decitabine, Sorafenib ; Gemtuzumab ; Entospletinib, Azacitidine ; 7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin ; BP1001 plus LDAC ; Vyxeos (Daunorubicin, Cytarabine - liposomal) ; Methotrexate ; Cytarabine, Midostaurin ; 7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin ; Gilteritinib or Placebo ; MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin ; Ruxolitinib, Venetoclax ; Ivosidenib ; PIM kinase inhibitor ; Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal) ; Gilteritinib (ASP2215) ; 7+3 (Cytarabine, Idarubicin) plus Midostaurin
CURRENT_STAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Stage of the most current treatment	Sample	Experimental ; Re-induction ; Consolidation ; Allogeneic - Sibling ; Supportive/Palliative Care ; Allogeneic - Matched Unrelated Donor ; Salvage ; NONE ; Induction ; Unknown ; Hypomethylating/Low Dose Cytarabine ; Maintenance ; Symptom Control ; Intensification ; Allogeneic - Mismatched Unrelated Donor ; Post-Transplant Relapse ; Allogeneic - Child ; Double Umbilical Cord Blood Transplant (DUCBT) ; CNS ; Haploidentical - Parent
CYTOGENETICS_OTHER	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	FISH results pulled from cytogenetics report in EMR	Sample	Normal ; Signal copy for CEP 8 and ETO ; trisomy 8 ; trisomy 13 ; Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal ; 6q deletion ; While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene ; CBFB rearrangement ; DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype. ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], ; t(6;9)(p22;q34) ; Trisomy 21 ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; AML/ETO fusion, t(8;21) ; Deleted 5q ; inv(16) ; Unusual t(15;17), with the fusion signal on the derivative chromosome 15 ; RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis. ; 16q deletion ; 12p deletion ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199] ; t(8;21) ; RUNX1T1/RUNX1 fusion ; Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone. ; RUNX1T1/ RUNX1 fusion and t(8;21), ; nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Monosomy 7 ; CBFB rearrangement and inv(16) ; nuc ish(DXZ1x2)[200] ; Positive ; Disruption of MLL signal and t(9;11) ; MLL disruption and t(9;11) ; nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200] ; Extra MLL signal ; nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200] ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20 ; Monosomy 21 ; Trisomy 22 ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; MLL rearrangement and t(9;11) ; 18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; PML-RARA+ 0.70743 ; normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22 ; Loss of ERG1 signal ; Monosomy 5 ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200] ; 8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present ; Trisomy 8 ; Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker. ; nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Missing ABL and ASS signal ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 20q deletion ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 5q deletion ; 20/200 cells (10%) were missing a signal for D20S108 (20q12) ; 48% PML/RARA translocation ; CBFB rearrangement and inverted 16 ; Extra chromosome 5 ; Previous FISH results were consistent with the deleted 5q and trisomy 9 ; MLL rearrangement ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200] ; Missing MLL signal ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200] ; nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; Missing D7S486 signal ; nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[ ; Low-level tetraploidy or near-tetraploidy ; deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored. ; 3q21.3q26.2 (RPN1/MECOM): rearrangement present ; nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200] ; 8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present ; 43% del 5q31, 56% del 7q31, 58% del20q ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 21q deletion ; Trisomy 9 ; Tetrasomy 8 ; c/w karyotype ; nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198] ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; PML/RARA fusion ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197] ; IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted ; EGR1/5p; 88% of cells were missing a signal for both probes, consistent with monosomy 5 ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Consistent with karyotype ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200] ; RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis. ; Nineteen of twenty metaphase cells examined had an extra derivative chromosome composed of a chromosome 1 long arm and a chromosome 9 short arm; two of these cells were in the tetraploid state with two copies of the derivative chromosome. ; all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype ; consistent with karyotype (68% del 17p13) ; TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha ; DEK-NUP214 fusion; MAF unavailable ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(D8Z2x3,D20S108x2)[27/200] ; 58% PML-RARA  (c/w karyotype) ; MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11). ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200] ; RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis ; FISH normal ; CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ; nuc ish(PML,RARA)x3(PML con RARAx2)[173/200] ; 1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above ( ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Positive for an EVI1 rearrangement ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200] ; nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199] ; Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7 ; nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200] ; nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; Positive for deletion of 20q12 in 11.5% of 200 cells ; deleted 5q and three short arm signals;  monosomy 7 and the metaphase karyotype;  no evidence for MLL deletion or rearrangement ; Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously. ; FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells. ; FISH c/w PML/RARA fusion ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells) ; loss of 7q31 sequences in 85% of assayed cells ; MLL:   14% of cells had a 1 red / 1 green / 1 fused split pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had two red / 1 green / 1 fused signal pattern, consistent with the clone with the +der(9). ; Loss of chromosome 5q31 sequences (73.5%)                Loss of chromosome 7 sequences (monosomy 7) (61.5%)                Gain of 21q22 (AML1) sequences (11.5%)                Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences ; FISH positive for CBFB rearrangement in 49% of cells ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11). ; (D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200], ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0% ; 5% trisomy 8 (c/w karyotype) ; Eighteen of twenty-one cells examined were trisomy 8, previously observed.Two of these cells also had an extra 1q attached to a chromosome 21 short arm, and two other cells had an extra 1q attached to a chromosome 22 short arm. These are new clonal change ; Seventeen of twenty cells examined were trisomy 8, previously observed.Two of the trisomy 8 cells had additional non-clonal abnormalities and two cells had an extra 1q attached to a chromosome 22 short arm, also previously observed. ; 37% trisomy 21, 38.5% XX, 61.5% XY (donor) ; positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells. ; 90.5% monosomy 17, 6% trisomy 11q23 ; nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200] ; 70% PML/RARA ; Gain of 8q22 and 21q22 (88%) ; MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm ; 44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8, ; 95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17) ; 9.5% gain 21q22 ; nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200] ; 71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype. ; MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia ; nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200] ; ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present ; - 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored. ; nuc ish(D5S2064,D5S630,EGR1)x3~4[193/200],(D7Z1,D7S522)x3~4[194/200],(D8Z2, D20S108)x3~4[195/200],(RUNX1T1,RUNX1)x3~4[191/200],(ABL1,BCR)x3~4[191/200],(5'MLL,3'MLL)x3~4(5'MLL con 3'MLLx3~4)[193/200],(PML,RARA)x3~4[191/200],(5'CBFB,3'CBFB)x3~4(5CBFB con 3C ; 65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%) ; EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second c ; 35% gain of 11q23 ; 11q23 (MLL): rearrangement present ; ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ; nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; - Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells ; FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells. ; EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUN ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH re ; CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype. ; 21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion. ; RUNX1T1/RUNX1: (92%) ; 62% t(8;21) (RUNX1T1;RUNX1) translocation present ; FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells. ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; EGR1 (73.5%) ;  TP53: (85.5%) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21). ; CBFB ; positive for rearrangement of CBFB in 60.5% of cells. ; RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis. ; 1% RUNX1T1 ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells e ; 85% MLL rearrangement (c/w karyotype) ; showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22). ; This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev ; 20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA ; FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in t ; Positive for 5q deletion in 91% of cells. ; CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype. ; trisomy 8 in 5 of 20 metaphase cells ; CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Not Available (no FISH done) ; CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype. ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] ; Negative ; EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal in ; nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200] ; Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338); ; RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba ; COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML ; nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells. ; D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q) ; Monosomy 7 is detected in 87% of cells. ; This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS. ; This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited ; t(8;22) clone observed, consistent with a neoplastic process ; nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198] ; Trisomy 8 is detected in 28% of cells. ; The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells. ; The translocations normally seen in AML are not detected. ; (FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ; - 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored. ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200] ; This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies. ; Not Available. Pathogenic alterations are DETECTED in the ASXL1, IDH1, JAK2 and RUNX1 genes. Genomic alterations of uncertain significance are DETECTED in the CEBPA and TET2 genes (not seeing specific mutations or MAF) ; 5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present ; RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). ; deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin ; PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype. ; RUNX1T1 signal consistent with the trisomy 8 clone ; EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, ; 94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8. ; RUNX1/RUNX1T1 fusion positive in 6.5% of cells ; RUNX1/RUNX1T1 fusion negative ; MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal ; This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored. ; D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the me ; Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel. ; CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone. ; Abnormal ; 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype. ; 9q deletion is present in all metaphase cells analyzed. All cells have also show either missing one X chromosome or an isochromosome for its long arm. It is most likely that the X chromosome abnormalities represent constitutional changes associated with T ; MLL Rearrangment ; The abnormalities normally seen in MDS are not detected. ; Translocation between the long arm of chromosome 3 and short arm of chromosome 12. ; 5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], ; nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200] ; evidence of monosomy 7 in 191/200 (95.5 percent) cells scored ; 5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 ch ; nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200] ; 11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200] ; Probe: 8 centromere/20q12 ; nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; CBFB, D7S486/ CEP 7 ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish (PML,RARA)x2[199] ; nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBF ; Positive for CBFB rearrangment for 91% of cells ; Loss of 5q31 sequences for 99% of total cells ; 7cen (D7Z1), 7q31 (D7S486): monosomy present ; 42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells. ; 86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. ; CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype. ; nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]
DIAGNOSIS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Diagnosis.	Patient	
DIAGNOSIS_AT_INCLUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Diagnosis at the time of earliest Specimen Inclusion	Patient	
DNMT3A_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	DNMT3A Mutation	Sample	Negative ; p.Q696fs*9; MAF 40% ; p.R882H; MAF 50% ; p.N879D; MAF 50% ; p. R882C; MAF 50% ; p.R882C; MAF 50% ; Foundation, R882H; MAF 9% ; R882H; MAF unlisted ; Positive ; p.R882C; MAF 47% ; p.T138I; MAF 50% ; p.R882H; MAF 30% ; p.R882C; MAF 46% ; p.R882C; MAF 39% ; p.R309G; MAF 31% ; p.R882C; MAF 45% ; F609fs*3; MAF 42% ; p.R882H; MAF 37% ; R882C; MAF 50% ; p.P777L; MAF 50% ; R882C; MAF 43% ; p.R882H; MAF 44% ; F827fs*4; MAF 35% ; W297*; MAF 44% ; p.Arg882Cys; MAF 47.1% ; p.F543C; MAF 35.7% ; F290fs*24; MAF 40% ; p.R882H; MAF 15% ; p.V468M; MAF 51.2% ; p.S307fs; MAF 45.6% ; c.2645G>A; MAF 41.8% ; p.R882H; MAF ~50% ; p.S714C; MAF 35% ; c.2251T>C; MAF 36.9% (33.1% on 3/13/15) ; p.R882C; MAF 0.9% ; p.R882C, MAF 6% ; p.R882H; MAF 45% ; p.R736H; MAF 45% ; p.R882C; MAF 44% ; c.2645G>A; MAF 45.4% ; p.R882H; MAF 48% ; p.R882H; MAF 39% ; p.R882H; MAF 34% ; p.Val716Asp; MAF 45% ; p.r882H; MAF 45% ; p.I824V; VAF 50% ; p.E285D; MAF 40% ; p.R882H; MAF 46% ; p.G707fs*72; MAF 45% ; c.2645G>A; MAF 43.9% ; c.2645G>A; p.R882H ; p.R326P; MAF 50% ; c.2644C>T; p.R882C ; p.R882C; MAF 40% ; p.R882C; MAF 20% ; p.R882H; MAF 41% ; p.P777S; MAF 90% ; p.Trp297* (NM_175629.2); MAF 82.1% ; p.E283*; MAF 30% ; p.Arg882His ; Foundation; R882H; MAFs: 44% ; p.R882C, MAF 51% ; p.Ala571Pro; MAF 51.5% ; p.G570E; MAF 44% ; p.R882H; MAF 42% ; p.Arg882His; MAF 39.1% ; p.R882C; MAF 14% ; p.Arg326Cys; MAF 44.5% ; p.R882H; MAF 35% (previously 32% on 10/10/16) ; p.Gln231fs; MAF 33.2% ; p.R882H; MAF 49% ; p.Thr835Met; MAF 47% ; VAF: 42.8% ; c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36         c.2656C>T; pQ886*    MAF 43%, 36% ; p.Arg882His; MAF 41.8% ; c.2644C>T; p.R882C     MAF 47%
DRUG_TESTING_IN_ANALYSIS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Is Drug Testing data of the sample used in analysis?	Sample	No ; Yes
DURATION_OF_INDUCTION_TREATMENT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Duration of Induction Treatment (Days)	Sample	5 ; 4 ; 7 ; 6 ; 2 ; 1025 ; 153 ; 23 ; 27 ; 9 ; -1 ; 253 ; 11 ; 133 ; 21 ; 8 ; 15 ; 24 ; 39 ; 249 ; 60 ; 177 ; 61 ; 74 ; 10 ; 38 ; 3 ; 63 ; 317 ; 116 ; 26 ; 365 ; 111 ; 117 ; 75 ; 79 ; 371 ; 4626 ; 33 ; 186 ; 206 ; 12 ; 40 ; 28 ; 29 ; 167 ; 22 ; 35 ; 136 ; 212 ; 232 ; 19 ; 20 ; 189 ; 151 ; 37 ; 1 ; 16 ; 165 ; 32 ; 498 ; 41 ; 45 ; 13 ; 0 ; 30 ; 70 ; 18 ; 1932 ; 25
ELN_2008	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Risk classification assigned to the Specimen based on European Leukemia Network 2008 guidelines	Sample	Intermediate-I ; Intermediate-II ; Not Enough Information ; Favorable ; Adverse
ELN_2017	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Risk classification assigned to the Specimen based on European Leukemia Network 2017 guidelines	Sample	Favorable or Intermediate ; Intermediate ; Adverse ; Intermediate or Adverse ; Unknown ; Favorable
EXOME_SEQ_ANALYSIS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Is Exome Seq data of the sample used in Analysis?	Sample	Yes ; No
EX_VIVO_DRUG_TESTING	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Is Ex Vivo Drug Testing performed on sample?	Sample	Yes ; No
FAB	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	FAB.	Sample ; Patient	M1 ; M4 ; NOS ; M0 ; M5 ; M2 ; M3 ; M7 ; M4eo ; M5a ; M5b
FLT3_ITD_CONSENSUS_CALL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Consensus call for FLT3 -ITD	Sample	Positive ; Negative
FLT3_NEGATIVE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Negative for FLT3	Sample	Negative
FUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Fusion	Sample	Unknown ; CBFB-MYH11 ; DEK-NUP214 ; RUNX1-RUNX1T1 ; PML-RARA ; MLLT3-KMT2A ; GATA2-MECOM ; Complex
GROUP	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Group	Sample	Initial Acute Leukemia Diagnosis ; Relapse|Post-Chemotherapy ; Residual Disease|Post-Chemotherapy ; Post-Transplant|Post-Chemotherapy|Relapse ; Post-Transplant|Residual Disease ; Residual Disease|Post-Transplant ; Residual Disease ; Post-Chemotherapy|Residual Disease ; Relapse ; Unknown ; Post-Chemotherapy|Relapse ; Relapse|Post-Transplant|Post-Chemotherapy ; Post-Chemotherapy|Residual Relapse ; Residual Disease|Post-Transplant|Post-DLI ; Post-Transplant|Post-Chemotherapy|Residual Disease ; Post-Chemotherapy ; Residual Disease|Post-Transplant|Post-Chemotherapy ; Relapse|Post-Chemotherapy|Post-Transplant ; Post-Chemotherapy|Post-Transplant|Residual Disease ; Residual Relapse|Post-Chemotherapy|Post-Transplant ; Post-Chemotherapy|Post-Transplant|Residual Relapse ; Post-Chemotherapy|Initial Acute Leukemia Diagnosis ; Post-Chemotherapy|Post-Transplant|Relapse ; Post-Chemotherapy|Post-Transplant ; Post-Transplant|Relapse ; Initial Acute Leukemia Diagnosis|Post-Transplant ; Initial Acute Leukemia Diagnosis|Post-Chemotherapy ; Post-Chemotherapy|Residual Disease|Post-Transplant ; Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis ; Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease ; Residual Disease|Post-Chemotherapy|Post-Transplant ; Residual Relapse|Post-Chemotherapy|Post-DLI|Post-Transplant ; Post-Transplant|Post-Chemotherapy|Residual Relapse ; Residual Relapse|Post-Transplant|Post-Chemotherapy ; Post-Transplant|Post-Chemotherapy ; Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant ; Residual Relapse|Post-Chemotherapy ; Post-Transplant|Relapse|Post-Chemotherapy ; Residual Relapse ; Post-Transplant|Initial Acute Leukemia Diagnosis|Post-Chemotherapy ; Post-Transplant|Residual Disease|Post-Chemotherapy
HEMATOCRIT_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Hematocrit Levels (%)	Sample	19.3 ; 27.8 ; 36 ; 26.3 ; 22.9 ; 32.5 ; 17.7 ; 31.6 ; 21.6 ; 22.2 ; 30.8 ; 25.8 ; 22 ; 30.9 ; 25.7 ; 27 ; 31.3 ; 25.9 ; 33.1 ; 35 ; 21.9 ; 28.2 ; 28.7 ; 21.8 ; 23.3 ; 24 ; 26.4 ; 26.6 ; 16.5 ; 41.6 ; 25.5 ; 31.7 ; 25.3 ; 32.6 ; 30.5 ; 33.7 ; 17.6 ; 24.7 ; 27.7 ; 32.3 ; 34 ; 41.1 ; 28.1 ; 23.9 ; 32.2 ; 20.7 ; 23.6 ; 23.4 ; 25 ; 29.3 ; 34.8 ; 18.5 ; 27.2 ; 21 ; 29.6 ; 31.9 ; 23 ; 22.1 ; 28.3 ; 37.2 ; 26.2 ; 33.4 ; 32.4 ; 14.3 ; 30.2 ; 27.9 ; 38.1 ; 32.8 ; 34.7 ; 26.1 ; 30.6 ; 31.1 ; 22.4 ; 25.4 ; 14.5 ; 11.1 ; 35.5 ; 22.7 ; 26.8 ; 25.6 ; 24.5 ; 21.2 ; 34.4 ; 20.6 ; 17.1 ; 25.2 ; 37 ; 28.6 ; 21.4 ; 33.3 ; 30.3 ; 30.4 ; 17.9 ; 28.8 ; 27.6 ; 19.5 ; 29.5 ; 24.6 ; 23.7 ; 36.8 ; 24.9 ; 28.4 ; 20.8 ; 35.4 ; 26.9 ; 24.2 ; 25.1 ; 23.5 ; 15.8 ; 20.1 ; 23.2 ; 20.3 ; 31.8 ; 17.3 ; 20.4 ; 20.9 ; 42.5 ; 18.6 ; 21.3 ; 18.9 ; 31.5 ; 27.3 ; 19.4 ; 37.6 ; 30.1 ; 18.8 ; 24.4 ; 32.9 ; 14 ; 22.6 ; 33.2 ; 18.2 ; 24.1 ; 22.3 ; 19.1 ; 27.5 ; 30 ; 27.4 ; 22.8 ; 19.9 ; 33 ; 19.8 ; 35.2 ; 47.3 ; 20.2 ; 29.4 ; 32.1 ; 42.1 ; 26 ; 39.5 ; 22.5 ; 24.3 ; 38.7 ; 27.1 ; 21.1 ; 24.8 ; 32 ; 36.3 ; 26.7 ; 20 ; 23.8 ; 19.6 ; 31 ; 48.8 ; 21.7 ; 36.5 ; 34.1 ; 30.7 ; 31.2 ; 28.5 ; 29 ; 29.1 ; 39.2 ; 29.8 ; 29.9 ; 37.1 ; 33.5 ; 35.6 ; 42.6 ; 18.4 ; 38.2 ; 41.7 ; 35.1 ; 32.7 ; 23.1 ; 17 ; 33.6 ; 36.9 ; 40 ; 38.3 ; 29.7
HEMOGLOBIN_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Hemoglobin result	Sample	6.8 ; 9.9 ; 7.7 ; 12.6 ; 9.2 ; 7.9 ; 10.9 ; 11.2 ; 6.3 ; 7.5 ; 10.6 ; 9.1 ; 7.4 ; 10.4 ; 9.3 ; 10.7 ; 8.7 ; 11.7 ; 12 ; 7.6 ; 9.6 ; 9.7 ; 7.3 ; 8.2 ; 8.8 ; 5.6 ; 14.3 ; 8.4 ; 11.3 ; 6.2 ; 9.4 ; 11.1 ; 13.4 ; 7.1 ; 8.1 ; 8 ; 9 ; 10.3 ; 10.2 ; 11 ; 8.5 ; 12.1 ; 4.8 ; 12.2 ; 11.6 ; 9.8 ; 8.6 ; 5.3 ; 6.6 ; 7.2 ; 3.7 ; 8.3 ; 10.1 ; 7 ; 6.4 ; 5.7 ; 8.9 ; 6.5 ; 10.5 ; 9.5 ; 5.5 ; 6.7 ; 10 ; 5.2 ; 14 ; 6.9 ; 6.1 ; 4.6 ; 10.8 ; 15.3 ; 11.4 ; 13.2 ; 7.8 ; 13 ; 11.9 ; 16.1 ; 12.7 ; 6 ; 12.4 ; 14.4 ; 15 ; 12.9 ; 5.9 ; 12.5
IDH1_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	IDH1 mutation is present	Sample	Negative ; p.R132H; MAF 40% ; Positive ; p.R132C; MAF 47% ; p.R132S; MAF 20% ; p.R132C; MAF 33% ; p.R132C; MAF 44% ; p.R132C; MAF 37% ; p.R132C; MAF 50% ; C.G395A; p.R132H; MAF unknown ; p.R132G; MAF 51% ; p.G105G; MAF 50% ; p.A1312V; MAF 32.1% ; p.G105G; MAF 52.8% ; p.R132C; MAF 34% ; p.R132C; MAF 16.3% ; p.R132C; MAF 48.7% ; c.C315T; p.G105G; MAF 46.6% ; p.R132C; MAF unlisted ; c.394C>T; MAF 46.7% ; p.R132S; MAF ~50% ; p.R132L; MAF 47% ; R132C; MAF 42% ; R132H; MAF 47.0% ; p.W288fs*12; MAF 50% ; p.R132C MAF 12% ; p.R132H; MAF 46% ; p.R132H; MAF 44% ; p.R132C; MAF 45% ; p.R132C; MAF 20% ; p.R132H; MAF 45%;p.R132H; MAF 41% ; p.Arg132Cys (NM_005896.3); MAF 39.1% ; p.R132H; MAF 37% ; p.R132S, MAF 46% ; p.R132S; MAF 48% ; p.Arg132Cys; MAF 2.9% ; p.R132H; MAF 25% ; c.395G>A; p.R132H; 44%
IDH2_NEGATIVE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Is the IDH2 status negative	Sample	Negative
INDUCTION_RESPONSE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Response to Induction Treatment	Sample	Complete Response ; Refractory ; Unknown ; Complete Response i ; UNKNOWN
JAK2_NEGATIVE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	JAK2 Negative	Sample	Negative
KARYOTYPE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Karyotype.	Sample	46,XY[20] ; 47,XY,+8[cp9]/46,XY[11] ; 47,XY,+8[cp20] ; 47,XX,+13[18]/46,XX[2] ; 46,XX[20] ; 46,XX,del(6)(q13q23)[18]/46,XY[2] ; 46,XX,del(6)(q13q23)[15]/46,XY[5] ; 46,XY[18] ; 46,XY[17] ; 46,XX,t(1;15)(p32;q15)[19]/46,XX[1] ; 46,XX,t(11;17)(q13;q21)[20] ; 46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12] ; 46,XY,inv(16)(p13q22)[20] ; 46,XY[4] ; 48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20] ; 46,XY,add(17)(p13)[19]/46,XY[1] ; 47,XY,+10[18]/46,XY[2] ; 46,XX[14] ; 46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20] ; 47,XY,+21[15]/46,XY[5] ; 47,XY,+8[6]/46,XY[13] ; 46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1] ; 46,XX,t(8;21)(q22;q22)[19]/46,XX[1] ; 45,X,-Y[19]/46,XY[1] ; 45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3] ; 46,XY[19] ; 47,XY,inv(16)(p13q22),+22[20] ; 46,XX[7] ; 46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] ; 46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2] ; 46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5] ; 46,XX[24] ; 46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8] ; 46,XY,del(12)(p11.2p13)[15]/46,XY[5] ; 46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14) ; 46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2] ; 46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2] ; 45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3] ; 46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2] ; 46,XY,-7,+13,i(17)(q10)[20] ; 46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1] ; 46,XX,del(16)(p11.2)[3]/46,XX[2] ; 46,XY[7] ; 46,XX ; 46,XX[5] ; 47,XX,t(16;16)(p13;q22),+22[20] ; 46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4] ; 46,XX,t(9;11)(p11;q34)[19]/46,XX[1] ; 46,XX,t(9;11)(p22;q23)[20]/46,XX[1] ; 46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2] ; 46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1] ; 89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18] ; 42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5] ; 47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5] ; 46,XY,del(9)(q13q34)[3]/46,XY[14] ; 46,XX,t(9;11)(p22;q23)[20] ; 46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5] ; 47~49,XY,-21,+1~4mar[cp21]/46,XY[2] ; 46~49,XY,-21,+1~4mar[cp20] ; 46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4] ; 46,XY ; 45,XY,der(12;16)(q10;p10)[2]/46,XY[18] ; 47,XX,inv(16)(p13.1q22),+22 ; 46,XY,t(9;11)(p22;q23)[20] ; 46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18] ; 46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2] ; 46,XX[19]/46,XY[1] ; 45,XY,-7,t(3;3)[20] ; 46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20] ; 46,XY[21] ; 42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42, ; 46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18] ; 46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2] ; 47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12] ; 46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2]. ; 46,XY,t(8;21)(q22;q22)[14] ; 45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1] ; 45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12] ; 47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11] ; 47,XY,+8[16]/46,XY[4] ; 46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3] ; 48,XYY,+8[21] ; 46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6] ; 46,XX,inv(3)?(q21q25)[21] ; 45,XY,inv(3)(q21q26),-7[20] ; 45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4] ; 47,XY,del(9)(q22),+13[18]/48,idem,+mar[2] ; 44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15] ; 46,XY,del(20)(q12)[14]/46,XY[6] ; 44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2] ; 42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21, ; 40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18] ; 46,XY,del(20)(q11.2)[2]/46,XY[18] ; 46,XX,inv(16)(p13q22)[17]/46,XX[3] ; 48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl ; 49,XX,+X,+8,+10[13]/46,XY[7] ; 43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4] ; 46,XY[14] ; 45,X,-Y,del(7)(p15)[4]/46,XY[16] ; 46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2] ; 46,XY[25] ; 46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20] ; 47,XX,+8,del(11)(q23)[18] ; 46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1] ; 45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12] ; 46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6] ; 50,XY,+8,+9,+13,+22[17]/46,XY[3] ; 46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10] ; 46,XX,inv(16)(p13.1q22)[cp20] ; 48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20] ; 48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1] ; 43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8] ; 46,XX,inv(3)(q21;q26.2)[20] ; 46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3] ; 48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2] ; 47,XY,+8[17]/46,XY[3] ; 47,XY,+8[18]/46,XY[2] ; 42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20] ; 46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21] ; 46,XX,inv(16)(p13q22)[20] ; 46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1] ; 47,XX,+8[20] ; 46,XX[1] ; 47,XX,+8,t(9;11)(p22;q23)[20] ; 46,XY,del(5)(q22q33),del(21)(q22q22)[cp20] ; 46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2] ; 47,XY,+8[2]/46,XY[18] ; 46,XX,t(9;11)(p22;q23)[22] ; 59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1] ; 46,XY,t(11;19)(q23;p13.1)[20] ; 46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1] ; 46,XX[21] ; 47,XX,del(5)(q22q35),+8[20] ; 46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1] ; 48,XX,+3,+10[2]/46,XX[18] ; 45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1] ; 46,XX,del(17)(p11.2p13)[19]/46,XX[1] ; 44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1] ; 46,XX,idic(7)(q11.2)[20] ; 47,XY,der(7)t(1;7)(q10;p10),+8[20] ; 47,XY,der(7)t(1;7)(q10;p10)+8[20] ; 42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1] ; 46,XX,del(9)(q22q34)[20]. ; 46,XY[22] ; 46,XX[8] ; 46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13] ; 46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17] ; 45,X,-Y,t(8;21)(q22;q22)[20] ; 47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1] ; 46,XY,del(13)(q12q2?1)[14] ; 46,XX,del(17)(p11.2)[15]/46,XX[5] ; 46,XY,i(17)(q10)[20] ; 50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20] ; 46,XY,t(6;9)(p23;q34)[18]/46,XY[2]. ; 47,XX,+8[13]/46,XX[7]. ; 47,XX,+8[3]/46,XX[17]. ; 46,XX,t(15;17)(q22;q21)[17]/46,XX[3] ; 46,XY[13] ; 45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1] ; 46,XY,t(6;11)(q27;q23)[20] ; 44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+ ; 47,XX,+8[11]/46,XX[10] ; 47,XY,t(1;11)(p32;q23),+8[cp20] ; 46,XX,inv(16)(p13.1q22)[20] ; 46,XY[23] ; 46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10] ; 46,XY,t(1;4)(q21;p14)[20] ; 46,XY[12] ; 47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5] ; 46,XX,t(5;16)(q31;p13)[3]/46,XX[14] ; 46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8] ; 45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16] ; 46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2] ; 43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1] ; 46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3] ; 47,XX,+11[5]/48,idem,+19[15] ; 46,XY,del(20)(q11.2q13.1)[15]/46,XY[5] ; 43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8] ; 47,XY,+4[9]/46,XY[11] ; 47,XY,+4[2]/46,XY[18] ; 45,XX,-7[20] ; 46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3] ; 46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1] ; 53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7] ; 46,XY,r(7)(p1?3q2?2)[12]/46,XY[5] ; 46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3] ; 41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2] ; 46,XY,inv(16)(p13q22)[17]/46,XY[3] ; 46,XY[6] ; 46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2] ; 46,XX,t(15;17)(q24;q21.1)[1] ; 46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11] ; 46,XY,del(13)(q12q14)[3]/46,XY[17] ; 45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2] ; 47,XX,+10[19]/46,XX[1] ; 48,XY,+8,+8[14]/46,XY[6] ; 47,XY,+8[3]/46,XY[17] ; 47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1] ; 47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2] ; 48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10] ; 46,XX,del(9)(q21q31-33)[10]/46,XX[10] ; 45,XX,-17[15]/46,XX[2] ; 47,XY,+21[19]/46,XY[1] ; 46,XY,inv(4)(p14p16.1)[3]/46,XY[16] ; 46,XY,t(15;17)(q22;q21)[20] ; 48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1] ; 46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7] ; 46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6] ; 46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1] ; 47,XY,+21[3]/46,XY[9] ; 46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14] ; 46,XX,t(6;11)(q27;q23)[19]/46,XX[1] ; 46,XX,t(6;11)(q27;q23)[12]/46,XX[8] ; 46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2] ; 42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del( ; 46,XX,del(7)(q22q36)[20] ; 46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2] ; 92<4n>,XXYY[13]/46,XY[7] ; 46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19] ; 60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1] ; 43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1] ; 47,XY,+11[8]/46,XY[12] ; 46,XX,t(9;11)(p22;q23)[5] ; 46,XY,del(12)(p11.2p13)[20] ; 46,XX,del(7)(q22q36)[11]/46,XX[2] ; 50,XX,+8,+10,+12,+21[20] ; 46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20] ; 45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2] ; 46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2] ; 47,XX,+6[6]/46,XX[19] ; 48,XX,+11,+13[19] ; 46,XX,inv(16)(p13.3q22)[21] ; 46,XX[19] ; 46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12] ; 46,XY,t(3;4)(p21;q25)[3]/46,XY[17] ; 45,X,-Y,t(8;2;21)(q22;p21;q22)[20] ; 46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3] ; 45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q2 ; 46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1] ; 46,XX[18] ; 46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4] ; 46,XY,add(3)(p24)[cp4]/46,XY[14] ; 46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3] ; 46,XY,inv(16)(p13.1q22)[20] ; 47,XY,+21c[20] ; 46,XX[22] ; 45,X,-Y[20] ; 48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20] ; 46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1] ; 46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20] ; 46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1] ; 46,XX,inv(3)(q21q26)[5] ; 46,XX,del(5)(q22q35)[20] ; 46,XX,t(16;16)(p13.2;q22)[20] ; 46,XY[15] ; 46,XY[29] ; 46,XX,inv(16)(p13.1q22)[16]/46,XX[4] ; 46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15] ; 46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18] ; 46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4]. ; 48,XX,+8,+21[16]/46,XX[4] ; 45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3] ; 45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19] ; 46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1] ; 46,XY[5] ; 45,XY,-7,del(12)(p11.2p13)[20] ; 46,XY,t(15;17)(q24;q21)[18]/46,XY[2] ; 48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6] ; 47,XY,t(8;22)(p11.2;q11.2),+19[20] ; 46,XY,t(1;12)(p32;p13)[3]/46,XY[17] ; 46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7] ; 47,XY,+8[20] ; 46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7] ; 46,XY,del(7)(q32),add(13)(p11.2)[15] ; 46,XY,del(7)(q32),add(13)(p11.2)[20] ; 43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21] ; 46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1] ; 41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7] ; 46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20] ; [46,XY] ; 47,XY,+8[19]/46,XY[1] ; 45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7] ; 46,XY,t(8;21)(q22;q22)[20] ; 46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9] ; 46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11] ; 46,XX[20], normal female chromosome complement. ; 47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8] ; 46,XX,t(1;11)(p32;q23)[20] ; 46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1] ; 46,XX,inv(16)(p13,1q22)[17]/46,XX[3] ; 46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4] ; 47,XX,+8[18] ; 44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7] ; 45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8] ; 44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2] ; 46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2] ; 46, XY [20] ; 47,XY,+13[2]/94,slx2[2]/46,XY[19] ; 46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11 ; 46,XX,t(3;3)(q21;q26)[20] ; 45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5] ; 47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18] ; 45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20] ; 88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12] ; 46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20] ; 45,XX,-7[4]/46,sl,+mar[2]/46,XX[14] ; 45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1] ; 46,X,t(X;2)(q22;p13)[20] ; 39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12] ; 46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3] ; 46,XX,t(15;17)(q24;q21)[20] ; 46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2] ; 47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3] ; 45,XX,der(13;14)(q10;q10)?c[20] ; 45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2] ; 46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ; 46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ; 46,XY[11] ; 46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1] ; 46,XX,t(15;17)(q22;q21)[20] ; 46,XX,inv(16)(p13q22)[cp20] ; 42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10] ; 46,XX,del(6)(q13)[cp3]/46,XX,t(4;7)(q11;p11)[2] ; 47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1] ; 47,XY,+21[14]/46,XY[6] ; 41~46,XY,add(4)(p16),del(5)(q15q33),inv(7)(q11q34),-13,add(14)(p11.1),-16,-17,-18,add(19)(q13.1),-20,i(21)(q10),+1~4mar[cp10]/43~45,idem,-add(4)(p16),der(4)add(4)(p16)add(4)(q31)[cp10] ; 46,XY,t(12;18)(p13;q12)[20] ; 44,XY,der(2)t(2;11)(p11.2;q13),add(3)(p12),-9,add(10)(q11.2),-12,add(16)(p13.1)[cp4]/43,idem,-add(10)(q11.2)[cp5]/46,XY[11] ; 46,XX,inv(16)(p13.1q22)[8]/46,XX[12] ; 47,XY,+8[6]/46,XY[13] (Specimen Source: Blood) ; 46,XX,del(16)(q22q23)[8]/46,XX[12] ; 46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation) ; 46,XY,t(15;17)(q24;q21.1)/46,XY ; 49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11) ; 92,XXYY[9]/46,XY[11] ; 46,XX,del(12)(p12p13)[23] ; 46, XX,t(2;16)(p23;p13.3)(13) ; 45,X,-Y[3]/46,XY[17] ; 47,XY,der(7)t(1;7)(q21;q36),+14[4]/46,XY[16] ; 46,XY,hsr(6)(p21p23)[17]/46,XY[5] ; 46,XY,t(6;9)(p23;q34)[18]/46,XY[2] ; 47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3] ; 47,XX,+8[13]/46,XX[7] ; 47,XX,+8[3]/46,XX[17] ; 48,XY,+8,+9[20] ; 46,XY,t(3;4)(p21;q21)[20] ; 47,XY,t(3;4)(p21;q35),+4,t(6;11)(q27;q23),del(12)(p11.2p13)[16]/46,XY[4] ; 46,XY[20) ; 46,XY,t(4;8)(q21;p23)[2]/46,XY[18] ; 46,XX,t(6;11)(q27;q23)[18]/46,XX[2] ; 41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,-10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7] ; 40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1] ; 39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5] ; 47, XY, del (6) (q13q23), +8, der(20) t (20;?) (q11.2-13.1;?) [6] ; 45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4] ; 46,X,t(X;7)(q21;q32)[20] ; 47,XY,+19[12]/46,XY[8] ; 46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/ ; 46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1] ; 46,XY,del(9)(q13q22)[4]/46,XY[16] ; 46,XX,del(1)(p22),der(15)t(15;?)(q15:?),-17,+mar[18]/46,XX[2] ; 46,XX,inv(16)(p13.1q22)[1]/46,XX[19] ; 46,XX,inv(16)(p13q22)[18]/46,XX[2] ; 48,XX,+8,+8,add(9)(q22)[1]/50,idem,+15,+18[5]/46,XX[14] (Six of twenty metaphase cells analyzed comprised two related hyperdiploid clones.) ; 49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11] ; 43-48,XY,add(2)(q11.2),add(3)(p13),add(3)(q29),del(5)(q15q33),der(7)add(7)(p11.2)add(7)(q22),?hsr(8)(q24),+10,+11, add(12)(p11.2),-13,add(14)(p13),add(15)(p12),add(15)(p13),-16,?hsr(16)(q22),-17,-20,+21,add(21)(q22),idic(21)(q22),-22, add(22)(p12),+mar1-5 ; 45,X,-X,t(8;21)(q22;q22)[20] ; 44-46,XX,del(1)(p32),del(5)(q31q35),del(7)(q11.2q32),-9,-15,-16,-18,add (21)(q22),-22,-22,+3mar[cp3]/46,XX[7] ; 47,XX,+8[1]/46,XX[19] ; 46,XX,del(9)(q13q22)[5]/46,sl,del(11)(q13q23)[14]  /46,sdl,t(2;4;7)(q33;q21;p15),add(8)(p11.2)[2] ; 47,XX,+8,del(8)(q11.2q22)[20] ; 45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8] ; 46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3] ; 46,XX,inv(16)(p13.1q22)[18]/46,XX[2] ; 43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20] ; 47,XX,+8[19]/46,XX[1] ; 42,XX,add(1)(q32),-5,-7,add(12)(p13),add(13)(q21.2),-17,-18,add(19)(q13.4)[3]/43,sl,+r[10]/44,sdl1,+8[6]/46,XX[1] ; 45,X,-Y[4]/46,XY[16] ; 46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20] ; 46,XX,der(2)del(2)(p23)inv(2)(p22q31),add(3)(p?14),der(12)add(12)(p11.2)t(3;12)(p?13;q?15)[12]/46,idem,der(7)t(7;11)(q11.2;q13)[7]/46,XX[1] ; 54~57,XY,+14,+19,+20,add(21)(q22),+add(21)x3~6,+22[cp19]/46,XY[1] ; 46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4] ; 46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5] ; 45,X,-Y,del(11)(q12)[20] ; 46,XX,t(9;11)(p22;q23)[10]/46,XX[10] ; 46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1] ; Normal ; 46,XX,der(22)t(1;22)(q12;p11.2)[1]/46,XX[19] ; 46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19] ; 45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2] ; 47,XX,psu dic(5;7)(q13;p10),r(7)(p12q11.2),+8,der(12)del(12)(p11.2p13)add(12)(q24.1)[2]/ 44,sl,add(3)(q12),-r(7)(p12q11.2),-8,-der(12)del(12)(p11.2p13)add(12)(q24.1),idic(22)(p11.2), +der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[16]/ 45,sdl1,+d ; 46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5] ; 43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5] ; 47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8] ; 46,XY,del(9)(q13q22)[20] ; 47~49,XY,+8[cp13]/46,XY[7] ; 49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8] ; 49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1] ; 46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1] ; 46,XY,t(9;11)(p22;q23),inv(9)(p11q12) ; 45,XY,del(7)(p13),-9[7]/4 5-47,idem,+13,-15,add(19) (p13.3),+20[cp11]/ 46,XY[2] ; 45,XX,del(3)(p13p26),-5[cp3]/48,idem,+8,der(9;12)(q10;q10),+19,+21,idic(21)(p11.2)x2,+mar[cp5]/50,idem,+8,der(9)t(5;9)(p13;p13),+19,+21,+21,idic(21)x2,+mar[cp8]/50,idem,del(9)(p13p22),der(9)t(5;9),+19,+21,+21,idic(21)x2,+mar[cp4] ; 46,XY,t(9;11)(p21;q23)[1]/46,idem,t(5;12)(q33;p13)[19] ; 47,XY,+21[19] ; 46,XY,del(1),del(5q),der(7)add(7)(p11.1)add(7)(q32),add(11)(q23),del(13)(q22)[12]/46,sl,-del(1),+der(1)del(1)(p13p32)del(1)(q12q25)[8] ; 47,XX,+8,inv(16)(p13.1q22.1)[20] ; 47,XX,del(11)(q23),+21[20] ; 45,XY,-4,-5,del(6)(p24),add(7)(q21),der(9)t(9;14)(q12;q11.2),-14,-21,+22,ad  d(22)(p11.2)x2,+2mar[20] ; 49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20] ; 46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3] ; 46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2] ; 30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20] ; 45,XX,inv(3)(q21q26),-7[20] ; 50-55,XX,+X,+6,+8,+10,+12,+13,+14,+21,+22[cp 18]/46,XX[2]. ; 46,XY,t(10;11)(p13;q23)[20] ; 47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1] ; 47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1] ; 46[XX] ; 46,XX,del(7)(q22q32)[cp4]/46,XX[16] ; 47,XY,+8[4]/46,XY[16] ; 46,XX,t(6;11)(q27;q23)[25] ; 46, XY[20] ; 47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4] ; 47,XY,+8[1]/47,idem,del(3)(q21q27)[19] ; 46,XX,t(3;21)(q26;q11.2)[1]/45,sl,-7[9]/45,sdl1,del(13)(q12q14)[10] ; 45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2] ; 46XY ; 47,XY,+13[20]/47,XY,+8[1] ; 46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20] ; 46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10] ; 44-45,XY,-3,-5,der(7)del(7)(q22)inv(7)(p13q22),del(12)9p11.2),add(19)(q13.1),+mar[cp20] ; 45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20] ; 46,XY,inv(16)(p13;q22)[20] ; 46,XX[15] ; 51~52,XX,+2,+6,add(7)(q31),+8,+9,+10,+15[cp14]/50~52,idem,del(19)(q11.2)[cp  5]/46,XX[1] ; 43,XY,add(5)(q11.2),add(9)(q12),add(10)(p11.2),-12,idic(12)(p11.2),t(14;14)  (q31;q32),-16,-17,add(17)(q21),add(19)(p13),-20,add(21)(p11.2),+mar[19]/46,  XY[1] ; 46,XY,del(12)(p11.2)[9]/46,XY[11] ; 47,XY,+8[12]/47,XY,+15[8]/46,XY[5] ; 46,XX,del(9)(q22q22)[20] ; 46,XY,del(2)(q11.2q21)[3] ; 46,XY,t(15;17)(q24;q21)[20] ; 46,XY,inv(4)(p14q21)[9]/47,sl,+8[2]/46,XY[10] ; 44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20] ; 48,XY,+11,+13[17]/46,XY[3] ; 46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1] ; 46,XX,i(14)(q10)[8]/46,XX[12] ; 46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2] ; 47,XX,+8[4]/46,XX[16] ; 49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20] ; 46,XX[20 ; 46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4] ; 47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7] ; 46,XX,t(8;16)(p11.2;p13.3)[19] /46,XX[1] ; Inv(3)(q21q26.2) ; 69~82<3n>,X,-X,+4,+8,+8,+8,+8,+8,+8,-9,+10,-12,-15,-17,+18,+20,+21,+22,+1~2mar[cp13]/47~48,X,-X,+4,+6,+8,+8,-9,-16,-17,+mar[cp3]/92,XXXX[2]/46,XX[2] ; 46,XY,del(7)(q32q36),inv(16)(p13.1q22)[20] ; 46,XY,inv(16)(p13.1q22)[cp20] ; 47,XX,+4[3]/46,XX[17] ; 46,XX,del(14)(q21q31)[20] ; 46,XY,t(10;11)(p12;q23)[8]/45,sl,-Y[12] ; 46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5] ; 47,XY,del(9)(q13q22),+10[3]/46,XY[17] ; 46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1] ; 49,XY,+10,+13,+21[6]/51,idem,+9,+15[14] ; 49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6] ; 46,XX,del(5)(q13q33)[14]/46,XX[6] ; 46,XY,t(2;12)(p13;q13)[20] ; 47,XY,+21[2]/46,XY[18] ; 46,XY,del(20)(q11.2)[cp20] ; 48,XY,+7,+mar[4]/46,XY[16] ; 47,XX,+2[8]/47,XX,+8[1]/46,XX[11] ; 46,XY,t(3;12)(q29;p13),ins(12;?)(p13;?)[20] ; 37~40,XX,add(2)(p11.2),add(4)(q21),add(5)(q13),-7,-11,-11,add(12)(p11.2),-13,add(13)(q34),-17,-17,-18,-19,-19,del(20)(q22),add(21)(q22),+1~3mar[cp9]//46,XY[11] ; 46,XY,del(20)(q11.2q13.3)[19]/46,XY[1] ; 47,XX,+8[11]/46,XX[9]
KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Difference in days of karyotype result reported and date of Specimen acquisition	Sample	0 ; 3 ; -15 ; -81 ; -20 ; 1 ; -36 ; -71 ; -112 ; -4 ; -121 ; -349 ; -1 ; -22 ; -14 ; -2 ; -93 ; -10 ; -8 ; 2 ; -480 ; -159 ; -13 ; -506 ; -98 ; -6 ; -28 ; -274 ; -18 ; -3 ; -7 ; -49 ; -77 ; -111 ; -17 ; -19 ; -33 ; -86 ; -710 ; -30 ; -29 ; -46 ; -21 ; -27 ; -142 ; -34 ; -11 ; -54 ; 6 ; -79 ; -37 ; -463 ; -39 ; -412 ; -178 ; -141 ; -24 ; -105 ; -44 ; -58 ; -195 ; -55 ; -52 ; -35 ; -224 ; -32 ; -83 ; -127 ; -119 ; -151 ; -73 ; -5 ; -25
KIT_NEGATIVE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Negative for KIT	Sample	Negative
KRAS_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	KRAS mutation is present.	Sample	Negative ; p.G13D; MAF 10% ; Positive ; p.G12V; MAF 30% ; p.G13D; MAF 27% ; p.G12D; MAF 9% ; p.G13D; MAF 6% ; p.G12D; MAF 27% ; Foundation; A59T mutation; MAF 47% ; p.Gly13Asp; MAF 38.9% ; p.G12A; MAF 36% ; p.G12V; MAF 49% ; p.G13D; MAF 8% ; p.G12D; MAF 4% ; p.K117N; MAF 48% ; G12R; MAF 5.0% ; p.Q61P, MAF 13% ; p.G12V, Mutant Allele frequency: 76% ; p.Q61L; MAF 10%
LDH_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Information related to the result of the medical procedure that involves testing a sample of blood for lactic dehydrogenase, a family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis.	Sample	441 ; 195 ; 4559 ; 575 ; 3587 ; 592 ; 386 ; 426 ; 527 ; 512 ; 1065 ; 137 ; 451 ; 268 ; 419 ; 696 ; 443 ; 226 ; 313 ; 678 ; 231 ; 673 ; 477 ; 888 ; 1165 ; 2700 ; 697 ; 454 ; 551 ; 123 ; 184 ; 438 ; 2037 ; 747 ; 460 ; 167 ; 660 ; 132 ; 399 ; 387 ; 683 ; 398 ; 389 ; 367 ; 373 ; 219 ; 324 ; 224 ; 588 ; 762 ; 486 ; 743 ; 808 ; 415 ; 183 ; 166 ; 2941 ; 613 ; 229 ; 505 ; 497 ; 208 ; 335 ; 145 ; 180 ; 175 ; 329 ; 682 ; 291 ; 536 ; 314 ; 645 ; 340 ; 1138 ; 556 ; 88 ; 284 ; 685 ; 514 ; 177 ; 702 ; 245 ; 435 ; 168 ; 1072 ; 409 ; 283 ; 550 ; 342 ; 136 ; 506 ; 266 ; 249 ; 16499 ; 1205 ; 155 ; 230 ; 819 ; 216 ; 4484 ; 444 ; 170 ; 766 ; 932 ; 158 ; 1816 ; 295 ; 1173 ; 434 ; 165 ; 452 ; 411 ; 241 ; 160 ; 148 ; 509 ; 3923 ; 162 ; 125 ; 130 ; 259 ; 517 ; 7759 ; 1873 ; 1004 ; 753 ; 484 ; 561 ; 178 ; 601 ; 639 ; 501 ; 227 ; 1304 ; 945 ; 1146 ; 379 ; 511 ; 235 ; 921 ; 1119 ; 275 ; 578 ; 297 ; 383 ; 612 ; 293 ; 289 ; 934 ; 475 ; 290 ; 599 ; 199 ; 688 ; 1086 ; 261 ; 194 ; 605 ; 970 ; 276 ; 861 ; 634 ; 821 ; 200 ; 330 ; 1211 ; 404 ; 453 ; 319 ; 296 ; 977 ; 191 ; 3615 ; 564 ; 321 ; 346 ; 2008 ; 1151 ; 244 ; 905 ; 339 ; 491 ; 252 ; 243 ; 176 ; 705 ; 728 ; 262 ; 508 ; 279 ; 533 ; 1259 ; 440 ; 189 ; 467 ; 887 ; 1897 ; 670 ; 364 ; 839 ; 215 ; 122 ; 722 ; 420 ; 197 ; 953 ; 479 ; 154 ; 1024 ; 2840 ; 519 ; 1033 ; 1805 ; 9928 ; 424 ; 353 ; 310 ; 369 ; 91 ; 304 ; 217 ; 333 ; 853 ; 337 ; 278 ; 222 ; 360 ; 394 ; 1195 ; 401 ; 608 ; 380 ; 675 ; 294 ; 272 ; 174 ; 665 ; 706 ; 807 ; 851
MDSMPN_DIAGNOSIS_AT_ACQUISITION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Diagnosis at inclusion was MDS/MPN related?	Patient	
MDSMPN_TWO_MONTHS_PRIOR_AML	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient been diagnosed with MDS/MPN at least two months prior AML diagnosis	Patient	
MDS_TWO_MONTHS_PRIOR_AML	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient been diagnosed with MDS at least two months prior AML diagnosis	Patient	
MEAN_CORPUSCULAR_VOLUME	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Mean corpuscular volume (fL)	Sample	100.5 ; 101.8 ; 91 ; 88.3 ; 90.5 ; 98.3 ; 101.6 ; 93.5 ; 91.5 ; 81 ; 103.1 ; 89.5 ; 89.7 ; 100.4 ; 86.8 ; 81.8 ; 103.3 ; 94.3 ; 95 ; 95.2 ; 102.9 ; 99.9 ; 99.6 ; 92.7 ; 97.7 ; 92.4 ; 114 ; 95.9 ; 87.8 ; 89.1 ; 85 ; 86.3 ; 102.8 ; 82.6 ; 100.6 ; 94.5 ; 89.2 ; 103.6 ; 86.1 ; 87.4 ; 87 ; 90.2 ; 94.4 ; 86.2 ; 96.9 ; 92.2 ; 92.8 ; 85.2 ; 105.8 ; 90.4 ; 97.8 ; 111.8 ; 89.8 ; 92.6 ; 104.8 ; 86.6 ; 87.2 ; 100.7 ; 87.6 ; 91.3 ; 83.8 ; 117.1 ; 88.9 ; 88 ; 90.9 ; 95.6 ; 93.7 ; 82 ; 95.7 ; 98.4 ; 88.6 ; 93.8 ; 100.9 ; 79 ; 87.5 ; 101.4 ; 99 ; 88.5 ; 95.3 ; 85.8 ; 107.7 ; 103.7 ; 98.8 ; 88.1 ; 104.3 ; 81.9 ; 101.7 ; 98.5 ; 83.5 ; 97.5 ; 90.3 ; 70.8 ; 93.9 ; 80.4 ; 86.5 ; 92.3 ; 97.1 ; 89 ; 93 ; 87.3 ; 105.5 ; 93.4 ; 103.4 ; 119.8 ; 89.9 ; 85.3 ; 77 ; 84.2 ; 102.3 ; 96.1 ; 90.1 ; 107.2 ; 97 ; 97.2 ; 85.6 ; 95.5 ; 94 ; 90.6 ; 103.8 ; 94.7 ; 87.7 ; 95.8 ; 93.3 ; 99.7 ; 104.5 ; 89.3 ; 100 ; 88.4 ; 83.7 ; 96.8 ; 118.6 ; 102.5 ; 92 ; 96.5 ; 96 ; 93.2 ; 88.7 ; 106.4 ; 107.3 ; 104.9 ; 92.1 ; 91.7 ; 100.3 ; 95.1 ; 96.3 ; 109.3 ; 91.9 ; 98.1 ; 81.2 ; 84.1 ; 89.4 ; 98.9 ; 99.4 ; 87.9 ; 96.2 ; 90.8 ; 91.1 ; 89.6 ; 85.7 ; 100.8 ; 80.6 ; 112.6 ; 91.8 ; 105.3 ; 108.3 ; 94.8 ; 110.4 ; 105.9 ; 105.1 ; 96.4 ; 94.9 ; 85.4 ; 132.4 ; 84.5 ; 105.4 ; 96.6 ; 95.4 ; 104.4 ; 113.6 ; 82.2 ; 103.5 ; 107 ; 98 ; 101 ; 84.4 ; 82.1 ; 106.7 ; 85.1 ; 91.4 ; 93.6 ; 110.7 ; 86.7
MOST_RECENT_TREATMENT_DURATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Most Recent Treatment Duration (Days)	Sample	30 ; 3 ; 4 ; 5 ; 105 ; -1 ; 155 ; 0 ; 18 ; 57 ; 9 ; 42 ; 108 ; 64 ; 7 ; 187 ; 43 ; 160 ; 80 ; 104 ; 74 ; 6 ; 62 ; 109 ; 133 ; 124 ; 137 ; 24 ; 53 ; 31 ; 34 ; 14 ; 95 ; 126 ; 94 ; 141 ; 103 ; 55 ; 33 ; 15 ; 2197 ; 127 ; 169 ; 52 ; 45 ; 60 ; 114 ; 111 ; 28 ; 29 ; 36 ; 182 ; 339 ; 8 ; 197 ; 63 ; 210 ; 196 ; 365 ; 129 ; 107 ; 10 ; 1131 ; 433 ; 193 ; 269 ; 44 ; 206 ; 2 ; 122 ; 113 ; 76 ; 115 ; 214 ; 125 ; 17 ; 13 ; 48 ; 77 ; 232 ; 19 ; 112 ; 78 ; 153 ; 38 ; 82 ; 151 ; 86 ; 424 ; 93 ; 81 ; 37 ; 100 ; 1 ; 97 ; 88 ; 253 ; 67 ; 498 ; 106 ; 143 ; 99 ; 268 ; 96 ; 120 ; 274 ; 56 ; 263 ; 22 ; 98 ; 267 ; 21 ; 23 ; 58 ; 40 ; 16 ; 164 ; 91 ; 449 ; 284 ; 382 ; 1013 ; 49 ; 752 ; 83 ; 35 ; 66 ; 12 ; 61 ; 135 ; 102 ; 496 ; 116 ; 69 ; 92 ; 165 ; 41 ; 11 ; 26 ; 191 ; 344 ; 317 ; 200 ; 84 ; 90 ; 734 ; 132 ; 101 ; 20 ; 149 ; 25
MOST_RECENT_TREATMENT_TYPE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Treatment type of the most recent treatment determined by start date	Sample ; Patient	Targeted Therapy - Kinase Inhibitor(s) ; Standard Chemotherapy ; Bone Marrow Transplant ; Supportive/Palliative Care ; NONE ; DLI ; Unknown ; Other ; Targeted Therapy - Other ; Intrathecal
MPN_TWO_MONTHS_PRIOR_AML	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient been diagnosed with MPN at least two months prior AML diagnosis	Patient	
NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Diagnosis at inclusion was not AML/MPN/MDN	Patient	
NPM1_CONSENSUS_CALL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Consensus call for NPM1	Sample	Positive ; Negative
NRAS_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	NRAS Mutation	Sample	Negative ; p.G13D; MAF 30% ; G13D; MAF 6% ; Positive ; p.G12R, MAF 50% ; p.G13D; MAF 17% ; p.Q61H; MAF 40% ; p.G13D, MAF 46% ; Q61H; MAF 5% ; p.G12C; MAF 86% ; p.G12C; MAF 97% ; p.G12D; MAF:11% ; p.G12S; MAF: 15% ; G13D; MAF 44% ; p.G12D; MAF 7% ; p.G12D; MAF 46% ; p.G12D; MAF 10% ; p.Q61K; MAF 37% ; G13V; MAF 37% ; p.Q61H; MAF 19% ; p.Q61K; MAF 24.1% ; p.G12D; MAF 5% ; p.G12D; MAF 15% ; p.G12S; MAF 19% ; p.G13D; MAF ~40% ; p.Q61R; MAF 30% ; p.Q61R MAF ~5% ; p.Q61P; MAF 15% ; p.G13V; MAF 6% ; p.G12D; MAF 45% ; p.G13D; MAF 35% ; p.G12C; MAF 40% ; p.G12D; MAF 49% ; p.G12S; MAF 6% ; p.G13R; MAF 50% ; p.G13R;MAF 47% ; Q61K; MAF 43.0% ; p.G12A; MAF 24% ; c.35G>A; MAF 30.2% ; p.Q61H, MAF 21% ; p.Q61H; MAF 45% ; p.G12D; MAF 6% ; p.G12S, MAF 18% ; p.G12D; MAF 47% ; p.G13R, MAF 48% ; p.G13D; MAF 38% ; p.G12S; MAF 40% ; p.Q61K; MAF45% ; p.G12D; 17% ; p.Q61K; MAF 9% ; p.Gln61Glu; MAF 47.8% ; p.G13D, MAF 3% ; p.G13D; MAF 24% ; p.G13D; MAF 34%
PB_ALBUMIN_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Albumin levels in the peripheral blood  (g/dL)	Sample	4.1 ; 3.8 ; 3.2 ; 3.9 ; 2.9 ; 1.9 ; 2.8 ; 2.3 ; 3.4 ; 3.6 ; 3.1 ; 3.7 ; 2.2 ; 2.6 ; 4 ; 3 ; 3.3 ; 1.7 ; 2.7 ; 4.3 ; 2.5 ; 2.4 ; 4.2 ; 3.5 ; 2.1 ; 1.8 ; 2 ; 4.6 ; 4.4 ; 4.5 ; 4.8 ; 4.7 ; 4.9 ; 1.6
PB_ALT_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Alanine aminotransferase levels in the peripheral blood (units/litre)	Sample	19 ; 21 ; 56 ; 14 ; 29 ; 84 ; 30 ; 26 ; 8 ; 13 ; 80 ; 23 ; 16 ; 36 ; 42 ; 34 ; 67 ; 61 ; 107 ; 90 ; 47 ; 15 ; 60 ; 71 ; 18 ; 43 ; 22 ; 81 ; 35 ; 242 ; 32 ; 250 ; 70 ; 24 ; 48 ; 20 ; 66 ; 57 ; 87 ; 31 ; 33 ; 37 ; 17 ; 93 ; 85 ; 27 ; 62 ; 45 ; 49 ; 10 ; 463 ; 152 ; 83 ; 38 ; 114 ; 28 ; 12 ; 52 ; 184 ; 9 ; 73 ; 11 ; 51 ; 58 ; 50 ; 25 ; 63 ; 82 ; 44 ; 6 ; 89 ; 54 ; 7 ; 46 ; 79 ; 41 ; 391 ; 40 ; 124 ; 59 ; 135 ; 76 ; 4 ; 101 ; 118 ; 77 ; 39 ; 195 ; 91 ; 393 ; 65 ; 117 ; 69 ; 119 ; 110
PB_AST_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Aspartate aminotransferase levels in the peripheral blood (units/litre)	Sample	28 ; 26 ; 56 ; 20 ; 36 ; 90 ; 38 ; 41 ; 15 ; 22 ; 180 ; 31 ; 29 ; 45 ; 67 ; 23 ; 24 ; 44 ; 47 ; 18 ; 37 ; 54 ; 19 ; 30 ; 64 ; 58 ; 48 ; 34 ; 11 ; 14 ; 341 ; 50 ; 10 ; 160 ; 53 ; 33 ; 9 ; 16 ; 27 ; 21 ; 39 ; 25 ; 104 ; 17 ; 477 ; 49 ; 40 ; 52 ; 32 ; 77 ; 116 ; 13 ; 131 ; 146 ; 152 ; 51 ; 42 ; 8 ; 12 ; 165 ; 282 ; 43 ; 65 ; 76 ; 35 ; 7 ; 57 ; 343 ; 137 ; 83 ; 106 ; 62 ; 113 ; 59 ; 55 ; 75 ; 150 ; 102 ; 350 ; 61 ; 151 ; 93 ; 255
PB_BASOPHILS_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Basophils in the peripheral blood	Sample	0 ; 2 ; 1 ; 5 ; 3 ; 11 ; 1.4 ; 1.8 ; 0.5 ; 6 ; 0.8 ; 2.6 ; 0.9 ; 1.7 ; 0.1 ; 3.2 ; 6.1 ; 0.3 ; 8 ; 0.6 ; 7.6 ; 0.4 ; 0.2 ; 10.8 ; 3.6 ; 1.5 ; 1.6 ; 1.1 ; 4.5 ; 0.7
PB_BLAST_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	PB blast percentage	Sample ; Patient	97 ; 84 ; 19 ; 80 ; 99 ; 66 ; 48 ; 51 ; 30 ; 41 ; 60 ; 77 ; 96 ; 75 ; 45 ; 63 ; 93 ; 9 ; 33 ; 13 ; 82 ; 15 ; 0 ; 94 ; 89 ; 83 ; 90 ; 78 ; 72 ; 59 ; 32 ; 6 ; 29 ; 24 ; 64 ; 57 ; 52 ; 2.1 ; 5 ; 17 ; 22 ; 47 ; 56 ; 1 ; 25 ; 23 ; 42 ; 65 ; 35 ; 71 ; 8 ; 2 ; 3.5 ; 66.3 ; 95 ; 44 ; 10 ; 28.6 ; 18 ; 58 ; 67 ; 40 ; 92 ; 54 ; 20 ; 28 ; 85 ; 42.4 ; 16 ; 26 ; 49.1 ; 14 ; 88 ; 46 ; 7 ; 0.5 ; 64.6 ; 79 ; 87 ; 20.4 ; 68 ; 5.3 ; 61 ; 17.4 ; 57.4 ; 43.8 ; 50 ; 37 ; 4 ; 3 ; 12 ; 81 ; 11 ; 90.5 ; 90.2 ; 55 ; 39 ; 31 ; 86 ; 47.4 ; 27.4 ; 39.6 ; 12.9 ; 15.4 ; 9.5 ; 62 ; 27.8 ; 69.14 ; 52.2 ; 91 ; 67.25 ; 49 ; 23.7 ; 48.6 ; 98 ; 74.8 ; 2.6 ; 43 ; 29.6 ; 47.5 ; 38 ; 2.5 ; 25.2 ; 3.56 ; 70 ; 99.2 ; 73 ; 26.7 ; 38.5 ; 7.7 ; 74 ; 93.3 ; 12.1 ; 11.2 ; 92.9 ; 98.4 ; 6.8 ; 10.5 ; 53 ; 3.1 ; 28.9 ; 72.9 ; 40.2 ; 3.3 ; 42.1 ; 11.5 ; 77.8 ; 3.8 ; 59.5 ; 21.7 ; 53.2
PB_EOSINOPHILS_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Eosinophils in the peripheral blood	Sample	0 ; 0.8 ; 1 ; 5 ; 11 ; 3 ; 0.1 ; 2 ; 0.9 ; 2.5 ; 1.8 ; 8.5 ; 1.5 ; 13 ; 1.2 ; 4.5 ; 1.7 ; 3.5 ; 1.4 ; 1.6 ; 4 ; 2.1 ; 0.6 ; 5.2 ; 7.1 ; 2.6 ; 7.2 ; 4.2 ; 2.9 ; 6.9 ; 2.8 ; 5.1 ; 1.1 ; 4.7 ; 3.6 ; 4.3 ; 1.9 ; 30 ; 24 ; 3.8 ; 0.5 ; 9 ; 6.1 ; 8 ; 0.2 ; 7.8 ; 3.4
PB_IMMATURE_GRANULOCYTES_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Immature Granulocytes Percent in Peripheral Blood	Sample	0.4 ; 0 ; 0.5 ; 1 ; 0.9 ; 1.7 ; 2.9 ; 16.5 ; 27.8 ; 7 ; 7.5 ; 0.8 ; 0.6 ; 32 ; 2.7 ; 2.6 ; 2 ; 12.5 ; 2.5 ; 8.5 ; 4.4 ; 4 ; 6.1 ; 0.2 ; 19.6 ; 28.8 ; 1.8 ; 6.8 ; 8.7 ; 1.6 ; 3 ; 3.4 ; 6.2 ; 19.4 ; 15.1 ; 4.3 ; 13 ; 9.4 ; 7.7 ; 2.1 ; 46 ; 0.7 ; 8.9 ; 3.5 ; 8.8 ; 2.3 ; 44 ; 16.2
PB_LYMPHOCYTES_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Lymphocytes in the peripheral blood	Sample	2 ; 3 ; 5 ; 11 ; 31 ; 10 ; 7 ; 59.4 ; 75.6 ; 21.6 ; 64 ; 17 ; 6 ; 19 ; 8 ; 30 ; 21 ; 28 ; 52 ; 1 ; 12 ; 16 ; 24 ; 78 ; 46 ; 0 ; 94.3 ; 60 ; 9 ; 42 ; 15 ; 26 ; 14 ; 36 ; 44 ; 67 ; 100 ; 33 ; 43 ; 40 ; 28.9 ; 9.9 ; 68 ; 54 ; 41.2 ; 9.5 ; 63 ; 25 ; 56.8 ; 27.7 ; 32.2 ; 19.6 ; 38 ; 11.4 ; 71.5 ; 19.7 ; 15.3 ; 25.6 ; 20 ; 45.3 ; 38.7 ; 14.9 ; 32.7 ; 54.5 ; 48.5 ; 20.5 ; 7.2 ; 9.4 ; 33.8 ; 10.5 ; 0.9 ; 3.6 ; 27.8 ; 84.1 ; 48 ; 17.7 ; 8.3 ; 57 ; 27 ; 25.8 ; 36.2 ; 67.3 ; 50 ; 75.2 ; 14.8 ; 64.3 ; 70 ; 38.9 ; 31.3 ; 59.3 ; 38.4 ; 26.7 ; 34 ; 75 ; 16.1 ; 18.2 ; 6.7 ; 7.9 ; 7.8 ; 61 ; 78.5 ; 37.5 ; 17.5 ; 32.6 ; 76 ; 31.2 ; 7.4 ; 75.9 ; 28.3 ; 28.2 ; 57.7 ; 33.6 ; 8.2 ; 31.8 ; 24.2 ; 45.5 ; 53 ; 4.9 ; 69 ; 4 ; 4.1 ; 58.4 ; 13.2 ; 77 ; 6.1 ; 78.1 ; 15.5 ; 22.3 ; 11.7 ; 80 ; 23.3 ; 31.9 ; 36.8 ; 47 ; 92.2 ; 14.6 ; 48.7 ; 83.2 ; 71.6 ; 17.4 ; 81.3 ; 20.2 ; 52.2 ; 60.3 ; 51.6 ; 18 ; 56.3 ; 72.2 ; 1.8 ; 7.5 ; 37 ; 46.1 ; 85.8 ; 2.6 ; 79.6 ; 51 ; 29.8 ; 8.8 ; 46.5 ; 24.7 ; 19.3 ; 29.1 ; 8.1 ; 9.3 ; 68.3 ; 62.6 ; 50.8 ; 40.6 ; 23.2 ; 14.3 ; 6.4 ; 9.6 ; 18.6 ; 10.2 ; 16.8 ; 22 ; 21.7 ; 2.7 ; 34.8 ; 18.4 ; 29 ; 23.9 ; 47.9 ; 39.1 ; 89.9 ; 13.9 ; 26.9 ; 10.3 ; 5.1 ; 33.4 ; 42.8 ; 41.7 ; 0.8 ; 90 ; 50.2 ; 16.2 ; 15.8 ; 54.1 ; 12.6 ; 55 ; 1.9 ; 13.6 ; 4.7 ; 11.5 ; 48.1 ; 39.2 ; 60.2 ; 76.5 ; 8.6 ; 18.8 ; 76.7 ; 13 ; 23 ; 5.7 ; 80.9 ; 30.3 ; 43.7 ; 47.3 ; 35.7 ; 30.8 ; 34.5 ; 14.7 ; 22.8 ; 19.8 ; 4.2 ; 4.6 ; 44.3 ; 20.3 ; 28.7 ; 26.3 ; 13.8 ; 13.3 ; 16.5 ; 44.2 ; 20.9 ; 21.2 ; 62 ; 20.4 ; 9.2 ; 50.4 ; 13.5 ; 81.8 ; 29.5 ; 22.1 ; 23.1
PB_MONOCYTES_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Monocytes in the peripheral blood	Sample	1 ; 3 ; 0 ; 16 ; 2 ; 1.9 ; 18.9 ; 4.5 ; 11 ; 14 ; 5 ; 49 ; 38 ; 24 ; 33 ; 71 ; 30 ; 40 ; 1.5 ; 10 ; 7 ; 4 ; 13 ; 52 ; 18 ; 61 ; 17 ; 6 ; 70 ; 77 ; 8 ; 19 ; 25.4 ; 9.9 ; 15 ; 23 ; 37.7 ; 20 ; 2.6 ; 37.5 ; 26 ; 8.5 ; 35 ; 12 ; 44 ; 7.4 ; 8.3 ; 59.6 ; 9.3 ; 44.7 ; 19.6 ; 3.4 ; 0.8 ; 12.6 ; 0.6 ; 28.2 ; 21 ; 21.2 ; 27 ; 8.8 ; 5.1 ; 14.9 ; 85.2 ; 1.1 ; 1.8 ; 22.1 ; 17.9 ; 13.1 ; 11.3 ; 21.1 ; 0.1 ; 1.7 ; 31.9 ; 5.7 ; 1.4 ; 9 ; 0.9 ; 5.3 ; 42 ; 12.2 ; 25.2 ; 76.3 ; 51.3 ; 15.1 ; 27.7 ; 4.6 ; 14.7 ; 35.2 ; 12.5 ; 17.7 ; 13.7 ; 2.7 ; 2.2 ; 82.3 ; 28.3 ; 5.2 ; 6.8 ; 23.7 ; 2.9 ; 6.9 ; 27.6 ; 12.4 ; 6.6 ; 2.4 ; 67 ; 30.1 ; 7.8 ; 16.3 ; 37.1 ; 38.5 ; 39.6 ; 9.8 ; 54 ; 5.5 ; 23.3 ; 27.2 ; 39 ; 20.8 ; 54.4 ; 17.6 ; 18.3 ; 15.6 ; 62.6 ; 9.7 ; 20.2 ; 4.4 ; 3.9 ; 10.4 ; 18.7 ; 1.6 ; 44.3 ; 13.5 ; 3.5 ; 48 ; 50 ; 3.6 ; 9.4 ; 45.5 ; 24.5 ; 22.2 ; 72.2 ; 47.9 ; 29.8 ; 32.2 ; 3.7 ; 42.7 ; 14.4 ; 9.5 ; 7.5 ; 8.4 ; 2.8 ; 64.4 ; 15.2 ; 57 ; 2.5 ; 8.9 ; 11.2 ; 10.3 ; 51.4 ; 11.6 ; 29 ; 12.9 ; 79.2 ; 89.8 ; 8.2 ; 33.4 ; 28 ; 9.6 ; 25.7 ; 25.9 ; 63.7 ; 46.1 ; 60.9 ; 22 ; 79.8 ; 24.3 ; 7.6 ; 6.2 ; 8.1
PB_NEUTROPHILS_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Neutrophils in the peripheral blood	Sample	0 ; 3 ; 11 ; 9 ; 1 ; 5 ; 18 ; 2 ; 12.3 ; 4.3 ; 23 ; 4 ; 28 ; 6 ; 8 ; 30 ; 22 ; 10 ; 7 ; 16 ; 2.7 ; 36 ; 27 ; 29 ; 24 ; 25 ; 20 ; 38 ; 84 ; 68 ; 19.3 ; 37.2 ; 19 ; 11.4 ; 4.8 ; 37.6 ; 39.2 ; 34.2 ; 7.1 ; 14 ; 34 ; 42 ; 9.9 ; 24.7 ; 55 ; 39 ; 30.7 ; 15.9 ; 5.3 ; 28.8 ; 35.1 ; 54 ; 44 ; 9.3 ; 13 ; 30.3 ; 2.5 ; 53.7 ; 37.7 ; 1.2 ; 17 ; 8.9 ; 49.6 ; 58.4 ; 7.3 ; 69 ; 20.6 ; 44.9 ; 10.7 ; 13.3 ; 35 ; 37 ; 4.6 ; 65 ; 36.6 ; 47.8 ; 13.9 ; 5.2 ; 6.6 ; 56.7 ; 21.8 ; 3.5 ; 3.2 ; 20.9 ; 4.5 ; 40.9 ; 19.1 ; 18.3 ; 6.4 ; 37.5 ; 51.8 ; 18.5 ; 60 ; 56 ; 2.6 ; 47.3 ; 43.6 ; 39.6 ; 18.1 ; 0.9 ; 3.4 ; 47 ; 15 ; 18.4 ; 28.7 ; 41 ; 1.6 ; 82.6 ; 12 ; 12.7 ; 2.1 ; 12.9 ; 31 ; 1.8 ; 1.7 ; 8.6 ; 13.5 ; 29.2 ; 0.8 ; 11.3 ; 10.4 ; 42.3 ; 8.5 ; 0.3 ; 1.9 ; 68.7 ; 3.6 ; 4.7 ; 24.8 ; 50 ; 9.4 ; 14.5 ; 20.2 ; 40.2 ; 14.2 ; 7.8 ; 35.9 ; 16.9 ; 62.1 ; 13.2 ; 23.9 ; 44.2 ; 43 ; 43.4 ; 69.3 ; 84.7 ; 8.1 ; 17.3 ; 70.1 ; 66 ; 7.9 ; 65.8 ; 34.8 ; 38.9 ; 6.8 ; 12.2 ; 18.8 ; 5.4 ; 8.3 ; 48.7 ; 66.6 ; 70.9 ; 3.1 ; 38.4 ; 1.5 ; 10.2 ; 1.3 ; 51 ; 38.1 ; 52.5 ; 29.4 ; 18.9 ; 59.5 ; 8.7 ; 56.2 ; 26.6 ; 1.4 ; 72.1 ; 71.4 ; 58 ; 7.5 ; 60.4 ; 29.7 ; 6.3 ; 36.8 ; 53.5 ; 6.1 ; 3.7 ; 71 ; 16.5 ; 60.2 ; 80 ; 76 ; 74.1 ; 68.6 ; 26.3 ; 23.8 ; 30.1 ; 76.4 ; 24.3 ; 40.5 ; 11.1 ; 66.7 ; 4.4 ; 64.9 ; 36.5 ; 40 ; 6.7 ; 10.9 ; 52.2 ; 71.9 ; 6.9 ; 46
PB_NUCLEATED_RBC_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	% Nucleated RBCs in the peripheral blood	Sample	3.2 ; 5.1 ; 0.6 ; 1.7 ; 0.8 ; 0 ; 0.2 ; 0.9 ; 0.3 ; 0.7 ; 7.1 ; 6 ; 1.6 ; 1.5 ; 0.5 ; 0.1 ; 1 ; 2 ; 43.4 ; 1.2 ; 2.9 ; 2.6 ; 0.4 ; 3.8 ; 4.8 ; 1.4 ; 5.5 ; 3.6 ; 32.3 ; 24.7 ; 1.8 ; 18.1 ; 1.3 ; 1.1 ; 23.2 ; 4.5 ; 3.7 ; 15.4 ; 5 ; 5.7 ; 50 ; 5.3 ; 6.9 ; 2.8 ; 2.3
PLATELET_COUNT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Platelet qualitative result	Sample	89 ; 20 ; 66 ; 134 ; 68 ; 48 ; 8 ; 25 ; 13 ; 33 ; 28 ; 17 ; 136 ; 43 ; 10 ; 57 ; 18 ; 21 ; 69 ; 15 ; 123 ; 93 ; 74 ; 125 ; 19 ; 47 ; 83 ; 322 ; 49 ; 62 ; 46 ; 51 ; 14 ; 9 ; 72 ; 50 ; 24 ; 32 ; 119 ; 71 ; 152 ; 228 ; 53 ; 22 ; 107 ; 122 ; 38 ; 34 ; 106 ; 23 ; 109 ; 63 ; 11 ; 99 ; 91 ; 45 ; 29 ; 39 ; 77 ; 92 ; 30 ; 40 ; 36 ; 90 ; 67 ; 108 ; 16 ; 243 ; 141 ; 42 ; 215 ; 55 ; 26 ; 75 ; 31 ; 299 ; 131 ; 138 ; 64 ; 115 ; 112 ; 105 ; 221 ; 87 ; 3 ; 283 ; 6 ; 127 ; 61 ; 59 ; 27 ; 5 ; 56 ; 60 ; 113 ; 58 ; 118 ; 12 ; 188 ; 110 ; 365 ; 117 ; 65 ; 176 ; 288 ; 4 ; 44 ; 96 ; 35 ; 80 ; 417 ; 178 ; 126 ; 104 ; 7 ; 247 ; 73 ; 193 ; 256 ; 166 ; 174 ; 133 ; 226 ; 139 ; 170 ; 345 ; 330 ; 150 ; 211 ; 358 ; 102 ; 206 ; 213 ; 103 ; 54 ; 81 ; 121 ; 84 ; 266 ; 41 ; 438 ; 222 ; 208 ; 101 ; 94 ; 162 ; 100 ; 202 ; 224 ; 219 ; 916 ; 148 ; 154 ; 52 ; 37 ; 88 ; 237 ; 410 ; 201 ; 360 ; 426 ; 146 ; 295 ; 175 ; 143 ; 395 ; 145 ; 95 ; 165
PRIORRADIATIONFOROTHERCANCER	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Did the patient receive radiation treatment for a prior non-heme malignancy	Patient	
PRIOR_CANCER	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Type of prior non-myeloid malignancy	Patient	
PRIOR_MDS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient ever been diagnosed with MDS	Patient	
PRIOR_MDSMPN	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient ever been diagnosed with MDS/MPN	Patient	
PRIOR_MPN	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Has the patient ever been diagnosed with MPN	Patient	
RNA_SEQUENCED	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	RNA Sequenced	Sample	No ; Yes
RNA_SEQ_ANALYSIS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Is RNA Seq data of the sample used in Analysis?	Sample	No ; Yes
SPECIFIC_DIAGNOSIS_AT_ACQUISITION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Specific Diagnosis at Acquisition	Sample	AML with mutated NPM1 ; Acute myelomonocytic leukaemia ; AML with minimal differentiation ; Acute monoblastic and monocytic leukaemia ; Acute myeloid leukaemia, NOS ; unknown ; Therapy-related myeloid neoplasms ; AML with myelodysplasia-related changes ; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 ; AML with maturation ; AML with t(6;9)(p23;q34); DEK-NUP214 ; AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 ; AML with mutated CEBPA ; Mixed phenotype acute leukaemia, T/myeloid, NOS ; Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA ; AML with t(9;11)(p22;q23); MLLT3-MLL ; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 ; Refractory anaemia with excess blasts ; Acute erythroid leukaemia ; Myelodysplastic syndrome, unclassifiable ; Atypical chronic myeloid leukaemia, BCR-ABL1 negative ; Acute undifferentiated leukaemia ; Blastic plasmacytoid dendritic cell neoplasm ; AML without maturation ; Essential thrombocythaemia ; Myeloid sarcoma ; Acute megakaryoblastic leukaemia ; Refractory cytopenia with multilineage dysplasia ; Myelodysplastic syndrome associated with isolated del(5q) ; Myeloid leukaemia associated with Down syndrome ; Chronic myelomonocytic leukaemia ; Myelodysplastic/myeloproliferative neoplasm, unclassifiable ; Plasma cell myeloma ; Primary myelofibrosis
SPECIFIC_DIAGNOSIS_AT_INCLUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Specific Diagnosis at Inclusion	Sample	AML with mutated NPM1 ; Acute myelomonocytic leukaemia ; AML with minimal differentiation ; Mastocytosis ; Acute monoblastic and monocytic leukaemia ; Chronic myelomonocytic leukaemia ; Acute myeloid leukaemia, NOS ; unknown ; Therapy-related myeloid neoplasms ; AML with myelodysplasia-related changes ; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 ; AML with maturation ; AML with t(6;9)(p23;q34); DEK-NUP214 ; AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 ; AML with mutated CEBPA ; Mixed phenotype acute leukaemia, T/myeloid, NOS ; Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA ; AML with t(9;11)(p22;q23); MLLT3-MLL ; Secondary myelofibrosis ; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 ; Refractory anaemia with excess blasts ; Acute erythroid leukaemia ; Myelodysplastic syndrome, unclassifiable ; Atypical chronic myeloid leukaemia, BCR-ABL1 negative ; Acute undifferentiated leukaemia ; Blastic plasmacytoid dendritic cell neoplasm ; AML without maturation ; Essential thrombocythaemia ; Myeloid sarcoma ; Unknown ; Acute megakaryoblastic leukaemia ; Refractory cytopenia with multilineage dysplasia ; Myelodysplastic syndrome associated with isolated del(5q) ; Myeloid leukaemia associated with Down syndrome ; Primary myelofibrosis ; Myelodysplastic/myeloproliferative neoplasm, unclassifiable ; Plasma cell myeloma
SURFACE_ANTIGENS	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Surface antigens as determined by clinical flow	Sample	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative ; CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive; Negative for expression of CD34 and HLA-DR ; dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive ; CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive ; CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive ; Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positi ; CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive ; CD13, CD33, CD38, CD56, CD117, and MPO positive ; partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive ; partial CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR, and partial TdT/positive ; partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive ; CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT ; partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive ; CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive ; CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive ; CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive ; CD13, CD33, partial CD34, CD38, CD117 and CD123 ; Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR ; partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive ; CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive ; CD13, CD34, CD38, CD117, CD123, HLA-DR ; dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive ; dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive ; partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive ; dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO ; Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive ; CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive ; CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+) ; CD13, CD33, CD34, CD38, CD117,  CD123, dim HLA-DR, partial MPO ; partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR ; CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO ; CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA- ; CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+) ; CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO ; CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123 ; Immunophenotype:  CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive ; CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive ; CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO + ; partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive ; - 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO ; partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive ; CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive ; CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+ ; atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, ; partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive ; CD13, dim CD33, CD34, CD38,     CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO ; CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive ; CD7, CD13, CD33, CD34, CD38, CD56, partial CD64,     CD117,        dim CD123, HLA-DR and MPO+ ; CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive ; CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +). ; dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO ; CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive ; CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive ; CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). ; CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive ; Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive ; CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR ; CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR ; CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial) ; CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +) ; CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive ; dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive ; CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO ; CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7 ; partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO ; CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR. ; CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive ; CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive ; CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38 ; brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-),  ; CD13, CD33, CD34. CD45, subset CD64, CD79a, CD117,HLA-DR, and subset TdT positive). ; CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, HLA-DR and partial TdT positive; aberrant monocytic population: CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive. ; Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. ; CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-). ; CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+) ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial  ; CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) ; CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) ; CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD7 ; CD7, CD13, CD33, CD34, dim CD45, CD56, CD117, CD123, and HLA-DR positive. ; Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes. ; CD13, CD33, CD34, dim CD38, CD117, and HLA-DR positive (10/31/13). ; CD13, CD33, CD34, CD117, and MPO+. ; Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia. ; CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo ; CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive ; Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45. ; CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO ; CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117 ; CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT ; Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia. ; CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive ; partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive ; CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive. ; CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive ; CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15 ; CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable). ; CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO ; CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR ; CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +) ; CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive ; CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+). ; The analysis shows CD34+ blasts comprise approximately 4.2% of total CD45+ events and show variable expression of CD13, CD33, CD117, and dim partial CD123.  Please see below for antibodies tested.  B-cells (2% of lymphocyte gate) show polytypic surface li ; CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-) ; partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive. ; CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive ; CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial). ; CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive ; CD10, CD13, CD33, CD34, CD56 and HLA-DR positive ; dim CD13, CD33, CD34, CD117, CD123, and dim HLADR ; CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+ ; CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO ; Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes ; partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive ; Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes ; CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR ; dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+ ; CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive ; CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+) ; CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+). ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+) ; dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive ; CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT ; CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-) ; CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO ; CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO ; A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. ; Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia ; Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64. ; CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +) ; CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+ ; CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-). ; CD13, CD33, CD34, CD117, MPO and HLA-DR ; CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT ; CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO. ; CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117 ; CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR ; CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR. ; CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117 ; CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression ; CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO ; CD13, CD34, CD58 and CD117 ; CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19 ; Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT ; Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia ; Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm ; partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable) ; partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive ; CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT ; CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +). ; CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive. ; CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7 ; dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative ; CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+). ; CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) ; CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-) ; CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+ ; CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive ; CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive ; dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive ; CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO ; CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-) ; dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive ; CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variab ; dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive. ; dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive ; Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia. ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+ ; dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive ; CD13, partial/dim CD33, CD38, CD58, CD117 and MPO ; Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. ; CD13, CD33, CD34, CD117, and HLA-DR positive ; ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-). ; CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and vari ; CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive ; dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive ; CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-) ; population of CD117+ progenitors (~3.5% of total      CD45+ events) that expresses CD13, dim CD33, CD38, CD58, CD117, dim CD123 and HLA-DR, without the expression of CD64. ; CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT ; CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive ; CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive ; CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+) ; maturing myeloid population. Myeloid blasts are about 2%. Monocytes are 6/7% and without antigen aberrancy.Lymphocytes are 10-11%. Mostly T cells and these have a 1:1 CD4:CD8 ratio.There are approximately 20% of lymphocytes as B cells and these are polycl ; large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leuk ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appea ; CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive ; CD34, dim CD45, CD117 ; CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim  ; CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO ; CD13, CD33, dim CD71, CD117, CD123, and MPO ; positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers ; CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-). ; positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT ; partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT ; positive for CD34, CD117,  CD13, CD33 and HLA-DR ; CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive ; CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(sma ; CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+ ; CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+) ; positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5 ; positive for CD34, CD117, CD13, CD33, and HLA-DR ; partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117 ; positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7 ; positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR ; The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56. ; dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive. ; CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-). ; CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-D ; dim CD4, dim CD7, dim CD11b,      CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT ; Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. ; partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO ; CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive ; Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia ; It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). ; Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with d ; CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-). ; dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive ; CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature c ; positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO ; CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +),  ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123 ; variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive ; variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive ; CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-). ; positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase. ; #1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive ; The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR positive. Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without  aberrant a ; partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive ; positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO ; CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +) ; weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61. ; positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR ; positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO ; Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive ; A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR ; variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive ; positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO ; CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive ; CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive ; partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive) ; CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR ; CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-). ; CD7, CD13, weak CD33, CD34, CD117, and HLA-DR ; CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably ; positive CD13, CD34, dim CD45, CD117 and HLA-DR ; The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (incl ; CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive ; CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56. ; CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. ; CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably
TOTAL_PROTEIN_LEVEL	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	Total Protein Levels in the Blood (g/dL)	Sample	7.6 ; 5.8 ; 5.4 ; 6.3 ; 4.7 ; 4.6 ; 6.7 ; 6.9 ; 5 ; 6.1 ; 5.9 ; 6.4 ; 6.6 ; 5.6 ; 5.5 ; 6.8 ; 7.1 ; 6.5 ; 4.4 ; 5.3 ; 4.9 ; 7 ; 4.5 ; 7.5 ; 3.6 ; 7.3 ; 6.2 ; 7.4 ; 7.9 ; 7.2 ; 6 ; 5.2 ; 8.2 ; 7.8 ; 5.1 ; 5.7 ; 8.8 ; 8 ; 4.8 ; 7.7 ; 4.3 ; 8.7 ; 0
TP53_MUTATION	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	TP53 mutation is present.	Sample	Negative ; Positive ; p.S366A; MAF 50% ; p.R273S; MAF 40% ; C238R; MAF 5% (not confirmed by Sanger seq) ; V173M; MAF 80% ; p.R273H, MAF 96% ; p.H193R; MAF 92% ; p.G245S; MAF 87% ; p.G245S; MAF 96% ; p.T312fs*25 (one nucleotide insertion); MAF 30% ; p.R280T;  MAF 36% ; p.I251M; MAF 34% ; p.R248Q; MAF 80% ; p.V272M; MAF 88% ; p.R283C; MAF 49% ; p.R273H; MAF 44% ; loss exons 10-11 ; p.R43H; MAF 76.7% ; p.N107D; MAF 97.6% ; Foundation; R337L ; Splice site (5' splice site mutation in intron 4); MAF 44% ; p.I254N; MAF 40% ; p.R248Q; MAF 56% ; Foundation; splice site 560-2insA; MAF 44% ; p.P19H; MAF 8.9% ; p.G266V; MAF 55% ; p.V272_R273insL; MAF 75% (previously 71% in 4/21/15 peripheral blood) ; H193Y; MAF 65.0% ; p.Y220C; MAF 35% ; p.?; MAF 91% ; p.R248W; MAF 57% ; R213fs; MAF 34% ; Foundation; L206fs*41; MAFs: 31% ; p.R282Q, MAF 51% ; p.K132R; MAF 45% ; c.610G>T;p.E204*    MAF 51%
TREATMENT_TYPE	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Treatment Type	Patient	
TYPE_INDUCTION_TREATMENT	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Type of Induction Treatment received	Sample	Standard Chemotherapy ; Other ; Intrathecal ; Targeted Therapy - Kinase Inhibitor(s) ; Supportive/Palliative Care
WBC	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	NUMBER	White bloodcell count.	Sample ; Patient	94 ; 53.5 ; 282.1 ; 35.9 ; 62.9 ; 29.7 ; 112.3 ; 31.1 ; 58.8 ; 5.3 ; 2.54 ; 17.79 ; 65.2 ; 2.5 ; 23.1 ; 48.2 ; 21.5 ; 79.7 ; 16.1 ; 459.6 ; 51.8 ; 18.4 ; 11.9 ; 14.9 ; 17.9 ; 21 ; 179.1 ; 7.6 ; 6.8 ; 64.3 ; 84.1 ; 37.1 ; 97 ; 20.7 ; 7.9 ; 16.5 ; 2.2 ; 0.6 ; 21.7 ; 53 ; 1.5 ; 0.9 ; 33.8 ; 85.9 ; 24.4 ; 4.8 ; 8.5 ; 14 ; 53.9 ; 13.8 ; 19.5 ; 11.8 ; 28 ; 61.2 ; 22.79 ; 9.8 ; 5.8 ; 6 ; 29.4 ; 22.8 ; 56.5 ; 5.1 ; 13.3 ; 26 ; 25.3 ; 40.8 ; 8.8 ; 8.7 ; 1.3 ; 140 ; 4.3 ; 4 ; 0.8 ; 29.25 ; 43.72 ; 16.2 ; 4.2 ; 3.42 ; 5.94 ; 5.23 ; 250.23 ; 2 ; 9.1 ; 13.63 ; 5.5 ; 7.2 ; 49.4 ; 1.8 ; 27.4 ; 26.3 ; 7.5 ; 10.21 ; 24.2 ; 13.9 ; 11.36 ; 3.2 ; 4.06 ; 1.04 ; 9.5 ; 96.64 ; 1.7 ; 13.22 ; 20.2 ; 43.3 ; 3.28 ; 33 ; 12.9 ; 1.2 ; 0.3 ; 2.1 ; 14.66 ; 11.93 ; 16.66 ; 12.44 ; 13.26 ; 35.91 ; 4.01 ; 3.85 ; 2.6 ; 58.5 ; 2.42 ; 47.2 ; 1.6 ; 2.31 ; 5.9 ; 4.34 ; 12.87 ; 5.98 ; 63.75 ; 2.22 ; 55.35 ; 38.47 ; 6.23 ; 20.82 ; 4.67 ; 9.7 ; 2.51 ; 3.6 ; 0.98 ; 95.2 ; 8.2 ; 31.85 ; 57.23 ; 16.95 ; 11.2 ; 51.64 ; 1.9 ; 0.49 ; 58.86 ; 99.3 ; 28.1 ; 40.76 ; 11.28 ; 0.92 ; 44.76 ; 152.75 ; 29.18 ; 0.94 ; 2.7 ; 2.12 ; 34.4 ; 25.11 ; 2.37 ; 137.6 ; 49.29 ; 5.6 ; 0.1 ; 2.23 ; 40.2 ; 10.75 ; 261.2 ; 2.78 ; 11.38 ; 16.11 ; 0.81 ; 45.6 ; 1 ; 11.7 ; 1.75 ; 16.03 ; 41.4 ; 5.92 ; 78.71 ; 22.95 ; 12.25 ; 11.13 ; 98.9 ; 29.1 ; 2.05 ; 41.35 ; 6.44 ; 8.15 ; 89.17 ; 1.31 ; 3.53 ; 5.39 ; 161.89 ; 3.8 ; 1.4 ; 19.99 ; 21.12 ; 1.09 ; 30 ; 7.62 ; 71.19 ; 427.46 ; 117.53 ; 53.76 ; 5.16 ; 180 ; 4.95 ; 31.66 ; 13.68 ; 3.65 ; 7.1 ; 64.6 ; 55 ; 66.67 ; 4.5 ; 33.1 ; 6.6 ; 17.63 ; 48.03 ; 2.9 ; 20.18 ; 12.8 ; 93.94 ; 3.3 ; 27.5 ; 50.74 ; 46.8 ; 4.85 ; 73.42 ; 50.58 ; 20.1 ; 4.7 ; 18.25 ; 68.79 ; 20.8 ; 70.84 ; 81 ; 25.63 ; 24.72 ; 8.69 ; 25.7 ; 26.5 ; 29 ; 1.46 ; 3.1 ; 0.7 ; 2.3 ; 39.69 ; 1.93 ; 73.4 ; 4.48 ; 3.4 ; 3.87 ; 2.8 ; 8 ; 7.19 ; 19.8 ; 1.23 ; 103.66 ; 139.9 ; 58.2 ; 133.63 ; 10.7 ; 57.08 ; 1.81 ; 25 ; 87.72 ; 133.7 ; 20.39 ; 9.4 ; 49.7 ; 0.5 ; 11.01 ; 40.53 ; 22.1 ; 84.96 ; 37.2 ; 134.36 ; 1.61 ; 35 ; 14.94 ; 206.64 ; 12.78 ; 2.56 ; 16.84 ; 12 ; 4.33 ; 42.34 ; 42.91 ; 24.98 ; 34 ; 21.6 ; 5.79 ; 140.18 ; 6.21 ; 3.74 ; 46.79 ; 1.39 ; 2.68 ; 16.65 ; 1.06 ; 20.77 ; 19.3 ; 137.54 ; 24.64 ; 8.94 ; 8.21 ; 6.3 ; 52.8 ; 67.53 ; 27.17 ; 44.8 ; 84.69 ; 24.01 ; 6.04 ; 8.43 ; 3.63 ; 21.84 ; 19.64 ; 6.5 ; 14.3 ; 4.26 ; 0.39 ; 10.08 ; 20.3 ; 4.42 ; 65.58 ; 67.36 ; 7.08 ; 7.7 ; 3.72 ; 69.84 ; 62.87 ; 97.26 ; 20.44 ; 1.36 ; 7.92 ; 3.38 ; 31.02 ; 181.08 ; 17.1 ; 0.2 ; 2.35 ; 175.91 ; 96 ; 42.57 ; 8.29 ; 25.02 ; 6.63 ; 42.35 ; 19.76 ; 49.93 ; 240.43 ; 56.03 ; 181.66 ; 67.7 ; 26.57 ; 125.9 ; 230.05 ; 11.4 ; 47.5 ; 55.42 ; 18.3 ; 100.2 ; 3.09 ; 125.16 ; 3.49 ; 10 ; 16.24 ; 116.52 ; 2.64 ; 2.41 ; 22.01 ; 53.3 ; 166.91 ; 122.89 ; 58.7 ; 5 ; 66.7 ; 109.77 ; 4.4 ; 70.01 ; 1.13 ; 5.35 ; 6.28 ; 9.87 ; 73.28 ; 5.84 ; 4.17 ; 214.49 ; 4.54 ; 8.35 ; 71.1 ; 4.53 ; 162.21 ; 39.25 ; 12.98 ; 104.44 ; 12.75 ; 5.54 ; 6.13 ; 8.98 ; 3.21 ; 9.27 ; 129.5 ; 7.14 ; 3.88 ; 239 ; 35.1 ; 6.69 ; 3.5 ; 42.9 ; 151.6 ; 16.4 ; 5.05 ; 61.22 ; 13.83 ; 39.12 ; 26.4 ; 44.83 ; 4.05 ; 34.6 ; 1.27 ; 3 ; 58.97 ; 30.2 ; 30.54 ; 16.43 ; 19.67 ; 2.49 ; 25.85 ; 10.6 ; 6.18 ; 18.38 ; 116.57 ; 2.18 ; 108.9 ; 4.9 ; 40.02 ; 34.36 ; 2.16 ; 2.43 ; 99.87 ; 44.63 ; 93.2 ; 115.15 ; 8.16 ; 1.65 ; 33.81 ; 119.6 ; 118 ; 9.28 ; 18.71 ; 24.23 ; 73 ; 63.4 ; 46.27 ; 47.35 ; 34.76 ; 9 ; 190 ; 85.5 ; 24.9 ; 92.55 ; 41.91 ; 7.4 ; 3.7 ; 3.9 ; 128 ; 15.8 ; 6.2 ; 1.1 ; 2.4 ; 9.6 ; 44.9 ; 12.2 ; 6.1 ; 5.2 ; 7 ; 5.7 ; 10.2 ; 6.4 ; 10.9 ; 13 ; 8.1 ; 20 ; 14.1 ; 4.1 ; 3.73 ; 2.27 ; 2.39 ; 5.72 ; 8.83 ; 13.99 ; 2.47 ; 6.7 ; 3.91 ; 1.53 ; 3.52 ; 7.73 ; 3.18 ; 4.11 ; 9.61 ; 2.88 ; 13.29 ; 4.49 ; 1.26 ; 5.82 ; 7.75 ; 3.68 ; 1.35 ; 4.13 ; 5.06 ; 4.89 ; 4.62 ; 3.93 ; 6.39 ; 9.03 ; 2.98 ; 4.15 ; 1.24 ; 3.86 ; 3.16 ; 6.37 ; 4.27 ; 3.89 ; 2.93 ; 3.26 ; 2.63 ; 6.33 ; 1.94 ; 8.61 ; 2.59 ; 8.47 ; 2.08 ; 7.16 ; 6.64 ; 6.61 ; 10.4 ; 8.4 ; 120.1 ; 59.2 ; 67.8 ; 47.9 ; 5.4 ; 7.8 ; 43.8 ; 8.6 ; 8.3 ; 6.571 ; 11.1 ; 6.9 ; 42.2 ; 4.6 ; 19.6 ; 9.2 ; 91.8 ; 39.7 ; 15 ; 13.7 ; 20.6 ; 31 ; 1.956 ; 16.6 ; 13.5 ; 7.82 ; 7.3 ; 10.8 ; 2.13 ; 9.04 ; 4.55 ; 8.9 ; 22.92 ; 6.51 ; 5.38 ; 2.28 ; 6.86 ; 5.42 ; 46.9 ; 2.25 ; 3.58 ; 2.71 ; 11.6 ; 2.65 ; 4.74 ; 4.31 ; 5.65 ; 2.19 ; 13.56 ; 1.73 ; 7.02 ; 45 ; 1.11 ; 4.69 ; 7.86 ; 1.21 ; 3.15 ; 4.25 ; 5.32 ; 4.97 ; 7.47 ; 1.64 ; 2.72 ; 2.85 ; 3.44 ; 28.61 ; 7.26 ; 17 ; 21.67 ; 3.07 ; 33.5 ; 5.47 ; 1.95 ; 24.39 ; 7.64 ; 1.49 ; 2.61 ; 14.74 ; 4.66 ; 4.44 ; 2.83 ; 5.49 ; 3.17 ; 15.81 ; 5.95 ; 5.15 ; 3.35 ; 6.12 ; 8.04 ; 1.45 ; 7.61 ; 5.01 ; 7.79 ; 28.7 ; 2.26 ; 15.5 ; 6.84 ; 2.55 ; 3.24 ; 5.08 ; 1.78 ; 4.16 ; 12.7 ; 1.96 ; 10.3 ; 4.08 ; 1.68 ; 5.86 ; 3.78 ; 3.81 ; 6.11 ; 1.42 ; 2.69 ; 3.33 ; 2.95 ; 5.69 ; 6.47 ; 26.9 ; 6.19 ; 2.79 ; 2.32 ; 6.02 ; 5.31 ; 12.3 ; 1.85 ; 3.19 ; 18 ; 1.58 ; 1.08 ; 11.3 ; 18.1 ; 10.1 ; 14.4 ; 15.3 ; 39.2 ; 9.3 ; 26.8 ; 10.5 ; 9.9 ; 3.83 ; 24.92 ; 13.37 ; 15.2 ; 2.91 ; 136.53 ; 50.13 ; 7.06 ; 1.59 ; 3.79 ; 9.26 ; 11.55 ; 12.01 ; 2.02 ; 0.72 ; 2.82 ; 20.4 ; 11.59 ; 23.3 ; 15.4 ; 42 ; 33.6 ; 0.4 ; 27.7 ; 29.9 ; 6.55 ; 8.65 ; 2.66 ; 3.46 ; 7.21 ; 6.71 ; 3.39 ; 3.06 ; 4.56 ; 154.4 ; 2.86 ; 3.82 ; 58.79 ; 1.62 ; 86.05 ; 10.57 ; 2.99 ; 1.83 ; 2.96 ; 3.71 ; 42.4 ; 36.9 ; 46 ; 70.4 ; 22 ; 57.5 ; 59 ; 95.1 ; 45.2 ; 30.6 ; 15.9 ; 60.4 ; 49.1 ; 16 ; 74 ; 37.7 ; 17.5 ; 89.6 ; 12.4 ; 11 ; 25.1 ; 12.1 ; 34.2 ; 134 ; 64.7 ; 74.3 ; 35.8 ; 38.8 ; 4.77 ; 3.51 ; 32 ; 24 ; 43 ; 105 ; 78 ; 23 ; 50 ; 12.6 ; 14.5 ; 22.9 ; 18.2 ; 96.8 ; 16.8 ; 57.2 ; 25.4 ; 36.6 ; 61 ; 37.4 ; 43.1 ; 21.4 ; 43.2 ; 51.2 ; 13.2 ; 3.31 ; 126 ; 21.9 ; 3.92 ; 8.02 ; 4.22 ; 8.37 ; 44.6 ; 6.76 ; 1.87 ; 4.68 ; 0.37 ; 2.04 ; 3.59 ; 3.43 ; 2.97 ; 2.57 ; 6.79 ; 5.18 ; 2.52 ; 25.6 ; 3.25 ; 4.65 ; 29.6 ; 1.91 ; 9.57 ; 34.8 ; 2.24 ; 3.55 ; 9.06 ; 9.18 ; 5.68 ; 31.5 ; 116 ; 3.32 ; 4.78 ; 3.36 ; 3.66 ; 7.77 ; 1.77 ; 5.51 ; 4.86 ; 4.37 ; 1.57 ; 7.89 ; 5.62 ; 2.81 ; 4.61 ; 7.03 ; 4.39 ; 22.7 ; 7.69 ; 7.54 ; 4.59 ; 2.09 ; 1.47 ; 53.8 ; 4.88 ; 30.4 ; 9.92 ; 12.5 ; 5.19 ; 5.26 ; 1.98 ; 1.76 ; 2.73 ; 9.59 ; 10.73 ; 1.88 ; 2.06 ; 3.94 ; 6.58 ; 2.48 ; 7.23 ; 0.21 ; 5.66 ; 3.02 ; 6.46 ; 4.04 ; 4.98 ; 4.51 ; 6.74 ; 23.28 ; 5.75 ; 7.35 ; 7.43 ; 5.63 ; 5.93 ; 8.28 ; 9.19 ; 3.69 ; 2.62 ; 1.84 ; 2.75 ; 7.65 ; 6.95 ; 3.11 ; 5.29 ; 3.03 ; 53.14 ; 13.1 ; 7.51 ; 1.86 ; 30.8 ; 3.12 ; 2.76 ; 6.65 ; 17.8 ; 4.09 ; 6.05 ; 14.31 ; 6.73 ; 6.66 ; 6.08 ; 2.45 ; 5.77 ; 6.52 ; 3.13 ; 6.85 ; 4.57 ; 33.36 ; 6.91 ; 5.37 ; 35.6 ; 8.64 ; 8.59 ; 6.92 ; 21.74 ; 3.04 ; 5.74 ; 33.03 ; 23.21 ; 2.38 ; 7.94 ; 7.25 ; 5.27 ; 0.97 ; 20.16 ; 31.9 ; 4.18 ; 4.24 ; 9.56 ; 4.83 ; 5.21 ; 2.84 ; 2.15 ; 26.2 ; 17.6 ; 4.29 ; 6.68 ; 3.14 ; 3.64 ; 3.27 ; 4.03 ; 10.65 ; 8.26 ; 1.79 ; 3.41 ; 6.24 ; 1.89 ; 3.08 ; 7.38 ; 6.42 ; 2.87 ; 7.96 ; 10.24 ; 15.55 ; 3.48 ; 3.45 ; 2.03 ; 11.04 ; 2.58 ; 1.33 ; 17.4 ; 3.98 ; 8.57 ; 2.29 ; 1.54 ; 2.14 ; 5.57 ; 1.66 ; 41.45 ; 6.17 ; 6.29 ; 3.96 ; 7.42 ; 32.52 ; 6.94 ; 2.46 ; 3.37 ; 1.17 ; 5.41 ; 3.54 ; 9.34 ; 11.74 ; 1.72 ; 6.45 ; 1.51 ; 1.63 ; 17.7 ; 2.07 ; 18.55 ; 22.34 ; 25.8 ; 4.179 ; 25.2 ; 2.11 ; 11.5 ; 2.89 ; 1.37
WHOLE_EXOME_SEQUENCING	LightSalmon	Acute Myeloid Leukemia (OHSU, Nature 2018)	STRING	Whole Exome Sequencing	Sample	Yes ; No
AGE_AT_SPECIMEN_ACQUISITION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	NUMBER	Difference in years between specimen collection date and patient's date of birth	Sample	27 ; 31 ; 36 ; 70 ; 71 ; 14 ; 77 ; 73 ; 74 ; 69 ; 59 ; 67 ; 61 ; 60 ; 72 ; 65 ; 66 ; 33 ; 41 ; 62 ; 55 ; 57 ; 68 ; 53 ; 18 ; 38 ; 50 ; 81 ; 58 ; 83 ; 34 ; 24 ; 75 ; 64 ; 7 ; 79 ; 56 ; 22 ; 5 ; 8 ; 78 ; 42 ; 51 ; 37 ; 32 ; 30 ; 47 ; 52 ; 54 ; 63 ; 40 ; 35 ; 39 ; 86 ; 48 ; 21 ; 80 ; 17 ; 46 ; 44 ; 10 ; 85 ; 23 ; 45 ; 49 ; 84 ; 26 ; 76 ; 82 ; 25 ; 29 ; 43 ; 16 ; 12 ; 3 ; 87 ; 2 ; 20 ; 0 ; 88 ; 28 ; 4
ALLELIC_RATIO	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	NUMBER	Ratio of FLT3-ITD mutated alleles to wild-type alleles	Sample	0.960784314 ; 1.173913043 ; 2.03030303 ; 0.923076923 ; 0.01010101 ; 0.851851852 ; 0 ; 2.448275862 ; 7.333333333 ; 19 ; 0.5625 ; 1.083333333 ; 1.272727273 ; 0.785714286 ; 4.555555556 ; 0.111111111 ; 0.587301587 ; 0.886792453 ; 2.125 ; 1 ; 0.041666667 ; 4 ; 15.66666667 ; 0.020408163 ; 0.538461538 ; 0.470588235 ; 10.11111111 ; 5.666666667 ; 1.222222222 ; 3 ; 5.25 ; 1.941176471 ; 3.761904762 ; 0.694915254 ; 3.166666667 ; 0.388888889 ; 0.333333333 ; 0.075268817 ; 0.449275362 ; 1.325581395 ; 9 ; 0.315789474 ; 0.234567901 ; 0.666666667 ; 0.639344262 ; 2.333333333 ; 0.612903226 ; 1.5 ; 0.176470588 ; 0.25 ; 0.428571429 ; 0.162790698 ; 0.086956522 ; 0.515151515 ; 13.28571429 ; 0.063829787 ; 11.5 ; 0.818181818 ; 0.492537313 ; 0.298701299 ; 0.724137931 ; 0.265822785 ; 0.136363636 ; 0.754385965 ; 1.127659574 ; 0.149425287 ; 32.33333333 ; 0.03092784 ; 1.040816327 ; 0.204819277
ASXL1	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Manual review of ASXL1 variant results from clinical testing and WES	Sample	ASXL1 (p.G646Wfs*12; 27.9%) ; ASXL1 (p.S846Vfs*21; 33.0%) ; ASXL1 (p.G644Wfs*12; 37.3%) ; ASXL1 (p.G646Wfs*12; 28.6%) ; ASXL1 (p.G646Wfs*12; 26.2%) ; ASXL1 (p.G645Wfs*12; 40.0%) ; ASXL1 (p.R693*; 42.5%) ; ASXL1 (p.A619Pfs*15; 38.1%) ; ASXL1 (p.A619fs*14; MAF 50%) ; ASXL1 (p.W583*; 47.9%) ; ASXL1 (p.G645Vfs*58; 12.5%) ; ASXL1 (p.V751Gfs*22; 17.4%) ; ASXL1 (p.G645Vfs*58; 8.3%)|ASXL1 (p.C789Wfs*2; 30.5%) ; ASXL1 (p.E635Rfs*15; 22.0%) ; ASXL1 (p.G646Wfs*12; 27.3%) ; ASXL1 (p.G645Vfs*58; 43.8%) ; ASXL1 (p.G646Wfs*12; 32.6%) ; ASXL1 (p.E635Rfs*15; 14.0%) ; ASXL1 (p.L823*; 38.0%) ; ASXL1 (p.R693*; 64.3%) ; ASXL1 (p.D943Qfs*6; 38.5%) ; ASXL1 (p.G645Vfs*58; 15.0%) ; ASXL1 (p.Q512*; 56.3%)|ASXL1 (p.G645Vfs*58; 9.1%) ; ASXL1 (p.G646Wfs*12; 31.2%) ; ASXL1 (p.G645Vfs*58; 10.5%) ; ASXL1 (p.R549Pfs*2; 42.0%) ; ASXL1 (p.E657*; 50.0%) ; ASXL1 (p.G646Wfs*12; 25.0%) ; ASXL1 (p.G645Vfs*58; 8.0%) ; ASXL1 (p.Q588*; MAF 43% ) ; ASXL1 (p.Q588*; MAF 49%) ; ASXL1 (p.E635Rfs*15; 18.8%) ; ASXL1 (p.D720Rfs*18; 14.1%) ; ASXL1 (p.G646Wfs*12; 47.4%) ; ASXL1 (p.S747Pfs*25; 32.6%) ; ASXL1 (p.G646Wfs*12; 20.0%) ; ASXL1 (p.G646Wfs*12; 21.1%) ; ASXL1 (p.W898*; 42.1%) ; ASXL1 (p.G646Wfs*12; 14.7%) ; ASXL1 (p.C687Yfs*30; 28.6%) ; ASXL1 (p.W960*; 48.8%) ; ASXL1 (p.E635Rfs*15; 20.2%) ; ASXL1 (p.E635Rfs*15; 10.5%) ; ASXL1 (p.R693*; 19.8%) ; ASXL1 (p.G645Wfs*12; 60.0%) ; ASXL1 (p.G646Wfs*12; 39.4%) ; ASXL1 (c.1940dup; MAF 37.9%) ; ASXL1 (p.Y425*; 46.8%) ; ASXL1 (p.G645Vfs*58; 16.7%) ; ASXL1 (p.S1028*; MAF 14%) ; ASXL1 (p.G646Wfs*12; 39.3%) ; ASXL1 (p.G645Vfs*58; 10.0%) ; ASXL1 (p.G646Wfs*12; 28.0%) ; ASXL1 (p.G646Wfs*12; 40.0%) ; ASXL1 (p.Q428*; 43.9%) ; ASXL1 (p.Q428*; 43.4%) ; ASXL1 (p.Q428*; 44.3%) ; ASXL1 (p.R693*; 38.7%) ; ASXL1 (p.G646Wfs*12; 50.0%) ; ASXL1 (p.G645Vfs*58; 14.3%) ; ASXL1 (p.G645Vfs*58; 12.0%) ; ASXL1 (p.G646Wfs*12; 11.9%)|ASXL1 (p.R417*; 23.6%) ; ASXL1 (p.R693*; 50.0%) ; ASXL1 (p.G646Wfs*12; 26.9%) ; ASXL1 (p.E635Dfs*22; 42.9%) ; ASXL1 (p.G646Wfs*12; 30.1%) ; ASXL1 (p.L823*; 45.9%) ; ASXL1 (p.G646Wfs*12; 12.8%) ; ASXL1 (p.G646Wfs*12; 10.8%) ; ASXL1 (p.G646Wfs*12; 30.2%) ; ASXL1 (p.A752Lfs*20; 43.9%) ; ASXL1 (p.E635Rfs*15; 24.3%) ; ASXL1 (p.G646Wfs*12; 36.4%) ; ASXL1 (p.C632*; 20.8%) ; ASXL1 (p.E865*; 39.7%) ; ASXL1 (p.G646Wfs*12; 24.8%) ; ASXL1 (p.E635Rfs*15; 16.4%) ; ASXL1 (p.R634Kfs*24; 38.6%) ; ASXL1 (p.H631N; 29.3%)|ASXL1 (p.R634Gfs*22; 25.0%) ; ASXL1 (p.G646Wfs*12; 34.3%) ; ASXL1 (p.G646Wfs*12; 16.3%) ; ASXL1 (p.C687Yfs*30; 45.2%) ; ASXL1 (p.G646Wfs*12; 33.3%) ; ASXL1 (p.G646Wfs*12; 32.0%) ; ASXL1 (p.G646Wfs*12; 36.6%) ; ASXL1 (p.G646Wfs*12; 35.0%) ; ASXL1 (p.G646Wfs*12; 29.2%) ; ASXL1 (p.K618_A619ins*; 43.5%) ; ASXL1 (p.G646Wfs*12; 36.2%) ; ASXL1 (p.G646Wfs*12; 26.8%) ; ASXL1 (p.D821Efs*15; 26.7%)|ASXL1 (p.D821Wfs*6; 20.1%) ; ASXL1 (p.G646Wfs*12; 37.6%) ; ASXL1 (p.G646Wfs*12; 31.3%) ; ASXL1 (p.G646Wfs*12; 37.2%) ; ASXL1 (p.C594Mfs*25; 38.2%) ; ASXL1 (p.G1397S; VAF 44%) ; ASXL1 (p.T514Nfs*15; 34.3%) ; ASXL1 (p.T806fs*16; VAF 4%)
CAUSE_OF_DEATH	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	"""Assessment of cause of death if vitalStatus is """"Dead"""""""	Patient	
CEBPA_BIALLELIC	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Was the CEBPA variant biallelic?	Sample	bi ; mono
CENTER_ID	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	NUMBER	Unique identifier for each institution that contributed specimens	Sample	1 ; 7 ; 3 ; 2 ; 4 ; 5 ; 6 ; 8
CUMULATIVE_CHEMO	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Has patient received chemotherapy during the course of their treatment for the current heme malignancy?	Patient	
DISEASE_STAGE_AT_SPECIMEN_COLLECTION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Description of the patient's stage of disease at the time of specimen collection.	Sample	Initial Diagnosis ; Relapse ; Residual ; Unknown ; Remission
DX_AT_INCLUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Diagnosis at time of earliest specimen inclusion by collection date	Patient	
ELN2017	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Risk classification assigned to the specimen based on European Leukemia Network 2017 guidelines	Sample	Intermediate ; NonInitial ; FavorableOrIntermediate ; Adverse ; IntermediateOrAdverse ; MissingMutations ; Favorable ; MissingKaryo ; NonAML
FAB_BLAST_MORPHOLOGY	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	French-American-British (FAB) morphological classification	Sample	M1 ; M4 ; M2 ; NOS ; M0 ; M5 ; M3 ; M6 ; M7 ; M4eo ; M5a ; M6b ; M0/M1 ; M6a ; M5b
FLT3_ITD	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Consensus result from internally run PCR assay and capillary electrophoresis and/or CLIA lab assay and/or whole-exome sequencing	Sample	Positive ; Negative ; FALSE ; TRUE
IS_DENOVO	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	The specimen was obtained at the time of de novo disease	Sample	FALSE ; TRUE ; unknown
IS_RELAPSE	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	The specimen was obtained at time of relapsed disease	Sample	FALSE ; TRUE ; unknown
IS_TRANSFORMED	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	The patient transformed from another heme malignancy before or at the time of specimen collection	Sample	FALSE ; TRUE ; unknown
NON_AML_MDSMPN_SPECIFIC_DX_AT_ACQUISITION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Patient's diagnosis at the time of specimen collection was not AML, MDS, MPN, or MDS/MPN	Sample	FALSE ; TRUE
NPM1	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Consensus result from internally run PCR assay and capillary electrophoresis and/or CLIA lab assay and/or whole-exome sequencing	Sample	Positive ; Negative
OTHER_CYTOGENETICS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	FISH results pulled from cytogenetics report in EMR	Sample	Normal ; Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%) ; 6q deletion (79%) ; normal ; DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype. ; Signal copy for CEP 8 and ETO ; trisomy 8 ; trisomy 13 ; Missing ABL and ASS signal (84%) ; 80% t(6;9)(p22;q34) ; Deletion of MB and 6q21 (Consistent with karyotype) ; 20/200 cells (10%) were missing a signal for D20S108 (20q12) ; 80% Trisomy 21 ; Trisomy 21 (48.5% had an extra AML1 signal, consistent with the karyotype.) ; While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene ; 71% CBFB rearrangement ; 5q deletion (64%) | Monosomy 16 and derivative chromosome 16 (91%) ; 7% 16q deletion ; cryptic t(14;21) (54.5% of cells had three signals for AML1) ; RUNX1-RUNX1T1 (All twenty metaphase cells examined had an 8;21 translocation withbreakpoints associated with AML1/ETO fusion.) ; inv(16) positive ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], ; trisomy 8 (Specimen Source: Blood) ; del(16q) ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 91.5% AML/ETO fusion, t(8;21) ; Deleted 5q ; 62.5% CBFB rearrangement|74% BCR/ABL/ASS ; 76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15 ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199] ; RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis. ; nuc ish(DXZ1x2)[200] ; 84% 12p deletion ; RUNX1T1/RUNX1 fusion ; t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%) ; Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone. ; RUNX1T1/ RUNX1 fusion and t(8;21) (94%) ; nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; D7S486/ CEP 7: Â 92/100 cells (92%) had a 1 red/ 1 green signal pattern, indicating monosomy 7, consistent with the metaphase karyotype. | RARA: Â 79/100 cells (79%) had three signals, consistent with the isochromosome 17q observed in the metaphase karyot ; CBFB rearrangement and inv(16) (64%) | +22 (71%) ; CEP7-7q31: Positive for heterozygous deletion 7q31 (44%). ; nuc ish(PML,RARA)x3(PML con RARAx2)[164/200] (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | nuc ish(PML,RARA)x3(PML con RARAx2)[190/200] (Labs conducted twice on day of specimen collection. This is result 2 of 2 ; CBFB inv(16) ; Disruption of MLL signal and t(9;11) (65%) ; MLL disruption and t(9;11) (70%) ; nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200] ; Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%) ; nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200] ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20 ; Monosomy 21 (30%) ; Monosomy 21 (45%) ; 8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL) ; Trisomy 22 (16%) | t(16;16) (90%) ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5â€™CBFB sep 3â€™CBFBx1)[140/200] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; MLL rearrangement and t(9;11) (86%) ; 18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; PML-RARA+ 0.70743 ; normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22 ; Loss of ERG1 signal (2%) ; Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%) ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Monosomy 7 (74%) | Extra copy of RUNX1 (39%) ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200] ; 8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22) ; Trisomy 8 (82%) ; Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker. ; nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 20q deletion (38%) ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 5q deletion (85%) | Loss of RARA on 17q21 (46%) ; 48% PML/RARA translocation ; CBFB rearrangement and inverted 16 (85%) ; Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%) ; Trisomy 8 (24%) ; Previous FISH results were consistent with the deleted 5q and trisomy 9 ; MLL rearrangement (76%) ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200] ; Missing MLL signal (79.5%) | Trisomy 8 (70.5%) ; Missing D7S486 signal (9.5%) | Three MLL signals (10%) ; nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200] ; nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[ ; Low-level tetraploidy or near-tetraploidy (5%) ; Low-level tetraploidy or near-tetraploidy ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[197], (RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200] ; deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored. ; 3q21.3q26.2 (RPN1/MECOM): rearrangement present (86%) ; nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200] ; 8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present (96%, 71.5%, 11% respectively) ; Trisomy 8 (84%) ; 43% del 5q31, 56% del 7q31, 58% del20q ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 21q deletion (35.5%) | Three MLL signals (32%) ; MLL (11q23): Â  88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid  ; Trisomy 8 (70%) ; MLL rearrangement (80%) | Trisomy 8 (78%) ; 5q deletion (92%) | 21q deletion (91%) ; Trisomy 8 ; Trisomy 9 (88%) | Missing ERG1 signal (75%) | 2 small red/2 normal red pattern with the PML probe (79%) | Trisomy 11 and i(11q) (92%) | Tetrasomy 8 (87%) | Trisomy 16 (81%) ; Tetrasomy 8 (67%) ; c/w karyotype ; nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198] ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 5q deletion (78%) | Trisomy 8 (80%) ; PML/RARA fusion (91%) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197] ; EGR1/5p; 88% , consistent with monosomy 5  | D7S486; 96% , consistent with deletion 7q  | BCR; 84% of cells had three signals for BCR (22q11.2)| MLL; 28% of cells had three intact signals for MLL, while another 76% of cells had four intact signals. ; IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Consistent with karyotype ; FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in t ; nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5â€™CBFB sep 3â€™CBFBx1)[164/200] ; RUNX1T1/RUNX1: Â  94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis. ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2, D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2 [198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Fluorescent in situ hybridization (FISH) was performed with a 9p/CEP 9 probe set. Both probes hybridized to the derivative chromosome. 90/100 (90%) interphase cells scored had a 3 red/ 3 green signal pattern, reflecting the extra derivative. ; all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype ; consistent with karyotype (68% del 17p13) ; TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha ; DEK-NUP214 fusion; MAF unavailable ; DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; nuc ish(D8Z2x3,D20S108x2)[27/200] ; 58% PML-RARA  (c/w karyotype) ; MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11). ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200] ; RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis ; nuc ish(D8Z2x3,D20S108x2)[170/200] ; FISH normal ; CEP 8:  56% had three signals, consistent with the trisomy 8 in the metaphase karyotype|RUNX1T1: 70% had three signals, consistent with the trisomy 8 in the metaphase karyotype|MLL: 72% reflected MLL rearrangement and its involvement in the 1;11 transloca ; CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ; nuc ish(PML,RARA)x3(PML con RARAx2)[173/200] ; 1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above ( ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Positive for an EVI1 rearrangement: < 0.9% |ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy:  < 0.3%) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5â€™CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200] ; nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199] ; Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7 ; Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously. ; Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells) ; deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement ; nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200] ; nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; Positive for deletion of 20q12 in 11.5% of 200 cells ; loss of 7q31 sequences in 85% of assayed cells ; Monosomy 7 (94%) ; FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells. ; FISH c/w PML/RARA fusion ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Loss of chromosome 5q31 sequences (73.5%)|Loss of chromosome 7 sequences (monosomy 7) (61.5%)|Gain of 21q22 (AML1) sequences (11.5%)|Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences ; MLL: Â  14% of cells had a pattern consistent with the t(9;11) seen on metaphase analysis. Â An addition 65% of cells had a signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS: Â  62% of cells had three signals for both ABL and ASS ( ; FISH positive for CBFB rearrangement in 49% of cells ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11). ; (D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200], ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; 5% trisomy 8 ; 50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8. ; 60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8. ; 37% trisomy 21, 38.5% XX, 61.5% XY (donor) ; nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0% ; positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells. ; 90.5% monosomy 17, 6% trisomy 11q23 ; nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm ; MLL:  87% of cells had a 1r1g1f split signal pattern consistent with MLL rearrangement. ; 70% PML/RARA ; nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200] ; Gain of 8q22 and 21q22 (88%) ; 44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8, ; 95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17) ; 9.5% gain 21q22 ; nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200] ; 71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype. ; MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia ; nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200] ; ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present ; - 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored. ; The AML FISH panel analysis showed evidence of extra copies of the RUNX1T1 (8q24) and RUNX1 (21q22) genes in 95.5%, extra copies of the PML (15q24) and RARA (17q21.1) genes in 95.5%, and extra copies of the CBFB (16q22) gene in 96% of the cells examined.) ; 65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%) ; EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second c ; 35% gain of 11q23 ; 11q23 (MLL): rearrangement present (89.5%) ; ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ; nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; - Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells ; FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells. ; EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUN ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH re ; CBFB: Â 83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype. ; 21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion. ; RUNX1T1/RUNX1: (92%) ; 62% t(8;21) (RUNX1T1;RUNX1) translocation present ; FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells. ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; EGR1 (73.5%) ;  TP53: (85.5%) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199] ; All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21). ; CBFB (77%) ; positive for rearrangement of CBFB in 60.5% of cells. ; RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis. ; 1% RUNX1T1 ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells e ; 85% MLL rearrangement (c/w karyotype) ; showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22). ; This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev ; 20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA ; This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells. ; RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba ; RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) ; Positive for 5q deletion in 91% of cells. ; CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype. ; trisomy 8 in 5 of 20 metaphase cells ; CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype. ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con ; Negative ; EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal in ; nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200] ; Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338); ; COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML ; nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] ; D5S721, EGR1 Â del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q) ; Monosomy 7 is detected in 87% of cells. ; This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS. ; This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited ; This test has not detected clonal abnormalities in the cells analyzed. ; t(8;22) clone observed, consistent with a neoplastic process ; nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198] ; Trisomy 8 is detected in 28% of cells. ; The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells. ; The translocations normally seen in AML are not detected. ; (FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ; - 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored. ; nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200] ; This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies. ; This test has detected  a 6;11 translocation in 18 of 20 metaphase cells analyzed. The translocation has led to rearrangement of the MLL gene as shown by FISH. This result is consistent with the diagnosis of AML. (Cytogenetics) | Except for 9;11 transloca ; 5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present ; RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). | FISH was also performed with a probe for chromosome 20, so that the stemline clone and all subclones could be followed by interphase FISH. 88/100 cells were mis ; deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin | Interestingly, metap ; PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype. ; EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, | 56/100 cells (56%) had a 2 red/ 4 green signal pattern, reflecting 4 copies of RUNX1 on 21q and consistent with the tetrasomy 21 observe ; 94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8. ; RUNX1T1 signal consistent with the trisomy 8 clone ; RUNX1/RUNX1T1 fusion positive in 6.5% of cells ; RUNX1/RUNX1T1 fusion negative ; RUNX1/RUNX1T1 fusion negative (Cytogenetics) ; Positive (Cells Scored: 200 Probe(s): Leica DEK (SG) / NUP 214 (SO) t(6;9) DC, DF) ; MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal ; This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored. ; D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the me ; Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel. ; CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone. ; 87% IgH/MAF fusion; 62% 5q deletion ; 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype. ; The abnormalities normally seen in MDS are not detected. ; MLL Rearrangment ; Translocation between the long arm of chromosome 3 and short arm of chromosome 12. ; 5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter) ; nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], ; nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20
PRIOR_MALIGNANCY_NON_MYELOID	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Did patient have a prior non-myeloid malignancy?	Patient	
PRIOR_MALIGNANCY_RADIATION_TX	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Has patient received radiation treatment for a prior non-heme malignancy?	Patient	
PRIOR_MALIGNANCY_TYPE	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Type of prior non-myeloid malignancy	Patient	
PRIOR_MDS_MORE_THAN_TWO_MTHS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Was the date difference between the earliest MDS diagnosis and AML diagnosis greater than 2 months?	Patient	
PRIOR_MDS_MPN	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Was the patient ever diagnosed with MDS/MPN?	Patient	
PRIOR_MDS_MPN_MORE_THAN_TWO_MTHS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Was the date difference between the earliest MDS/MPN diagnosis and AML diagnosis greater than 2 months?	Patient	
PRIOR_MPN_MORE_THAN_TWO_MONTHS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Was the date difference between the earliest MPN diagnosis and AML diagnosis greater than 2 months?	Patient	
RESPONSE_DURATION_TO_INDUCTION_TX	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Days between start and end dates of the first treatment record found with a stage of induction	Patient	
RESPONSE_TO_INDUCTION_TX	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Treatment response corresponding to the first treatment record found with a stage of induction	Sample	Complete Response ; Refractory ; Unknown ; Complete Response i ; UNKNOWN ; unknown
RUNX1	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Manual review of RUNX1 variant results from clinical testing and WES	Sample	RUNX1 (p.R166*; 40.0%) ; RUNX1 (p.R166*; 47.6%) ; RUNX1 (p.A147Gfs*13; 42.3%)|RUNX1 (p.R162S; 46.5%) ; RUNX1 (p.Q283*; 37.0%)|RUNX1 (p.M236Nfs*25; 20.0%) ; RUNX1 (p.Q283*; 40.7%) ; RUNX1 (p.Q283*; 51.5%) ; RUNX1 (p.R320*; 61.6%) ; RUNX1 (p.R204*; 43.0%) ; RUNX1 (p.X170_splice; 34.7%) ; RUNX1 (p.Q390Afs*210; 42.4%) ; RUNX1 (p.A142Gfs*4; 32.2%) ; RUNX1 (p.R201Q; 33.9%) ; RUNX1 (p.X205_splice; 56.7%) ; RUNX1 (p.X205_splice; 44.3%) ; RUNX1 (L89fs*49; MAF 20-30%) ; RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%) ; RUNX1 (p.R201Q; 47.2%) ; RUNX1 (p.R201Q; 51.8%) ; RUNX1 (p.P430S; 60.0%)|RUNX1 (p.R166*; 41.2%) ; RUNX1 (p.R201*; 33.3%) ; RUNX1 (p.R166G; MAF 22%) ; RUNX1 (p.S100F; 12.8%) ; RUNX1 (Y414*; MAF 16%) ; RUNX1 (p.F330Sfs*271; 17.4%) ; RUNX1 (p.S100Lfs*39; 35.6%) ; RUNX1 (p.R201*; 79.4%) ; RUNX1 (p.T437A; 24.0%) ; RUNX1 (p.R162K; 35.1%) ; RUNX1 (p.Q262*; 72.4%) ; RUNX1 (p.R107H; 21.1%) ; RUNX1 (p.R320*; 46.2%) ; RUNX1 (p.S331Afs*263; 65.2%) ; RUNX1 (p.S308Qfs*292; 40.7%) ; RUNX1 (p.S308Qfs*292; 52.1%) ; RUNX1 (p.S308Qfs*292; 42.4%) ; RUNX1 (p.S322Nfs*277; 9.7%) ; RUNX1 (p.H242Afs*14; 24.5%) ; RUNX1 (p.R162K; 95.1%) ; RUNX1 (p.R162K; 82.0%) ; RUNX1 (p.Y349*; 14.6%) ; RUNX1 (p.Y377*; 11.5%)|RUNX1 (p.I114Afs*25; 33.0%) ; RUNX1 (p.R320*; 24.2%)|RUNX1 (p.R207W; 20.0%) ; RUNX1 (p.R250Lfs*13; 50.0%) ; RUNX1 (p.E422Afs*173; 53.3%) ; RUNX1 (p.E422Afs*173; 58.1%) ; RUNX1 (p.Q213Rfs*24; 85.5%) ; RUNX1 (p.R162G; 80.6%) ; RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%) ; RUNX1 (p.R250Lfs*13; 46.7%) ; RUNX1 (p.A338Rfs*262; 22.2%) ; RUNX1 (p.A338Rfs*256; 73.3%) ; RUNX1 (p.A338Rfs*256; 71.0%) ; RUNX1 (p.A338Rfs*256; 76.9%) ; RUNX1 (p.R201*; 48.0%) ; RUNX1 (p.E223*; 64.8%) ; RUNX1 (p.R166Q; 41.5%)|RUNX1 (p.R162K; 47.6%) ; RUNX1 (p.R166Q; 46.0%)|RUNX1 (p.R162K; 44.5%) ; RUNX1 (p.R162S; 96.2%) ; RUNX1 (p.D198N; 35.5%) ; RUNX1 (p.P240Qfs*22; 40.0%) ; RUNX1 (p.P383Afs*217; 46.0%) ; RUNX1 (N260fs*223+; MAF 26%) ; RUNX1 (p.R320*; 40.9%) ; RUNX1 (c.319C>G; MAF 73.9%) ; RUNX1 (p.L98Pfs*40; 46.8%) ; RUNX1 (p.E454Gfs*149; 21.4%) ; RUNX1 (p.E454Gfs*149; MAF 51%) ; RUNX1 (p.E223*; 41.0%) ; RUNX1 (p.E223*; MAF 1%) ; RUNX1 (p.R320*; 44.9%) ; RUNX1 (p.G165Dfs*2; 11.1%) ; RUNX1 (p.S322Ffs*278; 45.9%) ; RUNX1 (p.G408Vfs*193; 34.8%) ; RUNX1 (p.G408Vfs*193; 20.4%) ; RUNX1 (p.S322Nfs*277; 44.4%) ; RUNX1 (p.G170Efs*7; 32.5%)|RUNX1 (p.R162W; 36.4%) ; RUNX1 (p.R166*; 44.9%) ; RUNX1 (p.I366Vfs*231; 65.5%) ; RUNX1 (p.A187T; MAF 42%) ; RUNX1 (p.D198G; 66.7%) ; RUNX1 (loss) ; RUNX1 (p.L89Pfs*49; 15.8%) ; RUNX1 (p.R201*; 45.8%) ; RUNX1 (p.R204*; 77.3%) ; RUNX1 (p.R166*; 41.5%) ; RUNX1 (p.S322*; 51.4%) ; RUNX1 (p.R107C; 43.8%)|RUNX1 (p.W106*; 36.8%) ; RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%) ; RUNX1 (p.D198N; 47.6%)|RUNX1 (p.P113L; 42.7%) ; RUNX1 (p.D198G; 94.2%) ; RUNX1 (p.X170_splice; 26.1%) ; RUNX1 (p.T246Hfs*15; 25.0%) ; RUNX1 (p.R107H; 59.2%) ; RUNX1 (p.S100Lfs*38; 45.6%) ; RUNX1 (p.S100Lfs*38; 47.8%) ; RUNX1 (p.S100Lfs*38; 36.8%) ; RUNX1 (p.L429Pfs*171; 82.9%) ; RUNX1 ; RUNX1 (p.P49T; MAF 69%) ; RUNX1 (p.R76Pfs*62; 66.7%) ; RUNX1 (p.R162K; 58.7%) ; RUNX1 (p.M267Ifs*44; 77.6%) ; RUNX1 (p.S100F; 39.6%) ; RUNX1 (p.R162S; 84.5%) ; RUNX1 (p.H105Afs*33; 41.2%)|RUNX1 (p.T104R; 53.3%) ; RUNX1 (p.F259Sfs*338; 18.3%) ; RUNX1 (p.D198N; MAF 6%) ; RUNX1 (p.F396Vfs*204; 55.4%) ; RUNX1 (p.T196Dfs*17; 40.6%)|RUNX1 (p.X20_splice; 49.2%) ; RUNX1 (p.D198N; 44.9%) ; RUNX1 (p.R320*; 49.8%) ; RUNX1 (p.F416Lfs*185; 24.0%) ; RUNX1 (p.X269_splice; 48.1%) ; RUNX1 (p.D198N; 47.7%) ; RUNX1 (p.D198N; 47.3%) ; RUNX1 (p.R166Q; VAF 6%) ; RUNX1 (p.S322*; 49.8%) ; RUNX1 (p.S322*; 17.2%) ; RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%) ; RUNX1 (p.L98Sfs*24; 36.0%)
SPECIFIC_DX_AT_ACQUISITION_MDSMPN	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Patient's diagnosis at the time of specimen collection was MDS, MPN, or MDS/MPN	Sample	FALSE ; TRUE
SPECIFIC_DX_AT_INCLUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Specific diagnosis at time of earliest specimen inclusion by collection date	Patient	
SPECIMEN_GROUPS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Concatenated list of specimen groups, referring to disease stage at the time point of this specimen collection	Sample	Initial Acute Leukemia Diagnosis ; Relapse|Post-Transplant|Post-Chemotherapy ; Post-Transplant|Residual Disease ; Residual Disease|Post-Transplant ; Post-Chemotherapy|Residual Disease ; Relapse|Post-Chemotherapy ; Residual Disease|Post-Chemotherapy ; Relapse ; Residual Disease ; Post-DLI|Residual Disease|Post-Transplant ; Initial Acute Leukemia Diagnosis|Post-Chemotherapy ; Unknown ; Post-Chemotherapy ; Post-Transplant|Post-Chemotherapy|Residual Disease ; Post-Chemotherapy|Post-Transplant|Relapse ; Post-Chemotherapy|Post-Transplant|Residual Disease ; Residual Disease|Post-Transplant|Post-Chemotherapy ; Post-Chemotherapy|Relapse ; Residual Disease|Post-Chemotherapy|Post-Transplant ; Post-Chemotherapy|Post-Transplant ; Initial Acute Leukemia Diagnosis|Post-Transplant|Post-Chemotherapy ; Post-Chemotherapy|Initial Acute Leukemia Diagnosis ; Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant ; Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant ; Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis ; Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease ; Post-Chemotherapy|Residual Disease|Post-Transplant ; Post-Transplant|Post-Chemotherapy ; Relapse|Post-Chemotherapy|Post-Transplant ; Post-Transplant|Relapse|Post-Chemotherapy ; Post-Transplant|Relapse ; Post-Chemotherapy|Post-Transplant|Initial Acute Leukemia Diagnosis ; Post-Chemotherapy|Relapse|Post-Transplant
SURFACE_ANTIGENS_IMMUNOHISTOCHEMICAL_STAINS	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Positive surface antigens, as determined by clinical flow	Sample	CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive ; partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive ; partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR ; CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive ; CD13, CD33, CD38, CD56, CD117, and MPO positive ; CD13, CD33, CD34, CD38, CD117,CD123, dim HLA-DR, partial MPO ; CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive ; CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative ; CD13, dim CD33, CD56, and CD117 positive ; dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive ; CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive ; CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive ; Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positi ; CD13, CD33, partial CD34, CD38, CD117 and CD123 ; partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive ; partial CD7, CD13, CD33, partial CD34, CD58, CD64, CD117, and CD123 positive ; CD7, CD13, CD33, CD34, CD117, CD123, and HLA-DR-positive ; partial CD7, CD11b, CD13, CD33, CD34, partial CD64, partial CD117, CD123, HLA-DR, and TdT-positive. ; partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive ; CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT ; CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive ; CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive ; CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO ; Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR ; CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive ; CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive ; CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive ; partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive ; CD13, CD34, CD38, CD117, CD123, HLA-DR ; dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive ; dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive ; CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123 ; partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive ; dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO ; Blast phenotype: Â CD13, partial CD33, CD34, CD38, CD58, CD123, HLA-DR and TdT-positive; Monocytic phenotype: Â CD11b, CD14, CD33, CD38, CD58, CD64 and HLA-DR-positive ; CD13, CD33, CD34, CD56, CD117, dim CD123, HLA-DR, partial TdT positive ; CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+) ; dim CD33, CD38, CD58, CD117, dim CD123, and MPO positive ; CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive ; CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive ; CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO ; CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA- ; CD13, CD33, CD34, CD38, CD58, CD117, and MPO ; CD2(-), CD4(-), CD7(+), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (variably +), CD34(+), CD36(-), CD38(variably +), CD45(moderate to slightly dim +), CD56(-), CD64(partial +), CD117 (variably +), HLA-DR(partial +), MPO(-), and TdT(-). ; CD11b, variable CD13, variable CD14, CD15, variable CD16, CD33, CD38, CD56, CD58, CD64, dim HLA-DR positive ; partial CD11b, dim CD13, dim CD19, dim CD33, CD34,variable CD38, CD58, dim CD64, CD117, CD123, HLA-DR, dim MPO, and dim TDT ; CD34+ myeloblasts (60%) and a small population of monoblasts (5%) ; CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+) ; CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive ; CD13, dim CD14, CD33, CD34, CD38, CD58, CD123, CD117, HLA-DR, partial cTdT and cMPO positive ; CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR, and partial MPO ; CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive ; CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO + ; partial CD7, CD13, CD33, CD34, partial CD56, CD58, HLA-DR, and partial MPO-positive CD117, CD123, ; partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive ; - 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO ; increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia ; partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive ; CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive ; CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+ ; atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, (and increased atypical CD117 positive, CD34 negative myeloblasts showing weak expression   of ; partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive ; CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +). ; CD13, dim CD33, CD34, CD38, CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(partial +), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(-) MPO(-), and TdT(-) ; partial CD7 ,dim/partial CD10 , CD13 , CD33 , CD34 , CD38 , CD56 , CD64 , dim CD123 , HLA-DR , and MPO positive ; Myeloid blast immunophenotype: CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive | Promonocyte immunophenotype: CD11b, CD13, CD14, CD33, CD38, CD56, CD58, CD64 and HLA-DR positive ; CD13, dim CD33, CD34, partal CD117, dim CD123, HLA-DR, MPO, and partial dim TdT ; dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO ; CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive ; CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive ; CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells) ; CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive ; Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive ; dim/partial CD7, variable CD13, CD33, dim/partial     CD64,     CD117, CD123, HLA-DR and cMPO positive ; CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR ; CD117,HLA-DR, CD13 and CD33.  Blasts also show partial expression of CD34, CD7, CD11c, CD38, CD15, dim CD64, and dim CD4 ; CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(+), CD117(+), HLA-DR(-), MPO(+), TdT(-) (Labs conducted twice on day of specimen collection ; CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR ; Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM),  ; CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial) ; CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive ; dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive ; CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +) ; CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO ; CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7 ; partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO ; CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR. ; CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive ; CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive ; CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38 ; CD64, DIM CD14, BRIGHT CD56, CD13, AND CD33,SUBSET EXPRESSING CD34 ; brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells) ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-),  ; Blasts (15-20%): CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, and HLA-DR, and partial TdT positive - Aberrant monocytic population (20%): CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive ; Myeloid blasts:CD13, CD33, CD34, CD38, CD58, dimCD64, CD117, and HLA-DR+ Â Â  Promonocytes/immature monocytes:CD11b, CD13, CD14, CD33, CD64, and HLA-DR+ ; CD4+, CD33+, CD117+, HLA-DR+ myeloblasts ; CD13, dim CD33, CD34, CD38, dim CD45, CD58, CD71, CD117,CD123, HLA-DR, and TdT positive ; The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increa ; Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. (Included both populatio ; CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-). ; CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+) ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial  ; CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+ ; CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO ; CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that i ; Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes. ; CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4 ; CD1a(-), CD2(-), surface CD3(-), cytoplasmic CD3(partial dim +), CD4(partial dim +), CD5(dim +), CD7(+), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16 (-), CD22(partial dim +), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45 ; Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes ; CD13, CD33, CD34, partial CD56, CD58, CD117, partial CD123, and HLA-DR positive ; CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+ ; CD34, partial CD117, CD38, CD33, partial CD13,partial CD11C, CD4, partial CD14, partial CD64, partial CD2, and HLA-DR ; Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia. ; CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo ; CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD7 ; dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive ; CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive ; The findings reveal a slightly expanded population of myeloblasts with an essentially unremarkable immunophenotype. There is no definitive immunophenotypic evidence of a hematolymphoid malignancy. ; CD7(+), CD11b(-), CD13(dim +), CD14(-), CD15(partial +), CD16(-), CD33(variably +/subset bright +), CD34(+), CD36(-), CD38(+), CD45(+), CD56(partial +), CD64(partial +), CD117(+), HLA-DR(+), MPO(+), TdT(-). ; Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45. (Most of the atypical cells are CD34 posi ; CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO ; CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117 ; CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT ; Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia. ; CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive ; partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive ; CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive. ; CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive ; CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15 ; CD13, CD14, CD16, CD33, CD64 and HLA-DR ; CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable). ; CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO ; CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR ; CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +) ; CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive ; CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+). ; CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-) ; CD13, partial CD33, CD34, CD38, moderate CD45, CD58, CD117, CD123, TdT, and partial MPO positive. ; partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive. ; CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype) ; CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial). ; CD117+, HLA-DR negative, partial CD34+ (Right inguinal biopsy) ; CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, dim/partial HLA-DR, and MPO positive ; CD10, CD13, CD33, CD34, CD56 and HLA-DR positive ; dim CD13, CD33, CD34, CD117, CD123, and dim HLADR ; CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+ ; CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO ; Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes ; partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive ; Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes ; CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive ; CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123 ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR ; dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive ; dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+ ; CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive ; CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+) ; CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+). ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+) (6.2% population) ; CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT ; CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive ; CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-) ; CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO ; CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO ; A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demo ; Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia ; Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64. (Increased atypical CD34 pos ; CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +) ; Relative increase of CD34 positive myeloblasts representing approximately 20% of the leukocytes and increased promonocytes/monoblasts consistent with acute myeloid leukemia with   myelomonocytic differentiation ; CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+ ; CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-). ; CD13, CD33, CD34, CD117, MPO and HLA-DR ; CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin) ; CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT ; CD2, CD13, CD33, CD34, CD56, CD58, CD64, CD117, CD123, dim/partial HLA-DR, dim/partial TdT and MPO positive ; CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117 ; CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO. ; CD4, partial CD11b, CD15, CD33, CD56, CD58, CD64, CD117, CD123, HLA-DR, and butyrate esterase positive ; CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR ; CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR. ; CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression ; CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO ; CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117 ; CD13, CD34, CD58 and CD117 ; CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19 ; Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT ; Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia ; Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm ; partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable) ; partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive ; CD7, CD13, CD33, CD34, CD38, and CD123 positive (Initial 7/8/2014 diagnosis: dim CD7, CD13, CD33, CD34, CD38, CD58, and CD117-positive) ; CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-) ; CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT ; CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +). ; CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive. ; CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7 ; dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative ; CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+). ; CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+ ; CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Pop ; CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-) ; CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive ; CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive ; CD34, CD13, HLA-DR, CD123, and CD58.  In addition there is a predominant (about      60%) and atypical monocytic population expressing: CD11b, CD13, CD14,      patial CD16, CD33dim, partial CD56, CD64bright, HLA-DR. ; dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive ; CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO ; CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-) ; dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive ; CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variab ; CD2(-), CD4(- to partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD19(few +), CD33(variably +), CD34(variably +), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR (+), MPO(partial +), TdT(partial +) ; Relative increase of phenotypically normal, slightly left shifted myeloid cells without flow cytometric evidence of monoclonality, acute leukemia, plasma cell dyscrasia, or   lymphoproliferative disorder. ; dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive. ; dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive ; CD2(-), CD4(+), CD7(-), CD11b(few dim +), CD13(-), CD14(-), CD15(partial +), CD16(-), CD19(partial +), CD20(-), CD22(partial +), CD25(partial +), CD33(partial +), CD34(+), CD36(-), CD38(+), CD45(partial +) | CD64(-), CD79a(partial +), CD117 (-), HLA-DR(pa ; Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia. ; CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+ ; dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive ; CD13, partial/dim CD33, CD38, CD58, CD117 and MPO ; Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (pe ; CD13, CD33, CD34, CD117, and HLA-DR positive ; ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-). ; CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and vari ; CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(+ to bright +), CD34(-), CD38(+), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(dim +). ; CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive ; ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR ; dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive ; dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive. ; CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-) ; CD2(-), CD4(appears partial dim +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(partial +), CD64(partial +), CD117 (+), HLA-DR(+). ; CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT ; CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive (Myeloid blasts) | CD13, CD14,CD33, CD64, dimCD34, and MPO positive (Monocytes) ; CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive ; CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+) ; Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a pr ; large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leuk ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appea ; CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive ; partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive ; CD34, dim CD45, CD117 ; CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive ; Partial CD34, cd38, cd117, cd15, cd33, partial cd13, partial cd64, cd11c, dim partial cd4, hla-dr and mpo ; CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim  ; CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO (15% population of variably-sized blasts) ; CD13, CD33, dim CD71, CD117, CD123, and MPO ; positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers ; CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-). ; positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT ; partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT ; positive for CD34, CD117,  CD13, CD33 and HLA-DR ; CD7, CD
TIME_OF_SAMPLE_COLLECTION_RELATIVE_TO_INCLUSION	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	NUMBER	Difference in days between collection dates of earliest specimen and this specimen	Sample	0 ; 1339 ; 1354 ; 1465 ; 574 ; 337 ; 950 ; 166 ; 1 ; 378 ; 163 ; 333 ; 386 ; 138 ; 181 ; 1207 ; 185 ; 151 ; 687 ; 385 ; 309 ; 34 ; 783 ; 262 ; 297 ; 349 ; 488 ; 215 ; 132 ; 93 ; 12 ; 234 ; 15 ; 1020 ; 1496 ; 8 ; 4 ; 160 ; 147 ; 506 ; 43 ; 7 ; 178 ; 883 ; 254 ; 37 ; 49 ; 3 ; 2 ; 89 ; 14 ; 5 ; 265 ; 19 ; 424 ; 111 ; 201 ; 100 ; 461 ; 184 ; 112 ; 196 ; 494 ; 716 ; 152 ; 979 ; 46 ; 30 ; 55 ; 281 ; 423 ; 375 ; 33 ; 769 ; 568 ; 417 ; 472 ; 1079 ; 397 ; 249 ; 462 ; 616 ; 72 ; 412 ; 63 ; 75 ; 40 ; 42 ; 25 ; 44 ; 58 ; 225 ; 487 ; 35 ; 56 ; 252 ; 261 ; 429 ; 36 ; 224 ; 57 ; 315 ; 38 ; 126 ; 6 ; 27 ; 9 ; 21 ; 73 ; 129 ; 82 ; 119 ; 81 ; 232 ; 41 ; 28 ; 148 ; 504 ; 573 ; 23 ; 383 ; 124 ; 168 ; 122 ; 80 ; 29 ; 120 ; 455 ; 893 ; 99 ; 267 ; 248 ; 366 ; 316 ; 48
TP53	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	TP53 Pathway	Sample	TP53 (p.Y205H; 67.9%) ; TP53 (p.R175H; 43.2%) ; TP53 (p.V216M; 66.9%) ; TP53 ; TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%) ; TP53 (p.R273C; 15.4%) ; TP53 (C238R; MAF 5% (not confirmed by Sanger seq)) ; TP53 (p.R248Q; 96.4%) ; TP53 (p.R282W; 72.5%) ; TP53 (p.R248W; 72.2%) ; TP53 (p.R306*; 28.8%)|TP53 (p.X187_splice; 21.9%) ; TP53 (p.E343*; 56.0%) ; TP53 (p.V173M; 77.4%) ; TP53 (p.R273H; 90.9%) ; TP53 (p.H193R; 90.7%) ; TP53 (p.X307_splice; 76.3%) ; TP53 (p.G245S; 83.1%) ; TP53 (p.G245S; 89.1%) ; TP53 (p.R273H; 46.8%) ; TP53 (p.R337C; 58.9%)|TP53 (p.R175H; 47.3%) ; TP53 (p.T312Nfs*25; 28.0%) ; TP53 (p.R280T; 41.1%)|TP53 (p.X33_splice; 37.9%) ; TP53 (p.I251M; 29.0%)|TP53 (p.R249M; 18.6%) ; TP53 (p.R248W; 87.0%) ; TP53 (p.R248Q; 95.8%) ; TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%) ; TP53 (p.V272M; 91.9%) ; TP53 (p.G266E; 82.1%) ; TP53 (p.P151S; 96.9%) ; TP53 (p.S215R; 15.2%) ; TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%) ; TP53 (p.R283C; 47.5%) ; TP53 (p.R283C; 45.1%) ; TP53 (loss exons 10-11) ; TP53 (p.R280Efs*65; 35.7%)|TP53 (p.R175H; 27.2%) ; TP53 (p.R175H; 92.9%) ; TP53 (p.R337L; 45.2%) ; TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%) ; TP53 (p.L130Pfs*19; 33.3%) ; TP53 (p.R248Q; 53.3%) ; TP53 (p.X187_splice; 30.4%) ; TP53 (p.P151H; 97.9%) ; TP53 (p.G266V; 65.7%) ; TP53 (p.G266V; 91.4%) ; TP53 (p.R175H; 91.7%) ; TP53 (p.V272_R273insL; MAF 75%) ; TP53 (p.H193Y; 42.5%) ; TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%) ; TP53 (p.Y220C; 42.0%) ; TP53 (p.R248W; 8.8%) ; TP53 (p.X225_splice; 93.2%) ; TP53 (p.R248W; 57.8%) ; TP53 (p.X225_splice; 46.1%) ; TP53 (p.X225_splice; 75.0%) ; TP53 (p.R248Q; 71.7%) ; TP53 (p.R213Dfs*34; 85.5%) ; TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%) ; TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%) ; TP53 (p.R282Q; 46.6%) ; TP53 (p.K132R; 39.4%)|TP53 (p.X126_splice; 51.3%) ; TP53 (p.M340Cfs*5; 41.0%)|TP53 (p.R273H; 47.8%) ; TP53 (p.M340Cfs*5; 50.0%)|TP53 (p.R273H; 42.2%) ; TP53 (p.D281G; 43.9%) ; TP53 (p.N239*; 57.9%) ; TP53 (p.E204*; 52.3%) ; TP53 (p.R248Q; 58.8%) ; TP53 (p.Q167*; 91.3%) ; TP53 (p.Y220C; 90.9%) ; TP53 (p.T155N; 81.0%) ; TP53 (p.R175H; 55.0%) ; TP53 (p.P153Afs*28; 75.8%) ; TP53 (p.L257Q; 84.5%) ; TP53 (p.X125_splice; 75.0%) ; TP53 (p.R273C; 67.5%) ; TP53 (p.Y220H; 63.6%) ; TP53 (p.H179N; 16.9%)|TP53 (p.I195Mfs*13; 9.9%)|TP53 (p.I195Yfs*14; 11.4%) ; TP53 (p.V122Dfs*26; 87.5%) ; TP53 (p.R248Q; 80.3%) ; TP53 (p.X187_splice; 9.3%) ; TP53 (p.R248W; 71.9%) ; TP53 (p.G266R; 41.8%)|TP53 (p.Y220C; 46.5%) ; TP53 (p.V216M; 78.5%) ; TP53 (p.L194R; 86.6%) ; TP53 (p.R196*; 89.6%) ; TP53 (p.L194R; 88.3%) ; TP53 (p.V143M; 44.0%)
TYPE_INDUCTION_TX	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Treatment type corresponding to the first treatment record found with a stage of induction	Patient	
USED_IN_MANUSCRIPT	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	This specimen was used in the manuscript analyses	Sample	Yes ; No
VARIANT_SUMMARY	LightSalmon	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	STRING	Clinical gene variant testing result	Sample	CEBPA|FLT3-ITD|NPM1 ; FLT3-ITD|NPM1 ; FLT3-ITD ; FLT3-D835|FLT3-ITD ; FLT3-ITD (Low Level)|NPM1 ; NPM1 ; FLT3-ITD|NPM1 (exon 12 insertion W288fs*1) ; RUNX1 (p.A147fs*13 (1 bp insertion frameshift); MAF 35%)|RUNX1 (p.R162S; MAF 50%)|SRSF2 (p.P95R; MAF 44%) ; FLT3-ITD|NPM1 (Insertion mutation detected in a minority of cells ) ; BRAF (G596R)|WT1 (2400/10000 copies) ; JAK2 (V617F; MAF 1.3% (Clinical significance of this very low-level mutation is unknown.) )|SRSF2 (p.P95H ; MAF 40%) ; FLT3-ITD|NPM1|WT1 (8000/10000 copies (High)) ; JAK2 (87% allele burden) ; FLT3 (FLT3 I836 deletion)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM ; CEBPA (Q305?Q312del RNVETQ; MAF 50%)|CEBPA (Y108*(premature stop codon); MAF 50%)|IKZF1 (p.G151R; MAF 40%)|NOTCH1 (p.G2152S; MAF: 50%) ; FLT3 (A680V)|NPM1 (W288fs*12 )|WT1 (5000/10,000 copies) ; FLT3-D835 ; IDH1 (p.R132S; MAF 20%)|NPM1 (p.W288fs*12; MAF 36%)|SRSF2 (p.P95L; MAF 35%)|TET2 (p.Q642*, p.C1135Y; MAF 7%,7%  ) ; FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%) ; NOTCH1 (p.V1578delV; MAF 50%) ; PAX5 (P284A; MAF ~33%)|TET2 (Q876*; MAF ~50%)|TP53 (Y205H; MAF ~66%) ; NRAS (G12D; MAF 40%) ; KIT ; FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.) ; IDH2 (p.R140Q; MAF 50%)|RUNX1 (p.Q390Afs; MAF 50%) ; KIT (D816V; MAF 50%) ; CEBPA (1031?1032 ins AAC; MAF 50%)|CEBPA (347?348 del GACCTGT; MAF 50%)|WT1 (p.R369R; MAF 50%) ; DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%) ; KIT (p.D816H; MAF ~50%)|WT1 (rs16754; MAF ~50%) ; RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%) ; CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%) ; DNMT3A (p.N879D; MAF 50%)|FLT3-ITD (MAF 50%)|NPM1 (W228fs*12; MAF 50%) ; FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%) ; TP53 ; TET2 (p.N752fs*60; MAF 40% ) ; BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%) ; CEBPA (p.D107fs*; MAF ~50%)|WT1 (p.Y385*; MAF 20%)|WT1 (rs16754; MAF ~50%) ; ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%) ; KDM6A (p.Q154fs*7; MAF 8%)|KDM6A (p.V1113fs*; MAF 30%)|KIT (p.D820G; MAF 4%) ; CEBPA (p.V119?M120insV; MAF 30% ) ; TP53 (p.S366A; MAF 50% ) ; ASXL1 (p.W583*; MAF 50%)|ETV6 (p.N384*; MAF 40%)|FBXW7 (p.T196A; MAF 50%)|SRSF2 (p.P95H; MAF 70%) ; KRAS (p.G13D; MAF 10%)|NRAS (p.G13D; MAF 30%) ; DNMT3A (p.R882H; MAF 50%)|FLT3-ITD (exon 14 )|NPM1 (p.W288fs*12; MAF 40%)|WT1 (rs16754; no MAF available) ; IDH2 (R140Q) ; FLT3 (N676K; MAF:30%)|GATA2 (A372T; MAF:50%)|NRAS (G13R; MAF: 5%)|U2AF1 (S34F; MAF:50%) ; FLT3-D835|IDH1|NPM1 ; CEBPA (Double mutation) ; CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%) ; FLT3-D835 (MAF 70%) ; FLT3-D835 (NOT FOUNDATION NO MAF AVAILABLE)|FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE) ; TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%) ; DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%) ; FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12) ; CSF3R (p. T618I; MAF: 50%)|WT1 (benign SNP rs16754 (R369R: no amino acid change); MAF: 50%) ; IDH1 (R132H; MAF 30%)|RUNX1 (L89fs*49; MAF 20-30%) ; CREBBP (P552S; MAF 50%)|KDM6A (K395N; MAF 50%)|KIT (D816V; MAF 1%)|NRAS (G13D; MAF 6%) ; CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%) ; CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted) ; No gene mutations found in the 43 genes tested ; FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE) ; CSF3R (p. H599N; MAF 50%)|TP53 (C238R; MAF 5% (not confirmed by Sanger seq)) ; CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%) ; NRAS ; CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%) ; NRAS (p.G12R, MAF 50%) ; CBL (p.L370del; MAF 63%)|JAK2 (p.V617F; MAF 43%)|RUNX1 (p.R166G; MAF 22%)|U2AF1 (p.Q157R; MAF 40%) ; FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%) ; FLT3-D835|NPM1 ; NPM1 (p.W288fs*>9 (C-terminal frame-shift); MAF 44%)|PTPN11 (p.E76Q; MAF 40%) ; CEBPA (c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%)|CEBPA (c.912?913insTTG (3 bp in-frame insertion); MAF 50%) ; IDH2 ; U2AF1 (p.S34F, MAF 34) ; MLL (PTD)|WT1 (MAF A382fs*6; 40%)|WT1 (MAF p.R462G; 40%)|WT1 (p.R462G ; MAF 40%) ; SUZ12 (V186D)|TP53 (V173M; MAF 80%) ; CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%) ; NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%) ; DNMT3A (p.R882H; MAF 30%)|FLT3-ITD (Weakly positive; MAF 1.3%)|JAK3 (p.V722I; MAF 50%) ; TP53 (p.H193R; MAF 92%) ; CEBPA (Double positive) ; RUNX1 (p.A142?E143insGA; MAF 14%)|RUNX1 (p.S100F; MAF 17%) ; NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%) ; ETV6 (p.V66I; MAF 50%)|TET2 (p.Q491fs*8 (4 bp insertion with frame-shift); MAF 40%) ; DNMT3A (p.G413V; MAF 32%)|DNMT3A (p.R309G; MAF 31%)|IDH1 (p.R132C; MAF 33%)|MLL (PTD) ; DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%) ; DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%) ; CREBBP (MYST3-CREBBP fusion; MAF unlisted)|RUNX1 (Y414*; MAF 16%) ; TYK2 (V15A; MAF 49.0%) ; IDH1 ; DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%) ; BCOR (V1445fs*8; MAF 65%)|ETV6 (A215fs*2; MAF 35%)|RUNX1 (F330fs*154+; MAF 35%)|U2AF1 (S34F; MAF 34%) ; CEBPA (Double positive: p.Ser17Profs*99 and p.Lys313dup)|KRAS ; NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%) ; NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%) ; DNMT3A (p.R882C; MAF 45%)|IDH1 (p.R132C; MAF 44%)|TET2 (p.P455R; MAF 45%) ; ASXL1 (L823fs*1; MAF 47%)|DNMT3A (F609fs*3; MAF 42%)|DNMT3A (F909V; MAF 46%)|IDH2 (R172K; MAF 45%)|ROS1 (R560C; MAF 45%) ; TP53 (p.T312fs*25 (one nucleotide insertion); MAF 30%) ; EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid  ; FLT3-ITD (MAF 40%) ; ASXL1 (p.A636V; MAF 52%)|IDH2 (p.R140Q; MAF 27%)|MLL (PTD)|RUNX1 (p.T437A; MAF 13%)|SRSF2 (p.P95R; MAF 28%) ; FLT3-D835 (MAF 10%)|JAK1 (p.I878V; MAF 50%) ; BCOR (p.L1483* (premature protein truncation); MAF 90%)|MLL (PTD)|U2AF1 (p.S34F; MAF 40%) ; WT1 (p.A382fs*4; MAF 44%) ; GATA1 (p.N160S; MAF:40%)|NRAS (p.G12D; MAF 11%)|TP53 (Intron 4, 3' Splice site (C.97-1G>A); MAF 26%)|TP53 (p.R280T;  MAF 36% ; BCOR (p.N119fs*40; MAF 65%)|RUNX1 (p.K117R; MAF 36%)|RUNX1 (p.R162K; MAF 31%) ; GATA2 (p.L359V; MAF: 40%)|NRAS (p.A59D; MAF: 10%)|NRAS (p.G12S; MAF: 15%)|RUNX1 (p.R107H; MAF: 19%) ; ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion) ; DNMT3A (p.R882H; MAF 37%)|EZH2 (p.K400del; MAF 48%)|IDH1 (p.R132C; MAF 37%)|TP53 (p.I251M; MAF 34%)|TP53 (p.R249M; MAF 37%) ; TP53 (p.R248Q; MAF 80%) ; DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%) ; BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% ) ; CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 86%)|EZH2 (p.S538L; MAF 85% )|GATA2 (p.K389delinTFFM; MAF 46% )|RUNX1 (p.S308fs*174; MAF 46% ) ; CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 94%)|EZH2 (p.S538L; MAF 89%)|GATA2 (p.K389delins; MAF 47%)|RUNX1 (p.S308fs*174; MAF 46%) ; DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% ) ; CEBPA (Triple positive)|IDH2 ; DNMT3A (R882C; MAF 43%)|IDH2 (R140Q; MAF 3%)|WT1 (splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%) ; MLL (PTD)|RUNX1 (p.H242fs*14; MAF 42% )|RUNX1 (p.N136K; MAF 30%)|U2AF1 (p.S34F; MAF 40%) ; FLT3-ITD|IDH1 ; ATM (S1993fs*23; MAF 44%)|CEBPA (L81fs*72; MAF 92%)|MUTYH (G382D; MAF 49%)|STAG2 (R1205*; MAF 92%)|TET2 (C1273S; MAF 46%)|TET2 (M823fs*1; MAF 47%) ; KRAS (p.G12V; MAF 30%)|NRAS (p.G12D; MAF 7%)|RUNX1 (p.R162K; MAF 85% ) ; EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% ) ; IKZF1 (Foundation; S63fs*2) ; RUNX1 (p.Y349*; MAF 26% )|SRSF2 (p.P95H; MAF 32% ) ; RUNX1 (p.I114fs*25; MAF ~50% )|U2AF1 (p.S34F; MAF 43%) ; ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%) ; DNMT3A (p.R882H; MAF 44% )|IDH2 (p.R172K; MAF 43%) ; ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% ) ; DNMT3A (F827fs*4; MAF 35%)|FLT3 (S585_D586ins28; MAF 14% )|ZRSR2 (D242fs*13; MAF 25%) ; DNMT3A (F827fs*4)|FLT3-ITD ; PTPN11 (G60A; MAF 18%) ; IKZF1 (p.E80X; MAF 37%)|WT1 (p.E340X; MAF 32%) ; JAK2 (p.V617F; MAF 53% )|TP53 (p.V272M; MAF 88% ) ; MLL (PTD) ; ASXL1 (p.E1416G; MAF 52% ) ; BCOR (P512fs*7; MAF 66%)|EP300 (R1462*; MAF 8%)|ETV6 (ETV6-FOXJ2)|HIST1H2BK (T20I; MAF 47%)|PTPN11 (S502P;MAF 41.0%)|STK11 (F354L;MAF 46.0%)|U2AF1 (S34F; MAF 38%) ; CEBPA (p.K313del; MAF 34%)|CEBPA (p.P23fs*81; MAF 41%)|TET2 (p.G1160E; MAF 51%)|TET2 (p.S1039L; MAF 48%)|WT1 (p.R380fs*5; MAF 31%) ; CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%) ; CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%) ; KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%) ; CBL (p.C404Y; MAF 28%)|SF3B1 (p.K666N; MAF 36% )|TET2 (p.L1047fs*11; MAF 34% ) ; ZRSR2 (p.R452C; MAF 4%) ; FLT3-ITD (MAF 45%) ; BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%) ; FLT3-V491L (p.V491L; MAF 9%)|NPM1 (p.W288fs*12; MAF ~50% )|PTPN11 (p.S502L; MAF 44%) ; IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%) ; ASXL1 (Foundation, G646fs*12; MAF 33%)|FLT3 (Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%)|IDH2 (Foundation, R140Q; MAF 45%)|RUNX1 (Foundation, Q213fs24; MAF 82%)|SRSF2 (FOUNDATION, P95R; MAF 48%) ; IDH1 (C.G395A; p.R132H; MAF unknown) ; ASXL1 (p.Q588*; MAF 43% ) ; ASXL1 (p.Q588*; MAF 49%) ; NPM1 (p.W288fs*12; MAF 45%)|NRAS (p.G12D; MAF 4%)|NRAS (p.G13D; MAF 17%)|PTPN11 (p.T73I; MAF4% ) ; DNMT3A|IDH1|NPM1|NRAS ; DNMT3A (p.R882C; MAF 47%)|DNMT3A (p.V778M; MAF 48% )|FLT3-ITD (MAF ~3-4%)|IDH1 (p.R132C; MAF 47%)|NPM1 (p.W288fs*9; MAF 50%)|NRAS (p.G13D; MAF 17%) ; IDH2 (p.R140Q; MAF 46% )|NOTCH1 (p.H2488R; MAF 47%)|NPM1 (p.W288fs*12; MAF 45%)|PTPN11 (p.D61A; MAF 44%) ; NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%) ; FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%) ; ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%) ; ASXL1 (p.G643fs; MAF 32.9%)|GATA2 (p.A318T; MAF 48.8%)|IDH1 (p.G105G; MAF 50%)|SRSF2 (p.P95H; MAF 46.9%)|TET2 (p.E798X; 49.6%)|TET2 (p.Q414X; MAF 49.6%) ; IDH2 (p.R140Q; MAF 46.4%)|KIT (p.M541L; MAF 48.7%) ; ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%) ; ETV6 (IL34-ETV6 rearrangement)|IDH1 (p.G105G; MAF 52.8%)|MEN1 (rearrangement intron 3)|NF1 ((From Foundation Medicine) R192*, R1968* - subclonal, R765fs*26 - subclonal, FCHSD2-NF1 fusion)|TP53 (loss exons 10-11) ; FLT3-ITD (MAF 44%) ; FLT3-ITD (MAF 50%)|MLL (PTD) ; DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%) ; ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%) ; FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%) ; CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%) ; FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%) ; FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%) ; ASXL1 (p.S747fs*25; MAF 38%)|IDH1 (p.R132C; MAF 34%)|SRSF2 (p.P95R; MAF 35%) ; ASXL1 (p.E1102D; MAF 31.1%)|DNMT3A (p.F543C; MAF 35.7%) ; KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%) ; KRAS (p.G12D; MAF 27%)|NOTCH1 (p.G2299S; MAF 47%) ; CEBPA (p.F77*83; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|TET2 (p.I1025L; MAF 50%) ; KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF 19%) ; ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%) ; DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%) ; NRAS (p.Q61K; MAF 24.1%) ; BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%) ; JAK2 (p.V617F; MAF 3.8%)|TET2 (p.R1261L; MAF 27.7%) ; IDH2 (p.R172K; MAF 30.2%)|TET2 (p.G335D; MAF 20.7%) ; CEBPA (p.G96fs*12; MAF ~50% )|CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12A; MAF 6% )|NRAS (p.G12D; MAF 5% )|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF ; CBL (p.Y371H; MAF 43%)|EZH2 (p.K30fs*8; MAF 48%)|RUNX1 (p.A338fs*; MAF 41%)|SF3B1 (p.H662Q; MAF 28%) ; ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%) ; ASXL1 (p.G642fs; MAF 26.4%)|IDH2 (p.R140Q; MAF 36.4%)|PHF6 (p.G306E; MAF 65%)|U2AF1 (p.Q157R; MAF 43.1%) ; ASXL1 (p.686_687del; MAF 40.4%)|ASXL1 (p.E1102D; MAF 30.7%)|CEBPA (p.E10K; MAF 26.7%)|RUNX1 (p.R142fs; MAF 30%) ; DNMT3A (p.V468M; MAF 51.2%)|IDH2 (p.R172K; MAF 46.1%)|RUNX1 (p.R174X; MAF 48.2%)|TET2 (p.G355D; MAF 50.5%)|TP53 (p.R43H; MAF 76.7%) ; KDM6A (p.R1363* MAF:32%)|NRAS (p.G12D; MAF 15%) ; CBL (p.P494A; VAF 16%)|CREBBP (p.E1561fs*72; VAF 30%)|EP300 (p.V1926G; VAF 19%)|PTPN11 (p.G503A; VAF 33%)|TCF3 (p.K522Q; VAF 31%) ; CEBPA (c.117delC; MAF 27.2%)|CEBPA (c.938_939insATC; MAF 18.1%)|TET2 (c.3454G>T; MAF 40.9%)|WT1 (c.1137_1138insA; MAF 43.7%)|WT1 (c.872+1G>A; MAF 40%) ; FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% ) ; BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%) ; ASXL1 (p.W960X; MAF 29.4%)|PTPN11 (p.E76V; MAF 29.5%) ; IDH1 (p.R132C; MAF 16.3%) ; FLT3-ITD (MAF 50%) ; ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%) ; RUNX1 (PB)|SF3B1 (PB) ; CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%) ; ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%) ; ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%) ; ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%) ; TP53 (Foundation; R337L) ; FLT3-ITD (MAF 4%)|WT1 (c.1138delinsAA; MAF 31.2%) ; IDH1 (p.R132C; MAF unlisted) ; BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%) ; FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%) ; NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%) ; CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%) ; TP53 (p.I254N; MAF 40%) ; ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% ) ; KRAS (p.Gly13Asp; MAF 38.9%) ; NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%) ; FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%) ; DNMT3A (c.2645G>A; MAF 41.8%)|FLT3-ITD (c.1797delins22; MAF 19%)|IDH1 (c.394C>T; MAF 46.7%)|RUNX1 (c.486G>C; MAF 89.5%) ; DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% ) ; EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%) ; FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%) ; IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%) ; TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%) ; CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%) ; BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% )) ; NRAS (p.Q61P; MAF 15% ) ; FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%) ; NPM1 (p.W288fs*12; MAF ~11%) ; FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%) ; DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%) ; DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15)) ; CBL (p.E369_Y371delinsH; MAF 31%) ; BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted) ; TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%) ; ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%) ; JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%) ; IDH1 (R132C; MAF 42%)|NF1 (N935H; MAF 49%)|RUNX1 (N260fs*223+; MAF 26%)|SRSF2 (P95L; MAF 38%) ; CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%) ; FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%) ; CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%) ; DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%) ; DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%) ; DNMT3A (p.R882H; MAF 45%)|FLT3-D835 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%) ; KIT (p.D816V; MAF 45% ) ; FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%) ; EZH2 (p.D146H; MAF 50%) ; NPM1 (p.W288fs*12; MAF 50%) ; ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%) ; BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%) ; CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%) ; CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%) ; CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%) ; FLT3 (p.N841I; MAF 40%)|NPM1 (p.W288fs*12; MAF 20%)|U2AF1 (p.R156H; MAF 40%) ; NRAS (p.G12C; MAF 40%) ; DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%) ; NPM1 (W288FS*10+; MAF 24.0%) ; ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%) ; No gene mutations found in the 76 genes tested ; JAK2 (p.V16F. MAF 15%) ; NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%) ; CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%) ; FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%) ; CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%) ; IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%) ; DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%) ; ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%) ; KIT (p.T417_D419delinsY; MAF 33%) ; IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%) ; DNMT3A (p.R882H; MAF 39%)|GATA1 (p.R191C; MAF 51%)|IDH2 (p.R172K; MAF 36%) ; CEBPA (p.A240fs*83 (7 bp insertion with frameshift); MAF 19%)|CREBBP (p.P1150S; MAF 18%)|FLT3-ITD (MAF 56%)|IDH2 (p.R140Q; MAF 29%)|NPM1 (p.W288fs*12; MAF 29%)|SRSF2 (p.P95L; MAF 22%) ; DNMT3A (p.R882H; MAF 34%)|FLT3-D835 (p.D835V; MAF 11%)|KRAS (p.G13D; MAF 8%)|MYD88 (p.L265P; MAF 8%)|NPM1 (p.W288fs*12; MAF 25%) ; DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%) ; FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%) ; KDM6A (p.I598V; MAF 50%)|KRAS (p.G12D; MAF 4%)|NRAS (p.G12S; MAF 6%) ; FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%) ; DNMT3A (p.r882H; MAF 45%)|FLT3-ITD|MLL |RUNX1 (p.E454Gfs*149; MAF 51%) ; DNMT3A (p.R882H; MAF 50%)|NPM1 (p.W288fs*12;MAF 40%)|SOCS1 (p.Q210H; MAF 50%)|TET2 (p.S460F; MAF 45%) ; BCOR (p.Y1350*; MAF 65%)|FBXW7 (p.T15_G16insP; MAF 50%)|RUNX1 (p.E223*; MAF 25%)|STAG2 (p.G977fs*8; MAF 55%) ; ASXL1 (p.S1028*; MAF 14%)|BCOR (p.Y1350*; MAF 6%)|FBXW7 (p.T15_G16insP; MAF 49%)|FLT3|RUNX1 (p.E223*; MAF 1%) ; DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%) ; NRAS (p.G13R;MAF 47%) ; DNMT3A (p.E285D; MAF 40% )|KDM6A (p.Y215fs*2; MAF 40%)|TP53 (p.V272_R273insL; MAF 75%) ; CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%) ; BRCA2 (T3085FS*26; MAF 45.0%)|TP53 (H193Y; MAF 65.0%) ; FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% ) ; IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%) ; NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%) ; ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%) ; FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%) ; FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%) ; CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%) ; NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs) ; EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X) ; IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%) ; ATM (p.P604S; VAF ~50%)|PHF6 (p.G306R; VAF ~75%)|RUNX1 (p.S322fs*278 (Single base pair insertion, frame shift  mutation); MAF ~40%) ; ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%) ; DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% ) ; DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%) ; CREBBP (p.M118I; MAF 50%) ; BCOR (p.KB39Qfs*5; MAF 45%)|KIT (p.T916A; MAF 50%)|NRAS (p.G12A; MAF 24%)|SRSF2 (p.P95R; MAF 40%) ; BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%) ; BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%) ; NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%) ; FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%) ; FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%) ; CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%) ; DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs) ; FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%) ; DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%) ; ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs) ; ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%) ; ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%) ; FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%) ; DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%) ; CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%) ; KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%) ; NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%) ; ASXL1 (p.N1036S; MAF 50%)|CEBPA (p.N321D; MAF 20%)|DNMT3A (p.R882C; MAF 20%)|IDH1 (p.R132C; MAF 20%)|MLL (Partial tandem duplication ) ; TET2 (p.L307R; MAF 51%) ; GATA1 (p.M1V; MAF 32%)|MPL (p.S505N; MAF 70%)|TET2 (p.V636fs*3; MAF 46%) ; MLL2 (p.P2557L; MAF 51%)|TP53 (p.R248W; MAF 57%) ; DNMT3A (p.R882H; MAF 41%)|SF3B1 (p.K700E; MAF 43%) ; GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%) ; DNMT3A (p.P777S; MAF 90%)|FLT3-ITD (MAF 75%)|IDH1 (p.R132H; MAF 45%)|NPM1 (p.W288fs*12; MAF 40%) ; ASXL2 (p.Val1277Ala; MAF 89.5%)|DNMT3A (p.Trp297* (NM_175629.2); MAF 82.1%)|IDH1 (p.Arg132Cys (NM_005896.3); MAF 39.1%) ; FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%) ; ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%) ; KRAS (p.G12V; MAF 76%) ; DNMT3A (p.E283*; MAF 30%) ; FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%) ; FLT3 (R311Q; MAF 48%) ; NRAS (p.Q61H; MAF 45%) ; CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%) ; NRAS (p.G12D; MAF 6%) ; PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%) ; FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%) ; ASXL1 (p.A640Dfs*20, MAF 40%)|BRAF (p.G469A, MAF 7%)|EZH2 (MAF 43%)|JAK2 (p.V617F, MAF 46%)|NRAS (p.G12S, MAF 18%)|SETBP1 (p.D868N, MAF 15%)|SETBP1 (p.G870S, MAF 11%) ; EZH2 (p.L128S ,MAF 49%)|NF1 (p.F2388I, MAF 45%)|TET2 (p.R1452*, MAF 98%) ; FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs) ; FLT3-ITD|MLL ; GATA2 (c.1145G>A; p.R382Q)|TET2 (c.5162T>G; p.L1721W (SNP)) ; ASXL1|EZH2|PTPN11|RUNX1|STAG2 ; DNMT3A (p.Arg882His)|FLT3-ITD (p.Val579_Leu601dup)|NPM1 (p.Trp288Cysfs*12) ; BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX ; TP53 (R213fs; MAF 34%) ; CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%) ; NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%) ; EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%) ; BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%) ; CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%) ; IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%) ; CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%) ; FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%) ; DNMT3A (p.G570E; MAF 44%)|JAK2 (p.V617F; MAF 3%)|TP53 (Intron 4 3' splice site mutation; MAF 42%)|TP53 (p.K132R; MAF 45%) ; CEBPA ([c.937A>C; c.940G>A; c.941T>A;c.943C>G] p.K313_V314_L315delinsQKV) ; IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss) ; DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%) ; FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%) ; CEBPA (p.Ala40fs; MAF 20.3%)|CEBPA (p.Lys304Thr; MAF 26.5%)|DNMT3A (p.Arg882His; MAF 39.1%)|NPM1 (p.Trp288fs; MAF 9.6%)|TET2 (p.Gln1501*; MAF 39%) ; BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%) ; IDH2 (p.R140Q, MAF 46%)|NRAS (p.Q61K, MAF 45%)|SRSF2 (p.P95H, MAF 47%) ; TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%) ; ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%) ; DNMT3A (p.R882C; MAF 45%)|FLT3 (p.D835A; MAF 4%)|FLT3 (p.N841K; MAF; 7%)|NPM1 (p.W288fs*12; MAF 46%)|NRAS (p.G12D; 17%)|TET2 (p.G1137D; MAF 31%) ; DNMT3A (p.R882C; MAF 14%) ; DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%) ; IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%) ; ASXL1 (p.T601A; MAF 45%)|BCOR (p.Y1350fs*1; MAF 43%)|DNMT3A (p.R882H; MAF 46%)|FLT3 (p.A680V; MAF 37%)|IDH2 (p.R140Q; MAF 43%)|NRAS (p.Q61K; MAF 9%)|PRDM1 (p.I117M; MAF 49%)|RUNX1 (p.N434fs*166; MAF 37%)|RUNX1 (p.R201*; MAF 45%) ; ATM (p.R3047*; MAF 9%)|CSF3R (p.A832V; MAF 49%)|IDH2 (p.R140W; MAF 16%)|SRSF2 (p.P95_R102del; MAF 25%) ; FLT3-ITD (MAF 42%)|NOTCH1 (p.P2438L ; MAF 47%) ; FLT3-ITD (MAF 3%)|FLT3(p.D839G; MAF 3%)|DNMT3A(p.R882H; MAF 16%) ; TET2 (c.652G>A; p.V218M; MAF 50%) ; DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%) ; DNMT3A (p.R882H; MAF 35% )|FLT3-ITD (MAF 20%)|JAK3 (p.H529R; MAF 49% )|NPM1 (p.W288fs*12; MAF 20%) ; DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%) ; FLT3-ITD (ITD; MAF 60%) ; ASXL1 (p.Gly646fs; MAF 2.4%)|ASXL1 (p.Ser1143Arg; MAF 49.2%)|KIT (p.Asn822Lys; MAF 5.6%)|NRAS (p.Gly12Cys; MAF 1.2%)|SF3A1 (p.Arg95Cys; MAF 49.9%)|TET2 (p.Gln913fs; MAF 3%)|TET2 (p.Glu537*; MAF 19.3%) ; ASXL1 (p.D656N; MAF 46%)|CEBPA (p.Q311*; MAF 15%)|TET2 (p.R544*; MAF 16%) ; CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%) ; BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N) ; DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%) ; DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%) ; BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%) ; CEBPA (p
DISEASE_AT_DIAGNOSIS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Disease at Diagnosis	Patient	
DOR_MONTHS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Duration of Response (Months)	Patient	
DOR_STATUS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Duration of Response Event	Patient	
DOSE_REDUCTION	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Any dose reduction	Patient	
DOT_MONTHS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Duration of Treatment (Months)	Patient	
ECOG_STATUS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	ECOG status	Patient	
EVALUABLE_FOR_PET	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Evaluable for PET?	Patient	
EVALUABLE_FOR_RECIST	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Evaluable for RECIST?	Patient	
IMMUNOSUPPRESSION	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Suppression of the immune system.	Patient	
INTERFERON_ALPHA	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Was Interferon Alpha Therapy Used?	Patient	
KINASE_INHIBITOR	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Was a kinase inhibitor used?	Patient	
MAPK_PATHWAY_ALTERATION	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	MAPK Pathway Alteration	Patient	
NERVOUS_SYSTEM_INVOLVEMENT	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Was there nervous system involvement?	Patient	
ON_STUDY	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Patient on study	Patient	
ON_TREATMENT	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Patient on treatment	Patient	
PATIENT_ASSAYS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Summarized assays of patient's samples	Patient	
PERCENT_CHANGE_BY_PET	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Percent change by PET	Patient	
PERCENT_CHANGE_BY_RECIST	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Percent change by RECIST	Patient	
PET_BEST_RESPONSE	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	PET Best Response (SD, PR, CR)	Patient	
PRIOR_SYSTEMIC_THERAPIES	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	STRING	Any prior systemic therapies?	Patient	
TIME_TO_BEST_PET_RESPONSE	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Time to best PET response	Patient	
TIME_TO_FIRST_PET_RESPONSE	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Time to first PET response	Patient	
TOTAL_MUTATIONS	LightSalmon	Histiocytosis Cobimetinib (MSK, Nature 2019)	NUMBER	Total Mutations	Patient	
GERMLINE_CONTROL	LightSalmon	Myelodysplasia (UTokyo, Nature 2011)	STRING	Germline Control	Sample	CD3+ T cell ; Buccal mucosa
IPSS_SCORE	LightSalmon	Myelodysplasia (UTokyo, Nature 2011)	STRING	IPSS (the International Prognostic Scoring System) Score	Patient	
WHO_CLASS	LightSalmon	Myelodysplasia (UTokyo, Nature 2011)	STRING	WHO class.	Patient	
DETAILED_CANCER_TYPE	LightSalmon	Myelodysplastic (MSK, 2020)	STRING	Cancer Type Other	Sample	AML with mutated NPM1 ; Acute myelomonocytic leukemia ; AML with minimal differentiation ; Mastocytosis ; AML, NOS ; AML with t(6;9)(p23;q34.1);DEK-NUP214 ; AML with mutated CEBPA ; AML with myelodysplasia-related changes ; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 ; AML with maturation ; Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA ; AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 ; Therapy-related myeloid neoplasms ; Acute monoblastic/monocytic leukemia ; AML with t(9;11)(p22;q23); MLLT3-MLL ; Secondary myelofibrosis ; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 ; RAEB ; Acute erythroid leukemia ; MDS-U ; Mixed Phenotype Acute Leukemia, T/Myeloid, NOS ; Atypical chronic myeloid leukaemia, BCR-ABL1 negative ; Acute undifferentiated leukaemia ; Blastic plasmacytoid dendritic cell neoplasm ; AML without maturation ; Essential thrombocythemia ; Acute Myeloid Leukemia ; Acute myeloid leukemia ; Acute megakaryoblastic leukemia ; Refractory cytopenia with multilineage dysplasia ; MDS with isolated del(5q) ; Myeloid sarcoma ; Myeloid leukaemia associated with Down syndrome ; CMML ; Primary myelofibrosis ; Acute myeloblastic leukemia ; Acute myeloid leukemia with multilineage dysplasia ; Acute myeloblastic leukemia, in relapse ; Acute myeloid leukemia with multilineage dysplasia, not having achieved remission ; Myelodysplastic Syndromes ; Polycythemia Vera ; Myeloproliferative Neoplasms ; Mixed Phenotype Acute Leukemia, B/Myeloid, NOS ; Therapy-Related Myelodysplastic Syndrome ; MDS with excess blasts-2 ; Polycythaemia Vera Myelofibrosis ; Chronic Myelogenous Leukemia ; Primary Myelofibrosis,Overt Fibrotic Stage ; MDS with Ring Sideroblasts and Multilineage Dysplasia ; MDS with excess blasts-1 ; MDS with Excess Blasts ; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM ; MDS with Single Lineage Dysplasia ; MDS with Multilineage Dysplasia ; MDS with Ring Sideroblasts and Single Lineage Dysplasia ; AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 ; MDS with Ring Sideroblasts ; Chronic Myeloid Leukemia, BCR-ABL1+ ; AML with mutated RUNX1 ; Essential Thrombocythemia Myelofibrosis ; Acute Leukemias of Ambiguous Lineage ; RCMD ; RA ; RT ; MDSMPN ; RARS ; RCMD-RS ; RARS-T ; AML-MDS ; RAEB1
ANC	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Absolute Neutrophil Count in Giga/L	Sample	0.2 ; 2.4 ; 2.1 ; 1.9 ; 9.7 ; 12.6 ; 3 ; 1.5 ; 1.4 ; 0.5 ; 1.2 ; 2.3 ; 2.6 ; 1.7 ; 1.1 ; 1 ; 0.1 ; 0.8 ; 7.5 ; 0.6 ; 0.3 ; 0.7 ; 1.6 ; 40.1 ; 3.9 ; 0.9 ; 8.9 ; 3.6 ; 4.2 ; 2.7 ; 15.8 ; 5.63 ; 3.35 ; 3.4 ; 6.1 ; 1.8 ; 2.9 ; 2.8 ; 4.1 ; 8.7 ; 0.53 ; 2.2 ; 6.7 ; 0.96 ; 3.1 ; 5.8 ; 4.5 ; 7.1 ; 2.5 ; 5 ; 4.4 ; 1.3 ; 6.5 ; 4.9 ; 5.2 ; 17.5 ; 3.3 ; 12.5 ; 3.2 ; 1.67 ; 0.46 ; 1.07 ; 8.05 ; 3.71 ; 6.26 ; 9.78 ; 1.47 ; 4.82 ; 1.99 ; 1.32 ; 3.18 ; 3.65 ; 0.69 ; 0.78 ; 5.45 ; 1.97 ; 4.85 ; 4.01 ; 4.65 ; 1.59 ; 3.12 ; 1.15 ; 11.2 ; 2.64 ; 0.42 ; 4.15 ; 3.92 ; 6.16 ; 2.02 ; 0.92 ; 1.94 ; 1.95 ; 3.19 ; 2.82 ; 2.16 ; 2.89 ; 4.46 ; 5.91 ; 1.38 ; 4.06 ; 3.14 ; 2.68 ; 0.44 ; 1.31 ; 2.97 ; 4.84 ; 1.78 ; 2.67 ; 2.24 ; 1.24 ; 1.19 ; 0.89 ; 1.52 ; 1.71 ; 1.18 ; 2.36 ; 1.79 ; 4.45 ; 0.79 ; 5.05 ; 1.48 ; 5.06 ; 1.04 ; 1.64 ; 2.23 ; 3.09 ; 3.52 ; 5.21 ; 0.962 ; 1.86 ; 0.617 ; 3.562 ; 0.84 ; 1.85 ; 8.496 ; 5.048 ; 2.479 ; 8.632 ; 1.3064 ; 1.416 ; 1.984 ; 0.448 ; 2.31 ; 5.699 ; 2.835 ; 0.945 ; 3.08 ; 6.636 ; 0.966 ; 1.481 ; 1.428 ; 1.516 ; 0.264 ; 2.73 ; 2.15 ; 40.954 ; 17.937 ; 34.645 ; 25.626 ; 0.085 ; 4.3125 ; 1.862 ; 1.96 ; 1.833 ; 4.118 ; 3.77 ; 3.016 ; 0.392 ; 3.4705 ; 1.406 ; 3.41 ; 1.204 ; 3.24 ; 0.323 ; 0.4092 ; 0.893 ; 1.26 ; 0.836 ; 4.224 ; 1.092 ; 0.13 ; 2.379 ; 3.7878 ; 0.837 ; 3.198 ; 0.6275 ; 0.612 ; 0.861 ; 0.352 ; 0.513 ; 1.132 ; 1.641 ; 0.272 ; 5.576 ; 0.645 ; 3.172 ; 1.457 ; 2.145 ; 6.333 ; 2.301 ; 1.33 ; 3.015 ; 19.097 ; 0.72 ; 1.43 ; 1.392 ; 1.995 ; 4.343 ; 3.525 ; 0.118 ; 1.159 ; 3.36 ; 6.059 ; 4.6 ; 4.312 ; 0.627 ; 2.304 ; 3.69 ; 0.375 ; 2.484 ; 0.68 ; 2.295 ; 3.657 ; 1.61 ; 0.608 ; 6.789 ; 7.42 ; 1.131 ; 1.596 ; 2.03 ; 0.377 ; 0.108 ; 3.05 ; 0.792 ; 2.208 ; 2.856 ; 3.195 ; 1.701 ; 2.538 ; 1.007 ; 3.04 ; 1.922 ; 3.712 ; 1.976 ; 28.696 ; 5.096 ; 2.958 ; 3.995 ; 2.597 ; 1.292 ; 23.87 ; 3.136 ; 3.5 ; 3.478 ; 7.26 ; 0.408 ; 1.452 ; 0.832 ; 1.935 ; 1.53 ; 1.21 ; 0.455 ; 1.72 ; 1.702 ; 0.725 ; 1.29 ; 4.18 ; 2.457 ; 0.65 ; 0.336 ; 2.829 ; 3.876 ; 0.868 ; 1.65 ; 0.27 ; 0.384 ; 1.74 ; 8.232 ; 3.294 ; 6.586 ; 3.519 ; 1.92 ; 3.38 ; 1.28 ; 5.52 ; 5.07 ; 1.287 ; 1.536 ; 9.072 ; 1.334 ; 5.538 ; 0.936 ; 0.429 ; 0.55 ; 7.865 ; 2.052 ; 2.278 ; 1.584 ; 3.339 ; 0.4 ; 0.743 ; 2.773 ; 5.457 ; 5.7 ; 0.03 ; 1.998 ; 0.635 ; 1.836 ; 4.896 ; 65.178 ; 0.16 ; 1.548 ; 2.028 ; 0.969 ; 1.026 ; 1.75 ; 0.299 ; 0.703 ; 2.56 ; 3.894 ; 1.656 ; 3.392 ; 1.196 ; 2.016 ; 4.83 ; 23.951 ; 3.358 ; 2.137 ; 4.86 ; 1.576 ; 0.49 ; 0.998 ; 0.76 ; 0.928 ; 1.973 ; 1.848 ; 1.843 ; 3.922 ; 4.814 ; 0.616 ; 3.248 ; 5.786 ; 2.25 ; 6.37 ; 7.2 ; 15.444 ; 4.588 ; 0.36 ; 2.754 ; 3.99 ; 4.09 ; 0.816 ; 1.02 ; 5.194 ; 5.18 ; 1.378 ; 0.51 ; 0.324 ; 5.75 ; 0.48 ; 5.369 ; 1.44 ; 1.216 ; 12.056 ; 5.336 ; 0.64 ; 0.527 ; 2.376 ; 0.06 ; 0.298899994 ; 1.05 ; 0.651 ; 9.676 ; 1.722 ; 1.16 ; 5.141 ; 1.512 ; 6.052 ; 3.233 ; 0.161 ; 2.498 ; 2.915 ; 2.967 ; 1.62 ; 3.285 ; 1.54 ; 3.286 ; 0.636 ; 1.76 ; 1.036 ; 8.614 ; 2.646 ; 3.363 ; 1.767 ; 5.088 ; 0.24 ; 1.316 ; 0.144 ; 1.479 ; 4.295 ; 4.736 ; 0.066 ; 2.09 ; 9.476 ; 0.975 ; 8.37 ; 0.43 ; 1.312 ; 0.135 ; 1.008 ; 0.18 ; 1.575 ; 6.136 ; 0.54 ; 0.912 ; 3.619 ; 1.175 ; 0.35 ; 3.654 ; 3.315 ; 3.526 ; 1.102 ; 7.77 ; 0.56 ; 8.1 ; 0.77 ; 3.51 ; 2.38 ; 7.938 ; 6.844 ; 0.468 ; 0.19 ; 2.904 ; 1.653 ; 0.799 ; 1.63 ; 1.288 ; 0.25 ; 2.13 ; 8 ; 2.108 ; 1.386 ; 0.004 ; 11.9 ; 6.78 ; 3.21 ; 0.672 ; 0.98 ; 4.968 ; 5.17 ; 2.756 ; 5.162 ; 0.648 ; 4.858700195 ; 7.7 ; 12.528 ; 3.58701001 ; 0.93323999 ; 4.17 ; 1.763 ; 0.551 ; 0.075 ; 0.168 ; 3.126 ; 1.736 ; 2.263 ; 1.936 ; 1.666 ; 0.250800003 ; 10.24 ; 2.17 ; 1.652 ; 0.736 ; 3.029780029 ; 0.9165 ; 1.7575 ; 0.637 ; 32.83 ; 0.016799999 ; 1.624 ; 0.806 ; 1.01025 ; 0.57 ; 3.504 ; 0.598 ; 6.116 ; 4.979 ; 3.053 ; 3.024 ; 2.140840088 ; 3.276 ; 3.068 ; 2.162 ; 2.652 ; 3.002 ; 1.218 ; 4.872 ; 2.437 ; 0.66 ; 3.318 ; 0.432 ; 1.535199951 ; 0.715 ; 2.87 ; 0.552 ; 1.537 ; 3.164 ; 0.175 ; 1.34 ; 6.509 ; 1.785 ; 1.038 ; 1.877 ; 2.046 ; 3.573 ; 24.8 ; 2.736 ; 1.359 ; 2 ; 1.353 ; 4.851 ; 0.105 ; 1.739 ; 2.58 ; 23.05 ; 7.4 ; 4.8 ; 1.84 ; 3.47 ; 10.4 ; 2.66 ; 4.3 ; 1.98 ; 0.084 ; 1.11 ; 0.74 ; 6.4 ; 0.12 ; 2.75 ; 0.524 ; 1.37 ; 6.44 ; 4.7 ; 9.69 ; 19.22 ; 13.4 ; 1.13 ; 13.98 ; 0.07 ; 2.78 ; 6.34 ; 2.979 ; 0.99 ; 9.28 ; 1.77 ; 3.66 ; 1.36 ; 4.69 ; 1.14 ; 3.689 ; 2.911 ; 1.339 ; 1.809 ; 4.025 ; 4.957 ; 5.949 ; 3.232 ; 0.463 ; 4.261 ; 3.456 ; 4.284 ; 15.785 ; 0.7458 ; 8.99 ; 4.582 ; 1.325 ; 5.022 ; 1.231 ; 2.818 ; 2.844 ; 4.019 ; 1.765 ; 0.569 ; 2.204 ; 6.64 ; 2.286 ; 3.174 ; 2.739 ; 2.194 ; 1.755 ; 2.747 ; 0.646 ; 2.987 ; 1.632 ; 0.94 ; 3.047 ; 1.281 ; 6.832 ; 1.285 ; 2.248 ; 0.624 ; 1.398 ; 2.212 ; 1.165 ; 0.504 ; 1.496 ; 1.504 ; 4.552 ; 4.205 ; 19.906 ; 0.461 ; 0.129 ; 2.092 ; 5.471 ; 4.577 ; 0.252 ; 0.185 ; 2.072 ; 2.648 ; 2.283 ; 1.87 ; 1.926 ; 2.01 ; 7.29 ; 0.15 ; 2.51 ; 0.85 ; 4.75 ; 2.26 ; 2.06 ; 0.28 ; 10.3 ; 5.38 ; 0.62 ; 0.21 ; 2.29 ; 1.08 ; 0.97 ; 0.14 ; 6.02 ; 0.88 ; 0.47 ; 4.48 ; 3.17 ; 2.27 ; 5.61 ; 0.32 ; 9.84 ; 8.4 ; 1.91 ; 6.29 ; 2.63 ; 3.91 ; 3.67 ; 0.95 ; 2.99 ; 0.81 ; 4.34 ; 2.65 ; 7.32 ; 2.79 ; 2.07 ; 4.47 ; 9.41 ; 5.08 ; 0.34 ; 5.3 ; 0.23 ; 1.22 ; 9.06 ; 2.08 ; 3.87 ; 1.89 ; 5.73 ; 5.71 ; 2.86 ; 2.48 ; 2.93 ; 6.21 ; 2.14 ; 4.96 ; 6.86 ; 2.98 ; 5.12 ; 8.27 ; 2.18 ; 1.06 ; 4.62 ; 6.28 ; 6.07 ; 5.27 ; 9.92 ; 7.49 ; 0.59 ; 1.03 ; 3.01 ; 3.98 ; 2.61 ; 5.68 ; 1.49 ; 20.78 ; 2.22 ; 4.36 ; 5.1 ; 3.95 ; 3.46 ; 4.51 ; 2.52 ; 5.23 ; 5.33 ; 2.43 ; 6.9 ; 0.87 ; 7.95 ; 2.74 ; 3.48 ; 3.02 ; 3.97 ; 2.32 ; 0.91 ; 3.32 ; 4.54 ; 6.06 ; 2.62 ; 4.55 ; 9.72 ; 3.76 ; 1.25 ; 2.46 ; 3.84 ; 3.94 ; 5.09 ; 1.73 ; 3.74 ; 0.38 ; 2.04 ; 2.96 ; 1.68 ; 3.15 ; 13.13 ; 0.39 ; 1.17 ; 3.68 ; 2.71 ; 2.21 ; 1.23 ; 1.88 ; 9.88 ; 2.84 ; 5.76 ; 6.43 ; 2.54 ; 4.35 ; 5.39 ; 1.39 ; 16.6 ; 8.82 ; 6.66 ; 1.42 ; 5.25 ; 43.69 ; 25.17 ; 3.27 ; 4.88 ; 3.37 ; 6 ; 6.04 ; 1.01 ; 2.57 ; 2.42 ; 5.93 ; 0.459 ; 12.03 ; 3.58 ; 0.86 ; 4.32 ; 16.07 ; 4.66 ; 6.8 ; 9.9 ; 4 ; 0 ; 14 ; 26.9 ; 2.05 ; 6.24 ; 1.51 ; 0.83 ; 4.08 ; 0.52 ; 2.35 ; 3.61 ; 6.6 ; 4.76 ; 3.72 ; 2.39 ; 5.43 ; 2.81 ; 15.28 ; 22.91 ; 3.54 ; 5.56 ; 2.85 ; 17.1 ; 0.61 ; 2.88 ; 1.56 ; 1.41 ; 1.12 ; 10.81 ; 7.15 ; 19.29 ; 0.05 ; 3.8 ; 25.7 ; 6.3 ; 15.2 ; 9.6 ; 7.6 ; 14.8 ; 5.6 ; 6.2 ; 11 ; 8.5 ; 15.4 ; 29.9 ; 8.3 ; 34.2 ; 25.9 ; 28 ; 25.5 ; 9 ; 10.9 ; 5.5 ; 9.4 ; 30.8 ; 10.8 ; 3.7 ; 31.8 ; 9.8 ; 3.13 ; 3.25 ; 6.15 ; 35.5 ; 23.8 ; 67.6 ; 7.9 ; 9.1 ; 7 ; 25.1 ; 20 ; 19.8 ; 33 ; 14.7 ; 0.37 ; 2.59 ; 3.89 ; 16 ; 21 ; 18 ; 15 ; 74 ; 13 ; 38 ; 22 ; 30 ; 25 ; 9.5 ; 9.3 ; 42.2 ; 12.9 ; 12.2 ; 5.9 ; 25.2 ; 18.4 ; 7.3 ; 12.8 ; 16.5 ; 8.8 ; 12.7 ; 24.1 ; 12.1 ; 28.1 ; 12.01 ; 109.62 ; 17.3 ; 4.28 ; 2.44 ; 5.82 ; 31.22 ; 4.53 ; 19.4 ; 7.23 ; 0.33 ; 8.06 ; 1.46 ; 0.41 ; 15.62 ; 2.11 ; 0.73 ; 18.35 ; 7.75 ; 10.44 ; 8.16 ; 8.53 ; 4.22 ; 0.71 ; 87 ; 0.82 ; 1.55 ; 2.53 ; 1.27 ; 4.23 ; 1.58 ; 0.75 ; 30.67 ; 6.18 ; 22.19 ; 31.01 ; 8.51 ; 2.33 ; 6.05 ; 2.47 ; 0.26 ; 7.73 ; 0.45 ; 0.01 ; 0.58 ; 2.28 ; 4.38 ; 6.38 ; 15.36 ; 0.67 ; 3.82 ; 4.31 ; 3.56 ; 8.36 ; 1.81 ; 1.82 ; 1.66 ; 3.07 ; 2.12 ; 4.41 ; 19.13 ; 4.59 ; 10.78 ; 4.44 ; 13.88 ; 3.33 ; 11.48 ; 5.88 ; 3.53 ; 5.26 ; 5.01 ; 4.52 ; 8.42 ; 27.69 ; 17.8 ; 0.17 ; 9.61 ; 4.61 ; 5.54 ; 10 ; 7.13 ; 6.73 ; 3.63 ; 8.47 ; 1.323 ; 8.6 ; 3.11 ; 6.88 ; 6.51 ; 3.49 ; 0.63 ; 0.93 ; 4.16 ; 1.93 ; 0.31 ; 21.58 ; 0.22 ; 6.72 ; 5.4 ; 3.85 ; 12 ; 18.2 ; 21.69 ; 1.69 ; 6.56 ; 3.59 ; 7.44 ; 3.29 ; 1.35 ; 3.64 ; 2.75712 ; 1.5876 ; 1.464 ; 1.40344 ; 1.16432 ; 1.786 ; 2.695 ; 5.9358 ; 1.79679 ; 0.848 ; 0.576 ; 2.688 ; 1.456 ; 1.768 ; 2.944 ; 4.25 ; 3.948 ; 1.974 ; 6.19 ; 1.638 ; 4.13 ; 1.83 ; 13.8 ; 3.62 ; 5.37 ; 13.18 ; 14.9 ; 17.14 ; 2.19 ; 4.11 ; 6.98 ; 2.49 ; 8.48
BM_BLAST	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	BM Blast in %	Sample	14 ; 1 ; 15 ; 6 ; 3 ; 12 ; 4 ; 7 ; 5 ; 0 ; 2 ; 9 ; 20 ; 10 ; 8 ; 19 ; 11 ; 18 ; 13 ; 11.6 ; 2.5 ; 1.3 ; 6.8 ; 11.1 ; 13.4 ; 3.4 ; 1.7 ; 1.6 ; 5.7 ; 0.4 ; 1.8 ; 15.2 ; 7.2 ; 0.9 ; 15.8 ; 2.2 ; 8.8 ; 7.1 ; 13.3 ; 5.4 ; 0.8 ; 4.2 ; 0.2 ; 3.2 ; 16.4 ; 1.1 ; 0.6 ; 3.5 ; 12.4 ; 0.5 ; 5.3 ; 1.4 ; 13.7 ; 2.1 ; 16 ; 5.2 ; 11.3 ; 10.4 ; 4.7 ; 9.4 ; 12.6 ; 5.8 ; 14.2 ; 3.1 ; 9.6 ; 7.7 ; 2.6 ; 5.5 ; 8.6 ; 6.2 ; 1.2 ; 12.5 ; 17 ; 27 ; 25 ; 26 ; 28 ; 24 ; 30 ; 22 ; 29 ; 39 ; 21 ; 60 ; 6.5 ; 46 ; 23 ; 11.5 ; 7.5 ; 8.5 ; 4.8 ; 4.4 ; 2.8 ; 13.2 ; 2.4 ; 7.6 ; 9.2 ; 5.6 ; 10.8 ; 3.6 ; 14.5 ; 48 ; 36 ; 4.5 ; 1.5 ; 15.5 ; 31 ; 10.5 ; 33 ; 17.5 ; 9.5 ; 20.5 ; 45 ; 6.4 ; 4.6 ; 54 ; 13.5 ; 73 ; 21.5 ; 50 ; 91 ; 23.8 ; 38 ; 11.8 ; 24.5 ; 80 ; 90 ; 35 ; 37 ; 55 ; 6.3 ; 34 ; 19.5 ; 16.5 ; 40 ; 0.7 ; 0.3 ; 2.7 ; 11.2
CHR_TP53_LOCUS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	Chromosomal Status with Allelic Imbalance at TP53 locus	Sample	normal ; del ; cnloh ; iso17q ; gain
CNACS_CHRARM_GAIN	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Chromosomal Arm Gain	Sample	11p ; 19p ; 8 ; 9p,9q ; 1p ; 5p,5q,6p ; 4q ; 8q ; 17q ; 20q,22q ; 1p,13q ; 6q ; 1q ; 9,11q,22q ; 1 ; 11q ; 11 ; 1q,8 ; 6p ; 21q ; 5p ; 3q,21q ; 5,15q,19q,21q ; 22q ; 8p,9p,11q ; 1p,1,11q ; 6p,19p ; 15q ; 9p ; 8,19p,19q ; 13q ; 3q,5,8 ; 3q ; 11,11q ; 19p,19q ; 14q ; 8,13q ; 5,6p ; 16q ; 13q,20 ; 9p,17p,20q,22q ; 9q ; 1p,1,5,5q,6,8,11,14q ; 8,11q,12q ; 12,12q ; 12q ; 19q,21q ; 17 ; 19q ; 1p,2p ; 1,5q,11,22q ; 7q ; 17p ; 1,11 ; 20q ; 17q,21q ; 20 ; 1,5q,14q ; 6p,7q,11q ; 19 ; 20,20q ; 1q,8,10,19,20 ; 1p,21q ; 21q,22q ; 1,14q ; 5p,9q ; 16p,21q ; 8,21q ; 5q,12 ; 8,17q
CNACS_CHRARM_LOSS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Chromosomal Arm Loss	Sample	5q,17p ; 4p,4q,5q,9q,12p,17p ; 5q,7q,12p,17p,18q ; 5q,17 ; 7 ; 3,5q,7q,12p,16q ; 9q,11p ; 5q,7q,18,20q ; 5q ; 3p ; 11q ; 9,11q ; 20q ; 2p,5q ; 4,5q,17p ; 2p ; 3p,5q,9q,12,12q ; 9q,11q ; 5 ; 5,7q ; 8p ; 5q,12q ; 4q,5q,11q ; 4q,5q,7q,12p,17p,17,20q,22q ; 7q ; 4p,4q,5q,6p,12p,13q ; 5q,17p,17 ; 3q,5q,7,12q,17p,17,20q ; 5q,7,18 ; 3p,5q,6p,13q ; 5,7,12p,15q,18,21q ; 12p ; 5q,12p,18q ; 1p,5q ; 5q,7,21q ; 5q,7q,12p,20p ; 3p,5q,9,16p,17p ; 1p,4q,5q,7,17p,18 ; 5q,7,12p ; 5q,7q,12p,17p ; 17p ; 1p ; 3p,12p ; 5q,7q,14q,17p,20p ; 11p ; 3p,5q,6p ; 3p,5q,7q,12p,17p ; 2q,3p,5q,6q,7,12p ; 3,5q,7q,9q,12p,16,19q ; 14q ; 3p,4q,5q,7q,17p,19q,20q ; 7,18p ; 5q,18 ; 1q ; 3p,5q,7q,12p,12,12q,15q,20p ; 5q,16q,20 ; 3q,5q,7,13q,16q,18,20q ; 13q ; 15q ; 20 ; 5q,7,12p,20q ; 1q,3p,5q,7q,10p,12q,19q,20q,21q ; 5,6p,18 ; 5q,18q ; 18p ; 5q,11p,17p ; 16q ; 17 ; 5q,20q ; 5q,7q,9q ; 5q,7q,12p ; 20p ; 20q,17p ; 2p,3p,5q ; 5q,7,9q,12p ; 7,20q ; 2p,5q,7 ; 5q,7q,13q,16q,17p,20q ; 3,5q,12p ; 4q,5q ; 7q,20q ; 5q,13q,18,20q ; 7p ; 2q,17p ; 12q ; 5q,7,17p,17q,18,22q ; 2p,5q,7q,11p,18 ; 5q,7q,18q ; 1p,5q,12q,13q,16q,17q,18 ; 5q,7,12p,13q,16 ; 7,12p ; 4q ; 1,5q,11q,16p ; 9p ; 12 ; 5q,17p,18,20p ; 3,5q,7q,11q,12p,15q ; 4q,5q,6p,11q ; 5q,11q ; 5q,15q ; 5,7q,11p,12,13q ; 5q,6p,7q,18q ; 7p,15q,17p,18 ; 4q,5,7q,12,12q,16,16q ; 5q,18,20q ; 5q,7,12p,13q ; 5q,7q,13q,15q,20q ; 5q,7,11p,17p ; 7,17p,18q ; 7,17p ; 3p,5q,6p,8p ; 5q,7,13q,16q,17p,20q ; 5q,7,17,18q,21q ; 5q,7,17p ; 5q,18,20 ; 5q,7,9q,12,12q ; 5q,12 ; 6q ; 5q,7,14q ; 5q,6p ; 3p,5q,7,12q,16,18q,17p ; 3p,5q,7p,12p ; 5q,7,8p,9q,12p,16,17p,18 ; 3p,5q,7,21q ; 3,4p,5,7q,13q,20q ; 7q,12p ; 3p,5q ; 5q,7,11q,12p,16q,20q ; 5q,12p ; 5q,7q,17,19q ; 1p,5q,18 ; 5q,7q,20q ; 5q,7 ; 5q,6p,12p,16q,20q ; 1p,7,16q ; 11q,20q ; 5q,7q,12,12q,16,20 ; 7,11q,13q ; 3,5q,6p,15q,17p ; 5q,7,15q,17p ; 5q,7q,16q,17p ; 5q,7q,12,12q,18q ; 18q ; 4q,12q ; 3q,5q,7q ; 6p,12q ; 1p,5q,18q ; 5q,12p,17p ; 3p,5q,6p,9q ; 7,17p,18 ; 6p,9q,18 ; 1p,2p,5,13q ; 4q,5q,7,12p,13q,16,17p ; 5q,7q,17p,20q ; 5q,7q,15q,20 ; 5q,7q,12,16q,17p,18 ; 3p,5q,12p,13q,17p ; 5q,7,12p,17p ; 2q,5q,11q ; 5q,7q,13q,18q ; 5q,16p,17,18 ; 5q,7,11p,12p,20q ; 3p,5q,7p,18 ; 5q,13q,18q,22q ; 5q,12p,16p,16q,17p ; 5q,7q,18 ; 2p,5q,10q,16p,16,18 ; 5q,12p,13q,16q,17q ; 3p,5q,6p,7,13q,18 ; 5q,6q,7q,12p,20q ; 3q,5q,11,11q,17p,20q ; 2p,5q,7,12p,17p ; 5q,7,13q,17p ; 1p,5q,7q,17p ; 1p,3q,4p,4q,5q,7,17,18 ; 5q,7q,11q,12p ; 4q,5q,6q,7q,16,17,18,20q ; 1p,5q,7 ; 5q,7,12p,16q,17p,17 ; 3p,5q,7 ; 5q,17p,20q ; 2p,5q,11p,18q,20q ; 5q,16q,17,18q,20q ; 7q,17p,17 ; 2q,11q ; 5q,7,12p,18q ; 5q,7,12q,16q ; 1p,2p,5q,17p ; 3,5q,7p,17p ; 4q,20q ; 1,5q,11q,13q,20p ; 7q,16q ; 21q,17 ; 17p,20q ; 2q,17 ; 5,7q,13q ; 4p,4q,5,7q,12p,17p,18 ; 5q,7q ; 5q,17p,17,18,21q ; 3,5q,17p,20q ; 3q ; 5q,17p,18 ; 5q,7q,11p,12p ; 4q,17p ; 3,5q,7q,9q,11q ; 3p,5q,16q ; 1p,4q,5q,7q ; 4q,5q,7,10p,12p,13q ; 7,16q,17p ; 5q,7q,13q,17 ; 5q,17p,18,20q ; 7,11p,17p ; 3p,5q,7q ; 11p,12,20q,17p ; 1 ; 5q,13q,14q ; 5q,6p,7q,12p,20 ; 4q,5q,7q,16q ; 4q,7q,20q ; 5q,7q,11q ; 2p,4p,4q,5q,7q,12p,17p ; 3p,5q,7q,9 ; 5q,11p,17 ; 5q,7p,11q ; 5q,7,13q ; 16q,20q ; 5q,16q ; 5,7 ; 1q,5q,7,12p,13q,16q ; 2p,2,4q,5q ; 2p,5q,17p ; 9,9q,11q ; 5q,6q,7q,16q ; 2,4p,4q,5q,18q
CNACS_CHRARM_UPD	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Chromosomal Arm Upd (i.e. copy-neutral LOH)	Sample	11p ; 17p ; 4 ; 7q ; 4q ; 9p,12p ; 9p ; 2p ; 14q ; 11q,14q ; 17 ; 1q ; 11q ; 17,20p ; 3q,17p ; 17q ; 6p,11 ; 1p ; 7q,14q ; 12q ; 1p,11q ; 13q,22q ; 21q ; 7 ; 1p,6p ; 3q ; 1 ; 4q,7q ; 11p,17q ; 9p,14q ; 7q,17q ; 13q ; 18q ; 4q,11q ; 4q,21q ; 6q ; 6p ; 14q,21q ; 3q,21q ; 22q ; 11 ; 18 ; 3q,11p,18q,17p ; 2q ; 7,11q ; 7p ; 16q ; 3q,9p ; 4q,11p ; 15q
CNACS_GENE_GAIN	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Gene (from panel) Gain	Sample	HRAS ; CALR,JAK3 ; MYC,RAD21 ; ABL1,CDKN2A,CDKN2B,JAK2 ; CDKN2C,CSF3R,MPL,PTPRF,RBBP4 ; DDX41,IRF4,JARID2,NIPBL,NPM1 ; KIT ; MIR142,PPM1D ; CSF2RB,GNAS,NF2,SF3A1 ; ARID1A,FLT3 ; PDSS2,PHIP ; H3F3A,SETDB1 ; ABL1,CBL,CDKN2A,CDKN2B,CHEK2,CSF2RB,EP300,JAK2,NF2,NOTCH1,PAX5,SF3A1 ; BCL10,CSF3R,GFI1,GNB1,RBBP4 ; NOTCH2,SETDB1 ; H3F3B,PPM1D,SRSF2 ; CBL,EED,MLL,NXF1,SF1 ; CBL,EED,HRAS,MLL,NXF1,SF1,WT1 ; MYC,RAD21,SETDB1 ; RUNX1,U2AF1 ; NIPBL ; PIK3CA,RUNX1,U2AF1 ; CSF3R,GNB1,MPL,RBBP4 ; CEBPA,IDH2,MIR-516A,MIR-516B,NIPBL,RASGRF1,RRAS,U2AF2 ; CHEK2,EP300,NF2,SF3A1 ; CBL,JAK2,MLL ; ARID1A,BCL10,CBL,CDKN2C,CSF3R,EED,GFI1,GNB1,H3F3A,MLL,MPL,NOTCH2,NRAS,NXF1,PTPRF,RBBP4,SETDB1,SF1 ; PPM1D ; CALR,JARID2 ; ARID1A,BCL10,CDKN2C,CSF3R,GFI1,GNB1,MPL,PTPRF,RBBP4 ; IDH2,RASGRF1 ; CDKN2A,CDKN2B,JAK2,PAX5 ; CALR,JAK3,MIR-516A,MIR-516B,MYC,RAD21,RRAS,U2AF2 ; ARID1A,CSF3R,MPL,RBBP4 ; MIRN1267 ; DDX4,GATA2,MYC,PIK3CA,RAD21,STAG1 ; PIK3CA ; FLT3 ; CALR,CEBPA,JAK3,RRAS ; CM003625,DICER1,YLPM1 ; CHEK2,CSF2RB,EP300,NF2,SF3A1 ; H3F3A ; FLT3,MYC,RAD21 ; NIPBL,ZNF318 ; CBL,EED,MLL ; IRF8 ; ASXL1,FLT3 ; CBL,MLL ; CDKN2C,CSF3R,MPL,PTPRF ; ASXL1,CHEK2,DHX33,DNMT3B,JAK2,NF2,PRPF8,SAMHD1,SF3A1,TP53 ; ABL1,NOTCH1 ; CSF3R,MPL ; IDH2,MGA,RAD51,RASGRF1 ; ZNF318 ; ABL1 ; ARID1A,BCL10,CBL,CDKN2C,CM003625,CSF3R,DDX4,DDX41,DICER1,EED,GFI1,GNB1,H3F3A,HRAS,IRF4,JARID2,MLL,MPL,MYC,NIPBL,NOTCH2,NPM1,NRAS,NXF1,PDSS2,PHIP,PTPRF,RBBP4,SETDB1,SF1,WT1,YLPM1,ZNF318 ; CBL,MLL,MYC,RAD21 ; ARID2,CDK4,DDX23,DDX54,MLL2,NFE2,PRPF40B,PTPN11,SH2B3 ; ARID2,CDK4,DDX23,MLL2,NFE2,PRPF40B ; MIR-516B,RRAS,U2AF1 ; H3F3B,MIR142,MIRN632,NF1,PPM1D,SRSF2,STAT3,STAT5A,SUZ12 ; MIR-516A,MIR-516B,RRAS,U2AF2 ; FLT3,MIRN1267,MYC,RB1 ; ARID1A,CDKN2C,CSF3R,GNB1,MPL,PTPRF,RBBP4,SPRED2 ; ARID1A,BCL10,CBL,CDKN2C,CHEK2,CSF2RB,CSF3R,DDX41,EED,EP300,GFI1,GNB1,HRAS,MLL,MPL,NF2,NOTCH2,NPM1,NRAS,NXF1,PTPRF,RBBP4,SETDB1,SF1,SF3A1,WT1 ; TYW1 ; TP53 ; ARID1A,BCL10,CBL,CDKN2C,CSF3R,EED,GFI1,GNB1,MLL,MPL,NOTCH2,NRAS,NXF1,PTPRF,RBBP4,SETDB1,SF1 ; ARID2,DDX23,KRAS,MLL2,PRPF40B ; GNAS ; ARID1A,CDKN2C,CSF3R,GNB1,MPL,PTPRF,RBBP4 ; U2AF1 ; MIR142,PPM1D,RUNX1,STAT3,STAT5A,U2AF1 ; CM003625,DICER1 ; ARID1A,BCL10,CDKN2C,CM003625,CSF3R,DDX41,DICER1,GFI1,GNB1,MPL,NOTCH2,NPM1,NRAS,PTPRF,RBBP4,SETDB1,YLPM1 ; CBL,IRF4,JARID2,MLL,MLL3,ZNF318 ; MYC ; CDKN2A,CDKN2B,JAK2 ; CALR,CEBPA,JAK3,MIR-516A,MIR-516B,RRAS,U2AF2 ; ASXL1,CALR,CEBPA,FGFR2,H3F3A,JAK3,MIR-516A,MIR-516B,MYC,PTEN,RAD21,RRAS,SETDB1,SMC3,U2AF2 ; ARID2,CDK4,CDKN1B,DDX23,DDX54,ETNK1,ETV6,KRAS,MLL2,NFE2,PRPF40B,PTPN11,SH2B3 ; CSF3R,MPL,PTPRF,RBBP4,RUNX1,U2AF1 ; H3F3A,NOTCH2,SETDB1 ; CHEK2,CSF2RB,EP300,NF2,RUNX1,SF3A1,U2AF1 ; BCL10,CDKN2C,CSF3R,GFI1,MPL,NOTCH2,NRAS,PTPRF,RBBP4,SETDB1,YLPM1 ; ABL1,NIPBL,NOTCH1 ; CREBBP,RUNX1,SMG1,SRCAP,U2AF1 ; MYC,RAD21,RUNX1,U2AF1 ; ARID2,DDX23,DDX41,ETNK1,KRAS,MLL2,NPM1 ; H3F3B,MIR142,MYC,PPM1D,RAD21,SRSF2,STAT3,STAT5A
CNACS_GENE_LOSS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Gene (from panel) Loss	Sample	CSF1R,CSNK1A1,DDX41,IRF1,NPM1,RAD50,TP53 ; CSF1R,CSNK1A1,DDX4,DDX41,DHX33,IRF1,NPM1,PRPF8,RAD50,TET2,TP53,WHSC1 ; ARID2,BCL2,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX23,DDX4,DDX41,DHX33,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MLL2,MLL3,NPM1,PRPF40B,PRPF8,RAD50,SETBP1,TP53 ; DHX33,NF1,NPM1,PRPF8,TP53 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1,TYW1 ; BAP1,BRAF,CDKN1B,CSF1R,CSNK1A1,CTCF,CTNNB1,CUX1,DDX41,ETNK1,ETV6,EZH2,GATA2,HIPK2,IRF1,IRF8,LEU1007FSINSC,LUC7L2,MLL3,NPM1,PAPD5,RAD50,RHOA,ROBO1,ROBO2,SETD2,STAG1 ; WT1 ; ASXL1,BCL2,BRAF,CSF1R,CSNK1A1,DNMT3B,EZH2,IRF1,NPM1,RAD50,SAMHD1,SETBP1 ; CSF1R,CSNK1A1,IRF1,RAD50 ; ROBO1,ROBO2 ; EED ; CBL,MLL,PAX5 ; DNMT3B,GNAS,SAMHD1 ; ASXL1,DNMT3B,SAMHD1 ; CSF1R,CSNK1A1,DNMT3A,IRF1,NPM1,RAD50 ; CSF1R,CSNK1A1,DDX4,DHX33,FAM175A,KIT,NIPBL,PRPF8,RAD50,TP53,WHSC1 ; ABL1,BAP1,CDKN1B,CSF1R,CSNK1A1,CTNNB1,ETNK1,ETV6,IRF1,KRAS,NOTCH1,RAD50,RHOA,ROBO2,SETD2 ; MLL ; CTNNB1,SETD2 ; CSF1R,CSNK1A1,DDX4,DDX41,IRF1,NPM1,RAD50 ; CSF1R,CSNK1A1,DDX4,IRF1,LUC7L2,MLL3,NIPBL,NPM1,RAD50 ; CSF1R,CSNK1A1,DDX54,NFE2,NPM1,PRPF40B,PTPN11,RAD50,SH2B3 ; SAMHD1 ; CBL,CSF1R,CSNK1A1,DDX4,DDX41,EED,FAM175A,IRF1,MLL,NPM1,RAD50,TET2 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EP300,ETV6,EZH2,FAM175A,HIPK2,IRF1,LUC7L2,NF1,NFE2,NPM1,RAD50,SAMHD1,TET2,TP53,TYW1 ; DNMT3B,SAMHD1 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2,MLL3,TYW1 ; CDKN1B,CSF1R,CSNK1A1,ETNK1,ETV6,FBXW7,IRF1,IRF4,JARID2,KRAS,RAD50,RB1,TET2 ; CSF1R,CSNK1A1,DDX4,DDX41,DHX33,IRF1,NF1,NPM1,PRPF8,RAD50,TP53 ; BRAF,CDK4,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,DHX33,EGFR,EZH2,GATA2,HIPK2,IRF1,LUC7L2,NF1,NFE2,NPM1,PRPF8,RAC1,RAD50,TP53,TYW1 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,EZH2,HIPK2,LUC7L2,MLL3,NPM1,SETBP1,TYW1 ; CSF1R,CSNK1A1,DDX41,IRF1,JARID2,NPM1,RAD50,RB1,ROBO1,ROBO2 ; BCL2,BRAF,CDKN1B,CSF1R,CSNK1A1,DDX4,DDX41,EGFR,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MLL3,NIPBL,NPM1,RAC1,RAD50,RASGRF1,RUNX1,SETBP1,U2AF1 ; CBL,EED,MLL ; CDKN1B,ETNK1,ETV6,KRAS ; BCL2,CDKN1B,CSF1R,CSNK1A1,DDX4,ETNK1,ETV6,IRF1,KRAS,RAD50,SETBP1 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2,MLL3 ; CDKN2C,CSF1R,CSNK1A1,IRF1,RAD50 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,RUNX1,TYW1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50 ; BAP1,CREBBP,CSF1R,CSNK1A1,CTNNB1,DDX41,DHX33,IRF1,NPM1,PAX5,PRPF8,RAD50,RHOA,SETD2,SMG1,TP53 ; ARID1A,BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,DHX33,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,PRPF8,RAD50,SETBP1,TET2,TP53 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,EGFR,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,RAC1,RAD50,TYW1 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DHX33,ETNK1,ETV6,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,RAD50,TP53,TYW1 ; DHX33,PRPF8,TP53 ; ARID1A ; ETV6,ROBO2 ; BRAF,CSF1R,CSNK1A1,CUX1,DHX33,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,TP53 ; CSF1R,CSNK1A1,CTNNB1,DDX4,DDX41,IRF1,IRF4,JARID2,NPM1,RAD50,SETD2 ; BRAF,CDKN1B,CSF1R,CSNK1A1,DDX4,DDX41,DHX33,ETV6,EZH2,HIPK2,IRF1,LUC7L2,NPM1,PRPF8,RAD50,ROBO2,TP53 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,ETV6,EZH2,GATA2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,ROBO1,ROBO2,STAG1,TYW1 ; CSF1R,CSNK1A1,DDX41,IRF1,NPM1,RAD50 ; DHX33,PRPF8 ; CDKN1B,ETV6 ; CBL,MLL ; BAP1,BRAF,CDKN1B,CREBBP,CSF1R,CSNK1A1,CTCF,CTNNB1,CUX1,DDX41,ETV6,EZH2,GATA2,HIPK2,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MIR-516A,MIR-516B,MLL3,NPM1,PAPD5,RAD50,RHOA,ROBO1,ROBO2,RRAS,SETD2,SMG1,SRCAP,STAG1,U2AF2 ; YLPM1 ; ASXL1,BRAF,CEBPA,CSF1R,CSNK1A1,CTNNB1,CUX1,DDX41,DHX33,DNMT3B,EZH2,FAM175A,HIPK2,LUC7L2,MLL3,NPM1,PRPF8,RHOA,SAMHD1,SETD2,TET2,TP53 ; BCL2,DDX41,SETBP1 ; CUX1,HIPK2,LUC7L2 ; SETDB1 ; BRAF,CDK4,CSF1R,CSNK1A1,CTNNB1,ETNK1,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MGA,RAD50,RAD51,RHOA,SETD2 ; ASXL1,CSF1R,CSNK1A1,DNMT3B,IRF1,IRF8,RAD50,SAMHD1 ; CBL ; BCL2,BRAF,CSF1R,CSNK1A1,CTCF,CUX1,EGFR,EZH2,GATA2,GNAS,HIPK2,IRF1,IRF8,LEU1007FSINSC,LUC7L2,MLL3,PAPD5,RAC1,RAD50,RB1,SAMHD1,SETBP1,TYW1 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2 ; RB1 ; IRF1,RAD50 ; BCL2,CSF1R,CSNK1A1,IRF1,NPM1,RAD50,SETBP1 ; MGA,RAD51 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,EGFR,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,SAMHD1,TYW1 ; BRAF,CEBPA,CSF1R,CSNK1A1,CUX1,DDX41,EZH2,GNAS,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,ROBO1,ROBO2,RUNX1,U2AF1 ; BCL2,CSF1R,CSNK1A1,IRF1,IRF4,JARID2,RAD50,SETBP1 ; BCL2,CSF1R,CSNK1A1,IRF1,RAD50 ; CSF1R,CSNK1A1,DHX33,HRAS,IRF1,PRPF8,RAD50,TP53 ; IRF8 ; DHX33,NF1,PRPF8,TP53 ; CSF1R,CSNK1A1,GNAS,IRF1,RAD50,SAMHD1 ; CSF1R,CSNK1A1,DDX41,HIPK2,IRF1,LUC7L2,NPM1,RAD50 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,ETNK1,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50 ; CSF1R,CSNK1A1,DHX33,H3F3B,IRF1,MIR142,MIRN632,NF1,PPM1D,PRPF8,RAD50,SRSF2,STAT3,STAT5A,SUZ12,TP53 ; GNAS,TP53 ; ASXL2,BAP1,CSF1R,CSNK1A1,CTNNB1,DDX4,DDX41,DNMT3A,IRF1,NPM1,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; ABL1,BRAF,CSF1R,CSNK1A1,CUX1,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,RAC1,RAD50 ; ASXL1,BRAF,CUX1,DNMT3B,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1,SAMHD1,TYW1 ; GNAS,SAMHD1 ; ALK,ASXL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DNMT3A,EGFR,EZH2,IRF1,MLL3,NPM1,RAC1,RAD50,TYW1 ; ASXL1,BRAF,CSF1R,CSNK1A1,CTCF,CUX1,DDX41,DHX33,DNMT3B,EZH2,FLT3,HIPK2,IRF1,IRF8,LUC7L2,MLL3,NPM1,PRPF8,RAD50,RB1,SAMHD1,TP53,TYW1 ; BAP1,CDKN1B,CSF1R,CSNK1A1,CTNNB1,DDX41,ETV6,IRF1,NPM1,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; CSF1R,CSNK1A1,IRF1,RAD50,TET2 ; MLL3,SAMHD1 ; BCL2,CSF1R,CSNK1A1,DDX41,DNMT3B,FLT3,IRF1,MIRN1267,NPM1,RAD50,RB1,SAMHD1,SETBP1 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2,MLL3,RAC1 ; EGFR,RAC1 ; BRAF,CUX1,HIPK2,LUC7L2 ; CSF1R,CSNK1A1,IRF1,RAD50,SAMHD1 ; CSF1R,CSNK1A1,RAD50 ; BCL2,BRAF,CHEK2,CSF2RB,DHX33,EGFR,EP300,EZH2,H3F3B,HIPK2,MIR142,MIRN632,NF1,NF2,PPM1D,PRPF8,RAD50,SETBP1,SF3A1,SRSF2,STAT3,STAT5A,SUZ12,TP53,TYW1 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,EZH2,HIPK2,HRAS,IRF1,LUC7L2,MLL3,RAD50,SETBP1,SPRED2,WT1 ; BCL2,BRAF,CSF1R,CSNK1A1,HIPK2,IRF1,LUC7L2,NPM1,RAD50 ; CDKN1B,ETNK1,ETV6 ; BCL10,BCL2,CTCF,GFI1,IRF1,IRF8,MIR142,NRAS,PPM1D,RAD50,RB1,SETBP1,STAT3,STAT5A ; BRAF,CDKN1B,CREBBP,CSF1R,CSNK1A1,CTCF,CUX1,EGFR,ETNK1,ETV6,EZH2,FLT3,HIPK2,IRF1,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MLL3,PAPD5,RAC1,RAD50,RB1,SMG1,SRCAP,TYW1 ; BRAF,CDKN1B,EGFR,ETNK1,ETV6,EZH2,HIPK2,KRAS,LUC7L2,MLL3,RAC1 ; FAM175A,TET2 ; BCL10,CDKN2C,CREBBP,CSF1R,CSNK1A1,EED,GFI1,IRF1,MLL,NOTCH2,NPM1,NRAS,RAD50,SMG1 ; CDKN2A,CDKN2B,JAK2,PAX5 ; ARID2,CDKN1B,ETNK1,ETV6,KRAS ; CSF1R,CSNK1A1,DNMT3B,GNAS,IRF1,RAD50,SAMHD1 ; TET2 ; CUX1,LUC7L2,MLL3 ; BCL2,CSF1R,CSNK1A1,DHX33,IRF1,PRPF8,RAD50,SETBP1,TP53 ; BAP1,CSF1R,CSNK1A1,CTNNB1,IRF1,IRF4,JARID2,RAD50,RHOA,SETD2 ; BAP1,BRAF,CDK4,CDKN1B,CSF1R,CSNK1A1,CTNNB1,CUX1,DDX4,DDX41,EED,ETV6,EZH2,GATA2,HIPK2,IRF1,LUC7L2,MGA,MLL3,NFE2,PIK3CA,PRPF40B,RAD50,RAD51,RHOA,ROBO1,ROBO2,SETD2,STAG1 ; CSF1R,CSNK1A1,EED,FBXW7,IRF1,IRF4,JARID2,RAD50,TET2 ; CBL,CSF1R,CSNK1A1,DDX4,IRF1,MLL,RAD50 ; CSF1R,CSNK1A1,IRF1,MGA,RAD50,RAD51 ; BRAF,CDKN1B,CSF1R,CSNK1A1,DDX41,ETNK1,ETV6,EZH2,HIPK2,HRAS,IRF1,KRAS,LUC7L2,MLL3,NPM1,RAD50,RB1 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,EZH2,HIPK2,IRF1,IRF4,LUC7L2,MLL3,NPM1,RAD50,SETBP1 ; BCL2,DHX33,MGA,PRPF8,RAC1,RAD51,SETBP1,TP53 ; BRAF,CDKN1B,CREBBP,CSF1R,CUX1,DDX4,DDX41,DDX54,ETNK1,ETV6,EZH2,FBXW7,HIPK2,IRF1,IRF8,KRAS,LUC7L2,MLL3,NPM1,PAPD5,PTPN11,RAD50,SH2B3,SMG1,SRCAP ; BCL2,CSF1R,CSNK1A1,IRF1,RAD50,SAMHD1,SETBP1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,ETNK1,ETV6,EZH2,FLT3,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,RB1,TYW1 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX41,EZH2,HIPK2,IRF1,LUC7L2,MGA,MIRN1267,MLL3,RAD50,RAD51,SAMHD1 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX41,DHX33,EGFR,EZH2,HIPK2,HRAS,IRF1,LUC7L2,MLL3,PRPF8,RAC1,RAD50,TP53,TYW1 ; BCL2,BRAF,CUX1,DHX33,EGFR,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,SETBP1,TP53,TYW1 ; BRAF,CUX1,DHX33,EGFR,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,TP53,TYW1 ; BAP1,CSF1R,CSNK1A1,CTNNB1,DDX41,IRF1,IRF4,JARID2,NPM1,RAD50,RHOA,ROBO2,SETD2 ; BRAF,CSF1R,CSNK1A1,CTCF,CUX1,DHX33,EGFR,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,RAC1,RB1,SAMHD1,TP53,TYW1 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DHX33,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MIRN632,MLL3,NF1,PRPF8,RAD50,RUNX1,SUZ12,TP53 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DHX33,EZH2,HIPK2,IRF1,LUC7L2,MLL3,PRPF8,RAC1,RAD50,TP53 ; BCL2,CSF1R,CSNK1A1,DDX4,DDX41,IRF1,NPM1,RAD50,SETBP1 ; CSF1R,CSNK1A1,IRF1,NPM1,RAD50 ; ABL1,ARID2,BRAF,CDKN1B,CSF1R,CSNK1A1,DDX4,EGFR,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MLL3,NIPBL,NPM1,RAC1,RAD50,TYW1 ; ARID2,CDKN1B,CSF1R,CSNK1A1,DDX41,ETNK1,ETV6,IRF1,KRAS,NPM1,RAD50 ; BRAF,EZH2,HIPK2,LUC7L2 ; BRAF,CDKN1B,CUX1,EGFR,ETV6,EZH2,HIPK2,LUC7L2,MLL3,RAC1,TYW1 ; ARID2 ; CSF1R,CSNK1A1,DDX4,IRF1,RAD50 ; PHIP ; ASXL1,DNMT3B,GNAS,SAMHD1 ; BRAF,CSF1R,CSNK1A1,CUX1,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,RAC1,RAD50,TYW1,YLPM1 ; CSF1R,CSNK1A1,DDX41,IRF1,IRF4,NPM1,RAD50 ; NPM1 ; BRAF,CREBBP,CTCF,CUX1,EGFR,EZH2,HIPK2,IRF1,IRF8,LEU1007FSINSC,LUC7L2,PAPD5,RAC1,RAD50,ROBO1,ROBO2,SMG1,SRCAP,TP53,TYW1 ; BAP1,CDKN1B,CSF1R,CSNK1A1,CTNNB1,ETV6,IRF1,RAC1,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; BCL2,BRAF,CDKN1B,CREBBP,CSF1R,CSNK1A1,CTCF,CUX1,DHX33,EGFR,ETV6,EZH2,HIPK2,IRF1,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MIRN632,MLL3,NF1,PAPD5,PRPF8,RAC1,RAD50,SETBP1,SMG1,SRCAP,STAT3,STAT5A,SUZ12,TP53,TYW1 ; BAP1,BRAF,CSF1R,CSNK1A1,CUX1,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,RHOA,ROBO1,ROBO2,RUNX1,SETD2,TYW1,U2AF1 ; ASXL1,BAP1,BRAF,CSF1R,CSNK1A1,CTNNB1,CUX1,DNMT3B,EZH2,GATA2,HIPK2,IRF1,LUC7L2,NIPBL,NPM1,RAD50,RB1,RHOA,ROBO1,ROBO2,SAMHD1,SETD2,STAG1 ; BRAF,CDKN1B,CUX1,ETV6,EZH2,HIPK2,LUC7L2,MLL3,TYW1 ; CSF1R,CSNK1A1,CTNNB1,DDX4,DDX41,IRF1,NPM1,RAD50,SETD2 ; BRAF,CUX1,DNMT3B,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1,SAMHD1,TYW1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX4,EED,ETV6,EZH2,HIPK2,IRF1,IRF8,LUC7L2,MLL3,RAC1,RAD50,SAMHD1 ; CDKN1B,CSF1R,CSNK1A1,ETNK1,ETV6,IRF1,KRAS,RAD50 ; BRAF,CEBPA,CSF1R,CSNK1A1,DHX33,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NF1,PRPF8,RAD50,TP53 ; ARID1A,BCL2,CSF1R,CSNK1A1,DDX4,DDX41,IRF1,NPM1,RAD50,SETBP1 ; CBL,EED,IRF1,MLL,RAD50 ; BRAF,CSF1R,CSNK1A1,DDX41,DNMT3B,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,SAMHD1 ; CSF1R,CSNK1A1,EGFR,IRF1,MLL3,RAC1,RAD50,TYW1 ; ASXL1,CDKN1B,CSF1R,CSNK1A1,CTCF,DNMT3B,ETV6,IRF1,IRF4,IRF8,JARID2,LEU1007FSINSC,PAPD5,RAD50,SAMHD1,ZNF318 ; BCL10,BRAF,CDKN2C,CTCF,CUX1,EGFR,EZH2,GFI1,HIPK2,IRF8,LEU1007FSINSC,LUC7L2,MLL3,NRAS,PAPD5,RAC1,TYW1 ; CBL,EED,MLL,SAMHD1 ; ARID2,ASXL1,BRAF,CDK4,CDKN1B,CREBBP,CSF1R,CSNK1A1,CTCF,CUX1,DDX23,DDX41,DDX54,DNMT3B,ETNK1,ETV6,EZH2,HIPK2,IRF1,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MLL2,MLL3,NFE2,NPM1,PAPD5,PRPF40B,PTPN11,RAD50,SAMHD1,SH2B3,SMG1,SRCAP ; TP53 ; BRAF,CBL,CUX1,EED,EGFR,EZH2,HIPK2,LUC7L2,MIRN1267,MLL,MLL3,RAC1,RB1,TYW1 ; BAP1,CSF1R,CSNK1A1,CTNNB1,IRF1,IRF4,MGA,NPM1,RAD50,RAD51,RHOA,ROBO1,ROBO2,SETD2,TP53 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,DHX33,EGFR,EZH2,HIPK2,IDH2,IRF1,LUC7L2,MGA,MLL3,NPM1,PRPF8,RAD50,RAD51,TP53,TYW1 ; BRAF,CTCF,CUX1,DHX33,EZH2,HIPK2,IRF8,LEU1007FSINSC,LUC7L2,MLL3,PAPD5,PRPF8,TP53,TYW1 ; CSF1R,CSNK1A1,CUX1,EGFR,HIPK2,IRF1,LUC7L2,RAC1,RAD50,TYW1 ; BCL2,CDKN1B,CSF1R,CSNK1A1,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MLL3,RAD50 ; BCL2 ; SH2B3,TET2 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,ETV6,EZH2,FLT3,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,RB1 ; CSF1R,CSNK1A1,EZH2,IRF1,MLL3,RAD50 ; DDX54,IRF4,JARID2,PTPN11,SH2B3 ; ARID1A,BCL2,CSF1R,CSNK1A1,DDX4,DDX41,IRF1,NPM1,RAD50 ; CDKN1B,CSF1R,CSNK1A1,DHX33,ETNK1,ETV6,IRF1,KRAS,PRPF8,RAD50,TP53 ; BRAF,CUX1,DDX41,DHX33,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,PRPF8,RAC1,RAD50,TP53,TYW1 ; ABL1,BAP1,CSF1R,CSNK1A1,CTNNB1,DDX41,IRF1,IRF4,JARID2,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; ABL1,BCL2,IRF4,JARID2,NOTCH1,SETBP1 ; ALK,ASXL2,CSF1R,CSNK1A1,DDX4,DNMT3A,GFI1,IRF1,RAD50,RB1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CTCF,CUX1,DDX4,DHX33,EGFR,ETNK1,ETV6,EZH2,FBXW7,HIPK2,IRF1,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MIRN1267,MLL3,PAPD5,PRPF8,RAD50,RB1,SRCAP,TP53,TYW1 ; ASXL1,BRAF,CSF1R,CSNK1A1,CUX1,DNMT3B,EZH2,HIPK2,LUC7L2,MLL3,SAMHD1,TP53 ; ASXL1,CSF1R,CSNK1A1,CUX1,DNMT3B,IRF1,MGA,RAD50,RAD51,SAMHD1 ; ARID2,BCL2,BRAF,CDK4,CDKN1B,CTCF,CUX1,DDX23,DDX4,DDX54,DHX33,ETNK1,ETV6,EZH2,HIPK2,IRF1,IRF8,KRAS,LEU1007FSINSC,LUC7L2,MLL2,NFE2,PRPF40B,PRPF8,PTPN11,RAD50,SETBP1,SH2B3,TP53 ; BAP1,CDKN1B,CSF1R,CSNK1A1,CTNNB1,ETNK1,ETV6,FLT3,IRF1,RAD50,RB1,RHOA,ROBO2,SETD2,TP53 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DHX33,EGFR,ETNK1,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,PRPF8,RAC1,RAD50,TP53,TYW1 ; CBL,CSF1R,CSNK1A1,EED,IDH1,IRF1,MLL,RAD50,WT1 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX41,EZH2,HIPK2,IRF1,LUC7L2,MIRN1267,MLL3,NPM1,RAD50,RB1,TYW1 ; BCL2,CREBBP,CSF1R,CSNK1A1,DHX33,IRF1,NF1,PRPF8,RAD50,SETBP1,SMG1,TP53 ; ASXL1,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,DNMT3B,EGFR,ETV6,EZH2,GNAS,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,SAMHD1,WT1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAC1,RAD50,TYW1 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,EZH2,HIPK2,IRF1,LUC7L2,NPM1,RAC1,RAD50 ; BCL2,CSF1R,CSNK1A1,IRF1,RAD50,SETBP1 ; BCL2,CSF1R,CSNK1A1,IRF1,NIPBL,RAC1,RAD50,ROBO1,ROBO2,SETBP1 ; BCL2,CHEK2,CSF1R,CSF2RB,CSNK1A1,DDX41,EP300,FLT3,IRF1,NF2,NPM1,RAD50,RB1,SETBP1,SF3A1 ; CDKN1B,CREBBP,CSF1R,CSNK1A1,CTCF,DDX54,DHX33,ETV6,IRF1,IRF8,LEU1007FSINSC,PAPD5,PRPF8,PTPN11,RAD50,SH2B3,TP53 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX41,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,SETBP1 ; ALK,ASXL2,BCL2,CREBBP,CSF1R,CSNK1A1,DDX4,DDX41,DNMT3A,FGFR2,IRF1,NPM1,PAPD5,PTEN,RAD50,SETBP1,SMC3,SMG1,SRCAP ; CDKN1B,CSF1R,CSNK1A1,CTCF,DDX41,DDX54,ETNK1,ETV6,IRF1,IRF8,KRAS,LEU1007FSINSC,MIR142,MIRN632,NPM1,PAPD5,PTPN11,RAD50,RB1,SH2B3,STAT3,STAT5A,SUZ12 ; BAP1,BCL2,CSF1R,CSNK1A1,CTNNB1,DDX41,EGFR,IRF1,IRF4,JARID2,MIRN1267,NPM1,RAC1,RAD50,RB1,RHOA,ROBO1,ROBO2,SETD2 ; ASXL1,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DNMT3B,ETV6,EZH2,GNAS,HIPK2,IRF1,LUC7L2,PHIP,RAD50,SAMHD1 ; ASXL1,CBL,CSF1R,CSNK1A1,DHX33,DNMT3B,EED,GATA2,GNAS,HRAS,IRF1,NXF1,PIK3CA,PRPF8,RAD50,SF1,STAG1,TP53,WT1 ; ASXL2,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DHX33,DNMT3A,EZH2,HIPK2,IRF1,LUC7L2,MLL3,PRPF8,RAC1,RAD50 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,DHX33,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,PRPF8,RAD50,RB1,TP53 ; CSF1R,CSNK1A1,CUX1,DDX41,IRF1,NPM1,RAD50,TP53 ; BCL10,BRAF,CDKN2C,CSF1R,CSNK1A1,CUX1,DHX33,EGFR,EZH2,GATA2,HIPK2,IRF1,LUC7L2,MIRN632,MLL3,NF1,NPM1,RAC1,RAD50,STAG1,SUZ12,TET2,TP53,TYW1 ; BRAF,CBL,CDKN1B,CSF1R,CSNK1A1,CUX1,EED,ETV6,EZH2,HIPK2,IRF1,LUC7L2,RAD50 ; BCL2,BRAF,CREBBP,CSF1R,CSNK1A1,CTCF,DDX4,DHX33,EZH2,FBXW7,GNAS,HIPK2,IRF1,IRF8,LEU1007FSINSC,LUC7L2,MIRN632,MLL3,NF1,PAPD5,PDSS2,PHIP,PRPF8,RAD50,SAMHD1,SETBP1,SMG1,SRCAP,STAT3,STAT5A,SUZ12,TET2,TP53 ; BCL10,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,GFI1,IRF1,MLL3,NPM1,NRAS,RAD50,TYW1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CTCF,CUX1,DHX33,EGFR,ETNK1,ETV6,EZH2,HIPK2,IRF1,IRF8,KRAS,LUC7L2,MIRN632,MLL3,NF1,PRPF8,RAD50,SUZ12,TP53,TYW1 ; BAP1,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,RHOA,SETD2,TYW1 ; CUX1,DDX41,DHX33,EGFR,MLL3,NPM1,PRPF8,RAC1,TP53,TYW1 ; CSF1R,CSNK1A1,DDX41,DHX33,GNAS,IRF1,NPM1,PRPF8,RAD50,SAMHD1,TP53 ; ASXL1,BCL2,CSF1R,CSNK1A1,DNMT3B,HRAS,IRF1,RAD50,SPRED2,WT1 ; CSF1R,CSNK1A1 ; BCL2,CSF1R,CSNK1A1,DHX33,GNAS,IRF1,IRF8,NF1,NPM1,PRPF8,RAD50,SAMHD1,TP53 ; BRAF,CUX1,DHX33,EZH2,HIPK2,LUC7L2,MIR142,MIRN632,MLL3,NF1,PPM1D,PRPF8,STAT3,STAT5A,SUZ12,TP53 ; ASXL1,CSF1R,CSNK1A1,DDX41,DNMT3B,GNAS,IRF1,NPM1,RAD50,SAMHD1 ; BCL2,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,EGFR,ETV6,EZH2,HIPK2,IRF1,LUC7L2,MLL3,RAC1,RAD50,TYW1 ; BRAF,CSF1R,CSNK1A1,CTCF,CUX1,DDX41,DDX54,EGFR,EZH2,HIPK2,IRF1,IRF8,LEU1007FSINSC,LUC7L2,MLL3,NPM1,PAPD5,PTPN11,RAC1,RAD50,SH2B3,TYW1 ; ALK,ASXL2,BCL10,CSF1R,CSNK1A1,DDX4,DNMT3A,GFI1,IRF1,RAD50,TP53 ; BAP1,CSF1R,CSNK1A1,CTNNB1,DHX33,IRF1,PRPF8,RAC1,RAD50,RHOA,ROBO1,ROBO2,SETD2,TP53 ; DNMT3B,SAMHD1,TET2 ; BCL10,CSF1R,CSNK1A1,EED,FLT3,GFI1,IRF1,NOTCH2,NRAS,RAD50,SETDB1 ; BRAF,CTCF,CUX1,EZH2,HIPK2,IRF8,LUC7L2,MLL3 ; RAD50 ; DHX33,H3F3B,MIR142,MIRN632,NF1,PPM1D,PRPF8,RUNX1,SRSF2,STAT3,STAT5A,SUZ12,TP53 ; MIRN1267,RB1 ; CDK4 ; CSF1R,CSNK1A1,DHX33,IRF1,NF1,PRPF8,RAD50,TP53 ; DHX33,PRPF8,SAMHD1,TP53 ; CSF1R,CSNK1A1,DDX4,DDX41,ETV6,IRF1,NPM1,RAD50 ; IDH1,NF1,NFE2L2,PRPF40A,SF3B1,TP53 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DDX41,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,RB1 ; BCL2,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,DHX33,ETNK1,EZH2,FAM175A,HIPK2,IRF1,KRAS,LUC7L2,MLL3,PRPF8,RAD50,SETBP1,TET2,TP53,WHSC1 ; ARID1A,BRAF,CSF1R,CSNK1A1,CUX1,DHX33,EZH2,HIPK2,IRF1,LUC7L2,MLL3,PRPF8,RAD50,RBBP4,TP53 ; BRAF,CSF1R,CSNK1A1,CUX1,EZH2,HIPK2,IRF1,LUC7L2,RAD50 ; BCL2,CSF1R,CSNK1A1,DDX41,DHX33,IRF1,MIR142,MIRN632,NF1,NPM1,PRPF8,RAD50,RUNX1,SETBP1,STAT3,STAT5A,SUZ12,TP53 ; ASXL1,BAP1,CSF1R,CSNK1A1,CTNNB1,DHX33,DNMT3B,GNAS,IRF1,PRPF8,RAD50,RHOA,SAMHD1,SETD2,TP53 ; GATA2,STAG1 ; BCL2,CSF1R,CSNK1A1,DDX41,DHX33,IRF1,NPM1,PRPF8,RAD50,SETBP1,TP53 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,RAD50,WT1 ; ETV6 ; MGA ; DHX33,FAM175A,FBXW7,PRPF8,TET2,TP53 ; ABL1,BRAF,CSF1R,CSNK1A1,CUX1,EZH2,GATA2,HIPK2,IRF1,LUC7L2,MLL3,NOTCH1,NPM1,RAD50,STAG1,TYW1,WT1 ; BAP1,CSF1R,CSNK1A1,DDX41,IRF1,IRF8,NPM1,RAD50,RHOA,ROBO1,ROBO2 ; ARID1A,BRAF,CSF1R,CSNK1A1,CUX1,DDX4,EZH2,FBXW7,HIPK2,IRF1,LUC7L2,MLL3,NPM1,RAD50,RBBP4 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DDX41,EGFR,ETNK1,ETV6,EZH2,HIPK2,IRF1,KRAS,LUC7L2,MLL3,NPM1,RAC1,RAD50,RB1,TET2,TYW1 ; BRAF,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1,TYW1 ; BRAF,CDKN1B,CUX1,EGFR,ETNK1,ETV6,EZH2,HIPK2,KRAS,LUC7L2,MLL3,RAC1,TYW1 ; BRAF,CTCF,CUX1,DHX33,EGFR,EZH2,HIPK2,IRF8,LEU1007FSINSC,LUC7L2,MLL3,PRPF8,RAC1,TP53,TYW1 ; BRAF,EZH2,MLL3 ; BRAF,CSF1R,CSNK1A1,CUX1,DDX41,DHX33,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NPM1,PRPF8,RAC1,RAD50,TP53,TYW1 ; CSF1R,CSNK1A1,DHX33,IRF1,PRPF8,RAD50,TP53 ; BRAF,CSF1R,CSNK1A1,CUX1,DHX33,EZH2,HIPK2,IRF1,LUC7L2,MLL3,NF1,NPM1,PRPF8,RAD50,RB1,TP53,TYW1 ; ASXL1,BRAF,CUX1,DNMT3B,HIPK2,LUC7L2,MLL3,SAMHD1 ; ASXL1,BCL2,CSF1R,CSNK1A1,DDX4,DDX41,DHX33,DNMT3B,IRF1,NPM1,PRPF8,RAD50,SAMHD1,SETBP1,TP53 ; BRAF,CUX1,DHX33,EGFR,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,RAC1,TP53,TYW1,WT1 ; CBL,EED,IDH1,MLL ; SH2B3 ; BAP1,BRAF,CSF1R,CSNK1A1,CTNNB1,CUX1,EZH2,HIPK2,IRF1,LUC7L2,MLL3,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; CDKN1B,DHX33,DNMT3B,ETNK1,GNAS,KRAS,SAMHD1,TP53,WT1 ; BCL10,CDKN2C,GFI1,NOTCH2,NRAS,SETDB1 ; CUX1,HIPK2,IRF1,LUC7L2,RAD50 ; CSF1R,CSNK1A1,IRF1,RAD50,RB1,YLPM1 ; ASXL1,BRAF,CDKN1B,CSF1R,CSNK1A1,CUX1,DNMT3B,ETV6,EZH2,HIPK2,IRF1,IRF4,LUC7L2,MLL3,RAD50,SAMHD1 ; BRAF,CSF1R,CSNK1A1,EZH2,FAM175A,FBXW7,HIPK2,IRF1,IRF8,LUC7L2,MLL3,RAD50,TET2 ; ASXL1,BRAF,CUX1,DNMT3B,EZH2,HIPK2,LUC7L2,MLL3,SAMHD1,TET2 ; BRAF,CSF1R,CSNK1A1,CUX1,HIPK2,IRF1,LUC7L2,RAD50 ; CSF1R,CSNK1A1,IRF1,MLL3,RAD50 ; ASXL2,BRAF,CSF1R,CSNK1A1,CUX1,DNMT3A,EZH2,HIPK2,IRF1,MLL3,NPM1,RAD50,TET2,TP53 ; ABL1,BAP1,BRAF,CSF1R,CSNK1A1,CTNNB1,DDX41,EZH2,IRF1,MLL3,NOTCH1,NPM1,RAD50,RHOA,ROBO1,ROBO2,SETD2 ; CSF1R,CSNK1A1,DHX33,H3F3B,HRAS,IRF1,MIR142,MIRN632,NF1,PPM1D,PRPF8,RAD50,SRSF2,STAT3,STAT5A,TP53,WT1 ; CBL,CSF1R,CSNK1A1,IRF1,MLL,RAC1,RAD50 ; BRAF,CSF1R,CSNK1A1,CUX1,EGFR,EZH2,HIPK2,IRF1,LUC7L2,MIRN1267,MLL3,RAD50,RB1 ; CSF1R,CSNK1A1,DDX4,DDX41,DHX33,IRF1,NPM1,PRPF8,RAD50,TP53 ; CTCF,IRF8,LEU1007FSINSC,PAPD5,SAMHD1 ; ASXL1,CUX1,DNMT3B,SAMHD1 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,RAC1,TYW1 ; DHX33,IRF1,PRPF8,RAD50,TP53 ; CSF1R,CSNK1A1,CTCF,IRF1,IRF8,LEU1007FSINSC,PAPD5,RAD50 ; DHX33,TP53 ; BRAF,CUX1,DDX4,EGFR,EZH2,IRF1,NIPBL,RAC1,RAD50,TYW1 ; BRAF,CDKN1B,CSF1R,CSNK1A1,CTCF,CUX1,ETV6,EZH2,H3F3A,HIPK2,IRF1,IRF8,LUC7L2,MIRN1267,MLL3,RAC1,RAD50,RB1 ; BAP1,CSF1R,CSNK1A1,CTNNB1,DDX41,IRF1,NPM1,RAD50,RHOA,ROBO2,SETD2 ; CSF1R,CSNK1A1,EED,IRF1,RAD50 ; BRAF,CSF1R,CSNK1A1,CUX1,ETNK1,EZH2,GNAS,HIPK2,IRF1,KRAS,LUC7L2,MLL3,RAC1,RAD50,SAMHD1 ; ASXL2,CSF1R,CSNK1A1,DNMT3A,IRF1,RAD50 ; ALK,CSF1R,CSNK1A1,DNMT3A,IDH1,IRF1,NFE2L2,PRPF40A,RAD50,SF3B1,SPRED2,TET2 ; ARID1A,CSF1R,CSF3R,CSNK1A1,GNB1,IRF1,RAD50,RBBP4 ; CSNK1A1,DNMT3B,GNAS,IRF1,RAD50,SAMHD1 ; CSF1R,CSNK1A1,DDX4,IRF1,NPM1,RAD50 ; CSF1R,CSNK1A1,DHX33,IRF1,PRPF8,RAD50,SPRED2,TP53 ; EED,PAX5 ; BRAF,CSF1R,CSNK1A1,CUX1,EZH2,HIPK2,IRF1,IRF8,LUC7L2,MLL3,PHIP,RAD50 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,PRPF8,TP53 ; BCL2,CSF1R,CSNK1A1,FAM175A,IRF1,NFE2L2,NPM1,PRPF40A,RAD50,SPRED2,TET2,WHSC1 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,RAC1,SAMHD1,TYW1
CNACS_GENE_UPD	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	CNACS Called Gene (from panel) Upd (i.e. copy-neutral LOH)	Sample	HRAS,WT1 ; TP53 ; FAM175A,FBXW7,KIT,TET2 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2,MLL3 ; FBXW7,TET2 ; ETV6,JAK2 ; CDKN2A,CDKN2B,JAK2,PAX5 ; FAM175A,FBXW7,TET2 ; ALK,ASXL2,DNMT3A,SPRED2 ; CM003625,DICER1,YLPM1 ; TET2 ; YLPM1 ; NF1,TP53 ; H3F3A ; DHX33,NF1,PRPF8,TP53 ; CBL ; CM003625,DICER1 ; BRAF,EZH2,HIPK2,MLL3 ; EED,MLL ; DHX33,PRPF8,TP53 ; FAM175A,TET2 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2 ; DHX33,PIK3CA,PRPF8 ; H3F3B,MIR142,PPM1D,SRSF2,STAT3,STAT5A ; EED ; CBL,EED,HRAS,IRF4,JARID2,MLL ; ARID1A,GNB1,RBBP4 ; ALK,ASXL2,DNMT3A ; BRAF,EZH2,HIPK2,LUC7L2,MLL3 ; BRAF,CM003625,CUX1,DICER1,EZH2,HIPK2,LUC7L2,MLL3,YLPM1 ; ASXL2,DNMT3A ; H3F3B,MIR142,MIRN632,NF1,PPM1D,SRSF2,STAT3,STAT5A,SUZ12 ; BRAF,CUX1,EZH2,HIPK2,LUC7L2,MLL3,TYW1 ; DDX54,PTPN11,SH2B3 ; ARID1A,CBL,CSF3R,EED,GNB1,MLL,MPL,PTPRF,RBBP4 ; MIRN632,NF1,STAT3,STAT5A,SUZ12,TP53 ; CHEK2,CSF2RB,EP300,FLT3,MIRN1267,NF2,RB1,SF3A1 ; ARID1A,BCL10,CDKN2C,CSF3R,GFI1,GNB1,MPL,NRAS,PTPRF,RBBP4 ; CDKN2A,CDKN2B,JAK2 ; ARID1A,CSF3R,GNB1,RBBP4 ; HRAS ; RUNX1,U2AF1 ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,TYW1 ; ARID1A,BCL10,CDKN2C,CSF3R,GFI1,GNB1,IRF4,JARID2,MPL,PTPRF,RBBP4,ZNF318 ; CBL,MLL ; PIK3CA ; ARID1A,BCL10,CDKN2C,CSF3R,GFI1,GNB1,MPL,NOTCH2,NRAS,PTPRF,RBBP4,SETDB1 ; CUX1 ; BRAF,CUX1,EZH2,FAM175A,FBXW7,HIPK2,LUC7L2,MLL3,TET2 ; HIPK2,LUC7L2 ; H3F3B,HRAS,MIR142,MIRN632,PPM1D,SRSF2,STAT3,STAT5A,SUZ12 ; DHX33,H3F3B,MIR142,MIRN632,NF1,PPM1D,PRPF8,SRSF2,STAT3,STAT5A,SUZ12,TP53 ; JAK2,YLPM1 ; BCL10,CDKN2C,GFI1,NRAS ; CDKN2C,PTPRF ; EZH2,H3F3B,MIR142,MIRN632,MLL3,PPM1D,SRSF2,STAT3,STAT5A,SUZ12 ; ALK,ASXL2 ; CUX1,HIPK2,LUC7L2 ; NF1,SUZ12,TP53 ; FBXW7 ; BCL2,SETBP1 ; BRAF,EZH2,MLL3 ; ARID1A,CDKN2C,CSF3R,GNB1,MPL,PTPRF,RBBP4 ; BRAF,EZH2,HIPK2,LUC7L2 ; CBL,EED,MLL ; CBL,EED,FBXW7,MLL,TET2 ; FBXW7,RUNX1,TET2,U2AF1 ; PDSS2,PHIP ; CBL,EED,MLL,NXF1,SF1 ; RUNX1 ; DHX33,NF1,PRPF8,SUZ12,TP53 ; ARID1A,CSF3R,GNB1,MPL,PTPRF,RBBP4 ; CDK4,NFE2 ; GATA2,PIK3CA,STAG1 ; IRF4,JARID2 ; PIK3CA,RUNX1,U2AF1 ; CHEK2,CSF2RB,EP300,NF2,SF3A1 ; ARID1A ; GNB1 ; BCL2,HRAS,PIK3CA,STAG1,TP53 ; ALK,ASXL2,SPRED2 ; IDH1,NFE2L2,PRPF40A,SF3B1 ; JAK2 ; DNMT3A ; BRAF,CUX1,EGFR,EZH2,HIPK2,LUC7L2,MLL3,NXF1,SF1,TYW1 ; RAC1 ; CTCF,IRF8 ; HRAS,NXF1,WT1 ; JAK2,PIK3CA,STAG1 ; ARID1A,BCL10,CDKN2C,CSF3R,GFI1,GNB1,MPL,PTPRF,RBBP4 ; FBXW7,HRAS,TET2,WT1 ; H3F3B,MIR142,PPM1D,SRSF2 ; IDH1,SF3B1 ; IDH2,RASGRF1
COMPLEX_KARYOTYPE	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	Complex Karyotype	Sample	non-complex ; complex
CYTO_IPSSR	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	IPSS-R Cytogenetic Risk Category	Sample	Good ; Int ; Very-Poor ; Poor ; Very-Good
HB	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Hemoglobin in g/dL	Sample	7.6 ; 11.6 ; 14.2 ; 8.9 ; 11.1 ; 8 ; 9.6 ; 9.4 ; 8.8 ; 7.4 ; 12.8 ; 7.2 ; 10.6 ; 10.9 ; 10.8 ; 8.5 ; 7.1 ; 10.7 ; 10.4 ; 9.1 ; 12.1 ; 10 ; 11.5 ; 11.2 ; 11.3 ; 8.2 ; 12.7 ; 11.8 ; 7.5 ; 6.5 ; 12.6 ; 13.9 ; 12.3 ; 9.5 ; 8.4 ; 8.7 ; 9 ; 7.8 ; 7.9 ; 11.4 ; 12.9 ; 11.9 ; 12.2 ; 15 ; 6.7 ; 8.6 ; 10.3 ; 14.5 ; 10.2 ; 14.3 ; 10.1 ; 12.4 ; 11 ; 9.8 ; 9.9 ; 7.3 ; 13.5 ; 6.8 ; 13.3 ; 14.9 ; 12 ; 12.5 ; 14.6 ; 9.7 ; 10.5 ; 9.2 ; 9.3 ; 16.1 ; 7.7 ; 13.1 ; 15.7 ; 13.6 ; 6.3 ; 6.4 ; 5.8 ; 13.7 ; 4 ; 6.9 ; 13 ; 8.1 ; 6.2 ; 5.5 ; 5.4 ; 3.8 ; 13.8 ; 5.6 ; 4.1 ; 5 ; 4.5 ; 5.1 ; 6 ; 7 ; 8.3 ; 5.3 ; 4.3 ; 16.6 ; 13.4 ; 6.6 ; 15.1 ; 11.7 ; 13.2 ; 5.9 ; 14.8 ; 15.3 ; 14.4 ; 14.7 ; 4.9 ; 4.2 ; 14.1 ; 14 ; 6.1 ; 3.5 ; 3.1 ; 4.4 ; 15.2 ; 16.5 ; 7.43 ; 9.56 ; 8.54 ; 8.17 ; 9.86 ; 15.8 ; 16 ; 9.18 ; 9.31 ; 9.49 ; 9.48 ; 9.42 ; 9.32 ; 8.07 ; 9.26 ; 7.96 ; 3.33 ; 8.83 ; 8.33 ; 8.96 ; 8.32 ; 7.69 ; 9.22 ; 8.48 ; 8.85 ; 9.06 ; 7.95 ; 9.71 ; 8.26 ; 8.58 ; 9.98 ; 9.76 ; 9.38 ; 8.81 ; 9.35 ; 8.71 ; 9.47 ; 8.01 ; 7.77 ; 10.24 ; 8.16 ; 7.52 ; 12.96 ; 8.64 ; 6.88 ; 7.68 ; 12.16 ; 9.12 ; 7.84 ; 6.24 ; 6.72 ; 10.08 ; 9.44 ; 7.04 ; 11.36 ; 9.92 ; 7.36 ; 10.56 ; 9.28 ; 10.72 ; 5.92 ; 8.204 ; 6.703 ; 12.906 ; 10.505 ; 9.404 ; 13.006 ; 6.903 ; 11.605 ; 10.198 ; 12.308 ; 9.505 ; 9.005 ; 10.697 ; 9.102 ; 8.409 ; 12.405 ; 8.893 ; 8.297 ; 7.411 ; 8.007 ; 11.809 ; 7.507 ; 9.022 ; 10.633 ; 6.444 ; 11.116 ; 10.794 ; 8.216 ; 9.666 ; 11.277 ; 9.988 ; 6.122 ; 6.927 ; 7.572 ; 12.566 ; 8.699 ; 5.961 ; 8.538 ; 11.921 ; 7.733 ; 9.344 ; 8.055 ; 10.31 ; 11.438 ; 8.377 ; 8.861 ; 7.088 ; 10.149 ; 9.827 ; 9.183 ; 10.472 ; 16.2 ; 15.4 ; 11.84 ; 11.52 ; 14.72 ; 11.68 ; 11.04 ; 13.44 ; 10.34 ; 12.48 ; 13.28 ; 10.88 ; 13.12 ; 12.32 ; 7.72
IPSSM	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	IPSS-M Risk Category	Sample	Very-High ; Moderate-Low ; Moderate-High ; High ; Low ; Very-Low
IPSSM_SCORE	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	IPSS-M Risk Score	Sample	3.48 ; -0.41 ; 0.35 ; 1.28 ; 1.42 ; 0.93 ; 2.45 ; 2.16 ; 2.49 ; 3.1 ; -1.49 ; 0.99 ; -1.26 ; 2.05 ; 1.75 ; -0.64 ; 1.83 ; -1.04 ; 0.4 ; 3.17 ; 0.53 ; -1.39 ; -1.23 ; -1.12 ; -0.76 ; 1.39 ; 0.07 ; 1.3 ; -0.47 ; -0.12 ; -1.51 ; 0.58 ; -0.88 ; -1.79 ; 0.36 ; 4.91 ; -1.53 ; -1.54 ; -1.03 ; -1.33 ; 0.29 ; -0.62 ; 0.18 ; -0.54 ; 1.26 ; -0.66 ; -1 ; 1.03 ; -0.97 ; 0.31 ; 3.14 ; -1.08 ; -1.24 ; -0.99 ; -1.37 ; -1.36 ; -1.73 ; -0.87 ; -1.43 ; 2.62 ; -2.59 ; -1.52 ; 0.68 ; -0.98 ; -1.16 ; 0.77 ; -0.06 ; -2.09 ; -0.91 ; -0.69 ; -0.15 ; -0.57 ; -0.81 ; 0.3 ; 0.87 ; -1.27 ; -1.8 ; 0.82 ; -1.44 ; -1.1 ; -0.5 ; -1.77 ; 1.62 ; -2.04 ; 0.49 ; -1.48 ; -0.4 ; -0.42 ; 0.88 ; 1.82 ; 2.17 ; 0.33 ; -2.11 ; -1.32 ; -1.76 ; -1.2 ; -1.72 ; 1.67 ; -1.3 ; 3.05 ; -0.17 ; -2.72 ; -0.2 ; 0.26 ; 0.42 ; 0.55 ; -1.13 ; 0.56 ; 1.88 ; -0.72 ; -1.56 ; 0.86 ; 0.1 ; 2.35 ; -1.41 ; -0.05 ; -1.92 ; -0.08 ; -2.37 ; 0.44 ; -0.38 ; 0.76 ; -0.68 ; 0.41 ; -0.35 ; 1.81 ; 2.57 ; 3.83 ; -0.95 ; -0.82 ; -2.16 ; -1.46 ; 0.59 ; -1.06 ; -0.85 ; -1.02 ; -1.05 ; 1.29 ; 1.33 ; -0.65 ; -1.35 ; 2.8 ; -1.58 ; -2.35 ; 0.48 ; -0.3 ; 1.78 ; -0.14 ; -0.26 ; 0.57 ; 2.31 ; -0.37 ; 3.62 ; -0.45 ; 3.28 ; -0.9 ; -1.67 ; 0.67 ; -0.19 ; 1 ; 0.39 ; 4.64 ; 2.18 ; 1.04 ; -0.44 ; 4.24 ; 3.32 ; 1.91 ; -0.22 ; 1.55 ; -1.22 ; -0.75 ; -0.02 ; 4.56 ; 5.11 ; 0.83 ; -0.96 ; -0.24 ; -0.67 ; 1.41 ; -1.28 ; 3.92 ; -0.13 ; -1.19 ; 1.5 ; 0.69 ; 3.55 ; -0.63 ; 1.77 ; 2.26 ; 1.22 ; -0.07 ; 1.95 ; 0.14 ; 2.06 ; 0.37 ; 2.25 ; 3.27 ; -0.71 ; -0.09 ; 3.75 ; 2.12 ; 4 ; -1.25 ; 1.45 ; 3.44 ; 0.19 ; 2.93 ; -1.18 ; 3.33 ; 4.48 ; 0.71 ; 1.46 ; -0.83 ; 3.63 ; -0.61 ; 0.45 ; -0.79 ; 1.58 ; -0.46 ; 1.25 ; -0.1 ; -1.9 ; -0.01 ; 0.79 ; -1.11 ; 4.12 ; 0.06 ; 1.56 ; -0.23 ; 2.4 ; -1.55 ; 0.46 ; -0.39 ; 0.23 ; 1.37 ; 2.58 ; 0.47 ; -0.59 ; 2.73 ; -0.03 ; -1.42 ; -1.86 ; 1.79 ; 0.9 ; -1.88 ; 0.27 ; 0.95 ; -1.61 ; -1.14 ; 4.38 ; 3.24 ; -0.78 ; 2.44 ; -1.09 ; 0.98 ; 0.94 ; -1.81 ; -1.93 ; 0.05 ; 0.04 ; -2.07 ; 2.13 ; 2.67 ; -0.51 ; -1.31 ; 2.99 ; 1.15 ; -0.29 ; 3.76 ; -0.6 ; -1.68 ; -0.7 ; -0.74 ; 2.42 ; 1.52 ; 0 ; 1.32 ; 1.14 ; -1.71 ; 0.17 ; 0.25 ; 2.63 ; -0.58 ; 2.76 ; 1.4 ; -0.77 ; 3.85 ; -0.93 ; -1.83 ; -1.15 ; 2.19 ; 2.07 ; 0.21 ; 0.02 ; 0.89 ; 2.66 ; 1.57 ; 1.19 ; 2.78 ; 3.7 ; -0.94 ; 4.16 ; -0.73 ; 1.63 ; 1.31 ; 0.15 ; 2.53 ; 0.34 ; 1.16 ; 2.5 ; 1.59 ; 1.92 ; 0.91 ; -1.57 ; 1.48 ; 1.44 ; -2.42 ; 1.51 ; 2.69 ; -0.52 ; 2.68 ; 1.06 ; -1.6 ; -1.65 ; 3.91 ; -0.86 ; 0.51 ; 1.97 ; 0.28 ; -1.84 ; 1.08 ; 0.54 ; 2.72 ; 2.01 ; 1.61 ; -1.91 ; 2.55 ; -0.31 ; 1.01 ; 2.98 ; 1.11 ; 0.32 ; 0.84 ; 0.75 ; 0.52 ; -0.33 ; -0.49 ; 0.12 ; -0.36 ; 1.43 ; 2.94 ; 1.65 ; -1.45 ; 1.98 ; -1.87 ; 4.4 ; -1.07 ; 2.09 ; 1.7 ; -1.66 ; -1.74 ; 2.28 ; 0.24 ; -0.32 ; 2.38 ; 3.4 ; 3.08 ; 3.06 ; 0.62 ; -0.18 ; 2.02 ; 2.86 ; 3.52 ; 0.61 ; 0.2 ; 1.85 ; 0.11 ; -0.56 ; 1.76 ; 0.01 ; -0.34 ; 2.24 ; -0.8 ; -1.7 ; -1.63 ; -1.21 ; 1.93 ; 0.16 ; -0.89 ; -0.16 ; 1.74 ; -1.59 ; -0.25 ; -2.28 ; 1.24 ; 1.34 ; 0.65 ; 2.75 ; 1.86 ; 3.77 ; 0.38 ; 0.5 ; 1.02 ; 0.72 ; -0.55 ; 1.1 ; 1.8 ; -2.45 ; 2.47 ; 2.79 ; 2.14 ; 1.99 ; -2.73 ; 3.3 ; 0.08 ; -1.29 ; 2.54 ; -1.64 ; 2.71 ; 0.73 ; 1.71 ; -1.17 ; 1.89 ; -1.4 ; 0.03 ; -2.24 ; -1.78 ; 0.13 ; 0.64 ; -2.26 ; 2.03 ; 5.32 ; -0.53 ; 1.47 ; -0.27 ; 1.07 ; -1.34 ; -2.7 ; 2.92 ; 1.13 ; 1.66 ; -2 ; -1.82 ; 2.41 ; -2.08 ; 0.81 ; 2.64 ; 0.09 ; -1.69 ; -1.96 ; 3.59 ; 3.04 ; -0.04 ; 2.9 ; 2.56 ; -2.06 ; 3.31 ; 3.34 ; -2.01 ; 1.05 ; -1.47 ; 3.95 ; 1.6 ; -1.62 ; -1.5 ; -0.48 ; 1.94 ; 2.04 ; 2.36 ; 2.88 ; 2.77 ; 3.39 ; 4.69 ; 3.16 ; -1.97 ; 2.22 ; 4.63 ; 0.78 ; 3.64 ; 1.12 ; 3.41 ; 3.74 ; 2.3 ; 0.85 ; 1.68 ; -2.17 ; 2.82 ; 0.63 ; -2.15 ; 3 ; 2.32 ; -0.11 ; 1.69 ; -0.92 ; 0.66 ; 3.73 ; 0.43 ; 4.06 ; 2.46 ; -2.05 ; 4.92 ; -0.28 ; 1.21 ; -0.84 ; -0.43 ; 1.73 ; 2.37 ; 3.46 ; 2.15 ; 1.2 ; 2.34 ; 2 ; -2.5 ; -2.18 ; 2.65 ; 2.97 ; 3.22 ; 1.18 ; -1.89 ; 0.8 ; 3.07 ; -2.49 ; 1.64 ; -1.38 ; 2.89 ; -1.01 ; -2.34 ; 4.09 ; -2.6 ; 0.6 ; -1.95 ; 1.09 ; -2.83 ; 2.7 ; -2.19 ; -2.14 ; 3.25 ; 2.23 ; -2.27 ; -2.1 ; -2.58 ; -1.98 ; -2.36 ; -2.31 ; -1.85 ; 3.38 ; 4.14 ; 4.98 ; 4.29 ; 3.5 ; 3.36 ; 3.98 ; 3.82 ; 1.87 ; 2.74 ; 1.72 ; 2.33 ; 1.53 ; 4.51 ; 1.27 ; 3.45 ; 0.92 ; 2.84 ; 1.9 ; 0.97 ; -2.56 ; -2.54 ; 3.26 ; 4.19 ; 2.08 ; 4.34 ; 1.84 ; 2.51 ; -2.25 ; -2.71 ; 3.01 ; -2.3 ; 1.38 ; 0.7 ; 3.11 ; 3.2 ; -2.81 ; 3.03 ; -1.99 ; 2.11 ; 3.69 ; 1.54 ; -2.75 ; 0.96 ; -2.21 ; 0.22 ; 2.6 ; -2.39 ; -2.13 ; -2.87 ; 0.74 ; 3.67 ; -2.43 ; -1.94 ; 2.59 ; 4.27 ; 4.37 ; 2.2 ; 3.13 ; -0.21 ; 4.58 ; -2.02 ; 1.23 ; 2.52 ; 2.91 ; 2.21 ; 3.71 ; -1.75 ; 2.87 ; 3.18 ; 3.9 ; 1.49
IPSSR	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	IPSS-R Risk Category	Sample	High ; Low ; Int ; Very-High ; Very-Low
IPSSR_SCORE	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	IPSS-R Risk Score	Sample	6 ; 2 ; 5.5 ; 3.5 ; 4 ; 3 ; 5 ; 6.5 ; 7 ; 8.5 ; 4.5 ; 8 ; 2.5 ; 1 ; 9.5 ; 1.5 ; 0 ; 0.5 ; 9 ; 7.5 ; 10
LFS_MONTHS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Leukemia free survival in months since time of sampling	Patient	
LFS_STATUS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	Leukemia free survival patient  status.	Patient	
MDS_TYPE	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	Type of MDS (i.e., primary of secondary/therapy-related MDS)	Sample	s_t_MDS ; primary
MLL_PTD	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	BOOLEAN	Presence of MLL PTD	Sample	FALSE ; TRUE
MONOCYTES	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Monocyte Count in Giga/L	Sample	0.7 ; 0.1 ; 0.9 ; 0.88 ; 0.8 ; 0 ; 0.2 ; 1.2 ; 0.4 ; 0.3 ; 1 ; 2.3 ; 1.3 ; 0.76 ; 0.95 ; 0.45 ; 0.6 ; 0.5 ; 0.02 ; 0.22 ; 0.24 ; 0.67 ; 0.18 ; 0.05 ; 0.39 ; 0.72 ; 0.87 ; 0.66 ; 0.43 ; 0.47 ; 0.26 ; 0.04 ; 0.69 ; 0.46 ; 0.16 ; 0.52 ; 0.54 ; 0.11 ; 0.96 ; 0.65 ; 0.55 ; 0.34 ; 0.07 ; 0.08 ; 0.27 ; 0.79 ; 0.86 ; 0.29 ; 0.89 ; 0.35 ; 0.37 ; 0.63 ; 0.41 ; 0.17 ; 0.13 ; 1.17 ; 0.23 ; 0.28 ; 0.53 ; 0.15 ; 0.32 ; 1.01 ; 0.06 ; 0.19 ; 1.18 ; 0.585 ; 0.372 ; 0.408 ; 0.182 ; 0.144 ; 0.826 ; 0.319 ; 0.259 ; 0.208 ; 0.624 ; 1.792 ; 0.42 ; 0.246 ; 0.609 ; 0.33 ; 0.85 ; 0.168 ; 0.147 ; 0.364 ; 0.276 ; 0.294 ; 0.903 ; 0.315 ; 43.476 ; 18.411 ; 9.559 ; 14.8969 ; 0.034 ; 0.4125 ; 0.486 ; 0.735 ; 0.284 ; 0.464 ; 0.2805 ; 0.342 ; 0.3025 ; 0.14 ; 0.051 ; 0.1056 ; 0.076 ; 0.019 ; 0.264 ; 0.429 ; 0.091 ; 0.663 ; 0.2773 ; 0.297 ; 0.078 ; 0.2075 ; 0.576 ; 0.016 ; 0.162 ; 0.25 ; 0.191 ; 0.357 ; 1.312 ; 0.21 ; 0.61 ; 0.399 ; 0.062 ; 1.265 ; 0.298 ; 1.357 ; 16.25 ; 0.385 ; 0.203 ; 0.688 ; 0.423 ; 0.177 ; 0.299 ; 0.952 ; 0.498 ; 0.131 ; 0.155 ; 0.777 ; 0.085 ; 0.68 ; 0.072 ; 0.312 ; 0.125 ; 0.495 ; 0.292 ; 4.93 ; 0.56 ; 0.133 ; 0.525 ; 0.054 ; 0.235 ; 3.04 ; 0.38 ; 10.128 ; 0.282 ; 0.595 ; 0.165 ; 0.645 ; 0.215 ; 0.966 ; 0.037 ; 0.12 ; 0.041 ; 0.064 ; 5.292 ; 0.305 ; 0.483 ; 0.192 ; 0.552 ; 0.858 ; 1.152 ; 0.09 ; 2.431 ; 0.275 ; 1.026 ; 0.031 ; 0.112 ; 0.021 ; 0.749 ; 0.588 ; 1.628 ; 0.635 ; 0.216 ; 0.126 ; 11.934 ; 0.288 ; 0.026 ; 0.095 ; 0.069 ; 0.792 ; 0.583 ; 0.138 ; 0.123 ; 0.075 ; 0.108 ; 0.065 ; 0.092 ; 0.972 ; 0.066 ; 0.426 ; 0.819 ; 4.5 ; 1.188 ; 0.434 ; 0.306 ; 0.048 ; 1.666 ; 0.128 ; 0.222 ; 0.104 ; 0.068 ; 0.195 ; 0.036 ; 0.252 ; 0.137 ; 0.189 ; 0.513 ; 0.042 ; 0.116 ; 0.468 ; 0.027 ; 0.156 ; 0.336 ; 0.122 ; 0.111 ; 0.575 ; 0.231 ; 1.325 ; 0.096 ; 0.848 ; 0.225 ; 0.032 ; 0.36 ; 0.962 ; 0.228 ; 6.18 ; 12.09 ; 0.11736 ; 1.162 ; 1.02 ; 0.779 ; 0.052 ; 6.885 ; 3.003 ; 0.612 ; 4.3792 ; 0.102 ; 1.222 ; 3.066 ; 1.406 ; 0.343 ; 0.432 ; 0.51 ; 0.1491 ; 0.2825 ; 0.009 ; 0.117 ; 2.356 ; 0.686 ; 0.5424 ; 0.039 ; 0.371 ; 0.304 ; 0.979 ; 0.539 ; 4.584 ; 1.8228 ; 0.1617 ; 1.4 ; 0.114 ; 0.029 ; 1.14 ; 0.196 ; 0.99 ; 0.266 ; 0.028 ; 0.44 ; 1.1298 ; 0.1824 ; 1.0976 ; 0.384 ; 0.035 ; 0.3794 ; 0.074 ; 2.345 ; 0.784 ; 0.405 ; 0.684 ; 0.528 ; 0.046 ; 1.946 ; 0.387 ; 0.329 ; 0.4296 ; 0.756 ; 0.828 ; 0.056 ; 0.271 ; 0.255 ; 0.5929 ; 0.841 ; 0.696 ; 0.435 ; 1.817 ; 0.024 ; 0.1855 ; 0.5214 ; 0.352 ; 0.3456 ; 1.5516 ; 0.565 ; 1.56 ; 1.0293 ; 3.5256 ; 0.1557 ; 0.5066 ; 0.351 ; 5.4 ; 4.632 ; 0.396 ; 0.567 ; 0.344 ; 0.428 ; 0.621 ; 0.4095 ; 2.2 ; 0.022 ; 0.121 ; 2.39 ; 2.6 ; 0.533 ; 0.014 ; 0.597 ; 4.6 ; 0.93 ; 4.08 ; 6.5 ; 4.98 ; 0.01 ; 12.92 ; 1.98 ; 0.62 ; 2.8 ; 1.76 ; 0.476 ; 2.698 ; 2.317 ; 0.737 ; 0.673 ; 0.964 ; 0.493 ; 0.456 ; 1.947 ; 0.224 ; 0.752 ; 0.229 ; 0.485 ; 0.457 ; 0.376 ; 0.166 ; 0.339 ; 4.14 ; 0.334 ; 0.135 ; 0.515 ; 0.326 ; 0.151 ; 1.582 ; 3.024 ; 0.491 ; 0.419 ; 0.061 ; 0.107 ; 0.221 ; 1.198 ; 0.511 ; 0.383 ; 0.388 ; 3.497 ; 0.163 ; 0.742 ; 0.608 ; 1.967 ; 0.063 ; 0.301 ; 0.796 ; 0.642 ; 2.4 ; 0.64 ; 0.91 ; 3.6 ; 12.1 ; 1.1 ; 0.49 ; 0.48 ; 0.31 ; 0.57 ; 0.58 ; 1.44 ; 1.45 ; 0.94 ; 3.36 ; 0.78 ; 0.71 ; 4.34 ; 0.98 ; 1.65 ; 1.84 ; 2.02 ; 0.84 ; 3 ; 1.05 ; 1.51 ; 2.29 ; 3.33 ; 1.67 ; 0.77 ; 2.16 ; 2.28 ; 7.04 ; 2.24 ; 4.31 ; 2.22 ; 1.28 ; 1.55 ; 0.83 ; 1.35 ; 2.64 ; 8.51 ; 1.83 ; 5.46 ; 1.21 ; 6.97 ; 3.23 ; 0.81 ; 1.42 ; 0.74 ; 0.59 ; 6.72 ; 2.67 ; 3.99 ; 1.86 ; 40 ; 7.77 ; 1.85 ; 1.93 ; 1.73 ; 5.09 ; 0.073 ; 6.3 ; 0.149 ; 1.95 ; 3.02 ; 1.16 ; 2.9 ; 1.12 ; 0.73 ; 2 ; 0.03 ; 1.19 ; 2.19 ; 4.29 ; 1.25 ; 5.1 ; 1.94 ; 1.11 ; 8.2 ; 3.1 ; 1.9 ; 9 ; 2.7 ; 1.5 ; 27.6 ; 1.6 ; 1.7 ; 13.8 ; 44.2 ; 26.6 ; 2.5 ; 7.1 ; 10 ; 17.5 ; 4.9 ; 3.7 ; 1.24 ; 1.13 ; 0.97 ; 26.4 ; 3.4 ; 6.8 ; 1.8 ; 6.4 ; 4 ; 6.2 ; 3.5 ; 19.2 ; 13.5 ; 8 ; 15 ; 5 ; 11 ; 13 ; 14 ; 7 ; 6 ; 19.4 ; 4.8 ; 4.7 ; 38.1 ; 0.92 ; 3.43 ; 1.71 ; 1.33 ; 2.76 ; 1.96 ; 2.21 ; 17.94 ; 34.16 ; 2.52 ; 2.59 ; 1.52 ; 6.74 ; 1.64 ; 1.47 ; 3.64 ; 6.43 ; 12.06 ; 3.45 ; 12.28 ; 2.14 ; 1.06 ; 4.2 ; 13.86 ; 2.63 ; 0.75 ; 1.38 ; 8.92 ; 1.26 ; 10.09 ; 4.61 ; 1.48 ; 1.43 ; 1.29 ; 7.68 ; 8.88 ; 12.88 ; 2.48 ; 1.22 ; 14.81 ; 22.04 ; 1.72 ; 2.08 ; 5.33 ; 1.61 ; 2.46 ; 1.15 ; 4.26 ; 18.83 ; 6.55 ; 11.63 ; 3.51 ; 3.13 ; 1.49 ; 2.42 ; 3.38 ; 1.32 ; 1.66 ; 2.79 ; 1.04 ; 13.82 ; 18.79 ; 2.49 ; 4.06 ; 2.27 ; 0.82 ; 1.08 ; 1.99 ; 3.34 ; 14.24 ; 3.62 ; 2.23 ; 4.78 ; 1.36 ; 3.97 ; 1.23 ; 7.26 ; 1.79 ; 3.75 ; 1.58 ; 1.09 ; 4.28 ; 0.023 ; 3.3 ; 2.87 ; 7.74 ; 2.34 ; 2.26 ; 2.31 ; 0.176 ; 0.212 ; 5.81 ; 2.58 ; 3.78 ; 0.045 ; 1.27 ; 1.31 ; 1.74
PB_BLAST	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	PB Blast in %	Sample	0 ; 10 ; 3.4 ; 3.3 ; 6 ; 9 ; 3 ; 5.1 ; 1.8 ; 1 ; 2 ; 0.5 ; 9.3 ; 3.5 ; 5 ; 13 ; 1.5 ; 4 ; 8 ; 14 ; 7 ; 11 ; 29 ; 16 ; 17 ; 12 ; 18 ; 20 ; 0.13 ; 0.8 ; 25 ; 15 ; 28 ; 38 ; 24 ; 63 ; 19 ; 64 ; 30 ; 49 ; 21 ; 35 ; 22 ; 53 ; 23 ; 34 ; 0.9 ; 3.7 ; 5.3
PLT	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Platelet in Giga/L	Sample	119 ; 42 ; 81 ; 77 ; 195 ; 492 ; 61 ; 142 ; 23 ; 183 ; 18 ; 167 ; 842 ; 716 ; 111 ; 158 ; 65 ; 34 ; 6 ; 248 ; 148 ; 166 ; 10 ; 51 ; 506 ; 101 ; 67 ; 36 ; 131 ; 86 ; 172 ; 383 ; 44 ; 14 ; 147 ; 326 ; 150 ; 241 ; 341 ; 96 ; 5 ; 230 ; 258 ; 197 ; 97 ; 145 ; 99 ; 1398 ; 52 ; 106 ; 378 ; 201 ; 91 ; 418 ; 375 ; 88 ; 114 ; 304 ; 287 ; 256 ; 175 ; 71 ; 210 ; 151 ; 238 ; 279 ; 219 ; 146 ; 254 ; 134 ; 87 ; 714 ; 115 ; 199 ; 139 ; 128 ; 98 ; 27 ; 190 ; 596 ; 141 ; 48 ; 330 ; 63 ; 512 ; 274 ; 319 ; 133 ; 296 ; 567 ; 159 ; 20 ; 323 ; 176 ; 113 ; 94 ; 109 ; 224 ; 93 ; 393 ; 218 ; 105 ; 200 ; 179 ; 188 ; 267 ; 58 ; 68 ; 187 ; 236 ; 317 ; 356 ; 84 ; 275 ; 332 ; 112 ; 194 ; 180 ; 191 ; 272 ; 79 ; 102 ; 55 ; 62 ; 126 ; 295 ; 286 ; 271 ; 100 ; 31 ; 130 ; 281 ; 69 ; 121 ; 24 ; 57 ; 124 ; 177 ; 454 ; 253 ; 160 ; 170 ; 46 ; 315 ; 64 ; 171 ; 137 ; 75 ; 386 ; 76 ; 89 ; 74 ; 95 ; 336 ; 163 ; 30 ; 120 ; 53 ; 153 ; 9 ; 410 ; 215 ; 85 ; 157 ; 546 ; 47 ; 531 ; 132 ; 83 ; 108 ; 38 ; 39 ; 116 ; 16 ; 7 ; 78 ; 54 ; 416 ; 282 ; 231 ; 60 ; 227 ; 45 ; 212 ; 138 ; 543 ; 377 ; 17 ; 29 ; 439 ; 50 ; 380 ; 13 ; 189 ; 633 ; 49 ; 129 ; 143 ; 37 ; 82 ; 612 ; 8 ; 239 ; 72 ; 56 ; 174 ; 362 ; 107 ; 736 ; 66 ; 265 ; 453 ; 216 ; 358 ; 198 ; 278 ; 300 ; 92 ; 435 ; 154 ; 25 ; 650 ; 127 ; 184 ; 28 ; 686 ; 103 ; 381 ; 600 ; 70 ; 1007 ; 284 ; 423 ; 135 ; 22 ; 40 ; 243 ; 339 ; 676 ; 412 ; 196 ; 26 ; 297 ; 367 ; 473 ; 234 ; 264 ; 80 ; 276 ; 21 ; 32 ; 104 ; 173 ; 211 ; 260 ; 458 ; 73 ; 431 ; 35 ; 90 ; 156 ; 542 ; 294 ; 1350 ; 404 ; 273 ; 451 ; 237 ; 43 ; 3 ; 371 ; 240 ; 400 ; 280 ; 15 ; 181 ; 465 ; 419 ; 283 ; 370 ; 229 ; 642 ; 144 ; 207 ; 293 ; 344 ; 117 ; 316 ; 432 ; 118 ; 152 ; 277 ; 33 ; 269 ; 349 ; 228 ; 168 ; 334 ; 552 ; 235 ; 309 ; 472 ; 203 ; 289 ; 497 ; 528 ; 11 ; 305 ; 582 ; 333 ; 257 ; 185 ; 19 ; 217 ; 391 ; 125 ; 41 ; 308 ; 303 ; 123 ; 122 ; 351 ; 209 ; 357 ; 266 ; 162 ; 262 ; 593 ; 149 ; 463 ; 314 ; 232 ; 826 ; 388 ; 313 ; 674 ; 517 ; 306 ; 250 ; 502 ; 470 ; 742 ; 204 ; 169 ; 252 ; 426 ; 165 ; 715 ; 110 ; 301 ; 413 ; 213 ; 208 ; 363 ; 186 ; 523 ; 222 ; 576 ; 193 ; 223 ; 422 ; 140 ; 518 ; 251 ; 350 ; 59 ; 299 ; 594 ; 205 ; 214 ; 155 ; 488 ; 526 ; 507 ; 178 ; 263 ; 441 ; 206 ; 396 ; 12 ; 387 ; 2 ; 607 ; 1451 ; 460 ; 327 ; 292 ; 530 ; 399 ; 773 ; 390 ; 402 ; 136 ; 353 ; 1117 ; 302 ; 414 ; 477 ; 835 ; 285 ; 161 ; 318 ; 859 ; 246 ; 192 ; 382 ; 437 ; 225 ; 321 ; 487 ; 346 ; 672 ; 491 ; 28.5 ; 681 ; 504 ; 440 ; 415 ; 226 ; 515 ; 37.70000076 ; 291 ; 298 ; 244 ; 245 ; 247 ; 268 ; 1354 ; 385 ; 544 ; 429 ; 581 ; 374 ; 182 ; 328 ; 329 ; 574 ; 255 ; 379 ; 80.7 ; 97.5 ; 83.8 ; 76.8 ; 406 ; 364 ; 708 ; 352 ; 579 ; 559 ; 588 ; 474 ; 573 ; 355 ; 407 ; 709 ; 384 ; 307 ; 1015 ; 376 ; 348 ; 878 ; 424 ; 751 ; 312 ; 164 ; 288 ; 202 ; 831 ; 347 ; 557 ; 819 ; 928 ; 361 ; 372 ; 337 ; 342 ; 389 ; 368 ; 469 ; 457 ; 509 ; 392 ; 1234 ; 220 ; 373 ; 501 ; 354 ; 4 ; 249 ; 505 ; 532 ; 448 ; 572 ; 345 ; 450 ; 874 ; 395 ; 578 ; 510 ; 484 ; 397 ; 551 ; 310 ; 639 ; 455 ; 433 ; 775 ; 394 ; 324 ; 366 ; 233 ; 610 ; 38.5 ; 495 ; 261 ; 76.1 ; 270 ; 83.7 ; 322 ; 259 ; 69.8 ; 398 ; 46.6 ; 82.4 ; 72.9 ; 43.7 ; 688 ; 34.5 ; 408 ; 445 ; 69.7 ; 11.5 ; 40.2 ; 18.4 ; 26.9 ; 1055 ; 956 ; 87.5 ; 33.8 ; 34.6 ; 525 ; 320 ; 40.8 ; 72.2 ; 27.8 ; 24.5 ; 98.9 ; 38.9 ; 63.1 ; 5.67 ; 508 ; 88.4 ; 57.8 ; 83.1 ; 8.5 ; 790 ; 85.6 ; 535 ; 442 ; 33.5 ; 420 ; 568 ; 608 ; 446 ; 411 ; 335 ; 480 ; 343 ; 534 ; 221 ; 906 ; 359 ; 467 ; 475 ; 77.5 ; 9.76 ; 87.8 ; 76.2 ; 738 ; 32.1 ; 91.2 ; 558 ; 634 ; 614 ; 405 ; 499
RINGED_SIDEROBLASTS	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	NUMBER	Ringed Sideroblast in %	Sample	0 ; 46 ; 16 ; 44 ; 7 ; 80 ; 86 ; 58 ; 76 ; 65 ; 5 ; 35 ; 1 ; 73 ; 10 ; 23 ; 26 ; 33.9 ; 20 ; 32 ; 30 ; 77.5 ; 23.3 ; 34 ; 38.8 ; 69 ; 3 ; 8 ; 47 ; 45 ; 70 ; 2.4 ; 25 ; 64 ; 28 ; 75 ; 60 ; 9 ; 74 ; 41 ; 40 ; 36 ; 24 ; 33 ; 85 ; 17 ; 55 ; 53 ; 31 ; 4 ; 57 ; 52 ; 38 ; 21 ; 54 ; 42 ; 51 ; 59 ; 13 ; 14 ; 3.5 ; 15 ; 29 ; 2 ; 37.5 ; 77 ; 50 ; 78 ; 94 ; 79 ; 90 ; 6 ; 82 ; 27 ; 95 ; 11 ; 81 ; 61 ; 92 ; 48 ; 71 ; 84 ; 49 ; 37 ; 62 ; 12 ; 67
WHO_2016	LightSalmon	Myelodysplastic Syndromes (MDS IWG, IPSSM, NEJM Evidence 2022)	STRING	WHO 2016 Classification	Sample	MDS-EB2 ; MDS-MLD ; MDS-U ; MDS-EB1 ; MDS-SLD/MLD ; CMML ; MDS/MPN-U ; MDS-SLD ; MDS-RS-SLD ; AML ; aCML ; MDS/MPN-RS-T ; MDS-del5q ; MDS-RS-MLD ; MDS-RS-SLD/MLD ; other
AML_FAB	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	AML into subtypes are the French-American-British (FAB) classification (not available with UC cases)	Patient	
CLINICAL_ONSET_AML	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Clinical onset (AML cases only)	Patient	
CYCLES_COMPLETED	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	NUMBER	Cycles Completed.	Patient	
CYTOGENETIC_RESPONSE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Cytogenetic Response.	Patient	
CYTOGENETIC_RISK	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Cytogenetic Risk	Patient	
DISEASE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Disease	Patient	
IPSS_MDS	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	IPSS (MDS cases only)	Patient	
KYRYOTYPE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Karyotype.	Patient	
MORPHOLOGIC_RESPONSE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Morphologic Response.	Patient	
PERFORMANCE_STATUS	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Performance Status.	Patient	
PERIPHERAL_BLASTS_PERCENTAGE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	NUMBER	Peripheral blasts percentage.	Patient	
PERIPHERAL_BLOOD_WBC	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	NUMBER	Perpheral blood white blood cells.	Patient	
PRIOR_TREATMENT	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Prior treatment.	Patient	
SOURCE	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Source	Patient	
TRANSPLANT	LightSalmon	Acute myeloid leukemia or myelodysplastic syndromes (WashU, 2016)	STRING	Transplant.	Patient	
AGE_IN_DAYS	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	NUMBER	Age at which a condition or disease was first diagnosed.	Patient	
ANALYSIS_COHORT	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Analysis Cohort	Sample	DISCOVERY ; INDUCTION FAILURE - DISCOVERY ; VALIDATION
BONE_MARROW_SITE_OF_RELAPSE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Bone Marrow Site of Relapse	Sample	Yes ; Not done ; No
CBFT2A3_GLIS	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	CBFT2A3 GLIS gene fusion	Sample	Not Done ; NO ; YES ; MAYBE
CHLOROMA	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Chloroma	Patient	
CHLOROMA_RELAPSE_SITE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Recurrent Disease Chloroma Present Indicator	Patient	
CKIT_EXON_17_MUTATION	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Gene Mutation C-KIT Exon 17 Status Indicator	Patient	
CKIT_EXON_8_MUTATION	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Gene Mutation C-KIT Exon 8 Status Indicator	Patient	
CNS_DISEASE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	CNS disease.	Patient	
CNS_SITE_OF_RELAPSE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	CNS Site of Relapse	Sample	No ; Not done ; Yes
CR_STATUS_AT_END_OF_COURSE_1	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	CR status at end of course 1.	Patient	
CR_STATUS_AT_END_OF_COURSE_2	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	CR status at end of course 2.	Patient	
CYTOGENETIC_CODE_OTHER	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Cytogenetic code (other).	Patient	
CYTOGENETIC_COMPLEXITY	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Cytogenetic Abnormality Number of abnormalities	Patient	
CYTOGENETIC_RELAPSE_SITE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Recurrent Disease Cytogenetics Present Indicator	Patient	
DAYS_TO_EVENT	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	NUMBER	Time To Event (days)	Patient	
DEL_5Q	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	5Q deletion.	Sample	Unknown ; No ; Yes
DEL_7Q	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	7Q deletion.	Sample	Unknown ; No ; Yes
DEL_9Q	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	9Q deletion.	Sample	Unknown ; No ; Yes
FIRST_EVENT	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	First Event	Patient	
FLT3_ITD_ALLELIC_RATIO	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	FLT3-ITD allelic ratio.	Sample	0.82 ; 0.55 ; 0.83 ; 0.76 ; 0.54 ; 0.4 ; 0.65 ; 0.15 ; 0.22 ; 0.74 ; 0.05 ; 0.69 ; 0.61 ; 0.21 ; 0.23 ; 0.62 ; 0.25 ; 0.49 ; 0.09 ; 0.63 ; 0.44 ; 0.75 ; 2.67 ; 0.14 ; 0.71 ; 1.15 ; 0.39 ; 0.34 ; 0.56 ; 2.2 ; 0.03 ; 0.3 ; 0.13 ; 1.3 ; 0.35 ; 1.43 ; 0.81 ; 1.67 ; 1.03 ; 1.18 ; 1.21 ; 0.26 ; 0.46 ; 1.96 ; 0.52 ; 0.73 ; 0.84 ; 0.07 ; 0.47 ; 0.37 ; 0.6 ; 0.8 ; 0.85 ; 0.99 ; 0.04 ; 0.93 ; 1.25 ; 0.48 ; 0.9 ; 0.68 ; 0.18 ; 1 ; 0.7 ; 0.72 ; 0.51 ; 0.88 ; 0.38 ; 0.79 ; 0.92 ; 1.1 ; 0.87 ; 2.95 ; 1.23 ; 7.7 ; 1.77 ; 0.19 ; 0.78 ; 0.1 ; 0.57 ; 1.02 ; 2.92 ; 1.4 ; 0.5 ; 9.5 ; 1.11 ; 0.12 ; 5.18 ; 0.45
FLT3_ITD_POSITIVE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	FLT3-ITD positive.	Sample	Yes ; No ; Unknown ; NO ; YES
FLT3_PM	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	FLT3-PM.	Sample	No ; Yes ; Unknown ; NO
INV_16	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	inv(16) gene fusion status	Sample	Unknown ; No ; Yes
ISCN	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	ISCN.	Patient	
MINUS_X	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Minus-X.	Sample	Unknown ; No ; Yes
MINUS_Y	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Minus-Y.	Sample	Unknown ; No ; Yes
MLL	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	MLL.	Sample	Unknown ; No ; Yes
MONOSOMY_5	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Monosomy 5.	Sample	Unknown ; No ; Yes
MONOSOMY_7	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Monosomy 7.	Sample	Unknown ; No ; Yes
MRD_AT_END_OF_COURSE_1	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	MRD at end of course 1.	Patient	
MRD_AT_END_OF_COURSE_2	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	MRD at end of course 2.	Patient	
MRD_PERCENTAGE_AT_END_OF_COURSE_1	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	NUMBER	MRD percentage at end of course 1.	Patient	
MRD_PERCENTAGE_AT_END_OF_COURSE_2	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	NUMBER	MRD percentage at end of course 2.	Patient	
NPM_MUTATION	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	NPM mutation.	Sample	No ; Unknown ; Yes ; NO ; YES
NUP98_NSD1	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	NUP98 NSD1 gene fusion	Sample	Not Done ; No ; Yes
OS_DAYS	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	NUMBER	Overall patient survival days	Patient	
OTHER_MLL	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Other MLL.	Patient	
OTHER_SITE_OF_RELAPSE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Other Site of Relapse	Sample	No ; Yes ; Not done
PRIMARY_CYTOGENETIC_CODE	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Primary cytogenetic code.	Patient	
RISK_GROUP	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Risk group.	Patient	
SCT_IN_FIRST_CR	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	SCT in first CR.	Patient	
TRISOMY_21	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Trisomy 21.	Sample	Unknown ; No ; Yes
TRISOMY_8	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	Trisomy 8.	Sample	Unknown ; No ; Yes
T_10_11_P11_2_Q23	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(10;11)(p11.2;q23) gene fusion status	Sample	Unknown ; No ; Yes
T_11_19_Q23_P13_1	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(11:19)(q23:p13.1) gene fusion status	Sample	Unknown ; No ; Yes
T_3_5_Q25_Q34	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(3;5)(q25;q34) gene fusion status	Sample	Unknown ; No ; Yes
T_6_11_Q27_Q23	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(6;11)(q27;q23) gene fusion status	Sample	Unknown ; No ; Yes
T_6_9	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(6;9) gene fusion status	Sample	Unknown ; No ; Yes
T_8_21	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(8;21) gene fusion status	Sample	Unknown ; No ; Yes
T_9_11_P22_Q23	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	t(9;11)(p22;q23) gene fusion status	Sample	Unknown ; No ; Yes
WT1_MUTATION	LightSalmon	Pediatric Acute Myeloid Leukemia (TARGET, 2018)	STRING	WT1 mutation.	Sample	No ; Yes ; Unknown ; NO
ABNORMAL_LYMPHOCYTE_PERCENT	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	NUMBER	Abnormal Lymphocyte Percent	Patient	
ATRA_EXPOSURE	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	STRING	Atra Exposure	Patient	
BASOPHILS_COUNT	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	NUMBER	Basophils Cell Count	Patient	
BLAST_COUNT	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	NUMBER	Blast Count	Patient	
CYTOGENETIC_ABNORMALITY_TYPE	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	STRING	Cytogenetic abnormality type	Patient	
MOLECULAR_STUDIES_OTHERS_PERFORMED	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	STRING	Molecular Analysis Performed Indicator	Patient	
PERFORMANCE_STATUS_OTHER_TIMING	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	STRING	Performance status assessment timepoint category other text	Patient	
PLATELET_COUNT_PRERESECTION	LightSalmon	Acute Myeloid Leukemia (TCGA, Firehose Legacy)	NUMBER	Platelet count preresection	Patient	
AML_IN_SKIN_PERCENTAGE	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	AML in skin, determined by WGS.	Patient	
DARK_ZONE_STAT	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Dark zone stat at transplant.	Patient	
INDUCTION	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Induction.	Patient	
INFERRED_GENOMIC_REARRANGEMENT	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Inferred genomic rearrangement (from RNA-Seq fusion).	Sample	t(15;17)(q22;q21) ; t(21;8)(q22.3;q22), dup1p36.33 ; t(16;16)(p13.11;q22.1) ; t(21;8)(q22.3;q22) ; t(16;16)(p13.11;q22.1), dup3q12.2, inv16q21-16q12.1 ; t(15;17)(q22;q21), dup12q24.12-13, dup13q34 ; dup1q21.3, t(21;8)(q22.3;q22) ; t(16;16)(p13.11;q22.1), dup17q25.3 ; t(16;16)(p13.11;q22.1), t(3;3)(p14.1;q29) ; t(15;17)(q22;q21), inv7q36.1-36.2 ; t(15;17)(q22;q21),  inv19q13.1-q13.32 ; dup12q24.1-31 ; t(21;5)(q22.3;q23.3), t(21;5)(q22.3;q23.2) ; dup3q12.2 ; t(11;9)(q23;p22) ; dup19q13.3 ; dup2p22.3 ; dup7q36.1 ; t(17;19)(p13.1;p13.3), t(17;19)(p13.1;p13), dup1q41-q43 ; t(1;9)(p36.13;q32) ; t(11;9)(q23;p22), dup14q24.1 ; t(2;3)(p16.1; p24-p23) ; dup4q31.3 ; dup13q34 ; t(22;9)(q11.23;q34.1) ; del17q11.2 ; t(10;11)(p12;q23.2), t(10;11)(p12;q23), inv11q23.1, inv11q23.2 ; t(11;19)(q23;p13.1) ; t(16;17)(q22;p11.2), t(16;17)(q22.1;p11.2) ; t(10;11)(p12;q23) ; t(10;11)(p12;q14) ; t(10;11)(p12;q14), dup13q34 ; t(11;5)(p15.5;q35) ; t(11;19)(q23.3;p13.3), inv1p21.1-p11.1, t(19;11)(q13.12;q23.3) ; inv21q11.2-q22.3 ; dup4q33, inv9q31.3-33.3, inv9q33.3-34 ; inv8q24.21, inv8q24.1-q24.2 ; t(11;6)(q23;q27) ; t(12;3)(q24.22-23;p26.1) ; t(22;9)(q11.23;q34.1), inv6q21 ; t(1;20)(q32;q11.2) ; inv21q22.11 ; t(16;8)(p13.3;p11) ; t(10;20)(q22;q13.13), t(21;3)(q22.3;q26) ; dup3q12.2, t(11;5)(p15.5;q35), t(11;5)(p15.5;q35) ; t(12;X)(p13.2;q25), t(12;X)(q?;q24), del17q21.3-23.3, t(17;X)(q11.1-q11.2;q25), t(12;X)(p13.2-p12.3;q25), t(18;5)(p11.3-p11.2;q33.3), del17q11.1-q21.31 ; t(1;5)(p36.2;q15-q21), t(1;5)(q25;q15), t(5;7)(q14;q32) ; t(22;9)(q11.23;q34.1),  inv19p13.2 ; inv2p25.2-p11.2 ; del3q21.3-q26 ; t(10;11)(p12;q23.3), t(10;11)(p12;q23)
RISK_CYTO	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Risk (Cyto).	Patient	
RISK_MOLECULAR	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Risk (Molecular).	Patient	
STRUCTURAL_VARIANTS	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Structural variants from WGS.	Sample	15:72113342-17:35755293(CTX),15:72113343-17:35755292(CTX) ; 15:72113381-17:35749505(CTX),15:72113386-17:35749588(CTX),15:72113410-17:35749505(CTX) ; 15:72103063-17:35756005(CTX),7:56712048-7:57544681(INV) ; 15:72113496-17:35750399(CTX),15:72113490-17:35750402(CTX) ; 15:72102828-17:35748107(CTX),15:72102815-17:35748106(CTX),15:72102829-17:35748106(CTX) ; 15:72113514-17:35752358(CTX),15:72113524-17:35752347(CTX) ; 15:72113429-17:35756719(CTX),15:72052994-17:35833384(CTX) ; 15:72104255-17:35741663(CTX),15:72104247-17:35741661(CTX),15:72104257-17:35741661(CTX) ; 15:72113191-17:35756597(CTX),15:72129457-17:35756833(CTX),3:46994998-3:46995128(DEL) ; 15:72103872-17:35752513(CTX),15:72103870-17:35752514(CTX) ; 15:72103777-17:35744690(CTX) ; 15:72112749-17:35755472(CTX),15:72112751-17:35755469(CTX) ; 1:166453112-3:53150925(CTX),12:128688979-12:128689118(DEL),14:84366862-14:84371916(DEL),15:32718038-15:32718374(DEL),15:66836622-15:66836965(DEL),15:70173020-15:70175225(DEL),19:21508936-19:21509184(DEL),21:10155090-21:10156148(DEL),3:61450089-3:61450426( ; 6:104234249-6:104234390(DEL) ; 3:140959414-3:140959497(DEL) ; 2:88210954-2:88211270(DEL),20:61859659-20:61859782(DEL),3:8697749-3:8697853(DEL) ; 20:23051193-20:23051633(DEL) ; 5:168977114-5:168977145(DEL),5:585454-5:585654(DEL),6:150735535-6:150735635(DEL),9:36352882-9:36354094(DEL)
SUB_CLONES	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Subclones detected by WGS.	Sample	n.d. ; 0 ; 1 ; 2 ; 3 ; 4
TRANSPLANT_TYPE	LightSalmon	Acute Myeloid Leukemia (TCGA, NEJM 2013)	STRING	Type of transplant (sib Allo, MUD, Auto, etc).	Patient	
AGE_AT_CHEMOTHERAPY_START	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Chemotherapy Start	Sample	1945 ; 193 ; 1076 ; 8350 ; 4224 ; 272 ; 4707 ; 5250 ; 691 ; 4630 ; 8266 ; 2619 ; 2463 ; 11201 ; 2317 ; 6837 ; 1923 ; 4405 ; 1868 ; 3828 ; 6814 ; 2897 ; 577 ; 4733 ; 8263 ; 5454 ; 6172 ; 4636 ; 3723 ; 3442 ; 2381 ; 5646 ; 3362 ; 642 ; 7426 ; 3585 ; 1266 ; 4095 ; 3061 ; 1589
AGE_AT_CHEMOTHERAPY_STOP	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Chemotherapy Stop	Sample	1163 ; 921 ; 2469 ; 269 ; 8606 ; 6019 ; 274 ; 4786 ; 719 ; 4720 ; 676 ; 3376 ; 2521 ; 11242 ; 2355 ; 1969 ; 4466 ; 2011 ; 3869 ; 6864 ; 2944 ; 998 ; 5783 ; 6789 ; 3827 ; 3834 ; 2696 ; 5961 ; 3752 ; 1246 ; 7510 ; 3113 ; 3845 ; 1421 ; 4536 ; 3467 ; 1649 ; 6025
AGE_AT_INITIAL_DIAGNOSIS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Initial Diagnosis	Patient	
AGE_AT_LAST_KNOWN_CLINICAL_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Last Known Clinical Status	Patient	
AGE_AT_RADIATION_START	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Radiation Start	Sample	1183 ; 528 ; 2097 ; 3539 ; 8402 ; 610 ; 2424 ; 322 ; 411 ; 441 ; 4373 ; 4631 ; 2373 ; 6324 ; 4801 ; 1853 ; 749 ; 4556 ; 4222 ; 4410 ; 2619 ; 8266 ; 2637 ; 7911 ; 2475 ; 11215 ; 7389 ; 1923 ; 4416 ; 2227 ; 3831 ; 6814 ; 2897 ; 7985 ; 4171 ; 4309 ; 4880 ; 3641 ; 5563 ; 3355 ; 867 ; 2727 ; 3585 ; 1449 ; 4095 ; 3055 ; 5697
AGE_AT_RADIATION_STOP	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Radiation Stop	Sample	1225 ; 572 ; 2141 ; 3582 ; 8409 ; 657 ; 2469 ; 363 ; 455 ; 483 ; 4422 ; 4679 ; 2424 ; 6368 ; 4847 ; 1901 ; 794 ; 4600 ; 4269 ; 4457 ; 2667 ; 8303 ; 2687 ; 7955 ; 2524 ; 11247 ; 7434 ; 1969 ; 4476 ; 2272 ; 3873 ; 6864 ; 2944 ; 8028 ; 4212 ; 4352 ; 4926 ; 4649 ; 3688 ; 2338 ; 5606 ; 3398 ; 908 ; 2770 ; 3626 ; 1491 ; 4135 ; 3098 ; 5740
AGE_AT_SPECIMEN_DIAGNOSIS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	NUMBER	Age at Specimen Diagnosis	Sample	1038 ; 1904 ; 1506 ; 738 ; 383 ; 544 ; 398 ; 190 ; 713 ; 1936 ; 170 ; 535 ; 1344 ; 2143 ; 2834 ; 2241 ; 2800 ; 4295 ; 2963 ; 2927 ; 1828 ; 2541 ; 3529 ; 1985 ; 4994 ; 3511 ; 3725 ; 3355 ; 797 ; 2967 ; 1878 ; 8339 ; 481 ; 576 ; 2365 ; 4199 ; 230 ; 371 ; 3941 ; 395 ; 4337 ; 4590 ; 1223 ; 2338 ; 5028 ; 6256 ; 4738 ; 1808 ; 6152 ; 4710 ; 5233 ; 660 ; 4519 ; 2280 ; 3143 ; 4188 ; 4379 ; 55 ; 54 ; 2589 ; 1441 ; 2507 ; 8226 ; 4186 ; 362 ; 1645 ; 5012 ; 3676 ; 4776 ; 155 ; 1464 ; 271 ; 2816 ; 2964 ; 6287 ; 1302 ; 3472 ; 4482 ; 2606 ; 7884 ; 2446 ; 11184 ; 3633 ; 2307 ; 6381 ; 636 ; 7354 ; 1897 ; 6234 ; 2530 ; 4402 ; 1840 ; 2203 ; 5694 ; 2199 ; 3324 ; 4808 ; 9602 ; 9714 ; 3810 ; 7387 ; 6779 ; 2869 ; 1986 ; 560 ; 4216 ; 5804 ; 2480 ; 4938 ; 3747 ; 1982 ; 4676 ; 3977 ; 3917 ; 1232 ; 7945 ; 3109 ; 4457 ; 735 ; 4774 ; 4438 ; 7562 ; 4334 ; 1469 ; 1391 ; 1571 ; 1956 ; 2857 ; 5203 ; 2419 ; 675 ; 996 ; 1389 ; 6938 ; 1855 ; 4326 ; 4740 ; 1357 ; 3354 ; 6236 ; 5738 ; 637 ; 4087 ; 7149 ; 4361 ; 5262 ; 5399 ; 6552 ; 2810 ; 3765 ; 1818 ; 1857 ; 623 ; 1436 ; 5401 ; 796 ; 2478 ; 809 ; 5984 ; 5213 ; 3870 ; 4937 ; 6061 ; 779 ; 3998 ; 1612 ; 6149 ; 2399 ; 4261 ; 4786 ; 1359 ; 6286 ; 3979 ; 4574 ; 5766 ; 2687 ; 3602 ; 421 ; 1083 ; 4932 ; 8422 ; 6259 ; 1933 ; 3991 ; 4222 ; 3402 ; 3902 ; 1352 ; 1178 ; 5937 ; 5083 ; 4344 ; 4513 ; 2396 ; 2750 ; 4417 ; 4601 ; 3606 ; 1545 ; 1221 ; 3408 ; 2265 ; 5534 ; 6992 ; 4021 ; 3332 ; 715 ; 604 ; 7398 ; 2696 ; 3557 ; 1235 ; 1384 ; 4068 ; 4234 ; 3026 ; 1575 ; 5666
AGE_CLASS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Age class	Patient	
BRAF_RELA_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	BRAF_RELA status	Patient	
BRAF_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	BRAF status	Patient ; Sample	Fusion ; - ; p.V600E ; p.R506_insVLR ; p.T599_insT ; Fusion; p.E451D
BRAF_STATUS2	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	BRAF status2	Patient	
CANCER_PREDISPOSITIONS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Cancer Predispositions	Sample	None documented ; Not Reported ; Li-Fraumeni syndrome ; NF-2 ; Other inherited conditions NOS ; Tuberous Sclerosis
CHEMOTHERAPY_AGENTS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Chemotherapy Agents	Sample	Not Reported ; Vincristine, Cisplatin, Doxorubicin, Etoposide, IT Methotrexate ; Cyclophosphamide, Doxorubicin, Cisplatin, Vincristine, Etoposide ; Vincristine, Doxorubicin, Cisplatin, Cyclophosphamide, Etoposide ; Cisplatin, vincrisinte, cyclophosphamide, doxorubicin ; Temozolomide ; Immunotherapy - Indoximod ; Etoposide, Carboplatin, Ifosfamide ; Not Applicabe ; Vincristine, Cyclophosphamide, Carboplatin ; Cisplatin, vincristine, etoposide, cyclophosphamide ; Etoposide ; Carboplatin, Cyclophosphamide, Etoposide ; Cisplatin, Cyclophosphamide, Etoposide, Vincristine ; Bevacizumab, Temozolomide, Irinotecan ; Vincristine, Cisplatin, Carboplatin, Cyclophosphamide ; Temozolomide, Bevacizumab, Irinotecan ; Temozolamide ; Irinotecan, Temozolomide, Bevacizumab ; Temodar ; Everolimus ; Temozolomide, Bevacizumab ; Carboplatin, Vincristine ; Vincristine, Thioguanine, Procarbazine, Lomustine ; Avastin ; Vincristine, Lomustine, Cisplatin ; Cisplatin, vincristine, cyclophosphamide, amifostine ; Cyclophosphamide, Cisplatin, Vincristine, Etoposide ; Unavailable ; Cisplatin, Lomustine, Vincristine ; Vincristine, Cisplatin, Etoposide, Cyclophosphamide, Isotretinoin, Vorinostat, Carboplatin/Thiotepa, Vorinostat, Isotretinoin ; Topotecan, Cyclophosphamide ; Vincristine, Carboplatin, Cisplatin, Isotretinoin, Cyclophosphamide ; Cisplatin, Vincristine, Cyclophosphamide, Etoposide ; Lomustine, Vincristine, Cisplatin, Etoposide, Cyclophosphamide ; Cisplatin, Lomustine ; Cisplatin, Vincristine, Etoposide, Cyclophosphamide ; Vincristine, Cyclophosphamide, Cisplatin
CHEMOTHERAPY_TYPE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Chemotherapy Type	Sample	Treatment follows a protocol and subject is enrolled on a protocol ; Treatment follows a protocol but subject is not enrolled ; Treatment follows other standard of care not associated with a current or past protocol
CLINICAL_STATUS_AT_COLLECTION_EVENT	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Clinical Status at Collection Event	Sample	Alive ; Deceased-due to disease
COMPLETED_RADIATION_DOSE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Completed Radiation Dose	Sample	Not Reported ; 1980 cGy ; 5400 cGy ; 3000 cGy ; Conformal RT ; 5940cGy ; 5940 cGy ; 3600 cGy ; UNKNOWN ; 2340 cGy ; 2700cGy ; 6000 cGy ; 5036 cGy ; 3060 cGy ; 1800 cGy ; 5580 cGy
COMPLETED_TOTAL_RADIATION_DOSE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Completed Total Radiation Dose	Sample	5400 cGy ; 5580 cGy ; 5396 cGy ; Not Reported ; 5940 cGy ; 5389 cGy ; 5760 cGy ; 5040 cGy ; 6000 cGy ; 4500 cGy ; 5036 cGy ; 3060 cGy ; 5340 cGy
CTNNB1_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	CTNNB1 status	Patient	
EPENDYMOMA_RELA_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Ependymoma_RELA status	Patient	
EXTENT_OF_TUMOR_RESECTION	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Extent of Tumor Resection	Sample	Gross/Near total resection ; Partial resection ; Biopsy only
EXTERNAL_PATIENT_ID	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	External Patient Identifier	Patient	
FORMULATION	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Formulation	Sample	Not Reported ; Cyclophosphamide 156 mg in sodium chloride 0.9% 26 mL; Doxorubicin 15.6 mg in dextrose 5% 35 mL inj ; Cisplatin 47 mg in sodium chloride 0.9% 470 mL infusion;  Vincristine 0.78 mg in sodium chloride 0.9% 25 mL inj;  Etoposide 51 mg in sodium chloride 0.9% ; Vincristine 0.34 mg in sodium chloride 0.9% 25 mL inj; Cyclophosphamide 220 mg in sodium chloride 0.9% 36 mL infusion; Carboplatin 86 mg in sodium chloride 0.9% 43 mL infusion ; Lowered doses of vincristine ; Reduced cisplatin dose by 50% due to high frequency hearing loss and reduced CCNU dose by 25% due to persistent neutropenia. ; Vincristine: 2 mg in sodium chloride 0.9% 25 mL inj; Cyclophosphamide: 1,400 mg in sodium chloride 0.9%; Cisplatin: 104 mg, potassium chloride 20.8 mEq, magnesium sulfate 10.4 mEq Mg++, mannitol 1.04 g in sodium chloride 0.9% 1,040 mL infusion
H3F3A_CTNNB1_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	H3F3A_CTNNB1 status	Patient	
HGG_H3F3A_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	HGG_H3F3A status	Patient	
INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Initial CNS Tumor Diagnosis Related to OS	Patient	
INITIAL_DIAGNOSIS_TYPE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Initial Diagnosis Type	Patient	
LGG_BRAF_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	LGG_BRAF status	Patient	
MEDICAL_CONDITIONS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Medical Conditions	Patient	
MULTIPLE_CANCER_PREDISPOSITIONS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Multiple Cancer Predispositions	Sample	No
MULTIPLE_MEDICAL_CONDITIONS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Multiple Medical Conditions	Patient	
MULTIPLE_TUMOR_LOCATIONS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Multiple Tumor Locations	Patient	
PROTOCOL_AND_TREATMENT_ARM	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Protocol and Treatment Arm	Sample	SJYC07 ; IRS-3 ; IRS3 ; Not Reported ; ACNS0831 Observational Arm ; ACNS0831 ; COG trial ACNS0831 ; A9952-like ; CHP 455 ; SJMB03 like ; CHP 455 NOS ; ACNS0331 ; PBTC-026 ; ACNS0331-like ; ACNS0332 ; CCG 99703 ; CHP-455 ; ACNS0322
RADIATION	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Radiation	Sample	Yes ; No ; Not Reported ; Unavailable
RADIATION_SITE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Radiation Site	Sample	Focal/Tumor bed ; Craniospinal with focal boost ; Other ; Not Reported
RADIATION_TYPE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Radiation Type	Sample	Protons ; Not Reported ; Photons ; Combination of Protons and Photons
SAMPLE_ANNOTATION	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Sample annotation	Sample	Treatment naive ; Post-treatment ; Post-mortem
TIMING_OTHER_NOTES	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Timing Other Notes	Sample	Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide ; Not Reported ; Subject received temozolomide for 5 days 6 months after chemotherapy start date. ; Observational only, no drugs given.  According to this protocol, subject will have an MRI of the brain and physical exam every four months, until 36 months off treatment, when it will be every 6 months. Every 12 months he will, in addition, have an audiog ; Concurrent with radiation ; Carboplatin/Vincristine. 8 cycles. ; Weekly vincristine, he returned to an outside hospital to continue his maintenance chemotherapy per ACNS0331. His Cycle 2 (CCNU/Cisplatin) was switched with Cycle 3 Cyclophosphamide) in order to mobilize hematopoietic stem cells for collection. He underwe ; Carboplatin during radiotherapy, isotretinoin,  vincristine, cisplatin, and cyclophosphamide
TREATMENT	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Treatment	Sample	New ; Modified Treatment ; No treatment
TREATMENT_CHANGED	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Treatment Changed	Sample	Diagnosis ; 12 Month Update ; 6 Month Update ; 18 Month Update ; 3 Month Update ; 42 Month Update ; 24 Month Update
TREATMENT_STATUS	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Treatment status	Sample	Treatment naive ; Post-treatment ; Untreated ; Treated
TUMOR_LOCATION_CONDENSED	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	Tumor location	Sample	Supratentorial ; Infratentorial ; Suprasellar/Hypothalamic/Pituitary ; Posterior Fossa ; Posterior Fossa>SPINE ; SPINE ; Temporal Lobe ; Frontal Lobe ; Occipital Lobe,Temporal Lobe ; Parietal Lobe,Temporal Lobe ; Frontal Lobe,Parietal Lobe ; Midline ; Cortical ; Cerebellar ; Cerebellum/Posterior Fossa ; Brain Stem ; Thalamic/cortical ; Optic Pathway ; Spinal ; Optic Pathway,Suprasellar/Hypothalamic/Pituitary ; Ventricles ; Thalamus
UPDATED_GRADE	Gray	Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)	STRING	updated grade	Patient	
PRETREATMENT_HISTORY	Gray	Glioblastoma (TCGA, Nature 2008)	STRING	Pre-treatment history.	Patient	
PRIOR_GLIOMA	Gray	Glioblastoma (TCGA, Nature 2008)	STRING	Prior glioma.	Patient	
EXPRESSION_SUBTYPE	Gray	Glioblastoma (TCGA, Cell 2013)	STRING	Gene Expression Subtype	Sample	Classical ; Proneural ; Mesenchymal ; G-CIMP ; Neural
G_CIMP_METHYLATION	Gray	Glioblastoma (TCGA, Cell 2013)	STRING	G-CIMP  Methylation	Sample	non-G-CIMP ; G-CIMP
METHYLATION_STATUS	Gray	Glioblastoma (TCGA, Cell 2013)	STRING	Yes/No indicator for methylation data	Sample	CL_1 ; CL_3 ; CL_2 ; CL_4 ; G-CIMP ; CL_6
MGMT_STATUS	Gray	Glioblastoma (TCGA, Cell 2013)	STRING	MGMT Status	Sample ; Patient	UNMETHYLATED ; METHYLATED ; Unmethylated ; Methylated ; Unknown ; Equivocal
IMPLANT_GRADE	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Implant Grade	Sample	IV
INITIAL_DIAGNOSIS_OF_RECURRENT_TUMORS	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Initial Diagnosis of Recurrent Tumors	Sample	Anaplastic astrocytoma ; Glioblastoma ; Astrocytoma, subtype indeterminate
INITIAL_DIAGNOSIS_YEAR	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	NUMBER	Initial Diagnosis Year	Sample	2015 ; 2013 ; 2014 ; 1995 ; 2016 ; 2017
MORPHOLOGY	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Morphology	Sample	Fibrillary and giant cell ; Fibrillary and gemistocytic ; Fibrillary ; Oligoastrocytoma ; NOS ; Gliosarcoma ; Small Cell ; Fibrillary with focal astroblastic pattern ; Fibrillary and small cell ; Small cell ; PNET ; Unusual morphology with focal astroblastic pattern, eosinophilic granular bodies, and Rosenthal fibers ; Small cell and giant cell ; Giant cell features ; Oligoastrocytoma, predominantly oligodendroglial ; Markedly pleomorphic and poorly differentiated ; Extensive giant cell features ; Glioblastoma with evidence of recent hemorrhage ; Giant cell and PNET-like features ; Oligodendroglioma
ORIGINAL_DIAGNOSIS_AT_IMPLANT	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Original Diagnosis at Implant	Sample	Glioblastoma
TREATMENT_DETAIL_BEFORE_PDX	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Treatment summary prior to passing in PDX (only show in summary table)	Patient	
TUMOR_LOCATION	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	STRING	Tumor Location	Sample	Right frontal ; Right temporal ; Left frontal ; Right parietal ; Right parietal occipital ; Right frontotemporal ; Left temporoparietal ; Left occipital ; Left cerebellum ; Right temporo-occipital ; Left temporal ; Left temporal-occipital ; Left parietal ; Left parietotemporal ; Right frontal/basal ganglia ; Left parietal, Right parietal ; Right parieto-occipital ; Left parieto-occipital ; Multifocal (left frontal/temporal/parietal; right occipital) ; Left frontal lobe ; Right parietal; right temporal ; Left frontotemporal ; Left occipital-parietal ; Right cerebellum/occipital ; Left posterior temporal ; Frontal ; frontoparietal ; temporal ; parietal ; Parietal ; frontal ; Frontal - crosses midline ; Temporal - anterior ; Temporal ; Parieto-occipital ; Patietal ; Thalamus ; Cerebellopontine Angle ; Cerebellum ; Optic chiasm ; 4th ventricle ; 3rd ventricle ; Brainstem ; Optic nerve ; Hypothalamus ; Parietal Lobe ; Occipital lobe ; Temporal lobe ; Parietal lobe ; Frontal lobe ; Corpus callosum ; Insular lobe
YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS	Gray	Brain Tumor PDXs (Mayo Clinic, Clin Cancer Res 2020)	NUMBER	Year of initial pathologic diagnosis.	Patient	
AGE_AT_PD1	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Patient age at the starting of PD1 inhibitor	Patient	
BEST_RESPONSE_TO_PD1_INHIBITOR(RANO)	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Best Response to PD1 Inhibitor (RANO)	Patient	
BEV_FAILURE_ BEFORE_PD1 INHIBITOR	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Bev Failure Before PD1 Inhibitor	Patient	
DOSE_MG_DAY_STEROID_DURING_PD1	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Drug Dose (mg/day) (Steroids During PD1 Inhibitor)	Patient	
DOSE_MG_DAY_STEROID_PD1_START	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Drug Dose (mg/day) (Steroids When Started PD1 Inhibitor) 	Patient	
DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Dose Of Pembrolizumab Per Injection (mg/kg)	Patient	
DOSE_OF_RE-IRRADIATION	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Dose Of Re-irradiation	Patient	
DRUG_AND_DOSE_STEROID_DURING_PD1	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Drug Name (Steroids During PD1 Inhibitor) 	Patient	
ENDOCRINE_TOXICITIES	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Endocrine Toxicities	Patient	
EXTENT_OF_RESECTION	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Extent of Resection	Sample	Gross Total Resection ; Subtotal Resection ; Resection at OSH ; OSH (Gross Total Resection) ; Bx ; Total ; Subtotal ; Biopsy
FIRST_RECURRENCE	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	First Recurrence = 0	Patient	
KPS	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Karnofsky Performance Status to demonstrate patient prognosis	Patient	
KPS_AT_PD1_INHIBITOR_START	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Karnofsky Performance Status at the start of PD1i therapy 	Patient	
LIVER_DISFUNCTION	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Liver Disfunction	Patient	
NUMBER_OF_PD1_INHIBITOR_INJECTIONS	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Number Of PD1 Inhibitor Injections	Patient	
NUMBER_OF_PRIOR_RECURRENCES	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Number Of Prior Recurrences	Patient	
OS_FROM_PD1I_MONTHS	Gray	Glioblastoma (Columbia, Nat Med. 2019)	NUMBER	Overall survival in months since PD1 Inhibitor	Patient	
OS_FROM_PD1I_STATUS	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Overall Survival Status From PD1 Inhibitor	Patient	
PD1_INHIBITOR	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_BCNU/CCNU	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With BCNU/CCNU	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_BEV	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With Bev	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_DC_VAX	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With DC Vax	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_HYDROXYUREA	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With Hydroxyurea	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_NOVO-TTF	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With Novo-TTF	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_RE-IRRADIATION	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With Re-irradiation	Patient	
PD1_INHIBITOR_CONCURRENTLY_WITH_TEMODAR	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Concurrently With Temodar	Patient	
PD1_INHIBITOR_DRUG	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor Drug	Patient	
PD1_INHIBITOR_STARTED_FOR_PD	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor started for PD (Yes/No)	Patient	
PD1_INHIBITOR_WITH_CELECOXIB	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor With Celecoxib	Patient	
PD1_INHIBITOR_WITH_IMATINIB	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	PD1 Inhibitor With Imatinib	Patient	
RASH	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Rash	Patient	
RESPONSE	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Response to PD1	Patient	
SEQUENCED_CENTER	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Sequenced Center	Sample	Foundation ; FdnOne ; GlioSeq ; Tempus
STEROIDS_WHEN_STARTED_PD1_INHIBITOR	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Steroids When Started PD1 Inhibitor	Patient	
STEROID_PD1_STARTING_DRUG_NAME	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Drug Name (Steroids When Started PD1 Inhibitor)	Patient	
STREOIDS_DURING_PD1_INHIBITOR	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Steroids During PD1 Inhibitor	Patient	
TREATMENT_ONGOING	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Treatment Ongoing	Patient	
TUMOR_HEMISPHERE	Gray	Glioblastoma (Columbia, Nat Med. 2019)	STRING	Tumor Hemisphere	Sample	Left ; Right
BMI	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Body mass index	Patient	
COUNTRY_OF_ORIGIN	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Country of origin	Patient	
ETHNICITY_SELF_IDENTIFY	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Ethnicity, as self identified 	Patient	
EXCLUDED_IN_DOWNSTREAM_ANALYSIS	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Was the patient excluded from downstream analysis	Patient	
EXPERT_PATH_REVIEW	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Expert pathological review	Patient	
EXPERT_PATH_REVIEW_DETAILS	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Details of expert pathological review	Patient	
EXPERT_PATH_REVIEW_NUM_SEGMENTS	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Number of segments in expert pathological review	Patient	
FOLLOW_UP_PERIOD	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Follow-up period	Patient	
HEIGHT	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Height in centimeters	Patient	
LOST_TO_FOLLOW_UP	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Was the patient lost to follow-up	Patient	
PATH_DIAG_TO_DEATH_DAYS	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Time from diagnostic to death in days	Patient	
PATH_DIAG_TO_LAST_CONTACT_DAYS	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Time from diagnostic to last contact in days	Patient	
PATH_DIAG_TO_TUMOR_REOCCUR_DAYS	Gray	Glioblastoma (CPTAC, Cell 2021)	NUMBER	Time from diagnostic to tumor reoccurrence	Patient	
SECONDHAND_SMOKE_EXPOSURE	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Secondhand smoke exposure, in categories 	Patient	
SMOKING_HISTORY	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Smoking history, in categories 	Patient	
TUMOR_LATERALITY	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Tumor laterality	Sample	Left ; Right ; Bilateral
TUMOR_REOCCUR_AFTER_TREATMENT	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Did the tumor reoccur after treatment	Patient	
TUMOR_SITE_CURATED	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Tumor site, curated 	Sample	Frontal Lobe ; Parietal Lobe ; Temporal Lobe ; Occipital Lobe ; Parietal and Temporal Lobe ; Parietal, Occipital, Temporal Lobe ; Parietal and Occipital Lobe ; Frontal and Temporal Lobe ; Frontal and Parietal Lobe ; Temporal, Parietal Lobe, and lateral  ventricle ; hemisphere ; Thalamus ; Occipital lobe ; Parietal, Occipital and Temporal Lobe ; Basal Ganglia ; Temporal Lobe and Basal ganglia and thalamus ; Occipital and Temporal Lobe ; Frontal, Parietal and Temporal Lobe
TUMOR_SITE_CURATION_NOTES	Gray	Glioblastoma (CPTAC, Cell 2021)	STRING	Tumor site, curation notes 	Sample	Diagnostic pathology report ; MRI review
ACQUIRED_AFTER_ALKALATOR_TREATMENT	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Acquired after alkylator treatment	Sample	No ; Yes
ACQUIRED_AFTER_ANY_SYSTEMIC_TREATMENT	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Acquired after any systemic treatment	Sample	No ; Yes
ACQUIRED_AFTER_RADIOTHERAPY	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Acquired after radiotherapy	Sample	No ; Yes
ACTIONABLE_LESION1	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Actionable lesion1	Patient	
ENHANCING	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Enhancing	Sample	No ; Yes
HIGHEST_ONCOKB_LEVEL	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Highest OncoKB level	Patient	
PRIOR_LINES_OF_THERAPY	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Prior lines of therapy	Sample	0 ; 1 ; 2 ; 3 ; 4 ; 7 ; 5 ; 6 ; 8
RECEIVED_TARGETED_TX	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	Received targeted treatment	Patient	
SURGERY_DATE_RELATIVE_TO_DX_MONTHS	Gray	Glioma (MSK, Clin Cancer Res 2019)	NUMBER	Surgery Date Relative to Dx (Months)	Sample	0 ; 61 ; 4.93 ; 4.54 ; 7.53 ; 5.49 ; 5.69 ; 2.99 ; 4.8 ; 2.83 ; 15.8 ; 64.1 ; 2.14 ; 5.06 ; 9.37 ; 16 ; 19.7 ; 3.35 ; 26.4 ; 1.38 ; 8.98 ; 12.8 ; 16.4 ; 47.5 ; 40 ; 7.82 ; 53.5 ; 6.9 ; 18.6 ; 22.1 ; 8.05 ; 19.2 ; 33.1 ; 29.3 ; 7.63 ; 15.9 ; 43.3 ; 37.9 ; 51.6 ; 13.6 ; 16.8 ; 26.1 ; 20.2 ; 26 ; 58.2 ; 35.3 ; 4.27 ; 49 ; 31.1 ; 5.46 ; 8.58 ; 1.18 ; 25.4 ; 9.44 ; 12 ; 1.02 ; 67.8 ; 5.29 ; 8.25 ; 6.71 ; 0.263 ; 35.7 ; 29.2 ; 4.04 ; 20.1 ; 50.3 ; 4.37 ; 13.8 ; 40.5 ; 23.5 ; 5.13 ; 17.7 ; 2.1 ; 7.43 ; 7.86 ; 15.6 ; 33.8 ; 54.7 ; 9.01 ; 30 ; 337 ; 17.6 ; 8.81 ; 9.9 ; 7.46 ; 35.8 ; 191 ; 6.08 ; 42.5 ; 11.9 ; 85.3 ; 0.493 ; 62.5 ; 50.6 ; 73.6 ; 7.13 ; 64.4 ; 27 ; 95.6 ; 40.1 ; 33.5 ; 242 ; 32.9 ; 3.48 ; 96 ; 41.6 ; 31.4 ; 46 ; 133 ; 138 ; 1.84 ; 47.1 ; 50.2 ; 58.7 ; 21.9 ; 82.8 ; 39.6 ; 38 ; 31.8 ; 68.4 ; 6.81 ; 117 ; 84.5 ; 65.5 ; 44.4 ; 43.5 ; 71.8 ; 69.8 ; 61.5 ; 219 ; 110 ; 75.9 ; 78 ; 99.9 ; 126 ; 24.8 ; 145 ; 63.8 ; 20.5 ; 62.8 ; 21.6 ; 129 ; 7.36 ; 103 ; 128 ; 157 ; 178 ; 14.3 ; 113 ; 140 ; 150 ; 90.4 ; 26.2 ; 11.7 ; 147 ; 166 ; 74.7 ; 108 ; 66.5 ; 36.2 ; 54.8 ; 116 ; 72.3 ; 65.1 ; 50.9 ; 33.9 ; 41.5 ; 31.7 ; 44.2 ; 77.5 ; 88.1 ; 27.4 ; 45.1 ; 109 ; 154 ; 7.07 ; 120 ; 237 ; 144 ; 170 ; 230 ; 11 ; 6.97 ; 48.3 ; 146 ; 2.73 ; 12.9 ; 3.78 ; 7.56 ; 3.62 ; 61.2 ; 75.3 ; 169 ; 171 ; 189 ; 5.98 ; 142 ; 167 ; 61.8 ; 156 ; 93.9 ; 62.6 ; 46.8 ; 80.7 ; 59.9 ; 95.5 ; 9.21 ; 5.52 ; 49.7 ; 21.4 ; 19.8 ; 91.1 ; 1.55 ; 43.2 ; 52 ; 7.92 ; 20.9 ; 10.9 ; 0.986 ; 0.427 ; 6.05 ; 4.5 ; 7.23 ; 10.4 ; 53 ; 29.7 ; 6.38 ; 12.5 ; 20.6
TMZ_HYPERMUTATED	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	TMZ hypermutated	Sample	No ; Yes
TUMOR_SURGERY_NUMBER	Gray	Glioma (MSK, Clin Cancer Res 2019)	NUMBER	Tumor Surgery Number	Sample	1 ; 2 ; 3 ; 4 ; 5 ; 6 ; 7
WHO_CLASSIFICATION_OF_DX_TUMOR	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	WHO classification of diagnostic tumor	Patient	
WHO_GRADE	Gray	Glioma (MSK, Clin Cancer Res 2019)	STRING	WHO Grade	Sample	G4 ; G3/G4 ; Indeterminate ; G3 ; G2 ; G1 ; G1/G2
TISSUE_SITE	Gray	Glioma (MSK, Nature 2019)	STRING	Tissue Site	Sample	
NON_SILENT_MUT_TP53_ATRX_CIC_FUBP1	Gray	Low-Grade Gliomas (UCSF, Science 2014)	STRING	Non-silent mutations in TP53, ATRX, CIC, FUBP1	Sample	TP53, ATRX ; TP53 ; CIC ; ATRX
NOTE	Gray	Low-Grade Gliomas (UCSF, Science 2014)	STRING	Note.	Sample	Patient lost follow up ; WGS for germline, primary and recurrence 1 ; WGS for primary and recurrence 1 ; WGS for primary, recurrence 1, and recurrence 2 ; WGS for germline, and recurrence 1
STATUS_1P_19Q	Gray	Low-Grade Gliomas (UCSF, Science 2014)	STRING	1p/19q Status	Sample	Intact ; 19q deletion ; Co-deletion
ABSOLUTE_EXTRACT_PLOIDY	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	Absolute extract ploidy.	Sample	2 ; 2.05 ; 3.92 ; 1.94 ; 1.97 ; 4.15 ; 1.95 ; 2.03 ; 2.02 ; 4.02 ; 3.39 ; 4.49 ; 2.01 ; 5.69 ; 1.81 ; 3.54 ; 3.62 ; 3.72 ; 1.96 ; 3.9 ; 1.91 ; 3.82 ; 3.8 ; 3.96 ; 3.83 ; 3.98 ; 5.76 ; 3.95 ; 3.65 ; 3.85 ; 3.97 ; 5.71 ; 3.64 ; 3.84 ; 3.69 ; 1.9 ; 2.04 ; 1.79 ; 1.98 ; 1.93 ; 2.07 ; 2.06 ; 4 ; 2.13 ; 2.08 ; 1.99 ; 2.1 ; 3.86 ; 1.92 ; 2.18 ; 4.24 ; 1.88 ; 2.09 ; 1.69 ; 1.89 ; 2.17 ; 4.11 ; 3.87 ; 4.65 ; 4.34 ; 4.06 ; 3.66 ; 5.54 ; 4.08 ; 3.46 ; 3.79 ; 3.28 ; 5.55 ; 2.94 ; 3.76 ; 4.07 ; 1.76 ; 1.85 ; 3.94 ; 2.11 ; 3.93 ; 1.86 ; 3.77 ; 3.59 ; 1.87 ; 3.91 ; 3.81 ; 3.74 ; 3.88 ; 3.68 ; 4.03 ; 8.33 ; 4.2 ; 3.89 ; 4.21 ; 3.75 ; 3.67 ; 1.83 ; 3.53 ; 1.49 ; 3.71 ; 5.75 ; 4.48 ; 3.78 ; 5.65 ; 4.73 ; 4.12 ; 4.1 ; 2.12 ; 1.8 ; 3.73 ; 3.47 ; 4.45 ; 2.41 ; 2.25 ; 3.21 ; 3.31 ; 2.9 ; 3.43 ; 1.51 ; 2.49 ; 6.62 ; 4.05 ; 2.21 ; 2.39 ; 2.14 ; 1.82 ; 3.2 ; 4.04 ; 1.84 ; 3.3 ; 2.16 ; 3.4 ; 2.15 ; 3.24 ; 3.41 ; 2.22 ; 2.24 ; 1.74 ; 1.08 ; 1.7 ; 2.19 ; 3.7 ; 1.14 ; 2.79 ; 3.58 ; 6.12 ; 4.71 ; 5.48 ; 3.99 ; 3.44 ; 3.52 ; 3.6 ; 5.96 ; 1.72 ; 5.82 ; 5.44 ; 3.03 ; 4.88 ; 2.55 ; 5.34 ; 2.71 ; 5.56 ; 3.48 ; 3.55 ; 3.49 ; 1.23 ; 3.13 ; 1.77 ; 4.29 ; 3.37 ; 4.18 ; 2.68 ; 4.01 ; 3.51 ; 6.04 ; 3.61 ; 4.46 ; 3.16 ; 4.13
ATRX_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	ATRX status	Sample	Mutant ; WT
BCR_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	BCR status.	Patient	
BRAF_KIAA1549_FUSION	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	BRAF-KIAA1549 fusion	Sample	WT ; Fusion
BRAF_V600E_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	BRAF V600E status	Sample	WT ; Mutant
CHR_19_20_CO_GAIN	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Chr 19/20 co-gain	Sample	No chr 19/20 gain ; Gain chr 19/20
CHR_7_GAIN_CHR_10_LOSS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Chr 7 gain/Chr 10 loss	Sample	No combined CNA ; Gain chr 7 & loss chr 10
DAXX_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	DAXX status	Sample	WT ; Mutant
ESTIMATE_COMBINED_SCORE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	ESTIMATE Score by ESTIMATE	Sample	1226.9936 ; 2990.1048 ; 2639.768 ; 1279.4188 ; 1983.1265 ; -100.8105 ; 1799.0866 ; -471.4155 ; 946.0665 ; 1073.3194 ; 2112.6072 ; 901.84028 ; 2623.971 ; 3729.502 ; 4435.957 ; 2249.016 ; 1479.2782 ; -925.3691 ; -832.8739 ; -194.0309 ; 2025.9087 ; 2994.795 ; 2304.157 ; 556.2211 ; 3081.247 ; 723.8668 ; 549.7397 ; 793.3525 ; 890.168 ; 1190.2612 ; -118.00316 ; 1711.2059 ; 235.8356 ; 1378.8384 ; 387.8663 ; 243.24672 ; 1552.934 ; -1373.958 ; -373.0203 ; 357.9937 ; 1370.5554 ; 1236.4608 ; -382.8812 ; -817.0818 ; 3120.345 ; 382.63535 ; 3238.968 ; -1669.9597 ; 507.3837 ; 2130.2086 ; 1089.2742 ; 1472.2293 ; 2387.8885 ; 1880.7146 ; 944.1078 ; 1263.811 ; 3593.656 ; 1429.6527 ; -59.66842 ; 1353.7889 ; 2793.5466 ; 2172.0164 ; 20.866195 ; 105.6488 ; 537.5994 ; 1564.3596 ; 778.2436 ; 1330.6869 ; 3224.2964 ; 595.8057 ; 947.2613 ; 3218.889 ; 2534.8862 ; 3624.885 ; 2203.1418 ; 1315.0731 ; 1448.131 ; 2579.287 ; -355.2521 ; 2634.216 ; -559.7887 ; 380.26157 ; 1283.1211 ; 4334.423 ; 1181.2073 ; 2347.8445 ; -276.33739 ; 2337.565 ; 3593.708 ; 1995.8309 ; 1625.6502 ; 1362.760648 ; 1966.7948 ; 922.1509 ; 1268.2724 ; -1317.5259 ; 2402.2724 ; 3551.828 ; 3619.066 ; -362.18305 ; -679.947 ; 1284.8621 ; 3797.941 ; 5203.959 ; 1644.3595 ; 1647.9075 ; 2454.5713 ; -373.61682 ; 2199.831 ; 3475.347 ; 625.9425 ; -47.58576 ; 929.1991 ; 1347.7797 ; 1204.3287 ; 2832.013 ; -649.4052 ; 2009.2949 ; 1844.3927 ; 1173.8353 ; 3443.62 ; 3717.547 ; 922.1706 ; 2447.4023 ; -804.7128 ; 3285.332 ; 929.9739 ; 2751.904 ; -809.5958 ; 3352.9318 ; 4632.244 ; 1209.831 ; 1490.4147 ; 2952.3927 ; 172.828223 ; 4137.605 ; -251.3638 ; -609.16885 ; -911.3642 ; 1459.0531 ; -322.3705 ; -173.8874 ; 4314.949 ; 2465.377 ; 506.243 ; 770.83492 ; 2457.615 ; 2107.8187 ; 401.80142 ; -139.70243 ; 3490.245 ; 940.39 ; 1882.1906 ; 1949.4538 ; 2265.9991 ; 3210.828 ; -909.6883 ; 1154.4231 ; 551.58206 ; -403.97299 ; 1042.5654 ; 1536.7584 ; 2117.6826 ; 807.566193 ; 3651.148 ; 1104.733 ; 617.7357 ; 2681.5233 ; 4019.639 ; 3435.796 ; 769.5348 ; 5800.798 ; -113.8472 ; 4649.987 ; -1140.0049 ; 637.3975 ; 71.86303 ; 1129.8944 ; 372.3226 ; -82.441099 ; 1668.301 ; 1415.6428 ; 847.0045 ; -830.8362 ; -932.4061 ; -497.6077 ; 126.93618 ; 4125.638 ; 2101.7867 ; 1795.2322 ; 3011.1173 ; 1546.9742 ; 1655.6867 ; 2848.9016 ; 2347.5052 ; 3126.492 ; 592.207367 ; 643.262 ; 620.8729 ; -1241.8954 ; 1051.4971 ; 488.94692 ; 1577.67 ; 490.2538 ; 1835.4621 ; 854.7066 ; 1451.9265 ; -909.9052 ; 1946.763 ; 308.9997 ; 3687.296 ; 1483.0844 ; 708.7329 ; 1135.025 ; 1333.4143 ; 267.61555 ; 2500.8576 ; 479.98228 ; 1423.376 ; 4246.149 ; 2048.0075 ; 3182.377 ; 2540.9888 ; 54.42529 ; 67.20597 ; 285.2885 ; 3768.818 ; 3761.262 ; 590.9217 ; 468.0291 ; 766.9814 ; 866.0183 ; 2302.8635 ; 2375.6591 ; 3426.9914 ; 435.4601 ; -649.2373 ; 2025.8563 ; 1028.0359 ; 4117.178 ; 2594.617 ; -168.304185 ; -41.0483 ; 2193.1899 ; 1366.4423 ; 1020.8196 ; 4439.505 ; 1671.816 ; -402.43787 ; 445.13219 ; 296.79714 ; 502.8283 ; 826.9125 ; 1397.5684 ; 1529.7625 ; -149.2858 ; 1850.4595 ; 3653.459 ; 888.6467 ; 2227.7085 ; 311.53373 ; 2662.3481 ; 1052.9588 ; 2373.55 ; 3594.822 ; 908.4978 ; -347.30018 ; 1145.8547 ; 3335.225 ; 3160.728 ; 181.5363 ; 2307.187 ; -565.26794 ; -265.07405 ; 2872.3615 ; 818.5055 ; -27.96094 ; 6715.326 ; 2768.211 ; 2677.2272 ; 865.0229 ; -134.5348 ; -496.56473 ; -57.39142 ; 1621.102 ; 634.0664 ; -673.95765 ; 7626.793 ; -68.19016 ; 842.2428 ; 993.1139 ; 859.1499 ; 370.3969 ; 3253.3828 ; 1943.1094 ; 3620.073 ; -318.49666 ; 1952.9013 ; 452.8641 ; 6870.153 ; 235.8324 ; 2047.7749 ; 475.4253 ; 3740.5973 ; 2154.2242 ; -575.43479 ; 3339.962 ; -414.1817 ; 6130.298 ; 1651.6505 ; 2834.7588 ; 1010.3727 ; 2486.4642 ; 463.2874 ; 119.48878 ; 2599.949 ; -164.3883 ; 2070.6911 ; 937.3164 ; 1932.0676 ; 108.83425 ; 3392.874 ; 3446.6627 ; -577.2774 ; 3596.6463 ; 2430.0918 ; 2750.974 ; 870.7084 ; 2199.0441 ; 595.8964 ; 3638.108 ; 1295.4446 ; -570.4137 ; 429.131 ; 2032.678 ; -111.291745 ; 2165.3642 ; -128.5496 ; 371.96962 ; 1339.2818 ; 1595.3229 ; 487.469 ; -4.902851 ; 3499.82 ; 1147.6704 ; 4688.717 ; 307.6184 ; 548.0627 ; 359.89888 ; 1017.5752 ; -440.66313 ; 3207.573 ; 1077.9341 ; 1240.0811 ; 4266.136 ; 1440.7595 ; 2340.3267 ; -1140.7908 ; 2087.4514 ; -118.74518 ; -100.4198 ; 1483.3668 ; 4219.963 ; 848.35165 ; 1898.4707 ; -730.7877 ; 841.1562 ; 1875.2543 ; 394.5097 ; 249.5462 ; 3505.437 ; 134.13629 ; -377.82086 ; -863.4801 ; 2006.818 ; 408.9813 ; 116.76332 ; 1463.6913 ; 711.2827 ; 1867.9918 ; -244.89562 ; 1675.5137 ; 2487.4804 ; 1840.662 ; 2589.3198 ; -58.95553 ; -796.3221 ; 906.1492 ; -290.783734 ; 357.9584 ; 373.64993 ; -49.39886 ; 944.0002 ; 1318.7291 ; 21.23285 ; 98.10681 ; 155.4347 ; -345.52664 ; 1064.4531 ; 446.0325 ; -636.9353 ; -242.92733 ; 1019.4718 ; 663.4334 ; -430.2131 ; 617.0798 ; 205.7318 ; 1445.5584 ; 1367.4081 ; 2502.738 ; 4033.237 ; 1468.4913 ; 731.963 ; -1409.77 ; 1542.0505 ; 4737.798 ; 1102.1535 ; 1024.6929 ; 1717.893 ; 410.442 ; 1756.361 ; 3405.677 ; 5130.565 ; -902.3931 ; -588.8206 ; 331.2419 ; 4358.183 ; -410.8304 ; -116.5545 ; 930.55049 ; 1867.2739 ; 3775.309 ; 1383.2752 ; 1549.9793 ; 2170.8657 ; -919.6504 ; 1042.0082 ; 2908.474 ; 1786.0181 ; 1451.6783 ; -9.018713 ; 748.1585 ; -262.55633 ; 658.0873 ; -778.5948 ; 1353.8486 ; -171.2771 ; -786.9655 ; -510.0003 ; 3111.6446 ; 1739.1837 ; 2880.519 ; 4088.395 ; 1739.0094 ; 1391.0886 ; 3408.063 ; 1120.5515 ; -411.2922 ; -52.73952 ; -113.78019 ; -524.4064 ; 549.0549 ; 2557.409 ; 3926.304 ; -856.2614 ; -94.83099 ; 559.5625 ; 421.5598 ; 2342.4184 ; -839.3983 ; 1110.0286 ; 2214.0408 ; -327.9827 ; 841.04 ; 1180.6907 ; 842.19249 ; 831.9775 ; 1975.0366 ; 436.1706 ; 1370.2345 ; 91.04053 ; -622.1889 ; -156.77316 ; 63.0844 ; 2123.6562 ; -1026.461 ; 1505.6078 ; -378.91388 ; -143.45188 ; 232.4311 ; 2574.4344 ; 232.43778 ; 1057.8797 ; 4522.041 ; 2205.469 ; -801.1665 ; 2679.758 ; 980.1369 ; 3158.353 ; 2160.4278 ; 1187.3541 ; 1488.1761 ; -266.104509 ; 1947.0463 ; -639.2461 ; 1357.1696 ; 3940.015 ; -705.4771 ; 614.3609 ; 2079.8634 ; 1070.6975 ; 1041.6264 ; -483.0623 ; 3824.016 ; 6748.518 ; 3264.993 ; 1912.6479 ; 5076.035 ; 1611.6301 ; 2689.905 ; 7400.577 ; 5939.523 ; 4502.505 ; 5861.987 ; 3897.975 ; 3467.901 ; 3466.257 ; 4796.915 ; 1745.493 ; 3289.367 ; 5267.756 ; 3724.279 ; 5695.265 ; 4015.014 ; 2231.2348 ; 3213.136 ; 3524.249 ; 5456.386 ; 6331.065 ; 3915.05 ; 4613.529 ; 2611.381 ; 2798.0918 ; 2320.0326 ; 3643.139 ; 1268.4401 ; 3477.2366 ; 4732.342 ; 4045.857 ; 4371.502 ; 2107.7063 ; 5073.506 ; 3007.183 ; 2544.571 ; 3740.253 ; 3673.726 ; 2813.979 ; 3193.428 ; 2259.27 ; 3985.093 ; 1627.7431 ; 3455.585 ; 2300.0472 ; 7521.694 ; 2952.14 ; 6079.506 ; 4611.28 ; 3789.02 ; 1951.3007 ; 329.7489 ; 768.5984 ; 3316.518 ; 3243.513 ; 3396.791 ; 2984.9572 ; 1432.9988 ; 2518.1315 ; 806.9722 ; 4402.331 ; 1736.8018 ; 2479.684 ; 2205.0534 ; 1421.9455 ; 2747.3444 ; 3784.305 ; 3184.067 ; 4858.139 ; 2792.988 ; 4954.241 ; 1220.0818 ; 5140.777 ; 816.8375 ; 3952.609 ; 4486.26 ; 1100.2115 ; 4377.107 ; 3680.592 ; 1204.3061 ; 3618.977 ; 3553.324 ; 5916.095 ; 762.453 ; 3157.7801 ; 1784.5344 ; 2844.957 ; 409.4175 ; 2287.6575 ; 3429.877 ; 4974.17 ; -61.16922 ; 1700.828 ; 2659.0789 ; 1460.2451 ; 1872.3252 ; 3832.379 ; 3767.882 ; 3076.225 ; 4188.712 ; 4235.353 ; 4638.328 ; 3493.239 ; 1291.6287 ; 2999.49 ; 4341.051 ; 1213.1281 ; 1352.0894 ; 4128.518 ; 3049.6684 ; 2208.7982 ; 3424.4616 ; 5403.599 ; 2295.7425 ; 2628.176 ; 2549.4708 ; 5728.667 ; 2123.5143 ; 2667.2026 ; 3042.159 ; 3093.284 ; 2203.476 ; 6227.634 ; 4285.8 ; 3112.95 ; 6407.015 ; 2344.3799 ; 2030.3331 ; 5042.433 ; 4913.765 ; 3835.339 ; 2538.4334 ; 4657.188 ; 1716.2844 ; 4584.927 ; 5711.147 ; 3952.02 ; 1746.8644 ; 3374.627 ; 4902.932 ; 4607.52 ; 872.6431 ; 1393.8612 ; 1644.4224 ; 4183.658 ; 3652.671 ; 2222.977 ; 1187.0872 ; 2179.1498
HM27	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	HM27	Sample	No ; Yes
HM450	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	HM450	Sample	Yes ; No
IDH_1P19Q_SUBTYPE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	IDH-1P10Q subtype.	Sample	Non-codel ; Codel ; 1p deleted ; Co-deleted ; Not deleted
IDH_CODEL_SUBTYPE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	IDH/codel subtype	Sample ; Patient	IDHmut-non-codel ; IDHwt ; IDHmut-codel
IDH_SPECIFIC_DNA_METHYLATION_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	IDH-specific DNA Methylation Cluster	Sample	IDHmut-K2 ; IDHwt-K2 ; IDHmut-K3 ; IDHwt-K1 ; IDHmut-K1 ; IDHwt-K3
IDH_SPECIFIC_RNA_EXPRESSION_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	IDH-specific RNA Expression Cluster	Sample	IDHmut-R3 ; IDHwt-R2 ; IDHmut-R1 ; IDHwt-R4 ; IDHwt-R3 ; IDHmut-R2 ; IDHwt-R1
IDH_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	IDH status	Sample ; Patient	Mutant ; WT ; IDHwt ; IDHmut
MGMT_PROMOTER_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	MGMT promoter status	Sample	Unmethylated ; Methylated
ORIGINAL_SUBTYPE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Original Subtype	Sample	IDHmut-non-codel ; IDHwt ; IDHmut-codel ; Classical ; Proneural ; Mesenchymal ; G-CIMP ; Neural
PAN_GLIOMA_DNA_METHYLATION_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Pan-Glioma DNA Methylation Cluster	Sample	LGm2 ; LGm5 ; LGm3 ; LGm4 ; LGm1 ; LGm6
PAN_GLIOMA_RNA_EXPRESSION_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Pan-Glioma RNA Expression Cluster	Sample	LGr3 ; LGr4 ; LGr1 ; LGr2 ; unclassified
PERCENT_ANEUPLOIDY	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	Percent aneuploidy	Sample	0.069411737 ; 0.224149226 ; 0.093693446 ; 0.172371054 ; 0.060307007 ; 0.051144394 ; 0.057785896 ; 0.046938447 ; 0.186123148 ; 0.179512208 ; 0.285381623 ; 0.151773246 ; 0.140632184 ; 0.013278287 ; 0.524813675 ; 0.403165128 ; 0.066712803 ; 0.114883345 ; 9.89E-06 ; 0.05993084 ; 0.061381977 ; 0.017349195 ; 0.234427033 ; 0.206946718 ; 0.00302201 ; 0.821252896 ; 0.051077676 ; 0.945943231 ; 0.028538352 ; 0.311681897 ; 0.095740577 ; 0.1442725 ; 0.051164527 ; 0.02248508 ; 0.245379721 ; 0.204487967 ; 0.063460281 ; 0.088152361 ; 0.051102987 ; 8.71E-06 ; 0.051764185 ; 0.07717302 ; 0.123656217 ; 0.08311908 ; 0.062290168 ; 0.11468665 ; 0.015790069 ; 0.096711279 ; 0.048291631 ; 0.231272091 ; 0.051579709 ; 0.112075218 ; 1.63E-05 ; 0.05582584 ; 0.571285717 ; 0.287854893 ; 0.192947518 ; 0.051070531 ; 0.157254978 ; 0.096090229 ; 0.061169695 ; 0.204840295 ; 0.116777692 ; 0.080396345 ; 0.202337721 ; 0.104560727 ; 0.064121426 ; 0.161024593 ; 0.097621782 ; 0.165181706 ; 0.101937655 ; 0.125972025 ; 0.185353191 ; 0.045576569 ; 0.066341965 ; 0.146773116 ; 0.163412101 ; 0.051322041 ; 0.095827341 ; 0.16834851 ; 0.14039477 ; 0.144615258 ; 0.293727337 ; 0.165351565 ; 0.157723154 ; 0.122333932 ; 0.117890848 ; 0.137197864 ; 0.146686205 ; 0.274907624 ; 0.160242254 ; 0.165761568 ; 0.154079856 ; 0.208149912 ; 0.346159536 ; 0.107814398 ; 0.092996777 ; 0.635907935 ; 0.000335566 ; 0.199718345 ; 0.212238798 ; 0.197249797 ; 0.141449197 ; 0.167952524 ; 0.049749911 ; 0.200587829 ; 0.121583533 ; 0.115885826 ; 0.200874945 ; 0.075350198 ; 0.080147627 ; 0.113304684 ; 0.135109975 ; 0.229171051 ; 0.103648078 ; 0.070012526 ; 0.41489159 ; 0.263951081 ; 0.009521402 ; 0.054421461 ; 0.05274221 ; 0.498608812 ; 0.086435503 ; 0.183695412 ; 0.185805222 ; 0.026880922 ; 0.098120223 ; 0.215247227 ; 0.270027306 ; 0.225325218 ; 0.138419013 ; 0.243985673 ; 0.051743821 ; 0.116043461 ; 0.124344838 ; 0.144639486 ; 0.798688381 ; 0.217007761 ; 0.162556867 ; 0.090321929 ; 0.424752984 ; 0.24976636 ; 0.140785716 ; 0.325515813 ; 0.038380938 ; 0.119565542 ; 0.154101463 ; 0.010258559 ; 0.066014053 ; 0.175996709 ; 0.186385129 ; 0.092286768 ; 0.656226846 ; 0.158418253 ; 0.170623284 ; 0.190924835 ; 0.071555237 ; 0.060609253 ; 0.155850991 ; 0.557405362 ; 0.211787788 ; 0.026134886 ; 0.172742641 ; 0.161861176 ; 0.127001877 ; 0.224175989 ; 0.160078039 ; 0.148040382 ; 0.051081999 ; 0.680271039 ; 0.935998526 ; 0.040411492 ; 0.316144333 ; 0.06234041 ; 9.73E-05 ; 0.194998589 ; 0.02428067 ; 0.094743361 ; 0.025972375 ; 0.216241234 ; 0.116113083 ; 0.116101742 ; 0.515323259 ; 0.517422121 ; 0.175968796 ; 0.152515243 ; 0.137086653 ; 0.064967003 ; 0.041886615 ; 0.09317283 ; 0.142016101 ; 0.335227523 ; 0.118608363 ; 0.086050656 ; 0.051242594 ; 0.084861034 ; 0.150950432 ; 6.98E-06 ; 0.019481437 ; 0.094821225 ; 0.074928694 ; 0.051142256 ; 0.060252057 ; 6.08E-06 ; 0.019876338 ; 0.09769253 ; 0.147986975 ; 0.168027552 ; 0.033809253 ; 0.22501935 ; 0.053945413 ; 0.051601311 ; 0.107994241 ; 0.15028742 ; 0.116968339 ; 0.505741665 ; 0.053308179 ; 0.143534597 ; 0.051734004 ; 0.062512465 ; 0.069264551 ; 0.072818582 ; 0.196470908 ; 0.021220731 ; 0.051687749 ; 0.1004457 ; 0.615851639 ; 0.096925407 ; 0.293039192 ; 0.021373522 ; 0.14666407 ; 0.063653869 ; 0.184557275 ; 0.212684814 ; 0.681390542 ; 0.086454705 ; 0.065196266 ; 0.078841925 ; 0.051685647 ; 0.111670625 ; 0.042597054 ; 0.013419587 ; 0.045283081 ; 0.000677618 ; 0.038147897 ; 0.081549376 ; 0.051674959 ; 0.285139555 ; 0.084382454 ; 0.051573926 ; 0.076216624 ; 0.040327137 ; 0.049030322 ; 0.141555587 ; 0.054353679 ; 0.025472974 ; 0.069098926 ; 4.78E-05 ; 0.06121353 ; 0.046140657 ; 0.111740994 ; 0.051678318 ; 0.332887683 ; 0.206937714 ; 0.113557504 ; 0.000794934 ; 0.813885049 ; 0.095301714 ; 0.051718379 ; 0.051031853 ; 0.000443653 ; 0.114856682 ; 0.131429491 ; 0.081956696 ; 0.016324723 ; 0.171275527 ; 0.121010881 ; 0.051563186 ; 0.056738938 ; 0.051028281 ; 0.09092968 ; 5.52E-06 ; 0.062554565 ; 0.143116155 ; 0.077589273 ; 0.061109954 ; 0.061200044 ; 0.182032112 ; 0.078849057 ; 0.146852272 ; 0.00022608 ; 0.045596195 ; 2.47E-05 ; 0.192116008 ; 0.051046259 ; 0.011236364 ; 0.000114912 ; 0.078899239 ; 0.056155754 ; 0.139576987 ; 0.04192296 ; 0.000219956 ; 0.054121194 ; 9.61E-06 ; 0.173855384 ; 0.71791584 ; 0.453851717 ; 0.053485585 ; 0.166706894 ; 0.170497979 ; 0.176037395 ; 0.030380511 ; 0.153035493 ; 0.111606586 ; 0.087655604 ; 0.096253694 ; 0.27192458 ; 0.207254674 ; 0.398900628 ; 0.273603335 ; 0.173702651 ; 0.182266266 ; 0.121027822 ; 0.191043477 ; 0.113327617 ; 0.124899428 ; 0.05102588 ; 0.115936384 ; 0.055161054 ; 0.045930152 ; 0.793083469 ; 0.021753312 ; 0.07838109 ; 0.089108122 ; 0.012363122 ; 0.111236242 ; 0.095251982 ; 0.592213448 ; 0.145369293 ; 0.116137358 ; 0.130743667 ; 0.94152744 ; 0.109116058 ; 0.106566657 ; 0.077460192 ; 0.107962707 ; 0.200138245 ; 0.947727817 ; 0.151979395 ; 0.234237275 ; 0.015630592 ; 0.14650225 ; 0.051710168 ; 0.048414204 ; 0.096148776 ; 0.030449278 ; 0.025037894 ; 0.159786595 ; 0.248668103 ; 0.092974385 ; 0.268680193 ; 0.063571302 ; 0.077596028 ; 0.203741253 ; 0.051166176 ; 0.097244003 ; 0.084857942 ; 0.252224894 ; 0.078494406 ; 0.483567114 ; 0.027403936 ; 0.135368771 ; 0.084864363 ; 0.147335219 ; 0.035574972 ; 0.125484244 ; 0.051051571 ; 0.111957119 ; 0.088688259 ; 0.027967542 ; 0.144971914 ; 0.051615243 ; 0.084639632 ; 0.064072395 ; 0.051661512 ; 0.051719419 ; 0.084126158 ; 0.080049059 ; 0.094564308 ; 0.051112385 ; 0.481405024 ; 0.116932649 ; 2.90E-05 ; 0.055566103 ; 0.072512451 ; 0.18057603 ; 0.00773354 ; 0.127291493 ; 0.228156338 ; 0.087623643 ; 0.201484614 ; 0.064665464 ; 0.112146975 ; 0.027562355 ; 0.078020866 ; 0.051559708 ; 0.037587786 ; 2.44E-05 ; 0.052151901 ; 0.092071643 ; 0.07885906 ; 0.151559989 ; 0.05177428 ; 0.03095134 ; 0.200727387 ; 6.44E-06 ; 0.181996179 ; 0.546311489 ; 0.084396756 ; 0.081271179 ; 0.117547722 ; 0.053627981 ; 0.115555544 ; 0.15322937 ; 0.250674789 ; 0.051094188 ; 0.182389044 ; 0.287108414 ; 0.059811569 ; 0.051077223 ; 0.084893707 ; 0.168088017 ; 0.113471879 ; 0.191986992 ; 0.078014839 ; 0.161525604 ; 0.146151008 ; 0.062372911 ; 0.002433157 ; 0.091200692 ; 0.096570425 ; 0.084641472 ; 0.216153571 ; 0.257747962 ; 0.092555588 ; 0.14286196 ; 0.0570482 ; 0.106384249 ; 0.204121994 ; 7.96E-06 ; 0.048662183 ; 0.099367487 ; 0.209591127 ; 0.345452859 ; 0.153144192 ; 0.039653472 ; 0.115725642 ; 0.051036109 ; 0.16947204 ; 0.085319165 ; 0.083867719 ; 0.052406226 ; 0.100654865 ; 0.051581078 ; 0.241858648 ; 0.131769403 ; 0.065425568 ; 0.074577442 ; 0.357320859 ; 0.098591377 ; 0.078560585 ; 0.161085398 ; 0.102237 ; 0.194818311 ; 0.053081364 ; 0.118344795 ; 0.065648881 ; 0.15360983 ; 0.130375593 ; 0.314365509 ; 0.062702728 ; 0.432549579 ; 0.109335389 ; 0.217355836 ; 0.051580303 ; 0.361330062 ; 0.017143189 ; 0.1311745 ; 0.127757066 ; 0.086236429 ; 0.107532583 ; 0.062593112 ; 0.161447534 ; 0.120068227 ; 0.204846542 ; 0.063879594 ; 0.164998317 ; 0.052710092 ; 0.067446893 ; 0.175593812 ; 0.4249 ; 0.147988208 ; 0.117881415 ; 0.239054564 ; 0.257453671 ; 0.159619337 ; 0.2131371 ; 0.61314995 ; 0.210571425 ; 0.172790476 ; 0.213670085 ; 0.174349346 ; 0.186982904 ; 0.336508382 ; 0.215985841 ; 0.159871113 ; 0.161795767 ; 0.208086201 ; 0.16427307 ; 0.188533504 ; 0.179284592 ; 0.181728213 ; 0.17468023 ; 0.103762974 ; 0.083556744 ; 0.258624099 ; 0.423659392 ; 0.13178753 ; 0.205529853 ; 0.325988625 ; 0.152110179 ; 0.12729265 ; 0.222514926 ; 0.172465249 ; 0.150757476 ; 0.501569352 ; 0.169481762 ; 0.141049303 ; 0.577797439 ; 0.351285024 ; 0.32378597 ; 0.086282305 ; 0.130291135 ; 0.170216818 ; 0.118050127 ; 0.411167139 ; 0.132101681 ; 0.158100848 ; 0.27033195 ; 0.132941763 ; 0.243684428 ; 0.630923266 ; 0.130448583 ; 0.195704766 ; 0.825841217 ; 0.16085076 ; 0.227486409 ; 0.192866067 ; 0.214891735 ; 0.12283837 ; 0.740134054 ; 0.229584167 ; 0.132488542 ; 0.50640838 ; 0.184181344 ; 0.167714096 ; 0.153100846 ; 0.137991654 ; 0.190455336 ; 0.37468282 ; 0.37558445 ; 0.070870903 ; 0.392556534 ; 0.326992304 ; 0.200400412 ; 0.13822956 ; 0.021881454 ; 0.11696737 ; 0.137207042 ; 0.18278246 ; 0.167607547 ; 0.170119694 ; 0.149924943 ; 0.193478742 ; 0.218283143 ; 0.261013476 ; 0.568422516 ; 0.114035451 ; 0.295886312 ; 0.188306195 ; 0.204362823 ; 0.151734048 ; 0.197177695 ; 0.176404315 ; 0.152158906 ; 0.165720659 ; 0.101566118 ; 0.244674062 ; 0.17797196 ; 0.286963169 ; 0.274399282 ; 0.172705803 ; 0.182235863 ; 2.12E-05 ; 0.164336194 ; 0.04743409 ; 0.001318189 ; 0.133053702 ; 0.149645328 ; 0.132166913 ; 0.144901546 ; 0.156514368 ; 0.183940558 ; 0.173628169 ; 0.723186271 ; 0.349369074 ; 0.147727858 ; 0.130333467 ; 0.150093889 ; 0.20354741 ; 0.386795004 ; 0.242574937 ; 0.488051751 ; 0.260023175 ; 0.130610833 ; 0.189859392 ; 0.177899353 ; 0.133599512 ; 0.259767587 ; 0.086830428 ; 0.588146746 ; 0.203393087 ; 0.143054316 ; 0.284326077 ; 0.228398313 ; 0.18099369 ; 0.465363198 ; 0.169736285 ; 0.244174274 ; 0.141439542 ; 0.540978071 ; 0.191535226 ; 0.155120185 ; 0.257132198 ; 0.138575889 ; 0.492234921 ; 0.195671353 ; 0.210388757 ; 0.16261596 ; 0.210430269 ; 0.622491835 ; 0.174584443 ; 0.422394089 ; 0.168375025 ; 0.170176032 ; 0.142822245 ; 0.180393426 ; 0.214858787 ; 0.462606187 ; 0.646421503 ; 0.162830795 ; 0.169777944 ; 0.629451537 ; 0.258865193 ; 0.202674785 ; 0.16505126 ; 0.198242568 ; 0.363515159 ; 0.066031814 ; 0.277582116 ; 0.227806301 ; 0.201932279 ; 0.229790148 ; 0.167392329 ; 0.156272024 ; 0.192514986 ; 0.275076834 ; 0.135976295 ; 0.275943701 ; 0.216829064 ; 0.217713573 ; 0.001109495 ; 0.166447943 ; 0.135197707 ; 0.290081703 ; 0.374190869 ; 0.643497305 ; 0.244381189 ; 0.154246467 ; 0.202966942 ; 0.163400697 ; 0.101999934 ; 0.197371883 ; 0.272115087 ; 0.216156403 ; 0.121609081 ; 0.309676446 ; 0.198867899 ; 0.169662868 ; 0.112195636 ; 0.140426778 ; 0.081574215 ; 0.176738054 ; 0.547758171 ; 0.093933249 ; 0.241895201 ; 6.78E-06 ; 0.142673699 ; 0.185223161 ; 0.179870104 ; 0.186463606 ; 0.255676829 ; 0.368235445 ; 0.165795038 ; 0.769065386 ; 0.079989319 ; 0.904751684 ; 0.165581809 ; 0.281167919 ; 0.245692181 ; 0.104278875 ; 0.428330416 ; 0.402011458 ; 0.171501162 ; 0.204752269 ; 0.274207541 ; 0.164502937 ; 0.116694689 ; 0.049813562 ; 0.235417973 ; 0.323404042 ; 0.198857045 ; 0.261902058 ; 0.194409622 ; 0.185548472 ; 0.186569053 ; 0.868043945 ; 0.556355107 ; 0.061456543 ; 0.175524431 ; 0.254631672 ; 0.150056258 ; 0.170365904 ; 0.254657044 ; 0.202727258 ; 0.111350115 ; 0.157783945 ; 0.138374621 ; 0.164389759 ; 0.22860422 ; 0.15538647 ; 0.144824346 ; 0.172020946 ; 0.179683374 ; 0.217186683 ; 0.191330969 ; 0.198221793 ; 0.173986381 ; 0.116420945 ; 0.561115192 ; 0.151979726 ; 0.156500565 ; 0.196879907 ; 0.168880099 ; 0.527822574 ; 0.148517489 ; 0.192857962 ; 0.202472215 ; 0.47929938 ; 0.457128641 ; 0.184121542 ; 0.327383841 ; 0.046589895 ; 0.207668481 ; 0.12258477 ; 0.336290479 ; 0.153048156 ; 0.289670568 ; 0.322119041 ; 0.182483735 ; 0.168421176 ; 0.507591755 ; 0.166341941 ; 0.154255814 ; 0.223673335 ; 0.174356785 ; 0.143040216 ; 0.249944659 ; 0.202934445 ; 0.14545233 ; 0.387336709 ; 0.189063194 ; 0.151055098 ; 0.211734694 ; 0.168386428 ; 0.217360017 ; 0.135431748 ; 0.140677769 ; 0.306089874 ; 0.356585944 ; 0.183870962 ; 0.223081131 ; 0.286425102 ; 0.152609674 ; 0.382560133 ; 0.224374945 ; 0.351100495 ; 0.32811468 ; 0.105779699 ; 0.187500633 ; 0.306672054 ; 0.14096923 ; 0.091157962 ; 0.643113253 ; 0.278704666 ; 0.256797853 ; 0.180554552 ; 0.172858619 ; 0.220838059 ; 0.18379003 ; 0.281655333 ; 0.550375789 ; 0.220611869 ; 0.586633002 ; 0.137387117 ; 0.262568428 ; 0.11538992 ; 0.599429317 ; 0.25883302 ; 0.683609195 ; 0.160233933 ; 0.175754301 ; 0.129701282 ; 0.206631609 ; 0.17497295 ; 0.947695708 ; 0.246806056 ; 0.163054098 ; 0.148013444 ; 0.606172801 ; 0.841697659 ; 0.102132073 ; 0.35520517 ; 0.143413771 ; 0.203901133 ; 0.126184229 ; 0.172084782 ; 0.16729891 ; 0.305402102 ; 0.477485331 ; 0.703918944 ; 0.869239921 ; 0.146840987 ; 0.496511724 ; 0.669174283 ; 0.534244575 ; 0.162172914 ; 0.121256024 ; 0.176134855 ; 0.272092687 ; 0.109010713 ; 0.142630301 ; 0.188177934 ; 0.187310011 ; 0.176744651 ; 0.794209308 ; 0.40312755 ; 0.189269284 ; 0.094413818 ; 0.224230767 ; 0.123323838 ; 0.308268667 ; 0.102711336 ; 0.229210431 ; 0.828086067 ; 0.281381991 ; 0.142255781 ; 0.200083194 ; 0.213501283 ; 0.145267421 ; 0.219657182 ; 0.714792357 ; 0.162790795 ; 0.26642733 ; 0.099363182 ; 0.111599767 ; 0.886113503 ; 0.442605303 ; 0.333309852 ; 0.219372257 ; 0.104026295 ; 0.817702328 ; 0.192682318 ; 0.284026483 ; 0.174285204 ; 0.195310348 ; 0.157663857 ; 0.124122437 ; 0.138428554 ; 0.146229777 ; 0.174826338 ; 0.046893359 ; 0.212572681 ; 0.172372959 ; 0.203643836 ; 0.181218061 ; 0.145376738 ; 0.078224075 ; 0.133807492 ; 0.164006767 ; 0.181533688 ; 0.643790562 ; 0.190433981 ; 0.631137131 ; 0.585175401 ; 0.417559845 ; 0.723473074 ; 0.03959398 ; 0.106846095 ; 0.143401591 ; 0.177661548 ; 0.208152425 ; 0.175117551 ; 0.105118372 ; 0.288493697 ; 0.10726244 ; 0.23567947 ; 0.758477282 ; 0.144038405 ; 0.453824885 ; 0.162918165 ; 0.313517313 ; 0.159672104 ; 0.096855987 ; 0.162568673 ; 0.179422605 ; 0.140281359 ; 0.18395126 ; 0.219465044 ; 0.146258946 ; 0.146812241 ; 0.84795021 ; 0.179032029 ; 0.624275072 ; 0.231558961 ; 0.15488567 ; 0.548296949 ; 0.284121832 ; 0.076337064 ; 0.123102689 ; 0.13032592 ; 0.170621352 ; 0.864103045 ; 0.080263834 ; 0.107627899 ; 0.279971279 ; 0.129631816 ; 0.273633015 ; 0.121408754 ; 0.119778643 ; 0.235925875 ; 0.097699129 ; 0.237215055 ; 0.186490029 ; 0.503949341 ; 0.19472078 ; 0.068224021 ; 0.10264776 ; 0.202989385 ; 0.127730234 ; 0.239724368 ; 0.358065325 ; 0.127960297 ; 0.374413371 ; 0.181626771 ; 0.124823249 ; 0.113233665 ; 0.001924079 ; 0.192401882 ; 0.109159449 ; 0.150582375 ; 0.43127603 ; 0.184341823 ; 0.196510266 ; 0.12714407 ; 0.120466312 ; 0.139873021 ; 0.149217497 ; 0.232494766 ; 0.157789257 ; 0.178363075 ; 0.613391597 ; 0.636623197 ; 0.198652607 ; 0.155055459 ; 0.412023486 ; 0.325648469 ; 0.229607704 ; 0.118701325 ; 0.224077869 ; 0.129703418 ; 0.24009534 ; 0.161778528 ; 0.446407974 ; 0.437866174 ; 0.700762806 ; 0.291372846 ; 0.626100169 ; 0.16587896 ; 0.260215363 ; 0.54739289 ; 0.330457885 ; 0.161754455 ; 0.351036234 ; 0.153694168 ; 1.97E-05 ; 0.131541288 ; 0.16001396 ; 0.282873113 ; 0.116688222 ; 0.199553403 ; 0.166463047 ; 0.295488143 ; 0.942848846 ; 0.560052679 ; 0.1457772 ; 0.269615413 ; 0.757587263 ; 0.153019616 ; 0.163563174 ; 0.769112854 ; 0.758865421 ; 0.216095763 ; 0.120654794 ; 0.258812095 ; 0.305337178 ; 0.192347005 ; 0.22880921 ; 0.367492742 ; 0.326128977 ; 0.233587254 ; 0.166749127 ; 0.478910688 ; 0.298685003 ; 0.255302657 ; 0.147858453 ; 0.798434733 ; 0.264916109 ; 0.168309792 ; 0.20663296 ; 0.191185046 ; 0.18723733 ; 0.127076861 ; 0.16375622 ; 0.20040733 ; 0.262735246 ; 0.115562064 ; 0.178277558 ; 0.790365314 ; 0.154705979 ; 0.195053845 ; 0.583439751 ; 0.219488203 ; 0.152956177 ; 0.107514413 ; 0.172276123 ; 0.267032233 ; 0.192024339 ; 0.377731985 ; 0.908221956 ; 0.454639354 ; 0.124082893 ; 0.152291556 ; 0.353392328 ; 0.150768666 ; 0.121174298 ; 0.122387586 ; 0.151111372 ; 0.141411011 ; 0.175311447 ; 0.14959944 ; 0.675850433 ; 0.142157229 ; 0.177621524 ; 0.154589771
PURITY_ABSOLUTE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	Absolute purity.	Sample	0.79 ; 0.61 ; 0.76 ; 0.83 ; 0.74 ; 0.85 ; 0.53 ; 0.92 ; 0.81 ; 0.89 ; 0.65 ; 0.68 ; 0.54 ; 0.24 ; 0.98 ; 0.82 ; 0.58 ; 0.71 ; 1 ; 0.36 ; 0.9 ; 0.78 ; 0.88 ; 0.28 ; 0.87 ; 0.96 ; 0.8 ; 0.84 ; 0.7 ; 0.77 ; 0.23 ; 0.59 ; 0.69 ; 0.75 ; 0.56 ; 0.95 ; 0.44 ; 0.52 ; 0.63 ; 0.73 ; 0.91 ; 0.64 ; 0.27 ; 0.97 ; 0.33 ; 0.66 ; 0.93 ; 0.67 ; 0.2 ; 0.46 ; 0.72 ; 0.47 ; 0.57 ; 0.86 ; 0.48 ; 0.42 ; 0.5 ; 0.37 ; 0.38 ; 0.29 ; 0.22 ; 0.99 ; 0.94 ; 0.16 ; 0.62 ; 0.55 ; 0.35 ; 0.4 ; 0.6 ; 0.43 ; 0.18 ; 0.34 ; 0.21 ; 0.41 ; 0.26 ; 0.45 ; 0.49 ; 0.39 ; 0.51 ; 0.17 ; 0.3 ; 0.32
RANDOM_FOREST_STURM_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Random Forest Sturm Cluster	Sample	IDH ; Mesenchymal ; RTK II 'Classic' ; RTK I 'PDGFRA' ; G34 ; K27
RNASEQ_DATA	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	RNA-SEQ data.	Sample	Yes ; No ; Yes, primary and recurrence
RPPA	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	RPPA	Sample	Yes ; No
SNP6	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	SNP6	Sample	Yes ; No
SUPERVISED_DNA_METHYLATION_CLUSTER	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Supervised DNA Methylation Cluster	Sample	G-CIMP-high ; Mesenchymal-like ; Codel ; Classic-like ; G-CIMP-low ; PA-like ; LGm6-GBM
TELOMERE_LENGTH_ESTIMATE_IN_BLOOD_NORMAL_KB	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	Telomere length estimate in blood normal (Kb)	Sample	8.1119 ; 1.4191 ; 3.2645 ; 6.678 ; 2.9974 ; 3.711 ; 4.1844 ; 4.9587 ; 8.2067 ; 7.2886 ; 6.266 ; 2.7011 ; 7.8519 ; 2.7433 ; 5.0392 ; 3.8841 ; 4.1945 ; 2.3717 ; 4.3255 ; 4.0524 ; 3.6419 ; 5.5833 ; 4.5276 ; 6.2307 ; 4.724 ; 4.9616 ; 5.0474 ; 8.6892 ; 4.8431 ; 5.0039 ; 5.9552 ; 4.9394 ; 7.8905 ; 5.1395 ; 5.6833 ; 4.7249 ; 5.7253 ; 6.4557 ; 10.6402 ; 5.484 ; 4.6005 ; 4.4932 ; 6.2068 ; 3.8837 ; 5.9201 ; 5.9569 ; 4.5594 ; 5.2593 ; 5.2519 ; 4.9204 ; 7.5407 ; 7.5188 ; 5.6811 ; 4.1177 ; 6.6483 ; 4.8603 ; 4.0427 ; 5.5788 ; 5.7343 ; 5.4884 ; 6.6047 ; 5.3617 ; 4.4265 ; 8.7083 ; 5.072 ; 6.3253 ; 5.4533 ; 5.6305 ; 3.3161 ; 3.126 ; 4.0291 ; 2.8391 ; 5.5645 ; 9.8736 ; 4.8081 ; 5.75 ; 7.2014 ; 3.9309 ; 4.0557 ; 5.226 ; 6.9039 ; 6.8801 ; 3.1814 ; 3.4226 ; 5.152 ; 5.15 ; 4.1016 ; 4.4631 ; 6.0662 ; 6.0381 ; 3.2392 ; 6.4733 ; 7.6244 ; 6.2408 ; 6.5201 ; 6.7316 ; 5.1947 ; 6.3329 ; 5.84 ; 4.6853 ; 6.7685 ; 6.0767 ; 5.2201 ; 6.0758 ; 6.8598 ; 4.3388 ; 6.0293 ; 5.5283 ; 7.6428 ; 6.4159 ; 5.5188 ; 6.074 ; 4.842 ; 7.4459 ; 7.3688 ; 5.5782 ; 6.5938 ; 4.0534 ; 3.3464 ; 4.0808 ; 5.9953 ; 5.739 ; 6.3528 ; 6.1813 ; 6.2051 ; 5.9884 ; 8.8696 ; 5.1887 ; 6.51 ; 6.3588 ; 6.6709 ; 5.1261 ; 6.3102 ; 3.8446 ; 3.8834 ; 5.7031 ; 4.8883 ; 4.5671 ; 5.0068 ; 5.1076
TELOMERE_LENGTH_ESTIMATE_IN_TUMOR_KB	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	Telomere length estimate in tumor (Kb)	Sample	5.1859 ; 1.6129 ; 1.4981 ; 16.669 ; 1.6563 ; 1.7498 ; 3.8833 ; 11.3163 ; 5.0426 ; 8.4559 ; 4.4024 ; 6.3505 ; 5.3447 ; 3.1208 ; 7.1049 ; 1.3661 ; 1.8981 ; 4.6462 ; 0.7282 ; 0.4822 ; 1.059 ; 2.1886 ; 5.9032 ; 12.532 ; 29.2683 ; 3.3614 ; 5.4398 ; 14.5523 ; 2.093 ; 1.7225 ; 1.7927 ; 12.158 ; 12.4753 ; 14.2681 ; 3.9526 ; 22.8888 ; 6.1162 ; 6.0016 ; 10.3677 ; 4.6692 ; 2.5294 ; 2.0732 ; 1.0503 ; 1.6178 ; 9.3394 ; 7.1714 ; 6.2238 ; 4.7248 ; 4.9876 ; 6.2087 ; 4.6651 ; 3.9472 ; 17.723 ; 2.7294 ; 6.8852 ; 10.7412 ; 7.4008 ; 7.9554 ; 4.2922 ; 12.4102 ; 4.009 ; 2.9339 ; 5.1528 ; 19.2986 ; 2.5218 ; 11.9708 ; 4.3576 ; 6.3539 ; 5.229 ; 3.3896 ; 13.9573 ; 2.5206 ; 10.9635 ; 14.8776 ; 6.4153 ; 2.0724 ; 8.9998 ; 2.4953 ; 3.7721 ; 3.7045 ; 4.682 ; 2.6097 ; 8.8434 ; 8.0973 ; 10.8207 ; 7.367 ; 10.4544 ; 4.6869 ; 15.2656 ; 2.6509 ; 2.31 ; 1.9312 ; 1.3743 ; 6.7009 ; 5.5551 ; 7.9907 ; 2.3549 ; 10.9089 ; 4.2007 ; 1.528 ; 2.7628 ; 4.8623 ; 2.1719 ; 12.8147 ; 3.8863 ; 1.9881 ; 4.0336 ; 3.0644 ; 4.1952 ; 4.0657 ; 8.5018 ; 2.0718 ; 9.4949 ; 2.4553 ; 3.0986 ; 3.0463 ; 2.1149 ; 3.1376 ; 5.3583 ; 2.2925 ; 4.3306 ; 2.9666 ; 4.6279 ; 12.5638 ; 1.2377 ; 13.9348 ; 5.5038 ; 2.5571 ; 2.4228 ; 16.8716 ; 5.3965 ; 1.523 ; 4.5576 ; 2.9753 ; 1.8876 ; 2.4021 ; 7.6945 ; 4.9429 ; 5.2246
TELOMERE_MAINTENANCE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Telomere Maintenance	Sample	ATRX ; TERT ; -/-
TERT_EXPRESSION_LOG2	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	NUMBER	TERT expression (log2)	Sample	0 ; 3.807354922 ; 2.584962501 ; 5.247927513 ; 1 ; 5.614709844 ; 3 ; 4.087462841 ; 3.906890596 ; 5.754887502 ; 3.459431619 ; 2.321928095 ; 1.584962501 ; 3.584962501 ; 5.64385619 ; 4 ; 4.459431619 ; 5.044394119 ; 4.754887502 ; 5.906890596 ; 2.807354922 ; 5.426264755 ; 6.392317423 ; 4.857980995 ; 4.392317423 ; 3.700439718 ; 5.459431619 ; 6 ; 3.169925001 ; 4.584962501 ; 5.129283017 ; 5.700439718 ; 6.321928095 ; 5.857980995 ; 4.321928095 ; 6.022367813 ; 4.169925001 ; 3.321928095 ; 6.523561956 ; 5.882643049 ; 5.584962501 ; 5.523561956 ; 4.906890596 ; 5.554588852 ; 4.700439718 ; 5.832890014 ; 6.442943496 ; 6.50779464 ; 5 ; 4.95419631 ; 2 ; 4.247927513 ; 6.303780748 ; 6.129283017 ; 7.199672345 ; 9.076815597 ; 6.584962501 ; 6.209453366 ; 5.321928095 ; 4.807354922 ; 4.64385619 ; 4.523561956 ; 7.483815777 ; 5.392317423 ; 6.409390936 ; 6.807354922 ; 5.169925001 ; 5.285402219 ; 6.189824559 ; 6.426264755 ; 5.781359714 ; 7.169925001 ; 6.64385619 ; 7 ; 7.285402219 ; 5.491853096 ; 6.266786541 ; 5.087462841 ; 6.857980995 ; 5.977279923 ; 6.108524457 ; 6.339850003 ; 9.523561956 ; 6.06608919 ; 5.727920455 ; 5.672425342 ; 7.129283017 ; 8.204571144 ; 7.851749041 ; 10.509775 ; 7.055282436 ; 6.14974712 ; 6.599912842
TERT_EXPRESSION_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	TERT expression status	Sample	Not expressed ; Expressed
TERT_PROMOTER_STATUS	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	TERT promoter status	Sample	WT ; Mutant
TRANSCRIPTOME_SUBTYPE	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Transcriptome Subtype	Sample	CL ; PN ; NE ; ME
U133A	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	U133a	Sample	No ; Yes
WHOLE_GENOME_SEQUENCING	Gray	Merged Cohort of LGG and GBM (TCGA, Cell 2016)	STRING	Whole Genome Sequencing	Sample	Yes ; No
PRIMARY_SITE_PROGRESSION	Gray	Medulloblastoma (ICGC, Nature 2012)	STRING	Primary site progression.	Patient	
RADICALITY	Gray	Medulloblastoma (ICGC, Nature 2012)	STRING	Radicality of Surgery: GTR = Gross Total Resection, STR = Sub-Total Resection	Sample	Sub-total resection ; Gross total resection ; GTR ; STR
SUBGROUP	Gray	Medulloblastoma (ICGC, Nature 2012)	STRING	Subgroup	Patient	
FOLLOWUP_LENGTH	Gray	Medulloblastoma (PCGP, Nature 2012)	STRING	Follow up length	Patient	
TUMOR_CELLULARITY_PATHOLOGY_REVIEW	Gray	Medulloblastoma (PCGP, Nature 2012)	STRING	Tumor cellularity dominant pathology review	Sample	MB-CL ; MB-DN ; MB-AN
LOCATION	Gray	Medulloblastoma (Sickkids, Nature 2016)	STRING	Location	Patient	
SOURCE_OF_RECURRENCE_TISSUE	Gray	Medulloblastoma (Sickkids, Nature 2016)	STRING	Source of Recurrence Tissue	Patient	
COVERAGE_CONTROL	Gray	Medulloblastoma (DKFZ, Nature 2017)	NUMBER	Coverage Control	Sample	46.09 ; 41.05 ; 45.08 ; 37.69 ; 37.32 ; 35.26 ; 47.68 ; 38.48 ; 36.69 ; 73.39 ; 38.77 ; 42.57 ; 37.14 ; 36.27 ; 35.59 ; 58.29 ; 35.19 ; 35.64 ; 32.58 ; 36.9 ; 36.74 ; 55.61 ; 33.81 ; 38.66 ; 37.16 ; 32.24 ; 41.39 ; 41.76 ; 56.36 ; 34.43 ; 47.69 ; 44.27 ; 55.44 ; 54.23 ; 40 ; 37.1 ; 28.05 ; 31.98 ; 44.25 ; 32.23 ; 49.33 ; 37.18 ; 30.31 ; 37.67 ; 33.83 ; 32.18 ; 33.22 ; 31.5 ; 34.35 ; 32.51 ; 30.9 ; 34.39 ; 38.61 ; 38.57 ; 35.11 ; 32.27 ; 32.05 ; 34.75 ; 38.09 ; 36.36 ; 36.92 ; 37.34 ; 35.42 ; 33.12 ; 35.14 ; 33.38 ; 43.79 ; 33.93 ; 34.53 ; 30.84 ; 45.22 ; 39.68 ; 32.68 ; 41.23 ; 31.79 ; 41.68 ; 44.01 ; 35.28 ; 43.21 ; 37.29 ; 39.9 ; 43.12 ; 41.37 ; 39.63 ; 38.98 ; 38.74 ; 51.52 ; 35.7 ; 30.71 ; 31.27 ; 36.09 ; 37.11 ; 35.48 ; 33.85 ; 35.53 ; 34.57 ; 33.8 ; 32.77 ; 36.78 ; 33.37 ; 31.13 ; 30.81 ; 40.07 ; 38 ; 39.73 ; 38.01 ; 36.26 ; 32.67 ; 40.39 ; 25.64 ; 29.97 ; 39.84 ; 37.55 ; 38.69 ; 41.5 ; 40.74 ; 39.13 ; 33.64 ; 35.96 ; 34.1 ; 36.18 ; 33.01 ; 29.31 ; 32.38 ; 41.62 ; 40.7 ; 41.29 ; 38.84 ; 38.73 ; 34.56 ; 38.6 ; 36.67 ; 41.74 ; 40.82 ; 31.59 ; 37.08 ; 42.96 ; 43.97 ; 35.4 ; 41.41 ; 39.5 ; 40.44 ; 39.82 ; 29.64 ; 34.33 ; 40.46 ; 41.12 ; 38.67 ; 40.77 ; 36.25 ; 36.8 ; 38.78 ; 41.95 ; 34.23 ; 40.01 ; 38.5 ; 35.18 ; 35.25 ; 32.82 ; 37.5 ; 37.43 ; 38.65 ; 37.19 ; 34.88 ; 36.33 ; 34.18 ; 38.72 ; 35.71 ; 43.36 ; 39.11 ; 35.21 ; 42.12 ; 33.71 ; 36.51 ; 35.45 ; 35.81 ; 36.15 ; 34.96 ; 27.52 ; 39.35 ; 37.41 ; 35.44 ; 32.85 ; 31.56 ; 34.95 ; 34.28 ; 35.83 ; 35.12 ; 35.57 ; 33.44 ; 36.16 ; 32.79 ; 37.54 ; 34.36 ; 32.41 ; 35.03 ; 38.18 ; 35.54 ; 35.65 ; 33.63 ; 33.06 ; 47.4 ; 54.69 ; 43.65 ; 30.49 ; 40.45 ; 31.49 ; 36.43 ; 36.68 ; 32.8 ; 38.83 ; 40.72 ; 39.33 ; 40.75 ; 31.4 ; 30.48 ; 30.38 ; 64.24 ; 70.16 ; 96.43 ; 64.85 ; 52.39 ; 55.33 ; 63.51 ; 80.24 ; 51.87 ; 69.36 ; 87.65 ; 64.9 ; 70.32 ; 64.82 ; 56.98 ; 66.77 ; 70.5 ; 164.33 ; 68.56 ; 67.96 ; 70.54 ; 69.57 ; 68.12 ; 89.52 ; 71.34 ; 74.7 ; 85.97 ; 82.6 ; 69.49 ; 72.49 ; 88.82 ; 71.47 ; 73.41 ; 90.98 ; 70.79 ; 74.1 ; 79.47 ; 75.86 ; 92.07 ; 85.84 ; 67.05 ; 83.06 ; 75.08 ; 79.9 ; 77.01 ; 84.21 ; 74.07 ; 72.65 ; 72.72 ; 72.06 ; 72.03 ; 62.39 ; 70.75 ; 84.85 ; 87.57 ; 68.69 ; 71.61 ; 181.53 ; 160.29 ; 161.61 ; 165.02 ; 171.31 ; 173.75 ; 155 ; 153.02 ; 118.54 ; 155.15 ; 165.78 ; 147.3 ; 171.37 ; 183.98 ; 161.7 ; 166.36 ; 187.46 ; 137.56 ; 147.27 ; 134.87 ; 165.66 ; 179.49 ; 168.05 ; 157.65 ; 83.26 ; 82.36 ; 79.32 ; 85.05 ; 89.32 ; 92.86 ; 85.94 ; 85.36 ; 82.61 ; 82.5 ; 84.4 ; 88.78 ; 78.03 ; 79.26 ; 89.41 ; 89.07 ; 89.73 ; 83.59 ; 88.77 ; 38.35 ; 25.67 ; 28.99 ; 33.7 ; 31.07 ; 33.79 ; 35.95 ; 28.25 ; 33.62 ; 34.04 ; 33.48 ; 35.69 ; 34.82 ; 25.8 ; 34.97 ; 34.55 ; 30.25 ; 36.63 ; 30.77 ; 34.48 ; 33.54 ; 29.66 ; 32.49 ; 34.85 ; 37.31 ; 40.2 ; 36.22 ; 35.32 ; 33.73 ; 26.94 ; 31.38 ; 32.48 ; 30.29 ; 32.33 ; 37.07 ; 33.56 ; 34.27 ; 39.36 ; 43.41 ; 35.46 ; 31.62 ; 36.29 ; 34.94 ; 22.63 ; 19.02 ; 31.41 ; 30.06 ; 32.11 ; 26.17 ; 33.82 ; 28.77 ; 32.36 ; 38.34 ; 26.51 ; 31.08 ; 34.17 ; 31.67 ; 30.68 ; 30.37 ; 36.1 ; 34.6 ; 28.78 ; 31.2 ; 29 ; 28.58 ; 24.5 ; 28.76 ; 31.36 ; 28.35 ; 33.29 ; 37.6 ; 32.56 ; 36.83 ; 35.15 ; 39.15 ; 34.3 ; 29.1 ; 31.51 ; 34.44 ; 36.28 ; 39.86 ; 28.6 ; 32.62 ; 37.48 ; 35.58 ; 36.77 ; 35.85 ; 40.96 ; 36.53 ; 39.96 ; 35.86 ; 32.29 ; 31.65 ; 32.09 ; 25.81 ; 27.8 ; 28.17 ; 29.92 ; 33.68 ; 31.87 ; 34.83 ; 39.69 ; 32.28 ; 34.61 ; 28.39 ; 35.1 ; 32.52 ; 41.78 ; 26.69 ; 34.08 ; 40.41 ; 29.36 ; 35.01 ; 29.47 ; 57.76 ; 28.4 ; 29.49 ; 29.45 ; 38.16 ; 27.58 ; 27 ; 40.55 ; 37.57 ; 29.56 ; 32.74
COVERAGE_TUMOR	Gray	Medulloblastoma (DKFZ, Nature 2017)	NUMBER	Tumor Sample Coverage(fold)	Sample	37.06 ; 40.69 ; 47.96 ; 36.92 ; 36.78 ; 34.85 ; 48.63 ; 32.79 ; 34.64 ; 25.62 ; 38.47 ; 39.56 ; 36.74 ; 35.68 ; 34.59 ; 60.09 ; 36.76 ; 44.68 ; 36.25 ; 33.64 ; 33.12 ; 54.33 ; 37.87 ; 38.92 ; 30.72 ; 31.68 ; 38.42 ; 41.94 ; 56.01 ; 38.84 ; 46.33 ; 32.12 ; 61.45 ; 51.58 ; 43.09 ; 39.95 ; 34.54 ; 48.87 ; 38.64 ; 31.49 ; 45.04 ; 53.28 ; 34.04 ; 42.52 ; 32.67 ; 32.41 ; 33.22 ; 33.33 ; 36.67 ; 34.55 ; 36.27 ; 32.33 ; 39.04 ; 37.97 ; 39.21 ; 37.68 ; 32.68 ; 36.48 ; 35.98 ; 43 ; 32.08 ; 38.81 ; 36.02 ; 34.73 ; 39.32 ; 40.27 ; 37.83 ; 41.03 ; 43.85 ; 37.35 ; 35.37 ; 38.6 ; 41.81 ; 31.45 ; 33.01 ; 33.27 ; 46.03 ; 41.26 ; 45.01 ; 43.74 ; 38.13 ; 43.23 ; 40.67 ; 38.2 ; 34.58 ; 37.27 ; 39.41 ; 37.31 ; 35.22 ; 37.56 ; 40.18 ; 32.44 ; 37.49 ; 36.71 ; 35.92 ; 31.96 ; 34.72 ; 35.26 ; 32.95 ; 38.67 ; 33.67 ; 36.04 ; 36.58 ; 31.17 ; 40.72 ; 46.16 ; 39.53 ; 39.78 ; 40.51 ; 32.75 ; 28.87 ; 35.15 ; 35.69 ; 35.9 ; 38.03 ; 34.08 ; 39.07 ; 31.39 ; 34.63 ; 40.88 ; 36.2 ; 36.24 ; 37.93 ; 42.62 ; 40.66 ; 43.1 ; 41.36 ; 39.02 ; 40.26 ; 40.1 ; 40.82 ; 42.96 ; 36.52 ; 37.09 ; 36.77 ; 33.92 ; 44.64 ; 38.04 ; 33.25 ; 39.9 ; 42.54 ; 39.57 ; 39.13 ; 40.61 ; 40.7 ; 45.43 ; 36.53 ; 37.84 ; 39.43 ; 38.49 ; 39.31 ; 33.56 ; 36.07 ; 34.5 ; 39.69 ; 35.14 ; 37.15 ; 33.42 ; 33.59 ; 34.3 ; 32.82 ; 30.49 ; 42.34 ; 36.61 ; 36.55 ; 34.78 ; 38.38 ; 39.44 ; 34.37 ; 36.47 ; 38.08 ; 37.22 ; 41.02 ; 39.72 ; 36.12 ; 35.63 ; 32.58 ; 37.64 ; 33.91 ; 32.5 ; 36.3 ; 34.67 ; 33.49 ; 35.36 ; 35.47 ; 34.69 ; 31.63 ; 35.2 ; 31.38 ; 34.65 ; 31.44 ; 34.82 ; 35.5 ; 34.21 ; 33.52 ; 32.29 ; 33.84 ; 35.86 ; 35.04 ; 35.11 ; 34.09 ; 33.1 ; 40.89 ; 30.37 ; 55.75 ; 36.96 ; 28.31 ; 30.5 ; 32.32 ; 46.52 ; 31.01 ; 34.53 ; 38.28 ; 34.99 ; 39.65 ; 40.57 ; 41.38 ; 37.86 ; 38.09 ; 33.6 ; 35.77 ; 32.15 ; 32.87 ; 32.64 ; 192.78 ; 32.7 ; 30.39 ; 31.64 ; 36.4 ; 29.73 ; 33.07 ; 121.37 ; 83.38 ; 115.89 ; 34.05 ; 29.71 ; 142.4 ; 34.9 ; 29.81 ; 69.08 ; 139.02 ; 72.8 ; 73.9 ; 74.42 ; 74.17 ; 74.7 ; 90.09 ; 69.38 ; 74.9 ; 88.2 ; 87.41 ; 70.86 ; 72.44 ; 87.37 ; 69.28 ; 70.41 ; 85.63 ; 70 ; 74 ; 81.23 ; 69.02 ; 84.16 ; 90.47 ; 70.3 ; 93.96 ; 72.08 ; 72.97 ; 78.49 ; 89.42 ; 73.4 ; 69.25 ; 72.5 ; 64.62 ; 76.12 ; 63.38 ; 71.86 ; 80.36 ; 83.77 ; 73.76 ; 72.35 ; 191.3 ; 176.78 ; 170.21 ; 157.23 ; 135.61 ; 168.36 ; 154.12 ; 163.29 ; 123.03 ; 162.99 ; 162.63 ; 154.58 ; 172.62 ; 143.22 ; 116.33 ; 128.84 ; 161.62 ; 130.48 ; 158.14 ; 169.25 ; 158.38 ; 159.29 ; 160.17 ; 162.82 ; 84.54 ; 91.41 ; 93.56 ; 81.97 ; 85.58 ; 80.94 ; 86.77 ; 94.13 ; 83.64 ; 91.12 ; 82.51 ; 90.92 ; 93.57 ; 88.58 ; 81.98 ; 97.04 ; 84.53 ; 98.02 ; 83.94 ; 36.06 ; 30.88 ; 30.7 ; 37.3 ; 35 ; 34.4 ; 30.64 ; 33.37 ; 33.55 ; 29.53 ; 30.47 ; 29.96 ; 35.41 ; 26.94 ; 32.56 ; 32.63 ; 39.77 ; 33.61 ; 30.19 ; 30.89 ; 34.01 ; 41.01 ; 31.91 ; 32.55 ; 33.86 ; 32.51 ; 31.59 ; 37.26 ; 32.57 ; 35.3 ; 31.92 ; 32.01 ; 35.31 ; 35.48 ; 37.34 ; 35.64 ; 35.79 ; 27.22 ; 33.48 ; 34.68 ; 40.28 ; 29.06 ; 21.92 ; 32.85 ; 30.29 ; 37.05 ; 30.76 ; 29.51 ; 34.98 ; 31.89 ; 31.26 ; 34.28 ; 31.33 ; 34.7 ; 32.73 ; 32.37 ; 33.54 ; 35.08 ; 34.48 ; 36.13 ; 35.96 ; 33.63 ; 31.1 ; 31.16 ; 33.79 ; 35.43 ; 26.93 ; 29.52 ; 37.24 ; 35.76 ; 36.8 ; 34.2 ; 29.13 ; 39.47 ; 40.47 ; 36.86 ; 30.05 ; 28.9 ; 38.31 ; 34.02 ; 33.98 ; 38.65 ; 39.23 ; 36.37 ; 34.1 ; 36.73 ; 41.12 ; 36.75 ; 41.4 ; 34.18 ; 40.68 ; 30.57 ; 29.93 ; 29.61 ; 31.15 ; 35.58 ; 33.94 ; 31.83 ; 32.27 ; 32.52 ; 36.72 ; 36.16 ; 35.17 ; 35.45 ; 37.2 ; 36 ; 34.24 ; 43.18 ; 34.89 ; 34.26 ; 36.29 ; 37.82 ; 33.5 ; 34.88 ; 41.45 ; 33.8 ; 41.44 ; 35.23 ; 36.9 ; 33.66 ; 30.66 ; 34.57 ; 43.32
GUESSED_PLOIDY	Gray	Medulloblastoma (DKFZ, Nature 2017)	NUMBER	Guessed Ploidy	Sample	4 ; 2 ; 3 ; 5 ; 6 ; 8
NGS_TYPE	Gray	Medulloblastoma (DKFZ, Nature 2017)	STRING	Sequencing Platform	Sample	WGS ; WES
SOURCE_CENTER	Gray	Medulloblastoma (DKFZ, Nature 2017)	STRING	Sample Source Center	Sample	ICGC ; Broad Institute ; MAGIC ; PCGP
CLINICAL_ASSOCIATION	Gray	Malignant Peripheral Nerve Sheath Tumor (MSK, Nat Genet 2014)	STRING	Clinical association.	Patient	
CG_1P	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	STRING	CG_1P	Sample	normal ; loss
CHROMOTRYPSIS_V2	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	STRING	CHROMOTRYPSIS V2	Sample	No ; Yes
INSS_STAGE	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	STRING	Staging according to the International Neuroblastoma Staging System	Patient	
MYCN	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	STRING	MYCN.	Sample	non-amp ; amp ; gain ; Amplified ; Not Amplified ; Unknown
PF_MONTHS	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	NUMBER	Pf months	Patient	
PF_STATUS	Gray	Neuroblastoma (AMC Amsterdam, Nature 2012)	STRING	Pf status	Patient	
MEAN_TARGET_COVERAGE_NORMAL	Gray	Neuroblastoma (Broad, Nature 2015)	NUMBER	mean target coverage normal	Sample	46.39 ; 30.17 ; 42.27 ; 29 ; 35.85 ; 31.32 ; 44.85 ; 33.79 ; 44.96 ; 31.23 ; 29.58 ; 31.99 ; 27.9 ; 30.29 ; 45.33 ; 46.17 ; 39.46 ; 34.8 ; 31.68 ; 41.51 ; 47.61 ; 32.61 ; 49.19 ; 27.41 ; 33.86 ; 31.57 ; 27.36 ; 29.45 ; 36.47 ; 33.58 ; 33.06 ; 43.41 ; 45.07 ; 44.21 ; 31.03 ; 30.41 ; 32.09 ; 27.17 ; 31.01 ; 46.34 ; 26.66 ; 26.57 ; 21.79 ; 26.61 ; 24.3 ; 24.76 ; 25.4 ; 26.08 ; 24.54 ; 25.06 ; 28.78 ; 24.37 ; 25.08 ; 29.32
MEAN_TARGET_COVERAGE_TUMOR	Gray	Neuroblastoma (Broad, Nature 2015)	NUMBER	mean target coverage tumor	Sample	34.43 ; 44.07 ; 35.37 ; 27.65 ; 33.39 ; 30.96 ; 41.78 ; 31.39 ; 39.22 ; 32.56 ; 31.32 ; 31.99 ; 28.25 ; 32.49 ; 44.67 ; 37.65 ; 35.99 ; 31.05 ; 37.27 ; 30.2 ; 40.12 ; 37.21 ; 29.88 ; 37.3 ; 40.41 ; 34.39 ; 40.13 ; 41.33 ; 29.71 ; 30.53 ; 34.9 ; 38.82 ; 35.96 ; 37.38 ; 29.89 ; 33.23 ; 32.95 ; 27.56 ; 30.03 ; 27.97 ; 42.1 ; 31.53 ; 48.92 ; 47.87 ; 43.07 ; 29.76 ; 39.37 ; 41.25 ; 40.67 ; 45.21 ; 38.99 ; 40.79 ; 46.74 ; 42.21 ; 47.2
MYCN_AMP	Gray	Neuroblastoma (Broad, Nature 2015)	STRING	MYCN Amplification	Sample	No ; Yes ; 1 ; 0 ; 9
ANALYSIS_ID	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	analysis id	Sample	NB-3508 ; NB-3254 ; NB-3355 ; TARGET-30-PAIFXV ; NB-3264 ; NB-3180 ; NB-3270 ; NB-3186 ; NB-3211 ; NB-3671 ; NB-3204 ; NB-3160 ; TARGET-30-PAIWRB ; NB-0038 ; NB-0058 ; NB-0061 ; NB-0072 ; NB-0230 ; NB-0198 ; NB-0232 ; NB-0192 ; NB-0153 ; NB-0121 ; TARGET-30-PAKVUY ; NB-0419 ; NB-3440 ; NB-0433 ; NB-0445 ; NB-0462 ; NB-0478 ; NB-0495 ; NB-0505 ; NB-1042 ; NB-3538 ; NB-1056 ; NB-1092 ; NB-1100 ; NB-1110 ; NB-1112 ; NB-1155 ; NB-3944 ; TARGET-30-PALRSD ; NB-1181 ; NB-1194 ; NB-1199 ; NB-1204 ; NB-0974 ; NB-0982 ; NB-0992 ; NB-0997 ; NB-1243 ; NB-1246 ; NB-1266 ; NB-1273 ; NB-3382 ; NB-1263 ; NB-1369 ; NB-1375 ; TARGET-30-PAMNYX ; NB-1480 ; TARGET-30-PAMVLG ; NB-1501 ; NB-1587 ; NB-1599 ; NB-1613 ; NB-1659 ; NB-2003 ; NB-1669 ; NB-1744 ; NB-1749 ; TARGET-30-PANLET ; NBL6 ; NB-1838 ; NB-3728 ; NBL7 ; TARGET-30-PANRVJ ; TARGET-30-PANSBN ; TARGET-30-PANUIF ; NB-1881 ; TARGET-30-PANWRR ; TARGET-30-PANXJL ; NB-1942 ; NB-1931 ; NB-1953 ; NB-1956 ; NB-1972 ; TARGET-30-PAPBJE ; NB-1987 ; NB-1977 ; TARGET-30-PAPCTS ; NB-3753 ; NB-2023 ; NB-2058 ; TARGET-30-PAPKXS ; TARGET-30-PAPLSD ; NB-2116 ; NB-2074 ; TARGET-30-PAPREJ ; TARGET-30-PAPRMJ ; TARGET-30-PAPRPR ; TARGET-30-PAPRXW ; TARGET-30-PAPSKM ; NB-2144 ; TARGET-30-PAPTAN ; TARGET-30-PAPTCR ; TARGET-30-PAPTFZ ; TARGET-30-PAPTJB ; TARGET-30-PAPTLA ; TARGET-30-PAPTLD ; TARGET-30-PAPTLV ; TARGET-30-PAPTMM ; TARGET-30-PAPUJU ; TARGET-30-PAPUWY ; TARGET-30-PAPVFD ; TARGET-30-PAPVRN ; TARGET-30-PAPVXS ; TARGET-30-PAPWFY ; TARGET-30-PAPYNZ ; TARGET-30-PAPZFW ; TARGET-30-PAPZYZ ; TARGET-30-PARABJ ; TARGET-30-PARACR ; TARGET-30-PARACS ; TARGET-30-PARAMT ; TARGET-30-PARASL ; TARGET-30-PARBGP ; TARGET-30-PARBLH ; TARGET-30-PARCRR ; TARGET-30-PARDCK ; TARGET-30-PARDIW ; TARGET-30-PARDUJ ; TARGET-30-PARDVT ; TARGET-30-PARDYU ; TARGET-30-PAREAG ; TARGET-30-PAREGK ; TARGET-30-PARETE ; TARGET-30-PARFWB ; TARGET-30-PARGHY ; TARGET-30-PARGKK ; TARGET-30-PARGUX ; TARGET-30-PARGZK ; TARGET-30-PARHDE ; TARGET-30-PARHUX ; TARGET-30-PARIRD ; TARGET-30-PARJEN ; TARGET-30-PARJMX ; TARGET-30-PARKAG ; TARGET-30-PARKGJ ; TARGET-30-PARKNP ; TARGET-30-PARKZF ; TARGET-30-PARLMK ; TARGET-30-PARLTG ; TARGET-30-PARMDD ; TARGET-30-PARMLF ; TARGET-30-PARMPP ; TARGET-30-PARNLJ ; TARGET-30-PARNNG ; TARGET-30-PARNTS ; TARGET-30-PARPGU ; NBL9 ; TARGET-30-PARRLH ; TARGET-30-PARSBI ; NBL10 ; TARGET-30-PARSRJ ; TARGET-30-PARUPN ; TARGET-30-PARURB ; TARGET-30-PARVFJ ; TARGET-30-PARVLK ; TARGET-30-PARVNT ; TARGET-30-PARYNK ; TARGET-30-PARYXW ; TARGET-30-PARZIP ; TARGET-30-PARZMY ; TARGET-30-PASAAN ; TARGET-30-PASAJU ; TARGET-30-PASAZJ ; TARGET-30-PASBGV ; TARGET-30-PASCDX ; TARGET-30-PASCJJ ; TARGET-30-PASCKI ; NBL5 ; NBL1 ; TARGET-30-PASEGA ; TARGET-30-PASFGG ; TARGET-30-PASFNY ; NBL2 ; TARGET-30-PASGAP ; NBL3 ; TARGET-30-PASGUT ; TARGET-30-PASKFV ; TARGET-30-PASKTB ; NBL4_common ; TARGET-30-PASMJG ; TARGET-30-PASMNT ; TARGET-30-PASNEF ; TARGET-30-PASNZU ; TARGET-30-PASPER ; TARGET-30-PASRFS ; TARGET-30-PASSRN ; TARGET-30-PASSRS ; TARGET-30-PASSWB ; TARGET-30-PASTCN ; TARGET-30-PASTKC ; TARGET-30-PASTKW ; TARGET-30-PASTXR ; TARGET-30-PASUCB ; TARGET-30-PASUYG ; TARGET-30-PASVRU ; TARGET-30-PASWAU ; TARGET-30-PASWFB ; TARGET-30-PASWIJ ; TARGET-30-PASWLY ; TARGET-30-PASWVY ; TARGET-30-PASWYR ; TARGET-30-PASXGP ; TARGET-30-PASXHE ; TARGET-30-PASXIE ; TARGET-30-PASXNN ; TARGET-30-PASXRG ; TARGET-30-PASXRJ ; TARGET-30-PASYLD ; TARGET-30-PASYMX ; TARGET-30-PASYPX ; TARGET-30-PASZPI ; TARGET-30-PATBMM ; TARGET-30-PATCFL ; TARGET-30-PATDWN ; TARGET-30-PATDXC ; TARGET-30-PATDXG ; TARGET-30-PATEKG ; TARGET-30-PATEPF ; TARGET-30-PATESI ; TARGET-30-PATFCY ; TARGET-30-PATFIN ; TARGET-30-PATFXV ; TARGET-30-PATGLU ; TARGET-30-PATGWT ; TARGET-30-PATHVK ; TARGET-30-PATILE ; TARGET-30-PATINJ
ATRX_DELETION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	ATRX Deletion	Sample	0 ; 1
A_C	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	A>C	Sample	0 ; 1 ; 2 ; 3 ; 7 ; 4 ; 6 ; 5 ; 8
A_G	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	A>G	Sample	1 ; 0 ; 2 ; 3 ; 6 ; 9 ; 4 ; 5 ; 23
A_T	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	A>T	Sample	2 ; 1 ; 0 ; 3 ; 5 ; 4 ; 6 ; 8
COVERED_BASES	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Covered Bases	Sample	28578363 ; 28435079 ; 28246669 ; 27284003 ; 28735621 ; 27998670 ; 28928788 ; 28586392 ; 29093812 ; 28605378 ; 28166303 ; 28516970 ; 30380245 ; 27157490 ; 27658357 ; 28879733 ; 27707442 ; 28713627 ; 28954879 ; 27888471 ; 28757974 ; 29087865 ; 27851589 ; 29755383 ; 26608662 ; 28659665 ; 27706561 ; 28597353 ; 27257771 ; 27342549 ; 29330329 ; 27759955 ; 27890813 ; 27791057 ; 27766928 ; 28373230 ; 27729438 ; 27287990 ; 28070524 ; 27358666 ; 28824433 ; 29906069 ; 27503567 ; 25739384 ; 27794827 ; 29433089 ; 28097322 ; 27563773 ; 29262799 ; 27390519 ; 28862214 ; 27239629 ; 27151898 ; 26871603 ; 28465860 ; 28792461 ; 28228273 ; 28674312 ; 28385230 ; 29608154 ; 30038306 ; 29439096 ; 28782615 ; 28627839 ; 28926376 ; 28998512 ; 29540485 ; 28877623 ; 27283930 ; 28847491 ; 29855702 ; 26719433 ; 28913611 ; 28021730 ; 24588969 ; 29903733 ; 30180342 ; 29879190 ; 29094983 ; 29923729 ; 29921114 ; 28022160 ; 29086662 ; 28442505 ; 28327888 ; 28905116 ; 29981331 ; 29836214 ; 29204718 ; 29924137 ; 28719977 ; 26824603 ; 28760141 ; 29674844 ; 29921837 ; 28522085 ; 29173264 ; 29900338 ; 29950392 ; 30226340 ; 30006277 ; 30555234 ; 28427967 ; 29458541 ; 28766312 ; 29903550 ; 29653225 ; 29665619 ; 30126231 ; 30173017 ; 30757874 ; 30063950 ; 29936331 ; 29880795 ; 30135890 ; 30075424 ; 29189106 ; 29588242 ; 30110120 ; 29759260 ; 28773435 ; 29768886 ; 29794951 ; 30284865 ; 30147317 ; 29247771 ; 28980171 ; 29383876 ; 29322201 ; 29279686 ; 30768832 ; 28780812 ; 29007609 ; 28621861 ; 31016437 ; 28487944 ; 29245810 ; 30329068 ; 29003550 ; 30968144 ; 29079514 ; 29316324 ; 29076123 ; 30470102 ; 29126896 ; 29408054 ; 29008652 ; 29135406 ; 29065776 ; 29386100 ; 29449582 ; 29432397 ; 28073116 ; 29254163 ; 29299173 ; 28715348 ; 29063975 ; 29266648 ; 29580562 ; 24097797 ; 28900552 ; 29213356 ; 23753102 ; 28567699 ; 29417922 ; 29089808 ; 29213809 ; 28415313 ; 28769388 ; 28529985 ; 28934222 ; 24466813 ; 30238224 ; 28782611 ; 29048507 ; 30650873 ; 29252493 ; 28283125 ; 28744777 ; 30888077 ; 24614163 ; 25348598 ; 29373473 ; 29249479 ; 29062544 ; 26935063 ; 29094000 ; 26143771 ; 28332605 ; 28765566 ; 30374265 ; 30670466 ; 29239213 ; 28550562 ; 27655582 ; 27990223 ; 28487550 ; 28134418 ; 28631534 ; 28863723 ; 28647506 ; 27962889 ; 28586291 ; 28914809 ; 28923650 ; 28379464 ; 28607613 ; 28566379 ; 28534543 ; 28693873 ; 28374955 ; 28203822 ; 28648242 ; 28249892 ; 28238504 ; 28156569 ; 28714964 ; 28519845 ; 28458691 ; 28977700 ; 28686640 ; 27451760 ; 27928666 ; 28859772 ; 28966132 ; 29064249 ; 28751342 ; 28713214 ; 28573939 ; 28834071 ; 28377598 ; 28688509 ; 28804590 ; 28821113 ; 29056544 ; 28424539 ; 28609832 ; 28740367 ; 30112404 ; 28806132
C_A	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	C>A	Sample	4 ; 2 ; 0 ; 9 ; 6 ; 19 ; 11 ; 1 ; 5 ; 23 ; 3 ; 12 ; 14 ; 15 ; 10 ; 17 ; 7 ; 8 ; 99 ; 13 ; 16 ; 25 ; 24 ; 18 ; 20 ; 32 ; 47 ; 26 ; 66 ; 29 ; 22 ; 31
C_G	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	C>G	Sample	3 ; 2 ; 0 ; 7 ; 1 ; 5 ; 8 ; 4 ; 12 ; 6 ; 10 ; 9 ; 16
C_T	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	C>T	Sample	4 ; 1 ; 0 ; 13 ; 7 ; 8 ; 11 ; 21 ; 18 ; 10 ; 2 ; 3 ; 5 ; 6 ; 17 ; 12 ; 9 ; 26 ; 23 ; 25 ; 19 ; 14 ; 128 ; 15 ; 28
DATA_SOURCE	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Data Source	Patient	
DE_NOVO_START_OUTOFFRAME	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	de novo start outofframe	Sample	0 ; 1
EFS_MONTHS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	In cancer, the length of time after primary treatment for a cancer ends that the patient remains free of certain complications or events that the treatment was intended to prevent or delay. These events may include the return of the cancer or the onset of certain symptoms, such as bone pain from cancer that has spread to the bone.	Patient	
FRAMESHIFT_DELETION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Frameshift Deletion	Sample	0 ; 2 ; 1 ; 3 ; 14 ; 5 ; 6 ; 7
FRAMESHIFT_INSERTION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Frameshift Insertion	Sample	1 ; 4 ; 2 ; 0 ; 3 ; 5
HYPERDIPLOID	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Hyper-diploid.	Sample	1 ; 0 ; 9
INDEL	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Insertion And Deletion	Sample	1 ; 7 ; 3 ; 2 ; 0 ; 5 ; 4 ; 19 ; 12 ; 9 ; 8 ; 11
IN_FRAME_DELETION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	In frame Deletion	Sample	0 ; 1 ; 2
IN_FRAME_INSERTION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	In frame Insertion	Sample	0 ; 1
MISSENSE_MUTATIONS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Missense Mutations	Sample	10 ; 7 ; 0 ; 25 ; 15 ; 12 ; 16 ; 32 ; 35 ; 4 ; 11 ; 19 ; 2 ; 8 ; 41 ; 5 ; 13 ; 26 ; 1 ; 9 ; 18 ; 21 ; 20 ; 79 ; 38 ; 6 ; 14 ; 28 ; 34 ; 50 ; 17 ; 22 ; 42 ; 29 ; 140 ; 3 ; 31 ; 23 ; 24 ; 49 ; 36 ; 27 ; 43 ; 45 ; 61
MKI	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	MKI.	Sample	9 ; 3 ; 2 ; 1 ; 0 ; High ; Intermediate ; Unknown ; Low
NONSENSE_MUTATION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Nonsense Mutations	Sample	1 ; 0 ; 2 ; 4 ; 3 ; 10 ; 5 ; 11
NONSTOP_MUTATION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Nonstop Mutations	Sample	0 ; 1
NUM_NONSILENT_MUTATION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Total Number of Nonsilent Mutation	Sample	13 ; 3 ; 25 ; 17 ; 15 ; 35 ; 10 ; 12 ; 21 ; 9 ; 44 ; 11 ; 4 ; 1 ; 27 ; 2 ; 18 ; 55 ; 31 ; 24 ; 89 ; 5 ; 40 ; 8 ; 20 ; 22 ; 26 ; 16 ; 14 ; 6 ; 38 ; 7 ; 53 ; 19 ; 45 ; 29 ; 158 ; 23 ; 0 ; 33 ; 43 ; 37 ; 52 ; 30 ; 46 ; 34 ; 50 ; 74 ; 32 ; 47
SILENT_MUTATION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Silent Mutations	Sample	2 ; 1 ; 0 ; 9 ; 5 ; 8 ; 6 ; 18 ; 3 ; 4 ; 7 ; 11 ; 10 ; 28 ; 16 ; 20 ; 54 ; 12 ; 17 ; 14 ; 13
SILENT_PER_MB	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Silent per Mb	Sample	0.07 ; 0.04 ; 0 ; 0.33 ; 0.17 ; 0.29 ; 0.21 ; 0.62 ; 0.1 ; 0.28 ; 0.11 ; 0.18 ; 0.14 ; 0.25 ; 0.03 ; 0.41 ; 0.4 ; 0.32 ; 0.36 ; 1.03 ; 0.15 ; 0.27 ; 0.2 ; 0.19 ; 0.59 ; 0.6 ; 0.13 ; 0.34 ; 0.67 ; 0.37 ; 1.85 ; 0.23 ; 0.3 ; 0.24 ; 0.58 ; 0.31 ; 0.08 ; 0.26 ; 0.12 ; 0.38 ; 0.7 ; 0.49 ; 0.47
SPLICE_SITE	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Splice Site	Sample	1 ; 0 ; 2 ; 3 ; 4
SPLICE_SITE_INSERTION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Splice Site Insertion	Sample	0 ; 1
SPLICE_SITE_SNP	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	Splice Site SNP	Sample	0 ; 1 ; 2
SUBSTITUTION	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Substitution Mutations	Sample	14 ; 7 ; 0 ; 34 ; 21 ; 24 ; 39 ; 53 ; 9 ; 20 ; 27 ; 2 ; 12 ; 16 ; 11 ; 50 ; 13 ; 33 ; 3 ; 29 ; 1 ; 19 ; 49 ; 5 ; 10 ; 30 ; 31 ; 119 ; 51 ; 25 ; 17 ; 15 ; 4 ; 22 ; 45 ; 18 ; 23 ; 55 ; 28 ; 72 ; 57 ; 43 ; 210 ; 8 ; 42 ; 6 ; 36 ; 35 ; 74 ; 48 ; 32 ; 41 ; 60 ; 92 ; 44 ; 52
TARGET_ID	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	target id	Sample	6258_3508 ; 6258_3254 ; 6258_3355 ; 2106 ; 6258_3264 ; 6258_3180 ; 6258_3270 ; 6258_3186 ; 6258_3211 ; 6258_3671 ; 6258_3204 ; 6258_3160 ; 2352 ; 6258_0038 ; 6258_0058 ; 6258_0061 ; 6258_0072 ; 6258_0230 ; 6258_0198 ; 6258_0232 ; 6258_0192 ; 6258_0153 ; 6258_0121 ; 400 ; 6258_0419 ; 6258_3440 ; 6258_0433 ; 6258_0445 ; 6258_0462 ; 6258_0478 ; 6258_0495 ; 6258_0505 ; 6258_1042 ; 6258_3538 ; 6258_1056 ; 6258_1092 ; 6258_1100 ; 6258_1110 ; 6258_1112 ; 6258_1155 ; 6258_3944 ; 1015 ; 6258_1181 ; 6258_1194 ; 6258_1199 ; 6258_1204 ; 6258_0974 ; 6258_0982 ; 6258_0992 ; 6258_0997 ; 6258_1243 ; 6258_1246 ; 6258_1266 ; 6258_1273 ; 6258_3382 ; 6258_1263 ; 6258_1369 ; 6258_1375 ; 1386 ; 6258_1480 ; 1497 ; 6258_1501 ; 6258_1587 ; 6258_1599 ; 6258_1613 ; 6258_1659 ; 6258_2003 ; 6258_1669 ; 6258_1744 ; 6258_1749 ; 1798 ; 6258_1823 ; 6258_1838 ; 6258_3728 ; 6258_1849 ; 1853 ; 1858 ; 1878 ; 6258_1881 ; 1913 ; 1920 ; 6258_1942 ; 6258_1931 ; 6258_1953 ; 6258_1956 ; 6258_1972 ; 1973 ; 6258_1987 ; 6258_1977 ; 1992 ; 6258_3753 ; 6258_2023 ; 6258_2058 ; 2059 ; 2065 ; 6258_2116 ; 6258_2074 ; 2123 ; 2131 ; 2127 ; 2161 ; 6258_2142 ; 6258_2144 ; 2162 ; 2165 ; 2170 ; 2171 ; 2172 ; 6258_2173 ; 2203 ; 6258_2175 ; 2211 ; 2221 ; 2225 ; 2227 ; 2231 ; 2303 ; 2314 ; 2346 ; 2453 ; 2465 ; 2469 ; 2473 ; 2487 ; 2526 ; 2533 ; 2631 ; 2642 ; 2427 ; 2355 ; 6258_2464 ; 2356 ; 2371 ; 2372 ; 6258_2480 ; 2391 ; 2400 ; 2813 ; 2646 ; 6258_2638 ; 2653 ; 2685 ; 2692 ; 6258_2668 ; 2702 ; 2704 ; 2722 ; 2730 ; 2744 ; 2748 ; 2749 ; 2759 ; 2809 ; 2816 ; 2837 ; 2843 ; 2880 ; 2891 ; 3843 ; 6258_2870 ; 2902 ; 2924 ; 6258_2896 ; 3359 ; 6120 ; 6137 ; 6171 ; 6156 ; 6118 ; 6272 ; 6284 ; 6307 ; 6301 ; 6310 ; 6321 ; 6258_6338 ; 6357 ; 6379 ; 6389 ; 6258_6394 ; 6258_6393 ; 6258_6447 ; 7044 ; 7066 ; 7072 ; 6258_6448 ; 7086 ; 6258_6449 ; 7108 ; 7243 ; 7269 ; 6258_6450 ; 7321 ; 7326 ; 7348 ; 7373 ; 7390 ; 7403 ; 7456 ; 7457 ; 7460 ; 7472 ; 7483 ; 7485 ; 7504 ; 7511 ; 7544 ; 7566 ; 6331 ; 7590 ; 7594 ; 7597 ; 7605 ; 7610 ; 7621 ; 7625 ; 7623 ; 7628 ; 7635 ; 7631 ; 7664 ; 7667 ; 7671 ; 7693 ; 7760 ; 7776 ; 7821 ; 7856 ; 7823 ; 7860 ; 7868 ; 7869 ; 7885 ; 7888 ; 7904 ; 7918 ; 7928 ; 7951 ; 7967 ; 7971
TOTAL_PER_MB	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	TOTAL PER Mb	Sample	0.52 ; 0.49 ; 0.11 ; 1.25 ; 0.77 ; 0.82 ; 0.8 ; 1.43 ; 1.82 ; 0.45 ; 0.71 ; 0.95 ; 0.1 ; 0.59 ; 0.58 ; 0.42 ; 0.61 ; 1.71 ; 0.22 ; 0.73 ; 0.03 ; 1.22 ; 1.09 ; 0.72 ; 2.42 ; 0.41 ; 0.18 ; 0.43 ; 0.36 ; 1.19 ; 1.02 ; 1.12 ; 4.29 ; 0.25 ; 1.79 ; 0.35 ; 0.37 ; 0.44 ; 1.05 ; 0.92 ; 0.89 ; 1.2 ; 0.51 ; 0.62 ; 0.69 ; 0.84 ; 0.74 ; 0.6 ; 0.21 ; 1.66 ; 0.14 ; 0.34 ; 0.66 ; 0.48 ; 1.98 ; 0.9 ; 0.32 ; 0.2 ; 0.07 ; 2.38 ; 0.27 ; 0.7 ; 0.79 ; 0.99 ; 0.83 ; 1.03 ; 0.17 ; 1.88 ; 0.33 ; 0.24 ; 1.65 ; 1.4 ; 1.16 ; 7.27 ; 0.53 ; 0.4 ; 0.63 ; 0.26 ; 1.38 ; 0.98 ; 0.23 ; 1.17 ; 0.93 ; 1.1 ; 0.81 ; 0.28 ; 1.01 ; 0.75 ; 0.16 ; 1.08 ; 0.94 ; 1.06 ; 1.29 ; 2.37 ; 0.3 ; 1.69 ; 0 ; 0.65 ; 1.13 ; 0.38 ; 0.29 ; 0.67 ; 0.08 ; 0.55 ; 1.84 ; 2.11 ; 0.57 ; 3.29 ; 0.46 ; 1.27 ; 1.46 ; 0.91 ; 1.42 ; 1.54 ; 0.86 ; 0.56 ; 1.81
VAR_10Q_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	10q-	Sample	1 ; 0
VAR_11Q_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	11q-	Sample	0 ; 1
VAR_12P_POS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	12p+	Sample	0 ; 1
VAR_14Q_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	14q-	Sample	0 ; 1
VAR_17Q_POS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	17q+	Sample	1 ; 0
VAR_1P_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	1p-	Sample	0 ; 1
VAR_1Q_POS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	1q+	Sample	0 ; 1
VAR_2P_POS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	2p+	Sample	0 ; 1
VAR_3P_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	3p-	Sample	0 ; 1
VAR_4P_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	4p-	Sample	0 ; 1
VAR_6Q_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	6q-	Sample	0 ; 1
VAR_7Q_POS	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	7q+	Sample	0 ; 1
VAR_9P_NEG	Gray	Neuroblastoma (Broad, Nat Genet 2013)	STRING	9p-	Sample	0 ; 1
YEAR	Gray	Neuroblastoma (Broad, Nat Genet 2013)	NUMBER	Year	Patient	
BEST_RANO_RESPONSE	Gray	Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytoma (MSK, Neuro Oncol 2017)	STRING	Best Response Assessment in Neuro-Oncology Criteria (RANO) Response	Patient	
IMPACT_1P19Q	Gray	Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytoma (MSK, Neuro Oncol 2017)	STRING	1p/19q status based on IMPACT	Sample	Not deleted ; Co-deleted
TREATMENT_AT_MSK	Gray	Anaplastic Oligodendroglioma and Anaplastic Oligoastrocytoma (MSK, Neuro Oncol 2017)	STRING	Treatment at msk	Patient	
EFSCENS	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Event Free Survival Censored	Patient	
EFS_TIME	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	EFS time.	Patient	
ICDO	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	ICDO.	Patient	
ICDO_SNOMED_DESCRIPTION	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	ICDO snomed description.	Patient	
LAST_FOLLOWUP_YEAR	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Year of Last Followup	Patient	
PERCENTAGE_NECROSIS	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Percent necrosis.	Patient	
PERCENTAGE_TUMOR_PURITY	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Percent tumor purity.	Patient	
PERCENT_TUMOR_CELLS_RELAPSE	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Numeric value to represent the percentage of malignant cell tumor nuclei content in a tumor sample or specimen obtained at relapse stage	Patient	
PERCENT_TUMOR_VS_STROMA	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Numeric representation of the ratio of tumor to stroma.	Patient	
RELAPSE_PERCENT_NECROSIS	Gray	Pediatric Neuroblastoma (TARGET, 2018)	NUMBER	Numeric value to represent the percentage of cell death in a malignant tumor sample or specimen for the first relapse tissue.	Patient	
RELAPSE_PERCENT_STROMA	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	Numeric representation of the percent of tumor versus stroma for first relapse sample.	Patient	
SCENS	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	SCENS.	Patient	
SNOMED	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	SNOMED	Patient	
STIME	Gray	Pediatric Neuroblastoma (TARGET, 2018)	STRING	STIME.	Patient	
DISEASE_SUBTYPE	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	STRING	Disease Subtype	Patient	
MEDIAN_COVERAGE	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	NUMBER	Median coverage	Sample	702 ; 561 ; 517 ; 916 ; 801 ; 1002 ; 1020 ; 799 ; 639 ; 564 ; 789 ; 893 ; 211 ; 711 ; 605 ; 841 ; 994 ; 989 ; 782 ; 624 ; 846 ; 1008 ; 1057 ; 414 ; 398 ; 988 ; 859 ; 501 ; 481 ; 342 ; 880 ; 580 ; 436 ; 883 ; 779 ; 780 ; 661 ; 823 ; 630 ; 810 ; 712 ; 903 ; 271 ; 946 ; 812 ; 697 ; 563 ; 843 ; 797 ; 860 ; 710 ; 1191 ; 732 ; 826 ; 1065 ; 816 ; 583 ; 734 ; 1187 ; 648 ; 473 ; 1013 ; 953 ; 1054 ; 763 ; 862 ; 713 ; 957 ; 919 ; 857 ; 788 ; 540 ; 761 ; 579 ; 742 ; 737 ; 793 ; 871 ; 722 ; 503 ; 677 ; 762 ; 637 ; 667 ; 418 ; 772 ; 800 ; 773 ; 543 ; 472 ; 604 ; 817 ; 784 ; 738 ; 544 ; 599 ; 551 ; 344 ; 573 ; 280 ; 502 ; 595 ; 565 ; 617 ; 785 ; 640 ; 1206 ; 557 ; 607 ; 815 ; 510 ; 511 ; 798 ; 486 ; 967 ; 909 ; 592 ; 613 ; 603 ; 448 ; 764 ; 575 ; 461 ; 523 ; 87 ; 559 ; 687 ; 474 ; 480 ; 869 ; 642 ; 594 ; 305 ; 404 ; 602 ; 655 ; 441 ; 482 ; 493 ; 367 ; 663 ; 680 ; 520 ; 558 ; 615 ; 626 ; 682 ; 408 ; 505 ; 618 ; 528 ; 385 ; 933 ; 239 ; 676 ; 753 ; 593 ; 610 ; 864 ; 534 ; 588 ; 507 ; 361 ; 244 ; 668 ; 492 ; 258 ; 578 ; 568 ; 692 ; 1066 ; 696 ; 465 ; 484 ; 840 ; 670 ; 281 ; 679 ; 526 ; 230 ; 456 ; 454 ; 586 ; 644
SAMPLE_CODE	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	STRING	Sample code is a unique ordering of the tumors.	Sample	Relapse1 ; Therapy Resection1 ; Relapse2 ; Diagnosis1 ; Relapse3 ; Relapse4 ; Therapy Resection2 ; Re-resection1 ; Relapse5 ; Therapy Resection3 ; Diagnosis2
TIME_AT_LAST_FOLLOWUP_MONTHS	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	NUMBER	Time to Last Followup	Patient	
TUMOR_SITE_CATEGORY	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	STRING	Tumor Site Category	Patient	
TUMOR_SITE_DETAIL	Gray	Pediatric Neuroblastoma (MSK, Nat Genet 2023)	STRING	Tumor Site Detail	Patient	
NF1_GENOTYPE	Gray	Nerve Sheath Tumors (Johns Hopkins, Sci Data 2020)	STRING	NF1 Genotype of the patient	Patient	
NF2_GENOTYPE	Gray	Nerve Sheath Tumors (Johns Hopkins, Sci Data 2020)	STRING	NF2 Genotype of the patient	Patient	
FGFR1_MUTATION	Gray	Pilocytic Astrocytoma (ICGC, Nature Genetics 2013)	STRING	FGFR1 Mutation	Sample	- ; p.K655I, p.K656E ; p.N546K ; p.K656E ; ITD Kinase Domain
NF1_MUTATION	Gray	Pilocytic Astrocytoma (ICGC, Nature Genetics 2013)	STRING	NF1 Mutation	Sample	- ; Large deletion (germline); p.E291fs (somatic) ; Large deletion (somatic); p.Q1174fs (somatic) ; p.Q959X (germline); large deletion (somatic) ; p.R13912fs (germline); p.Q2245X (somatic)
PTPN11_MUTATION	Gray	Pilocytic Astrocytoma (ICGC, Nature Genetics 2013)	STRING	PTPN1 Mutation	Sample	- ; p.E76A ; p.E69K
HISTORY_LGG_DX_OF_BRAIN_TISSUE	Gray	Glioblastoma Multiforme (TCGA, Firehose Legacy)	STRING	History lgg dx of brain tissue	Patient	
1P19Q_STATUS	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Indicates whether chromosomal arms 1p and 19q were co-deleted within a sample.	Patient ; Sample	Codeleted ; Intact
AGE_AT_DX	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Integer rounded down to the nearest age at first diagnosis	Patient	
ALIQUOT_BARCODE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	A variable that stitches subject, sample type, portion, sequencing type, and a unique identifier together	Sample	GLSS-19-0266-TP-01D-WXS-F78XXN ; GLSS-19-0266-R1-01D-WXS-0AUVTN ; GLSS-19-0267-TP-01D-WXS-CS4K8X ; GLSS-19-0267-R1-01D-WXS-2AVAZ0 ; GLSS-19-0269-TP-01D-WXS-G5IWER ; GLSS-19-0269-R1-01D-WXS-BMTNI5 ; GLSS-19-0270-TP-01D-WXS-I69BAL ; GLSS-19-0270-R1-01D-WXS-4TBSF2 ; GLSS-19-0271-TP-01D-WXS-3TI55F ; GLSS-19-0271-R1-01D-WXS-9657ZY ; GLSS-19-0272-TP-01D-WXS-9YKK98 ; GLSS-19-0272-R1-01D-WXS-E5JC16 ; GLSS-19-0273-TP-01D-WXS-H00BNY ; GLSS-19-0273-R1-01D-WXS-ZEKWL8 ; GLSS-19-0274-TP-01D-WXS-F3BOIM ; GLSS-19-0274-R1-01D-WXS-IAULWM ; GLSS-19-0277-TP-01D-WXS-CK54HQ ; GLSS-19-0277-R1-01D-WXS-OX9LZT ; GLSS-19-0278-TP-01D-WXS-59Y0J0 ; GLSS-19-0278-R1-01D-WXS-5MU7K1 ; GLSS-19-0279-TP-01D-WXS-GQ9A87 ; GLSS-19-0279-R1-01D-WXS-92Q692 ; GLSS-19-0280-TP-01D-WXS-V4MP15 ; GLSS-19-0280-R1-01D-WXS-Z88Q0N ; GLSS-AT-00P1-TP-01D-WXS-EF0XQE ; GLSS-AT-00P1-R1-01D-WXS-437ED2 ; GLSS-AT-00P2-TP-01D-WXS-RBLYWF ; GLSS-AT-00P2-R1-01D-WXS-91HJSJ ; GLSS-AT-00P3-TP-01D-WXS-T88KH3 ; GLSS-AT-00P3-R1-01D-WXS-N2Q7XG ; GLSS-AT-00P4-TP-01D-WXS-EIOJQ8 ; GLSS-AT-00P4-R1-01D-WXS-REP89L ; GLSS-AT-00P5-TP-01D-WXS-QAIYAY ; GLSS-AT-00P5-R1-01D-WXS-8VNHLX ; GLSS-AT-00P6-TP-01D-WXS-A3KN92 ; GLSS-AT-00P6-R1-01D-WXS-JQX1ST ; GLSS-AT-GP01-TP-01D-WXS-TI55UY ; GLSS-AT-GP01-R1-01D-WXS-AZT8L7 ; GLSS-CU-R001-TP-01D-WXS-AMZ2L2 ; GLSS-CU-R001-R1-01D-WXS-JPX46R ; GLSS-CU-R002-TP-01D-WXS-UVO6E0 ; GLSS-CU-R002-R1-01D-WXS-K6YTXM ; GLSS-CU-R004-TP-01D-WXS-46GQ36 ; GLSS-CU-R004-R1-01D-WXS-WV26B3 ; GLSS-CU-R005-TP-01D-WXS-TOQ8RG ; GLSS-CU-R005-R1-01D-WXS-78REC1 ; GLSS-CU-R007-TP-01D-WXS-TUWWCG ; GLSS-CU-R007-R1-01D-WXS-Y6X0JQ ; GLSS-CU-R008-TP-01D-WXS-0238UJ ; GLSS-CU-R008-R1-01D-WXS-TCGMUM ; GLSS-CU-R009-TP-01D-WXS-6VKK28 ; GLSS-CU-R009-R1-01D-WXS-6KTSKN ; GLSS-CU-R010-TP-01D-WXS-MWMVOK ; GLSS-CU-R010-R1-01D-WXS-LC99UJ ; GLSS-CU-R011-TP-01D-WXS-BHD2A1 ; GLSS-CU-R011-R1-01D-WXS-FCKN39 ; GLSS-CU-R012-TP-01D-WXS-98HFOG ; GLSS-CU-R012-R1-01D-WXS-UM4BXY ; GLSS-CU-R013-TP-01D-WXS-90BYMA ; GLSS-CU-R013-R1-01D-WXS-PWPOB5 ; GLSS-CU-R014-TP-01D-WXS-E86YTX ; GLSS-CU-R014-R1-01D-WXS-C9ODK4 ; GLSS-CU-R015-TP-01D-WXS-CPT7WM ; GLSS-CU-R015-R1-01D-WXS-N22X13 ; GLSS-CU-R018-TP-01D-WXS-RTZK1Q ; GLSS-CU-R018-R1-01D-WXS-PKDTNA ; GLSS-CU-R019-TP-01D-WXS-ZMMX2S ; GLSS-CU-R019-R1-01D-WXS-NAXQ9K ; GLSS-DF-0006-TP-01D-WXS-O9DBZ4 ; GLSS-DF-0006-R1-01D-WXS-TXXURV ; GLSS-DF-0013-TP-01D-WXS-X404M0 ; GLSS-DF-0013-R1-01D-WXS-GGA62B ; GLSS-DF-0014-TP-01D-WXS-H9KDMM ; GLSS-DF-0014-R1-01D-WXS-ZZNMIY ; GLSS-DK-0001-TP-01D-WXS-CB26AA ; GLSS-DK-0001-R1-01D-WXS-D6A176 ; GLSS-DK-0002-TP-01D-WXS-A2DF51 ; GLSS-DK-0002-R1-01D-WXS-631C19 ; GLSS-DK-0003-TP-01D-WXS-E43D26 ; GLSS-DK-0003-R1-01D-WXS-89A5CD ; GLSS-DK-0004-TP-01D-WXS-6BD61E ; GLSS-DK-0004-R1-01D-WXS-BBC731 ; GLSS-DK-0005-TP-01D-WXS-EFBF4F ; GLSS-DK-0005-R1-01D-WXS-8A678C ; GLSS-DK-0006-TP-01D-WXS-47D949 ; GLSS-DK-0006-R1-01D-WXS-CB1447 ; GLSS-DK-0007-TP-01D-WXS-D7676B ; GLSS-DK-0007-R1-01D-WXS-EB6DFA ; GLSS-DK-0008-TP-01D-WXS-6C3ABC ; GLSS-DK-0008-R1-01D-WXS-DDD4B8 ; GLSS-DK-0009-TP-01D-WXS-291A6E ; GLSS-DK-0009-R1-01D-WXS-E4E4D7 ; GLSS-DK-0011-TP-01D-WXS-B8468B ; GLSS-DK-0011-R1-01D-WXS-F55FA3 ; GLSS-DK-0012-TP-01D-WXS-93BDF8 ; GLSS-DK-0012-R1-01D-WXS-59BDDF ; GLSS-DK-0013-TP-01D-WXS-48CFAE ; GLSS-DK-0013-R1-01D-WXS-5EF8E1 ; GLSS-DK-0014-TP-01D-WXS-731C2B ; GLSS-DK-0014-R1-01D-WXS-259416 ; GLSS-DK-0015-TP-01D-WXS-345234 ; GLSS-DK-0015-R1-01D-WXS-4B4982 ; GLSS-HF-2548-TP-01D-WXS-CPWUK8 ; GLSS-HF-2548-R1-01D-WXS-DN2HD4 ; GLSS-HF-2829-TP-01D-WXS-1OMY6S ; GLSS-HF-2829-R1-01D-WXS-W19NLP ; GLSS-HF-2869-TP-01D-WXS-PNBQFR ; GLSS-HF-2869-R3-01D-WXS-07LI3A ; GLSS-HF-2919-TP-01D-WXS-MIYI2Q ; GLSS-HF-2919-R1-01D-WXS-CG67L5 ; GLSS-HF-2934-TP-01D-WXS-OIDP86 ; GLSS-HF-2934-R1-01D-WXS-MXE1L3 ; GLSS-HF-2998-TP-01D-WXS-0R9KZC ; GLSS-HF-2998-R1-01D-WXS-LCQISE ; GLSS-HF-3016-TP-01D-WXS-LVAM11 ; GLSS-HF-3016-R1-01D-WXS-M4KINS ; GLSS-HF-3050-TP-01D-WXS-ECTQ63 ; GLSS-HF-3050-R1-01D-WXS-6ELHQ3 ; GLSS-HF-3081-TP-01D-WXS-V0EK51 ; GLSS-HF-3081-R2-01D-WXS-4LBL2G ; GLSS-HF-3118-TP-01D-WXS-KVSTBB ; GLSS-HF-3118-R1-01D-WXS-QRF6VZ ; GLSS-HF-3162-TP-01D-WXS-HTQZ6B ; GLSS-HF-3162-R1-01D-WXS-3HVQJ6 ; GLSS-HK-0001-TP-01D-WGS-HLH6TO ; GLSS-HK-0001-R1-01D-WGS-23BINE ; GLSS-HK-0002-TP-01D-WGS-DRX7N4 ; GLSS-HK-0002-R1-01D-WGS-S3QETN ; GLSS-HK-0003-TP-01D-WGS-WAGBN9 ; GLSS-HK-0003-R1-01D-WGS-R7P485 ; GLSS-HK-0004-TP-01D-WGS-SJJS0H ; GLSS-HK-0004-R1-01D-WGS-RYFPEB ; GLSS-HK-0005-TP-01D-WGS-9DKW7W ; GLSS-HK-0005-R1-01D-WGS-ODRHPZ ; GLSS-JX-0006-TP-01D-WXS-TJWESP ; GLSS-JX-0006-R1-01D-WXS-F732CR ; GLSS-LU-0B10-TP-01D-WXS-FUQXJ0 ; GLSS-LU-0B10-R1-01D-WXS-LL3UDE ; GLSS-LU-0B12-TP-01D-WXS-JX61DS ; GLSS-LU-0B12-R1-01D-WXS-NXWOWA ; GLSS-LU-0B13-TP-01D-WXS-H3ZZFP ; GLSS-LU-0B13-R1-01D-WXS-F05JM5 ; GLSS-LU-00B9-TP-01D-WXS-RXEX90 ; GLSS-LU-00B9-R1-01D-WXS-LM12XS ; GLSS-LU-00C1-TP-01D-WXS-K8YYUW ; GLSS-LU-00C1-R1-01D-WXS-4XD7S0 ; GLSS-LU-00C2-TP-01D-WXS-4OMXNF ; GLSS-LU-00C2-R1-01D-WXS-YYR15P ; GLSS-LU-00C4-TP-01D-WXS-S4OOP1 ; GLSS-LU-00C4-R1-01D-WXS-KYPFOQ ; GLSS-LU-00C7-TP-01D-WXS-WFSIQ7 ; GLSS-LU-00C7-R1-01D-WXS-3M3F98 ; GLSS-MD-0001-TP-01D-WGS-GETLNC ; GLSS-MD-0001-R1-01D-WGS-82NVSS ; GLSS-MD-0003-R1-01D-WGS-50P3GN ; GLSS-MD-0003-R3-01D-WGS-I78LK2 ; GLSS-MD-0004-R1-01D-WGS-1NXLKI ; GLSS-MD-0004-R2-01D-WGS-ZIOL89 ; GLSS-MD-0005-TP-01D-WGS-MKBGI6 ; GLSS-MD-0005-R1-01D-WGS-QG6Q3V ; GLSS-MD-0006-TP-01D-WGS-J297AW ; GLSS-MD-0006-R1-01D-WGS-GSVE2C ; GLSS-MD-0009-TP-01D-WGS-3XAL3U ; GLSS-MD-0009-R1-01D-WGS-BS97I9 ; GLSS-MD-0012-TP-01D-WGS-EOOJFG ; GLSS-MD-0012-R1-01D-WGS-BKW5E7 ; GLSS-MD-0014-TP-01D-WGS-F4GXRX ; GLSS-MD-0014-R1-01D-WGS-GLH38H ; GLSS-MD-0017-R1-01D-WGS-23D6A6 ; GLSS-MD-0017-R2-01D-WGS-96HR1I ; GLSS-MD-0018-R1-01D-WGS-VD14B5 ; GLSS-MD-0018-R2-01D-WGS-4784ZB ; GLSS-MD-0020-TP-01D-WGS-6T2E56 ; GLSS-MD-0020-R1-01D-WGS-UP9H2C ; GLSS-MD-0021-TP-01D-WGS-YMNBEZ ; GLSS-MD-0021-R1-01D-WGS-UYTS9R ; GLSS-MD-0022-TP-01D-WGS-ZAET2D ; GLSS-MD-0022-R1-01D-WGS-F5KYZ6 ; GLSS-MD-0023-TP-01D-WGS-JDO9G6 ; GLSS-MD-0023-R1-01D-WGS-DQH2SF ; GLSS-MD-0025-TP-01D-WGS-ZAU2VG ; GLSS-MD-0025-R1-01D-WGS-3BU9LU ; GLSS-MD-0026-TP-01D-WGS-2PPGFK ; GLSS-MD-0026-R1-01D-WGS-X87FCV ; GLSS-MD-0027-TP-01D-WGS-6HFKNZ ; GLSS-MD-0027-R2-01D-WGS-55XI5C ; GLSS-MD-0030-TP-01D-WGS-NBC5N6 ; GLSS-MD-0030-R1-01D-WGS-YWXQDS ; GLSS-MD-0035-TP-01D-WGS-DJ3SQ1 ; GLSS-MD-0035-R1-01D-WGS-HX1AIL ; GLSS-MD-0036-TP-01D-WGS-9FDX42 ; GLSS-MD-0036-R1-01D-WGS-YFD61N ; GLSS-MD-0038-TP-01D-WGS-KZL25H ; GLSS-MD-0038-R1-01D-WGS-0F9XP5 ; GLSS-MD-0041-TP-01D-WGS-HOGYPE ; GLSS-MD-0041-R1-01D-WGS-48VFHO ; GLSS-MD-0042-TP-01D-WGS-R5UYLI ; GLSS-MD-0042-R1-01D-WGS-60V40X ; GLSS-MD-0043-TP-01D-WGS-A5EGFI ; GLSS-MD-0043-R1-01D-WGS-U1JONN ; GLSS-MD-0044-TP-01D-WGS-HYEURJ ; GLSS-MD-0044-R1-01D-WGS-VG0QP6 ; GLSS-MD-0045-TP-01D-WGS-NJCMTP ; GLSS-MD-0045-R1-01D-WGS-C4DXSR ; GLSS-MD-0046-TP-01D-WGS-YZL1C9 ; GLSS-MD-0046-R1-01D-WGS-41DC6M ; GLSS-MD-0047-TP-01D-WGS-ZDKQVK ; GLSS-MD-0047-R1-01D-WGS-EYNB74 ; GLSS-MD-0048-TP-01D-WGS-0WRD31 ; GLSS-MD-0048-R1-01D-WGS-TTN4CQ ; GLSS-MD-0049-TP-01D-WGS-WP8NAY ; GLSS-MD-0049-R1-01D-WGS-5F93TI ; GLSS-MD-0082-TP-01D-WXS-YMHT7Q ; GLSS-MD-0082-R1-01D-WXS-TXII31 ; GLSS-MD-0086-TP-01D-WXS-CYNFLN ; GLSS-MD-0086-R1-01D-WXS-OH39R4 ; GLSS-MD-0088-TP-01D-WXS-APZEF6 ; GLSS-MD-0088-R1-01D-WXS-URR2ME ; GLSS-MD-0089-TP-01D-WXS-E45R14 ; GLSS-MD-0089-R1-01D-WXS-VKVV0H ; GLSS-MD-0090-TP-01D-WXS-LZ4WUR ; GLSS-MD-0090-R1-01D-WXS-XPV1K5 ; GLSS-MD-0091-TP-01D-WXS-VO372O ; GLSS-MD-0091-R1-01D-WXS-L6Z2QQ ; GLSS-MD-0092-TP-01D-WXS-MZ6SGD ; GLSS-MD-0092-R1-01D-WXS-XOX7KY ; GLSS-MD-0093-TP-01D-WXS-YMF2N3 ; GLSS-MD-0093-R1-01D-WXS-PR89I0 ; GLSS-MD-0094-TP-01D-WXS-VVCCM6 ; GLSS-MD-0094-R1-01D-WXS-K7SI29 ; GLSS-MD-0097-TP-01D-WXS-CLR2TN ; GLSS-MD-0097-R1-01D-WXS-NH5UNL ; GLSS-MD-0112-TP-01D-WXS-P1B0I2 ; GLSS-MD-0112-R1-01D-WXS-GI18JQ ; GLSS-MD-0113-R1-01D-WXS-OS8XKL ; GLSS-MD-0113-R4-01D-WXS-X31NXD ; GLSS-MD-LP01-TP-01D-WXS-RFYAC8 ; GLSS-MD-LP01-R1-01D-WXS-ONMB78 ; GLSS-MD-LP02-TP-01D-WXS-OC178I ; GLSS-MD-LP02-R1-01D-WXS-ZGA0ZV ; GLSS-MD-LP04-TP-01D-WXS-05SV1D ; GLSS-MD-LP04-R1-01D-WXS-V7XG09 ; GLSS-MD-LP10-TP-01D-WXS-2KGBKN ; GLSS-MD-LP10-R1-01D-WXS-K07GLN ; GLSS-MG-0001-TP-01D-WXS-7CRPEF ; GLSS-MG-0001-R1-01D-WXS-KUUHMO ; GLSS-MG-0002-TP-01D-WXS-W3JS2F ; GLSS-MG-0002-R1-01D-WXS-MLW9TC ; GLSS-MG-0003-TP-01D-WXS-SRC20T ; GLSS-MG-0003-R1-01D-WXS-Y1TGHY ; GLSS-MG-0005-TP-01D-WXS-MD8RED ; GLSS-MG-0005-R1-01D-WXS-8KI783 ; GLSS-MG-0006-TP-01D-WXS-VSER24 ; GLSS-MG-0006-R1-01D-WXS-072BAX ; GLSS-MG-0007-TP-01D-WXS-BNZXM5 ; GLSS-MG-0007-R2-01D-WXS-5XV0I5 ; GLSS-MG-0009-TP-01D-WXS-A83E13 ; GLSS-MG-0009-R1-01D-WXS-T777VC ; GLSS-MG-0010-TP-01D-WXS-V8HH7C ; GLSS-MG-0010-R1-01D-WXS-QLBYAS ; GLSS-MG-0011-TP-01D-WXS-3B08NI ; GLSS-MG-0011-R1-01D-WXS-8NM6IG ; GLSS-MG-0015-TP-01D-WXS-XPXMSK ; GLSS-MG-0015-R1-01D-WXS-K1FPBB ; GLSS-NS-0001-TP-01D-WGS-5A5UN4 ; GLSS-NS-0001-R2-01D-WGS-VEOP01 ; GLSS-SF-0001-TP-01D-WXS-F99505 ; GLSS-SF-0001-R1-01D-WXS-PUNEIR ; GLSS-SF-0002-TP-01D-WXS-EC52GX ; GLSS-SF-0002-R1-01D-WXS-6KLY6J ; GLSS-SF-0004-TP-01D-WXS-78O1ND ; GLSS-SF-0004-R3-01D-WXS-4F8MUY ; GLSS-SF-0005-TP-01D-WXS-0TWD9H ; GLSS-SF-0005-R1-01D-WXS-5SB5V7 ; GLSS-SF-0006-TP-01D-WXS-DPZUQR ; GLSS-SF-0006-R1-01D-WXS-H09GIV ; GLSS-SF-0007-TP-01D-WXS-HSNHN7 ; GLSS-SF-0007-R1-01D-WXS-2GZMIF ; GLSS-SF-0008-TP-01D-WXS-9702S9 ; GLSS-SF-0008-R1-01D-WXS-FEWO0E ; GLSS-SF-0009-TP-01D-WXS-31SKZ3 ; GLSS-SF-0009-R1-01D-WXS-5VVKB4 ; GLSS-SF-0010-TP-01D-WXS-XAUHJB ; GLSS-SF-0010-R1-01D-WXS-4GJVKE ; GLSS-SF-0011-TP-01D-WXS-YIYP4N ; GLSS-SF-0011-R1-01D-WXS-MOTXHW ; GLSS-SF-0012-TP-01D-WXS-SRHC7M ; GLSS-SF-0012-R1-01D-WXS-M12I6U ; GLSS-SF-0013-TP-01D-WXS-5X46IS ; GLSS-SF-0013-R1-01D-WXS-L8P0AA ; GLSS-SF-0015-TP-01D-WXS-4C169X ; GLSS-SF-0015-R1-01D-WXS-3OV08S ; GLSS-SF-0016-TP-01D-WXS-K4PGE4 ; GLSS-SF-0016-R1-01D-WXS-MEQ5DP ; GLSS-SF-0017-R2-01D-WXS-B07OW0 ; GLSS-SF-0017-R4-01D-WXS-538EL1 ; GLSS-SF-0018-TP-01D-WXS-KN7XVP ; GLSS-SF-0018-R1-01D-WXS-CLV5YX ; GLSS-SF-0020-TP-01D-WXS-K8Y64B ; GLSS-SF-0020-R1-01D-WXS-M3MLAF ; GLSS-SF-0021-TP-01D-WXS-C6VWGG ; GLSS-SF-0021-R1-01D-WXS-L2RH7S ; GLSS-SF-0024-TP-01D-WXS-BIE2XK ; GLSS-SF-0024-R2-01D-WXS-LJCU73 ; GLSS-SF-0025-TP-01D-WXS-QRHTEC ; GLSS-SF-0025-R1-01D-WXS-8OMVL5 ; GLSS-SF-0026-TP-01D-WXS-7VO69E ; GLSS-SF-0026-R1-01D-WXS-AXDNA7 ; GLSS-SF-0027-TP-01D-WXS-QW4L0L ; GLSS-SF-0027-R1-01D-WXS-DXCHYH ; GLSS-SF-0028-TP-01D-WXS-MURKV4 ; GLSS-SF-0028-R1-01D-WXS-QL95F2 ; GLSS-SF-0029-TP-01D-WXS-RS22IE ; GLSS-SF-0029-R1-01D-WXS-ZVHMTT ; GLSS-SF-0032-TP-01D-WXS-QSXK5U ; GLSS-SF-0032-R1-01D-WXS-2Z6C1O ; GLSS-SF-0039-TP-01D-WXS-TBB44D ; GLSS-SF-0039-R1-01D-WXS-7FTNOF ; GLSS-SF-0058-TP-01D-WXS-O9J9FW ; GLSS-SF-0058-R1-01D-WXS-N2AFHP ; GLSS-SF-0060-TP-01D-WXS-F9T3B8 ; GLSS-SF-0060-R1-01D-WXS-YKJ50W ; GLSS-SF-0065-TP-01D-WXS-1VUWY9 ; GLSS-SF-0065-R1-01D-WXS-E4LW7E ; GLSS-SF-0069-TP-01D-WXS-JF8SSL ; GLSS-SF-0069-R1-01D-WXS-PLEIXJ ; GLSS-SF-0157-TP-01D-WXS-NMIZPV ; GLSS-SF-0157-R1-01D-WXS-KSIL82 ; GLSS-SF-0161-TP-01D-WXS-S3V1GH ; GLSS-SF-0161-R1-01D-WXS-XPZCXZ ; GLSS-SF-0163-TP-01D-WXS-N80CE4 ; GLSS-SF-0163-R1-01D-WXS-OVVNPJ ; GLSS-SF-0170-TP-01D-WXS-2LVMI1 ; GLSS-SF-0170-R1-01D-WXS-1NVL4F ; GLSS-SF-0334-TP-01D-WXS-YSQ33X ; GLSS-SF-0334-R1-01D-WXS-0L7YS5 ; GLSS-SF-0339-TP-01D-WXS-3GNODK ; GLSS-SF-0339-R1-01D-WXS-VEE4IP ; GLSS-SM-R056-TP-01D-WXS-1BJVV2 ; GLSS-SM-R056-R3-01D-WXS-WNEBQS ; GLSS-SM-R057-TP-01D-WXS-8RSLYG ; GLSS-SM-R057-R2-01D-WXS-QYN028 ; GLSS-SM-R058-TP-01D-WXS-8BTMFP ; GLSS-SM-R058-R1-01D-WXS-USW92T ; GLSS-SM-R060-TP-01D-WXS-WWG8SV ; GLSS-SM-R060-R3-01D-WXS-UXGCSX ; GLSS-SM-R061-TP-01D-WXS-UZBY1Q ; GLSS-SM-R061-R1-01D-WXS-T05F82 ; GLSS-SM-R062-TP-01D-WXS-GVGM68 ; GLSS-SM-R062-R1-01D-WXS-PFNWTK ; GLSS-SM-R064-TP-01D-WXS-16OKWU ; GLSS-SM-R064-R2-01D-WXS-606Z2Z ; GLSS-SM-R066-TP-01D-WXS-YJN4OE ; GLSS-SM-R066-R1-01D-WXS-2R3RRY ; GLSS-SM-R067-TP-01D-WXS-LTGC1O ; GLSS-SM-R067-R1-01D-WXS-WG6N7X ; GLSS-SM-R068-TP-01D-WXS-5G9ZR6 ; GLSS-SM-R068-R1-01D-WXS-KBROK6 ; GLSS-SM-R070-TP-01D-WXS-VLPMYS ; GLSS-SM-R070-R1-01D-WXS-83NH8Q ; GLSS-SM-R071-TP-01D-WXS-45QCP2 ; GLSS-SM-R071-R1-01D-WXS-LZGI7S ; GLSS-SM-R075-TP-01D-WXS-06ZEZS ; GLSS-SM-R075-R1-01D-WXS-9J2QDT ; GLSS-SM-R076-R1-01D-WXS-1G879E ; GLSS-SM-R076-R3-01D-WXS-9993HH ; GLSS-SM-R096-TP-01D-WXS-VT1QFY ; GLSS-SM-R096-R1-01D-WXS-M2RDCL ; GLSS-SM-R097-TP-01D-WXS-CS9Y06 ; GLSS-SM-R097-R1-01D-WXS-6RUXOY ; GLSS-SM-R100-TP-01D-WXS-9D7AET ; GLSS-SM-R100-R1-01D-WXS-O61DWB ; GLSS-SM-R101-TP-01D-WXS-QXZ8TD ; GLSS-SM-R101-R1-01D-WXS-04ZGTS ; GLSS-SM-R106-TP-01D-WXS-8H4HYR ; GLSS-SM-R106-R1-01D-WXS-B6X7IN ; GLSS-SM-R107-TP-01D-WXS-NIBO3N ; GLSS-SM-R107-R1-01D-WXS-66033B ; GLSS-SM-R108-TP-01D-WXS-KC4OXZ ; GLSS-SM-R108-R1-01D-WXS-YRYRWN ; GLSS-SM-R109-TP-01D-WXS-G7JJJZ ; GLSS-SM-R109-R1-01D-WXS-QM3IL8 ; GLSS-SM-R110-TP-01D-WXS-5XSI28 ; GLSS-SM-R110-R1-01D-WXS-I5HNRJ ; GLSS-SU-0001-TP-01D-WXS-AAGX08 ; GLSS-SU-0001-R1-01D-WXS-KBPRAC ; GLSS-SU-0004-TP-01D-WXS-M55Z5F ; GLSS-SU-0004-R1-01D-WXS-J9A89B ; GLSS-SU-0005-TP-01D-WXS-I9QBMT ; GLSS-SU-0005-R2-01D-WXS-M1MPPT ; GLSS-SU-0007-TP-01D-WXS-JD8BBD ; GLSS-SU-0007-R1-01D-WXS-L2EDTA ; GLSS-SU-0202-TP-01D-WXS-ZHIFBQ ; GLSS-SU-0202-R1-01D-WXS-JMN5OU ; GLSS-SU-0270-TP-01D-WXS-DFN90U ; GLSS-SU-0270-R2-01D-WXS-YATWRO ; TCGA-06-0125-TP-01D-WGS-FZT8H0 ; TCGA-06-0125-R1-11D-WGS-MA69JO ; TCGA-06-0152-TP-02D-WGS-6HJBZJ ; TCGA-06-0152-R1-01D-WGS-EK2VYI ; TCGA-06-0171-TP-02D-WGS-LIDF0X ; TCGA-06-0171-R1-11D-WGS-8809O1 ; TCGA-06-0190-TP-01D-WGS-BM9MHX ; TCGA-06-0190-R1-01D-WGS-P20F5P ; TCGA-06-0210-TP-01D-WGS-CDCYDJ ; TCGA-06-0210-R1-01D-WGS-PS45ZE ; TCGA-06-0211-TP-01D-WGS-JJPE5C ; TCGA-06-0211-R1-02D-WGS-32OOWA ; TCGA-06-0221-TP-01D-WGS-0LWP9U ; TCGA-06-0221-R1-11D-WGS-XGUB7X ; TCGA-14-0736-TP-01D-WXS-GUOP0E ; TCGA-14-0736-R1-01D-WXS-ACUYOJ ; TCGA-14-1034-TP-01D-WGS-2521IS ; TCGA-14-1034-R1-01D-WGS-L9V6H0 ; TCGA-14-1402-TP-01D-WGS-WT36NV ; TCGA-14-1402-R1-01D-WGS-2EHMQ2 ; TCGA-19-0957-TP-02D-WXS-2GJCQI ; TCGA-19-0957-R1-11D-WXS-PQFJEA ; TCGA-DH-A669-TP-12D-WGS-LX89QR ; TCGA-DH-A669-R1-11D-WGS-A9RS5I ; TCGA-DU-5870-TP-11D-WGS-BQPWUS ; TCGA-DU-5870-R1-12D-WGS-UNYI3Z ; TCGA-DU-6397-TP-11D-WGS-OXOUDE ; TCGA-DU-6397-R1-12D-WGS-TX5QZZ ; TCGA-DU-6404-TP-11D-WGS-7DHU4O ; TCGA-DU-6404-R2-11D-WGS-9OCYC1 ; TCGA-DU-6407-TP-13D-WGS-XX8PCJ ; TCGA-DU-6407-R2-11D-WGS-C4L105 ; TCGA-DU-7304-TP-12D-WGS-KB0230 ; TCGA-DU-7304-R1-12D-WGS-TNHHDG ; TCGA-FG-5963-TP-11D-WXS-BX105O ; TCGA-FG-5963-R1-12D-WXS-XI05S1 ; TCGA-FG-5965-TP-11D-WGS-YPJ8SN ; TCGA-FG-5965-R2-11D-WGS-CEY3XC ; TCGA-FG-A4MT-TP-11D-WGS-CKF1QJ ; TCGA-FG-A4MT-R1-11D-WGS-1EGEOR ; TCGA-TM-A7CF-TP-11D-WGS-RON2FJ ; TCGA-TM-A7CF-R1-11D-WGS-R1PAAT ; TCGA-TQ-A7RK-TP-11D-WGS-HWJ4F6 ; TCGA-TQ-A7RK-R2-11D-WGS-1Z719P ; TCGA-TQ-A7RV-TP-21D-WGS-TR9682 ; TCGA-TQ-A7RV-R1-11D-WGS-CWZQZJ ; TCGA-TQ-A8XE-TP-11D-WGS-MF1R7Z ; TCGA-TQ-A8XE-R1-11D-WGS-M2U7J4
ALKYLATING_AGENT	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Alkylating Agent Treatment	Sample	Yes ; No
ANEUPLOIDY_AMP_SCORE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Aneuploidy Amplification Score	Sample	8 ; 4 ; 2 ; 3 ; 5 ; 1 ; 6 ; 0 ; 7 ; 14 ; 13 ; 9 ; 10 ; 15 ; 18 ; 17
ANEUPLOIDY_DEL_SCORE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Aneuploidy Deletion Score	Sample	1 ; 0 ; 4 ; 3 ; 2 ; 8 ; 5 ; 7 ; 6 ; 11 ; 9 ; 13 ; 14 ; 10
CASE_PROJECT	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Indicates whether the data was collected for the purpose of GLASS or TCGA	Patient	
CHEMO_OTHER	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	A comma separated list indicating combination of specific chemotherapeutic agents as well as unspecified agents	Sample	0 ; HSPPC-96 vaccine ; Bevacizumab ; Bevasizumab ; DC vaccine ; Procarbazine, Optune device ; dcVax ; Fotemustine ; Cisplatin ; Bevacizumab, Lomustine, Carboplatin, Cediranib, Cilengitide ; Cediranib, Cilengitide ; Bevacizumab, Irinotecan, Carboplatin ; Lomustine ; Dacomitinib ; Bevacizumab, Carboplatin, Lomustine ; Iniparib ; Celgene CC-15 ; Bevacizumab, Vorinostat ; Lomustine, Procarbazine ; Bevacizumab, Lomustine ; Carmustine ; Yes ; Mefloquine ; Pembrolizumab; Bevacizumab ; Tasadeoturev ; Isotretinoin; Bevacizumab, Carboplatin ; Isotretinoin ; Isotretinoin; Macitentan ; Lomustine; Nivolumab; Bevacizumab; Carboplatin; Galunisertib ; ROVA-T ; Crenolanib ; Mefloquine, Memantine ; Bevacizumab, Carboplatin ; Macitentan; Lapatinib; Tasadenoturev; Bevacizumab; Buparlisib; Lomustine; Pembrolizumab ; Bevacizumab, Lomustine; Carboplatin ; Lomustine, Procarbazine; Vincristine ; Pembrolizumab ; Cabivalizumab, Nivolumab; Bevacizumab; Lomustine ; Bevacizumab, Lomustine; Carboplatin; Bevacizumab, Irinotecan ; PCV ; Bevacizumab, Irinotecan ; Bevacizumab, Irinotecan; Isotretinoin ; Irinotecan, lenaloidomide ; Bevacizumab, EGFR inhibitor, CCNU, CPT-11 ; Bevacizumab, MET inhibitor ; Bevacizumab, MTOR inhibitor ; Bevacizumab, CXCR4 inhibitor ; Bevacizumab, MTOR/VEGF inhibitor ; Bevacizumab, EGFR inhibitor, CCNU, MGA271 anti B7H3 infusion ; Bevacizumab, HDAC inhibitor ; Bevacizumab, CCNU ; Nivolumab ; Isotretinoin; Thalidomide ; Steroids ; Rad001 ; Methotrexate ; Bevacizumab, Irinotecan; TMZ LD ; TMZ LD ; Irinotecan, Cisplatin ; Carboplatin, Etoposide ; Afatinib; TMZ LD ; PCV; TMZ LD ; Carmustine, Paclitaxel ; CI-980 ; CAI (NABTT 97212) ; SWOG9402/RTOG ; Irinotecan ; Afatinib ; Bevacizumab, Carmustine
CHEMO_OTHER_CYCLES	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Treatment cycles for the therapies listed in Chemotherapy Other.	Sample	5 ; 15 ; 25 ; 6 ; 3, 199 days ; 1 ; 3 ; 2 ; 22 mths ; 4, NA ; 1 injection to brain ; 1, 2 mths ; 58 mths ; > 6 mths ; NA, 12 ; 1 mth ; 11 ; 12, 8, 12, 2.5, 1, 5, 12 ; NA, 4yrs ; 5,2 ; 4, 4, >6, NA ; na, 6 ; 12 ; 0 ; 7,7 ; 4 ; 10 ; 3, 4 ; 13 ; NA, 5 ; 1, 2
CONCURRENT_TMZ	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Indicates whether temozolomide was administered concurrently with radiotherapy	Sample	Yes ; No
HYPERMUTATION_STATUS	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Recurrent tumor in the tumor pairs have a mutation burden (Mutations/Mb) > 10?	Patient	
INITIAL_GRADE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Initial Grade	Patient	
INITIAL_HISTOLOGY	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Initial Tumor Histology	Patient	
MGMT_METHYLATION	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Clinical assessment of MGMT methylation	Sample	Methylated ; Unmethylated
MGMT_METHYLATION_METHOD	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	MGMT Methylation Method	Sample	Array ; PCR
MNP_CLASSIFICATION	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	DNA methylation-based classification of central nervous system tumors	Sample	CONTR, INFLAM ; GBM, MES ; GBM, RTK II ; CONTR, HEMI ; GBM, RTK I ; O IDH ; GBM, MID ; A IDH ; A IDH, HG ; HGNET, BCOR
POST_RECURRENCE_SURVIVAL_MONTHS	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Post Recurrence Survival(months)	Patient	
RADIATION_DOSE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	The dosage of radiation a subject received, reported in Gray units.	Sample	60 ; 32 ; 78 ; 100 ; 54 ; 47.5 ; 30 ; 40 ; 50 ; 57 ; 36 ; 59.4 ; 50.4 ; 43.2 ; 44 ; 45 ; 19 ; 32.7 ; 180 ; 28
RADIATION_OTHER	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Additional details about the specific application of radiotherapy	Sample	IMRT, Gamma knife ; IMRT ; Gamma knife ; Systemic ; EBRT ; FSRT ; Other ; Proton beam ; Conformal ; Proton 3d conformal
RADIOTHERAPY	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Indicates whether a subject received radiotherapy	Sample	Yes ; No
RADIOTHERAPY_FRACTIONS	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	The number of smaller number of radiation doses	Sample	30 ; 4 ; 31 ; 33 ; 50 ; 25 ; 20 ; 48 ; 28 ; 36 ; 27 ; 10 ; 18 ; 34 ; 200 ; 180
SURGERY NUMBER	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	An integer beginning at 1 to indicate temporal order of surgical samples	Sample	1 ; 2 ; 3 ; 4 ; 5
SURGERY_INDICATION	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	The listed reason why a surgery was performed.	Sample	Adjuvant ; Relapse ; Therapeutic ; Progression ; Prophylactic
TIME_TO_FIRST_RECURRENCE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Time to first recurrence (months)	Patient	
TISSUE_SOURCE	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	The Tissue source site for each subject	Patient	
TMZ_CYCLES	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	NUMBER	Number of temozolomide treatment cycles.	Sample	12 ; 5 ; 6 ; 7 ; 4 ; 2 ; 3 ; 9 ; 11 ; 20 ; 1 ; 35 ; 13 ; 24 ; 15 ; 8 ; 14 ; 26 ; 33
TMZ_TREATMENT	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Indicates whether a subject received temozolomide for each surgical sample	Sample	Yes ; No
TRANSCRIPTIONAL_SUBTYPES	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Transcriptional Subtype	Sample	Classical ; Proneural ; Mesenchymal
WHOLE_EXOME_SEQUENCED	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Whole Exome Sequenced	Patient	
WHOLE_GENOME_SEQUENCED	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	Whole Genome Sequenced	Patient	
WHO_CLASSIFICATION	Gray	Diffuse Glioma (GLASS Consortium, Nature 2019)	STRING	WHO Classification of tumors of the central nervous system.	Sample	Glioblastoma, IDH-wildtype ; Glioblastoma, IDH-mutant ; Diffuse Astrocytoma, IDH-mutant ; Anaplastic Astrocytoma, IDH-wildtype ; Anaplastic Astrocytoma, IDH-mutant ; Oligodendroglioma, IDH-mutant and 1p/19q-codeleted ; Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
ANIMAL_INSECT_ALLERGY_AGE	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Animal Insect Allergy Age	Patient	
ANIMAL_INSECT_ALLERGY_HIST	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Animal insect allergy history.	Patient	
ASTHMA_ECZEMA_ALLERGY_FIRST_DIAGNOSIS	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	First Diagnosis of Asthma Eczema Allergy	Patient	
ASTHMA_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Asthma history.	Patient	
ECZEMA_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	History of eczema.	Patient	
FAMILY_HISTORY_OF_CANCER	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Family history of cancer.	Patient	
FAMILY_HISTORY_OF_PRIMARY_BRAIN_TUMOR	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Family history of primary brain tumor.	Patient	
FIRST_SYMPTOM_LONGEST_DURATION	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	First symptom longest duration	Patient	
FOOD_ALLERGY_AGE	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Age of Food Allergy	Patient	
FOOD_ALLERGY_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Food allergy history.	Patient	
FOOD_ALLERGY_TYPES	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Food allergy types.	Patient	
HAY_FEVER_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Has history of fever.	Patient	
HEADACHE_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Has history of headaches.	Patient	
HISTORY_IONIZING_RT_TO_HEAD	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	History ionizing rt to head	Patient	
HISTORY_NEOADJUVANT_MEDICATION	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Text term to describe the patient's history of neoadjuvant treatment and the kind of treament given prior to resection of the tumor.	Patient	
HISTORY_NEOADJUVANT_STEROID_TX	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Preoperative corticosteroids	Patient	
IDH1_MUTATION_TEST_INDICATOR	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	IDH1 mutation test was performed.	Patient	
IDH1_MUTATION_TEST_METHOD	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Ldh1 mutation test method	Patient	
INHERITED_GENETIC_SYNDROME_INDICATOR	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Inherited genetic syndrome found	Patient	
INHERITED_GENETIC_SYNDROME_SPECIFIED	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Inherited genetic syndrome result	Patient	
MOLD_OR_DUST_ALLERGY_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	History of mold or dust allergy.	Patient	
PERFORMANCE_STATUS_DAYS_TO	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Days to initial score performance status scale	Patient	
RELATED_SYMPTOM_FIRST_PRESENT	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Related symptom first present	Patient	
SEIZURE_HISTORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Seizure history.	Patient	
SUPRATENTORIAL_LOCALIZATION	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Supratentorial localization.	Patient	
SYMP_CHANGES_MENTAL_STATUS	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Symp changes mental status	Patient	
SYMP_CHANGES_MOTOR_MOVEMENT	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Symp changes motor movement	Patient	
SYMP_CHANGES_SENSORY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Symp changes sensory	Patient	
SYMP_CHANGES_VISUAL	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Symp changes visual	Patient	
TARGETED_MOLECULAR_THERAPY	Gray	Brain Lower Grade Glioma (TCGA, Firehose Legacy)	STRING	Text term to signify postoperative adjuvant cancer therapies which use drugs to act upon specific molecules, metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. [Manually-curated]	Patient	
MOLECULAR_GROUP	Gray	Meningioma (University of Toronto, Nature 2021)	STRING	Indicator of Molecular Group	Sample	hypermetabolic ; Immunogenic ; MG2 ; proliferative
RECURRENCE	Gray	Meningioma (University of Toronto, Nature 2021)	STRING	Indicator of whether tumor recurred	Sample	yes ; no
CT_SCAN_PREOP_RESULTS	Gray	Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	STRING	Diagnostic ct result outcome	Patient	
DISEASE_DETECTED_ON_SCREENING	Gray	Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	STRING	Indicator to signify whether or not the disease was detected by screening.	Patient	
HISTORY_PHEO_OR_PARA_ANATOMIC_SITE	Gray	Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	STRING	Text field to describe the anatomic site of the prior pheochromocytoma or paraganglioma.	Patient	
HISTORY_PHEO_OR_PARA_INCLUDE_BENIGN	Gray	Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	STRING	Indicator to signify whether or not a patient has a history of pheochromocytoma or paraganglioma.	Patient	
RELATED_TUMORS_OUTSIDE_ADRENAL_GLANDS	Gray	Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	STRING	Text term to describe any tumor related to the specimen that is outside of the adrenal glands.	Patient	
ALIQUOT_ANALYSIS_TYPE	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Variable representing either whole genome sequencing (WGS) or whole exome sequencing (WXS)	Sample	WXS ; WXS, RNA ; RNA ; WGS, RNA ; WGS
ALKYLATING_AGENT_TX	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Treatment with alkylating agents	Sample	No ; Yes
CODEL_STATUS	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Codeletion status of chromosomal arms 1p and 19q	Sample	noncodel ; codel
DNA_ALIQUOT_BARCODE	Gray	Diffuse Glioma (GLASS Consortium)	STRING	A variable that stitches subject, sample type, portion, sequencing type, and a unique identifier together	Sample	GLSS-19-0266-R1-01D-WXS-0AUVTN ; GLSS-19-0266-TP-01D-WXS-F78XXN ; GLSS-19-0267-R1-01D-WXS-2AVAZ0 ; GLSS-19-0267-TP-01D-WXS-CS4K8X ; GLSS-19-0268-R1-01D-WXS-KDBRYM ; GLSS-19-0268-TP-01D-WXS-QGO6RP ; GLSS-19-0269-R1-01D-WXS-BMTNI5 ; GLSS-19-0269-TP-01D-WXS-G5IWER ; GLSS-19-0271-R1-01D-WXS-9657ZY ; GLSS-19-0271-TP-01D-WXS-3TI55F ; GLSS-19-0272-R1-01D-WXS-E5JC16 ; GLSS-19-0272-TP-01D-WXS-9YKK98 ; GLSS-19-0273-R1-01D-WXS-ZEKWL8 ; GLSS-19-0273-TP-01D-WXS-H00BNY ; GLSS-19-0274-R1-01D-WXS-IAULWM ; GLSS-19-0274-TP-01D-WXS-F3BOIM ; GLSS-19-0278-R1-01D-WXS-5MU7K1 ; GLSS-19-0278-TP-01D-WXS-59Y0J0 ; GLSS-19-0279-R1-01D-WXS-92Q692 ; GLSS-19-0279-R2-01D-WXS-TVJ8F8 ; GLSS-19-0279-TP-01D-WXS-GQ9A87 ; GLSS-19-0280-R1-01D-WXS-Z88Q0N ; GLSS-19-0280-TP-01D-WXS-V4MP15 ; GLSS-AT-00P1-R1-01D-WXS-437ED2 ; GLSS-AT-00P1-TP-01D-WXS-EF0XQE ; GLSS-AT-00P2-R1-01D-WXS-91HJSJ ; GLSS-AT-00P2-TP-01D-WXS-RBLYWF ; GLSS-AT-00P3-R1-01D-WXS-N2Q7XG ; GLSS-AT-00P3-TP-01D-WXS-T88KH3 ; GLSS-AT-00P4-R1-01D-WXS-REP89L ; GLSS-AT-00P4-TP-01D-WXS-EIOJQ8 ; GLSS-AT-00P5-R1-01D-WXS-8VNHLX ; GLSS-AT-00P5-TP-01D-WXS-QAIYAY ; GLSS-AT-00P6-R1-01D-WXS-JQX1ST ; GLSS-AT-00P6-TP-01D-WXS-A3KN92 ; GLSS-AT-00P7-R1-01D-WXS-K26V8Q ; GLSS-AT-00P7-TP-01D-WXS-N53RYM ; GLSS-AT-GP01-R1-01D-WXS-AZT8L7 ; GLSS-AT-GP01-TP-01D-WXS-TI55UY ; GLSS-CU-P003-R1-01D-WXS-C8CULF ; GLSS-CU-P003-TP-01D-WXS-RDWJOX ; GLSS-CU-P013-R1-01D-WXS-BXILBV ; GLSS-CU-P013-R2-01D-WXS-66RB3G ; GLSS-CU-P013-R3-01D-WXS-37WEX9 ; GLSS-CU-P020-R1-01D-WXS-8WJOL7 ; GLSS-CU-P020-R2-01D-WXS-4LGDBO ; GLSS-CU-P020-R3-01D-WXS-PG6PK1 ; GLSS-CU-P021-R1-01D-WXS-8QGOSS ; GLSS-CU-P021-R2-01D-WXS-ADYWU6 ; GLSS-CU-P021-TP-01D-WXS-Y82P1D ; GLSS-CU-P024-R1-01D-WXS-07EVRT ; GLSS-CU-P024-R2-01D-WXS-S4ILEI ; GLSS-CU-P024-TP-01D-WXS-GID8LY ; GLSS-CU-P046-R1-01D-WXS-GR5873 ; GLSS-CU-P046-TP-01D-WXS-T8ZFA7 ; GLSS-CU-P053-R1-01D-WXS-104YQT ; GLSS-CU-P053-R2-01D-WXS-XQU5PI ; GLSS-CU-P053-TP-01D-WXS-HNB8FO ; GLSS-CU-P055-R1-01D-WXS-CV1PJO ; GLSS-CU-P055-R2-01D-WXS-SCJCO1 ; GLSS-CU-P055-TP-01D-WXS-FS5YF2 ; GLSS-CU-P056-R1-01D-WXS-YP4X0P ; GLSS-CU-P056-R2-01D-WXS-MWYTTF ; GLSS-CU-P069-R1-01D-WXS-NI2L71 ; GLSS-CU-P069-TP-01D-WXS-9RCCCO ; GLSS-CU-P071-R1-01D-WXS-1VWGR3 ; GLSS-CU-P071-TP-01D-WXS-8HQOC8 ; GLSS-CU-P100-R1-01D-WXS-4YC6JF ; GLSS-CU-P100-R2-01D-WXS-H3H4QZ ; GLSS-CU-P101-R1-01D-WXS-572VXS ; GLSS-CU-P101-TP-01D-WXS-LOEA50 ; GLSS-CU-P102-R1-01D-WXS-5ZXJFT ; GLSS-CU-P102-TP-01D-WXS-3CTL6N ; GLSS-CU-R001-R1-01D-WXS-JPX46R ; GLSS-CU-R001-TP-01D-WXS-AMZ2L2 ; GLSS-CU-R002-R1-01D-WXS-K6YTXM ; GLSS-CU-R002-TP-01D-WXS-UVO6E0 ; GLSS-CU-R003-R1-01D-WXS-FGUFUE ; GLSS-CU-R003-TP-01D-WXS-2K70Z2 ; GLSS-CU-R004-R1-01D-WXS-WV26B3 ; GLSS-CU-R004-TP-01D-WXS-46GQ36 ; GLSS-CU-R005-R1-01D-WXS-78REC1 ; GLSS-CU-R005-TP-01D-WXS-TOQ8RG ; GLSS-CU-R006-R1-01D-WXS-OQXLD2 ; GLSS-CU-R006-TP-01D-WXS-NBP8Q6 ; GLSS-CU-R007-R1-01D-WXS-Y6X0JQ ; GLSS-CU-R007-TP-01D-WXS-TUWWCG ; GLSS-CU-R008-R1-01D-WXS-TCGMUM ; GLSS-CU-R008-TP-01D-WXS-0238UJ ; GLSS-CU-R009-R1-01D-WXS-6KTSKN ; GLSS-CU-R009-TP-01D-WXS-6VKK28 ; GLSS-CU-R010-R1-01D-WXS-LC99UJ ; GLSS-CU-R010-TP-01D-WXS-MWMVOK ; GLSS-CU-R011-R1-01D-WXS-FCKN39 ; GLSS-CU-R011-TP-01D-WXS-BHD2A1 ; GLSS-CU-R012-R1-01D-WXS-UM4BXY ; GLSS-CU-R012-TP-01D-WXS-98HFOG ; GLSS-CU-R013-R1-01D-WXS-PWPOB5 ; GLSS-CU-R013-TP-01D-WXS-90BYMA ; GLSS-CU-R014-R1-01D-WXS-C9ODK4 ; GLSS-CU-R014-TP-01D-WXS-E86YTX ; GLSS-CU-R015-R1-01D-WXS-N22X13 ; GLSS-CU-R015-TP-01D-WXS-CPT7WM ; GLSS-CU-R016-R1-01D-WXS-T8EO52 ; GLSS-CU-R016-TP-01D-WXS-536A57 ; GLSS-CU-R017-R1-01D-WXS-C0CBCW ; GLSS-CU-R017-TP-01D-WXS-80WCK4 ; GLSS-CU-R018-R1-01D-WXS-PKDTNA ; GLSS-CU-R018-TP-01D-WXS-RTZK1Q ; GLSS-CU-R019-R1-01D-WXS-NAXQ9K ; GLSS-CU-R019-TP-01D-WXS-ZMMX2S ; GLSS-DF-0002-R1-01D-WXS-9PUE7K ; GLSS-DF-0002-TP-01D-WXS-JA9RJG ; GLSS-DF-0003-R1-01D-WXS-BKUKVH ; GLSS-DF-0003-TP-01D-WXS-IMR04G ; GLSS-DF-0004-R1-01D-WXS-I8R74A ; GLSS-DF-0004-TP-01D-WXS-2I99NC ; GLSS-DF-0006-R1-01D-WXS-TXXURV ; GLSS-DF-0006-TP-01D-WXS-O9DBZ4 ; GLSS-DF-0007-R1-01D-WXS-C7TKYT ; GLSS-DF-0007-TP-01D-WXS-YYWNSP ; GLSS-DF-0010-R1-01D-WXS-FDYDJ7 ; GLSS-DF-0010-TP-01D-WXS-BBMLTJ ; GLSS-DF-0012-R1-01D-WXS-QGRYN1 ; GLSS-DF-0012-TP-01D-WXS-MRWC9M ; GLSS-DF-0013-R1-01D-WXS-GGA62B ; GLSS-DF-0013-TP-01D-WXS-X404M0 ; GLSS-DF-0014-R1-01D-WXS-ZZNMIY ; GLSS-DF-0014-TP-01D-WXS-H9KDMM ; GLSS-DK-0001-R1-01D-WXS-D6A176 ; GLSS-DK-0001-TP-01D-WXS-CB26AA ; GLSS-DK-0002-R1-01D-WXS-631C19 ; GLSS-DK-0002-TP-01D-WXS-A2DF51 ; GLSS-DK-0003-R1-01D-WXS-89A5CD ; GLSS-DK-0003-TP-01D-WXS-E43D26 ; GLSS-DK-0004-R1-01D-WXS-BBC731 ; GLSS-DK-0004-TP-01D-WXS-6BD61E ; GLSS-DK-0005-R1-01D-WXS-8A678C ; GLSS-DK-0005-TP-01D-WXS-EFBF4F ; GLSS-DK-0006-R1-01D-WXS-CB1447 ; GLSS-DK-0006-TP-01D-WXS-47D949 ; GLSS-DK-0007-R1-01D-WXS-EB6DFA ; GLSS-DK-0007-TP-01D-WXS-D7676B ; GLSS-DK-0008-R1-01D-WXS-DDD4B8 ; GLSS-DK-0008-TP-01D-WXS-6C3ABC ; GLSS-DK-0009-R1-01D-WXS-E4E4D7 ; GLSS-DK-0009-TP-01D-WXS-291A6E ; GLSS-DK-0010-R1-01D-WXS-5EDAC1 ; GLSS-DK-0010-TP-01D-WXS-7155DD ; GLSS-DK-0011-R1-01D-WXS-F55FA3 ; GLSS-DK-0011-TP-01D-WXS-B8468B ; GLSS-DK-0012-R1-01D-WXS-59BDDF ; GLSS-DK-0012-TP-01D-WXS-93BDF8 ; GLSS-DK-0013-R1-01D-WXS-5EF8E1 ; GLSS-DK-0013-TP-01D-WXS-48CFAE ; GLSS-DK-0014-R1-01D-WXS-259416 ; GLSS-DK-0014-TP-01D-WXS-731C2B ; GLSS-DK-0015-R1-01D-WXS-4B4982 ; GLSS-DK-0015-TP-01D-WXS-345234 ; GLSS-HF-1CCD-R1-01D-WXS-8NJYI2 ; GLSS-HF-1CCD-R2-01D-WXS-797PXN ; GLSS-HF-1DDC-R1-01D-WXS-Z3CV3L ; GLSS-HF-1DDC-TP-01D-WXS-78JBF3 ; GLSS-HF-4B46-R1-01D-WXS-2M66B0 ; GLSS-HF-4B46-TP-01D-WXS-RERKH8 ; GLSS-HF-4D9A-R1-01D-WXS-IZDOCT ; GLSS-HF-4D9A-TP-01D-WXS-FWAHDX ; GLSS-HF-4F0A-R1-01D-WXS-V6CC7C ; GLSS-HF-4F0A-R2-01D-WXS-YBRWA9 ; GLSS-HF-4F0A-TP-01D-WXS-TGKMFA ; GLSS-HF-7CAC-R1-01D-WXS-RYHJZB ; GLSS-HF-7CAC-TP-01D-WXS-GDULCW ; GLSS-HF-8FCD-R1-01D-WXS-EB7FNG ; GLSS-HF-8FCD-TP-01D-WXS-8ERISO ; GLSS-HF-9A7A-R1-01D-WXS-XNY5E8 ; GLSS-HF-9A7A-TP-01D-WXS-W98DVW ; GLSS-HF-50F3-R2-01D-WXS-HBGS0K ; GLSS-HF-50F3-TP-01D-WXS-PY09HK ; GLSS-HF-57AE-R1-01D-WXS-9SQZEU ; GLSS-HF-57AE-TP-01D-WXS-WT5SNZ ; GLSS-HF-2548-R1-01D-WXS-DN2HD4 ; GLSS-HF-2548-TP-01D-WXS-CPWUK8 ; GLSS-HF-2829-R1-01D-WXS-W19NLP ; GLSS-HF-2829-TP-01D-WXS-1OMY6S ; GLSS-HF-2869-R3-01D-WXS-07LI3A ; GLSS-HF-2869-TP-01D-WXS-PNBQFR ; GLSS-HF-2919-R1-01D-WXS-CG67L5 ; GLSS-HF-2919-TP-01D-WXS-MIYI2Q ; GLSS-HF-2934-R1-01D-WXS-MXE1L3 ; GLSS-HF-2934-TP-01D-WXS-OIDP86 ; GLSS-HF-3016-R1-01D-WXS-M4KINS ; GLSS-HF-3016-TP-01D-WXS-LVAM11 ; GLSS-HF-3050-R1-01D-WXS-6ELHQ3 ; GLSS-HF-3050-TP-01D-WXS-ECTQ63 ; GLSS-HF-3081-R2-01D-WXS-4LBL2G ; GLSS-HF-3081-TP-01D-WXS-V0EK51 ; GLSS-HF-3118-R1-01D-WXS-QRF6VZ ; GLSS-HF-3118-TP-01D-WXS-KVSTBB ; GLSS-HF-3162-R1-01D-WXS-3HVQJ6 ; GLSS-HF-3162-TP-01D-WXS-HTQZ6B ; GLSS-HF-6504-R1-01D-WXS-JWA7VK ; GLSS-HF-6504-TP-01D-WXS-V8VED1 ; GLSS-HF-6658-R1-01D-WXS-S2ACVZ ; GLSS-HF-6658-TP-01D-WXS-GISZKR ; GLSS-HF-B972-R1-01D-WXS-6UZ82C ; GLSS-HF-B972-TP-01D-WXS-9ZSCA1 ; GLSS-HF-BCDE-R3-01D-WXS-D9V6I1 ; GLSS-HF-BCDE-TP-01D-WXS-BP459O ; GLSS-HF-DE05-R1-01D-WXS-U9F8E7 ; GLSS-HF-DE05-TP-01D-WXS-44QP3Q ; GLSS-HF-DF35-R1-01D-WXS-B4D43W ; GLSS-HF-DF35-TP-01D-WXS-MGXP1N ; GLSS-HF-EE74-R1-01D-WXS-5AS51O ; GLSS-HF-EE74-TP-01D-WXS-E5C4YL ; GLSS-HF-EE77-R1-01D-WXS-TY2KA7 ; GLSS-HF-EE77-R2-01D-WXS-AVCL6Q ; GLSS-HF-EE77-R3-01D-WXS-ZRNNYZ ; GLSS-HK-0001-R1-01D-WGS-23BINE ; GLSS-HK-0001-TP-01D-WGS-HLH6TO ; GLSS-HK-0002-R1-01D-WGS-S3QETN ; GLSS-HK-0002-TP-01D-WGS-DRX7N4 ; GLSS-HK-0003-R1-01D-WGS-R7P485 ; GLSS-HK-0003-TP-01D-WGS-WAGBN9 ; GLSS-HK-0004-R1-01D-WGS-RYFPEB ; GLSS-HK-0004-TP-01D-WGS-SJJS0H ; GLSS-HK-0005-R1-01D-WGS-ODRHPZ ; GLSS-HK-0005-TP-01D-WGS-9DKW7W ; GLSS-JX-0006-R1-01D-WXS-F732CR ; GLSS-JX-0006-TP-01D-WXS-TJWESP ; GLSS-LU-0B10-R1-01D-WXS-LL3UDE ; GLSS-LU-0B10-TP-01D-WXS-FUQXJ0 ; GLSS-LU-0B12-R1-01D-WXS-NXWOWA ; GLSS-LU-0B12-TP-01D-WXS-JX61DS ; GLSS-LU-0B13-R1-01D-WXS-F05JM5 ; GLSS-LU-0B13-TP-01D-WXS-H3ZZFP ; GLSS-LU-00A1-R1-01D-WXS-6OOP64 ; GLSS-LU-00A1-TP-01D-WXS-41PMU1 ; GLSS-LU-00B9-R1-01D-WXS-LM12XS ; GLSS-LU-00B9-TP-01D-WXS-RXEX90 ; GLSS-LU-00C1-R1-01D-WXS-4XD7S0 ; GLSS-LU-00C1-TP-01D-WXS-K8YYUW ; GLSS-LU-00C2-R1-01D-WXS-YYR15P ; GLSS-LU-00C2-TP-01D-WXS-4OMXNF ; GLSS-LU-00C4-R1-01D-WXS-KYPFOQ ; GLSS-LU-00C4-TP-01D-WXS-S4OOP1 ; GLSS-LU-00C7-R1-01D-WXS-3M3F98 ; GLSS-LU-00C7-TP-01D-WXS-WFSIQ7 ; GLSS-MD-0001-R1-01D-WGS-82NVSS ; GLSS-MD-0001-TP-01D-WGS-GETLNC ; GLSS-MD-0003-R1-01D-WGS-50P3GN ; GLSS-MD-0003-R2-01D-WGS-ZHH6RG ; GLSS-MD-0003-R3-01D-WGS-I78LK2 ; GLSS-MD-0004-R1-01D-WGS-1NXLKI ; GLSS-MD-0004-R2-01D-WGS-ZIOL89 ; GLSS-MD-0005-R1-01D-WGS-QG6Q3V ; GLSS-MD-0005-TP-01D-WGS-MKBGI6 ; GLSS-MD-0006-R1-01D-WGS-GSVE2C ; GLSS-MD-0006-TP-01D-WGS-J297AW ; GLSS-MD-0007-R1-01D-WGS-DWNQLW ; GLSS-MD-0007-TP-01D-WGS-QCMUUE ; GLSS-MD-0008-R1-01D-WGS-A6VIV6 ; GLSS-MD-0008-R2-01D-WGS-RQXJPE ; GLSS-MD-0009-R1-01D-WGS-BS97I9 ; GLSS-MD-0009-TP-01D-WGS-3XAL3U ; GLSS-MD-0010-R1-01D-WGS-6IK49P ; GLSS-MD-0010-R2-01D-WGS-Y3RYTB ; GLSS-MD-0010-R3-01D-WGS-NYYC95 ; GLSS-MD-0012-R1-01D-WGS-BKW5E7 ; GLSS-MD-0012-TP-01D-WGS-EOOJFG ; GLSS-MD-0014-R1-01D-WGS-GLH38H ; GLSS-MD-0014-TP-01D-WGS-F4GXRX ; GLSS-MD-0017-R1-01D-WGS-23D6A6 ; GLSS-MD-0017-R2-01D-WGS-96HR1I ; GLSS-MD-0018-R1-01D-WGS-VD14B5 ; GLSS-MD-0018-R2-01D-WGS-4784ZB ; GLSS-MD-0020-R1-01D-WGS-UP9H2C ; GLSS-MD-0020-TP-01D-WGS-6T2E56 ; GLSS-MD-0021-R1-01D-WGS-UYTS9R ; GLSS-MD-0021-TP-01D-WGS-YMNBEZ ; GLSS-MD-0022-R1-01D-WGS-F5KYZ6 ; GLSS-MD-0022-TP-01D-WGS-ZAET2D ; GLSS-MD-0023-R1-01D-WGS-DQH2SF ; GLSS-MD-0023-TP-01D-WGS-JDO9G6 ; GLSS-MD-0025-R1-01D-WGS-3BU9LU ; GLSS-MD-0025-TP-01D-WGS-ZAU2VG ; GLSS-MD-0026-R1-01D-WGS-X87FCV ; GLSS-MD-0026-TP-01D-WGS-2PPGFK ; GLSS-MD-0027-R1-01D-WGS-88ST4Y ; GLSS-MD-0027-R2-01D-WGS-55XI5C ; GLSS-MD-0027-TP-01D-WGS-6HFKNZ ; GLSS-MD-0030-R1-01D-WGS-YWXQDS ; GLSS-MD-0030-TP-01D-WGS-NBC5N6 ; GLSS-MD-0031-R1-01D-WGS-PHHBPT ; GLSS-MD-0031-TP-01D-WGS-0XZCQS ; GLSS-MD-0032-R1-01D-WGS-3XUVX2 ; GLSS-MD-0032-TP-01D-WGS-FIN5CE ; GLSS-MD-0035-R1-01D-WGS-HX1AIL ; GLSS-MD-0035-TP-01D-WGS-DJ3SQ1 ; GLSS-MD-0036-R1-01D-WGS-YFD61N ; GLSS-MD-0036-TP-01D-WGS-9FDX42 ; GLSS-MD-0038-R1-01D-WGS-0F9XP5 ; GLSS-MD-0038-TP-01D-WGS-KZL25H ; GLSS-MD-0041-R1-01D-WGS-48VFHO ; GLSS-MD-0041-TP-01D-WGS-HOGYPE ; GLSS-MD-0042-R1-01D-WGS-60V40X ; GLSS-MD-0042-TP-01D-WGS-R5UYLI ; GLSS-MD-0043-R1-01D-WGS-U1JONN ; GLSS-MD-0043-TP-01D-WGS-A5EGFI ; GLSS-MD-0044-R1-01D-WGS-VG0QP6 ; GLSS-MD-0044-TP-01D-WGS-HYEURJ ; GLSS-MD-0045-R1-01D-WGS-C4DXSR ; GLSS-MD-0045-TP-01D-WGS-NJCMTP ; GLSS-MD-0046-R1-01D-WGS-41DC6M ; GLSS-MD-0046-TP-01D-WGS-YZL1C9 ; GLSS-MD-0047-R1-01D-WGS-EYNB74 ; GLSS-MD-0047-TP-01D-WGS-ZDKQVK ; GLSS-MD-0048-R1-01D-WGS-TTN4CQ ; GLSS-MD-0048-TP-01D-WGS-0WRD31 ; GLSS-MD-0049-R1-01D-WGS-5F93TI ; GLSS-MD-0049-TP-01D-WGS-WP8NAY ; GLSS-MD-0082-R1-01D-WXS-TXII31 ; GLSS-MD-0082-TP-01D-WXS-YMHT7Q ; GLSS-MD-0086-R1-01D-WXS-OH39R4 ; GLSS-MD-0086-TP-01D-WXS-CYNFLN ; GLSS-MD-0088-R1-01D-WXS-URR2ME ; GLSS-MD-0088-TP-01D-WXS-APZEF6 ; GLSS-MD-0089-R1-01D-WXS-VKVV0H ; GLSS-MD-0089-TP-01D-WXS-E45R14 ; GLSS-MD-0090-R1-01D-WXS-XPV1K5 ; GLSS-MD-0090-TP-01D-WXS-LZ4WUR ; GLSS-MD-0091-R1-01D-WXS-L6Z2QQ ; GLSS-MD-0091-TP-01D-WXS-VO372O ; GLSS-MD-0092-R1-01D-WXS-XOX7KY ; GLSS-MD-0092-TP-01D-WXS-MZ6SGD ; GLSS-MD-0093-R1-01D-WXS-PR89I0 ; GLSS-MD-0093-TP-01D-WXS-YMF2N3 ; GLSS-MD-0094-R1-01D-WXS-K7SI29 ; GLSS-MD-0094-TP-01D-WXS-VVCCM6 ; GLSS-MD-0097-R1-01D-WXS-NH5UNL ; GLSS-MD-0097-TP-01D-WXS-CLR2TN ; GLSS-MD-0112-R1-01D-WXS-GI18JQ ; GLSS-MD-0112-TP-01D-WXS-P1B0I2 ; GLSS-MD-0113-R1-01D-WXS-OS8XKL ; GLSS-MD-0113-R4-01D-WXS-X31NXD ; GLSS-MD-LP01-R1-01D-WXS-ONMB78 ; GLSS-MD-LP01-TP-01D-WXS-RFYAC8 ; GLSS-MD-LP02-R1-01D-WXS-ZGA0ZV ; GLSS-MD-LP02-TP-01D-WXS-OC178I ; GLSS-MD-LP04-R1-01D-WXS-V7XG09 ; GLSS-MD-LP04-TP-01D-WXS-05SV1D ; GLSS-MD-LP10-R1-01D-WXS-K07GLN ; GLSS-MD-LP10-TP-01D-WXS-2KGBKN ; GLSS-MG-0001-R1-01D-WXS-KUUHMO ; GLSS-MG-0001-TP-01D-WXS-7CRPEF ; GLSS-MG-0002-R1-01D-WXS-MLW9TC ; GLSS-MG-0002-TP-01D-WXS-W3JS2F ; GLSS-MG-0003-R1-01D-WXS-Y1TGHY ; GLSS-MG-0003-TP-01D-WXS-SRC20T ; GLSS-MG-0005-R1-01D-WXS-8KI783 ; GLSS-MG-0005-TP-01D-WXS-MD8RED ; GLSS-MG-0006-R1-01D-WXS-072BAX ; GLSS-MG-0006-TP-01D-WXS-VSER24 ; GLSS-MG-0007-R2-01D-WXS-5XV0I5 ; GLSS-MG-0007-TP-01D-WXS-BNZXM5 ; GLSS-MG-0009-R1-01D-WXS-T777VC ; GLSS-MG-0009-TP-01D-WXS-A83E13 ; GLSS-MG-0010-R1-01D-WXS-QLBYAS ; GLSS-MG-0010-TP-01D-WXS-V8HH7C ; GLSS-MG-0011-R1-01D-WXS-8NM6IG ; GLSS-MG-0011-TP-01D-WXS-3B08NI ; GLSS-MG-0015-R1-01D-WXS-K1FPBB ; GLSS-MG-0015-TP-01D-WXS-XPXMSK ; GLSS-NS-0001-M1-01D-WGS-3EWGRP ; GLSS-NS-0001-R1-01D-WGS-BTT5FG ; GLSS-NS-0001-R2-01D-WGS-VEOP01 ; GLSS-NS-0001-TP-01D-WGS-5A5UN4 ; GLSS-SF-0001-R1-01D-WXS-PUNEIR ; GLSS-SF-0001-TP-01D-WXS-F99505 ; GLSS-SF-0002-R1-01D-WXS-6KLY6J ; GLSS-SF-0002-TP-01D-WXS-EC52GX ; GLSS-SF-0004-R1-01D-WXS-XMXOQ8 ; GLSS-SF-0004-R2-01D-WXS-5WQPVK ; GLSS-SF-0004-R3-01D-WXS-4F8MUY ; GLSS-SF-0004-TP-01D-WXS-78O1ND ; GLSS-SF-0005-R1-01D-WXS-5SB5V7 ; GLSS-SF-0005-TP-01D-WXS-0TWD9H ; GLSS-SF-0006-R1-01D-WXS-H09GIV ; GLSS-SF-0006-TP-01D-WXS-DPZUQR ; GLSS-SF-0007-R1-01D-WXS-2GZMIF ; GLSS-SF-0007-TP-01D-WXS-HSNHN7 ; GLSS-SF-0008-R1-01D-WXS-FEWO0E ; GLSS-SF-0008-TP-01D-WXS-9702S9 ; GLSS-SF-0009-R1-01D-WXS-5VVKB4 ; GLSS-SF-0009-TP-01D-WXS-31SKZ3 ; GLSS-SF-0010-R1-01D-WXS-4GJVKE ; GLSS-SF-0010-TP-01D-WXS-XAUHJB ; GLSS-SF-0011-R1-01D-WXS-MOTXHW ; GLSS-SF-0011-TP-01D-WXS-YIYP4N ; GLSS-SF-0012-R1-01D-WXS-M12I6U ; GLSS-SF-0012-TP-01D-WXS-SRHC7M ; GLSS-SF-0013-R1-01D-WXS-L8P0AA ; GLSS-SF-0013-TP-01D-WXS-5X46IS ; GLSS-SF-0015-R1-01D-WXS-3OV08S ; GLSS-SF-0015-TP-01D-WXS-4C169X ; GLSS-SF-0016-R1-01D-WXS-MEQ5DP ; GLSS-SF-0016-TP-01D-WXS-K4PGE4 ; GLSS-SF-0017-R1-01D-WXS-GS3ZR5 ; GLSS-SF-0017-R2-01D-WXS-B07OW0 ; GLSS-SF-0017-R3-01D-WXS-1GIK2T ; GLSS-SF-0017-R4-01D-WXS-538EL1 ; GLSS-SF-0017-TP-01D-WXS-D3XB6V ; GLSS-SF-0018-R1-01D-WXS-CLV5YX ; GLSS-SF-0018-TP-01D-WXS-KN7XVP ; GLSS-SF-0020-R1-01D-WXS-M3MLAF ; GLSS-SF-0020-TP-01D-WXS-K8Y64B ; GLSS-SF-0021-R1-01D-WXS-L2RH7S ; GLSS-SF-0021-TP-01D-WXS-C6VWGG ; GLSS-SF-0024-R1-01D-WXS-3Z2SQY ; GLSS-SF-0024-R2-01D-WXS-LJCU73 ; GLSS-SF-0024-TP-01D-WXS-BIE2XK ; GLSS-SF-0025-R1-01D-WXS-8OMVL5 ; GLSS-SF-0025-TP-01D-WXS-QRHTEC ; GLSS-SF-0026-R1-01D-WXS-AXDNA7 ; GLSS-SF-0026-TP-01D-WXS-7VO69E ; GLSS-SF-0027-R1-01D-WXS-DXCHYH ; GLSS-SF-0027-TP-01D-WXS-QW4L0L ; GLSS-SF-0028-R1-01D-WXS-QL95F2 ; GLSS-SF-0028-TP-01D-WXS-MURKV4 ; GLSS-SF-0029-R1-01D-WXS-ZVHMTT ; GLSS-SF-0029-TP-01D-WXS-RS22IE ; GLSS-SF-0032-R1-01D-WXS-2Z6C1O ; GLSS-SF-0032-TP-01D-WXS-QSXK5U ; GLSS-SF-0039-R1-01D-WXS-7FTNOF ; GLSS-SF-0039-TP-01D-WXS-TBB44D ; GLSS-SF-0058-R1-01D-WXS-N2AFHP ; GLSS-SF-0058-TP-01D-WXS-O9J9FW ; GLSS-SF-0060-R1-01D-WXS-YKJ50W ; GLSS-SF-0060-TP-01D-WXS-F9T3B8 ; GLSS-SF-0065-R1-01D-WXS-E4LW7E ; GLSS-SF-0065-TP-01D-WXS-1VUWY9 ; GLSS-SF-0069-R1-01D-WXS-PLEIXJ ; GLSS-SF-0069-TP-01D-WXS-JF8SSL ; GLSS-SF-0131-R1-01D-WXS-LK7F32 ; GLSS-SF-0131-TP-01D-WXS-3LDK21 ; GLSS-SF-0157-R1-01D-WXS-KSIL82 ; GLSS-SF-0157-TP-01D-WXS-NMIZPV ; GLSS-SF-0159-R1-01D-WXS-H36CYT ; GLSS-SF-0159-TP-01D-WXS-5CJXK9 ; GLSS-SF-0161-R1-01D-WXS-XPZCXZ ; GLSS-SF-0161-TP-01D-WXS-S3V1GH ; GLSS-SF-0163-R1-01D-WXS-OVVNPJ ; GLSS-SF-0163-TP-01D-WXS-N80CE4 ; GLSS-SF-0170-R1-01D-WXS-1NVL4F ; GLSS-SF-0170-TP-01D-WXS-2LVMI1 ; GLSS-SF-0334-R1-01D-WXS-0L7YS5 ; GLSS-SF-0334-TP-01D-WXS-YSQ33X ; GLSS-SF-0338-R1-01D-WXS-MG249I ; GLSS-SF-0338-TP-01D-WXS-XV38AN ; GLSS-SF-0339-R1-01D-WXS-VEE4IP ; GLSS-SF-0339-TP-01D-WXS-3GNODK ; GLSS-SM-R056-R2-01D-WXS-A7U2KL ; GLSS-SM-R056-R3-01D-WXS-WNEBQS ; GLSS-SM-R056-TP-01D-WXS-1BJVV2 ; GLSS-SM-R057-R2-01D-WXS-QYN028 ; GLSS-SM-R057-TP-01D-WXS-8RSLYG ; GLSS-SM-R058-R1-01D-WXS-USW92T ; GLSS-SM-R058-TP-01D-WXS-8BTMFP ; GLSS-SM-R060-R1-01D-WXS-MHAES3 ; GLSS-SM-R060-R3-01D-WXS-UXGCSX ; GLSS-SM-R060-TP-01D-WXS-WWG8SV ; GLSS-SM-R061-R1-01D-WXS-T05F82 ; GLSS-SM-R061-TP-01D-WXS-UZBY1Q ; GLSS-SM-R062-R1-01D-WXS-PFNWTK ; GLSS-SM-R062-TP-01D-WXS-GVGM68 ; GLSS-SM-R063-R1-01D-WXS-SF2PHH ; GLSS-SM-R063-TP-01D-WXS-UQC9Y9 ; GLSS-SM-R064-R1-01D-WXS-GFA2BL ; GLSS-SM-R064-R2-01D-WXS-606Z2Z ; GLSS-SM-R064-TP-01D-WXS-16OKWU ; GLSS-SM-R065-R1-01D-WXS-1VWQ26 ; GLSS-SM-R065-TP-01D-WXS-4X5O86 ; GLSS-SM-R066-R1-01D-WXS-2R3RRY ; GLSS-SM-R066-TP-01D-WXS-YJN4OE ; GLSS-SM-R067-R1-01D-WXS-WG6N7X ; GLSS-SM-R067-TP-01D-WXS-LTGC1O ; GLSS-SM-R068-R1-01D-WXS-KBROK6 ; GLSS-SM-R068-TP-01D-WXS-5G9ZR6 ; GLSS-SM-R069-R2-01D-WXS-HN45QX ; GLSS-SM-R069-TP-01D-WXS-EIPTR4 ; GLSS-SM-R070-R1-01D-WXS-83NH8Q ; GLSS-SM-R070-TP-01D-WXS-VLPMYS ; GLSS-SM-R071-R1-01D-WXS-LZGI7S ; GLSS-SM-R071-TP-01D-WXS-45QCP2 ; GLSS-SM-R072-R1-01D-WXS-XOT8LM ; GLSS-SM-R072-TP-01D-WXS-QZZEMI ; GLSS-SM-R075-R1-01D-WXS-9J2QDT ; GLSS-SM-R075-TP-01D-WXS-06ZEZS ; GLSS-SM-R076-R1-01D-WXS-1G879E ; GLSS-SM-R076-R3-01D-WXS-9993HH ; GLSS-SM-R095-R1-01D-WXS-2E7A4I ; GLSS-SM-R095-TP-01D-WXS-KK4AF3 ; GLSS-SM-R096-R1-01D-WXS-M2RDCL ; GLSS-SM-R096-TP-01D-WXS-VT1QFY ; GLSS-SM-R097-R1-01D-WXS-6RUXOY ; GLSS-SM-R097-TP-01D-WXS-CS9Y06 ; GLSS-SM-R099-R1-01D-WXS-I52D70 ; GLSS-SM-R099-TP-01D-WXS-5Z45O8 ; GLSS-SM-R100-R1-01D-WXS-O61DWB ; GLSS-SM-R100-TP-01D-WXS-9D7AET ; GLSS-SM-R101-R1-01D-WXS-04ZGTS ; GLSS-SM-R101-TP-01D-WXS-QXZ8TD ; GLSS-SM-R103-R1-01D-WXS-0YX7OK ; GLSS-SM-R103-TP-01D-WXS-TBB9NO ; GLSS-SM-R104-R1-01D-WXS-PT2HTZ ; GLSS-SM-R104-TP-01D-WXS-5BHW5V ; GLSS-SM-R106-R1-01D-WXS-B6X7IN ; GLSS-SM-R106-TP-01D-WXS-8H4HYR ; GLSS-SM-R107-R1-01D-WXS-66033B ; GLSS-SM-R107-TP-01D-WXS-NIBO3N ; GLSS-SM-R108-R1-01D-WXS-YRYRWN ; GLSS-SM-R108-TP-01D-WXS-KC4OXZ ; GLSS-SM-R109-R1-01D-WXS-QM3IL8 ; GLSS-SM-R109-TP-01D-WXS-G7JJJZ ; GLSS-SM-R110-R1-01D-WXS-I5HNRJ ; GLSS-SM-R110-TP-01D-WXS-5XSI28 ; GLSS-SN-0001-R1-01D-WGS-QNMZN7 ; GLSS-SN-0001-TP-01D-WGS-J7WGL3 ; GLSS-SN-0002-R1-01D-WGS-OMWX5F ; GLSS-SN-0002-TP-01D-WGS-W0ZJ2R ; GLSS-SN-0003-R1-01D-WGS-3RRCOG ; GLSS-SN-0003-TP-01D-WGS-KK9G4Q ; GLSS-SN-0004-R1-01D-WGS-FVYBOQ ; GLSS-SN-0004-TP-01D-WGS-SKSAL9 ; GLSS-SN-0006-R1-01D-WGS-JQUJSO ; GLSS-SN-0006-TP-01D-WGS-V6M4DM ; GLSS-SN-0007-R1-01D-WGS-46Y2GQ ; GLSS-SN-0007-R2-01D-WGS-7PEKT5 ; GLSS-SN-0008-R1-01D-WGS-TZ9G3B ; GLSS-SN-0008-TP-01D-WGS-VZS82U ; GLSS-SN-0009-R1-01D-WGS-X1YPCJ ; GLSS-SN-0009-TP-01D-WGS-Z9WB19 ; GLSS-SN-0010-R1-01D-WGS-OMIXM7 ; GLSS-SN-0010-TP-01D-WGS-9FP5P5 ; GLSS-SN-0013-R2-01D-WGS-D7EM0Y ; GLSS-SN-0013-TP-01D-WGS-SIA18T ; GLSS-SN-0015-R2-01D-WGS-5MPD7P ; GLSS-SN-0015-TP-01D-WGS-A2C1OP ; GLSS-SN-0016-R1-01D-WGS-5ZOY6H ; GLSS-SN-0016-TP-01D-WGS-UMRP2Z ; GLSS-SN-0017-R1-01D-WGS-OLID4Z ; GLSS-SN-0017-TP-01D-WGS-RV0KYF ; GLSS-SU-0001-R1-01D-WXS-KBPRAC ; GLSS-SU-0001-TP-01D-WXS-AAGX08 ; GLSS-SU-0002-R1-01D-WXS-A06MIB ; GLSS-SU-0002-R2-01D-WXS-2O25DI ; GLSS-SU-0002-R3-01D-WXS-RHXECW ; GLSS-SU-0002-TP-01D-WXS-GLD7C5 ; GLSS-SU-0003-R1-01D-WXS-9NN9XD ; GLSS-SU-0003-TP-01D-WXS-6YDDYD ; GLSS-SU-0004-R1-01D-WXS-J9A89B ; GLSS-SU-0004-TP-01D-WXS-M55Z5F ; GLSS-SU-0005-R1-01D-WXS-0AMY0L ; GLSS-SU-0005-R2-01D-WXS-M1MPPT ; GLSS-SU-0005-TP-01D-WXS-I9QBMT ; GLSS-SU-0007-R1-01D-WXS-L2EDTA ; GLSS-SU-0007-TP-01D-WXS-JD8BBD ; GLSS-SU-0202-R1-01D-WXS-JMN5OU ; GLSS-SU-0202-TP-01D-WXS-ZHIFBQ ; GLSS-SU-0239-R1-01D-WXS-7U2QLD ; GLSS-SU-0239-TP-01D-WXS-22RFIM ; GLSS-SU-0270-R1-01D-WXS-WMLMUH ; GLSS-SU-0270-R2-01D-WXS-YATWRO ; GLSS-SU-0270-TP-01D-WXS-DFN90U ; TCGA-06-0125-R1-11D-WGS-MA69JO ; TCGA-06-0125-TP-01D-WGS-FZT8H0 ; TCGA-06-0152-R1-01D-WGS-EK2VYI ; TCGA-06-0152-TP-02D-WGS-6HJBZJ ; TCGA-06-0171-R1-11D-WGS-8809O1 ; TCGA-06-0171-TP-02D-WGS-LIDF0X ; TCGA-06-0190-R1-01D-WGS-P20F5P ; TCGA-06-0190-TP-01D-WGS-BM9MHX ; TCGA-06-0210-R1-01D-WGS-PS45ZE ; TCGA-06-0210-TP-01D-WGS-CDCYDJ ; TCGA-06-0211-R1-02D-WGS-32OOWA ; TCGA-06-0211-TP-01D-WGS-JJPE5C ; TCGA-06-0221-R1-11D-WGS-XGUB7X ; TCGA-06-0221-TP-01D-WGS-0LWP9U ; TCGA-14-0736-R1-01D-WXS-ACUYOJ ; TCGA-14-0736-TP-01D-WXS-GUOP0E ; TCGA-14-1034-R1-01D-WGS-L9V6H0 ; TCGA-14-1034-TP-01D-WGS-2521IS ; TCGA-14-1402-R1-01D-WGS-2EHMQ2 ; TCGA-14-1402-TP-01D-WGS-WT36NV ; TCGA-19-0957-R1-11D-WXS-PQFJEA ; TCGA-19-0957-TP-02D-WXS-2GJCQI ; TCGA-19-1389-R1-02D-WXS-TWOEYE ; TCGA-19-1389-TP-01D-WXS-OB8O0T ; TCGA-DH-A669-R1-11D-WGS-A9RS5I ; TCGA-DH-A669-TP-12D-WGS-LX89QR ; TCGA-DU-5870-R1-12D-WGS-UNYI3Z ; TCGA-DU-5870-TP-11D-WGS-BQPWUS ; TCGA-DU-5872-R1-21D-WGS-FF05FR ; TCGA-DU-5872-TP-11D-WGS-WTQAIF ; TCGA-DU-6397-R1-12D-WGS-TX5QZZ ; TCGA-DU-6397-TP-11D-WGS-OXOUDE ; TCGA-DU-6404-R1-21D-WGS-QTV17D ; TCGA-DU-6404-R2-11D-WGS-9OCYC1 ; TCGA-DU-6404-TP-11D-WGS-7DHU4O ; TCGA-DU-6407-R1-12D-WGS-V765KQ ; TCGA-DU-6407-R2-11D-WGS-C4L105 ; TCGA-DU-6407-TP-13D-WGS-XX8PCJ ; TCGA-DU-7304-R1-12D-WGS-TNHHDG ; TCGA-DU-7304-TP-12D-WGS-KB0230 ; TCGA-FG-5963-R1-12D-WXS-XI05S1 ; TCGA-FG-5963-TP-11D-WXS-BX105O ; TCGA-FG-5965-R1-11D-WGS-YWHSSO ; TCGA-FG-5965-R2-11D-WGS-CEY3XC ; TCGA-FG-5965-TP-11D-WGS-YPJ8SN ; TCGA-FG-A4MT-R1-11D-WGS-1EGEOR ; TCGA-FG-A4MT-TP-11D-WGS-CKF1QJ ; TCGA-TM-A7CF-R1-11D-WGS-R1PAAT ; TCGA-TM-A7CF-TP-11D-WGS-RON2FJ ; TCGA-TQ-A7RK-R1-11D-WGS-CF4MA8 ; TCGA-TQ-A7RK-R2-11D-WGS-1Z719P ; TCGA-TQ-A7RK-TP-11D-WGS-HWJ4F6 ; TCGA-TQ-A7RV-R1-11D-WGS-CWZQZJ ; TCGA-TQ-A7RV-TP-21D-WGS-TR9682 ; TCGA-TQ-A8XE-R1-11D-WGS-M2U7J4 ; TCGA-TQ-A8XE-TP-11D-WGS-MF1R7Z
ESTIMATE_SCORE	Gray	Diffuse Glioma (GLASS Consortium)	NUMBER	The ESTIMATE score that is calculated using both the stromal and immune score that represents non-tumor content in a tumor.	Sample	-1490.12737799866 ; -453.566316476032 ; 293.856152804959 ; -1850.76728692681 ; -1116.85837631778 ; -701.332184950865 ; -539.437738931386 ; 317.726708597806 ; -203.407895389754 ; 1485.71458954178 ; -584.854305218273 ; 1484.11960460509 ; -22.2534874329573 ; 2135.63358643359 ; -931.584570527515 ; -928.073169046215 ; 194.066700814739 ; -217.521383860044 ; -3383.81379442822 ; -2911.67234981032 ; -3301.73302108436 ; 102.658223313099 ; -1117.53898688911 ; 2647.56105253594 ; 394.599481041094 ; -778.372113856395 ; -377.197458267832 ; 359.065903952156 ; 1136.58836470606 ; 32.4934012446435 ; 535.585533594772 ; 1036.89044534856 ; 1161.47491164773 ; 2650.99416744243 ; 267.992909741186 ; 1431.57298664108 ; 1876.32275653262 ; 482.759387368964 ; 25.1608183986349 ; 2538.88526502385 ; -1226.95605565612 ; 2775.98725994766 ; -335.866978308608 ; 2495.31694760783 ; 1311.23587819445 ; -499.932217751668 ; 1912.0256522055 ; 3091.56050457011 ; -1432.57596566977 ; 2357.5148585182 ; 1263.06317556136 ; -791.844912851318 ; 459.759399025041 ; 214.616970597938 ; 735.358269743052 ; 433.640794726968 ; -429.747554472812 ; 1081.90889060947 ; 955.901403254109 ; -1567.09792520563 ; -594.906986547048 ; -22.9418114539247 ; -824.33360057045 ; 2799.28311783223 ; 879.093695970823 ; -1963.28731974115 ; -1126.69833370315 ; -860.173432646729 ; -1778.11514710981 ; -779.171562517339 ; 922.526270066434 ; -2556.8662867341 ; -1945.66183732945 ; 862.265577432758 ; 1251.83285934964 ; 1366.09898958278 ; -210.049488035724 ; -2626.34720070147 ; -1730.1013160452 ; 4691.72137365075 ; 124.250982395333 ; -2296.10027013058 ; -2192.47451877689 ; -610.03730177334 ; 255.908649717792 ; 291.110038729202 ; -1078.6549011579 ; 374.784083443936 ; 1080.3353532587 ; 97.9567065438112 ; 339.524693864767 ; 336.457775406055 ; 1722.25048774909 ; 2402.48369873481 ; 3243.60143580558 ; 1103.7504605044 ; -933.447431629688 ; -183.846367599733 ; 1545.3232213712 ; -968.180740236727 ; -1971.21908432229 ; 885.240755097819 ; -384.200020294579 ; -527.187174862554 ; 2326.27509837337 ; 538.000188644573 ; 1565.77310095318 ; 343.379053356531 ; -2115.20723066603 ; -1103.03071066057 ; 403.537935551289 ; 592.597595362829 ; 1910.15055576806 ; 2769.2079487353 ; 697.329206304992 ; 156.979404871359 ; -2551.48964136958 ; 186.705711197714 ; -605.351860851369 ; 192.732928714869 ; 340.958077019129 ; -1113.62796156262 ; -2066.21155152937 ; -2810.94231448568 ; -2671.16243131012 ; -1563.42165869918 ; -1810.20732544735 ; 1211.94593458215 ; -867.628214336156 ; -404.868830931554 ; -753.40226542906 ; 1004.74020547574 ; -647.192300189439 ; 1314.42444085884 ; 336.089227147855 ; -1776.99629691761 ; -2233.22659309547 ; -3389.75866997665 ; -1879.66250374402 ; 1754.46457315908 ; -1106.13776216919 ; -2431.45742010212 ; -2310.93264374319 ; -2565.16361296189 ; 449.537159394469 ; -300.584454615208 ; -849.577446054089 ; 1454.60135743174 ; 549.808101035455 ; 391.240872415718 ; 1088.00677774833 ; 645.843469376182 ; 632.769293464209 ; -381.365388400725 ; 755.080258405491 ; -308.766502297832 ; 2420.20238191084 ; 572.741212851394 ; -1564.27254553938 ; -1828.50434355774 ; 778.263131112707 ; -955.090606131445 ; 1642.05418129783 ; -1051.30731786497 ; -1874.83578652538 ; 58.3066536693367 ; 1159.68978500267 ; 1535.32235852574 ; 1978.29666949211 ; -2761.73272860185 ; -2232.18356597373 ; -1292.25683360124 ; -624.418184705957 ; -645.058339807225 ; -1644.34286143553 ; -79.9506790412058 ; 600.243544216621 ; -1665.24539883332 ; -1691.0116243482 ; 1436.09455132241 ; 396.193521069539 ; -672.031591749273 ; 638.205226534747 ; -581.73947121392 ; -1602.45011687995 ; -879.738132599669 ; 132.761723580386 ; -1308.56203497024 ; -575.840232506215 ; -1.24642575704942 ; -75.4859299791594 ; 1203.14053360756 ; -123.490479728271 ; 411.409853004201 ; 737.925962744645 ; 996.579681479536 ; 1784.47560441115 ; -1763.13592071032 ; -1705.68026787496 ; -2340.42853488267 ; -2427.73915661746 ; -749.567287287859 ; -379.454741225329 ; 717.446540717031 ; -2383.78698886284 ; -900.709169916645 ; -1933.58135493494 ; -607.058294775395 ; -611.101051345552 ; 520.011235452007 ; -1309.31238500055 ; 160.97063384925 ; 448.325663485165 ; 427.036338146482 ; 1529.56789021244 ; 2020.89238303706 ; -1770.0745690651 ; -958.907064452571 ; 464.54200658862 ; -206.822471603498 ; -472.160579975566 ; 632.231730213937 ; 517.279704470737 ; 1649.65890481364 ; 1318.31398561104 ; -111.63722241413 ; 268.097004287242 ; -2449.49185856245 ; -1411.9475090198 ; -739.0347142521 ; -231.663217074929 ; 250.456050368946 ; -189.15006127159 ; -3090.68231133798 ; -3234.03250138191 ; -356.837523118672 ; -412.335928734759 ; -1455.03866773292 ; -133.404800603606 ; -4890.10141879675 ; -1401.60726621877 ; 1255.52166222902 ; 1698.11448590296 ; -777.537335656978 ; 3077.15762580466 ; 1359.38333335349 ; 2059.53733624243 ; -1953.44855288495 ; 1514.24643092902 ; -509.046823289635 ; 1278.97910470876 ; -2203.24162295219 ; -463.455630447929 ; 39.1068225383553 ; -520.580985649521 ; 3106.8947298868 ; 475.344673955914 ; 1020.33141527563 ; -42.5020716903492 ; 1621.44020361165 ; 687.778681291655 ; 2708.48628283193 ; -97.3078284743541 ; 827.607977102657 ; -1059.47404083907 ; 2113.39282874609 ; -636.811998963706 ; -1545.27045367008 ; 335.353959425799 ; 1875.92885514422 ; -135.416073861555 ; -2403.41014541514 ; -476.006326410142 ; 490.140573290233 ; 2736.42513433684 ; -799.614264200729 ; 1487.97621097926 ; 1849.80730062838 ; 732.352010646569 ; -859.270769123556 ; -1245.3233462676 ; 932.272628164139 ; 308.098920227978 ; -334.456804787804 ; -920.433136907627 ; 90.592760136102 ; 953.856043179207 ; 1290.03013878374 ; 715.855795051965 ; -94.9536595331218 ; 2824.4527857058 ; -1199.2074367462 ; -2229.67727560537 ; -173.356376577598 ; -3105.43832562411 ; -958.583146314346 ; -869.343578977175 ; -1121.9137783589 ; 1515.45302855218 ; 2011.26546444661 ; 1025.43079410746 ; -133.138969081456 ; 886.192350513971 ; -255.773996007089 ; 565.902939756284 ; 361.27088431225 ; 417.929863124596 ; -1287.32676324271 ; -649.186579887364 ; 348.454571575564 ; -1080.13196381645 ; 2921.28130186665 ; 1753.92658293442 ; 1778.50948670595 ; 815.426713387267 ; 1337.75975466782 ; 153.210780380018 ; -2230.33295956597 ; 736.668650278268 ; -133.748254912152 ; -1321.44059909974 ; 1040.0125159015 ; 1538.43536227361 ; -1282.87268050176 ; -1319.41611742337 ; -2241.02118171606 ; -1306.55332530069 ; 2928.31208108432 ; -433.668442415128 ; -1498.88954694366 ; -1540.5123723914 ; -793.487348338584 ; -2994.52871100082 ; -1341.23554286977 ; -812.173413134946 ; -1143.52939438472 ; -1506.41927942341 ; -2489.40794404497 ; -691.404204526821 ; -1349.81384006542 ; 610.278816026061 ; -735.452379990153 ; -3342.47025040619 ; -866.211692445408 ; -1596.52295768875 ; -1877.89630335885 ; -2606.64585590136 ; -2628.59974616413 ; -1226.11635223474 ; -1621.15770353156 ; -2190.87472799922 ; -767.307736676244 ; -2156.76789103003 ; -604.846260664513 ; -1792.9117795448
IDH_CODEL_STATUS	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Combination of the idh_status and codel_status variables	Sample	IDHwt ; IDHmut-noncodel ; IDHmut-codel
IMMUNE_SCORE	Gray	Diffuse Glioma (GLASS Consortium)	NUMBER	An ssGSEA-based enrichment score calculated from the ESTIMATE immune signature. Represents general immune content in a given tumor.	Sample	-748.25342551258 ; 5.80056065362918 ; 644.321628534264 ; -567.406104088223 ; -130.833199762693 ; 389.296387150186 ; 129.925428229869 ; 468.912933553976 ; 331.454424148945 ; 891.976143645664 ; 245.047321810272 ; 1040.20043689816 ; 467.523819144062 ; 1595.96714984255 ; -339.436091616975 ; -178.522506673777 ; 478.155632506564 ; 406.682901003929 ; -1811.45254274092 ; -1514.17992546993 ; -1420.04742319469 ; 618.662850526437 ; -317.549148107532 ; 1640.13451862008 ; 610.726938542642 ; -23.1309003614484 ; 284.288855438369 ; 827.705297453427 ; 1116.60536605219 ; 257.543557351167 ; 822.344645160427 ; 948.979423613612 ; 830.215394875389 ; 2097.3816537653 ; 553.324462157413 ; 1391.74854590781 ; 1707.01482536539 ; 844.577027258378 ; 788.892577104772 ; 1764.89083577305 ; -18.4732181382196 ; 1753.98051105436 ; 240.955822777947 ; 2364.2134509252 ; 1387.64827627833 ; 244.958061724149 ; 1646.4456694768 ; 2323.4361151582 ; -389.275433666766 ; 1556.99425925865 ; 1209.5829919773 ; 180.283905205555 ; 937.591705298413 ; 555.724568134551 ; 680.161406502546 ; 806.397062139152 ; 151.734912445939 ; 1107.64195506281 ; 922.843372275499 ; -275.239433291035 ; 183.367834830046 ; 409.243449793773 ; 68.4981310075537 ; 2424.50941669889 ; 856.501095234309 ; -518.585804290272 ; -291.22347900429 ; 239.266335292316 ; -613.06445307528 ; 118.23502637085 ; 607.893285454318 ; -1065.77602315809 ; -627.675318521501 ; 907.958168248255 ; 1323.53151138804 ; 1294.65915575907 ; 279.562467575808 ; -887.84938511987 ; -621.04324281603 ; 3323.50058849527 ; 613.249231443197 ; -1156.71379456806 ; -875.157534770749 ; 313.663537179744 ; 199.21154563416 ; 600.492430691469 ; -162.803670829275 ; 694.437369581366 ; 1256.35170021081 ; 635.75724251111 ; 761.358877832795 ; 752.212809252469 ; 1566.10990137899 ; 1983.5381864567 ; 1668.14327350582 ; 978.006312411168 ; 18.9706345918379 ; 416.27258394083 ; 1543.27760140129 ; 154.678901668636 ; -345.700820973207 ; 1240.84176193502 ; 445.863597394594 ; 336.538407333828 ; 1809.02563425415 ; 1187.02381561753 ; 1539.26060870087 ; 749.835157152537 ; -440.166304315796 ; 56.8195040240847 ; 536.24242919849 ; 791.038835048241 ; 1563.65001364087 ; 2114.43350775604 ; 899.852811389114 ; 645.614124721836 ; -1234.72533241226 ; 659.683454054826 ; -149.771613875483 ; 724.161855070034 ; 739.363586321236 ; -25.9419519967236 ; -715.726133296236 ; -1147.04173462388 ; -1287.9030260089 ; -440.923965550548 ; -645.160455005568 ; 1250.99252848541 ; 8.94714826102957 ; 83.9192749743789 ; 77.472334972817 ; 1001.06237848434 ; -123.963437432435 ; 1361.21963618147 ; 1023.23474845372 ; -126.129153325161 ; -714.463711226252 ; -1515.74761990003 ; -565.072231443417 ; 1415.82883327913 ; -115.305594594605 ; -812.190109047851 ; -522.315045788 ; -720.641185454935 ; 475.559717550681 ; 400.818743546288 ; -44.2776556556582 ; 1183.79360247209 ; 950.210122946008 ; 744.569279883431 ; 1084.62335840944 ; 587.513083857934 ; 505.514805362414 ; 142.717533555606 ; 993.266434970574 ; 177.970346530756 ; 1951.07778788333 ; 313.33916220618 ; -497.548441694075 ; -565.544205792277 ; 999.356268228876 ; -276.618634458509 ; 1416.17869557555 ; -144.37340659834 ; -675.546807379417 ; 502.134164781199 ; 1551.60124131271 ; 1187.11742958429 ; 1393.56127444596 ; -1070.74356201525 ; -730.784097545125 ; -475.725328054383 ; -18.5282733355738 ; -149.975432231873 ; -580.452602263288 ; -9.90788016045387 ; 502.375008065695 ; -481.614125061988 ; -697.572518603662 ; 1355.97367826939 ; 550.983401774153 ; -112.669592417497 ; 419.392211301497 ; 96.8899863260295 ; -624.033262038256 ; -248.296510394848 ; 225.22620962276 ; -287.5245891199 ; 290.996313135619 ; 238.714166181386 ; 351.332441553239 ; 852.65290977314 ; 198.305079278055 ; 711.179198658861 ; 705.912308942121 ; 983.977101334621 ; 1655.39253868574 ; -242.455369187106 ; -405.834233595895 ; -816.249033565243 ; -918.965773659357 ; 99.0629718574252 ; 333.991975584447 ; 940.57926761155 ; -824.197671891088 ; 29.413860149954 ; -434.979698668127 ; 189.400731458176 ; 109.60759079824 ; 901.874777188973 ; -58.8381551600628 ; 836.889220531418 ; 755.397713415032 ; 1007.44174479211 ; 1486.23487498987 ; 1728.86701490771 ; -421.776835162911 ; 86.2123541106762 ; 921.642722108825 ; 374.510296904642 ; 222.005699141694 ; 846.523889363891 ; 735.907550212755 ; 1502.39111824617 ; 1439.68673528878 ; 156.976934912649 ; 243.479250780244 ; -843.921981072348 ; -297.889912666166 ; -344.959915272657 ; 55.6587273740686 ; 344.476273184093 ; 409.286022411719 ; -1370.39307984005 ; -1663.21796524826 ; 376.471728831439 ; 614.113075451143 ; -81.330669853343 ; 630.319953110721 ; -2191.12557385595 ; -485.175813951759 ; 1270.10411741565 ; 1310.60880949135 ; -158.321466859073 ; 1835.56596275252 ; 1117.25459276592 ; 1479.44862786546 ; -440.656450590055 ; 1403.19204560821 ; 527.69141679569 ; 1727.69863980756 ; -945.712969501922 ; 659.365752604268 ; 676.509533927314 ; 107.936948362464 ; 2098.39531588055 ; 888.266500328403 ; 882.71139047825 ; 580.276769674541 ; 994.261974952742 ; 644.419868975 ; 1689.26945485044 ; 498.68298710247 ; 846.278196580104 ; -208.784711270338 ; 1766.29813155048 ; 29.4706516733527 ; -688.591683035098 ; 582.112232125983 ; 1557.60997566631 ; 540.464802239803 ; -879.721296227214 ; 433.663644503591 ; 254.214346490408 ; 1693.75175204146 ; 74.3206244403511 ; 1303.23204531367 ; 1549.06798516162 ; 922.789813171007 ; 22.9820380039127 ; -588.356765311317 ; 1004.44472388336 ; 747.648838428713 ; 422.851698734059 ; -85.6759850977485 ; 685.024704055094 ; 984.623893628497 ; 1360.62048046441 ; 905.890585487815 ; 653.188498662238 ; 2173.08006254355 ; -142.273303860621 ; -1025.06296216095 ; 622.521606587019 ; -1076.26405411572 ; 33.8925173842399 ; 37.2043452861985 ; -324.044939428982 ; 1311.16722029741 ; 1478.65812246282 ; 1108.32260295031 ; 513.905333854276 ; 867.900244681978 ; 526.612948339445 ; 963.796354943021 ; 632.261489128711 ; 749.563387410275 ; -91.8876322091998 ; 201.652145956798 ; 485.846396301994 ; -214.650698962563 ; 1711.56144558362 ; 1304.72067060961 ; 1594.43121177092 ; 1237.0652723891 ; 1316.06793397172 ; 636.454852365805 ; -562.669771651846 ; 1055.44815518925 ; 303.441897970404 ; -380.291802341598 ; 803.925307015221 ; 1499.62228889195 ; -79.6022398220321 ; -56.4397121613833 ; -645.532702774379 ; -237.718656042485 ; 2372.42026258486 ; 331.586618451232 ; -413.815080418893 ; -341.847705047875 ; 208.780991834137 ; -1567.36596735251 ; -375.713174949492 ; 321.908400822149 ; 32.7220181569198 ; -332.966597505636 ; -706.997715806334 ; 249.197338722596 ; -660.909417108033 ; 1076.39350183462 ; 263.713834786618 ; -1573.32678363566 ; 187.104390548406 ; -427.679701971864 ; -431.38281136621 ; -872.97256199235 ; -1008.47759202417 ; -59.2362225329412 ; -426.912509962477 ; -623.023301068517 ; -16.8058666376017 ; -629.747893482199 ; 345.578096735002 ; -318.620557865207
RNA_ALIQUOT_BARCODE	Gray	Diffuse Glioma (GLASS Consortium)	STRING	A variable that stitches subject, sample type, portion, sequencing type, and a unique identifier together	Sample	GLSS-19-0267-R1-01R-RNA-NCCNA9 ; GLSS-19-0267-TP-01R-RNA-UETVPC ; GLSS-19-0268-R1-01R-RNA-A1U9K5 ; GLSS-19-0268-TP-01R-RNA-YXIXQF ; GLSS-19-0269-R1-01R-RNA-1ITEOF ; GLSS-19-0269-TP-01R-RNA-MP0LYE ; GLSS-19-0271-R1-01R-RNA-ZGQFM3 ; GLSS-19-0271-TP-01R-RNA-UD7X6J ; GLSS-19-0272-R1-01R-RNA-MW1TDZ ; GLSS-19-0272-TP-01R-RNA-SJ0YBY ; GLSS-19-0273-R1-01R-RNA-7LI1X7 ; GLSS-19-0273-TP-01R-RNA-89TZ9X ; GLSS-19-0274-R1-01R-RNA-TB5KM6 ; GLSS-19-0274-TP-01R-RNA-ZZD8PZ ; GLSS-19-0275-R1-01R-RNA-72HPX6 ; GLSS-19-0275-TP-01R-RNA-C7VBPY ; GLSS-19-0278-R1-01R-RNA-IZ869X ; GLSS-19-0278-TP-01R-RNA-GRPJQ4 ; GLSS-19-0279-R1-01R-RNA-J1DZC9 ; GLSS-19-0279-R2-01R-RNA-G733J7 ; GLSS-19-0279-TP-01R-RNA-R37O1O ; GLSS-19-0280-R1-01R-RNA-CZ9ZTK ; GLSS-19-0280-TP-01R-RNA-WBZ8RC ; GLSS-CU-P003-R1-01R-RNA-2OJ4BA ; GLSS-CU-P003-TP-01R-RNA-QNW0T1 ; GLSS-CU-P013-R1-01R-RNA-E2JDYX ; GLSS-CU-P013-R2-01R-RNA-GA0HYI ; GLSS-CU-P013-R3-01R-RNA-V38ZQ5 ; GLSS-CU-P020-R1-01R-RNA-7RU49D ; GLSS-CU-P020-R2-01R-RNA-0MKZM3 ; GLSS-CU-P020-R3-01R-RNA-NXTUET ; GLSS-CU-P021-R2-01R-RNA-RBSRHF ; GLSS-CU-P021-TP-01R-RNA-Q4LSD8 ; GLSS-CU-P046-R1-01R-RNA-IQAYII ; GLSS-CU-P046-TP-01R-RNA-OGSYJ8 ; GLSS-CU-P053-R2-01R-RNA-2HP24A ; GLSS-CU-P053-TP-01R-RNA-DAMM5M ; GLSS-CU-P055-R1-01R-RNA-NLRM27 ; GLSS-CU-P055-TP-01R-RNA-1XD78B ; GLSS-CU-P056-R1-01R-RNA-6UGZ93 ; GLSS-CU-P056-R2-01R-RNA-3FSDD0 ; GLSS-CU-P069-R1-01R-RNA-95RLAP ; GLSS-CU-P069-TP-01R-RNA-CVOV9T ; GLSS-CU-P100-R1-01R-RNA-Z1G7JQ ; GLSS-CU-P100-R2-01R-RNA-ZXKTQ7 ; GLSS-CU-P101-R1-01R-RNA-FLI06Y ; GLSS-CU-P101-TP-01R-RNA-2II6XG ; GLSS-CU-P102-R1-01R-RNA-QODUFA ; GLSS-CU-P102-TP-01R-RNA-8PXZZ1 ; GLSS-CU-P104-R1-01R-RNA-L5UZ2L ; GLSS-CU-P104-R2-01R-RNA-CWEZ91 ; GLSS-CU-R001-R1-01R-RNA-SRFKW8 ; GLSS-CU-R001-TP-01R-RNA-YFIDWZ ; GLSS-CU-R002-R1-01R-RNA-MH7LMQ ; GLSS-CU-R002-TP-01R-RNA-7CO09H ; GLSS-CU-R003-R1-01R-RNA-TSQJII ; GLSS-CU-R003-TP-01R-RNA-690QLH ; GLSS-CU-R004-R1-01R-RNA-H8JS8M ; GLSS-CU-R004-TP-01R-RNA-U0DEP1 ; GLSS-CU-R005-R1-01R-RNA-5O1VW3 ; GLSS-CU-R005-TP-01R-RNA-LOURPF ; GLSS-CU-R006-R1-01R-RNA-4EGGFS ; GLSS-CU-R006-TP-01R-RNA-VRCJGW ; GLSS-CU-R007-R1-01R-RNA-QIALTQ ; GLSS-CU-R007-TP-01R-RNA-P6YJGF ; GLSS-CU-R008-R1-01R-RNA-1UZMY7 ; GLSS-CU-R008-TP-01R-RNA-YR7H68 ; GLSS-CU-R009-R1-01R-RNA-QREUYE ; GLSS-CU-R009-TP-01R-RNA-625BJL ; GLSS-CU-R010-R1-01R-RNA-7LMTWC ; GLSS-CU-R010-TP-01R-RNA-SURYRR ; GLSS-CU-R012-R1-01R-RNA-JC21H3 ; GLSS-CU-R012-TP-01R-RNA-21UZH1 ; GLSS-CU-R019-R1-01R-RNA-BGF7KM ; GLSS-CU-R019-TP-01R-RNA-S5OA7D ; GLSS-HF-1DDC-R1-01R-RNA-BUA6E0 ; GLSS-HF-1DDC-TP-01R-RNA-9YZGBJ ; GLSS-HF-4B46-R1-01R-RNA-6IFROU ; GLSS-HF-4B46-TP-01R-RNA-9CXEEM ; GLSS-HF-4D9A-R1-01R-RNA-1NEQO3 ; GLSS-HF-4D9A-TP-01R-RNA-C8NU0J ; GLSS-HF-4F0A-R1-01R-RNA-WMJWU0 ; GLSS-HF-4F0A-R2-01R-RNA-U8EJIU ; GLSS-HF-4F0A-TP-01R-RNA-GG6762 ; GLSS-HF-4FBF-R1-01R-RNA-D3G6JZ ; GLSS-HF-4FBF-R2-01R-RNA-R8L1KG ; GLSS-HF-8FCD-R1-01R-RNA-TM9C6H ; GLSS-HF-8FCD-TP-01R-RNA-NI3IMQ ; GLSS-HF-9A7A-R1-01R-RNA-RQWI9I ; GLSS-HF-9A7A-R2-01R-RNA-Q00IRD ; GLSS-HF-9A7A-TP-01R-RNA-KGGESL ; GLSS-HF-50F3-R2-01R-RNA-DFV350 ; GLSS-HF-50F3-TP-01R-RNA-5BOOW9 ; GLSS-HF-57AE-R1-01R-RNA-QYF4I1 ; GLSS-HF-57AE-R2-01R-RNA-NAVDEK ; GLSS-HF-57AE-TP-01R-RNA-D8DT15 ; GLSS-HF-2548-R1-01R-RNA-F7XJ9B ; GLSS-HF-2548-TP-01R-RNA-4R6KR6 ; GLSS-HF-2829-R1-01R-RNA-D71HI8 ; GLSS-HF-2829-TP-01R-RNA-90I02Y ; GLSS-HF-2869-R3-01R-RNA-TF6NT8 ; GLSS-HF-2869-TP-01R-RNA-2H6MOF ; GLSS-HF-2919-R1-01R-RNA-R6L8SO ; GLSS-HF-2919-TP-01R-RNA-3AV46F ; GLSS-HF-2934-R1-01R-RNA-IBE7TN ; GLSS-HF-2934-TP-01R-RNA-WUQKHB ; GLSS-HF-3050-R1-01R-RNA-7FET5L ; GLSS-HF-3050-TP-01R-RNA-DR0HT8 ; GLSS-HF-3081-R2-01R-RNA-939287 ; GLSS-HF-3081-TP-01R-RNA-EE79OQ ; GLSS-HF-3162-R1-01R-RNA-JUILFB ; GLSS-HF-3162-TP-01R-RNA-K5P3FT ; GLSS-HF-6504-R1-01R-RNA-BSOQQB ; GLSS-HF-6504-TP-01R-RNA-5OSIEV ; GLSS-HF-6658-R1-01R-RNA-6U0Z1B ; GLSS-HF-6658-TP-01R-RNA-QK2ECG ; GLSS-HF-B92C-R2-01R-RNA-JYMG28 ; GLSS-HF-B92C-TP-01R-RNA-NAGUSB ; GLSS-HF-B972-R1-01R-RNA-JFLQPN ; GLSS-HF-B972-TP-01R-RNA-4B7AA8 ; GLSS-HF-BCDE-R3-01R-RNA-PI4RZS ; GLSS-HF-BCDE-TP-01R-RNA-00UPA1 ; GLSS-HF-CB66-R1-01R-RNA-W5T2MP ; GLSS-HF-CB66-R2-01R-RNA-5NA0F9 ; GLSS-HF-CB66-TP-01R-RNA-9MRJMX ; GLSS-HF-DE05-R1-01R-RNA-SCGI6P ; GLSS-HF-DE05-TP-01R-RNA-XEMNN8 ; GLSS-HF-DF35-R1-01R-RNA-KMLJLA ; GLSS-HF-DF35-TP-01R-RNA-IH1LVD ; GLSS-HF-EE74-R1-01R-RNA-0ZZ3C0 ; GLSS-HF-EE74-TP-01R-RNA-7O75ZV ; GLSS-HF-EE77-R1-01R-RNA-Q9225H ; GLSS-HF-EE77-R2-01R-RNA-ZNRTM7 ; GLSS-HF-EE77-R3-01R-RNA-UD3SIX ; GLSS-HK-0001-R1-01R-RNA-QD9QOC ; GLSS-HK-0001-TP-01R-RNA-BYEBS0 ; GLSS-HK-0002-R1-01R-RNA-YMHB61 ; GLSS-HK-0002-TP-01R-RNA-E3957A ; GLSS-HK-0003-R1-01R-RNA-34VZDE ; GLSS-HK-0003-TP-01R-RNA-Y29F2O ; GLSS-HK-0004-R1-01R-RNA-1PAW5U ; GLSS-HK-0004-TP-01R-RNA-2POKNB ; GLSS-HK-0005-R1-01R-RNA-EHMVQA ; GLSS-HK-0005-TP-01R-RNA-HJUBXN ; GLSS-LU-0B10-R1-01R-RNA-L1NER4 ; GLSS-LU-0B10-TP-01R-RNA-LNPBXB ; GLSS-LU-0B12-R1-01R-RNA-3P44CC ; GLSS-LU-0B12-TP-01R-RNA-KNI3OS ; GLSS-LU-0B13-R1-01R-RNA-CZ1AHH ; GLSS-LU-0B13-TP-01R-RNA-96LHFD ; GLSS-LU-00B9-R1-01R-RNA-1IVJNJ ; GLSS-LU-00B9-TP-01R-RNA-S9XA8D ; GLSS-LU-00C1-R1-01R-RNA-0LP4B5 ; GLSS-LU-00C1-TP-01R-RNA-7FZMWR ; GLSS-LU-00C2-R1-01R-RNA-OWC50D ; GLSS-LU-00C2-TP-01R-RNA-2QRUOC ; GLSS-LX-0083-R1-01R-RNA-VS46JF ; GLSS-LX-0083-R2-01R-RNA-EXTF60 ; GLSS-LX-0267-R1-01R-RNA-FKU91L ; GLSS-LX-0267-TP-01R-RNA-79Y8W0 ; GLSS-LX-0304-R1-01R-RNA-68YN4U ; GLSS-LX-0304-TP-01R-RNA-JOXRS1 ; GLSS-LX-0357-R1-01R-RNA-M07N75 ; GLSS-LX-0357-R2-01R-RNA-HBTTUU ; GLSS-LX-0357-R3-01R-RNA-X524U5 ; GLSS-LX-0561-R1-01R-RNA-JXGAE0 ; GLSS-LX-0561-TP-01R-RNA-0G61GD ; GLSS-MD-0003-R2-01R-RNA-HAAQ2N ; GLSS-MD-0003-R3-01R-RNA-10TJHG ; GLSS-MD-0006-R1-01R-RNA-JRYD3E ; GLSS-MD-0006-TP-01R-RNA-YFNFKJ ; GLSS-MD-0011-R1-01R-RNA-YJECGY ; GLSS-MD-0011-TP-01R-RNA-I0YFV6 ; GLSS-MD-0012-R1-01R-RNA-GB101L ; GLSS-MD-0012-TP-01R-RNA-49NNFK ; GLSS-MD-0017-R1-01R-RNA-8FU0BP ; GLSS-MD-0017-R2-01R-RNA-L5HMEO ; GLSS-MD-0020-R1-01R-RNA-T579O9 ; GLSS-MD-0020-TP-01R-RNA-NVJSCE ; GLSS-MD-0022-R1-01R-RNA-WC0V3T ; GLSS-MD-0022-TP-01R-RNA-EDOJNO ; GLSS-MD-0026-R1-01R-RNA-CSEWG6 ; GLSS-MD-0026-TP-01R-RNA-7PF2HB ; GLSS-MD-0027-R1-01R-RNA-E771C5 ; GLSS-MD-0027-R2-01R-RNA-1RO1LP ; GLSS-MD-0027-TP-01R-RNA-9J243C ; GLSS-MD-0032-R1-01R-RNA-O40TAB ; GLSS-MD-0032-TP-01R-RNA-WWNW5R ; GLSS-MD-0035-R1-01R-RNA-ZXNEZ3 ; GLSS-MD-0035-TP-01R-RNA-Z13ESW ; GLSS-MD-0042-R1-01R-RNA-YL9QDQ ; GLSS-MD-0042-TP-01R-RNA-D2P9XH ; GLSS-MD-0049-R1-01R-RNA-ZYZJTS ; GLSS-MD-0049-TP-01R-RNA-HFW0T1 ; GLSS-MD-LP04-R1-01R-RNA-TPSKGU ; GLSS-MD-LP04-TP-01R-RNA-LTGS2F ; GLSS-SF-0003-R1-01R-RNA-NFZJI2 ; GLSS-SF-0003-TP-01R-RNA-X4RQRL ; GLSS-SF-0014-R1-01R-RNA-IKKTTY ; GLSS-SF-0014-TP-01R-RNA-ZOZ3WP ; GLSS-SF-0022-R1-01R-RNA-TZXI6R ; GLSS-SF-0022-TP-01R-RNA-7HO37W ; GLSS-SF-0037-R1-01R-RNA-G1369R ; GLSS-SF-0037-TP-01R-RNA-WUJZCU ; GLSS-SF-0038-R1-01R-RNA-T73T2Y ; GLSS-SF-0038-TP-01R-RNA-TSEK1M ; GLSS-SM-R056-R2-01R-RNA-DHLJ2T ; GLSS-SM-R056-R3-01R-RNA-ZNDAN5 ; GLSS-SM-R056-TP-01R-RNA-JWKQQG ; GLSS-SM-R060-R1-01R-RNA-6SGM43 ; GLSS-SM-R060-R3-01R-RNA-PO2KDQ ; GLSS-SM-R060-TP-01R-RNA-ZI9YVM ; GLSS-SM-R061-R1-01R-RNA-0NG539 ; GLSS-SM-R061-TP-01R-RNA-AZSPBW ; GLSS-SM-R063-R1-01R-RNA-YQOR0G ; GLSS-SM-R063-TP-01R-RNA-WIVUSX ; GLSS-SM-R064-R1-01R-RNA-GLLBN3 ; GLSS-SM-R064-R2-01R-RNA-TUJCN7 ; GLSS-SM-R064-TP-01R-RNA-W6PIW2 ; GLSS-SM-R065-R1-01R-RNA-V35ETA ; GLSS-SM-R065-TP-01R-RNA-OM7S2C ; GLSS-SM-R066-R1-01R-RNA-MKHTJ4 ; GLSS-SM-R066-TP-01R-RNA-G9A6CK ; GLSS-SM-R067-R1-01R-RNA-O82WJY ; GLSS-SM-R067-TP-01R-RNA-JYXPKW ; GLSS-SM-R068-R1-01R-RNA-7I5H9P ; GLSS-SM-R068-TP-01R-RNA-0UPMYO ; GLSS-SM-R070-R1-01R-RNA-PXOL5Z ; GLSS-SM-R070-TP-01R-RNA-QWG60O ; GLSS-SM-R071-R1-01R-RNA-7AZ6G2 ; GLSS-SM-R071-TP-01R-RNA-OAXGI8 ; GLSS-SM-R072-R1-01R-RNA-1DQIND ; GLSS-SM-R072-TP-01R-RNA-K18OXT ; GLSS-SM-R076-R1-01R-RNA-FWI4IR ; GLSS-SM-R076-R3-01R-RNA-OZ1U5H ; GLSS-SM-R078-R1-01R-RNA-L8DCW9 ; GLSS-SM-R078-R2-01R-RNA-ZQZRSP ; GLSS-SM-R080-R1-01R-RNA-GHDR0Y ; GLSS-SM-R080-TP-01R-RNA-2N8175 ; GLSS-SM-R081-R1-01R-RNA-S67IFC ; GLSS-SM-R081-TP-01R-RNA-4GQW1O ; GLSS-SM-R082-R1-01R-RNA-9RBAL7 ; GLSS-SM-R082-TP-01R-RNA-WZ4QXK ; GLSS-SM-R083-R1-01R-RNA-8JLBVA ; GLSS-SM-R083-TP-01R-RNA-RZOKGO ; GLSS-SM-R085-R1-01R-RNA-WN1ZYO ; GLSS-SM-R085-TP-01R-RNA-92DLZP ; GLSS-SM-R087-R1-01R-RNA-Z69T3R ; GLSS-SM-R087-TP-01R-RNA-M99T61 ; GLSS-SM-R088-R1-01R-RNA-9CCN54 ; GLSS-SM-R088-TP-01R-RNA-AAPVD7 ; GLSS-SM-R091-R1-01R-RNA-M356AA ; GLSS-SM-R091-TP-01R-RNA-RUF3X9 ; GLSS-SM-R093-R1-01R-RNA-56NKHA ; GLSS-SM-R093-TP-01R-RNA-KR8RON ; GLSS-SM-R095-R1-01R-RNA-BQ7VMI ; GLSS-SM-R095-TP-01R-RNA-5T2HT4 ; GLSS-SM-R099-R1-01R-RNA-MNTPMI ; GLSS-SM-R099-TP-01R-RNA-YGXA72 ; GLSS-SM-R100-R1-01R-RNA-46UW5U ; GLSS-SM-R100-TP-01R-RNA-EUI7AZ ; GLSS-SM-R101-R1-01R-RNA-7ATA59 ; GLSS-SM-R101-TP-01R-RNA-G7G4Q5 ; GLSS-SM-R102-R1-01R-RNA-8OZGEA ; GLSS-SM-R102-TP-01R-RNA-RB5HS0 ; GLSS-SM-R103-R1-01R-RNA-TSX1I7 ; GLSS-SM-R103-TP-01R-RNA-7YEFHB ; GLSS-SM-R104-R1-01R-RNA-YF3DT7 ; GLSS-SM-R104-TP-01R-RNA-G52UET ; GLSS-SM-R106-R1-01R-RNA-MFHIBQ ; GLSS-SM-R106-TP-01R-RNA-P5JI35 ; GLSS-SM-R107-R1-01R-RNA-ID07M4 ; GLSS-SM-R107-TP-01R-RNA-ZSYP37 ; GLSS-SM-R108-R1-01R-RNA-NICL65 ; GLSS-SM-R108-TP-01R-RNA-KUU8QP ; GLSS-SM-R109-R1-01R-RNA-R5I1C7 ; GLSS-SM-R109-TP-01R-RNA-I4HTPP ; GLSS-SM-R110-R1-01R-RNA-F7JINL ; GLSS-SM-R110-TP-01R-RNA-RSRC7U ; GLSS-SM-R111-R1-01R-RNA-WM5ESA ; GLSS-SM-R111-TP-01R-RNA-1EFVGV ; GLSS-SM-R112-R1-01R-RNA-V3XS3H ; GLSS-SM-R112-TP-01R-RNA-T1QQYH ; GLSS-SN-0001-R1-01R-RNA-PZAYRK ; GLSS-SN-0001-TP-01R-RNA-TJEI6A ; GLSS-SN-0002-R1-01R-RNA-1R2HV5 ; GLSS-SN-0002-TP-01R-RNA-F7DBXG ; GLSS-SN-0003-R1-01R-RNA-Y7F49T ; GLSS-SN-0003-TP-01R-RNA-QVRC11 ; GLSS-SN-0004-R1-01R-RNA-986YHA ; GLSS-SN-0004-TP-01R-RNA-4JGHFD ; GLSS-SN-0006-R1-01R-RNA-EB8LM9 ; GLSS-SN-0006-TP-01R-RNA-N5ULKZ ; GLSS-SN-0007-R1-01R-RNA-BEKDTG ; GLSS-SN-0007-R2-01R-RNA-D9ZGBX ; GLSS-SN-0008-R1-01R-RNA-AK537W ; GLSS-SN-0008-TP-01R-RNA-RSO2L6 ; GLSS-SN-0009-R1-01R-RNA-T7P20X ; GLSS-SN-0009-TP-01R-RNA-1DY2G0 ; GLSS-SN-0010-R1-01R-RNA-8FJJ2W ; GLSS-SN-0010-TP-01R-RNA-E97Z4T ; GLSS-SN-0013-R2-01R-RNA-A9XVF7 ; GLSS-SN-0013-TP-01R-RNA-5952RG ; GLSS-SN-0015-R2-01R-RNA-8AQFBB ; GLSS-SN-0015-TP-01R-RNA-BTS96L ; GLSS-SN-0016-R1-01R-RNA-J5JX7F ; GLSS-SN-0016-TP-01R-RNA-H317OA ; GLSS-SN-0017-R1-01R-RNA-OEK8D6 ; GLSS-SN-0017-TP-01R-RNA-FX5HYW ; TCGA-06-0125-R1-11R-RNA-EKH06U ; TCGA-06-0125-TP-01R-RNA-RCQ5QS ; TCGA-06-0190-R1-01R-RNA-HWTLG4 ; TCGA-06-0190-TP-01R-RNA-S2074S ; TCGA-06-0210-R1-01R-RNA-WB10MK ; TCGA-06-0210-TP-01R-RNA-JMBENW ; TCGA-06-0211-R1-02R-RNA-3YQ1G4 ; TCGA-06-0211-TP-01R-RNA-Y9DKHR ; TCGA-14-1034-R1-01R-RNA-GSNR8T ; TCGA-14-1034-TP-01R-RNA-S6SBZH ; TCGA-19-0957-R1-01R-RNA-7WHBFU ; TCGA-19-0957-TP-01R-RNA-KXSOY0 ; TCGA-19-4065-R1-11R-RNA-7AFF5V ; TCGA-19-4065-TP-01R-RNA-UGJCJV ; TCGA-DH-A669-R1-11R-RNA-KJQZGQ ; TCGA-DH-A669-TP-12R-RNA-XG7CTS ; TCGA-DU-5870-R1-12R-RNA-GIZUWN ; TCGA-DU-5870-TP-11R-RNA-CSQWQZ ; TCGA-DU-5872-R1-21R-RNA-0EW2ZH ; TCGA-DU-5872-TP-11R-RNA-HS9DNI ; TCGA-DU-6397-R1-12R-RNA-N760C1 ; TCGA-DU-6397-TP-11R-RNA-NYNT65 ; TCGA-DU-6404-R1-21R-RNA-LJZDP3 ; TCGA-DU-6404-R2-11R-RNA-9T47IZ ; TCGA-DU-6404-TP-11R-RNA-A7XMXJ ; TCGA-DU-6407-R1-12R-RNA-T3UMCW ; TCGA-DU-6407-R2-11R-RNA-F6PNTL ; TCGA-DU-6407-TP-13R-RNA-6NHIOE ; TCGA-DU-7304-R1-12R-RNA-OMXRQS ; TCGA-DU-7304-TP-12R-RNA-23D1EM ; TCGA-FG-5963-R1-12R-RNA-1EJ1SV ; TCGA-FG-5963-TP-11R-RNA-2Y6I4P ; TCGA-FG-5965-R1-11R-RNA-QSA7Y3 ; TCGA-FG-5965-R2-11R-RNA-UCBSIY ; TCGA-FG-5965-TP-11R-RNA-0XBPNY ; TCGA-FG-A4MT-R1-11R-RNA-9OU9UC ; TCGA-FG-A4MT-TP-11R-RNA-K4BQG0 ; TCGA-TM-A7CF-R1-11R-RNA-EZWWA2 ; TCGA-TM-A7CF-TP-11R-RNA-YLP5PU ; TCGA-TQ-A7RK-R1-11R-RNA-PKFXB3 ; TCGA-TQ-A7RK-R2-11R-RNA-BJMJ93 ; TCGA-TQ-A7RK-TP-11R-RNA-LRGF1D ; TCGA-TQ-A7RV-R1-11R-RNA-TIRW8I ; TCGA-TQ-A7RV-TP-21R-RNA-6F23HF ; TCGA-TQ-A8XE-R1-11R-RNA-47VZAQ ; TCGA-TQ-A8XE-TP-11R-RNA-0YPLAZ
STROMAL_SCORE	Gray	Diffuse Glioma (GLASS Consortium)	NUMBER	An ssGSEA-based enrichment score calculated from the ESTIMATE stromal signature. Represents stromal content in a given tumor.	Sample	-741.873952486084 ; -459.366877129661 ; -350.465475729305 ; -1283.36118283858 ; -986.025176555085 ; -1090.62857210105 ; -669.363167161255 ; -151.18622495617 ; -534.8623195387 ; 593.73844589612 ; -829.901627028544 ; 443.919167706932 ; -489.777306577019 ; 539.666436591041 ; -592.14847891054 ; -749.550662372439 ; -284.088931691824 ; -624.204284863973 ; -1572.3612516873 ; -1397.49242434039 ; -1881.68559788967 ; -516.004627213338 ; -799.989838781578 ; 1007.42653391585 ; -216.127457501548 ; -755.241213494947 ; -661.486313706201 ; -468.639393501271 ; 19.9829986538687 ; -225.050156106524 ; -286.759111565655 ; 87.9110217349472 ; 331.259516772346 ; 553.61251367713 ; -285.331552416226 ; 39.8244407332711 ; 169.307931167228 ; -361.817639889413 ; -763.731758706137 ; 773.9944292508 ; -1208.4828375179 ; 1022.0067488933 ; -576.822801086555 ; 131.103496682631 ; -76.4123980838744 ; -744.890279475816 ; 265.579982728708 ; 768.124389411914 ; -1043.300532003 ; 800.520599259553 ; 53.4801835840614 ; -972.128818056873 ; -477.832306273372 ; -341.107597536613 ; 55.1968632405053 ; -372.756267412184 ; -581.48246691875 ; -25.7330644533402 ; 33.0580309786101 ; -1291.85849191459 ; -778.274821377095 ; -432.185261247697 ; -892.831731578004 ; 374.773701133331 ; 22.592600736514 ; -1444.70151545087 ; -835.474854698858 ; -1099.43976793905 ; -1165.05069403453 ; -897.406588888189 ; 314.632984612116 ; -1491.09026357601 ; -1317.98651880795 ; -45.6925908154972 ; -71.6986520383975 ; 71.4398338237159 ; -489.611955611533 ; -1738.4978155816 ; -1109.05807322917 ; 1368.22078515548 ; -488.998249047864 ; -1139.38647556252 ; -1317.31698400614 ; -923.700838953084 ; 56.6971040836328 ; -309.382391962267 ; -915.851230328621 ; -319.653286137431 ; -176.016346952106 ; -537.800535967299 ; -421.834183968028 ; -415.755033846414 ; 156.140586370098 ; 418.945512278109 ; 1575.45816229976 ; 125.744148093229 ; -952.418066221525 ; -600.118951540564 ; 2.04561996990646 ; -1122.85964190536 ; -1625.51826334909 ; -355.601006837204 ; -830.063617689173 ; -863.725582196383 ; 517.249464119227 ; -649.023626972957 ; 26.512492252312 ; -406.456103796006 ; -1675.04092635023 ; -1159.85021468465 ; -132.704493647202 ; -198.441239685412 ; 346.500542127181 ; 654.774440979268 ; -202.523605084122 ; -488.634719850477 ; -1316.76430895732 ; -472.977742857112 ; -455.580246975886 ; -531.428926355164 ; -398.405509302107 ; -1087.68600956589 ; -1350.48541823313 ; -1663.90057986181 ; -1383.25940530122 ; -1122.49769314864 ; -1165.04687044179 ; -39.0465939032594 ; -876.575362597185 ; -488.788105905933 ; -830.874600401877 ; 3.67782699140141 ; -523.228862757005 ; -46.7951953226309 ; -687.145521305866 ; -1650.86714359245 ; -1518.76288186922 ; -1874.01105007662 ; -1314.5902723006 ; 338.635739879955 ; -990.832167574582 ; -1619.26731105427 ; -1788.61759795519 ; -1844.52242750695 ; -26.0225581562128 ; -701.403198161496 ; -805.299790398431 ; 270.807754959652 ; -400.402021910553 ; -353.328407467712 ; 3.38341933889461 ; 58.3303855182477 ; 127.254488101795 ; -524.08292195633 ; -238.186176565083 ; -486.736848828588 ; 469.124594027511 ; 259.402050645214 ; -1066.72410384531 ; -1262.96013776546 ; -221.093137116169 ; -678.471971672936 ; 225.87548572228 ; -906.93391126663 ; -1199.28897914596 ; -443.827511111862 ; -391.911456310043 ; 348.204928941443 ; 584.735395046149 ; -1690.9891665866 ; -1501.3994684286 ; -816.531505546852 ; -605.889911370383 ; -495.082907575352 ; -1063.89025917225 ; -70.0427988807519 ; 97.8685361509256 ; -1183.63127377134 ; -993.439105744536 ; 80.1208730530169 ; -154.789880704614 ; -559.361999331776 ; 218.813015233249 ; -678.629457539949 ; -978.416854841693 ; -631.441622204821 ; -92.4644860423743 ; -1021.03744585034 ; -866.836545641834 ; -239.960591938435 ; -426.818371532399 ; 350.487623834422 ; -321.795559006326 ; -299.76934565466 ; 32.0136538025233 ; 12.602580144915 ; 129.083065725411 ; -1520.68055152322 ; -1299.84603427907 ; -1524.17950131743 ; -1508.7733829581 ; -848.630259145285 ; -713.446716809775 ; -223.132726894519 ; -1559.58931697175 ; -930.123030066599 ; -1498.60165626681 ; -796.459026233571 ; -720.708642143791 ; -381.863541736967 ; -1250.47422984048 ; -675.918586682169 ; -307.072049929867 ; -580.405406645625 ; 43.3330152225754 ; 292.025368129348 ; -1348.29773390219 ; -1045.11941856325 ; -457.100715520205 ; -581.33276850814 ; -694.16627911726 ; -214.292159149954 ; -218.627845742018 ; 147.267786567468 ; -121.372749677744 ; -268.614157326779 ; 24.6177535069984 ; -1605.5698774901 ; -1114.05759635363 ; -394.074798979443 ; -287.321944448998 ; -94.0202228151469 ; -598.436083683309 ; -1720.28923149793 ; -1570.81453613365 ; -733.309251950111 ; -1026.4490041859 ; -1373.70799787958 ; -763.724753714327 ; -2698.9758449408 ; -916.431452267007 ; -14.5824551866261 ; 387.505676411617 ; -619.215868797905 ; 1241.59166305215 ; 242.128740587571 ; 580.088708376969 ; -1512.79210229489 ; 111.054385320813 ; -1036.73824008533 ; -448.719535098798 ; -1257.52865345027 ; -1122.8213830522 ; -637.402711388958 ; -628.517934011985 ; 1008.49941400625 ; -412.921826372488 ; 137.620024797383 ; -622.77884136489 ; 627.17822865891 ; 43.3588123166556 ; 1019.21682798149 ; -595.990815576824 ; -18.6702194774469 ; -850.689329568734 ; 347.094697195602 ; -666.282650637059 ; -856.678770634984 ; -246.758272700185 ; 318.318879477902 ; -675.880876101358 ; -1523.68884918793 ; -909.669970913733 ; 235.926226799825 ; 1042.67338229538 ; -873.93488864108 ; 184.744165665591 ; 300.739315466754 ; -190.437802524438 ; -882.252807127468 ; -656.966580956288 ; -72.1720957192204 ; -439.549918200735 ; -757.308503521863 ; -834.757151809878 ; -594.431943918992 ; -30.7678504492904 ; -70.5903416806786 ; -190.034790435851 ; -748.14215819536 ; 651.372723162258 ; -1056.93413288558 ; -1204.61431344442 ; -795.877983164617 ; -2029.17427150839 ; -992.475663698586 ; -906.547924263373 ; -797.868838929918 ; 204.285808254773 ; 532.607341983798 ; -82.8918088428504 ; -647.044302935732 ; 18.2921058319923 ; -782.386944346533 ; -397.893415186736 ; -270.990604816461 ; -331.633524285679 ; -1195.43913103351 ; -850.838725844162 ; -137.39182472643 ; -865.481264853885 ; 1209.71985628303 ; 449.205912324815 ; 184.078274935027 ; -421.63855900183 ; 21.691820696095 ; -483.244071985787 ; -1667.66318791413 ; -318.779504910978 ; -437.190152882556 ; -941.148796758142 ; 236.087208886279 ; 38.8130733816596 ; -1203.27044067973 ; -1262.97640526199 ; -1595.48847894168 ; -1068.83466925821 ; 555.891818499465 ; -765.25506086636 ; -1085.07446652477 ; -1198.66466734353 ; -1002.26834017272 ; -1427.16274364832 ; -965.522367920281 ; -1134.08181395709 ; -1176.25141254164 ; -1173.45268191778 ; -1782.41022823864 ; -940.601543249417 ; -688.904422957385 ; -466.114685808557 ; -999.166214776771 ; -1769.14346677053 ; -1053.31608299381 ; -1168.84325571689 ; -1446.51349199264 ; -1733.67329390901 ; -1620.12215413996 ; -1166.8801297018 ; -1194.24519356909 ; -1567.85142693071 ; -750.501870038643 ; -1527.01999754784 ; -950.424357399515 ; -1474.29122167959
SURGERY_EXTENT_OF_RESECTION	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Indicated extent of resection needed for sample collection	Sample	Total ; Subtotal ; Biopsy
SURGERY_LATERALITY	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Hemisphere from which the tumor was resected	Sample	Right ; Left ; Both
SURGERY_LOCATION	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Brain region from which tumor was resected	Sample	Occipital lobe ; Temporal lobe ; Parietal lobe ; Frontal lobe ; Frontoparietal ; Frontal ; Occipitial lobe ; Cerebellum ; Corpus callosum ; Fronto-Temporal lobe ; Multifocal ; Temporo-Occipital lobe ; Insular lobe ; Fronto-Parietal lobe ; Parieto-Occipital lobe
SURGERY_TYPE	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Surgery type	Sample	Craniotomy ; Stereotactic ; Autopsy
TREATMENT_CONCURRENT_TMZ	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Indicate whether temozolomide was administered concurrently with radiotherapy	Sample	No ; Yes
TREATMENT_RADIATION_DOSE_GY	Gray	Diffuse Glioma (GLASS Consortium)	NUMBER	Radiation Dose (Gy)	Sample	60 ; 35 ; 25 ; 36 ; 61.3 ; 59.4 ; 59 ; 32 ; 78 ; 84 ; 58 ; 53 ; 100 ; 47.5 ; 54 ; 30 ; 40 ; 50 ; 57 ; 50.4 ; 43.2 ; 44 ; 45 ; 19 ; 20 ; 61.2 ; 0 ; 49 ; 32.7 ; 180 ; 28
TREATMENT_RADIOTHERAPY	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Indicates whether a subject received radiotherapy	Sample	No ; Yes
TREATMENT_TMZ	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Indicates whether a subject received temozolomide (tmz) for each surgical sample	Sample	No ; Yes
TREATMENT_TMZ_CYCLES	Gray	Diffuse Glioma (GLASS Consortium)	NUMBER	Number of temozolomide treatment cycles	Sample	12 ; 5 ; 6 ; 4 ; 2 ; 3 ; 9 ; 11 ; 1 ; 7 ; 24 ; 21 ; 10 ; 0 ; 8 ; 20 ; 13 ; 35 ; 15 ; 14 ; 18 ; 26 ; 33 ; 42
TREATMENT_TMZ_CYCLES_6	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Indicates whether a subject received at least six cycles of temozolomide	Sample	Yes ; No
TUMOR_CLASSIFICATION	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Tumor classification according to WHO	Sample	Glioblastoma, IDH-wildtype ; Glioblastoma, NOS ; Glioblastoma, IDH-mutant ; Glioblastoma, IDHwt ; Glioblastoma, IDH-mutant and 1p/19q-codeleted ; Oligodendroglioma, IDH-mutant and 1p/19q-codeleted ; Oligoastrocytoma, IDH-mutant ; Astrocytoma, IDH-wildtype ; Anaplastic Oligoastrocytoma, IDH-wildtype ; Diffuse Astrocytoma, IDH-mutant ; Anaplastic Astrocytoma, IDH-wildtype ; Anaplastic Astrocytoma, IDH-mutant ; Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted ; Glioblastoma, IDH_mutant ; Anaplastic Astrocytoma, NOS ; Astrocytoma, IDH-mutant ; Anaplastic Oligoastrocytoma, IDH-mutant ; Diffuse Astrocytoma, IDH-wildtype
TUMOR_GRADE	Gray	Diffuse Glioma (GLASS Consortium)	STRING	Pathological tumor grade	Sample	IV ; III ; II
CLINICAL_OR_RESEARCH_IMPACT	Gray	IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)	STRING	Clinical or Research Impact.	Sample	Clinical ; Research
PERIOD1_GROWTH_RATE	Gray	IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)	NUMBER	Refers to low-grade glioma tumor volume growth rate prior to first surgery.	Sample	-64.01480545 ; -89.5688604 ; 69.30161094 ; 17.18861755 ; 104.0296968 ; -17.06249671 ; 360.6660078 ; 47.49877131 ; -6.710012605 ; 40.72441082 ; -15.06524782 ; -17.05788056 ; -46.86535207 ; -26.86898612 ; 21.4282273 ; 41.06159589 ; 33900.22523 ; -99.7495965 ; 140.1541384 ; 12.53797075 ; 10.76477955 ; 22.05568501 ; -77.81373392 ; 14.23110974 ; 27.7591952 ; -46.27328 ; 630.8127264 ; -72.72653068 ; 0.070234559 ; 421.1673199
PERIOD2_GROWTH_RATE	Gray	IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)	NUMBER	Refers to low-grade glioma tumor volume growth rate following first surgery up to next treatment.	Sample	30.68288089 ; 21.90991792 ; 19.91153916 ; 95.8247489 ; 16.29506742 ; 11.68064769 ; 8.786389688 ; 31.0456886 ; 9.362564666 ; 3.770742652 ; 56.4967085 ; 26.70920933 ; 19.62484695 ; 53.02281564 ; 21.36941474 ; 9.013502099 ; 16.93634251 ; 9.863006438 ; 6.679850044 ; 32.75997739 ; 43.89952901 ; 9.293309537 ; 25.88910681 ; 13.04258796 ; 60.56503842 ; 51.00984848 ; 42.37394281 ; 145.7966991 ; 20.63019276 ; 46.12564882 ; 43.15840781 ; 44.34240566 ; 24.9422505 ; 19.57431466 ; 16.46983885 ; 33.47818425 ; 44.90450362 ; 21.4097227 ; 2.213637482 ; 18.23082184 ; 6.72422762 ; 8.916483788 ; 77.27186402 ; 71.44455189 ; 28.68914982 ; 34.51603007 ; 53.21079954 ; 20.15402855 ; 6.177434949 ; 21.06802008
QUARTILE_PERIOD1_GROWTH_RATE	Gray	IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)	NUMBER	Quartiles from the data in the previous Period1_Growth_Rate column.	Sample	1 ; 4 ; 3 ; 2
QUARTILE_PERIOD2_GROWTH_RATE	Gray	IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)	NUMBER	Quartiles from the data in the previous Period2_Growth_Rate column.	Sample	3 ; 2 ; 4 ; 1
CHEMO_CYCLES	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Chemotherapy Cycles	Patient	
CHEMO_FIRST_LINE	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Chemo First Line	Patient	
CHEMO_REGIMEN_CATEGORY	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Chemo Regimen Category	Patient	
CHEMO_RESISTANT	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Chemo Resistance	Patient	
DETAILED_SAMPLE_HISTOLOGY_CATEGORY	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Detailed Sample Histology Category	Sample	Mixed NSGCT ; YST ; S ; EC ; CC ; GCT w/ trophoblastic differentiation ; NSGCT unspecified ; Chorionic-type intermediate trophoblastic differentiation
FOLLOW_UP_TIME_MONTHS	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	NUMBER	Follow up time months	Patient	
IGCCCG_STAGE	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Igcccg stage	Patient	
PC_RPLND	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	RPLND	Sample	0 ; 1
PRIMARY_HISTOLOGY	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Primary Histology	Patient	
PRIMARY_RPLND	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Primary RPLND	Sample	0 ; 1
PROGRESSION_OF_DISEASE	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Progression of Disease	Patient	
RPLND_PATH	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	RPLND Path	Sample	necrosis, fibrosis ; T ; EC, YST ; treatment effect ; YST ; S ; MT, cystic trophoblastic tumor ; fibrosis ; necrosis ; benign ; MT ; YST, T ; T, trophoblastic tumor ; EC transitioning to T ; EC ; EC, YST, T ; MT with cystic trophoblastic tumor ; fibrosis, necrosis ; incomplete ; S, EC ; negative ; YST and T ; EC, T ; 1st RPLND T 2nd RPLND T and YST ; no viable tumor ; SEM ; primary RPLND:YST, EC 2nd RPLND - YST, S 3rd RPLND (msk) YST, T ; YST, MT, IT ; MT, fibrosis, necrosis ; T, YST
SALVAGE_CHEMO	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Salvage Chemo	Patient	
SAMPLE_DETAILED_SUBHISTOLOGIES	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Sample Detailed Subhistologies	Sample	CC, S ; IT, YST, EC ; EC(80%), MT ; YS and T ; T, S, YST ; T and YST ; EC, MT, YST ; NSGCT ; YST (50%), IT (45%), EC ; EC (predominant) ; EC(65%), S, YST ; S, EC, YST, MT ; T, YST, TMT to spindle cell sarcoma NOS ; CC (85%), MT ; S (45%), EC (25%), T (20%), YST (10%) ; EC, YST ; S (>98%), EC ; EC (55%), YST, MT, IT ; EC (75%), S, YST, IT ; EC (80%), YST, MT, CC ; IT, S, EC, YST, MT ; EC, T ; EC (65%), YST ; EC (predominant), YS, MT ; S (60%), EC (20%), YST (5%), MT, IT, CC (10%) ; EC (70%), S, YST ; CC, S (10%) ; CC (85%), S (5%), T, EC, YST ; S (60%), EC, YST, T ; EC (85%), S, YST, IT ; EC (90%), S ; S, EC (>80%), MT, YST ; YST, S, MT (90%) ; EC, T, YST ; EC (90%), YST, MT ; S, EC, YST, MT, IT ; EC (65%), YST, MT ; S (90%), EC ; YST, IT ; MT (60%), EC, YST ; S (predominant) w/ marked atypia, EC (focal) ; MT, YST ; S (predominant, EC ; EC, YST, MT ; EC (>95%), YST ; EC, YST, MT, IT ; EC (80%), YST, MT ; EC, MT, CC ; 80% YST, 10% EC, 10% IT ; CC, YST ; EC (80%), S, YST ; EC, S, YST ; T (65%), EC, YST ; MT and YST ; EC, YST, CC, MT ; EC (75%), MT, IT ; YST, MT ; YS and MT ; YST (predominant), MT (Focal) ; EC (90%), S, YST ; TMT (sarcoma), S, YST, EC, T
SPECIMEN_COLLECTION_PRE_OR_POST_CHEMO	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Specimen Collection Pre or Post Chemo	Sample	pre ; post
STAGE_AT_PRESENTATION	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	Stage at Presentation	Sample	IB ; Distant ; IIIC ; IIIB ; IA ; IIA ; IIC ; Regional ; Localized ; IIB ; IIIA ; IS
S_STAGE	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	STRING	S indicates the serum (blood) levels of tumor markers that are made by some testicular cancers	Sample	S0 ; S3 ; S2 ; Sx ; S1
TIME_TO_PROGRESSION_OF_DISEASE	Red	Germ Cell Tumors (MSK, J Clin Oncol 2016)	NUMBER	Time to Progression of Disease (Months)	Patient	
SAMPLE_DISPLAY_NAME	Red	Germ Cell Tumors and Shared Leukemias (MSK, J Clin Invest 2020)	STRING	Sample Display Name	Sample	P-0003533-T03-IM5 ; s_AML_GCT_2T1 ; s_AML_GCT_2T2 ; s_AML_GCT_2T3 ; s_OA_gct_002_T ; P-0019394-T01-IH3 ; s_OA_gct_017_T1 ; s_OA_gct_019_T3 ; s_OA_gct_019_T1 ; s_OA_gct_008_T ; s_OA_gct_008_P ; s_C_H3KMT7_P004_d ; s_OA_gct_012_T1 ; s_OA_gct_007_T ; s_OA_gct_007_P ; s_OA_gct_006_T ; s_OA_gct_006_M ; s_OA_gct_014_T1 ; s_OA_gct_005_T ; s_AML_GCT_1T_GCT ; s_AML_GCT_1T_BM
AJCC_CLINICAL_TUMOR_STAGE	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	The extent of a cancer, especially whether the disease has spread from the original site to other parts of the body based on AJCC staging criteria.	Patient	
AJCC_METASTASIS_CLINICAL_CM	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.	Patient	
AJCC_NODES_CLINICAL_CN	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	The codes that represent the stage of cancer based on the nodes present (N stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	Patient	
AJCC_NODES_CLINICAL_CT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	The codes that represent the stage of cancer based on the nodes present (T stage) according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.	Patient	
BILATERAL_DIAGNOSIS_TIMING_TYPE	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Bilateral Diagnosis Timing Type	Patient	
DAYS_TO_BILATERAL_TUMOR_DX	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Days to bilateral tumor dx	Patient	
DAYS_TO_POST_ORCHI_SERUM_TEST	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Days to post orchi serum test	Patient	
DAYS_TO_PRE_ORCHI_SERUM_TEST	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Days to pre orchi serum test	Patient	
FAMILY_HISTORY_CANCER_RELATIONSHIP	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Text indicator to represent a report or record of a cancer diagnosis in any relative with whom one half of an individuals genes is shared (i.e., parent, sibling, offspring).	Patient	
FAMILY_HISTORY_OTHER_CANCER	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Family history other cancer	Patient	
FAMILY_HISTORY_TESTICULAR_CANCER	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Family history testicular cancer	Patient	
FIRST_TREATMENT_SUCCESS	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	First treatment success	Patient	
HISTOLOGIC_DIAGNOSIS_PERCENT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Histological percentage	Patient	
HISTORY_FERTILITY	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	History fertility	Patient	
HISTORY_HYPOSPADIAS	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	History hypospadias	Patient	
HISTORY_OF_UNDESCENDED_TESTIS	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	History of undescended testis	Patient	
INTRATUBULAR_GERM_CELL_NEOPLASM	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Intratubular germ cell neoplasm	Patient	
LEVEL_OF_NON_DESCENT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Level of non descent	Patient	
LYMPHOVASCULAR_INVASION_PRESENT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Lymphovascular invasion present	Patient	
MOLECULAR_TEST_RESULT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Molecular test result	Patient	
PATIENT_DEATH_REASON	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Text term to identify the cause of death for a patient.	Patient	
POSTOPERATIVE_TX	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Postoperative tx	Patient	
POST_ORCHI_AFP	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Post orchi afp	Patient	
POST_ORCHI_HCG	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Post orchi hcg	Patient	
POST_ORCHI_LDH	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Post orchi ldh	Patient	
POST_ORCHI_LH	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Post orchi lh	Patient	
POST_ORCHI_LYMPH_NODE_DISSECTION	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Post orchi lymph node dissection	Patient	
POST_ORCHI_TESTOSTERONE	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Post orchi testosterone	Patient	
PRE_ORCHI_AFP	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Pre orchi afp	Patient	
PRE_ORCHI_HCG	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Pre orchi hcg	Patient	
PRE_ORCHI_LDH	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Pre orchi ldh	Patient	
PRE_ORCHI_LH	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	NUMBER	Pre orchi lh	Patient	
PRE_ORCHI_TESTOSTERONE	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Pre orchi testosterone	Patient	
RELATION_TESTICULAR_CANCER	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Relation testicular cancer	Patient	
RELATIVE_FAMILY_CANCER_HX_TEXT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Relative family cancer hx text	Patient	
SERUM_MARKERS	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Serum markers	Patient	
SYNCHRONOUS_TUMOR_HISTOLOGY_PCT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Synchronous tumor histology pct	Patient	
TESTIS_TUMOR_MACROEXTENT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Testis tumor macroextent	Patient	
TESTIS_TUMOR_MACROEXTENT_OTHER	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Testis tumor macroextent other	Patient	
TESTIS_TUMOR_MICROEXTENT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Testis tumor microextent	Patient	
UNDESCENDED_TESTIS_CORRECTED	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Undescended testis corrected	Patient	
UNDESCENDED_TESTIS_CORRECTED_AGE	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Undescended testis corrected age	Patient	
UNDESCENDED_TESTIS_METHOD_LEFT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Undescended testis method left	Patient	
UNDESCENDED_TESTIS_METHOD_RIGHT	Red	Testicular Germ Cell Cancer (TCGA, Firehose Legacy)	STRING	Undescended testis method right	Patient	
AGE_RESECTED	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	NUMBER	Patient age when the tumor was resected	Sample	48 ; 76 ; 69 ; 87 ; 60 ; 88 ; 89 ; 67 ; 78 ; 92 ; 77 ; 79 ; 41 ; 74 ; 62 ; 63 ; 80 ; 66 ; 93 ; 65 ; 83 ; 64 ; 56 ; 68 ; 46 ; 54 ; 82 ; 86 ; 49 ; 70 ; 71 ; 90 ; 44 ; 81 ; 75 ; 85 ; 91 ; 61 ; 37 ; 38 ; 43 ; 35 ; 57 ; 55 ; 58 ; 73 ; 59 ; 47 ; 42 ; 84 ; 72 ; 53
GORLIN_SPORADIC	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	Gorlin Sporadic	Sample	sporadic ; gorlin
MULTIPLE_TUMORS	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	Patients that have more than one tumor	Sample	No ; Yes
POPULATION	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	Population	Sample	non-reduntant sample ; clonal samples
RNA	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	RNA was extracted for this sample: NA=not available, paired: tumor and normal skin RNA available, unpaired: only tumor RNA available.	Sample	unpaired ; paired
SCNA_ANALYSIS	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	SCNA Analysis	Sample	No ; Good ; OK ; Bad
TUMOR_NUMBER	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	Tumor number	Sample	T1 ; T2 ; T4 ; T3 ; T5 ; T6 ; T7 ; T16 ; T11 ; T14
VISMO_STATUS	Black	Basal Cell Carcinoma (UNIGE, Nat Genet 2016)	STRING	Vismo Status	Sample	naive ; sensitive ; resistant
CATEGORY_SAMPLE	Black	NCI-60 Cell Lines (NCI, Cancer Res 2012)	STRING	Category of Sample	Sample	Metastasis ; Primary ; Pleural effusion ; Ascites ; PBL ; PB
DOUBLING_TIME	Black	NCI-60 Cell Lines (NCI, Cancer Res 2012)	NUMBER	Doubling time  (hrs)	Sample	53.9 ; 53.8 ; 25.4 ; 41.9 ; 45.5 ; 33.1 ; 29.5 ; 35.4 ; 34.6 ; 62.8 ; 23.8 ; 31.5 ; 17.4 ; 20.6 ; 19.5 ; 23.7 ; 20.4 ; 22.9 ; 43.6 ; 39 ; 79.5 ; 61 ; 33.4 ; 35.3 ; 17.8 ; 38.2 ; 26.7 ; 28.6 ; 19.6 ; 27.9 ; 33.5 ; 28.7 ; 20.5 ; 26.3 ; 46.2 ; 25.8 ; 22.5 ; 35.1 ; 25.2 ; 38.5 ; 31.3 ; 31 ; 34 ; 34.7 ; 41.4 ; 48.8 ; 26.1 ; 48.7 ; 32.3 ; 27.1 ; 22.4 ; 66.8 ; 27.5 ; 62.9 ; 51.3 ; 41.7 ; 450 ; 123.2 ; 81.2 ; 386.7 ; 80.3 ; 49.5 ; 151.7 ; 187.6 ; 148.6 ; 127.3 ; 70.2 ; 110 ; 70.1 ; 181.8 ; 51.4 ; 42.7 ; 104.2 ; 93.1 ; 98.9 ; 979 ; 88.3 ; 131.8 ; 171.6 ; 56.4 ; 35.6 ; 60.9 ; 103.3 ; 145.6 ; 118.2 ; 138.7 ; 41.6 ; 133.7 ; 67.8 ; 49.8 ; 258.6 ; 324.8 ; 80.5 ; 121.2 ; 60.7 ; 30 ; 35.8 ; 188.6 ; 142.7 ; 85.6 ; 119.4 ; 67.6 ; 68.9 ; 31.6 ; 88.4 ; 38.4 ; 69.7 ; 122.9 ; 60 ; 62.1 ; 93.7 ; 25.5 ; 102.2 ; 66 ; 88.1 ; 404.8 ; 160.3 ; 221.1 ; 96.8 ; 49.7 ; 90.6 ; 42.9 ; 83.1 ; 95.9 ; 67.9 ; 91.2 ; 181.7 ; 46.4 ; 58.2 ; 36.2 ; 70.3 ; 105.1 ; 85.2 ; 61.3 ; 266.5 ; 130 ; 98.2 ; 88.8 ; 47.3 ; 40.3 ; 48.5 ; 47.8 ; 34.4 ; 51.7 ; 164.5 ; 78.9 ; 174.6 ; 207.6 ; 45.07 ; 35.2966 ; 57.6 ; 89.9 ; 43.3 ; 34.1 ; 106 ; 147.7 ; 33.2 ; 73.2 ; 70 ; 40.4 ; 85.9 ; 112.8 ; 37.7 ; 111.4 ; 137.9 ; 65 ; 118.1 ; 56.9 ; 63 ; 116 ; 90.5 ; 101.8 ; 40 ; 50.6 ; 114.8 ; 74.6 ; 82.2 ; 92 ; 120.7 ; 198.1 ; 63.3 ; 63.7 ; 79 ; 44.4 ; 67 ; 25.7 ; 53.6 ; 74.1 ; 148.4 ; 165.5 ; 73.9 ; 80.2 ; 52.2 ; 98.1 ; 48.6 ; 59.2 ; 47.9 ; 32.9 ; 33.3 ; 168.2 ; 58.6 ; 52.6 ; 29.3 ; 31.2 ; 64.6 ; 95.3 ; 21.6 ; 76.7 ; 214.2 ; 38.8 ; 243.4 ; 107.3 ; 178.9 ; 106.5 ; 79.7 ; 121.8 ; 153.6 ; 288.6 ; 77.1 ; 143.2 ; 194.2 ; 55.9 ; 51.6 ; 89.8 ; 87 ; 110.9 ; 79.1 ; 157.4 ; 52.9 ; 62.3 ; 110.4 ; 42.1 ; 77.7 ; 77 ; 155.8 ; 77.5 ; 59 ; 52 ; 112.1 ; 77.8 ; 83.3 ; 42 ; 50.3 ; 107.4 ; 38 ; 156.8 ; 46.3 ; 261.8 ; 56.2 ; 72.5 ; 139.2 ; 190 ; 123.4 ; 54.5 ; 50 ; 40.9 ; 40.6 ; 126.9 ; 67.7 ; 55 ; 156.9 ; 76 ; 72.7 ; 176 ; 46.5 ; 163.8 ; 54.1 ; 49.9 ; 24.8 ; 137.5 ; 59.7 ; 81.8 ; 150.3 ; 36.9 ; 143.9 ; 40.2 ; 40.8 ; 37.6 ; 136.6 ; 144.4 ; 67.4 ; 153.8 ; 187.5 ; 97.2 ; 63.5 ; 472.8 ; 42.5 ; 96.9 ; 45.4 ; 98.3 ; 88.7 ; 78.5 ; 48.4 ; 202.6 ; 189.6 ; 467.4 ; 72 ; 183.9 ; 208.5 ; 555.4 ; 68.5 ; 69.1 ; 41 ; 56.5 ; 94.7 ; 92.9 ; 25.6 ; 133.4 ; 84.9 ; 115.9 ; 261.1 ; 62.7 ; 51.8 ; 32.7 ; 41.8 ; 101.3 ; 106.4 ; 47.4 ; 40.7 ; 425 ; 115.6 ; 44.01717 ; 29 ; 96.7 ; 73.3 ; 75.3 ; 110.8 ; 57 ; 86.1 ; 101.6 ; 71 ; 44.1 ; 387 ; 171.5 ; 61.7 ; 279 ; 57.4 ; 37 ; 113.3 ; 54.2 ; 47.77519 ; 36.4 ; 20.9 ; 73.6 ; 161 ; 35.9 ; 37.3 ; 98.8 ; 54 ; 67.5 ; 69.3 ; 151.3 ; 39.4 ; 58.5 ; 62.5 ; 45.2 ; 68.6 ; 61.1 ; 121.5 ; 82.6 ; 33 ; 62 ; 93.9 ; 59.5 ; 53 ; 69.9 ; 49.1 ; 94.3 ; 194.7 ; 40.12291 ; 43 ; 41.1 ; 92.1 ; 60.6 ; 284.1 ; 96 ; 58.4 ; 76.6 ; 94.2 ; 197.3 ; 93.8 ; 103.6 ; 365 ; 184.8 ; 244 ; 45 ; 315 ; 35.5 ; 98.4 ; 30.8 ; 294 ; 42.3 ; 53.2 ; 36.1 ; 34.2 ; 78.3 ; 99.1 ; 55.2 ; 38.7 ; 68.7 ; 63.9 ; 88.9 ; 440 ; 310.4 ; 55.3 ; 46.1 ; 305.5 ; 423.2 ; 136 ; 117.6 ; 49.4 ; 46.6 ; 265 ; 121.6 ; 219.2 ; 74 ; 139.1 ; 142.8 ; 46 ; 65.8 ; 63.1 ; 368 ; 123.5 ; 179.8 ; 70.4 ; 45.1 ; 51.1 ; 78.8 ; 142.9 ; 100.6 ; 119.2 ; 64.5 ; 127.7 ; 63.2 ; 77.9 ; 72.8 ; 117.7 ; 279.2 ; 54.7 ; 126.8 ; 82.5 ; 81.4 ; 53.7 ; 207.3 ; 74.3 ; 206.3 ; 149.9 ; 108.7 ; 61.6 ; 257.6 ; 37.5 ; 175.9 ; 40.5 ; 81.1 ; 58.8 ; 38.3 ; 66.5 ; 65.6 ; 103.9 ; 107.6 ; 93 ; 26 ; 97.6 ; 26.8 ; 60.54 ; 48 ; 39.3 ; 52.4 ; 92.4 ; 220.4 ; 49.3 ; 66.9 ; 57.8 ; 112.7 ; 152.5 ; 50.9 ; 37.8 ; 68.4 ; 28.8 ; 27.8 ; 38.9 ; 105.3 ; 122.2
EPITHELIAL	Black	NCI-60 Cell Lines (NCI, Cancer Res 2012)	STRING	Epithelial.	Sample	Yes ; No
MDR	Black	NCI-60 Cell Lines (NCI, Cancer Res 2012)	NUMBER	MDR.	Sample	-45 ; 14 ; 29 ; 19 ; -38 ; 91 ; -40 ; -41 ; -19 ; 7 ; -5 ; 26 ; 414 ; 15 ; 31 ; 10 ; -9 ; 61 ; -4 ; -2 ; -10 ; 25 ; 16 ; 35 ; -11 ; -1 ; -3 ; 4 ; 12 ; 22 ; 20 ; 11 ; 8 ; 352 ; -12 ; 13 ; -44 ; 78 ; 120 ; 171 ; 42 ; -86 ; 59
P53	Black	NCI-60 Cell Lines (NCI, Cancer Res 2012)	STRING	P53.	Sample	? ; MT ; WT
ANNOTATION_SOURCE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Annotation Source	Sample	CCLE ; COSMIC ; collaborator ; ACHILLES ; COSMIC_MINT
CELL_LINE_SOURCE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Cell Line Source	Sample	ATCC ; NIBRI ; GNF ; ECACC ; RIKEN ; HSSRB ; DSMZ ; JCRB ; HSRRB ; ICLC ; EACC ; KCLB ; Riken ; HPACC ; ECAAC ; WISTAR ; ACADEMIC ; NIBRI/ATCC ; NCI/DCTD ; Acd Lab ; ACDC LAB ; Academic Lab ; JHSF ; PT-6ZZI ; Garraway Lab
CHARACTERISTICS	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Characteristics	Sample	Adherent ; suspension line; lots of debris ; Adherent epithelial ; suspension ; Mixed (lymphoblasts) ; mixed ; adherent ; adherent epithelial ; lymphocyte-like ; epithelial-like ; Adherent epitheloid cells in monolayer ; fibroblast-like ; adherent epithelial-like ; Elongated polygonal ; Mixed, majority adherent ; suspension, lymphoblast ; Epithelial Adherent ; Polyglonal and fusiform adherent ; mixed line ; Adherent epithelial. ; Suspension ; Epithelial adherent ; Lymphocyte like with partially attached cells ; adherenet ; adherent, single cells and loosely attached clusters ; suspension, multicell aggregates ; mix ; ADHERENT, EPITHIAL-LIKE ; Monolayer Epithelial ; adherent fibroblasts ; Adherent , small pools of cells with large extracel. Space ; adherent fibroblast ; ADHERENT ; Adherent keratinocyte ; epithelial- like polygonal or round and flat cells (sometimes spindle- form, very heterogenous) growing in monolayers ; mixture of spindle-shaped and epithelial-like cells ; adherent growing in monolayers(very dense colonies) ; Adherent large epitheloid cells with long processes growing in monolayers with multilayer foci ; Round cells to occasionally polynucleated, single cells in suspension, few adherent ; ADHERENT EPITHELIAL; ; ADHERENT; EPITHELIAL-LIKE ; ROUND TO OVOID CELLS GROWING SINGLY OR IN CLUMPS ; epithelial; monolayer ; adherent; epithelial, keratinocyte ; neuroblast-like ; Suspension; plamacyte-like ; other ; polygonal; monolayer ; epithelial;monolayer and floating ; mixed cells ; polypoid; monolayer ; floating aggregates; suspention ; scatlered floating; suspention ; Epithelial-like ; EPITHELIAL, ADHERENT ; Fibroblast like adherent ; AHDHERENT; ` ; EPITHELIAL-LIKE ADHERENT CELLS ; ADHRENT EPITHELIAL; was clumpy ; Epithelial monolayer. Some look like fibroblasts or neurons. ; epithelial adherent ; mixed; dt= 72-96 hrs ; ADHERENT FIBROBLAST LIKE ; Epithelial adherent monolayer ; Epithelial Adherent cells in monolayer ; Adherent; dt=42.7 hrs ; Mix ; ADHERENT EPITHELOID CELLS GROWING IN MONOLAYERS ; Adherent monolayer ; EPITHELOID CELLS GROWING AS ADHERENT MONOLAYER ; adherent; dt=40-50hrs ; EPITHELOID CELLS GROWING IN MONOLAYERS ; SUSPENSION ; polygonal-epithelial ; Fibroblast-like ; Supsension ; SUSPENSION, LYMPHOCYTE-LIKE ; round cells with vacuolization ; lymphoblast-like ; Biporar polyglonal ; suspension; grows in aggregates ; epithelial, adherent ; Suspension Lymphoblast ; Adherenet ; aggregates in suspension ; ADHERENT; fast grower ; SUSPENSION LYMPHOBLASTS ; Suspension with some loosely attached cells ; mixed line  ~ 50-50 ; adherenet; epithelial ; adherent; epithelial ; loosely adherent epithelial ; Fibroblast  adherent ; adherent; line grows as large epithelial cells with tendency to float at high cell  densitites ; ADHERENT EPITHELIAL ; adherent with some suspension cells ; Epithelial; mixed adherent and suspension ; monolayer ; Epithelial Monolayer ; ADHERENT FIBROBLASTS, NOT LIMITED TO MONOLAYER GROWTH ; ADHERENT, EPITHELIAL MONOLAYER ; adherent, polygonal & fusiform ; Large irregular aggregates, difficult to count ; Aggregates in suspension ; Adherent polygonal and fusiform ; round cells growing singly or in clumps in suspension ; Mixed cells ; Lymphoblastoid, suspension ; Adhrent cells growing as monolayers; dt=30-40hrs ; SPINDLE, FIBROBLAST-LIKE CELLS GROWING MOSTLY ADHERENT AS MONOLAYER ; Lymphoblast like; suspension ; MIX ; adherent epithelial-like cells growing as monolayer ; epitheloid cells growing adherent in monolayers ; spindle; monolayer ; lymphoblast-like, round; suspention ; spendle; monolayer ; suspention ; epithelial; monolayer, clumping ; Epithelial monolayer ; adherent polygonal ; Mixed cell line. ; single, multiformed, large cells growing in suspension, sometimes loosely adherent (<3%); 2-3% giant, multinucleated cells ; round single cells growing in suspention ; Adherent astrocytic ; adherent; extremely slow grower ; Mixed line, loosely adherent ; Adherent epthelial ; Large adherent cells, quite a bit of debris ; floating aggregates ; ADHERENT CELLS GROWING IN MONOLAYERS ; Mixed line, majority in suspension ; Adherent, single cells and clusters loosely attached ; Mixed Line ; Mixed adherent and suspension ; ADHERENT CELLS ; Lymphoblast suspension ; Epithelial-like grown as monolayer ; Epithelial-like grown in monolayer ; Adherent Fibroblast ; Adherent; DT=27hrs ; Adherent fibroblast. ; Grow as clusters and single cells in suspension; dt=30-40hrs ; Monolayer and suspension ; clusters in suspension ; Adherent; fibroblasts; very slow grower ; Suspension; floating clusters ; ADHERENT OVOID TO EPITHELOID CELLS GROWING IN MONOLAYERS ; Adherent / Mixed 0.05% TRYPSIN ; Adherent; DT=58hrs ; ADHERENT; 0.05% TRYPSIN ; suspension; do not allow cell concentration to exceed 1e6cells/ml ; ADHERENT FIBROBLAST ; Adherent epithelial, monolayer ; Mixed ; polyglonal adherent ; adherent; epithelial; DT=22 hrs ; Adherent fibroblastic but not limited to monolayer. ; Adherent Epithelial ; epitheloid, growing in clusters at first, then monolayer ; EPITHELIAL-LIKE ADHERENT CELLS WITH LONG, NARROW, OFTEN BRANCHING CELL BODIES ; fibroblst-like cells growing as monolayers ; SUSPENSION (round polygonal single, rather small cells) ; Adhrent cells growing as monolayers; dt=30hrs ; Epitheloid cells growing in monolayers ; ADHERENT, LARGE, SPINDLE-LIKE CELLS GROWING AS MONOLAYERS ; adherent epitheloid cells growing in monolayers ; Epithelial like ; Variable morphology ; Adhrent and aggregates; dt=60-70hrs ; Adherent; 0.25% TRYPSIN ; Lymphoblast, suspension ; ADHERENT FIBROBLASTS ; Suspension; multicell aggregates ; Mixed adherent and suspension (spherical) ; round clusters in suspension ; adherent; ; Mixed; adherent and suspension ; AHERENT EPITHELIAL; ; MIXED ; suspension; dt=50hrs ; round to polymorph cells growing singly or in small clumps ; adherent, fibroblast-like cells growing as monolayers ; spheroid cells growing in suspention, singly or in clumps ; single, round/ multiformed cells or small clusters of cells in suspention, sometimes loosely adherent; 1-5% giant cells ; Adherent epithelial monolayer ; Suspension; Extremely slow grower ; ovoid- to round, sometimes irregular, occasinally with apical processes, growing in suspention, singly or in small clumps ; adherent, sarcomatoid-like cells growing in monolayers ; suspension; lots of debris ; Adherent Spindle cells and large multinucleated cells ; large adherent cells ; Fibroblast Adherent ; Adherent large spindle-shaped cells growing in monolayer ; mostly adherent epithelial, some clusters in suspension ; Mostly round cellsgrowing singly or in small clusters in suspention ; small round cells growing singly or in small clumps in suspension; some loosely adherent ; round cells growing singl or, occasionally, in clumps ; SINGLE IN SUSPENSION ; LARGE, ADHERENT CELLS; very slow grower ; single round to oval cells showing  a morphological range from mononuclear to occasionally multinucleated cells growing in suspention ; single, round to polymorph  in suspention ; strongly adherent epitheloid cells growing in monolayers and forming islets ; Round Cells or clumps in suspension ; Epitheloid cells as single cells or as clumps in suspension and monolayer ; small single round cells growing in suspension; small clumps ; rond or polymorph cells growing singly  or in clusters in suspentipn ; adherent ephithelial-like cells growing as monolayers and in aggregates ; Mixed line ; SINGLE OR CLUSTERED OVOID TO ROUND; SOMETIMES IRREGULAR SHPAED CELLS GROWING IN SUSPENSION ; single, mostly round cells growing in suspention ; round lymphoid cells growing singly or in clumps in suspention ; adherent, epithelial-like cells growing as monolayers ; suspension;dt=55hrs ; spheroidal cells growing as clumps in suspension; grows as semi-adherent monolayer on surfaces coated with poly-L-lysine ; Adherent, epitheloid cells growing in monolayers ; round or spindle - shaped adherent cells growing as monolayer ; single, round to polymorph cellsgrowing in suspention, some cells areloosely adherent ; single, round cells insuspension ; lymphoblastoid, round to polygonal, single or clustered cells in suspention ; epitheloid, adherent cells growing in monolayers ; SUSPENSION ( small round cells, slow to grow) ; cells grow as sinngle cells or in clumps in suspention ; (relatively small) round cells growing in suspention, singly or in small clusters ; single, small, round cells in suspention ; adherent epithelial-like growing as monolayer ; single, round/multiformed cells in suspention ; single cells in suspention; cells have a rather monoblastic morphology  without the typical APL granules ; single, round to oval cells in suspention ; small, single, round cells in suspention ; single, round to oval cells  in suspention ; single,relatively small round cells growing in suspention ; round cells growing singly or in small clusters in suspention ; round cells growing singly or in clumps in suspention ; round single cells growing in suspention (cell pellet shows dedish color hemoglobin) ; large round cells growing in suspention ; supension ; round cells growing singly in suspention ; Adherent fibroblast, extremely slow. A lot of debris present ; adherent monolayers ; single, round cells growing in suspention, partly in clusters ; single round rather small cells growing in suspention ; growing in suspention in mall or very big clusters(sheets)- cells are not adherent ; Adherent, single cells loosely attached ; ADHRENT EPITHELIAL ; Adherent; large epithelial cells with occasional vacuole formation ; Grows often in cluster in suspention, most cells are polygonal ( some cells are round) ; undifferentiated, round cells in suspension and loosely adherent in  monolayers ; polymorphic cells growing in suspention, singly or in small clusters ; single, polymorph cells in suspention ; epithelial-like (spindle) cells growing in monolayers; cells contain considerable amounts of small, dark granules ; adherent cells of various size, single or in small clusters, growing as monolayer ; lymphoblastoid cells growing in clumps in suspention ; round, single cells in suspention, sometimes in small clusters ; round or fusiform cells growing in clumps as adherent or semi-adherent multicellular spheroids ; epithelial-like cells growing in monolayers ; pleomorphic, gigantic, adherent cells growing as monolayer ; single, relatively small round cells growing in suspention ; single round cells in suspention, a few cells are lightly adherent ; round to elongated single cells growing in suspention ; single cells in suspention, round or polymorphic cells, very few are giant cells ; adherent epitheloid cells densely packed in islets,growing as monolayers ; aderent epithelial cells growing as confluent monolayers ; epithelial- like cells growing in monolayers ; lymphoblastoid, round to polygonal cells growing in clusters in suspention ; epithelial-like adherent cells growing in monolayers; the culture contains usually a large amount of cell debris ; cell shape is bipolar, cells growing as monolayer or forming foci ; polymorphic cells growing singly in suspention ; single round to polymorph cells growing in suspension ; small round cells growing singly or in  clumps in suspention ; round cells growind singly in suspention ; round  to polymorphic cells growing in suspention, singly or partly in small aggregates, a few cells  are slightly adherent ; large round cells growing singly  in suspention ; Spindle- or round-shaped cells growing adherently as monolayer ; adherent epitheloid cells growing in monolayers and forming islets ; small cells growing adherent but irregularly in monolayers ; epithelial-like cells growing as monolayer; cells do not grow to complete confluency ; small round cells growing singly or in small clumps in suspention; accasional adherent cells present ; ADHERENT CELLS, GROWING IN MONOLAYERS ; large transparent epitheloid cells, partially with long extentions, growing as monolayers ; single or small clumps in suspension ; polymorph cells growing as adherent cells and singly in suspention ; ADHERENT MONOLAYERS ; single suspension ; single round cells in suspention, some cells loosely adherent
DEPMAPID	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	DepMap ID	Sample	ACH-000698 ; ACH-000489 ; ACH-000431 ; ACH-000707 ; ACH-000509 ; ACH-000522 ; ACH-000613 ; ACH-000829 ; ACH-000557 ; ACH-000614 ; ACH-000523 ; ACH-000691 ; ACH-000424 ; ACH-000610 ; ACH-001039 ; ACH-000420 ; ACH-000648 ; ACH-000091 ; ACH-000584 ; ACH-000865 ; ACH-000701 ; ACH-000293 ; ACH-000043 ; ACH-000595 ; ACH-000770 ; ACH-000505 ; ACH-000022 ; ACH-000203 ; ACH-000609 ; ACH-000774 ; ACH-000296 ; ACH-000974 ; ACH-001150 ; ACH-001171 ; ACH-000875 ; ACH-000155 ; ACH-000135 ; ACH-000069 ; ACH-000285 ; ACH-000144 ; ACH-000054 ; ACH-000841 ; ACH-000256 ; ACH-000451 ; ACH-000871 ; ACH-000433 ; ACH-000491 ; ACH-000727 ; ACH-000129 ; ACH-000298 ; ACH-001021 ; ACH-000842 ; ACH-000616 ; ACH-000438 ; ACH-000413 ; ACH-000967 ; ACH-000972 ; ACH-000335 ; ACH-000654 ; ACH-000465 ; ACH-000953 ; ACH-000848 ; ACH-000612 ; ACH-000905 ; ACH-000276 ; ACH-000258 ; ACH-000916 ; ACH-000360 ; ACH-000893 ; ACH-000939 ; ACH-000759 ; ACH-000059 ; ACH-001016 ; ACH-000367 ; ACH-000448 ; ACH-000883 ; ACH-000569 ; ACH-000675 ; ACH-000951 ; ACH-000563 ; ACH-001249 ; ACH-001145 ; ACH-000801 ; ACH-000529 ; ACH-000837 ; ACH-000539 ; ACH-000340 ; ACH-000071 ; ACH-000164 ; ACH-000718 ; ACH-000147 ; ACH-000230 ; ACH-000771 ; ACH-000503 ; ACH-000318 ; ACH-000615 ; ACH-000415 ; ACH-000548 ; ACH-001015 ; ACH-000441 ; ACH-000028 ; ACH-001023 ; ACH-000495 ; ACH-000501 ; ACH-000004 ; ACH-000270 ; ACH-000189 ; ACH-000237 ; ACH-000114 ; ACH-000515 ; ACH-000605 ; ACH-000324 ; ACH-000086 ; ACH-000245 ; ACH-000715 ; ACH-000161 ; ACH-000255 ; ACH-000412 ; ACH-000803 ; ACH-000159 ; ACH-000671 ; ACH-000042 ; ACH-000458 ; ACH-000794 ; ACH-001188 ; ACH-000592 ; ACH-000513 ; ACH-000345 ; ACH-000992 ; ACH-000917 ; ACH-001162 ; ACH-000560 ; ACH-000317 ; ACH-000836 ; ACH-000741 ; ACH-000305 ; ACH-000998 ; ACH-000537 ; ACH-000532 ; ACH-000434 ; ACH-000933 ; ACH-000723 ; ACH-000731 ; ACH-001088 ; ACH-000459 ; ACH-000941 ; ACH-001234 ; ACH-000949 ; ACH-000947 ; ACH-000302 ; ACH-001078 ; ACH-000266 ; ACH-000986 ; ACH-000726 ; ACH-000452 ; ACH-000908 ; ACH-000173 ; ACH-000471 ; ACH-000416 ; ACH-000635 ; ACH-000286 ; ACH-000970 ; ACH-000746 ; ACH-000197 ; ACH-000578 ; ACH-000959 ; ACH-001214 ; ACH-000325 ; ACH-000225 ; ACH-000485 ; ACH-000658 ; ACH-000333 ; ACH-000768 ; ACH-000291 ; ACH-000874 ; ACH-000663 ; ACH-000617 ; ACH-000393 ; ACH-000997 ; ACH-000470 ; ACH-000376 ; ACH-000304 ; ACH-000476 ; ACH-000383 ; ACH-000963 ; ACH-000620 ; ACH-000748 ; ACH-000447 ; ACH-000261 ; ACH-000665 ; ACH-000395 ; ACH-000734 ; ACH-000633 ; ACH-000401 ; ACH-000729 ; ACH-000965 ; ACH-000396 ; ACH-000878 ; ACH-000152 ; ACH-000264 ; ACH-000309 ; ACH-000669 ; ACH-000425 ; ACH-000192 ; ACH-000988 ; ACH-000879 ; ACH-000027 ; ACH-000756 ; ACH-000030 ; ACH-000809 ; ACH-000201 ; ACH-000599 ; ACH-000789 ; ACH-000062 ; ACH-000702 ; ACH-000243 ; ACH-000463 ; ACH-000823 ; ACH-000693 ; ACH-000118 ; ACH-000435 ; ACH-000047 ; ACH-000764 ; ACH-000103 ; ACH-000755 ; ACH-000598 ; ACH-000588 ; ACH-000576 ; ACH-000498 ; ACH-000419 ; ACH-000445 ; ACH-000479 ; ACH-000446 ; ACH-000444 ; ACH-000541 ; ACH-000351 ; ACH-000758 ; ACH-000108 ; ACH-000076 ; ACH-000564 ; ACH-000472 ; ACH-000126 ; ACH-000480 ; ACH-000862 ; ACH-000250 ; ACH-000976 ; ACH-000773 ; ACH-000157 ; ACH-000231 ; ACH-000990 ; ACH-000005 ; ACH-000808 ; ACH-001036 ; ACH-000946 ; ACH-000826 ; ACH-000146 ; ACH-000697 ; ACH-000149 ; ACH-000859 ; ACH-000783 ; ACH-000984 ; ACH-000269 ; ACH-000831 ; ACH-000778 ; ACH-000546 ; ACH-000714 ; ACH-000265 ; ACH-000507 ; ACH-001048 ; ACH-000167 ; ACH-000484 ; ACH-000847 ; ACH-000390 ; ACH-000239 ; ACH-000626 ; ACH-000674 ; ACH-001017 ; ACH-000721 ; ACH-000464 ; ACH-000889 ; ACH-000662 ; ACH-000851 ; ACH-000843 ; ACH-000811 ; ACH-000094 ; ACH-000583 ; ACH-000869 ; ACH-000440 ; ACH-000555 ; ACH-000923 ; ACH-000052 ; ACH-000248 ; ACH-000253 ; ACH-000354 ; ACH-000892 ; ACH-000860 ; ACH-000138 ; ACH-000001 ; ACH-000035 ; ACH-000888 ; ACH-000589 ; ACH-000858 ; ACH-000148 ; ACH-000536 ; ACH-000483 ; ACH-000039 ; ACH-000061 ; ACH-000846 ; ACH-001189 ; ACH-000934 ; ACH-000573 ; ACH-000031 ; ACH-000334 ; ACH-000041 ; ACH-000832 ; ACH-000449 ; ACH-000890 ; ACH-000496 ; ACH-000835 ; ACH-000017 ; ACH-000581 ; ACH-000355 ; ACH-000427 ; ACH-000364 ; ACH-000389 ; ACH-000081 ; ACH-000374 ; ACH-000018 ; ACH-000096 ; ACH-000223 ; ACH-000930 ; ACH-000247 ; ACH-000410 ; ACH-000055 ; ACH-000181 ; ACH-000699 ; ACH-000200 ; ACH-000397 ; ACH-001093 ; ACH-000694 ; ACH-000622 ; ACH-000637 ; ACH-000873 ; ACH-000928 ; ACH-000469 ; ACH-000672 ; ACH-000153 ; ACH-001064 ; ACH-000341 ; ACH-000260 ; ACH-000162 ; ACH-000221 ; ACH-000493 ; ACH-000238 ; ACH-000877 ; ACH-000111 ; ACH-000478 ; ACH-000786 ; ACH-000914 ; ACH-000077 ; ACH-000151 ; ACH-000009 ; ACH-000087 ; ACH-000585 ; ACH-000535 ; ACH-000666 ; ACH-000303 ; ACH-000422 ; ACH-000996 ; ACH-000454 ; ACH-000011 ; ACH-000891 ; ACH-000026 ; ACH-000348 ; ACH-000682 ; ACH-000618 ; ACH-000314 ; ACH-000812 ; ACH-000901 ; ACH-000228 ; ACH-000278 ; ACH-000968 ; ACH-000123 ; ACH-000765 ; ACH-000165 ; ACH-000007 ; ACH-000929 ; ACH-000867 ; ACH-000844 ; ACH-000695 ; ACH-000897 ; ACH-000749 ; ACH-000903 ; ACH-000187 ; ACH-000912 ; ACH-000921 ; ACH-000827 ; ACH-000429 ; ACH-000884 ; ACH-000661 ; ACH-000987 ; ACH-000899 ; ACH-000394 ; ACH-000199 ; ACH-000514 ; ACH-000421 ; ACH-000217 ; ACH-000882 ; ACH-000780 ; ACH-000830 ; ACH-000586 ; ACH-000382 ; ACH-000608 ; ACH-000982 ; ACH-000619 ; ACH-000508 ; ACH-000743 ; ACH-000735 ; ACH-000606 ; ACH-001047 ; ACH-001183 ; ACH-000732 ; ACH-000688 ; ACH-000926 ; ACH-000704 ; ACH-000935 ; ACH-000116 ; ACH-000652 ; ACH-001113 ; ACH-000263 ; ACH-000226 ; ACH-000361 ; ACH-000696 ; ACH-000924 ; ACH-000961 ; ACH-000628 ; ACH-000945 ; ACH-000677 ; ACH-000646 ; ACH-000400 ; ACH-000053 ; ACH-000332 ; ACH-000547 ; ACH-000740 ; ACH-000840 ; ACH-000244 ; ACH-000907 ; ACH-000834 ; ACH-000944 ; ACH-001075 ; ACH-000520 ; ACH-000040 ; ACH-001233 ; ACH-000712 ; ACH-000833 ; ACH-000720 ; ACH-000736 ; ACH-000518 ; ACH-000344 ; ACH-000257 ; ACH-000738 ; ACH-000524 ; ACH-001043 ; ACH-000864 ; ACH-001101 ; ACH-001072 ; ACH-000407 ; ACH-001037 ; ACH-000316 ; ACH-001084 ; ACH-000110 ; ACH-000109 ; ACH-000898 ; ACH-000543 ; ACH-000991 ; ACH-000788 ; ACH-001094 ; ACH-000999 ; ACH-000549 ; ACH-000989 ; ACH-000955 ; ACH-000623 ; ACH-000426 ; ACH-000466 ; ACH-000461 ; ACH-000209 ; ACH-000868 ; ACH-000710 ; ACH-000289 ; ACH-000762 ; ACH-000368 ; ACH-000708 ; ACH-000500 ; ACH-000141 ; ACH-000630 ; ACH-000268 ; ACH-000377 ; ACH-000517 ; ACH-000692 ; ACH-000683 ; ACH-000195 ; ACH-000807 ; ACH-000370 ; ACH-000182 ; ACH-000686 ; ACH-000280 ; ACH-000460 ; ACH-000089 ; ACH-000550 ; ACH-000211 ; ACH-000625 ; ACH-000607 ; ACH-000705 ; ACH-001089 ; ACH-000641 ; ACH-000753 ; ACH-000310 ; ACH-000656 ; ACH-000085 ; ACH-001044 ; ACH-000468 ; ACH-000994 ; ACH-001049 ; ACH-000813 ; ACH-000761 ; ACH-001318 ; ACH-000227 ; ACH-000329 ; ACH-000050 ; ACH-000313 ; ACH-000781 ; ACH-000594 ; ACH-000866 ; ACH-000095 ; ACH-000177 ; ACH-000179 ; ACH-000214 ; ACH-000519 ; ACH-000373 ; ACH-000322 ; ACH-000640 ; ACH-000180 ; ACH-000814 ; ACH-000158 ; ACH-000224 ; ACH-000358 ; ACH-000925 ; ACH-000097 ; ACH-000386 ; ACH-000312 ; ACH-000668 ; ACH-000092 ; ACH-000932 ; ACH-000104 ; ACH-000467 ; ACH-000766 ; ACH-000125 ; ACH-001071 ; ACH-000319 ; ACH-000417 ; ACH-000359 ; ACH-000307 ; ACH-000284 ; ACH-000900 ; ACH-000051 ; ACH-000437 ; ACH-000331 ; ACH-000845 ; ACH-000870 ; ACH-000744 ; ACH-000131 ; ACH-000733 ; ACH-000559 ; ACH-000306 ; ACH-000093 ; ACH-000229 ; ACH-000402 ; ACH-000687 ; ACH-000082 ; ACH-000565 ; ACH-000185 ; ACH-000063 ; ACH-000240 ; ACH-000175 ; ACH-000008 ; ACH-000282 ; ACH-001001 ; ACH-000482 ; ACH-000021 ; ACH-000384 ; ACH-000067 ; ACH-000943 ; ACH-000133 ; ACH-000132 ; ACH-000019 ; ACH-000406 ; ACH-000145 ; ACH-000538 ; ACH-000725 ; ACH-000072 ; ACH-000960 ; ACH-000776 ; ACH-001182 ; ACH-000722 ; ACH-000366 ; ACH-000530 ; ACH-000561 ; ACH-001146 ; ACH-000567 ; ACH-001144 ; ACH-000962 ; ACH-000418 ; ACH-000621 ; ACH-000819 ; ACH-000411 ; ACH-000649 ; ACH-000713 ; ACH-000739 ; ACH-001127 ; ACH-000816 ; ACH-000290 ; ACH-000601 ; ACH-000796 ; ACH-000670 ; ACH-000644 ; ACH-000115 ; ACH-001042 ; ACH-000915 ; ACH-000107 ; ACH-000117 ; ACH-000178 ; ACH-000936 ; ACH-000657 ; ACH-000752 ; ACH-000966 ; ACH-000297 ; ACH-000639 ; ACH-001092 ; ACH-000952 ; ACH-000822 ; ACH-000404 ; ACH-000724 ; ACH-000525 ; ACH-000060 ; ACH-001065 ; ACH-000799 ; ACH-001024 ; ACH-000176 ; ACH-000769 ; ACH-000885 ; ACH-000423 ; ACH-000222 ; ACH-000409 ; ACH-000638 ; ACH-000442 ; ACH-000521 ; ACH-000931 ; ACH-000574 ; ACH-000477 ; ACH-000380 ; ACH-000571 ; ACH-000002 ; ACH-000863 ; ACH-000542 ; ACH-000311 ; ACH-000881 ; ACH-000651 ; ACH-000971 ; ACH-000171 ; ACH-000979 ; ACH-000763 ; ACH-000685 ; ACH-001190 ; ACH-000681 ; ACH-000558 ; ACH-000587 ; ACH-000805 ; ACH-000281 ; ACH-000475 ; ACH-000910 ; ACH-000235 ; ACH-000430 ; ACH-000527 ; ACH-000330 ; ACH-000450 ; ACH-000371 ; ACH-000572 ; ACH-000378 ; ACH-000102 ; ACH-000782 ; ACH-000797 ; ACH-000323 ; ACH-001098 ; ACH-000667 ; ACH-000784 ; ACH-001000 ; ACH-000098 ; ACH-000343 ; ACH-000978 ; ACH-000205 ; ACH-001198 ; ACH-000582 ; ACH-000190 ; ACH-000853 ; ACH-000977 ; ACH-000985 ; ACH-000562 ; ACH-000570 ; ACH-000913 ; ACH-000232 ; ACH-000488 ; ACH-000631 ; ACH-000954 ; ACH-000647 ; ACH-000909 ; ACH-001126 ; ACH-000791 ; ACH-000408 ; ACH-000259 ; ACH-000980 ; ACH-000353 ; ACH-000528 ; ACH-000137 ; ACH-000747 ; ACH-000880 ; ACH-000347 ; ACH-000207 ; ACH-000927 ; ACH-000046 ; ACH-000950 ; ACH-000015 ; ACH-000839 ; ACH-000810 ; ACH-000443 ; ACH-000956 ; ACH-000580 ; ACH-000139 ; ACH-000817 ; ACH-001061 ; ACH-000906 ; ACH-000327 ; ACH-000379 ; ACH-000252 ; ACH-000375 ; ACH-000506 ; ACH-000958 ; ACH-000120 ; ACH-000957 ; ACH-000820 ; ACH-000403 ; ACH-000242 ; ACH-000793 ; ACH-000080 ; ACH-000236 ; ACH-000680 ; ACH-000540 ; ACH-000876 ; ACH-000703 ; ACH-000904 ; ACH-000163 ; ACH-000849 ; ACH-000767 ; ACH-000048 ; ACH-000288 ; ACH-000399 ; ACH-000857 ; ACH-000308 ; ACH-000219 ; ACH-000552 ; ACH-000800 ; ACH-000014 ; ACH-000730 ; ACH-000632 ; ACH-000502 ; ACH-001063 ; ACH-000719 ; ACH-000090 ; ACH-000551 ; ACH-000473 ; ACH-000911 ; ACH-000075 ; ACH-000234 ; ACH-000679 ; ACH-000709 ; ACH-000577 ; ACH-000919 ; ACH-000045 ; ACH-001239 ; ACH-000684 ; ACH-000969 ; ACH-001045 ; ACH-000381 ; ACH-000511 ; ACH-000750 ; ACH-000481 ; ACH-000553 ; ACH-000940 ; ACH-000186 ; ACH-000579 ; ACH-000824 ; ACH-000362 ; ACH-000213 ; ACH-001125 ; ACH-000777 ; ACH-000855 ; ACH-000320 ; ACH-000510 ; ACH-000023 ; ACH-000650 ; ACH-000673 ; ACH-000246 ; ACH-000642 ; ACH-000494 ; ACH-000591 ; ACH-001018 ; ACH-000455 ; ACH-000272 ; ACH-000279 ; ACH-000064 ; ACH-000690 ; ACH-001194 ; ACH-001207 ; ACH-001205 ; ACH-000887 ; ACH-000170 ; ACH-000036 ; ACH-001175 ; ACH-000328 ; ACH-000676 ; ACH-000300 ; ACH-000208 ; ACH-001067 ; ACH-000049 ; ACH-000600 ; ACH-000385 ; ACH-000490 ; ACH-000283 ; ACH-000128 ; ACH-000575 ; ACH-001225 ; ACH-000215 ; ACH-000629 ; ACH-001224 ; ACH-001058 ; ACH-001079 ; ACH-000016 ; ACH-000760 ; ACH-000634 ; ACH-000029 ; ACH-000127 ; ACH-001087 ; ACH-000499 ; ACH-000262 ; ACH-000216 ; ACH-000025 ; ACH-000453 ; ACH-000188 ; ACH-001230 ; ACH-000078 ; ACH-000624 ; ACH-000073 ; ACH-000006 ; ACH-000678 ; ACH-000566 ; ACH-000795 ; ACH-000338 ; ACH-000254 ; ACH-000531 ; ACH-000785 ; ACH-001138 ; ACH-000737 ; ACH-000012 ; ACH-000169 ; ACH-001321 ; ACH-000387 ; ACH-000088 ; ACH-000275 ; ACH-000079 ; ACH-001306 ; ACH-000568 ; ACH-000105 ; ACH-000728 ; ACH-000981 ; ACH-000439 ; ACH-000742 ; ACH-000357 ; ACH-000653 ; ACH-000388 ; ACH-000342 ; ACH-000604 ; ACH-000645 ; ACH-000902 ; ACH-000130 ; ACH-000942 ; ACH-000122 ; ACH-000798 ; ACH-000044 ; ACH-000349 ; ACH-000196 ; ACH-001203 ; ACH-001130 ; ACH-000336 ; ACH-000271 ; ACH-000365 ; ACH-000100 ; ACH-000124 ; ACH-000321 ; ACH-000363 ; ACH-000166 ; ACH-000850 ; ACH-000554 ; ACH-000220 ; ACH-000136 ; ACH-000717 ; ACH-000350 ; ACH-000301 ; ACH-000920 ; ACH-000038 ; ACH-000457 ; ACH-000432 ; ACH-000056 ; ACH-000198 ; ACH-000938 ; ACH-000545 ; ACH-000204 ; ACH-000787 ; ACH-001129 ; ACH-000218 ; ACH-000937 ; ACH-000462 ; ACH-000113 ; ACH-000032 ; ACH-000326 ; ACH-000065 ; ACH-000101 ; ACH-000241 ; ACH-000398 ; ACH-000315 ; ACH-000806 ; ACH-000516 ; ACH-000643 ; ACH-000156 ; ACH-000492 ; ACH-000013 ; ACH-000267 ; ACH-000142 ; ACH-001106 ; ACH-000659 ; ACH-000392 ; ACH-000852 ; ACH-000886 ; ACH-000894 ; ACH-000274 ; ACH-000277 ; ACH-000818 ; ACH-000083 ; ACH-000194 ; ACH-000066 ; ACH-000352 ; ACH-000074 ; ACH-000790 ; ACH-000772 ; ACH-000804 ; ACH-000134 ; ACH-000140 ; ACH-000828 ; ACH-000119 ; ACH-000292 ; ACH-000526 ; ACH-000414 ; ACH-000121 ; ACH-000233 ; ACH-000603 ; ACH-000202 ; ACH-000636 ; ACH-000664 ; ACH-000372 ; ACH-000802 ; ACH-000792 ; ACH-000391 ; ACH-000346 ; ACH-000168 ; ACH-000775 ; ACH-000184 ; ACH-000150 ; ACH-000154 ; ACH-000356 ; ACH-001307 ; ACH-000486 ; ACH-000983 ; ACH-000210 ; ACH-000037 ; ACH-000295 ; ACH-000024 ; ACH-000174 ; ACH-000627 ; ACH-000995 ; ACH-000070 ; ACH-000020 ; ACH-000602 ; ACH-000754 ; ACH-000918 ; ACH-000294 ; ACH-000596 ; ACH-000948 ; ACH-000191 ; ACH-000106 ; ACH-000856 ; ACH-000183 ; ACH-000815 ; ACH-000099 ; ACH-000287 ; ACH-000593 ; ACH-000611 ; ACH-000193 ; ACH-000068 ; ACH-000751 ; ACH-000405 ; ACH-000112 ; ACH-000660 ; ACH-000456 ; ACH-000973 ; ACH-000249 ; ACH-000716 ; ACH-001121 ; ACH-000895 ; ACH-000922 ; ACH-000212 ; ACH-000896 ; ACH-000689 ; ACH-000369 ; ACH-000487 ; ACH-000821 ; ACH-000534 ; ACH-000711 ; ACH-000058 ; ACH-000838 ; ACH-000745 ; ACH-001041 ; ACH-000993 ; ACH-001108 ; ACH-001107 ; ACH-001118 ; ACH-001120 ; ACH-000544 ; ACH-001187 ; ACH-001199 ; ACH-000590 ; ACH-001090 ; ACH-001091 ; ACH-000299 ; ACH-000034 ; ACH-001656 ; ACH-000964 ; ACH-000861 ; ACH-000706 ; ACH-001151 ; ACH-000428 ; ACH-001208 ; ACH-000655 ; ACH-000273 ; ACH-000504 ; ACH-000825 ; ACH-001011 ; ACH-000084 ; ACH-000757 ; ACH-000160 ; ACH-000206 ; ACH-000003 ; ACH-000143 ; ACH-000975 ; ACH-000339 ; ACH-000872 ; ACH-000512 ; ACH-001099 ; ACH-001109 ; ACH-001128 ; ACH-000533 ; ACH-000010 ; ACH-000700 ; ACH-000251 ; ACH-000033 ; ACH-000337 ; ACH-001142 ; ACH-000854 ; ACH-000436 ; ACH-000057 ; ACH-000779 ; ACH-001192 ; ACH-001193 ; ACH-001200 ; ACH-000556 ; ACH-000172 ; ACH-000597 ; ACH-001210 ; ACH-001211 ; ACH-001212 ; ACH-001020 ; ACH-001050 ; ACH-001052 ; ACH-001053 ; ACH-001054 ; ACH-001055 ; ACH-001096 ; ACH-001122 ; ACH-001123 ; ACH-001170 ; ACH-001196 ; ACH-001201 ; ACH-002212 ; ACH-002213 ; ACH-001331 ; ACH-001332 ; ACH-002043 ; ACH-002234 ; ACH-002239 ; ACH-002244 ; ACH-002045 ; ACH-002249 ; ACH-002250 ; ACH-001542 ; ACH-002260 ; ACH-002265 ; ACH-001625 ; ACH-001626 ; ACH-002294 ; ACH-002295 ; ACH-002296 ; ACH-002297 ; ACH-002298 ; ACH-001385 ; ACH-002029 ; ACH-001641 ; ACH-002305 ; ACH-001496 ; ACH-001497 ; ACH-001500 ; ACH-002243 ; ACH-001544 ; ACH-002263 ; ACH-002264 ; ACH-001368 ; ACH-002292 ; ACH-001654 ; ACH-002311 ; ACH-002218 ; ACH-002222 ; ACH-002258 ; ACH-002290 ; ACH-002299 ; ACH-002211 ; ACH-002255 ; ACH-002272 ; ACH-002275 ; ACH-001639 ; ACH-002308 ; ACH-001680 ; ACH-002214 ; ACH-002220 ; ACH-002221 ; ACH-001498 ; ACH-002253 ; ACH-002254 ; ACH-001638 ; ACH-001642 ; ACH-002062 ; ACH-002307 ; ACH-002313 ; ACH-002314 ; ACH-001703 ; ACH-002236 ; ACH-002252 ; ACH-002293 ; ACH-002300 ; ACH-002302 ; ACH-002270 ; ACH-002242 ; ACH-002274 ; ACH-002339 ; ACH-002245 ; ACH-002262 ; ACH-002209 ; ACH-002216 ; ACH-002238 ; ACH-002241 ; ACH-002256 ; ACH-002267 ; ACH-002059 ; ACH-002058 ; ACH-002240 ; ACH-002316 ; ACH-001709 ; ACH-002317 ; ACH-002210 ; ACH-002247 ; ACH-002099 ; ACH-002094 ; ACH-002103 ; ACH-002104 ; ACH-002105 ; ACH-002106 ; ACH-002108 ; ACH-002109 ; ACH-002110 ; ACH-002111 ; ACH-002112 ; ACH-002113 ; ACH-002114 ; ACH-002115 ; ACH-002116 ; ACH-002117 ; ACH-002118 ; ACH-002119 ; ACH-001715 ; ACH-002142 ; ACH-001526 ; ACH-002067 ; ACH-002178 ; ACH-001820 ; ACH-001358 ; ACH-001819 ; ACH-002163 ; ACH-002179 ; ACH-001494 ; ACH-002237 ; ACH-001861 ; ACH-002312 ; ACH-002345 ; ACH-001345 ; ACH-001081 ; ACH-002287 ; ACH-002122 ; ACH-002141 ; ACH-002161 ; ACH-002301 ; ACH-002198 ; ACH-001653 ; ACH-001401 ; ACH-002090 ; ACH-002139 ; ACH-002150 ; ACH-002151 ; ACH-002155 ; ACH-002167 ; ACH-002168 ; ACH-002187 ; ACH-002188 ; ACH-002189 ; ACH-002191 ; ACH-002192 ; ACH-002195 ; ACH-002199 ; ACH-002089 ; ACH-002101 ; ACH-002102 ; ACH-002157 ; ACH-001137 ; ACH-002174 ; ACH-002177 ; ACH-001417 ; ACH-001362 ; ACH-001363 ; ACH-001490 ; ACH-002095 ; ACH-001489 ; ACH-002144 ; ACH-002145 ; ACH-002154 ; ACH-002051 ; ACH-001549 ; ACH-002052 ; ACH-002077 ; ACH-001958 ; ACH-001591 ; ACH-002170 ; ACH-002171 ; ACH-001364 ; ACH-002173 ; ACH-001599 ; ACH-002176 ; ACH-001365 ; ACH-002196 ; ACH-002123 ; ACH-002124 ; ACH-002125 ; ACH-002126 ; ACH-002127 ; ACH-002128 ; ACH-002129 ; ACH-002130 ; ACH-002131 ; ACH-002132 ; ACH-002133 ; ACH-002134 ; ACH-002135 ; ACH-002136 ; ACH-002224 ; ACH-002225 ; ACH-002226 ; ACH-002227 ; ACH-002229 ; ACH-002230 ; ACH-002231 ; ACH-002259 ; ACH-002269 ; ACH-002304 ; ACH-001711 ; ACH-002217 ; ACH-001338 ; ACH-001344 ; ACH-001716 ; ACH-002248 ; ACH-001355 ; ACH-002277 ; ACH-002278 ; ACH-002279 ; ACH-002280 ; ACH-002281 ; ACH-002282 ; ACH-002283 ; ACH-002284 ; ACH-002083 ; ACH-002285 ; ACH-001603 ; ACH-001674 ; ACH-002164 ; ACH-002185 ; ACH-002186 ; ACH-002096 ; ACH-002097 ; ACH-002120 ; ACH-002121 ; ACH-002040 ; ACH-002143 ; ACH-002152 ; ACH-002153 ; ACH-002162 ; ACH-002165 ; ACH-002166 ; ACH-002205 ; ACH-002206 ; ACH-002207 ; ACH-001442 ; ACH-001328 ; ACH-002100 ; ACH-002309 ; ACH-002194 ; ACH-002271 ; ACH-002310 ; ACH-001274 ; ACH-001702 ; ACH-001443 ; ACH-001528 ; ACH-002148 ; ACH-001384 ; ACH-002235 ; ACH-002266 ; ACH-001333 ; ACH-001334 ; ACH-002091 ; ACH-001336 ; ACH-001341 ; ACH-001525 ; ACH-001359 ; ACH-001360 ; ACH-001650 ; ACH-002020 ; ACH-001402 ; ACH-002201 ; ACH-001517 ; ACH-002146 ; ACH-002149 ; ACH-001373 ; ACH-002181 ; ACH-002183 ; ACH-001374 ; ACH-001630 ; ACH-001399 ; ACH-001418 ; ACH-001453 ; ACH-001383 ; ACH-001578 ; ACH-002288 ; ACH-002291 ; ACH-001529 ; ACH-001530 ; ACH-001400 ; ACH-002200 ; ACH-001655 ; ACH-002215 ; ACH-001452 ; ACH-002107 ; ACH-002233 ; ACH-002190 ; ACH-001398 ; ACH-002184 ; ACH-002175 ; ACH-002169 ; ACH-002228 ; ACH-002261 ; ACH-002160 ; ACH-002098 ; ACH-002246 ; ACH-002180 ; ACH-002140 ; ACH-002251 ; ACH-002315 ; ACH-001617 ; ACH-002092 ; ACH-002093 ; ACH-002147 ; ACH-002306 ; ACH-002276 ; ACH-002289 ; ACH-002208 ; ACH-002193 ; ACH-002223 ; ACH-001704 ; ACH-002182 ; ACH-002202 ; ACH-002392 ; ACH-002204 ; ACH-002273 ; ACH-002232 ; ACH-001738 ; ACH-001519 ; ACH-001136 ; ACH-002197 ; ACH-002341 ; ACH-002257 ; ACH-002268 ; ACH-001605 ; ACH-001606 ; ACH-001002 ; ACH-002159 ; ACH-001350 ; ACH-001086 ; ACH-002286 ; ACH-002318 ; ACH-002018 ; ACH-001396 ; ACH-002485 ; ACH-001554 ; ACH-002500 ; ACH-002015 ; ACH-001795 ; ACH-002397 ; ACH-002390 ; ACH-001546 ; ACH-001550 ; ACH-001670 ; ACH-002391 ; ACH-002396 ; ACH-001552 ; ACH-002340 ; ACH-002394 ; ACH-001116 ; ACH-002156 ; ACH-001270 ; ACH-001329 ; ACH-001278 ; ACH-001454 ; ACH-001456 ; ACH-001458 ; ACH-001459 ; ACH-001460 ; ACH-001461 ; ACH-001028 ; ACH-001300 ; ACH-001030 ; ACH-001282 ; ACH-001031 ; ACH-001032 ; ACH-001033 ; ACH-001035 ; ACH-001034 ; ACH-001322 ; ACH-001289 ; ACH-001038 ; ACH-001301 ; ACH-001302 ; ACH-001339 ; ACH-001057 ; ACH-002348 ; ACH-001060 ; ACH-001066 ; ACH-001068 ; ACH-002349 ; ACH-001521 ; ACH-001522 ; ACH-001523 ; ACH-001955 ; ACH-001353 ; ACH-001097 ; ACH-001100 ; ACH-001111 ; ACH-001354 ; ACH-001119 ; ACH-001356 ; ACH-001551 ; ACH-001555 ; ACH-001556 ; ACH-001557 ; ACH-001558 ; ACH-001559 ; ACH-001560 ; ACH-001561 ; ACH-001562 ; ACH-001563 ; ACH-001566 ; ACH-001567 ; ACH-001568 ; ACH-001569 ; ACH-001570 ; ACH-001132 ; ACH-001956 ; ACH-001134 ; ACH-001303 ; ACH-001143 ; ACH-001147 ; ACH-001148 ; ACH-001375 ; ACH-001376 ; ACH-001377 ; ACH-001379 ; ACH-001380 ; ACH-001382 ; ACH-001433 ; ACH-001767 ; ACH-001740 ; ACH-001751 ; ACH-001765 ; ACH-001745 ; ACH-001386 ; ACH-001184 ; ACH-001280 ; ACH-001645 ; ACH-001197 ; ACH-001390 ; ACH-001391 ; ACH-001394 ; ACH-001275 ; ACH-001283 ; ACH-001430 ; ACH-001431 ; ACH-001673 ; ACH-001750 ; ACH-001206 ; ACH-001957 ; ACH-001408 ; ACH-001409 ; ACH-001411 ; ACH-001414 ; ACH-001228 ; ACH-001232 ; ACH-001295 ; ACH-001277 ; ACH-002389 ; ACH-002393 ; ACH-002395 ; ACH-001131 ; ACH-001140 ; ACH-002342 ; ACH-002343 ; ACH-002344 ; ACH-002380 ; ACH-002346 ; ACH-002347 ; ACH-002350 ; ACH-002378 ; ACH-002373 ; ACH-002382 ; ACH-002374 ; ACH-002375 ; ACH-002384 ; ACH-002381 ; ACH-002383 ; ACH-002377 ; ACH-002336 ; ACH-002379 ; ACH-002337 ; ACH-002351 ; ACH-002352 ; ACH-002353 ; ACH-002354 ; ACH-002355 ; ACH-002356 ; ACH-002357 ; ACH-002358 ; ACH-002359 ; ACH-002376 ; ACH-002386 ; ACH-002387 ; ACH-002338 ; ACH-002388 ; ACH-002360 ; ACH-002361 ; ACH-002362 ; ACH-002363 ; ACH-002364 ; ACH-002365 ; ACH-002366 ; ACH-002367 ; ACH-002368 ; ACH-002369 ; ACH-002370 ; ACH-002371 ; ACH-002372 ; ACH-002303 ; ACH-001450 ; ACH-001022 ; ACH-001029 ; ACH-001340 ; ACH-001059 ; ACH-001346 ; ACH-001310 ; ACH-001737 ; ACH-001524 ; ACH-001532 ; ACH-001536 ; ACH-001367 ; ACH-001610 ; ACH-001611 ; ACH-001369 ; ACH-001624 ; ACH-001378 ; ACH-001425 ; ACH-001743 ; ACH-001279 ; ACH-001412 ; ACH-001413 ; ACH-001407 ; ACH-001410 ; ACH-001415 ; ACH-001416 ; ACH-002172 ; ACH-002024 ; ACH-002584 ; ACH-002219 ; ACH-001601 ; ACH-001594 ; ACH-001597 ; ACH-001671 ; ACH-001451 ; ACH-001592 ; ACH-002668 ; ACH-002158 ; ACH-002478 ; ACH-001602 ; ACH-002623 ; ACH-002624 ; ACH-002625 ; ACH-002626 ; ACH-002335
DISEASE_ONTOLOGY	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Disease Ontology	Patient	
DOUBLING_TIME_FROM_VENDOR	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Doubling Time From Vendor	Sample	~ 30 hrs ; ~  70 hrs ; ~  50 hrs ; 20-25hrs ; 36 hrs ; 40 hrs ; 96 hrs ; 60 hrs ; 153 hrs ; 19.8 hrs ; 24 hrs ; 39 hrs ; 52 hrs ; 25.3 hrs ; 43 hrs ; 48 hrs ; 53 hrs ; 42 hrs ; 67 hrs ; 27 hrs ; 43hrs ; 95 hrs ; 33 hrs ; 40-50 hrs ; 92 hrs ; 1 week ; ~50 hrs ; 26-28 hrs ; 5-7 DAYS ; 38.2 hrs ; ~ 48 - 72 hrs ; 40-50hrs ; 30 hrs ; 30-40 hrs ; 50 hrs ; 120hrs ; ~  35 hrs ; 30-40hrs ; 20 hrs ; 25 hrs ; 63 hrs ; 61 hrs ; 54 hrs ; 21.6 hrs ; 36hrs ; 29.3 hrs ; 72 hrs ; 56 hrs ; 40 ; 44 ; 34hrs ; ~  40-50 hrs ; ~  48-72 hrs ; 70hrs ; 53hrs ; 1.2 days ; 58 ; 64 hrs ; 30 ; 50-80 hrs ; 60-70 hrs ; 120hrs?? ; 4 days ; ~  100 hrs ; ~ 49 hrs ; ~  60 hrs ; ~  30 hrs ; 54hrs ; ~  48 hrs ; ~  20-35 hrs ; ~  170 hrs ; 50-70 hrs ; ~  3-4 days ; ~  35-40 hrs ; ~ 30-50 hrs ; ~  2-3 days ; ~ 72 hrs ; ~  60-70 hrs ; ~  48-60 hrs ; ~  50-70 hrs ; ~  72 hrs ; ~  40 hrs ; ~  36 hrs ; ~  30-50 hrs ; ~ 50 hrs ; ~  120 hrs ; 240hrs ; 72hrs ; ~  80-100 hrs ; ~  2 days ; 110 hrs ; ~  38 hrs ; ~  50hrs ; ~  28 hrs ; ~  24 hrs ; ~ 35 hrs ; ~  25-35 hrs ; ~  35-45 hrs ; > 50 hrs ; >60 hrs ; highly variable ~  34-100 hrs ; ~  30-36 hrs ; ~  20-40 hrs ; ~ 3-4 days ; ~  60-80 hrs ; 50-80hrs ; ~  24-36 hrs ; ~  30-40 hrs ; 4-7 DAYS ; 50-90hrs ; ~38 hrs
FREEZING_MEDIUM	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Freezing Medium	Sample	5%DMSO ; 5% DMSO ; 10% DMSO ; 10%DMSO ; 5 % DMSO ; ? ; 5%DMSo ; 5-7.5%DMSO ; 5 ; 0.05
GENOME_DOUBLINGS	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Genome Doublings	Sample	1 ; 0 ; 2
GEOGRAPHIC_DISTRIBUTION	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Geographic Distribution	Patient	
GROWTH_MEDIUM	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Growth Medium	Sample	Waymouth's +10%FBS ; L15+10%FBS ; DMEM:F12 (1:1) + 5% FBS ; EMEM +10%FBS ; IMDM+5%FBS ; RPMI1640+10%FBS ; RPMI-1640 + 10% FBS ; DMEM:HAM's F12  1:1  +5% FBS ; RPMI+10%FBS ; DMEM:F12 + 10% FBS ; RPMI 1640 medium with 10% fetal calf serum ; Han's F12 medium 90% with 10% fetal bovine serum ; DMEM + 10%FBS ; alpha-MEM with 10% fetal calf serum ; Eagle's minimal essential medium with 10% fetal bovine serum ; RPMI-1640+10% FBS ; Dulbecco's modified Eagle's medium with 10% fetal bovine serum ; Ham's F12 medium with 20% fetal bovine serum ; DMEM+10%FBS ; RPMI 1640 +10% FBS ; EMEM+10%FBS ; DMEM:F12 (1:1) + 10% FBS ; DMEM + 10% FBS ; F-12K  ATCC  + 10% FBS ; McCoy's 5A +10%FBS ; DMEM:HAM's F12  1:1 (ATCC catalog # 30-2006) + 5%  FBS ; RPMI-1640   + 5% FBS ; DMEM:HAM's F12  1:1  + 5%  FBS ; RPMI 1640+10%FBS ; Eagle's minimal essential medium with 15%  fetal calf serum ; DMEM/F12(1:1) +10 % FBS ; EMEM + 10% FBS ; DMEM:F:12 (1:1) +10 %FBS ; RPMI-1640  +10% FBS ; DMEM:F12(1:1) + 10%FBS ; MEM+10%FBS ; RPMI-1640+ 5% FBS ; DMEM +10 %FBS ; DMEM+10% FBS ; RPMI 1640 +10%FBS ; 90% Dulbecco's MEM + 10% h.i. FBS ; DMEM:F12 + 5% FBS ; DMEM:F12+10% FBS ; RPMI-1640+20% FBS ; (DMEM: HamF12=1:1) +10%FBS ; RPMI + 10 % FBS ; RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10% ; HamF10 +10% FBS ; RPMI 1640 with glutamine(300mg/L), 90%,heat inactivated fetal bovine serum (FBS)10% ; RPMI + 10% FBS ; DMEM+20% FBS ; DMEM:F12 +10% FBS ; MEM +10%FBS ; RPMI 1640 medium with 10% fetal bovine serum ; McCoy's 5A +20% FBS ; RPMI-1640+10%FBS ; 2/3 DMEM:1/3 RPMI+10%FBS ; HamF12+10%FBS ; RPMI 1640(or DM-160AU) +10%FBS ; RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBs),10% ; EMEM+10% FBS ; DMEM +5%FBS ; MEM+10% FBS ; DMEM+15%FBS ; (DMEM:HamF12=1:1) +10%FBS ; (DMEM:HamF12=1:1) + 10%FBS ; MCDB 105 (1:1)Medium 199 +15%FBS ; DMEM+5% FBS ; EMEM +10 % FBS ; Williams E Medium + 10%FBS ; RPMI-1640 + 10%FBS ; RPM:MEM +20% FBS ; RPMI-1640+ 10%FBS ; RPMI-1640 +10% FBS ; RPMI 1640 medium with 10% fetal bovine serum. ; MEM + 10% FBS ; RPMI +10%FBS ; Dulbecco's modified Eagle's medium with 5% fetal bovine serum ; RPMI 1640 medium wiyh10% fetal bovine serum ; RPMI 1640 medium with 10% fetal calf serum. ; RPMI 1640 medium with 10% heat inactivated fetal bovine serum ; Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Refer cancer Res. 42:3858 (1982) for other medium with low serum concentration. ; Ham's F12 +10% FBS ; RPMI-10% FBS ; Eagle's minimal essential medium with 15%  fetal bovine serum ; RPMI 1640 + 10%FBS ; Eagle's minimal essential medium with 15% fetal calf serum ; Eagle's minimal essential with 20% heat inactivated fetal bovine serum ; Eagle's minimal essential medium with 10% calf serum (FCS can be used) ; RPMI 1640+20%FBS ; IMDM+10%FBS ; RPMI1640+15%FBS ; DMEM +10%FBS ; RPMI-1640+20%FBS ; RPMI +20% FBS ; IMDM +20% FBS ; IMDM+10%fbs ; RPMI+20%FBS ; DMEM:F12 ; EMEM +20%FBS ; RPMI-20% FBS ; McCoy's 5A + 10%FBS ; Leibovitz's L-15 Medium + 10%FBS ; McCoy's 5A +10% ; McCoy's 5A +15%FBS ; EMEM + 5% FBS ; DMEM:F12(1:1) +15%FBS ; EMEM + 20% FBS ; HAMSF10+ 10% FBS ; RPMI-1640  +10 % FBS ; Eagle ; RPI-1640+10% FBS ; DMEM:F12 (1:1)+5%FBS ; RPMI-1640 + 5% FBS ; DMEM:HAM's F12  1:1  +10% FBS ; IMDM+10% FBS ; RPMI-F12 (1:1) +10% FBS ; RPMI-1640+ 20% FBS ; EMEM +10% FBS ; McCoy's 5A + 10% FBS ; MEM + 10 % FBS ; 90-95% RPMI 1640 +5-10 h.i. FBS ; Dulbecco's modified Eagle's medium with 10% fetal calf serum ; RPMI 1640 with L-glutamine(300mg/L), 90%; heat inactivatedfetal bovine serum (FBS), 10% ; RPMI-1640 + 20% FBS ; ACL-4 ; 80% RPMI 1640 + 20% h.i. FBS ; 80% RPMI 1640 +20% h.i. FBS ; DMEM+ 10% FBS ; DMEM:HAM's F12  1:1 + 5 % FBS ; Waymouth MB 7521 medium+10%FBS ; RPMI 1640 medium with fetal calf serum ; McCoy 5A+15%FBS ; DEMEM+10%FBS ; RPMI 1640 + 10% FBS ; IMDM+20%FBS ; RPMI 1640 +10 FBS ; RPMI:F12 1:1+10% FBS ; RPMI1640+5%FBS ; L15 + 10% FBS ; EMEM+ 10% FBS ; RPMI1640 + 10%FBS ; EMEM+20%FBS ; HAMS F12 +20% FBS ; DMEM:F12+5% FBS ; MCDB 105 1:1 Media 199 +10%FBS ; RPMI-1640 10% FBS +1 mM Sodium pyruvate ; IMDM+20 % FBS ; RPMI-1640+ 10% FBS ; F-12 +10%FBS ; RPMI1640+20%FBS ; RPMI:EMEM (1:1) +20 % FBS ; RPMI-1640+15% FBS ; McCOY'S5A + 10%FBS ; IMDM + 20%FBS ; RPMI-1640 + 15% FBS ; MCDB 105:MEDIUM 199 (1:1) +15% FBS ; RPMI:Ham F12 +5%FBS ; 90% RPMI 1640 +10% h. i. FBS ; 90% Dulbecco's MEM(4.5 g/L glucose) +10% h.i.FBS ; 90% RPMI 1640 +10% h.i. FBS ; DMEM + 15% FBS ; RPMI-1640 +20% FBS ; 85% RPMI 1640 +15% h.i. FBS ; 90% NCTC-109 + 10% h.i. FBS ; DMEM:HAM's F12  1:1 + 5% FBS ; RPMI-1640 10% FBS ; DEMEM+10%fbs ; 80-90% RPHI 1640+10-20% h.i.FBS ; 90%RPMI 1640+ 10% h.i. FBS ; 40% Dulbecco's MEM +40% Iscove's MDM + 20% h.i. FBS ; 80-90% RPMI 1640+ 10-20% h. i. FBS ; DMEM:HAM's F12  1:1  +20% FBS ; DMEM+20%FBS ; 80-90% RPMI 1640 +10-20% h.i. FBS ; 80% mixture of Dulbecco's MEM + Ham's F 12 at 1:1 + 20% h.i. FBS ; L15+20%FBS ; McCOY'S 5A+20% FBS ; 80% alpha-MEM + 20% h. i. FBS ; 90% RPMI 1640 +10% h,i, FBS ; alphaMEM+20%FBS ; RPMI-1640 +20%FBS ; 80% RPMI 1640 +20% h.i.FBS ; 90% RPMI 1640 + 10% h.i.FBS ; 90% RPMI 1640 + 10% h.i. FBS ; 90 % Iscove's MDMD or RPMI 1640 + 10% h.i. FBS ; 90% RPMI 1640 +10% h.i.FBS ; 85% Dulbecco's MEM +15% h.i.FBS ; 90% RPMI + 10% h.i.FBS ; IMDM + 20% FBS ; Hams F10+10% FBS ; 80% RPMI 1640 +20% h.i. FBs ; 80-90% RPMI 1640 +10-20% h. i. FBS ; 80% RPMI 1640 + 20% h. i. FBS ; 90% RPMI1640 +10%h.i. FBS ; 70% alpha-MEM + 20% h. i. FBS ; 90% Dulbecco's MEM (4.5g/L glucose) + 10% h.i. FBS ; 90% Dulbecco'sMEM(4.5g/l glucose) +10% h.i.FBS ; 90% RPMI 1640 + 10% h. i. FBS ; Eagle's minimal essential medium with 10% fetal calf serum ; 90% RPMI 1640 +10%  h. i. FBS ; 80% RPMI 1640 +20% h. i. FBS ; 80-90% Iscove's MDM or RPMI 1640 +10-20% h. i. FBS ; 90% rPMI 1640 + 10% h. i. FBS ; 90%RPMI 1640+10% h.i FBS ; 80% Dulbecco's MEM +20% h.i. FBS +0.5% human serum (+0.005 lu/ml TSH +5ug/ml human insulin-cells grow also without these latter supplements) ; 80% Dulbecco's MEM(4.5g/L glucose) +20% h.i.FBS ; RPMI-1640+ 15% FBS ; 85% RPMI 1640 +15% h. i. FBS ; McCoy's 5A +10% FBS ; 80%RPMI-1640+20% FBS ; 80-90% Iscove's MDM +10-20% h.i. FBS ; 90% Iscove's MDM +10% h. i. FBS ; 80% Iscove's MDM + 20% h.i. FBS ; 80% mixture of Ham's F12 + Dulbecco's MEM (at 1:1) +20% h.i FBS ; 80-85% RPMI 1640 +15-20% h.i. FBS ; DMEM +15%FBS ; 80% RPMI 1640 + 10% h.i.FBS ; IMDM+ 20% FBS ; 90% Dulbecco's MEM +10% h.i. FBS ; MEM + 20% FBS
HIST_SUBTYPE1	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Hist Subtype 1	Sample	small_cell_carcinoma ; adenocarcinoma ; Burkitt_lymphoma ; mycosis_fungoides-Sezary_syndrome ; transitional_cell_carcinoma ; NS ; plasma_cell_myeloma ; acute_myeloid_leukaemia ; ductal_carcinoma ; hepatocellular_carcinoma ; squamous_cell_carcinoma ; astrocytoma_Grade_IV ; astrocytoma ; Hodgkin_lymphoma ; diffuse_large_B_cell_lymphoma ; clear_cell_renal_cell_carcinoma ; non_small_cell_carcinoma ; acute_lymphoblastic_T_cell_leukaemia ; acute_lymphoblastic_B_cell_leukaemia ; bronchioloalveolar_adenocarcinoma ; astrocytoma_Grade_III ; follicular_carcinoma ; renal_cell_carcinoma ; clear_cell_carcinoma ; hepatoblastoma ; small_cell_adenocarcinoma ; mucoepidermoid_carcinoma ; large_cell_carcinoma ; endometrioid_carcinoma ; carcinosarcoma-malignant_mesodermal_mixed_tumour ; mixed_carcinoma ; metaplasia ; diffuse_adenocarcinoma ; mixed_adenosquamous_carcinoma ; undifferentiated_carcinoma ; gliosarcoma ; tubular_adenocarcinoma ; chronic_myeloid_leukaemia ; anaplastic_large_cell_lymphoma ; undifferentiated_adenocarcinoma ; signet_ring_adenocarcinoma ; B_cell_lymphoma_unspecified ; adult_T_cell_lymphoma-leukaemia ; metaplastic_carcinoma ; granulosa_cell_tumour ; alveolar ; essential_thrombocythaemia ; oligodendroglioma ; Brenner_tumour ; papilloma ; blast_phase_chronic_myeloid_leukaemia ; B_cell ; serous_carcinoma ; mucinous_carcinoma ; anaplastic_carcinoma ; intestinal_adenocarcinoma ; immortalized_epithelial ; immortalized_fibroblast ; immortalized_embryonic_fibroblast ; astrocytoma_Grade_III-IV ; barrett_associated_adenocarcinoma ; mantle_cell_lymphoma ; embryonal ; medullary_carcinoma ; peripheral_T_cell_lymphoma_unspecified ; T_cell_large_granular_lymphocytic_leukaemia ; chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma ; dedifferentiated ; papillary_carcinoma
HIST_SUBTYPE2	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Hist Subtype 2	Sample	NS ; M5 ; glioblastoma_multiforme ; anaplastic ; M6 ; M2 ; M7 ; M4 ; medullary ; papillary_transitional_cell_carcinoma ; papillary ; Ph_positive ; M5a ; squamous_cell_carcinoma ; L2 ; M3 ; M0
HIST_SUBTYPE3	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Hist Subtype 3	Sample	NS
LIFE_STAGE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Life Stage	Patient	
LINEAGE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Lineage	Sample	lung ; colorectal ; lymphocyte ; urinary_tract ; bone ; plasma_cell ; blood ; skin ; breast ; liver ; ovary ; esophagus ; uterus ; fibroblast ; central_nervous_system ; soft_tissue ; pancreas ; peripheral_nervous_system ; gastric ; kidney ; upper_aerodigestive ; thyroid ; bile_duct ; prostate ; unknown ; engineered_breast ; engineered_ovary ; engineered_lung ; engineered_prostate ; engineered_kidney ; engineered_central_nervous_system ; cervix ; engineered ; adrenal_cortex ; epidermoid_carcinoma ; embryo ; eye
LINEAGE_MOLECULAR_SUBTYPE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Lineage Molecular Subtype	Sample	basal_A ; MYCN_amp ; MSI ; luminal_HER2_amp ; HER2_amp ; luminal ; basal_B ; EWS_FLI ; MYC_exp ; non_MYC ; MYC_amp ; EWS_ERG ; PAX3_FKHR ; basal ; EWS_FEV
LINEAGE_SUBTYPE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Lineage Subtype	Sample	SCLC ; colorectal_adenocarcinoma ; non_hodgkin_lymphoma ; bladder_carcinoma ; osteosarcoma ; multiple_myeloma ; AML ; melanoma ; breast_ductal_carcinoma ; Ewing_sarcoma ; hepatocellular_carcinoma ; mesothelioma ; ovary_adenocarcinoma ; esophagus_squamous ; endometrial_adenocarcinoma ; fibroblast_skin ; glioma ; leiomyosarcoma ; exocrine ; neuroblastoma ; NSCLC ; chondrosarcoma ; hodgkin_lymphoma ; gastric_adenocarcinoma ; fibrosarcoma ; renal_cell_carcinoma ; fibroblast_breast ; ALL ; lymphoma_unspecified ; breast_carcinoma ; caecum_adenocarcinoma ; fibroblast_bone ; fibroblast_lung ; upper_aerodigestive_squamous ; duodenal_adenocarcinoma ; thyroid_carcinoma ; hepatoblastoma ; gastric_small_cell ; mullerian_carcinoma ; esophagus_adenocarcinoma ; endometrial_adenosquamous ; malignant_rhabdoid_tumor ; CML ; cholangiocarcinoma ; breast_adenocarcinoma ; rhabdomyosarcoma ; uterine_sarcoma ; pleomorphic_sarcoma ; medulloblastoma ; clear_cell_carcinoma ; fibroblast_lymphocyte ; fibroblast_colorectal ; ovary_carcinoma ; MMMT ; gallbladder_adenocarcinoma ; brenner_tumor ; prostate_small_cell ; fibroblast_upper_aerodigestive ; fibroblast_soft_tissue ; prostate_adenocarcinoma ; endometrial_stromal_sarcoma ; endocrine ; thyroid_squamous ; meningioma ; fibroblast_urinary_tract ; CLL ; lung_carcinoid ; thyroid_sarcoma ; ATRT ; ATL ; cervical_carcinoma ; merkel_cell_carcinoma ; upper_aerodigestive_carcinoma ; hairy_cell_leukemia ; NKC ; choriocarcinoma ; adrenal_carcinoma ; lung_carcinoma ; PNET ; skin_squamous ; malignant_fibrous_histiocytoma ; liposarcoma ; synovial_sarcoma ; epithelioid_sarcoma ; cervical_squamous ; cervical_adenocarcinoma ; cervical_small_cell ; granulosa_cell_tumor ; mixed_germ_cell ; prostate_hyperplasia ; embryo_carcinoma ; endometrial_squamous ; acute_biphenotypic_leukemia ; chordoma ; uveal_melanoma ; SCCOHT ; retinoblastoma ; undifferentiated_sarcoma
LINEAGE_SUB_SUBTYPE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Lineage Sub-subtype	Sample	b_cell_burkitt ; t_cell_cutaneous ; bladder_transitional_cell ; M5 ; ERneg_HER2neg ; serous ; high_grade_serous ; mucinous ; glioblastoma ; exocrine_adenocarcinoma ; astrocytoma ; NSCLC_adenocarcinoma ; DLBCL ; clear_cell ; NSCLC_large_cell ; t_cell ; ERpos_HER2neg ; b_cell ; NSCLC_squamous ; oral ; follicular ; M6 ; laryngeal ; tongue ; endometrioid ; diffuse_gastric ; ERneg_HER2pos ; M2 ; exocrine_adenosquamous ; oligodendroglioma ; intrahepatic ; t_cell_ALCL ; tubular ; plasmacytoma ; ERpos_HER2pos ; med_group_3 ; hypopharyngeal ; anaplastic ; amelanotic ; basaloid ; mixed_serous_clear_cell ; NSCLC_adenosquamous ; salivary_gland ; NSCLC_mucoepidermoid ; alveolar ; signet_ring_cell ; extrahepatic ; M7 ; mixed_endometrioid_clear_cell ; M3 ; low_grade_serous ; hbs_antigen_carrier ; somatostatinoma ; pharynx ; bladder_squamous ; renal_leiomyoblastoma ; blast_crisis ; b_cell_mantle_cell ; embryonal ; M4 ; transitional_cell ; papillary ; gingival ; lymphoblastic_lymphoma ; b_cell_primary_effusion ; b_cell_mediastinal_large ; b_cell_follicular ; chordoma_sacral ; giant_cell ; WDLPS ; keratoacanthoma ; buccal_mucosa
MUTATION_RATE	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	NUMBER	Mutation Rate	Sample	157.2416381 ; 94.37319183 ; 109.534987 ; 166.4564059 ; 118.2175686 ; 124.7079624 ; 127.9796713 ; 187.9138764 ; 133.3686368 ; 134.1563317 ; 173.1865428 ; 116.191956 ; 136.788956 ; 153.5990748 ; 144.0712209 ; 85.71718592 ; 160.5655743 ; 324.7573697 ; 178.9165928 ; 96.20381721 ; 56.09099205 ; 139.4221578 ; 220.9309703 ; 165.9472722 ; 82.48705026 ; 115.6076715 ; 136.2988662 ; 215.9785902 ; 137.2592429 ; 788.4232098 ; 250.704126 ; 103.2181425 ; 81.50141124 ; 73.30584648 ; 88.11498549 ; 113.3381055 ; 79.58792792 ; 212.0987614 ; 99.50888996 ; 111.5684726 ; 259.731865 ; 116.8955149 ; 118.5641877 ; 161.4303635 ; 84.02451807 ; 89.90036362 ; 240.1277804 ; 130.8366927 ; 139.7910668 ; 147.0067171 ; 667.1912736 ; 741.7712612 ; 124.150508 ; 170.4549408 ; 112.654321 ; 509.7698434 ; 257.2902848 ; 135.5808971 ; 278.0195779 ; 96.75975762 ; 107.2866384 ; 337.2852014 ; 94.03118402 ; 272.2196239 ; 448.08848 ; 157.8873017 ; 76.86299598 ; 93.36313254 ; 110.7362811 ; 273.8360546 ; 114.6441614 ; 153.1393568 ; 508.1042285 ; 161.3592702 ; 172.2454153 ; 101.6822973 ; 207.8568338 ; 108.9966548 ; 90.68523156 ; 83.60584105 ; 90.99857815 ; 159.0117836 ; 89.96583328 ; 100.7269609 ; 157.1906164 ; 124.7421995 ; 126.1761027 ; 124.5888771 ; 108.9208548 ; 158.748475 ; 109.5410231 ; 117.7551518 ; 119.3989118 ; 110.6272486 ; 98.18537713 ; 98.3442931 ; 130.9359681 ; 102.7469499 ; 82.22981768 ; 126.7459796 ; 151.5654424 ; 155.1495548 ; 112.0205451 ; 84.59612727 ; 193.9530872 ; 86.52454761 ; 127.4914675 ; 150.2724369 ; 185.27297 ; 96.71783566 ; 174.0189681 ; 65.59323234 ; 148.4423551 ; 178.5846787 ; 173.450738 ; 162.6978801 ; 121.7551211 ; 212.3890798 ; 398.1513421 ; 158.8387503 ; 125.6648224 ; 195.9930868 ; 142.3789895 ; 120.3791123 ; 2211.992655 ; 174.4659694 ; 150.4874262 ; 109.1253001 ; 451.4936983 ; 175.5844253 ; 189.5257761 ; 168.6101635 ; 863.7979174 ; 506.6036089 ; 545.552709 ; 115.6656794 ; 147.6715363 ; 112.5727703 ; 1262.320071 ; 186.2431572 ; 120.1788709 ; 354.1772098 ; 123.7704907 ; 139.1518781 ; 111.3158979 ; 171.7364057 ; 131.1462669 ; 802.4440016 ; 191.9872147 ; 139.2167544 ; 125.157705 ; 583.5595209 ; 134.9948889 ; 113.5833254 ; 179.8861578 ; 142.7412221 ; 166.1463911 ; 93.71418335 ; 266.6254865 ; 178.2922066 ; 151.2441609 ; 141.7095708 ; 2069.977291 ; 90.61710247 ; 99.51877855 ; 135.0621286 ; 148.7392775 ; 99.55688748 ; 689.3931011 ; 184.9301198 ; 160.4233812 ; 108.3070776 ; 124.6755319 ; 148.3603289 ; 102.7445013 ; 187.8191737 ; 194.2359967 ; 99.23578991 ; 157.897507 ; 580.6253132 ; 119.6549586 ; 264.6207321 ; 86.55945863 ; 87.77718147 ; 72.9598821 ; 144.2755307 ; 110.2041138 ; 86.69118242 ; 1280.547998 ; 267.7106602 ; 91.51669099 ; 189.8293645 ; 151.0705525 ; 201.1053808 ; 92.67187107 ; 140.2362937 ; 172.2500773 ; 105.6808319 ; 160.8997968 ; 90.38433048 ; 119.6353574 ; 203.6248043 ; 158.794456 ; 116.5594164 ; 115.679843 ; 88.66578456 ; 207.7215689 ; 77.29245748 ; 168.9209571 ; 160.2806444 ; 149.7017082 ; 169.0552943 ; 151.6802434 ; 142.794309 ; 163.5303777 ; 146.3354631 ; 165.0898898 ; 136.827034 ; 148.071063 ; 190.5846245 ; 110.455866 ; 110.6743889 ; 142.2057449 ; 155.9651961 ; 108.9491102 ; 156.8998825 ; 254.4430402 ; 148.6365519 ; 1458.405477 ; 208.2736925 ; 116.4358582 ; 129.4083436 ; 1579.742482 ; 97.3391703 ; 550.0652135 ; 208.5600477 ; 149.7150398 ; 211.4255162 ; 198.1647591 ; 168.5219909 ; 971.9750615 ; 137.2704639 ; 231.9100059 ; 231.7658238 ; 148.2821902 ; 191.3080362 ; 143.110198 ; 148.4340211 ; 117.1043494 ; 107.4506264 ; 247.1007226 ; 108.9028042 ; 146.9369947 ; 125.3581906 ; 175.0163689 ; 204.8327614 ; 119.2694501 ; 279.6134094 ; 137.3378769 ; 232.8053039 ; 233.5534525 ; 198.9679444 ; 85.29688898 ; 132.9188091 ; 238.7618945 ; 135.0411689 ; 108.0383796 ; 353.1008508 ; 61.21045057 ; 223.3824299 ; 94.61007254 ; 94.4755242 ; 272.0403023 ; 218.724336 ; 79.90153548 ; 83.80695109 ; 60.12771707 ; 282.9219689 ; 126.2080661 ; 223.1421586 ; 93.3026384 ; 114.1400879 ; 140.778944 ; 53.24884517 ; 79.63113609 ; 193.3167422 ; 413.9923146 ; 151.8206873 ; 53.8707524 ; 120.7925694 ; 75.29215428 ; 186.1487595 ; 121.3182747 ; 261.0557486 ; 125.0865901 ; 179.4906831 ; 170.5817104 ; 154.3977156 ; 108.504952 ; 111.3392806 ; 103.6905353 ; 108.47913 ; 83.72081463 ; 113.6520826 ; 94.67528958 ; 90.26965062 ; 82.85897134 ; 486.8665091 ; 133.8681685 ; 109.3601177 ; 85.48175072 ; 80.66946436 ; 131.1519698 ; 99.42966602 ; 147.1543657 ; 161.0305019 ; 168.9199906 ; 168.9136858 ; 245.3804386 ; 434.989757 ; 159.4333834 ; 196.5950713 ; 89.75888173 ; 112.135783 ; 93.765726 ; 91.70436082 ; 127.2397008 ; 141.3075379 ; 97.45092224 ; 210.5005154 ; 82.86196811 ; 144.2324724 ; 172.3342748 ; 442.9371418 ; 83.34526686 ; 101.6673444 ; 115.8861966 ; 72.55788779 ; 144.8513809 ; 127.6408716 ; 137.1709772 ; 147.8163642 ; 142.4243554 ; 1999.28989 ; 115.3890534 ; 137.8568194 ; 270.8323858 ; 145.6658473 ; 98.68563984 ; 151.3516713 ; 148.1733319 ; 107.6232242 ; 163.6031843 ; 273.6119221 ; 90.85145988 ; 107.9320481 ; 587.5783867 ; 88.95089442 ; 173.5115056 ; 112.3495388 ; 405.948948 ; 225.7579361 ; 210.1982336 ; 154.5972613 ; 326.7336556 ; 161.6675583 ; 371.3529985 ; 100.2513257 ; 316.7710366 ; 346.1350217 ; 205.7239289 ; 114.8901438 ; 237.862854 ; 134.4578729 ; 1032.474137 ; 258.8512253 ; 111.3986434 ; 123.7011381 ; 122.759174 ; 98.94407367 ; 145.2749828 ; 250.6880546 ; 168.8752061 ; 199.5771765 ; 136.0086473 ; 116.9513426 ; 94.6799169 ; 953.9152084 ; 142.3040162 ; 132.5932561 ; 147.0863414 ; 163.3873835 ; 131.7594832 ; 164.2044753 ; 154.7010879 ; 390.8079423 ; 189.4438445 ; 368.6769634 ; 83.53376636 ; 189.3621976 ; 118.4482717 ; 107.1948767 ; 144.8941285 ; 154.9416008 ; 395.8472824 ; 659.2084687 ; 130.0234562 ; 436.1001821 ; 122.6052624 ; 173.2330942 ; 101.3983234 ; 68.12312717 ; 115.5254055 ; 122.3953732 ; 150.1577888 ; 220.2101945 ; 73.93675728 ; 337.6637815 ; 186.0987209 ; 670.6935477 ; 117.719142 ; 110.6123314 ; 73.11071221 ; 159.9833699 ; 195.104647 ; 139.2351999 ; 198.6286534 ; 127.7052288 ; 133.8217124 ; 82.96418803 ; 165.5943803 ; 130.3578322 ; 235.4484219 ; 133.0971004 ; 148.5261257 ; 103.844001 ; 87.00395836 ; 343.1649394 ; 177.451507 ; 1759.696678 ; 164.676892 ; 3119.618365 ; 165.3148578 ; 1460.745797 ; 525.9938628 ; 155.5880127 ; 130.7608683 ; 129.3811699 ; 120.7640014 ; 110.0440816 ; 254.5878645 ; 158.1433375 ; 136.3793212 ; 181.1896531 ; 140.8929088 ; 115.4161995 ; 176.5833238 ; 127.2186628 ; 128.9700561 ; 171.5300854 ; 166.6743593 ; 164.5923193 ; 122.3425095 ; 268.24918 ; 138.2523835 ; 113.3518553 ; 184.9312508 ; 124.2318571 ; 143.4597182 ; 74.74545221 ; 92.55663852 ; 135.4595398 ; 189.0330306 ; 196.9383482 ; 179.7006765 ; 215.6502451 ; 100.7506738 ; 151.013337 ; 112.486802 ; 169.5441881 ; 1614.899687 ; 235.9576427 ; 218.0148775 ; 282.9433237 ; 131.5423981 ; 112.4321587 ; 74.63707721 ; 142.0877631 ; 183.4098616 ; 129.2287935 ; 246.7023651 ; 86.33349346 ; 86.31007528 ; 99.00667914 ; 91.81570439 ; 129.0002319 ; 164.6000219 ; 99.35271705 ; 133.3183855 ; 88.09491949 ; 184.4223473 ; 109.4602923 ; 85.72875647 ; 101.4376589 ; 381.1379084 ; 65.39011856 ; 128.4480014 ; 108.8196649 ; 131.4398136 ; 72.36669085 ; 456.8609593 ; 95.836918 ; 139.4057997 ; 177.9776725 ; 74.60365229 ; 92.85643096 ; 109.1740429 ; 98.02781332 ; 149.1504963 ; 99.73208336 ; 261.733481 ; 59.08921113 ; 92.53520266 ; 93.92467241 ; 237.0403961 ; 154.9801859 ; 62.62303384 ; 152.9435432 ; 108.2605181 ; 77.45248546 ; 96.91151978 ; 116.6768714 ; 155.2288707 ; 71.10858281 ; 132.1193181 ; 83.04201116 ; 81.50921629 ; 90.39089653 ; 96.53034257 ; 78.14512866 ; 101.8703799 ; 161.3323387 ; 103.8152089 ; 93.14475754 ; 85.7317995 ; 495.0790703 ; 87.6060673 ; 121.5827559 ; 95.02326297 ; 125.2330331 ; 81.05910683 ; 129.2237006 ; 159.6353575 ; 98.17774552 ; 485.4417354 ; 222.6179875 ; 201.5597753 ; 105.5585115 ; 140.1947167 ; 170.0951327 ; 91.43886081 ; 532.8167513 ; 104.8362941 ; 136.815293 ; 204.7916266 ; 104.2734932 ; 170.9658415 ; 140.9123842 ; 169.6811465 ; 187.2021362 ; 98.23803075 ; 139.6416545 ; 232.1814139 ; 180.3660079 ; 113.6271407 ; 84.97649095 ; 317.892098 ; 75.23691952 ; 81.56505021 ; 74.11662251 ; 426.5639766 ; 206.5489916 ; 168.9440631 ; 633.1090359 ; 104.7870455 ; 144.3860352 ; 547.7072342 ; 180.5878482 ; 95.97901737 ; 164.4186284 ; 123.3168857 ; 77.83727094 ; 167.0747294 ; 91.72271944 ; 191.7691364 ; 241.6461598 ; 108.4491201 ; 88.07978724 ; 129.7340268 ; 131.3333424 ; 150.1872136 ; 113.2454435 ; 366.8132605 ; 168.063347 ; 111.6048074 ; 127.1502309 ; 130.3439871 ; 81.13367296 ; 204.713137 ; 111.0355795 ; 116.8282791 ; 232.6444366 ; 165.1945605 ; 726.558281 ; 84.80017445 ; 762.9231088 ; 176.9697115 ; 138.1852917 ; 159.4917529 ; 135.6190716 ; 121.5085676 ; 191.6418942 ; 139.9638893 ; 141.6481844 ; 295.7364988 ; 102.7035533 ; 169.3989178 ; 166.3965156 ; 116.3127807 ; 103.1827089 ; 108.5911079 ; 131.5867088 ; 113.2413473 ; 81.82765444 ; 192.3275958 ; 163.0529962 ; 107.0508799 ; 142.2243369 ; 201.4414623 ; 74.35849532 ; 95.03061174 ; 1022.278488 ; 130.923183 ; 127.682666 ; 105.1129182 ; 209.1259946 ; 826.0027861 ; 1024.430529 ; 101.6889757 ; 162.4755531 ; 369.3726971 ; 78.37300866 ; 161.0920797 ; 181.7136747 ; 941.9709071 ; 181.4703636 ; 353.0598376 ; 211.7713008 ; 132.1647346 ; 94.73768069 ; 686.7647964 ; 131.4062314 ; 146.9349526 ; 88.33759451 ; 166.6783902 ; 279.1727872 ; 136.6267225 ; 92.96836238 ; 359.6409124 ; 68.18873896 ; 453.4224896 ; 105.484781 ; 173.1708489 ; 180.5771581 ; 539.8308684 ; 125.507998 ; 87.6416756 ; 169.3069282 ; 317.8007086 ; 93.0620724 ; 89.94197218 ; 80.78238474 ; 97.12610232 ; 126.0743491 ; 563.7096269 ; 89.60933679 ; 529.8257616 ; 177.3707209 ; 123.0807102 ; 89.00340325 ; 213.4511981 ; 83.25472569 ; 93.40282504 ; 145.6289472 ; 110.7616206 ; 229.0732806 ; 154.1632015 ; 259.7926564 ; 90.3074789 ; 188.2526523 ; 178.8354237 ; 71.79702895 ; 100.4679692 ; 102.005835 ; 176.8432245 ; 104.5920312 ; 150.0581377 ; 110.863065 ; 177.0097006 ; 73.81343009 ; 138.4460038 ; 111.4636539 ; 181.2273729 ; 217.4137109 ; 80.19387358 ; 131.2836569 ; 116.3492966 ; 334.9102022 ; 88.68010645 ; 97.33436222 ; 153.3131471 ; 207.7442122 ; 200.1671139 ; 387.6541767 ; 70.07829872 ; 123.3526453 ; 204.6747718 ; 558.2436121 ; 101.5163334 ; 120.70541 ; 159.042239 ; 120.027116 ; 166.3312692 ; 485.2864575 ; 84.93713188 ; 116.3503166 ; 200.0668926 ; 147.478632 ; 144.7327222 ; 188.0952893 ; 248.1113517 ; 137.8566605 ; 136.1844623 ; 91.40122228 ; 128.2141157 ; 160.7552819 ; 136.5311627 ; 115.9910046 ; 117.8995842 ; 115.146489 ; 103.3429006 ; 90.36904673 ; 136.4879764 ; 167.7649252 ; 268.4871106 ; 64.44913312 ; 116.6695226 ; 108.0220019 ; 126.6253024 ; 69.89031879 ; 128.6331408 ; 94.25285833 ; 115.8864018 ; 73.42339937 ; 125.3439438 ; 87.23638256 ; 166.4767598 ; 88.30682348 ; 152.9863676 ; 133.5386942 ; 102.7949058 ; 121.2384185 ; 119.1843755 ; 92.03767299 ; 80.64616702 ; 78.03854857 ; 147.7800001 ; 99.74078602 ; 94.72120064 ; 134.9305217 ; 73.86512393 ; 77.06523381 ; 163.7412888 ; 113.5397743 ; 169.7847622 ; 103.6805732 ; 98.65716635 ; 125.6526304 ; 177.9362885 ; 154.6284895 ; 82.92654033 ; 90.01144255 ; 85.58672632 ; 141.2661995 ; 80.89833473 ; 86.93934853 ; 53.55550329 ; 200.9082363 ; 117.5512763 ; 122.8998449 ; 243.9954747 ; 723.5425088 ; 166.1564374 ; 117.6972064 ; 159.114053 ; 152.3137588 ; 124.3967492 ; 104.9664515 ; 187.9377337 ; 150.7056669 ; 280.808519 ; 117.228861 ; 498.9830467 ; 76.68730425 ; 180.3106621 ; 56.69106407 ; 89.26905347 ; 78.58675429 ; 96.19953871 ; 92.25565066 ; 96.79794358 ; 85.54240658 ; 82.42671335 ; 175.6826251 ; 97.98150618 ; 131.6466792 ; 166.7572084 ; 114.8285989 ; 107.6976326 ; 80.1104476 ; 150.9132136 ; 104.598553 ; 107.9394111 ; 383.5382966 ; 59.02873727 ; 106.5512635 ; 119.0742413 ; 86.31442483 ; 93.78945683 ; 470.0581531 ; 98.84264251 ; 90.81465525 ; 187.3366314 ; 93.81800176 ; 141.5984896 ; 514.4327731 ; 130.1010779 ; 102.9637208 ; 76.82971012 ; 99.11920898 ; 86.42270075 ; 90.43769726 ; 122.7622018 ; 124.7637218 ; 108.0711108 ; 189.6209433 ; 104.7531753 ; 148.6957261 ; 82.3890816 ; 130.1232045 ; 76.722086 ; 66.73799006 ; 233.7822526 ; 163.6472921 ; 107.5576589 ; 227.3039762 ; 295.7446546 ; 425.9997682 ; 127.6629264 ; 95.68871956 ; 178.1897318 ; 80.65809322 ; 104.7757336 ; 89.30922036 ; 102.3734306 ; 91.91227013 ; 171.4584855 ; 152.0671211 ; 209.2744565 ; 107.2860755 ; 175.8765413 ; 93.18150052 ; 131.4714216 ; 129.9112801 ; 111.6303064 ; 99.09336648 ; 105.7726022 ; 138.0393183 ; 86.85764298 ; 146.5725381 ; 125.341816 ; 145.9780565 ; 177.9929204 ; 167.9478402 ; 101.0836765 ; 108.0362974 ; 120.1151389 ; 165.1770758 ; 84.80855584 ; 84.68601916 ; 109.9014919 ; 130.5479853 ; 141.2085595 ; 164.7429793 ; 857.8398766 ; 129.370936 ; 70.22262185 ; 117.0396003 ; 149.10268 ; 89.02444689 ; 133.4069632 ; 1452.954999 ; 75.69945569 ; 58.29266472 ; 112.4325512 ; 157.597842 ; 346.9044201 ; 110.9067632 ; 147.9145815 ; 521.3552528 ; 103.9713223 ; 84.15284963 ; 206.8416265 ; 92.88219793 ; 217.276314 ; 84.11208291 ; 87.64649975 ; 117.9901815 ; 128.1284701 ; 86.34912544 ; 84.25322655 ; 171.0793336 ; 123.8583783 ; 93.0784535 ; 126.2473501 ; 112.5260944 ; 683.9508067 ; 94.32458717 ; 147.7576774 ; 289.0129884 ; 348.9953553 ; 99.29632008 ; 262.2241885 ; 138.7127299 ; 136.4703782 ; 167.7509478 ; 162.7989126 ; 100.8372372 ; 158.027178 ; 67.7006558 ; 237.2233013 ; 211.6889833 ; 1638.262089 ; 108.4608605 ; 121.5058245 ; 529.6768544 ; 236.5238841 ; 169.3654686 ; 98.6867442 ; 157.8096027 ; 107.540583 ; 106.3647836 ; 198.739234 ; 83.53472646
NAME	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Name	Sample	DMS 53 ; SW1116 ; NCI-H1694 ; P3HR-1 ; HuT 78 ; UM-UC-3 ; HOS ; HuNS1 ; AML-193 ; RVH-421 ; NCI-H1184 ; HCC2157 ; TC-71 ; NCI-H2227 ; COLO 205 ; SNU-449 ; NCI-H28 ; OV56 ; JHOS-4 ; KYSE-450 ; RMUG-S ; KLE ; Hs 895.T ; LN-229 ; P31/FUJ ; RKN ; PA-TU-8988S ; NH-6 ; SF126 ; RERF-LC-Ad2 ; OUMS-23 ; SNG-M ; OUMS-27 ; PL45 ; NCI-H2347 ; SW 1990 ; Hs 940.T ; Hs 611.T ; Toledo ; RERF-GC-1B ; HT-1080 ; NCI-H2087 ; COV318 ; NCI-H2085 ; NCI-H510 ; Caki-1 ; NCI-H716 ; NCI-H2066 ; NCI-H1341 ; NCI-H2029 ; C3A ; SW480 ; Hs 746T ; LU65 ; Hs 739.T ; SNU-C2A ; HEC-151 ; MSTO-211H ; Raji ; SK-MEL-1 ; SUP-T1 ; JHH-7 ; HuT 102 ; 5637 ; HCC38 ; DU4475 ; NCI-H1573 ; NCI-H508 ; NCI-H1651 ; SK-UT-1 ; MDA-MB-175-VII ; SUP-B15 ; Becker ; NCI-H226 ; NCI-H1666 ; SW 1783 ; IST-MES1 ; NCI-H1734 ; NCI-H2342 ; EBC-1 ; YMB-1 ; OC 316 ; Hs 936.T ; T1-73 ; NCI-H322 ; Hs 618.T ; Hs 870.T ; Hs 706.T ; PANC-1 ; NCI-H2291 ; T-47D ; Hs 742.T ; BICR 56 ; BICR 16 ; TE-10 ; SK-MEL-28 ; BICR 6 ; BHY ; AZ-521 ; SH-4 ; KPL-1 ; CGTH-W-1 ; TUHR4TKB ; LS123 ; HEL ; HPAC ; RCC10RGB ; JHOM-1 ; SU.86.86 ; HCC-33 ; TE-6 ; JHOC-5 ; ACC-MESO-1 ; BL-41 ; SNU-1214 ; COR-L105 ; LMSU ; SNU-1197 ; COLO 668 ; OS-RC-2 ; HuH-6 ; Panc 02.03 ; CJM ; BICR 22 ; SH-SY5Y ; TM-31 ; SNU-1272 ; KP-N-RT-BM-1 ; BICR 18 ; TE-4 ; PCM6 ; ECC10 ; TUHR14TKB ; YD-15 ; U-BLC1 ; EC-GI-10 ; CW-2 ; SNU-761 ; SNU-61 ; NCI-H1915 ; SNU-324 ; YD-10B ; HCC-2279 ; HLC-1 ; TUHR10TKB ; HEC-1-B ; VMRC-LCP ; TGBC11TKB ; OVK18 ; SNU-1077 ; HCC-1588 ; SNU-213 ; HT115 ; TE-14 ; TE-8 ; SNU-520 ; JHUEM-3 ; Li-7 ; NCI-H838 ; SNU-119 ; SNU-1033 ; SNU-C5 ; GSS ; TALL-1 ; HCC-1171 ; SNU-C4 ; U-138 MG ; SNU-620 ; ECC12 ; GSU ; KMS-18 ; JHOM-2B ; MDA-MB-231 ; OV-90 ; RS4;11 ; OVTOKO ; OVCAR-4 ; HLF ; HCT-15 ; SW1463 ; SF-295 ; WM-115 ; JHH-4 ; OE33 ; CCK-81 ; JHH-1 ; SJSA-1 ; NCI-H2228 ; RERF-LC-AI ; SK-MES-1 ; NCI-H520 ; JHH-5 ; FU97 ; COLO-800 ; NCI-H1963 ; RL95-2 ; J82 ; HCC-15 ; M059K ; Calu-6 ; SK-LU-1 ; SW 900 ; UACC-62 ; MFE-280 ; MFE-319 ; MFE-296 ; GOS-3 ; GI-1 ; PC-14 ; KYSE-410 ; A-204 ; PA-TU-8902 ; NCI-H810 ; RERF-LC-MS ; L-1236 ; DAN-G ; NCI-H460 ; KYSE-140 ; KYSE-180 ; HUP-T3 ; EFE-184 ; GCIY ; SH-10-TC ; Caov-4 ; HCC2218 ; KMS-21BM ; KMS-26 ; KMS-27 ; KO52 ; KMS-28BM ; KNS-60 ; KNS-81 ; KP-N-SI9s ; LU99 ; KMS-34 ; MKN1 ; MKN74 ; KP-3 ; NCO2 ; KHM-1B ; HSC-2 ; KG-1-C ; HuH-7 ; KMBC-2 ; KMRC-20 ; HuCCT1 ; Ki-JK ; A4/Fuk ; KALS-1 ; HEC-108 ; HEL 92.1.7 ; HuH28 ; CMK-11-5 ; HEC-265 ; CAL-12T ; THP-1 ; A3/KAW ; SK-N-SH ; HCC1954 ; CAMA-1 ; HEC-6 ; AM-38 ; HEC-50B ; HSC-3 ; HSC-4 ; KMS-11 ; KP4 ; KE-39 ; COV504 ; KE-97 ; VMRC-RCW ; HGC-27 ; LUDLU-1 ; HuG1-N ; U266B1 ; NUGC-4 ; BGC-823 ; HMC-1-8 ; CAS-1 ; KMM-1 ; COR-L23 ; MOR/CPR ; HARA ; SK-OV-3 ; HPAF-II ; MC116 ; NCI-H1568 ; CA46 ; A-498 ; BCP-1 ; A-673 ; AU565 ; COLO 201 ; Capan-1 ; NCI-H1563 ; NCI-H358 ; CFPAC-1 ; NIH:OVCAR-3 ; NCI-H1650 ; NCI-H1793 ; NCI-H1437 ; KNS-62 ; Hs 578T ; BT-20 ; SNU-182 ; SK-N-MC ; HH ; FaDu ; SJRH30 ; MDA-MB-361 ; MDA-MB-436 ; Panc 02.13 ; DB ; RD-ES ; CAL 27 ; MES-SA ; SW 1271 ; NCI-H1792 ; GCT ; SK-BR-3 ; SNU-16 ; NCI-H82 ; NCI-N87 ; U-2 OS ; H4 ; GDM-1 ; HCC1143 ; T24 ; G-401 ; HCC1937 ; HCC1569 ; OCUM-1 ; Saos-2 ; D283 Med ; SCC-9 ; HCC1395 ; NMC-G1 ; TEN ; Hs 604.T ; TE-9 ; KNS-42 ; KYSE-520 ; KYSE-270 ; JHUEM-1 ; YH-13 ; IA-LM ; NCI-H2052 ; EB2 ; SK-N-FI ; SK-N-AS ; GA-10 ; SNU-398 ; SNU-423 ; SCC-4 ; EB1 ; HCC1187 ; SNU-387 ; Daudi ; HT ; MJ ; JM1 ; C2BBe1 ; SK-ES-1 ; EPLC-272H ; BxPC-3 ; NCI-H1355 ; SNU-5 ; SNU-475 ; HEC-251 ; HCC-95 ; 253J ; HCC-1438 ; 253J-BV ; RPMI-7951 ; SNU-1066 ; SNU-1041 ; HCC-2108 ; COLO-783 ; HCC-1359 ; BICR 31 ; COV362 ; COLO 792 ; COV434 ; WM-983B ; Hs 751.T ; LS513 ; NCI-H2110 ; ChaGo-K-1 ; DMS 454 ; COR-L47 ; FTC-238 ; DMS 273 ; FTC-133 ; COR-L311 ; NCI-H2286 ; NCI-H1339 ; WM-793 ; A-704 ; MDA-MB-435S ; WM1799 ; MeWo ; WM-88 ; NCI-H2081 ; Hs 255.T ; NCI-H1092 ; SW837 ; JHH-6 ; IGR-1 ; NCI-H1105 ; NCI-H1436 ; NCI-H1876 ; COR-L24 ; COV644 ; GP2d ; PE/CA-PJ15 ; COR-L88 ; COR-L95 ; PE/CA-PJ49 ; PE/CA-PJ34 (clone C12) ; COR-L51 ; RT112/84 ; PE/CA-PJ41 (clone D2) ; OV7 ; HT55 ; OAW42 ; MDST8 ; OAW28 ; SUIT-2 ; LC-1/sq-SF ; KASUMI-1 ; SUP-M2 ; SK-HEP-1 ; OVCAR-8 ; NCI-H2172 ; Ishikawa (Heraklio) 02 ER- ; NCI-H596 ; NCI-H650 ; SW 1573 ; OVMANA ; SK-CO-1 ; KARPAS-299 ; YAPC ; HT-1197 ; A-253 ; HCC-366 ; DK-MG ; SNU-349 ; UM-UC-1 ; NAMALWA ; NCI-H292 ; 59M ; U-118 MG ; VMRC-LCD ; HCC-1833 ; RH-30 ; TCCSUP ; SNU-601 ; CAL-33 ; SNU-668 ; COR-L279 ; GB-1 ; KURAMOCHI ; COLO 775 ; COLO 684 ; KLM-1 ; GR-M ; SNU-685 ; CMK-86 ; SNU-886 ; HCT-8 ; NCC-StC-K140 ; NCI-H3255 ; SNU-719 ; SNU-489 ; SNU-81 ; A2058 ; HTK- ; SNU-1040 ; SNU-1076 ; SNU-175 ; SNU-407 ; SNU-201 ; KMS-20 ; SNU-216 ; SNU-1196 ; SNU-1079 ; HCC-1195 ; NCI-H854 ; SNU-466 ; YD-38 ; SNU-1105 ; SNU-283 ; SNU-46 ; SNU-308 ; YD-8 ; SNU-245 ; SNU-478 ; SNU-410 ; SNU-899 ; SNU-503 ; Set-2 ; SNU-738 ; SNU-626 ; SNU-869 ; SNU-878 ; SNU-840 ; SNU-8 ; NCI-H684 ; IGR-39 ; Daoy ; Hep 3B2.1-7 ; KYM-1 ; LC-1F ; HLE ; CMK ; JMSU-1 ; IMR-32 ; SU-DHL-8 ; T3M-4 ; COLO-818 ; PK-45H ; HEC-59 ; CPC-N ; T3M-10 ; NUGC-2 ; PLC/PRF/5 ; KP-N-YN ; CCF-STTG1 ; NCI-H929 ; KMRC-3 ; NCI-H2023 ; DMS 153 ; NCI-H1048 ; D341 Med ; NCI-H660 ; NCI-H1618 ; Hs 675.T ; PEER ; SKM-1 ; HT-144 ; SK-MEL-31 ; Hs 839.T ; Hs 939.T ; OCI-LY3 ; Hs 819.T ; NCI-H69 ; DV-90 ; ZR-75-1 ; KG-1 ; SK-N-BE(2) ; HCC70 ; NCI-H2452 ; SNU-1 ; Loucy ; HCC-56 ; NCI-H1648 ; TO 175.T ; GLC-82 ; MPP 89 ; Panc 08.13 ; MG-63 ; PK-1 ; Hs 840.T ; NCI-H23 ; TE 617.T ; SW 1088 ; IST-MES2 ; NCI-H1373 ; NCI-H1930 ; NCI-H1623 ; Hs 229.T ; NCI-H1838 ; NCI-H1836 ; Hs 688(A).T ; Panc 05.04 ; Hs 822.T ; BL-70 ; CI-1 ; G-292, clone A141B1 ; RCM-1 ; Hs 737.T ; Hs 616.T ; Hs 600.T ; TE 159.T ; A101D ; NCI-H1755 ; 143B ; RERF-LC-KJ ; NCI-H1693 ; SW 780 ; Hs 683 ; RKO ; Hs 729 ; JHOS-2 ; MCF7 ; U-937 ; SK-LMS-1 ; HuTu 80 ; HCC202 ; MEG-01 ; Reh ; ONS-76 ; RPMI 6666 ; SNU-C1 ; SK-N-DZ ; DMS 114 ; OCI-LY10 ; ST486 ; OC 315 ; OC 314 ; SW 1353 ; MDA-MB-157 ; LN-18 ; 769-P ; 786-O ; Caov-3 ; Hep G2 ; MOLT-4 ; NCI-H524 ; NCI-H209 ; MIA PaCa-2 ; MCAS ; SBC-5 ; COLO 829 ; VCaP ; COLO-704 ; IPC-298 ; Capan-2 ; EFM-192A ; Hs 766T ; EFO-27 ; A2780 ; NCI-H196 ; IGROV1 ; NCI-H889 ; NCI-H211 ; Hs 571.T ; MDA PCa 2b ; SK-MEL-24 ; K029AX ; HT-1376 ; NCI-H2171 ; Panc 10.05 ; EVSA-T ; Hs 695T ; CHL-1 ; LOU-NH91 ; LK-2 ; TOV-21G ; SK-MEL-3 ; AsPC-1 ; OVSAHO ; NCI-H441 ; RERF-LC-Sq1 ; NCI-H2030 ; HMCB ; FU-OV-1 ; Malme-3M ; KMS-12-BM ; T98G ; HL-60 ; DBTRG-05MG ; Hey-A8 ; NCI-H2122 ; MEL-JUSO ; SW620 ; HCT 116 ; VMRC-RCZ ; DU 145 ; MM1-S ; L3.3 ; SK-MEL-2 ; A549 ; A172 ; NCI-H1975 ; COLO-679 ; KP-2 ; huH-1 ; MDA-MB-453 ; Panc 04.03 ; TYK-nu ; OVISE ; EFM-19 ; MEL-HO ; RL ; G-361 ; NCI-H647 ; GMS-10 ; SEM ; HLF-a ; 42-MG-BA ; KCI-MOH1 ; HCC-44 ; KYSE-70 ; 1321N1 ; GAMG ; NCI-H522 ; EN ; PK-59 ; SNB-19 ; COLO 741 ; HD-MY-Z ; NCI-H661 ; LNCaP clone FGC ; LS411N ; HCC-78 ; YKG1 ; ESS-1 ; U-251 MG ; TE-11 ; KS-1 ; HEC-1-A ; TE-1 ; JHUEM-2 ; MOG-G-UVW ; RERF-LC-Ad1 ; TE-5 ; KELLY ; NCI-H1155 ; TE-15 ; ABC-1 ; 8-MG-BA ; NCI-H1703 ; AGS ; QGP-1 ; Detroit 562 ; BT-474 ; ACHN ; LoVo ; NCI-H1581 ; SCaBER ; SK-MEL-30 ; OVKATE ; 22Rv1 ; C32 ; Panc 03.27 ; RPMI 8226 ; DLD-1 ; ES-2 ; NCI-H1395 ; NCI-H1781 ; LS1034 ; G-402 ; NCI-H146 ; SW48 ; CHP-212 ; LS 180 ; SW403 ; NCI-H747 ; RT4 ; KATO III ; BDCM ; SW1417 ; SW948 ; Hs 606.T ; MDA-MB-415 ; DMS 79 ; NCI-H2106 ; SW579 ; MDA-MB-468 ; NCI-H526 ; TOV-112D ; BT-549 ; NCI-H2196 ; CAL-85-1 ; EFO-21 ; A-375 ; HT-29 ; NCI-H446 ; Hs 294T ; SK-MEL-5 ; Hs 944.T ; TCC-PAN2 ; DOV13 ; RMG-I ; PC-3 ; K-562 ; RT-112 ; NUGC-3 ; U-87 MG ; Caki-2 ; OE19 ; KMRC-2 ; JHH-2 ; IM95 ; MV-4-11 ; WM-266-4 ; KMRC-1 ; KM12 ; COLO-849 ; T84 ; Calu-1 ; LOX IMVI ; NCI-H2170 ; Sq-1 ; AN3 CA ; NCI-H2444 ; UACC-257 ; KYSE-510 ; MOLM-13 ; HUP-T4 ; MOG-G-CCM ; KYSE-30 ; KYSE-150 ; PSN1 ; NCI-H1299 ; PA-TU-8988T ; IGR-37 ; LN-443 ; SLR 23 ; HMEL ; OELE ; LN-235 ; BJ hTERT ; LN-428 ; SLR 24 ; EWS502 ; SALE ; HCC-2814 ; SK-RC 31 ; TIG-3 TD ; TC-32 ; SF-172 ; PrEC LH ; U343 ; RCC-4 ; LN-215 ; LN-464 ; SLR 25 ; U-178 ; F5 ; HEK TE ; SLR 26 ; SK-RC-20 ; SF767 ; A1207 ; LN-319 ; HCC364 ; UMRC6 ; LN382 ; IOMM-Lee ; UMRC2 ; DFCI024 ; HCC-1897 ; SLR 21 ; LNZ308 ; LN-340 ; HCC827 GR5 ; SLR 20 ; HK-2 ; EW8 ; UOK101 ; JH-EsoAd1 ; CH-157MN ; MOLP-2 ; SCC-25 ; UT-7 ; MHH-NB-11 ; HCC1806 ; GRANTA-519 ; MONO-MAC-6 ; MKN7 ; SW-1710 ; MOLT-13 ; SR-786 ; SCC-15 ; RS-5 ; NCI-H2126 ; NCI-H2141 ; NCI-H1385 ; HCC827 ; RD ; TT ; TF-1 ; Hs 172.T ; Hs 834.T ; TE 125.T ; 8305C ; UACC-812 ; ALL-SIL ; KASUMI-2 ; DND-41 ; ME-1 ; DM-3 ; JeKo-1 ; JJN-3 ; NU-DHL-1 ; CL-14 ; KYO-1 ; JL-1 ; CAL-148 ; NALM-19 ; HPB-ALL ; SUP-T11 ; CL-40 ; MDA-MB-134-VI ; HCC1500 ; HCC1599 ; SUP-HD1 ; MOTN-1 ; OCI-AML3 ; SU-DHL-10 ; SU-DHL-4 ; RH-41 ; OCI-LY-19 ; MOLM-6 ; SK-MM-2 ; Kasumi-6 ; Hs 698.T ; UACC-893 ; Mino ; CHP-126 ; COLO-680N ; COLO-678 ; LAMA-84 ; CML-T1 ; EHEB ; CAL-54 ; BV-173 ; DOHH-2 ; EOL-1 ; NALM-6 ; VM-CUB1 ; LP-1 ; LXF-289 ; MONO-MAC-1 ; PL-21 ; PF-382 ; NALM-1 ; OCI-AML2 ; MHH-CALL-3 ; JURL-MK1 ; OCI-AML5 ; KE-37 ; JK-1 ; RI-1 ; KARPAS-422 ; L-540 ; CAL-78 ; HDQ-P1 ; MHH-CALL-4 ; MUTZ-5 ; ONCO-DG-1 ; HDLM-2 ; CAL-29 ; KOPN-8 ; SCLC-21H ; Calu-3 ; NCI-H1435 ; NCI-H2009 ; NCI-H1869 ; Hs 852.T ; HCC1419 ; BT-483 ; Hs 281.T ; Hs 934.T ; HCC4006 ; HCC1428 ; KU812 ; SHP-77 ; TE 441.T ; NB-1 ; Hs 274.T ; Pfeiffer ; ZR-75-30 ; Hs 863.T ; NCI-H841 ; Hs 821.T ; NCI-H1944 ; NCI-H2405 ; DEL ; BEN ; COLO-320 ; RPMI-8402 ; SU-DHL-1 ; P12-ICHIKAWA ; BFTC-905 ; BFTC-909 ; MHH-ES-1 ; JVM-3 ; NOMO-1 ; NCI-H727 ; Hs 343.T ; HCC2935 ; Hs 888.T ; MKN-45 ; 8505C ; KU-19-19 ; KCL-22 ; CADO-ES1 ; S-117 ; EM-2 ; OPM-2 ; CAL-62 ; LCLC-103H ; JURKAT ; 697 ; MHH-CALL-2 ; M-07e ; L-428 ; MOLT-16 ; NB-4 ; LCLC-97TM1 ; 23132/87 ; BHT-101 ; JVM-2 ; CAL-51 ; L-363 ; KM-H2 ; SIMA ; NU-DUL-1 ; BC-3C ; SU-DHL-6 ; KARPAS-620 ; REC-1 ; OCI-M1 ; MEC-1 ; SIG-M5 ; SU-DHL-5 ; B-CPAP ; 639-V ; CL-11 ; TT2609-C02 ; MEC-2 ; CL-34 ; RCH-ACV ; CAL-120 ; 647-V ; RH-18 ; MOLM-16 ; F-36P ; EJM ; WSU-DLCL2 ; JIMT-1 ; ML-1 ; AMO-1 ; MOLP-8 ; COLO-699 ; JHUEM-7 ; KP-1NL ; KP-1N ; MB 157 ; OE21 ; SF8657 ; SNU-C2B ; NCI-H2073 ; HN ; HRT-18 ; PLB-985 ; SKNO-1 ; MOLT-3 ; HOP-62 ; EKVX ; OVCAR-5 ; UO-31 ; SF268 ; SF539 ; SNB75 ; HOP-92 ; ACCS ; MUTZ-3
PATHOLOGIST_ANNOTATION	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Pathologist Annotation	Sample	Lung:SCLC ; Colorectal:Carcinoma ; Lymphoma:NH_B_cell ; Lymphoma:NH_T_cell ; Bladder:Carcinoma ; Bone:Sarcoma_Osteo ; Lymphoma:Multiple_Myeloma ; Leukemia:AML ; Skin:Melanoma ; Bone:Sarcoma_Ewing ; Liver:HCC ; Lung:Mesothelioma ; Ovary:Carcinoma ; Oesophagus:Carcinoma ; Endometrium:Carcinoma ; CNS:Glioma_HighGrade ; Soft_Tissue:Sarcoma_Leiomyo ; Pancreas:Carcinoma ; PNET:Neuroblastoma ; CNS:Glioma ; Lung:NSCLC_Adeno ; Bone:Sarcoma_Chondro ; Lymphoma:Hodgkin ; Gastric:Carcinoma ; Soft_Tissue:Sarcoma_Fibro ; Kidney:Carcinoma ; Lung:NSCLC_Large_Cell ; Leukemia:ALL ; Breast:Carcinoma ; Lung:NSCLC_Squamous ; Upper_Aerodigestive_Tract:Carcinoma ; Thyroid:Carcinoma ; Liver:Hepatoblastoma ; Salivary_Gland:Carcinoma ; Endometrium:Others ; Lung:NSCLC_Others ; Oesophagus:Benign ; Soft_Tissue:Sarcoma_Rhabdoid ; Leukemia:CML ; Biliary_Tract:Carcinoma ; Soft_Tissue:Sarcoma_Others ; Soft_Tissue:Sarcoma_FibrousHistiocytoma ; CNS:Medulloblastoma ; Ovary:Germline ; Lung:Others ; Liver:Carcinoma_Adeno ; Leukemia:MPD ; Prostate:Carcinoma ; Leukemia:CLL ; Endocrine
PROTEOMICS_10PLEX_ID	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Proteomics 10-Plex ID used in proteomics assay	Sample	41 ; 5 ; 25 ; 20 ; 39 ; 35 ; 9 ; 31 ; 27 ; 42 ; 26 ; 22 ; 34 ; 36 ; 14 ; 10 ; 17 ; 11 ; 12 ; 16 ; 37 ; 29 ; 6 ; 8 ; 1 ; 3 ; 18 ; 23 ; 13 ; 33 ; 15 ; 4 ; 40 ; 32 ; 28 ; 24 ; 21 ; 38 ; 2 ; 7 ; 19 ; 30
PROTEOMICS_TMT_LABEL	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Proteomics TMT label used in proteomics assay	Sample	130c ; 129c ; 126 ; 128n ; 129n ; 127c ; 128c ; 130n ; 127n
SITE_OF_FINDING	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Site of Finding	Sample	ascites ; brain ; lymph_node ; pleura ; lung ; liver ; acetabulum ; skin ; cervix ; muscle ; breast ; soft_tissue ; abdominal_wall ; NS ; sternum ; bone_marrow ; spleen ; peritoneum ; supra_orbital_area ; central_nervous_system ; ovary ; cerebrospinal_fluid ; subcutaneous_tissue ; vertebra ; omentum ; bone ; abdomen ; pericardial_effusion ; pelvic_wall ; axillary_node ; adrenal ; connective_tissue_trunk
SITE_SUBTYPE1	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Site Subtype 1	Sample	NS ; colon ; skin ; bladder ; middle_third ; brain ; smooth_muscle ; spleen ; fibrous_tissue_and_uncertain_origin ; caecum ; mouth ; pharynx ; head_neck ; larynx ; tongue ; rectum ; lower_third ; femur ; upper_third ; striated_muscle ; bile_duct ; bronchus ; cerebellum ; lymph_node ; submaxillary ; parietal_lobe ; upper_leg ; duodenum ; humerus ; thigh ; temporal_lobe ; frontal_lobe ; foreskin ; meninges ; left_upper_lobe ; pelvis ; ureter
SITE_SUBTYPE2	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Site Subtype 2	Sample	NS ; ovary ; uterus ; tongue ; glottis ; hypopharynx ; kidney ; subglottis ; gingiva ; supraglottis ; vulva ; sigmoid ; right ; thyroid ; abdomen ; mouth_roof
SITE_SUBTYPE3	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Site Subtype 3	Sample	NS
SUPPLEMENTS	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Supplements	Sample	.005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol, 10 mM HEPES, 2 mM L-glutamine ; 0.005mg/ml insulin, 0.005mg/ml transferrin and 5ng/ml GM-CSF ; 0.005 mg/ml Insulin, 0.01 mg/ml transferrin, 30 nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol, 10 mM HEPES, 1 mM L-glutamine ; 0.5 ug/ml hydrocortisone + 10ug/ml insulin ; 0.1 mM NEAA ; 2mM L-Glutamine ; 0.02 mg/ml insulin, 0.01 mg/ml transferrin, 25 nM sodium selenite, 50 nM Hydrocortisone, 1 ng/ml EGF(don't filter), 0.01 mM ethanolamine, 0.01 mM phosphorylethanolamine, 100 pM triiodothyronine, 0.5% bovine serum albumin, 0.5 mM sodium pyruvate,  2mM L-gl ; 2mM Glutamine ; .02 mg/ml insulin, .01 mg/ml transferrin, 25nM sodium selenite, 1ng/mL EGF,  50 nM hydrocortisone, 2 mM L-glutamine, 0.5 sodium pyruvate ; .005 mg/ml insulin, .01 mg/ml transferrin, 25nM sodium selenite, 50nM hydrocortisone, 1 ng/mL epidermal growth factor, 0.01mM ethanolamine, 0.01mM phosphorylethanolamine, 100pM triiodothyronine, 0.5%(w/v) bovine serum albumin, 0.5 mM sodium pyruvate, 2mM  ; .005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol,  2 mM L-glutamine ; 4.5 g/L glucose, 1.5 g/L sodium bicarbonate ; 0.2 Units/ml bovine insulin ; 2mM GLUTAMINE+0.4UG/ML HYDROCORTISONE ; 2mM L-GLUTAMINE + 0.4UG/ML HYDROCORTISONE ; 2mM L-Glutamine ; 0.4 ug/ml Hydrocortisone ; Insulin + EGF ; 0.1mM NEAA ; 25mM Hepes and 25mM NaHCo3 ; 2mM L-glutamine, 0.4ug/ml hydrocortisone ; 2mM GLUTAMINE ; NEAA ; 2Mm L-Glutamine ; 0.1mMNEAA ; 2mM l-GLUTAMINE ; 10mg/L INSULIN ; 2mM L-glutamine, Insulin, Transferrin, Selenite ; 1% NEAA + 1% sodium pyruvate ; 0.05 mM 2-mercaptoethanol ; 2mM L-glutamine ; 2mM glutamine; 1ug/ml cisplatin ; plethora; see sheet ; 10ug/ml bovine insulin; 16ug/ml glutathione ; .02 mg/ml insulin, .01 mg/ml transferrin, 25nM sodium selenite, 50 nM hydrocortisone, 2 mM L-glutamine, 0.5 sodium pyruvate, 1ng/mL EGF ; 2mM L-GLUTAMINE ; 5ug/ml insulin, 10ug/ml transferrin, 3.0x10^-8 M Na Selenite (added 5ml Insulin-Transferrin-Selenium); 1.0x10^-8 M Hydrocortisone, 1.0x10^-8 beta estradiol, 2mM L-glutamine, 10mM HEPES ; 0.005 mg/mL insulin, 0.01 mg/mL transferrin, 30nM sodium selenite, 2mM L-glutamine ; 2mM L-glutamine, 0.5ug/ml hydrocortisone, 10ug/ml insulin ; 2mM L-Glutamine, 20 IU/L Bovine Insuline ; 2mM GLUTAMINE + 1% NEAA ; 4.5g/L glucose +1.5 g/Lsodium bicarbonate ; 2mM L-GLUTAMINE, 1X NEAA ; L-glutamine ; 0.01 mg/ml bovine insulin ; 5ug/ml insulin, 10ug/ml transferrin, 30nM Na Selenite, 10nM Hydrocortisone, 10nM Beta-estradiol, 10mM HEPES, 2mM L-glutamine ; NEAA, 10mM Hepes, 10mM Sodium Pyruvate ; HEPES, ADENOSINE TRIPHOSPHATE, AMINO ACIDS ; 20 Units/ml human recombinant insuline ; 2mM L-GLUTAMINE, 4X MEM NON-ESSENTIAL AMINO ACIDS ; 2 mM L-Glutamine ; 1.5 g/L sodium bicarbonate; 0.1 mM NEAA; 1.0 mM sodium pyruvate ; 10 UNITS/ML INSULIN ; 0.01 mg/ml insulin; 0.01 mg/ml glutathione ; 10mM L-GLUTAMINE ; 10mg/L insulin ; 2mM L -glutamine +MEM non-essential amino acids ; 2mM L-glutamine + non-essential amino acids +1 mM sodium pyruvate + 10ug/ml human insulin ; .005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 2 mM L-glutamine ; 2ng/ml human GM-CSF ; 4 mM L-glutamine, 1 mM sodium puruvate, 0.4 ug/ml hydrocortisone, 10 ng/ml EGF ; N/a ; 2mM L- glutamine+1x non-essential amino acids+1mM sodium pyruvate ; 10% vol conditioned medium of cell line 5637 (DSM ACC 35) (or 10ng/ml GM-CSF ; 1L-3 ( 10ng/ml) or GM-CSF(10ng/ml) or 10-20% vol conditioned medium of cell line 5637(DSM-ACC 35) ; 0.5%human serum(+0.005 ; 1mM sodium pyruvate + insulin-transferrin-selentite medium supplement ; 2 mM L-glutamine ; 10ng/ml GM-CSF ; 10 ng/ml GM-CSF ; 10ng/ml SCF
TYPE_REFINED	Black	Cancer Cell Line Encyclopedia (Broad, 2019)	STRING	Type Refined	Sample	lung_small_cell ; colorectal ; lymphoma_Burkitt ; T-cell_lymphoma_other ; urinary_tract ; osteosarcoma ; multiple_myeloma ; AML ; melanoma ; breast ; Ewings_sarcoma ; liver ; mesothelioma ; ovary ; esophagus ; endometrium ; fibroblast_like ; glioma ; pancreas ; neuroblastoma ; lung_NSC ; chondrosarcoma ; lymphoma_Hodgkin ; lymphoma_DLBCL ; stomach ; soft_tissue ; kidney ; T-cell_ALL ; B-cell_ALL ; giant_cell_tumour ; upper_aerodigestive ; other ; thyroid ; CML ; bile_duct ; B-cell_lymphoma_other ; medulloblastoma ; leukemia_other ; prostate ; meningioma ; cervix
IMMUNE_STATUS	Black	Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015)	STRING	Immune Status	Sample ; Patient	0 ; 7 ; 5 ; -1 ; 2
MERKEL_CELL	Black	Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015)	STRING	Merkel cells are oval receptor cells found in the skin of vertebrates that have synaptic contacts with somatosensory afferents.	Sample	Yes ; No
SECOND_PRIMARY_CANCER	Black	Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015)	STRING	Refers to a new primary cancer in a person with a history of cancer	Sample	No ; Yes
SMOKER	Black	Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015)	STRING	Indicates if person is a smoker.	Patient	
ABSOLUTE_CANCER_DNA_FRACTION	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Absolute cancer dna fraction	Sample	0.41 ; 0.35 ; 0.55 ; 0.31 ; 0.28 ; 0.3 ; 0.7 ; 0.4 ; 0.75 ; 0.33 ; 0.82 ; 0.5 ; 0.6 ; 0.78 ; 0.59 ; N.D. ; 0.37 ; 0.25 ; 0.65 ; 0.17 ; 0.47 ; 0.53 ; 0.54 ; 0.32 ; 0.23 ; 0.51 ; 0.61 ; 0.27 ; 0.18 ; 0.45
CC_TT	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	NUMBER	CC>TT	Sample	0 ; 0.0072 ; 0.12 ; 0.0572 ; 0.0486 ; 0.045 ; 0.0576 ; 0.0372 ; 0.0587 ; 0.0548 ; 0.0592 ; 0.053 ; 0.0613 ; 0.057 ; 0.0411 ; 0.0636 ; 0.0375 ; 0.0638 ; 0.0342 ; 0.0485 ; 0.0407 ; 0.076 ; 0.0495 ; 0.0642 ; 0.0301 ; 0.0528 ; 0.0473 ; 0.0023 ; 0.0489 ; 0.0498 ; 0.0421 ; 0.0395 ; 0.0735 ; 0.0314 ; 0.0657 ; 0.0119 ; 0.0117 ; 0.0343 ; 0.0595
CLARK_LEVEL_AT_DIAGNOSIS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Melanoma clark level value	Patient	
DETAILED_METASTATIC_SITE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Detailed Metastatic Site	Sample	Parotid ; Orbit ; Dermal
DIFFERENTIATION	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Differentiation	Sample	Moderate ; Poor ; well
DISEASE_RECURRENCE_OR_PERSISTENCE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Disease Recurrence or Persistence	Patient	
DISTANT_METS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Distant Metastasis	Sample	No ; Yes
DISTANT_RECURRENCE_NUM	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	NUMBER	Number of Distant Recurrence	Patient	
EFS_STATUS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Event Free Status	Patient	
EVENT_DETAILS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Event Details	Patient	
HAS_OTHER_CANCER	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Has other cancer.	Patient	
INTERVAL_FROM_INDEX_LESION_TO_PRESENT_LESION	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Interval From Index Lesion to Present Lesion (months)	Patient	
INTERVAL_FROM_LAST_LESION_TO_STUDY	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Interval From Previous Lesion to Tumor Studied (months)	Patient	
INVADE_BONE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Invade Bone	Patient	
INVADE_LARGER_THAN_SUBCUTANEOUS_TISSUE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Invade > Subcutaneous Tissue	Sample	Yes ; No
INVADE_PAROTID	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Invade Parotid	Patient	
INVADE_SKULL_BASE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Invade Skull Base	Patient	
INVASION_DEPTH	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Invasion depth (mm).	Sample	7.9 ; 5.7 ; N.d. ; 8 ; 13 ; 9 ; 3 ; 3.8 ; 3.9 ; 14 ; 5.3 ; 4.8 ; 0.5 ; 10 ; 8.1 ; 4.4 ; 11 ; 9.6 ; 4.3 ; 27 ; 25 ; 7.1 ; 18.5 ; 12.5 ; 2.3 ; 6.2 ; 9.5 ; 15
LOCAL_RECURRENCE_NUM	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	NUMBER	Number of Local Recurrence	Patient	
MULTIPLE_HN_CSCC	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Multiple Head and Neck cSCC	Patient	
OTHER_CANCER_TYPE	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Types of Other Cancers	Patient	
OTHER_DNP	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	NUMBER	other DNP	Sample	0.0164 ; 0.0145 ; 0.0122 ; 0.0075 ; 0.0054 ; 0.0077 ; 0.0078 ; 0.0062 ; 0.0092 ; 0.0058 ; 0.0066 ; 0.0098 ; 0.0082 ; 0.0051 ; 0.0087 ; 0.0073 ; 0.0071 ; 0.0047 ; 0.0069 ; 0.0121 ; 0.0083 ; 0.0085 ; 0.0035 ; 0.0065 ; 0.0135 ; 0.0064 ; 0.0063 ; 0.0053 ; 0.0099 ; 0.0081 ; 0.0108 ; 0.0238 ; 0.0117 ; 0.0074
OTHER_SKIN_TUMORS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Other Skin Tumors	Patient	
PAROTID_LN	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Parotid Lymph Node	Patient	
PERSISTANT_DISEASE_TUMOR_STUDIED	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Persistant Disease Tumor Studied	Patient	
PNI	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	PNI.	Patient	
RADIATION_OR_CHEMOTHERAPY	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Patient received Radiation or Chemotherapy	Patient	
RECURRENT_DISEASE_TUMOR_STUDIED	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Recurrent Disease Tumor Studied	Patient	
RECURRENT_FREE_INTERVAL_MONTHS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Recurrent Free Interval (Months)	Patient	
SUBSEQUENT_CANCERS	Black	Cutaneous Squamous Cell Carcinoma (MD Anderson, Clin Cancer Res 2014)	STRING	Subsequent Cancers	Patient	
ANATOMIC_REGION	Black	Desmoplastic Melanoma (Broad Institute, Nat Genet 2015)	STRING	Anatomic Region.	Patient	
SECONDARY_PLATFORM	Black	Desmoplastic Melanoma (Broad Institute, Nat Genet 2015)	STRING	Secondary Platform	Sample	Exome CN Inference
AGE_AT_SCC	Black	Cutaneous Squamous Cell Carcinoma (UCSF, NPJ Genom Med 2021)	NUMBER	Patient age at scc extraction	Patient	
HERED_DISORDER	Black	Cutaneous Squamous Cell Carcinoma (UCSF, NPJ Genom Med 2021)	STRING	Hereditary disorder influencing SCC	Patient	
SITE	Black	Cutaneous Squamous Cell Carcinoma (UCSF, NPJ Genom Med 2021)	STRING	site	Patient	
BIOPSY_TIME	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Biopsy Time	Sample	Pre-treatment ; On-treatment ; post ; pre
CBEST_B_MEM	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT B cells memory	Sample	0 ; 0.02 ; 0.06 ; 0.01 ; 0.22 ; 39.00393483 ; -15.1834805 ; -6.357807912 ; 26.17031962 ; 2.177795119 ; 13.74328398 ; -8.362793331 ; 0.003155964 ; 0.049626633 ; 0.020043613 ; 0.026258405 ; 0.016086291 ; 0.001494363 ; 0.030264403 ; 0.019027683 ; 0.040752522 ; 0.012229589 ; 0.004559486 ; 0.137482951 ; 0.015486186 ; 0.001451917 ; 0.010910629 ; 0.238193365 ; 0.006990659 ; 0.003453091 ; 0.012431282 ; 0.006705862 ; 0.064933898 ; 0.009449193 ; 0.057763684 ; 0.030272756 ; 0.047660929 ; 0.009361822 ; 0.009299268 ; 0.01639361 ; 0.026834341 ; 0.040208647 ; 0.048508919
CBEST_B_NAIVE	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT B cells naive	Sample	0.02 ; 0 ; 0.01 ; 0.03 ; 0.06 ; 0.9 ; 97.19549898 ; 67.76040068 ; 153.4118066 ; 173.2235173 ; 67.57111287 ; -0.638135708 ; 1.234208669 ; 749.0189501 ; 4.393690588 ; 1.609857507 ; -84.68369748 ; 27.11609727 ; 110.1935689 ; 31.08359782 ; 0.276318256 ; 272.1663334 ; 0.023225696 ; 0.005936525 ; 0.296795207 ; 0.016604127 ; 0.009064887 ; 0.051715525 ; 0.000276983 ; 0.037670072 ; 0.0007633 ; 0.24870984 ; 0.000132439 ; 0.019578816 ; 0.143648664 ; 0.014978935 ; 0.049169239 ; 0.013023957 ; 0.02096449 ; 0.00349012
CBEST_DENDRITIC_ACT	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Dendritic cells activated	Sample	0 ; 0.01 ; 0.02 ; 0.09 ; 1.752558437 ; -2.886692012 ; 0.002502296 ; 0.002039867 ; 0.007475225 ; 0.010750231 ; 0.006769663
CBEST_DENDRITIC_REST	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Dendritic cells resting	Sample	0.03 ; 0 ; 0.01 ; 0.04 ; 0.02 ; 38.27488648 ; 20.98309491 ; -0.714268853 ; 0.869877937 ; 32.33110467 ; 21.26456151 ; 9.622008402 ; 23.86708313 ; 0.01100519 ; 0.000338889 ; 0.006297828 ; 0.008675997 ; 0.08088798 ; 0.011016859 ; 0.008029184 ; 0.013008677 ; 0.000720961 ; 0.000512871 ; 0.002689068 ; 0.00024103 ; 0.003116275 ; 0.017084557 ; 0.010040703 ; 0.007308663 ; 0.001439077 ; 0.005252867 ; 0.001447537 ; 0.006123352 ; 0.000923431 ; 0.000853462 ; 0.014774269 ; 0.016829783 ; 0.002404348
CBEST_EOSINOPHILS	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Eosinophils	Sample	0 ; 0.01 ; 7.186864719 ; 1.720146692 ; -11.09007459 ; 0.000173147 ; 0.007892911 ; 0.002857481 ; 0.001557328 ; 0.004836136 ; 0.00363083 ; 0.003264639 ; 0.004005317 ; 0.00176637 ; 0.000416425 ; 0.00360328 ; 0.00247703 ; 0.002932626 ; 0.003697884
CBEST_MACRO_M0	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Macrophages M0	Sample	0.07 ; 0.2 ; 0.14 ; 0.1 ; 0 ; 0.01 ; 0.17 ; 0.02 ; 0.12 ; 0.13 ; 0.23 ; 0.11 ; 0.04 ; 973.0397529 ; 125.9290836 ; 62.0436017 ; 364.8512445 ; 294.8004415 ; 103.7656731 ; -194.3634758 ; 13.06188748 ; 672.9876797 ; 10.06251714 ; 19.59649272 ; -248.9871108 ; -477.3923484 ; 52.54526812 ; 383.108595 ; 480.3637718 ; 90.60045824 ; 127.1292129 ; 142.1900782 ; -114.4396558 ; 264.1317169 ; 0.626216015 ; 0.020768464 ; 0.045567961 ; 0.079596382 ; 0.233202072 ; 0.026654462 ; 0.039531178 ; 0.134657504 ; 0.053998808 ; 0.014856591 ; 0.446506326 ; 0.002581336 ; 0.387384115 ; 0.087489209 ; 0.181575665 ; 0.117937065 ; 0.082913858 ; 0.058221901 ; 0.2894711 ; 0.016639161 ; 0.180502452 ; 0.037334471 ; 0.001143344 ; 0.030887937 ; 0.154211392 ; 0.109601348 ; 0.046225858 ; 0.086772372 ; 0.055225357 ; 0.315997966 ; 0.040572398 ; 0.087816186 ; 0.069534051 ; 0.150396918 ; 0.108927232 ; 0.263243659
CBEST_MACRO_M1	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Macrophages M1	Sample	0.1 ; 0 ; 0.01 ; 0.04 ; 0.02 ; 0.03 ; 0.13 ; 0.12 ; 0.11 ; 363.3099633 ; 187.3582315 ; 66.89259259 ; 211.5962254 ; 155.3941373 ; 47.48480645 ; -7.88678907 ; 87.16832152 ; 11.96633117 ; 14.62439009 ; -3.023346496 ; -78.3081996 ; 262.6261694 ; 263.2404967 ; 160.6888107 ; 47.40880607 ; 307.1441963 ; 177.2419254 ; -44.05699831 ; 222.5141832 ; 0.017438523 ; 0.00042086 ; 0.022255444 ; 0.105149954 ; 0.104516767 ; 0.098610807 ; 0.021805925 ; 0.012480809 ; 0.02797612 ; 0.018398013 ; 0.001168976 ; 0.065016947 ; 0.095800464 ; 0.016606476 ; 0.004167702 ; 0.115822071 ; 0.029854917 ; 0.001227299 ; 0.002835452 ; 0.018100983 ; 0.070760226 ; 0.005770809 ; 0.008323365 ; 0.135413913 ; 0.006346226 ; 0.007048268 ; 0.203616556 ; 0.016298997 ; 0.014157865 ; 0.034140578 ; 0.002041774 ; 0.074640459 ; 0.270064074 ; 0.02332376 ; 0.111921848 ; 0.079375535 ; 0.035924789
CBEST_MACRO_M2	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Macrophages M2	Sample	0.23 ; 0.01 ; 0.1 ; 0.18 ; 0.24 ; 0.26 ; 0.04 ; 0.05 ; 0.13 ; 0.37 ; 0.35 ; 0.11 ; 0.22 ; 0.29 ; 0.03 ; 0.07 ; 0.25 ; 0.27 ; 416.8534513 ; 152.9507593 ; 276.7793255 ; 442.8769148 ; 309.7566896 ; 63.33119835 ; -117.4801373 ; 17.99643759 ; 754.8139964 ; 20.61991021 ; 55.71433969 ; -167.4115795 ; -176.3746283 ; 490.246939 ; 281.6675883 ; 517.528305 ; 166.1490281 ; 363.1736423 ; 149.3711922 ; -235.4890405 ; 639.8709958 ; 0.06931586 ; 0.206682749 ; 0.105871752 ; 0.464862423 ; 0.128129598 ; 0.195826052 ; 0.053444118 ; 0.054552341 ; 0.087628179 ; 0.118995764 ; 0 ; 0.062546297 ; 0.197481464 ; 0.100139074 ; 0.128169168 ; 0.05424399 ; 0.143202445 ; 0.024386321 ; 0.005040123 ; 0.059149984 ; 0.219120381 ; 0.379674368 ; 0.076878563 ; 0.374470489 ; 0.023193769 ; 0.000142548 ; 0.06419787 ; 0.080348575 ; 0.215510525 ; 0.055979744 ; 0.014308751 ; 0.055486288 ; 0.055234419 ; 0.079002972 ; 0.214020913 ; 0.169969557 ; 0.04059812 ; 0.072390505 ; 0.048396524
CBEST_MAST_ACT	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Mast cells activated	Sample	0 ; 0.01 ; 0.04 ; 0.15 ; 0.03 ; 0.02 ; 54.01843328 ; 27.06365447 ; 305.9571915 ; 6.508351576 ; 71.04889206 ; 11.7792381 ; 8.03183847 ; -17.33009227 ; 1.19E-01 ; 24.44077724 ; 55.58073093 ; -92.07326743 ; 86.64573152 ; 0.017881246 ; 0.017878899 ; 0.02140638 ; 0.004632068 ; 0.035689149 ; 0.055434966 ; 0.00112565 ; 0.075994957 ; 0.00828655 ; 0.008856055 ; 0.012722473 ; 0.015878779 ; 0.008904086 ; 0.07787297 ; 0.012607132 ; 0.111375682 ; 0.004319667 ; 0.095230832 ; 0.021666342 ; 0.024186498 ; 0.023208873 ; 0.017842134 ; 0.272889685 ; 0.017848887 ; 0.111012109 ; 0.045241192
CBEST_MAST_REST	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Mast cells resting	Sample	0.06 ; 0 ; 0.03 ; 0.01 ; 0.02 ; 35.63393748 ; 98.31236827 ; 1.42663727 ; -245.4644749 ; -21.72895366 ; 53.15939828 ; 53.47855848 ; 10.60789069 ; 1.693342111 ; 0.012022482 ; 0.143766647 ; 0.003182819 ; 0.027417223 ; 0.023105581 ; 0.000889213 ; 0.004762022 ; 0.00372178 ; 0.014479025 ; 0.083237391 ; 0.012226628 ; 0.018453582 ; 0.013091829 ; 0.015730109 ; 0.034378169
CBEST_MONO	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Monocytes	Sample	0.04 ; 0 ; 0.03 ; 0.15 ; 0.01 ; 0.09 ; 0.05 ; 0.18 ; 0.06 ; 0.02 ; 0.08 ; 87.81877018 ; 248.5960789 ; 36.35151404 ; 3.45511275 ; -105.5844467 ; 1.275990797 ; 18.78574848 ; 1.127658731 ; 8.653749795 ; -42.31123861 ; 286.0139891 ; 18.07554093 ; 51.95016388 ; 20.62090901 ; 62.35106242 ; -21.84638046 ; 164.9408615 ; 0.044924794 ; 0.010576969 ; 0.283987839 ; 0.028199589 ; 0.020047402 ; 0.013729216 ; 0.005755699 ; 0.017345116 ; 0.066690212 ; 0.009185613 ; 0.050163663 ; 0.020293428 ; 0.041604193 ; 0.00967239 ; 0.018649986 ; 0.034742353 ; 0.146492041 ; 0.027734671 ; 0.048317036 ; 0.0000348 ; 0.000976782 ; 0.041408843 ; 0.002521242 ; 0.021341481 ; 0.002275526 ; 0.015309296 ; 0.011803565 ; 0.020371925 ; 0.026872657 ; 0.105456895 ; 0.034155267 ; 0.04777778 ; 0.021776381 ; 0.001930826
CBEST_NEUTROPHILS	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Neutrophils	Sample	0 ; 0.03 ; 0.01 ; 0.17 ; 0.02 ; 0.06 ; 0.05 ; 0.04 ; 75.58093996 ; -2.701227519 ; 4.357252916 ; 0.973756694 ; -22.08092338 ; 1.016957164 ; 0.000537719
CBEST_NK_ACT	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT NK cells activated	Sample	0 ; 0.04 ; 0.02 ; 0.08 ; 0.05 ; 0.03 ; 0.01 ; 75.73006776 ; 28.03648421 ; 24.62946428 ; 184.0421299 ; 112.1759813 ; 221.9681191 ; -41.92660701 ; 79.90035883 ; 0.004281346 ; 0.051133414 ; 0.022182839 ; 0.005922705 ; 0.006799164 ; 0.020960623 ; 0.027572375 ; 0.062924255 ; 0.044432204 ; 0.068995678 ; 0.206561298 ; 0.00556079 ; 0.038254261 ; 0.106896502 ; 0.014576658 ; 0.05299048 ; 0.023486442
CBEST_NK_REST	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT NK cells resting	Sample	0 ; 0.01 ; 0.04 ; 0.05 ; 0.02 ; 0.03 ; 24.79434286 ; 41.61277076 ; 8.373066939 ; -33.32976255 ; 3.04620826 ; 45.63936478 ; 0.376104354 ; -6.038141072 ; 1.792319551 ; 14.39670512 ; 0.027808745 ; 0.005948531 ; 0.012706096 ; 0.013147426 ; 0.017227366 ; 0.024450378 ; 0.009485045 ; 0.019426294 ; 0.012737213 ; 0.017492569 ; 0.005622407 ; 0.012600006 ; 0.025292363 ; 0.024365318 ; 0.009400207 ; 0.030043112 ; 0.034438279 ; 0.014267922 ; 0.023087514 ; 0.029867816
CBEST_PLASMA	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Plasma cells	Sample	0.01 ; 0 ; 0.02 ; 0.14 ; 0.03 ; 38.90266612 ; 79.38554988 ; 149.9158446 ; 7.442046706 ; 11.993899 ; 0.087269981 ; 177.9680625 ; 4.994136958 ; 2.405349782 ; -16.94634905 ; 50.65805767 ; 8.614326472 ; 440.4776245 ; 18.00311718 ; 164.8151255 ; 16.39768569 ; -45.59956119 ; 12.17632637 ; 0.002611951 ; 0.002150258 ; 0.229643524 ; 0.014715785 ; 0.011322724 ; 0.007276197 ; 0.004241796 ; 0.029264602 ; 0.019117041 ; 0.002794239 ; 0.067926655 ; 0.00299985 ; 0.150566565 ; 0.000289316 ; 0.006113719 ; 0.023083926 ; 0.001302527 ; 0.054421245 ; 0.000443079 ; 0.017425252 ; 0.170111359 ; 0.023145846 ; 0.007325168 ; 0.008678446 ; 0.059204479 ; 0.041813898 ; 0.001939034 ; 0.025839546 ; 0.045336662 ; 0.001127938
CBEST_T_CD4_MEM_ACT	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells CD4 memory activated	Sample	0.04 ; 0 ; 0.05 ; 0.01 ; 0.02 ; 0.1 ; 0.17 ; 0.06 ; 266.4153797 ; 56.75468657 ; 64.25006487 ; 160.9852607 ; 162.8503199 ; 10.41776303 ; 3.474107112 ; 181.2466074 ; 42.08228243 ; 7.039767408 ; -9.578611004 ; 325.1114288 ; 81.13316661 ; 118.7923849 ; 8.629249934 ; 33.16877653 ; 234.3755242 ; 168.4749012 ; 0.007939459 ; 0.047699535 ; 0.285727662 ; 0.123057831 ; 0.032076451 ; 0.026518013 ; 0.033394878 ; 0.003654861 ; 0.002315265 ; 0.068389679 ; 0.046926474 ; 0.00989049 ; 0.027976058 ; 0.086708295 ; 0.053912168 ; 0.004791564 ; 0.07675244 ; 0.07124399 ; 0.005950952 ; 0.041278783 ; 0.002418353 ; 0.027598577 ; 0.244303786 ; 0.026095269 ; 0.076130989 ; 0.0533325 ; 0.016863657 ; 0.003328079 ; 0.084048035 ; 0.013542898 ; 0.002350381
CBEST_T_CD4_MEM_REST	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells CD4 memory resting	Sample	0.13 ; 0 ; 0.03 ; 0.09 ; 0.04 ; 0.01 ; 0.06 ; 0.18 ; 0.12 ; 0.02 ; 0.15 ; 0.05 ; 136.5742697 ; 90.67711019 ; 201.5903019 ; 221.6936686 ; 127.6544761 ; -171.5914414 ; 5.673782077 ; 4.970201932 ; 11.75158268 ; 202.3057237 ; 26.11788864 ; 323.648597 ; -79.44695987 ; 3.535052098 ; 0.053291683 ; 0.189684594 ; 0.010036689 ; 0.085920712 ; 0.054568913 ; 0.198079093 ; 0.103906136 ; 0.002649201 ; 0.092674546 ; 0.177061595 ; 0.034611535 ; 0.048949916 ; 0.018292301 ; 0.008461347 ; 0.139147444 ; 0.043057331 ; 0.001072828 ; 0.325640145 ; 0.009207055 ; 0.115288507 ; 0.000523877 ; 0.045492503 ; 0.085460281 ; 0.037992765 ; 0.015892307 ; 0.038091259 ; 0.041742476 ; 0.127093141 ; 0.02838112
CBEST_T_CD4_NAIVE	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells CD4 naive	Sample	0 ; 0.02 ; 0.063155437 ; 0.015672819 ; 0.006000597
CBEST_T_CD8	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells CD8	Sample	0.14 ; 0 ; 0.24 ; 0.03 ; 0.17 ; 0.01 ; 0.09 ; 0.07 ; 0.56 ; 0.19 ; 0.18 ; 0.21 ; 0.12 ; 0.13 ; 0.06 ; 573.9711772 ; 201.973667 ; 177.6715422 ; 300.5403939 ; 221.666255 ; 61.93511559 ; -145.0604384 ; 4.660769612 ; 459.1874297 ; 32.34769998 ; 99.54127514 ; -18.72554537 ; -78.14114276 ; 1074.051721 ; 231.7465146 ; 596.0434657 ; 58.81836495 ; 333.9619662 ; 686.1622271 ; -18.86746985 ; 591.4918199 ; 0.04659999 ; 0.109833063 ; 0.12930839 ; 0.046140024 ; 0.036672798 ; 0.019264272 ; 0.054000802 ; 0.029885822 ; 0.030433025 ; 0.110946992 ; 0.139971931 ; 0.110905519 ; 0.0195283 ; 0.270628217 ; 0.00311097 ; 0.001800749 ; 0.05384247 ; 0.277366564 ; 0.076773613 ; 0.026682122 ; 0.352621122 ; 0.015479473 ; 0.410683592 ; 0.053747772 ; 0.046122189 ; 0.065557146 ; 0.281496412 ; 0.528967185 ; 0.049853224 ; 0.322276325 ; 0.0810071 ; 0.041053149
CBEST_T_FOLLI_HEL	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells follicular helper	Sample	0.03 ; 0.05 ; 0.02 ; 0.01 ; 0.07 ; 0.04 ; 0.11 ; 0.06 ; 0.08 ; 0.09 ; 0.17 ; 0 ; 118.1983591 ; 108.0500056 ; 34.27966394 ; 293.9048341 ; 120.0000221 ; 56.37259053 ; -162.0060135 ; 173.0417044 ; 4.219459131 ; 24.49235102 ; -37.56543482 ; -170.2923372 ; 193.3121674 ; 141.458111 ; 232.0609771 ; 30.53501948 ; 206.0778788 ; 56.47293688 ; -78.04587934 ; 174.7933003 ; 0.022818832 ; 0.018702245 ; 0.025635874 ; 0.032506601 ; 0.03166518 ; 0.006819357 ; 0.015556958 ; 0.034311533 ; 0.04261859 ; 0.029004026 ; 0.003069048 ; 0.113574884 ; 0.050137491 ; 0.05616172 ; 0.01265564 ; 0.030668965 ; 0.073916161 ; 0.018030309 ; 0.001810014 ; 0.023083783 ; 0.120233223 ; 0.005139076 ; 0.027437235 ; 0.103036892 ; 0.005392078 ; 0.01704799 ; 0.012713653 ; 0.023197099 ; 0.134012531 ; 0.025431747 ; 0.035401514 ; 0.043486305 ; 0.001930351 ; 0.026588829 ; 0.230811304 ; 0.030424023 ; 0.08786527 ; 0.03195845 ; 0.059359942
CBEST_T_G_D	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells gamma delta	Sample	0 ; 0.01 ; 0.02 ; 0.11 ; 0.04 ; 0.07 ; 0.03 ; 175.3503782 ; 62.04931651 ; 251.6121449 ; 126.8999576 ; 1.341498267 ; -22.46802461 ; 204.1827786 ; 4.173708606 ; 87.98711145 ; 7.902073821 ; 53.30827397 ; 88.09244179 ; 128.8662594 ; 0.001221761 ; 0.009777378 ; 0.095078354 ; 0.034745858 ; 0.005273202 ; 0.030471817 ; 0.050645052 ; 0.019126202 ; 0.013347777 ; 0.000145901 ; 0.000390524 ; 0.046849116 ; 0.082326465 ; 0.003667777 ; 0.006328818 ; 0.032381609 ; 0.001836021
CBEST_T_REG	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT T cells regulatory (Tregs)	Sample	0.01 ; 0 ; 0.02 ; 21.0150045 ; 1.322205901 ; -15.81447005 ; 83.98315203 ; 30.17061147 ; 12.18710239 ; -13.56378398 ; 0.00976999 ; 0.006993126 ; 0.001698233 ; 0.011661634 ; 0.00448481 ; 0.050261683 ; 0.005037709 ; 0.040327263
CIBERSORT_ABSOLUTE	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Absolute Immune Score	Sample	0.92 ; 0.35 ; 0.38 ; 1.05 ; 0.57 ; 0.74 ; 0.67 ; 0.43 ; 0.56 ; 1.44 ; 1.4 ; 1.11 ; 0.54 ; 0.73 ; 0.6 ; 1.08 ; 0.51 ; 0.59 ; 0.44 ; 0.34 ; 2.34 ; 0.11 ; 0.37 ; 0.28 ; 0.65 ; 0.94 ; 0.954056521 ; 0.605461187 ; 0.45508842 ; 2.09766758 ; 0.865641521 ; 0.888813894 ; 0.356665503 ; 0.232946763 ; 0.436574148 ; 0.730255034 ; 0.112424786 ; 0.577134899 ; 1.224781451 ; 0.50617395 ; 0.622561307 ; 0.766504587 ; 1.227672573 ; 0.234436824 ; 0.170180436 ; 0.35505214 ; 1.282482879 ; 1.423959273 ; 0.486705164 ; 0 ; 1.510235787 ; 0.083801964 ; 0.146855068 ; 0.548868314 ; 0.34915195 ; 1.828444008 ; 0.41368994 ; 0.387429385 ; 0.641805633 ; 0.245201228 ; 0.727882402 ; 1.921508668 ; 0.406555314 ; 1.093942382 ; 0.661076719 ; 0.600840903
CIBERSORT_CORRELATION	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT Correlation	Sample	0.06 ; 0.11 ; 0.13 ; 0.3 ; 0.28 ; 0.14 ; 0.22 ; 0.19 ; 0.08 ; 0.18 ; 0.32 ; 0.05 ; 0.16 ; 0.07 ; 0.52 ; 0.12 ; 0.185659626 ; 0.186957772 ; 0.160698916 ; 0.178314222 ; 0.146769116 ; 0.244979316 ; -0.005189477 ; 0.024117012 ; 0.332225521 ; 0.101808391 ; 0.030980112 ; 0.129922366 ; 0.137842288 ; 0.213199096 ; 0.117746464 ; 0.254411643 ; 0.071273279 ; 0.241939174 ; 0.336687573 ; 0.016278584 ; 0.046895885 ; 0.752588045 ; 0.061090053 ; 0.048505218 ; 0.345682777 ; 0.064975787 ; 0.063061835 ; 0.007953998 ; 0.103035408 ; 0.018108069 ; 0.15830123 ; 0.085868613 ; 0.124257927 ; 0.125388988 ; 0.293500566 ; 0.40683345 ; 0.160240549 ; 0.486858746 ; 0.043676861 ; 0.107837576 ; 0.134023811 ; 0.189334458 ; 0.343914921 ; 0.298905911 ; 0.03265575 ; 0.080143707 ; -0.001353813 ; -0.013637903 ; 0.214397564 ; 0.132506255 ; 0.212129445 ; 0.172994703 ; 0.154734049 ; 0.082103562 ; -0.005097096 ; 0.160298299 ; 0.10156389 ; 0.027884776 ; 0.082364879 ; 0.187615478 ; 0.130766347
CIBERSORT_P	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT P-value	Sample	0.2 ; 0.09 ; 0.08 ; 0.01 ; 0.06 ; 0.02 ; 0.04 ; 0.11 ; 0.15 ; 0.27 ; 0.05 ; 0.07 ; 0.19 ; 0 ; 0.21 ; 0.032 ; 0.044 ; 0.034 ; 0.052 ; 0.612 ; 0.356 ; 0.008 ; 0.1 ; 0.322 ; 0.066 ; 0.057 ; 0.027 ; 0.077 ; 0.018 ; 0.162 ; 0.021 ; 0.412 ; 0.246 ; 0.186 ; 0.237 ; 0.006 ; 0.175 ; 0.18 ; 0.477 ; 0.098 ; 0.388 ; 0.045 ; 0.122 ; 0.073 ; 0.072 ; 0.011 ; 0.004 ; 0.043 ; 0.256 ; 0.093 ; 0.064 ; 0.035 ; 0.303 ; 0.136 ; 0.554 ; 0.698 ; 0.065 ; 0.037 ; 0.048 ; 0.131 ; 0.604 ; 0.099 ; 0.318
CIBERSORT_RMSE	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	CIBERSORT RMSE	Sample	1.06 ; 1.11 ; 1.07 ; 0.96 ; 0.99 ; 1.03 ; 1.05 ; 1.09 ; 1.01 ; 1.1 ; 1.04 ; 1.02 ; 1.08 ; 0.85 ; 1.020436103 ; 1.015540679 ; 1.01392146 ; 1.014869485 ; 1.027122126 ; 0.990967736 ; 1.087506334 ; 1.089682227 ; 0.949363763 ; 1.043155916 ; 1.100127036 ; 1.091352001 ; 1.058763501 ; 1.011394861 ; 1.047175139 ; 0.985554987 ; 1.067742798 ; 0.995471999 ; 0.960217778 ; 1.08341138 ; 1.074220438 ; 0.667401616 ; 1.065740745 ; 1.080739217 ; 0.940141888 ; 1.064301707 ; 1.059362636 ; 1.089679361 ; 1.045662547 ; 1.078867569 ; 1.02017272 ; 1.095785468 ; 1.053978789 ; 1.057619351 ; 0.969599074 ; 0.95010305 ; 1.046139373 ; 0.873278883 ; 1.122667334 ; 1.083640219 ; 1.02572908 ; 1.01387315 ; 0.943398889 ; 0.988018654 ; 1.137382241 ; 1.059277019 ; 1.07728166 ; 1.110040587 ; 1.008001912 ; 1.045876491 ; 1.012450077 ; 1.015514102 ; 1.017683088 ; 1.096515981 ; 1.076753543 ; 1.034421873 ; 1.065213263 ; 1.078765592 ; 1.0692091 ; 1.013491565 ; 1.063788361
CYTOLYTIC_SCORE	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	RNA-Seq Cytolytic Score	Sample	19.48 ; 1.3 ; 5.97 ; 32.07 ; 14.47 ; 13.63 ; 7.09 ; 8.15 ; 7.83 ; 134.96 ; 24.76 ; 30.12 ; 40.21 ; 24.19 ; 1.96 ; 23.98 ; 11.58 ; 13.5 ; 12.46 ; 12.34 ; 42.13 ; 11.63 ; 0.79 ; 3.12 ; 5.41 ; 8.05 ; 22.23 ; 228.5193604 ; 10.44805366 ; 15.86093165 ; 67.11187819 ; 58.40948022 ; 8.627671247 ; 1.766302124 ; 3.234588194 ; 46.44948562 ; 11.69056481 ; 13.8445728 ; 1.428082103 ; 1.590191469 ; 240.1187752 ; 25.29744494 ; 61.81301725 ; 21.9502614 ; 33.08700539 ; 102.0615521 ; 0.614679081 ; 50.8792872 ; 29.24764035 ; 3.13331056 ; 25.14707067 ; 30.65983275 ; 16.0172869 ; 27.62456443 ; 5.534072093 ; 2.790171988 ; 7.831121997 ; 9.03377732 ; 0 ; 13.71499623 ; 30.48983799 ; 8.482151149 ; 6.499866325 ; 44.28641235 ; 14.2710529 ; 1.817014964 ; 1.786462588 ; 9.085585056 ; 84.56916088 ; 28.98656871 ; 4.445498914 ; 85.1103321 ; 0.083947555 ; 0.09272782 ; 4.844804064 ; 1.683372202 ; 98.16224309 ; 3.729911244 ; 8.675383365 ; 13.34433186 ; 1.161452339 ; 35.09007139 ; 101.0326545 ; 7.584851831 ; 73.8423645 ; 9.107946351 ; 9.165366238
DURABLE_CLINICAL_BENEFIT	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Durable Clinical Benefit	Patient	
HLA_A	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Polysolver HLA-A	Sample	A0101/A0201 ; A0201/A0201 ; A0101/A0301 ; A0101/A2402 ; A2501/A3101 ; A0201/A2402 ; A0201/A0301 ; A0301/A3101 ; A0301/A2501 ; A0301/A2902 ; A0201/A1101 ; A2601/A2902 ; A2501/A2601 ; A0301/A3201 ; A0301/A1101 ; A0101/A3301 ; A2901/A6801 ; A0301/A0301 ; A1101/A6801 ; A2301/A6802 ; A0301/A3004 ; A0201/A2403 ; A0201/A2301 ; A0201/A6801 ; A2402/A3201 ; A0301/A0302 ; A0201/A3101 ; A0201/A3201 ; A2402/A2601 ; A2601/A3301 ; A0205/A6801 ; A2402/A2402 ; A2301/A2601 ; A3002/A3201 ; A0206/A6802 ; A1101/A2402 ; A1101/A1101 ; A0101/A2902 ; A0201/A3001 ; A2902/A3201 ; A3402/A6801 ; A3201/A6801 ; A0201/A2601 ; A0101/A3101 ; A0201/A3301 ; A2901/A6802 ; A0201/A0205 ; A0101/A0101 ; A2301/A3601 ; A0301/A2402 ; A3001/A3301 ; A2402/A6802 ; A0301/A2901 ; A2601/A6801 ; A0101/A2301 ; A0301/A3303 ; A2402/A3101 ; A2601/A2601 ; A1101/A2902 ; A0101/A6801 ; A3001/A6802 ; A2301/A2402 ; A2601/A3303 ; A0201/A2902 ; A2902/A6601 ; A0301/A3002 ; A1101/A3004 ; A0101/A6601 ; A1101/A2601 ; A0101/A2601 ; A2301/A3201 ; A0101/A1101 ; A2601/A3101 ; A1101/A3001 ; A3001/A6801
HLA_B	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Polysolver HLA-B	Sample	B4001/B4402 ; B4001/B4001 ; B1801/B5701 ; B3508/B5201 ; B3901/B4001 ; B0801/B3501 ; B5101/B5801 ; B4901/B5101 ; B0801/B4405 ; B0702/B5101 ; B0702/B1801 ; B0801/B1302 ; B1801/B3503 ; B2705/B3701 ; B4402/B4402 ; B2704/B4001 ; B1801/B3801 ; B3501/B3801 ; B4402/B5601 ; B1402/B5701 ; B4402/B5701 ; B0705/B2705 ; B0702/B3501 ; B0801/B4402 ; B1803/B3501 ; B1402/B4901 ; B3503/B4403 ; B0702/B4402 ; B0702/B0801 ; B3501/B3503 ; B5101/B5101 ; B4002/B4402 ; B1507/B4402 ; B3501/B3501 ; B3503/B3801 ; B4402/B5501 ; B5101/B5301 ; B3502/B3906 ; B1801/B4403 ; B4101/B5001 ; B1402/B1801 ; B0801/B4001 ; B4402/B5101 ; B3501/B5101 ; B3502/B4402 ; B2705/B4403 ; B1501/B1801 ; B1801/B4801 ; B3501/B4402 ; B3508/B4402 ; B0702/B3901 ; B0801/B4403 ; B0801/B0801 ; B3501/B4101 ; B1302/B4001 ; B4402/B4501 ; B1503/B1503 ; B1401/B4402 ; B0702/B0702 ; B1801/B3501 ; B0702/B4201 ; B1402/B1501 ; B2705/B4402 ; B0702/B5107 ; B5101/B5501 ; B1501/B3503 ; B1402/B3502 ; B2702/B5101 ; B0702/B1402 ; B2705/B5701 ; B0801/B1501 ; B0702/B1517 ; B4002/B5001 ; B3501/B4001 ; B3901/B3906 ; B1501/B4901 ; B0801/B5701 ; B3701/B4402 ; B3801/B4901 ; B5301/B5301 ; B2705/B3906 ; B1402/B3901 ; B3502/B3502 ; B1302/B1402 ; B1402/B3501 ; B1801/B5501 ; B0705/B3501 ; B1501/B4405 ; B2702/B5501 ; B4001/B4403 ; B0702/B4403 ; B0801/B5001 ; B0702/B1501 ; B1302/B1501 ; B1501/B4001 ; B0702/B5801 ; B4002/B4405 ; B0801/B1402 ; B0801/B2702 ; B3503/B4402 ; B1509/B4402 ; B1302/B5101 ; B0702/B2702 ; B5501/B5501 ; B4403/B5101 ; B1501/B4002 ; B0801/B1801 ; B1402/B4402 ; B1501/B3901 ; B5301/B5701 ; B1302/B4002 ; B1501/B1501 ; B0801/B5502 ; B0702/B0704 ; B2702/B4402 ; B0702/B4901 ; B1501/B5101 ; B0801/B3901 ; B1501/B4402 ; B0702/B4001 ; B1302/B5801 ; B4402/B5801 ; B4402/B5301 ; B3501/B3508 ; B0801/B4002 ; B4403/B5502 ; B1501/B5701 ; B4002/B4403 ; B1801/B5101 ; B1517/B4002 ; B0801/B5101 ; B2705/B4901 ; B3501/B5201 ; B1501/B4403 ; B3701/B5701 ; B1801/B2703 ; B0702/B5501 ; B0702/B5701 ; B3901/B4403 ; B2705/B5101 ; B4402/B4405 ; B5501/B5801 ; B0702/B3503 ; B0702/B3801 ; B3801/B5101 ; B1302/B5201 ; B3801/B5502 ; B1402/B2705 ; B0801/B3502 ; B2702/B2705 ; B1302/B3503 ; B1402/B4403 ; B1801/B4002 ; B3501/B3701 ; B0801/B3503
HLA_C	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Polysolver HLA-C	Sample	C0304/C0501 ; C0304/C0304 ; C0501/C0602 ; C0401/C1202 ; C0304/C1203 ; C0401/C0701 ; C0102/C0302 ; C1502/C1504 ; C0202/C0701 ; C0202/C0702 ; C0701/C0702 ; C0602/C0701 ; C0202/C0602 ; C0501/C0501 ; C0304/C1502 ; C1203/C1203 ; C0401/C1203 ; C0102/C0501 ; C0602/C0802 ; C0202/C1505 ; C0401/C0702 ; C0501/C0701 ; C0701/C0802 ; C0401/C0706 ; C0501/C0702 ; C0401/C0401 ; C1402/C1502 ; C0202/C0501 ; C0303/C0704 ; C0303/C0501 ; C0401/C1502 ; C1203/C1601 ; C0602/C1701 ; C0304/C0701 ; C0501/C1502 ; C0602/C1203 ; C0401/C0602 ; C0401/C1604 ; C0102/C0401 ; C0501/C0803 ; C0401/C0501 ; C0702/C1203 ; C0701/C1601 ; C0401/C1701 ; C0304/C0602 ; C0210/C0210 ; C0704/C0802 ; C0702/C0702 ; C0202/C0802 ; C0702/C1402 ; C0102/C0303 ; C0303/C0401 ; C0401/C0802 ; C0102/C0202 ; C0702/C0802 ; C0102/C0602 ; C0303/C0701 ; C0304/C0401 ; C0701/C1203 ; C0802/C1203 ; C0303/C1203 ; C0401/C1505 ; C0202/C0303 ; C0304/C1601 ; C0702/C1601 ; C0304/C0702 ; C0102/C0304 ; C0302/C0702 ; C0202/C0202 ; C0701/C0701 ; C0303/C0702 ; C0501/C0704 ; C0202/C0401 ; C0602/C1502 ; C0303/C0303 ; C1502/C1602 ; C0202/C0304 ; C0501/C0802 ; C0303/C0304 ; C0102/C0701 ; C1502/C1601 ; C0202/C0704 ; C0302/C0602 ; C0302/C0704 ; C0102/C1601 ; C0303/C0602 ; C0202/C1601 ; C0701/C1502 ; C0602/C0602 ; C0704/C1203 ; C0303/C1502 ; C0102/C1402 ; C0401/C1602 ; C1203/C1502 ; C0102/C1203 ; C0706/C1402 ; C0802/C1601
MUTATION_LOAD	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	Number of non-synonymous mutations	Sample	1974 ; 260 ; 267 ; 148 ; 519 ; 1271 ; 857 ; 595 ; 703 ; 204 ; 716 ; 2122 ; 722 ; 112 ; 266 ; 331 ; 405 ; 163 ; 1286 ; 1200 ; 933 ; 313 ; 863 ; 573 ; 606 ; 184 ; 729 ; 121 ; 252 ; 109 ; 486 ; 150 ; 4285 ; 365 ; 263 ; 1309 ; 604 ; 282 ; 2102 ; 590 ; 539 ; 334 ; 141 ; 2570 ; 562 ; 930 ; 503 ; 1389 ; 1228 ; 543 ; 627 ; 117 ; 399 ; 171 ; 531 ; 393 ; 1124 ; 216 ; 537 ; 25 ; 54 ; 1277 ; 80 ; 635 ; 6 ; 146 ; 451 ; 444 ; 1165 ; 358 ; 513 ; 39 ; 128 ; 3 ; 2 ; 1699 ; 323 ; 295 ; 1061 ; 37 ; 1148 ; 269 ; 1081 ; 525 ; 139 ; 1741 ; 277 ; 3267 ; 915 ; 38 ; 136 ; 256 ; 74 ; 156 ; 338 ; 594 ; 233 ; 372 ; 336 ; 174 ; 265 ; 50 ; 630 ; 35 ; 125 ; 30 ; 286 ; 1976 ; 6301 ; 317 ; 76 ; 689 ; 113 ; 301 ; 63 ; 482 ; 441 ; 397 ; 107 ; 110 ; 197 ; 102 ; 1862 ; 228 ; 238 ; 5120 ; 1429 ; 46 ; 326 ; 878 ; 542 ; 227 ; 242 ; 1754 ; 132 ; 471 ; 1911 ; 94 ; 69 ; 57 ; 33 ; 245 ; 219 ; 234 ; 99 ; 668 ; 89 ; 32 ; 470 ; 1375 ; 51 ; 750 ; 714 ; 15 ; 12 ; 108 ; 2398 ; 75 ; 345 ; 168 ; 937 ; 244 ; 137 ; 669 ; 866 ; 484 ; 44 ; 56 ; 1921 ; 273 ; 738 ; 1379 ; 209 ; 659 ; 327 ; 27 ; 77 ; 243 ; 509 ; 198 ; 375 ; 154 ; 321 ; 193 ; 111 ; 408 ; 62 ; 1597 ; 207 ; 0.807459635 ; 4.844757811 ; 1.61491927 ; 3.22983854 ; 7.267136716 ; 5.652217446 ; 2.422378905 ; 8.074596351 ; 4.037298175 ; 0 ; 8.882055986 ; 6.459677081 ; 11.30443489 ; 20.18649088 ; 13.7268138 ; 15.34173307 ; 45.21773957 ; 12.11189453 ; 25.83870832 ; 58.13709373 ; 33.10584504 ; 67.82660935 ; 25.03124869 ; 77.51612497 ; 12.91935416 ; 21.80141015 ; 9.689515621 ; 39.56552212 ; 59.752013 ; 33.91330467 ; 35.52822394 ; 18.57157161 ; 36.33568358 ; 58.94455336 ; 19.37903124 ; 427.146147 ; 42.79536066 ; 20.99395051 ; 10.49697526 ; 22.60886978 ; 24.22378905 ; 43.6028203 ; 140.4979765 ; 54.90725519 ; 41.18044139 ; 16.1491927 ; 26.64616796 ; 23.41632942 ; 29.8760065 ; 32.2983854 ; 46.83265884 ; 50.86995701 ; 62.1743919 ; 17.76411197 ; 48.44757811 ; 16.95665234 ; 44.41027993 ; 50.06249738 ; 57.32963409 ; 80.74596351 ; 27.45362759 ; 51.67741665 ; 62.98185154 ; 53.29233592 ; 41.98790102 ; 257.5796236 ; 96.89515621 ; 14.53427343 ; 78.3235846 ; 100.1249948 ; 34.72076431 ; 56.52217446 ; 28.26108723 ; 61.36693227 ; 113.0443489 ; 150.9949518 ; 103.3548333 ; 85.59072132 ; 37.95060285 ; 95.28023694 ; 89.6280195 ; 88.82055986 ; 55.71471482 ; 49.25503774 ; 52.48487628 ; 72.67136716 ; 79.93850387 ; 83.97580205 ; 66.21169008 ; 102.5473737 ; 98.51007548 ; 40.37298175 ; 38.75806248 ; 54.09979555 ; 65.40423044 ; 84.78326168 ; 30.68346613 ; 125.1562434 ; 67.01914971 ; 127.5786223 ; 132.4233802 ; 60.55947263 ; 73.47882679 ; 79.13104424 ; 31.49092577
NEOAGCNT	Black	Metastatic Melanoma (UCLA, Cell 2016)	NUMBER	Number of neoepitops per sample	Sample	2265 ; 100 ; 417 ; 143 ; 1014 ; 2814 ; 825 ; 528 ; 813 ; 227 ; 870 ; 4060 ; 1313 ; 224 ; 263 ; 330 ; 473 ; 219 ; 3197 ; 1238 ; 2012 ; 437 ; 334 ; 1051 ; 955 ; 350 ; 1491 ; 164 ; 372 ; 862 ; 230 ; 5072 ; 399 ; 444 ; 2473 ; 1201 ; 186 ; 1993 ; 358 ; 245 ; 217 ; 45 ; 2026 ; 450 ; 959 ; 425 ; 214 ; 413 ; 333 ; 666 ; 125 ; 344 ; 93 ; 529 ; 104 ; 1469 ; 123 ; 384 ; 10 ; 43 ; 960 ; 75 ; 764 ; 5 ; 268 ; 142 ; 561 ; 246 ; 864 ; 237 ; 294 ; 32 ; 7 ; 22 ; 3 ; 0 ; 801 ; 243 ; 187 ; 223 ; 591 ; 21 ; 112 ; 190 ; 909 ; 494 ; 105 ; 899 ; 178 ; 2611 ; 459 ; 492 ; 4 ; 42 ; 305 ; 30 ; 174 ; 540 ; 1515 ; 113 ; 131 ; 271 ; 167 ; 99 ; 311 ; 280 ; 26 ; 348 ; 66 ; 28 ; 1188 ; 3644 ; 139 ; 69 ; 549 ; 60 ; 201 ; 24 ; 255 ; 238 ; 62 ; 25 ; 85 ; 140 ; 74 ; 910 ; 114 ; 3166 ; 1918 ; 23 ; 257 ; 1063 ; 236 ; 1633 ; 77 ; 1606 ; 29 ; 76 ; 44 ; 27 ; 306 ; 59 ; 181 ; 40 ; 355 ; 416 ; 679 ; 13 ; 15 ; 508 ; 50 ; 8 ; 6 ; 2503 ; 89 ; 261 ; 713 ; 80 ; 323 ; 523 ; 483 ; 38 ; 1971 ; 309 ; 472 ; 1340 ; 48 ; 559 ; 242 ; 11 ; 726 ; 281 ; 611 ; 82 ; 251 ; 154 ; 96 ; 179 ; 239 ; 716 ; 115 ; 16
PREVIOUS_MAPKI	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Previous MAPKi treatment	Patient	
TREATMENT_RESPONSE	Black	Metastatic Melanoma (UCLA, Cell 2016)	STRING	Treatment Response	Sample ; Patient	Non-responder ; Responder
AJCC_7	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	AJCC 7th	Patient	
AJCC_8	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	AJCC 8th	Patient	
BONE	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Bone	Patient	
CNS	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	CNS?	Patient	
DMT_PRIMARY_SITE	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	DMT Primary Site	Sample	Skin, face ; Skin, external ear ; Skin, scalp ; Skin, neck ; Skin, eyelid ; Skin, lip ; Skin, trunk ; Skin, Site Unspecified ; Skin, arm/shoulder ; Skin, hand ; Skin, leg/hip ; Skin, foot ; Unknown Primary
DMT_PRIMARY_SITE_CLASSIFIED	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	DMT Primary Site, Classified	Sample	Head ; Trunk ; Upper Extremity ; Lower Extremity ; Unknown
DRIVER_CLASS	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Driver Class	Sample	NF1 ; Unknown_Driver ; BRAF_CLASS_1_Other ; Other_Driver ; NRAS_Q61 ; BRAF_CLASS_1_V600E ; KIT_PDGFRA ; BRAF_CLASS_2_3 ; RAS_OTHER
ECOG	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	ECOG	Patient	
LDH	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	LDH	Patient ; Sample	360 ; 832 ; 1403 ; 229 ; 385 ; 299 ; 204 ; 477 ; 1571 ; 342 ; 412 ; 191 ; 1692 ; 255 ; 214 ; 189 ; 136 ; 150 ; 256 ; 2844 ; 175 ; 783 ; 650
LDH_ABNL	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	LDH Abnl	Patient	
LDH_RATIO	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	LDH Ratio	Patient	
LIVER_METS	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Liver Mets	Patient	
LUNG	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Lung?	Patient	
NLR	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	NLR (neutrophil to lymphocyte ratio) in all treated patients	Patient	
NLR_GREATER_THAN_4_DOT_73	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	NLR >4.73?	Patient	
REC_GREATER_THAN_1_DOT_5	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	REC >=1.5% if mono tx	Patient	
RLC_GREATER_THAN_17_DOT_5	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	RLC >=17.5% if mono tx	Patient	
SIMPLIFIED_METASTATIC_SITE	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Simplified Metastatic Site	Sample	Liver ; LR / In-Transit / Regional LN ; Brain ; Soft Tissue / Distant LN ; Lung ; Other Visceral ; Bone
ULCERATION	Black	Melanoma (MSK, Clin Cancer Res 2021)	STRING	Ulceration: Yes/No/Unknown? NA if ocular, primary CNS, or unknown primary	Sample	No ; Yes ; Unknown ; [ERROR]
DNA_INPUT	Black	MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017)	NUMBER	DNA Input	Sample	250 ; 198 ; 50 ; 144 ; 234 ; 151.58 ; 236.6 ; 195 ; 125 ; 130.9 ; 240 ; 54.4 ; 225.4 ; 115.6 ; 90 ; 94.8 ; 65 ; 174.3 ; 212.5 ; 75 ; 84 ; 107 ; 114.24 ; 221.1 ; 54 ; 172.5 ; 245 ; 191.2 ; 200 ; 160 ; 185 ; 62.4 ; 197.2 ; 110 ; 133 ; 175 ; 225 ; 72.2 ; 105 ; 128.52 ; 150 ; 124 ; 211.5 ; 233 ; 70.85 ; 118.8 ; 73.6 ; 89.32 ; 231.88 ; 131.44 ; 78.54 ; 208 ; 116.6 ; 117.7 ; 137.5 ; 182 ; 133.56 ; 238.68 ; 60.5 ; 113 ; 121.8 ; 136 ; 103.68 ; 87.98 ; 158.08 ; 249.6 ; 215.8 ; 143.04 ; 118 ; 212 ; 63.6 ; 104.4 ; 247 ; 155 ; 185.6 ; 63.8 ; 72 ; 174.24 ; 161.2 ; 242 ; 137.8 ; 80 ; 77 ; 114 ; 243.8 ; 245.3 ; 244.2 ; 112.9 ; 96.2 ; 112.36 ; 95.76 ; 210 ; 150.3 ; 106 ; 207 ; 209 ; 145.6 ; 244.8 ; 140 ; 246.8 ; 100.65 ; 74.8 ; 219.1 ; 114.4 ; 203.5 ; 81.6 ; 210.1 ; 209.76 ; 181.5 ; 112.2 ; 190.3 ; 243.1 ; 56.5 ; 147.4 ; 121 ; 91 ; 143.5 ; 71.5 ; 115.2 ; 63.25 ; 64.2 ; 54.57 ; 159.6 ; 189 ; 82.8 ; 70.8 ; 102.6 ; 64 ; 141.6 ; 99 ; 84.6 ; 75.9 ; 108 ; 224.4 ; 176 ; 59.22 ; 75.6 ; 112.5 ; 58.85 ; 61.6 ; 135.3 ; 211 ; 226.6 ; 115 ; 128.26 ; 55 ; 86.14 ; 174 ; 76 ; 191.763 ; 73.7 ; 180.36 ; 82.5 ; 146.88 ; 100.98 ; 191.4 ; 177.6 ; 170 ; 109.8 ; 83.3 ; 124.3 ; 173.7 ; 235.32 ; 108.12 ; 148.4 ; 69 ; 107.87 ; 129.86 ; 130.8 ; 127.6 ; 213 ; 71.04 ; 226.2 ; 183.6 ; 85.26 ; 165.6 ; 79.2 ; 115.44 ; 188 ; 176.3 ; 176.4 ; 106.2 ; 89.09 ; 129.72 ; 218 ; 113.12 ; 102.29 ; 100 ; 161 ; 153 ; 125.4 ; 179.3 ; 220 ; 192 ; 116 ; 120 ; 129.8 ; 123.3 ; 141.955 ; 141.94 ; 132.65 ; 155.7 ; 101.2 ; 73.35 ; 190.4 ; 181.8 ; 192.5 ; 152.1 ; 142.5 ; 135 ; 216.7 ; 166.1 ; 186 ; 222 ; 145.2 ; 133.2 ; 164.4 ; 180.18 ; 175.14 ; 220.82 ; 157.76 ; 66.27 ; 111 ; 83.6 ; 187 ; 172.8 ; 91.98 ; 214.2 ; 236.5 ; 195.64 ; 105.86 ; 227.12 ; 189.6 ; 238 ; 74 ; 181.2 ; 123 ; 204.1 ; 238.5 ; 178.02 ; 60.9 ; 244.76 ; 69.85 ; 67.84 ; 95.19 ; 216.6 ; 211.12 ; 237.12 ; 69.3 ; 73.2 ; 248.4 ; 70.4 ; 154.8 ; 93.1 ; 188.1 ; 97.2 ; 66.5 ; 198.8 ; 246 ; 77.5 ; 172.7 ; 169 ; 124.8 ; 176.8 ; 126.5 ; 235.4 ; 111.6 ; 122.4 ; 148.5 ; 90.75 ; 66 ; 149.4 ; 136.8 ; 83.4 ; 188.4 ; 142 ; 162 ; 244 ; 236 ; 178.2 ; 155.1 ; 249.7 ; 226.8 ; 89.5 ; 151.2 ; 54.52 ; 81 ; 97.5 ; 132 ; 62.1 ; 81.45 ; 230.4 ; 246.6 ; 214.8 ; 142.8 ; 135.75 ; 147.74 ; 110.5 ; 156.2 ; 217 ; 171 ; 67 ; 185.92 ; 163 ; 157 ; 72.45 ; 61 ; 149 ; 105.6 ; 204.12 ; 86 ; 99.4 ; 232.2 ; 238.74 ; 165 ; 88.4 ; 134.82 ; 108.75 ; 102.05 ; 78.75 ; 119 ; 151 ; 79.65 ; 103 ; 206.8 ; 104.8 ; 179 ; 180 ; 112 ; 101 ; 218.4 ; 170.8 ; 219.7 ; 135.8 ; 199.1 ; 126 ; 211.2 ; 93.5 ; 194.9 ; 243.6 ; 228.6 ; 104 ; 221 ; 216 ; 82.2 ; 127.5 ; 131.56 ; 96.8 ; 119.9 ; 147 ; 133.9 ; 182.6 ; 122.1 ; 98.8 ; 213.2 ; 127 ; 69.55 ; 113.4 ; 94.05 ; 54.74 ; 140.22 ; 204 ; 89.4 ; 169.4 ; 133.1 ; 151.8 ; 233.2 ; 128.7 ; 233.6 ; 134.4 ; 146 ; 145.95 ; 245.7 ; 116.55 ; 64.32 ; 183.7 ; 60 ; 130 ; 76.5 ; 87.1 ; 214 ; 105.45 ; 147.84 ; 141 ; 206 ; 248.16 ; 129.28 ; 225.5 ; 235.2 ; 214.5 ; 131.04 ; 83.7 ; 248.06 ; 171.9 ; 214.56 ; 213.12 ; 157.68 ; 162.15 ; 87.9 ; 227.7 ; 230 ; 136.4 ; 69.2 ; 203.06 ; 154 ; 157.3 ; 96.5 ; 199.8 ; 141.9 ; 172.2 ; 159 ; 119.78 ; 137.24 ; 188.7 ; 101.7 ; 144.2 ; 166.5 ; 143.85 ; 117.65 ; 88 ; 192.08 ; 187.8 ; 176.88 ; 173.6 ; 91.8 ; 209.04 ; 107.21 ; 157.56 ; 218.3 ; 115.5 ; 241.5 ; 224 ; 144.32 ; 108.64 ; 133.85 ; 134.42 ; 235.52 ; 99.2 ; 61.2 ; 169.05 ; 173.8 ; 245.1 ; 130.02 ; 100.8 ; 170.1 ; 169.6 ; 182.7 ; 113.75 ; 135.45 ; 197.96 ; 83.72 ; 138.6 ; 166.95 ; 207.9 ; 144.5 ; 106.6 ; 228 ; 185.2 ; 235.8 ; 131.25 ; 232 ; 92.82 ; 94.5 ; 220.8 ; 101.12 ; 226 ; 217.6 ; 110.4 ; 122.85 ; 107.1 ; 72.1 ; 128 ; 152.8 ; 58.05 ; 145 ; 130.5 ; 190 ; 233.7 ; 159.3 ; 243.54 ; 166.68 ; 183.33 ; 167.2 ; 173.79 ; 104.76 ; 142.02 ; 182.34 ; 165.4 ; 148.2 ; 193 ; 224.37 ; 137.16 ; 204.126 ; 244.343 ; 140.16 ; 140.295 ; 191.68 ; 248.3 ; 114.6 ; 118.872 ; 197.184 ; 217.1 ; 229.245 ; 206.388 ; 198.815 ; 92.96 ; 111.86 ; 211.99 ; 242.925 ; 132.1 ; 243.746 ; 128.69 ; 215.86 ; 180.3 ; 168.66 ; 108.45 ; 117.18 ; 103.14 ; 195.21 ; 203.84 ; 75.06 ; 162.3 ; 235.17 ; 182.8 ; 161.352 ; 110.1 ; 157.7 ; 200.6 ; 127.33 ; 154.28 ; 110.175 ; 215.745 ; 185.44 ; 130.73 ; 151.47 ; 168 ; 137.465 ; 201.195 ; 150.45 ; 205.83 ; 142.2 ; 128.59 ; 164 ; 215.1 ; 159.222 ; 217.71 ; 68.72 ; 133.76 ; 158.7 ; 220.2 ; 222.3 ; 129.654 ; 143.325 ; 205.6 ; 78.5 ; 121.2 ; 234.8 ; 240.2 ; 207.7 ; 111.7 ; 243.3 ; 193.5 ; 224.49 ; 182.4 ; 164.5 ; 155.3 ; 76.8 ; 195.615 ; 216.9 ; 213.5 ; 200.34 ; 246.1 ; 151.29 ; 224.1 ; 182.1 ; 91.6 ; 222.7 ; 159.5 ; 183.4 ; 90.2 ; 233.3 ; 58.9 ; 139.5 ; 143.2 ; 200.8 ; 228.1 ; 165.06 ; 135.18 ; 226.7 ; 234.63 ; 130.68 ; 72.96 ; 115.74 ; 142.74 ; 107.4 ; 166.4 ; 163.9 ; 214.4 ; 118.75 ; 139 ; 81.9 ; 160.6 ; 193.2 ; 162.675 ; 128.1 ; 200.3 ; 247.85 ; 234.7 ; 147.6 ; 167.8 ; 80.35 ; 212.1 ; 166.6 ; 138 ; 135.6 ; 124.6 ; 241.6 ; 142.9 ; 122.2 ; 225.6 ; 91.85 ; 132.6 ; 216.5 ; 125.55 ; 204.75 ; 181.9 ; 100.4 ; 76.32 ; 134 ; 195.47 ; 183 ; 207.1 ; 100.1 ; 215.9 ; 172.665 ; 100.9 ; 245.5 ; 101.145 ; 198.1 ; 125.2 ; 131 ; 210.4 ; 56.87 ; 229.3 ; 109 ; 63.46 ; 116.4 ; 167.7 ; 185.9 ; 230.8 ; 120.6 ; 177.66 ; 197.7 ; 147.2 ; 158.5 ; 193.1 ; 224.6 ; 57.824 ; 161.8 ; 111.2 ; 134.3 ; 117.6 ; 170.4 ; 248.2 ; 124.1 ; 159.7 ; 146.2 ; 95 ; 135.7 ; 136.3 ; 216.3 ; 209.6 ; 77.58 ; 239.9 ; 93.275 ; 214.3 ; 137.3 ; 175.5 ; 117 ; 167.5 ; 238.9 ; 171.6 ; 64.435 ; 238.08 ; 159.04 ; 142.3 ; 69.625 ; 202.6 ; 73.152 ; 224.14 ; 171.8 ; 136.7 ; 132.4 ; 239.4 ; 108.775 ; 230.02 ; 105.3 ; 105.8 ; 208.8 ; 236.1 ; 163.4 ; 120.9 ; 223.132 ; 109.2 ; 136.9 ; 129 ; 93.15 ; 86.805 ; 193.95 ; 163.7 ; 228.5 ; 204.8 ; 148.6 ; 224.9 ; 88.56 ; 53.505 ; 134.8 ; 156.3 ; 142.6 ; 181.3 ; 188.6 ; 122 ; 203.3 ; 135.1 ; 95.4 ; 94 ; 62.9 ; 183.2 ; 117.3 ; 160.9 ; 202.8 ; 94.7 ; 107.6 ; 184.1 ; 201.066 ; 247.4 ; 78.585 ; 227.2 ; 139.9 ; 61.8 ; 129.9 ; 161.7 ; 193.6 ; 76.45 ; 143 ; 225.85 ; 88.38 ; 65.376 ; 158.6 ; 201.6 ; 200.5 ; 187.6 ; 173 ; 55.55 ; 171.4 ; 229.4 ; 87.78 ; 105.2 ; 151.42 ; 212.4 ; 247.41 ; 160.3 ; 217.7 ; 182.3 ; 224.7 ; 222.145 ; 226.1 ; 232.95 ; 209.055 ; 213.9 ; 231.7 ; 103.2 ; 108.2 ; 194.56 ; 93.6 ; 226.9 ; 143.4 ; 108.5 ; 97 ; 99.63 ; 56.154 ; 238.8 ; 208.1 ; 224.5 ; 99.96 ; 155.5 ; 195.7 ; 108.7 ; 200.4 ; 211.9 ; 221.7 ; 159.9 ; 140.5 ; 246.9 ; 157.1 ; 102.7 ; 197.5 ; 153.2 ; 228.9 ; 202.4 ; 192.6 ; 242.2 ; 197.9 ; 230.3 ; 131.6 ; 75.2 ; 214.7 ; 134.2 ; 161.28 ; 210.7 ; 90.6 ; 97.4 ; 92.6 ; 123.75 ; 70.453 ; 88.2 ; 129.4 ; 108.3 ; 116.7 ; 198.5 ; 203.8 ; 183.3 ; 192.7 ; 87.55 ; 236.94 ; 98 ; 189.7 ; 140.1 ; 59.34 ; 159.1 ; 233.9 ; 95.7 ; 140.4 ; 59.67 ; 157.6 ; 105.1 ; 102.2 ; 191 ; 203 ; 53.775 ; 231 ; 151.4 ; 96.25 ; 86.25 ; 201.1 ; 85.15 ; 195.1 ; 119.5 ; 228.8 ; 92.34 ; 232.3 ; 117.4 ; 93.3 ; 239.7 ; 80.28 ; 206.9 ; 135.09 ; 167.65 ; 247.2 ; 158.2 ; 145.7 ; 211.3 ; 181.1 ; 185.1 ; 152.5 ; 243.9 ; 127.764 ; 153.3 ; 133.84 ; 171.5 ; 245.9 ; 169.7 ; 205.5 ; 184.5 ; 218.6 ; 174.6 ; 141.33 ; 220.3 ; 133.4 ; 169.3 ; 129.1 ; 193.7 ; 103.5 ; 137.2 ; 156.9 ; 185.4 ; 136.2 ; 139.7 ; 170.9 ; 191.5 ; 195.3 ; 240.8 ; 176.9 ; 225.9 ; 171.215 ; 146.8 ; 117.9 ; 196.4 ; 106.9 ; 104.995
MATCHED_STATUS	Black	MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017)	STRING	Matched Status	Sample	Matched ; Unmatched
SAMPLE_COLLECTION_SOURCE	Black	MSK-IMPACT Clinical Sequencing Cohort (MSK, Nat Med 2017)	STRING	Sample Collection Source	Sample	Outside ; In-House
AGE_TESTING_YEARS	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	NUMBER	Age at Testing (Years)	Patient	
DIAGNOSTIC_CATEGORY	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	STRING	DIAGNOSTIC_CATEGORY	Sample	Sarcoma ; Renal ; Myeloid ; Lymphoid ; Germ cell ; Other- Solid Tumor ; Brain ; Adrenal ; Hepatic ; Germ Cell
GMED_OS_MONTHS	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	NUMBER	GMED Overall Survival Months	Patient	
NGS_TEST	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	STRING	Sample was NGS tested	Sample	RNA-seq ; Tumor-normal  WES; RNA-seq ; Tumor-normal  WES ; 467 cancer gene panel ; 467 cancer gene panel; RNA-seq
SAMPLE_TESTED_CATEGORY	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	STRING	Sample Tested Category	Sample	Primary disease ; Relapse/refractory
TISSUE_SEQUENCED	Black	Pediatric Pan-cancer (Columbia U, Genome Med 2016)	STRING	Tissue Sequenced	Sample	Lung ; Bone marrow ; Rib ; Spleen ; Sternum ; Peritoneum ; Femur ; Brain ; Lymph node ; Portal vein ; Liver ; Penis/scrotum ; Kidney ; Brain- vermis ; Lower back mass ; Myeloid Sarcoma-epidural tumor ; Diaphragmatic mass ; Anterior thigh ; Bone-rib ; Brain- frontal lobe ; Brain- midline mass ; Peri pancreatic lymph node ; Hepatic artery ; Abdominal wall soft tissue mass ; Pelvic lesion ; Multiple abdominal tumors, nos ; Peripheral blood ; Anterior chest wall ; Testis ; Brain- thalamus (biopsy) ; Brain- thalamus (excision) ; Soft tissue, left thigh ; Leg, left above the knee amputation ; Main pelvic mass ; Groin mass, left ; Bone- tibia ; Tumor not specified (nasopharyngeal/ sinus) ; Brain- pontine mass ; Scalp ; Pulmonary nodules ; Gallbladder ; Brain- mesial left temporal brain tumor ; Brain- 4th ventricle ; Thigh ; Bone- pelvis ; Placenta ; Soft tissue mass, unspecified site ; Brain- soft tissue mass-orbital excision ; Brain- optic nerve tumor ; Brain- cerebellopontine angle mass ; Brain- region of the pineal gland ; Brain- posterior fossa ; Brain- pons ; Pelvic soft tissue mass ; Brain- Broca's area ; Brain- suprasellar/ 3rdventricle region ; Pelvic mass ; Brain- frontal
AGE_START_IO	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	Age Start IO	Patient	
CENSORED	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	Survival Time Censored; True or False	Sample	LIVING ; DECEASED
DRUG_TYPE	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	What type of drug was administered?	Patient	
OTHER_CONCURRENT_THERAPY	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	Did the patient receive any other concurrent therapy	Patient	
P16_ISH	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	p16 ISH	Patient	
RECIST	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	RECIST Status	Patient	
ROH_RESPONSE	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	ROH Response	Patient	
SMOKING_PACK_YEARS	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	NUMBER	Numeric computed value to represent lifetime tobacco exposure defined as number of cigarettes smoked per day x number of years smoked divided by 20.	Patient	
VA_RESPONSE	Black	MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)	STRING	VA Response	Patient	
APC_CLUSTER	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	APC Cluster	Sample	1 ; 0
BIOPSY_SITE	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	Biopsy Site	Sample	Liver ; Skin ; Dura ; Shoulder ; Subq Nodule ; Lymph Node ; Lung ; Chest Wall ; Subq Abdom. Mass ; Forearm Mass ; Retroperitoneum ; Pancreas ; Breast ; Bone ; Hip ; Thyroid ; Adrenal ; Neck ; Vertebra ; Esophagus ; Buttock ; Colon ; Mandible ; Periaortic Mass ; Abdom. Wall ; Unknown ; Thoracic Epidural ; Paraspinal Mass ; Thymus ; Cheek ; Brain ; Bladder ; Epidural ; Rectus Muscle ; Pelvis ; Tongue ; Pelvic Mass ; Peritoneum ; Pleura ; Gluteus Muscle ; ULMS Abdomen ; Gluteal Mass ; Subq Nodule (Arm) ; Peritoneal Fluid ; Subcut. Abdomen ; Subcut. Periumbilical ; Acetabulum ; Lung Nodule ; Perirectal Mass ; Thigh ; Chest Wall Nodule ; Parotid ; Omentum ; Hilum ; Abdom. Nodule ; Skin Punch ; Sternal Mass ; Infraclavicular Mass ; Abdom. Mass ; Subq ; Neck Mass ; Subq Chest Wall ; Shoulder Mass ; Pleural Mass ; Back ; Thigh Mass ; Scapular Mass ; Submandible ; Mesenteric Mass ; Peritoneal Nodule ; MISC ; Psoas Muscle ; Ovary ; Thoracic Fluid ; Hip Lesion ; Axillary Mass ; Omental Mass ; Cervix ; Spinal Mass ; Lacrimal Gland ; Prostate ; Arm ; Sphenoid Sinus ; skin ; brain ; lymph node ; adrenal gland ; soft tissue ; nasal cavity ; stomach ; lung ; liver ; maxillary sinus, hard palate ; intestinal metastasis ; rectal/anal ; colon ; pancreas ; Sinus ; Bone Marrow ; Abdominal Wall ; Chest wall ; Trachea ; Vagina ; Rectroperitoneum ; Neck mass ; Upper Back Mass ; Spine ; Abdominal Mass ; Peritoneal Mass ; Lower Back ; Rectum ; Maxilla ; Flank Mass ; Scapula Mass ; Mediastinal Lesion ; Skull Base ; Sternal ; Vaginal Vault ; Scalp ; Bronchus ; Perirenal space ; Intranasal ; Sternal mass ; Pericecal Mass ; Masticular Space ; Rib ; Peripheral Blood ; Sacrum ; Vaginal Wall ; Epigastric mass ; Oral Cavity ; Pancreatic Mass ; Orbital mass ; Gluteus medius ; Diaphragm ; Abdomen ; Intracranial tumor ; Stomach ; Supraclavicular Mass ; Leg ; Groin ; Calf ; Submandibular Gland ; Sternum ; Spleen
IMMUNE_CLUSTER	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	Immune Cluster	Sample	5 ; 7 ; 1 ; 6 ; 2 ; 3
INFILTRATION_NOMINATION	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	Infiltration Nomination	Sample	positive ; negative
INTERVAL_MONTHS	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	Time in nearest month of interval between initial diagnosis of primary cancer and biopsy of metastatic site used in this study	Patient	
MIMM_SCORE	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	Mimm Score	Sample	154.2 ; 129.5 ; 195.4 ; -180 ; 147.4 ; -144.1 ; -182.2 ; -149 ; 159.1 ; -187.4 ; -152.6 ; -135.5 ; 170.1 ; 74.8
NUM_TCRB_CLONES	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	# TCRb clones	Sample	3768 ; 35432 ; 13200 ; 1969 ; 33552 ; 6285 ; 2907 ; 920 ; 12557 ; 802 ; 3587 ; 960 ; 21099 ; 21684
NUM_TCRB_TEMPLATE	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	# TCRb templates	Sample	66695 ; 174078 ; 87642 ; 3483 ; 274016 ; 16901 ; 4917 ; 1111 ; 121675 ; 1295 ; 7697 ; 1695 ; 105473 ; 93459
OTHER_CANCER_HISTORY	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	Other Cancer History	Patient	
PRIOR_THERAPY	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	Systemic or radiation therapy in the interval between initial diagnosis and metastatic biopsy	Patient	
STROMA_SCORE	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	STROMA Score	Sample	74.8 ; 60.7 ; 67.6 ; -169.4 ; -38.4 ; -79.7 ; -64.1 ; -58.4 ; 6.3 ; -65.8 ; -70.6 ; -134.5 ; 8.7 ; 39.9
TUMOR_CONTENT	Black	Metastatic Solid Cancers (UMich, Nature 2017)	NUMBER	Tumor Content	Sample	0.58 ; 0.35 ; 0.69 ; 0.3 ; 0.52 ; 0.34 ; 0.86 ; 0.42 ; 0.25 ; 0.6 ; 0.85 ; 0.54 ; 73 ; 59 ; 43 ; 60 ; 100 ; 50 ; 47 ; 57 ; 70 ; 30 ; 29 ; 56 ; 81 ; 44 ; 62 ; 90 ; 46 ; 55 ; 45 ; 24 ; 35 ; 80 ; 63 ; 84 ; 40 ; 72 ; 86 ; 76 ; 64 ; 69 ; 82 ; 20 ; 17 ; 42 ; 65 ; 61 ; 41 ; 54 ; 52 ; 66 ; 75 ; 48 ; 87 ; 77 ; 31 ; 83 ; 67 ; 68 ; 51 ; 79 ; 94 ; 34 ; 32 ; 78 ; 36 ; 71 ; 92 ; 85 ; 49 ; 25 ; 74 ; 39 ; 89 ; 26 ; 37 ; 38 ; 97 ; 58 ; 53 ; 91 ; 22 ; 95 ; 33 ; 23 ; 99 ; 28 ; 27 ; 88 ; 96 ; 98 ; 93 ; 21
T_CELL_CLUSTER	Black	Metastatic Solid Cancers (UMich, Nature 2017)	STRING	T-cell Cluster	Sample	1 ; 0
ACCESS	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	MSK-ACCESS Targeted cfDNA Sequencing Data	Patient	
ACCESS_TIMEPOINTS	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	cfDNA Longitudinal Sequencing Data	Patient	
ALT_TYPE	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Enrolled RET Alteration Type	Patient	
EXOME_DATA	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Whole Exome Tissue Sequencing Data	Patient	
IMPACT_DATA	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	MSK-IMPACT Targeted Tissue Sequencing Data	Patient	
MSI	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	NUMBER	MSI score	Patient	
ONCOTREE_PATIENT	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Oncotree Patient	Patient	
ONGOING_STATUS	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	BOOLEAN	Status of Patients Ongoing Treatment	Patient	
OVERALL_RESPONSE	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Overall Response	Patient	
PFS	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	NUMBER	Progression Free Survival (Weeks)	Patient	
POST_PROGRESSION	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Tissue Post-Progression Sequencing Data	Patient	
PRIOR_LINES	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	NUMBER	Number of Prior Lines of Therapy	Patient	
PRIOR_MKI	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	BOOLEAN	Received Prior MKI Therapy	Patient	
RET_AF	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	NUMBER	Allele Frequency of Enrolling RET Alteration in Baseline Plasma	Patient	
RET_ALT	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Specific RET Alteration	Patient	
SMOKING_STATUS	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Patient Smoking Status	Patient	
SOURCE_TYPE	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Source type defines where the sample is coming from , ex: Blood, bone marrow . etc	Sample	Tissue ; Plasma
TIMEPOINT	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	STRING	Timepoint of Sample	Sample	Pre-treatment ; Baseline ; C2 ; C3 ; Post-treatment ; C4 ; C5 ; C6 ; C7
WEEKS_ON_TREATMENT	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	NUMBER	Weeks on Treatment with Selpercatinib	Patient	
WGD	Black	Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)	BOOLEAN	Whole Genome Duplication	Patient ; Sample	wgd ; no_wgd
COLLAB_ID	Black	Mixed cfDNA (MSK, Genome Med 2021)	STRING	Collaboration id.	Sample	DS_fastcf_120_MZ ; DS_FastCF120_CFDNA01 ; DS_fastcf_043_M1Z ; DS_fastcf_043_M2Z ; DS_FastCF043_CFDNA01 ; DS_fastcf_007_MZ ; DS_FastCF007_CFDNA01 ; DS_fastcf_009_PZ ; DS_FastCF009_CFDNA01 ; DS_fastcf_124_MZ ; DS_fastcf_124_PZ ; DS_FastCF124_CFDNA01 ; DS_fastcf_023_MZ ; DS_fastcf_023_PZ ; DS_FastCF023_CFDNA01 ; DS_fastcf_097_PZ ; DS_FastCF097_CFDNA01 ; DS_fastcf_098_PZ ; DS_FastCF098_CFDNA01 ; DS_fastcf_014_M1Z ; DS_fastcf_014_M2Z ; DS_fastcf_014_M3Z ; DS_FastCF014_CFDNA01 ; DS_fastcf_096_PZ ; DS_FastCF096_CFDNA01 ; DS_fastcf_003_MZ ; DS_FastCF003_CFDNA01 ; DS_fastcf_004_MZ ; DS_FastCF004_CFDNA01 ; DS_fastcf_079_PZ ; DS_FastCF079_CFDNA01 ; DS_fastcf_029_PZ ; DS_FastCF029_CFDNA01 ; DS_fastcf_005_MZ ; DS_FastCF005_CFDNA01 ; DS_fastcf_031_PZ ; DS_FastCF031_CFDNA01 ; DS_fastcf_107_MZ ; DS_FastCF107_CFDNA01 ; DS_fastcf_042_PZ ; DS_FastCF042_CFDNA01 ; DS_fastcf_047_PZ ; DS_fastcf_047_M1Z ; DS_fastcf_047_M2Z ; DS_FastCF047_CFDNA01 ; DS_fastcf_025_PZ ; DS_FastCF025_CFDNA01 ; DS_fastcf_057_MZ ; DS_FastCF057_CFDNA01 ; DS_fastcf_125_MZ ; DS_FastCF125_CFDNA01 ; DS_fastcf_016_MZ ; DS_fastcf_016_PZ ; DS_FastCF016_CFDNA01 ; DS_fastcf_072_PZ ; DS_FastCF072_CFDNA01 ; DS_fastcf_055_MZ ; DS_FastCF055_CFDNA01 ; DS_fastcf_104_MZ ; DS_FastCF104_CFDNA01 ; DS_fastcf_076_P2Z ; DS_FastCF076_CFDNA01 ; DS_fastcf_061_PZ ; DS_FastCF061_CFDNA01 ; DS_fastcf_028_MZ ; DS_fastcf_028_P1Z ; DS_FastCF028_CFDNA01 ; DS_fastcf_054_PZ ; DS_fastcf_054_MZ ; DS_FastCF054_CFDNA01 ; DS_fastcf_011_PZ ; DS_FastCF011_CFDNA01 ; DS_fastcf_006_PZ ; DS_FastCF006_CFDNA01 ; DS_fastcf_039_PZ ; DS_FastCF039_CFDNA01 ; DS_fastcf_010_PZ ; DS_FastCF010_CFDNA01 ; DS_fastcf_012_MZ ; DS_FastCF012_CFDNA01 ; DS_fastcf_105_PZ ; DS_FastCF105_CFDNA01 ; DS_fastcf_052_M1Z ; DS_fastcf_052_M2Z ; DS_FastCF052_CFDNA01 ; DS_fastcf_017_PZ ; DS_FastCF017_CFDNA01 ; DS_fastcf_002_PZ ; DS_FastCF002_CFDNA01 ; DS_fastcf_056_MZ ; DS_FastCF056_CFDNA01 ; DS_fastcf_078_MZ ; DS_FastCF078_CFDNA01 ; DS_fastcf_038_PZ ; DS_FastCF038_CFDNA01 ; DS_fastcf_100_MZ ; DS_fastcf_100_PZ ; DS_FastCF100_CFDNA01 ; DS_fastcf_030_PZ ; DS_FastCF030_CFDNA01 ; DS_fastcf_050_PZ ; DS_FastCF050_CFDNA01 ; DS_FastCF099_CFDNA01 ; DS_fastcf_128_MZ ; DS_FastCF128_CFDNA01 ; DS_fastcf_026_PZ ; DS_FastCF026_CFDNA01 ; DS_fastcf_112_PZ ; DS_FastCF112_CFDNA01 ; DS_fastcf_111_MZ ; DS_FastCF111_CFDNA01 ; DS_fastcf_063_MZ ; DS_FastCF063_CFDNA01 ; DS_fastcf_022_PZ ; DS_FastCF022_CFDNA01 ; DS_fastcf_001_PZ ; DS_FastCF001_CFDNA01 ; DS_fastcf_075_PZ ; DS_FastCF075_CFDNA01 ; DS_fastcf_114_PZ ; DS_FastCF114_CFDNA01 ; DS_fastcf_032_MZ ; DS_FastCF032_CFDNA01 ; DS_fastcf_020_PZ ; DS_FastCF020_CFDNA01 ; DS_fastcf_048_MZ ; DS_FastCF048_CFDNA01 ; DS_FastCF048_CFDNA02 ; DS_fastcf_066_MZ ; DS_FastCF066_CFDNA01 ; DS_fastcf_019_PZ ; DS_FastCF019_CFDNA01 ; DS_fastcf_036_MZ ; DS_FastCF036_CFDNA01 ; DS_fastcf_062_PZ ; DS_FastCF062_CFDNA01 ; DS_fastcf_065_PZ ; DS_FastCF065_CFDNA01 ; DS_fastcf_049_MZ ; DS_FastCF049_CFDNA01 ; DS_fastcf_045_MZ ; DS_FastCF045_CFDNA01 ; DS_fastcf_070_PZ ; DS_FastCF070_CFDNA01 ; DS_fastcf_037_PZ ; DS_FastCF037_CFDNA01 ; DS_fastcf_073_MZ ; DS_FastCF073_CFDNA01 ; DS_fastcf_046_MZ ; DS_FastCF046_CFDNA01 ; DS_FastCF018_CFDNA01 ; DS_fastcf_089_PZ ; DS_FastCF089_CFDNA01 ; DS_fastcf_077_MZ ; DS_FastCF077_CFDNA01 ; DS_fastcf_102_PZ ; DS_FastCF102_CFDNA01 ; DS_fastcf_083_MZ ; DS_FastCF083_CFDNA01 ; DS_fastcf_081_MZ ; DS_FastCF081_CFDNA01 ; DS_fastcf_101_MZ ; DS_FastCF101_CFDNA01 ; DS_fastcf_080_TZ ; DS_FastCF080_CFDNA01 ; DS_fastcf_103_MZ ; DS_FastCF103_CFDNA01 ; DS_fastcf_127_MZ ; DS_FastCF127_CFDNA01 ; DS_fastcf_074_PZ ; DS_FastCF074_CFDNA01 ; DS_fastcf_091_MZ ; DS_FastCF091_CFDNA01 ; DS_fastcf_108_PZ ; DS_FastCF108_CFDNA01 ; DS_fastcf_109_PZ ; DS_FastCF109_CFDNA01 ; DS_fastcf_123_PZ ; DS_FastCF123_CFDNA01 ; DS_fastcf_094_MZ ; DS_FastCF094_CFDNA01 ; DS_FastCF113_CFDNA01 ; DS_FastCF121_CFDNA01 ; DS_FastCF130_CFDNA01 ; DS_FastCF119_CFDNA01 ; DS_FastCF115_CFDNA01 ; DS_FastCF117_CFDNA01 ; DS_FastCF068_CFDNA01 ; DS_FastCF008_CFDNA01 ; DS_FastCF013_CFDNA01 ; DS_FastCF015_CFDNA01 ; DS_FastCF021_CFDNA01 ; DS_FastCF024_CFDNA01 ; DS_FastCF027_CFDNA01 ; DS_FastCF033_CFDNA01 ; DS_FastCF034_CFDNA01 ; DS_FastCF035_CFDNA01 ; DS_FastCF041_CFDNA01 ; DS_FastCF058_CFDNA01 ; DS_FastCF067_CFDNA01 ; DS_FastCF071_CFDNA01 ; DS_FastCF082_CFDNA01 ; DS_FastCF084_CFDNA01 ; DS_FastCF085_CFDNA01 ; DS_FastCF086_CFDNA01 ; DS_FastCF087_CFDNA01 ; DS_FastCF088_CFDNA01 ; DS_FastCF090_CFDNA01 ; DS_FastCF092_CFDNA01 ; DS_FastCF093_CFDNA01 ; DS_FastCF095_CFDNA01 ; DS_FastCF122_CFDNA01 ; DS_FastCF126_CFDNA01 ; DS_FastCF129_CFDNA01
ALKYLATING_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Alkylating agent treatment prior to sequencing	Patient	
ALL_TX_AT_MSK	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Whether the patient received all cancer threrapy at MSKCC	Patient	
ANTHRACYCLINE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Anthracycline treatment prior to sequencing	Patient	
ANTIMETABOLITE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Anitimetabolite treatment prior to sequencing	Patient	
CARBOPLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Carboplatin treatment prior to sequencing	Patient	
CHEMO_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Chemotherapy treatment prior to sequencing	Patient	
CISPLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Cisplatin treatment prior to sequencing	Patient	
CYTOTOXIC_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Cytotoxic Chemotherapy Treatment prior to sequencing	Patient	
EQD_TERTILES	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	EQD tertiles	Patient	
FOLIC_ACID_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Folic acid analog treatment prior to sequencing	Patient	
IO_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Immunotherapy prior to sequencing	Patient	
MICROTUBULE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Microtubule damaging agent (other than Taxane) prior to sequencing	Patient	
NUCLEOSIDE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Nucleoside treatment prior to sequencing	Patient	
OTHER_CYTOTOXIC_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Other cytotoxic treatment prior to sequencing	Patient	
OXALIPLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Oxaliplatin treatment prior to sequencing	Patient	
PLATINUM_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Platinum treatment prior to sequencing	Patient	
RADIOTHERAPY_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Radioisotope treatment prior to sequencing	Patient	
TARGETED_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Targeted therapy prior to sequencing	Patient	
TAXANE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Taxane treatment prior to sequencing	Patient	
TERT_ALKYLATING_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to alkylatin agent	Patient	
TERT_ANTHRACYCLINE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to anthracycline	Patient	
TERT_ANTIMETABOLITE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to antimetabolite	Patient	
TERT_CARBOLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to carboplatin	Patient	
TERT_CISPLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to cisplatin	Patient	
TERT_CYTOTOXIC_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to cytotoxic therapy	Patient	
TERT_IO_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to immunotherapy	Patient	
TERT_MICROTUBULE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to microtubule damaging agent	Patient	
TERT_OTHER_CYTOTOXIC_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to other cytotoxic therapy	Patient	
TERT_OXALIPLATIN_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to oxaliplatin	Patient	
TERT_PLATINUM_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to platinum	Patient	
TERT_TARGETED_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to targeted therapy	Patient	
TERT_TAXANE_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to taxane	Patient	
TERT_TOPO_II_INH_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to topoisomerase II inhibitor	Patient	
TERT_TOPO_I_INH_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Tertiles of cumulative exposure to topoisomerase I inhibitor	Patient	
TIME_FROM_DX_TO_SEQ	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	NUMBER	Time from Diagnosis to sequencing (days)	Patient	
TIME_TO_BLOOD_DRAW_FROM_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	NUMBER	From time of end of cytotoxic therapy to MSK-IMPACT blood draw (in days)	Patient	
TOPO_II_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Toposiomerase II treatment prior to sequencing	Patient	
TOPO_I_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Toposiomerase I treatment prior to sequencing	Patient	
XRT_TX	Black	Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)	STRING	Radiation therapy prior to sequencing	Patient	
AGE_AT_DEATH	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Age at Death	Patient	
AGE_AT_EVIDENCE_OF_METS	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Age at First Mets Dx	Patient	
AGE_AT_LAST_CONTACT	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Age at Last Contact	Patient	
AGE_AT_SEQUENCING	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Age at Sequencing	Patient	
AGE_AT_SURGERY	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Surgical Procedure Age	Patient	
DMETS_DX_ADRENAL_GLAND	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Adrenal Gland	Sample	No ; Yes
DMETS_DX_BILIARY_TRACT	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Biliary tract	Sample	No ; Yes
DMETS_DX_BLADDER_UT	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Bladder/UT	Sample	No ; Yes
DMETS_DX_BONE	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Bone	Sample	Yes ; No
DMETS_DX_BOWEL	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Bowel	Sample	No ; Yes
DMETS_DX_BREAST	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Breast	Sample	No ; Yes
DMETS_DX_CNS_BRAIN	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: CNS/Brain	Sample	No ; Yes
DMETS_DX_DIST_LN	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Distant LN	Sample	No ; Yes
DMETS_DX_FEMALE_GENITAL	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Female Genital	Sample	No ; Yes
DMETS_DX_HEAD_NECK	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Head and Neck	Sample	No ; Yes
DMETS_DX_INTRA_ABDOMINAL	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Intra-Abdominal	Sample	No ; Yes
DMETS_DX_KIDNEY	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Kidney	Sample	No ; Yes
DMETS_DX_LIVER	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Liver	Sample	Yes ; No
DMETS_DX_LUNG	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Lung	Sample	No ; Yes
DMETS_DX_MALE_GENITAL	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Male Genital	Sample	No ; Yes
DMETS_DX_MEDIASTINUM	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Mediastinum	Sample	No ; Yes
DMETS_DX_OVARY	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Ovary	Sample	No ; Yes
DMETS_DX_PLEURA	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Pleura	Sample	No ; Yes
DMETS_DX_PNS	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: PNS	Sample	No ; Yes
DMETS_DX_SKIN	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Skin	Sample	No ; Yes
DMETS_DX_UNSPECIFIED	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Distant Metastasis at Diagnosis: Unspecified	Sample	No ; Yes
FGA	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	FGA	Sample	0.278 ; 0.35 ; 0.388 ; 0.102 ; 0.42 ; 0.029 ; 0.159 ; 0.148 ; 0.182 ; 0.404 ; 0.21 ; 0.451 ; 0.343 ; 0.216 ; 0.069 ; 0.532 ; 0.001 ; 0.377 ; 0.407 ; 0.505 ; 0.098 ; 0.447 ; 0.724 ; 0.005 ; 0.05 ; 0.337 ; 0 ; 0.324 ; 0.361 ; 0.28 ; 0.004 ; 0.065 ; 0.345 ; 0.229 ; 0.585 ; 0.2 ; 0.41 ; 0.127 ; 0.136 ; 0.288 ; 0.473 ; 0.247 ; 0.358 ; 0.374 ; 0.187 ; 0.034 ; 0.264 ; 0.231 ; 0.596 ; 0.072 ; 0.363 ; 0.035 ; 0.335 ; 0.276 ; 0.201 ; 0.509 ; 0.003 ; 0.403 ; 0.268 ; 0.008 ; 0.032 ; 0.087 ; 0.45 ; 0.626 ; 0.57 ; 0.03 ; 0.604 ; 0.546 ; 0.013 ; 0.147 ; 0.113 ; 0.313 ; 0.141 ; 0.548 ; 0.197 ; 0.167 ; 0.101 ; 0.135 ; 0.507 ; 0.351 ; 0.464 ; 0.1 ; 0.485 ; 0.294 ; 0.06 ; 0.306 ; 0.194 ; 0.047 ; 0.041 ; 0.11 ; 0.122 ; 0.169 ; 0.238 ; 0.398 ; 0.29 ; 0.042 ; 0.056 ; 0.105 ; 0.158 ; 0.154 ; 0.319 ; 0.064 ; 0.23 ; 0.272 ; 0.375 ; 0.002 ; 0.048 ; 0.198 ; 0.309 ; 0.088 ; 0.007 ; 0.408 ; 0.468 ; 0.496 ; 0.01 ; 0.235 ; 0.109 ; 0.483 ; 0.13 ; 0.37 ; 0.02 ; 0.225 ; 0.052 ; 0.617 ; 0.16 ; 0.082 ; 0.08 ; 0.19 ; 0.024 ; 0.053 ; 0.12 ; 0.17 ; 0.207 ; 0.52 ; 0.489 ; 0.366 ; 0.355 ; 0.559 ; 0.316 ; 0.107 ; 0.534 ; 0.575 ; 0.093 ; 0.028 ; 0.253 ; 0.426 ; 0.263 ; 0.455 ; 0.145 ; 0.009 ; 0.061 ; 0.564 ; 0.378 ; 0.312 ; 0.143 ; 0.121 ; 0.627 ; 0.084 ; 0.178 ; 0.033 ; 0.224 ; 0.171 ; 0.168 ; 0.138 ; 0.118 ; 0.615 ; 0.233 ; 0.629 ; 0.115 ; 0.199 ; 0.425 ; 0.213 ; 0.222 ; 0.083 ; 0.221 ; 0.318 ; 0.243 ; 0.185 ; 0.554 ; 0.091 ; 0.449 ; 0.572 ; 0.586 ; 0.484 ; 0.422 ; 0.179 ; 0.126 ; 0.054 ; 0.09 ; 0.471 ; 0.176 ; 0.214 ; 0.152 ; 0.362 ; 0.164 ; 0.326 ; 0.142 ; 0.058 ; 0.651 ; 0.401 ; 0.348 ; 0.018 ; 0.568 ; 0.051 ; 0.117 ; 0.133 ; 0.271 ; 0.537 ; 0.571 ; 0.446 ; 0.731 ; 0.174 ; 0.421 ; 0.006 ; 0.15 ; 0.267 ; 0.017 ; 0.277 ; 0.116 ; 0.612 ; 0.239 ; 0.217 ; 0.282 ; 0.021 ; 0.391 ; 0.044 ; 0.3 ; 0.205 ; 0.252 ; 0.108 ; 0.274 ; 0.33 ; 0.325 ; 0.828 ; 0.131 ; 0.016 ; 0.569 ; 0.752 ; 0.365 ; 0.081 ; 0.339 ; 0.156 ; 0.296 ; 0.175 ; 0.094 ; 0.273 ; 0.103 ; 0.165 ; 0.698 ; 0.144 ; 0.31 ; 0.139 ; 0.012 ; 0.266 ; 0.111 ; 0.69 ; 0.527 ; 0.261 ; 0.248 ; 0.303 ; 0.162 ; 0.346 ; 0.307 ; 0.18 ; 0.025 ; 0.699 ; 0.477 ; 0.046 ; 0.616 ; 0.285 ; 0.384 ; 0.149 ; 0.432 ; 0.563 ; 0.53 ; 0.561 ; 0.074 ; 0.038 ; 0.24 ; 0.155 ; 0.415 ; 0.031 ; 0.441 ; 0.204 ; 0.151 ; 0.097 ; 0.092 ; 0.218 ; 0.071 ; 0.467 ; 0.397 ; 0.383 ; 0.057 ; 0.512 ; 0.086 ; 0.011 ; 0.328 ; 0.059 ; 0.157 ; 0.068 ; 0.259 ; 0.14 ; 0.269 ; 0.302 ; 0.368 ; 0.573 ; 0.414 ; 0.593 ; 0.495 ; 0.372 ; 0.055 ; 0.132 ; 0.022 ; 0.26 ; 0.327 ; 0.474 ; 0.511 ; 0.416 ; 0.396 ; 0.049 ; 0.037 ; 0.244 ; 0.22 ; 0.386 ; 0.265 ; 0.075 ; 0.55 ; 0.219 ; 0.304 ; 0.334 ; 0.502 ; 0.166 ; 0.232 ; 0.744 ; 0.078 ; 0.323 ; 0.452 ; 0.317 ; 0.297 ; 0.394 ; 0.613 ; 0.393 ; 0.523 ; 0.341 ; 0.189 ; 0.291 ; 0.364 ; 0.338 ; 0.524 ; 0.043 ; 0.44 ; 0.195 ; 0.254 ; 0.436 ; 0.513 ; 0.293 ; 0.315 ; 0.128 ; 0.036 ; 0.56 ; 0.508 ; 0.494 ; 0.618 ; 0.181 ; 0.193 ; 0.461 ; 0.275 ; 0.137 ; 0.504 ; 0.321 ; 0.874 ; 0.095 ; 0.322 ; 0.039 ; 0.333 ; 0.332 ; 0.486 ; 0.344 ; 0.026 ; 0.129 ; 0.646 ; 0.498 ; 0.234 ; 0.649 ; 0.347 ; 0.588 ; 0.657 ; 0.628 ; 0.153 ; 0.027 ; 0.123 ; 0.188 ; 0.553 ; 0.371 ; 0.367 ; 0.389 ; 0.457 ; 0.466 ; 0.488 ; 0.54 ; 0.203 ; 0.472 ; 0.395 ; 0.112 ; 0.206 ; 0.439 ; 0.287 ; 0.58 ; 0.242 ; 0.51 ; 0.84 ; 0.49 ; 0.106 ; 0.48 ; 0.079 ; 0.551 ; 0.331 ; 0.716 ; 0.381 ; 0.662 ; 0.209 ; 0.099 ; 0.541 ; 0.706 ; 0.305 ; 0.134 ; 0.015 ; 0.707 ; 0.349 ; 0.186 ; 0.191 ; 0.435 ; 0.409 ; 0.286 ; 0.605 ; 0.685 ; 0.539 ; 0.192 ; 0.756 ; 0.599 ; 0.445 ; 0.211 ; 0.227 ; 0.226 ; 0.714 ; 0.249 ; 0.045 ; 0.419 ; 0.841 ; 0.369 ; 0.281 ; 0.948 ; 0.591 ; 0.417 ; 0.256 ; 0.063 ; 0.652 ; 0.517 ; 0.34 ; 0.418 ; 0.702 ; 0.863 ; 0.607 ; 0.014 ; 0.262 ; 0.39 ; 0.491 ; 0.085 ; 0.329 ; 0.469 ; 0.816 ; 0.125 ; 0.402 ; 0.428 ; 0.405 ; 0.236 ; 0.077 ; 0.212 ; 0.279 ; 0.674 ; 0.36 ; 0.353 ; 0.442 ; 0.514 ; 0.519 ; 0.636 ; 0.833 ; 0.692 ; 0.584 ; 0.119 ; 0.543 ; 0.215 ; 0.173 ; 0.223 ; 0.382 ; 0.096 ; 0.497 ; 0.518 ; 0.163 ; 0.944 ; 0.516 ; 0.228 ; 0.609 ; 0.574 ; 0.255 ; 0.311 ; 0.478 ; 0.622 ; 0.578 ; 0.775 ; 0.871 ; 0.184 ; 0.413 ; 0.062 ; 0.208 ; 0.429 ; 0.566 ; 0.25 ; 0.795 ; 0.88 ; 0.257 ; 0.289 ; 0.124 ; 0.677 ; 0.582 ; 0.434 ; 0.59 ; 0.769 ; 0.172 ; 0.746 ; 0.506 ; 0.587 ; 0.594 ; 0.379 ; 0.601 ; 0.237 ; 0.64 ; 0.937 ; 0.066 ; 0.073 ; 0.301 ; 0.999 ; 0.655 ; 0.202 ; 0.773 ; 0.454 ; 0.38 ; 0.492 ; 0.284 ; 0.708 ; 0.019 ; 0.411 ; 0.621 ; 0.356 ; 0.241 ; 0.608 ; 0.799 ; 0.759 ; 0.399 ; 0.336 ; 0.067 ; 0.04 ; 0.482 ; 0.643 ; 0.359 ; 0.762 ; 0.114 ; 0.555 ; 0.32 ; 0.61 ; 0.611 ; 0.354 ; 0.357 ; 0.308 ; 0.499 ; 0.47 ; 0.549 ; 0.778 ; 0.373 ; 0.023 ; 0.427 ; 0.635 ; 0.528 ; 0.503 ; 0.458 ; 0.314 ; 0.453 ; 0.196 ; 0.258 ; 0.27 ; 0.905 ; 0.536 ; 0.177 ; 0.681 ; 0.493 ; 0.606 ; 0.298 ; 0.68 ; 0.07 ; 0.444 ; 0.515 ; 0.104 ; 0.431 ; 0.463 ; 0.443 ; 0.522 ; 0.737 ; 0.642 ; 0.424 ; 0.602 ; 0.734 ; 0.531 ; 0.576 ; 0.645 ; 0.579 ; 0.459 ; 0.704 ; 0.741 ; 0.641 ; 0.922 ; 0.089 ; 0.552 ; 0.246 ; 0.684 ; 0.385 ; 0.623 ; 0.183 ; 0.533 ; 0.634 ; 0.686 ; 0.638 ; 0.694 ; 0.894 ; 0.581 ; 0.81 ; 0.701 ; 0.535 ; 0.352 ; 0.997 ; 0.251 ; 0.565 ; 0.392 ; 0.727 ; 0.146 ; 0.076 ; 0.376 ; 0.544 ; 0.595 ; 0.562 ; 0.476 ; 0.713 ; 0.747 ; 0.462 ; 0.525 ; 0.855 ; 0.161 ; 0.669 ; 0.299 ; 0.845 ; 0.676 ; 0.583 ; 0.811 ; 0.438 ; 0.729 ; 0.577 ; 0.456 ; 0.755 ; 0.983 ; 0.592 ; 0.5 ; 0.342 ; 0.538 ; 0.448 ; 0.292 ; 0.821 ; 0.521 ; 0.959 ; 0.557 ; 0.62 ; 0.761 ; 0.542 ; 0.739 ; 0.406 ; 0.653 ; 0.65 ; 0.725 ; 0.556 ; 0.614 ; 0.776 ; 0.597 ; 0.7 ; 0.295 ; 0.43 ; 0.923 ; 0.672 ; 0.825 ; 0.387 ; 0.545 ; 0.632 ; 0.76 ; 0.437 ; 0.283 ; 0.529 ; 0.625 ; 0.732 ; 0.475 ; 0.898 ; 0.465 ; 0.598 ; 0.742 ; 0.665 ; 0.589 ; 0.46 ; 0.479 ; 0.797 ; 0.947 ; 0.547 ; 0.695 ; 0.245 ; 0.654 ; 0.765 ; 0.718 ; 0.637 ; 0.487 ; 0.703 ; 0.639 ; 0.779 ; 0.774 ; 0.412 ; 0.754 ; 0.567 ; 0.433 ; 0.897 ; 0.957 ; 0.671 ; 0.481 ; 0.624 ; 0.501 ; 0.668 ; 0.817 ; 0.723 ; 0.807 ; 0.423 ; 0.4 ; 0.842 ; 0.648 ; 0.675 ; 0.791 ; 0.619 ; 0.733 ; 0.751 ; 0.658 ; 0.782 ; 0.696 ; 0.697 ; 0.633 ; 0.728 ; 0.71 ; 0.709 ; 0.783 ; 0.766 ; 0.945 ; 0.883 ; 0.667 ; 0.995 ; 0.72 ; 0.647 ; 0.526 ; 0.558 ; 0.8 ; 0.956 ; 0.943 ; 0.661 ; 0.663 ; 0.878 ; 0.74 ; 0.996 ; 0.818 ; 0.796 ; 0.678 ; 0.906 ; 0.631 ; 0.804 ; 0.715 ; 0.656 ; 0.903 ; 0.738 ; 0.784 ; 0.801 ; 0.717 ; 0.781 ; 0.969 ; 0.6 ; 0.664 ; 0.79 ; 0.689 ; 0.63 ; 0.688 ; 0.679 ; 0.848 ; 0.66 ; 0.854 ; 0.786 ; 0.683 ; 0.603 ; 0.67 ; 0.991 ; 0.712 ; 0.673 ; 0.745 ; 0.726 ; 0.722 ; 0.936 ; 0.888 ; 0.928 ; 0.873 ; 0.659 ; 0.946 ; 0.753 ; 0.77 ; 0.94 ; 0.771 ; 0.736 ; 0.823 ; 0.892 ; 0.851 ; 0.78 ; 0.827 ; 0.806 ; 0.644 ; 0.896 ; 0.98 ; 0.705 ; 0.904 ; 0.789 ; 0.768 ; 0.836 ; 0.719 ; 0.998 ; 0.847 ; 1 ; 0.711 ; 0.916 ; 0.794 ; 0.968 ; 0.829 ; 0.979 ; 0.912 ; 0.92 ; 0.758 ; 0.901 ; 0.987 ; 0.793 ; 0.691 ; 0.721 ; 0.792 ; 0.919 ; 0.934 ; 0.687 ; 0.809 ; 0.75 ; 0.984 ; 0.763 ; 0.843 ; 0.954 ; 0.921 ; 0.82 ; 0.832 ; 0.835 ; 0.808 ; 0.939 ; 0.83 ; 0.666 ; 0.859 ; 0.682 ; 0.814 ; 0.826 ; 0.757 ; 0.977 ; 0.924 ; 0.958 ; 0.785 ; 0.865 ; 0.831 ; 0.788 ; 0.868
IS_DIST_MET_MAPPED	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Metastatic patient	Sample	TRUE ; FALSE
MET_COUNT	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Met Count	Sample	2 ; 8 ; 13 ; 11 ; 3 ; 4 ; 1 ; 5 ; 9 ; 0 ; 7 ; 6 ; 12 ; 17 ; 10 ; 14 ; 21 ; 16 ; 15 ; 19 ; 18 ; 20 ; 22 ; 24 ; 23 ; 26 ; 31 ; 25
MET_SITE_COUNT	Black	MSK MetTropism (MSK, Cell 2021)	NUMBER	Met Site Count	Sample	2 ; 8 ; 5 ; 7 ; 3 ; 4 ; 1 ; 9 ; 0 ; 6 ; 11 ; 12 ; 10 ; 13 ; 14 ; 15
ORGAN_SYSTEM	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Organ System	Sample	Breast ; Gynecologic ; Thoracic ; Genitourinary ; Developmental GI Tract ; Core GI ; Soft Tissue ; Endocrine ; Head and Neck ; Skin ; URINARY BLADDER ; BREAST ; OVARY ; PANCREAS ; PROSTATE GLAND ; KIDNEY ; SKIN ; STOMACH ; THYROID GLAND ; LIVER ; BRAIN, & CRANIAL NERVES, & SPINAL CORD, (EXCL. VENTRICLE, CEREBELLUM) ; CERVIX UTERI ; BLOOD, BONE MARROW, & HEMATOPOIETIC SYS ; ESOPHAGUS ; GUM, FLOOR OF MOUTH, & OTHER MOUTH ; BONES & JOINTS ; LYMPH NODES ; GALLBLADDER & EXTRAHEPATIC BILE DUCTS ; LARGE INTESTINE, (EXCL. APPENDIX) ; BONE & SOFT TISSUE ; LUNG & BRONCHUS ; RECTUM ; UTERUS, NOS
SUBTYPE_ABBREVIATION	Black	MSK MetTropism (MSK, Cell 2021)	STRING	Subtype Abbreviation	Sample	IDC HR+HER2- ; UCEC ENDO ; UCEC SEROUS ; PLMESO ; BLCA ; HCC ; IDC HR+HER2+ ; STAD ; ESCA ; UTUC ; HGSOC ; UCEC HM ; CCOV ; LUAD ; SARC LMS ; ILC HR+HER2- ; TGCT SEM ; SCLC ; CHOL intra ; CRC MSS ; TGCT non-SEM ; GIST ; PAAD ; SARC LS ; LGSOC ; CHOL extra ; THPD ; IDC TN ; PRAD ; ACYC ; CESC ; ANSC ; LUSC ; CSCC ; THPA ; CCRCC ; HNSC ; LNET ; IDC HR-HER2+ ; SKCM ; SARC UPSMFS ; GBC ; UCEC CSRC ; UM ; CRC HM ; PANET ; APAD ; SBS ; MUCM ; GINET
CRDB_ADJ_TXT	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	Has the patient received adjuvant systemic therapy?	Patient	
CRDB_BASIC_COMMENTS	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	The basic comments at enrollment for 12-245.	Patient	
CRDB_BRAINMET	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	Does the patient have brain metastases?	Patient	
CRDB_CONSENT_DATE_DAYS	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	NUMBER	12-245 consent date.	Patient	
CRDB_ECOG	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	What is the patient's ECOG status?	Patient	
CRDB_NOSYSTXT	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	What is the number of prior systemic therapies (Inclusion of endocrine, cytotoxic, biologic therapies)?	Patient	
CRDB_OFF_STUDY_DAYS	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	The patient's 12-245 off study date.	Patient	
CRDB_PRIOR_RX	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	Has the patient received prior radiotherapy?	Patient	
CRDB_SURVIVAL_STATUS	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	The patient's survival status.	Patient	
CRDB_TREATMENT_END_DAYS	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	NUMBER	The patient's 12-245 treatment end date.	Patient	
MSK_SLIDE_ID	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	MSK Slide ID	Sample	471972 ; 745861 ; 745871 ; 552430 ; 884559 ; 1466446 ; 909679 ; 406656 ; 924746 ; 959147 ; 2364958 ; 482654 ; 713306 ; 743285 ; 881751 ; 940589 ; 1246453 ; 524113 ; 1804801 ; 538527 ; 2109720 ; 397982 ; 903669 ; 1898819 ; 649391 ; 1793503 ; 405971 ; 3555774 ; 2527735 ; 413417 ; 488611 ; 412980 ; 2318662 ; 415155 ; 433561 ; 2426881 ; 2155986 ; 434420 ; 2063707 ; 441820 ; 461029 ; 2433717 ; 468737 ; 623751 ; 480136 ; 482574 ; 1636356 ; 488389 ; 491067 ; 1564439 ; 2560422 ; 497616 ; 510632 ; 1314486 ; 512534 ; 515826 ; 518643 ; 987132 ; 518702 ; 974517 ; 526225 ; 531069 ; 536987 ; 537024 ; 540920 ; 642823 ; 544979 ; 2773988 ; 544307 ; 976818 ; 558834 ; 558274 ; 1537667 ; 581864 ; 589564 ; 2405823 ; 591851 ; 1113124 ; 2124639 ; 590003 ; 596221 ; 602942 ; 607952 ; 897466 ; 1783549 ; 638530 ; 656455 ; 670147 ; 686030 ; 1093219 ; 2137830 ; 679942 ; 682441 ; 682511 ; 2242384 ; 686694 ; 2124781 ; 699640 ; 1044126 ; 645024 ; 2360033 ; 700522 ; 711441 ; 712314 ; 2097874 ; 713367 ; 714451 ; 740760 ; 1261989 ; 1951311 ; 751094 ; 751320 ; 3263764 ; 766031 ; 1994879 ; 888301 ; 1695269 ; 907578 ; 2104450 ; 920266 ; 915017 ; 930967 ; 939108 ; 2523738 ; 939192 ; 1563602 ; 944485 ; 1869752 ; 979509 ; 988511 ; 2379561 ; 964031 ; 958091 ; 949229 ; 1851969 ; 963243 ; 1963008 ; 968598 ; 2749726 ; 964546 ; 974507 ; 979387 ; 986129 ; 1007120 ; 1155125 ; 1027807 ; 1024864 ; 1024740 ; 3291682 ; 1054381 ; 1056931 ; 3071612 ; 1091837 ; 2143947 ; 1106037 ; 1118003 ; 1090185 ; 1113588 ; 1136961 ; 1965418 ; 2701038 ; 1166646 ; 2904784 ; 1615655 ; 2531200 ; 2749549 ; 2197523 ; 1654650 ; 2105828 ; 2531218 ; 1239280 ; 2612457 ; 1413521 ; 2715093 ; 1898713 ; 1659235 ; 1331478 ; 1697726 ; 1453998 ; 1475351 ; 1516819 ; 1475343 ; 1499277 ; 1490745 ; 1527918 ; 1453739 ; 1543019 ; 1576682 ; 1578247 ; 1600948 ; 1600908 ; 2064008 ; 1615729 ; 1834595 ; 1617249 ; 1626804 ; 1629011 ; 1950732 ; 1673018 ; 1750488 ; 1677134 ; 1525485 ; 1718974 ; 2499585 ; 1690712 ; 2391754 ; 1697819 ; 1719009 ; 1704570 ; 1721584 ; 1721665 ; 1739044 ; 1779991 ; 1989951 ; 1793804 ; 1771276 ; 1790665 ; 1793843 ; 1812533 ; 1755638 ; 2704405 ; 1783622 ; 1775812 ; 730107 ; 1923168 ; 1719435 ; 1799805 ; 1935222 ; 1799746 ; 1802640 ; 1804655 ; 1837406 ; 1935142 ; 1860539 ; 1812506 ; 1841624 ; 1848353 ; 2342454 ; 2364716 ; 1950773 ; 2327731 ; 1931165 ; 1935496 ; 1852256 ; 2394784 ; 1873113 ; 1865461 ; 1898993 ; 1869891 ; 1869862 ; 1938433 ; 1908574 ; 1903724 ; 1930904 ; 1903655 ; 1903060 ; 1912720 ; 1903229 ; 1907973 ; 1965061 ; 3234502 ; 1659419 ; 1918145 ; 1922383 ; 3033677 ; 3165554 ; 3363709 ; 1951153 ; 1903708 ; 2137876 ; 2026335 ; 2026328 ; 2047204 ; 3238699 ; 2087854 ; 2067438 ; 2098024 ; 2087897 ; 2019223 ; 2026383 ; 2053935 ; 2078717 ; 2156056 ; 2072562 ; 2143902 ; 2109693 ; 2192937 ; 2078880 ; 2078747 ; 2072572 ; 3191089 ; 2124608 ; 2088028 ; 3134371 ; 2227336 ; 2129998 ; 2063783 ; 2087894 ; 2087850 ; 2788148 ; 2098144 ; 2104474 ; 3180382 ; 2098874 ; 2137528 ; 2156070 ; 2092260 ; 2318812 ; 2098717 ; 2098769 ; 2129121 ; 733201 ; 2249356 ; 2295003 ; 2109710 ; 2527531 ; 2208892 ; 2227296 ; 2105904 ; 2587431 ; 3560326 ; 2120044 ; 2143846 ; 2373632 ; 3015836 ; 2208352 ; 3221302 ; 3001706 ; 2137731 ; 3220829 ; 2137496 ; 2241268 ; 2321002 ; 2156006 ; 3220713 ; 3221411 ; 3220782 ; 2197530 ; 2198180 ; 2365132 ; 2218314 ; 2230683 ; 2227229 ; 2394743 ; 3096387 ; 2308575 ; 2323550 ; 2308535 ; 2324375 ; 2308377 ; 2287651 ; 2308538 ; 2379502 ; 2699901 ; 2308616 ; 2364810 ; 2324464 ; 2327834 ; 2323488 ; 2295010 ; 2405519 ; 2394806 ; 2726835 ; 2385050 ; 2587214 ; 2365974 ; 3406710 ; 2414111 ; 2379294 ; 3220013 ; 2433699 ; 2379517 ; 2379424 ; 2379264 ; 2379594 ; 2391299 ; 2391010 ; 2421345 ; 2391526 ; 2433587 ; 2405551 ; 2528053 ; 2467098 ; 2587112 ; 2592391 ; 2467672 ; 2483108 ; 2587610 ; 2507146 ; 2560274 ; 2537630 ; 2506950 ; 2531591 ; 3309814 ; 2553154 ; 2560262 ; 3033932 ; 3134738 ; 2856959 ; 2700910 ; 2587711 ; 2560346 ; 2639871 ; 2553335 ; 1691398 ; 1262440 ; 758534 ; 427870 ; 1758641 ; 556615 ; 597227 ; 1605925 ; 3309298 ; 1681646 ; 1251639 ; 2489797 ; 677164 ; 1185307 ; 732036 ; 730199 ; 1318662 ; 1586713 ; 979495 ; 968943 ; 926127 ; 1898801 ; 993646 ; 1588255 ; 1056443 ; 2088518 ; 1077113 ; 1093246 ; 1120575 ; 1147316 ; 1606312 ; 1325980 ; 1251576 ; 1564473 ; 1265329 ; 1490581 ; 1295579 ; 2390556 ; 1486644 ; 1492539 ; 1413539 ; 1543312 ; 3309652 ; 1580586 ; 1626844 ; 1677007 ; 1681418 ; 1629031 ; 2365806 ; 3388291 ; 2105866 ; 2072500 ; 2242217 ; 2699903 ; 2283682 ; 2342671 ; 2427588 ; 2499649 ; 2507487 ; 2928690 ; 2767116 ; 3033896 ; 3269828 ; 3315694 ; 3309987 ; 3174752 ; 3556058 ; 739966 ; 466714 ; 468429 ; 470196 ; 747868 ; 473360 ; 1965490 ; 945589 ; 484513 ; 540867 ; 1024848 ; 566250 ; 569084 ; 573406 ; 577031 ; 585805 ; 596202 ; 618744 ; 681482 ; 691545 ; 711473 ; 747378 ; 1236498 ; 908764 ; 922295 ; 972114 ; 971305 ; 1000626 ; 1042204 ; 1061766 ; 1036194 ; 1106155 ; 1329247 ; 1116182 ; 1306461 ; 1310050 ; 1522264 ; 1787182
OS_MONTHS_DMT	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	NUMBER	Overall Survival Months Reported by DMT	Patient	
OS_STATUS_DMT	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	Overall Status reported by DMT	Patient	
PARTA_CONSENTED_12_245	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	12-245 Part A Consented Status	Patient	
PARTC_CONSENTED_12_245	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	12-245 Part C Consented	Patient	
SEX_DMT	Black	MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021)	STRING	Sex Reported by DMT	Patient	
ASCN_PLOIDY	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	NUMBER	ASCN_PLOIDY	Sample	2.7 ; 2.1 ; 4.2 ; 2.5 ; 1.9 ; 2 ; 2.8 ; 2.3 ; 3.2 ; 2.2 ; 1.7 ; 2.4
ASCN_PURITY	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	NUMBER	ASCN_PURITY	Sample	0.87 ; 0.97 ; 0.73 ; 0.57 ; 0.53 ; 0.32 ; 0.95 ; 0.47 ; 0.85 ; 0.6 ; 0.74 ; 0.81 ; 0.65
ASCN_VERSION	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	STRING	ASCN_VERSION	Sample	0.5.14
ASCN_WGD	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	STRING	ASCN_WGD	Sample	WGD ; no WGD
CVR_TMB_COHORT_PERCENTILE	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	NUMBER	Percentile for the TMB within the MSK-IMAPCT cohort	Sample	13.8 ; 42.2 ; 13.1 ; 38.1 ; 37.9 ; 0 ; 44.1 ; 25.5 ; 14.3 ; 75.3 ; 43 ; 25.2 ; 54.1 ; 25.9 ; 52.4 ; 86.6 ; 7.7 ; 61.9 ; 18 ; 84.5 ; 94.2 ; 58.6 ; 85 ; 29.9 ; 78.6 ; 74.4 ; 95.7 ; 91.1 ; 17.3 ; 49.7 ; 86.8 ; 68 ; 59.8 ; 89.3 ; 63.5 ; 73.4 ; 89.5 ; 53.0 ; 73.7 ; 76.6 ; 87.1 ; 43.0 ; 85.9 ; 78.5 ; 96.6 ; 78.9 ; 93.7
CVR_TMB_SCORE	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	NUMBER	Calculated TMB score	Sample	0.9 ; 3.5 ; 2.6 ; 0 ; 1.8 ; 7 ; 4.4 ; 10.5 ; 0.8 ; 5.3 ; 1.6 ; 8.9 ; 20.1 ; 4.5 ; 2.2 ; 3 ; 7.8 ; 6.7 ; 25.7 ; 13.4 ; 1.1 ; 3.9 ; 2 ; 3.0 ; 10 ; 5.6 ; 4.9 ; 12.3 ; 6.1 ; 9.7 ; 7.9 ; 32.5 ; 18.4 ; 0.0 ; 2.0 ; 1 ; 9.8 ; 1.0 ; 60.6 ; 20.2 ; 16.7 ; 81.6 ; 8.8 ; 37.7 ; 3.3 ; 2.5 ; 79.9 ; 17.3 ; 70.0 ; 53.6 ; 4.1 ; 7.4
CVR_TMB_TT_COHORT_PERCENTILE	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	NUMBER	Percentile for the TMB within the Tumor type cohort (at least 10 cases are needed in that tumor type to have a result for this)	Sample	53.1 ; 84.6 ; 39.1 ; 73.5 ; 35.1 ; 0 ; 72.6 ; 77.9 ; 55.2 ; 43.2 ; 97 ; 76.4 ; 60.9 ; 87.1 ; 87.3 ; 33.4 ; 55.8 ; 74.1 ; 89.6 ; 62.8 ; 79.2 ; 27.1 ; 49 ; 71.8 ; 71 ; 77.2 ; -1 ; 65.5 ; 14.5 ; 78.3 ; 99.4 ; 66.7 ; 58.9 ; 68.2 ; 62.2 ; 81.8 ; 57.1 ; 12.7 ; 19.2 ; 38.1 ; 89.3 ; 16.2 ; 98.5 ; 75.6 ; 69.6 ; 50.1 ; 63.7 ; 86.1 ; 96.8 ; 42.2 ; 57.9 ; 19.9 ; 31.4 ; 15.8 ; 61.6 ; 57.5 ; 72.9 ; 63 ; 98.7 ; 86 ; 11.2 ; 34.6 ; 10.4 ; 43.1 ; 65.3 ; 64.2 ; 65.4 ; 27.5 ; 38.5 ; 82.3 ; 7.8 ; 46.4 ; 42.5 ; 31.9 ; 25.7 ; 58.8 ; 37.2 ; 9 ; 51.2 ; 65.6 ; 57.6 ; 30.4 ; 56.8 ; 42.4 ; 10.3 ; 51.3 ; 21.2 ; 89.8 ; 77.0 ; 28.8 ; 29.4 ; 47.3 ; 53.8 ; 67.2 ; 64.1 ; 37.5 ; 97.8 ; 92.9
GENOME_DOUBLED	Black	Pediatric Pancan Tumors (MSK,Nat Commun. 2022)	STRING	genome_doubled	Sample	TRUE ; FALSE
CRDB_SURVEY_COMMENTS	Black	Pan-Cancer MSK-IMPACT MET Validation Cohort (MSK 2022)	STRING	The survey comments at enrollment for 12-245.	Sample	
DATE_ADDED	Black	Pan-Cancer MSK-IMPACT MET Validation Cohort (MSK 2022)	STRING	Date added to cBioPortal	Sample	2015/04/07 ; 2015/09/16 ; 2015/05/28 ; 2015/09/10 ; 2015/06/17 ; 2015/07/16 ; 2015/10/04 ; 2015/12/02 ; 2017/07/07 ; 2019/09/11 ; 2018/02/17 ; 2016/10/25 ; 2017/01/17 ; 2018/05/07 ; 2017/03/01 ; 2017/03/09 ; 2017/03/11 ; 2017/03/17 ; 2017/04/01 ; 2017/04/14 ; 2017/05/13 ; 2017/08/17 ; 2017/09/07 ; 2017/09/06 ; 2017/09/23 ; 2017/11/05 ; 2018/11/16 ; 2018/07/14 ; 2018/01/20 ; 2018/03/17 ; 2018/03/14 ; 2018/04/10 ; 2018/05/19 ; 2018/06/14 ; 2018/06/15 ; 2018/07/11 ; 2018/07/19 ; 2019/02/07 ; 2018/12/14 ; 2018/07/30 ; 2018/10/23 ; 2018/11/10 ; 2018/12/03 ; 2018/11/28 ; 2019/01/02 ; 2018/12/13 ; 2019/04/17 ; 2019/07/24
MONTH_ADDED	Black	Pan-Cancer MSK-IMPACT MET Validation Cohort (MSK 2022)	STRING	Month added to cBioPortal	Sample	2015/04 ; 2015/09 ; 2015/05 ; 2015/06 ; 2015/07 ; 2015/10 ; 2015/12 ; 2017/07 ; 2019/09 ; 2018/02 ; 2016/10 ; 2017/01 ; 2018/05 ; 2017/03 ; 2017/04 ; 2017/05 ; 2017/08 ; 2017/09 ; 2017/11 ; 2018/11 ; 2018/07 ; 2018/01 ; 2018/03 ; 2018/04 ; 2018/06 ; 2019/02 ; 2018/12 ; 2018/10 ; 2019/01 ; 2019/04 ; 2019/07
WEEK_ADDED	Black	Pan-Cancer MSK-IMPACT MET Validation Cohort (MSK 2022)	STRING	Week added to cBioPortal	Sample	2015, Wk. 15 ; 2015, Wk. 38 ; 2015, Wk. 22 ; 2015, Wk. 37 ; 2015, Wk. 25 ; 2015, Wk. 29 ; 2015, Wk. 40 ; 2015, Wk. 49 ; 2017, Wk. 27 ; 2019, Wk. 37 ; 2018, Wk. 07 ; 2016, Wk. 43 ; 2017, Wk. 03 ; 2018, Wk. 19 ; 2017, Wk. 09 ; 2017, Wk. 10 ; 2017, Wk. 11 ; 2017, Wk. 13 ; 2017, Wk. 15 ; 2017, Wk. 19 ; 2017, Wk. 33 ; 2017, Wk. 36 ; 2017, Wk. 38 ; 2017, Wk. 44 ; 2018, Wk. 46 ; 2018, Wk. 28 ; 2018, Wk. 03 ; 2018, Wk. 11 ; 2018, Wk. 15 ; 2018, Wk. 20 ; 2018, Wk. 24 ; 2018, Wk. 29 ; 2019, Wk. 06 ; 2018, Wk. 50 ; 2018, Wk. 31 ; 2018, Wk. 43 ; 2018, Wk. 45 ; 2018, Wk. 49 ; 2018, Wk. 48 ; 2019, Wk. 01 ; 2019, Wk. 16 ; 2019, Wk. 30
ONCOTREE_CODE_CANCER_TYPE	Black	Pediatric Pan-Cancer (DKFZ, Nature 2017)	STRING	Oncotree Code	Sample	BLL ; TLL ; AML ; ATRT ; HGGNOS ; EPM ; ES ; LIHB ; MBL ; NBL ; OS ; RBL ; RMS ; WT ; ACC ; NHL ; EMBT ; PAST
RELAPSE_SEQUENCED	Black	Pediatric Pan-Cancer (DKFZ, Nature 2017)	STRING	Relapse/Sequenced	Sample	Relapse_of_ALL-B-10 ; Relapse_of_ALL-B-11 ; Relapse_of_ALL-B-12 ; Relapse_of_ALL-B-13 ; Relapse_of_ALL-B-14 ; Relapse_of_ALL-B-15 ; Relapse_of_ALL-B-16 ; Relapse_of_ALL-B-17 ; Relapse_of_ALL-B-18 ; Relapse_of_ALL-B-19 ; Relapse_of_ALL-B-2 ; Relapse_of_ALL-B-20 ; Relapse_of_ALL-B-21 ; Relapse_of_ALL-B-23 ; Relapse_of_ALL-B-3 ; Relapse_of_ALL-B-4 ; Relapse_of_ALL-B-5 ; Relapse_of_ALL-B-6 ; Relapse_of_ALL-B-8 ; Relapse_of_ALL-B-22 ; Relapse_of_ALL-B-7 ; Relapse_of_T-ALL_H_KI17 ; Relapse_of_T-ALL_H_MD40 ; Relapse_of_T-ALL_H_S-00169 ; Relapse_of_T-ALL_H_S-00207 ; Relapse_of_T-ALL_H_S-00285 ; Relapse_of_T-ALL_H_S-00438 ; Relapse_of_T-ALL_H_T128 ; Relapse_of_T-ALL_H_T92 ; Relapse_of_11EP32 ; Relapse_of_NG-6166_2EP20 ; Relapse_of_NG-6166_4EP28 ; Relapse_of_NG-6166_5EP29 ; Relapse_of_NG-6166_7EP26 ; Relapse_of_NG-6166_N1172_97 ; Relapse_of_NG-6166_N398_03 ; Relapse_of_11EP8 ; Relapse_of_NG-6166_3EP68 ; Relapse_of_NG-6166_4EP46 ; Relapse_of_NG-6166_BT2009037 ; Relapse_of_ES_TUM_K0014 ; Relapse_of_INF_10 ; Relapse_of_ICGC_GBM53 ; Relapse_of_ICGC_GBM19 ; Relapse_of_ICGC_GBM46 ; Relapse_of_SJHGG024 ; Relapse_of_SJHGG033
SUBTYPE_DETAILS	Black	Pediatric Pan-Cancer (DKFZ, Nature 2017)	STRING	Subtype Details	Sample	Diploid ; Hyperdiploid ; Hypodiploid ; Near Haploid ; Mature ; Pre-T ; Cortical ; M1Auer ; M2 ; M2Auer ; M3 ; M4Auer ; M5 ; M7 ; M7Down ; PFA ; PFB ; St-Relpos ; St-Se ; St-Yap ; No_Fusion ; Ews-Erg ; Ews-Fli1 ; GB ; 64 ; 100 ; 30 ; 32 ; 50 ; 20 ; 40 ; 70 ; 15 ; 35 ; 60 ; 1 ; 1.5 ; Unilateral ; Trilateral ; Bilateral ; Kataegis ; Chromothripsis ; Low Hypodiploid ; Masked Near Haploid ; Masked Low Hypodiploid ; Bcr-Abl1 ; Amlm ; Typical ; Rela-Fusion ; 160 ; 290 ; 260 ; Unchanged ; 0.5 ; 0 ; Pax3/Foxo1-Fusion ; Negative
TUMOR_DETAILS	Black	Pediatric Pan-Cancer (DKFZ, Nature 2017)	STRING	Tumor Details	Sample	B-cell acute lymphoblastic leukemia, non-hypodiploid ; B-cell acute lymphoblastic leukemia, hypodiploid ; T-cell acute lymphoblastic leukemia ; Acute myeloid leukemias ; Atypial teratoid/rhabdoid tumor ; High-grade glioma K27Mmut ; High-grade glioma K27Mwt ; Ependymoma supratentorial ; Ependymoma infratentorial ; Ewing's sarcoma ; Hepatoblastoma ; Medulloblastoma WNT ; Medulloblastoma SHH ; Medulloblastoma Group3 ; Medulloblastoma Group4 ; Neuroblastoma ; Osteosarcoma ; Retinoblastoma ; Rhabdomyosarcoma ; Wilms' tumors ; Adrenocortical carcinoma ; Atypical teratoid/rhabdoid tumor ; Burkitt's lymphoma ; Embryonal tumor with multilayered rosettes ; Pilocytic astrocytoma
ANY_LINE_CHEMO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Any Line Chemo	Patient	
ANY_LINE_HORMONE	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Anu Line Hormone	Patient	
ANY_LINE_IMMUNO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Any Line Immuno	Patient	
ANY_LINE_IODINE	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Any Line Iodine	Patient	
ANY_LINE_NTRK	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Any Line Ntrk	Patient	
ANY_LINE_TARGETED	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Any Line Targeted	Patient	
ANY_SYSTX	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Systematic Therapy	Patient	
CANCER_TYPE_HISTOLOGY	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Cancer Type Reported by Histology	Patient	
DEATH	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Death	Patient	
DOB_LASTFU_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB lastfu Time (years)	Patient	
DOB_PROG_START_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOG Prog Start Time (Years)	Patient	
DOB_PROG_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB Prog Time (Years)	Patient	
DOB_RECUR_START_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB Recur Start Time (years)	Patient	
DOB_RECUR_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB Recur Time (years)	Patient	
DOB_REPORT_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB Report Time (years)	Patient	
DOB_TISSUE_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	DOB Tissue Time (Years)	Patient	
GRAPH_ID	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Graph ID	Patient	
LINE1_BR_NOTRK	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line1 Br Notrk	Patient	
LINE1_BR_NOTRK_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line1 br notrk g	Patient	
LINE_OBR_CHEMO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr chemo	Patient	
LINE_OBR_CHEMO_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr chemo g	Patient	
LINE_OBR_IMMUNO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr immuno	Patient	
LINE_OBR_IMMUNO_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr immuno g	Patient	
LINE_OBR_NOTRK	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr notrk	Patient	
LINE_OBR_NOTRK_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr notrk g	Patient	
LINE_OBR_NTRK	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr ntrk	Patient	
LINE_OBR_NTRK_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr ntrk g	Patient	
LINE_OBR_TARGETED	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr targeted	Patient	
LINE_OBR_TARGETED_G	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Line obr targeted g	Patient	
LOCALIZED_VS_METS_AT_DX	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Localized or Metastaic at Diagnosis	Sample	Localized ; Metastatic ; Unknown
NUM_LINES	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Systematic Therapies	Patient	
NUM_LINES_CHEMO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Chemo	Patient	
NUM_LINES_HORMONE	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Hormone	Patient	
NUM_LINES_IMMUNO	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Immuno	Patient	
NUM_LINES_IODINE	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Iodine	Patient	
NUM_LINES_NTRK	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Link Ntrk	Patient	
NUM_LINES_TARGETED	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Num of Lines Targeted	Patient	
POS_ARCHER	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Pos Archer	Patient	
POS_CYTOGENETICS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Pos Cytogenetics	Patient	
POS_IMPACT	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Pos Impact	Patient	
POS_METHOD	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Pos Method	Patient	
PROG_DEATH	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Prog Death	Patient	
PROG_DEATH_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Prog Death Time (years)	Patient	
PROG_EVAL_C	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Prog Eval c	Patient	
RECUR_EVAL_C	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	STRING	Recur eval c	Patient	
TISSUE_REPORT_TIME_YRS	Black	Tumors with TRK fusions (MSK, Clin Cancer Res 2020)	NUMBER	Tissue Report Time (Years)	Patient	
COVERAGE_MEAN	Black	China Pan-cancer (OrigiMed, Nature 2022)	NUMBER	Sample coverage	Sample	1171 ; 476 ; 1277 ; 1667 ; 935 ; 759 ; 1421 ; 1514 ; 1060 ; 1643 ; 582 ; 1206 ; 1161 ; 1872 ; 838 ; 1417 ; 1281 ; 1978 ; 1760 ; 1239 ; 1479 ; 922 ; 1036 ; 705 ; 928 ; 1529 ; 1255 ; 1572 ; 1188 ; 1828 ; 772 ; 1426 ; 1752 ; 1435 ; 1414 ; 893 ; 579 ; 1212 ; 1023 ; 1468 ; 1366 ; 1390 ; 1475 ; 1501 ; 1415 ; 1371 ; 1680 ; 1068 ; 1309 ; 1165 ; 1052 ; 1953 ; 941 ; 880 ; 1379 ; 1547 ; 1621 ; 775 ; 755 ; 1061 ; 759.16344 ; 1037 ; 488 ; 1109 ; 948 ; 1496 ; 1199 ; 845 ; 653.618092 ; 896.764244 ; 1248 ; 869 ; 918 ; 1118 ; 658 ; 1440.082599 ; 1454.17 ; 749 ; 1092 ; 902 ; 687.966394 ; 925 ; 948.405402 ; 1096 ; 1103 ; 1025 ; 1099 ; 1228.971079 ; 1166 ; 872 ; 1226 ; 1035.495816 ; 602 ; 438 ; 1205 ; 555 ; 1730 ; 1156.092385 ; 1094.552886 ; 930 ; 583 ; 1166.136688 ; 1222.362461 ; 669.538065 ; 693.167028 ; 721 ; 809 ; 1831 ; 974 ; 778 ; 1125.757068 ; 975 ; 1285 ; 2059 ; 1436 ; 658.515094 ; 643.0228 ; 1057 ; 860 ; 1531 ; 753 ; 1015.465674 ; 968.896005 ; 1867.880346 ; 1194.728572 ; 1316.838695 ; 1143.505495 ; 836 ; 1311.033496 ; 907 ; 1128 ; 1178 ; 971 ; 1292 ; 717.868997 ; 1826 ; 1702 ; 1291 ; 1040.880253 ; 801 ; 1114 ; 1383 ; 1131.253119 ; 1047 ; 1573.316948 ; 910 ; 1132 ; 1237.583906 ; 560 ; 406 ; 1204 ; 1299.38786 ; 1506 ; 1144 ; 1516 ; 991 ; 1224.974782 ; 1662.694191 ; 1220 ; 1633 ; 1131 ; 1079 ; 1069 ; 1090 ; 1413 ; 1227.78194 ; 1118.016989 ; 1855 ; 946 ; 1065 ; 929 ; 1043 ; 1100 ; 1441 ; 1187 ; 1201 ; 1601 ; 754.442268 ; 1194 ; 1517 ; 1382 ; 1148 ; 577.470485 ; 1186 ; 1354 ; 988 ; 1506.148925 ; 1254 ; 1415.171617 ; 1152.287824 ; 1146 ; 1167.18433 ; 1078.878396 ; 700 ; 919.634281 ; 2213.73177 ; 605.193762 ; 987.458734 ; 391.805994 ; 1503.725058 ; 1502 ; 1122.139618 ; 1498 ; 1139 ; 1102.040842 ; 1089.506443 ; 672.799702 ; 1439.287793 ; 941.354856 ; 591.89686 ; 1521 ; 671 ; 800.445299 ; 1389.811246 ; 1111.769847 ; 1301 ; 1313.799183 ; 1151.626035 ; 1246 ; 783 ; 1586 ; 1154 ; 1194.55 ; 408.69 ; 777.715306 ; 1174 ; 1366.401248 ; 1476.682331 ; 1178.51978 ; 1080.607702 ; 1257 ; 985 ; 1630.25 ; 891 ; 1021 ; 1176.596994 ; 1217 ; 1566 ; 898.918367 ; 886.61983 ; 885 ; 1244 ; 1238.964334 ; 949.149658 ; 1198 ; 1511 ; 1544.031471 ; 725.654181 ; 940.160062 ; 1134.506685 ; 1175 ; 1568.582707 ; 1351.98953 ; 1255.533115 ; 999.500376 ; 917.97933 ; 668.590754 ; 1067.432334 ; 1126 ; 794.994498 ; 1371.270408 ; 687.413113 ; 1254.235864 ; 1007.808393 ; 1955.131678 ; 1092.460147 ; 1742.300523 ; 1195 ; 1266.308503 ; 1437.633051 ; 1115.2062 ; 1336.914995 ; 882 ; 876.232665 ; 1245.027867 ; 826 ; 821 ; 961.495966 ; 1179.401428 ; 480.393735 ; 941.906511 ; 1071 ; 718.703203 ; 1076.714909 ; 1299 ; 696 ; 1020 ; 879 ; 1071.998994 ; 1211.352554 ; 1347.789085 ; 858 ; 1030.127482 ; 1476.501937 ; 1315.288655 ; 1207 ; 1048.580886 ; 1568 ; 1461 ; 1142.646522 ; 953.220108 ; 1221.572606 ; 981.067954 ; 1493 ; 1316 ; 1127.310259 ; 1411 ; 1317 ; 1618 ; 1145.34828 ; 1551.13991 ; 1440.061086 ; 1497.47778 ; 1135.429749 ; 1282 ; 1072.795908 ; 1622.419525 ; 1408.466872 ; 1685.839552 ; 1385 ; 1578.132652 ; 1313.825585 ; 1054.608324 ; 1329.2814 ; 1192.898417 ; 1148.960868 ; 1258.574118 ; 1519.417724 ; 1225.911209 ; 1524.203865 ; 1340.404415 ; 934.691373 ; 1184 ; 1331.343596 ; 1268.359787 ; 1586.238218 ; 1328.08991 ; 1300.864645 ; 1218.909261 ; 820.968714 ; 773 ; 859.076502 ; 1429.2273 ; 1170.630928 ; 1230.124109 ; 1514.602235 ; 1319.264204 ; 1263.790832 ; 1222.185645 ; 948.375876 ; 978.309273 ; 694.122094 ; 1197.842606 ; 1463.236585 ; 1028.106077 ; 1228.342295 ; 1293.097333 ; 1095.959438 ; 1540 ; 1502.598632 ; 1966.869354 ; 1551.136712 ; 1252.135577 ; 1575.455477 ; 455.893604 ; 1124.822804 ; 1208.663688 ; 1305.6198 ; 832.8857 ; 1020.657813 ; 1387.8955 ; 1249.527858 ; 1089 ; 1460.973635 ; 1293.648899 ; 1279.429795 ; 1099.083296 ; 874.017256 ; 992 ; 1431.335895 ; 1258.93681 ; 1265 ; 652.054385 ; 1399.048304 ; 1276.60181 ; 1363.93656 ; 1739.825071 ; 1476.534508 ; 1462.825223 ; 1702.812446 ; 1245.852072 ; 1764.997065 ; 942.003072 ; 1701.151036 ; 1508 ; 366 ; 1220.614928 ; 1268 ; 1263 ; 840.398027 ; 1106 ; 678 ; 1434 ; 1134 ; 1606 ; 1269 ; 1403 ; 1157 ; 1480 ; 1027 ; 1315 ; 796 ; 1369 ; 1389 ; 915 ; 968 ; 1013 ; 1333 ; 1040 ; 611 ; 1359 ; 1274 ; 1560 ; 841 ; 368 ; 1119 ; 1000 ; 1378 ; 1238 ; 958 ; 1453 ; 1029 ; 1072 ; 1474 ; 1064 ; 1380 ; 1314 ; 1328 ; 1083 ; 1538 ; 1311 ; 1305 ; 1304 ; 1337 ; 920 ; 1208 ; 1302 ; 1104 ; 1143 ; 1091 ; 1353 ; 1705 ; 815 ; 839 ; 1180 ; 1589 ; 1452 ; 1004 ; 1595 ; 1289 ; 864 ; 1422 ; 1162 ; 1183 ; 1451 ; 1189 ; 1073 ; 1420 ; 319 ; 2091 ; 1231 ; 873 ; 1095 ; 1394 ; 1326 ; 1168 ; 444 ; 921 ; 1332 ; 1214 ; 1216 ; 1698 ; 1169 ; 1364 ; 620 ; 1185 ; 1113 ; 1293 ; 1398 ; 1133 ; 1122 ; 1729 ; 1276 ; 1472 ; 1127 ; 932 ; 1140 ; 751 ; 479 ; 1135 ; 618 ; 1343 ; 532 ; 995 ; 1345 ; 392 ; 665 ; 789 ; 912 ; 720 ; 307 ; 1124 ; 1243 ; 956 ; 1085 ; 693 ; 834 ; 1123 ; 874 ; 1028 ; 1230 ; 504 ; 822 ; 969 ; 1170 ; 1321 ; 1233 ; 942 ; 1030 ; 1222 ; 769 ; 1287 ; 1229 ; 1237 ; 790 ; 938 ; 750 ; 1097 ; 1149 ; 979 ; 1250 ; 607 ; 664 ; 976 ; 1491 ; 1112 ; 1469 ; 1192 ; 998 ; 1159 ; 1041 ; 1067 ; 832 ; 1381 ; 824 ; 615 ; 943 ; 1017 ; 1156 ; 949 ; 1423 ; 919 ; 1275 ; 805 ; 950 ; 936 ; 1340 ; 1012 ; 311 ; 593 ; 1318 ; 541 ; 1235 ; 939 ; 1298 ; 1218 ; 1404 ; 766 ; 1179 ; 1400 ; 986 ; 856 ; 1213 ; 1137 ; 1258 ; 1290 ; 1367 ; 994 ; 820 ; 1136 ; 1320 ; 955 ; 1151 ; 1486 ; 1446 ; 1196 ; 808 ; 1076 ; 1227 ; 1310 ; 1116 ; 529 ; 876 ; 1574 ; 1141 ; 1193 ; 677 ; 1272 ; 1324 ; 1234 ; 960 ; 670 ; 1323 ; 776 ; 645 ; 1341 ; 1570 ; 364 ; 1084 ; 1018 ; 784 ; 828 ; 867 ; 984 ; 1077 ; 868 ; 1048 ; 952 ; 1283 ; 963 ; 686 ; 1549 ; 539 ; 756 ; 977 ; 1002 ; 795 ; 757 ; 580 ; 1455 ; 890 ; 957 ; 1001 ; 1058 ; 1158 ; 818 ; 829 ; 1191 ; 635 ; 1223 ; 1074 ; 980 ; 1062 ; 470 ; 916 ; 1262 ; 1070 ; 1055 ; 752 ; 531 ; 1181 ; 1221 ; 1487 ; 412 ; 1308 ; 799 ; 1087 ; 587 ; 812 ; 844 ; 1279 ; 894 ; 898 ; 1093 ; 1256 ; 1338 ; 996 ; 648 ; 1150 ; 851 ; 917 ; 1101 ; 409 ; 1011 ; 1167 ; 871 ; 596 ; 1010 ; 388 ; 779 ; 794 ; 711 ; 859 ; 355 ; 990 ; 657 ; 884 ; 1647 ; 706 ; 731 ; 896 ; 877 ; 897 ; 962 ; 458 ; 683 ; 667 ; 331 ; 1386 ; 581 ; 1295 ; 1449 ; 1031 ; 396 ; 540 ; 889 ; 908 ; 797 ; 691 ; 640 ; 1266 ; 730 ; 647 ; 825 ; 913 ; 743 ; 562 ; 1078 ; 945 ; 804 ; 722 ; 1130 ; 857 ; 895 ; 538 ; 662 ; 850 ; 585 ; 754 ; 628 ; 973 ; 814 ; 970 ; 644 ; 1200 ; 1397 ; 1005 ; 694 ; 761 ; 861 ; 690 ; 878 ; 1019 ; 634 ; 849 ; 1691 ; 909 ; 513 ; 2110 ; 823 ; 888 ; 954 ; 840 ; 1107 ; 1081 ; 561 ; 603 ; 793 ; 1022 ; 1098 ; 624 ; 1147 ; 982 ; 1033 ; 1059 ; 1035 ; 1639 ; 865 ; 468 ; 817 ; 1046 ; 770 ; 835 ; 738 ; 901 ; 410 ; 1280 ; 940 ; 673 ; 981 ; 1210 ; 1271 ; 862 ; 552 ; 1032 ; 846 ; 1329 ; 1247 ; 1086 ; 1297 ; 883 ; 887 ; 972 ; 464 ; 904 ; 999 ; 649 ; 1418 ; 1319 ; 1240 ; 843 ; 1264 ; 791 ; 1552 ; 758 ; 707 ; 886 ; 636 ; 914 ; 1362 ; 810 ; 1182 ; 559 ; 623 ; 852 ; 1215 ; 625 ; 792 ; 911 ; 854 ; 875 ; 741 ; 937 ; 1105 ; 584 ; 1080 ; 1115 ; 1228 ; 1261 ; 692 ; 1007 ; 1172 ; 989 ; 1050 ; 786 ; 1356 ; 1909 ; 545 ; 933 ; 1334 ; 1284 ; 1392 ; 1357 ; 1407 ; 1236 ; 1042 ; 833 ; 993 ; 964 ; 1211 ; 1176 ; 1253 ; 377 ; 443 ; 1270 ; 1681 ; 1368 ; 732 ; 554 ; 1303 ; 1102 ; 1251 ; 1038 ; 1241 ; 1448 ; 987 ; 1026 ; 632 ; 903 ; 1009 ; 652 ; 668 ; 688 ; 1014 ; 329 ; 1396 ; 374 ; 400 ; 1267 ; 1743 ; 1155 ; 1120 ; 842 ; 1177 ; 1526 ; 813 ; 870 ; 1331 ; 1460 ; 1813 ; 1576 ; 1242 ; 1249 ; 1245 ; 1416 ; 1477 ; 1786 ; 477 ; 1462 ; 1447 ; 1440 ; 536 ; 1714 ; 2051 ; 1325 ; 1494 ; 1578 ; 1674 ; 1450 ; 1550 ; 1110 ; 863 ; 1584 ; 830 ; 1620 ; 1294 ; 1530 ; 1512 ; 1374 ; 1483 ; 1344 ; 1662 ; 1219 ; 1259 ; 1330 ; 1664 ; 1190 ; 748 ; 1986 ; 1224 ; 848 ; 478 ; 1745 ; 1145 ; 1066 ; 461 ; 1999 ; 953 ; 1053 ; 855 ; 715 ; 646 ; 881 ; 2335 ; 944 ; 1361 ; 1463 ; 674 ; 1499 ; 827 ; 1232 ; 1063 ; 590 ; 853 ; 1313 ; 892 ; 1056 ; 1015 ; 978 ; 702 ; 1585 ; 684 ; 669 ; 613 ; 1805 ; 1286 ; 638 ; 1433 ; 1346 ; 1505 ; 1495 ; 934 ; 1561 ; 1203 ; 1442 ; 712 ; 490 ; 1535 ; 1814 ; 1125 ; 1358 ; 1049 ; 1006 ; 2046 ; 780 ; 1075 ; 687 ; 1615 ; 1252 ; 767 ; 415 ; 2834 ; 1306 ; 1152 ; 1342 ; 1160 ; 621 ; 716 ; 831 ; 1045 ; 1016 ; 798 ; 2010 ; 735 ; 361 ; 608 ; 1537 ; 1051 ; 1736 ; 1372 ; 1649 ; 1708 ; 1464 ; 1836 ; 1877 ; 1847 ; 1054 ; 1153 ; 1693 ; 1869 ; 1692 ; 746 ; 1348 ; 1672 ; 1837 ; 1278 ; 1039 ; 1439 ; 2103 ; 1612 ; 1209 ; 1709 ; 1654 ; 2191 ; 1608 ; 1653 ; 1524 ; 572 ; 1605 ; 1406 ; 495 ; 959 ; 1916 ; 1564 ; 1312 ; 1626 ; 2631 ; 1202 ; 1347 ; 2264 ; 866 ; 1352 ; 1432 ; 1431 ; 1522 ; 1410 ; 1260 ; 1914 ; 1008 ; 672 ; 1544 ; 1465 ; 771 ; 1197 ; 1717 ; 1121 ; 1509 ; 1534 ; 961 ; 352 ; 997 ; 451 ; 1427 ; 1518 ; 764 ; 777 ; 1632 ; 899 ; 534 ; 1428 ; 1630 ; 905 ; 339 ; 433 ; 1484 ; 1350 ; 1401 ; 1588 ; 1377 ; 519 ; 1492 ; 1409 ; 1419 ; 1296 ; 1395 ; 1637 ; 1575 ; 1768 ; 1665 ; 1405 ; 1408 ; 1425 ; 1363 ; 1737 ; 1754 ; 1628 ; 710 ; 316 ; 2198 ; 1670 ; 1327 ; 1689 ; 1142 ; 1300 ; 1780 ; 2014 ; 1034 ; 1481 ; 1457 ; 1779 ; 1548 ; 553 ; 1360 ; 1129 ; 965 ; 1336 ; 811 ; 1111 ; 2370 ; 1503 ; 1594 ; 1117 ; 1556 ; 594 ; 763 ; 951 ; 703 ; 1866 ; 728 ; 1559 ; 1351 ; 661 ; 1697 ; 1335 ; 1807 ; 676 ; 1542 ; 1775 ; 630 ; 1751 ; 1545 ; 1656 ; 1489 ; 1393 ; 1470 ; 1539 ; 1600 ; 1921 ; 1044 ; 1857 ; 714 ; 2418 ; 1138 ; 563 ; 1466 ; 1783 ; 729 ; 1094 ; 589 ; 1108 ; 418 ; 785 ; 2444 ; 1842 ; 503 ; 617 ; 1082 ; 1430 ; 1666 ; 1675 ; 1571 ; 494 ; 2376 ; 709 ; 1676 ; 2195 ; 2450 ; 2172 ; 1687 ; 2814 ; 1886 ; 1644 ; 2209 ; 1976 ; 736 ; 2079 ; 1797 ; 1844 ; 1163 ; 900 ; 1619 ; 2096 ; 1949 ; 806 ; 1790 ; 1690 ; 2268 ; 1735 ; 565 ; 1954 ; 1541 ; 604 ; 1288 ; 2043 ; 1349 ; 1536 ; 1476 ; 2145 ; 1543 ; 1459 ; 1412 ; 1504 ; 557 ; 1891 ; 1994 ; 747 ; 739 ; 1706 ; 1024 ; 788 ; 819 ; 737 ; 417 ; 1307 ; 1322 ; 745 ; 724 ; 1947 ; 1617 ; 931 ; 467 ; 1731 ; 723 ; 1850 ; 600 ; 1646 ; 1375 ; 2651 ; 1437 ; 781 ; 480 ; 1565 ; 800 ; 1756 ; 1796 ; 1164 ; 1387 ; 1967 ; 1629 ; 1485 ; 1833 ; 1871 ; 1753 ; 1648 ; 1684 ; 1373 ; 1740 ; 1533 ; 1885 ; 1510 ; 1755 ; 1923 ; 1849 ; 1580 ; 1830 ; 1766 ; 1454 ; 1899 ; 1384 ; 1707 ; 1683 ; 1520 ; 1365 ; 2157 ; 485 ; 1839 ; 1355 ; 1823 ; 1712 ; 1658 ; 424 ; 502 ; 1995 ; 318 ; 2179 ; 1591 ; 639 ; 1993 ; 947 ; 1992 ; 927 ; 1581 ; 1699 ; 1507 ; 1822 ; 1642 ; 1569 ; 2140 ; 1700 ; 419 ; 1820 ; 2118 ; 551 ; 606 ; 760 ; 1825 ; 1555 ; 1636 ; 774 ; 588 ; 719 ; 653 ; 642 ; 2253 ; 566 ; 2081 ; 496 ; 2319 ; 1088 ; 2078 ; 1519 ; 1611 ; 1892 ; 659 ; 663 ; 837 ; 923 ; 1917 ; 924 ; 2069 ; 1598 ; 1965 ; 575 ; 1774 ; 1429 ; 1744 ; 1478 ; 1438 ; 1443 ; 2080 ; 548 ; 1841 ; 1567 ; 1682 ; 1635 ; 1623 ; 1641 ; 1562 ; 1339 ; 1725 ; 1789 ; 1645 ; 1927 ; 1671 ; 1471 ; 487 ; 2063 ; 1981 ; 568 ; 1650 ; 1546 ; 1661 ; 2016 ; 622 ; 1391 ; 1772 ; 2001 ; 1456 ; 1587 ; 768 ; 1582 ; 1603 ; 1604 ; 1922 ; 1660 ; 1716 ; 2356 ; 2153 ; 1640 ; 2300 ; 1577 ; 1458 ; 2391 ; 1974 ; 1961 ; 651 ; 2254 ; 1747 ; 1741 ; 2265 ; 2552 ; 1843 ; 2546 ; 1668 ; 1771 ; 1553 ; 1728 ; 2263 ; 3542 ; 1711 ; 1941 ; 1846 ; 2473 ; 2013 ; 2144 ; 1942 ; 926 ; 1832 ; 2285 ; 2806 ; 1273 ; 966 ; 626 ; 1528 ; 1609 ; 2352 ; 2192 ; 1563 ; 1695 ; 1759 ; 1781 ; 1732 ; 802 ; 1173 ; 421 ; 1669 ; 675 ; 1792 ; 1870 ; 1787 ; 1746 ; 1718 ; 354 ; 782 ; 1003 ; 1694 ; 1610 ; 1738 ; 762 ; 1444 ; 2556 ; 601 ; 727 ; 574 ; 1500 ; 2029 ; 1554 ; 2019 ; 1624 ; 2005 ; 1655 ; 2053 ; 1678 ; 2134 ; 1551 ; 1513 ; 1625 ; 1613 ; 1402 ; 1590 ; 1782 ; 740 ; 1710 ; 3398 ; 1370 ; 2004 ; 1622 ; 2825 ; 2528 ; 1811 ; 967 ; 4256 ; 906 ; 2283 ; 2692 ; 1983 ; 2608 ; 3185 ; 3169 ; 3196 ; 1685 ; 1596 ; 2685 ; 1593 ; 1490 ; 1911 ; 682 ; 1888 ; 1679 ; 1964 ; 2121 ; 1860 ; 1720 ; 2733 ; 2422 ; 3080 ; 1863 ; 2966 ; 1812 ; 2166 ; 2058 ; 2065 ; 1925 ; 2478 ; 1859 ; 2355 ; 1607 ; 2607 ; 610 ; 2411 ; 2113 ; 1473 ; 1597 ; 1767 ; 2761 ; 1616 ; 1557 ; 1734 ; 1701 ; 1763 ; 1791 ; 1773 ; 1904 ; 1824 ; 1794 ; 847 ; 1810 ; 2372 ; 1804 ; 2701 ; 765 ; 1651 ; 983 ; 816 ; 414 ; 1937 ; 2292 ; 1945 ; 2561 ; 708 ; 1445 ; 2246 ; 1424 ; 430 ; 1583 ; 2018 ; 1677 ; 660 ; 2143 ; 1663 ; 1614 ; 1659 ; 1376 ; 1739 ; 393 ; 1834 ; 591 ; 1984 ; 1910 ; 2503 ; 1929 ; 1802 ; 527 ; 1634 ; 1803 ; 512 ; 1905 ; 1764 ; 2416 ; 570 ; 2119 ; 2186 ; 469 ; 1943 ; 1599 ; 1907 ; 609 ; 1960 ; 744 ; 1930 ; 1896 ; 1523 ; 627 ; 305 ; 2148 ; 2142 ; 2189 ; 416 ; 586 ; 542 ; 1399 ; 2135 ; 597 ; 2115 ; 1788 ; 1525 ; 1532 ; 2412 ; 1906 ; 2049 ; 1874 ; 1968 ; 679 ; 1631 ; 1898 ; 2266 ; 734 ; 807 ; 1750 ; 573 ; 518 ; 2193 ; 803 ; 1893 ; 1627 ; 787 ; 413 ; 425 ; 401 ; 605 ; 550 ; 1225 ; 1497 ; 1727 ; 441 ; 2667 ; 2098 ; 701 ; 1488 ; 1388 ; 1467 ; 2408 ; 2168 ; 1558 ; 324 ; 2017 ; 524 ; 1801 ; 1902 ; 2295 ; 2020 ; 1827 ; 2323 ; 1876 ; 3090 ; 2071 ; 1894 ; 2083 ; 429 ; 473 ; 1673 ; 1908 ; 1884 ; 1733 ; 2446 ; 465 ; 1973 ; 1816 ; 1765 ; 493 ; 2011 ; 1913 ; 1715 ; 1963 ; 1722 ; 1934 ; 1817 ; 1776 ; 2000 ; 614 ; 650 ; 1932 ; 2709 ; 2156 ; 1573 ; 2303 ; 2012 ; 2109 ; 1757 ; 1749 ; 1657 ; 2296 ; 2347 ; 2124 ; 1991 ; 2308 ; 2027 ; 2206 ; 1778 ; 2102 ; 491 ; 6010 ; 1688 ; 1713 ; 2052 ; 1819 ; 1845 ; 1915 ; 717 ; 1858 ; 1928 ; 1742 ; 1777 ; 2032 ; 2181 ; 2045 ; 1602 ; 2679 ; 2398 ; 1962 ; 1652 ; 695 ; 455 ; 2159 ; 2184 ; 2169 ; 556 ; 335 ; 2270 ; 1785 ; 1956 ; 1686 ; 1719 ; 725 ; 2077 ; 2150 ; 507 ; 1853 ; 2037 ; 2024 ; 2453 ; 2688 ; 2123 ; 1861 ; 2242 ; 1840 ; 1851 ; 1592 ; 1882 ; 2787 ; 449 ; 1854 ; 1638 ; 1900 ; 2305 ; 2085 ; 1856 ; 2199 ; 2244 ; 2095 ; 2105 ; 1515 ; 459 ; 1868 ; 1835 ; 2419 ; 1867 ; 1704 ; 394 ; 2852 ; 2171 ; 1806 ; 2918 ; 2273 ; 309 ; 2129 ; 1829 ; 1703 ; 378 ; 1950 ; 1527 ; 654 ; 1809 ; 1969 ; 1818 ; 1912 ; 698 ; 2240 ; 2281 ; 1482 ; 598 ; 1926 ; 399 ; 2054 ; 1696 ; 515 ; 1579 ; 407 ; 1174.720891 ; 637 ; 1627.26123 ; 950.125535 ; 840.297987 ; 2239.188791 ; 559.157035 ; 1712.438649 ; 1042.521535 ; 1731.99357 ; 894.473815 ; 1393.369662 ; 1078.801302 ; 1121.944671 ; 1151.13861 ; 1248.087738 ; 585.75936 ; 952.271732 ; 1602.271026 ; 1356.135568 ; 1328.936392 ; 1067.905456 ; 925.879536 ; 950.95175 ; 1224.794677 ; 933.265684 ; 1083.440902 ; 1098.426919 ; 1054.028818 ; 1166.509391 ; 1036.398277 ; 1120.271267 ; 1194.907649 ; 1100.318719 ; 1178.762477 ; 1014.596684 ; 969.053912 ; 852.934588 ; 1152.59889 ; 1293.178138 ; 656.886798 ; 1459.453278 ; 1359.358538 ; 1331.599701 ; 1352.256081 ; 1232.569452 ; 1096.237915 ; 1839.656145 ; 1281.396644 ; 1173.251421 ; 1653.299822 ; 1147.2134 ; 1262.605778 ; 1122.830109 ; 1309.664683 ; 1150.321398 ; 1294.090058 ; 1036.282387 ; 1224.333062 ; 1538.808773 ; 1801.459969 ; 1820.137914 ; 963.94923 ; 1112.555605 ; 1677.17345 ; 1581.523977 ; 1103.290617 ; 2108 ; 516 ; 733 ; 426 ; 2594 ; 2424 ; 2486 ; 3699 ; 1879 ; 2575 ; 5420 ; 2133 ; 2774 ; 1793 ; 1895 ; 2405 ; 2155 ; 2200 ; 578 ; 2257 ; 1940 ; 454 ; 2055 ; 2236 ; 1798 ; 302 ; 1971 ; 537 ; 2227 ; 2364 ; 2590 ; 411 ; 619 ; 543 ; 501 ; 509 ; 697 ; 440 ; 592 ; 689 ; 481 ; 713 ; 492 ; 655 ; 506 ; 1957 ; 2003 ; 533 ; 343 ; 431 ; 499 ; 422 ; 656 ; 511 ; 1865 ; 474 ; 569 ; 633 ; 643 ; 405 ; 452 ; 482 ; 362 ; 666 ; 349 ; 367 ; 2107 ; 616 ; 2216 ; 567 ; 522 ; 304 ; 2021 ; 462 ; 680 ; 300 ; 595 ; 1862 ; 699 ; 1972 ; 384 ; 508 ; 466 ; 342 ; 472 ; 641 ; 2041 ; 2190 ; 1889 ; 1955 ; 704 ; 397 ; 448 ; 1989 ; 330 ; 535 ; 484 ; 685 ; 510 ; 450 ; 500 ; 528 ; 577 ; 486 ; 1762 ; 301 ; 350 ; 521 ; 356 ; 327 ; 346 ; 549 ; 1933 ; 1726 ; 326 ; 612 ; 726 ; 599 ; 404 ; 629 ; 1784 ; 369 ; 2201 ; 2219 ; 2250 ; 2073 ; 2472 ; 1848 ; 1982 ; 386 ; 576 ; 453 ; 631 ; 387 ; 2529 ; 2495 ; 2475 ; 1800 ; 1887 ; 2030 ; 3409 ; 2431
DIAGNOSIS AGE	Black	China Pan-cancer (OrigiMed, Nature 2022)	NUMBER	Age at which a condition or disease was first diagnosed.	Patient	
GDNA(NG)	Black	China Pan-cancer (OrigiMed, Nature 2022)	NUMBER	DNA input	Sample	4776 ; 3876 ; 9720 ; 33840 ; 2412 ; 3144 ; 6720 ; 3228 ; 1656 ; 6360 ; 672 ; 5244 ; 18660 ; 5820 ; 25680 ; 301 ; 3120 ; 3960 ; 5052 ; 1968 ; 5592 ; 1524 ; 25080 ; 2892 ; 3528 ; 18360 ; 5280 ; 6000 ; 2472 ; 732 ; 3444 ; 2856 ; 117 ; 5184 ; 4176 ; 34680 ; 3912 ; 18240 ; 449 ; 20160 ; 7140 ; 170 ; 654 ; 2328 ; 9540 ; 1170 ; 3324 ; 786 ; 1704 ; 13320 ; 294 ; 1452 ; 3096 ; 20040 ; 12240 ; 5352 ; 7290 ; 6984 ; 1332 ; 1056 ; 1260 ; 125 ; 3636 ; 2388 ; 101 ; 792 ; 2868 ; 1272 ; 6060 ; 4080 ; 56 ; 2604 ; 2376 ; 6960 ; 558 ; 63 ; 5952 ; 6120 ; 236 ; 5868 ; 4056 ; 1608 ; 864 ; 1404 ; 1416 ; 4140 ; 5088 ; 3588 ; 155 ; 2352 ; 2928 ; 3456 ; 133 ; 180 ; 774 ; 2088 ; 3888 ; 2172 ; 1164 ; 1860 ; 3672 ; 3792 ; 2124 ; 870 ; 3384 ; 503 ; 1146 ; 1932 ; 284 ; 3990 ; 2904 ; 2004 ; 2556 ; 2016 ; 4332 ; 140 ; 248 ; 606 ; 331 ; 4860 ; 1134 ; 4956 ; 2316 ; 527 ; 574 ; 2820 ; 178 ; 366 ; 2592 ; 575 ; 4452 ; 666 ; 2280 ; 5412 ; 451 ; 4224 ; 1872 ; 2664 ; 70 ; 334 ; 848 ; 2112 ; 828 ; 272 ; 3852 ; 302 ; 4236 ; 705 ; 107 ; 1110 ; 1908 ; 459 ; 5940 ; 447 ; 5049 ; 642 ; 368 ; 579 ; 825 ; 1992 ; 3072 ; 3360 ; 2550 ; 2028 ; 3594 ; 3390 ; 1248 ; 3828 ; 2298 ; 4872 ; 3744 ; 5262 ; 4212 ; 2502 ; 1302 ; 144 ; 276 ; 5328 ; 3108 ; 1440 ; 4242 ; 4464 ; 5796 ; 5568 ; 2442 ; 2082 ; 328 ; 4992 ; 4806 ; 5178 ; 310 ; 5712 ; 326 ; 954 ; 2118 ; 4524 ; 3894 ; 4986 ; 4530 ; 5358 ; 4794 ; 2574 ; 586 ; 4626 ; 497 ; 4086 ; 5004 ; 4878 ; 408 ; 216 ; 2268 ; 5982 ; 4602 ; 1620 ; 1950 ; 2784 ; 5652 ; 2262 ; 3600 ; 1122 ; 5478 ; 1476 ; 4824 ; 5040 ; 4692 ; 4254 ; 816 ; 771 ; 5136 ; 2958 ; 2850 ; 4644 ; 319 ; 3234 ; 4968 ; 3066 ; 258 ; 3954 ; 5292 ; 2676 ; 3816 ; 3180 ; 1788 ; 3858 ; 4830 ; 143 ; 4044 ; 14610 ; 5022 ; 4662 ; 404 ; 948 ; 3984 ; 6840 ; 4296 ; 5610 ; 3042 ; 3576 ; 768 ; 4716 ; 2484 ; 110 ; 418 ; 518 ; 2304 ; 1080 ; 804 ; 4752 ; 5808 ; 4416 ; 4260 ; 200 ; 2076 ; 2628 ; 1500 ; 1128 ; 1944 ; 4812 ; 3840 ; 1752 ; 3132 ; 4440 ; 3708 ; 4320 ; 5316 ; 7080 ; 2244 ; 3540 ; 4848 ; 5220 ; 888 ; 3864 ; 3756 ; 5436 ; 7200 ; 474 ; 3972 ; 1044 ; 5856 ; 3768 ; 4764 ; 4068 ; 6600 ; 5772 ; 480 ; 3396 ; 3936 ; 3480 ; 3516 ; 4356 ; 5976 ; 696 ; 2292 ; 232 ; 2700 ; 179 ; 846 ; 756 ; 61 ; 2544 ; 4980 ; 6480 ; 68 ; 6240 ; 930 ; 4572 ; 3906 ; 3336 ; 3948 ; 4164 ; 384 ; 5472 ; 360 ; 5076 ; 4032 ; 5232 ; 4920 ; 3552 ; 430 ; 1848 ; 5880 ; 523 ; 2340 ; 684 ; 3168 ; 5760 ; 1896 ; 5388 ; 3504 ; 3276 ; 4284 ; 4308 ; 3432 ; 4788 ; 124 ; 4404 ; 3300 ; 4380 ; 3924 ; 4020 ; 726 ; 4668 ; 522 ; 274 ; 191 ; 5508 ; 4500 ; 1074 ; 8040 ; 5304 ; 810 ; 1716 ; 563 ; 5748 ; 1344 ; 148 ; 211 ; 163 ; 4104 ; 3624 ; 4008 ; 354 ; 4512 ; 636 ; 5148 ; 780 ; 1158 ; 3288 ; 3996 ; 3240 ; 5700 ; 1050 ; 305 ; 494 ; 3468 ; 1668 ; 1212 ; 4728 ; 3060 ; 377 ; 3216 ; 20700 ; 19020 ; 5064 ; 13020 ; 11640 ; 407 ; 3252 ; 344 ; 3720 ; 1692 ; 4608 ; 4248 ; 4200 ; 112 ; 750 ; 3372 ; 900 ; 4896 ; 113 ; 3660 ; 4584 ; 3780 ; 410 ; 4092 ; 10800 ; 5916 ; 5580 ; 4932 ; 4392 ; 457 ; 3036 ; 4272 ; 5208 ; 3312 ; 924 ; 4344 ; 3612 ; 4836 ; 2496 ; 1728 ; 942 ; 2160 ; 4560 ; 4188 ; 187 ; 1194 ; 214 ; 298 ; 2208 ; 2976 ; 4536 ; 5376 ; 5604 ; 4800 ; 3696 ; 5892 ; 2064 ; 5964 ; 5736 ; 391 ; 918 ; 4548 ; 5340 ; 5640 ; 1098 ; 3564 ; 2196 ; 544 ; 1062 ; 380 ; 3084 ; 371 ; 4596 ; 2748 ; 89 ; 5028 ; 132 ; 624 ; 164 ; 188 ; 3192 ; 517 ; 438 ; 4704 ; 3492 ; 5400 ; 1572 ; 5160 ; 3156 ; 990 ; 2940 ; 88 ; 2052 ; 5664 ; 5448 ; 500 ; 398 ; 2988 ; 3732 ; 2652 ; 458 ; 2772 ; 3012 ; 278 ; 4488 ; 8340 ; 3000 ; 473 ; 5832 ; 560 ; 1296 ; 308 ; 176 ; 1236 ; 2640 ; 960 ; 67 ; 83 ; 526 ; 2712 ; 2580 ; 535 ; 1104 ; 5112 ; 1836 ; 1548 ; 5172 ; 2808 ; 271 ; 289 ; 1824 ; 1284 ; 71 ; 400 ; 1368 ; 593 ; 4116 ; 336 ; 131 ; 4428 ; 5268 ; 5256 ; 587 ; 2760 ; 54 ; 2520 ; 618 ; 454 ; 822 ; 347 ; 5124 ; 2880 ; 3408 ; 1320 ; 15420 ; 4476 ; 5628 ; 1464 ; 160 ; 1356 ; 2634 ; 978 ; 120 ; 119 ; 2148 ; 322 ; 2364 ; 5784 ; 442 ; 4152 ; 3420 ; 4620 ; 2220 ; 906 ; 280 ; 138 ; 5484 ; 4884 ; 203 ; 4680 ; 295 ; 2040 ; 5460 ; 385 ; 678 ; 2736 ; 299 ; 599 ; 882 ; 5016 ; 228 ; 420 ; 4368 ; 425 ; 972 ; 744 ; 762 ; 1980 ; 182 ; 116 ; 379 ; 852 ; 222 ; 281 ; 578 ; 3048 ; 1536 ; 3264 ; 4632 ; 1152 ; 2184 ; 9276 ; 1560 ; 100 ; 2400 ; 5364 ; 1776 ; 1068 ; 5556 ; 136 ; 277 ; 3024 ; 361 ; 130 ; 1026 ; 439 ; 2568 ; 3684 ; 5520 ; 966 ; 74 ; 1584 ; 514 ; 157 ; 4908 ; 1176 ; 1812 ; 256 ; 1512 ; 320 ; 341 ; 5904 ; 565 ; 486 ; 1428 ; 2460 ; 73 ; 91 ; 487 ; 288 ; 5100 ; 92 ; 3348 ; 367 ; 204 ; 1014 ; 443 ; 264 ; 15360 ; 5424 ; 11280 ; 168 ; 20820 ; 194 ; 714 ; 355 ; 21420 ; 15180 ; 568 ; 2508 ; 5616 ; 580 ; 233 ; 589 ; 2532 ; 1800 ; 1032 ; 23100 ; 14040 ; 413 ; 5928 ; 1884 ; 90 ; 1644 ; 570 ; 1182 ; 14160 ; 246 ; 10140 ; 2688 ; 114 ; 23400 ; 5844 ; 14280 ; 13620 ; 690 ; 156 ; 10080 ; 412 ; 416 ; 539 ; 202 ; 2916 ; 139 ; 1632 ; 401 ; 858 ; 80 ; 5688 ; 11700 ; 552 ; 1092 ; 292 ; 13980 ; 350 ; 630 ; 545 ; 490 ; 199 ; 1740 ; 720 ; 1392 ; 708 ; 239 ; 5544 ; 17940 ; 208 ; 1188 ; 16140 ; 2436 ; 2844 ; 2232 ; 1242 ; 293 ; 282 ; 738 ; 1308 ; 702 ; 383 ; 5496 ; 4656 ; 98 ; 984 ; 1086 ; 13680 ; 244 ; 798 ; 234 ; 600 ; 14700 ; 212 ; 2964 ; 252 ; 1002 ; 96 ; 936 ; 106 ; 19320 ; 409 ; 538 ; 142 ; 266 ; 150 ; 53 ; 158 ; 2832 ; 175 ; 612 ; 521 ; 69 ; 190 ; 2424 ; 648 ; 104 ; 72 ; 240 ; 270 ; 349 ; 515 ; 22920 ; 894 ; 378 ; 245 ; 370 ; 250 ; 3900 ; 215 ; 167 ; 304 ; 529 ; 79 ; 118 ; 462 ; 3648 ; 460 ; 17100 ; 660 ; 13080 ; 186 ; 472 ; 3804 ; 262 ; 15300 ; 13740 ; 4944 ; 4128 ; 834 ; 1008 ; 1200 ; 2448 ; 554 ; 51 ; 463 ; 135 ; 224 ; 508 ; 376 ; 9120 ; 197 ; 23340 ; 12180 ; 26100 ; 87 ; 23940 ; 2796 ; 373 ; 18600 ; 510 ; 1596 ; 318 ; 1140 ; 97 ; 173 ; 1488 ; 10620 ; 528 ; 1224 ; 448 ; 12540 ; 19080 ; 364 ; 307 ; 338 ; 1020 ; 145 ; 551 ; 66 ; 2190 ; 402 ; 524 ; 540 ; 5532 ; 263 ; 198 ; 1038 ; 268 ; 151 ; 206 ; 491 ; 840 ; 432 ; 1764 ; 353 ; 275 ; 4740 ; 484 ; 286 ; 365 ; 128 ; 571 ; 533 ; 550 ; 452 ; 2616 ; 343 ; 996 ; 210 ; 205 ; 103 ; 108 ; 58 ; 583 ; 1956 ; 122 ; 1680 ; 152 ; 576 ; 5988 ; 335 ; 488 ; 374 ; 126 ; 1920 ; 455 ; 581 ; 329 ; 166 ; 5676 ; 127 ; 506 ; 542 ; 247 ; 406 ; 485 ; 15900 ; 235 ; 115 ; 1380 ; 582 ; 137 ; 440 ; 520 ; 2724 ; 464 ; 65 ; 475 ; 548 ; 220 ; 502 ; 2100 ; 414 ; 468 ; 386 ; 598 ; 5724 ; 64 ; 427 ; 52 ; 564 ; 2952 ; 94 ; 11580 ; 15660 ; 15240 ; 223 ; 11880 ; 9240 ; 14580 ; 8640 ; 11100 ; 16200 ; 10500 ; 466 ; 534 ; 12300 ; 174 ; 21240 ; 12600 ; 81 ; 446 ; 181 ; 912 ; 217 ; 467 ; 492 ; 296 ; 154 ; 85 ; 450 ; 476 ; 469 ; 3606 ; 134 ; 184 ; 20940 ; 509 ; 4950 ; 434 ; 453 ; 109 ; 12480 ; 559 ; 226 ; 17160 ; 2799 ; 2241 ; 2421 ; 4203 ; 1926 ; 9600 ; 3054 ; 2097 ; 1611 ; 2826 ; 14340 ; 671 ; 388 ; 6144 ; 20610 ; 2970 ; 34200 ; 2295 ; 18060 ; 340 ; 1614 ; 17820 ; 11940 ; 22500 ; 16620 ; 19800 ; 16380 ; 19560 ; 1230 ; 6294 ; 1089 ; 4158 ; 5946 ; 12510 ; 5058 ; 541 ; 3750 ; 362 ; 5574 ; 2778 ; 4746 ; 22320 ; 753 ; 1197 ; 6300 ; 6102 ; 5802 ; 6540 ; 27240 ; 13830 ; 6072 ; 1866 ; 17040 ; 3006 ; 543 ; 3270 ; 5790 ; 4374 ; 1698 ; 16320 ; 2226 ; 1890 ; 1374 ; 1005 ; 1494 ; 6420 ; 4182 ; 3978 ; 516 ; 6024 ; 13050 ; 4014 ; 10260 ; 4314 ; 9030 ; 3654 ; 4734 ; 12060 ; 2658 ; 3822 ; 22290 ; 22140 ; 16980 ; 19920 ; 5235 ; 2814 ; 2346 ; 313 ; 22680 ; 19980 ; 4194 ; 14970 ; 11250 ; 192 ; 681 ; 3630 ; 3078 ; 225 ; 2136 ; 14670 ; 8700 ; 4026 ; 605 ; 4902 ; 9360 ; 566 ; 218 ; 23880 ; 14730 ; 16860 ; 4470 ; 415 ; 553 ; 8880 ; 2202 ; 14130 ; 8160 ; 15540 ; 105 ; 584 ; 22620 ; 20100 ; 15040 ; 11220 ; 9840 ; 18780 ; 8820 ; 8100 ; 22380 ; 11460 ; 10740 ; 9000 ; 9180 ; 7740 ; 7680 ; 4326 ; 8220 ; 283 ; 9060 ; 8280 ; 4890 ; 876 ; 17760 ; 17520 ; 161 ; 19140 ; 1362 ; 4650 ; 9810 ; 265 ; 669 ; 6312 ; 3678 ; 4350 ; 4386 ; 5128 ; 358 ; 7980 ; 627 ; 348 ; 24240 ; 783 ; 3966 ; 14520 ; 13200 ; 9960 ; 1722 ; 231 ; 10200 ; 20880 ; 21540 ; 2922 ; 2382 ; 253 ; 129 ; 11520 ; 18960 ; 10560 ; 13140 ; 16920 ; 19440 ; 111 ; 8940 ; 4206 ; 19860 ; 4218 ; 359 ; 6780 ; 1938 ; 7260 ; 20340 ; 13860 ; 17340 ; 1458 ; 2418 ; 3150 ; 5970 ; 1782 ; 7020 ; 2334 ; 2610 ; 18000 ; 2934 ; 19740 ; 1542 ; 2394 ; 1506 ; 3618 ; 16500 ; 30000 ; 933 ; 4362 ; 5190 ; 1830 ; 2562 ; 2238 ; 7560 ; 15960 ; 3378 ; 21180 ; 387 ; 269 ; 2370 ; 639 ; 10380 ; 15840 ; 7920 ; 20460 ; 27480 ; 24180 ; 21000 ; 2466 ; 21900 ; 22800 ; 13560 ; 12660 ; 572 ; 10920 ; 11160 ; 3546 ; 9300 ; 14640 ; 27360 ; 26400 ; 22080 ; 7500 ; 9420 ; 13380 ; 6180 ; 8580 ; 389 ; 8520 ; 499 ; 11760 ; 2256 ; 16260 ; 60 ; 7860 ; 22260 ; 25440 ; 11400 ; 57 ; 3204 ; 10860 ; 9660 ; 6660 ; 9780 ; 5910 ; 356 ; 21360 ; 16020 ; 9480 ; 6900 ; 15930 ; 10422 ; 22200 ; 14760 ; 317 ; 12000 ; 7620 ; 18120 ; 18300 ; 496 ; 16560 ; 27900 ; 15720 ; 479 ; 11340 ; 14460 ; 22980 ; 12120 ; 20280 ; 23280 ; 504 ; 59 ; 456 ; 5670 ; 12360 ; 10320 ; 7380 ; 16740 ; 20520 ; 15600 ; 7440 ; 15060 ; 14100 ; 25320 ; 18840 ; 547 ; 15000 ; 24720 ; 5250 ; 43680 ; 13440 ; 21300 ; 395 ; 7800 ; 21720 ; 5010 ; 11820 ; 27120 ; 26160 ; 14400 ; 24840 ; 445 ; 17280 ; 121 ; 7320 ; 260 ; 10680 ; 12840 ; 18900 ; 424 ; 5850 ; 22020 ; 11040 ; 505 ; 185 ; 9900 ; 590 ; 16800 ; 512 ; 23640 ; 12720 ; 12900 ; 209 ; 557 ; 18540 ; 8400 ; 19260 ; 390 ; 16080 ; 24480 ; 26820 ; 238 ; 10440 ; 444 ; 8460 ; 493 ; 19380 ; 12960 ; 290 ; 26760 ; 19680 ; 95 ; 25140 ; 15570 ; 146 ; 5370 ; 314 ; 397 ; 17400 ; 2514 ; 221 ; 14940 ; 436 ; 18180 ; 4410 ; 5310 ; 14820 ; 5922 ; 29640 ; 23460 ; 13260 ; 352 ; 337 ; 17880 ; 17460 ; 556 ; 482 ; 11790 ; 14220 ; 162 ; 426 ; 5694 ; 5154 ; 10020 ; 23820 ; 546 ; 12780 ; 4770 ; 316 ; 3870 ; 346 ; 18420 ; 1116 ; 17580 ; 18720 ; 596 ; 396 ; 297 ; 102 ; 5550 ; 86 ; 325 ; 382 ; 330 ; 5430 ; 10980 ; 5730 ; 461 ; 62 ; 428 ; 8760 ; 25260 ; 431 ; 4710 ; 21120 ; 50 ; 149 ; 77 ; 13800 ; 22560 ; 21840 ; 530 ; 251 ; 433 ; 14880 ; 588 ; 13920 ; 19620 ; 24060 ; 172 ; 4590 ; 4110 ; 1770 ; 30240 ; 241 ; 5490 ; 259 ; 15120 ; 20580 ; 394 ; 21480 ; 18480 ; 22860 ; 13500 ; 5130 ; 30360 ; 592 ; 24600 ; 242 ; 332 ; 16440 ; 17640 ; 12420 ; 31800 ; 498 ; 372 ; 2106 ; 5598 ; 569 ; 2142 ; 23160 ; 562 ; 3114 ; 11952 ; 963 ; 4422 ; 741 ; 4578 ; 2670 ; 2910 ; 837 ; 2586 ; 5898 ; 5502 ; 1566 ; 1554 ; 3126 ; 55 ; 169 ; 4106 ; 312 ; 93 ; 257 ; 193 ; 577 ; 909 ; 1278 ; 795 ; 603 ; 27540 ; 311 ; 99 ; 75 ; 323 ; 478 ; 7470 ; 76 ; 5196 ; 230 ; 306 ; 595 ; 300 ; 437 ; 28860 ; 1746 ; 2313 ; 207 ; 706 ; 2730 ; 4542 ; 1710 ; 803 ; 2367 ; 3450 ; 3222 ; 3186 ; 3522 ; 5718 ; 1686 ; 1626 ; 5466 ; 2058 ; 3642 ; 1806 ; 6630 ; 7650 ; 21780 ; 21960 ; 15104 ; 1674 ; 24000 ; 2790 ; 7771 ; 29032 ; 7505 ; 15086 ; 6783 ; 35150 ; 14212 ; 14706 ; 9766 ; 17708 ; 2322 ; 3246 ; 1410 ; 2010 ; 921 ; 1590 ; 861 ; 1662 ; 1914 ; 24540 ; 21600 ; 4050 ; 3810 ; 532 ; 17220 ; 23700 ; 25920 ; 536
SMOKE STATUS	Black	China Pan-cancer (OrigiMed, Nature 2022)	STRING	Smoke status	Patient	
TUMOR_PURTITY	Black	China Pan-cancer (OrigiMed, Nature 2022)	NUMBER	Tumor purity	Sample	45 ; 40 ; 60 ; 85 ; 75 ; 50 ; 20 ; 95 ; 15 ; 30 ; 90 ; 65 ; 35 ; 12 ; 80 ; 70 ; 10 ; 99 ; 25 ; 49 ; 98 ; 55 ; 96 ; 88 ; 48 ; 69
ALCOHOL	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Alcohol	Patient	
ALCOHOL_HISTORY_INTENSITY	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Alcohol History Intensity	Patient	
ANCESTRY_PRIMARY	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Primary Ancestry	Sample	EUR ; ASN ; SAN ; AFR ; AMR
FIRST THERAPY_RESPONSE	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	First Therapy Response	Patient	
FIRST_THERAPY	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	First Therapy	Patient	
HISTOLOGY_ABBREVIATION	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Histology Abbreviation	Sample	Bladder-TCC ; Breast-AdenoCA ; Ovary-AdenoCA ; Panc-Endocrine ; Prost-AdenoCA ; Kidney-RCC ; Skin-Melanoma ; Stomach-AdenoCA ; Thy-AdenoCA ; Liver-HCC ; CNS-Medullo ; Cervix-SCC ; Cervix-AdenoCA ; Panc-AdenoCA ; Myeloid-AML ; Eso-AdenoCA ; Lymph-CLL ; Head-SCC ; Bone-Epith ; Bone-Benign ; Bone-Osteosarc ; Bone-Osteoblast ; Bone-Cart ; Lymph-BNHL ; Myeloid-MPN ; Myeloid-MDS ; Biliary-AdenoCA ; Breast-LobularCA ; Breast-DCIS ; ColoRect-AdenoCA ; SoftTissue-Liposarc ; SoftTissue-Leiomyo ; Kidney-ChRCC ; CNS-GBM ; CNS-Oligo ; Lung-AdenoCA ; Lung-SCC ; CNS-PiloAstro ; Uterus-AdenoCA
HISTOLOGY_TIER1	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Histology Tier2	Sample	ENDODERM ; ECTODERM ; MESODERM ; NEURAL_CREST
HISTOLOGY_TIER2	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Histology Tier3	Sample	Bladder ; Breast ; Ovary ; Pancreas ; Prostate ; Kidney ; Skin ; Stomach ; Thyroid ; Liver ; CNS ; Cervix ; Myeloid ; Esophagus ; Lymphoid ; Head/Neck ; Bone/SoftTissue ; Biliary ; Colon/Rectum ; Lung ; Uterus
HISTOLOGY_TIER3	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Histology Tier4	Sample	Transitional cell carcinoma ; Adenocarcinoma ; Neuroendocrine tumor ; Renal cell carcinoma (proximal tubules) ; Melanoma ; Hepatocellular carcinoma ; Medulloblastoma ; Squamous cell carcinoma ; Acute myeloid leukemia ; Chronic lymphocytic leukemia ; Bone neoplasm, epithelioid ; Bone neoplasm, benign ; Sarcoma, bone ; Cartilaginous neoplasm, benign, bone ; Mature B-cell lymphoma ; Lymphoma, NOS ; Myeloproliferative neoplasm ; Myelodysplastic syndrome ; Lobular carcinoma ; In situ adenocarcinoma ; Liposarcoma, soft tissue ; Sarcoma, soft tissue ; Renal cell carcinoma (distal tubules) ; Diffuse glioma ; Non-diffuse glioma
HISTOLOGY_TIER4	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Histology Tier5	Sample	Transitional cell carcinoma, papillary ; Infiltrating duct carcinoma ; Transitional cell carcinoma ; Serous cystadenocarcinoma ; Adenocarcinoma ; Neoroendocrine carcinoma ; Adenocarcinoma, clear cell type ; Malignant melanoma ; Adenocarcinoma, mucinous ; Adenocarcinoma, papillary ; Adenocarcinoma, poorly cohesive ; Adenocarcinoma, tubular ; Adenocarcinoma, follicular type ; Adenocarcinoma, classical type ; Adenocarcinoma, papillary type ; Hepatocellular carcinoma ; Fibrolamellar hepatocellular carcinoma ; Desmoplastic medulloblastoma ; Medulloblastoma ; Large cell medulloblastoma ; Squamous Cell Carcinoma ; Pancreatic ductal carcinoma ; Acinar cell carcinoma ; Carcinoma, adenosquamous ; Invasive carcinoma arising in IPMN ; Acute myeloid leukemia ; Chronic lymphocytic leukemia ; Squamous cell carcinoma ; Chordoma ; Adamantinoma ; Osteofibrous dysplasia ; Osteosarcoma ; Osteoblastoma ; Chrondromyxoid fibroma ; Chondroblastoma ; Follicular lymphoma ; Diffse large B-cell lymphoma ; Marginal zone B-cell lymphoma ; Burkitt lymphoma ; Malignant lymphoma, NOS ; Essential thrombocythemia ; Myelodysplastic syndrome with ring sideroblasts ; Polycythemia vera ; Systemic mastocytosis ; Chronic myelomonocytic leukemia ; Cholangiocarcinoma, papillary ; Lobular carcinoma ; Cholangiocarcinoma ; Intraductal papillary adenocarcinoma with invasion ; Duct micropapillary carcinoma ; Medullary carcinonoma ; Liposarcoma ; Leiomyosarcoma ; Adenocarcinoma, chromophobe type ; Glioblastoma ; Mucinous adenocarcinoma ; Oligodendroglioma ; Adenocarcinoma, invasive ; Adenocarcinoma, in situ ; Adenocarcinoma, invasive, mucinous ; Basaloid squamous cell carcinoma ; Post-transplant lymphoproliferative disorder, early lesion ; Pilocytic astrocytoma ; Adenocarcinoma, columnar cell type ; Adenocarcinoma, endometrioid ; Combined hepatocellular + cholangiocarcinoma
ICGC_SAMPLE_ID	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	ICGC Sample ID	Sample	SA4557 ; SA48667 ; SA4666 ; SA49610 ; SA505244 ; SA505270 ; SA505282 ; SA505297 ; SA505316 ; SA505328 ; SA505351 ; SA505363 ; SA505379 ; SA505389 ; SA505404 ; SA505416 ; SA505437 ; SA505458 ; SA505492 ; SA505503 ; SA505516 ; SA505529 ; SA505540 ; SA505551 ; SA505563 ; SA505577 ; SA505591 ; SA505613 ; SA505633 ; SA505654 ; SA505676 ; SA505702 ; SA505730 ; SA505750 ; SA505780 ; SA505795 ; SA505808 ; SA505821 ; SA505835 ; SA505850 ; SA505863 ; SA505889 ; SA505904 ; SA505918 ; SA505933 ; SA505944 ; SA505950 ; SA505245 ; SA505258 ; SA505271 ; SA505352 ; SA505478 ; SA505493 ; SA505539 ; SA505545 ; SA505657 ; SA505675 ; SA505690 ; SA505701 ; SA505711 ; SA505727 ; SA505738 ; SA505754 ; SA505768 ; SA505781 ; SA505796 ; SA505809 ; SA505825 ; SA505861 ; SA505872 ; SA505885 ; SA505897 ; SA505919 ; SA506648 ; SA506656 ; SA506664 ; SA506672 ; SA506676 ; SA506682 ; SA506688 ; SA506694 ; SA506702 ; SA506706 ; SA506712 ; SA506657 ; SA506663 ; SA506669 ; SA506679 ; SA506687 ; SA506693 ; SA506701 ; SA506707 ; SA506713 ; SA506736 ; SA506738 ; SA506742 ; SA506746 ; SA506749 ; SA506725 ; SA506730 ; SA506887 ; SA507122 ; SA507128 ; SA507152 ; SA507164 ; SA507173 ; SA507185 ; SA507191 ; SA507213 ; SA507225 ; SA507234 ; SA507246 ; SA507258 ; SA507268 ; SA507296 ; SA507302 ; SA507314 ; SA507326 ; SA507332 ; SA507338 ; SA507348 ; SA507357 ; SA507363 ; SA507369 ; SA507381 ; SA507393 ; SA507405 ; SA507417 ; SA507421 ; SA507430 ; SA507436 ; SA507448 ; SA507463 ; SA507484 ; SA507491 ; SA507503 ; SA507536 ; SA507548 ; SA507554 ; SA507563 ; SA507572 ; SA507584 ; SA507132 ; SA507141 ; SA507171 ; SA507214 ; SA507223 ; SA507229 ; SA507238 ; SA507244 ; SA507250 ; SA507259 ; SA507269 ; SA507282 ; SA507300 ; SA507306 ; SA507312 ; SA507321 ; SA507330 ; SA507336 ; SA507352 ; SA507367 ; SA507373 ; SA507385 ; SA507431 ; SA507437 ; SA507443 ; SA507452 ; SA507464 ; SA507473 ; SA507488 ; SA507501 ; SA507585 ; SA507599 ; SA507607 ; SA508574 ; SA508988 ; SA509993 ; SA508441 ; SA509149 ; SA53799 ; SA510861 ; SA511031 ; SA511174 ; SA511841 ; SA512610 ; SA513126 ; SA510473 ; SA510551 ; SA511386 ; SA511683 ; SA512386 ; SA55269 ; SA512902 ; SA513601 ; SA514022 ; SA513543 ; SA5501 ; SA514077 ; SA492104 ; SA514999 ; SA515399 ; SA515781 ; SA515972 ; SA516035 ; SA514993 ; SA514891 ; SA515104 ; SA514903 ; SA514917 ; SA514905 ; SA515277 ; SA514919 ; SA514921 ; SA514951 ; SA514930 ; SA514933 ; SA514937 ; SA514936 ; SA514948 ; SA514961 ; SA515214 ; SA515218 ; SA515222 ; SA515233 ; SA515239 ; SA515248 ; SA515254 ; SA515261 ; SA515266 ; SA515270 ; SA515276 ; SA515281 ; SA515286 ; SA515292 ; SA515296 ; SA515298 ; SA515300 ; SA515302 ; SA515305 ; SA515307 ; SA515309 ; SA515312 ; SA515314 ; SA515316 ; SA515318 ; SA515322 ; SA515327 ; SA515333 ; SA515339 ; SA515347 ; SA515353 ; SA515360 ; SA515367 ; SA515373 ; SA515377 ; SA515383 ; SA515389 ; SA515397 ; SA515407 ; SA515415 ; SA515422 ; SA515427 ; SA515438 ; SA515444 ; SA515450 ; SA515456 ; SA515463 ; SA515472 ; SA515479 ; SA517314 ; SA517316 ; SA517318 ; SA517321 ; SA517323 ; SA517326 ; SA517328 ; SA517333 ; SA517337 ; SA517344 ; SA517351 ; SA517355 ; SA517362 ; SA517366 ; SA517370 ; SA517374 ; SA517378 ; SA517415 ; SA517416 ; SA517417 ; SA517418 ; SA517419 ; SA517252 ; SA517253 ; SA517254 ; SA517255 ; SA517257 ; SA517258 ; SA517259 ; SA517260 ; SA517262 ; SA517263 ; SA517264 ; SA517265 ; SA517266 ; SA517267 ; SA517268 ; SA517269 ; SA517270 ; SA517271 ; SA517272 ; SA517273 ; SA517274 ; SA517275 ; SA517276 ; SA517277 ; SA517278 ; SA517279 ; SA517280 ; SA517281 ; SA517282 ; SA517283 ; SA517284 ; SA517286 ; SA517287 ; SA517288 ; SA517289 ; SA517371 ; SA517373 ; SA517375 ; SA517376 ; SA517379 ; SA517381 ; SA517382 ; SA517384 ; SA517385 ; SA517387 ; SA517389 ; SA517390 ; SA517453 ; SA517715 ; SA517802 ; SA517839 ; SA517532 ; SA517730 ; SA517856 ; SA518599 ; SA518628 ; SA518721 ; SA518632 ; SA518634 ; SA518611 ; SA518723 ; SA518664 ; SA518680 ; SA518601 ; SA518622 ; SA518699 ; SA518703 ; SA518876 ; SA518866 ; SA518739 ; SA518764 ; SA518748 ; SA518804 ; SA518808 ; SA518816 ; SA518850 ; SA649 ; SA520420 ; SA520422 ; SA520425 ; SA520426 ; SA520427 ; SA520430 ; SA520431 ; SA520782 ; SA520910 ; SA60252 ; SA521593 ; SA521664 ; SA521717 ; SA521667 ; SA522399 ; SA524949 ; SA524966 ; SA525036 ; SA525054 ; SA61440 ; SA528686 ; SA528682 ; SA528674 ; SA528740 ; SA528671 ; SA528745 ; SA528754 ; SA528760 ; SA528708 ; SA528782 ; SA528784 ; SA528786 ; SA528788 ; SA528790 ; SA528792 ; SA528793 ; SA528795 ; SA528798 ; SA528799 ; SA528802 ; SA528805 ; SA528806 ; SA528807 ; SA528809 ; SA528810 ; SA528811 ; SA528813 ; SA528815 ; SA528816 ; SA528819 ; SA528822 ; SA528823 ; SA528825 ; SA528827 ; SA528829 ; SA528831 ; SA528833 ; SA528836 ; SA528838 ; SA528839 ; SA528843 ; SA528845 ; SA528846 ; SA528848 ; SA528850 ; SA528853 ; SA528854 ; SA528855 ; SA528858 ; SA528861 ; SA528863 ; SA528864 ; SA528866 ; SA528868 ; SA528870 ; SA528872 ; SA528874 ; SA528876 ; SA528878 ; SA528881 ; SA528883 ; SA528884 ; SA528886 ; SA528890 ; SA528892 ; SA528895 ; SA528896 ; SA528898 ; SA528899 ; SA528900 ; SA528901 ; SA528902 ; SA528903 ; SA528904 ; SA528906 ; SA528908 ; SA528909 ; SA528912 ; SA528914 ; SA528916 ; SA528918 ; SA528920 ; SA528922 ; SA528925 ; SA528926 ; SA528928 ; SA528930 ; SA528932 ; SA528938 ; SA528939 ; SA528941 ; SA528943 ; SA528945 ; SA528947 ; SA528954 ; SA528956 ; SA528959 ; SA528962 ; SA528964 ; SA528966 ; SA528968 ; SA528970 ; SA528971 ; SA528973 ; SA528974 ; SA528989 ; SA528961 ; SA528963 ; SA528965 ; SA528993 ; SA528995 ; SA528997 ; SA528999 ; SA528991 ; SA528949 ; SA1181 ; SA63181 ; SA270450 ; SA529714 ; SA529716 ; SA529718 ; SA529720 ; SA529722 ; SA529724 ; SA529726 ; SA529728 ; SA529730 ; SA529732 ; SA529735 ; SA529737 ; SA529739 ; SA529741 ; SA529743 ; SA529747 ; SA529749 ; SA529751 ; SA529753 ; SA529756 ; SA529759 ; SA529766 ; SA529770 ; SA529774 ; SA529777 ; SA529783 ; SA529787 ; SA529792 ; SA529796 ; SA529800 ; SA529803 ; SA529807 ; SA529811 ; SA529818 ; SA529823 ; SA529827 ; SA529830 ; SA529835 ; SA529841 ; SA529845 ; SA529849 ; SA529853 ; SA529858 ; SA529863 ; SA529869 ; SA529876 ; SA529881 ; SA529884 ; SA529897 ; SA529901 ; SA529905 ; SA492174 ; SA530426 ; SA530428 ; SA530430 ; SA530432 ; SA530434 ; SA530436 ; SA530438 ; SA530440 ; SA530442 ; SA530444 ; SA530446 ; SA530448 ; SA530450 ; SA530452 ; SA530458 ; SA530460 ; SA530462 ; SA530464 ; SA530466 ; SA530472 ; SA530475 ; SA530479 ; SA530483 ; SA530489 ; SA530493 ; SA530502 ; SA530506 ; SA530509 ; SA530514 ; SA530526 ; SA530530 ; SA530533 ; SA530538 ; SA530547 ; SA530551 ; SA530556 ; SA530559 ; SA530563 ; SA530567 ; SA530571 ; SA530575 ; SA530579 ; SA530582 ; SA530586 ; SA530591 ; SA530595 ; SA530599 ; SA530468 ; SA530470 ; SA530473 ; SA530478 ; SA530485 ; SA530488 ; SA530492 ; SA530496 ; SA530500 ; SA530503 ; SA530507 ; SA530512 ; SA530515 ; SA530519 ; SA530524 ; SA530527 ; SA530532 ; SA530535 ; SA530539 ; SA64750 ; SA530542 ; SA530546 ; SA530553 ; SA530558 ; SA530562 ; SA530566 ; SA530570 ; SA530578 ; SA530583 ; SA530587 ; SA530590 ; SA530598 ; SA530602 ; SA530604 ; SA530606 ; SA530608 ; SA530610 ; SA530612 ; SA530614 ; SA530616 ; SA530618 ; SA530620 ; SA530622 ; SA530624 ; SA530626 ; SA530628 ; SA530632 ; SA530634 ; SA530638 ; SA530642 ; SA530644 ; SA530646 ; SA530648 ; SA530650 ; SA530652 ; SA530654 ; SA530656 ; SA531152 ; SA1556 ; SA534051 ; SA534431 ; SA534591 ; SA534389 ; SA1694 ; SA538871 ; SA538877 ; SA538899 ; SA538905 ; SA538917 ; SA538869 ; SA538872 ; SA538885 ; SA538909 ; SA538911 ; SA539021 ; SA539023 ; SA538975 ; SA538977 ; SA538980 ; SA538983 ; SA538985 ; SA538992 ; SA538995 ; SA538998 ; SA539000 ; SA539002 ; SA539004 ; SA539006 ; SA539008 ; SA539010 ; SA539012 ; SA539014 ; SA539019 ; SA539321 ; SA540506 ; SA540527 ; SA540960 ; SA541742 ; SA541744 ; SA541747 ; SA541749 ; SA541751 ; SA541753 ; SA541755 ; SA541757 ; SA541759 ; SA541763 ; SA541731 ; SA541738 ; SA541741 ; SA541752 ; SA541768 ; SA541776 ; SA541778 ; SA541780 ; SA541782 ; SA541784 ; SA541786 ; SA541788 ; SA541790 ; SA541791 ; SA541792 ; SA541793 ; SA541812 ; SA541814 ; SA541816 ; SA541820 ; SA541822 ; SA541824 ; SA541826 ; SA541828 ; SA541830 ; SA541832 ; SA541834 ; SA541836 ; SA541838 ; SA541840 ; SA541842 ; SA541844 ; SA541846 ; SA541848 ; SA541850 ; SA541852 ; SA541854 ; SA541856 ; SA541858 ; SA541860 ; SA541946 ; SA541948 ; SA541952 ; SA541954 ; SA541960 ; SA541910 ; SA541964 ; SA541912 ; SA541966 ; SA541972 ; SA541914 ; SA541916 ; SA541918 ; SA541976 ; SA541978 ; SA541980 ; SA541982 ; SA541984 ; SA541920 ; SA541922 ; SA541924 ; SA541926 ; SA541928 ; SA541930 ; SA541932 ; SA541934 ; SA541936 ; SA541938 ; SA541940 ; SA541942 ; SA541944 ; SA541986 ; SA541868 ; SA541874 ; SA541876 ; SA541880 ; SA541882 ; SA541884 ; SA541886 ; SA541888 ; SA541890 ; SA541892 ; SA541990 ; SA541992 ; SA541994 ; SA541996 ; SA541998 ; SA542000 ; SA542002 ; SA542004 ; SA542006 ; SA542008 ; SA542010 ; SA542014 ; SA541894 ; SA541896 ; SA541898 ; SA541900 ; SA541902 ; SA541904 ; SA541906 ; SA542053 ; SA542063 ; SA542082 ; SA542021 ; SA542024 ; SA542027 ; SA542046 ; SA542049 ; SA542054 ; SA542058 ; SA542062 ; SA542018 ; SA542034 ; SA542040 ; SA542043 ; SA542030 ; SA542064 ; SA542069 ; SA542096 ; SA542099 ; SA542101 ; SA542158 ; SA542078 ; SA542084 ; SA542087 ; SA542090 ; SA542093 ; SA542120 ; SA542123 ; SA542126 ; SA542072 ; SA542075 ; SA542105 ; SA542108 ; SA542111 ; SA542114 ; SA542117 ; SA542134 ; SA542137 ; SA542140 ; SA542143 ; SA542146 ; SA542149 ; SA542152 ; SA542155 ; SA542129 ; SA542132 ; SA542160 ; SA542163 ; SA542165 ; SA542167 ; SA542169 ; SA542171 ; SA542173 ; SA542175 ; SA542179 ; SA542181 ; SA542183 ; SA542185 ; SA542187 ; SA542189 ; SA542191 ; SA542193 ; SA542195 ; SA542199 ; SA542201 ; SA542203 ; SA542205 ; SA542207 ; SA542209 ; SA542211 ; SA542215 ; SA542217 ; SA542296 ; SA542301 ; SA542304 ; SA542307 ; SA542311 ; SA542312 ; SA542318 ; SA542221 ; SA542225 ; SA542228 ; SA542233 ; SA542236 ; SA542242 ; SA542246 ; SA542249 ; SA542252 ; SA542254 ; SA542257 ; SA542261 ; SA542265 ; SA542267 ; SA542270 ; SA542274 ; SA542277 ; SA542279 ; SA542282 ; SA542285 ; SA542289 ; SA542292 ; SA542295 ; SA542425 ; SA542426 ; SA542427 ; SA533773 ; SA520223 ; SA520264 ; SA542448 ; SA533726 ; SA542454 ; SA520312 ; SA542492 ; SA520252 ; SA520290 ; SA542510 ; SA542525 ; SA542535 ; SA542560 ; SA542561 ; SA533665 ; SA520168 ; SA542577 ; SA542602 ; SA533803 ; SA542640 ; SA542641 ; SA542650 ; SA542651 ; SA542683 ; SA542686 ; SA542695 ; SA542715 ; SA542718 ; SA542719 ; SA542735 ; SA533613 ; SA542783 ; SA520278 ; SA520292 ; SA542830 ; SA520182 ; SA520274 ; SA533580 ; SA520169 ; SA542869 ; SA542879 ; SA542888 ; SA542919 ; SA542920 ; SA542923 ; SA542928 ; SA542938 ; SA542942 ; SA520270 ; SA520318 ; SA520201 ; SA542993 ; SA520235 ; SA543023 ; SA533741 ; SA543056 ; SA543057 ; SA533786 ; SA543073 ; SA533757 ; SA543090 ; SA543104 ; SA543105 ; SA543113 ; SA543114 ; SA543117 ; SA543124 ; SA543126 ; SA2042 ; SA543168 ; SA543178 ; SA543179 ; SA533681 ; SA543206 ; SA520203 ; SA520243 ; SA543254 ; SA520193 ; SA543282 ; SA533796 ; SA543302 ; SA543319 ; SA543349 ; SA520207 ; SA543399 ; SA543426 ; SA543433 ; SA533744 ; SA543482 ; SA543493 ; SA543496 ; SA543500 ; SA543530 ; SA543536 ; SA543541 ; SA543550 ; SA543553 ; SA543567 ; SA520304 ; SA533619 ; SA533716 ; SA520248 ; SA543590 ; SA533745 ; SA533702 ; SA533770 ; SA543605 ; SA543622 ; SA543631 ; SA520282 ; SA543663 ; SA543666 ; SA543681 ; SA543682 ; SA543685 ; SA533660 ; SA543705 ; SA543712 ; SA520215 ; SA543761 ; SA543762 ; SA533730 ; SA543785 ; SA543789 ; SA543790 ; SA543801 ; SA543820 ; SA543824 ; SA543843 ; SA543885 ; SA543895 ; SA543912 ; SA520283 ; SA543968 ; SA543977 ; SA544002 ; SA520214 ; SA520306 ; SA544029 ; SA544047 ; SA544050 ; SA544051 ; SA544072 ; SA533646 ; SA544083 ; SA533720 ; SA533651 ; SA520314 ; SA544135 ; SA544136 ; SA544186 ; SA544190 ; SA544229 ; SA544237 ; SA544238 ; SA533732 ; SA520258 ; SA544288 ; SA544289 ; SA544294 ; SA70945 ; SA533782 ; SA71810 ; SA72823 ; SA547730 ; SA74051 ; SA550978 ; SA551062 ; SA554224 ; SA554241 ; SA554313 ; SA554351 ; SA554370 ; SA554406 ; SA560590 ; SA554538 ; SA554562 ; SA554605 ; SA554627 ; SA554650 ; SA554674 ; SA554697 ; SA554721 ; SA554739 ; SA554785 ; SA75558 ; SA554807 ; SA554830 ; SA554852 ; SA553714 ; SA553777 ; SA553852 ; SA553891 ; SA554033 ; SA554054 ; SA554204 ; SA554247 ; SA554319 ; SA554379 ; SA554424 ; SA554446 ; SA554466 ; SA555030 ; SA556218 ; SA556241 ; SA556251 ; SA556263 ; SA556273 ; SA556295 ; SA556305 ; SA556315 ; SA556327 ; SA556337 ; SA556442 ; SA556462 ; SA556484 ; SA556506 ; SA556529 ; SA556571 ; SA556591 ; SA556610 ; SA556626 ; SA556647 ; SA556664 ; SA556682 ; SA556702 ; SA556719 ; SA556737 ; SA556816 ; SA556835 ; SA556859 ; SA556367 ; SA556410 ; SA556434 ; SA556458 ; SA556485 ; SA556530 ; SA556577 ; SA556600 ; SA556650 ; SA556675 ; SA556724 ; SA556791 ; SA556811 ; SA556832 ; SA556895 ; SA557043 ; SA557048 ; SA557050 ; SA557034 ; SA557036 ; SA557038 ; SA557046 ; SA557315 ; SA557318 ; SA557321 ; SA557322 ; SA557325 ; SA557327 ; SA557328 ; SA557331 ; SA557333 ; SA557338 ; SA557342 ; SA557347 ; SA557353 ; SA557357 ; SA557361 ; SA557366 ; SA557369 ; SA557373 ; SA557377 ; SA557381 ; SA557385 ; SA557389 ; SA557393 ; SA557397 ; SA557400 ; SA557404 ; SA557409 ; SA557413 ; SA557416 ; SA557420 ; SA557426 ; SA557431 ; SA557435 ; SA557437 ; SA557443 ; SA557447 ; SA557451 ; SA557454 ; SA557456 ; SA557459 ; SA557461 ; SA557464 ; SA557466 ; SA557470 ; SA557473 ; SA557476 ; SA557479 ; SA557480 ; SA557483 ; SA557486 ; SA557489 ; SA557491 ; SA557495 ; SA557498 ; SA557502 ; SA557505 ; SA557508 ; SA557512 ; SA557514 ; SA557519 ; SA557522 ; SA557526 ; SA557529 ; SA557532 ; SA557534 ; SA557537 ; SA557539 ; SA557541 ; SA557543 ; SA557546 ; SA557665 ; SA557668 ; SA557677 ; SA557689 ; SA558561 ; SA533750 ; SA533813 ; SA533688 ; SA533669 ; SA533643 ; SA533686 ; SA533647 ; SA533676 ; SA533703 ; SA533747 ; SA558678 ; SA520300 ; SA533768 ; SA533652 ; SA533801 ; SA533743 ; SA533706 ; SA533764 ; SA558699 ; SA533642 ; SA533714 ; SA533625 ; SA533649 ; SA558710 ; SA558715 ; SA533639 ; SA533709 ; SA533734 ; SA533666 ; SA533729 ; SA533724 ; SA533713 ; SA533723 ; SA533736 ; SA533674 ; SA533725 ; SA533746 ; SA520298 ; SA533784 ; SA533664 ; SA558648 ; SA533690 ; SA533615 ; SA558649 ; SA533661 ; SA533663 ; SA533753 ; SA533805 ; SA533684 ; SA520262 ; SA533695 ; SA533659 ; SA558653 ; SA533721 ; SA533781 ; SA533718 ; SA533815 ; SA520229 ; SA558655 ; SA558656 ; SA533777 ; SA520181 ; SA533698 ; SA558658 ; SA533668 ; SA533811 ; SA533758 ; SA533780 ; SA533779 ; SA533749 ; SA533797 ; SA533772 ; SA558659 ; SA520187 ; SA558660 ; SA533704 ; SA533653 ; SA560593 ; SA560599 ; SA560602 ; SA560605 ; SA560609 ; SA560612 ; SA560617 ; SA558645 ; SA82918 ; SA84185 ; SA3053 ; SA84360 ; SA84489 ; SA492581 ; SA84668 ; SA84896 ; SA86108 ; SA542382 ; SA86119 ; SA86126 ; SA86170 ; SA542383 ; SA86131 ; SA542384 ; SA86239 ; SA86276 ; SA86302 ; SA542385 ; SA542386 ; SA86314 ; SA86338 ; SA86347 ; SA86359 ; SA86383 ; SA86450 ; SA86476 ; SA86545 ; SA86551 ; SA86569 ; SA86575 ; SA86594 ; SA542387 ; SA86768 ; SA85244 ; SA85298 ; SA85340 ; SA542389 ; SA85506 ; SA85535 ; SA85553 ; SA542391 ; SA542392 ; SA569075 ; SA542932 ; SA560559 ; SA569081 ; SA569082 ; SA569072 ; SA560543 ; SA542966 ; SA543305 ; SA543730 ; SA544109 ; SA542564 ; SA542965 ; SA542473 ; SA542843 ; SA569080 ; SA543211 ; SA543593 ; SA544009 ; SA570833 ; SA570835 ; SA570837 ; SA542478 ; SA570839 ; SA542864 ; SA570841 ; SA543680 ; SA570843 ; SA542479 ; SA570845 ; SA570847 ; SA570849 ; SA570851 ; SA570853 ; SA570855 ; SA570857 ; SA570859 ; SA570861 ; SA542393 ; SA569077 ; SA543594 ; SA544185 ; SA570866 ; SA542619 ; SA544191 ; SA570870 ; SA542486 ; SA570874 ; SA543051 ; SA543199 ; SA570881 ; SA543781 ; SA570883 ; SA570885 ; SA570888 ; SA570892 ; SA570896 ; SA570899 ; SA570901 ; SA570903 ; SA570906 ; SA570911 ; SA570916 ; SA570921 ; SA570923 ; SA570925 ; SA570927 ; SA542394 ; SA542395 ; SA542396 ; SA3391 ; SA542397 ; SA85710 ; SA85722 ; SA3475 ; SA3721 ; SA3805 ; SA4138 ; SA5195 ; SA92158 ; SA93146 ; SA93904 ; SA95373 ; SA5378 ; SA5451 ; SA100712 ; SA101371 ; SA102816 ; SA5780 ; SA108597 ; SA111218 ; SA119548 ; SA121657 ; SA125187 ; SA126289 ; SA129949 ; SA130321 ; SA87265 ; SA88004 ; SA90162 ; SA100232 ; SA100868 ; SA102536 ; SA105050 ; SA6125 ; SA6128 ; SA6131 ; SA6134 ; SA6137 ; SA6140 ; SA6146 ; SA6149 ; SA6152 ; SA106552 ; SA6811 ; SA6158 ; SA6161 ; SA6167 ; SA6170 ; SA6173 ; SA6176 ; SA6179 ; SA112902 ; SA121680 ; SA6164 ; SA126265 ; SA130901 ; SA130905 ; SA130907 ; SA130909 ; SA130911 ; SA130913 ; SA130915 ; SA130868 ; SA130872 ; SA130876 ; SA130880 ; SA130882 ; SA130884 ; SA130886 ; SA130888 ; SA6155 ; SA130917 ; SA130919 ; SA130921 ; SA130963 ; SA130925 ; SA130927 ; SA6760 ; SA135301 ; SA136091 ; SA138061 ; SA138250 ; SA138738 ; SA141272 ; SA144576 ; SA146105 ; SA148718 ; SA151709 ; SA154417 ; SA155940 ; SA164299 ; SA164579 ; SA165304 ; SA167349 ; SA167759 ; SA173009 ; SA174372 ; SA183702 ; SA184257 ; SA494057 ; SA131728 ; SA132368 ; SA491558 ; SA139948 ; SA15776 ; SA142043 ; SA146608 ; SA18463 ; SA19615 ; SA150476 ; SA20573 ; SA152676 ; SA153016 ; SA20975 ; SA491600 ; SA560596 ; SA22515 ; SA158256 ; SA159460 ; SA163620 ; SA164854 ; SA166804 ; SA491630 ; SA176022 ; SA180317 ; SA182882 ; SA494103 ; SA26895 ; SA494168 ; SA191115 ; SA494229 ; SA494251 ; SA192727 ; SA192967 ; SA494271 ; SA194253 ; SA27437 ; SA195307 ; SA195900 ; SA494351 ; SA199271 ; SA200524 ; SA201351 ; SA201581 ; SA494507 ; SA202903 ; SA203048 ; SA203543 ; SA203853 ; SA494058 ; SA494078 ; SA494082 ; SA188108 ; SA494116 ; SA189208 ; SA494127 ; SA190261 ; SA191335 ; SA494253 ; SA494284 ; SA194387 ; SA195328 ; SA195822 ; SA494343 ; SA494399 ; SA494401 ; SA33121 ; SA200796 ; SA201430 ; SA201809 ; SA202848 ; SA33754 ; SA560606 ; SA209137 ; SA210843 ; SA213387 ; SA213642 ; SA214090 ; SA224647 ; SA227089 ; SA229532 ; SA230633 ; SA230964 ; SA231359 ; SA233294 ; SA37556 ; SA235957 ; SA236844 ; SA244508 ; SA245139 ; SA560614 ; SA247488 ; SA250087 ; SA250663 ; SA251496 ; SA204546 ; SA208440 ; SA211341 ; SA212393 ; SA212726 ; SA213217 ; SA215371 ; SA218331 ; SA219165 ; SA219639 ; SA226253 ; SA233266 ; SA240128 ; SA46800 ; SA246522 ; SA250273 ; SA254188 ; SA254332 ; SA254668 ; SA495538 ; SA494740 ; SA253172 ; SA253231 ; SA254758 ; SA255317 ; SA255656 ; SA495342 ; SA49664 ; SA50262 ; SA492021 ; SA492026 ; SA492027 ; SA261184 ; SA261595 ; SA262459 ; SA263853 ; SA266489 ; SA266786 ; SA266828 ; SA261436 ; SA262126 ; SA262624 ; SA492056 ; SA263196 ; SA264003 ; SA264069 ; SA264336 ; SA264474 ; SA264624 ; SA55071 ; SA266579 ; SA266783 ; SA267454 ; SA267658 ; SA267718 ; SA268117 ; SA268333 ; SA268465 ; SA268678 ; SA268889 ; SA268957 ; SA269167 ; SA269629 ; SA270088 ; SA267260 ; SA267307 ; SA267880 ; SA267949 ; SA268027 ; SA268288 ; SA268432 ; SA268591 ; SA268750 ; SA268834 ; SA269251 ; SA269323 ; SA269383 ; SA269680 ; SA270040 ; SA270380 ; SA270382 ; SA270384 ; SA270388 ; SA270390 ; SA270392 ; SA270394 ; SA270396 ; SA270398 ; SA270400 ; SA270402 ; SA270404 ; SA270406 ; SA270408 ; SA270412 ; SA270414 ; SA270416 ; SA270418 ; SA270420 ; SA270422 ; SA270423 ; SA270428 ; SA270430 ; SA270432 ; SA270434 ; SA270436 ; SA270438 ; SA270440 ; SA270442 ; SA270444 ; SA270446 ; SA270448 ; SA270452 ; SA57008 ; SA270454 ; SA270456 ; SA270458 ; SA270462 ; SA270464 ; SA270466 ; SA270468 ; SA275986 ; SA277382 ; SA277517 ; SA279763 ; SA279872 ; SA281267 ; SA281973 ; SA57479 ; SA283444 ; SA283996 ; SA286004 ; SA287592 ; SA290059 ; SA292647 ; SA294903 ; SA270862 ; SA271263 ; SA273031 ; SA273481 ; SA274485 ; SA60771 ; SA276242 ; SA278114 ; SA279342 ; SA279897 ; SA61837 ; SA281019 ; SA61999 ; SA283110 ; SA284573 ; SA62815 ; SA63265 ; SA286926 ; SA288366 ; SA289217 ; SA289879 ; SA290384 ; SA291007 ; SA291688 ; SA64373 ; SA292802 ; SA294650 ; SA295193 ; SA65784 ; SA296370 ; SA503211 ; SA503261 ; SA303138 ; SA305293 ; SA305520 ; SA305693 ; SA306668 ; SA503473 ; SA307650 ; SA503614 ; SA503701 ; SA66217 ; SA312300 ; SA313324 ; SA313680 ; SA503919 ; SA315264 ; SA315471 ; SA317999 ; SA504079 ; SA503179 ; SA298231 ; SA300605 ; SA301678 ; SA503358 ; SA304460 ; SA306087 ; SA306844 ; SA307536 ; SA503541 ; SA307934 ; SA308158 ; SA503612 ; SA503699 ; SA67692 ; SA309724 ; SA310244 ; SA310395 ; SA310500 ; SA68015 ; SA311872 ; SA68194 ; SA503898 ; SA503918 ; SA503921 ; SA313800 ; SA68521 ; SA315503 ; SA315959 ; SA317863 ; SA504055 ; SA320731 ; SA320818 ; SA320824 ; SA320830 ; SA320836 ; SA320842 ; SA320848 ; SA320854 ; SA320860 ; SA320866 ; SA320872 ; SA320878 ; SA320884 ; SA320890 ; SA320896 ; SA320902 ; SA320908 ; SA320914 ; SA320920 ; SA320926 ; SA320932 ; SA320938 ; SA320944 ; SA320950 ; SA320956 ; SA320962 ; SA320968 ; SA320974 ; SA320980 ; SA320986 ; SA320992 ; SA320998 ; SA321004 ; SA321012 ; SA321021 ; SA321030 ; SA321048 ; SA321057 ; SA321066 ; SA321023 ; SA321032 ; SA321041 ; SA321050 ; SA321103 ; SA321106 ; SA321111 ; SA321119 ; SA321128 ; SA321137 ; SA518422 ; SA518462 ; SA70525 ; SA518470 ; SA518485 ; SA350650 ; SA518504 ; SA518602 ; SA518890 ; SA359572 ; SA518893 ; SA518989 ; SA519317 ; SA72642 ; SA519788 ; SA519898 ; SA520037 ; SA520039 ; SA520043 ; SA74453 ; SA520082 ; SA520096 ; SA520113 ; SA520122 ; SA518254 ; SA324608 ; SA518379 ; SA518389 ; SA77461 ; SA518425 ; SA518448 ; SA518467 ; SA78527 ; SA518483 ; SA518547 ; SA518887 ; SA519106 ; SA80884 ; SA519499 ; SA81808 ; SA519854 ; SA519904 ; SA520028 ; SA82372 ; SA82966 ; SA83134 ; SA520078 ; SA520101 ; SA520105 ; SA520110 ; SA404138 ; SA407890 ; SA407922 ; SA407982 ; SA408406 ; SA411717 ; SA408562 ; SA408698 ; SA411002 ; SA408882 ; SA409179 ; SA409250 ; SA409294 ; SA409327 ; SA409438 ; SA409487 ; SA409538 ; SA409614 ; SA409651 ; SA409694 ; SA409882 ; SA410119 ; SA410202 ; SA410223 ; SA410303 ; SA410374 ; SA410399 ; SA410526 ; SA410574 ; SA410670 ; SA410847 ; SA410900 ; SA410918 ; SA410978 ; SA410997 ; SA411018 ; SA10195 ; SA411178 ; SA411205 ; SA411297 ; SA411401 ; SA411422 ; SA11798 ; SA408134 ; SA408187 ; SA12991 ; SA13738 ; SA14241 ; SA409766 ; SA410071 ; SA410190 ; SA410558 ; SA410851 ; SA410875 ; SA410892 ; SA410925 ; SA411225 ; SA411389 ; SA411549 ; SA411713 ; SA411737 ; SA411786 ; SA17443 ; SA411825 ; SA411995 ; SA412067 ; SA412207 ; SA412606 ; SA18702 ; SA412698 ; SA412707 ; SA412767 ; SA412935 ; SA413024 ; SA413072 ; SA413132 ; SA413193 ; SA413079 ; SA413127 ; SA413272 ; SA413275 ; SA413278 ; SA413282 ; SA413286 ; SA413290 ; SA413294 ; SA413298 ; SA413306 ; SA413318 ; SA413322 ; SA413326 ; SA413330 ; SA413334 ; SA413338 ; SA413342 ; SA413350 ; SA413354 ; SA413472 ; SA413480 ; SA413488 ; SA413492 ; SA413500 ; SA413504 ; SA413508 ; SA413512 ; SA413516 ; SA413520 ; SA413524 ; SA413540 ; SA413544 ; SA413552 ; SA413556 ; SA413560 ; SA413852 ; SA413855 ; SA413862 ; SA413886 ; SA413890 ; SA413894 ; SA413898 ; SA413902 ; SA413905 ; SA413910 ; SA413914 ; SA413918 ; SA413922 ; SA413926 ; SA413930 ; SA413934 ; SA413998 ; SA414026 ; SA414042 ; SA414046 ; SA414099 ; SA414135 ; SA414139 ; SA414143 ; SA414159 ; SA414167 ; SA414171 ; SA414175 ; SA414187 ; SA414191 ; SA414199 ; SA414203 ; SA414207 ; SA413356 ; SA413510 ; SA413518 ; SA413522 ; SA413538 ; SA413554 ; SA413558 ; SA413562 ; SA413566 ; SA413570 ; SA413574 ; SA413578 ; SA413582 ; SA413586 ; SA413590 ; SA413594 ; SA413598 ; SA413602 ; SA413606 ; SA413618 ; SA413622 ; SA413626 ; SA413630 ; SA413634 ; SA413638 ; SA413642 ; SA413646 ; SA413650 ; SA413652 ; SA413656 ; SA413660 ; SA413664 ; SA413668 ; SA413672 ; SA413676 ; SA413680 ; SA413684 ; SA413698 ; SA413702 ; SA413706 ; SA413710 ; SA413714 ; SA413718 ; SA413722 ; SA413726 ; SA413730 ; SA413734 ; SA413738 ; SA413742 ; SA413746 ; SA413750 ; SA413754 ; SA413758 ; SA413762 ; SA413766 ; SA413770 ; SA413774 ; SA413778 ; SA413782 ; SA413786 ; SA413794 ; SA413798 ; SA413802 ; SA413806 ; SA413814 ; SA413818 ; SA413822 ; SA413826 ; SA413830 ; SA413834 ; SA413837 ; SA413842 ; SA413846 ; SA413850 ; SA413854 ; SA413859 ; SA413864 ; SA413868 ; SA413871 ; SA413875 ; SA413880 ; SA413884 ; SA413888 ; SA413892 ; SA413896 ; SA413900 ; SA413904 ; SA413908 ; SA413912 ; SA413916 ; SA413920 ; SA413924 ; SA413928 ; SA413932 ; SA414401 ; SA414571 ; SA414677 ; SA414731 ; SA414744 ; SA414930 ; SA415032 ; SA415262 ; SA415950 ; SA416083 ; SA416401 ; SA417142 ; SA417676 ; SA417790 ; SA417841 ; SA417859 ; SA418289 ; SA420384 ; SA422769 ; SA423627 ; SA426710 ; SA427144 ; SA428143 ; SA22443 ; SA431122 ; SA419625 ; SA419987 ; SA422387 ; SA422904 ; SA23417 ; SA424790 ; SA426071 ; SA428353 ; SA428657 ; SA24487 ; SA433463 ; SA433988 ; SA434348 ; SA434417 ; SA434477 ; SA434525 ; SA434831 ; SA434996 ; SA435224 ; SA435287 ; SA435572 ; SA436373 ; SA437006 ; SA437192 ; SA437249 ; SA438092 ; SA438272 ; SA438378 ; SA438657 ; SA432539 ; SA433133 ; SA433364 ; SA433418 ; SA433847 ; SA433958 ; SA434306 ; SA435017 ; SA435509 ; SA435905 ; SA436508 ; SA438509 ; SA26595 ; SA440047 ; SA441129 ; SA441165 ; SA441308 ; SA512309 ; SA443468 ; SA443604 ; SA443864 ; SA510451 ; SA439921 ; SA440179 ; SA440471 ; SA440859 ; SA441075 ; SA511242 ; SA441363 ; SA442206 ; SA442786 ; SA511945 ; SA511976 ; SA443186 ; SA28475 ; SA443538 ; SA443714 ; SA444038 ; SA445778 ; SA445899 ; SA446028 ; SA446465 ; SA448334 ; SA448931 ; SA28963 ; SA449306 ; SA450608 ; SA450746 ; SA450806 ; SA451554 ; SA513879 ; SA452320 ; SA452376 ; SA513920 ; SA453724 ; SA454747 ; SA454801 ; SA455841 ; SA456681 ; SA30223 ; SA458506 ; SA444521 ; SA444829 ; SA445264 ; SA445536 ; SA446059 ; SA447303 ; SA447818 ; SA518007 ; SA448361 ; SA448570 ; SA449063 ; SA450222 ; SA32297 ; SA451013 ; SA451252 ; SA451533 ; SA32713 ; SA452353 ; SA453823 ; SA454678 ; SA454798 ; SA33508 ; SA456980 ; SA458075 ; SA458434 ; SA459470 ; SA460564 ; SA461590 ; SA514242 ; SA463369 ; SA34768 ; SA465631 ; SA466124 ; SA514298 ; SA514319 ; SA469543 ; SA471917 ; SA473193 ; SA474315 ; SA476204 ; SA480113 ; SA514439 ; SA484672 ; SA484822 ; SA488516 ; SA489209 ; SA489774 ; SA490033 ; SA459265 ; SA38132 ; SA460515 ; SA460859 ; SA461016 ; SA514228 ; SA462324 ; SA462416 ; SA468236 ; SA514311 ; SA471720 ; SA473026 ; SA40403 ; SA514358 ; SA514362 ; SA475881 ; SA476431 ; SA40999 ; SA478344 ; SA478484 ; SA480023 ; SA480851 ; SA3310 ; SA482408 ; SA514437 ; SA484286 ; SA491162 ; SA491195 ; SA491215 ; SA491106 ; SA491122 ; SA491143 ; SA491175 ; SA491186 ; SA491205 ; SA491225 ; SA491245 ; SA491668 ; SA491814 ; SA3616 ; SA43144 ; SA492388 ; SA492657 ; SA3742 ; SA86182 ; SA86680 ; SA86726 ; SA494805 ; SA494956 ; SA495048 ; SA495215 ; SA495321 ; SA495518 ; SA495070 ; SA495100 ; SA495155 ; SA495252 ; SA495380 ; SA4012 ; SA499742 ; SA499746 ; SA499801 ; SA499813 ; SA499815 ; SA499894 ; SA500054 ; SA500148 ; SA500397 ; SA500499 ; SA500699 ; SA500769 ; SA500830 ; SA45294 ; SA500100 ; SA500238 ; SA500643 ; SA500737 ; SA500759 ; SA500797 ; SA500820 ; SA500918 ; SA501060 ; SA501365 ; SA501371 ; SA501373 ; SA501375 ; SA501377 ; SA501379 ; SA501381 ; SA501383 ; SA501385 ; SA501387 ; SA501391 ; SA501393 ; SA501395 ; SA501397 ; SA501399 ; SA501401 ; SA501403 ; SA501405 ; SA501407 ; SA501409 ; SA501411 ; SA501413 ; SA501415 ; SA501417 ; SA501419 ; SA501421 ; SA501422 ; SA501423 ; SA501427 ; SA501431 ; SA501435 ; SA501439 ; SA501442 ; SA501446 ; SA501452 ; SA501456 ; SA501460 ; SA501464 ; SA501468 ; SA501471 ; SA501473 ; SA501477 ; SA501480 ; SA501484 ; SA501487 ; SA501491 ; SA501495 ; SA501499 ; SA501503 ; SA501506 ; SA501510 ; SA501514 ; SA501517 ; SA501519 ; SA501523 ; SA501527 ; SA501531 ; SA501535 ; SA501540 ; SA501544 ; SA501549 ; SA501553 ; SA501559 ; SA501563 ; SA501567 ; SA501571 ; SA501575 ; SA501579 ; SA501583 ; SA501587 ; SA501591 ; SA501595 ; SA501599 ; SA501603 ; SA501607 ; SA501611 ; SA501615 ; SA501619 ; SA501623 ; SA501627 ; SA501631 ; SA501633 ; SA501635 ; SA501637 ; SA501639 ; SA501641 ; SA501643 ; SA501645 ; SA501647 ; SA501649 ; SA501651 ; SA501653 ; SA501424 ; SA501428 ; SA501432 ; SA501436 ; SA501440 ; SA501445 ; SA501449 ; SA501453 ; SA501457 ; SA501461 ; SA501465 ; SA501469 ; SA501476 ; SA501481 ; SA501485 ; SA501490 ; SA501494 ; SA501498 ; SA501502 ; SA501507 ; SA501511 ; SA501515 ; SA501522 ; SA501526 ; SA501534 ; SA501537 ; SA501541 ; SA501545 ; SA501552 ; SA501562 ; SA501572 ; SA501576 ; SA501582 ; SA46697 ; SA501586 ; SA501590 ; SA501594 ; SA501598 ; SA501602 ; SA501606 ; SA501610 ; SA501614 ; SA501618 ; SA501622 ; SA501626 ; SA501630 ; SA491910
PURITY_CONFUGURATION	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	NUMBER	Purity Configuration	Sample	0.016 ; 0.002 ; 0.028 ; 0.031 ; 0.023 ; 0.01 ; 0.012 ; 0.018 ; 0.006 ; 0.001 ; 0.017 ; 0.003 ; 0.03 ; 0.004 ; 0.008 ; 0.013 ; 0.011 ; 0.022 ; 0.014 ; 0.021 ; 0.005 ; 0.015 ; 0.05 ; 0.033 ; 0.007 ; 0.009 ; 0.039 ; 0.024 ; 0 ; 0.02 ; 0.035 ; 0.04 ; 0.019 ; 0.043 ; 0.037 ; 0.027 ; 0.029 ; 0.034 ; 0.056 ; 0.083 ; 0.066 ; 0.054 ; 0.045 ; 0.215 ; 0.057 ; 0.096 ; 0.148 ; 0.061 ; 0.051 ; 0.044 ; 0.151 ; 0.086 ; 0.038 ; 0.117 ; 0.089 ; 0.025 ; 0.156 ; 0.053 ; 0.071 ; 0.113 ; 0.032 ; 0.059 ; 0.055 ; 0.291 ; 0.098 ; 0.234 ; 0.366 ; 0.048 ; 0.142 ; 0.049 ; 0.19 ; 0.046 ; 0.102 ; 0.042 ; 0.041 ; 0.036 ; 0.205 ; 0.15 ; 0.082 ; 0.128 ; 0.069 ; 0.076 ; 0.052 ; 0.12 ; 0.186 ; 0.157 ; 0.155 ; 0.026 ; 0.073 ; 0.199 ; 0.146 ; 0.418 ; 0.118 ; 0.17 ; 0.058 ; 0.109 ; 0.211 ; 0.068 ; 0.074 ; 0.088 ; 0.077 ; 0.136 ; 0.07 ; 0.101 ; 0.262 ; 0.097 ; 0.063 ; 0.143 ; 0.135 ; 0.065 ; 0.206 ; 0.08 ; 0.047 ; 0.119 ; 0.264 ; 0.169 ; 0.322 ; 0.067 ; 0.126 ; 0.416 ; 0.121 ; 0.134 ; 0.309 ; 0.246 ; 0.149 ; 0.079 ; 0.4 ; 0.197 ; 0.105 ; 0.145 ; 0.091 ; 0.084 ; 0.287 ; 0.107 ; 0.099 ; 0.177 ; 0.103 ; 0.06 ; 0.095 ; 0.062 ; 0.116 ; 0.081 ; 0.075 ; 0.11 ; 0.064 ; 0.104 ; 0.207 ; 0.141 ; 0.1 ; 0.092 ; 0.168 ; 0.139 ; 0.078 ; 0.14 ; 0.227 ; 0.085 ; 0.164 ; 0.124 ; 0.09
TOBACCO_SMOKING_HISTORY_INDICATOR	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Category describing current smoking status and smoking history as self-reported by a patient.	Patient	
TOBACCO_SMOKING_INTENSITY	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	NUMBER	Tobacco Smoking Intensity	Patient	
TUMOR_SAMPLE_HISTOLOGY_CODE	Black	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	STRING	Tumor Sample Histology Code	Sample	8130/3 ; 8500/3 ; 8120/3 ; 8441/3 ; 8140/3 ; 8246/3 ; 8550/3 ; 8310/3 ; 8720/3 ; 8480/3 ; 8050/3 ; 8145/3 ; 8144/3 ; 8211/3 ; 8340/3 ; 8170/3 ; 8171/3 ; 9471/3 ; 9470/3 ; 9474/3 ; 8070/3 ; 8560/3 ; 8453/3 ; 9861/3 ; 9823/3 ; 9370/3 ; 9261/3 ; 9180/3 ; 9200/0 ; 9241/0 ; 9230/0 ; 9695/3 ; 9698/3 ; 9680/3 ; 9699/3 ; 9691/3 ; 9687/3 ; 9590/3 ; 9962/3 ; 9982/3 ; 9872/3 ; 9950/3 ; 9741/3 ; 9945/3 ; 8260/3 ; 8022/3 ; 8160/3 ; 8520/3 ; 8503/3 ; 8507/3 ; 8510/3 ; 8858/3 ; 8890/3 ; 8317/3 ; 8470/3 ; 9440/3 ; 9450/3 ; 8252/3 ; 8255/3 ; 8083/3 ; 9971/1 ; 9679/3 ; 9421/1 ; 8344/3 ; 8380/3 ; 8180/3
BRESLOW_DEPTH	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	NUMBER	breslow depth	Patient ; Sample	0.76 ; 9 ; 2.3 ; 1.3 ; 1.46 ; 1.1 ; 1.5 ; 10 ; 1.63 ; 0.7 ; 2.4 ; 2.7 ; 1.9 ; 0.5 ; 6 ; 3 ; 1.6 ; 0.8 ; 2 ; 0.75 ; 4.5 ; 2.8 ; 7 ; 0.6 ; 8.5 ; 7.8 ; 2.5 ; 2.6 ; 1.2 ; 16 ; 1.32 ; 0.3 ; 0.45 ; 3.03 ; 1 ; 2.75 ; 4.6 ; 0.9 ; 3.5 ; 4 ; 3.7 ; 3.75 ; 3.3 ; 0.95 ; 1.7 ; 11 ; 30 ; 32 ; 5 ; 21 ; 8 ; 25 ; 7.5 ; 26 ; 2.75 mm ; 2.7 mm ; 2.4 mm ; 4.6 mm ; 2.6 mm ; 3.5 mm ; 0.75 mm ; Unknown ; 3.7 mm ; 2.5 mm ; 7.0 mm ; 3.3 mm ; 1 mm ; 0.95 mm ; 4 mm ; 1.7 mm
HISTORY_NEOADJUVANT_TX_TYPE	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Prior systemic therapy type	Patient	
IDH_LEVEL	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Idh level	Patient	
IFN_TX_90_DAYS_PRIOR_TO_RESECTION	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Interferon 90 day prior excision admin indicator	Patient	
NEW_TUMOR_EVENT_MELANOMA_COUNT	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Primary anatomic site count	Patient	
NEW_TUMOR_EVENT_PRIOR_TO_BCR_TUMOR	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	New tumor dx prior submitted specimen dx	Patient	
PRIMARY_AT_DX_COUNT	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	NUMBER	Primary melanoma at diagnosis count	Patient	
PRIMARY_MELANOMA_KNOWN_DX	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Primary neoplasm melanoma dx	Patient	
PRIMARY_MELANOMA_MITOTIC_RATE	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	NUMBER	Malignant neoplasm mitotic count rate	Patient	
PRIMARY_MELANOMA_SKIN_TYPE	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Melanoma origin skin anatomic site	Patient	
PRIMARY_MELANOMA_TUMOR_ULCERATION	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Melanoma ulceration indicator	Patient	
PRIMARY_MULTIPLE_AT_DX	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Primary tumor multiple present ind	Patient	
SUBMITTED_TUMOR_DX_DAYS_TO	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Days to submitted specimen dx	Patient	
TUMOR_TISSUE_SITE_OTHER	Black	Skin Cutaneous Melanoma (TCGA, Firehose Legacy)	STRING	Tumor tissue site other	Patient	
PRIMARY_DIAGNOSIS	Black	Skin Cutaneous Melanoma (Broad, Cell 2012)	STRING	Primary Diagnosis	Patient	
PRIMARY_TUMOR_LOCALIZATION_TYPE	Black	Skin Cutaneous Melanoma (Broad, Cell 2012)	STRING	Primary Tumor Localization Type	Patient	
AVE_PLOIDY	Black	Melanoma (Broad/Dana Farber, Nature 2012)	NUMBER	Average ploidy 	Sample	2.92 ; 1.99 ; 1.84 ; 1.93 ; 1.89 ; 3.5 ; 2.96 ; 2.06 ; 3.41 ; 2.55 ; 3.77 ; 1.37 ; 1.98 ; 2.19 ; 3.33 ; 3.34 ; 2.73 ; 1.96 ; 3.05 ; 2.04
NRAS_STATUS	Black	Melanoma (Broad/Dana Farber, Nature 2012)	STRING	nras status	Sample	Q61K ; wild type ; T50I ; Q61R
PATHOLOGIC_PRIMARY_TUMOR_STAGE	Black	Melanoma (Broad/Dana Farber, Nature 2012)	STRING	pathologic primary tumor stage	Sample	T3, NOS ; T4b ; T1, NOS ; T0* ; T3b ; T2, NOS
SUN_EXPOSURE	Black	Melanoma (Broad/Dana Farber, Nature 2012)	STRING	Exposure to Sun	Patient	
SURVIVAL_AFTER_BIOPSY_MONTHS	Black	Melanoma (Broad/Dana Farber, Nature 2012)	NUMBER	survival after biopsy months	Sample	86 ; 58 ; 82 ; 13 ; 6 ; 15 ; 50 ; 48 ; 8 ; 12 ; 3 ; 69 ; 1 ; 7 ; 17 ; 4 ; 0 ; 14 ; 2 ; 10
TREATMENT_PRIOR_TO_RESECTION	Black	Melanoma (Broad/Dana Farber, Nature 2012)	STRING	treatment prior to resection	Sample	Interferon therapy, Chemotherapy ; Interferon therapy, Chemotherapy, Immunotherapy, Vaccine ; Interferon therapy, Chemotherapy, Immunotherapy, Vaccine, Radiation ; Interferon therapy, Immunotherapy ; Interferon therapy ; Immunotherapy, Vaccine ; Chemotherapy ; Interferon therapy, Immunotherapy, Vaccine
DURATION_OF_THERAPY_WEEKS	Black	Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)	NUMBER	duration of therapy weeks	Patient	
EARLY_RESISTANCE	Black	Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)	STRING	Early Resistance	Patient	
MATCHED_NORMAL_TISSUE	Black	Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)	STRING	Matched Normal Tissue	Sample	Whole Blood ; Paraffin Embedded Tissue ; Unavailable ; Lymphocytes
MEDICATION	Black	Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)	STRING	medication	Patient	
DOSAGE	Black	Melanoma (MSK, NEJM 2014)	STRING	Dosage	Patient	
HLA_DPA1	Black	Melanoma (MSK, NEJM 2014)	STRING	HLA_DPA1	Sample	DPA1_0103/DPA1_0103 ; DPA1_0103/DPA1_0202 ; DPA1_0103/DPA1_0201 ; DPA1_0201/DPA1_0201
HLA_DPB1	Black	Melanoma (MSK, NEJM 2014)	STRING	HLA_DPB1	Sample	DPB1_0301/DPB1_0401 ; DPB1_0101/DPB1_0101 ; DPB1_0401/DPB1_0401 ; DPB1_0201/DPB1_0401 ; DPB1_0201/DPB1_1301 ; DPB1_0401/DPB1_1001 ; DPB1_0401/DPB1_1901 ; DPB1_0401/DPB1_10401 ; DPB1_0201/DPB1_10501 ; DPB1_0101/DPB1_0401 ; DPB1_1001/DPB1_10401 ; DPB1_0201/DPB1_0202 ; DPB1_0202/DPB1_0401 ; DPB1_0401/DPB1_1101 ; DPB1_0401/DPB1_0402 ; DPB1_0201/DPB1_0301 ; DPB1_10501/DPB1_10501 ; DPB1_0201/DPB1_0402 ; DPB1_0401/DPB1_1301 ; DPB1_0402/DPB1_1901 ; DPB1_0201/DPB1_0201 ; DPB1_0402/DPB1_1001 ; DPB1_1101/DPB1_13101 ; DPB1_0301/DPB1_1701
HLA_DQA1	Black	Melanoma (MSK, NEJM 2014)	STRING	HLA_DQA1	Sample	DQA1_0301/DQA1_0401 ; DQA1_0201/DQA1_0303 ; DQA1_0102/DQA1_0201 ; DQA1_0102/DQA1_0102 ; DQA1_0201/DQA1_0501 ; DQA1_0103/DQA1_0104 ; DQA1_0303/DQA1_0501 ; DQA1_0103/DQA1_0505 ; DQA1_0201/DQA1_0505 ; DQA1_0201/DQA1_0201 ; DQA1_0105/DQA1_0505 ; DQA1_0101/DQA1_0102 ; DQA1_0301/DQA1_0505 ; DQA1_0104/DQA1_0501 ; DQA1_0301/DQA1_0501 ; DQA1_0102/DQA1_0501 ; DQA1_0102/DQA1_0104 ; DQA1_0101/DQA1_0501 ; DQA1_0103/DQA1_0105 ; DQA1_0101/DQA1_0101 ; DQA1_0501/DQA1_0505 ; DQA1_0201/DQA1_0301 ; DQA1_0105/DQA1_0303 ; DQA1_0101/DQA1_0505 ; DQA1_0101/DQA1_0104 ; DQA1_0102/DQA1_0401 ; DQA1_0101/DQA1_0201 ; DQA1_0303/DQA1_0303 ; DQA1_0505/DQA1_0505 ; DQA1_0101/DQA1_0103 ; DQA1_0102/DQA1_0505
HLA_DQB1	Black	Melanoma (MSK, NEJM 2014)	STRING	HLA_DQB1	Sample	DQB1_0305/DQB1_0402 ; DQB1_0202/DQB1_0301 ; DQB1_0602/DQB1_0602 ; DQB1_0302/DQB1_0609 ; DQB1_0201/DQB1_0202 ; DQB1_0503/DQB1_0603 ; DQB1_0201/DQB1_0301 ; DQB1_0603/DQB1_0603 ; DQB1_0301/DQB1_0303 ; DQB1_0202/DQB1_0303 ; DQB1_0301/DQB1_0501 ; DQB1_0501/DQB1_0501 ; DQB1_0301/DQB1_0302 ; DQB1_0503/DQB1_0503 ; DQB1_0503/DQB1_0602 ; DQB1_0501/DQB1_0603 ; DQB1_0202/DQB1_0202 ; DQB1_0303/DQB1_0501 ; DQB1_0601/DQB1_0604 ; DQB1_0202/DQB1_0302 ; DQB1_0302/DQB1_0501 ; DQB1_0501/DQB1_0602 ; DQB1_0301/DQB1_0503 ; DQB1_0301/DQB1_0301 ; DQB1_0201/DQB1_0302
HLA_DRB1	Black	Melanoma (MSK, NEJM 2014)	STRING	HLA_DRB1	Sample	DRB1_0403/DRB1_0801 ; DRB1_0407/DRB1_0701 ; DRB1_0701/DRB1_1501 ; DRB1_0402/DRB1_1302 ; DRB1_0301/DRB1_0701 ; DRB1_1301/DRB1_1454 ; DRB1_0301/DRB1_0401 ; DRB1_0801/DRB1_1301 ; DRB1_0901/DRB1_1101 ; DRB1_0701/DRB1_0701 ; DRB1_1001/DRB1_1104 ; DRB1_0101/DRB1_0101 ; DRB1_0401/DRB1_1104 ; DRB1_1454/DRB1_1454 ; DRB1_0301/DRB1_0403 ; DRB1_1501/DRB1_1601 ; DRB1_1454/DRB1_1501 ; DRB1_0103/DRB1_0301 ; DRB1_1301/DRB1_1301 ; DRB1_0301/DRB1_0901 ; DRB1_0101/DRB1_0701 ; DRB1_0301/DRB1_0801 ; DRB1_0701/DRB1_1302 ; DRB1_0403/DRB1_0701 ; DRB1_0801/DRB1_1101 ; DRB1_0101/DRB1_0404 ; DRB1_1501/DRB1_1501 ; DRB1_0101/DRB1_1501 ; DRB1_0401/DRB1_0401 ; DRB1_0102/DRB1_1217 ; DRB1_0101/DRB1_0401 ; DRB1_1101/DRB1_1454 ; DRB1_0401/DRB1_1501 ; DRB1_1101/DRB1_1301 ; DRB1_0404/DRB1_1501 ; DRB1_0102/DRB1_1104 ; DRB1_0801/DRB1_1501 ; DRB1_1302/DRB1_1501 ; DRB1_0701/DRB1_1104 ; DRB1_1104/DRB1_1501 ; DRB1_0102/DRB1_1301 ; DRB1_0301/DRB1_1101 ; DRB1_0301/DRB1_0301 ; DRB1_1101/DRB1_1201 ; DRB1_0102/DRB1_1101 ; DRB1_0801/DRB1_1104 ; DRB1_0301/DRB1_1201
RAF_RAS_STATUS	Black	Melanoma (MSK, NEJM 2014)	STRING	RAF_RAS Status	Sample	BRAF V600E ; WT BRAF, WT NRAS ; BRAF V600K ; NRAS Q61K ; BRAF G469R ; NRAS Q61L ; WT BRAF, NRAS ; BRAF E501K ; NRAS Q61R ; BRAF L597R ; NRAS G12C ; BRAF S363F ; BRAF A652T ; BRAF G469E ; BRAF P367L
RESPONSE_DURATION	Black	Melanoma (MSK, NEJM 2014)	NUMBER	Response duration in weeks	Patient	
SERUM_LACTATE_DEHYDROGENASE	Black	Melanoma (MSK, NEJM 2014)	NUMBER	LDH (normal <246)	Sample	113 ; 181 ; 243 ; 92 ; 211 ; 357 ; 121 ; 191 ; 180 ; 129 ; 156 ; 327 ; 664 ; 250 ; 178 ; 286 ; 232 ; 225 ; 293 ; 203 ; 309 ; 237 ; 341 ; 330 ; 160 ; 266 ; 209 ; 144 ; 176 ; 199 ; 2502 ; 202 ; 169 ; 167 ; 187 ; 210 ; 324 ; 439 ; 195 ; 133 ; 183 ; 179 ; 322 ; 234 ; 1 ; 0
SIMPLIFIED_TUMOR_SITE	Black	Melanoma (MSK, NEJM 2014)	STRING	Tumor Site	Sample	Met lymph node ; Met skin or soft tissue ; Met lung ; Met adrenal ; Met bone ; Met GI ; Met spleen ; Met CNS
AGE_AT_INITIAL_PATHOLOGIC_DIAGNOSIS	Black	Melanomas (TCGA, Cell 2015)	NUMBER	Age At Initial Pathological Diagnosis	Patient	
AGE_AT_TCGA_SPECIMEN	Black	Melanomas (TCGA, Cell 2015)	NUMBER	Age at TCGA Specimen	Patient	
BRESLOW	Black	Melanomas (TCGA, Cell 2015)	NUMBER	Breslow	Patient	
DISTANT_ANATOMIC_SITE	Black	Melanomas (TCGA, Cell 2015)	STRING	Pathologic AJCC7 Stage at Diagnosis (Simple)	Patient	
MUTATION_TYPE	Black	Melanomas (TCGA, Cell 2015)	STRING	Mutation Type	Sample	BRAF_Hotspot_Mutants ; RAS_Hotspot_Mutants ; Triple_WT ; NF1_Any_Mutants
M_STAGE_AT_DIAGNOSIS_COMPLEX	Black	Melanomas (TCGA, Cell 2015)	STRING	M-Stage at Diagnosis (Complex)	Patient	
M_STAGE_AT_DIAGNOSIS_SIMPLE	Black	Melanomas (TCGA, Cell 2015)	STRING	M-Stage at Diagnosis (Simple)	Patient	
N_STAGE_AT_DIAGNOSIS_COMPLEX	Black	Melanomas (TCGA, Cell 2015)	STRING	N-Stage at Diagnosis (Complex)	Patient	
N_STAGE_AT_DIAGNOSIS_SIMPLE	Black	Melanomas (TCGA, Cell 2015)	STRING	N-Stage at Diagnosis (Simple)	Patient	
PATHOLOGIC_STAGE_AJCC7_AT_DIAGNOSIS_COMPLEX	Black	Melanomas (TCGA, Cell 2015)	STRING	Pathologic AJCC7 Stage at Diagnosis (Complex)	Patient	
PATHOLOGIC_STAGE_AJCC7_AT_DIAGNOSIS_SIMPLE	Black	Melanomas (TCGA, Cell 2015)	STRING	Pathologic AJCC7 Stage at Diagnosis (Simple)	Patient	
REGIONAL_VS_PRIMARY	Black	Melanomas (TCGA, Cell 2015)	STRING	RegioNAl or Primary	Sample	Primary_Disease ; RegioNAl_Lymph_Node ; RegioNAl_Skin_or_Soft_Tissue ; Distant_Metastases
SITE_OF_PRIMARY_TUMOR_INCLUDING_UNKNOWN	Black	Melanomas (TCGA, Cell 2015)	STRING	Site of Primary Tumor Including Unknown	Sample	Trunk ; Extremities ; Unknown ; Trunk|Extremities ; Head and Neck ; Other  Specify ; [ERROR] ; Trunk|Head and Neck
SITE_OF_PRIMARY_TUMOR_KNOWN_PRIMARY_ONLY	Black	Melanomas (TCGA, Cell 2015)	STRING	Site of Primary Tumor Known (Primary Only)	Sample	Trunk ; Extremities ; Trunk|Extremities ; Head and Neck ; Other  Specify ; [ERROR] ; Trunk|Head and Neck
TCGA_DAYS_TO_DEATH_OR_LAST_FU	Black	Melanomas (TCGA, Cell 2015)	NUMBER	TCGA Days to Death or Last Followup	Patient	
TCGA_SPECIMEN_DISTANT	Black	Melanomas (TCGA, Cell 2015)	STRING	TCGA Specimen (Distant)	Sample	Primary Tumor ; Regional Lymph Node ; Regional Skin or Soft Tissue ; Distant Metastasis ; Distant Lymph Node
TCGA_SPECIMEN_SITE	Black	Melanomas (TCGA, Cell 2015)	STRING	TCGA Specimen Site	Sample	Primary Tumor ; Regional Lymph Node ; Regional Skin or Soft Tissue ; Distant Metastasis
TERT_PROMOTER_MUTATION	Black	Melanomas (TCGA, Cell 2015)	STRING	TERT promoter mutations were assessed by PCR-Sanger sequencing in a subset of 115 samples.	Sample	C250T ; C228T ; WT ; C250T,C229T ; C228T,C229T
TERT_PROMOTER_MUTATION_STATUS	Black	Melanomas (TCGA, Cell 2015)	STRING	TERT promoter mutations were assessed by PCR-Sanger sequencing in a subset of 115 samples.	Sample	Mutant ; Wild-type ; Not Sequenced
T_STAGE_AT_DIAGNOSIS_COMPLEX	Black	Melanomas (TCGA, Cell 2015)	STRING	T-Stage at Diagnosis (Complex)	Patient	
T_STAGE_AT_DIAGNOSIS_SIMPLE	Black	Melanomas (TCGA, Cell 2015)	STRING	T-Stage at Diagnosis (Simple)	Patient	
UV_RATE	Black	Melanomas (TCGA, Cell 2015)	NUMBER	UV Rate	Patient	
UV_SIGNATURE	Black	Melanomas (TCGA, Cell 2015)	STRING	UV Signature	Patient	
MUTATION_STATUS	Black	Skin Cutaneous Melanoma (Yale, Nat Genet 2012)	STRING	Mutation Status	Sample	WT ; NRAS-Q61R ; BRAF-V600K ; BRAF-V600E ; KIT-L576P ; NRAS-Q61H ; NRAS-Q61K ; HRAS-Q61H ; NRAS-Q61L ; NRAS-Q61K, KIT-L160V ; NRAS-G12V ; BRAF-V600K, NRAS-G13D ; NRAS-G13R ; KIT-V559D ; KIT-N822Y ; KIT-K642E ; NRAS-G12D ; BRAF-V600R
TYPE	Black	Skin Cutaneous Melanoma (Yale, Nat Genet 2012)	STRING	Type	Sample	sun-exposed ; uveal ; acral ; unknown ; mucosal
AGENT	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	AGENT	Patient	
BORR	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	BORR	Patient	
BRAIN_METS	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Brain Metatstasis	Patient	
GREATER_THAN_3_SITES	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Greater than 3 sites	Sample	1 ; 0
IMMUNE_TREATMENT	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Immunotherapy	Patient	
LIVER_INVOLVEMENT	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Liver Involvement	Patient	
NUMBER_OF_SITES	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	NUMBER	Number Of Sites	Sample	5 ; 1 ; 4 ; 2 ; 3 ; 7 ; 6
RECIST_BURDEN_OF_DISEASE	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	NUMBER	RECIST burden of disease (mm)	Patient	
RESPONSE_GRADE	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Response grade	Patient	
RESPONSE_TO_TARGET_THERAPY	Black	Metastatic Melanoma (MSK, JCO Precis Oncol 2017)	STRING	Did the patient respond to Target Therapy	Patient	
AMPLIFICATION_STATUS	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Amplification Status	Sample	no ; yes
BEST_ORR	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Best objective response rate	Patient	
BUBBLE_GROUP	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Bubble Group	Sample	S310 Hotspot ; Other Nonhotspot ; Exon20 Insertion Hotspot ; PKD Hotspot ; Other Hotspot ; V777 Hotspot ; L755 Hotspot ; PKD Nonhotspot ; ERBB3 Hotspot ; ERBB3 Nonhotspot
CENTRAL	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Central	Sample	NONE ; DISCORDANT ; CONCORDANT
CLONALITY	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Clonality	Sample	clonal ; subclonal
COVERAGE	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	NUMBER	Coverage	Sample	346 ; 653 ; 1051 ; 273 ; 703 ; 528 ; 1001 ; 716 ; 1036 ; 357 ; 722 ; 1217 ; 552 ; 351 ; 1130 ; 451 ; 753 ; 1111 ; 363 ; 294 ; 729 ; 1041 ; 748 ; 771 ; 516 ; 743 ; 854 ; 274 ; 1160 ; 1053 ; 258 ; 513 ; 883 ; 1072 ; 881 ; 944 ; 805 ; 856 ; 616 ; 514 ; 356 ; 667 ; 612 ; 1077 ; 1003 ; 777 ; 375 ; 530 ; 671 ; 290 ; 851 ; 790 ; 1158 ; 835 ; 463 ; 763 ; 1198 ; 1024 ; 795 ; 1006 ; 366 ; 453 ; 466 ; 385 ; 1020 ; 489 ; 914 ; 473 ; 1112 ; 477 ; 365 ; 1028 ; 985 ; 304 ; 611 ; 802 ; 720 ; 905 ; 376 ; 342 ; 713 ; 972 ; 630 ; 1030 ; 1050 ; 1128 ; 1095 ; 1038 ; 735 ; 902 ; 684 ; 581 ; 669 ; 548 ; 766 ; 1383 ; 999 ; 910 ; 971 ; 253
CRITERIA	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Criteria	Sample	NE ; RECIST ; PET
DATA	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Data	Sample	NONE ; cfIMPACT ; NONE (cfERBB2) ; IMPACT_cfERBB2 ; IMPACT ; cfERBB2_cfIMPACT
DOMAIN	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Domain	Sample	Furin-like _ECD ; PKD ; ICD ; TMD
DURATION_OF_THERAPY_DAYS	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	NUMBER	Duration of Therapy Days	Patient	
ER_PR_STATUS	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	ER_PR	Sample	POSITIVE ; NEGATIVE
GENE	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Gene	Sample	ERBB2 ; ERBB3
IMPACT	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	IMPACT	Sample	410 ; 341
LOCAL_TEST	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Local Test	Sample	NGS-GUARDANT HEALTH ; FOUNDATION ; PCR-Brigham and Women's ; qPCR-FundaciÃƒÆ’_n JimÃƒÆ’Ã‚Â©nez DÃƒÆ’_az ; MSK-IMPACT ; SEQUENOM-MSKCC ; SEQUENOM-VHIO ; MISEQ PANEL-FundaciÃƒÆ’_n JimÃƒÆ’Ã‚Â©nez DÃƒÆ’_az ; AMPLICON - VHIO ; AMPLICON-Clara Campal ; NGS-RESPONSEDX ; PCR/FISH-St Mary's Hospital ; NGS-MGH ; MISEQ PANEL-MSK ; NGS-WASHU ; PCR-FundaciÃƒÆ’_n JimÃƒÆ’Ã‚Â©nez DÃƒÆ’_az ; NGS-MDA ; molecular report not received ; NGS-KNIGHT CANCER INSTITUTE ; NGS-SMART GENOMICS ; NGS-STANFORD ; MGH - SNAPSHOT Tumor Genotyping ; NGS/FISH- HADASSAH ; NGS-HARVARD ; MISEQ PANEL-IVO ; NGS-ASHION ; NGS- CARIS LIFE SCIENCES ; NGS-CARIS LIFE SCIENCES ; NGS-Brigham and Women's ; NGS-McIntyre ; PCR-Pangaea Biotech ; NGS-Guardant Health ; PCR-HMN Sanchinarro ; PCR/SEQUENOM-MSKCC-does not report insertion ; PCR/SEQUENOM-MSKCC ; NGS-Oncologica ; NGS-Peter McCallum Cancer Center (APA)
MSI_STATUS	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	MSI status.	Sample	MSS ; MSI ; MSI ambiguous ; MSI unknown ; MSI-H
MULTI_ERBB2	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Multi ERBB2	Sample	no ; yes
ONCOPRINT	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Oncoprint	Sample	NO ; YES
ONGOING_TREATMENT	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Ongoing Treatment	Patient	
QUALIFYING_MUT	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Qualifying Mutation	Sample	S310F ; D251fs ; G778_P780dup ; V842I ; S310Y ; Y772_A775dup ; V697L ; G776V ; V777L ; L755S ; R784H ; V659E ; R814H ; V777L_L755S_R1153X ; R678Q ; V777_G778insG ; V777L_V842I ; G776_V777insVGC ; D769Y ; R849W ; ERBB2-GRB7 ; D277G_S310F ; E930D ; D769H ; N319D ; P761del ; L755P ; G292R ; K831N ; L755A ; L841V ; G778A ; T862A ; T733I ; L786V ; D769N ; G776delinsVC ; L755_E757delinsS ; L869R ; T355A ; D297Y_G508R ; A232V ; V104L ; Q809R ; V104L_S236P ; P306H ; V104M ; E928G ; D297Y ; germline_V773M ; G284R ; E322K ; V104M_R667H ; R103G
TUMOR_CHANGE	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	NUMBER	Tumor Change	Sample	79.16666667 ; 32.60869565 ; 34.82142857 ; -23.91304348 ; 5.555555556 ; 200 ; 0 ; 15.78947368 ; 33.33333333 ; 44.44444444 ; 100 ; 7.142857143 ; 30.76923077 ; 50.87719298 ; 36.8159204 ; 50.26852846 ; 42.10526316 ; 38.57142857 ; 36.36363636 ; 27.17391304 ; 29.6 ; 10.25641026 ; 4.937629938 ; 11.11111111 ; 31.31132917 ; 32 ; 9.913793103 ; 30.98591549 ; 9.375 ; 26.10526316 ; 6.666666667 ; 16.66666667 ; 14.72868217 ; -9.243697479 ; 14.27221172 ; 17.74193548 ; 9.714285714 ; 26.5560166 ; 35.63218391 ; 45.23809524 ; 8.219178082 ; 2.027027027 ; 54.44444444 ; 88.88888889 ; 5.454545455 ; 4.268292683 ; 2.542372881 ; 1.410105758 ; 1.265822785 ; 13.15789474 ; -6.849315068 ; -20 ; -18.75 ; 18.66666667 ; -3.125 ; -4.301075269 ; -8.333333333 ; -2.857142857 ; -12.67605634 ; -14.35185185 ; -1.639344262 ; -21.21212121 ; 1.121304791 ; -25 ; 9.119496855 ; 13.23529412 ; 15.6424581 ; -18.18181818 ; -22.22222222 ; -28.57142857 ; -14.11637931 ; -32 ; -33.75594295 ; -8.372093023 ; -58.94736842 ; -14.70588235 ; -100 ; -51 ; -39.84063745 ; -59.45945946 ; -15.33219761 ; -63.26530612 ; -63.63636364 ; -11.9047619 ; -56.52173913 ; -76.66666667 ; -21.73913043 ; -19.23076923 ; -4 ; -11.86440678 ; -58.33333333 ; -28.05755396 ; -17.39130435 ; -10.46511628 ; -23.33333333 ; 19.73684211 ; 19.04761905 ; 16.91176471 ; 9.090909091 ; -25.29538131 ; 43.39622642 ; 6.976744186 ; -1.19047619 ; 12.19512195 ; 37.03703704 ; 2.631578947 ; 72.22222222 ; -5.970149254 ; 24.48979592 ; 10.52631579 ; -10.63829787
WATERFALL_GROUP	Black	SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018)	STRING	Waterfall Group	Sample	S310 Hotspot ; Other Nonhotspot ; Exon20 Insertion Hotspot ; PKD Hotspot ; Other Hotspot ; ERBB3 Hotspot ; ERBB3 Nonhotspot
AGE_AT_SEQ_REPORT	Black	TMB and Immunotherapy (MSK, Nat Genet 2019)	NUMBER	Age (in days) at which sequencing was reported	Sample	41 ; 80 ; 62 ; 66 ; 61 ; 63 ; 47 ; 44 ; 67 ; 60 ; 56 ; 69 ; 64 ; 29 ; 76 ; 50 ; 49 ; 58 ; 65 ; 22 ; 71 ; 52 ; 40 ; 36 ; 81 ; 51 ; 42 ; 59 ; 35 ; 79 ; 78 ; 75 ; 43 ; 85 ; 73 ; 72 ; 28 ; 54 ; 33 ; 90 ; 70 ; 16 ; 45 ; 77 ; 23 ; 46 ; 34 ; 55 ; 57 ; 17 ; 37 ; 48 ; 53 ; 26 ; 24 ; 74 ; 68 ; 86 ; 31 ; 30 ; 39 ; 84 ; 19 ; 32 ; 82 ; 15 ; 25 ; 38 ; 83 ; 27 ; 21 ; 87 ; 88 ; 20 ; 89
AGE_GROUP	Black	TMB and Immunotherapy (MSK, Nat Genet 2019)	STRING	Age Group at Diagnosis in Years	Patient	
CFDNA_TMB	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	cfDNA TMB	Patient	
COLLAPSED_FRAGMENT_MEAN_COVERAGE	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	The unique coverage across target regions of collapsed reads	Sample	5950 ; 1781 ; 3429 ; 4337 ; 5602 ; 4457 ; 4957 ; 5309 ; 6528 ; 4580 ; 7240 ; 5238 ; 2893 ; 4664 ; 6426 ; 3682 ; 4592 ; 1924 ; 5735 ; 5910 ; 5317 ; 5013 ; 4038 ; 6761 ; 4719 ; 1777 ; 5435 ; 5621 ; 4670 ; 5804 ; 6285 ; 1965 ; 2312 ; 2675 ; 1976 ; 4197 ; 2276 ; 4015 ; 2816 ; 6198 ; 4773 ; 4570 ; 4961 ; 3520 ; 1989 ; 2746 ; 2728 ; 2335 ; 3724 ; 6728 ; 2626 ; 3770 ; 2284 ; 4936 ; 2757 ; 4340 ; 4804 ; 5047 ; 3181 ; 5130 ; 3354 ; 5323 ; 3411 ; 4425 ; 5481 ; 2950 ; 4739 ; 5234 ; 3669 ; 4933 ; 4021 ; 2398 ; 3985 ; 4862 ; 3356 ; 2762 ; 2289 ; 833 ; 2251 ; 2322 ; 3620 ; 4408 ; 1520 ; 5675 ; 4496 ; 2494 ; 5185 ; 4522 ; 3767 ; 3510 ; 5378 ; 5192 ; 2895 ; 3204 ; 4468 ; 5789 ; 4399 ; 4733 ; 4693 ; 6073 ; 3946 ; 3114 ; 4795 ; 5445 ; 5326 ; 4635 ; 4756 ; 2055 ; 6249 ; 2499 ; 4049 ; 2048 ; 5035 ; 5115 ; 6202 ; 2509 ; 4244 ; 4783 ; 4085 ; 5208 ; 3289 ; 2373 ; 3927
COLLAPSED_MEAN_COVERAGE	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	The mean coverage of all baits in the experiment after collapsing and stitching	Sample	5951 ; 1782 ; 3431 ; 4339 ; 5604 ; 4458 ; 4959 ; 5309 ; 6533 ; 4582 ; 7243 ; 5240 ; 2894 ; 4665 ; 6428 ; 3683 ; 4593 ; 1925 ; 5739 ; 5912 ; 5318 ; 5014 ; 4040 ; 6762 ; 4720 ; 1778 ; 5435 ; 5621 ; 4670 ; 5805 ; 6287 ; 1966 ; 2312 ; 2676 ; 1977 ; 4198 ; 2276 ; 4016 ; 2817 ; 6199 ; 4774 ; 4571 ; 4962 ; 3522 ; 1990 ; 2746 ; 2728 ; 2336 ; 3725 ; 6730 ; 2627 ; 3771 ; 2284 ; 4937 ; 2758 ; 4340 ; 4805 ; 5047 ; 3182 ; 5132 ; 3355 ; 5324 ; 3412 ; 4426 ; 5484 ; 2951 ; 4739 ; 5235 ; 3671 ; 4934 ; 4021 ; 2398 ; 3986 ; 4863 ; 3356 ; 2763 ; 2289 ; 833 ; 2252 ; 2322 ; 3620 ; 4409 ; 1521 ; 5677 ; 4498 ; 2495 ; 5187 ; 4524 ; 3768 ; 3511 ; 5380 ; 5193 ; 2896 ; 3205 ; 4469 ; 5793 ; 4400 ; 4734 ; 4698 ; 6074 ; 3947 ; 3116 ; 4796 ; 5447 ; 5327 ; 5314 ; 4636 ; 4758 ; 2056 ; 6251 ; 2500 ; 4054 ; 2049 ; 5037 ; 5117 ; 6205 ; 2510 ; 4245 ; 4784 ; 4086 ; 5210 ; 3290 ; 2373 ; 3928
CTDNA_FRACTION	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	ctDNA Fraction	Sample	0.073732064 ; 0.02764977 ; 0.00347207 ; 0.013192612 ; 0.622256567 ; 0.187706809 ; 0.05182121 ; 0.597333242 ; 0.13143483 ; 0.287519766 ; 0.781453453 ; 0.013158296 ; 0.108379888 ; 0.023892395 ; 0.019562526 ; 0.052524851 ; 0.018266397 ; 0.924556827 ; 0.889147406 ; 0.306436978 ; 0.113634007 ; 0.252579155 ; 0.075780646 ; 0.190455868 ; 0.018493493 ; 0.001735525 ; 0.225088908 ; 0.449105515 ; 0.122533636 ; 0.017441781 ; 0.095949802 ; 0.324566225 ; 0.045961473 ; 0.016599309 ; 0.055063405 ; 0.02431869 ; 0.000918 ; 0.314781002 ; 0.003653072 ; 0.391929465 ; 0.013520117 ; 0.014484789 ; 0.009809664 ; 0.007060667 ; 0.196734694 ; 0.002383105 ; 0.018502768 ; 0.001323491 ; 0.048096192 ; 0.222210484 ; 0.121342354 ; 0.065329124 ; 0.190320197 ; 0.085638999 ; 0.009685998 ; 0.001941399 ; 0.021325459 ; 0.007520285 ; 0.006653518 ; 0.542084906 ; 0.016348899 ; 0.073435837 ; 0.002104486 ; 0.003705023 ; 0.025405431 ; 0.000263 ; 0.007363095 ; 0.00298122 ; 0.001583113 ; 0.716128867 ; 0.163392352 ; 0.003926481 ; 0.467587427 ; 0.001807047 ; 0.000372 ; 0.617760742 ; 0.003736572 ; 0.004269427 ; 0.179817453 ; 0.562287895 ; 0.005005688 ; 0.000895 ; 0.59904785 ; 0.293099471 ; 0.258537703 ; 0.276956221 ; 0.087923729 ; 0.148964762 ; 0.420248193 ; 0.438935765 ; 0.102101125 ; 0.422466478 ; 0.623824934 ; 0.390621845 ; 0.333333333 ; 0.409788194 ; 0.252588275 ; 0.476511394 ; 0.018505951 ; 0.000676 ; 0.309865514 ; 0.027164354 ; 0.330582112 ; 0.221051745 ; 0.122148939
TUMOR_TMB	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	Tumor TMB	Patient	
UNCOLLAPSED_MEAN_COVERAGE	Black	Mixed cfDNA (MSK, Nature Medicine 2019)	NUMBER	The raw deduplicated mean coverage of all baits in the experiment	Sample	75238 ; 51684 ; 67098 ; 80489 ; 66254 ; 58802 ; 81690 ; 65071 ; 77760 ; 75650 ; 78587 ; 77001 ; 81723 ; 79625 ; 88665 ; 59391 ; 54805 ; 82745 ; 74390 ; 69088 ; 76771 ; 57978 ; 54224 ; 77831 ; 57410 ; 63240 ; 79937 ; 67433 ; 50482 ; 91337 ; 86464 ; 64232 ; 91280 ; 71984 ; 85181 ; 82969 ; 56879 ; 92269 ; 85690 ; 73770 ; 45542 ; 74735 ; 80793 ; 48839 ; 81361 ; 65899 ; 50102 ; 56340 ; 89060 ; 73289 ; 61608 ; 59497 ; 80065 ; 56835 ; 76815 ; 49161 ; 85343 ; 90024 ; 43566 ; 83613 ; 91267 ; 59691 ; 55224 ; 87704 ; 75623 ; 73651 ; 74686 ; 82812 ; 79667 ; 63275 ; 97053 ; 75410 ; 95512 ; 90864 ; 54155 ; 51291 ; 77077 ; 49571 ; 80678 ; 85627 ; 47786 ; 48453 ; 93514 ; 73787 ; 51121 ; 93933 ; 85783 ; 87022 ; 45327 ; 59892 ; 89799 ; 81284 ; 55207 ; 88334 ; 95460 ; 87450 ; 62606 ; 86076 ; 48975 ; 91514 ; 31522 ; 83368 ; 52261 ; 84069 ; 86746 ; 89251 ; 51178 ; 54182 ; 97249 ; 89837 ; 61238 ; 77269 ; 61992 ; 45907 ; 41198 ; 59810 ; 62779 ; 64760 ; 68046 ; 89460 ; 63890 ; 89863 ; 90272 ; 61017
AFP_AT_PROCUREMENT	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	NUMBER	Alpha Fetoprotein At Procurement (ng/mL)	Sample	1986 ; 35800 ; 0.7 ; 293 ; 16000 ; 24000 ; 39400 ; 30073.6 ; 5400 ; 3953.3 ; >1800 ; 29.4 ; >100000 ; 2164 ; 48000 ; 19847 ; 39.4 ; 3900 ; 125 ; 10073 ; 1700 ; 61226 ; 481 ; 124.7 ; 990 ; 1530 ; >1600 ; >13000 ; 2200 ; 70.6 ; >20000 ; 3.2 ; 72.1 ; 733 ; 891 ; 60.6 ; 3184 ; 57476 ; 3627 ; 5350.4 ; 100 ; 41700 ; 333580 ; 280 ; 4.7 ; 102404 ; 11891 ; 252590.4 ; 4241.7
BHCG	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	NUMBER	BHCG (mIU/mL)	Patient	
CA_125	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	NUMBER	CA-125 (U/mL)	Patient	
DX_MSK	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Pathology diagnosis at MSK	Patient	
DX_ORG_INST	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Diagnosis at Original Institution 	Sample	Yolk Sac Tumor ; Immature Teratoma ; 20% Dysgerminoma and 80% Yolk Sac tumor ; Dysgerminoma ; Extragonadal Germ Cell Tumor ; Mixed Germ Cell Tumor ; Squamous Cell Carcinoma arising in a Mature Cystic Teratoma of the Ovary ; Adenocarcinoma ; Mullerian carcinosarcoma and Yolk Sac Tumor ; Malignant Sacrococcygeal Teratoma ; Metastatic Carcinoma ; Mature Teratoma ; Choriocarcinoma ; Adenocarcinoma and Mature Cystic Teratoma ; Germ cell tumor (embryonal carcinoma)
DX_ORIGINAL	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Diganosis at patient's originial institute	Patient	
FIFTH_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Fifth line	Patient	
FIFTH_LINE_THERAPY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Fifth line therapy	Patient	
FIRST_LINE_THERAPY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	First Line Therapy	Patient	
FOURTH_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Fourth line	Patient	
FOURTH_LINE_THERAPY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Fourth line therapy	Patient	
LOCATION_RECURRED	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Location Recurred	Patient	
METASTATIC_DX	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	The anatomic location to which the cancer has spread.	Sample	Gliomatosis peritonei ; Intra-abd bladder mass, soft tissue ; Lung, Lymph node ; Liver, Lung ; Lymph Node ; Liver ; Lung, Left iliac ; Peritoneum ; Omentum ; Abdomen ; Abdominal Wall ; Omentum, appendix, peritoneum ; Pelvis, Omentum ; Peritonuem, Omentum ; Placenta ; Lung ; Pelvis - mature teratoma ; Pelvis ; Peritoneum, Omentum ; Lymph Node, Peritonuem ; Breast, Neck ; Soft tissue ; Pulmonary mets ; Spine, Lungs ; Liver and Pancreas ; Liver, lung ; Peritoneum,
PATH_DX_MSK	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Path Diagnosis at MSK	Sample	Yolk Sac tumor ; Mature Teratoma ; Dysgerminoma ; Mixed Germ Cell Tumor ; Mixed Germ cell (Behaving aggressively) ; Yolk Sac Tumor ; Sacrococcygeal Teratoma ; Immature Teratoma ; Trophoblastic Germ Cell tumor
RECURRENCE_AFTER_FIRST_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Recurrence after first line therapy	Patient	
RECURRENCE_LOCATION	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Recurrence location	Patient	
REC_AFTER_FIRST_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Recurred AFTER first line	Patient	
RESPONDED_SECOND_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Responded to second line	Patient	
RESPONSE_TO_SECOND_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Response to second line therapy	Patient	
SECOND_LINE_TC_OR_SURGERY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Second line Tx or Surgery	Patient	
SECOND_LINE_THERAPY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Second line therapy or surgery	Patient	
THIRD_LINE	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Third line	Patient	
THIRD_LINE_THERAPY	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Third line therapy	Patient	
TIME_TO_NED	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	STRING	Time to No Evidence of Disease	Patient	
TIME_TO_RECURRENCE_MONTHS	Black	MSK Make-an-IMPACT Rare Cancers (MSK, Clin Cancer Res 2023)	NUMBER	Time to Recurrence (months)	Patient	
RADIATION_ASSOCIATED	Black	Sarcoma (MSK, J Pathol 2023)	STRING	RT Associated Sarcoma	Sample	Yes
ALTERNATE_THERAPY_OTHER	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Other Alternative Therapy Given	Patient	
IN_TRANSIT	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	In Transit	Patient	
KBASE_ID	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Kbase Identifier	Patient	
OR_TIME	Black	Acral Melanoma (TGEN, Genome Res 2017)	NUMBER	OR Date from Diagnosis	Patient	
OTHER_TREATMENT_RESPONSE	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Other Treatment Responses	Patient	
PRIMARY_DEPTH	Black	Acral Melanoma (TGEN, Genome Res 2017)	NUMBER	Primary Depth	Sample	0.5 ; 5.5 ; 4 ; 1 ; 2.6 ; 6 ; 8 ; 7 ; 25 ; 3 ; 4.2 ; 2.5 ; 2.1 ; 4.3 ; 3.2 ; 12 ; 1.9 ; 1.5 ; 0.9 ; 1.8 ; 3.5 ; 4.5 ; 15
PRIMARY_MITOSES	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Primary Mitoses	Sample	<1 ; 6 ; 4 ; 2 ; Unknown ; 1 ; 3 ; 10 ; 13 ; 15 ; 0 ; 5 ; 14 ; 28 ; 7 ; 8
SITE_FIRST_RECURRENCE	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Site First Recurrence	Patient	
SUB_SITE	Black	Acral Melanoma (TGEN, Genome Res 2017)	STRING	Sub-site.	Sample	Inguninal( LN Regional) ; Foot ; Leg( In-Transit) ; Mesentery (Distant Met) ; Arm (In-Transit) ; Pelvic LN (Deep Regional) ; Chest Wall (Distant Met) ; Thumb ; Heel ; Inguninal LN (Regional LN) ; Ankle (In-Transit) ; Foot/Ankle ; Obturator LN (Regional LN) ; Greater Right Toe ; Great Toe Skin ; Lymph Node ; Left Toe Tumor ; Inguinal ; Upper Extremities ; Toe ; Lower Extremity ; Lung ; Leg
ALKYLATING_CHEMOTHERAPY	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Each Value Represents the Estimated Number of Mutations From the Alkylating Chemotherapy Per Sample	Patient	
BIOPSY_CONTEXT	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Biopsy Context	Patient	
BIOPSY_SITE_CATEG	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Biopsy Site Category	Sample	skin ; brain ; lymph node ; liver/visceral ; soft tissue ; lung ; bone
BR	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Best Radiographic Response (RECIST 1.1)	Patient	
CNA_PROP	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	CNA Prop	Sample	0.321417021 ; 0.391383951 ; 0.02944673 ; 0.169389493 ; 0.206518421 ; 0.394305859 ; 0.22414699 ; 0.144822308 ; 0.125993376 ; 0.238964456 ; 0.12034143 ; 0.347155573 ; 0.131587444 ; 0.392475013 ; 0.072497872 ; 0.21215863 ; 0.347430017 ; 0.085643565 ; 0.018852639 ; 0.070364788 ; 0.231090779 ; 0.13403875 ; 0.132201041 ; 0.062751333 ; 0.129693461 ; 0.048566109 ; 0.079132106 ; 0.030461458 ; 0.267523683 ; 0.096268104 ; 0.244658956 ; 0.188948385 ; 0.130179253 ; 0.117839207 ; 0.206019013 ; 0.171967485 ; 0.224408315 ; 0.231218754 ; 0.076011666 ; 0.252572663 ; 0.115692174 ; 0.187909079 ; 0.213885141 ; 0.131364345 ; 0.188740935 ; 0.251593523 ; 0.276335904 ; 0.1579233 ; 0.280752813 ; 0.123756314 ; 0.193168456 ; 0.324660445 ; 0.151364891 ; 0.541130726 ; 0.178141854 ; 0.196949537 ; 0.059114148 ; 0.116162455 ; 0.061750916 ; 0.168239373 ; 0.125244494 ; 0.147651333 ; 0.052105997 ; 0.333306508 ; 0.143139474 ; 0.165677406 ; 0.084780734 ; 0.201951363 ; 0.160872322 ; 0.251935266 ; 0.197113039 ; 0.110598811 ; 0.145393374 ; 0.178066367 ; 0.222592175 ; 0.241796322 ; 0.447039513 ; 0.13463337 ; 0.155330759 ; 0.02425638 ; 0.134906799 ; 0.187823806 ; 0.132058145 ; 0.308646455 ; 0.236006699 ; 0.102086979 ; 0.184649305 ; 0.136561942 ; 0.010357407 ; 0.194713842 ; 0.303313324 ; 0.233946178 ; 0.376051775 ; 0.023681914 ; 0.006697878 ; 0.162618152 ; 0.18582013 ; 0.074993396 ; 0.190553631 ; 0.013900327 ; 0.121665383 ; 0.353402367 ; 0.079081162 ; 0.123826962 ; 0.431160567 ; 0.457883791 ; 0.216010791 ; 0.127562586 ; 0.19079258 ; 0.188372462 ; 0.215760304 ; 0.223036883 ; 0.15900598 ; 0.106449389 ; 0.092364302 ; 0.062731432 ; 0.257008203 ; 0.064360264 ; 0.470864328 ; 0.484152028 ; 0.231012549 ; 0.148674622 ; 0.472099143 ; 0.124770087 ; 0.168904284 ; 0.171137069 ; 0.232352565 ; 0.201142567 ; 0.180587685 ; 0.390218557 ; 0.214096097 ; 0.273852935 ; 0.146472332 ; 0.20502101 ; 0.135187708 ; 0.100521216 ; 0.034541373 ; 0.251171185 ; 0.369739491 ; 0.111034165 ; 0.902095292 ; 0.196499246 ; 0.223074401 ; 0.187194201
COSMIC_AGING	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Each Value Represents the Estimated Number of Mutations From the Cosmic (Aging) Mutational Signature	Patient	
CUT_SUBQ_MET	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Cutaneous Subcutaneous Metastasis	Patient	
CYCLES_ON_THERAPY	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Cycles On Therapy	Patient	
HETEROGENEITY	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Heterogeneity	Sample	0.454545455 ; 0.314285714 ; 0.196721311 ; 0.107883817 ; 0.301075269 ; 0.212962963 ; 0.156521739 ; 0.130718954 ; 0.311111111 ; 0.210843373 ; 0.042417815 ; 0.2 ; 0.177570093 ; 0.451612903 ; 0.12195122 ; 0.474358974 ; 0.040719697 ; 0.17877095 ; 0.14893617 ; 0.129133858 ; 0.124688279 ; 0.092334495 ; 0.174545455 ; 0.237623762 ; 0.027642276 ; 0.228915663 ; 0.248427673 ; 0.080862534 ; 0.110124334 ; 0.185851319 ; 0.3 ; 0.095073892 ; 0.036363636 ; 0.212765957 ; 0.098159509 ; 0.105 ; 0.046931408 ; 0.102639296 ; 0.074144487 ; 0.128378378 ; 0.121495327 ; 0.234285714 ; 0.260869565 ; 0.128571429 ; 0.251012146 ; 0.183673469 ; 0.137209302 ; 0.134427684 ; 0.295454545 ; 0.020221787 ; 0.0625 ; 0.096774194 ; 0.4 ; 0.261904762 ; 0.161290323 ; 0.174332344 ; 0.145658263 ; 0.142857143 ; 0.176287051 ; 0.134328358 ; 0.137711864 ; 0.125373134 ; 0.16958042 ; 0.149019608 ; 0.191616766 ; 0.122257053 ; 0.147916667 ; 0.181208054 ; 0.178294574 ; 0.272727273 ; 0.304347826 ; 0.150036417 ; 0.168539326 ; 0.135849057 ; 0.042060988 ; 0.099820681 ; 0.134615385 ; 0.171052632 ; 0.56802244 ; 0.245614035 ; 0.295774648 ; 0.171494786 ; 0.114068441 ; 0.23721374 ; 0.469387755 ; 0.275862069 ; 0.139534884 ; 0.138059701 ; 0.144200627 ; 0.257142857 ; 0.115646259 ; 0.126506024 ; 0.222222222 ; 0.333333333 ; 0.307692308 ; 0.11299435 ; 0.41025641 ; 0.144414169 ; 0.883257307 ; 0.069059044 ; 0.096385542 ; 0.256097561 ; 0.301587302 ; 0.244827586 ; 0.061538462 ; 0.093352192 ; 0.37037037 ; 0.097056982 ; 0.081967213 ; 0.101725704 ; 0.137323944 ; 0.200431034 ; 0.176470588 ; 0.193181818 ; 0.218649518 ; 0.970982143 ; 0.251336898 ; 0.241833252 ; 0.036224126 ; 0.303030303 ; 0.442857143 ; 0.373333333 ; 0.127118644 ; 0.197674419 ; 0.087694484 ; 0.220930233 ; 0.23255814 ; 0.243654822 ; 0.208333333 ; 0.181818182 ; 0.033379694 ; 0.207446809 ; 0.347826087 ; 0.271375465 ; 0.162790698 ; 0.194444444 ; 0.124610592 ; 0.084677419 ; 0.078369906 ; 0.252559727 ; 0.215909091
IO_THERAPY	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Immunotherapy	Patient	
LDH_ELEVATED	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	LDH Elevated	Patient	
LIVER_VISC_MET	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Liver Visceral Metastasis	Patient	
LN_MET	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	LN Metastasis	Patient	
LUNG_MET	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Lung Metastasis	Patient	
MET_BONE	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Bone Metastasis	Patient	
MET_BRAIN	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Brain Metastasis	Patient	
MUTS_CLONAL	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Mutations Clonal	Sample	12 ; 48 ; 98 ; 215 ; 65 ; 85 ; 194 ; 133 ; 31 ; 131 ; 903 ; 188 ; 176 ; 17 ; 180 ; 41 ; 1013 ; 588 ; 40 ; 553 ; 351 ; 521 ; 227 ; 231 ; 598 ; 256 ; 239 ; 341 ; 501 ; 679 ; 21 ; 1837 ; 53 ; 37 ; 294 ; 716 ; 264 ; 306 ; 487 ; 258 ; 134 ; 61 ; 185 ; 160 ; 371 ; 1951 ; 1502 ; 560 ; 6 ; 26 ; 1113 ; 305 ; 528 ; 58 ; 407 ; 293 ; 475 ; 217 ; 135 ; 280 ; 1636 ; 122 ; 106 ; 16 ; 32 ; 3501 ; 370 ; 458 ; 1822 ; 1506 ; 45 ; 315 ; 308 ; 43 ; 50 ; 1430 ; 466 ; 3997 ; 52 ; 42 ; 111 ; 273 ; 156 ; 130 ; 145 ; 7 ; 27 ; 157 ; 23 ; 8 ; 314 ; 691 ; 8924 ; 450 ; 44 ; 219 ; 732 ; 641 ; 1442 ; 168 ; 989 ; 245 ; 14 ; 71 ; 243 ; 1555 ; 5401 ; 46 ; 39 ; 47 ; 103 ; 69 ; 645 ; 67 ; 33 ; 149 ; 152 ; 1390 ; 30 ; 196 ; 72 ; 29 ; 562 ; 690
MUTS_SUBCLONAL	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Mutations Subclonal	Sample	10 ; 22 ; 24 ; 26 ; 28 ; 23 ; 36 ; 20 ; 14 ; 35 ; 40 ; 47 ; 38 ; 25 ; 37 ; 43 ; 128 ; 7 ; 82 ; 50 ; 53 ; 48 ; 72 ; 17 ; 76 ; 79 ; 30 ; 62 ; 155 ; 9 ; 193 ; 2 ; 32 ; 84 ; 13 ; 39 ; 41 ; 6 ; 59 ; 303 ; 31 ; 12 ; 60 ; 4 ; 11 ; 5 ; 235 ; 52 ; 8 ; 113 ; 65 ; 42 ; 97 ; 284 ; 27 ; 618 ; 75 ; 80 ; 167 ; 405 ; 21 ; 296 ; 1243 ; 46 ; 16 ; 18 ; 54 ; 3 ; 5228 ; 662 ; 19 ; 71 ; 66 ; 15 ; 112 ; 93 ; 68 ; 870 ; 94 ; 496 ; 203 ; 73 ; 74 ; 190
NONSYNONYMOUS_MUTATION_COUNT	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Nonsynonymous Mutation Count	Sample	22 ; 71 ; 126 ; 246 ; 96 ; 125 ; 245 ; 158 ; 45 ; 172 ; 1007 ; 241 ; 230 ; 34 ; 221 ; 80 ; 1090 ; 767 ; 57 ; 656 ; 414 ; 593 ; 281 ; 311 ; 630 ; 341 ; 328 ; 388 ; 577 ; 860 ; 30 ; 2077 ; 60 ; 48 ; 334 ; 824 ; 288 ; 375 ; 542 ; 320 ; 219 ; 182 ; 23 ; 72 ; 255 ; 202 ; 443 ; 2296 ; 46 ; 1566 ; 201 ; 641 ; 10 ; 42 ; 31 ; 1382 ; 365 ; 56 ; 678 ; 478 ; 342 ; 583 ; 275 ; 173 ; 327 ; 1983 ; 157 ; 133 ; 50 ; 4234 ; 461 ; 571 ; 1963 ; 1734 ; 59 ; 394 ; 735 ; 58 ; 1772 ; 572 ; 5426 ; 105 ; 132 ; 276 ; 217 ; 167 ; 270 ; 18 ; 40 ; 180 ; 39 ; 11 ; 384 ; 6103 ; 9835 ; 507 ; 84 ; 64 ; 293 ; 833 ; 756 ; 29 ; 1624 ; 195 ; 1134 ; 17 ; 91 ; 315 ; 935 ; 392 ; 2117 ; 6249 ; 74 ; 79 ; 121 ; 90 ; 725 ; 92 ; 43 ; 205 ; 194 ; 33 ; 1477 ; 47 ; 279 ; 87 ; 37 ; 652 ; 268 ; 649 ; 302 ; 909
NUM_PRIOR_THERAPIES	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Num Prior Therapies	Patient	
POAR_COMBINED_CTLA_PD1	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Post Conbined CTLA PD1	Patient	
POST_CTLA4	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Post CTLA4	Patient	
POST_MAPK_TX	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Post MAPK Tx	Patient	
PRIMARY_TYPE	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Primary Type	Sample	occult ; skin ; acral ; mucosal
PRIOR_CTLA4	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Prior CTLA4	Patient	
PRIOR_MAPK_TX	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Prior MAPK Tx	Patient	
STEROIDS_GT_10MG_DAILY	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	Steroids > 10mg Daily	Patient	
TIME_TO_BR	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Time to Best Radiographic Response (BR)	Patient	
TOTAL_NEOANTIGEN	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Total Neoantigen	Sample	49 ; 230 ; 301 ; 825 ; 329 ; 334 ; 726 ; 489 ; 189 ; 560 ; 2949 ; 947 ; 636 ; 110 ; 729 ; 263 ; 3786 ; 2257 ; 92 ; 1862 ; 770 ; 1733 ; 728 ; 790 ; 2078 ; 999 ; 1029 ; 1137 ; 1895 ; 2250 ; 52 ; 6997 ; 194 ; 198 ; 1163 ; 2594 ; 1033 ; 1173 ; 1540 ; 1103 ; 690 ; 530 ; 41 ; 216 ; 784 ; 630 ; 1074 ; 6776 ; 204 ; 4779 ; 470 ; 2015 ; 20 ; 73 ; 94 ; 4545 ; 821 ; 148 ; 2400 ; 212 ; 1485 ; 983 ; 2146 ; 757 ; 557 ; 938 ; 6173 ; 490 ; 328 ; 54 ; 134 ; 10277 ; 1419 ; 1570 ; 5347 ; 5696 ; 185 ; 1216 ; 1897 ; 85 ; 141 ; 5582 ; 1702 ; 17933 ; 184 ; 203 ; 450 ; 837 ; 1088 ; 717 ; 481 ; 372 ; 769 ; 35 ; 24 ; 112 ; 543 ; 60 ; 1321 ; 13972 ; 24622 ; 1610 ; 291 ; 101 ; 793 ; 2022 ; 2511 ; 87 ; 4836 ; 599 ; 3069 ; 536 ; 1421 ; 42 ; 303 ; 1025 ; 2041 ; 1106 ; 5854 ; 18457 ; 188 ; 281 ; 138 ; 371 ; 262 ; 2304 ; 201 ; 123 ; 591 ; 638 ; 104 ; 4650 ; 539 ; 576 ; 222 ; 131 ; 1996 ; 929 ; 2136 ; 2796
TX_START_ECOG	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	STRING	ECOG performance status when treatment start	Patient	
TX_START_LDH	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Low lactate dehydrogenase (LDH) when treatment start	Patient	
UV_INDUCED_MUTATIONS	Black	Metastatic Melanoma (DFCI, Nature Medicine 2019)	NUMBER	Each Value Represents the Estimated Number of Mutations From the UV Mutational Signature Per Sample	Patient	
CANCER_SUBTYPE_CURATED	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Cancer Subtype Curated	Sample	MLL-ALL ; Fusion+ RMS ; ASPS ; Astrocytoma ; ATRT ; Extracranial Rhabdoid ; BCP-ALL ; Ph+-ALL ; Ph-likeALL ; Clear Cell Sarcoma ; Colon Carcinoma ; DIPG ; CNS embryonal NOS ; Ependymoblastoma ; CNS EFT-CIC ; Ependymoma ; Fusion- RMS ; Ewing Sarcoma ; ETMR ; ETP-ALL ; Glioblastoma ; CNS germinoma ; Hepatoblastoma ; Medulloblastoma ; Neuroblastoma ; Osteosarcoma ; Small Cell Carcinoma ; T-ALL ; Wilms
EXPRESSION	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	EXPRESSION	Sample	NO
INFERRED_ETHNICITY	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Inferred Ethnicity	Patient	
PHASE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	PHASE	Sample	Diagnosis ; Relapse ; Unknown ; Progressing Disease ; Post-treatment
REPORTED_ETHNICITY	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Reported Ethnicity	Patient	
SITE_OF_SPECIMEN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	SPECIMEN_SITE	Sample	Bone marrow ; Peripheral blood ; R. Breast metastasis ; Perineum ; Bone Marrow metastasis ; Bone Marrow ; Liver metastasis ; Cervical node ; Unknown ; Cerebrum ; L. Occipital mass ; R. Sylvian Fissure ; Frontal Lobe ; Kidney ; Cerebellum ; Ventricular mass ; Lung metastasis ; R. Parietal Lobe ; Lymph Node met ; Transverse Colon ; Brain stem ; R. Buttock ; Shoulder ; Orbit ; Paratesticular ; R. Neck mass ; Lung ; Left thigh ; Lung/pleura ; R. femur/rib/verebra ; Femur ; Paraspinal mass ; Abdominal mass ; Lung met ; Pleural effusion met ; Humerus ; Liver ; 4th ventricle ; post mortem blood ; tumor ; post mortem liver tumor ; bone marrow ; Left Bone marrow ; Right Bone marrow ; Retroperitoneal mass ; Adrenal mass ; Posterior mediastil mass (mediastinum) ; R. Proximal Ulna ; Tibia ; Lung mass ; R. Distal Femur ; R. Humerus ; L. Femur ; Distal femur ; L. Distal Femur ; Os frontalis ; L. Proximal Tibia ; Arm ; Paracaval Lymph Node metastasis ; L. Kidney ; R. Kidney ; Bilateral
TX_17-DMAG	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment 17-DMAG	Sample	2 ; 4 ; 0 ; 1 ; 3
TX_19D12	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment 19D12	Sample	1 ; 0 ; 2 ; 5 ; 6
TX_ABRAXANE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment ABRAXANE	Sample	0 ; 6 ; 5 ; 2 ; 4 ; 1
TX_ABT-199	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment ABT-199	Sample	0 ; 1 ; 5 ; 2
TX_ABT-263	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment ABT-263	Sample	5 ; 0 ; 1 ; 2 ; 6
TX_ACTINOMYCIN D	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment ACTINOMYCIN D	Sample	0 ; 1 ; 2 ; 6 ; 5
TX_APLIDIN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment APLIDIN	Sample	3 ; 0 ; 1 ; 2 ; 5
TX_AZD-2171	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment AZD-2171	Sample	1 ; 0 ; 2 ; 5 ; 3
TX_AZD-6244	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment AZD-6244	Sample	2 ; 0 ; 1 ; 3
TX_AZD1480	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment AZD1480	Sample	0 ; 2 ; 1 ; 5 ; 6
TX_AZD8055	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment AZD8055	Sample	0 ; 1 ; 2 ; 3
TX_BAL101553	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BAL101553	Sample	0 ; 2 ; 1
TX_BI6727 (VOLASERTIB)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BI6727 (VOLASERTIB)	Sample	0 ; 1 ; 2 ; 5 ; 3
TX_BMN-673	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BMN-673	Sample	0 ; 1 ; 2 ; 6
TX_BMS-354825	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BMS-354825	Sample	3 ; 1 ; 0 ; 2 ; 5
TX_BMS-754807	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BMS-754807	Sample	1 ; 2 ; 0
TX_BORTEZOMIB	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment BORTEZOMIB	Sample	2 ; 1 ; 0 ; 5 ; 4
TX_CABOZANTINIB (XL-148)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CABOZANTINIB (XL-148)	Sample	0 ; 2 ; 4 ; 1 ; 3
TX_CBL0137	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CBL0137	Sample	0 ; 2 ; 1 ; 4
TX_CDX-011 (GLEMBATUMUMAB)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CDX-011 (GLEMBATUMUMAB)	Sample	0 ; 1 ; 2 ; 6
TX_CGC(PG)-11047	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CGC(PG)-11047	Sample	2 ; 1 ; 0
TX_CISPLATIN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CISPLATIN	Sample	2 ; 4 ; 1 ; 0 ; 6 ; 3
TX_CLORETAZINE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CLORETAZINE	Sample	0
TX_CPX351	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CPX351	Sample	0 ; 5 ; 4
TX_CX-5461 (POL1)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CX-5461 (POL1)	Sample	0 ; 1 ; 2 ; 6
TX_CYCLOPHOSPHAMIDE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CYCLOPHOSPHAMIDE	Sample	6 ; 5 ; 2 ; 0 ; 1 ; 4
TX_CYTARABINE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment CYTARABINE	Sample	0 ; 1
TX_E7438/EPZ6438	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment E7438/EPZ6438	Sample	0 ; 1 ; 3 ; 2
TX_EC1456	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment EC1456	Sample	0 ; 5
TX_ERIBULIN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment ERIBULIN	Sample	0 ; 6 ; 2 ; 5 ; 1 ; 3 ; 4
TX_FENRETINIDE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment FENRETINIDE	Sample	0 ; 1
TX_GENZ-644282	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment GENZ-644282	Sample	0 ; 6
TX_GS-9820	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment GS-9820	Sample	0 ; 1
TX_GSK690693	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment GSK690693	Sample	1 ; 2 ; 0
TX_GSK923295A	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment GSK923295A	Sample	0 ; 6 ; 2 ; 5 ; 3 ; 4
TX_HGS-ETR1	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment HGS-ETR1	Sample	1 ; 0 ; 2
TX_IMC-A12	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment IMC-A12	Sample	0 ; 2 ; 1
TX_INK128-1110-028	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment INK128-1110-028	Sample	0 ; 2 ; 1
TX_JNJ26481585	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment JNJ26481585	Sample	3 ; 0 ; 1 ; 2 ; 5 ; 6
TX_JNJ26854165	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment JNJ26854165	Sample	4 ; 2 ; 1 ; 0 ; 5 ; 6
TX_KPT-330	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment KPT-330	Sample	0 ; 1 ; 2 ; 6 ; 5
TX_LAPATINIB	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment LAPATINIB	Sample	1 ; 0 ; 2
TX_LENOLIDAMIDE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment LENOLIDAMIDE	Sample	1 ; 2 ; 0
TX_LY 2606368	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment LY 2606368	Sample	0 ; 2 ; 1
TX_MK-2206	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment MK-2206	Sample	0 ; 2 ; 1
TX_MK-8242	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment MK-8242	Sample	0 ; 2 ; 3 ; 4 ; 5 ; 1
TX_MLN4924	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment MLN4924	Sample	3 ; 1 ; 2 ; 0
TX_MLN8237	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment MLN8237	Sample	5 ; 0 ; 1 ; 6 ; 3 ; 2
TX_MM-141	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment MM-141	Sample	0 ; 1 ; 2
TX_NSC060043	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment NSC060043	Sample	0
TX_NSC750854	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment NSC750854	Sample	0 ; 5 ; 2 ; 4 ; 1 ; 3 ; 6
TX_PCI-32765	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment PCI-32765	Sample	1 ; 0
TX_PF-03084014	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment PF-03084014	Sample	0 ; 2 ; 1
TX_PIXANTRONE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment PIXANTRONE	Sample	0 ; 1 ; 2 ; 5
TX_PR-104	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment PR-104	Sample	6 ; 5 ; 4 ; 0 ; 2
TX_RAPAMYCIN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment RAPAMYCIN	Sample	2 ; 4 ; 0 ; 3 ; 1 ; 6
TX_RG7112	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment RG7112	Sample	0 ; 1 ; 5 ; 3 ; 4 ; 2
TX_RO4929097	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment RO4929097	Sample	1 ; 0 ; 2
TX_RUXOLITINIB	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment RUXOLITINIB	Sample	0 ; 1 ; 2
TX_SAHA	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SAHA	Sample	1 ; 0 ; 2
TX_SAR3419	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SAR3419	Sample	2 ; 0 ; 4 ; 5 ; 1
TX_SB-715992	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SB-715992	Sample	4 ; 0 ; 2 ; 5 ; 6 ; 1 ; 3
TX_SCH 727965	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SCH 727965	Sample	0 ; 2 ; 1 ; 6 ; 3 ; 4
TX_SGI-1776	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SGI-1776	Sample	1 ; 0 ; 2
TX_SGN-CD19A	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SGN-CD19A	Sample	0 ; 5 ; 3
TX_SORAFENIB	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SORAFENIB	Sample	1 ; 2 ; 0
TX_STA9090 (GANETESPIB)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment STA9090 (GANETESPIB)	Sample	0 ; 1 ; 2
TX_STF-118804	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment STF-118804	Sample	0 ; 2 ; 1
TX_SU11248	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SU11248	Sample	2 ; 0 ; 1 ; 4
TX_SVV-001	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment SVV-001	Sample	0 ; 5 ; 6 ; 2 ; 1 ; 4
TX_TAK-701	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment TAK-701	Sample	0 ; 1
TX_TB-403	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment TB-403	Sample	0 ; 1
TX_TL32711	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment TL32711	Sample	0 ; 1 ; 6 ; 5 ; 2
TX_TOPOTECAN	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment TOPOTECAN	Sample	5 ; 0 ; 2 ; 6 ; 4 ; 1 ; 3
TX_TRISENOX(ATO)	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment TRISENOX(ATO)	Sample	0 ; 1 ; 2
TX_VINCRISTINE	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment VINCRISTINE	Sample	6 ; 2 ; 4 ; 3 ; 0 ; 1 ; 5
TX_VS-4718	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment VS-4718	Sample	0 ; 1 ; 2
TX_XL147	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment XL147	Sample	0 ; 2 ; 1
TX_XL765	Black	Pediatric Preclinical Testing Consortium  (CHOP, Cell Rep 2019)	STRING	Treatment XL765	Sample	0
BIOPSY_COHORT	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Biopsy Cohort	Sample	Liver ; Skin ; Head & Neck ; Bone ; Abdomen ; Lymphatic System ; Chest Wall ; Pancreas ; Soft Tissue ; Respiratory System ; Reproductive System ; Brain ; Adrenal Gland ; Intestine ; Breast ; Spine ; Blood ; Stomach
GENDER	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Patient gender.	Patient	
HRD_SCORE	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	HRD Score	Sample	16 ; 31 ; 35 ; 0 ; 1 ; 49 ; 19 ; 29 ; 27 ; 21 ; 33 ; 34 ; 36 ; 2 ; 25 ; 7 ; 15 ; 65 ; 40 ; 11 ; 24 ; 62 ; 63 ; 52 ; 48 ; 8 ; 38 ; 4 ; 55 ; 45 ; 18 ; 32 ; 17 ; 41 ; 9 ; 23 ; 13 ; 73 ; 30 ; 37 ; 42 ; 47 ; 43 ; 3 ; 22 ; 28 ; 26 ; 5 ; 53 ; 14 ; 46 ; 6 ; 60 ; 10 ; 12 ; 20 ; 56 ; 58 ; 64 ; 51 ; 50 ; 54 ; 44 ; 39 ; 67 ; 57
ICI	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Immune Checkpoint Inhibitor	Patient	
ICI_BEST_RESPONSE	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Immune Checkpoint Inhibitor Treatment Best Response	Patient	
ICI_DURABLE_CLINICAL_BENEFIT	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Immune Checkpoint Inhibitor Treatment Durable Clinical Benefit	Patient	
ICI_MUTATION_CATEGORY	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Mutation Category	Patient	
TREATED_WITH_ICI	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	Immune Checkpoint Inhibitor Treated	Patient	
TREATMENT_CATEGORY	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	STRING	ICI Treatment Catgory	Patient	
T_CELLS_CD4_MEMORY_ACTIVATED	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells CD4 Memory Activated Score	Patient	
T_CELLS_CD4_MEMORY_RESTING	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells CD4 Memory Resting Score	Patient	
T_CELLS_CD4_NAIVE	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells CD4 Naive Score	Patient	
T_CELLS_CD8	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells CD8 Score	Patient	
T_CELLS_FOLLICULAR_HELPER	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells Follicular Helper Score	Patient	
T_CELLS_GAMMA_DELTA	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells Gamma Delta Score	Patient	
T_CELLS_REGULATORY_TREGS	Black	Pan-cancer Analysis of Advanced and Metastatic Tumors (BCGSC, Nature Cancer 2020)	NUMBER	T Cells Regulatory Tregs Score	Patient	
MITOTIC_RATE_10HPF	Black	Leiomyosarcoma  (MSK,2024)	NUMBER	Mitotic Rate 10HPF	Sample	25 ; 50 ; 34 ; 12 ; 19 ; 21 ; 20 ; 43 ; 13 ; 16 ; 23 ; 14 ; 30 ; 38 ; 5 ; 22 ; 6 ; 59 ; 100 ; 10 ; 15 ; 40 ; 17 ; 35 ; 27 ; 47 ; 24 ; 62 ; 65 ; 11 ; 41 ; 28 ; 7 ; 48 ; 37 ; 9 ; 33 ; 2 ; 36 ; 51 ; 54 ; 42 ; 55 ; 31 ; 4 ; 8 ; 29 ; 3 ; 45 ; 63 ; 79 ; 32 ; 75 ; 102 ; 64 ; 26 ; 44 ; 1 ; 68 ; 18 ; 39 ; 52
NECROSIS	Black	Leiomyosarcoma  (MSK,2024)	STRING	Necrosis	Sample	Yes ; No
FINAL_DIAGNOSIS	Black	Soft Tissue and Bone Sarcoma (MSK, Nat Commun 2022)	STRING	Final corrected patient diagnosis determined by the presence or absence of pathognomonic genomic rearrangements or signatures	Patient	
GENOME_LOH	Black	Soft Tissue and Bone Sarcoma (MSK, Nat Commun 2022)	NUMBER	Genome loss of heterozygosity (percent)	Sample	17.56 ; 40.06 ; 0.43 ; 13.23 ; 10.44 ; 8.67 ; 29.24 ; 7.76 ; 21.61 ; 20.44 ; 0.23 ; 43.95 ; 0 ; 6.13 ; 10.32 ; 4.2 ; 2.75 ; 19.94 ; 1.17 ; 24.14 ; 12.92 ; 3.36 ; 31.91 ; 18.22 ; 20.77 ; 13.94 ; 10.06 ; 3.61 ; 2.16 ; 9.01 ; 31.89 ; 0.84 ; 14.53 ; 3.59 ; 7.24 ; 5.16 ; 17.19 ; 13.14 ; 2.86 ; 2.74 ; 2.24 ; 14.94 ; 8.75 ; 0.37 ; 4.24 ; 0.16 ; 11.46 ; 1.12 ; 21.5 ; 0.56 ; 3.83 ; 21.32 ; 11.2 ; 4.86 ; 0.22 ; 4.1 ; 9.13 ; 3.92 ; 20.54 ; 3.76 ; 15.88 ; 15.95 ; 1.65 ; 43.12 ; 22.75 ; 25.58 ; 4.5 ; 13.28 ; 0.58 ; 16.71 ; 10.81 ; 14.15 ; 10.13 ; 16.44 ; 1.26 ; 0.01 ; 15.77 ; 31.53 ; 12.99 ; 25.88 ; 5.3 ; 10.41 ; 4.11 ; 2 ; 21.65 ; 9.21 ; 24.26 ; 5.47 ; 9.64 ; 0.4 ; 26.22 ; 24.77 ; 10.04 ; 7.37 ; 17.37 ; 6.23 ; 16.02 ; 12.67 ; 5.97 ; 7.01 ; 10.09 ; 0.88 ; 9.28 ; 14.02 ; 6.49 ; 3.29 ; 1.13 ; 15.35 ; 3.7 ; 17.94 ; 6.56 ; 19.36 ; 8.64 ; 19.59 ; 4.97 ; 2.1 ; 17.15 ; 23.63 ; 4.96 ; 14.98 ; 0.67 ; 26.73 ; 13.58 ; 2.56 ; 6.58 ; 3.19 ; 2.27 ; 9.84 ; 21.01 ; 2.31 ; 18.53 ; 23.6 ; 10.37 ; 7.73 ; 5.71 ; 4.38 ; 4.27 ; 16.67 ; 12.16 ; 34.7 ; 23.69 ; 3.95 ; 1.76 ; 17.09 ; 24.69 ; 9.75 ; 14.35 ; 5.76 ; 3.49 ; 15.64 ; 0.89 ; 14.56 ; 24.94 ; 14.61 ; 5.09 ; 22.5 ; 0.03 ; 9.31 ; 8.86 ; 7.75 ; 3.13 ; 15.5 ; 1.88 ; 3.24 ; 12.04 ; 3.43 ; 3.17 ; 11.15 ; 1.85 ; 0.07 ; 4.09 ; 14.7 ; 5.82 ; 7.25 ; 18.86 ; 3.09 ; 1.91 ; 7.06 ; 15.86 ; 18.25 ; 5.37 ; 16.59 ; 18.15 ; 11.25 ; 6.77 ; 26.56 ; 14.86 ; 7.21 ; 1.27 ; 5.9 ; 13.29 ; 7.53 ; 17.05 ; 0.15 ; 0.46 ; 2.01 ; 6.7 ; 0.91 ; 14.08 ; 13.53 ; 26.58 ; 13.89 ; 8.19 ; 14.38 ; 8.03 ; 23.34 ; 11.24 ; 14.33 ; 10.02 ; 16.17 ; 9.06 ; 0.21 ; 10.83 ; 26.97 ; 2.97 ; 0.77 ; 2.09 ; 27.33 ; 25.92 ; 2.3 ; 12.19 ; 12.55 ; 9.83 ; 13.61 ; 9.48 ; 13.96 ; 24.7 ; 22.51 ; 7.38 ; 4.71 ; 3.47 ; 3.02 ; 16.5 ; 2.53 ; 4.14 ; 27.75 ; 0.82 ; 0.02 ; 3.03 ; 12.5 ; 6.62 ; 18.35 ; 5.02 ; 13.59 ; 7.71 ; 0.44 ; 1.53 ; 6.83 ; 5.7 ; 10.31 ; 5.26 ; 2.65 ; 1.78 ; 0.76 ; 13.48 ; 17.58 ; 20.13 ; 7.51 ; 6.32 ; 11.67 ; 0.8 ; 14.05 ; 9.6 ; 6.8 ; 9.78 ; 10.78 ; 7.7 ; 0.64 ; 7.74 ; 12.91 ; 5.77 ; 7.36 ; 14.82 ; 5.53 ; 1.23 ; 28.36 ; 60.32 ; 22.15 ; 15.36 ; 27.4 ; 20.19 ; 0.95 ; 2.67 ; 1.54 ; 11.08 ; 10.8 ; 31.93 ; 13.54 ; 21.43 ; 12.69 ; 0.54 ; 0.24 ; 5.27 ; 1.02 ; 2.5 ; 17.38 ; 19.58 ; 34.23 ; 2.98 ; 5.48 ; 14.11 ; 24.88 ; 3.82 ; 26.79 ; 0.31 ; 1.3 ; 1.2 ; 17.06 ; 8.32 ; 17.8 ; 2.44 ; 4.31 ; 10.45 ; 13.18 ; 20.11 ; 8.47 ; 10.73 ; 12.25 ; 1.35 ; 20.62 ; 17.98 ; 21.41 ; 18.66 ; 22.59 ; 0.11 ; 13.63 ; 2.99 ; 1.41 ; 48.57 ; 20.9 ; 17.76 ; 16.55 ; 18.93 ; 3.1 ; 22.61 ; 1.96 ; 1.71 ; 7.11 ; 0.81 ; 6.2 ; 2.32 ; 5.52 ; 3.86 ; 6.92 ; 17.54 ; 14.66 ; 24.91 ; 29.5 ; 27.54 ; 7.96 ; 12.4 ; 2.77 ; 5.56 ; 2.41 ; 34.14 ; 22.28 ; 6.36 ; 20.59 ; 40.89 ; 16.77 ; 15.43 ; 4.34 ; 12.66 ; 2.91 ; 10.17 ; 10.61 ; 18.24 ; 6.4 ; 20.28 ; 0.59 ; 0.29 ; 28.85 ; 7.13 ; 15.23 ; 12 ; 29.7 ; 9.18 ; 8.17 ; 1.29 ; 5.95 ; 26.33 ; 1.69 ; 3.38 ; 1.57 ; 5.07 ; 11.65 ; 0.1 ; 28.59 ; 16.29 ; 18.29 ; 15.4 ; 17.45 ; 13.92 ; 4.59 ; 7.99 ; 13.69 ; 8.82 ; 15.66 ; 8.49 ; 18.14 ; 4.42 ; 12.14 ; 12.09 ; 2.81 ; 11.04 ; 2.33 ; 20.98 ; 16.34 ; 2.71 ; 1.4 ; 14 ; 2.64 ; 4.04 ; 7.39 ; 0.28 ; 10.34 ; 4.54 ; 8.95 ; 17.5 ; 26.98 ; 5.49 ; 27.69 ; 14.04 ; 15.9 ; 8.63 ; 11.53 ; 6.29 ; 4.51 ; 3.6 ; 8.53 ; 3.68 ; 19.44 ; 12.48 ; 20.2 ; 7.98 ; 8.72 ; 9.1 ; 5.5 ; 12.53 ; 4.3 ; 9.16 ; 9.27 ; 14.48 ; 0.27 ; 2.22 ; 5.38 ; 6.63 ; 12.15 ; 1.94 ; 2.59 ; 2.96 ; 20.71 ; 0.45 ; 6.19 ; 33.57 ; 16.62 ; 5.22 ; 2.51 ; 8.42 ; 7.29 ; 18 ; 12.72 ; 18.6 ; 1.42 ; 9.66 ; 13.55 ; 23.21 ; 1.11 ; 1.19 ; 30.39 ; 36.17 ; 15.19 ; 10.48 ; 17.07 ; 0.87 ; 24.49 ; 0.12 ; 1.56 ; 8.34 ; 1.73 ; 7.58 ; 14.22 ; 16.06 ; 13.73 ; 0.68 ; 16.22 ; 12.26 ; 2.89 ; 16.49 ; 0.74 ; 17.3 ; 0.33 ; 6.31 ; 7.17 ; 14.09 ; 13.72 ; 3.94 ; 1.87 ; 9.73 ; 6.44 ; 1.33 ; 13.62 ; 4.35 ; 17.28 ; 1.01 ; 8.55 ; 14.83 ; 5.39 ; 7.46 ; 8.56 ; 11.02 ; 0.51 ; 20.14 ; 2.43 ; 2.29 ; 18.83 ; 18.59 ; 15.31 ; 9.77 ; 16.21 ; 1.34 ; 12.23 ; 5.43 ; 0.34 ; 1.52 ; 0.75 ; 25.86 ; 15.6 ; 1.46 ; 4.45 ; 27.41 ; 10.92 ; 1.5 ; 8.65 ; 12.41 ; 19.83 ; 25.95 ; 15.52 ; 3.07 ; 4.75 ; 2.34 ; 6.76 ; 4.64 ; 22.35 ; 10.01 ; 6.59 ; 0.53 ; 1.38 ; 13.38 ; 16.08 ; 5.75 ; 0.79 ; 5.42 ; 10.5 ; 9.93 ; 6.65 ; 3.06 ; 25.37 ; 19.68 ; 14.47 ; 11.27 ; 27.07 ; 6.16 ; 0.25 ; 11.52 ; 27.78 ; 8.1 ; 15.81 ; 40.98 ; 2.78 ; 30.45 ; 8.58 ; 13.74 ; 1.9 ; 20.93 ; 13.39 ; 8.35 ; 13.88 ; 14.39 ; 12.47 ; 13.11 ; 1.16 ; 2.4 ; 20.97 ; 20.21 ; 8.69 ; 19.26 ; 12.43 ; 11.98 ; 11.88 ; 17.79 ; 8.18 ; 15.54 ; 3.32 ; 19.05 ; 11.63 ; 18.26 ; 7.19 ; 10.97 ; 6.78 ; 9.76 ; 7.16 ; 7.45 ; 13.6 ; 7.44 ; 3.88 ; 29.95 ; 13.93 ; 25.74 ; 20.78 ; 9.09 ; 4.83 ; 11.66 ; 15.92 ; 17.22 ; 8.78 ; 14.8 ; 9.11 ; 4.93 ; 15.38 ; 14.71 ; 9.29 ; 35.9 ; 21.09 ; 24.81 ; 7.09 ; 16.33 ; 18.61 ; 16.25 ; 12.64 ; 20.26 ; 6.89 ; 16.19 ; 6.88 ; 7.4 ; 15.06 ; 1.79 ; 5.03 ; 2.25 ; 21.31 ; 16.78 ; 24.19 ; 13.33 ; 31.51 ; 7.6 ; 12.11 ; 14.14 ; 10.94 ; 24.64 ; 32.76 ; 12.17 ; 19.21 ; 17.89 ; 18.81 ; 18.21 ; 13.8 ; 23.67 ; 11.58 ; 18.23 ; 18.97 ; 1.45 ; 22.73 ; 1.98 ; 8.44 ; 20.4 ; 8.27 ; 12.44 ; 19.48 ; 10.71 ; 8.61 ; 0.35 ; 1.75 ; 7.15 ; 11.09 ; 13.82 ; 4.55 ; 1.43 ; 12.29 ; 6.93 ; 1.22 ; 1.7 ; 14.55 ; 11.57 ; 5.72 ; 2.7 ; 24.12 ; 29.09 ; 12.73 ; 18.06 ; 25.75 ; 3.97 ; 3.37 ; 14.97 ; 0.49 ; 1.44 ; 5.86 ; 8.74 ; 7.62 ; 4.18 ; 0.05 ; 0.69 ; 19.1 ; 8.08 ; 15.44 ; 18.87 ; 2.11 ; 20.29 ; 14.6 ; 15.07 ; 2.06 ; 9.05 ; 8.12 ; 25.39 ; 5.6 ; 19.66 ; 2.76 ; 10.89 ; 2.04 ; 16.72 ; 14.45 ; 11.77 ; 2.9 ; 14.92 ; 5.81 ; 1.61 ; 0.86 ; 3.44 ; 9.45 ; 18.64 ; 1.51 ; 12.13 ; 8.21 ; 17.33 ; 30.28 ; 0.26 ; 6.61 ; 10.08 ; 16.42 ; 2.84 ; 17.74 ; 10.03 ; 1.48 ; 5.2 ; 19.33 ; 24.98 ; 0.62 ; 0.78 ; 7.08 ; 15.87 ; 33.06 ; 4.62 ; 14.17 ; 5.06 ; 9.02 ; 26.99 ; 17.02 ; 20.5 ; 16.66 ; 4.77 ; 3.34 ; 7.23 ; 0.04 ; 1 ; 1.25 ; 9.23 ; 27.51 ; 7.14 ; 2.69 ; 20.05 ; 8.54 ; 5.78 ; 6.11 ; 19.25 ; 24.31 ; 28.46 ; 21.38 ; 13.03 ; 3.45 ; 10.47 ; 3.08 ; 1.83 ; 39.65 ; 2.15 ; 9.26 ; 37.64 ; 24.01 ; 14.24 ; 9.8 ; 25.68 ; 15.24 ; 58.49 ; 5.64 ; 11.64 ; 3.21 ; 23.08 ; 12.54 ; 17.16 ; 18.77 ; 2.13 ; 11.93 ; 1.31 ; 5.88 ; 12.87 ; 7.97 ; 17.03 ; 0.63 ; 7.92 ; 13.27 ; 16.98 ; 8.5 ; 11.79 ; 13.91 ; 17.62 ; 9.51 ; 1.09 ; 10.26 ; 24.45 ; 11.39 ; 2.82 ; 9.41 ; 33.75 ; 8.83 ; 8.6 ; 22.07 ; 9.91 ; 4.65 ; 3.67 ; 5.79 ; 4.06 ; 12.32 ; 12.1 ; 10.05 ; 15.13 ; 9.25 ; 0.47 ; 25.45 ; 5.01 ; 7.61 ; 3.65 ; 3.35 ; 18.18 ; 4.57 ; 10.9 ; 31.32 ; 5.08 ; 9.82 ; 9.99 ; 16.69 ; 15.67 ; 15.26 ; 21.96 ; 6.22 ; 14.64 ; 6.52 ; 2.72 ; 14.69 ; 15.1 ; 18.43 ; 12.97 ; 19.43 ; 15.37 ; 10.55 ; 6.14 ; 6.03 ; 20.08 ; 15.55 ; 11.81 ; 10.15 ; 21.12 ; 12.57 ; 17.86 ; 15.14 ; 3.16 ; 2.17 ; 8.68 ; 17.27 ; 1.99 ; 31.39 ; 32.3 ; 0.3 ; 7.52 ; 14.25 ; 29.58 ; 22.87 ; 11.34 ; 5.69 ; 5.94 ; 20.69 ; 10.86 ; 13.79 ; 15.78 ; 25.18 ; 22.13 ; 16.84 ; 7.3 ; 4.58 ; 4.76 ; 7.81 ; 6 ; 13.05 ; 14.99 ; 24.07 ; 16.97 ; 27.57 ; 1.62 ; 39.81 ; 9.96 ; 1.97 ; 7.28 ; 7.48 ; 12.24 ; 6.38 ; 55.21 ; 4.4 ; 13.01 ; 13.31 ; 3.4 ; 16.53 ; 3.25 ; 27.45 ; 24.2 ; 3.28 ; 25.56 ; 10.18 ; 10.93 ; 22.1 ; 12.63 ; 20.09 ; 19.8 ; 18.58 ; 25.43 ; 7.82 ; 16.58 ; 2.28 ; 30.82 ; 26.26 ; 4.33 ; 4.9 ; 11.21 ; 17.66 ; 20.7 ; 16.96 ; 32.42 ; 18.54 ; 3.69 ; 2.02 ; 7.93 ; 4.85 ; 16.61 ; 17.67 ; 18.52 ; 26.72 ; 8.41 ; 26.81 ; 6.57 ; 4.61 ; 0.94 ; 8.22 ; 8.48 ; 14.84 ; 26.78 ; 8.3 ; 14.01 ; 35.74 ; 19.34 ; 9.98 ; 3.84 ; 22.27 ; 34.1 ; 2.55 ; 19.5 ; 23.88 ; 3.58 ; 2.05 ; 0.83 ; 20.75 ; 4.03 ; 3.96 ; 18.32 ; 14.37 ; 9.43 ; 25.53 ; 18.11 ; 11.73 ; 4.98 ; 16.73 ; 4.95 ; 12.06 ; 13.4 ; 4.74 ; 22.64 ; 1.6 ; 29.55 ; 5.12 ; 4.94 ; 32.77 ; 18.37 ; 17.87 ; 31.86 ; 11.47 ; 3.85 ; 4.99 ; 6.54 ; 10.66 ; 11.38 ; 5.31 ; 18.51 ; 11.28 ; 0.14 ; 13.13 ; 29.9 ; 18.92 ; 3.11 ; 26.2 ; 1.82 ; 15.2 ; 6.25 ; 5.36 ; 16.63 ; 10.67 ; 14.28 ; 12.3 ; 30.52 ; 4 ; 2.2 ; 5.55 ; 20.73 ; 8.81 ; 8.59 ; 4.84 ; 4.39 ; 6.69 ; 3.18 ; 4.66 ; 8.24 ; 9.46 ; 37.36 ; 13 ; 16.64 ; 24.43 ; 0.71 ; 21.2 ; 18.16 ; 9.35 ; 12.75 ; 1.59 ; 1.05 ; 11.29 ; 7.86 ; 24.84 ; 15.97 ; 10.07 ; 8.39 ; 29.14 ; 16.03 ; 12.27 ; 0.08 ; 1.8 ; 5.17 ; 6.55 ; 6.66 ; 17.71 ; 13.32 ; 17.64 ; 8.79 ; 15.75 ; 17.01 ; 4.13 ; 0.9 ; 1.39 ; 12.37 ; 7.2 ; 4.29 ; 13.07 ; 14.76 ; 0.48 ; 20.43 ; 12.22 ; 1.04 ; 10.96 ; 17.63 ; 0.2 ; 7.63 ; 7.87 ; 9.4 ; 17.08 ; 28.29 ; 33.29 ; 15.56 ; 1.68 ; 15.7 ; 14.03 ; 14.77 ; 11.14 ; 39.44 ; 4.78 ; 15.01 ; 8.2 ; 20.22 ; 18.99 ; 0.13 ; 36.86 ; 12.8 ; 2.66 ; 2.08 ; 4.72 ; 30.67 ; 17.57 ; 17.18 ; 20.92 ; 40.07 ; 6.72 ; 17.13 ; 5.13 ; 20.01 ; 21.13 ; 24.39 ; 0.52 ; 10.2 ; 2.92 ; 15.18 ; 4.81 ; 2.12 ; 1.15 ; 2.45 ; 8.71 ; 24.09 ; 15.21 ; 20.88 ; 11.75 ; 6.24 ; 17.81 ; 15.99 ; 8.33 ; 13.47 ; 7.67 ; 12.84 ; 19.28 ; 9.14 ; 18.62 ; 34.63 ; 16.88 ; 19.93 ; 24.57 ; 1.47 ; 14.57 ; 0.36 ; 18.75 ; 27.96 ; 10.12 ; 23.75 ; 11.07 ; 0.55 ; 21.05 ; 8.04 ; 26.42 ; 14.18 ; 4.46 ; 8.76 ; 3.23 ; 22.69 ; 4.37 ; 8.26 ; 18.36 ; 10.64 ; 16.1 ; 21.45 ; 0.92 ; 7.56 ; 12.01 ; 25.87 ; 11.33 ; 15.17 ; 16.26 ; 9.12 ; 32.51 ; 25.91 ; 7.78 ; 33.27 ; 23.82 ; 18.74 ; 13.81 ; 4.79 ; 7.03 ; 7.88 ; 10.56 ; 11.68 ; 9.15 ; 15.12 ; 25.49 ; 15.27 ; 4.15 ; 20.38 ; 14.07 ; 1.93 ; 5.89 ; 6.05 ; 27.39 ; 18.12 ; 24.06 ; 26.09 ; 26.36 ; 13.19 ; 8.4 ; 2.6 ; 14.67 ; 10.54 ; 8.85 ; 2.85 ; 11.61 ; 24.16 ; 7.9 ; 0.6 ; 15.39 ; 9.19 ; 1.89 ; 17.2 ; 3.2 ; 3 ; 5.29 ; 13.87 ; 6.04 ; 22.77 ; 1.08 ; 9.24 ; 18.7 ; 2.79 ; 3.51 ; 2.19 ; 10.88 ; 24.15 ; 19.35 ; 6.79 ; 24.79 ; 19.61 ; 18.39 ; 5.74 ; 19.76 ; 21.28 ; 13.24 ; 1.07 ; 19.92 ; 4.89 ; 1.86 ; 30.85 ; 16.46 ; 12.08 ; 10.21 ; 2.83 ; 19.09 ; 5.62 ; 2.63 ; 3.42 ; 27.18 ; 3.26 ; 8.87 ; 21.64 ; 16.27 ; 15.32 ; 0.72 ; 10.95 ; 6.37 ; 26.28 ; 17.59 ; 8.29 ; 4.32 ; 2.8 ; 28.82 ; 4.8 ; 4.12 ; 18.78 ; 28.2 ; 16.35 ; 18.02 ; 15.61 ; 11.84 ; 11.85 ; 5.24 ; 30.86 ; 17.1 ; 10.46 ; 6.86 ; 9.85 ; 8.05 ; 31.27 ; 22.94 ; 47.74 ; 17.29 ; 0.42 ; 46.59 ; 21.34 ; 35.23 ; 10.57 ; 16.52 ; 16.79 ; 14.44 ; 3.48 ; 6.08 ; 6.96 ; 19.14 ; 15.89 ; 20.99 ; 4.43 ; 7.18 ; 23 ; 4.63 ; 8.13 ; 13.21 ; 9.3 ; 11.12 ; 28.73 ; 8.91 ; 9.52 ; 12.74 ; 29.45 ; 3.04 ; 21.85 ; 20.17 ; 28.16 ; 6.67 ; 17.6 ; 13.78 ; 15.45 ; 4.22 ; 3.99 ; 16.36 ; 13.46 ; 21.56 ; 14.46 ; 13.1 ; 16.28 ; 22.95 ; 9.2 ; 21.14 ; 13.5 ; 31.76 ; 16.38 ; 3.39 ; 9.68 ; 11.56 ; 7.77 ; 19.77 ; 5.25 ; 11 ; 9.08 ; 1.21 ; 7.42 ; 9.37 ; 5.99 ; 5.54 ; 13.3 ; 13.52 ; 15.25 ; 8.94 ; 22.79 ; 10.23 ; 4.26 ; 5.98 ; 23.66 ; 19.95 ; 2.03 ; 2.73 ; 7.69 ; 18.91 ; 3.72 ; 28.53 ; 7.02 ; 4.05 ; 17.42 ; 2.52 ; 9.07 ; 34.54 ; 16.54 ; 3.31 ; 20.96 ; 10.74 ; 27.2 ; 9.33 ; 3.63 ; 11.6 ; 16.37 ; 18.69 ; 5.18 ; 21.06 ; 18.19 ; 3.93 ; 23.62 ; 8.66 ; 2.07 ; 3.87 ; 11.97 ; 39.99 ; 8.25 ; 11.92 ; 6.12 ; 14.32 ; 19.73 ; 12.33 ; 5.33 ; 6.51 ; 37.37 ; 19.56 ; 11.19 ; 11.96 ; 18.08 ; 7.04 ; 18.79 ; 15.74 ; 4.7 ; 5.04 ; 3.05 ; 41.85 ; 38.25 ; 18.71 ; 5.91 ; 0.97 ; 20.87 ; 4.82 ; 46.71 ; 6.18 ; 22.39 ; 21.03 ; 36.44 ; 23.83 ; 1.03 ; 1.84 ; 2.88 ; 24.41 ; 4.08 ; 7.72 ; 32.72 ; 16.86 ; 3.55 ; 8.93 ; 2.26 ; 14.62 ; 3.66 ; 9.81 ; 8 ; 30.05 ; 9.54 ; 40.7 ; 15.08 ; 22.83 ; 15.58 ; 9.58 ; 14.3 ; 10.85 ; 5.32 ; 0.06 ; 4.17 ; 4.92 ; 10 ; 6.5 ; 11.95 ; 7.35 ; 6.43 ; 1.37 ; 15.3 ; 18.68 ; 19.46 ; 1.67 ; 2.62 ; 21.15 ; 13.95 ; 42.8 ; 33.45 ; 2.58 ; 17.43 ; 39.82 ; 14.4 ; 0.17 ; 45.1 ; 12.31 ; 15.69 ; 18.98 ; 1.66 ; 10.3 ; 11.72 ; 12.52 ; 33.9 ; 21.67 ; 18.76 ; 18.56 ; 17.65 ; 0.38 ; 8.9 ; 10.19 ; 22.49 ; 9.67 ; 14.13 ; 24.21 ; 6.1 ; 18.5 ; 33 ; 16.51 ; 20.64 ; 6.41 ; 3.77 ; 6.27 ; 2.42 ; 3.75 ; 29.22 ; 12.96 ; 19.85 ; 28.87 ; 5.34 ; 10.84 ; 19.6 ; 10.11 ; 0.32 ; 18.57 ; 3.27 ; 4.67 ; 2.37 ; 18.95 ; 15.16 ; 2.38 ; 8.88 ; 9.5 ; 20.95 ; 20.48 ; 16.01 ; 0.19 ; 2.35 ; 12.07 ; 15.02 ; 21.51 ; 12.05 ; 17.17 ; 1.32 ; 7.26 ; 22.41 ; 22.31 ; 3.52 ; 8.89 ; 1.64 ; 37.74 ; 43.85 ; 12.88 ; 2.93 ; 3.62 ; 13.04 ; 23.42 ; 2.94 ; 12.89 ; 5.63 ; 26.25 ; 20.37 ; 14.23 ; 20.79 ; 14.43 ; 5.85 ; 23.03 ; 29.44 ; 18.73 ; 20.61 ; 8.97 ; 2.95 ; 17.77 ; 15.73 ; 5.87 ; 14.65 ; 22.23 ; 21.98 ; 11.89 ; 9.39 ; 17.83 ; 22.9 ; 13.67 ; 0.57 ; 45.83 ; 24.5 ; 6.95 ; 5.15 ; 23.18 ; 16.83 ; 15.28 ; 5.68 ; 2.49 ; 0.93 ; 32.6 ; 15.63 ; 17.73 ; 17.35 ; 25.32 ; 33.25 ; 9.94 ; 32.15 ; 66.8 ; 6.26 ; 14.78 ; 17.7 ; 8.98 ; 2.61 ; 17.88 ; 7.5 ; 14.52 ; 1.36 ; 4.07 ; 2.57 ; 12.21 ; 20.18 ; 1.58 ; 6.68 ; 8.06 ; 3.53 ; 23.25 ; 21.77 ; 27.63 ; 8.77 ; 19.45 ; 9.7 ; 10.27 ; 23.91 ; 19.08 ; 6.07 ; 12.65 ; 3.64 ; 16.3 ; 7.94 ; 21.21 ; 7.89 ; 19.15 ; 28.32 ; 24.25 ; 13.36 ; 29.08 ; 2.39 ; 22.55 ; 9.42 ; 12.12 ; 4.02 ; 12.82 ; 1.74 ; 11.43 ; 35.21 ; 19.67 ; 0.61 ; 12.6 ; 20.42 ; 6.97 ; 18.27 ; 6.9 ; 19.63 ; 28.17 ; 31.24 ; 13.9 ; 46.31 ; 12.68 ; 14.91 ; 7.95 ; 20.6 ; 46.43 ; 27.43 ; 4.48 ; 21.36 ; 19.32 ; 18.67 ; 23.11 ; 5.35 ; 26.27 ; 16.15 ; 24.85 ; 21.44 ; 4.41 ; 17.34 ; 17.25 ; 31.19 ; 3.01 ; 10.42 ; 26.69 ; 8.92 ; 15.15 ; 23.49 ; 4.69 ; 6.85 ; 16 ; 0.41 ; 6.21 ; 12.94 ; 24.78 ; 0.98 ; 21.55 ; 23.54 ; 13.68 ; 31.14 ; 23.65 ; 2.46 ; 8.8 ; 7.1 ; 29.97 ; 52.15 ; 1.92 ; 9.55 ; 22.29 ; 0.85 ; 24.56 ; 21.27 ; 9.17 ; 29.05 ; 2.68 ; 46.86 ; 20.91 ; 20.74 ; 15 ; 0.09 ; 22.26 ; 14.85 ; 4.88 ; 21.26 ; 7.31 ; 24.6 ; 20 ; 9.32 ; 30.96 ; 27.82 ; 5.93 ; 12.62 ; 4.25 ; 59.28 ; 23.44 ; 16.56 ; 17.32 ; 24.86 ; 13.44 ; 26.75 ; 23.24 ; 6.09 ; 15.47 ; 12.79 ; 8.15 ; 7.83 ; 9.61 ; 17.99 ; 14.81 ; 8.57 ; 41.49 ; 10.72 ; 29.1 ; 17.48 ; 15.33 ; 9.38 ; 1.18 ; 39.13 ; 22.8 ; 0.96 ; 40.05 ; 19.91 ; 21.58 ; 2.18 ; 10.36 ; 14.54 ; 19.42 ; 29.28 ; 12.2 ; 19.41 ; 23.15 ; 1.77 ; 26.86 ; 21.02 ; 11.9 ; 13.86 ; 22.37 ; 7.22 ; 1.63 ; 35.27 ; 16.65 ; 37.76 ; 10.29 ; 11.31 ; 5.83 ; 5.41 ; 14.41 ; 17.11 ; 31 ; 6.45 ; 27.87 ; 12.78 ; 21.68 ; 21.72 ; 30.68 ; 9.53 ; 3.57 ; 13.57 ; 16.75 ; 16.14 ; 4.01 ; 13.98 ; 11.87 ; 6.48 ; 14.31 ; 11.49 ; 13.99 ; 15.79 ; 20.33 ; 18.88 ; 9.65 ; 23.36 ; 9.34 ; 11.23 ; 11.51 ; 2.14 ; 7.47 ; 12.95 ; 21.48 ; 32.22 ; 13.22 ; 1.14 ; 10.87 ; 23.38 ; 4.47 ; 12.85 ; 2.23 ; 18.65 ; 26.43 ; 19.39 ; 26.52 ; 4.28 ; 22.2 ; 12.38 ; 6.17 ; 5.57 ; 13.37 ; 1.28 ; 18.34 ; 13.97 ; 16.18 ; 11.05 ; 17.52 ; 14.5 ; 6.94 ; 16.05 ; 11.55 ; 38.45 ; 22.32 ; 12.03 ; 2.47 ; 9.97 ; 24.35 ; 21.17 ; 15.05 ; 19.78 ; 24.61 ; 11.59 ; 26.01 ; 8.11 ; 8.09 ; 6.71 ; 22.6 ; 24.03 ; 27.3 ; 5.96 ; 14.73 ; 24 ; 20.8 ; 3.79 ; 22.68 ; 9.88 ; 17.78 ; 14.34 ; 21.52 ; 19.57 ; 28.06 ; 8.16 ; 23.23 ; 6.74 ; 3.54 ; 21.29 ; 15.91 ; 6.3 ; 16.2 ; 10.43 ; 21.24 ; 15.71 ; 18.96 ; 4.87 ; 15.98 ; 8.62 ; 47.33 ; 28.88 ; 18.28 ; 10.35 ; 25.51 ; 14.26 ; 31.43 ; 7.57 ; 33.61 ; 27.65 ; 12.9 ; 7.32 ; 5.8 ; 36.65 ; 1.06 ; 18.2 ; 16.87 ; 4.52 ; 21.08 ; 16.24 ; 38.53 ; 3.14 ; 22.21 ; 10.22 ; 6.06 ; 19.02 ; 10.1 ; 41.02 ; 14.16 ; 18.04 ; 19.18 ; 14.49 ; 16.45 ; 21.11 ; 23.16 ; 9.44 ; 28.77 ; 22.7 ; 14.95 ; 23.35 ; 19.03 ; 5.44 ; 10.59 ; 4.16 ; 25.12 ; 9.69 ; 18.84 ; 20.89 ; 8.51 ; 19.69 ; 10.4 ; 26.59 ; 2.54 ; 9.63 ; 3.73 ; 19.22 ; 7.05 ; 13.65 ; 25.78 ; 5.46 ; 20.86 ; 22 ; 6.02 ; 12.59 ; 16.09 ; 4.73 ; 16.81 ; 1.72 ; 20.04 ; 10.6 ; 29.75 ; 38.74 ; 62.54 ; 16.9 ; 0.18 ; 18.72 ; 35.71 ; 3.89 ; 11.5 ; 18.48 ; 12.35 ; 23.99 ; 19.82 ; 8.07 ; 16.47 ; 31.84 ; 3.3 ; 38.68 ; 12.42 ; 23.07 ; 13.09 ; 5.23 ; 15.29 ; 19.01 ; 23.28 ; 10.68 ; 16.31 ; 46.94 ; 27.46 ; 7.84 ; 6.46 ; 3.12 ; 7.41 ; 36.05 ; 28.78 ; 23.74 ; 17.9 ; 7.65 ; 5.21 ; 6.34 ; 12.51 ; 27.19 ; 26.57 ; 4.36 ; 40.91 ; 21.93 ; 23.47 ; 25.24 ; 34.91 ; 17.44 ; 28.71 ; 8.45 ; 24.38 ; 8.28 ; 13.02 ; 19.98 ; 18.85 ; 2.21 ; 44.26 ; 12.71 ; 11.22 ; 26.21 ; 24.11 ; 31.75 ; 7.85 ; 20.81 ; 14.19 ; 26.87 ; 23.04 ; 37.77 ; 29.69 ; 3.8 ; 14.27 ; 17.39 ; 6.87 ; 15.76 ; 28.33 ; 25.8 ; 16.23 ; 32.17 ; 5.4 ; 20.31 ; 27 ; 35.31 ; 29 ; 13.34 ; 20.35 ; 5.19 ; 5.51 ; 9.62 ; 5.67 ; 19.17 ; 5.1 ; 25.69 ; 21.86 ; 17.55 ; 6.6 ; 37.62 ; 21.66 ; 0.66 ; 27.79 ; 14.74 ; 33.97 ; 23.87 ; 19.87 ; 22.62 ; 14.2 ; 8.38 ; 19.3 ; 21.18 ; 20.94 ; 26.3 ; 22.48 ; 24.75 ; 20.83 ; 13.83 ; 24.76 ; 26.83 ; 11.01 ; 25.03 ; 27.12 ; 37.14 ; 2.87 ; 28.99 ; 17.21 ; 4.6 ; 25.07 ; 29.51 ; 14.36 ; 27.52 ; 16.68 ; 12.56 ; 28.52 ; 19.31 ; 25.99 ; 38.66 ; 17.95 ; 26.54 ; 47.49 ; 17.24 ; 22.34 ; 12.45 ; 26.7 ; 1.55 ; 16.04 ; 19.71 ; 25.81 ; 20.3 ; 31.16 ; 25.1 ; 27.26 ; 45.66 ; 9.47 ; 15.48 ; 9.92 ; 42.88 ; 24.1 ; 3.81 ; 13.15 ; 12.7 ; 27.68 ; 5.65 ; 17.51 ; 10.16 ; 11.94 ; 13.7 ; 11.1 ; 20.82 ; 1.49 ; 20.68 ; 24.22 ; 0.5 ; 32.31 ; 7.54 ; 17.04 ; 19.23 ; 3.33 ; 16.4 ; 24.23 ; 30.34 ; 26.6 ; 19.65 ; 8.7 ; 9.95 ; 6.73 ; 23.22 ; 12.28 ; 10.24 ; 31.79 ; 18.38 ; 34.9 ; 13.51 ; 31.95 ; 1.24 ; 28.38 ; 21.81 ; 22.65 ; 15.51 ; 22.45 ; 10.28 ; 22.47 ; 14.63 ; 38.44 ; 17.69 ; 39.61 ; 19.96 ; 11.42 ; 36.48 ; 10.14 ; 33.92 ; 11.74 ; 21.92 ; 10.51 ; 26.66 ; 8.84 ; 27.42 ; 16.12 ; 30.47 ; 33.4 ; 20.34 ; 17.47 ; 26.88 ; 20.46 ; 32.47 ; 34.85 ; 28.41 ; 47.75 ; 5.66 ; 11.99
INITIAL_DIAGNOSIS	Black	Soft Tissue and Bone Sarcoma (MSK, Nat Commun 2022)	STRING	Initial patient diagnosis according to original submitted pathology results	Patient	
SAMPLE_TISSUE	Black	Soft Tissue and Bone Sarcoma (MSK, Nat Commun 2022)	STRING	Sample tissue 	Sample	Liver ; Pelvis ; Lymph Node ; Lung ; Uterus ; Soft Tissue ; Bone ; Head And Neck ; Mediastinum ; Abdomen ; Stomach ; Spine ; Breast ; Skin ; Chest Wall ; Retroperitoneum ; Colon ; Brain ; Fallopian Tube ; Pleura ; Mouth ; Peritoneum ; Pancreas ; Nasal Cavity ; Small Intestine ; Abdominal Wall ; Unknown ; Heart ; Adrenal Gland ; Endometrium ; Omentum ; Duodenum ; Eye ; Cervix ; Bladder ; Rectum ; Testes ; Bone Marrow ; Kidney ; Larynx ; Prostate ; Anus ; Nasopharynx And Paranasal Sinuses ; Ovary ; Thyroid Gland ; Pericardium ; Diaphragm ; Parotid Gland ; Muscle ; Pleural Fluid ; Vagina ; Peritoneal Fluid ; Spleen ; Blood ; Esophagus ; Iliac Crest ; Gastro-Esophageal Junction ; Gallbladder ; Whipple Resection ; Vulva ; Ureter ; Penis ; Tonsil ; Salivary Gland ; Trachea ; Ear ; Pericardial Fluid ; Tongue ; Placenta ; Central Nervous System (Cns) ; Urethra
HISTORY_ASBESTOS_EXPOSURE	Blue	Pleural Mesothelioma (NYU, Cancer Res 2015)	STRING	History Asbestos Exposure	Patient	
SITE_OF_RECURRENCE	Blue	Pleural Mesothelioma (NYU, Cancer Res 2015)	STRING	Site of Recurrence	Sample	Died Postop ; Local Ribs ; Local, Contralateral ; Perciardium, Contralateral ; Local, Then Pulm Mets ; Pulm Mets ; Local ; Abdomen ; Contralateral Lung ; Local And Abdomen ; No
TREATMENT_PRIOR_TO_SURGERY_INDICATOR	Blue	Pleural Mesothelioma (NYU, Cancer Res 2015)	STRING	Treatment prior to surgery	Patient	
CREATININE_NORM_RANGE_LOWER	Blue	Mesothelioma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure creatinine result lower limit of normal value	Patient	
CREATININE_NORM_RANGE_UPPER	Blue	Mesothelioma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure creatinine result upper limit of normal value	Patient	
FAMILY_HISTORY_CANCER_TYPE	Blue	Mesothelioma (TCGA, Firehose Legacy)	STRING	Family history cancer type.	Patient	
OCCUPATION_PRIMARY	Blue	Mesothelioma (TCGA, Firehose Legacy)	STRING	The primary occupation of the participant for most of their adult employment.	Patient	
OCCUPATION_PRIMARY_YEARS_WORKED	Blue	Mesothelioma (TCGA, Firehose Legacy)	NUMBER	The number that describes the duration of time expressed in number of years that a person has worked in a job.	Patient	
GNH	Blue	Pleural Mesothelioma (MSK, Clin Cancer Res 2024)	STRING	Genomic near haploidization	Sample	Yes
CANER_TYPE_DETAILED	Orange	Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)	STRING	Cancer Type Detailed	Sample	Renal Clear Cell Carcinoma
FUHRMAN_GRADE	Orange	Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)	STRING	Fuhrman Grade	Sample	1-4 ; 1 ; 1-3 ; 1-2 ; 2-3
TNMSTAGE	Orange	Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)	STRING	TNM stage.	Sample	T3N2M1 ; T3N0M1 ; T2N0M1 ; T4N0M1 ; T3N0M0 ; T2N0M0 ; T1N0M0 ; T1NxMx ; T4N0M0 ; T1bN0M0 ; T1NxM1 ; T1aN0M0 ; T2bN0M0 ; T2NxMx ; T3bNxMx ; T1NXMX ; T4NxM1
GENE_EXPRESSION_CLUSTER	Orange	Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)	STRING	Gene expression cluster.	Sample	ccB ; ccA
SARCOMATOID_COMPONENT	Orange	Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)	STRING	Sarcomatoid Component	Sample	present
VHL_MUTATION_AA	Orange	Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)	STRING	VHL Mutation (AA)	Sample	p.F76fs ; p.Q145fs ; p.N78K ; p.L89P ; p.R108_I109insIHSYRG ; p.V155fs ; p.H115fs ; p.H115Y ; p.S80N ; p.T157I ; p.P59fs ; p.E70X ; p.N78S ; p.L158fs ; p.V155splice ; p.W88C ; p.E70fs ; p.K171fs ; p.E134fs ; p.D121F ; p.R177X ; p.V74D ; p.Q73fs ; p.D121G ; p.G114A ; p.V130L ; p.P86S ; p.D190fs ; p.N131Y ; p.F119fs ; p.L129fs ; p.S68X ; p.A207fs ; p.S65L ; p.F148fs ; p.L178P ; p.L118P ; p.R167Q ; p.L158V ; p.L153fs ; p.P86T ; p.Y185X ; p.H115Q ; p.F76 del ; p.H125fs ; p.L85P ; p.W117X ; p.R58fs ; p.W88X ; p.P172fs ; p.S65X ; p.D121Y ; p.P86R ; p.P102_G104R ; p.E160fs ; p.W117fs ; p.G144X ; p.Y156X ; p.C162Y ; p.G106fs
VHL_MUTATION_CODON	Orange	Renal Clear Cell Carcinoma (UTokyo, Nat Genet 2013)	STRING	VHL Mutation (Codon)	Sample	c.224_225delTC ; c.433_442delCAGCCTATTT ; c.234T>A ; c.266T>C ; c.322_323insGCATCCACAGCTACCGAG ; c.464-25_465delGAGGATTTGGTTTTTGCCCTTCCAGTG ; c341_342insT ; c.343C>T ; c.239G>A ; c.T266C ; c.470C>T ; c.173delG ; c.G208T ; c.233A>G ; c.473delT ; c.464-3_-2insA ; c.264G>T ; c.208-210delGAGinsA ; c.512_513delinsC ; c.463+2_3TA>CC ; c.401delA ; c.361_362GA>TT ; c.529A>T ; c.221T>A ; c.217_218insC ; c.362A>G ; c.341G>C ; c.388G>C ; c.256C>T ; c.569_577 delACCACCCAAinsT ; c.391 A>T ; c.355 delT ; c.384_385 delTC ; c.203 C>A ; c.616_617insT ; c.194 C>T ; c.440 delT ; c.533 T>C ; c.353 T>C ; c.G500A ; c.472 C>G ; c.452_453 insCA ; c.256 C>A ; c.554_555 insGCTCTA ; c.345 C>A ; c.224_226 delTCT ; c.374 delAinsTT ; c.254 T>C ; c.203_204 delCG ; c.351 G>A ; c.173_192 delGCGGCCGCGGCCCGTGCTGC ; c.263 G>A ; c.510 delCinsAA ; c194 C>A ; c361 G>T ; c.471delT ; c.257C>G ; c.305_310delCGCCTG ; c.474_475insA ; c.346_347insT ; c.254T>C ; c.463+3A>C ; c.464-2A>C ; c.430G>T ; c.399delT ; c.480delG ; c.466_472delTATACTC ; c.G485A ; c.315delG
ALL_MUTS	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	All Mutations	Sample	84 ; 135 ; 166 ; 152 ; 104 ; 100 ; 83 ; 90 ; 86 ; 97 ; 128 ; 110 ; 81 ; 80 ; 157 ; 125 ; 126 ; 102 ; 171 ; 82 ; 132 ; 70 ; 78 ; 117 ; 140 ; 255 ; 116 ; 155
ALL_SYNS	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	All Synonymous Mutations	Sample	23 ; 50 ; 51 ; 47 ; 28 ; 37 ; 24 ; 26 ; 21 ; 35 ; 42 ; 20 ; 30 ; 46 ; 44 ; 36 ; 40 ; 29 ; 45 ; 31 ; 22 ; 25 ; 38 ; 34 ; 98 ; 53
CELL_MEMBRANE_PDL1_0PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Cell Membrane PDL1 0%	Patient	
CELL_MEMBRANE_PDL1_1PLUS_PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Cell Membrane PDL1 1%+	Patient	
CELL_MEMBRANE_PDL1_2PLUS_PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Cell Membrane PDL1 2%+	Patient	
CELL_MEMBRANE_PDL1_3PLUS_PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Cell Membrane PDL1 3%+	Patient	
DRUG	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	STRING	Drug	Patient	
FRAMESHIFT_INDELS	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	FrameShift Indels	Sample	4 ; 7 ; 8 ; 5 ; 2 ; 6 ; 9 ; 0 ; 10 ; 1 ; 3
IMMUNOTHERAPY_RESPONSE	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	STRING	Response to Immunotherapy	Patient	
MAX_TUMOR_CHANGE	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Max Tumor Change	Patient	
MUTS_UNEVAL	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Mutations Uneval	Sample	7 ; 25 ; 30 ; 16 ; 8 ; 11 ; 12 ; 1 ; 14 ; 10 ; 15 ; 17 ; 9 ; 18 ; 19 ; 6 ; 5 ; 65 ; 13 ; 34
NONSYNS_CLONAL	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	Nonsynonymous Clonal	Sample	50 ; 65 ; 73 ; 87 ; 44 ; 48 ; 39 ; 53 ; 60 ; 75 ; 58 ; 40 ; 33 ; 68 ; 79 ; 63 ; 77 ; 81 ; 92 ; 43 ; 32 ; 57 ; 22 ; 35 ; 59 ; 70 ; 78 ; 61 ; 62 ; 49
NONSYNS_SUBCLONAL	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	NonSynonymous Subclonal	Sample	9 ; 17 ; 38 ; 15 ; 21 ; 18 ; 8 ; 22 ; 11 ; 2 ; 10 ; 13 ; 27 ; 32 ; 4 ; 20 ; 54 ; 25 ; 68 ; 23 ; 16 ; 0 ; 30 ; 12 ; 83 ; 48
NONSYNS_UNEVAL	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	NonSynonymous Uneval	Sample	2 ; 3 ; 4 ; 5 ; 1 ; 0 ; 7 ; 14 ; 8 ; 6 ; 13
OS_CENSOR	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	STRING	Overall patient censor.	Patient	
PDL1_POSITIVE_1PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	PDL1 Positive 1%	Patient	
PDL1_POSITIVE_5PERCENT	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	NUMBER	PDL1 Positive 5%	Patient	
PFS_CENSOR	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	STRING	Progression Free Censor	Patient	
TREATMENT_GROUP	Orange	Clear Cell Renal Cell Carcinoma (DFCI, Science 2019)	STRING	Treatment Group	Patient	
SMOKING_YEAR_STARTED	Orange	Kidney Chromophobe (TCGA, Cancer Cell 2014)	NUMBER	The year in which the participant began smoking.	Patient	
SMOKING_YEAR_STOPPED	Orange	Kidney Chromophobe (TCGA, Cancer Cell 2014)	NUMBER	The year in which the participant quit smoking.	Patient	
NORMAL_SITE	Orange	Rhabdoid Cancer (BCGSC, Cancer Cell 2016)	STRING	Tissue where normal was derived.	Sample	Kidney ; Peripheral blood
HAS_OTHER_KIDNEY_CONDITION	Orange	Unclassified Renal Cell Carcinoma (MSK, Nature 2016)	STRING	Has other kidney condition.	Patient	
LAST_STATUS	Orange	Unclassified Renal Cell Carcinoma (MSK, Nature 2016)	STRING	Last Status.	Patient	
LOCAL_RECURRENCE	Orange	Unclassified Renal Cell Carcinoma (MSK, Nature 2016)	STRING	Local recurrence.	Patient	
LOCAL_RECURRENCE_MONTHS	Orange	Unclassified Renal Cell Carcinoma (MSK, Nature 2016)	NUMBER	Local recurrence (months).	Patient	
PATH_CANCER_MAX_DIM_CM	Orange	Unclassified Renal Cell Carcinoma (MSK, Nature 2016)	NUMBER	Pathology cancer maximum dimension (cm).	Patient	
EVENT_TYPE	Orange	Pediatric Wilms' Tumor (TARGET, 2018)	STRING	Event Type	Patient	
HISTOLOGY_CLASSIFICATION_IN_PRIMARY_TUMOR	Orange	Pediatric Wilms' Tumor (TARGET, 2018)	STRING	Histology classification in primary tumor	Sample	FHWT ; DAWT ; MXED
ICD_0_3_T	Orange	Pediatric Wilms' Tumor (TARGET, 2018)	STRING	ICD-0-3-T	Sample	C649 ; C220 ; C000
ERYTHROCYTE_SEDIMENTATION_RATE	Orange	Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Erythrocyte sedimentation rate result	Patient	
SERUM_CALCIUM_LEVEL	Orange	Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Serum calcium result	Patient	
SARCOMATOID_FEATURES	Orange	Kidney Chromophobe (TCGA, Firehose Legacy)	STRING	Presence of sarcomatoid features	Patient	
SARCOMATOID_PERCENT_OF_TUMOR	Orange	Kidney Chromophobe (TCGA, Firehose Legacy)	STRING	Percent tumor sarcomatoid	Patient	
FUSION_BY_RNA_PCR	White	Pediatric Ewing Sarcoma (DFCI, Cancer Discov 2014)	STRING	Fusion By RNA PCR	Sample	EWS-FLI1 7-7 ; EWS-FLI1 type 2 ; EWS-FLI1 type 1 ; EWS-ERG 7-6 ; EWS-FLI1 10-5 ; EWS-FLI type 1 ; EWS-ERG 7-9 ; EWS-FLI1
PRIMARY_TISSUE	White	Ewing Sarcoma (Institut Curie, Cancer Discov 2014)	STRING	Primary tissue	Patient	
CHOMOPLEXY	White	Ewing Sarcoma (MSK, 2023)	STRING	Chomoplexy	Patient	
DATE_OF_FOLLOWUP	White	Ewing Sarcoma (MSK, 2023)	STRING	Date of FollowUp	Patient	
DATE_OF_INITIAL_DIAGNOSIS	White	Ewing Sarcoma (MSK, 2023)	STRING	Date of Initial Diagnosis	Patient	
FUSION_EVENT	White	Ewing Sarcoma (MSK, 2023)	STRING	Fusion Event per Status	Patient	
STATUS_PRESENTATION	White	Ewing Sarcoma (MSK, 2023)	STRING	Status Presentation	Patient	
BEST_OVERALL_RESPONSE_BOR	Green	Metastatic Biliary Tract Cancers (SUMMIT - Neratinib Basket Trial, 2022)	STRING	Best Overall Response (BOR)	Patient	
ANATOMICAL_SUBTYPE	Green	Cholangiocarcinoma (National Cancer Centre of Singapore, Nat Genet 2013)	STRING	Anatomical Subtype	Sample	Extrahepatic ; Intrahepatic ; Perihilar ; Distal
ANTI_O_VIVERRINI_IGG	Green	Cholangiocarcinoma (National Cancer Centre of Singapore, Nat Genet 2013)	STRING	anti_O_viverrini_IgG	Sample	Negative
POD_FIRST_LINE	Green	Cholangiocarcinoma (MSK, Clin Cancer Res 2018)	STRING	Progression on First Line Treatment	Patient	
STAGE_4_DX	Green	Cholangiocarcinoma (MSK, Clin Cancer Res 2018)	STRING	Yes or No Status for Stage 4 Diagnosis	Sample	Yes ; No
SYSTEMIC_TREATMENT	Green	Cholangiocarcinoma (MSK, Clin Cancer Res 2018)	STRING	Systemic Treatment	Patient	
TIME_TO_METASTASIS_MONTHS	Green	Cholangiocarcinoma (MSK, Clin Cancer Res 2018)	NUMBER	TIme to Metastasis Months	Sample	0 ; 25 ; 1 ; 17 ; 9 ; 24 ; 12 ; 2 ; 33 ; 19 ; 8 ; 3 ; 11 ; 10 ; 14 ; 5 ; 16 ; 27 ; 26 ; 37 ; 7 ; 30 ; 44 ; 15 ; 57 ; 31 ; 23 ; 6 ; 4 ; 46 ; 20 ; 22
HBV	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	HBV	Patient	
HCV	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	HCV	Patient	
LIVER_FLUKE_STATUS	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	Liver Fluke Status (Fluke-Pos/Fluke-Neg)	Patient	
PSC	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	Primary Sclerosing Cholangitis	Patient	
TARGETED_SEQ	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	Targeted Sequencing	Sample	Yes ; No
TNM_STAGE	Green	Cholangiocarcinoma (ICGC, Cancer Discov 2017)	STRING	TNM Stage	Sample	T3NxMx ; T3N0M1 ; T1N0M0 ; T2bN1M0 ; T2aN0M0 ; T2bN0M0 ; T3N1M0 ; T3N0M0 ; T1N1M0 ; T1NxM0 ; T3NxM0 ; T4NxM0 ; T2N0M0 ; T4N0M0 ; T2N1M0 ; T4N1M0 ; T2aN1M0 ; T2aN0 ; T2bN0 ; T3N1Mx ; T2N0M1 ; T4N0M1 ; T3N1M1 ; T1NXM0 ; TNxMx ; T3NXM0 ; T1N0MX ; T2bNxM0 ; t2nxmo ; T3N2M0 ; T3n0m1 ; T1N0M1 ; T1aN0M0 ; T2bN1M1 ; T3Nx ; T1Nx ; T1N1Mx ; T2bNxM1 ; T1N0Mx ; TxN1Mx ; T4N1M1 ; TisN0M0 ; TisN0m0 ; T4NXM0
ERBB_PATHWAY_MUTATION	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	ErbB Pathway Mutation	Sample	NO ; YES
GALLBLADDER_STONES	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	Gallbladder Stone	Sample	NO ; YES ; Present ; Not Present
JAUNDICE	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	Jaundice	Patient	
LYMPH_NODE_METASTASIS	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	Lymph nodes metastasis.	Sample	NO ; YES
MARGIN_STATUS	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	Margin Status	Sample	R1 ; R0
PERINEURAL_INVASION	Green	Gallbladder Carcinoma (Shanghai, Nat Genet 2014)	STRING	Perineural invasion.	Sample ; Patient	NO ; YES
CBIOPORTAL_SAMPLE_CLASS	Green	Gallbladder Cancer (MSK, 2022)	STRING	The cbioportal sample classification (i.e., tumor, cellline, xenograph).	Sample	Tumor
CHOLELITHIASIS	Green	Gallbladder Cancer (MSK, 2022)	STRING	Cholelithiasis	Sample	0 ; 1
OS_MONTHS_DIAGNOSIS_TO_FU	Green	Gallbladder Cancer (MSK, 2022)	NUMBER	OS Months from Diagnosis to Follow Up	Sample	7.457905544 ; 16.88706366 ; 10.67761807 ; 18.98973306 ; 173.2402464 ; 36.10677618 ; 37.05954825 ; 15.04722793 ; 19.31827515 ; 25.26488706 ; 49.21560575 ; 20.46817248 ; 52.00821355 ; 9.133470226 ; 14.91581109 ; 29.5687885 ; 44.48459959 ; 11.49897331 ; 43.30184805 ; 17.83983573 ; 67.97535934 ; 11.53182752 ; 12.12320329 ; 7.326488706 ; 50.52977413 ; 74.0862423 ; 11.86036961 ; 81.51129363 ; 16.39425051 ; 57.82340862 ; 3.219712526 ; 81.01848049 ; 73.0349076 ; 4.796714579 ; 40.73921971 ; 19.8110883 ; 45.70020534 ; 14.81724846 ; 13.73305955 ; 47.37577002 ; 28.15605749 ; 5.35523614 ; 27.8275154 ; 43.76180698 ; 44.97741273 ; 38.17659138 ; 49.51129363 ; 7.490759754 ; 17.7412731 ; 16.16427105 ; 39.26078029 ; 31.96714579 ; 66.92402464 ; 61.76591376 ; 25.92197125 ; 54.04517454 ; 14.29158111 ; 62.68583162 ; 78.85010267 ; 60.22176591 ; 12.38603696 ; 4.008213552 ; 74.97330595 ; 0.59137577 ; 28.94455852 ; 8.509240246 ; 10.11909651 ; 55.42505133 ; 4.698151951 ; 8.082135524 ; 8.213552361 ; 43.20328542 ; 61.07597536 ; 23.32648871 ; 27.49897331 ; 4.632443532 ; 6.570841889 ; 54.53798768 ; 8.772073922 ; 51.67967146 ; 0.854209446 ; 32.13141684 ; 91.17043121 ; 13.37166324 ; 24.77207392 ; 8.443531828 ; 13.14168378 ; 21.15811088 ; 21.28952772 ; 18.39835729 ; 15.44147844 ; 8.574948665 ; 3.186858316 ; 45.99589322 ; 55.78644764 ; 94.91581109 ; 6.308008214 ; 43.63039014 ; 13.30595483 ; 53.58521561 ; 13.07597536 ; 5.880903491 ; 44.74743326 ; 123.301848 ; 2.168377823 ; 5.453798768 ; 50.03696099 ; 38.43942505 ; 40.93634497 ; 6.209445585 ; 48.55852156 ; 23.52361396 ; 33.60985626 ; 9.166324435 ; 39.12936345 ; 47.77002053 ; 38.37371663 ; 37.65092402 ; 33.14989733 ; 43.17043121 ; 18.52977413 ; 7.293634497 ; 39.06365503 ; 36.50102669 ; 117.0595483 ; 4.369609856 ; 2.759753593 ; 35.05544148 ; 28.45174538 ; 25.85626283 ; 7.950718686 ; 30.75154004 ; 30.58726899 ; 56.04928131 ; 17.57700205 ; 29.33880903 ; 29.40451745 ; 12.05749487 ; 123.4661191 ; 23.39219713 ; 26.25051335 ; 38.20944559 ; 24.41067762 ; 27.40041068 ; 24.31211499 ; 25.46201232 ; 4.895277207 ; 5.585215606 ; 27.10472279 ; 27.17043121 ; 45.10882957 ; 24.87063655 ; 29.10882957 ; 16.82135524 ; 20.66529774 ; 28.5174538 ; 42.0862423 ; 32.6899384 ; 30.9486653 ; 9.002053388 ; 21.88090349 ; 23.2936345 ; 22.47227926 ; 21.81519507 ; 15.86858316 ; 20.23819302 ; 17.70841889 ; 16.03285421 ; 15.80287474 ; 16.59137577 ; 15.83572895 ; 31.04722793 ; 14.16016427 ; 2.924024641 ; 14.02874743 ; 24.08213552 ; 14.06160164 ; 31.14579055 ; 27.137577 ; 12.81314168 ; 13.17453799 ; 18.4312115 ; 3.613963039 ; 12.1889117 ; 20.43531828 ; 19.71252567 ; 10.71047228 ; 8.180698152 ; 42.51334702 ; 7.523613963 ; 13.60164271 ; 12.32032854 ; 11.72895277 ; 11.95893224 ; 5.289527721 ; 2.39835729 ; 4.533880903 ; 6.078028747 ; 8.049281314 ; 13.47022587 ; 6.603696099 ; 5.223819302 ; 1.80698152 ; 1.938398357
OS_MONTHS_DIAG_TO_COLL	Green	Gallbladder Cancer (MSK, 2022)	NUMBER	OS Months from Diagnosis to Collection	Sample	0 ; 32.62422998 ; 1.281314168 ; 12.38603696 ; 19.8110883 ; 25.33059548 ; 29.70020534 ; 35.84394251 ; 46.02874743 ; 2.036960986 ; 2.858316222 ; 27.137577 ; 40.27926078 ; 7.983572895 ; 0.722792608 ; 0.689938398 ; 27.72895277 ; 24.60780287 ; 1.215605749 ; 31.90143737 ; 9.560574949 ; 32.52566735 ; 2.759753593 ; 4.632443532 ; 6.767967146 ; 11.86036961 ; 0.854209446 ; 10.41478439 ; 1.609856263 ; 13.79876797 ; 14.52156057 ; 0.59137577 ; 82.39835729 ; 8.476386037 ; 99.18685832 ; 0.887063655 ; 41.42915811 ; 16.42710472 ; 3.712525667 ; 64.82135524 ; 9.232032854 ; 6.53798768 ; 0.821355236 ; 1.018480493 ; 6.176591376 ; 12.55030801 ; 22.63655031 ; 5.585215606 ; 4.501026694 ; 4.336755647 ; 26.84188912 ; 6.143737166 ; 2.464065708 ; 8.969199179 ; 1.77412731 ; 15.21149897 ; 3.351129363 ; 5.289527721 ; 13.83162218 ; 11.40041068 ; 0.788501027 ; 31.73716632 ; 4.533880903 ; 2.234086242 ; 3.909650924 ; 17.34702259
OVERALL_SURVIVAL_MONTHS	Green	Gallbladder Cancer (MSK, 2022)	NUMBER	OS Months from Collection to Follow Up	Sample	7.457905544 ; 16.88706366 ; 10.67761807 ; 18.98973306 ; 140.6160164 ; 36.10677618 ; 35.77823409 ; 37.05954825 ; 15.04722793 ; 19.31827515 ; 12.8788501 ; 5.453798768 ; 49.21560575 ; 23.88501027 ; 19.51540041 ; 13.37166324 ; 20.46817248 ; 5.979466119 ; 9.133470226 ; 14.91581109 ; 29.5687885 ; 44.48459959 ; 11.49897331 ; 43.30184805 ; 17.83983573 ; 67.97535934 ; 11.53182752 ; 12.12320329 ; 5.289527721 ; 47.67145791 ; 74.0862423 ; 11.86036961 ; 81.51129363 ; 54.37371663 ; 16.39425051 ; 17.54414784 ; 3.219712526 ; 73.0349076 ; 4.073921971 ; 40.73921971 ; 19.8110883 ; 45.70020534 ; 14.12731006 ; 13.73305955 ; 19.64681725 ; 3.54825462 ; 5.35523614 ; 27.8275154 ; 43.76180698 ; 38.17659138 ; 17.60985626 ; 7.490759754 ; 8.180698152 ; 16.16427105 ; 39.26078029 ; 6.735112936 ; 52.00821355 ; 31.96714579 ; 66.92402464 ; 61.76591376 ; 25.92197125 ; 54.04517454 ; 14.29158111 ; 59.92607803 ; 78.85010267 ; 60.22176591 ; 12.38603696 ; 4.008213552 ; 70.34086242 ; 0.59137577 ; 28.94455852 ; 8.509240246 ; 10.11909651 ; 55.42505133 ; 4.698151951 ; 8.082135524 ; 8.213552361 ; 43.20328542 ; 54.30800821 ; 23.32648871 ; 27.49897331 ; 4.632443532 ; 6.570841889 ; 54.53798768 ; 50.82546201 ; 8.772073922 ; 0.854209446 ; 21.71663244 ; 91.17043121 ; 17.7412731 ; 11.76180698 ; 10.97330595 ; 7.589322382 ; 13.14168378 ; 6.636550308 ; 21.28952772 ; 17.80698152 ; 15.44147844 ; 8.574948665 ; 3.186858316 ; 45.99589322 ; 55.78644764 ; 12.5174538 ; 6.308008214 ; 43.63039014 ; 13.30595483 ; 45.10882957 ; 13.07597536 ; 5.880903491 ; 44.74743326 ; 24.11498973 ; 123.301848 ; 2.168377823 ; 50.03696099 ; 38.43942505 ; 40.04928131 ; 6.209445585 ; 48.55852156 ; 23.52361396 ; 33.60985626 ; 9.166324435 ; 39.12936345 ; 6.340862423 ; 38.37371663 ; 37.65092402 ; 33.14989733 ; 43.17043121 ; 2.102669405 ; 3.58110883 ; 39.06365503 ; 36.50102669 ; 52.23819302 ; 4.369609856 ; 2.759753593 ; 25.82340862 ; 28.45174538 ; 25.85626283 ; 1.412731006 ; 29.9301848 ; 30.58726899 ; 56.04928131 ; 17.57700205 ; 28.32032854 ; 29.40451745 ; 122.2505133 ; 23.39219713 ; 26.25051335 ; 25.65913758 ; 24.41067762 ; 27.40041068 ; 24.31211499 ; 25.46201232 ; 4.895277207 ; 5.585215606 ; 27.10472279 ; 27.17043121 ; 24.87063655 ; 29.10882957 ; 16.82135524 ; 20.66529774 ; 28.5174538 ; 19.44969199 ; 26.4476386 ; 9.002053388 ; 4.665297741 ; 20.92813142 ; 21.88090349 ; 23.2936345 ; 16.32854209 ; 21.81519507 ; 13.40451745 ; 20.23819302 ; 11.26899384 ; 17.70841889 ; 16.03285421 ; 14.02874743 ; 16.59137577 ; 15.83572895 ; 1.314168378 ; 14.16016427 ; 2.924024641 ; 20.73100616 ; 14.06160164 ; 12.81314168 ; 13.17453799 ; 18.4312115 ; 3.613963039 ; 12.1889117 ; 20.43531828 ; 8.31211499 ; 9.921971253 ; 10.7761807 ; 2.98973306 ; 13.60164271 ; 10.0862423 ; 11.72895277 ; 4.041067762 ; 11.95893224 ; 2.39835729 ; 4.533880903 ; 6.078028747 ; 8.049281314 ; 3.811088296 ; 13.47022587 ; 6.603696099 ; 10.71047228 ; 5.223819302 ; 1.80698152 ; 1.938398357
SAMPLE_NAME	Green	Gallbladder Cancer (MSK, 2022)	STRING	Sample Name respective to Patient Id	Patient	
TUMOR_STAGE_COLLECTION	Green	Gallbladder Cancer (MSK, 2022)	STRING	Tumor Stage Collection	Sample	4 ; 3 ; 1/2
ANTI-HCV	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Hepatitis C Antibody Test	Patient	
CAPSULE_FORMATION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Capsule Formation	Patient	
CAVAL_VEIN_INVASION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Caval Vein Invasion	Patient	
CHOLECYSTOLITHIASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Cholecystolithiasis	Patient	
CHOLEDOCHOLITHIASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Choledocholithiasis	Patient	
CHRONIC_HEPATITIS_ANY_TYPE	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	History of chronic viral hepatitis	Patient	
CIRRHOSIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Cirrhosis.	Patient	
DM_AT_PRESENTATION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	DM at Presentation	Sample	No ; Yes
EXTRAHEPATIC_METASTASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Extrahepatic Metastasis	Patient	
FATTY_LIVER_DISEASE	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Fatty Liver Disease	Patient	
HBV_SEROPOSITIVE	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	HBV Seropositive	Patient	
HEPATECTOMY	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Hepatectomy	Patient	
HEPATIC_SEGMENTS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	NUMBER	Hepatic Segments	Patient	
HEPATIC_VEIN_INVASION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Hepatic vein invasion	Patient	
HEPATOLITHIASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Hepatolithiasis	Patient	
HYPERTENSION_DIAGNOSIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Hypertension diagnosis	Patient ; Sample	Yes ; No
LIVER_SCHISTOSOMIASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Liver Schistosomiasis	Patient	
LYMPHATIC_METASTASIS	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Lymphatic Metastasis	Patient	
MICROVASCULAR_INVASION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Microvascular Invasion	Patient	
PORTAL_VEIN_INVASION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Portal vein invasion	Patient	
RESECTION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Resection	Patient	
SMOKING	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Smoking	Patient	
SPLENOMEGALY	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Abnormal Spleen Enlargement	Patient	
TUMOR_DIFFERENTIATION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Tumor Differentiation	Sample	MODERATELY ; POOR ; WELL
VARIX	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Varix	Patient	
VARIX_DEGREE	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Varix Degree	Patient	
VASCULAR_INVASION	Green	Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)	STRING	Vascular invasion	Sample ; Patient	No ; Yes
CA19	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	NUMBER	CA19	Patient	
CA19_HIGH	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	CA19 High	Patient	
CLIN_PSC	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	History of primary sclerosing cholangitis	Patient	
DIABETES_STATUS	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Diabetes Status	Patient	
DUCT_TYPE	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Duct Type	Patient	
DZ_EXTENT	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	DZ Extent	Patient	
ECOG_BIN	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	ECOG BIN	Patient	
HAIC	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	HAIC	Patient	
HEP_B	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Hepatitis B	Patient	
HEP_C	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Hepatitis C	Patient	
LVI	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	LVI	Patient	
NEOADJ_CHEMO	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Neoadjuvant Chemotherapy	Patient	
OS_MONTHS_FROM_RX	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	NUMBER	OS Months from RX	Patient	
PD_INF	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	PD INF	Patient	
POSITIVE_LYMPH_NODE	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Positive Lymoh Node	Patient	
POSITIVE_MARGIN	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Positive Margin	Patient	
STEATOSIS	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Steatosis	Patient	
SYSTEMIC_CHEMO	Green	Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)	STRING	Systemic Chemotherapy	Patient	
BILATERAL	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Bilateral	Patient	
CHOR_INV	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Choroidal Invasion	Sample	No ; Yes
GAIN_1Q	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Gain 1q	Sample	Yes ; No
LOH_16Q	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	LOH 16q	Sample	No ; Yes
OPTIC_NERVE_INV	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Optic Nerve Invasion	Sample	Yes ; No
RUBEOSIS	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Rubeosis	Sample	Yes ; No
SRS	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Subretinal Seeds	Sample	Yes ; No
VS	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Vitreous Seeds	Sample	Yes ; No
WORSE_PROGNOSIS	Green	Retinoblastoma (MSK, Cancers 2021)	STRING	Worse Prognosis	Sample	Yes ; No
CELL_TYPE	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	STRING	The type of specimen isolated from blood or bone marrow, ex: Plasma, PBMC, Granulocytes.	Sample	Mixed Spindle and Epithelioid ; Mixed Spindle and Epithelioid (Predominantly Spindle B) ; Mixed Spindle and Epithelioid (Predominantly Spindle) ; Mixed Spindle and Epithelioid/ and invasion in Sclerae ; Mixed Spindle and Epithelioid/ and invasion in Sclerae and Extrascleral invasion ; Spindle Type ; Spindle Type B, Pre-Existing Nevus ; Spindle Type B ; Spindle type  A (40%) and spindle type B (60%) ; Spindle type B, small component of epitheliod cells ; Spindle type B ; Spindle type B (50%) and epitheliod cells (50%) ; Spindle type  A (75%) and spindle type B (25%)
COUNTRY_OF_PROCUREMENT	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	STRING	Country of procurement.	Patient	
GENOMIC_BURDEN	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	NUMBER	Genomic Burden	Sample	0.49 ; 0.57 ; 0.46 ; 0.63 ; 0.55 ; 0.48 ; 0.35 ; 0.66 ; 0.6 ; 0.22 ; 0.37
LAST_FOLLOWUP_STATUS	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	STRING	Last Followup Status	Patient	
NUM_PROTEIN_ALTERING_MUTATIONS	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	NUMBER	Number of Protein Altering Mutations	Sample	5 ; 6 ; 8 ; 14 ; 3 ; 9 ; 13 ; 12 ; 10 ; 4 ; 7 ; 11 ; 19 ; 0 ; 53 ; 15
TOTAL_EXONIC_MUTATION_BURDEN	Green	Uveal Melanoma (QIMR, Oncotarget 2016)	NUMBER	Total Exonic Mutation Burden	Patient	
ABLATION_EMBOLIZATION_TX_ADJUVANT	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Ablation embolization tx adjuvant	Patient	
AFP_NORM_RANGE_LOWER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	AFP Normal Range Lower Bound	Patient	
AFP_NORM_RANGE_UPPER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	AFP Normal Range Higher Bound	Patient	
BILIRUBIN_TOTAL	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Bilirubin Total	Patient	
BILIRUBIN_TOTAL_NORM_RANGE_LOWER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Bilirubin Total Norm Range Lower	Patient	
BILIRUBIN_TOTAL_NORM_RANGE_UPPER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Bilirubin Total Norm Range Upper	Patient	
CHILD_PUGH_CLASSIFICATION	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Child pugh classification grade	Patient	
DEFINITIVE_SURGICAL_PROCEDURE	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Specimen collection method name	Patient	
FAMILY_HISTORY_CANCER_NUMBER_RELATIVES	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Cancer diagnosis first degree relative number	Patient	
HISTORY_HEPATO_CARCINOMA_RISK_FACTORS	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	History hepato carcinoma risk factor	Patient	
ISHAK_FIBROSIS_SCORE	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	Liver fibrosis ishak score category	Patient	
OTHER_HEPATO_CARCINOMA_RISK_FACTORS	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	STRING	History hepato carcinoma risk factor other	Patient	
PLATELET_NORM_RANGE_LOWER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory prcoedure platelet result lower limit of normal value	Patient	
PLATELET_NORM_RANGE_UPPER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory prcoedure platelet result upper limit of normal value	Patient	
PROTHROMBIN_TIME_INR_AT_PROCUREMENT	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure prothrombin time result value	Patient	
PROTHROMBIN_TIME_NORM_RANGE_UPPER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure international normalization ratio result upper limit of normal value	Patient	
PROTHROM_TIME_INR_NORM_RANGE_LOWER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure international normalization ratio result lower limit of normal value	Patient	
SERUM_ALBUMIN_NORM_RANGE_LOWER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure albumin result lower limit of normal value	Patient	
SERUM_ALBUMIN_NORM_RANGE_UPPER	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure albumin result upper limit of normal value	Patient	
SERUM_ALBUMIN_PRERESECTION	Green	Cholangiocarcinoma (TCGA, Firehose Legacy)	NUMBER	Laboratory procedure albumin result specified value	Patient	
CAUSE_OF_DEATH_OTHER	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Death cause text	Patient	
EXTRANOCULAR_NODULE_SIZE	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Extranocular Nodule Size	Patient	
EXTRASCLERAL_EXTENSION	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Extrascleral Extension	Patient	
EXTRAVASCULAR_MATRIX_PATTERNS	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Extravascular Matrix Patterns	Patient	
EYE_COLOR	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Eye Color	Patient	
GENE_EXPRESSION_PROFILE	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Gene Expression Profile	Patient	
MICROVASCULAR_DENSITY_MVD	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Microvascular Density Mvd	Patient	
PET_CT_STANDARDIZED_VALUES	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Pet Ct Standardized Values	Patient	
TUMOR_BASAL_DIAMETER	Green	Uveal Melanoma (TCGA, Firehose Legacy)	NUMBER	Tumor Basal Diameter	Patient	
TUMOR_BASAL_DIAMETER_MX	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Tumor Basal Diameter Mx	Patient	
TUMOR_INFILTRATING_LYMPHOCYTES	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	 Tumor infiltrating lymphocytes (TILs) are a type of white blood cell found in tumors. TILs are implicated in killing tumor cells, and the presence of lymphocytes in tumors is often associated with better clinical outcomes.	Patient	
TUMOR_INFILTRATING_MACROPHAGES	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Tumor Infiltrating Macrophages	Patient	
TUMOR_MORPHOLOGY_PERCENTAGE	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Tumor Morphology Percentage	Patient	
TUMOR_SHAPE_PATHOLOGIC_CLINICAL	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Tumor Shape Pathologic Clinical	Patient	
TUMOR_THICKNESS	Green	Uveal Melanoma (TCGA, Firehose Legacy)	NUMBER	Tumor Thickness	Patient	
TUMOR_THICKNESS_MEASUREMENT	Green	Uveal Melanoma (TCGA, Firehose Legacy)	STRING	Tumor Thickness Measurement	Patient	
KATABI_PATH	DarkRed	Adenoid Cystic Carcinoma (MSK, Nat Genet 2013)	STRING	Katabi path.	Patient	
OFFICIAL_PATH	DarkRed	Adenoid Cystic Carcinoma (MSK, Nat Genet 2013)	STRING	Official pathology.	Patient	
ACTIONABLE_ALTERATIONS	DarkRed	Adenoid Cystic Carcinoma (FMI, Am J Surg Pathl. 2014)	NUMBER	Number of actionable alterations	Sample	0 ; 1 ; 3 ; 2 ; 5
FUSION_OTHER	DarkRed	Adenoid Cystic Carcinoma (MDA, Clin Cancer Res 2015)	STRING	Description of other gene fusions identified by RT-PCR/qPCR/WGS (non-MYB/MYBL1/NFIB).	Patient	
MYB_MYBL1_FUSION_METHOD	DarkRed	Adenoid Cystic Carcinoma (MDA, Clin Cancer Res 2015)	STRING	Method used to validate MYB or MYBL1 gene fusions.	Patient	
MYB_NFIB_TRANSLOCATION	DarkRed	Adenoid Cystic Carcinoma (MDA, Clin Cancer Res 2015)	STRING	Description of translocations resulting in MYB-NFIB gene fusions.	Patient	
NFIB_FUSION_OTHER	DarkRed	Adenoid Cystic Carcinoma (MDA, Clin Cancer Res 2015)	STRING	Description of other NFIB fusions.	Patient	
MYB_ACTIVATION	DarkRed	Adenoid Cystic Carcinoma (Sanger/MDA, JCI 2013)	STRING	Presence of MYB activation	Patient	
MYB_VALIDATION	DarkRed	Adenoid Cystic Carcinoma (Sanger/MDA, JCI 2013)	STRING	Method used for validating MYB activation	Patient	
ALCOHOL_CONSUMPTION_FREQUENCY	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Alcohol Consumption Frequency	Patient	
ALCOHOL_HISTORY_DOCUMENTED	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Alcohol History Documented	Patient	
CLINICAL_TRIAL	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Clinical Trial	Patient	
DETAILED_PRIMARY_SITE	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Detailed Primary Site	Patient	
DISEASE_EXTENT	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Disease Extent At Time IMPACT Was Sent	Patient	
DISTANT_METASTASIS_PATHOLOGIC_SPREAD	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Distant metastasis pathologic spread.	Sample	yes ; no ; Yes ; No
HPV_STATUS	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	HPV status.	Patient	
INITIAL_TREATMENT	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Initial Treatment	Patient	
PRIOR_TX_TO_IMPACT_SAMPLE	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Prior Treatment to IMPACT Sample	Patient	
SITE_SEQUENCED	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Site Sequenced	Sample	Regional recurrence ; Distant metastasis ; Local recurrence ; Index primary ; Index primary and local recurrence ; Index primary & Regional Recurrence ; Local & regional recurrence ; Original Primary
TNM	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	TNM.	Sample	TxN2cMX ; T4N2cMX ; T4N3M0 ; T3N2cM1 ; T2N0M0 ; T4aN0MX ; T3N0M0 ; T3N2cM0 ; T1bN0M0 ; T4N0MX ; T1N0M0 ; T1N2bM0 ; T3N2bM0 ; T2N1M0 ; T4N1M0 ; T4aN2bM0 ; T4N2bM0 ; T2N0MX ; T3N2aMX ; T2N2bMX ; T1N2bMX ; T3N2bM1 ; T2N2CM1 ; T4aN3MX ; T2N2bM0 ; T2N2cMX ; TXN2bM0 ; T1N0MX ; T2N2bM1 ; T2N2cM0 ; T4bN2cMX ; T3N2MX ; T2N2M0 ; T1N3MX ; T3N3bMX ; T1N3bMX ; TXNXM1 ; T4N1M1 ; T3NXMX ; T2N1MX ; T3-T4NXM1 ; T3N0MX ; T3N0M1 ; T4bN0M1 ; TXN0MX ; Stage IV ; T3N2bMX ; T4aNXMX ; T4bN0M0 ; T2N0Mx ; T2N2cM1 ; T2NXM1 ; T2N2cMx ; T2N1M1 ; T4bN2M1 ; T4 [outside--rest unknown] ; T4N0M0 ; Unknown ; T1N1M0
TOBACCO_TYPE	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	Tobacco Type	Patient	
VAR_12_245	DarkRed	Recurrent and Metastatic Head & Neck Cancer (MSK, JAMA Oncol 2016)	STRING	12-245	Patient	
DRINKER	DarkRed	Head and Neck Squamous Cell Carcinoma (Broad, Science 2011)	STRING	Drinker.	Patient	
HPV_ISH	DarkRed	Head and Neck Squamous Cell Carcinoma (Broad, Science 2011)	STRING	Tumor human papilloma virus status by in situ hybridization: Positive/Negative/Not Evaluated	Sample	Negative ; Positive
HPV_PATHSEQ	DarkRed	Head and Neck Squamous Cell Carcinoma (Broad, Science 2011)	STRING	Tumor human papilloma virus status by PathSeq: Positive/Negative	Sample	Negative ; Positive
HPV_PCR	DarkRed	Head and Neck Squamous Cell Carcinoma (Broad, Science 2011)	STRING	Tumor human papilloma virus status by HPV-16 PCR: Positive/Negative/Not Evaluated	Sample	Negative ; Positive
CELL_DIFFERENTIATION	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	Cell Differentiation	Sample	Moderate ; Poor ; Well
CNE	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	NUMBER	Conserved Noncoding Element	Sample	2 ; 4 ; 5 ; 3
DAILY_ALCOHOL	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	Daily alcohol	Patient	
EXTRACAPSULAR_SPREAD	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	extracapsular spread (ECS), can be yes or no	Sample	No ; Yes
NODAL_STAGE	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	Nodal stage	Patient	
NON_SILENT_MUTATION	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	NUMBER	Non Silent Mutations	Sample	48 ; 105 ; 70 ; 53 ; 114 ; 85 ; 74 ; 34 ; 66 ; 41 ; 16 ; 13 ; 56 ; 54 ; 15 ; 72 ; 17 ; 45 ; 69 ; 68 ; 52 ; 176 ; 46 ; 109 ; 22 ; 39 ; 67 ; 112 ; 60 ; 79 ; 8 ; 84 ; 125 ; 83
NUMBER_OF_LYMPHNODES_POSITIVE	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	Positive Finding Lymph Node	Sample	7 ; 2 ; 1 ; 0 ; 3 ; 5 ; 6 ; 15 ; 14 ; 4
PREVIOUS_TREATMENT	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	STRING	Previous treatment.	Patient	
TOTAL_CNA	DarkRed	Oral Squamous Cell Carcinoma (MD Anderson, Cancer Discov 2013)	NUMBER	Total CNA	Sample	17 ; 30 ; 32 ; 39 ; 23 ; 10 ; 38 ; 27 ; 5 ; 12 ; 24 ; 25 ; 2 ; 29 ; 31 ; 13 ; 16 ; 28 ; 21 ; 4 ; 26 ; 1 ; 33 ; 15
PRIMARY_TUMOR_SIZE	DarkRed	Nasopharyngeal Carcinoma (Singapore, Nat Genet 2014)	STRING	Primary Tumor Size	Sample	3 ; 4 ; 1 ; 2 ; 2a
REGIONAL_LYMPH_NODE	DarkRed	Nasopharyngeal Carcinoma (Singapore, Nat Genet 2014)	STRING	Regional Lymph Node	Sample	0 ; 2 ; 1 ; 3 ; 3b
TUMOR_CELLULARITY_DOMINANT_CLONE_VAF	DarkRed	Nasopharyngeal Carcinoma (Singapore, Nat Genet 2014)	STRING	Tumor cellularity dominant clone vaf	Sample	84.21% ; 92.31% ; 92.68% ; 81.25% ; 81.82% ; 73.33% ; 89.66% ; 82.76% ; 78.79% ; 75.00% ; 77.11% ; 72.00% ; 88.89% ; 87.18% ; 63.16% ; 66.67% ; 69.57% ; 65.31% ; 85.71% ; 52.17% ; 98.40% ; 83.33% ; 87.27% ; 92.11% ; 77.92% ; 83.58% ; 46.43% ; 45.76% ; 69.77% ; 73.17% ; 52.38% ; 62.07% ; 38.71% ; 63.38% ; 89.41% ; 84.85% ; 46.15% ; 40.00% ; 62.34% ; 29.79% ; 48.78% ; 20.31% ; 51.85% ; 63.33% ; 22.22% ; 59.38% ; 75.56% ; 68.70% ; 41.38% ; 37.50% ; 70.00% ; 19.61%
EXTRACAPSULAR_SPREAD_PATHOLOGIC	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Presence of pathological nodal extracapsular spread	Patient	
HPV_STATUS_ISH	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Hpv status by ish testing	Patient	
HPV_STATUS_P16	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Hpv status by p16 testing	Patient	
INITIAL_SAMPLE_WEIGHT_GRAMS	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	NUMBER	Initial Sample Weight Grams	Sample	270 ; 260 ; 180 ; 190 ; 130 ; 280 ; 230 ; 240 ; 220 ; 70 ; 80 ; 60 ; 100 ; 120 ; 330 ; 50 ; 30 ; 160 ; 110 ; 170 ; 380 ; 250 ; 210 ; 690 ; 140 ; 150 ; 750 ; 90 ; 870 ; 310 ; 630 ; 800 ; 10 ; 20 ; 360 ; 200 ; 440 ; 410 ; 600 ; 300 ; 40 ; 420 ; 510 ; 640 ; 550 ; 400 ; 290
LYMPH_NODE_DISSECTION_METHOD	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Lymphnode dissection method left	Patient	
LYMPH_NODE_NECK_DISSECTION_INDICATOR	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	Lymphnode neck dissection	Patient	
P53_GENE_ANALYSIS	DarkRed	Head and Neck Squamous Cell Carcinoma (TCGA, Firehose Legacy)	STRING	P53 gene analysis	Patient	
ADMINISTRATION_OF_DRUG_WEEKS	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	NUMBER	Administration Of Drug Weeks	Patient	
MOLECULAR_SMOKING_SIGNATURE	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	STRING	Molecular Smoking Signature	Patient	
NEOANTIGEN_BURDEN	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	NUMBER	Neoantigen Burden	Patient	
NONSYNONYMOUS_MUTATION_BURDEN	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	NUMBER	Nonsynonymous Mutation Burden	Patient	
PDL1_EXPRESSION	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	STRING	PDL1 Expression	Patient	
PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY	Gainsboro	Lung Adenocarcinoma (MSK, Science 2015)	NUMBER	Prior Treatment Of Cytotoxic Chemotherapy	Patient	
PRIMARY_TUMOR_PATHOLOGIC_SPREAD	Gainsboro	Lung Adenocarcinoma (TCGA, Nature 2014)	STRING	Primary tumor pathologic spread.	Patient	
PRIOR_DIAGNOSIS	Gainsboro	Lung Adenocarcinoma (TCGA, Nature 2014)	STRING	Prior diagnosis.	Patient	
DRIVER_MUTATIONS	Gainsboro	Non-Small Cell Cancer (MSK, Cancer Discov 2017)	STRING	Driver Mutations	Sample	ROS1 ; KRAS ; EGFR_WT_AMP ; PIK3CA ; ERBB2 ; No mutations ; EGFR ; RET ; UNKNOWN DRIVER ; BRCA ; PTEN_truncating ; MET ; CDK4 AMP ; BRAF non-V600 ; NF1_truncating ; ALK ; ARAF ; EGFR_exon20 ; ERBB2_AMP_MUT ; BRAF ; MDM2_AMP ; HRAS ; MET_AMP ; ERBB2_WT_AMP ; CDKN2A del ; FGFR1 ; NRAS ; CDKN2A_del ; AKT1 ; MAP2K1 ; CDKN2A loss ; TSC1/2 ; GNAS ; RAF1 ; MET AMP ; CD74-NRG ; FGFR2 ; KIT ; ERBB3_MUT ; FGFR3-TACC3 ; MTOR
LINES_OF_TX_PRIOR_IMPACT	Gainsboro	Non-Small Cell Cancer (MSK, Cancer Discov 2017)	NUMBER	Number Treatment Lines Prior To Receiving Impact Results	Sample	0 ; 1 ; 4 ; 3 ; 2 ; 5 ; 7 ; 6
RECURRENT_METASTATIC_DISEASE	Gainsboro	Non-Small Cell Cancer (MSK, Cancer Discov 2017)	STRING	Recurrent/metastatic disease	Sample	YES ; y
SAMPLE_PRE_LUNG_THERAPY	Gainsboro	Non-Small Cell Cancer (MSK, Cancer Discov 2017)	STRING	Sample pre any Lung Therapy	Sample	YES ; NO
TARGET_THERAPY	Gainsboro	Non-Small Cell Cancer (MSK, Cancer Discov 2017)	STRING	Did the patient recieve target therapy	Patient	
CN_STATUS	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	STRING	Clinical Nodal Status	Patient	
CT_SIZE	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	NUMBER	CT Size	Patient	
DLCO	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	NUMBER	Diffusion lung capacity for carbon monoxide	Patient	
FEV1	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	NUMBER	FEV1	Patient	
FGA_FACETS	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	NUMBER	FGA Facets	Sample	0.190381903 ; 0.571482099 ; 0.181612611 ; 0.556202947 ; 0.426663234 ; 0.34265301 ; 0.178737453 ; 0.213703049 ; 0.115892837 ; 0.370460236 ; 0.051671281 ; 0.223464428 ; 0.680477508 ; 0.259734367 ; 0.34190044 ; 0.094597149 ; 0.056423933 ; 0.496179583 ; 0.167661749 ; 0.103334029 ; 0.016107427 ; 0.004188864 ; 0.471454926 ; 0.2680723 ; 0.578851887 ; 0.322057189 ; 0.472722296 ; 0.652051203 ; 0.117147149 ; 0.144452205 ; 0.34836405 ; 0.241974671 ; 0.081989708 ; 0.209492055 ; 0 ; 0.568150879 ; 0.508275032 ; 0.288786772 ; 0.368595499 ; 0.184344741 ; 0.054407486 ; 0.515392477 ; 0.218246544 ; 0.349963371 ; 0.185372477 ; 0.608281054 ; 0.002369757 ; 0.527930451 ; 0.613619019 ; 0.513506638 ; 0.022309233 ; 0.054564282 ; 0.115105585 ; 0.402390215 ; 0.18468715 ; 0.493264056 ; 0.058190374 ; 0.536457484 ; 0.56629485 ; 0.539468966 ; 0.572710723 ; 0.514987859 ; 0.300813767 ; 0.160172008 ; 0.287941224 ; 0.105122171 ; 0.107746856 ; 0.394152249 ; 0.372700243 ; 0.393877438 ; 0.102297397 ; 0.008106495 ; 0.299521415 ; 0.040230379 ; 0.418863594 ; 0.6552581 ; 0.475201124 ; 0.111766804 ; 0.30417194 ; 0.086304659 ; 0.12245571 ; 0.32610084 ; 0.346641058 ; 0.115114031 ; 0.369561933 ; 0.238958805 ; 0.051611424 ; 0.166812335 ; 0.388234081 ; 0.559149307 ; 0.343672837 ; 0.440764828 ; 0.49831903 ; 0.114135631 ; 0.417726106 ; 0.141475001 ; 0.163990243 ; 0.070547094 ; 0.068757839 ; 0.19754659 ; 0.220320135 ; 0.436470391 ; 0.016703459 ; 0.107206719 ; 0.155187392 ; 0.000242785 ; 0.118658956 ; 0.348533844 ; 0.55777551 ; 0.051580928 ; 0.146787259 ; 0.38012808 ; 0.225857025 ; 0.380342058 ; 0.093700278 ; 0.172200143 ; 0.478311909 ; 0.262490685 ; 0.107983308 ; 0.065361987 ; 0.335082584 ; 0.077866071 ; 0.224893057 ; 0.218629893 ; 0.064752636 ; 0.022448456 ; 0.038246118 ; 0.311000104 ; 0.114133925 ; 0.068736439 ; 0.453434196 ; 0.237191443 ; 0.170907745 ; 0.537570437 ; 0.308993228 ; 7.80E-07 ; 0.299939838 ; 0.328418842 ; 0.622208299 ; 0.094535802 ; 0.422951571 ; 0.474627514 ; 0.628856842 ; 0.051533282 ; 0.051587153 ; 0.088054146 ; 0.312828616 ; 0.289023597 ; 0.169839671 ; 0.464562226 ; 0.013377105 ; 0.510760847 ; 0.257353183 ; 0.116542997 ; 0.082107993 ; 0.286080349 ; 0.051553974 ; 0.284370555 ; 0.067963468 ; 0.074158088 ; 0.53603075 ; 0.470958696 ; 0.616674298 ; 0.073156527 ; 0.399806374 ; 0.06463386 ; 0.529370985 ; 0.065159342 ; 0.053119489 ; 0.584904751 ; 0.167769164 ; 0.342790223 ; 0.459578151 ; 0.549587499 ; 0.252641451 ; 0.104169995 ; 0.270575279 ; 0.05441807 ; 0.172702694 ; 0.176627959 ; 0.541809175 ; 0.051552638 ; 0.282134949 ; 0.529820336 ; 0.191029809 ; 0.222301105 ; 0.248677713 ; 0.206737641 ; 0.040387517 ; 0.481091271 ; 0.497732891 ; 0.279753865 ; 0.321475975 ; 0.051832747 ; 0.441983125 ; 0.201003528 ; 0.447906833 ; 0.186791893 ; 0.278172835 ; 0.641311951 ; 0.318625293 ; 0.459500702 ; 0.146417291 ; 0.539242726 ; 0.219970047 ; 0.13752961 ; 0.378918733 ; 0.502052908 ; 0.130214418 ; 0.026275791 ; 0.206816492 ; 0.107588191 ; 0.019915255 ; 0.021812367 ; 0.217775589 ; 0.428456046 ; 0.520423405 ; 0.059106534 ; 0.273288234 ; 0.551610303 ; 0.163058739 ; 0.371268096 ; 0.387509086 ; 0.049197989 ; 0.282471152 ; 0.25179362 ; 0.13757964 ; 0.123297485 ; 0.455679101 ; 0.331100114 ; 0.213490977 ; 0.379584213 ; 0.531793318 ; 0.152750288 ; 0.370676315 ; 0.299926879 ; 0.124872138 ; 0.010100357 ; 0.23453216 ; 0.650788686 ; 0.295338959 ; 0.57739283 ; 0.377468359 ; 0.551887395 ; 0.210143149 ; 0.232998988 ; 0.1609364 ; 0.137043308 ; 0.668341096 ; 0.670623537 ; 0.304266497 ; 0.077749215 ; 0.408045076 ; 0.069946285 ; 0.006866007 ; 0.11064072 ; 0.353831667 ; 0.144899758 ; 0.201835411 ; 0.274729389 ; 0.124320942 ; 0.061692154 ; 0.286328343 ; 0.089545905 ; 0.154806035 ; 0.048003006 ; 0.46977094 ; 0.367791219 ; 0.472994485 ; 0.062998035 ; 0.001475388 ; 0.090440554 ; 0.138598229 ; 0.025391076 ; 0.002581717 ; 0.365095233 ; 0.372491676 ; 0.052420918 ; 0.079515819 ; 0.237344023 ; 0.320053007 ; 0.020461616 ; 0.489177855 ; 0.384480901 ; 0.395102275 ; 0.22019896 ; 0.09781266 ; 0.110921474 ; 0.04159856 ; 0.499050819 ; 0.434502822 ; 0.34373361 ; 0.507609085 ; 0.151167409 ; 0.159377259 ; 0.214650896 ; 0.512517254 ; 0.370313386 ; 0.21840759 ; 0.454108391 ; 0.254124479 ; 0.222512184 ; 0.135088361 ; 0.250027766 ; 0.212814539 ; 0.104396453 ; 0.016440725 ; 0.656230907 ; 0.58935966 ; 0.467151118 ; 0.080314548 ; 0.00375779 ; 0.288404071 ; 0.112981141 ; 0.201596486 ; 0.213344875 ; 0.209757868 ; 0.305621318 ; 0.550494204 ; 0.049975943 ; 0.552701232 ; 0.00249861 ; 0.174759097 ; 0.114589234 ; 0.149344342 ; 0.444643645 ; 0.454556554 ; 0.268790092 ; 0.248775347 ; 0.658767446 ; 0.000554149 ; 0.458719928 ; 1.05E-05 ; 0.170837768 ; 0.44477493 ; 0.267108562 ; 0.280423346 ; 0.395012324 ; 0.276312335 ; 0.066469382 ; 0.316170435 ; 0.040206522 ; 0.102961382 ; 0.128255379 ; 0.472344765 ; 0.187615613 ; 0.208857158 ; 0.172633228 ; 0.282426751 ; 0.361690088 ; 0.243954114 ; 0.13634825 ; 0.212258092 ; 0.653430873 ; 0.364676874 ; 0.242023743 ; 0.316602759 ; 0.18680614 ; 0.506135282 ; 0.630655639 ; 0.402502926 ; 0.486074587 ; 0.088546189 ; 0.140414172 ; 0.526765152 ; 0.570507211 ; 0.35987051 ; 0.524863 ; 0.518263124 ; 0.155299695 ; 0.458777997 ; 0.112064886 ; 0.457895347 ; 0.324508553 ; 0.052340732 ; 0.488189159 ; 0.567997199 ; 0.439143801 ; 0.327497628 ; 0.106297811 ; 0.484143277 ; 0.089059781 ; 0.276769533 ; 0.651514298 ; 0.145904235 ; 0.227403812 ; 0.050932714 ; 0.480693886 ; 0.065688563 ; 0.322148825 ; 0.65060476 ; 0.158428131 ; 0.052348209 ; 0.061871836 ; 0.578382903 ; 0.118655027 ; 0.23707791 ; 0.589914349 ; 0.318187463 ; 0.594611493 ; 0.456055721 ; 0.080175803 ; 0.11868608 ; 0.47996869 ; 0.381745347 ; 0.502140291 ; 0.028003133 ; 0.327505841 ; 0.230654842 ; 0.275824038 ; 0.55309744 ; 0.328460892 ; 0.61262337 ; 0.233052319 ; 0.500989318 ; 0.464344446 ; 0.196684663 ; 0.217751937 ; 0.347711391 ; 0.147046287 ; 0.25430885 ; 0.100048221 ; 0.152407009 ; 0.159733852 ; 0.683547316 ; 0.514181731 ; 0.530682709 ; 0.27602054 ; 0.285929796 ; 0.435802903 ; 0.447388769 ; 0.241530804 ; 0.119347282 ; 0.589610493 ; 0.22251848 ; 0.056810607 ; 0.292667585 ; 0.020904912 ; 0.365884423 ; 0.611617835 ; 0.4164045 ; 0.105955377 ; 0.266830801 ; 0.225334853 ; 0.277856269 ; 0.316343401 ; 0.052370779 ; 0.469105702 ; 0.466706214 ; 0.39507813 ; 0.398576778 ; 0.21585639 ; 0.369482132 ; 0.545995755 ; 0.293269776 ; 0.103491017 ; 0.150737083 ; 0.277346006 ; 0.116303625 ; 0.504208139 ; 0.498910485 ; 0.521526681 ; 0.416432279 ; 0.09227546 ; 0.071177987 ; 0.37856314 ; 0.151078424 ; 0.14728909 ; 0.285403623 ; 0.344789398 ; 0.118034452 ; 0.186974197 ; 0.448955022 ; 0.068991441 ; 0.354381985 ; 0.322950382 ; 0.030751718 ; 0.206747204 ; 0.071746054 ; 0.372233205 ; 0.160580039 ; 0.098695304 ; 0.057290249 ; 0.025943999 ; 0.514914972 ; 0.195144791 ; 0.52426517 ; 0.227264887 ; 0.28597542 ; 0.002248825 ; 0.061997887 ; 0.209638496 ; 0.674465544 ; 0.413376548 ; 0.343010871 ; 0.280239201 ; 0.356411882 ; 0.230998489 ; 0.087124592 ; 0.271014895 ; 0.195061301 ; 0.209780115 ; 0.05858667 ; 0.153811387 ; 0.141839163 ; 0.371385321 ; 0.233148632 ; 0.454050242 ; 0.174585258 ; 0.204669946 ; 0.704996228 ; 0.532158319 ; 0.081307161 ; 0.431714095 ; 0.222094402 ; 0.125296477 ; 0.550286829 ; 0.059816725 ; 0.140723458 ; 0.052431644 ; 0.110560457 ; 0.668901588 ; 0.45308491 ; 0.113975971 ; 0.112371682 ; 0.084016058 ; 0.286207184 ; 0.383442083 ; 0.09871679 ; 0.050842476 ; 0.244350803 ; 0.102418725 ; 0.03162305 ; 0.077247139 ; 0.415619473 ; 0.340113523 ; 0.310575272 ; 0.642337357 ; 0.597022457 ; 0.583355592 ; 0.229136768 ; 0.183475073 ; 0.05146708 ; 0.161036976 ; 0.332234177 ; 0.302221837 ; 0.445113276 ; 0.331554151 ; 0.622402333 ; 0.114571699 ; 0.242101339 ; 0.475952462 ; 0.119238108 ; 0.40636017 ; 0.207829632 ; 0.105327091 ; 0.052467272 ; 0.27859881 ; 0.145188873 ; 0.20286742 ; 2.70E-05 ; 0.123165977 ; 0.308271935 ; 0.064390988 ; 0.500256753 ; 0.394961786 ; 0.004162213 ; 0.124192905 ; 0.047900766 ; 0.067737444 ; 0.250439266 ; 0.033662447 ; 0.216920074 ; 0.031754342 ; 0.052480444 ; 0.160481066 ; 0.494839995 ; 0.08656721 ; 0.360502239 ; 0.475059911 ; 0.42641561 ; 0.158573676 ; 0.352875096 ; 0.130188104 ; 0.695456103 ; 0.572461326 ; 0.18634815 ; 0.203927458 ; 0.520870022 ; 0.036758243 ; 0.095649867 ; 0.318461713 ; 0.057427716 ; 0.138837836 ; 0.329971011 ; 0.697185686 ; 0.581256596 ; 0.212180063 ; 0.587367488 ; 0.421592268 ; 0.111320177 ; 0.028236786 ; 0.657319054 ; 0.171289437 ; 0.377293482 ; 0.07182441 ; 0.196613552 ; 0.085532372 ; 0.135837785 ; 0.391304808 ; 0.466742554 ; 0.180181165 ; 0.258594487 ; 0.310142838 ; 0.367358506 ; 0.342928133 ; 0.60475783 ; 0.101670433 ; 0.358828658 ; 0.073091646 ; 0.043436861 ; 0.03592156 ; 0.179734184 ; 0.145593146 ; 0.444501714 ; 0.304756238 ; 0.454258672 ; 0.083920158 ; 0.477763308 ; 0.433216932 ; 0.393951809 ; 0.078097644 ; 0.18304724 ; 0.501696137 ; 0.150072817 ; 0.025309603 ; 0.503231894 ; 0.442921565 ; 0.26014499 ; 0.223601657 ; 0.143388636 ; 0.165788486 ; 0.058181355 ; 0.673792559 ; 0.060384529 ; 0.313437771 ; 0.364278266 ; 0.459326874 ; 0.157227051 ; 0.622280566 ; 0.218380187 ; 0.170873259 ; 0.531615275 ; 0.419606057 ; 0.176294498 ; 0.307576854 ; 0.176307792
PATHOLOGIC_STAGE	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	STRING	Pathologic Stage	Sample	3 ; 1 ; 2
PN_STATUS	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	STRING	Pathologic Nodal Status	Sample	Positive ; Negative
PREDOMINANT_HISTOLOGIC_SUBTYPE	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	STRING	Predominant Histologic Subtype	Sample	Solid ; Acinar ; Papillary ; Micropapillary ; Lepidic
SUBTYPE_GROUP	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	STRING	Subtype Group	Sample	Micropapillary/ Solid ; Acinar/ Papillary ; Lepidic
SUV	Gainsboro	Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)	NUMBER	Standardized uptake values 	Patient	
ADJUVANT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If adjuvant therapy was given	Patient	
ADJUVANT_CHEMOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If adjuvant chemotherapy was given	Patient	
ADJUVANT_IMMUNOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If adjuvant immunotherapy was given	Patient	
ADJUVANT_TARGETED	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If adjuvant targeted therapy was given	Patient	
ADJUVANT_THERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Adjuvant Therapy	Sample	Yes ; No
ADJUVANT_XRT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If adjuvant radiation was given	Patient	
ADRENAL_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Adrenal Met Status (Months)	Patient	
ADRENAL_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Adrenal Met Status	Patient	
AGE_AT_DOS_BX	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Age at Surgery/Biopsy	Sample	51.25479452 ; 38.48767123 ; 52.91780822 ; 52.74520548 ; 65.08767123 ; 43.08219178 ; 77.18082192 ; 59.82191781 ; 76.7260274 ; 42.04383562 ; 64.50136986 ; 55.88219178 ; 68.68493151 ; 67.98630137 ; 66.77808219 ; 51.50958904 ; 66.10410959 ; 39.49041096 ; 53.68493151 ; 65.85205479 ; 64.81643836 ; 67.13150685 ; 57.12876712 ; 77.31232877 ; 74.06027397 ; 73.1260274 ; 65.12054795 ; 70.43835616 ; 66.44383562 ; 56.02191781 ; 48.05205479 ; 64.94794521 ; 83.05479452 ; 58.16438356 ; 58.72054795 ; 71.57260274 ; 61.60821918 ; 54.37808219 ; 64.59452055 ; 80.55068493 ; 65.4 ; 61.61369863 ; 67.20273973 ; 71.30684932 ; 72.8 ; 65.24383562 ; 39.66849315 ; 52.24109589 ; 62.38630137 ; 58.41369863 ; 60.02191781 ; 67.35890411 ; 83.17808219 ; 64.30136986 ; 70.62191781 ; 64.24109589 ; 44.60547945 ; 58.76712329 ; 66.81917808 ; 50.90136986 ; 73.36438356 ; 56.90410959 ; 51.71232877 ; 57.78356164 ; 62.26575342 ; 83.10958904 ; 65.79726027 ; 69.42191781 ; 50.24383562 ; 60.03013699 ; 54.56712329 ; 57.23287671 ; 60.52876712 ; 60.59178082 ; 80.17808219 ; 80.71232877 ; 55.07123288 ; 75.00821918 ; 74.61917808 ; 76.09315068 ; 67.64657534 ; 63.29589041 ; 59.56712329 ; 38.03013699 ; 56.42739726 ; 52.53424658 ; 58.71232877 ; 88.65479452 ; 59.2109589 ; 30.4 ; 79.16164384 ; 54.11780822 ; 60.33150685 ; 62.88219178 ; 70.3369863 ; 74.84931507 ; 75.74794521 ; 56.00547945 ; 62.78082192 ; 63.65205479 ; 39.00547945 ; 63.32328767 ; 70.12876712 ; 80.01917808 ; 65.87123288 ; 63.63561644 ; 55.32876712 ; 73.30684932 ; 65.82739726 ; 76.85205479 ; 49.2 ; 65.65479452 ; 71.14246575 ; 76.1890411 ; 63.36986301 ; 79.49863014 ; 59.07123288 ; 72.58356164 ; 73.09041096 ; 56.97260274 ; 35.36164384 ; 77.96712329 ; 59.12876712 ; 84.17808219 ; 73.49041096 ; 68.78630137 ; 63.50136986 ; 65.15342466 ; 51.36712329 ; 54.75342466 ; 55.34246575 ; 59.52328767 ; 64.85753425 ; 66.83013699 ; 70.1890411 ; 60.98082192 ; 56.19452055 ; 58.63835616 ; 54.64931507 ; 53.96712329 ; 19.83013699 ; 37.65205479 ; 48.7369863 ; 70.83561644 ; 55.78630137 ; 58.8739726 ; 65.42191781 ; 80.11780822 ; 57.7369863 ; 46.74794521 ; 66.89315068 ; 68.02191781 ; 73.5260274 ; 74.36986301 ; 77.52054795 ; 43.1890411 ; 65.85753425 ; 55.29863014 ; 75.37808219 ; 68.79726027 ; 60.16164384 ; 76.44931507 ; 52.65753425 ; 65.10958904 ; 54.61369863 ; 76.23287671 ; 80.09041096 ; 70.96438356 ; 70.07945205 ; 61.39452055 ; 64.05205479 ; 34.98630137 ; 55.23287671 ; 70.01917808 ; 66.13150685 ; 69.10136986 ; 63.62465753 ; 65.56986301 ; 62.66575342 ; 62.44931507 ; 57.90958904 ; 75.79452055 ; 77.92328767 ; 57.42739726 ; 75.46849315 ; 68.7890411 ; 57.50410959 ; 66.8739726 ; 72.31780822 ; 52.96986301 ; 67.0109589 ; 71.64657534 ; 74.10958904 ; 73.88767123 ; 72.20273973 ; 49.19452055 ; 83.42465753 ; 81.02739726 ; 58.69589041 ; 66.79726027 ; 57.97260274 ; 43.30684932 ; 75.03287671 ; 70.42191781 ; 60.3260274 ; 66.69315068 ; 64.15890411 ; 35.48493151 ; 58.83835616 ; 85.34246575 ; 55.20547945 ; 56.31780822 ; 74.20273973 ; 71.34246575 ; 66.36164384 ; 64.70136986 ; 59.97808219 ; 74.11232877 ; 61.98630137 ; 74.16712329 ; 62.65479452 ; 67.1890411 ; 69.91506849 ; 63.6109589 ; 63.99452055 ; 63.29041096 ; 66.50410959 ; 65.17534247 ; 73.29863014 ; 60.90958904 ; 75.94246575 ; 66.51780822 ; 81.64109589 ; 43.38630137 ; 47.31780822 ; 83.89589041 ; 68.85479452 ; 64.43835616 ; 69.35616438 ; 63.46027397 ; 75.26027397 ; 78.2109589 ; 63.73972603 ; 68.67123288 ; 76.91780822 ; 55.74794521 ; 68.08493151 ; 64.3890411 ; 80.34794521 ; 69.09315068 ; 56.50136986 ; 88.08767123 ; 65.39726027 ; 57.55342466 ; 58.36712329 ; 59.19178082 ; 50.62739726 ; 74.18356164 ; 79.05479452 ; 69.58356164 ; 74.95616438 ; 77.19452055 ; 60.61369863 ; 67.13972603 ; 72.8109589 ; 64.69041096 ; 41.53424658 ; 68.52876712 ; 67.30684932 ; 57.88219178 ; 54.75616438 ; 83.40273973 ; 68.61643836 ; 49.41369863 ; 67.84383562 ; 36.95342466 ; 76.66027397 ; 67.32876712 ; 67.94520548 ; 60.78630137 ; 79.67123288 ; 72.68767123 ; 65.63835616 ; 66.35890411 ; 53.8109589 ; 45.4739726 ; 49.4109589 ; 74.80273973 ; 64.80547945 ; 80.03561644 ; 55.59452055 ; 79.51780822 ; 69.34794521 ; 82.96164384 ; 64.08767123 ; 69.56164384 ; 60.87123288 ; 62.75068493 ; 82.74794521 ; 65.70136986 ; 60.62465753 ; 54.57534247 ; 76.71506849 ; 62.82465753 ; 67.28219178 ; 77.65205479 ; 62.18356164 ; 63.90958904 ; 64.32054795 ; 57.58082192 ; 53.70684932 ; 58.86027397 ; 76.70958904 ; 79.92328767 ; 72.12876712 ; 77.99726027 ; 76.16712329 ; 78.36986301 ; 66.04109589 ; 59.18356164 ; 60.52328767 ; 81.3890411 ; 58.43835616 ; 59.49315068 ; 65.54794521 ; 48.3260274 ; 71.06027397 ; 73.01917808 ; 76.91506849 ; 78.79452055 ; 75.00547945 ; 59.27945205 ; 50.9369863 ; 59.84657534 ; 63.3260274 ; 60.04657534 ; 34.70684932 ; 76.28219178 ; 63.77808219 ; 73.12054795 ; 66.22465753 ; 64.53424658 ; 49.17260274 ; 52.26849315 ; 70.29041096 ; 69.21369863 ; 58.70684932 ; 83.46849315 ; 67.66027397 ; 62.85205479 ; 61.30958904 ; 63.30410959 ; 69.97260274 ; 51.8109589 ; 64.46027397 ; 66.49041096 ; 65.96164384 ; 66.88219178 ; 68.43287671 ; 90.87945205 ; 61.21369863 ; 50.26027397 ; 67.03561644 ; 60.13150685 ; 58.19178082 ; 76.95068493 ; 58.46027397 ; 63.15342466 ; 67.10136986 ; 75.05205479 ; 73.36712329 ; 67.73972603 ; 73.18082192 ; 35.95890411 ; 66.68767123 ; 55.00821918 ; 63.70136986 ; 64.82739726 ; 59.69315068 ; 70.90958904 ; 65.40273973 ; 73.10136986 ; 83.73150685 ; 44.63561644 ; 53.45753425 ; 75.7890411 ; 60.35068493 ; 57.85205479 ; 65.90136986 ; 50.73972603 ; 62.63013699 ; 69.50684932 ; 68.00821918 ; 44.13150685 ; 51.31780822 ; 66.27671233 ; 82.18356164 ; 47.8 ; 56.17534247 ; 84.84657534 ; 75.24931507 ; 69.11780822 ; 55.58630137 ; 64.44931507 ; 64.66575342 ; 72.99726027 ; 82.7260274 ; 78.68493151 ; 69.15068493 ; 73.99726027 ; 72.63835616 ; 52.59726027 ; 57.54520548 ; 43.7369863 ; 75.80273973 ; 78.45753425 ; 63.24383562 ; 66.52876712 ; 78.23561644 ; 70.47671233 ; 76.74246575 ; 41.16164384 ; 43.26027397 ; 44.57260274 ; 38.35616438 ; 66.85479452 ; 83.91780822 ; 67.74794521 ; 85.92876712 ; 67.96164384 ; 49.59178082 ; 72.04383562 ; 67.31780822 ; 65.07671233 ; 63.43835616 ; 81.17260274 ; 81.2630137 ; 76.52876712 ; 70.15342466 ; 58.12328767 ; 61.67671233 ; 66.14794521 ; 72.70684932 ; 57.64657534 ; 76.34520548 ; 65.92054795 ; 76.97808219 ; 56.10136986 ; 65.90958904 ; 67.9890411 ; 67.43835616 ; 52.25753425 ; 64.97260274 ; 60.56986301 ; 70.92328767 ; 64.79452055 ; 73.18356164 ; 56.15616438 ; 59.80273973 ; 63.27945205 ; 55.6739726 ; 66.30136986 ; 58.10958904 ; 60.0630137 ; 76.64931507 ; 79.03561644 ; 66.10958904 ; 66.49589041 ; 77.05205479 ; 66.22739726 ; 59.86027397 ; 63.76986301 ; 67.07123288 ; 50.67671233 ; 51.04931507 ; 70.75068493 ; 55.63561644 ; 66.72876712 ; 62.77534247 ; 55.89863014 ; 74.99452055 ; 57.8109589 ; 46.24109589 ; 69.11232877 ; 56.87123288 ; 76.73972603 ; 53.27123288 ; 62.69863014 ; 79.64383562 ; 70.96164384 ; 51.60273973 ; 69.01917808 ; 68.78082192 ; 54.3260274 ; 75.16712329 ; 79.75342466 ; 55.88767123 ; 76.21917808 ; 57.75890411 ; 80.54520548 ; 53.11232877 ; 51.53424658 ; 71.18630137 ; 18.56712329 ; 60.37260274 ; 37.29863014 ; 72.30684932 ; 72.27123288 ; 62.14520548 ; 79.08219178 ; 81.13150685 ; 73.80821918 ; 59.91232877 ; 69.31232877 ; 62.67945205 ; 31.93424658 ; 57.33150685 ; 70.4109589 ; 80.06575342 ; 61.46849315 ; 63.55890411 ; 68.46027397 ; 78.27945205 ; 55.61643836 ; 70.36438356 ; 62.42739726 ; 45 ; 51.00273973 ; 60.27671233 ; 70.95890411 ; 60.7260274 ; 57.93424658 ; 38.68767123 ; 47.16164384 ; 48.98082192 ; 50.64931507 ; 72.87123288 ; 63.46849315 ; 73.12328767 ; 64.71780822 ; 70.51506849 ; 50.18630137 ; 75.33424658 ; 72.03287671 ; 59.61917808 ; 86.10684932 ; 56.88219178 ; 78.96438356 ; 70.21643836 ; 63.60273973 ; 70.53424658 ; 73.79726027 ; 69.63835616 ; 65.96438356 ; 72.59726027 ; 74.45753425 ; 64.2739726 ; 71.4 ; 46.93972603 ; 67.03287671 ; 68.09041096 ; 58.7890411 ; 72.36986301 ; 82.90684932 ; 70.93150685 ; 65.16712329 ; 73.83287671 ; 82.23013699 ; 49.68767123 ; 51.02191781 ; 73.54246575 ; 75.81917808 ; 69.78630137 ; 81.32054795 ; 53.2739726 ; 64.10410959 ; 43.0109589 ; 63.63287671 ; 89.14246575 ; 56.77808219 ; 68.77534247 ; 61.04109589 ; 65.86027397 ; 75.58630137 ; 71.6739726 ; 81.08493151 ; 75.48493151 ; 47.4 ; 45.74794521 ; 55.34520548 ; 57.36164384 ; 67.32054795 ; 68.60547945 ; 84.42739726 ; 70.0739726 ; 68.59178082 ; 53.11780822 ; 73.11232877 ; 57.30136986 ; 71.64109589 ; 61.11780822 ; 75.97260274 ; 69.75616438 ; 82.48219178 ; 55.01917808 ; 61.76712329 ; 73.64657534 ; 41.57260274 ; 65.76986301 ; 76.22465753 ; 72.89315068 ; 62.51506849 ; 67.04931507 ; 67.39178082 ; 67.50136986 ; 60.91506849 ; 73.1369863 ; 76.12876712 ; 65.15616438 ; 73.33972603 ; 61.68219178 ; 54.88767123 ; 33.68767123 ; 69.67123288 ; 62.27671233 ; 55.48767123 ; 69.32328767 ; 70.6630137 ; 66.2739726 ; 58.9369863 ; 61.70958904 ; 53.99726027 ; 58.48493151 ; 78.69041096 ; 80.2630137 ; 61.0630137 ; 77.48493151 ; 85.84931507 ; 77.40547945 ; 72.94520548 ; 65.83561644 ; 80.4739726 ; 65.80821918 ; 71.25479452 ; 59.0630137 ; 60.2739726 ; 55.6109589 ; 55.42191781 ; 74.67123288 ; 85.1890411 ; 60.46849315 ; 70.46849315 ; 74.76986301 ; 72.52328767 ; 65.53150685 ; 58.69315068 ; 87.96164384 ; 56.7890411 ; 76.88219178 ; 82.63287671 ; 62.76438356 ; 60.42739726 ; 82.27671233 ; 54.23561644 ; 78.52328767 ; 43.80547945 ; 56.62191781 ; 76.08767123 ; 61.56986301 ; 77.93424658 ; 44.95342466 ; 62.93150685 ; 64.47123288 ; 65.91506849 ; 69.34520548 ; 72.89863014 ; 62.23287671 ; 62.43287671 ; 64.06027397 ; 73.05205479 ; 70.17260274 ; 62.02739726 ; 60.84931507 ; 82.09041096 ; 69.38356164 ; 71.81917808 ; 75.63835616 ; 73.59726027 ; 76.10684932 ; 72.90684932 ; 70.23561644 ; 78.64383562 ; 59.68767123 ; 80.9260274 ; 68.7260274 ; 61.26027397 ; 66.4 ; 71.69315068 ; 62.51232877 ; 74.57808219 ; 57.88767123 ; 65.32328767 ; 62.8 ; 72.3890411 ; 74.88493151 ; 56.63013699 ; 54.36986301 ; 69.36438356 ; 56.50684932 ; 56.40821918 ; 43.19726027 ; 69.46027397 ; 54.79178082 ; 62.20821918 ; 67.35616438 ; 66.92054795 ; 49.47671233 ; 48.95890411 ; 57.01917808 ; 74.96712329 ; 63.54520548 ; 64.77260274 ; 87.34246575 ; 73.96986301 ; 61.03561644 ; 58.36986301 ; 68.97534247 ; 69.52054795 ; 66.56438356 ; 48.86849315 ; 71.99726027 ; 67.52328767 ; 68.68219178 ; 58.19452055 ; 58.97260274 ; 70.7890411 ; 57.34246575 ; 75.73150685 ; 72.4739726 ; 41.77260274 ; 78.34520548 ; 57.76438356 ; 61.16712329 ; 74.96438356 ; 55.5890411 ; 70.63287671 ; 79 ; 75.41643836 ; 66.55068493 ; 68.23835616 ; 69.03287671 ; 68.36164384 ; 56.87945205 ; 75.9369863 ; 72.05205479 ; 76.86575342 ; 77.3369863 ; 68.32054795 ; 72.07671233 ; 59.32876712 ; 61.5260274 ; 73.41643836 ; 72.80273973 ; 33.8109589 ; 66.05753425 ; 74.43287671 ; 63.53150685 ; 70.49315068 ; 70.23013699 ; 73.46575342 ; 69.2 ; 72.42739726 ; 74.01369863 ; 51.77808219 ; 79.56712329 ; 60.45753425 ; 61.35068493 ; 70.69863014 ; 60.74794521 ; 63.8 ; 54.37260274 ; 70.20821918 ; 75.78630137 ; 81.48493151 ; 71.64931507 ; 83.24657534 ; 79.32054795 ; 81.61917808 ; 50.89863014 ; 57.96164384 ; 59.47123288 ; 72.50958904 ; 85.93972603 ; 74.90684932 ; 62.54520548 ; 61.29863014 ; 86.36712329 ; 71.92054795 ; 27.51232877 ; 30.35616438 ; 68.20821918 ; 67.55890411 ; 64.86849315 ; 71.19452055 ; 47.53424658 ; 71.08767123 ; 79.39178082 ; 71.62465753 ; 73.24931507 ; 79.95616438 ; 75.95068493 ; 57.28767123 ; 78.39452055 ; 74.20547945 ; 63.90410959 ; 65.55616438 ; 66.54246575 ; 76.44657534 ; 69.69863014 ; 73.04931507 ; 45.04383562 ; 58.05479452 ; 74.52876712 ; 69.28767123 ; 72.19178082 ; 69.85753425 ; 56.30410959 ; 52.64657534 ; 70.9369863 ; 55.97260274 ; 59.02191781 ; 55.48219178 ; 61.86849315 ; 59.46849315 ; 60.22739726 ; 75.97534247 ; 59.1260274 ; 75.32054795 ; 81.10958904 ; 58.85753425 ; 48.69041096 ; 79.63287671 ; 59.09315068 ; 54.27945205 ; 73.9369863 ; 85.09315068 ; 60.69863014 ; 55.3260274 ; 62.37808219 ; 80.36438356 ; 66.79452055 ; 61.81917808 ; 74.64657534 ; 53.13150685 ; 69.33424658 ; 78.70958904 ; 76.72054795 ; 79.69863014 ; 52.56438356 ; 80.36986301 ; 53.07945205 ; 66.78630137 ; 77.99178082 ; 66.53972603 ; 84.93972603 ; 68.66027397 ; 49.3369863 ; 65.10410959 ; 71.67123288 ; 65.02465753 ; 62.29041096 ; 71.28219178 ; 70.69589041 ; 72.54520548 ; 64.29315068 ; 78.5260274 ; 71.8 ; 73.44931507 ; 53.51232877 ; 54.50136986 ; 72.7369863 ; 68.48767123 ; 70.26849315 ; 58.89589041 ; 58.95068493 ; 82.55342466 ; 61.4739726 ; 74.99726027 ; 71.66027397 ; 72.63561644 ; 76.49863014 ; 58.75890411 ; 67.21643836 ; 73.38630137 ; 50.04657534 ; 76.4109589 ; 76.60547945 ; 77.2 ; 71.76164384 ; 45.6109589 ; 69.25479452 ; 57.15342466 ; 68.69315068 ; 48.08493151 ; 82.09863014 ; 78.84657534 ; 75.55890411 ; 70.52328767 ; 66.27945205 ; 65.78630137 ; 70.82465753 ; 74.71506849 ; 72.34246575 ; 73.69863014 ; 84.27123288 ; 50.21369863 ; 51.6739726 ; 82.02191781 ; 67.59726027 ; 65.43561644 ; 59.64383562 ; 74.82191781 ; 62.84109589 ; 78.57534247 ; 71.78630137 ; 74.83561644 ; 87.38356164 ; 60.91232877 ; 64.13972603 ; 69.65753425 ; 48.34794521 ; 59.50958904 ; 56.77260274 ; 77.24657534 ; 63.87123288 ; 45.71232877 ; 78.16986301 ; 72.58082192 ; 62.38356164 ; 68.34794521 ; 68.16164384 ; 57.77260274 ; 74.09589041 ; 71.87671233 ; 66.21369863 ; 64.03287671 ; 64.07123288 ; 67.93150685 ; 70.35342466 ; 55.75616438 ; 66.08219178 ; 71.29863014 ; 65.14794521 ; 64.07671233 ; 70.37808219 ; 57.44383562 ; 58.5260274 ; 48.24109589 ; 80.54246575 ; 66.19452055 ; 73.4739726 ; 60.1260274 ; 57.24657534 ; 78.23013699 ; 62.2630137 ; 81.74794521 ; 78.30958904 ; 72.35342466 ; 77.83561644 ; 57.29041096 ; 61.25205479 ; 78.5890411 ; 46.15890411 ; 70.91232877 ; 86.27945205 ; 37.16712329 ; 54.96438356 ; 66.92328767 ; 45.23561644 ; 50.11232877 ; 63.41643836 ; 63.84109589 ; 68.90958904 ; 54.06575342 ; 48.63013699 ; 71.6630137 ; 75.08493151 ; 68.71780822 ; 70.32876712 ; 81.89863014 ; 66.21917808 ; 55.28767123 ; 41.91232877 ; 67.96438356 ; 57.10136986 ; 52.07123288 ; 59.82465753 ; 81.88767123 ; 83.56712329 ; 56.15068493 ; 57.51232877 ; 65.19452055 ; 64.7890411 ; 79.66575342 ; 73.17260274 ; 43.38082192 ; 75.29863014 ; 69.45479452 ; 71.76712329 ; 71.70684932 ; 71.22739726 ; 70.60547945 ; 74.24109589 ; 79.69315068 ; 58.11232877 ; 56.10958904 ; 82.99726027 ; 36.50136986 ; 43.95068493 ; 66.5369863 ; 60.42465753 ; 52.83835616 ; 57.19452055 ; 71.56986301 ; 81.66027397 ; 64.49589041 ; 61.34520548 ; 61.65753425 ; 59.06027397 ; 57.55616438 ; 63.26575342 ; 60.03835616 ; 51.86027397 ; 68.73150685 ; 73.64109589 ; 70.59452055 ; 70.67671233 ; 69.0630137 ; 55.51506849 ; 85.49315068 ; 68.11232877 ; 89.08493151 ; 69.20547945 ; 65.71506849 ; 43.84931507 ; 72.60821918 ; 73.9260274 ; 52.23287671 ; 53.92054795 ; 65.38630137 ; 51.96438356 ; 69.2630137 ; 57.40273973 ; 64.60821918 ; 53.69315068 ; 60.23561644 ; 62.58630137 ; 60.35890411 ; 76.63561644 ; 59.16712329 ; 68.70684932 ; 74.84657534 ; 66.84931507 ; 71.82739726 ; 71.00273973 ; 73.35068493 ; 76.75890411 ; 55.81917808 ; 54.78630137 ; 53.03013699 ; 66.86849315 ; 65.99452055 ; 53.73424658 ; 66.93150685 ; 68.00273973 ; 62.66849315 ; 73.45205479 ; 64.96438356 ; 66.93972603 ; 75.38082192 ; 78.26849315 ; 60.48767123 ; 63.88219178 ; 71.71780822 ; 76.63287671 ; 58.29863014 ; 71.09589041 ; 78.55342466 ; 67.07671233 ; 63.88767123 ; 71.07945205 ; 74.15342466 ; 72.46849315 ; 57.6109589 ; 59.44657534 ; 70.16164384 ; 58.63287671 ; 53.88493151 ; 58.39726027 ; 59.41369863 ; 64.94520548 ; 68.8630137 ; 60.5890411 ; 49.95616438 ; 62.30684932 ; 51.48219178 ; 50.47123288 ; 71.31506849 ; 64.63835616 ; 69.06027397 ; 66.28219178 ; 75.3890411 ; 63.22465753 ; 66.00547945 ; 62.6 ; 64.38082192 ; 68.91232877 ; 59.8 ; 67.76986301 ; 73.5369863 ; 49.03561644 ; 61.0739726 ; 65.52876712 ; 80.99178082 ; 76.01369863 ; 68.89041096 ; 60.01369863 ; 85.4109589 ; 73.78356164 ; 73.51232877 ; 50.55068493 ; 65.0739726 ; 53.98630137 ; 81.09315068 ; 55.86027397 ; 56.43013699 ; 67.37260274 ; 77.59452055 ; 70.63013699 ; 64.4109589 ; 47.38356164 ; 77.22465753 ; 59.36986301 ; 61.79726027 ; 46.69589041 ; 50.09041096 ; 68.05753425 ; 84.43287671 ; 66.91506849 ; 74.81917808 ; 53.2630137 ; 65.23561644 ; 78.41917808 ; 75 ; 38.68493151 ; 65.57534247 ; 61.42465753 ; 72.86575342 ; 74.03561644 ; 63.67671233 ; 65.1369863 ; 57.11506849 ; 63.83013699 ; 67.42739726 ; 80.28767123 ; 59.49863014 ; 70.90684932 ; 88.10958904 ; 79.70410959 ; 69.68219178 ; 70.47123288 ; 64.28219178 ; 75.04657534 ; 74.40821918 ; 52.42465753 ; 57.86027397 ; 49.24383562 ; 67.80273973 ; 62.60821918 ; 70.4 ; 65.47123288 ; 63.20821918 ; 75.74246575 ; 52.95890411 ; 57.99726027 ; 71.29315068 ; 68.59726027 ; 89.26027397 ; 43.18082192 ; 47.87945205 ; 69.63287671 ; 60.51232877 ; 75.36438356 ; 84.29589041 ; 83.58356164 ; 56.55342466 ; 56.18356164 ; 70.94794521 ; 54.80273973 ; 57.32876712 ; 59.01643836 ; 75.0109589 ; 51.25205479 ; 73.31506849 ; 58.96164384 ; 75.66849315 ; 79.10684932 ; 79.78630137 ; 55.84109589 ; 60.64931507 ; 64.49863014 ; 69.1260274 ; 63.18630137 ; 66.15068493 ; 77.62739726 ; 61.33150685 ; 70.77260274 ; 60.83287671 ; 80.20547945 ; 56.63287671 ; 79.26575342 ; 65.89589041 ; 63.68493151 ; 49.9260274 ; 77.20821918 ; 64.47671233 ; 66.23835616 ; 56.42465753 ; 67.15890411 ; 71.13150685 ; 75.02739726 ; 76.36438356 ; 64.91232877 ; 59.28493151 ; 62.57260274 ; 67.44383562 ; 67.99178082 ; 66.35068493 ; 72.84657534 ; 60.24383562 ; 72.53972603 ; 74.46849315 ; 68.81917808 ; 65.28767123 ; 67.1260274 ; 75.61917808 ; 30.27671233 ; 61.82191781 ; 63.32876712 ; 63.52054795 ; 63.6739726 ; 63.86849315 ; 64.40273973 ; 47.25479452 ; 48.30684932 ; 66.1890411 ; 66.98630137 ; 70.2 ; 71.52876712 ; 74.06575342 ; 76.85479452 ; 77.89863014 ; 62.55616438 ; 65.95890411 ; 62.25753425 ; 74.08219178 ; 54.52054795 ; 56.30958904 ; 62.96164384 ; 61.7369863 ; 76.27671233 ; 62.41917808 ; 51.78082192 ; 72.28493151 ; 72.89589041 ; 64.16986301 ; 68.2630137 ; 44.42191781 ; 45.0109589 ; 85.38630137 ; 86.93150685 ; 52.59452055 ; 43.93972603 ; 44.77534247 ; 74.12054795 ; 75.80547945 ; 61.63835616 ; 72.49589041 ; 48.24657534 ; 55.26849315 ; 77.68219178 ; 63.57260274 ; 71.87945205 ; 67.54520548 ; 71.84383562 ; 58.10410959 ; 47.35890411 ; 69.9369863 ; 78.16712329 ; 80.55616438 ; 62.52054795 ; 88.83287671 ; 81.29589041 ; 63.82191781 ; 58.35342466 ; 61.18082192 ; 62.03835616 ; 60.71780822 ; 61.94246575 ; 55.63287671 ; 68.90136986 ; 55.69863014 ; 49.26575342 ; 64.18356164 ; 80.96712329 ; 48.82191781 ; 37.80273973 ; 67.14794521 ; 71.6109589 ; 36.50684932 ; 38.34520548 ; 70.17534247 ; 67.41917808 ; 59.6739726 ; 71.72876712 ; 62.91780822 ; 63.91780822 ; 55.99452055 ; 66.29863014 ; 57.91506849 ; 68.25479452 ; 71.9369863 ; 80.40273973 ; 71.10410959 ; 77.04931507 ; 79.58356164 ; 54.40821918 ; 76.55890411 ; 66.4109589 ; 76.83561644 ; 60.78082192 ; 63.35616438 ; 63.94794521 ; 63.44931507 ; 67.93424658 ; 47.00273973 ; 68.09315068 ; 75.12876712 ; 62.95068493 ; 56.18082192 ; 73.41917808 ; 82.09315068 ; 56.44109589 ; 71.70958904 ; 75.98082192 ; 80.97534247 ; 70.71780822 ; 77.91506849 ; 69.93150685 ; 55.38356164 ; 70.13972603 ; 68.35890411 ; 93.64657534 ; 48 ; 73.56712329 ; 74.23561644 ; 49.83013699 ; 52.45205479 ; 65.75068493 ; 77.90136986 ; 79.53150685 ; 71.95342466 ; 72.19452055 ; 54.01643836 ; 71 ; 63.9369863 ; 91.05479452 ; 59.98082192 ; 72.86027397 ; 66.73972603 ; 69.44109589 ; 71.48493151 ; 66.76438356 ; 73.74246575 ; 56.15342466 ; 60.30410959 ; 56.51506849 ; 68.86575342 ; 80.76438356 ; 59.22739726 ; 75.09041096 ; 45.8630137 ; 63.42465753 ; 71.08219178 ; 60.18630137 ; 63.02739726 ; 70.57808219 ; 60.57534247 ; 64.4630137 ; 36.02739726 ; 49.49041096 ; 69.56438356 ; 74.91232877 ; 71.43835616 ; 63.25753425 ; 63.59452055 ; 68.54794521 ; 50.91232877 ; 46.41369863 ; 67.62191781 ; 71.50684932 ; 61.20547945 ; 80.68219178 ; 72.29041096 ; 75.62739726 ; 47.32054795 ; 70.2109589 ; 71.24109589 ; 58.18082192 ; 65.56164384 ; 77.8739726 ; 62.7369863 ; 79.87945205 ; 77.35068493 ; 63.66849315 ; 67.93972603 ; 61.69589041 ; 70.82191781 ; 44.69589041 ; 68.67671233 ; 70.02191781 ; 76.83835616 ; 79.86575342 ; 64.02465753 ; 62.70684932 ; 79.6109589 ; 62.49589041 ; 63.88493151 ; 75.53972603 ; 76.82191781 ; 78.15342466 ; 61.79452055 ; 84.97534247 ; 60.67945205 ; 58.2 ; 63.10136986 ; 80.87945205 ; 68.14246575 ; 69.51780822 ; 79.88767123 ; 50.36712329 ; 78.89041096 ; 56.74794521 ; 66.5890411 ; 68.38082192 ; 70.03835616 ; 70.54794521 ; 83.7369863 ; 73.7890411 ; 84.27945205 ; 58.37808219 ; 51.02739726 ; 52.88493151 ; 53.06027397 ; 63.91506849 ; 64.98356164 ; 66.66027397 ; 65.25205479 ; 34.60273973 ; 52.57808219 ; 55.14794521 ; 69.55068493 ; 70.6739726 ; 71.47945205 ; 63.61369863 ; 65.12328767 ; 78.91506849 ; 57.63013699 ; 69.66575342 ; 59.43561644 ; 68.44931507 ; 82.60547945 ; 71.08493151 ; 61.24109589 ; 74.97260274 ; 75.43561644 ; 62.93424658 ; 58.35068493 ; 65.32054795 ; 79.30684932 ; 53.75890411 ; 77.91780822 ; 70.14794521 ; 73.70958904 ; 51.68767123 ; 72.33972603 ; 81.60273973 ; 67.58082192 ; 69.77808219 ; 52.12054795 ; 74.31506849 ; 59.34794521 ; 56.68219178 ; 48.23287671 ; 77.00273973 ; 29.62191781 ; 31.89589041 ; 25.45479452 ; 73.89589041 ; 67.76438356 ; 69.40547945 ; 76.39178082 ; 71.93424658 ; 72.79452055 ; 55.69041096 ; 68.85753425 ; 70.10684932 ; 55.68219178 ; 67.10410959 ; 28.00821918 ; 76.65753425 ; 72.08767123 ; 83.51780822 ; 85.82465753 ; 62.73972603 ; 66.38630137 ; 73.51506849 ; 74.11780822 ; 57.68219178 ; 57.44931507 ; 74.65479452 ; 72.45479452 ; 73.3369863 ; 64.44657534 ; 82.53972603 ; 61.07123288 ; 73.47123288 ; 68.93424658 ; 65.18356164 ; 56.78630137 ; 45.78356164 ; 83.0109589 ; 85.71232877 ; 83.19726027 ; 56.72876712 ; 48.70958904 ; 45.3369863 ; 46.00547945 ; 63.16712329 ; 77.60821918 ; 73.06849315 ; 70.20273973 ; 74.00821918 ; 70.00547945 ; 61.55342466 ; 61.69863014 ; 59.83287671 ; 67.29589041 ; 73.25753425 ; 67.86849315 ; 72.68219178 ; 81.3369863 ; 74.92328767 ; 58.90136986 ; 81.90684932 ; 67.16986301 ; 74.89041096 ; 63.15616438 ; 64.68767123 ; 68.21369863 ; 71.60547945 ; 65.70410959 ; 63.73424658 ; 75.47123288 ; 69.8 ; 51.37260274 ; 75.61643836 ; 51.30410959 ; 67.76164384 ; 80.32054795 ; 81.04931507 ; 50.66575342 ; 54.47671233 ; 55.19178082 ; 66.44931507 ; 85.06027397 ; 54.96712329 ; 61.38082192 ; 75.85479452 ; 87.61643836 ; 64.9890411 ; 72.13972603 ; 65.84383562 ; 56.58356164 ; 75.15890411 ; 76.16438356 ; 67.27671233 ; 68.75342466 ; 69.08493151 ; 69.32876712 ; 69.48493151 ; 78.07123288 ; 54.57808219 ; 71.88219178 ; 61.45479452 ; 69.95068493 ; 77.2630137 ; 80.2109589 ; 56.70136986 ; 38.23287671 ; 60.75616438 ; 81.25205479 ; 65.53972603 ; 48.22739726 ; 71.96712329 ; 62.26027397 ; 55.83287671 ; 55.77808219 ; 73.26849315 ; 69.78082192 ; 57.5369863 ; 92.19726027 ; 73.34520548 ; 60.21369863 ; 64.05479452 ; 83.29041096 ; 67.63287671 ; 77.42465753 ; 46.05205479 ; 75.89041096 ; 70.76438356 ; 60.8630137 ; 38.87671233 ; 54.99452055 ; 71.68219178 ; 66.2630137 ; 68.40547945 ; 72.94246575 ; 59.93150685 ; 50.88767123 ; 64.57260274 ; 52.89863014 ; 74.98082192 ; 73.05479452 ; 53.43561644 ; 85.65753425 ; 51.64657534 ; 76.76438356 ; 86.67123288 ; 72.4109589 ; 62.62191781 ; 63.92054795 ; 65.09863014 ; 73.55890411 ; 71.49863014 ; 66.29589041 ; 61.1260274 ; 51.56164384 ; 81.28767123 ; 68.42465753 ; 71.40273973 ; 75.57260274 ; 63.94246575 ; 80.97808219 ; 69.22191781 ; 60.10136986 ; 68.75616438 ; 64.44383562 ; 60.70136986 ; 78.03835616 ; 80.63835616 ; 65.68219178 ; 66.77534247 ; 52.38082192 ; 43.31780822 ; 59.11780822 ; 67.33424658 ; 49.61369863 ; 66.10136986 ; 66.69041096 ; 70.36986301 ; 44.8739726 ; 72.87671233 ; 75.23561644 ; 50.63835616 ; 57.37534247 ; 70.05479452 ; 43.64931507 ; 76.10136986 ; 68.0630137 ; 55.57260274 ; 52.60821918 ; 57.01643836 ; 71.21643836 ; 82.60273973 ; 70.78356164 ; 50.13424658 ; 75.83561644 ; 71.1890411 ; 66.85753425 ; 76.8630137 ; 58.80273973 ; 60.3369863 ; 70.59726027 ; 63.8109589 ; 55.51232877 ; 76.79178082 ; 51.29315068 ; 51.81369863 ; 51.96986301 ; 52.44931507 ; 52.58356164 ; 69.92876712 ; 70.40273973 ; 55.93424658 ; 56.72054795 ; 66.14520548 ; 46.68493151 ; 59.6630137 ; 72.51780822 ; 65.73150685 ; 66.23561644 ; 73.29041096 ; 30.46849315 ; 31.19726027 ; 71.74794521 ; 35.2109589 ; 70.22465753 ; 69.13150685 ; 73.6109589 ; 74.35890411 ; 82.44383562 ; 88.70684932 ; 66.17808219 ; 81.22739726 ; 55.2630137 ; 65.33972603 ; 71.86027397 ; 70.77534247 ; 60.09863014 ; 62.47945205 ; 71.9890411 ; 77.65753425 ; 60.62191781 ; 62.4739726 ; 83.8739726 ; 72.06575342 ; 68.64931507 ; 72.26575342 ; 62.28767123 ; 63.01643836 ; 62.69589041 ; 72.62739726 ; 53.1369863 ; 53.23287671 ; 88.45753425 ; 67.78356164 ; 52.10410959 ; 77.26027397 ; 83.33424658 ; 82.04383562 ; 29.91780822 ; 84.24109589 ; 72.0630137 ; 70.73972603 ; 63.39452055 ; 71.0739726 ; 59.89041096 ; 43.72876712 ; 44.95068493 ; 53.93424658 ; 64.5890411 ; 88.70958904 ; 71.85753425 ; 72.50410959 ; 72.8630137 ; 63.56438356 ; 94.42191781 ; 65.29589041 ; 64.19726027 ; 44.29589041 ; 61.61643836 ; 53.82191781 ; 72.51232877 ; 78.06027397 ; 66.99178082 ; 70.4630137 ; 61.32328767 ; 44.41643836 ; 57.09315068 ; 64.01369863 ; 64.04383562 ; 66.37808219 ; 58.55342466 ; 67.89315068 ; 54.49589041 ; 65.27671233 ; 77.86849315 ; 70.93424658 ; 44.15890411 ; 66.80547945 ; 66.67123288 ; 68.62465753 ; 69.12328767 ; 56.3369863 ; 59.71780822 ; 71.97260274 ; 79.25205479 ; 68.57808219 ; 67.71506849 ; 70.10410959 ; 82.16164384 ; 68.32328767 ; 61.95890411 ; 64.50684932 ; 60.6109589 ; 69.52328767 ; 70.24931507 ; 86.22465753 ; 60.97260274 ; 55.21917808 ; 88.44931507 ; 66.15616438 ; 67.17808219 ; 59.56986301 ; 69.01643836 ; 72.77260274 ; 80.36712329 ; 81.73150685 ; 90.55342466 ; 75.58356164 ; 78.66575342 ; 67.19726027 ; 59.91506849 ; 77.63835616 ; 77.03835616 ; 78.80547945 ; 76.27945205 ; 77.80547945 ; 82.57534247 ; 75.48219178 ; 61.44383562 ; 55.43561644 ; 69.8109589 ; 79.09863014 ; 68.47671233 ; 68.44109589 ; 71.56712329 ; 57.09041096 ; 83.66575342 ; 78.60547945 ; 77.86575342 ; 79.68493151 ; 77.7369863 ; 85.37808219 ; 85.26849315 ; 78.35342466 ; 85.60821918 ; 65.54246575 ; 66.76712329 ; 66.03561644 ; 74.28767123 ; 43.12876712 ; 66.42739726 ; 85.11506849 ; 66.34794521 ; 63.23835616 ; 65.84109589 ; 58.86849315 ; 74.10684932 ; 72.83835616 ; 75.91506849 ; 89.18082192 ; 57.52054795 ; 68.42191781 ; 39.13424658 ; 74.78630137 ; 75.1260274 ; 68.20273973 ; 78.63561644 ; 63.78630137 ; 77.0109589 ; 78.56438356 ; 78.77534247 ; 34.7890411 ; 70.97534247 ; 69.24931507 ; 78.72876712 ; 66.09041096 ; 73.70684932 ; 38.25753425 ; 68.50136986 ; 78.46027397 ; 38.82465753 ; 40.98082192 ; 63.57808219 ; 67.83287671 ; 57.49589041 ; 55.64383562 ; 61.54246575 ; 63.69041096 ; 46.04931507 ; 65.14520548 ; 53.81369863 ; 72.22739726 ; 51.0630137 ; 83.11232877 ; 28.11232877 ; 29.68493151 ; 50.64383562 ; 81.65479452 ; 69.81369863 ; 79.81369863 ; 66.9890411 ; 80.31506849 ; 63.2 ; 62.33150685 ; 78.32054795 ; 79.89863014 ; 73.50684932 ; 62.92328767 ; 73.23835616 ; 81.27123288 ; 76.54520548 ; 78.19452055 ; 56.14246575 ; 60.34794521 ; 67.57534247 ; 48.29041096 ; 49.38356164 ; 59.73150685 ; 40.8630137 ; 59.96438356 ; 54.81369863 ; 49.22465753 ; 61.51506849 ; 62.26849315 ; 67.44931507 ; 83.44383562 ; 67.75890411 ; 88.92054795 ; 44.44931507 ; 74.91780822 ; 53.5260274 ; 57.15068493 ; 89.37260274 ; 76.1369863 ; 73.02191781 ; 60.70410959 ; 75.70136986 ; 76.58082192 ; 58.48219178 ; 59.87123288 ; 81.6739726 ; 78.51506849 ; 68.95616438 ; 46.50410959 ; 67.98356164 ; 58.02739726 ; 61.15890411 ; 79.71780822 ; 51.9260274 ; 52.23835616 ; 81.12328767 ; 63.1890411 ; 60.91780822 ; 42.40821918 ; 39.03287671 ; 79.4630137 ; 63.49041096 ; 63.42191781 ; 70.8 ; 61.49041096 ; 73.56164384 ; 41.10684932 ; 53.84931507 ; 91.37808219 ; 72.88767123 ; 59.39726027 ; 77.24383562 ; 59.44109589 ; 59.66027397 ; 84.97808219 ; 77.34246575 ; 72.75068493 ; 67.49863014 ; 63.34794521 ; 71.65479452 ; 56.05205479 ; 30.51232877 ; 73.44383562 ; 60.21917808 ; 80.3260274 ; 58.68767123 ; 89.35342466 ; 63.48219178 ; 74.14794521 ; 75.85205479 ; 59.85205479 ; 56.52876712 ; 68.46575342 ; 40.84657534 ; 83.06575342 ; 54.59726027 ; 56.23835616 ; 75.04109589 ; 50.79452055 ; 51.45753425 ; 76.96712329 ; 70.84657534 ; 88.02465753 ; 56.00273973 ; 61.31780822 ; 56.99178082 ; 40.23287671 ; 87.68219178 ; 80.25479452 ; 63.71780822 ; 65.67671233 ; 61.14246575 ; 37.60273973 ; 64.27945205 ; 65.09041096 ; 80.10684932 ; 63.80547945 ; 65.35068493 ; 37.60821918 ; 54.13150685 ; 67.97808219 ; 68.97808219 ; 77.43287671 ; 51.82465753 ; 51.95342466 ; 63.95068493 ; 64.49315068 ; 65.11780822 ; 48.97808219 ; 73.09863014 ; 55.6 ; 70.98356164 ; 65.91780822 ; 60.35342466 ; 79.94794521 ; 77.37260274 ; 78.8109589 ; 70.94246575 ; 40.67945205 ; 73.54794521 ; 75.70684932 ; 56.33972603 ; 74.54794521 ; 73.81643836 ; 52.98356164 ; 70.84383562 ; 53.10958904 ; 84.16438356 ; 69.17808219 ; 68.43835616 ; 64.36986301 ; 56.90958904 ; 72.05479452 ; 59.75616438 ; 48.99178082 ; 68.06575342 ; 37.3260274 ; 73.96164384 ; 76.23561644 ; 76.2 ; 81.8 ; 67.81917808 ; 44.69041096 ; 81.44383562 ; 57.8 ; 74.19178082 ; 65.8109589 ; 73.32328767 ; 55.37534247 ; 46.16164384 ; 77.11780822 ; 59.79452055 ; 65.60821918 ; 74.32876712 ; 47.75068493 ; 48.99726027 ; 72.30410959 ; 75.39178082 ; 76.26575342 ; 76.62191781 ; 56.17808219 ; 81.69315068 ; 67.92328767 ; 71.42191781 ; 72.25479452 ; 64.84383562 ; 77.97260274 ; 78.92876712 ; 63.96438356 ; 73.84931507 ; 61.00547945 ; 71.92328767 ; 69.66849315 ; 73.75342466 ; 73.93150685 ; 62.38082192 ; 63.59178082 ; 97.06027397 ; 57.58630137 ; 66.32328767 ; 56.3260274 ; 73.62465753 ; 84.98356164 ; 76.52328767 ; 54.6739726 ; 55.55342466 ; 61.19178082 ; 72.65479452 ; 74.40273973 ; 79.62739726 ; 67.35068493 ; 64.57808219 ; 81.03287671 ; 76.89863014 ; 77.72328767 ; 56.30684932 ; 58.44657534 ; 59.15342466 ; 73.65479452 ; 73.0630137 ; 45.19726027 ; 46.11506849 ; 58.29041096 ; 77.74794521 ; 78.53150685 ; 79.16712329 ; 84.78630137 ; 67.54794521 ; 77.07945205 ; 66.84657534 ; 76.94246575 ; 59.83013699 ; 59.04109589 ; 73.17808219 ; 70.53150685 ; 70.93972603 ; 61.50410959 ; 83.30136986 ; 60.57808219 ; 72.30958904 ; 55.96438356 ; 64.58082192 ; 65.54520548 ; 82.67945205 ; 77.61917808 ; 72.07945205 ; 63.00821918 ; 61.01369863 ; 59.82739726 ; 74.69863014 ; 67.66575342 ; 72.92876712 ; 64.96164384 ; 55.9260274 ; 32.37534247 ; 68.7369863 ; 86.60547945 ; 47.55890411 ; 80.03013699 ; 58.47671233 ; 58.27945205 ; 79.19178082 ; 60.72328767 ; 47.42191781 ; 80.32876712 ; 76.9369863 ; 56.03561644 ; 69.1890411 ; 36.08493151 ; 79.18630137 ; 51.70410959 ; 59.11232877 ; 78.43835616 ; 67.51780822 ; 70.6109589 ; 41.83835616 ; 67.01917808 ; 76.99178082 ; 64.31506849 ; 83.61643836 ; 64.4 ; 44.70136986 ; 57.12328767 ; 69.42465753 ; 69.89041096 ; 46.95342466 ; 69.24657534 ; 75.92054795 ; 79.10136986 ; 49.04383562 ; 46.2 ; 71.16164384 ; 46.13972603 ; 70.64657534 ; 62.62739726 ; 62.06027397 ; 32.83835616 ; 67.18630137 ; 34.3890411 ; 73.95068493 ; 54.38630137 ; 62.1260274 ; 82.13972603 ; 50.81369863 ; 56.58630137 ; 69.96986301 ; 66.17260274 ; 78.93424658
BONE_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Bone Met Status (Months)	Patient	
BONE_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Bone Met Status	Patient	
CELL_CYCLE	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Cell Cycle	Sample	Yes ; No
CIGARETTE_HX	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Tobacco History	Patient	
CNS_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	CNS Met Status (Months)	Patient	
CNS_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	CNS Met Status	Patient	
CSTAGE	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Clinical Stage	Sample	Stage I ; Stage III ; Stage IV ; Stage II ; Unknown
EVER_MET_SITE_ADRENAL	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Adrenal	Sample	0 ; 1
EVER_MET_SITE_BONE	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Bone	Sample	1 ; 0
EVER_MET_SITE_CNS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: CNS	Sample	0 ; 1
EVER_MET_SITE_LIVER_BILIARY_TRACT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Liver	Sample	0 ; 1
EVER_MET_SITE_LN	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Lymph Nodes	Sample	1 ; 0
EVER_MET_SITE_LUNG	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Lung	Sample	0 ; 1
EVER_MET_SITE_PLEURA	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Ever Met to Site: Pleura	Sample	0 ; 1
FU_2YRS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	At Least 2 Years Follow Up	Sample	Yes ; No
GROUP_NO	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Group Number	Sample	Group4 ; Group2 ; Group3 ; Group5 ; Group1
HAD_SURGERY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	If Patient underwent surgical resection	Patient	
HIPPO	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	HIPPO Signalling pathway	Sample	No ; Yes
IMPACT_METASTATIC_LESION	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Samples used in Metastatic Lesion (ML) group	Sample	Yes ; No
IMPACT_PRIMARY_GROUP	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Group Assignment for Primary Samples	Sample	Early Stage-Metastatic (ES-M) ; Late Stage-Metastatic (LS-M) ; Non-Metastatic Primary (NM)
IN_MATCHED	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Samples used in Matched Analysis (Group 5)	Sample	No ; Yes
IS_WGD	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Is WGD	Sample	1 ; 0
LIVER_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Liver Met Status (Months)	Patient	
LIVER_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Liver Met Status	Patient	
LN_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	LN Met Status (Months)	Patient	
LN_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	LN Met Status	Patient	
LUNG_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Lung Met Status (Months)	Patient	
LUNG_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Lung Met Status	Patient	
METASTATIC_BURDEN	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Number of distinct met sites 	Sample	2 ; 3 ; 4 ; 1 ; 5 ; 6 ; 0
MONTHS_FROM_MATCHED_PRIM	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Populated for patients in matched analysis only.  The time in moths between the sequenced primary and sequenced met.	Patient	
MYC_PATH	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	MYC Signalling pathway	Sample	No ; Yes
NEOADJUVANT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If neoadjuvant therapy was given	Patient	
NEOADJUVANT_CHEMOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If neoadjuvant chemotherapy was given	Patient	
NEOADJUVANT_IMMUNOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If neoadjuvant immunotherapy was given	Patient	
NEOADJUVANT_TARGETED	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If neoadjuvant targeted therapy was given	Patient	
NEOADJUVANT_XRT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Populated for patients with surgery only.  If neoadjuvant radiation was given	Patient	
NOTCH	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	NOTCH Signalling pathway	Sample	No ; Yes
NRF2	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	NRF2 Signalling pathway	Sample	No ; Yes
PI3K	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	PI3K Signalling pathway	Sample	No ; Yes
PLEURA_MONTHS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	NUMBER	Pleura Met Status (Months)	Patient	
PLEURA_STATUS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pleura Met Status	Patient	
POST_SAMPLE_CHEMOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Post Sample Chemotherapy	Sample	Yes ; No
POST_SAMPLE_IMMUNOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Post Sample Immunotherapy	Sample	No ; Yes
POST_SAMPLE_TARGETED	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Post Sample Targeted	Sample	Yes ; No
POST_SAMPLE_TX	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Treatment admistered after to IMPACT Sample Acquisition.  Captures any treatment administered after to impact sample acquisition.  If a patient has multiple samples, this captures treatment administered between samples. 	Sample	Yes ; No
POST_SAMPLE_XRT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Post Sample XRT 	Sample	Yes ; No
PREDOM_HISTO_SUBTYPE	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Predominant Histologic Subtype	Sample	Solid ; Papillary ; Unknown ; Acinar ; Micropapillary ; Lepidic
PRE_SAMPLE_CHEMOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pre Sample Chemotherapy	Sample	No ; Yes
PRE_SAMPLE_IMMUNOTHERAPY	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pre Sample Immunotherapy	Sample	No ; Yes
PRE_SAMPLE_TARGETED	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pre Sample Targeted	Sample	Yes ; No
PRE_SAMPLE_TX	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Treatment admistered prior to IMPACT Sample Acquisition.  Captures any treatment administered prior to impact sample acquisition.  If a patient has multiple samples, this captures treatment administered between samples. 	Sample	Yes ; No
PRE_SAMPLE_XRT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pre Sample XRT 	Sample	No ; Yes
PSTAGE	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	Pathologic Stage	Sample	Stage III ; Stage IV ; Stage II ; Stage I
RTK_RAS	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	RTK_RAS Signalling pathway	Sample	Yes ; No
TGF_BETA	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	TGF-BETA Signalling pathway	Sample	No ; Yes
TP53_PATH	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	TP53 Signalling pathway	Sample	No ; Yes
WNT	Gainsboro	Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)	STRING	WNT Signalling pathway	Sample	No ; Yes
ADENOCARCINOMA_SUBTYPE_WHO2015	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	STRING	Adenocarcinoma subtype WHO2015	Patient	
EXOME_SEQ	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	STRING	Exome Sequencing Status	Patient	
HISTOLOGICAL_GRADE	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	STRING	Histological grade	Patient	
IMSIG_B_CELLS	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG B-cells	Sample	0.055154 ; 0.068338 ; 0.054882 ; 0.064277 ; 0.058464 ; 0.074917 ; 0.055504 ; 0.058049 ; 0.059968 ; 0.075555 ; 0.060135 ; 0.054111 ; 0.068559 ; 0.044102 ; 0.055213 ; 0.052883 ; 0.047442 ; 0.079577 ; 0.042012 ; 0.074964 ; 0.044498 ; 0.064825 ; 0.068275 ; 0.047231 ; 0.048237 ; 0.097657 ; 0.062186 ; 0.064331 ; 0.055367 ; 0.065128 ; 0.070725 ; 0.061826 ; 0.053438 ; 0.048375 ; 0.086864 ; 0.03832 ; 0.061371 ; 0.050757 ; 0.072899 ; 0.043032 ; 0.095835 ; 0.0814 ; 0.069428 ; 0.06774 ; 0.052669 ; 0.060609 ; 0.049014 ; 0.060843 ; 0.037364 ; 0.058032 ; 0.048184 ; 0.026546 ; 0.045078 ; 0.05695 ; 0.056852 ; 0.048542 ; 0.056448 ; 0.057947 ; 0.048162 ; 0.052308 ; 0.073074 ; 0.068126 ; 0.077621 ; 0.067902 ; 0.052585 ; 0.066407 ; 0.066359 ; 0.064968 ; 0.048546 ; 0.062023 ; 0.054284 ; 0.059542 ; 0.076658 ; 0.049691 ; 0.072417 ; 0.056442 ; 0.061068 ; 0.057978 ; 0.059125 ; 0.061889 ; 0.04982 ; 0.073618 ; 0.067342 ; 0.034986 ; 0.066322 ; 0.079208 ; 0.072191 ; 0.066053 ; 0.078615 ; 0.047487 ; 0.045934 ; 0.068436 ; 0.072205 ; 0.044329 ; 0.038703 ; 0.035481 ; 0.067309 ; 0.058618 ; 0.054787 ; 0.076766 ; 0.082803 ; 0.045803 ; 0.066973 ; 0.054498 ; 0.069525 ; 0.078729 ; 0.058995 ; 0.057235 ; 0.06246 ; 0.061151 ; 0.088271 ; 0.062823 ; 0.045356 ; 0.069277 ; 0.052055 ; 0.057437 ; 0.057376 ; 0.058697 ; 0.05326 ; 0.048931 ; 0.059062 ; 0.05472 ; 0.092891 ; 0.0645 ; 0.031588 ; 0.078022 ; 0.076456 ; 0.057426 ; 0.06527 ; 0.061986 ; 0.081089 ; 0.09143 ; 0.092374 ; 0.10112 ; 0.058699 ; 0.058649 ; 0.078734 ; 0.05166 ; 0.04501 ; 0.061758 ; 0.041756 ; 0.052004 ; 0.067409 ; 0.055556 ; 0.040941 ; 0.069551 ; 0.071193 ; 0.063055 ; 0.087469 ; 0.06778 ; 0.021228 ; 0.051433 ; 0.068706 ; 0.031763 ; 0.046942 ; 0.052322 ; 0.060266 ; 0.052705 ; 0.072329 ; 0.034878 ; 0.059997 ; 0.088251 ; 0.058763 ; 0.084285 ; 0.052819 ; 0.081904 ; 0.061555 ; 0.049023 ; 0.056086 ; 0.086816 ; 0.089621 ; 0.062563
IMSIG_INTERFERON	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG interferon	Sample	0.099536 ; 0.098956 ; 0.098017 ; 0.100497 ; 0.096791 ; 0.096599 ; 0.093498 ; 0.08734 ; 0.102673 ; 0.099872 ; 0.094792 ; 0.091558 ; 0.096088 ; 0.096114 ; 0.094677 ; 0.103131 ; 0.092884 ; 0.092262 ; 0.088851 ; 0.099647 ; 0.102313 ; 0.101088 ; 0.109826 ; 0.091214 ; 0.108619 ; 0.097134 ; 0.097047 ; 0.100409 ; 0.100944 ; 0.094966 ; 0.096519 ; 0.101836 ; 0.100815 ; 0.097917 ; 0.099293 ; 0.091194 ; 0.095949 ; 0.101595 ; 0.094733 ; 0.103189 ; 0.099712 ; 0.104363 ; 0.094365 ; 0.107383 ; 0.103466 ; 0.093594 ; 0.089796 ; 0.093764 ; 0.092358 ; 0.091041 ; 0.098383 ; 0.076218 ; 0.094034 ; 0.104109 ; 0.106515 ; 0.093298 ; 0.105925 ; 0.108166 ; 0.100465 ; 0.096422 ; 0.103112 ; 0.094609 ; 0.105228 ; 0.09695 ; 0.101526 ; 0.089516 ; 0.099928 ; 0.098396 ; 0.09136 ; 0.106108 ; 0.103312 ; 0.105946 ; 0.099271 ; 0.088893 ; 0.097396 ; 0.101857 ; 0.091809 ; 0.101497 ; 0.100818 ; 0.101276 ; 0.106573 ; 0.107822 ; 0.094951 ; 0.0977 ; 0.10421 ; 0.094591 ; 0.103945 ; 0.101047 ; 0.090433 ; 0.100073 ; 0.089266 ; 0.09742 ; 0.10294 ; 0.1003 ; 0.100357 ; 0.098312 ; 0.095318 ; 0.096602 ; 0.102938 ; 0.094186 ; 0.106211 ; 0.09315 ; 0.094946 ; 0.096256 ; 0.100968 ; 0.093554 ; 0.093522 ; 0.100641 ; 0.095218 ; 0.092334 ; 0.095798 ; 0.104104 ; 0.091258 ; 0.092092 ; 0.102409 ; 0.101623 ; 0.094961 ; 0.092635 ; 0.094059 ; 0.101329 ; 0.105232 ; 0.09295 ; 0.089589 ; 0.099796 ; 0.081594 ; 0.100261 ; 0.102323 ; 0.106849 ; 0.095933 ; 0.097425 ; 0.103894 ; 0.096763 ; 0.101588 ; 0.100044 ; 0.091234 ; 0.103709 ; 0.089816 ; 0.104119 ; 0.101622 ; 0.096621 ; 0.096852 ; 0.093394 ; 0.094031 ; 0.085338 ; 0.086077 ; 0.090178 ; 0.106726 ; 0.106207 ; 0.101227 ; 0.099478 ; 0.081782 ; 0.093094 ; 0.105081 ; 0.101925 ; 0.086867 ; 0.094188 ; 0.094871 ; 0.092737 ; 0.096102 ; 0.086364 ; 0.099182 ; 0.096058 ; 0.091498 ; 0.09521 ; 0.096683 ; 0.100531 ; 0.099583 ; 0.084729 ; 0.094705 ; 0.095946 ; 0.098628 ; 0.09774
IMSIG_MACROPHAGES	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG macrophages	Sample	0.101484 ; 0.101303 ; 0.104452 ; 0.105357 ; 0.087169 ; 0.101326 ; 0.094394 ; 0.092106 ; 0.099916 ; 0.097644 ; 0.10021 ; 0.110722 ; 0.107281 ; 0.089862 ; 0.102699 ; 0.107348 ; 0.085842 ; 0.097105 ; 0.084174 ; 0.097815 ; 0.081105 ; 0.103204 ; 0.106212 ; 0.092161 ; 0.09546 ; 0.117702 ; 0.096446 ; 0.107131 ; 0.10456 ; 0.100576 ; 0.102862 ; 0.098575 ; 0.092776 ; 0.098902 ; 0.105193 ; 0.094707 ; 0.096566 ; 0.101054 ; 0.091454 ; 0.086037 ; 0.097932 ; 0.111188 ; 0.102546 ; 0.107244 ; 0.104442 ; 0.095672 ; 0.082701 ; 0.092657 ; 0.082575 ; 0.091241 ; 0.097744 ; 0.071965 ; 0.085456 ; 0.102252 ; 0.102042 ; 0.094413 ; 0.085223 ; 0.093353 ; 0.085068 ; 0.096425 ; 0.115051 ; 0.105089 ; 0.100058 ; 0.112275 ; 0.098878 ; 0.081879 ; 0.104351 ; 0.101102 ; 0.079972 ; 0.097906 ; 0.098174 ; 0.101519 ; 0.107279 ; 0.081104 ; 0.103836 ; 0.097568 ; 0.095746 ; 0.110272 ; 0.096564 ; 0.106634 ; 0.099749 ; 0.100858 ; 0.077021 ; 0.074067 ; 0.099337 ; 0.093691 ; 0.106326 ; 0.091267 ; 0.083354 ; 0.092884 ; 0.084281 ; 0.090697 ; 0.088726 ; 0.100892 ; 0.099745 ; 0.081163 ; 0.091613 ; 0.091914 ; 0.09395 ; 0.095907 ; 0.093697 ; 0.085183 ; 0.088545 ; 0.087183 ; 0.10054 ; 0.095584 ; 0.095582 ; 0.100109 ; 0.104326 ; 0.091971 ; 0.104585 ; 0.108619 ; 0.093502 ; 0.089559 ; 0.094504 ; 0.094005 ; 0.097332 ; 0.099098 ; 0.098973 ; 0.09716 ; 0.094788 ; 0.090315 ; 0.102749 ; 0.089926 ; 0.09948 ; 0.102806 ; 0.103475 ; 0.097103 ; 0.107226 ; 0.107651 ; 0.109663 ; 0.1078 ; 0.108846 ; 0.101215 ; 0.09859 ; 0.088019 ; 0.089228 ; 0.106663 ; 0.097916 ; 0.091502 ; 0.102752 ; 0.10125 ; 0.092389 ; 0.090114 ; 0.090986 ; 0.100961 ; 0.101274 ; 0.118982 ; 0.107021 ; 0.056599 ; 0.103938 ; 0.099106 ; 0.080951 ; 0.075397 ; 0.084102 ; 0.089348 ; 0.088373 ; 0.102204 ; 0.0903 ; 0.104975 ; 0.096814 ; 0.098529 ; 0.105263 ; 0.104674 ; 0.101443 ; 0.099027 ; 0.083448 ; 0.105524 ; 0.104732 ; 0.100214 ; 0.097936
IMSIG_MONOCYTES	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG monocytes	Sample	0.094311 ; 0.096664 ; 0.09733 ; 0.099582 ; 0.085387 ; 0.09862 ; 0.09359 ; 0.086742 ; 0.095367 ; 0.092294 ; 0.100816 ; 0.10705 ; 0.098918 ; 0.085886 ; 0.095581 ; 0.101767 ; 0.083322 ; 0.094984 ; 0.083308 ; 0.092209 ; 0.076914 ; 0.101366 ; 0.099047 ; 0.091143 ; 0.093995 ; 0.113049 ; 0.094514 ; 0.105841 ; 0.103977 ; 0.09787 ; 0.105831 ; 0.100815 ; 0.093536 ; 0.09528 ; 0.101183 ; 0.095941 ; 0.093805 ; 0.100892 ; 0.090284 ; 0.083426 ; 0.094752 ; 0.105604 ; 0.099456 ; 0.09927 ; 0.100463 ; 0.095086 ; 0.083284 ; 0.091981 ; 0.081249 ; 0.088297 ; 0.096011 ; 0.06889 ; 0.083501 ; 0.101519 ; 0.098899 ; 0.083035 ; 0.091498 ; 0.08238 ; 0.090475 ; 0.109716 ; 0.10155 ; 0.094839 ; 0.106304 ; 0.100516 ; 0.081359 ; 0.102387 ; 0.097362 ; 0.081731 ; 0.095841 ; 0.094637 ; 0.098509 ; 0.104236 ; 0.077898 ; 0.101957 ; 0.09626 ; 0.093977 ; 0.105245 ; 0.092384 ; 0.103752 ; 0.098844 ; 0.09646 ; 0.076603 ; 0.075175 ; 0.097896 ; 0.089801 ; 0.097467 ; 0.088168 ; 0.080995 ; 0.092484 ; 0.081138 ; 0.088504 ; 0.083669 ; 0.097909 ; 0.097228 ; 0.079887 ; 0.088918 ; 0.090517 ; 0.08934 ; 0.093966 ; 0.088186 ; 0.085213 ; 0.087888 ; 0.086786 ; 0.095462 ; 0.094874 ; 0.100177 ; 0.102401 ; 0.090471 ; 0.09899 ; 0.107747 ; 0.091062 ; 0.089039 ; 0.092837 ; 0.090244 ; 0.093679 ; 0.094672 ; 0.096987 ; 0.092739 ; 0.094319 ; 0.091952 ; 0.087829 ; 0.105093 ; 0.095317 ; 0.102128 ; 0.102344 ; 0.102245 ; 0.10216 ; 0.101832 ; 0.107364 ; 0.110963 ; 0.104772 ; 0.102133 ; 0.100525 ; 0.094796 ; 0.086438 ; 0.085776 ; 0.104451 ; 0.091581 ; 0.089293 ; 0.099407 ; 0.097601 ; 0.091533 ; 0.088403 ; 0.088259 ; 0.095773 ; 0.095866 ; 0.116963 ; 0.101513 ; 0.063224 ; 0.097259 ; 0.094692 ; 0.079105 ; 0.075359 ; 0.08338 ; 0.086036 ; 0.087523 ; 0.102616 ; 0.091505 ; 0.102955 ; 0.093393 ; 0.097851 ; 0.100425 ; 0.103732 ; 0.097445 ; 0.097444 ; 0.083668 ; 0.102097 ; 0.101804 ; 0.097158 ; 0.096329
IMSIG_NEUTROPHILS	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG neutrophils	Sample	0.087068 ; 0.090387 ; 0.093404 ; 0.088741 ; 0.083026 ; 0.087259 ; 0.092435 ; 0.087067 ; 0.086802 ; 0.090419 ; 0.092524 ; 0.100562 ; 0.089381 ; 0.087972 ; 0.088068 ; 0.091617 ; 0.08296 ; 0.085582 ; 0.081584 ; 0.088205 ; 0.071448 ; 0.096011 ; 0.087909 ; 0.092277 ; 0.090214 ; 0.09743 ; 0.086577 ; 0.102209 ; 0.098654 ; 0.090756 ; 0.097901 ; 0.097563 ; 0.089811 ; 0.087013 ; 0.093999 ; 0.084134 ; 0.084578 ; 0.09709 ; 0.089145 ; 0.072686 ; 0.080183 ; 0.093728 ; 0.092339 ; 0.08912 ; 0.086584 ; 0.082909 ; 0.072422 ; 0.07712 ; 0.081025 ; 0.076448 ; 0.091134 ; 0.071854 ; 0.069701 ; 0.097747 ; 0.092267 ; 0.08561 ; 0.075787 ; 0.091778 ; 0.078193 ; 0.086872 ; 0.098653 ; 0.088825 ; 0.088769 ; 0.092942 ; 0.101123 ; 0.076937 ; 0.095446 ; 0.092602 ; 0.071405 ; 0.087932 ; 0.088914 ; 0.090606 ; 0.093737 ; 0.074471 ; 0.092029 ; 0.088054 ; 0.087874 ; 0.091375 ; 0.080955 ; 0.099731 ; 0.089075 ; 0.089286 ; 0.067255 ; 0.065634 ; 0.089276 ; 0.07981 ; 0.085356 ; 0.080335 ; 0.072252 ; 0.081581 ; 0.07584 ; 0.078071 ; 0.071679 ; 0.085627 ; 0.081571 ; 0.068363 ; 0.077532 ; 0.077051 ; 0.080916 ; 0.084507 ; 0.078244 ; 0.073395 ; 0.077661 ; 0.077024 ; 0.087597 ; 0.085388 ; 0.078385 ; 0.095251 ; 0.089621 ; 0.080833 ; 0.089261 ; 0.097585 ; 0.082395 ; 0.078427 ; 0.076221 ; 0.079362 ; 0.082802 ; 0.082765 ; 0.086507 ; 0.083943 ; 0.084277 ; 0.084188 ; 0.079455 ; 0.094507 ; 0.085762 ; 0.089915 ; 0.088708 ; 0.0968 ; 0.083048 ; 0.090375 ; 0.09581 ; 0.097169 ; 0.09105 ; 0.095185 ; 0.09081 ; 0.088125 ; 0.073963 ; 0.073763 ; 0.089339 ; 0.080553 ; 0.075317 ; 0.089144 ; 0.086001 ; 0.080248 ; 0.080298 ; 0.078086 ; 0.083352 ; 0.084919 ; 0.100625 ; 0.091426 ; 0.062511 ; 0.082657 ; 0.082472 ; 0.073453 ; 0.066355 ; 0.088417 ; 0.075951 ; 0.078523 ; 0.089474 ; 0.08211 ; 0.093026 ; 0.083458 ; 0.090577 ; 0.088257 ; 0.095248 ; 0.086046 ; 0.089084 ; 0.077925 ; 0.093323 ; 0.095125 ; 0.090804 ; 0.084982
IMSIG_NK_CELLS	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG NK cells	Sample	0.035941 ; 0.034496 ; 0.026549 ; 0.031788 ; 0.031835 ; 0.037675 ; 0.024597 ; 0.02383 ; 0.033899 ; 0.045923 ; 0.043293 ; 0.03455 ; 0.038971 ; 0.029378 ; 0.034001 ; 0.040376 ; 0.025638 ; 0.045767 ; 0.023695 ; 0.032452 ; 0.021992 ; 0.047581 ; 0.037644 ; 0.029963 ; 0.040727 ; 0.050072 ; 0.035437 ; 0.049853 ; 0.036955 ; 0.029477 ; 0.062648 ; 0.063231 ; 0.042189 ; 0.032706 ; 0.04986 ; 0.019721 ; 0.033455 ; 0.050101 ; 0.028778 ; 0.023259 ; 0.055931 ; 0.048831 ; 0.034177 ; 0.054848 ; 0.026189 ; 0.029577 ; 0.02215 ; 0.018218 ; 0.015705 ; 0.053378 ; 0.039818 ; 0.011845 ; 0.015872 ; 0.052781 ; 0.044969 ; 0.02105 ; 0.028839 ; 0.028471 ; 0.023702 ; 0.030624 ; 0.047287 ; 0.040423 ; 0.046667 ; 0.03698 ; 0.057303 ; 0.028939 ; 0.054715 ; 0.038006 ; 0.017793 ; 0.029493 ; 0.040034 ; 0.031576 ; 0.03262 ; 0.025367 ; 0.037383 ; 0.033504 ; 0.03547 ; 0.038567 ; 0.0265 ; 0.053326 ; 0.028436 ; 0.041636 ; 0.019634 ; 0.011778 ; 0.037858 ; 0.033323 ; 0.043886 ; 0.041783 ; 0.027113 ; 0.01764 ; 0.029041 ; 0.024842 ; 0.032351 ; 0.030175 ; 0.02201 ; 0.023584 ; 0.036497 ; 0.030111 ; 0.027322 ; 0.037418 ; 0.038407 ; 0.026222 ; 0.030315 ; 0.029044 ; 0.036161 ; 0.042934 ; 0.032455 ; 0.06043 ; 0.04207 ; 0.036243 ; 0.048795 ; 0.024767 ; 0.020179 ; 0.032943 ; 0.039147 ; 0.040778 ; 0.042705 ; 0.039918 ; 0.029468 ; 0.024826 ; 0.04964 ; 0.036703 ; 0.032981 ; 0.042429 ; 0.016225 ; 0.040442 ; 0.031483 ; 0.034171 ; 0.025779 ; 0.027093 ; 0.05007 ; 0.046153 ; 0.055853 ; 0.048351 ; 0.03135 ; 0.037316 ; 0.025062 ; 0.026534 ; 0.02853 ; 0.026362 ; 0.029932 ; 0.032102 ; 0.026184 ; 0.02037 ; 0.021375 ; 0.021904 ; 0.038863 ; 0.037449 ; 0.062166 ; 0.041089 ; 0.019273 ; 0.023332 ; 0.045504 ; 0.020899 ; 0.026874 ; 0.035825 ; 0.026803 ; 0.02183 ; 0.031624 ; 0.021468 ; 0.036301 ; 0.04165 ; 0.027583 ; 0.046103 ; 0.049426 ; 0.034664 ; 0.031645 ; 0.030941 ; 0.037122 ; 0.051699 ; 0.041165 ; 0.033729
IMSIG_PLASMA_CELLS	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG plasma cells	Sample	0.102029 ; 0.103745 ; 0.082673 ; 0.079749 ; 0.085114 ; 0.111978 ; 0.092442 ; 0.103702 ; 0.088208 ; 0.108362 ; 0.095428 ; 0.084818 ; 0.092854 ; 0.074214 ; 0.096414 ; 0.061466 ; 0.088976 ; 0.116676 ; 0.080444 ; 0.083532 ; 0.082664 ; 0.080425 ; 0.099952 ; 0.072464 ; 0.077264 ; 0.113723 ; 0.095317 ; 0.07 ; 0.085604 ; 0.075515 ; 0.092908 ; 0.084687 ; 0.101152 ; 0.063419 ; 0.115973 ; 0.071919 ; 0.084398 ; 0.072584 ; 0.092136 ; 0.081978 ; 0.121496 ; 0.102164 ; 0.078989 ; 0.078263 ; 0.06402 ; 0.098424 ; 0.079909 ; 0.085876 ; 0.057009 ; 0.091833 ; 0.068897 ; 0.04633 ; 0.062617 ; 0.074033 ; 0.07941 ; 0.081134 ; 0.090636 ; 0.092304 ; 0.087876 ; 0.076481 ; 0.095118 ; 0.094635 ; 0.104628 ; 0.087848 ; 0.069521 ; 0.090792 ; 0.085417 ; 0.100494 ; 0.081444 ; 0.094541 ; 0.09057 ; 0.092484 ; 0.105458 ; 0.090165 ; 0.110228 ; 0.082003 ; 0.097466 ; 0.09745 ; 0.105526 ; 0.078865 ; 0.073364 ; 0.111777 ; 0.085278 ; 0.043916 ; 0.092046 ; 0.093501 ; 0.119941 ; 0.083672 ; 0.085133 ; 0.075157 ; 0.086854 ; 0.09088 ; 0.084635 ; 0.069937 ; 0.053499 ; 0.067868 ; 0.081943 ; 0.074286 ; 0.075126 ; 0.10158 ; 0.108218 ; 0.067955 ; 0.102133 ; 0.077755 ; 0.106468 ; 0.107712 ; 0.090366 ; 0.076554 ; 0.082609 ; 0.096104 ; 0.111847 ; 0.089848 ; 0.091496 ; 0.096129 ; 0.056426 ; 0.076572 ; 0.079293 ; 0.087998 ; 0.079017 ; 0.068855 ; 0.074207 ; 0.07706 ; 0.086022 ; 0.090681 ; 0.051643 ; 0.099911 ; 0.109193 ; 0.091559 ; 0.096638 ; 0.088376 ; 0.11265 ; 0.10779 ; 0.121434 ; 0.114981 ; 0.077581 ; 0.087201 ; 0.080134 ; 0.08237 ; 0.061028 ; 0.089877 ; 0.068121 ; 0.078847 ; 0.088718 ; 0.084451 ; 0.08448 ; 0.105965 ; 0.100754 ; 0.090064 ; 0.112226 ; 0.096563 ; 0.056118 ; 0.093593 ; 0.114729 ; 0.060575 ; 0.080096 ; 0.07868 ; 0.075125 ; 0.080677 ; 0.104745 ; 0.059021 ; 0.086155 ; 0.104406 ; 0.085935 ; 0.107087 ; 0.0862 ; 0.106381 ; 0.098401 ; 0.089553 ; 0.091814 ; 0.113761 ; 0.099294 ; 0.085874
IMSIG_PROLIFERATION	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG proliferation	Sample	0.088166 ; 0.084485 ; 0.066602 ; 0.082492 ; 0.088324 ; 0.062647 ; 0.084305 ; 0.060683 ; 0.080572 ; 0.090095 ; 0.070454 ; 0.072081 ; 0.069711 ; 0.097765 ; 0.067078 ; 0.073931 ; 0.093704 ; 0.05519 ; 0.067762 ; 0.081484 ; 0.062028 ; 0.069116 ; 0.074333 ; 0.082579 ; 0.07764 ; 0.058468 ; 0.088096 ; 0.064194 ; 0.052495 ; 0.064973 ; 0.06266 ; 0.058748 ; 0.090522 ; 0.0606 ; 0.075565 ; 0.073248 ; 0.081113 ; 0.054852 ; 0.064454 ; 0.069382 ; 0.080084 ; 0.076413 ; 0.067836 ; 0.087849 ; 0.081279 ; 0.067029 ; 0.083518 ; 0.058588 ; 0.074029 ; 0.079889 ; 0.054148 ; 0.089905 ; 0.076374 ; 0.059053 ; 0.069774 ; 0.061787 ; 0.087131 ; 0.087256 ; 0.06823 ; 0.071586 ; 0.065379 ; 0.068186 ; 0.083906 ; 0.064988 ; 0.05143 ; 0.060914 ; 0.0665 ; 0.083135 ; 0.068277 ; 0.072999 ; 0.071459 ; 0.085941 ; 0.075055 ; 0.061683 ; 0.070194 ; 0.073981 ; 0.059385 ; 0.066473 ; 0.070385 ; 0.065061 ; 0.074407 ; 0.077676 ; 0.086341 ; 0.067553 ; 0.08704 ; 0.067203 ; 0.082949 ; 0.086779 ; 0.065188 ; 0.074394 ; 0.061228 ; 0.072093 ; 0.074346 ; 0.069902 ; 0.061644 ; 0.065604 ; 0.086174 ; 0.076384 ; 0.088547 ; 0.068546 ; 0.087153 ; 0.091976 ; 0.075548 ; 0.078623 ; 0.080413 ; 0.063337 ; 0.068716 ; 0.052297 ; 0.07452 ; 0.089143 ; 0.079438 ; 0.079978 ; 0.071274 ; 0.082513 ; 0.071892 ; 0.069403 ; 0.061349 ; 0.063132 ; 0.063367 ; 0.062291 ; 0.066506 ; 0.074877 ; 0.070643 ; 0.063187 ; 0.05183 ; 0.065131 ; 0.081303 ; 0.085559 ; 0.069543 ; 0.079787 ; 0.077071 ; 0.069108 ; 0.068724 ; 0.085436 ; 0.083138 ; 0.066779 ; 0.063123 ; 0.086794 ; 0.068835 ; 0.070565 ; 0.066634 ; 0.062218 ; 0.064595 ; 0.064019 ; 0.063478 ; 0.06945 ; 0.083766 ; 0.065443 ; 0.065449 ; 0.080752 ; 0.084423 ; 0.063252 ; 0.088792 ; 0.068884 ; 0.067717 ; 0.088317 ; 0.072082 ; 0.072495 ; 0.081183 ; 0.063227 ; 0.069935 ; 0.064475 ; 0.069096 ; 0.067646 ; 0.062796 ; 0.081276 ; 0.072793 ; 0.065397 ; 0.059413 ; 0.075912 ; 0.073304 ; 0.059159
IMSIG_TRANSLATION	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG translation	Sample	0.130849 ; 0.133816 ; 0.137537 ; 0.132714 ; 0.141814 ; 0.139625 ; 0.131228 ; 0.135086 ; 0.135641 ; 0.136597 ; 0.134408 ; 0.134363 ; 0.131252 ; 0.132494 ; 0.13461 ; 0.130272 ; 0.127158 ; 0.133248 ; 0.133363 ; 0.131429 ; 0.139459 ; 0.132587 ; 0.131311 ; 0.134118 ; 0.134912 ; 0.138968 ; 0.140443 ; 0.130528 ; 0.131279 ; 0.133271 ; 0.143201 ; 0.129213 ; 0.13558 ; 0.131618 ; 0.133916 ; 0.129289 ; 0.13265 ; 0.128921 ; 0.130445 ; 0.139356 ; 0.142557 ; 0.136931 ; 0.13501 ; 0.133945 ; 0.135492 ; 0.136416 ; 0.138308 ; 0.139182 ; 0.141109 ; 0.141772 ; 0.132764 ; 0.145087 ; 0.136751 ; 0.130816 ; 0.130564 ; 0.134463 ; 0.139071 ; 0.132861 ; 0.13865 ; 0.142654 ; 0.135133 ; 0.133068 ; 0.138303 ; 0.138073 ; 0.132291 ; 0.1341 ; 0.133197 ; 0.136112 ; 0.14553 ; 0.127423 ; 0.127777 ; 0.127707 ; 0.131315 ; 0.139431 ; 0.134121 ; 0.128431 ; 0.134742 ; 0.136581 ; 0.13437 ; 0.131926 ; 0.128137 ; 0.129034 ; 0.139509 ; 0.127407 ; 0.140102 ; 0.140743 ; 0.142666 ; 0.132321 ; 0.137621 ; 0.134034 ; 0.14572 ; 0.134951 ; 0.133992 ; 0.135718 ; 0.142874 ; 0.140057 ; 0.140252 ; 0.128849 ; 0.132402 ; 0.139864 ; 0.131854 ; 0.129881 ; 0.136383 ; 0.139076 ; 0.135775 ; 0.135379 ; 0.143547 ; 0.127843 ; 0.129884 ; 0.132143 ; 0.137418 ; 0.132574 ; 0.136978 ; 0.139156 ; 0.130319 ; 0.134138 ; 0.132991 ; 0.132377 ; 0.139281 ; 0.129137 ; 0.133748 ; 0.140725 ; 0.141219 ; 0.145404 ; 0.152922 ; 0.150044 ; 0.143196 ; 0.146153 ; 0.146837 ; 0.133684 ; 0.143835 ; 0.149823 ; 0.152855 ; 0.15155 ; 0.146212 ; 0.130562 ; 0.143874 ; 0.139004 ; 0.141725 ; 0.139879 ; 0.145503 ; 0.14197 ; 0.139913 ; 0.146766 ; 0.146695 ; 0.137579 ; 0.141138 ; 0.142379 ; 0.154594 ; 0.137977 ; 0.136516 ; 0.148338 ; 0.133237 ; 0.13801 ; 0.142664 ; 0.129501 ; 0.13518 ; 0.149624 ; 0.137651 ; 0.141469 ; 0.136299 ; 0.140901 ; 0.137679 ; 0.137306 ; 0.134706 ; 0.134237 ; 0.136515 ; 0.143842 ; 0.13962 ; 0.139187 ; 0.138435 ; 0.14297
IMSIG_T_CELLS	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	NUMBER	IMSIG T-cells	Sample	0.082562 ; 0.085436 ; 0.077242 ; 0.092048 ; 0.080006 ; 0.089114 ; 0.073687 ; 0.071954 ; 0.082281 ; 0.085261 ; 0.087753 ; 0.08527 ; 0.087811 ; 0.071685 ; 0.079818 ; 0.085252 ; 0.068152 ; 0.089049 ; 0.071886 ; 0.091036 ; 0.069315 ; 0.087825 ; 0.090051 ; 0.067814 ; 0.078632 ; 0.106782 ; 0.078533 ; 0.089753 ; 0.086013 ; 0.083811 ; 0.090758 ; 0.088085 ; 0.076135 ; 0.08002 ; 0.096693 ; 0.06812 ; 0.080625 ; 0.083802 ; 0.084085 ; 0.067278 ; 0.09681 ; 0.094202 ; 0.087086 ; 0.093586 ; 0.083565 ; 0.075934 ; 0.06662 ; 0.077884 ; 0.059328 ; 0.077695 ; 0.079751 ; 0.04574 ; 0.065141 ; 0.086716 ; 0.085555 ; 0.073211 ; 0.071331 ; 0.072364 ; 0.068436 ; 0.080225 ; 0.094063 ; 0.091517 ; 0.088167 ; 0.090573 ; 0.085048 ; 0.077287 ; 0.091256 ; 0.084209 ; 0.063624 ; 0.079853 ; 0.079887 ; 0.080371 ; 0.089054 ; 0.071768 ; 0.087455 ; 0.07989 ; 0.081195 ; 0.089691 ; 0.079935 ; 0.09147 ; 0.078031 ; 0.08914 ; 0.071457 ; 0.05594 ; 0.083559 ; 0.088637 ; 0.090452 ; 0.079575 ; 0.082881 ; 0.071059 ; 0.074286 ; 0.080007 ; 0.081191 ; 0.075659 ; 0.07302 ; 0.063914 ; 0.081299 ; 0.078941 ; 0.076156 ; 0.089017 ; 0.08798 ; 0.068196 ; 0.079312 ; 0.072998 ; 0.088731 ; 0.089734 ; 0.084497 ; 0.086746 ; 0.086368 ; 0.075474 ; 0.096624 ; 0.082043 ; 0.068616 ; 0.082066 ; 0.080562 ; 0.080022 ; 0.080484 ; 0.081863 ; 0.080781 ; 0.074588 ; 0.083995 ; 0.080754 ; 0.087112 ; 0.086453 ; 0.059975 ; 0.090604 ; 0.09088 ; 0.080429 ; 0.077665 ; 0.083676 ; 0.093218 ; 0.097313 ; 0.100779 ; 0.11126 ; 0.084594 ; 0.081728 ; 0.085789 ; 0.072038 ; 0.080468 ; 0.081882 ; 0.071472 ; 0.079685 ; 0.083888 ; 0.0743 ; 0.068993 ; 0.080767 ; 0.088273 ; 0.088014 ; 0.098651 ; 0.088532 ; 0.046759 ; 0.081773 ; 0.085819 ; 0.064068 ; 0.071247 ; 0.071681 ; 0.07816 ; 0.071378 ; 0.088368 ; 0.07118 ; 0.088466 ; 0.094916 ; 0.081949 ; 0.093787 ; 0.087027 ; 0.091367 ; 0.080802 ; 0.075043 ; 0.084154 ; 0.094697 ; 0.09388 ; 0.083664
TKI_TREATMENT	Gainsboro	Lung Adenocarcinoma (OncoSG, Nat Genet 2020)	STRING	TKI Treatment	Patient	
AGE_AT_RESECTION	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	NUMBER	Age at Resection	Patient	
BIOPSY_CONTAINS_MIP	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	STRING	Biopsy contains MIP	Patient	
BIOPSY_CONTAINS_SOLID	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	STRING	Biopsy contains Solid	Patient	
CLIN_N_STAGE_CODE	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	STRING	Clinical N Stage Code	Patient	
TUMOR_MORPHOLOGIC_APPEARANCE_ON_CT	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	STRING	Tumor Morphologic Appearance on CT	Patient	
TUMOR_SIZE_ON_CT	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	STRING	Tumor Size on CT	Patient	
TUMOR_SUVMAX	Gainsboro	Lung Adenocarcinoma (MSK, NPJ Precision Oncology 2021)	NUMBER	Tumor SUV Max	Patient	
ALIQUOT_ID	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Aliquot ID for sample aliquot used in experiment	Sample	CPT0089340003 ; CPT0092930003 ; CPT0015410003 ; CPT0146980004 ; CPT0148280004 ; CPT0011710004 ; CPT0117970003 ; CPT0069360003 ; CPT0148080004 ; CPT0083100003 ; CPT0118160003 ; CPT0105510003 ; CPT0091240003 ; CPT0148180004 ; CPT0068100003 ; CPT0092240003 ; CPT0014860003 ; CPT0082850004 ; CPT0091860003 ; CPT0067940003 ; CPT0098130003 ; CPT0118340003 ; CPT0110860004 ; CPT0083780003 ; CPT0069700003 ; CPT0053040004 ; CPT0109680004 ; CPT0105940003 ; CPT0090170004 ; CPT0105330003 ; CPT0105710003 ; CPT0118620003 ; CPT0147080004 ; CPT0082740004 ; CPT0146580004 ; CPT0001660013 ; CPT0147580004 ; CPT0068610003 ; CPT0052940004 ; CPT0113990003 ; CPT0086310003 ; CPT0011910004 ; CPT0106110003 ; CPT0052170004 ; CPT0023310003 ; CPT0105630003 ; CPT0067450003 ; CPT0147380004 ; CPT0104970003 ; CPT0090340003 ; CPT0083390004 ; CPT0090860003 ; CPT0051690004 ; CPT0070060003 ; CPT0067620003 ; CPT0013600003 ; CPT0001580009 ; CPT0105270003 ; CPT0086750003 ; CPT0118810003 ; CPT0090570004 ; CPT0109720004 ; CPT0118570003 ; CPT0147980004 ; CPT0104630003 ; CPT0066780003 ; CPT0092530003 ; CPT0055100004 ; CPT0118880003 ; CPT0146780004 ; CPT0090700003 ; CPT0008450003 ; CPT0084140003 ; CPT0000920017 ; CPT0001960003 ; CPT0111300003 ; CPT0146680004 ; CPT0114660004 ; CPT0021450003 ; CPT0110980004 ; CPT0008410003 ; CPT0001380003 ; CPT0067070003 ; CPT0105600003 ; CPT0118200003 ; CPT0001800013 ; CPT0147480004 ; CPT0063730003 ; CPT0109830004 ; CPT0146880004 ; CPT0001060010 ; CPT0067250003 ; CPT0105060003 ; CPT0105230003 ; CPT0102450003 ; CPT0115070003 ; CPT0125810003 ; CPT0068800003 ; CPT0063810003 ; CPT0014260003 ; CPT0069520003 ; CPT0147880004 ; CPT0104750003 ; CPT0112060003 ; CPT0079830003 ; CPT0109740004 ; CPT0013880003 ; CPT0097580003 ; CPT0113210003 ; CPT0114840003
ALK_FUSION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator of ALK fusions in sample 	Sample	0 ; 1
ARAF_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	ARAF mutations present in sample	Sample	Missense_Mutation
ARAF_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any ARAF mutations	Sample	0 ; 1
BRAF_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any BRAF mutations	Sample	0 ; 1
CIGARETTES_PER_DAY	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Number of cigarettes smoked by the person per day	Patient	
CIMP_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	CpG island methylator phenotype (CIMP)	Sample	CIMP-1 ; CIMP-2 ; CIMP+
DNP_GG_TO_TT_OR_CC_TO_AA_COUNT_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Count of GG -> TT or CC -> AA di-nucleotide polymorphisms (DNP) using WGS mutation calls	Sample	0 ; 84 ; 2 ; 127 ; 1 ; 47 ; 224 ; 432 ; 153 ; 101 ; 175 ; 277 ; 388 ; 14 ; 200 ; 3 ; 123 ; 38 ; 220 ; 154 ; 6 ; 61 ; 290 ; 241 ; 181 ; 91 ; 429 ; 134 ; 444 ; 336 ; 30 ; 75 ; 5 ; 265 ; 78 ; 7 ; 775 ; 136 ; 9 ; 65 ; 34 ; 387 ; 60 ; 116 ; 303 ; 1206 ; 240 ; 74 ; 42 ; 1002 ; 380 ; 37 ; 23 ; 496 ; 172 ; 32 ; 479 ; 159 ; 165
DOMINANT_HISTOLOGICAL_SUBTYPE	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Histological subtypes	Sample	acinar ; micropapillary ; solid ; invasive-mucinous ; lepidic ; papillary ; sarcomatoid ; intestinal
DOMINANT_SIGNATURE_FRACTION_WGS_NOTSMOKING	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Signature fraction for dominant non-smoking signature with fraction > 0.5 (WGS mutation calls)	Patient	
DOMINANT_SIGNATURE_WGS_NOTSMOKING_50PERC	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Dominant non-smoking signature with fraction > 0.5 (WGS mutation calls)	Patient	
EGFR_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	EGRF mutations present in sample	Sample	Missense_Mutation ; In_Frame_Del
EGFR_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any EGFR mutations	Sample	1 ; 0
ERBB2_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	ERBB2 mutations present in sample	Sample	In_Frame_Ins
ERBB2_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any ERBB2 mutations	Sample	0 ; 1
ESTIMATE IMMUNESCORE	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	ESTIMATE immune score	Sample	5317.602599 ; 2955.666928 ; 4154.233352 ; 5409.147558 ; 2716.148926 ; 6009.804888 ; 3162.00003 ; 3578.035582 ; 4146.195774 ; 3717.26955 ; 4773.782403 ; 4685.748256 ; 4287.74716 ; 3012.07198 ; 4763.260024 ; 2172.464146 ; 3579.026988 ; 3862.991258 ; 5545.132967 ; 3917.846342 ; 3185.638758 ; 3537.238325 ; 5586.099289 ; 3112.673835 ; 2676.632913 ; 3131.099322 ; 3964.017696 ; 5229.321091 ; 4873.182145 ; 4103.618849 ; 5102.44039 ; 3319.601494 ; 5290.487872 ; 5058.155846 ; 4380.312816 ; 5447.448688 ; 3696.023946 ; 4122.800524 ; 4615.37442 ; 4343.74049 ; 4859.177491 ; 2286.084043 ; 5032.86933 ; 3566.627987 ; 5037.834105 ; 3842.42518 ; 676.7145462 ; 4552.818493 ; 3604.085859 ; 4670.917034 ; 3647.152597 ; 3746.280343 ; 4661.691883 ; 3813.654173 ; 3924.428861 ; 3415.367158 ; 3417.429527 ; 2723.12758 ; 2486.85276 ; 2010.833604 ; 2652.349345 ; 3230.984645 ; 3563.925875 ; 3291.499211 ; 4935.514535 ; 1301.884614 ; 4085.748303 ; 3722.877167 ; 3716.434972 ; 3759.944047 ; 4654.0796 ; 3483.264435 ; 3990.201789 ; 3596.329924 ; 4628.39431 ; 4814.890885 ; 2875.066947 ; 4507.522049 ; 6793.083764 ; 6722.430635 ; 3720.363406 ; 4386.742524 ; 4714.191565 ; 3082.660167 ; 5420.285081 ; 3412.340558 ; 4800.668657 ; 4237.534916 ; 3557.220141 ; 3025.211155 ; 3172.532974 ; 2746.115508 ; 4382.909915 ; 2759.800838 ; 5472.784546 ; 4860.656551 ; 4880.373619 ; 3304.567246 ; 3343.331083 ; 2608.501304 ; 4448.678863 ; 3429.934066 ; 5224.220518 ; 5135.585019 ; 3277.841448 ; 5848.844226 ; 3729.338867 ; 4212.570759 ; 4044.648931 ; 2165.138406
ESTIMATE STROMALSCORE	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	ESTIMATE stromal score	Sample	2079.741498 ; 2066.261097 ; 1182.617858 ; 3038.230117 ; 1828.449721 ; 3330.68177 ; 1498.023281 ; 2030.988133 ; 1040.817318 ; 1311.396858 ; 3299.771008 ; 2358.19358 ; 2911.843412 ; 1340.20074 ; 2334.631885 ; 920.3685776 ; 1777.712288 ; 561.8624359 ; 3957.656619 ; 2371.946209 ; 1474.479888 ; 223.8904813 ; 2636.331705 ; 1848.616692 ; 882.5235595 ; 2751.141108 ; 2178.965198 ; 2962.96537 ; 2077.736848 ; 1211.135413 ; 2984.938307 ; 1710.015624 ; 2293.436368 ; 3646.620365 ; 1596.146813 ; 3473.893725 ; 2108.037849 ; 1719.39627 ; 2140.485468 ; 2913.372112 ; 3116.263319 ; -939.241204 ; 2460.505188 ; 2459.993119 ; 3558.243176 ; 2211.958102 ; 262.8039272 ; 2752.33499 ; 2840.701757 ; 1529.671751 ; 1386.840323 ; 2398.220929 ; 2696.392179 ; 1122.528106 ; 1355.755001 ; 1410.090629 ; 3161.568488 ; 998.4685614 ; 2063.621776 ; -81.19142571 ; 1317.357697 ; 853.9197576 ; 2503.058125 ; 1452.710007 ; 2142.840012 ; 451.7482423 ; 2141.595454 ; 1131.421738 ; 854.6087871 ; 2850.372868 ; 3674.458707 ; 1685.49785 ; 2438.935509 ; 1765.313925 ; 2195.441954 ; 2321.746235 ; 561.1026521 ; 2344.876716 ; 3817.224503 ; 4368.302253 ; 1566.438302 ; 2943.286005 ; 1846.490307 ; 1445.859436 ; 2786.94259 ; 458.4561882 ; 2195.202666 ; 1929.989792 ; 1193.178516 ; 1118.350264 ; 459.7890423 ; 1377.466515 ; 1945.57905 ; 1283.269605 ; 2652.236537 ; 1697.055787 ; 4262.684415 ; 556.6004961 ; 2001.974658 ; 1346.456148 ; 1761.293096 ; 1313.000384 ; 2044.24765 ; 3625.343839 ; 1280.309944 ; 2311.402276 ; 2109.88445 ; 1899.344066 ; 898.7741143 ; 1231.518043
ESTIMATESCORE	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Overall ESTIMATE score	Sample	7397.344097 ; 5021.928025 ; 5336.85121 ; 8447.377675 ; 4544.598647 ; 9340.486658 ; 4660.023311 ; 5609.023715 ; 5187.013092 ; 5028.666408 ; 8073.553411 ; 7043.941836 ; 7199.590572 ; 4352.27272 ; 7097.891909 ; 3092.832723 ; 5356.739276 ; 4424.853694 ; 9502.789586 ; 6289.792551 ; 4660.118646 ; 3761.128807 ; 8222.430994 ; 4961.290527 ; 3559.156473 ; 5882.24043 ; 6142.982894 ; 8192.286461 ; 6950.918993 ; 5314.754262 ; 8087.378698 ; 5029.617118 ; 7583.92424 ; 8704.776211 ; 5976.45963 ; 8921.342414 ; 5804.061794 ; 5842.196794 ; 6755.859888 ; 7257.112602 ; 7975.44081 ; 1346.842839 ; 7493.374518 ; 6026.621105 ; 8596.077282 ; 6054.383282 ; 939.5184734 ; 7305.153483 ; 6444.787616 ; 6200.588785 ; 5033.99292 ; 6144.501272 ; 7358.084062 ; 4936.182279 ; 5280.183862 ; 4825.457787 ; 6578.998015 ; 3721.596142 ; 4550.474536 ; 1929.642178 ; 3969.707042 ; 4084.904403 ; 6066.984 ; 4744.209218 ; 7078.354547 ; 1753.632857 ; 6227.343757 ; 4854.298905 ; 4571.043759 ; 6610.316915 ; 8328.538307 ; 5168.762284 ; 6429.137298 ; 5361.643849 ; 6823.836264 ; 7136.63712 ; 3436.1696 ; 6852.398765 ; 10610.30827 ; 11090.73289 ; 5286.801708 ; 7330.028529 ; 6560.681872 ; 4528.519603 ; 8207.227671 ; 3870.796747 ; 6995.871323 ; 6167.524708 ; 4750.398658 ; 4143.56142 ; 3632.322016 ; 4123.582023 ; 6328.488965 ; 4043.070443 ; 8125.021083 ; 6557.712339 ; 9143.058033 ; 3861.167742 ; 5345.30574 ; 3954.957453 ; 6209.971959 ; 4742.93445 ; 7268.468168 ; 8760.928859 ; 4558.151393 ; 8160.246502 ; 5839.223317 ; 6111.914825 ; 4943.423045 ; 3396.656449
EXPERIMENT	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Plex number of the TMT experiment that contained the sample	Sample	1 ; 2 ; 3 ; 4 ; 5 ; 6 ; 7 ; 8 ; 9 ; 10 ; 11 ; 12 ; 13 ; 14 ; 15 ; 16 ; 17 ; 18 ; 19 ; 20 ; 21 ; 22 ; 23 ; 24 ; 25
KEAP1_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	KEAP1 mutations present in sample	Sample	Nonsense_Mutation ; Missense_Mutation ; Frame_Shift_Del ; In_Frame_Del
KEAP1_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any KEAP1 mutations	Sample	0 ; 1
KRAS_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any KRAS mutations	Sample	0 ; 1
MRNA_EXPRESSION_SUBTYPE_TCGA	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	RNA expression subtype for sample based on TCGA classification	Sample	Terminal Respiratory Unit ; Proximal-inflammatory ; Proximal-proliferative
MRNA_STEMNESS_INDEX	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Sample stemness index derived from mRNA data	Sample	0.515138549 ; 0.572553954 ; 0.890017332 ; 0.671643415 ; 0.613638525 ; 0.542321169 ; 0.824549248 ; 0.780610872 ; 0.730123199 ; 0.507683596 ; 0.667436719 ; 0.668486868 ; 0.790175128 ; 0.703120642 ; 0.672709428 ; 0.709873974 ; 0.740176802 ; 0.735741087 ; 0.368620668 ; 0.787216353 ; 0.72801391 ; 0.876461065 ; 0.616713668 ; 0.724226638 ; 0.983008344 ; 0.790917398 ; 0.645480886 ; 0.789541177 ; 0.699357609 ; 0.851296266 ; 0.692436561 ; 0.792356239 ; 0.800928944 ; 0.666516578 ; 0.821199202 ; 0.69262286 ; 0.532562714 ; 0.582230533 ; 0.695205538 ; 0.816805592 ; 0.725373755 ; 0.655102725 ; 0.885137444 ; 0.743551441 ; 0.502009983 ; 0.799701619 ; 0.785093612 ; 0.569120395 ; 0.572914328 ; 0.95197317 ; 0.645846171 ; 0.872320304 ; 0.804773531 ; 0.834125759 ; 0.782059689 ; 0.674386504 ; 0.5668573 ; 1 ; 0.856789454 ; 0.803050549 ; 0.787393338 ; 0.619027969 ; 0.588198262 ; 0.527946196 ; 0.655988823 ; 0.63747055 ; 0.845123025 ; 0.708657459 ; 0.808915721 ; 0.607644466 ; 0.769020392 ; 0.876095788 ; 0.708604168 ; 0.789804186 ; 0.69431562 ; 0.544898059 ; 0.388017634 ; 0.724268378 ; 0.503520014 ; 0.533435458 ; 0.461999652 ; 0.73904517 ; 0.731670255 ; 0.873108689 ; 0.773800399 ; 0.843737352 ; 0.74242011 ; 0.598388879 ; 0.726335964 ; 0.672014397 ; 0.732832432 ; 0.648555852 ; 0.819536071 ; 0.92545065 ; 0.536347523 ; 0.631736173 ; 0.686754507 ; 0.752950692 ; 0.705203109 ; 0.614806867 ; 0.760014977 ; 0.693337343 ; 0.516336698 ; 0.532504975 ; 0.672092164 ; 0.87735708 ; 0.493280918 ; 0.736684443 ; 0.752851517 ; 0.810414459
MUTATION_COUNT_EXCLUDINGINDELS_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Total number of somatic mutations in sample after excluding INDELs, based on WGS mutation calls	Sample	866 ; 573 ; 10330 ; 2318 ; 92 ; 15766 ; 1727 ; 619 ; 3476 ; 24963 ; 769 ; 50848 ; 1223 ; 1054 ; 16981 ; 9577 ; 308 ; 73 ; 24057 ; 23369 ; 62717 ; 1427 ; 24298 ; 71470 ; 1794 ; 963 ; 17578 ; 6468 ; 30779 ; 1472 ; 26730 ; 1129 ; 13209 ; 2221 ; 41560 ; 896 ; 1588 ; 36172 ; 15377 ; 1220 ; 2255 ; 7634 ; 61073 ; 1351 ; 19987 ; 41252 ; 1627 ; 907 ; 24827 ; 1404 ; 1011 ; 3716 ; 10596 ; 1167 ; 931 ; 3993 ; 28901 ; 8318 ; 4450 ; 63649 ; 1154 ; 1373 ; 12192 ; 1721 ; 9931 ; 5149 ; 38641 ; 1519 ; 13976 ; 34920 ; 2429 ; 25948 ; 192876 ; 995 ; 674 ; 27939 ; 956 ; 115 ; 4388 ; 9265 ; 3717 ; 26048 ; 539 ; 4868 ; 2319 ; 4304 ; 1178 ; 101455 ; 46041 ; 7119 ; 2662 ; 375 ; 3221 ; 133 ; 101120 ; 1675 ; 17619 ; 2181 ; 1537 ; 681 ; 2581 ; 407 ; 2504 ; 68123 ; 17720 ; 664 ; 19158
MUTATION_SIGNATURE_ACTIVITY_W1_COSMIC5	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Activity score for COSMIC5 mutation signature, based on WXS mutation calls 	Sample	18.75253398 ; 10.00045566 ; 23.87575525 ; 25.95534146 ; 2.12581547 ; 25.09150097 ; 15.50102212 ; 13.8727398 ; 12.29704642 ; 2.058124774 ; 31.22851041 ; 7.17E-174 ; 37.65268623 ; 30.31292014 ; 16.65479438 ; 19.56133892 ; 6.549378947 ; 20.54229503 ; 1.508375178 ; 103.6366759 ; 16.61703878 ; 18.1935466 ; 35.36191111 ; 35.49228596 ; 14.92866474 ; 3.76E-169 ; 26.26540024 ; 18.89066918 ; 39.84409255 ; 32.65753065 ; 18.90818371 ; 4.28E-81 ; 40.46987846 ; 3.51E-36 ; 30.32790323 ; 33.27470533 ; 26.6977093 ; 17.01726958 ; 17.82817217 ; 28.62179722 ; 21.05344269 ; 5.056204667 ; 9.740679908 ; 19.03358836 ; 10.29968962 ; 36.80115403 ; 15.85975316 ; 23.77203811 ; 40.56514623 ; 32.88691162 ; 30.93614574 ; 88.05101134 ; 31.76981951 ; 18.84724824 ; 27.44470802 ; 13.89128141 ; 8.080228958 ; 45.19683784 ; 40.43685257 ; 22.56348713 ; 14.05017055 ; 22.71239525 ; 30.91800451 ; 14.12691674 ; 38.53092778 ; 5.03E-64 ; 22.29005705 ; 19.09126865 ; 7.650575261 ; 6.92E-212 ; 60.23790621 ; 10.45434911 ; 2.37E-148 ; 21.17369985 ; 18.20070809 ; 68.07690058 ; 14.11219272 ; 2.61854792295861e-322 ; 53.0664895 ; 74.67428033 ; 48.4165069 ; 26.85716724 ; 20.77623317 ; 11.23640835 ; 38.3555863 ; 5.612327555 ; 32.7567476 ; 43.57394573 ; 68.6842684 ; 24.44102235 ; 12.99977772 ; 20.17572813 ; 24.62847276 ; 5.853219955 ; 2.47E-200 ; 23.79106904 ; 32.98057949 ; 34.99758815 ; 62.89688535 ; 24.62508306 ; 24.06086328 ; 21.17344286 ; 196.4600674 ; 6.88E-11 ; 29.04278282 ; 18.27628847 ; 40.86627981
MUTATION_SIGNATURE_ACTIVITY_W2_COSMIC4	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Activity score for COSMIC4 mutation signature, based on WXS mutation calls 	Sample	4.651348286 ; 5.56699992 ; 200.368822 ; 3.699831565 ; 4.264122766 ; 218.9520478 ; 7.874537692 ; 5.624444814 ; 78.77413056 ; 543.3718276 ; 9.542477708 ; 678.7648008 ; 7.815199673 ; 3.43E-82 ; 155.4313825 ; 127.0544052 ; 1.019850742 ; 558.9729274 ; 390.6179032 ; 914.2371465 ; 73.19289458 ; 352.4993524 ; 934.0125266 ; 9.276117229 ; 11.45221097 ; 676.7719299 ; 73.76702129 ; 356.190442 ; 9.846405084 ; 473.5819182 ; 32.45372952 ; 610.560692 ; 5.048408403 ; 738.3347815 ; 11.13331286 ; 4.593385012 ; 536.8270848 ; 200.9379462 ; 3.038405723 ; 3.178433384 ; 179.1914247 ; 986.2289908 ; 109.3879622 ; 497.0484415 ; 400.4728046 ; 2.18E-49 ; 12.21373279 ; 399.3519407 ; 6.83E-102 ; 10.66824315 ; 39.18002864 ; 234.0471 ; 8.983188638 ; 7.985574302 ; 13.74103634 ; 462.4606177 ; 159.3611102 ; 31.32294513 ; 556.4097338 ; 13.33891413 ; 7.679269157 ; 85.15242654 ; 53.09428587 ; 96.31337249 ; 111.1983479 ; 573.7567339 ; 9.329134993 ; 0.912215214 ; 144.7076619 ; 73.92880943 ; 5.903388385 ; 215.1621202 ; 1647.967485 ; 5.136525554 ; 14.85760555 ; 521.1659563 ; 104.1546504 ; 12.7924908 ; 159.1123861 ; 211.0266307 ; 70.7821594 ; 510.7810234 ; 1.34E-192 ; 30.03214098 ; 19.61156191 ; 92.0026262 ; 3.40E-49 ; 7.736763777 ; 646.4524036 ; 656.6200445 ; 161.7645712 ; 1.63E-290 ; 27.76726157 ; 4.569663379 ; 1230.357512 ; 13.10307027 ; 224.8318677 ; 6.269452672 ; 12.45840412 ; 13.37893788 ; 136.4556577 ; 5.000008161 ; 1.5069002198158e-321 ; 1202.966134 ; 419.6143449 ; 9.923782608 ; 298.1757731
MUTATION_SIGNATURE_ACTIVITY_W3_COSMIC2	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Activity score for COSMIC2 mutation signature, based on WXS mutation calls 	Sample	26.92401834 ; 1.959126952 ; 214.4509034 ; 1.297495169 ; 0.49264097 ; 1.57E-105 ; 2.71736105212686e-322 ; 0.918460926 ; 2.030035507 ; 4.83E-168 ; 0 ; 60.02871617 ; 6.829023091 ; 1.484795286 ; 3.448610972 ; 24.2146083 ; 0.171534884 ; 2.069455979 ; 15.48500457 ; 3.78E-271 ; 6.013965529 ; 1.18E-81 ; 5.65E-51 ; 3.712497473 ; 8.17E-190 ; 23.31132413 ; 82.74644033 ; 38.23487842 ; 34.54719281 ; 22.56228358 ; 3.64449962 ; 2.55029573 ; 4.756664763 ; 44.71948644 ; 4.190505251 ; 6.617145998 ; 3.07E-17 ; 3.360202481 ; 96.09144114 ; 4.927037793 ; 33.95020066 ; 3.70E-73 ; 8.20E-42 ; 22.14376475 ; 7.15E-82 ; 9.471744462 ; 1.225806147 ; 15.5983009 ; 4.730262704 ; 6.906836702 ; 12.10770846 ; 20.76250333 ; 9.097915806 ; 9.382369466 ; 7.82E-99 ; 14.99805498 ; 67.27481059 ; 8.761372337 ; 5.005472649 ; 4.543613131 ; 0.852889903 ; 3.450411216 ; 2.494825705 ; 3.187196141 ; 17.0184316 ; 2.408039753 ; 7.022805642 ; 331.1385878 ; 1119.680881 ; 4.392171124 ; 1.39E-22 ; 14.95331624 ; 2.766115592 ; 5.008089492 ; 9.453538262 ; 27.75197308 ; 2.076422446 ; 82.2100834 ; 14.00853742 ; 11.24686021 ; 2.85E-83 ; 17.81392512 ; 4.026810378 ; 43.95416528 ; 0.724826463 ; 1.07E-49 ; 13.81015414 ; 5.22E-07 ; 0.000381788 ; 1.989144878 ; 1.490198445 ; 0.322749738 ; 7.50E-90 ; 5.935778048 ; 1.84052148 ; 17.75660602 ; 15.65440109 ; 11.54192825 ; 1.17E-195 ; 113.137556 ; 85.53382156 ; 25.42930397 ; 0.058710432 ; 25.1618798
NMF_CLUSTER_MEMBERSHIP	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Membership score for the NMF cluster ID indicating strength of similarity to cluster centroid	Sample	0.455 ; 0.633 ; 0.428 ; 0.808 ; 0.947 ; 0.761 ; 1 ; 0.515 ; 0.693 ; 0.845 ; 0.843 ; 0.647 ; 0.909 ; 0.363 ; 0.605 ; 0.758 ; 0.739 ; 0.535 ; 0.667 ; 0.764 ; 0.669 ; 0.797 ; 0.532 ; 0.651 ; 0.537 ; 0.89 ; 0.836 ; 0.56 ; 0.714 ; 0.584 ; 0.854 ; 0.831 ; 0.61 ; 0.514 ; 0.533 ; 0.81 ; 0.661 ; 0.706 ; 0.382 ; 0.41 ; 0.862 ; 0.498 ; 0.419 ; 0.847 ; 0.655 ; 0.986 ; 0.86 ; 0.809 ; 0.865 ; 0.837 ; 0.556 ; 0.876 ; 0.407 ; 0.4 ; 0.627 ; 0.642 ; 0.944 ; 0.51 ; 0.954 ; 0.73 ; 0.458 ; 0.883 ; 0.618 ; 0.958 ; 0.504 ; 0.653 ; 0.525 ; 0.643 ; 0.924 ; 0.721 ; 0.772 ; 0.846 ; 0.567 ; 0.786 ; 0.588 ; 0.536 ; 0.544 ; 0.538 ; 0.734 ; 0.787 ; 0.392 ; 0.587 ; 0.939 ; 0.871 ; 0.768 ; 0.517 ; 0.895 ; 0.453 ; 0.713 ; 0.645 ; 0.866 ; 0.472 ; 0.774 ; 0.59 ; 0.962 ; 0.811 ; 0.879 ; 0.441 ; 0.505 ; 0.801 ; 0.543
NMF_CONSENSUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Cluster ID derived from mutli-omics NMF clustering	Sample	C4 ; C3 ; C1 ; C2
NUMBER_SOMATIC_MUTATIONS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Total number of non-synonymous somatic mutations in sample, based on WXS mutation calls	Sample	40 ; 19 ; 378 ; 27 ; 5 ; 220 ; 23 ; 20 ; 77 ; 487 ; 34 ; 643 ; 54 ; 32 ; 149 ; 158 ; 10 ; 1 ; 515 ; 347 ; 890 ; 90 ; 322 ; 850 ; 47 ; 612 ; 151 ; 357 ; 72 ; 443 ; 55 ; 563 ; 49 ; 652 ; 41 ; 499 ; 210 ; 86 ; 33 ; 216 ; 860 ; 108 ; 472 ; 367 ; 26 ; 396 ; 67 ; 281 ; 39 ; 413 ; 167 ; 137 ; 35 ; 21 ; 94 ; 81 ; 101 ; 141 ; 543 ; 29 ; 422 ; 1000 ; 69 ; 209 ; 1443 ; 28 ; 37 ; 540 ; 129 ; 13 ; 265 ; 263 ; 119 ; 471 ; 38 ; 42 ; 95 ; 89 ; 30 ; 45 ; 625 ; 569 ; 152 ; 50 ; 24 ; 1075 ; 218 ; 57 ; 157 ; 260 ; 1117 ; 398 ; 325
PACK_YEARS_SMOKED	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Product of the number of packs smoked per day by the number of years the person has smoked	Patient	
PUTATIVE_DRIVER_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Putative driver mutation for samples missing a traditional driver mutation	Sample	ALK-Fusion ; BRAF-Missense ; RET-Fusion ; CCNG1-AMP ; STK11-SV ; HRAS-Missense ; NRAS-Missense ; EGFR-AMP ; TP53-SV ; ROS1-Fusion ; CDK4-AMP ; ERBB2-Inframe
RB1_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	RB1 mutations present in sample	Sample	Splice_Site ; Nonsense_Mutation ; Splice_Site;Missense_Mutation ; Missense_Mutation ; Frame_Shift_Del
RB1_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any RB1 mutations	Sample	0 ; 1
REGION_OF_ORIGIN	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Geographical region; samples from China and Vietnam are marked as 'asian'; all other countries fall under 'western'	Patient	
RET_FUSION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator of RET fusions in sample	Sample	0 ; 1
ROS1_FUSION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator of ROS1 fusions in sample	Sample	0 ; 1
SECONDHAND_SMOKE	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	Was the participant exposed to second hand smoke	Patient	
SMOKING_SCORE_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Smoking score derived from WGS-based mutations and smoking signature (see Supp Fig S6B)	Patient	
SMOKING_SIGNATURE_FRACTION_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Fraction of WGS-based mutations contributing to smoking signature	Patient	
STK11_MUTATION	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	STRING	STK11 mutations present in sample	Sample	Splice_Site ; Nonsense_Mutation ; Missense_Mutation ; Frame_Shift_Ins
STK11_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any STK11 mutations	Sample	0 ; 1
TOTAL_DNP_COUNT_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Total number of di-nucleotide polymorphisms (DNP) in sample, based on WGS mutation calls	Sample	4 ; 5 ; 140 ; 14 ; 0 ; 249 ; 8 ; 82 ; 422 ; 2 ; 762 ; 292 ; 153 ; 315 ; 455 ; 793 ; 26 ; 358 ; 986 ; 221 ; 67 ; 425 ; 301 ; 18 ; 114 ; 11 ; 556 ; 484 ; 326 ; 3 ; 13 ; 155 ; 842 ; 22 ; 260 ; 776 ; 563 ; 9 ; 56 ; 135 ; 24 ; 516 ; 139 ; 28 ; 1388 ; 237 ; 121 ; 68 ; 664 ; 7 ; 125 ; 216 ; 534 ; 2650 ; 460 ; 64 ; 132 ; 37 ; 381 ; 85 ; 70 ; 1840 ; 721 ; 79 ; 12 ; 1 ; 39 ; 1156 ; 291 ; 6 ; 49 ; 15 ; 994 ; 290 ; 303
TOTAL_MUTATION_COUNT_WGS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Total number of somatic mutations in sample, based on WGS mutation calls	Sample	942 ; 626 ; 10869 ; 2476 ; 97 ; 16706 ; 1838 ; 664 ; 3728 ; 26439 ; 828 ; 53339 ; 1303 ; 1155 ; 18100 ; 10174 ; 325 ; 88 ; 25347 ; 24878 ; 65843 ; 1540 ; 25643 ; 74770 ; 1936 ; 1032 ; 18603 ; 6846 ; 32351 ; 1619 ; 28171 ; 1230 ; 13853 ; 2399 ; 43793 ; 976 ; 1697 ; 38126 ; 16396 ; 1274 ; 2408 ; 8165 ; 64290 ; 1464 ; 21039 ; 43670 ; 1758 ; 986 ; 1534 ; 1078 ; 3981 ; 11195 ; 1264 ; 1031 ; 4233 ; 30602 ; 8832 ; 4720 ; 67335 ; 1269 ; 1516 ; 12858 ; 1839 ; 10513 ; 5510 ; 40808 ; 1088 ; 1625 ; 14623 ; 35682 ; 2574 ; 27728 ; 203771 ; 1065 ; 733 ; 29648 ; 1023 ; 125 ; 4706 ; 9875 ; 3942 ; 27570 ; 580 ; 5205 ; 2463 ; 4566 ; 615 ; 1279 ; 107898 ; 48503 ; 7478 ; 2917 ; 411 ; 3408 ; 144 ; 105694 ; 1783 ; 18593 ; 2295 ; 1667 ; 764 ; 2832 ; 452 ; 2616 ; 71923 ; 18774 ; 721 ; 20247
TP53_MUTATION_STATUS	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Binary indicator for presence of any TP53 mutations	Sample	0 ; 1
TSNET PURITY	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Purity estimate derived from TSNet score	Sample	0.51806364 ; 0.840421591 ; 0.688116768 ; 0.522514491 ; 0.900639428 ; 0.344294829 ; 0.828393635 ; 0.769371147 ; 0.711808008 ; 0.73921556 ; 0.594848329 ; 0.589567408 ; 0.68618818 ; 0.892435735 ; 0.648070796 ; 0.966578093 ; 0.757978692 ; 0.817743512 ; 0.407616908 ; 0.727455822 ; 0.826501281 ; 0.905797096 ; 0.398414343 ; 0.830571933 ; 0.985895154 ; 0.812836705 ; 0.715050071 ; 0.507395137 ; 0.572038982 ; 0.709960866 ; 0.494527584 ; 0.831158301 ; 0.504689873 ; 0.550540083 ; 0.69503521 ; 0.469223165 ; 0.763427947 ; 0.691805375 ; 0.6541561 ; 0.658987516 ; 0.546289963 ; 0.997155027 ; 0.56154546 ; 0.773668579 ; 0.437682107 ; 0.735846747 ; 0.99921136 ; 0.599242247 ; 0.702519713 ; 0.680471594 ; 0.696171683 ; 0.711961492 ; 0.536688679 ; 0.741351743 ; 0.749306841 ; 0.777689851 ; 0.836497054 ; 0.900382591 ; 0.922124976 ; 0.996200331 ; 0.965513672 ; 0.810692935 ; 0.762155347 ; 0.811480603 ; 0.55802069 ; 0.998641224 ; 0.723304647 ; 0.770613065 ; 0.786814906 ; 0.74301049 ; 0.639354182 ; 0.893548909 ; 0.736513074 ; 0.796764737 ; 0.636616395 ; 0.543647218 ; 0.843234869 ; 0.639362505 ; 0.048837663 ; 0.063786811 ; 0.748096267 ; 0.568997156 ; 0.653444563 ; 0.847807606 ; 0.467864564 ; 0.847240415 ; 0.581121323 ; 0.644005063 ; 0.770955627 ; 0.853313745 ; 0.835503132 ; 0.943902096 ; 0.675222127 ; 0.92839963 ; 0.465940486 ; 0.587198849 ; 0.431033682 ; 0.878232641 ; 0.817455569 ; 0.904509177 ; 0.631271602 ; 0.823713388 ; 0.504111648 ; 0.451938726 ; 0.822916556 ; 0.391429887 ; 0.723043553 ; 0.664115596 ; 0.751306961 ; 0.987474466
TUMOR_PURITY_BYESTIMATE_RNASEQ	Gainsboro	Lung Adenocarcinoma (CPTAC, Cell 2020)	NUMBER	Tumor purity derived by applying the ESTIMATE algorithm to RNA data	Sample	0.522233472 ; 0.674321767 ; 0.451350157 ; 0.707749971 ; 0.384625519 ; 0.719140036 ; 0.655340111 ; 0.67053895 ; 0.687434496 ; 0.472440241 ; 0.559222582 ; 0.54546523 ; 0.728907539 ; 0.538307332 ; 0.804636118 ; 0.675185459 ; 0.713668461 ; 0.351476701 ; 0.611129898 ; 0.723865437 ; 0.760926497 ; 0.475725477 ; 0.699331642 ; 0.769077065 ; 0.633348788 ; 0.620129076 ; 0.472088355 ; 0.563806322 ; 0.669199514 ; 0.481679256 ; 0.699351021 ; 0.509327714 ; 0.431392327 ; 0.633898867 ; 0.416780975 ; 0.631111347 ; 0.639764059 ; 0.569717075 ; 0.541380714 ; 0.491377837 ; 0.87168665 ; 0.531829634 ; 0.62917401 ; 0.447733645 ; 0.624889096 ; 0.890619267 ; 0.537970793 ; 0.603873195 ; 0.611051565 ; 0.684366165 ; 0.630581133 ; 0.530820939 ; 0.693979387 ; 0.671534479 ; 0.699991987 ; 0.582011583 ; 0.770499914 ; 0.724374848 ; 0.854110748 ; 0.756088512 ; 0.7385595 ; 0.62283772 ; 0.703196264 ; 0.548357068 ; 0.863047938 ; 0.622632334 ; 0.70012662 ; 0.719908978 ; 0.583914987 ; 0.460827981 ; 0.679153866 ; 0.600956195 ; 0.679406916 ; 0.576159752 ; 0.539628419 ; 0.766097014 ; 0.568608092 ; 0.256627535 ; 0.223226816 ; 0.678206545 ; 0.53756111 ; 0.581003327 ; 0.732047806 ; 0.467063567 ; 0.752120386 ; 0.5596731 ; 0.614639246 ; 0.702755179 ; 0.740846909 ; 0.762792106 ; 0.749053152 ; 0.605758121 ; 0.746367807 ; 0.475643916 ; 0.589765594 ; 0.39836447 ; 0.761731556 ; 0.664154562 ; 0.754334479 ; 0.616679453 ; 0.705943832 ; 0.535571967 ; 0.44120101 ; 0.73020374 ; 0.469317999 ; 0.638462068 ; 0.628117626 ; 0.699062134 ; 0.779270172
NONSILENT_PER_MB	Gainsboro	Lung Squamous Cell Carcinoma (TCGA, Nature 2012)	NUMBER	Non Silent per Mb	Sample	8.07 ; 6.77 ; 2.97 ; 69.6 ; 10.45 ; 10.56 ; 7.42 ; 11.37 ; 5 ; 16.02 ; 6.76 ; 13.99 ; 13.5 ; 7.72 ; 3.9 ; 3.71 ; 7.02 ; 5.34 ; 12.41 ; 4.56 ; 7.38 ; 1.71 ; 4.48 ; 9.79 ; 5.35 ; 9.94 ; 10.72 ; 2.84 ; 5.51 ; 2.52 ; 6.35 ; 7.79 ; 5.43 ; 4.36 ; 7.59 ; 8.89 ; 4.72 ; 6.2 ; 2.37 ; 15.03 ; 6.27 ; 9.54 ; 18.16 ; 2.7 ; 4.01 ; 4.46 ; 3.81 ; 4 ; 5.22 ; 6.03 ; 8.62 ; 5.56 ; 8.77 ; 6.98 ; 4.55 ; 5.25 ; 30.33 ; 4.63 ; 12.62 ; 8.42 ; 5.93 ; 12.15 ; 3.53 ; 15.14 ; 4.2 ; 4.82 ; 5.29 ; 5.61 ; 0.03 ; 6.65 ; 9.29 ; 4.76 ; 8.61 ; 16.54 ; 6.7 ; 6.84 ; 7.84 ; 19.06 ; 8.34 ; 4.16 ; 3.46 ; 6.93 ; 5.04 ; 7.89 ; 3.58 ; 6.45 ; 14.67 ; 3.66 ; 7.23 ; 5.65 ; 4.14 ; 5.57 ; 10.91 ; 16.07 ; 7.92 ; 4.07 ; 4.74 ; 13.39 ; 8.16 ; 11.14 ; 21.93 ; 4.6 ; 4.93 ; 8.88 ; 6.79 ; 4.75 ; 4.59 ; 2.66 ; 3.65 ; 8.13 ; 28.87 ; 2.95 ; 4.73 ; 4.44 ; 4.83 ; 2.8 ; 2.12 ; 5.83 ; 4.21 ; 10.16 ; 1.93 ; 7.54 ; 6.56 ; 7.81 ; 3.48 ; 6.29 ; 7.17 ; 6.91 ; 8.27 ; 7.28 ; 9.09 ; 8.78 ; 4.67 ; 12.06 ; 6.42 ; 10.14 ; 9.25 ; 2.51 ; 8.72 ; 8.18 ; 5.89 ; 5.46 ; 6.69 ; 13.31 ; 4.08 ; 3.33 ; 3.08 ; 3.41 ; 8.05 ; 5.79 ; 5.68 ; 15.44 ; 5.17 ; 9.48 ; 9.65 ; 4.71 ; 7.62 ; 3.72 ; 11.95 ; 5.27 ; 6.75 ; 2.85 ; 1.46 ; 10.57 ; 24.26
PDX_SAMPLE_DAYS_FROM_DIAGNOSIS	Gainsboro	Thoracic PDX (MSK, Provisional)	NUMBER	PDX Sample Days from Diagnosis	Sample	563 ; 24 ; 257 ; 1786 ; 974 ; 36 ; 0 ; 790 ; 119 ; 97 ; 261 ; 2364 ; 19 ; 299 ; 170 ; 207 ; 59 ; 1419 ; 22 ; 161 ; 20 ; 1837 ; 154 ; 211 ; 93 ; 27 ; 2258 ; 92 ; 945 ; 780 ; 263 ; 222 ; 623 ; 286 ; 1503 ; 1924 ; 43 ; 68 ; 691 ; 1399 ; 858 ; 727 ; 865 ; 273 ; 455 ; 491 ; 104 ; 187 ; 420 ; 267 ; 14 ; 362 ; 334 ; 132 ; 28 ; 13 ; 1 ; 51 ; 18 ; 33 ; 15
PRETREATED	Gainsboro	Thoracic PDX (MSK, Provisional)	STRING	Pre-treated	Patient	
CDKN2A_PATHWAY_ALTERATION_STATUS	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Binary indicator for presence of mutations on genes in the CDKN2A pathway	Sample	1 ; 0
CHANNEL	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	TMT channel containing the sample	Sample	128C ; 130C ; 129C ; 127C ; 126C
CIBERSORT_ABSOLUTESCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	RNA based CIBERSORT absolute score	Sample	0.371967892 ; 0.813604757 ; 0.500121402 ; 0.833328294 ; 0.820578526 ; 0.791634975 ; 1.227991053 ; 0.474407948 ; 0.535089514 ; 0.401633506 ; 0.834067908 ; 0.245094415 ; 1.124357243 ; 0.745096983 ; 0.685533995 ; 0.696342904 ; 0.628598539 ; 0.471381244 ; 0.796423269 ; 0.31968123 ; 1.406930866 ; 0.580456631 ; 1.135092631 ; 0.69226717 ; 0.471099145 ; 0.84429172 ; 0.997659706 ; 0.653922516 ; 1.058943299 ; 0.590148882 ; 1.09171524 ; 0.60526841 ; 0.657768869 ; 0.417587488 ; 0.910291588 ; 0.930966247 ; 0.63281689 ; 0.582104725 ; 1.021976625 ; 0.946090393 ; 0.987971394 ; 0.905132003 ; 1.080201238 ; 1.196598344 ; 0.658931696 ; 0.489236974 ; 1.474430136 ; 0.342153265 ; 1.115206455 ; 0.567680151 ; 0.277995154 ; 0.58769922 ; 1.142319931 ; 0.56740535 ; 0.438515547 ; 0.263098549 ; 1.43642525 ; 1.236468588 ; 0.62975349 ; 0.657761592 ; 0.962311529 ; 0.399674163 ; 0.941250283 ; 0.987737749 ; 0.435004378 ; 0.458821286 ; 0.819163429 ; 1.052595092 ; 0.84760469 ; 0.243104715 ; 0.213115445 ; 0.697009427 ; 0.715563681 ; 0.853344456 ; 0.715525883 ; 0.562575448 ; 0.528732236 ; 0.549183 ; 0.428153575 ; 0.880137132 ; 0.414616998 ; 0.578967781 ; 0.954786477 ; 0.456886602 ; 0.251408372 ; 1.226074891 ; 0.634899568 ; 0.333120778 ; 0.588517635 ; 1.045433004 ; 1.142190683 ; 0.374751673 ; 1.112891985 ; 0.708578807 ; 0.912693717 ; 0.748830462 ; 0.462508435 ; 1.293159476 ; 0.444930701 ; 0.58595956 ; 0.408285713 ; 0.864743969 ; 0.250478589 ; 0.321202302 ; 0.852812255 ; 0.919901584 ; 0.303012049 ; 0.475343566
CIMP_STATUS_METH	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	CIMP status - See STAR methods CpG Island Methylator Phenotype	Sample	CIMP-high ; CIMP-intermediate ; CIMP-low
CIN	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Chromosome instability index (CIN) derived from whole exome data	Sample	5.760979799 ; 2.46041786 ; 4.764818591 ; 2.27211906 ; 5.169279956 ; 2.76942064 ; 0.981444187 ; 5.170868313 ; 4.685940174 ; 4.589964998 ; 4.321691962 ; 9.298195231 ; 1.998561606 ; 1.815571256 ; 2.827353359 ; 1.58399587 ; 4.329913424 ; 5.148229445 ; 2.369230783 ; 6.13682543 ; 0.217310621 ; 4.242922298 ; 0.698632123 ; 4.927278181 ; 5.899207053 ; 2.690806281 ; 0.926117122 ; 2.951011267 ; 2.55239971 ; 4.681450761 ; 0.924567809 ; 3.151910056 ; 2.361840612 ; 6.054765747 ; 1.728411228 ; 2.422352188 ; 4.372802464 ; 2.751589873 ; 2.315541489 ; 1.742708465 ; 1.432669778 ; 2.178077412 ; 3.696400948 ; 2.986930551 ; 4.837699013 ; 2.898583797 ; 0.615396271 ; 4.616781951 ; 3.746781421 ; 4.98665751 ; 7.097788811 ; 4.619285267 ; 1.949737502 ; 2.916868337 ; 2.641541689 ; 6.321320627 ; 0.471041174 ; 2.20803303 ; 4.209129154 ; 3.23323357 ; 2.236293671 ; 6.095146192 ; 2.753151832 ; 1.823283408 ; 7.319048468 ; 5.086841313 ; 2.426646763 ; 1.973284831 ; 3.810014264 ; 8.033923122 ; 6.281448192 ; 2.746337565 ; 4.603090057 ; 1.569706634 ; 2.813301688 ; 2.799867554 ; 3.806549654 ; 4.888395205 ; 5.457733093 ; 2.105085155 ; 6.02396797 ; 4.498572393 ; 3.149706071 ; 4.280301673 ; 6.777583656 ; 1.973708752 ; 3.124377331 ; 5.559477231 ; 3.975719766 ; 2.578740722 ; 1.587768958 ; 6.570004761 ; 1.77855862 ; 2.902580107 ; 1.820540601 ; 2.693892212 ; 7.176490171 ; 0.661171743 ; 4.310297843 ; 4.153870066 ; 5.375710149 ; 3.832577599 ; 7.859251913 ; 7.999791959 ; 3.127962124 ; 1.364998346 ; 6.968039549 ; 5.813947859
DNP_COUNT	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Count of  di-nucleotide polymorphisms (DNP) using WES mutation calls	Sample	5 ; 0 ; 2 ; 4 ; 7 ; 1 ; 3 ; 11 ; 8 ; 13 ; 6 ; 14 ; 9 ; 10 ; 15
DNP_COUNT_GG_TO_TT_OR_CC_TO_AA	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Count of GG -> TT or CC -> AA di-nucleotide polymorphisms (DNP) using WES mutation calls	Sample	2 ; 0 ; 4 ; 3 ; 7 ; 1 ; 5 ; 11 ; 6 ; 12 ; 9 ; 8
ESTIMATE_IMMUNESCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	ESTIMATE derived immune score	Sample	1850.506227 ; 3634.43975 ; 2319.926138 ; 4169.841088 ; 3534.985365 ; 3985.547093 ; 5394.605807 ; 2905.109589 ; 2153.902015 ; 1279.41044 ; 4490.011898 ; 405.9361769 ; 5330.954372 ; 3788.126479 ; 3717.742861 ; 3416.926084 ; 3230.676188 ; 2581.261611 ; 3842.135408 ; 989.7751726 ; 6101.857591 ; 3238.663307 ; 5078.629536 ; 3393.6251 ; 2143.304772 ; 4175.356362 ; 4760.171622 ; 3543.548394 ; 5236.915937 ; 3381.326228 ; 5360.811859 ; 3001.833 ; 3448.568682 ; 1792.294911 ; 4593.819494 ; 4321.309358 ; 3641.188383 ; 3189.465391 ; 4690.666641 ; 4502.871065 ; 4888.47203 ; 4791.029058 ; 5016.444478 ; 5615.102666 ; 3306.966702 ; 2437.643978 ; 6337.836177 ; 1030.660461 ; 5307.990585 ; 2653.320475 ; 392.1605065 ; 3057.315488 ; 5256.626476 ; 3423.615783 ; 2683.226122 ; 879.0686847 ; 6363.07783 ; 5869.831689 ; 3059.379486 ; 2983.714916 ; 5475.819032 ; 1683.861449 ; 4596.162128 ; 5252.15159 ; 2125.681793 ; 2468.396446 ; 4308.590147 ; 5231.733126 ; 4395.17512 ; -1291.375658 ; 492.6068172 ; 3545.714287 ; 3441.625789 ; 4216.91846 ; 3440.911159 ; 3256.998535 ; 2760.181995 ; 2535.938929 ; 1998.733848 ; 4746.88533 ; 1619.103767 ; 2305.586789 ; 4367.50292 ; 2270.373186 ; 677.0660767 ; 5801.631417 ; 3019.218248 ; 1900.006843 ; 3019.749921 ; 5279.202393 ; 5482.557939 ; 1535.340501 ; 5356.796508 ; 3355.652697 ; 4145.097187 ; 4114.969921 ; 2039.499775 ; 5607.358679 ; 1976.720418 ; 3430.34343 ; 1272.795569 ; 4459.794998 ; 851.7828005 ; 810.1854415 ; 3968.281851 ; 4828.098027 ; 1078.337822 ; 2007.443275
ESTIMATE_STROMALSCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	ESTIMATE derived stromal score	Sample	1977.164185 ; 316.4334554 ; 1851.651989 ; 2934.152644 ; 571.6210987 ; 1868.140234 ; 2666.730156 ; 1017.846728 ; 1088.942389 ; -265.785718 ; 1920.806633 ; -66.00068451 ; 3188.268729 ; 1416.056017 ; 2665.0108 ; 3552.596768 ; 856.3040033 ; 1549.595937 ; 2882.84311 ; 263.5490931 ; 3969.386886 ; 2943.263224 ; 3408.617531 ; 611.4170886 ; 1046.082882 ; 3111.997302 ; 4156.995182 ; 2095.626925 ; 1732.632979 ; 426.592805 ; 3940.309809 ; 1330.043234 ; 1510.735745 ; 201.8849668 ; 2117.11796 ; 3143.345677 ; 920.8529233 ; 2279.934951 ; 2534.059659 ; 3261.321144 ; 3352.64582 ; 2032.488734 ; 1789.436472 ; 2100.730623 ; 565.1084016 ; 748.7237123 ; 2871.356984 ; 461.2599321 ; 2644.175919 ; 1501.737131 ; -1388.407551 ; 1215.070048 ; 3102.914509 ; 3471.221966 ; 3248.848901 ; 350.7140613 ; 3233.221568 ; 2743.635409 ; 703.9485985 ; 325.9981739 ; 2443.867503 ; 577.8811275 ; 1997.70181 ; 1856.069132 ; 849.8606375 ; 2080.23161 ; 2617.701441 ; 2458.857871 ; 1993.984792 ; -1629.023315 ; -860.8692038 ; 1841.386738 ; 1037.334852 ; 3288.312958 ; 1675.322596 ; 3216.048123 ; 1501.240393 ; -95.14846075 ; -160.7223747 ; 3833.584163 ; -230.5713959 ; 2135.90916 ; 1835.319666 ; 1736.528024 ; -722.0595604 ; 2355.502071 ; 1032.147856 ; 2134.564522 ; 2527.175673 ; 2381.820826 ; 2442.905632 ; 373.7716887 ; 2864.308445 ; 1204.26131 ; 1932.893524 ; 747.6744461 ; 2309.961514 ; 3268.609096 ; 542.6763898 ; 1181.692526 ; 501.3419936 ; 1667.037394 ; -1227.999109 ; -535.4826503 ; 2914.103002 ; 2704.154485 ; 4.920723779 ; -411.053063
FGFR3_TACC3_FUSION	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Binary indicator for presence of fusion (1= present, 0- absent)	Sample	0 ; 1
IMMUNECLUSTER	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Immune cluster	Sample	Warm Tumor ; Cold Tumor ; Hot Tumor
MUTATION_COUNT_EXCLUDINGINDELS	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Mutation Count ExcludingINDELs	Sample	328 ; 164 ; 200 ; 271 ; 206 ; 334 ; 186 ; 227 ; 342 ; 273 ; 450 ; 283 ; 176 ; 333 ; 385 ; 124 ; 346 ; 191 ; 336 ; 237 ; 4 ; 418 ; 82 ; 437 ; 230 ; 64 ; 262 ; 392 ; 562 ; 90 ; 318 ; 296 ; 312 ; 219 ; 316 ; 581 ; 566 ; 102 ; 427 ; 152 ; 256 ; 270 ; 274 ; 424 ; 62 ; 280 ; 204 ; 457 ; 172 ; 130 ; 201 ; 41 ; 330 ; 31 ; 311 ; 255 ; 260 ; 252 ; 683 ; 308 ; 415 ; 143 ; 299 ; 543 ; 692 ; 559 ; 339 ; 234 ; 250 ; 699 ; 81 ; 243 ; 231 ; 52 ; 211 ; 266 ; 267 ; 286 ; 238 ; 337 ; 166 ; 134 ; 47 ; 341 ; 190 ; 442 ; 259 ; 470 ; 222 ; 12 ; 569 ; 129 ; 251 ; 240 ; 74 ; 325 ; 264
MUTATION_COUNT_EXCLUDING_SILENT	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Number of somatic mutations exluding silent (synonymous) mutations	Sample	272 ; 140 ; 184 ; 312 ; 175 ; 283 ; 161 ; 210 ; 294 ; 265 ; 415 ; 245 ; 194 ; 279 ; 422 ; 120 ; 318 ; 305 ; 215 ; 10 ; 364 ; 150 ; 393 ; 220 ; 79 ; 222 ; 343 ; 471 ; 97 ; 284 ; 255 ; 276 ; 213 ; 302 ; 512 ; 94 ; 369 ; 157 ; 183 ; 201 ; 250 ; 391 ; 132 ; 244 ; 204 ; 409 ; 139 ; 280 ; 133 ; 199 ; 40 ; 57 ; 232 ; 162 ; 229 ; 620 ; 290 ; 376 ; 143 ; 267 ; 459 ; 178 ; 596 ; 461 ; 319 ; 249 ; 675 ; 74 ; 231 ; 211 ; 170 ; 233 ; 240 ; 282 ; 205 ; 300 ; 223 ; 152 ; 45 ; 299 ; 414 ; 273 ; 389 ; 20 ; 456 ; 474 ; 119 ; 216 ; 206 ; 230 ; 64 ; 241
NMF_SUBTYPE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Cluster ID derived from multi-omics NMF clustering for tumor samples	Sample	Classical ; Basal inclusive ; Proliferative primitive ; Inflamed secretory ; EMT enriched
NMF_SUBTYPE_CORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Same as NMF.subtype but tumors with NMF membership score <=0.5 are designated as Mixed subtype	Sample	Classical ; Basal inclusive ; Mixed subtype ; Proliferative primitive ; Inflamed secretory ; EMT enriched
NMF_SUBTYPE_MEMBERSHIP_SCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Membership score for the NMF cluster ID indicating strength of similarity to cluster centroid	Sample	0.663 ; 0.759 ; 0.682 ; 0.457 ; 0.867 ; 0.466 ; 0.656 ; 0.429 ; 0.746 ; 0.416 ; 0.659 ; 0.673 ; 0.584 ; 0.719 ; 0.761 ; 0.851 ; 0.736 ; 0.504 ; 0.925 ; 0.574 ; 0.657 ; 0.521 ; 0.572 ; 0.585 ; 0.781 ; 0.932 ; 0.695 ; 0.409 ; 0.956 ; 0.556 ; 0.45 ; 0.461 ; 0.514 ; 0.519 ; 0.372 ; 0.448 ; 0.578 ; 0.524 ; 0.529 ; 0.711 ; 0.468 ; 0.617 ; 0.667 ; 0.444 ; 0.972 ; 0.485 ; 0.571 ; 0.498 ; 1 ; 0.376 ; 0.751 ; 0.569 ; 0.974 ; 0.992 ; 0.635 ; 0.939 ; 0.473 ; 0.462 ; 0.421 ; 0.53 ; 0.407 ; 0.43 ; 0.47 ; 0.732 ; 0.527 ; 0.704 ; 0.741 ; 0.51 ; 0.861 ; 0.733 ; 0.795 ; 0.865 ; 0.907 ; 0.566 ; 0.401 ; 0.638 ; 0.718 ; 0.965 ; 0.716 ; 0.708 ; 0.71 ; 0.599 ; 0.422 ; 0.641 ; 0.494 ; 0.929 ; 0.621 ; 0.525 ; 0.39 ; 0.582 ; 0.445 ; 0.911 ; 0.786
PATHOLOGY_BASED_HISTOLOGY_ASSESSMENT	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Pathology based assessment of all 108 LSCC tumors used in this study	Sample	classical SqCC ; MD SqCC with focal basaloid features ; PD SqCC with basaloid features ; SqCC ; MD SqCC with basaloid features ; Basaloid SqCC ; MD-PD SqCC  with basaloid features ; MD SqCC ; SqCC with myxoid stroma, fibroblasts ; MD-PD SqCC  with clear cell features ; PD SqCC ; Adenosquamous? With dominate SqCC ; PD SqCC with basaloid and sarcomatoid features ; MD-PD SqCC ; MD  SqCC
PIK3CA_PATHWAY_ALTERATION_STATUS	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Binary indicator for presence of mutations on genes in the PIK3CA pathway	Sample	1 ; 0
SMOKING_SCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	WES derived smoking score. For details see STAT methods	Sample	0.9982 ; 0.8809 ; 0.7959 ; 0.9993 ; 0.9994 ; 0.9997 ; 0.9529 ; 0.9586 ; 0.9922 ; 0.9929 ; 1 ; 0.9969 ; 0.9788 ; 0.9984 ; 0.905 ; 0.9999 ; 0.8192 ; 0.9998 ; 0.9575 ; 0.3115 ; 0.9857 ; 0.9957 ; 0.8048 ; 0.9972 ; 0.999 ; 0.8472 ; 0.9976 ; 0.9866 ; 0.9995 ; 0.8914 ; 0.96 ; 0.9986 ; 0.9991 ; 0.8967 ; 0.918 ; 0.9353 ; 0.9743 ; 0.9965 ; 0.9961 ; 0.08482 ; 0.02451 ; 0.9973 ; 0.9566 ; 0.9887 ; 0.9415 ; 0.9987 ; 0.8188 ; 0.7907 ; 0.978 ; 0.9988 ; 0.9589 ; 0.997 ; 0.7502 ; 0.9203 ; 0.9934 ; 0.1339 ; 0.9937 ; 0.9975 ; 0.9727 ; 0.9706 ; 0.8486 ; 0.7838 ; 0.808 ; 0.622 ; 0.9914 ; 0.8274 ; 0.695 ; 0.9906 ; 0.9974 ; 0.007783 ; 0.9791 ; 0.9746 ; 0.907 ; 0.965 ; 0.9949 ; 0.8846 ; 0.923 ; 0.9892
SMOKING_SCORE_CATEGORY	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Strong or Weak evidence based on Smoking score	Sample	Strong_evidence ; Weak_evidence
SMOKING_SIGNATURE_COUNT	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Number of mutations contributing to smoking siganture	Sample	224.5123161 ; 117.0636102 ; 110.2986024 ; 192.8706742 ; 192.0897723 ; 289.4135577 ; 145.166567 ; 180.1034333 ; 307.0005315 ; 151.6084994 ; 397.760676 ; 220.3844378 ; 90.70427617 ; 193.9250253 ; 280.9472098 ; 101.6544644 ; 293.1444189 ; 113.5633949 ; 301.4413825 ; 188.9374725 ; 3.932887198 ; 348.8614521 ; 72.7668988 ; 351.9803972 ; 190.3112055 ; 176.5146952 ; 53.30526123 ; 159.3876261 ; 222.9634935 ; 526.3549278 ; 41.15189406 ; 253.6237992 ; 278.528966 ; 124.7227055 ; 208.014313 ; 274.5194117 ; 508.8268401 ; 511.3101061 ; 52.21385101 ; 402.0946528 ; 84.07802416 ; 179.8088225 ; 229.8669301 ; 212.6824853 ; 215.1703918 ; 360.7177534 ; 60.71231144 ; 156.4417902 ; 148.1598754 ; 386.8990645 ; 108.0563894 ; 220.6548721 ; 71.51805703 ; 126.0551792 ; 13.21006406 ; 274.8076094 ; 5.405034612 ; 220.5243295 ; 214.2555771 ; 190.0045674 ; 132.3644555 ; 175.6554114 ; 595.9081572 ; 281.5225087 ; 313.2018942 ; 96.94408486 ; 116.9536639 ; 323.0648014 ; 180.1463667 ; 374.9311169 ; 462.733814 ; 245.7920453 ; 181.5037094 ; 209.3769967 ; 373.6082499 ; 59.55116049 ; 165.5446136 ; 173.2218653 ; 169.7027332 ; 17.18043042 ; 163.1716156 ; 202.5925033 ; 224.0612386 ; 238.0135021 ; 265.7706349 ; 116.3539672 ; 225.3521437 ; 131.740108 ; 98.84950354 ; 82.41010858 ; 29.66216202 ; 190.8191419 ; 109.214031 ; 63.74702818 ; 167.9636801 ; 353.1072222 ; 174.8761509 ; 1.969831725 ; 511.5758702 ; 512.2752965 ; 94.21654271 ; 184.1723547 ; 158.5297647 ; 201.0800862 ; 178.5489296 ; 31.65394022 ; 182.4761392 ; 166.9169897
SMOKING_SIGNATURE_FRACTION	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Fraction of WES-based mutations contributing to smoking signature	Sample	0.724414506 ; 0.745628087 ; 0.584548833 ; 0.753580519 ; 1 ; 0.925304349 ; 0.851752067 ; 0.826950134 ; 0.939356113 ; 0.593180554 ; 0.939928268 ; 0.846020854 ; 0.534017371 ; 0.623364936 ; 0.761990449 ; 0.848178524 ; 0.942586357 ; 0.624029095 ; 0.983789896 ; 0.815892622 ; 0.988207147 ; 0.875069771 ; 0.927554138 ; 0.85982796 ; 0.850058022 ; 0.8216493 ; 0.853855714 ; 0.642373597 ; 0.593443288 ; 0.987017517 ; 0.471596886 ; 0.821121653 ; 0.999474672 ; 0.427505223 ; 0.915760312 ; 0.929664395 ; 0.945795802 ; 0.53741244 ; 0.606115726 ; 0.947378669 ; 0.951722077 ; 0.851943084 ; 0.823498267 ; 0.891013151 ; 0.643039965 ; 0.769001621 ; 0.914759829 ; 0.672657569 ; 0.791144686 ; 0.586747276 ; 0.676856774 ; 0.33852548 ; 0.893689904 ; 0.185453381 ; 0.751625416 ; 0.896190712 ; 0.772191259 ; 0.753016356 ; 0.738263312 ; 0.912165428 ; 0.947586264 ; 0.778495146 ; 0.702015071 ; 0.409212816 ; 0.625947223 ; 0.567369712 ; 0.886920973 ; 0.758110464 ; 0.815079796 ; 0.86577215 ; 0.599392165 ; 0.76290432 ; 0.674505002 ; 0.772264155 ; 0.794379678 ; 0.36665002 ; 0.832251665 ; 0.825081162 ; 0.882517682 ; 0.869875395 ; 0.926114913 ; 0.524630559 ; 0.720328748 ; 0.587786617 ; 0.624011289 ; 0.66355986 ; 0.769531151 ; 0.593106572 ; 0.61670293 ; 0.15319672 ; 0.679104991 ; 0.782997719 ; 0.817798311 ; 0.16914526 ; 0.954371346 ; 0.774817012 ; 0.940998405 ; 0.667482754 ; 0.819242827 ; 0.802033708 ; 0.461924558 ; 0.590965153 ; 0.669449783
TCGA_PAN_CAN_IMMUNE_CLUSTERING	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	Immune clustering based on the TCGA pan-cancer study -  Thorsson et al, Immunity, 2018	Sample	Lymphocyte depleted ; IFN-gamma dominant ; Wound Healing ; TGF-beta dominant ; Inflammatory
TCGA_RNA_CLUSTER	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	STRING	RNA expression subtype for the sample based on TCGA classification	Sample	Classical ; Basal ; Primitive ; Secretory ; Unknown
TOTAL_MUTATION_COUNT	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Total number of somatic mutations	Sample	330 ; 165 ; 203 ; 272 ; 208 ; 338 ; 189 ; 228 ; 346 ; 276 ; 452 ; 286 ; 178 ; 334 ; 390 ; 125 ; 349 ; 195 ; 239 ; 4 ; 421 ; 83 ; 441 ; 238 ; 232 ; 64 ; 262 ; 394 ; 567 ; 91 ; 319 ; 297 ; 313 ; 221 ; 584 ; 571 ; 102 ; 428 ; 152 ; 202 ; 261 ; 270 ; 62 ; 283 ; 204 ; 460 ; 172 ; 296 ; 131 ; 201 ; 43 ; 333 ; 32 ; 312 ; 259 ; 260 ; 188 ; 254 ; 684 ; 310 ; 418 ; 146 ; 301 ; 544 ; 191 ; 694 ; 564 ; 340 ; 236 ; 252 ; 719 ; 81 ; 256 ; 245 ; 235 ; 52 ; 215 ; 269 ; 271 ; 289 ; 240 ; 167 ; 134 ; 48 ; 341 ; 445 ; 473 ; 223 ; 12 ; 552 ; 130 ; 206 ; 242 ; 74 ; 328 ; 267
TOTAL_MUTATION_COUNT_PER_MB	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Total number of somatic mutations per megabase (Mb)	Sample	11.330145 ; 5.459931 ; 7.290427 ; 12.340074 ; 6.46986 ; 11.203903 ; 6.53298 ; 7.921633 ; 11.92979 ; 10.478016 ; 16.032633 ; 9.152484 ; 7.511349 ; 11.424825 ; 16.221992 ; 4.670923 ; 11.677307 ; 7.953193 ; 11.614187 ; 8.521279 ; 0.4102838 ; 14.454612 ; 5.996455 ; 15.212062 ; 7.763831 ; 8.489718 ; 2.9982272 ; 9.909932 ; 14.044333 ; 18.462768 ; 3.7556744 ; 11.519506 ; 10.067733 ; 11.708868 ; 7.700711 ; 12.056031 ; 19.567378 ; 20.798228 ; 4.292199 ; 14.549291 ; 6.343619 ; 7.448229 ; 8.110995 ; 10.225535 ; 9.468087 ; 15.653905 ; 5.649292 ; 8.552839 ; 8.079434 ; 15.275183 ; 5.870214 ; 10.79362 ; 5.049647 ; 7.479789 ; 1.6411354 ; 10.509577 ; 2.2407802 ; 9.026243 ; 8.710641 ; 6.406739 ; 8.742201 ; 23.985818 ; 11.235464 ; 15.148943 ; 5.36525 ; 10.572698 ; 19.157098 ; 6.564541 ; 24.080501 ; 18.557452 ; 12.276953 ; 9.499647 ; 25.437597 ; 3.0297876 ; 8.836881 ; 8.395037 ; 7.542909 ; 2.0514194 ; 6.848583 ; 10.698939 ; 9.373407 ; 9.878371 ; 8.61596 ; 11.235463 ; 8.584399 ; 6.185817 ; 5.743973 ; 1.5780142 ; 7.858512 ; 17.074122 ; 10.667378 ; 15.432984 ; 0.8205675 ; 17.76844 ; 19.030855 ; 4.639363 ; 8.174116 ; 8.268796 ; 9.72057 ; 2.6195044 ; 10.8883 ; 9.436527
TSNET_PURITY	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	Purity estimate derived from TSNet score	Sample	0.781920044 ; 0.564153779 ; 0.634757443 ; 0.433151284 ; 0.558364852 ; 0.516698373 ; 0.253414374 ; 0.696322842 ; 0.658292207 ; 0.870384513 ; 0.323642753 ; 0.989241836 ; 0.27091251 ; 0.478788185 ; 0.436116768 ; 0.503000852 ; 0.62692299 ; 0.67710423 ; 0.441475165 ; 0.915552986 ; 0.113640423 ; 0.522784699 ; 0.262624628 ; 0.508074092 ; 0.704957638 ; 0.413940846 ; 0.302541081 ; 0.516159239 ; 0.339259357 ; 0.577779081 ; 0.257275925 ; 0.567951733 ; 0.557690389 ; 0.742925329 ; 0.349460535 ; 0.361346785 ; 0.531167061 ; 0.588831218 ; 0.349439092 ; 0.361162551 ; 0.326244699 ; 0.376158257 ; 0.32023373 ; 0.258518423 ; 0.574294385 ; 0.689344359 ; 0.095055193 ; 0.860867882 ; 0.240276208 ; 0.541734393 ; 0.99 ; 0.521743301 ; 0.300005309 ; 0.5193188 ; 0.659073282 ; 0.913842421 ; 0.072293319 ; 0.212972468 ; 0.596237088 ; 0.607578234 ; 0.263463662 ; 0.782550211 ; 0.371414897 ; 0.333864304 ; 0.758215779 ; 0.671845772 ; 0.427255354 ; 0.286847101 ; 0.402181327 ; 0.490634422 ; 0.51469568 ; 0.383904166 ; 0.540793979 ; 0.568383274 ; 0.630644944 ; 0.695617511 ; 0.799523155 ; 0.343858745 ; 0.833777348 ; 0.693125679 ; 0.407104057 ; 0.69573098 ; 0.238948598 ; 0.58259975 ; 0.786871601 ; 0.549057227 ; 0.213141278 ; 0.293179436 ; 0.862478097 ; 0.241199492 ; 0.589530803 ; 0.368084116 ; 0.487545453 ; 0.743905117 ; 0.219227498 ; 0.704485244 ; 0.534068842 ; 0.770392476 ; 0.437153984 ; 0.983732391 ; 0.933732697 ; 0.442296463 ; 0.315650623 ; 0.87091203 ; 0.789901808
XCELL_IMMUNESCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	xCel Immune score	Sample	0.0834 ; 0.1537 ; 0.0619 ; 0.2164 ; 0.1051 ; 0.1676 ; 0.3495 ; 0.0649 ; 0.0722 ; 0.0271 ; 0.1923 ; 0.0192 ; 0.2241 ; 0.1342 ; 0.1134 ; 0.1142 ; 0.0569 ; 0.0627 ; 0.1621 ; 0.0097 ; 0.7217 ; 0.1339 ; 0.2591 ; 0.1167 ; 0.0221 ; 0.159 ; 0.2202 ; 0.1527 ; 0.3275 ; 0.0931 ; 0.2799 ; 0.0677 ; 0.0687 ; 0.0668 ; 0.2501 ; 0.1531 ; 0.0778 ; 0.1065 ; 0.2743 ; 0.2918 ; 0.3151 ; 0.1861 ; 0.3385 ; 0.3702 ; 0.1402 ; 0.0574 ; 0.8346 ; 0.0491 ; 0.3314 ; 0.0779 ; 0.0068 ; 0.1035 ; 0.3195 ; 0.1379 ; 0.0875 ; 0.0145 ; 0.568 ; 0.4431 ; 0.1294 ; 0.1989 ; 0.323 ; 0.0628 ; 0.2824 ; 0.388 ; 0.024 ; 0.0449 ; 0.1976 ; 0.2771 ; 0.1438 ; 0.0109 ; 0.0019 ; 0.1108 ; 0.1497 ; 0.1859 ; 0.0793 ; 0.1023 ; 0.0738 ; 0.0743 ; 0.0572 ; 0.2097 ; 0.0259 ; 0.0484 ; 0.3265 ; 0.0551 ; 0.0203 ; 0.3985 ; 0.1113 ; 0.0537 ; 0.1683 ; 0.2983 ; 0.3235 ; 0.0187 ; 0.3754 ; 0.1305 ; 0.1868 ; 0.1059 ; 0.0313 ; 0.4435 ; 0.1073 ; 0.1333 ; 0.0281 ; 0.2854 ; 0.0273 ; 0.0127 ; 0.1932 ; 0.326 ; 0.0194 ; 0.0253
XCELL_MICROENVIRONMENTSCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	RNA based xCell derived microenvionment score	Sample	0.0895 ; 0.1565 ; 0.1175 ; 0.3008 ; 0.12 ; 0.2476 ; 0.4972 ; 0.0765 ; 0.1308 ; 0.0283 ; 0.3254 ; 0.0698 ; 0.3514 ; 0.1998 ; 0.2036 ; 0.2392 ; 0.0839 ; 0.0704 ; 0.3066 ; 0.026 ; 0.9502 ; 0.1919 ; 0.4507 ; 0.176 ; 0.0768 ; 0.2837 ; 0.4471 ; 0.2088 ; 0.358 ; 0.1166 ; 0.4779 ; 0.1025 ; 0.1014 ; 0.1078 ; 0.3325 ; 0.3553 ; 0.1034 ; 0.1674 ; 0.3765 ; 0.3864 ; 0.4752 ; 0.2305 ; 0.4039 ; 0.418 ; 0.1446 ; 0.09 ; 0.9624 ; 0.0588 ; 0.4271 ; 0.1497 ; 0.0068 ; 0.148 ; 0.4077 ; 0.1989 ; 0.0342 ; 0.6776 ; 0.5846 ; 0.1373 ; 0.2333 ; 0.4041 ; 0.072 ; 0.3199 ; 0.4416 ; 0.0695 ; 0.1203 ; 0.2877 ; 0.3432 ; 0.2707 ; 0.0244 ; 0.0219 ; 0.1758 ; 0.1839 ; 0.3535 ; 0.1518 ; 0.2527 ; 0.0996 ; 0.086 ; 0.0751 ; 0.3221 ; 0.0386 ; 0.1004 ; 0.3963 ; 0.0807 ; 0.0545 ; 0.5069 ; 0.1248 ; 0.0646 ; 0.243 ; 0.344 ; 0.3835 ; 0.0398 ; 0.5332 ; 0.1379 ; 0.2772 ; 0.1273 ; 0.082 ; 0.5661 ; 0.1722 ; 0.1469 ; 0.2894 ; 0.0292 ; 0.0201 ; 0.2388 ; 0.383 ; 0.0236 ; 0.0301
XCELL_STROMASCORE	Gainsboro	Lung Squamous Cell Carcinoma (CPTAC, Cell 2021)	NUMBER	xCell stroma score	Sample	0.0061 ; 0.0028 ; 0.0556 ; 0.0844 ; 0.0149 ; 0.08 ; 0.1476 ; 0.0116 ; 0.0586 ; 0.0012 ; 0.1331 ; 0.0506 ; 0.1274 ; 0.0656 ; 0.0902 ; 0.125 ; 0.027 ; 0.0076 ; 0.1444 ; 0.0162 ; 0.2285 ; 0.058 ; 0.1917 ; 0.0594 ; 0.0548 ; 0.1247 ; 0.2269 ; 0.0561 ; 0.0305 ; 0.0235 ; 0.198 ; 0.0348 ; 0.0328 ; 0.041 ; 0.0824 ; 0.2022 ; 0.0256 ; 0.061 ; 0.1022 ; 0.0946 ; 0.1601 ; 0.0444 ; 0.0654 ; 0.0478 ; 0.0044 ; 0.0326 ; 0.1278 ; 0.0096 ; 0.0957 ; 0.0718 ; 0 ; 0.0445 ; 0.0881 ; 0.0799 ; 0.0197 ; 0.1096 ; 0.1415 ; 0.0079 ; 0.0344 ; 0.0811 ; 0.0092 ; 0.0375 ; 0.0536 ; 0.0455 ; 0.0754 ; 0.0901 ; 0.0662 ; 0.1269 ; 0.0134 ; 0.02 ; 0.065 ; 0.0342 ; 0.1676 ; 0.0724 ; 0.1504 ; 0.0258 ; 0.0117 ; 0.0179 ; 0.1124 ; 0.0126 ; 0.052 ; 0.0698 ; 0.1084 ; 0.011 ; 0.0747 ; 0.0458 ; 0.06 ; 0.0212 ; 0.1578 ; 0.0074 ; 0.0904 ; 0.0214 ; 0.0507 ; 0.1226 ; 0.0649 ; 0.0136 ; 0.0418 ; 0.004 ; 0.0018 ; 0.0457 ; 0.057 ; 0.0042 ; 0.0048
HLA_LOH	Gainsboro	Lung Cancer in Never Smokers (NCI, Nature Genetics 2021)	STRING	Loss of Heterozygosity in Human Leukocyte Antigen	Sample	Yes
MUTS_SUBCLONAL_RATIO	Gainsboro	Lung Cancer in Never Smokers (NCI, Nature Genetics 2021)	NUMBER	Subclonal Mutation Ratio	Sample	0 ; 0.261606485 ; 0.304592086 ; 0.801623034 ; 0.642575558 ; 0.293922652 ; 0.322142097 ; 0.096986301 ; 0.339449541 ; 0.684563758 ; 0.042119118 ; 0.200110924 ; 0.433823529 ; 0.641434263 ; 0.055963535 ; 0.597318163 ; 0.203284672 ; 0.104421839 ; 0.198430004 ; 0.219115549 ; 0.437287367 ; 0.388 ; 0.53661698 ; 0.226984127 ; 0.296841194 ; 0.042070485 ; 0.200307929 ; 0.026641651 ; 0.303068253 ; 0.247200689 ; 0.110447761 ; 0.104680423 ; 0.213946386 ; 0.441102457 ; 0.27857589 ; 0.041177939 ; 0.076937828 ; 0.152842105 ; 0.335747763 ; 0.44143167 ; 0.275543041 ; 0.684942717 ; 0.662262156 ; 0.05911563 ; 0.916613214 ; 0.104575163 ; 0.163326653 ; 0.647288055 ; 0.764418377 ; 0.157476523 ; 0.057745918 ; 0.222762252 ; 0.546317216 ; 0.640268456 ; 0.645699128 ; 0.315236427 ; 0.286320255 ; 0.109698301 ; 0.186416185 ; 0.644774415 ; 0.750138309 ; 0.261073476 ; 0.073145246 ; 0.384994641 ; 0.84591195 ; 0.192505133 ; 0.777081468 ; 0.839874411 ; 0.197055344 ; 0.061664954 ; 0.560846561 ; 0.144484959 ; 0.015313493 ; 0.307379225 ; 0.369680851 ; 0.070092671 ; 0.299879808 ; 0.594227504 ; 0.047096144 ; 0.475479744 ; 0.615419917 ; 0.341189675 ; 0.197242606 ; 0.607282913 ; 0.742756804 ; 0.158223201 ; 0.024597631 ; 0.21919234 ; 0.646511628 ; 0.253617021 ; 0.535971223 ; 0.676409186 ; 0.870069606 ; 0.154157667 ; 0.545152355 ; 0.068430335 ; 0.097530082 ; 0.674673677 ; 0.07160759 ; 0.063486283 ; 0.102567953 ; 0.548683042 ; 0.074008811 ; 0.467179903 ; 0.017157941 ; 0.041497976 ; 0.183893196 ; 0.221178225 ; 0.022274326 ; 0.146781116 ; 0.365691142 ; 0.263079777 ; 0.139113429 ; 0.191025012 ; 0.285208776 ; 0.028515625 ; 0.650398406 ; 0.269513642 ; 0.136566463 ; 0.150328947 ; 0.505113986 ; 0.65225335 ; 0.256805342 ; 0.152385839 ; 0.110366997 ; 0.178470255 ; 0.147341772 ; 0.05115486 ; 0.267306721 ; 0.20812263 ; 0.264181234 ; 0.123671783 ; 0.089292617 ; 0.849027237 ; 0.13655914
NRPCC	Gainsboro	Lung Cancer in Never Smokers (NCI, Nature Genetics 2021)	NUMBER	Numer of Reads Per Tumor Chromosomal Copy	Sample	8.379260117 ; 19.41653284 ; 26.22414861 ; 6.207004914 ; 22.16776734 ; 30.16104571 ; 11.10129735 ; 21.6807391 ; 6.178483606 ; 5.54499841 ; 14.42036405 ; 9.871970324 ; 20.94548162 ; 32.72402844 ; 9.911201813 ; 37.68344577 ; 16.55493238 ; 10.18169098 ; 6.829619967 ; 21.58063178 ; 10.07788026 ; 30.52398516 ; 41.42329304 ; 6.063979628 ; 6.543083647 ; 10.30814111 ; 23.67349725 ; 14.16283449 ; 21.08211366 ; 6.157492435 ; 14.85668605 ; 27.88250209 ; 22.30657649 ; 30.80498238 ; 42.01650673 ; 7.687466433 ; 6.960603405 ; 11.38820217 ; 21.20108256 ; 13.30346963 ; 5.772444187 ; 19.10127454 ; 7.13298496 ; 13.53262413 ; 17.63877192 ; 6.082501095 ; 10.83641945 ; 14.25932628 ; 5.67716403 ; 25.90317993 ; 15.94607554 ; 16.23548468 ; 6.620012904 ; 16.74127514 ; 8.558895256 ; 5.672031011 ; 26.56184796 ; 5.474459539 ; 11.29843115 ; 5.669690685 ; 12.12489399 ; 20.33628083 ; 22.86278975 ; 8.357583475 ; 6.660378889 ; 18.90550392 ; 7.103803381 ; 28.34149959 ; 12.27943275 ; 7.948049981 ; 6.889104973 ; 29.16253805 ; 10.26369675 ; 12.3390779 ; 16.9436986 ; 18.22673549 ; 5.45835479 ; 26.8569222 ; 6.309928051 ; 29.06288056 ; 6.586107667 ; 17.27621844 ; 8.504383215 ; 8.067793554 ; 23.04101955 ; 13.95984037 ; 5.594617127 ; 12.90675474 ; 5.22626741 ; 14.83726648 ; 33.77979348 ; 12.23564338 ; 10.38091516 ; 7.533751622 ; 6.510503403 ; 7.335160986 ; 6.657031145 ; 25.90433763 ; 10.83549223 ; 10.96059961 ; 20.98662018 ; 29.0066925 ; 6.456226008 ; 23.35683375 ; 16.9594118 ; 27.12712951 ; 21.14993311 ; 11.01956506 ; 12.00288189 ; 23.52385695 ; 42.32440187 ; 9.168875619 ; 8.222089401 ; 25.5829489 ; 14.61955054 ; 5.987352179 ; 29.08814102 ; 37.99025436 ; 16.77836813 ; 22.85074892 ; 5.341963821 ; 16.99910437 ; 15.54042755 ; 27.59937942 ; 5.159061769 ; 33.3227643 ; 13.58328596 ; 18.33367554 ; 26.91489565 ; 6.412695595 ; 17.63349724 ; 12.97802944 ; 27.8666516 ; 6.276009875 ; 6.892624961 ; 5.626743135 ; 14.93873476 ; 8.207410822 ; 18.05521132 ; 36.11153001 ; 30.41379024 ; 16.50637828 ; 23.24841133 ; 26.46103176 ; 13.58574735 ; 7.626427773 ; 10.56897548 ; 14.18822498 ; 31.62734072 ; 20.626178 ; 6.972636611 ; 7.240385575 ; 13.38333374 ; 11.64578274 ; 35.79716062 ; 36.26965776 ; 15.32927048 ; 24.76647973 ; 10.66224152 ; 16.13563369 ; 9.621775895 ; 6.55415959 ; 15.31017176 ; 20.84045239 ; 12.6804713 ; 7.826810209 ; 15.10165237 ; 6.980748073 ; 6.325883418 ; 22.35336757 ; 8.974512482 ; 24.70991622 ; 7.221875864 ; 14.18975535 ; 11.92802098 ; 11.8199733 ; 16.43599726 ; 5.438854643 ; 8.369239066 ; 12.37461695 ; 8.350989206 ; 7.949034206 ; 6.462577819 ; 20.81573519 ; 18.00500817 ; 13.46315695 ; 14.97928719 ; 18.80971347 ; 6.248807456 ; 15.48965028 ; 15.80050159 ; 12.1239958 ; 16.47071463 ; 11.68225779 ; 12.06149239 ; 12.31767259 ; 5.135606431 ; 14.81670691 ; 13.98554535 ; 14.33538719 ; 6.234864946 ; 13.83680564 ; 8.34207316 ; 7.217773445 ; 11.85754116 ; 12.24679804 ; 8.033044924 ; 7.563891566 ; 10.06212068 ; 11.70542394 ; 6.89876677 ; 20.49962003 ; 13.13365802 ; 16.29125936 ; 14.67772656 ; 5.827606351 ; 15.04448273 ; 8.100747832 ; 12.42743185 ; 10.34664656 ; 21.44580734 ; 17.36930268 ; 6.559018067 ; 28.14926346 ; 5.518180083 ; 13.08900148 ; 6.200909948 ; 14.6993992 ; 15.8557419 ; 6.172938003 ; 5.835733742 ; 31.42327167
PASSIVE_SMOKING	Gainsboro	Lung Cancer in Never Smokers (NCI, Nature Genetics 2021)	STRING	Patients Exposed to Secondar Smoking	Patient	
SCNA_CLUSTER	Gainsboro	Lung Cancer in Never Smokers (NCI, Nature Genetics 2021)	STRING	SCNA Cluster	Sample	Mezzo-forte ; Forte ; Piano
CFDNA_INPUT_NG	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	cfDNA isolated from plasma analysed for circulating tumor DNA content	Patient	
CT_SLICE_SPACING	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	Distance in mm between CT scan images used to assess quality of volumetric analysis	Patient	
KI_67	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	Percentage of Ki67 positive cells on central pathological review of TMA	Patient	
LNI	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	STRING	Lymphnode involvement noted on pathological specimen	Patient	
PET_TBR	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	Positron emission tomography, tumor background ratio	Patient	
PLEURAL_INVASION	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	STRING	Pleural Invasion	Sample	Yes ; No
TUMOR_VOLUME	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	Tumor volume calculated through computational volumetric analysis of preoperative CT scans	Patient	
UBIQUITOUS_ASSAY_PANEL	Gainsboro	Non-Small Cell Lung Cancer (TRACERx, NEJM & Nature 2017)	NUMBER	Number of SNVs targed by assay panel that were found in all tumor regions analysed	Patient	
IRB	Gainsboro	Non-Small Cell Lung Cancer (MSK, J Clin Oncol 2018)	STRING	IRB	Patient	
LINES_OF_TX	Gainsboro	Non-Small Cell Lung Cancer (MSK, J Clin Oncol 2018)	STRING	Lines of treatment	Patient	
PDL1_SCORE	Gainsboro	Non-Small Cell Lung Cancer (MSK, J Clin Oncol 2018)	NUMBER	PD-L1 Score in percent	Sample	100 ; 3 ; 0 ; 50 ; 2 ; 10 ; 30 ; 80 ; 20 ; 5 ; 95 ; 40 ; 1 ; 75 ; 25 ; 90 ; 60
SMOKER_PACK_YEARS	Gainsboro	Non-Small Cell Lung Cancer (MSK, Science 2015)	NUMBER	Numeric computed value to represent lifetime tobacco exposure defined as number of cigarettes smoked per day x number of years smoked divided by 20	Patient	
TREATMENT_SCHEDULE	Gainsboro	Non-Small Cell Lung Cancer (MSK, Science 2015)	NUMBER	Schedule of Administration in Weeks (Pembrolizumab dosed every 2 or 3 weeks)	Patient	
AGE_YRS	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	NUMBER	Age (yrs)	Patient	
BEST_OVERALL_RESPONSE	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	Best Overall Response	Patient	
ECOG_PERFORMANCE_STATUS	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	ECOG performance status	Patient	
HLA_A1_ALLELE	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_A1 allele	Sample	A*29:02 ; A*01:01 ; A*02:03 ; A*02:01 ; A*11:01 ; A*24:02 ; A*69:01 ; A*68:02 ; A*03:01 ; A*33:01 ; A*02:05 ; A*33:03 ; A*66:02 ; A*30:01 ; A*31:01 ; A*68:01 ; A*29:01 ; A*30:11 ; A*02:02 ; A*32:01
HLA_A2_ALLELES	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_A2 alleles	Sample	A*24:02 ; A*25:01 ; A*02:07 ; A*11:01 ; A*26:01 ; A*68:01 ; A*02:01 ; A*03:01 ; A*03:02 ; A*01:01 ; A*23:01 ; A*68:02 ; A*32:01 ; A*30:01 ; A*32:03 ; A*66:01 ; A*24:03 ; A*31:01
HLA_B1_ALLELES	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_B1 alleles	Sample	B*44:03 ; B*08:01 ; B*46:01 ; B*45:01 ; B*55:01 ; B*40:01 ; B*13:02 ; B*35:02 ; B*58:02 ; B*07:02 ; B*41:01 ; B*42:01 ; B*27:05 ; B*38:01 ; B*44:02 ; B*40:02 ; B*58:01 ; B*14:02 ; B*15:17 ; B*57:01 ; B*18:01 ; B*35:01 ; B*35:03 ; B*15:01 ; B*07:05
HLA_B2_ALLELES	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_B2 alleles	Sample	B*40:01 ; B*15:18 ; B*38:02 ; B*51:01 ; B*07:02 ; B*13:02 ; B*15:01 ; B*35:02 ; B*18:01 ; B*38:01 ; B*35:03 ; B*37:01 ; B*44:02 ; B*14:02 ; B*49:01 ; B*54:01 ; B*35:01 ; B*57:01 ; B*50:01 ; B*35:14 ; B*55:01 ; B*35:08 ; B*15:17 ; B*14:01 ; B*18:04 ; B*41:02 ; B*44:03 ; B*15:03 ; B*08:01 ; B*27:05
HLA_C1_ALLELES	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_C1 alleles	Sample	C*03:04 ; C*07:04 ; C*01:03 ; C*02:02 ; C*03:03 ; C*07:02 ; C*06:02 ; C*17:01 ; C*07:01 ; C*01:02 ; C*12:03 ; C*04:01 ; C*05:01 ; C*15:05 ; C*02:10
HLA_C2_ALLELES	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	STRING	HLA_C2 alleles	Sample	C*16:01 ; C*07:01 ; C*07:02 ; C*06:02 ; C*03:04 ; C*04:01 ; C*12:03 ; C*07:04 ; C*08:02 ; C*05:01 ; C*01:02 ; C*08:04 ; C*14:02 ; C*02:10 ; C*17:01
PDL1_EXP	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	NUMBER	PD-L1 expression (Percentage)	Patient	
PREDICTED_NEOANTIGEN_BURDEN	Gainsboro	Non-Small Cell Lung Cancer (MSK, Cancer Cell 2018)	NUMBER	Predicted neoantigen burden	Patient	
AGE_GT_MEDIAN	Gainsboro	Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)	STRING	Age Greater than Median	Patient	
EXTRAPULMONARY	Gainsboro	Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)	STRING	Extrapulmonary	Patient	
METABOLIC_TUMOR_VOL	Gainsboro	Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)	NUMBER	Metabolic Tumor Volume	Patient	
STAGE_AT_DRAW	Gainsboro	Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)	STRING	Stage at Draw	Patient	
SUCCESSFUL_CTDX_LUNG	Gainsboro	Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)	STRING	Successful ctDx Lung	Patient	
UICC_TUMOR_STAGE	Gainsboro	Small Cell Lung Cancer (U Cologne, Nature 2015)	STRING	UICC Tumor Stage	Patient	
BM_OCCURENCE	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	BM occurrence	Sample	BM at the Primary Disease Presentation ; BM as Primary Disease Recurrence (90 days after primary dx)
BM_TO_PRIMARY_DX	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	NUMBER	Day difference from BM to primary dx	Sample	0 ; 1380 ; 2178 ; 459 ; 1640 ; 1230 ; 1059 ; 5 ; 282 ; 1496 ; 1238 ; 720 ; 1 ; 1587 ; 43 ; 538 ; 1681 ; 427 ; 344 ; 657 ; 625 ; 9 ; 37 ; 981 ; 4 ; 2050 ; 544 ; 21 ; 799 ; 889 ; 406 ; 20 ; 617 ; 22 ; 809 ; 571 ; 542 ; 385 ; 1011 ; 367 ; 718 ; 1544 ; 1009 ; 275 ; 1416 ; 1926 ; 2 ; 358 ; 1303 ; 1127 ; 26 ; 2392 ; 533 ; 35 ; 315 ; 1498 ; 861 ; 36 ; 1834 ; 2479 ; 229 ; 1605 ; 285 ; 524 ; 8 ; 1115 ; 10 ; 1432 ; 4077 ; 1221 ; 693 ; 1809 ; 568 ; 2793 ; 2953 ; 1577 ; 1503 ; 2612 ; 401 ; 61 ; 429 ; 1044 ; 97 ; 2416 ; 600 ; 143 ; 468 ; 6220 ; 448 ; 453 ; 359 ; 210 ; 443 ; 376 ; 304 ; 846 ; 1208 ; 266 ; 638 ; 507 ; 898 ; 438 ; 601 ; 45 ; 1597 ; 169 ; 929 ; 372 ; 301 ; 1231 ; 1123 ; 269 ; 650 ; 451 ; 264 ; 3555 ; 258 ; 663 ; 323 ; 17 ; 620 ; 1170 ; 27 ; 591 ; 493 ; 3 ; 250 ; 3557 ; 3819 ; 419 ; 525 ; 901 ; 15 ; 1443 ; 14 ; 777 ; 485
DIAMETER_RESECTED_BM_LESION_MM	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	NUMBER	Largest diameter of resected BM lesion, mm	Sample	58 ; 26 ; 47 ; 13 ; 18 ; 22 ; 27 ; 21 ; 20 ; 31 ; 44 ; 37 ; 48 ; 19 ; 51 ; 35 ; 25 ; 30 ; 39 ; 28 ; 29 ; 38 ; 16 ; 43 ; 23 ; 33 ; 64 ; 53 ; 50 ; 36 ; 57 ; 24 ; 60 ; 32 ; 17 ; 15 ; 14 ; 70 ; 62 ; 52 ; 40 ; 45 ; 11 ; 76 ; 67 ; 63 ; 34 ; 59 ; 42 ; 56 ; 54 ; 66 ; 9 ; 10 ; 41
INTRACRANIAL_DISEASE_PROGRESSION	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Intracranial disease progression	Sample	Yes ; No
INTRACRANIAL_DISEASE_PROGRESSION_TYPE	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Type of intracranial disease progression	Sample	Regional progression (1 new lesion) ; No progression ; Local Progression ; No progression (6 months of followup) ; Regional progression (2 or more new lesions) ; LMD (imaging or CSF) ; Unclear
LINES_OF_THERAPY_PRIOR_TO_BM_RESECTION	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	How many lines of therapy did patient have prior to BM resection?	Sample	0 ; 3 ; 1 ; 8 ; 2 ; 5 ; 4
NSCLC_SUBTYPE	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	NSCLC SubType	Sample	Squamous cell carcinoma ; Adenocarcinoma ; Other ; Large cell carcinoma ; Mixed
NUMBER_BMS_AT_DX	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Number of BMS at Diagnosis	Sample	2-5 lesions ; 6 - 15 lesions ; 1 lesion ; >15 lesions
PRIOR_PCI	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Prior Percutaneous Intervention	Sample	No ; Yes
PRIOR_TKI	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Prior TKI at any time	Sample	No ; Yes
PRIOR_WBRT	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Prior Whole Brain Radiation Therapy 	Sample	No ; Yes
SYMPTOM_AT_BM_DIAGNOSIS	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Symptom at BM diagnosis?	Sample	Yes ; No
SYSTEMIC_THERAPY_PRIOR_TO_BM_RESECTION	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Systemic therapy prior to BM resection?	Sample	No ; Yes
TISSUE_SPECIMEN_TYPE	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Tissue Specimen Type (BM=Brain Mets, PT=Primary Tumor, EM=Extracranial Mets)	Sample	BM ; EM ; PT
TREATMENT_PRIOR_TO_BM_RESECTION	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Treatment prior to BM resection	Sample	No treatment ; RT (+/- systemic) ; Chemo only ; IO only ; TKI only ; Other ; VEGF only
TYPES_OF_SYMPTOMS	Gainsboro	Non-Small Cell Lung Cancer Brain Metastasis (MSK, Nat Commun 2023)	STRING	Types of symptoms	Sample	Speech difficulties (Word Finding Difficulty/Expressive Aphasia) ; Other ; Ataxia ; Motor weakness ; Seizures ; AMS
ALBUMIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Albumin	Patient	
ALK_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ALK driver	Sample	FALSE
ALK_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ALK protein change	Sample	P1456H ; L63I ; E275* ; G718A ; F255L ; EML4-ALK fusion ; S62L ; R121Q ; E273* ; L1044H ; G1473E ; A207Qfs*42 ; G2R
ARID1A_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ARID1A driver	Sample	FALSE ; TRUE
ARID1A_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ARID1A protein change	Sample	Q1552H ; C2094Ffs*41 (driver) ; H173R ; Q520* (driver) ; Q354* (driver) ; A1029S ; E1774* (driver) ; Q521* (driver) ; Q766Sfs*67 (driver) ; D1850Tfs*33 (driver) ; Q1098* (driver) ; Q611* (driver) ; E1032* (driver) ; S711* (driver) ; Q372Afs*28 (driver) ; F2141Sfs*59 (driver) ; K1862* (driver) ; K1124M ; Y803C ; D1850Gfs*4 (driver)
BOR	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	BOR	Patient	
BRAF_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	BRAF driver	Sample	FALSE ; TRUE
BRAF_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	BRAF protein change	Sample	G469A (driver) ; I572F ; G464R (driver) ; V600E (driver) ; N581I (driver) ; S616Y ; X380_splice ; R260C ; V487L ; P328S ; L185P
CLINICAL_PDL1_SCORE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Clinically reported PD-L1 score	Sample	0 ; 80 ; 70 ; 20 ; 10 ; 5 ; 1 ; 95 ; 40 ; 2 ; 100 ; 60 ; 90 ; 50 ; 30 ; 75 ; 25 ; 15
CT_SCAN_TYPE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	CT scan type	Patient	
CYTOLOGY_FIXATION_TYPE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Cytology fixation type	Sample	Cytolyt ; Formalin ; SSL
DCR	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Durable clinical response	Patient	
DEATH_DATE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Date of death	Patient	
DNLR	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	dNLR	Patient	
DRUG_LAST_ADMIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Date of last drug administration	Patient	
DRUG_START	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Drug start date	Patient	
EGFR_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	EGFR driver	Sample	FALSE ; TRUE
EGFR_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	EGFR protein change	Sample	L858R (driver) ; AMP (driver), L858R (driver) ; E746_A750del (driver) ; A24S ; AMP (driver), EGFR-intragenic ; G1185S ; G719S (driver), E709A (driver) ; L747_T751del (driver) ; AMP (driver) ; AMP (driver), L861Q (driver) ; H773dup (driver) ; A120G ; L747P (driver) ; AMP (driver), EGFR-LANCL2 fusion ; L369F ; D416Y ; R98L
ERBB2_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ERBB2 driver	Sample	FALSE ; TRUE
ERBB2_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ERBB2 protein change	Sample	S310F (driver) ; V659E (driver) ; AMP (driver) ; G778_P780dup (driver) ; AMP (driver), L755P (driver) ; L755P (driver) ; Y772_A775dup (driver) ; AMP (driver), G778_P780dup (driver) ; G660D (driver) ; L755F (driver) ; R929Q ; R970L ; P627S
FOLLOW_UP_DATE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Date of any contact directly with patient	Patient	
HALO_TUMOR_QUALITY	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Halo tumor quality score	Sample	80 ; 95 ; 70 ; 50 ; 90 ; 60
IMPACT_PDL1_SAME	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Was IMPACT done on the same tissue that PD-L1 IHC was done on?	Sample	Yes ; No
IO_DRUG	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	IO drug name	Patient	
IO_LINE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	Line of therapy	Patient	
JS_PDL1_SCORE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	JS PD-L1 score	Sample	80 ; 5 ; 70 ; 0 ; 10 ; 95 ; 20 ; 90 ; 30 ; 50 ; 1 ; 60 ; 75
MANUAL_ANNOTATION	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Manual tumor annotation	Sample	Yes ; No
MET_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	MET driver	Sample	FALSE ; TRUE
MET_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	MET protein change	Sample	X963_splice (driver) ; X1010_splice (driver) ; AMP (driver) ; D1010H (driver) ; D1228H (driver) ; MET-intragenic - Archer ; AMP (driver), D1010Y (driver) ; AMP (driver), X963_splice (driver), MET-intragenic - Archer ; C584Wfs*10 ; H1094Y (driver)
MONO_COMBO	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Monotherapy vs. Combination	Patient	
OS_INT	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	OS from start of therapy	Patient	
PACK_YEARS	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	please put 0 for never smokers	Patient	
PDL1_TISSUE_SITE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	PD-L1 tissue site	Sample	lung ; brain ; pelvis ; pleura ; liver ; lymph node ; bone ; adrenal ; trachea ; unknown ; skin, muscle, fat ; mediastinum ; soft tissue (neck) ; soft tissue (L3) ; chest wall ; ascites ; soft tissue (chest wall) ; soft tissue (glenoid) ; bone, soft tissue ; soft tissue (rib) ; duodenum ; soft tissue (L2) ; soft tissue (abdomen) ; soft tissue (iliac) ; soft tissue (thigh) ; soft tissue (gluteus) ; soft tissue (humerus) ; soft tissue (spine) ; soft tissue (T9) ; soft tissue (C2) ; pleural fluid ; peritoneum
PFS_DATE	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	NUMBER	PFS date	Patient	
PROTO_NUM	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Clinical trial IRB	Patient	
RET_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	RET driver	Sample	FALSE
RET_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	RET protein change	Sample	AMP, S829I ; H352P ; E61K, Q371K ; P720L ; C528S ; A479P ; R820C ; P181S ; W324R ; R231L ; G798D ; R144L
ROS1_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ROS1 driver	Sample	FALSE
ROS1_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	ROS1 protein change	Sample	K1422N ; Y802C ; L1945Sfs*17 ; ROS1-EYS fusion ; W21C ; L806F ; A1459V ; S1626Y ; S66C ; X833_splice ; L1665Ffs*7 ; S340F ; P826L ; L545F ; P2183S ; C2252F
STK11_DRIVER	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	STK11 driver	Sample	FALSE ; TRUE
STK11_PROTEIN	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	STK11 protein change	Sample	L286R ; Q220* (driver) ; D194Y (driver) ; S428L ; E165* (driver) ; X245_splice (driver) ; STK11-intragenic ; H174R (driver) ; E120* (driver) ; W308C (driver) ; P281Rfs*6 (driver) ; R40L ; V110D ; HOMDEL (driver) ; W239L (driver) ; X199_splice (driver) ; G163V (driver) ; Q37* (driver) ; G251C (driver) ; E57_G58del ; C134Lfs*27 (driver) ; L282Sfs*5 (driver) ; X200_splice (driver) ; H174P (driver) ; E130* (driver) ; E256* (driver) ; E70* (driver) ; D176Tfs*111 (driver) ; A241P ; E138Rfs*20 (driver) ; E138* (driver) ; K84* (driver) ; X97_splice (driver) ; R103_R104del ; K62* (driver) ; R28Pfs*135 (driver) ; L282Afs*3 (driver) ; K44* (driver) ; Y253Gfs*15 (driver) ; P281Rfs*6 (driver), Y166* (driver) ; D237H ; P221Lfs*66 (driver) ; Q220Pfs*45 (driver) ; F231Sfs*56 (driver) ; E199* (driver)
TX_SETTING	Gainsboro	Lung Adenocarcinoma (MSK Mind,Nature Cancer 2022)	STRING	Treatment Setting	Patient	
ALK_ANALYSIS_TYPE	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	ALK Analysis Type	Patient	
ALK_TRANSLOCATION_STATUS	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	ALK Translocation Status	Patient	
ALK_TRANSLOCATION_VARIANT	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	ALK Translocation Variant	Patient	
CARBON_MONOXIDE_DIFFUSION_DLCO	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Carbon monoxide diffusion dlco	Patient	
FEV1_FVC_RATIO_POSTBRONCHOLIATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Fev1 fvc ratio postbroncholiator	Patient	
FEV1_FVC_RATIO_PREBRONCHOLIATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Fev1 fvc ratio prebroncholiator	Patient	
FEV1_PERCENT_REF_POSTBRONCHOLIATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Fev1 percent ref postbroncholiator	Patient	
FEV1_PERCENT_REF_PREBRONCHOLIATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Fev1 percent ref prebroncholiator	Patient	
HISTORY_IMMUNOLOGICAL_DISEASE	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior immunologic disease type	Patient	
HISTORY_IMMUNOLOGICAL_DISEASE_OTHER	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior immunologic disease other	Patient	
HISTORY_RELEVANT_INFECTIOUS_DX	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior infectious disease	Patient	
HIV_STATUS	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	HIV Status	Patient	
KRAS_GENE_ANALYSIS_INDICATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Kras gene analysis indicator	Patient	
KRAS_MUTATION_IDENTIFIED_TYPE	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Kras mutation identified type	Patient	
LOCATION_LUNG_PARENCHYMA	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Location lung parenchyma	Patient	
NUMBER_OF_LYMPHNODES_POSITIVE_BY_IHC	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Number of lymphnodes positive by ihc	Patient	
POS_LYMPH_NODE_LOCATION	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Lymph node location positive pathology name	Patient	
PULMONARY_FUNCTION_TEST_INDICATOR	Gainsboro	Lung Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Pulmonary function test indicator	Patient	
AGE_AT_METS	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	NUMBER	Age at Metastasis	Patient	
BEST_RESPONSE	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	STRING	Best Response	Patient	
CRS_NUMBER	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	NUMBER	Number of Cytoreductive surgeries	Patient	
FIRSTLINE_CHEMO_GROUP	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	STRING	Firstline Chemo Group	Patient	
IPCHEMO_FIRST_CRS	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	STRING	IP Chemo first Cytoreductive surgeries	Patient	
MOLECULAR_SUBTYPE	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	STRING	Gene Cluster V2	Patient ; Sample	MSS ; MSI ; POLE ; mss ; MSI Status
PCI	SaddleBrown	Appendiceal Cancer (MSK, J Clin Oncol 2022)	NUMBER	Peritonial Cancer Index	Sample	30 ; 10 ; 4 ; 24 ; 18 ; 23 ; 12 ; 14 ; 21 ; 5 ; 17 ; 1 ; 19 ; 32 ; 8 ; 2 ; 6 ; 33 ; 22 ; 3 ; 11 ; 9 ; 28 ; 25 ; 16 ; 29 ; 13 ; 38 ; 39 ; 26 ; 31 ; 35 ; 34 ; 20 ; 27 ; 15 ; 7
ANTI_INTEGRIN	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Anti-integrin (Yes/No)	Patient	
BONE_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Bone FSM	Sample	Yes
BONE_TIME_INTERVAL	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	NUMBER	Bone Time Interval	Sample	0 ; 8.711374096 ; 58.02103879 ; 10.02629849 ; 11.90006575 ; 22.55095332 ; 36.68639053 ; 33.00460224 ; 1.347797502 ; 9.59894806 ; 0.657462196 ; 26.42998028 ; 17.91584484 ; 5.358316897 ; 4.043392505 ; 5.851413544 ; 24.45759369 ; 49.53977646
BRAIN_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Brain FSM	Sample	
CLASSIFICATION_OF_PRIMARY_SITE	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Classification of primary site 	Sample	R side ; L side ; Small Intestine ; Anal Fistula
CYTOTOXIC_TREATMENT	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Cytotoxic Treatment	Patient	
DURATION_IBD_AT_DX_10_20_YEARS	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Duration of IBD at diagnosis (=<10yrs, 11-20yrs, >20yrs)	Patient	
DURATION_IBD_AT_DX_10_YEARS	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Duration of IBD at diagnosis (<10yrs or >/=10yrs)	Sample	Greater ; Less
ERROR_PERCENT	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Error percent.	Sample	0.25% ; 0.34% ; 0.23% ; 0.38% ; 0.30% ; 0.33% ; 0.32% ; 0.31% ; 0.28% ; 0.27% ; 0.29% ; 0.36% ; 0.26%
FIRST_SITE_OF_METS	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	First Site of Mets	Sample	Liver ; Bone ; Lungs ; Peritoneum, Small Intestine ; Lungs, Peritoneum ; Peritoneum ; Lung ; Peritoneum, Pelvis ; Liver, Lung, Bone ; Pelvis, Ovary ; LNs, Liver, Lungs ; LN ; Lung, Liver, Bone ; Bone, Liver, LNs, Lungs ; PAO ; Skin ; Liver, LNs ; Pelvis ; LNs ; Peritoneum, Ovaries ; Lymph Nodes ; Liver, Regional Nodal, Peritoneum ; Omentum, Pelvic Nodule ; Liver, Peritoneum ; Liver, Peritoneum, LNs ; Liver, lungs, LNs ; Liver, Adrenal ; Ovary, Fallopian Tube, Omentum ; Abdominal ; Lymph Nodes, Lung, Peritoneum ; Liver, Lymph Nodes ; Liver, Spleen, Lymph Nodes ; Liver, Lymph Nodes, Lung ; Liver, Ovary ; Ovary, Peritoneum ; Lymph Nodes, Peritoneum ; Lung, Liver, Lymph Nodes ; Liver, Chest Wall ; Brain ; Peritoneum, Lymph Nodes ; Liver, Pelvis ; Liver, Lymph Nodes, Pelvis ; Liver, Lung, Lymph Nodes ; Liver, Lung ; Liver, Peritoneum, Lymph Nodes ; Liver, Peritoneum, Pelvis ; Liver, Lymph Nodes, Psoas ; Liver, Peritoneum, Ovary, Fallopian Tube ; Pancreas ; Peritoneum, Pelvis, Ovary, Fallopian Tube ; Liver, Lymph Nodes, Peritoneum ; Liver, Lung, Peritoneum ; Lung, Liver ; Lymph Nodes, Adrenal ; Liver, Ovary, Fallopian Tube ; Lung, Lymph Nodes ; Liver, Lymph Nodes, Peritoneum, Ovary ; Liver, Pleura ; Peritoneum, Ovary ; Liver, Lung, Lymph Nodes, Ovary, Fallopian Tube ; Small Bowel, Sigmoid Colon, Uterus, Cervix, Lymph Nodes ; Liver, Ovary, Peritoneum ; Lung, Lymph Nodes, Liver ; Soft Tissue ; Lung, Bladder ; Peritoneum, Ovary, Lymph Nodes ; Lung, Lymph Nodes, Bone, Peritoneum ; Liver, Lung, Lymph Nodes, Peritoneum ; Lymph Nodes, Liver, Lung, Bone ; Lung, Liver, Lymph Nodes, Pelvis ; Ovary, Fallopian Tube, Pelvis, Liver ; Ovary, Fallopian Tube ; Liver, Peritoneum, Small Bowel ; Ovary ; Pelvis, Cervix ; Small Bowel, Peritoneum ; Abdominal, Lymph Nodes ; Liver, Pelvis, Ovary ; Mesentry, Lymph Nodes ; Omentum, Abdominal ; Liver, Lung, Omentum ; Small Bowel, Omentum, Pelvis ; Adnexa, Ovary, Fallopian Tube, Peritoneum ; Omentum ; Liver, Pelvis, Omentum, Peritoneum ; Peritoneum, Duodenum ; Jejunum, Peritoneum ; Pelvis, Ureter ; Liver, Lung, Mesentery ; Liver, Peritoneum, Mesentery ; Lung, Pelvis, Lymph Nodes ; Lung, Liver, Pelvis ; Lung, Liver, Bone, Peritoneum ; Omentum, Peritoneum, Lymph Nodes ; Liver, Pancreas, Spleen ; Peritoneum, Omentum, Spleen ; Liver, Lung, Brain ; Liver, Lung, Bone, Lymph Nodes ; Liver, Soft Tissue ; Lung, Peritoneum ; Liver, Omentum ; Brain, Lung, Liver ; Cervix ; Omentum, Lymph Nodes ; Lung, Liver, Spleen, Uterus ; Liver, Ovary, Uterus, Fallopian Tube, Peritoneum ; Liver,Peritoneum ; Peritoneum, Ureter, Bladder ; Peritoneum, Cervix, Vagina, Lymph Nodes, Bone, Lung, ; Peritoneum, Liver, Lymph Nodes ; Lung, Lymph Nodes, Pelvis ; Liver, Peritoneum, Ovary ; Ovary, Pelvis, Peritoneum ; Omentum, Ovary, Fallopian Tube ; Bone, Lymph Nodes, Liver, Pelvis ; Lung, Ovary, Fallopian Tube ; Ovary, Omentum, Lung, Lymph Nodes, Bone ; Lymph Nodes, Soft Tissue ; Omentum, Umbilical Hernia Sac ; Peritoneum, Lung, Lymph Nodes ; Liver, Uterus, Ovary, Lymph Nodes, ; Liver, Lung, Lymph Nodes, Bone ; Bone, Stomach, Pancreas, Spleen, Peritoneum ; Rectum, Peritoneum, Lymph Nodes ; Rectum, Pelvis, Ovary ; Liver, Omentum, Peritoneum, Ovary ; Peritoneum, Small Bowel ; Skin, Bone ; Liver, Omentum, Lung ; Kidney, Lymph Nodes ; Ovary, Peritoneum, ; Ovary, Bladder ; Brain, Lung, Lymph Nodes, Bone ; Omentum, Peritoneum ; Pelvis, Lung ; Bone, Lymph Nodes ; Liver, Bone, Lymph Nodes, Abdominal ; Liver, Lymph Nodes, Bone ; Ovary, Fallopian Tube, Uterus, Peritoneum ; Liver, Bone, Lymph Nodes ; Omentum, Peritoneum, Pelvis ; Peritoneum, Abdominal ; Liver, Small Bowel, Ovary, Fallopian Tube ; Coloanal Anastamosis ; Peritoneum, Ovary, Fallopian Tube, ; Rectovaginal Fistula ; Liver, Lung, Iliac ; Brain, Liver, Lung
GYN_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Gyn FSM	Sample	Yes
IBD	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	IBD	Patient	
IBD_STATUS_AT_DIAGNOSIS	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	IBD Status At Diagnosis	Sample	Quiescent ; Active IBD ; Procto/Colectomy ; No Prior Symptoms ; Quiescent many years
INTERVAL_FROM_LAST_COLONOSCOPY_TO_CAC_DX	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Interval From Last Colonoscopy to CAC Dx	Sample	>5_YEARS ; 1_3_YEARS ; 3_5_YEARS ; 1_YEAR
LIVER_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Liver FSM	Sample	Yes
LIVER_TIME_INTERVAL	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	NUMBER	Liver Time Interval	Sample	0 ; 9.763313609 ; 3.320184089 ; 0.06574622 ; 1.808021039 ; 32.05128205 ; 28.43523997 ; 2.728468113 ; 13.90532544 ; 0.460223537 ; 11.34122288 ; 0.591715976 ; 0.03287311 ; 0.131492439 ; 5.456936226 ; 18.40894149 ; 57.23208416
LN_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	LNs FSM	Sample	Yes
LUNG_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Lung FSM	Sample	Yes
LUNG_TIME_INTERVAL	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	NUMBER	Lung Time Interval	Sample	0 ; 95.2991453 ; 29.12557528 ; 1.808021039 ; 11.27547666 ; 16.89677844 ; 15.97633136 ; 32.05128205 ; 26.42998028 ; 13.54372124 ; 35.8974359 ; 2.333990796 ; 24.45759369 ; 18.67192636 ; 13.773833 ; 12.91913215 ; 37.31097962 ; 12.19592373
OTHER_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Other FSM	Sample	Yes
PAO_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	PAO FSM	Sample	Yes
PATHOLOGY_OF_NORMAL_MUCOSA	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Pathology of Normal Mucosa	Sample	Active enteritis ; Chronic inactive enteritis ; Unremarkable ; active enteritis
PELVIS_FSM	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Pelvis FSM	Sample	Yes
PRESENTATION	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Presentation	Sample	Bowel Symptoms ; Screening Colonoscopy ; Fistula/Abscess/Stricture ; Imaging ; Metastatic Disease
RADADJUVANTRX	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Radiation Adjuvant Therapy	Patient	
RESECTABLE	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Resectable	Sample	No ; Yes ; YES ; NO
SALICYLATES	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Salicylates	Patient	
SPECIAL_HISTOLOGY	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Special Histology	Sample	No ; Combined adenocarcinoma - high grade neuroendocrine carcinoma of small cell type ; Mucinous features, signet ring features ; Mucinous features; signet ring features ; Mucinous ; Signet ring cell ; Focal neuroendocrine component ; Signet Ring ; Mucinous Features ; mucinous ; Signet ring ; Focal mucinous features ; Mucinous features ; Diffuse (Linitus-Plasticus) ; Signet Ring, Mucinous Features ; One Focus Nec ; Focal Signet Ring
STEROIDS	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Steroids (Yes/No)	Patient	
TNF	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	TNF (Yes/No)	Patient	
VITAL_STATUS_CODE	SaddleBrown	Colorectal Adenocarcinoma (MSK, Nat Commun 2022)	STRING	Vital Status Code	Patient	
MATCHED_NORMAL_ID	SaddleBrown	Colon Adenocarcinoma (CaseCCC, PNAS 2015)	STRING	Matched Normal ID	Patient	
SAMPLE_SITE_SOURCE	SaddleBrown	Colon Adenocarcinoma (CaseCCC, PNAS 2015)	STRING	Source of Sample Site	Sample	Colon ; Liver
BRAF_GENE_ANALYSIS_INDICATOR	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Firehose Legacy)	STRING	BRAF Gene Analysis Indicator	Patient	
BRAF_GENE_ANALYSIS_RESULT	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Firehose Legacy)	STRING	BRAF Gene Analysis Result	Patient	
INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Initial pathologic diagnosis method	Patient	
RESECTION_TIMING	SaddleBrown	Colorectal Adenocarcinoma Triplets (MSK, Genome Biol 2014)	STRING	Resection timing	Sample	Concurrent ; Subsequent
TUMOR_TREATED	SaddleBrown	Colorectal Adenocarcinoma Triplets (MSK, Genome Biol 2014)	STRING	Tumor treated	Sample	Both_treated ; Chemonaive ; Before_both_resections ; Metastasis_treated ; Primary_treated
CIMP_CATEGORY	SaddleBrown	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	STRING	CIMP category.	Sample	CIMP-0/low ; CIMP-high
PRIMARY_TUMOR_GRADE	SaddleBrown	Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)	STRING	Histologic grading criteria for adenoid cystic carcinoma (Szanto, et. al, 1984)	Sample	Well-Moderate ; Poor
COPY_NUMBER	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	NUMBER	Copy number.	Sample	1 ; 0
INTEGRATED_PHENOTYPE	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Integrated phenotype.	Patient	
MICRORNA_DATA	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	NUMBER	microRNA.	Sample	1 ; 0
MUTATION_PHENOTYPE	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Mutation Phenotype.	Patient	
PATHOLOGY_N_STAGE	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Pathology N stage.	Patient	
PATHOLOGY_STATUS	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Pathology report.	Sample	Malignant
PATHOLOGY_T_STAGE	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Pathology T stage.	Patient	
PHOSPHOPROTEIN	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	NUMBER	Phosphoprotein data.	Sample	0 ; 1
POLYPS_HISTORY	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	History of polyps.	Patient	
POLYPS_PRESENT	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Polyps currently present.	Patient	
PROTEIN	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	NUMBER	Protein data.	Sample	0 ; 1
SPECIMEN_PRESERVATION	SaddleBrown	Colon Cancer (CPTAC-2 Prospective, Cell 2019)	STRING	Specimen preservation method.	Sample	Frozen Tissue
AGE_GROUPS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Age Groups	Patient	
AGE_SUBGROUPS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Age Subgroups	Patient	
BMI_CATEGORIES	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	BMI categories	Patient	
DIABETES_MELLITUS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Diabetes mellitus history	Patient	
FIRST_SYMPTOMS_AT_DX	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	First symptoms at diagnosis	Patient	
HYPERTENSION	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Hypertension history	Patient	
METASTASECTOMY	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Metastasectomy	Patient ; Sample	0 ; 1
OS_MET_MONTHS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	NUMBER	Overall survival in months since metastasis diagnosis.	Patient	
OS_MET_STATUS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Overall patient survival status.	Patient	
PRIMARY_TUMOR_LOCATION	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Text term to describe the organ sub-division in an individual with cancer.	Sample	Right ; Left ; Rectum
PUMP	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	PUMP	Patient	
SMOKER_STATUS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Smoker Status	Patient	
STAGE_AT_DX	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	Stage at Diagnosis	Patient	
TREATMENT_AT_METASTASIS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	STRING	First line treatment at time of metastasis	Patient	
USED_FOR_RESPONSE	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	NUMBER	Used for Response	Sample	1 ; 0
USED_IN_CLINICAL_ANALYSIS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	NUMBER	Used in Clinical Analysis	Sample	1 ; 0
USED_IN_GENOMIC_MSS_ANALYSIS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	NUMBER	Used in Genomic MSS Analysis	Sample	1 ; 0
USED_IN_GENOMIC_MSS_MET_SURVIVAL_ANALYSIS	SaddleBrown	Colorectal Cancer (MSK, JNCI 2021)	NUMBER	Used in Genomic MSS Met Survival Analysis	Sample	1 ; 0
AGE_AT_MET	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	NUMBER	Age at Metastases	Patient	
APC_GROUPS	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	APC Groups	Sample	N_Terminal_Side ; C_Terminal_Side ; Other ; Unaltered
CARCINOMATOSIS	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Carcinomatosis	Sample	No ; Yes
FIRST_LINE_MET_TX	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	First line treatment at time of metastasis	Sample	Fluropyrimidine + oxaliplatin +/-Bev ; FOLFIRI AntiEGFR ; Fluropyrimidine + irinotecan +/-Bev ; Fluropyrimidine  +/-Bev ; Other regimens ; FOLFOXIRI +/- Bev ; FOLFOX AntiEGFR
LST	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	NUMBER	LST	Sample	3 ; 0 ; 2 ; 1 ; 5 ; 4 ; 7 ; 14 ; 6 ; 10 ; 9 ; 13 ; 12 ; 11 ; 8 ; 30 ; 19
METASTASIS_BONE	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Bone Metastasis	Patient	
METASTASIS_LIVER	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Liver Metastasis	Patient	
METASTASIS_LUNG	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Lung Metastasis	Patient	
METASTASIS_OTHER	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Metastasis Other	Patient	
PRIOR_ADJUVANT_CHEMO	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Prior Adjuvant Chemo	Sample	No ; Yes
SURGERY_PRIMARY_TUMOR	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Surgery Primary Tumor	Sample	No ; Yes
TIMING_METS	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Timing Mets	Sample	Synchronous ; Metachronous ; 2
USED_IN_GENOMIC_ANALYSIS	SaddleBrown	Colorectal Cancer (MSK, Gastroenterology 2020)	STRING	Used in Genomic Analysis	Sample	Yes ; No
INITIAL_STAGE	SaddleBrown	Disparities in metastatic colorectal cancer between Africans and Americans (MSK, 2020)	STRING	Initial Stage	Patient	
MSI_PREDICTION_SCORE	SaddleBrown	Disparities in metastatic colorectal cancer between Africans and Americans (MSK, 2020)	NUMBER	MSI Prediction Score	Sample	1.49 ; 46.13 ; 22.86 ; 34.83 ; 0.14 ; 17.74 ; 0 ; 4.92 ; 0.45 ; 0.56 ; 2.27 ; 0.88 ; 0.62 ; 1.48 ; 1.58 ; 1.85 ; 1.73 ; 1.69 ; 17.21 ; 2.08 ; 39.81 ; 0.75 ; 15.06 ; 2.75 ; 0.91 ; 2.54 ; 36.43 ; 42.14 ; 0.5 ; 35.74 ; 36.44 ; 0.34 ; 37.91 ; 5.34 ; 0.64 ; 35.18 ; 0.49 ; 8.5 ; 27.7 ; 2.1 ; 2.49 ; 1.07 ; 17.99 ; 1.16 ; 0.79 ; 1.88 ; 0.71 ; 2.29 ; 0.54 ; 0.83 ; 2.5 ; 0.51 ; 1.24 ; 0.7 ; 1.1 ; 3.21 ; 0.57 ; 0.46 ; 16.19 ; 36.78 ; 1.31 ; 1.64 ; 0.59
DRIVER1_AI	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 Allelic Imbalance	Sample	No ; Yes
DRIVER1_CCF	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver1 CCF	Sample	1 ; 1.00 ; 0.99 ; 0.77 ; 0.95 ; 0.98 ; 0.94 ; 0.78 ; 0.54 ; 0.67 ; 0.79 ; 0.31 ; 0.57 ; 0.84 ; 0.35 ; 0.85 ; 0.86 ; 0.60 ; 0.88 ; 0.65 ; 0.30 ; 0.93 ; 0.89 ; 0.97 ; 0.81 ; 0.921
DRIVER1_CELLULAR_FRACTION	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver1 Cellular Fraction	Sample	1.00 ; 0.04 ; 0.40 ; 0.14 ; 0.13 ; 0.44 ; 0.35 ; 0.25 ; 0.38 ; 0.45 ; 0.05 ; 0.53
DRIVER1_CLONAL_CALL	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 Clonal Call	Sample	Clonal ; Subclonal ; Indeterminate
DRIVER1_EXPECTED_MUTANT_COPIES	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver1 Expected Mutant Copies	Sample	1.20 ; 1.04 ; 1.31 ; 0.99 ; 1.03 ; 1.29 ; 0.95 ; 0.98 ; 1.89 ; 1.49 ; 2.02 ; 1.96 ; 1.22 ; 1.21 ; 2.36 ; 0.86 ; 1.26 ; 1.87 ; 3.51 ; 0.93 ; 0.97 ; 0.81 ; 1.01 ; 0.92
DRIVER1_FACETS_PLOIDY_CALL	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 Facets Ploidy Call	Sample	DIPLOID ; GAIN ; TETRAPLOID ; HOMDEL ; DIPLOID or CNLOH ; CNLOH AFTER ; LOSS AFTER ; CNLOH ; LOSS BEFORE ; DOUBLE LOSS AFTER
DRIVER1_LCN	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 LCN	Sample	1 ; 2 ; 0
DRIVER1_MUTATION	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 Mutation	Sample	BRAF p.V600E ; KRAS p.G13D ; KRAS p.A59T ; KRAS p.G12D ; NRAS p.Q61K ; KRAS p.G12A ; KRAS p.A146T ; KRAS p.G12S ; NRAS p.G13D ; KRAS p.V14I ; KRAS p.G12C ; NRAS p.G12S ; KRAS p.K117N ; KRAS p.G12V ; NRAS p.G12D ; NRAS p.G13V ; KRAS p.Q61H ; NRAS p.G12V
DRIVER1_TCN	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver1 TCN	Sample	2 ; 3 ; 4 ; 0
DRIVER2_AI	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 Allelic Imbalance	Sample	No ; Yes
DRIVER2_CCF	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver2 CCF	Sample	0.572 ; 0.872 ; 1 ; 0.92 ; 0.636 ; 0.336 ; 0.723 ; 0.956 ; 0.148 ; 0.415 ; 0.87 ; 0.782 ; 0.086 ; 0.244 ; 0.206 ; 0.945 ; 0.315 ; 0.145 ; 0.17 ; 0.45 ; 0.18 ; 0.12 ; 0.25 ; 1.00 ; 0.80 ; 0.11 ; 0.52 ; 0.47 ; 0.26 ; 0.78 ; 0.30 ; 0.29 ; 0.14 ; 0.21 ; 0.50 ; 0.23 ; 0.69 ; 0.77
DRIVER2_CELLULAR_FRACTION	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver2 Cellular Fraction	Sample	1.00 ; 0.36 ; 0.04 ; 0.62 ; 0.47 ; 0.14 ; 0.13 ; 0.44 ; 0.40 ; 0.35 ; 0.25 ; 0.38 ; 0.53 ; 0.05 ; 0.51 ; 0.23 ; 0.26
DRIVER2_CLONAL_CALL	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 Clonal Call	Sample	Subclonal ; Clonal ; Indeterminate
DRIVER2_EXPECTED_MUTANT_COPIES	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	NUMBER	Driver2 Expected Mutant Copies	Sample	1.48890174 ; 0.919762365 ; 0.920098675 ; 0.955948452 ; 0.869974706 ; 0.945332431 ; 1.05
DRIVER2_FACETS_PLOIDY_CALL	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 Facets Ploidy Call	Sample	DIPLOID ; HETLOSS ; GAIN ; CNLOH BEFORE & LOSS ; HOMDEL ; DIPLOID or CNLOH ; CNLOH AFTER ; LOSS AFTER ; CNLOH ; TETRAPLOID
DRIVER2_LCN	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 LCN	Sample	1 ; 0 ; 2
DRIVER2_MUTATION	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 Mutation	Sample	KRAS p.G13D ; KRAS p.G12D ; KRAS p.G12A ; KRAS p.G12V ; NRAS p.G12A ; KRAS p.G12C ; NRAS p.Q61K ; BRAF p.V600E ; KRAS p.V14I ; KRAS p.G12R ; NRAS p.G12V ; KRAS p.A146T ; KRAS p.K117N ; KRAS p.G12S ; NRAS p.G13V
DRIVER2_TCN	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Driver2 TCN	Sample	2 ; 1 ; 3 ; 0 ; 4
GENOMIC_QC	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Genomic QC	Sample	PASS ; FAIL
HIGHEST_LEVEL_ONCOKB	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Highest Level OncoKB	Sample	LEVEL_1 ; LEVEL_3B ; LEVEL_4 ; LEVEL_2
METASTATIC	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Indicates whether the patient had metastatic cancer or not	Patient	
METASTATIC_AT_DX	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Indicates whether the patient had metastatic cancer when first diagnosed	Patient	
SURVIVAL_STATUS	SaddleBrown	Colorectal Cancer (MSK, JCO Precis Oncol 2022)	STRING	Survival Status	Patient	
AGE_AT_DERIVATION	SaddleBrown	Rectal Cancer (MSK,Nature Medicine 2019)	NUMBER	Age at derivation	Sample	55 ; 56 ; 41 ; 70 ; 42 ; 59 ; 65 ; 69 ; 43 ; 45 ; 84 ; 57 ; 44 ; 51 ; 52 ; 76 ; 85 ; 73 ; 61
THERAPY_PRIOR_TO_DERIVATION	SaddleBrown	Rectal Cancer (MSK,Nature Medicine 2019)	STRING	Therapy Prior to derivation	Sample	FOLFOX, FOLFIRI, SCRT and FUDR ; none ; FOLFOX and SCRT ; FOLFOX ; FOLFOX, CRT ; FOLFOX only (Prospect trial) ; FOLFOX, CRT then FOLFIRI ; FOLFOX + CRT ; FOLFOX, then CRT then combo resection ; CRT ; CRT + FOLFOX ; pembrolizumab
TISSUE_SITE_OF_DERIVATION	SaddleBrown	Rectal Cancer (MSK,Nature Medicine 2019)	STRING	Tissue site of derivation	Sample	distal rectum ; very distal rectum (recurrence) ; Upper rectum/distal sigmoid ; Distal rectum ; mid-distal rectum ; Mid rectum ; mid-rectum ; Upper rectum ; mid-to-distal rectum ; pelvic recurrence ; Splenic metastasis ; mid to distal rectum ; distal rectal recurrence post LAR ; mid rectal tumor ; distal rectum, tumor recurrence ; distal rectal tumor ; Rectum
ADJUVANT_CHEMO_REGIMEN	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Adjuvant Chemo Regimen	Patient	
ADJUVANT_CT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Adjuvant chemotherapy receivec	Patient	
ADJUVANT_CYCLES_NUM	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Adjuvant Cycles Number	Patient	
APC_GROUP	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	APC Group	Sample	N ; C
BMI_CLASS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Initial BMI Class	Patient	
BMI_DELTA_DAYS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	BMI Delta Days	Patient	
BMI_DELTA_VALUE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	BMI Delta Value	Patient	
CCR	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	cCR.0.no.1.yes.	Patient	
CLINICAL_LN_POSITIVE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Clinical LN positive	Patient	
CMS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	CMS	Patient	
CRT_CHEMOAGENT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	CRT chemoagent	Patient	
DFS_FROM_NEO_MONTHS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	DFS months from neo	Patient	
DFS_FROM_NEO_STATUS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	DFS status from neo	Patient	
DFS_FROM_SURGERY_MONTHTS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	DFS monthts from surgery	Patient	
DISTAL_RECURRENCE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Distal Recurrence	Patient	
DISTANCE_FROM_AV_CM	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Distance From AV (cm)	Patient	
DISTANT_METS_SITE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Distant mets site	Patient	
EM_FLAGS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Em Flags	Sample	
EXCLUDE_FROM_DFS_1_EXCLUDE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Exclude.from.DFS..1.exclude.	Patient	
FACETS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	With Facets	Sample	0 ; 1
FACETS_FGA	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Facets FGA	Sample	0.76 ; 0.86 ; 0.85 ; 0.35 ; 0.056 ; 0.9 ; 0.64 ; 0.33 ; 0.55 ; 0.84 ; 0.45 ; 0.41 ; 0.75 ; 0.16 ; 0.61 ; 0.62 ; 0.36 ; 0.8 ; 0.14 ; 0.06 ; 0.72 ; 0.052 ; 0.23 ; 0.18 ; 0.24 ; 0.68 ; 0.92 ; 0.91 ; 0.085 ; 0.67 ; 0.6 ; 0.08 ; 0.32 ; 0.59 ; 0.42 ; 0.44 ; 0.49 ; 0.2 ; 0.69 ; 0.15 ; 0.17 ; 0.27 ; 0.53 ; 0.71 ; 0.57 ; 0.89 ; 0.34 ; 0.46 ; 0.83 ; 0.97 ; 0.13 ; 0.31 ; 0.26 ; 0.87 ; 0.11 ; 0.28 ; 0.079 ; 0.88 ; 0.54 ; 0.29 ; 0.58 ; 0.4 ; 0.3 ; 0.1 ; 0.99 ; 0.39 ; 0.19 ; 0.43 ; 0.82 ; 0.79 ; 0.73 ; 0.22 ; 0.48 ; 0.5 ; 0.94 ; 0.77 ; 0.78 ; 0.38 ; 0.002 ; 0.81 ; 0.95 ; 0.028 ; 0.075 ; 0.7 ; 0.66 ; 0 ; 0.65 ; 0.21 ; 0.087 ; 0.082 ; 0.064 ; 0.12 ; 0.47 ; 0.02 ; 0.51 ; 0.63 ; 0.065 ; 0.083 ; 0.37 ; 0.74 ; 0.98 ; 0.092 ; 0.25 ; 0.07 ; 0.053 ; 0.035 ; 0.52 ; 0.066 ; 0.095 ; 0.091 ; 0.077 ; 0.069
FINAL_BMI_CLASS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Final BMI Class	Patient	
FINAL_BMI_NUMBER	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Final BMI (Numeric)	Patient	
FRACTION_CNA	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Fraction CNA	Sample	0.566467863 ; 0.896540734 ; 1 ; 0.173740359 ; 0.848027226 ; 0.352256997 ; 0.467048286 ; 0.055634775 ; 0.929232819 ; 0.742766723 ; 0.423911726 ; 0.45366593 ; 0.675870372 ; 0.928660914 ; 0.445955087 ; 0.775086384 ; 0.957908062 ; 0.056182393 ; 0.158249706 ; 0.881257804 ; 0.890131347 ; 0.616022568 ; 0.352425472 ; 0.870998216 ; 0.13881811 ; 0.113379108 ; 0.296272102 ; 0.621256412 ; 0.230202519 ; 0.175562105 ; 0.215655591 ; 0.914426751 ; 0.330858371 ; 0.933671382 ; 0.083187733 ; 0.305635609 ; 0.799072088 ; 0.079529149 ; 0.317563439 ; 0.32754501 ; 0.421691547 ; 0.788356913 ; 0.4441002 ; 0.490855804 ; 0.799507251 ; 0.492482623 ; 0.14994522 ; 0.174118573 ; 0.265102865 ; 0.169931907 ; 0.084394368 ; 0.694093055 ; 0.932581296 ; 0.861078957 ; 0.617454222 ; 0.932256821 ; 0.488314381 ; 0.335403186 ; 0.556085661 ; 0.138407319 ; 0.458115936 ; 0.624684471 ; 0.317030018 ; 0.987894147 ; 0.873347856 ; 0.859004172 ; 0.31752252 ; 0.128283629 ; 0.312857439 ; 0.173685876 ; 0.94571729 ; 0.522637542 ; 0.623756673 ; 0.880450465 ; 0.114296543 ; 0.279730601 ; 0.078820296 ; 0.923712926 ; 0.644145211 ; 0.987941311 ; 0.917197503 ; 0.277994346 ; 0.945606221 ; 0.535352777 ; 0.332793208 ; 0.290888809 ; 0.38240409 ; 0.396949301 ; 0.599674315 ; 0.29734517 ; 0.26985525 ; 0.099822082 ; 0.315400155 ; 0.41348138 ; 0.38523801 ; 0.544187686 ; 0.192105079 ; 0.580805197 ; 0.157643642 ; 0.906862006 ; 0.42974148 ; 0.907794305 ; 0.491806653 ; 0.887343678 ; 0.127713301 ; 0.611257001 ; 0.391439838 ; 0.362944466 ; 0.971765452 ; 0.96316969 ; 0.711590803 ; 0.149048506 ; 0.241384967 ; 0.174109799 ; 0.281763787 ; 0.969088752 ; 0.225338467 ; 0.848302294 ; 0.400328333 ; 0.444120798 ; 0.227468507 ; 0.847748594 ; 0.572761554 ; 0.348784583 ; 0.113659115 ; 0.229468173 ; 0.593359011 ; 0.59534389 ; 0.554894834 ; 0.932193673 ; 0.444211505 ; 0.94887511 ; 0.995458201 ; 0.082205099 ; 0.233913787 ; 0.662787083 ; 0.654293812 ; 0.396765564 ; 0.126000111 ; 0.93016713 ; 0.66022203 ; 0.892921278 ; 0.88046153 ; 0.106092668 ; 0.320235479 ; 0.780406114 ; 0.223311487 ; 0.178835413 ; 0.924496328 ; 0.292270378 ; 0.968298557 ; 0.828142015 ; 0.9373933 ; 0.420488574 ; 0.158504299 ; 0.209756288 ; 0.209118367 ; 0.26112618 ; 0.289268166 ; 0.104725468 ; 0.123023289 ; 0.382413692 ; 0.365640045 ; 0.183958318 ; 0.133825145 ; 0.794278737 ; 0.065844811 ; 0.067030316 ; 0.326456876 ; 0.807297013 ; 0.982605249 ; 0.915732333 ; 0.742665298 ; 0.771124401 ; 0.712462563 ; 0.105391897 ; 0.95421348 ; 0.467917102 ; 0.178039292 ; 0.195649582 ; 0.35886331 ; 0.992797694 ; 0.754922287 ; 0.54798234 ; 0.13652216 ; 0.492439302 ; 0.945603598 ; 0.730670117 ; 0.896939179 ; 0.623550006 ; 0.450674065 ; 0.418115493 ; 0.898073747 ; 0.798218365 ; 0.506717463 ; 0.347257357 ; 0.074292576 ; 0.107545298 ; 0.835458066 ; 0.714243239 ; 0.943460935 ; 0.762519073 ; 0.434254207 ; 0.159204398 ; 0.231330935 ; 0.101234105 ; 0.070188297 ; 0.756286134 ; 0.725233964 ; 0.462417401 ; 0.51334891 ; 0.835601066 ; 0.943742968 ; 0.454533752 ; 0.107334433 ; 0.344000592 ; 0.275077529 ; 0.391543616 ; 0.735662912 ; 0.636451789 ; 0.467063648 ; 0.254079493 ; 0.945026153 ; 0.819583276 ; 0.776536178 ; 0.71609986 ; 0.306511694 ; 0.538815385 ; 0.912398309 ; 0.790449166 ; 0.694504383 ; 0.051568188 ; 0.052868609 ; 0.5171048 ; 0.592812101 ; 0.341570328 ; 0.344960175 ; 0.470546997 ; 0.610137481 ; 0.234954312 ; 0.862909334 ; 0.162508221 ; 0.162641612 ; 0.478276032 ; 0.380546117 ; 0.339530883 ; 0.892727197 ; 0.481091454 ; 0.432347081 ; 0.581195379 ; 0.831112004 ; 0.726967235 ; 0.318248087 ; 0.333047644 ; 0.637358608 ; 0.207545068 ; 0.070981621 ; 0.35682512 ; 0.407227325 ; 0.317419682 ; 0.375447306 ; 0.357173414 ; 0.095762386 ; 0.758845205 ; 0.347451554 ; 0.433995897 ; 0.563341065 ; 0.847336798 ; 0.874144819 ; 0.945402518 ; 0.923899205 ; 0.330844784 ; 0.503854714 ; 0.640139077 ; 0.502593176 ; 0.370436877 ; 0.41671986 ; 0.36342036 ; 0.249482386 ; 0.716147397 ; 0.655755826 ; 0.568490609 ; 0.749896714 ; 0.807360148 ; 0.758056571 ; 0.951604826 ; 0.804307198 ; 0.368653759 ; 0.90715695 ; 0.781473055 ; 0.292214861 ; 0.85143072 ; 0.429743653 ; 0.886626656 ; 0.904022716 ; 0.896282545 ; 0.341101567 ; 0.821794752 ; 0.679699757 ; 0.551849651 ; 0.887068923 ; 0.79334792 ; 0.914258797 ; 0.962412674 ; 0.920373719 ; 0.548787472 ; 0.728818205 ; 0.606631659 ; 0.967747606 ; 0.35521074 ; 0.971473082 ; 0.624409945 ; 0.409709275 ; 0.18957222 ; 0.766495458 ; 0.850285401 ; 0.753992357 ; 0.980299758 ; 0.438160046 ; 0.32626995 ; 0.290752976 ; 0.685138159 ; 0.998455604 ; 0.829499038 ; 0.713936368 ; 0.70492374 ; 0.937926612 ; 0.734327868 ; 0.764046892 ; 0.971542537 ; 0.783533031 ; 0.431997373 ; 0.321708657 ; 0.996916944 ; 0.91716511 ; 0.500703664 ; 0.538576463 ; 0.300393121 ; 0.731985418 ; 0.820535216 ; 0.831272068 ; 0.364514849 ; 0.251272983 ; 0.315898466 ; 0.605408221 ; 0.252220661 ; 0.786638411 ; 0.744476703 ; 0.313855721 ; 0.753577402 ; 0.381009488 ; 0.071795248 ; 0.323036439 ; 0.816414826 ; 0.243981432 ; 0.937216481 ; 0.731522809 ; 0.267097073 ; 0.615624593 ; 0.160415596 ; 0.245594804 ; 0.435819629 ; 0.303530868 ; 0.559815783 ; 0.034338837 ; 0.371386664 ; 0.403336369 ; 0.696968729 ; 0.746066206 ; 0.276430164 ; 0.846745701
FRACTION_GENOME_ALTERED_REPORTED	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Fraction Genome Altered Reported	Sample	0.2851 ; 0.1405 ; 0.2626 ; 0.021 ; 0.028 ; 0.2115 ; 0.1897 ; 0.0441 ; 4.00E-04 ; 0.2503 ; 0.5278 ; 0.0573 ; 0.0143 ; 0.1088 ; 0.1333 ; 0.2685 ; 0.0871 ; 0.0989 ; 0.3721 ; 0.0051 ; 0.0699 ; 0.1791 ; 0.0524 ; 0.189 ; 0.2485 ; 0.2396 ; 0.4586 ; 0.0322 ; 0 ; 0.0269 ; 0.3332 ; 0.0145 ; 0.051 ; 0.0134 ; 0.123 ; 0.391 ; 0.1504 ; 0.247 ; 0.4005 ; 0.0018 ; 0.4482 ; 0.0605 ; 0.1827 ; 0.6505 ; 0.2479 ; 0.0077 ; 0.158 ; 0.0912 ; 0.2209 ; 0.0189 ; 0.1542 ; 0.2119 ; 0.1433 ; 0.2947 ; 0.4176 ; 0.3506 ; 0.0099 ; 0.2692 ; 0.0561 ; 0.2113 ; 0.0577 ; 0.0295 ; 0.0755 ; 0.0816 ; 0.1003 ; 0.1449 ; 0.1122 ; 0.3561 ; 0.1352 ; 0.1497 ; 0.2024 ; 0.0784 ; 0.1781 ; 2.00E-04 ; 0.0877 ; 0.296 ; 0.0655 ; 7.00E-04 ; 0.0804 ; 0.1939 ; 0.5212 ; 0.0772 ; 0.4404 ; 0.0909 ; 0.0245 ; 0.0431 ; 0.129 ; 0.1125 ; 0.3356 ; 0.1272 ; 0.2356 ; 0.1507 ; 0.0142 ; 0.2806 ; 0.2608 ; 0.0866 ; 0.3373 ; 0.3166 ; 0.1207 ; 0.4346 ; 0.4512 ; 0.1863 ; 0.1657 ; 0.2101 ; 0.3167 ; 0.2066 ; 0.067 ; 0.211 ; 0.1878 ; 0.1911 ; 0.0127 ; 1.00E-04 ; 0.2232 ; 0.3719 ; 0.0333 ; 0.0536 ; 0.1169 ; 0.0626 ; 0.3046 ; 0.3099 ; 0.0473 ; 0.1329 ; 0.2421 ; 0.161 ; 0.4349 ; 0.2083 ; 0.0808 ; 0.2103 ; 0.0367 ; 0.0221 ; 0.0248 ; 0.3995 ; 0.0896 ; 0.2966 ; 0.0079 ; 0.4033 ; 0.171 ; 0.2648 ; 0.1511 ; 0.1039 ; 0.0574 ; 0.2176 ; 0.0298 ; 0.0599 ; 0.1952 ; 0.2153 ; 0.0037 ; 0.1395 ; 0.2312 ; 0.1851 ; 0.1098 ; 0.1105 ; 0.2656 ; 0.4485 ; 0.2082 ; 0.1257 ; 0.2459 ; 0.2188 ; 0.2524 ; 0.3505 ; 0.0012 ; 6.00E-04 ; 0.0583 ; 0.0591 ; 0.1085 ; 0.2723 ; 0.0384 ; 0.0182 ; 0.1266 ; 0.267 ; 0.3047 ; 5.00E-04 ; 0.0754 ; 0.1562 ; 0.5772 ; 0.2086 ; 0.1937 ; 0.2017 ; 0.1551 ; 0.0348 ; 0.0764 ; 0.2226 ; 0.2891 ; 0.2049 ; 0.0461 ; 0.2581 ; 0.1176 ; 0.1907 ; 0.0594 ; 0.1128 ; 0.142 ; 0.1246 ; 0.1177 ; 0.1308 ; 0.1672 ; 0.4104 ; 0.4835 ; 0.2501 ; 0.14 ; 0.3009 ; 0.0021 ; 0.2089 ; 0.295 ; 0.0137 ; 0.1157 ; 0.1071 ; 0.1812 ; 0.134 ; 0.0278 ; 0.2187 ; 0.0081 ; 0.0123 ; 0.2265 ; 0.1967 ; 0.1536 ; 0.1491 ; 0.0087 ; 0.1772 ; 0.2461 ; 0.172 ; 0.0011 ; 0.1843 ; 0.0163 ; 0.0548 ; 0.1407 ; 0.1256 ; 0.3377 ; 0.251 ; 0.2144 ; 0.0019 ; 0.1912 ; 0.2004 ; 0.6228 ; 0.0067 ; 0.0014 ; 0.3121 ; 0.331 ; 0.2051 ; 0.149 ; 0.1238 ; 0.4206 ; 0.1622 ; 0.2371 ; 0.0942 ; 0.0167 ; 0.2308 ; 0.1376 ; 0.231 ; 0.1661 ; 0.0619 ; 0.0511 ; 0.3865 ; 0.2163 ; 0.1341 ; 0.1649 ; 0.1892 ; 0.0584 ; 0.0643 ; 0.1058 ; 0.1489 ; 0.4971 ; 0.0962 ; 0.4806 ; 0.0753 ; 0.1391 ; 0.2213 ; 0.0427 ; 0.3779 ; 0.2557 ; 0.099 ; 0.0491 ; 0.0174 ; 0.1644 ; 0.2484 ; 0.3262 ; 0.025 ; 0.0664 ; 0.1905 ; 0.097 ; 0.3404 ; 0.0761 ; 0.0525 ; 0.2456 ; 0.3632 ; 0.0184 ; 0.043 ; 0.0025 ; 0.0016 ; 0.0704 ; 0.0532 ; 0.1557 ; 0.1332 ; 0.1958 ; 0.244 ; 0.0727 ; 0.1001 ; 0.2455 ; 0.2534 ; 0.2404 ; 0.2733 ; 0.2783 ; 0.0538 ; 0.1604 ; 0.0411 ; 0.0264 ; 0.1471 ; 0.0352 ; 0.0418 ; 0.1457 ; 0.026 ; 0.0064 ; 0.0434 ; 0.1069 ; 0.1424 ; 0.1691 ; 0.2399 ; 0.148 ; 0.2835 ; 0.1683 ; 0.0114 ; 0.2859 ; 0.0244 ; 0.0709 ; 0.1574 ; 0.1367 ; 0.4144 ; 0.2099 ; 0.1195 ; 0.4054 ; 0.174 ; 0.0581 ; 0.3255 ; 0.101 ; 0.1724 ; 0.2563 ; 0.1639 ; 0.2826 ; 0.3871 ; 0.1289 ; 0.1962 ; 0.2941 ; 0.0426 ; 0.0405 ; 0.1715 ; 0.0151 ; 0.0606 ; 0.0444 ; 0.2968 ; 0.0904 ; 0.2096 ; 0.1132 ; 0.3003 ; 0.0024 ; 0.2963 ; 0.1602 ; 0.0178 ; 0.1406 ; 0.0864 ; 0.2536 ; 0.0031 ; 0.1826 ; 0.4569 ; 0.5463 ; 0.1317 ; 0.139 ; 0.3149 ; 0.0445 ; 0.0308 ; 0.0345 ; 0.0743 ; 0.2827 ; 0.2094 ; 0.2285 ; 0.1041 ; 0.0147 ; 0.1667 ; 0.19 ; 0.1904 ; 0.1803 ; 0.1021 ; 0.1899 ; 0.2974 ; 0.3461 ; 0.1326 ; 0.3609 ; 0.5485 ; 0.1521 ; 0.0102 ; 0.0842 ; 0.2829 ; 0.4678 ; 0.0417 ; 0.2855 ; 0.0094 ; 0.3633 ; 0.0931 ; 0.2319 ; 0.2347 ; 0.0058 ; 0.2751 ; 0.1963 ; 0.4297 ; 0.0063 ; 0.1156 ; 0.0355 ; 0.3001 ; 0.0213 ; 0.1864 ; 0.1817 ; 0.0212 ; 0.5213 ; 0.216 ; 0.4994 ; 0.0153 ; 0.1123 ; 0.033 ; 0.0092 ; 0.6089 ; 0.0713 ; 0.186 ; 0.0228 ; 0.0247 ; 0.1908 ; 0.1906 ; 0.1856 ; 0.0045 ; 0.2344 ; 0.3718 ; 0.4839 ; 0.4045 ; 0.3515 ; 0.586 ; 0.5427 ; 0.4918 ; 0.3932 ; 0.2535 ; 0.2628 ; 0.5606 ; 0.1879 ; 0.507 ; 0.1848 ; 0.529 ; 0.294 ; 0.2879 ; 0.1036 ; 0.1074 ; 0.0888 ; 0.1915 ; 0.0985 ; 0.0121 ; 0.1301 ; 0.0976 ; 0.1835 ; 0.2749 ; 0.2354 ; 0.3289 ; 0.1614 ; 0.1605 ; 0.2469 ; 0.0841 ; 0.3195 ; 0.1013 ; 0.3027 ; 0.0523 ; 0.3068 ; 0.5679 ; 0.2547 ; 0.3566 ; 0.1811 ; 0.2223 ; 0.2787 ; 0.0902 ; 0.0097 ; 0.1867 ; 0.3301 ; 0.1941 ; 0.3464 ; 0.1948 ; 0.4239 ; 0.1775 ; 0.2848 ; 0.258 ; 0.0846 ; 0.3799 ; 0.3547 ; 0.1969 ; 0.462 ; 0.2401 ; 0.1202 ; 0.2174 ; 0.3889 ; 0.1366 ; 0.3235 ; 0.1111 ; 0.3037 ; 0.234 ; 0.1263 ; 0.0622 ; 0.0466 ; 0.1059 ; 0.4223 ; 0.1184 ; 0.1322 ; 0.1423 ; 0.126 ; 0.2625 ; 0.5604 ; 0.0261 ; 0.4353 ; 0.4391 ; 0.523 ; 0.1816 ; 0.2195 ; 0.0521 ; 0.0522 ; 0.3288 ; 0.1439 ; 0.0023 ; 0.078 ; 0.1323 ; 0.081 ; 0.2672 ; 0.2218 ; 0.0066 ; 0.2847 ; 0.0199 ; 0.1438 ; 0.4423 ; 0.0635 ; 0.2667 ; 0.3168 ; 0.4947 ; 0.056 ; 0.0924 ; 0.0375 ; 0.0999 ; 0.2478 ; 0.0856 ; 0.4846 ; 0.3835 ; 0.2378 ; 0.0043 ; 0.4484 ; 0.6121 ; 0.239 ; 0.0032 ; 0.3529 ; 0.2716 ; 0.3624 ; 0.1258 ; 0.6018 ; 0.5052 ; 0.3508 ; 0.0968 ; 0.3694 ; 0.6079 ; 0.367 ; 0.5372 ; 0.285 ; 0.6186 ; 0.6651 ; 0.1922 ; 0.3693 ; 0.3275 ; 0.2775 ; 0.1741 ; 0.0258 ; 0.3293 ; 0.3778 ; 0.2556 ; 0.2517 ; 0.4917 ; 0.2759 ; 0.3129 ; 0.0381 ; 0.2822 ; 0.1665 ; 0.3064 ; 0.0456 ; 0.4787 ; 0.2238 ; 0.4355 ; 0.382 ; 0.0705 ; 0.1382 ; 0.0963 ; 0.2684 ; 0.2717 ; 0.2961 ; 0.3317 ; 0.2377 ; 0.6929 ; 0.0869 ; 0.1284 ; 0.4127 ; 0.3128 ; 0.2251 ; 0.089 ; 0.379
FRACTION_LOH	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Fraction LOH	Sample	0.1037162 ; 0.039970941 ; 0.247117572 ; 0 ; 0.486568464 ; 0.19287929 ; 0.239700785 ; 0.186530483 ; 0.088152352 ; 0.126862853 ; 0.241629454 ; 0.062851652 ; 0.217524397 ; 0.23633059 ; 0.086735705 ; 0.027366773 ; 0.183918804 ; 0.151038646 ; 0.561717918 ; 0.228819912 ; 0.312534051 ; 0.02977898 ; 0.011668439 ; 0.257999351 ; 0.297831205 ; 0.083033848 ; 0.058242021 ; 0.234773482 ; 0.078711417 ; 0.404524333 ; 0.582990158 ; 0.189776499 ; 0.23459394 ; 0.21612891 ; 0.417390504 ; 0.147473232 ; 0.120378576 ; 0.230414583 ; 0.128812506 ; 0.213235481 ; 0.432594237 ; 0.39525872 ; 0.257711554 ; 0.258570084 ; 0.118923132 ; 0.041291077 ; 0.567020249 ; 0.262255091 ; 0.279862314 ; 0.006689705 ; 0.188865921 ; 0.250158758 ; 0.210816047 ; 0.381062773 ; 0.136508737 ; 0.193223457 ; 0.213271973 ; 0.390720657 ; 0.007772022 ; 0.143551197 ; 0.148503399 ; 0.275777248 ; 0.238922466 ; 0.017512636 ; 0.071003547 ; 0.191201689 ; 0.13630873 ; 0.341072524 ; 0.192220573 ; 0.048158425 ; 0.115889659 ; 0.060489865 ; 0.325184488 ; 0.345712201 ; 0.623285199 ; 0.160935435 ; 0.272772795 ; 0.240801178 ; 0.136360593 ; 0.24571917 ; 0.257209738 ; 0.244590968 ; 0.130475885 ; 0.070530611 ; 0.191284119 ; 0.295309165 ; 0.121881344 ; 0.206785301 ; 0.034105727 ; 0.25896973 ; 0.041108517 ; 0.332825608 ; 0.454951138 ; 0.113848086 ; 0.469999724 ; 0.028847572 ; 0.295773935 ; 0.2745236 ; 0.23671028 ; 0.186123126 ; 0.090520019 ; 0.0506113 ; 0.440088278 ; 0.374408271 ; 0.09295762 ; 0.207139532 ; 0.147344165 ; 0.490430518 ; 0.231593681 ; 0.052985163 ; 0.173614359 ; 0.086664266 ; 0.122679103 ; 0.127889558 ; 0.154241011 ; 0.295403582 ; 0.065483379 ; 0.773478239 ; 0.444603363 ; 0.177068995 ; 0.051781597 ; 0.103338259 ; 0.481515467 ; 0.366048237 ; 0.370901266 ; 0.12472015 ; 0.250453822 ; 0.491733113 ; 0.2264258 ; 0.0795662 ; 0.210877666 ; 0.434987201 ; 0.370351045 ; 0.0180473 ; 0.27338995 ; 0.410364272 ; 0.324928731 ; 0.269228185 ; 0.043496593 ; 0.138743834 ; 0.564377722 ; 0.136698134 ; 0.172519047 ; 0.232871152 ; 0.165913837 ; 0.16532477 ; 0.168720862 ; 0.195418792 ; 0.126151726 ; 0.369243298 ; 0.028636579 ; 0.116313997 ; 0.10993734 ; 0.09018485 ; 0.10617658 ; 0.013983142 ; 0.06722507 ; 0.096290331 ; 0.06548157 ; 0.089876871 ; 0.11194259 ; 0.214583843 ; 0.24260994 ; 0.01522965 ; 0.066420563 ; 0.11353288 ; 0.127149093 ; 0.118597817 ; 0.09513779 ; 0.045653408 ; 0.08396392 ; 0.264254162 ; 0.33090745 ; 0.026918705 ; 0.04151788 ; 0.286242935 ; 0.33471197 ; 0.104737123 ; 0.4119177 ; 0.099336819 ; 0.18000288 ; 0.011754666 ; 0.50697727 ; 0.161716766 ; 0.3701226 ; 0.139214303 ; 0.21450483 ; 0.032849843 ; 0.01067886 ; 0.01655623 ; 0.04436201 ; 0.218804236 ; 0.23018445 ; 0.376606503 ; 0.37841033 ; 0.030737255 ; 0.24509012 ; 0.063586558 ; 0.17668913 ; 0.008246805 ; 0.01546109 ; 0.313481079 ; 0.27346517 ; 0.026575308 ; 0.03769627 ; 0.16526014 ; 0.340635336 ; 0.17799956 ; 0.054518045 ; 0.220262921 ; 0.066074826 ; 0.211947953 ; 0.393544673 ; 0.073572885 ; 0.16674392 ; 0.12994265 ; 0.54779797 ; 0.69336768 ; 0.183995826 ; 0.33917597 ; 0.15463883 ; 0.24346133 ; 0.23347461 ; 0.00025373 ; 0.424363149 ; 0.141295263 ; 0.40585503 ; 0.212669112 ; 0.26386246 ; 0.306961494 ; 0.2056723 ; 0.034803734 ; 0.111575351 ; 0.103721879 ; 0.11487498 ; 0.290856912 ; 0.047288943 ; 0.06008128 ; 0.20330418 ; 0.388555918 ; 0.31690364 ; 0.390682125 ; 0.32187771 ; 0.492773721 ; 0.74276684 ; 0.227245028 ; 0.184944113 ; 0.504526046 ; 0.085814854 ; 0.230956267 ; 0.27446521 ; 0.048437423 ; 0.215316199 ; 0.26658548 ; 0.505631186 ; 0.111787309 ; 0.292998623 ; 0.23168037 ; 0.240988787 ; 0.15098507 ; 0.601927656 ; 0.4111204 ; 0.122020887 ; 0.25100001 ; 0.15789966 ; 0.409666949 ; 0.156860337 ; 0.15931967 ; 0.21311219 ; 0.065712789 ; 0.160657652 ; 0.2154969 ; 0.177743351 ; 0.52201099 ; 0.528309094 ; 0.59076806 ; 0.690164934 ; 0.060384996 ; 0.237971358 ; 0.089636539 ; 0.26371692 ; 0.576013185 ; 0.054510998 ; 0.350652781 ; 0.329802453 ; 0.297609028 ; 0.148643288 ; 0.045335549 ; 0.050197825 ; 0.172836061 ; 0.426065361 ; 0.365471509 ; 0.299326966 ; 0.189867188 ; 0.081292758 ; 0.076914539 ; 0.224653166 ; 0.535767912 ; 0.268998757 ; 0.191893798 ; 0.684574919 ; 0.199913303 ; 0.1196801 ; 0.210922145 ; 0.174999533 ; 0.325543671 ; 0.187793844 ; 0.02875435 ; 0.666755291 ; 0.21464316 ; 0.222627538 ; 0.35550145 ; 0.136647592 ; 0.10119547 ; 0.101368153 ; 0.07388768 ; 0.092240929 ; 0.525567084 ; 0.5436699 ; 0.046051818 ; 0.04171684 ; 0.647369398 ; 0.12113336 ; 0.105940864 ; 0.521981809 ; 0.19094115 ; 0.33032217 ; 0.27784352 ; 0.141415586 ; 0.06430911 ; 0.152846718 ; 0.17453214 ; 0.138896091 ; 0.22319459 ; 0.244836733 ; 0.14558017 ; 0.27404078 ; 0.59216147 ; 0.25529347 ; 0.15329249 ; 0.00057714 ; 0.14276823 ; 0.2994203 ; 0.09505668 ; 0.32322053 ; 0.17131078 ; 0.09917226 ; 0.11525412 ; 0.15612942 ; 0.14008537 ; 0.10765905 ; 0.09823806 ; 0.17472566 ; 0.35670541 ; 0.08032321 ; 0.32901484 ; 0.04191618 ; 0.12176425 ; 0.20830566 ; 0.12387581 ; 0.47042503 ; 0.19392871 ; 0.20926435 ; 0.18925861 ; 0.21757149 ; 0.08993443 ; 0.32962375
HAS_ANY_DNA	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Has Any DNA	Patient	
HAS_MSK_IMPACT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Has MSK IMPACT	Patient	
HAS_RNASEQ	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Has RNASeq	Patient	
HAS_WES	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Has WES	Patient	
HRD_LOH	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	HRD LOH	Sample	8 ; 5 ; 2 ; 0 ; 3 ; 9 ; 6 ; 1 ; 4 ; 13 ; 10 ; 11 ; 12 ; 7 ; 16 ; 17 ; 15
HYPODIPLOID	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Hypodiploid	Sample	FALSE ; TRUE
IGO_PROJECT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	IGO Project	Sample	5240_J ; 5240_G ; 5240_O ; 5240_R ; 4976
INITIAL_BMI_NUMBER	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Initial BMI (Numeric)	Patient	
INTERSTITIAL_AI_MEAN_SIZE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Interstitial Ai Mean Size	Sample	65065401 ; 57176544.5 ; 125845450 ; 131209835 ; 136487550 ; 75528450 ; 23222272 ; 91545348.25 ; 29307581 ; 57235881.5 ; 93667827 ; 18691106 ; 86651578.67 ; 88348244.5 ; 146403667 ; 118095902 ; 39185972 ; 140718678 ; 13983422 ; 75060818 ; 123888400 ; 124493734 ; 74872236 ; 55893065 ; 54951370.5 ; 64646115 ; 40261112.5 ; 94715599.67 ; 35765717 ; 59246938 ; 33054775 ; 106044362.3 ; 91815975 ; 65375703.67 ; 94019600.5 ; 70068150 ; 58973750 ; 100128886 ; 101653080.5 ; 76820670.25 ; 34113942 ; 25237582 ; 57649632.5 ; 119611649.3 ; 95233313 ; 66990706 ; 130797693 ; 39869777 ; 86081417.57 ; 101766111.2 ; 95415365.5 ; 72344874 ; 102355060 ; 39359879 ; 75804808.5 ; 25236781 ; 36900542.67 ; 105884559.5 ; 56222821.33 ; 108526736.5 ; 40660293 ; 43870888 ; 136253829 ; 79569272.5 ; 81634592.5 ; 67480829 ; 84583179.25 ; 41541637.75 ; 90766955.67 ; 125185810 ; 65991435.5 ; 88195902 ; 20564074.5 ; 53323889.5 ; 141574507 ; 89157676 ; 85049478.57 ; 25237505 ; 89137873.5 ; 95714690 ; 66374800.67 ; 19214710 ; 63428965.44 ; 66760394 ; 53656939 ; 67494225 ; 72743406 ; 48387486 ; 75718863.5 ; 126388927 ; 73739625 ; 91449772 ; 86526482 ; 70041381 ; 87988916.67 ; 82632375 ; 93693466 ; 37679788.71 ; 10302474 ; 46189150.33 ; 15538781.5 ; 116537947 ; 47929519.27 ; 43759261.5 ; 82844366 ; 30835825.69 ; 87992154.5 ; 48880226.88 ; 106877886.5 ; 52351810 ; 108146229 ; 106161750 ; 52710678.63 ; 141746598 ; 37532281 ; 54054984.35 ; 23384871.57 ; 30304302.17 ; 129644216 ; 62289879 ; 142848983 ; 60458633 ; 95983028 ; 49891225.4 ; 63669054.33 ; 41154376.89 ; 127435801 ; 55510531.2 ; 38538230.5 ; 97085297 ; 70519597.67 ; 143958273.5 ; 64973612.08 ; 112290264 ; 125366177 ; 110299853.7 ; 32273802.44 ; 126246588 ; 36458293.18 ; 44169844 ; 55603953.55 ; 44388389.64 ; 102728546 ; 72453301 ; 97924729.6 ; 31302281.46 ; 15947811 ; 42931970 ; 52535092 ; 9419068 ; 53433403.14 ; 82210814 ; 38585260.93 ; 38206236 ; 24863664.57 ; 102866437.5 ; 80163793.67 ; 9010345 ; 122522273 ; 133084374 ; 89213191 ; 30208200 ; 51860454.67 ; 56247623.6 ; 68656939.56 ; 48809269 ; 40330508.33 ; 41230000.75 ; 48048780.5 ; 121178105 ; 96216870.13 ; 142474065 ; 86061320.5 ; 26800680 ; 53148397 ; 121063484 ; 90393050 ; 63667409 ; 101047278 ; 80970183.5 ; 126174557 ; 80123546.33 ; 87610367 ; 65133000 ; 90355214 ; 91306505 ; 85428683 ; 124626153 ; 142793260 ; 26889332.76 ; 47102873.78 ; 34045702.2 ; 98061824 ; 81015548.5 ; 108863481.5 ; 32669198.88 ; 43816094.56 ; 67356952 ; 39886897.6 ; 92979250 ; 66312888.7 ; 4363259.5 ; 68794825.67 ; 70618118.17 ; 80442907 ; 35810250.81 ; 47193350 ; 53977502.2 ; 45559600.91 ; 60566851 ; 83455180.67 ; 96727817.67 ; 49788404 ; 39927983.14 ; 59118655.75 ; 35843759.67 ; 87000835 ; 48106259.25 ; 23436241.86 ; 44604220.14 ; 71510859.33 ; 43647648.5 ; 18115090.67 ; 68236582.58 ; 36016687.2 ; 84946213 ; 45795024.5 ; 10668391.25 ; 38037551.77 ; 27274571.67 ; 33294939.57 ; 29982744.55 ; 21023160.3 ; 10095327.33 ; 89762139.75 ; 58713813.8 ; 71959883.89 ; 67613726.89 ; 50419852.5 ; 49986581.93
INTERSTITIAL_LOH_MEAN_SIZE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Interstitial LOH Mean Size	Sample	65065401 ; 29307581 ; 86749413 ; 111995061 ; 146403667 ; 118095902 ; 113523522.5 ; 66732608 ; 47376414 ; 94715599.67 ; 35765717 ; 37566764 ; 70068150 ; 107971678 ; 32699306 ; 25237582 ; 89122650 ; 118144650 ; 56509351 ; 99625344 ; 136253727 ; 55420315.5 ; 43506917 ; 25236781 ; 105884559.5 ; 54916264 ; 108526736.5 ; 136253829 ; 73390386.5 ; 81634592.5 ; 71821385 ; 76168030 ; 26255750 ; 105904410.5 ; 65991435.5 ; 28978818 ; 101577404 ; 141574507 ; 92634027.6 ; 25237505 ; 89137873.5 ; 53455151 ; 25237550 ; 85266446 ; 102823150 ; 55495954 ; 52779897 ; 91449772 ; 46994359 ; 70041381 ; 94367757 ; 93693466 ; 49251804.2 ; 17165394.5 ; 32813192 ; 15538781.5 ; 116537947 ; 8111661.2 ; 46732621 ; 77192350 ; 23701929.42 ; 25334816.86 ; 146385073 ; 97401179.33 ; 72708883.2 ; 141746598 ; 37532281 ; 48805904.2 ; 17002900.5 ; 35902372.6 ; 65478237.6 ; 10357364 ; 95983028 ; 57601773.5 ; 43005544.14 ; 38048653.67 ; 38538230.5 ; 97085297 ; 55164544.33 ; 8137188 ; 124220083.5 ; 40124423.09 ; 126246588 ; 48385740.75 ; 48392060.5 ; 34762853.5 ; 52694236.75 ; 103128202.3 ; 30704756 ; 28478146 ; 29381017 ; 38866563.5 ; 9419068 ; 59960025.83 ; 10795100 ; 32836445.57 ; 47426088 ; 150518316 ; 74589785 ; 158264401 ; 30208200 ; 30512271 ; 80862547.2 ; 62068037.33 ; 48809269 ; 42326679.4 ; 48113223.67 ; 48048780.5 ; 148063716 ; 72681182 ; 142474065 ; 31775348 ; 65133000 ; 90355214 ; 85428683 ; 34586955.33 ; 39520653.25 ; 15741087.33 ; 81015548.5 ; 29586369 ; 17689490.33 ; 30481773.8 ; 26554924.2 ; 92979250 ; 58087758.25 ; 4363259.5 ; 103409453 ; 21001867.38 ; 114782085 ; 51878486.5 ; 56268251.43 ; 170712140.5 ; 89942375 ; 20836969 ; 110502878.5 ; 6800650.333 ; 87000835 ; 89351377.33 ; 21721433 ; 33250396 ; 14752164.5 ; 28041600 ; 12810450 ; 29171167 ; 68083420 ; 18686319.67 ; 48506791.2 ; 25963512.25 ; 24227198.17 ; 36030553.67 ; 10095327.33 ; 100730048 ; 66002889 ; 48737061.5 ; 141510376 ; 31064398.67 ; 43068243.33
LARC_CRT_OUTCOME_CASES_DFS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	LARC CRT outcome cases DFS	Patient	
LARC_CRT_OUTCOME_CASES_RESPONSE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	LARC CRT outcome cases Response	Patient	
LOH_CHROMOSOMES	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	LOH Chromosomes	Sample	14,18 ; 18 ; 2,5,9,15 ; 3,4,5,9,10,11,14,15,17,18 ; 4,14,16,18,22 ; 4,8,14,18 ; 4,14,15,22 ; 18,NA ; 18,20,21 ; 10,12,15,16,17,18 ; 15 ; 11,14,15,18 ; 14,16,17,18,22 ; 15,17 ; 14,17,18,19,21,22 ; 4,18 ; 1,4,5,8,10,11,12,15,17,18,19,20,22 ; 6,7,17,18 ; 4,5,7,11,14,18,21 ; 4,10,14,15,16,18,19 ; 8,14,15,16,17,18,21,22 ; 1,5,18,19,21,22 ; 18,22 ; 1,4,8,10,16,17,18,22 ; 1,4,5,7,8,9,10,14,16,18,19,21,22 ; 3,10,16,19 ; 4,6,9,14,22 ; 11,15,17,18,20,22 ; 4,10,17,18,19,21,22 ; 9,17,18 ; 4,18,21,22 ; 2,9,15,18 ; 14,15,18,22 ; 7,9,18,20 ; 4,6,9,10,11,14,15,17,18,19,21 ; 3,5,9,14,16,18,21,22 ; 6,8,15,16,17,18,21,22 ; 2,4,9 ; 13,18 ; 1,2,3,4,13,14,15,16,17,18,19,20,21,22 ; 1,4,12,17,18 ; 1,6,16,17,18,21 ; 4,5,8,18 ; 4,10,18,21 ; 1,4,9,13,17,18,22 ; 3,5 ; 5,14,18 ; 4,9,14 ; 2,4,8,9,12,14,18,21,22 ; 14,18,19,22 ; 10,14,18,21 ; 4,9,14,18,21,22 ; 2,14,18,22 ; 1,4,18 ; 14,18,21,22 ; 2,6,7,9,15,18,21 ; 11,15,17,18,22 ; 12 ; 4 ; 3,4,8,15,17,18,21,22 ; 1,3,5,8,16,18 ; 1,3,4,5,7,8,9,11,14,16,17,18 ; 4,15,21,22 ; 4,13,14,17,18,21 ; 4,11,18,21,22 ; 10 ; 6,8,13,18,21,22 ; 4,10,14,15,18,21,22 ; 5,15,17,18,20,22 ; 17,21 ; 9,11,15,18,22 ; 4,6,16,18,22 ; 18,21,22 ; 4,5,18,21 ; 12,18,22 ; 5,6,10,11,18 ; 3,9,12,18,22 ; 18,21 ; 6,9,11,13,14,15,16,17,18,22 ; 4,5,10,15,17,18,22 ; 4,5,11,15,17,18 ; 14,15,17,18 ; 5,11,15,18,22 ; 11,18 ; 3,4,5,14,15,18,21,22 ; 3,9,14,15,17,18,22 ; 13,18,22 ; 8,11,15,17,18 ; 9,18,22 ; 5,10,11,12,14,15,16,18,19,21,22 ; 11,18,22 ; 13,19,21,22 ; 15,17,18,21,22 ; 5,22 ; 2,9,10,14,15,18 ; 1,3,4,5,6,8,9,10,13,14,15,17,18,19,20,21,22 ; 4,5,6,10,14,15,16,18,21,22 ; 2,14,18 ; 13,15,18,22 ; 2,4,5,9,10,11,14,18,19 ; 4,5,8,10,15,17,18,19,21 ; 3,4,6,14,15,18,21,22 ; 6,10,22 ; 9,12,14,15,17,18,21,22 ; 3,5,9,11,14,17,18,21,22 ; 6,7,18,21 ; 2,15,18 ; 4,8,9,10,14,15,16,18,19,20,22 ; 6,8,9,14,15,17,18,19,21,22 ; 3,9,10,16,18,21 ; 4,5,14,15,17,18,22 ; 1,4,13,14,15,18,22 ; 10,11,14,15,18,22 ; 11,18,21,22 ; 2,4,5,8,9,10,11,14,17,18,21,22 ; 15,18 ; 8,15,18,22 ; 8,14,15,17,18 ; 4,18,21 ; 10,14,15,18,22 ; 6,15,18 ; 10,15,17 ; 2,18,22 ; 4,5,9,10,11,14,18,21 ; 12,18 ; 9,18 ; 14,18,21 ; 5,9,10,14 ; 5,9,10,14,18,22 ; 6 ; 6,17,21 ; 11,14,NA,22 ; 14 ; 4,14,18,21,22 ; 4,6,9,14,18,21,22 ; 2,9,17,18,21,22 ; 2,8,9,17,18,21,22 ; 15,17,18,22 ; 4,5,6,7,12,15,17,18,21,22 ; 17,18,22 ; 4,17,18,21,22 ; 1,3,4,5,6,10,14,15,18 ; 5,14,18,22 ; 4,5,10,14,15,17,18,21,22 ; 12,15,17,18 ; 1,15,17,18 ; 1,5,15,18,21 ; 1,15,18,21 ; 1,6,9,11,14,17,22 ; 6,9,10,11,15,17 ; 17 ; 7,12,15,17,18 ; 6,15,18,21 ; 4,6,15,18,21 ; 22 ; 14,15,18,21 ; 4,6,7,14 ; 7,14,15,18,21,22 ; 7,13,14,15,18,22 ; 10,12,15,18 ; 4,9,11,14,18,21 ; 1,3,8,9,12,13,17,18,21,22 ; 1,3,4,8,9,10,12,13,16,17,18,21,22 ; 3,9,12,21 ; 3,9,10,12,14,18,21,22 ; 10,17,18 ; 4,6,18,21 ; 4,6,16,18,21 ; 5,6,9,10,11,14,15 ; 2,9,10,12,14,15,18,22 ; 4,14,15,18,21 ; 5,8,15,17,18,21,22 ; 10,14,17,18,19 ; 10,15,18 ; 14,15,17,18,20,21,22 ; 6,9,18 ; 5,8,10,11,14,15,17,18,19,21,22 ; 5,8,10,14,15,17,18,21,22 ; 2,5,6,14,15,18,21,22 ; 5,6,14,15,16,18,21,22 ; 3,5,7,9,14,15,18,21,22 ; 1,2,4,8,9,10,12,13,14,15,16,17,18,19,21,22 ; 3,8,10,15,18 ; 1,4,5,8,10,12,14,15,17,18,21 ; 7,9,11,13,22 ; 7,9,10,11,13,21,22 ; 18,19 ; 13,14,18,20,22 ; 3,4,10,11,12,15,16,17,18,21 ; 1,4,7,15,18,20 ; 9,11,NA,14,NA ; 4,6,12,18 ; 4,6 ; 3,4,5,6,8,9,10,14,15,18,21,22 ; 3,4,8,9,10,14,15,18,22 ; 2,18,NA ; 2,14,15,17,18,22 ; 2,17,18 ; 1,4,10,14,15,16,17,18,19,21,22 ; 4,6,20 ; 4,18,22 ; 5 ; 5,16,18,22 ; 5,9,10,18,22 ; 4,11,14,17 ; 1,3,4,5,10,11,15,16,17,18,21 ; 3,5,9,10,12,13,14,15,16,18 ; 3,5,7,9,10,12,13,14,15,18,22 ; 1,2,4,5,7,8,9,10,12,14,16,17,18 ; 4,5,14,17 ; 7,21 ; 3,5,9,16,17,21 ; 1,4,5,6,7,9,13,15,16,18,21,22 ; 1,5,7,11,14,15,NA,21,NA ; 1,3,10,14,15,17,18 ; 4,6,9,14,18,21 ; NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA ; 11,14,15,18,22 ; 5,6,7,9,10,14,15,17,18,21 ; 1,6,7,14,15,18 ; 9,10,14,15,17,18,22 ; 5,17,18,22 ; 2 ; 1,2,5,6,8,14,15,16,18,19,22 ; 2,9,14,18,21 ; NA,9,10,NA,14,NA,16,NA ; 1,4,6,8,9,10,11,12,13,14,15,16,17,18,19,22 ; 7,9,18 ; 5,11,14,16,18 ; 1,4,5,14,18,19,21,22 ; 1,9,18,21,NA ; 19 ; 1,3,4,8,9,10,11,12,NA,14,15,17,18,NA,NA,21,NA ; 6,13,14,18,NA ; 5,11,14,15,18,22 ; 4,5,6,10,15,18,21,22 ; 5,17 ; 17,18 ; 12,21,22 ; 2,4,5,9,10,11,14,15,17,18,19,22 ; 2,4,5,8,9,10,13,14,15,18,19,22 ; 1,3,4,5,9,10,12,14,15,16,17,18,21,22 ; 9,17,19 ; 3,4,8,11,12,14,18,19,NA,22 ; 8,11,12,18,22 ; 3,4,5,12,15 ; 3,4,5,15 ; 3,6 ; 4,10,18 ; 5,18,22 ; 5,6,8,16,18,22 ; 8,16,18,22 ; 14,15,18,19 ; 4,8,9,10,12,14,15,17,18,21,22 ; 3,4,5,18,21 ; 6,14,18 ; 2,8,12,14,18,20,21,22 ; 2,3,10,11,15,18 ; 6,11,17,18 ; 14,15,18 ; 14,16,18,21 ; 9,11,15,18 ; 1,5,10,11,14,17,18,21 ; 17,18,21 ; 8,9,10,14,18 ; 2,18,21 ; 3,4,5,6,9,10,14,18,21,22 ; 4,15,18 ; 12,14,15,17,18,22 ; 11,14,18,22 ; 4,9,15,17,18,21
MSI_SOMATIC_SITES	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	MSI Somatic Sites	Sample	82 ; 110 ; 151 ; 159 ; 73 ; 274 ; 1704 ; 3065 ; 240 ; 317 ; 512 ; 141 ; 62 ; 375 ; 231 ; 109 ; 1605 ; 193 ; 39 ; 139 ; 249 ; 72 ; 35 ; 2545 ; 79 ; 243 ; 210 ; 424 ; 388 ; 256 ; 136 ; 4071 ; 359 ; 584 ; 120 ; 454 ; 59 ; 442 ; 160 ; 202 ; 3816 ; 152 ; 373 ; 105 ; 95 ; 173 ; 137 ; 613 ; 544 ; 670 ; 462 ; 629 ; 86 ; 751 ; 196 ; 239 ; 823 ; 101 ; 36 ; 104 ; 27 ; 227 ; 5 ; 31 ; 81 ; 37 ; 89 ; 55 ; 280 ; 22 ; 6 ; 90 ; 56 ; 205 ; 47 ; 30 ; 131 ; 68 ; 174 ; 138 ; 130 ; 49 ; 23 ; 43 ; 326
MSI_TOTAL_SITES	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	MSI Total Sites	Sample	21204 ; 23354 ; 20456 ; 20713 ; 21493 ; 24051 ; 21173 ; 25540 ; 20353 ; 20343 ; 17747 ; 28206 ; 19976 ; 20754 ; 20938 ; 19213 ; 21383 ; 21401 ; 18289 ; 21007 ; 20095 ; 21427 ; 19367 ; 19121 ; 19395 ; 19605 ; 18580 ; 18691 ; 17920 ; 19434 ; 20745 ; 20554 ; 22451 ; 22220 ; 21785 ; 18258 ; 17766 ; 18942 ; 18051 ; 18089 ; 20590 ; 18237 ; 14588 ; 14469 ; 14169 ; 15879 ; 14056 ; 14801 ; 13925 ; 13648 ; 21884 ; 26767 ; 36563 ; 28459 ; 23058 ; 22702 ; 26841 ; 24259 ; 23889 ; 21258 ; 20974 ; 23244 ; 14541 ; 13620 ; 13658 ; 14608 ; 13712 ; 14628 ; 14226 ; 14731 ; 13713 ; 14986 ; 14985 ; 14898 ; 14232 ; 15246 ; 13652 ; 13837 ; 13419 ; 14290 ; 14072 ; 14617 ; 14865 ; 14304 ; 14138 ; 13892 ; 15671 ; 16082 ; 14728 ; 13828 ; 13224 ; 14511 ; 15041 ; 13692 ; 13857
MUTATION_COUNT_341	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Mutation Count 341	Sample	6 ; 5 ; 9 ; 7 ; 3 ; 2 ; 8 ; 4 ; 13 ; 10 ; 11 ; 23 ; 1 ; 12 ; 14 ; 140 ; 34 ; 43 ; 29 ; 17 ; 24 ; 117 ; 145 ; 52 ; 95 ; 57 ; 98 ; 16 ; 97 ; 39 ; 78 ; 15 ; 50 ; 74 ; 472 ; 101 ; 33 ; 28 ; 71 ; 148 ; 199 ; 118 ; 65 ; 90 ; 135 ; 66 ; 58 ; 122 ; 25 ; 44 ; 55 ; 86 ; 92 ; 99 ; 18 ; 21 ; 94 ; 46
MUTATION_RATE_341	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Mutation Rate 341	Sample	6.691462252 ; 5.576218543 ; 10.03719338 ; 7.80670596 ; 3.345731126 ; 2.230487417 ; 8.921949669 ; 4.460974835 ; 6.88652386 ; 4.918945614 ; 12.7892586 ; 9.837891228 ; 5.902734737 ; 10.82168035 ; 1.967578246 ; 3.9 ; 7.870312983 ; 2.951367369 ; 8.9 ; 22.62714983 ; 0.983789123 ; 5.3 ; 1.755429984 ; 9.654864911 ; 3.510859968 ; 7.021719935 ; 5.266289951 ; 4.388574959 ; 8.777149919 ; 4.4 ; 2.633144976 ; 7.899434927 ; 6.144004943 ; 10.5325799 ; 12.28800989 ; 123.7578139 ; 29.84230972 ; 39.49717464 ; 6.1 ; 25.5 ; 14.92115486 ; 1.8 ; 7 ; 21.06515981 ; 10.5 ; 2.6 ; 9.7 ; 7.9 ; 8.8 ; 3.5 ; 103.6 ; 0.9 ; 127.3 ; 12.3 ; 46.51889457 ; 11.41029489 ; 83.38292423 ; 50.02975454 ; 86 ; 14.9 ; 85.1 ; 34.23088468 ; 68.5 ; 13.2 ; 43.9 ; 65 ; 415.2 ; 88.6 ; 29 ; 11.4 ; 24.6 ; 62.3 ; 15.8 ; 0.877714992 ; 4.38857496 ; 129.9 ; 5.8 ; 6.6 ; 164 ; 3.3 ; 2.5 ; 4.9 ; 98 ; 53.6 ; 4.1 ; 9.9 ; 10.7 ; 8.2 ; 7.4 ; 9.1 ; 1.6 ; 75 ; 0.8 ; 111.2 ; 54.4 ; 47.8 ; 100.5 ; 82.52803444 ; 15.61341192 ; 17.84389934 ; 14.49816821 ; 13.3829245 ; 18.95914305 ; 11.15243709 ; 12.26768079 ; 25.6506053 ; 1.115243709 ; 27.88109272 ; 49.07072318 ; 61.33840397 ; 15.74062597 ; 84.60586456 ; 3.935156491 ; 8.854102106 ; 90.5085993 ; 13.77304772 ; 97.39512316 ; 16.72441509 ; 14.75683684 ; 11.80546947 ; 20.07438676 ; 23.42011788 ; 104.8329086 ; 51.3012106 ; 16.72865563
NCENTROMERIC_AI	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Ncentromeric AI	Sample	5 ; 10 ; 12 ; 1 ; 13 ; 6 ; 4 ; 0 ; 17 ; 7 ; 8 ; 14 ; 9 ; 11 ; 3 ; 16 ; 15 ; 2 ; 19 ; 18
NCENTROMERIC_LOH	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Ncentromeric LOH	Sample	0 ; 1 ; 5 ; 11 ; 4 ; 2 ; 3 ; 6 ; 12 ; 7 ; 8 ; 13 ; 9 ; 10 ; 16
NEOADJUVANT_TREATMENT_DETAILS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Neoadjuvant Treatment Details	Patient	
NEOADJ_CHEMOAGENT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Neoadj Chemoagent	Patient	
NEOADJ_CHEMOCYCLES	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Neoadj ChemoCycles	Patient	
NINTERSTITIAL_AI	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Interstitial AI	Sample	1 ; 2 ; 0 ; 4 ; 3 ; 5 ; 7 ; 9 ; 8 ; 11 ; 39 ; 26 ; 16 ; 17 ; 6 ; 18 ; 13 ; 27 ; 22 ; 14 ; 10 ; 15 ; 12 ; 20
NINTERSTITIAL_LOH	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Interstitial  LOH	Sample	1 ; 0 ; 2 ; 3 ; 5 ; 12 ; 7 ; 11 ; 4 ; 8 ; 9 ; 6 ; 10
NORMALS_USE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Normals Use	Sample	Blood ; Normal_Colon
NTELOMERIC_AI	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Ntelomeric AI	Sample	2 ; 1 ; 0 ; 3 ; 4 ; 5 ; 8 ; 7 ; 10 ; 6 ; 9 ; 27 ; 13 ; 12 ; 17 ; 11 ; 15 ; 16
NTELOMERIC_AI_SIZE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Ntelomeric Size AI	Sample	58665211.5 ; 50682750 ; 108385542 ; 54212798.5 ; 44256038 ; 68536978 ; 107002338 ; 73512273.33 ; 40429059 ; 41369564 ; 91725069 ; 35974512.5 ; 50050573.33 ; 62576226.67 ; 36954683 ; 46540266 ; 72756837.5 ; 96577898 ; 54677732 ; 24612797 ; 76914434.33 ; 52066541 ; 40429084 ; 54846445 ; 41868015 ; 78923412.25 ; 43911301.67 ; 65947388.67 ; 85002051.5 ; 40558129 ; 52268617.8 ; 58367779.4 ; 101388844 ; 48674201.5 ; 61587549 ; 50125471.75 ; 100356005 ; 14683497 ; 64592594.25 ; 57929996.5 ; 19873913 ; 87397732 ; 78927995 ; 72699303.33 ; 27194279 ; 21430051 ; 84497472 ; 44709013.38 ; 82327521.4 ; 45643345.5 ; 38948796 ; 9820251 ; 18461006 ; 68750191.5 ; 46508455.67 ; 34844331.67 ; 41079635 ; 69603008.2 ; 21375634 ; 39912734.14 ; 75308262.33 ; 68361435.3 ; 44895086.8 ; 52564692.67 ; 39986938.86 ; 56399187 ; 52437372.83 ; 39319637.67 ; 54251664.33 ; 48138991.67 ; 54533039.33 ; 46230695.5 ; 93963400 ; 112493876.5 ; 89923446 ; 74391780.67 ; 68843090.11 ; 79295781 ; 66379597.67 ; 9052650 ; 23235859.67 ; 21514254.75 ; 51353069.2 ; 29133721 ; 57778212.33 ; 65713323.33 ; 25686581.33 ; 56590596.6 ; 54904986.2 ; 75942504.67 ; 120483444 ; 76830261.5 ; 38193234 ; 33021843.33 ; 67967476.33 ; 39539601 ; 31348366.25 ; 37522667.33 ; 38563289.5 ; 86033605.33 ; 95220450 ; 51032474.5 ; 42257056.33 ; 18015406 ; 19761682 ; 43555638 ; 109692521 ; 79839081 ; 131601519 ; 67502751.6 ; 5338257 ; 28780006.5 ; 52871065.25 ; 31003591.67 ; 76881071 ; 18912462 ; 42085877 ; 80436710.25 ; 52089599.57 ; 72763143.5 ; 119904123 ; 63014140.75 ; 49527439 ; 73758286.5 ; 48665592.75 ; 66091593.75 ; 40646127.5 ; 115681997 ; 32932224 ; 34173355 ; 20900676.29 ; 33319189 ; 17329234 ; 29253205.83 ; 37873300 ; 20881867.33 ; 80507959 ; 47141061 ; 101771892 ; 28700733.7 ; 42531031 ; 95657700 ; 42736366 ; 26616200.96 ; 61613563 ; 28513176.54 ; 104795687 ; 54872844.57 ; 38009997 ; 85207351.67 ; 45678499.42 ; 106522805 ; 43133868 ; 42218489.54 ; 22867578.67 ; 27506284.4 ; 105476100 ; 35027214.15 ; 90054063 ; 43499114.6 ; 37747250 ; 84920954.57 ; 55390352 ; 39900918.65 ; 68363300 ; 47074309.67 ; 26628151 ; 51739097 ; 21590375.5 ; 46009711.5 ; 41469365.38 ; 67035052 ; 37348434.55 ; 48717849.33 ; 65595207.75 ; 40324098.5 ; 112924721 ; 101938956 ; 83411392 ; 26001990.67 ; 75330179.5 ; 44126406.78 ; 44117547.71 ; 54236916 ; 109882673 ; 48711562.13 ; 65704550 ; 68742048 ; 40625331 ; 38347533 ; 35023234.1 ; 47278503.5 ; 34223894 ; 58383182 ; 32519236 ; 79015042 ; 102986219 ; 34437111 ; 23654921.5 ; 42290739.3 ; 36904682 ; 44168593 ; 35028624 ; 38266460.45 ; 83615046.43 ; 58020147 ; 33101397 ; 28306807 ; 29093347 ; 31807203.5 ; 98408150 ; 33101046 ; 29885091.5 ; 49584939 ; 118416947 ; 118059979 ; 83017493.5 ; 145881408 ; 50459066 ; 40518728 ; 49778206.83 ; 32847015 ; 40520945.25 ; 80342656 ; 50270545 ; 31523149 ; 30253558 ; 51189622 ; 108332148 ; 49906584.67 ; 93456410 ; 62939584.67 ; 118021897 ; 26742575 ; 35426542 ; 69771567.5 ; 118123746 ; 88176434.2 ; 81007882 ; 68075700 ; 74293340 ; 62470928 ; 105786918.7 ; 62125682.33 ; 56459255 ; 120489550 ; 44989977.67 ; 94684357.25 ; 47534113 ; 107279821.3 ; 100696396 ; 42971583.9 ; 51036809.25 ; 20475812 ; 24321126.5 ; 63720800.33 ; 87020231.33 ; 33773999 ; 37849432 ; 31095855.5 ; 30679319.38 ; 115237080 ; 50467859.56 ; 101332565.5 ; 42504401.9 ; 68080720 ; 82084492.33 ; 50201887.43 ; 26515011 ; 37948378.63 ; 9403679 ; 40570478.83 ; 46719204.2 ; 57291868.33 ; 57612636.09 ; 120451700 ; 41355953 ; 28590952.63 ; 25777436.83 ; 22010095.2 ; 74664561.33 ; 37870896.38 ; 36974495.71 ; 35043261 ; 40291618.71 ; 36679758 ; 43282592.14 ; 21099842.82 ; 45849276 ; 51750619.2 ; 29444124.43 ; 1910701 ; 46402805.5 ; 60190198 ; 24721757.33 ; 40052560.5 ; 35584542.22 ; 29826286 ; 13090181 ; 47999432.6 ; 49655640.57 ; 33427884.1 ; 32354416.5 ; 46273954.67 ; 40020242.25
NTELOMERIC_LOH	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Ntelomeric LOH	Sample	1 ; 0 ; 2 ; 3 ; 4 ; 5 ; 6 ; 12 ; 9 ; 8 ; 7
NUMBER_OF_MUTATIONS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Number of Mutations	Sample	175 ; 256 ; 304 ; 469 ; 258 ; 872 ; 199 ; 286 ; 185 ; 157 ; 285 ; 268 ; 138 ; 379 ; 195 ; 225 ; 1869 ; 400 ; 51 ; 182 ; 173 ; 245 ; 188 ; 1310 ; 280 ; 275 ; 222 ; 196 ; 217 ; 181 ; 305 ; 2149 ; 204 ; 159 ; 142 ; 241 ; 192 ; 180 ; 203 ; 145 ; 140 ; 3828 ; 289 ; 301 ; 170 ; 177 ; 252 ; 738 ; 395 ; 206 ; 207 ; 201 ; 149 ; 274 ; 298 ; 155 ; 215 ; 187 ; 260 ; 193 ; 152 ; 141 ; 126 ; 172 ; 191 ; 98 ; 153 ; 127 ; 108 ; 117 ; 92 ; 190 ; 267 ; 132 ; 109 ; 194 ; 135 ; 136 ; 67 ; 129 ; 151
OS_FROM_SURGERY_MONTHS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Overall Survival from surgery	Patient	
OS_NEO_MONTHS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Overall Survival Neo	Patient	
OS_NEO_STATUS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Overall Survival Status	Patient	
PATHOLOGICAL_TUMORRESPONSE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Pathological TumorResponse	Patient	
PATIENTS_IN_GROUP0	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group0 Patients	Patient	
PATIENTS_IN_GROUP1	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group1 Patients	Patient	
PATIENTS_IN_GROUP2	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group2 Patients	Patient	
PATIENTS_IN_GROUP3	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group3 Patients	Patient	
PATIENTS_IN_GROUP4	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group4 Patients	Patient	
PATIENTS_IN_GROUP5	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group5 Patients	Patient	
PATIENTS_IN_GROUP6	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Group6 Patients	Patient	
PCR	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	pCR.0.no.1.yes.	Patient	
POSTCRT_PATHOLOGICAL_LN	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PostCRT Pathological LN	Patient	
POSTCRT_PATHOLOGIC_NSTAGE_YPN	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PostCRT Pathologic.Nstage.ypN.	Patient	
POSTCRT_PATHOLOGIC_TSTAGE_YPT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PostCRT Pathologic.Tstage.ypT.	Patient	
POSTCRT_TNM_STAGE_YPTNM	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PostCRT TNM Stage.ypTNM.	Patient	
PRECRT_AJCC_CLASSIFICATION	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PreCRT AJCC classification	Patient	
PRECRT_CLINICAL_MSTAGE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PreCRT Clinical Mstage	Patient	
PRECRT_CLINICAL_NSTAGE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PreCRT Clinical Nstage	Patient	
PRECRT_CLINICAL_T_STAGE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	PreCRT Clinical Tstage	Patient	
RADIATION_DOSE_PELVIC_NODES_PRIMARY_TUMOR.	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Radiation Dose.Pelvic nodes.Primary tumor.	Patient	
RECTAL_LOCATION	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Rectal Location	Patient	
RESPONSE_PCR_OR_CCR	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Response.0.no.1.pCR OR cCR	Patient	
RESPONSE_PCR_OR_CCR_TWO_YEARS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Response.0.no.1.pCR OR cCR two years	Patient	
SNP_COUNT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	SNP Count	Sample	270982 ; 294216 ; 285075 ; 288784 ; 283434 ; 258691 ; 276869 ; 26732 ; 278829 ; 283610 ; 260161 ; 265574 ; 285271 ; 299231 ; 287266 ; 270531 ; 287082 ; 272266 ; 268640 ; 265969 ; 295931 ; 290193 ; 297652 ; 281473 ; 260045 ; 274606 ; 283909 ; 282543 ; 271755 ; 278992 ; 287130 ; 284926 ; 296985 ; 303504 ; 307920 ; 290492 ; 264100 ; 258496 ; 270806 ; 244617 ; 268386 ; 259629 ; 268220 ; 263982 ; 269171 ; 250655 ; 284429 ; 261460 ; 263236 ; 254796 ; 256611 ; 288491 ; 279671 ; 265067 ; 295898 ; 285527 ; 259907 ; 303010 ; 254041 ; 266116 ; 283151 ; 264772 ; 258088 ; 275615 ; 269664 ; 263208 ; 282778 ; 272083 ; 279032 ; 276290 ; 273083 ; 274975 ; 282766 ; 277867 ; 283558 ; 264158 ; 295727 ; 262096 ; 258011 ; 265368 ; 266421 ; 273205 ; 287261 ; 266516 ; 283007 ; 263879 ; 261575 ; 301704 ; 303845 ; 282119 ; 269455 ; 256401 ; 282167 ; 283993 ; 254900 ; 261952
TELOMERIC_LOH_MEAN_SIZE	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Telomeric LOH Mean Size	Sample	62147600 ; 9050164 ; 44256038 ; 68536978 ; 107002338 ; 85587608 ; 40429059 ; 41369564 ; 91725069 ; 35974512.5 ; 70501235 ; 36954683 ; 17043149 ; 96577898 ; 31562781 ; 24612797 ; 117690903 ; 68277367.5 ; 78923412.25 ; 43911301.67 ; 65947388.67 ; 21421381 ; 24927758 ; 62556487 ; 48841286.5 ; 52228182 ; 61587549 ; 52148845.67 ; 100356005 ; 64025737 ; 127862351 ; 21694911 ; 112897950 ; 91121518.75 ; 72699303.33 ; 24782970.5 ; 21430051 ; 107078850 ; 46621665.4 ; 93358326 ; 45643345.5 ; 38948796 ; 9820251 ; 18461006 ; 68750191.5 ; 21694905 ; 34844331.67 ; 41079635 ; 45043372.33 ; 21375634 ; 24652322.5 ; 96333103 ; 60956043 ; 52981068.5 ; 50251640.5 ; 43594260.6 ; 60513916.67 ; 32904870.5 ; 33804873 ; 54752069 ; 67594568 ; 46230695.5 ; 93963400 ; 112493876.5 ; 124415950 ; 64139437.5 ; 81465117.5 ; 79295781 ; 9052650 ; 17398294.5 ; 14000639.67 ; 29133721 ; 66734993.5 ; 94180622 ; 19137652.5 ; 56590596.6 ; 47509478 ; 65023306.5 ; 76778538 ; 38193234 ; 33021843.33 ; 126652148 ; 39539601 ; 29077615.5 ; 21695029 ; 86033605.33 ; 95220450 ; 54415958 ; 39099666 ; 21421638 ; 32923148 ; 117345069 ; 131601519 ; 121098251 ; 5338257 ; 28780006.5 ; 59661748.25 ; 25845262.5 ; 76881071 ; 18912462 ; 21421225 ; 80436710.25 ; 46766328.33 ; 78822959 ; 119904123 ; 43893478 ; 51713909 ; 73758286.5 ; 80789500 ; 54301713.67 ; 14081353 ; 32932224 ; 19227708.33 ; 16870324.33 ; 17329234 ; 29272037 ; 37873300 ; 20881867.33 ; 80507959 ; 38635095.5 ; 14000093 ; 42531031 ; 45230791.5 ; 32198281.83 ; 84089315 ; 28584391 ; 112486910 ; 47463463.83 ; 38009997 ; 83582976.5 ; 77808516 ; 43133868 ; 48220371.75 ; 23699873 ; 33820799.67 ; 105476100 ; 36049593.4 ; 43455150 ; 117746006.7 ; 62535436 ; 43315390.25 ; 37309849.25 ; 23386326.5 ; 51739097 ; 21590375.5 ; 24618997 ; 47118915.17 ; 59737067 ; 47416047.33 ; 65595207.75 ; 32525547 ; 112924721 ; 101938956 ; 83411392 ; 53507813.5 ; 75330179.5 ; 58097625.33 ; 49115533.83 ; 45902761.33 ; 118996571 ; 26954956.17 ; 80680921 ; 68742048 ; 45125627.4 ; 29619281.5 ; 27905116.33 ; 47278503.5 ; 34223894 ; 32519236 ; 79015042 ; 102986219 ; 34437111 ; 30099695.33 ; 44479870.75 ; 36904682 ; 47933713.25 ; 37739153.5 ; 41641936.11 ; 91354255.67 ; 58020147 ; 28306807 ; 29093347 ; 23828517.33 ; 33101046 ; 24792394.67 ; 70739150 ; 118416947 ; 118059979 ; 83253812 ; 145881408 ; 51184349.5 ; 61067082.63 ; 32847015 ; 43991087 ; 80342656 ; 50270545 ; 30920235.67 ; 18663672.6 ; 51189622 ; 58150832.29 ; 62939584.67 ; 118021897 ; 26742575 ; 35426542 ; 74449050 ; 118123746 ; 71126081.67 ; 81007882 ; 68075700 ; 74293340 ; 62470928 ; 103112644 ; 28311661.5 ; 56459255 ; 120489550 ; 33784777 ; 93498959.67 ; 47534113 ; 107279821.3 ; 50464268.83 ; 39813978 ; 28306797 ; 28968172 ; 87020231.33 ; 33773999 ; 14066311 ; 26888973 ; 115237080 ; 57225982.44 ; 101896500 ; 44433625.6 ; 68080720 ; 78812113.5 ; 46686105.8 ; 42440834.33 ; 47169804.6 ; 47189287 ; 68503789 ; 51064843.6 ; 42325702 ; 24204577.25 ; 22010095.2 ; 90889420 ; 23800678.25 ; 37327174.33 ; 20970453.33 ; 50583047.8 ; 35797730 ; 14106095.67 ; 45849276 ; 61558382.5 ; 31506170.67 ; 52322905.63 ; 73671430.67 ; 20521897 ; 44192640.33 ; 39676579 ; 26142796 ; 43583774 ; 65828771 ; 30046509.8 ; 57226453.67 ; 67512920 ; 41590405.43
TIME_FROM_NEO_TO_SURGERY	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Time from neo to surgery	Patient	
TOTAL_CYCLES_NUM_NEOADJUVANT_ADJUVANT	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	NUMBER	Total Cycles Number (Neoadjuvant, Adjuvant)	Patient	
TRG_AJCC	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	TRG AJCC	Patient	
TRG_GROUPS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	TRG groups	Patient	
TUMORSIZE_CM	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	TumorSize cm	Patient	
TUMOR_SIZE_GROUPS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Tumor Size in groups	Patient	
USE_FOR_DFS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Use for DFS	Patient	
USE_FOR_RESPONSE_2YEAR	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Use for Response 2year	Patient	
USE_IN_OUTCOME_ANALYSIS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Use in Outcome Analysis	Patient	
YEAR_NAT_START	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Year Nat Start	Patient	
YEAR_NAT_START_GROUPS	SaddleBrown	Rectal Cancer (MSK, Nature Medicine 2022)	STRING	Year Nat Start in groups	Patient	
ADJUVANT_TREATMENT	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Description of treatment of colon cancer and metastasis after surgery.Values: systemic chemotherapy, chemotherapy incl. platinum.	Patient	
AJCC_PATH_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Pathologically determined tumor stage as classified by AJCC.Values: 1, 2, 3, 4, [Not Available], Not Applicable] (for example when patient sample appears not to be malignant)	Patient	
CLINICAL_M_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Clinically determined metastasis stadium Values: 0, 1, [Not Available], [Not Applicable]	Patient	
CLINICAL_N_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Clinically determined node stadium Values: 0, 1, 2, [Not Available], [Not Applicable]	Patient	
CLINICAL_T_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Clinically determined tumor stadium Values: 1, 2, 3, 4, Tis, [Not Available], [Not Applicable]	Patient	
DISTANT_RECURRENCE_STATUS	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	indicator of distant recurrence status Values: Yes, No	Patient	
HISTORY_OF_CANCER	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Occurance of other malignancy in colon cancer patients primary history other than basal cell carcinoma or cervical carcinoma in situ Values: Yes, No	Patient	
ICRSCORE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	NUMBER	Mean normalized log2(x+1) transformed expression value of 20 Immunologic Constant of Rejection (ICR) genes of primary tumor.Values: Numerical	Patient	
ICR_HML	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	ICR consensus cluster of primary tumor.Values: ICR High, ICR Medium, ICR Low.	Patient	
IES	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	IES	Patient	
LOCAL_RECURRENCE_STATUS	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	indicator of local recurrence status Values: Yes, No	Patient	
LOCATION_METASTASIS_AT_DX	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Anatomic location of distant metastasis present at initial diagnosis (only applies to stage IV patients) Values: liver, lymph node intra-abdominal, bronchus, lung, #N/A	Patient	
MBR_GROUP	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Binarized MBR score using the cutoff threshold 0 to classify samples into High Risk and Low Risk groups.	Patient	
MBR_SCORE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	NUMBER	Microbiome Risk Score calculated by the MBR classifier. The MBR classifier that was built by a relaxed multivariate elastic-net cox regression model including 41 genera	Patient	
MICROBIOME_COHORT	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Label for microbiome cohort as used in the analysis by Roelands et al. Samples of 246 patients were used for landmark analysis and 42 samples were used as internal validation cohort (ICAM42)	Patient	
MICROSCORE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Integrated score combining ICR and MBR group. Samples with the co-presence of ICR High and MBR Low risk are referred to as mICRoScore High.	Patient	
NEOADJUVANT_TREATED	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Treatment of colon cancer in advance of surgery.Values: Yes, No	Patient	
NEW_PRIMARY_TUMOR_IN_FU	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Indicator of a new primary tumor other than basal cell carcinoma or cervical carcinoma in situ in follow up. New primary tumor, not including recurrence of colon cancer. Values: Yes (between incidence and surgery), Yes (after surgery), No.	Patient	
PATH_METASTASIS_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Pathologically determined metastasis pm as classified by AJCC.Values: 0, 1, [Not Available], Not Applicable] (for example when patient sample appears not to be malignant)	Patient	
PATH_NODES_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Pathologically determined node pn as classified by AJCC.Values: 0, 1, 2, [Not Available], Not Applicable] (for example when patient sample appears not to be malignant)	Patient	
PATH_TUMOR_STAGE	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Pathologically determined tumor pt as classified by AJCC.Values: 1, 2, 3, 4, [Not Available], [Not Applicable] (for example when patient sample appears not to be malignant)	Patient	
REGIONAL_RECURRENCE_STATUS	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	indicator of regional recurrence status Values: Yes, No	Patient	
TCR_PRODUCTIVE_CLONALITY	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	NUMBER	TCR clonality is calculated by normalizing the productive entropy using the total number of productive rearrangements and subtracting the result from 1. Values for clonality range from 0 to 1, with values near 0 reflecting more polyclonal samples, and values near 1 representing	Patient	
TCR_PRODUCTIVE_REARRANGEMENTS	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	NUMBER	The total number of productive rearrangements is the total number of unique T cell clones.	Patient	
TCR_PRODUCTIVE_TEMPLATES	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	NUMBER	The total number of templates directly reflects the total number of T cells analyzed, of which only the productive templates can produce a functional protein receptor (rearrangement in the sample are in-frame and do not contain a stop codon).	Patient	
THERAPY_METASTASIS_AT_DX	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Applied therapy to remove distant metastasis present at initial diagnosis (only applies to stage IV patients) Values: systemic chemotherapy, metastasectomy etc.	Patient	
TUMOR_ANATOMIC_LOCATION	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Anatomical location of primary tumour Values: ceceum, colon sigmoideum, colon ascendens, colon descendens, flexura hepatica, flexura lienalis, rectum, rectosigmoid.	Patient	
TUMOR_MORPHOLOGY	SaddleBrown	Colon Cancer (Sidra-LUMC AC-ICAM, Nat Med 2023)	STRING	Tumor morphology as assessed by pathology department Values: adenocarcinoma, mucineus adenocarcinoma, adenocarcinoma intestinal type, cribriform carcinoma, malignant large b cell lymphoma, signet ring cell carcinoma, neuroendocrine carcinoma, large cell neuroendocrine carcinoma, adenocarcinoma in villeus adenoma, adenocarcinoma with mixed subtypes.	Patient	
HYPERMUTATED	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Nature 2012)	STRING	Hyper-mutated.	Sample	0 ; 1
ICLUSTER	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Nature 2012)	STRING	ICluster.	Sample	1 ; 3 ; 2a ; 2b
METHYLATION_SUBTYPE	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Nature 2012)	STRING	Methylation subtype.	Sample	Cluster3 ; Cluster4 ; CIMP.L ; CIMP.H
MLH1_SILENCING	SaddleBrown	Colorectal Adenocarcinoma (TCGA, Nature 2012)	STRING	Epigenetic silencing status of MLH1.	Sample	0 ; 1
CHEMO_EXP_SEQ_SPECIMEN	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Chemo Exposure of sequenced specimen	Sample	Yes ; No
MCRC_TYPE	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	mCRC Type	Sample	mCRC Metastasis ; mCRC Primary ; Early Stage Primary
METASTASECTOMY_SITE	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastasectomy Site	Sample	Abdominal Wall ; Liver ; Abdominal Mass ; Peritoneum ; (Suboptimal Debulking) ; Ovary, Peritoneum ; Brain ; Ovary, Liver ; (Hepatectomy And Within One Month, Lung Mets More Apparent) ; Liver, Peritoneum ; Lung ; Liver, Ovary ; Lns ; Rfa-Lung ; Pancreas ; Lung, Liver ; Liver, Adrenal ; Peritoneum, Ovary ; Soft Tissue ; Rfa - Lung ; Pelvis ; Lung (3Rd Metastasectomy) ; Ovary ; Liver, Lung ; Peritoneum, Liver ; Small Bowel ; Mesentery, Lns ; Iver ; Lung (Resection -> Rt) ; Peritoneum, Duodenum ; Pelvis, R Ureter ; Rp Mass ; Omentum, Abd Wall ; Liver + Lung ; Ablation ; Peritoneum, Ovaries ; Ovaries ; Lung (2Nd Metastectomy) ; Omentum ; Liver, Ln ; Rfa - Liver ; Debulking ; Liver, Omentum ; Liver - Cr ; Lung- Cryoablation ; Ln ; Omentum, Ovaries ; Omentum, Liver ; Liver, Ovaries ; Lung (Several Surgeries) ; Peritoneum, Liver, Ovary ; Ovaries, Peritoneum ; Scheduled ; Ovary, Uterus ; Liver (2Nd Metastasectomy) ; Ln - Rt ; Local Recurrence ; Peritoneum, Omentum ; Liver - Rt ; Liver - Rfa
METASTASES_SITE_FIRST_BONE	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Bone	Sample	0 ; 1
METASTASES_SITE_FIRST_BRAIN	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Brain	Sample	0 ; 1
METASTASES_SITE_FIRST_GYN	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Gynecological	Sample	0 ; 1
METASTASES_SITE_FIRST_LIVER	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Liver	Sample	1 ; 0
METASTASES_SITE_FIRST_LN	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Ln	Sample	0 ; 1
METASTASES_SITE_FIRST_LUNG	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Lung	Sample	0 ; 1
METASTASES_SITE_FIRST_PELVIS	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Pelvis	Sample	0 ; 1
METASTASES_SITE_FIRST_PERITONEUM_OMENTUM_ABDOMEN	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastases Site First: Peritoneum, omentum, abdomen	Sample	1 ; 0
METASTATIC_BIOPSY_SITE	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Metastatic Biopsy Site	Sample	Ovary ; Peritoneum ; Liver ; Chest Wall ; Abdomen ; Lymph Node ; Skin ; Lung ; Omentum ; Brain ; Pelvis ; Soft Tissue ; Vagina ; Sigmoid Colon ; Peritoneal Fluid ; Pleura ; Small Bowel ; Paracolic Gutter ; Lymph node ; Mesentery ; RetroPeritoneum ; Abdominal Wall ; Bladder ; Adrenal Gland ; Peritoneal Implant ; Peritoneal implant on Sigmoid Colon ; Rectum ; Spine ; Diaphragm ; Paraspinal Mass ; Kidney ; Cerebellum ; Sacral Mass ; Skull base
OS_MONTHS_ADDITIONAL	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	NUMBER	OS Months (Additonal Data)	Patient	
OTHER_SITES_OF_METS	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	STRING	Other Metastasis Sites Description	Sample	0 ; 1
TIME_FROM_MET_DX_SEQUENCING	SaddleBrown	Metastatic Colorectal Cancer (MSK, Cancer Cell 2018)	NUMBER	Time from Met Dx to Sequencing	Sample	38.93333333 ; 32.2 ; 37.3 ; 22.13333333 ; 12.96666667 ; 97.16666667 ; 22.9 ; 15.6 ; 11.16666667 ; 25.96666667 ; 25.73333333 ; 21.43333333 ; 12.3 ; 10.83333333 ; 23.66666667 ; 24.4 ; 44.1 ; 35.16666667 ; 28.96666667 ; 13.23333333 ; 16.4 ; 15.1 ; 20.86666667 ; 78.4 ; 25.63333333 ; 44.96666667 ; 54.96666667 ; 26.1 ; 42.33333333 ; 52.96666667 ; 23.16666667 ; 14.23333333 ; 46.7 ; 20.03333333 ; 96.76666667 ; 52.23333333 ; 71.03333333 ; 14.33333333 ; 43.86666667 ; 135.9333333 ; 32 ; 155.8333333 ; 16.8 ; 98.6 ; 10.7 ; 94.73333333 ; 33.3 ; 10.23333333 ; 22.26666667 ; 19.93333333 ; 10.5 ; 66.2 ; 9.2 ; 10.13333333 ; 9.566666667 ; 9.9 ; 31.3 ; 47.36666667 ; 11.9 ; 41.8 ; 31.23333333 ; 48.76666667 ; 10.73333333 ; 64.4 ; 85.86666667 ; 26.5 ; 9.433333333 ; 88.53333333 ; 13.33333333 ; 33.8 ; 68.8 ; 23.43333333 ; 11.53333333 ; 33.96666667 ; 41.9 ; 21 ; 12.36666667 ; 17.1 ; 17.33333333 ; 136.9 ; 8.1 ; 9.5 ; 8.4 ; 10.06666667 ; 26.4 ; 18.2 ; 23.2 ; 33.1 ; 33.33333333 ; 19.46666667 ; 7.466666667 ; 11.26666667 ; 28.46666667 ; 23.9 ; 7.566666667 ; 24.46666667 ; 28.6 ; 7.4 ; 3.066666667 ; 7.133333333 ; 7.6 ; 7.3 ; 8.866666667 ; 11.46666667 ; 22.53333333 ; 30.9 ; 11.03333333 ; 63.03333333 ; 103.9666667 ; 27 ; 8.466666667 ; 31.26666667 ; 42.06666667 ; 71.06666667 ; 28.1 ; 6.266666667 ; 28.56666667 ; 91.43333333 ; 10.1 ; 14.13333333 ; 73.56666667 ; 50.8 ; 54.13333333 ; 16.86666667 ; 70.2 ; 7.066666667 ; 24.86666667 ; 8.9 ; 5.8 ; 10.76666667 ; 5.233333333 ; 12.6 ; 15.03333333 ; 12.5 ; 12.2 ; 9.833333333 ; 9.233333333 ; 7.166666667 ; 42.83333333 ; 10 ; 25.33333333 ; 7.633333333 ; 17.76666667 ; 16.03333333 ; 8.266666667 ; 8.433333333 ; 20.13333333 ; 5.933333333 ; 7.266666667 ; 24.56666667 ; 6.666666667 ; 6.233333333 ; 19.26666667 ; 6.733333333 ; 5.9 ; 59.56666667 ; 42.13333333 ; 16.2 ; 17.53333333 ; 69.86666667 ; 6 ; 4.833333333 ; 37.9 ; 36.93333333 ; 4.366666667 ; 70.5 ; 34.86666667 ; 4.8 ; 45.23333333 ; 9.7 ; 15 ; 5.666666667 ; 5.333333333 ; 92.33333333 ; 60.03333333 ; 17.2 ; 4.3 ; 13.53333333 ; 4.166666667 ; 4.566666667 ; 19.76666667 ; 54.8 ; 32.43333333 ; 70.16666667 ; 5.133333333 ; 11.56666667 ; 6.6 ; 4.133333333 ; 14.9 ; 31.46666667 ; 6.7 ; 22.23333333 ; 26.9 ; 9.666666667 ; 6.166666667 ; 3.166666667 ; 4.9 ; 3.233333333 ; 77.1 ; 12.4 ; 65.33333333 ; 11.96666667 ; 14.93333333 ; 26.73333333 ; 17.83333333 ; 3.5 ; 45.9 ; 36.4 ; 3 ; 3.533333333 ; 20.66666667 ; 28.36666667 ; 2.8 ; 7.733333333 ; 1.833333333 ; 17.36666667 ; 2.6 ; 4.533333333 ; 4.6 ; 3.866666667 ; -14.73333333 ; 40.26666667 ; 5 ; 8.8 ; 5.266666667 ; 14.66666667 ; 2.933333333 ; 12 ; 21.73333333 ; 62.13333333 ; 37.5 ; 24.43333333 ; 28.26666667 ; 33.16666667 ; 34.06666667 ; 43.9 ; 43.76666667 ; 2.366666667 ; 7 ; 14.73333333 ; 2.133333333 ; 18.7 ; 9.1 ; 7.233333333 ; -15.33333333 ; 4.2 ; 7.5 ; 12.63333333 ; 4.066666667 ; 3.833333333 ; 6.8 ; 4.733333333 ; 8.066666667 ; -1365.8 ; 8.366666667 ; 48.23333333 ; 2.666666667 ; 53.86666667 ; 16.16666667 ; 2.2 ; 2.5 ; 3.766666667 ; 8.3 ; 2.266666667 ; -3.966666667 ; 40.3 ; 28.53333333 ; 54.1 ; -8.033333333 ; 5.166666667 ; 22.36666667 ; 80.8 ; 1.533333333 ; -14.96666667 ; 1.666666667 ; 17.13333333 ; 39.73333333 ; 9.3 ; 13.43333333 ; 19.33333333 ; 19.13333333 ; 2.466666667 ; 55 ; 13.86666667 ; 2.533333333 ; 3.033333333 ; 31.53333333 ; 1.566666667 ; 41.16666667 ; 22.1 ; 32.96666667 ; 2.566666667 ; -3.466666667 ; 5.766666667 ; 8.033333333 ; 116.0333333 ; 100.8 ; 1.8 ; 11.06666667 ; 2.233333333 ; 1.5 ; 1.2 ; 28.3 ; 2.066666667 ; 21.06666667 ; 2.3 ; 11.1 ; 2.333333333 ; 30.4 ; 3.433333333 ; 15.96666667 ; 8.333333333 ; 10.86666667 ; 31.83333333 ; 8.633333333 ; 2.1 ; 35.66666667 ; 1.633333333 ; 10.4 ; 1.133333333 ; 3.933333333 ; 3.7 ; 94.66666667 ; 73.63333333 ; 26.13333333 ; 2.033333333 ; 9.033333333 ; 3.266666667 ; 10.46666667 ; 6.533333333 ; 3.733333333 ; 8.833333333 ; 21.66666667 ; -19.63333333 ; 1.7 ; 1.333333333 ; 34.2 ; 3.566666667 ; 1.366666667 ; 28.16666667 ; 75.46666667 ; 22.4 ; 2.4 ; 53.73333333 ; 10.6 ; 7.7 ; 17.23333333 ; 14.2 ; -13.06666667 ; 11.5 ; 12.46666667 ; -4.733333333 ; 9 ; 19.53333333 ; 3.1 ; 4.333333333 ; 137.9333333 ; 19.6 ; 22.46666667 ; 42.76666667 ; 5.466666667 ; 15.26666667 ; 21.76666667 ; 10.2 ; 33.93333333 ; 76.06666667 ; 49.8 ; 1.733333333 ; 104.9 ; 29.06666667 ; 33.46666667 ; 16.13333333 ; 107.1666667 ; 29.23333333 ; 36.1 ; 19.56666667 ; 11.3 ; 24.26666667 ; 8.566666667 ; 16.66666667 ; 31.5 ; 20.9 ; 34.1 ; 30 ; 86.06666667 ; 62.73333333 ; 179.2666667 ; 36.63333333 ; 25.36666667 ; 2.166666667 ; 54.66666667 ; 75.8 ; 86.5 ; 70.93333333 ; 39.86666667 ; 17.56666667 ; 14.53333333 ; 5.4 ; 14.5 ; 16.1 ; 5.833333333 ; 51.16666667 ; 57.53333333 ; 107.9666667 ; 10.33333333 ; 54.26666667 ; 21.83333333 ; 37.96666667 ; 185.9 ; 44.9 ; 72.36666667 ; 34.23333333 ; 6.766666667 ; 9.6 ; 65.63333333 ; 41.23333333 ; 26.23333333 ; 47.3 ; 9.366666667 ; 17.93333333 ; 17.3 ; 10.43333333 ; 2.833333333 ; 43.33333333 ; 52.03333333 ; 107.4 ; 91.63333333 ; 91.83333333 ; 42.16666667 ; 103.4333333 ; 35.73333333 ; 49.83333333 ; 13.66666667 ; 0.9 ; 59.23333333 ; 53.23333333 ; 139.9666667 ; 53.33333333 ; 62.06666667 ; 1.966666667 ; 59.76666667 ; 270.5333333 ; 193.3333333 ; 40.56666667 ; 8.666666667 ; 40.33333333 ; 45.36666667 ; 30.63333333 ; 35.53333333 ; 18.4 ; 1.466666667 ; 62.83333333 ; 94.1 ; 84.53333333 ; 55.2 ; 17.7 ; 15.43333333 ; 53.8 ; 14.8 ; 43.96666667 ; 13.06666667 ; 40.6 ; 42.1 ; 1.866666667 ; 5.433333333 ; 69.06666667 ; 49.5 ; 39.23333333 ; 154.2333333 ; 4.7 ; 29 ; 43.3 ; 96.6 ; 48.06666667 ; 44.13333333 ; 63.36666667 ; 73.66666667 ; 28.83333333 ; 165.8666667 ; 0.8 ; 61.7 ; 47.46666667 ; 2.733333333 ; 24.76666667 ; 28.66666667 ; 48.1 ; 80.43333333 ; 141.0666667 ; 5.1 ; 13.83333333 ; 156.5666667 ; 106.1333333 ; 154.0666667 ; 30.53333333 ; 9.133333333 ; 21.6 ; 50.73333333 ; 18 ; 20.46666667 ; 98.56666667 ; 29.46666667 ; 62.33333333 ; 103.0333333 ; 126.3666667 ; 106.5333333 ; 145.0666667 ; 61.36666667 ; 54.36666667 ; 9.966666667 ; 39.76666667 ; 0.2 ; 1.266666667 ; 4.966666667 ; 21.2 ; 1 ; 53.7 ; 52.2 ; 67.63333333 ; 43.83333333 ; 66.66666667 ; 44 ; 100.3333333 ; 130.6666667 ; 1.9 ; 142.8 ; 3.466666667 ; 6.1 ; 73.06666667 ; 49.7 ; 1.033333333 ; 13.7 ; 113.3666667 ; 20.16666667 ; 41.2 ; 2.866666667 ; 138.0666667 ; 0.866666667 ; 3.666666667 ; 97.13333333 ; 29.4 ; 3.133333333 ; 23.13333333 ; 7.533333333 ; 8.733333333 ; 6.066666667 ; 97.2 ; 64.26666667 ; 15.33333333 ; 46.93333333 ; 9.266666667 ; 77.3 ; 13.26666667 ; 114.1333333 ; 59.86666667 ; -4.9 ; 18.56666667 ; 2.9 ; 6.866666667 ; -2 ; 8.133333333 ; 0.833333333 ; 0.966666667 ; 18.33333333 ; 1.1 ; 5.633333333 ; 45.3 ; 2 ; 1.066666667 ; 7.1 ; 7.833333333 ; 12.1 ; 82.33333333 ; 34.8 ; 32.23333333 ; 11.76666667 ; 5.066666667 ; 41.43333333 ; 87.86666667 ; 47.33333333 ; 28.03333333 ; 18.83333333 ; 3.9 ; 24.16666667 ; 63.1 ; 163.6333333 ; 1.766666667 ; 20.93333333 ; 14.83333333 ; 69.26666667 ; 106.7 ; 58.9 ; 214.4 ; 9.533333333 ; 18.5 ; 131.3 ; 22.66666667 ; -4.033333333 ; 1.3 ; 4.666666667 ; 7.8 ; 78.1 ; 3.4 ; 55.6 ; 13 ; 5.5 ; 13.46666667 ; 17.16666667 ; 11.36666667 ; 31.6 ; 20.26666667 ; 114.6333333 ; 40.9 ; 2.766666667 ; 10.53333333 ; 16.93333333 ; -0.1 ; 55.5 ; 55.86666667 ; 32.46666667 ; 30.73333333 ; 133.1333333 ; 19.83333333 ; 36.13333333 ; 72.03333333 ; 5.6 ; 15.16666667 ; 37.16666667 ; 5.966666667 ; 32.7 ; 1.4 ; 4.633333333 ; 20.36666667 ; 12.66666667 ; 1.433333333 ; 13.6 ; 1.933333333 ; 38.86666667 ; 49.36666667 ; 101.6333333 ; 7.766666667 ; 48.56666667 ; 3.366666667 ; 19.86666667 ; 39.33333333 ; 98.4 ; 35.7 ; 13.4 ; 113 ; 105.3333333 ; 11.6 ; 69.9 ; 1.233333333 ; 45.33333333 ; 3.966666667 ; 2.7 ; 36.16666667 ; 6.333333333 ; 37.2 ; 11.66666667 ; 7.033333333 ; 1.166666667 ; 20.7 ; 2.966666667 ; 4.933333333 ; -11.03333333 ; 65.36666667 ; -7.533333333 ; 19.63333333 ; 20.2 ; 12.73333333 ; 159.3666667 ; 25.06666667 ; 18.73333333 ; 30.6 ; 0.766666667 ; 21.13333333 ; 6.466666667 ; 5.733333333 ; 14.06666667 ; 25.16666667 ; -10.76666667 ; 61.63333333 ; 130.3 ; -4.166666667 ; -1.633333333 ; 2.433333333 ; 14.3 ; 93.03333333 ; 4.4 ; 43.56666667 ; 1.6
ATOMIC_SITE_DETAIL	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Tumor atomic site detailed	Patient	
CA19_9	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Carbohydrate antigen (u/ml)	Patient	
CEA	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Carcinoembryonic antigen (ng/ml)	Patient	
DISTANT_LM	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Distant liver metastatic tissues	Patient	
FOLLOW_UP	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Patient follow-up time in days	Patient	
INTRAVASCULAR_TUMOR_THROMBUS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Indicates tumor progression into vessels	Patient	
METASTATIC_NECROSIS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Precent tissue necrosis in metastatic tumor cells	Sample	10 ; 50 ; 20 ; 70 ; 35 ; 60 ; 1 ; 15 ; 25 ; 80 ; 30 ; 40 ; 45
METASTATIC_PURITY	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Precent metastatic tumor cell purity	Sample	80 ; 40 ; 20 ; 60 ; 25 ; 30 ; 90 ; 45 ; 70 ; 15 ; 65 ; 50
METASTATIC_STATUS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Metastatic status	Sample	Metastatic ; Non-Metastatic ; Metastatic (Preoperative Treatment) ; Non-Metastatic (Preoperative Treatment) ; Metastatic, mini PDX done ; Metastatic (Preoperative Treatment), mini PDX done
NEUROLOGICAL_INVASION	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Indicates invasion of cancer cells into nerves	Patient	
PAIRED_STATUS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Paired primary tumor samples that underwent whole exome sequencing	Sample	Paired primary tumor and peripheral blood cell samples ; Paired primary tumor and remote normal tissues
POSTOPERATIVE_THERAPY_WITH_TARGETED_AGENTS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Indicates whether the patient received post-operative therapy	Patient	
PREOPERATIVE_TREATMENT_EFFECT	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Preoperative treatment effect	Patient	
PRETHERAPY	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Indicates whether the patient received therapy before sequencing	Patient	
PRETHERAPY_WITH_TARGETED_AGENTS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Indicates whether the patient received pre-tharapy with targeted agents	Patient	
PRIMARY_NECROSIS	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Precent tissue necrosis in primary tumor cells	Sample	10 ; 15 ; 5 ; 20 ; 30 ; 25 ; 2 ; 40
PRIMARY_PURITY	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Precent primary tumor cell purity	Sample	80 ; 70 ; 85 ; 60 ; 90 ; 75 ; 50 ; 65 ; 55
PROGRESSION	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Tumor progression	Patient	
PROGRESSION_SITE	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	STRING	Progression site	Patient	
PROGRESSION_TIME	SaddleBrown	Colorectal Cancer (CAS Shanghai, Cancer Cell 2020)	NUMBER	Progression time (days)	Patient	
ACQUISITION_METHOD	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Acquisition Method Type	Sample	Biopsy ; Other Acquisition Method
ADVANCED	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Developed or Progressed State	Sample	Not Stated ; No ; Yes ; Not stated
ATLAS_NAME	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Atlas Name	Patient	
ATYPIA	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Atypia	Sample	Not stated ; Low-grade dysplasia ; High-grade dysplasia ; No dysplasia ; Not Stated
HPTYPE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Hyperplastic Type	Sample	Not Hyperplastic ; Not Stated ; Microvesicular ; Goblet-cell rich ; Not stated
PCAD	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Proportion of Adenoma within the polyp	Sample	1-25% ; 100% ; 76-99% ; 26-50% ; Not Stated ; 0% ; Not stated ; 51-75%
PCNORMAL	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Proportion of Normal cells within the polyp	Sample	>=31% ; 0% ; 21-30% ; 11-20% ; 6-10% ; 3-5% ; Not stated ; 1-2%
PCVILLOUS	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Villous Component within the polyp	Sample	0% ; 1-25% ; 51-75% ; 26-50% ; Not Stated ; Not stated
PDIM	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	NUMBER	Polyp Dimension	Sample	1 ; 0.8 ; 0.4 ; 0.7 ; 0.6 ; 0.3 ; 0.2 ; 0.5 ; 1.7 ; 1.2 ; 0.9 ; Not Stated ; 1.4 ; 2 ; 1.3 ; 1.5
POLYP_OF_COLON_OR_RECTUM	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Have you ever been told by a Doctor that you have polyps of the Colon or Rectum?	Patient	
POLYP_SUBTYPE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Polyp Subtype	Sample	Tubular Adenoma ; Unknown ; Tubulovillous Adenoma ; Sessile Serrated Lesion ; Microvesicular Hyperplastic Polyp ; Hyperplastic Polyp ; Goblet cell-rich Hyperplastic Polyp
POLYP_TYPE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Polyp Type	Sample	AD ; Unknown ; SER
PRESERVATION_METHOD	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Preservation Method	Sample	Fresh ; Frozen ; Snap Frozen
PSHAPE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Polyp Shape	Sample	Sessile ; Not stated ; Pedunculated ; Not Stated ; Flat
SAMPLE_SIZEINVIVO_CM	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	NUMBER	Sample Size Invivo (cm)	Sample	0.4 ; 0.7 ; 0.6 ; 0.8 ; 0.5 ; 2.5 ; 1.2 ; 1 ; 2 ; 1.5 ; 8.8
SEGMENT	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Location of polyp	Sample	Descending colon ; Transverse colon ; Cecum ; Sigmoid colon ; Ascending colon ; Hepatic flexure ; Rectum
SIDE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Location of polyp	Sample	Distal ; Proximal
TISSUE_TYPE	SaddleBrown	Pre-cancer Colorectal Polyps (HTAN Vanderbilt, Cell 2021)	STRING	Tumor Tissue Type	Sample	Premalignant ; Atypia - hyperplasia ; Not Otherwise Specified
CHEMO_DETAILS	Yellow	Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)	STRING	Chemotherapy details	Patient	
GERMLINE_TYPE	Yellow	Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)	STRING	Germline Type	Sample	Whole Blood ; Adjacent Normal Tissue
NONSYNONYMOUS_MUTATION_RATE	Yellow	Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)	NUMBER	Non-synonymous Mutation Rate	Sample	6.77E-06 ; 6.14E-06 ; 2.84E-06 ; 5.00E-06 ; 1.05E-05 ; 8.15E-06 ; 6.69E-06 ; 1.03E-05 ; 2.64E-06 ; 4.48E-06 ; 1.22E-07 ; 9.16E-06 ; 6.98E-06 ; 2.10E-06 ; 3.79E-06 ; 3.10E-06 ; 4.39E-06 ; 1.93E-05 ; 4.14E-06 ; 4.25E-06 ; 1.83E-06 ; 1.84E-06 ; 7.44E-06 ; 2.61E-06 ; 2.08E-05 ; 3.34E-06 ; 9.39E-06 ; 2.87E-06 ; 1.41E-05 ; 1.18E-05 ; 7.18E-06 ; 2.76E-06 ; 1.69E-06 ; 8.47E-06 ; 8.85E-07 ; 6.00E-06 ; 1.96E-05 ; 4.05E-06 ; 3.53E-06 ; 3.88E-06 ; 1.11E-05 ; 3.33E-06 ; 1.13E-05 ; 4.19E-06 ; 2.33E-06 ; 2.27E-06 ; 5.60E-06
CONCOMITANT_CIS	Yellow	Bladder Cancer (MSK, Eur Urol 2014)	STRING	Concomitant Carcinoma in situ	Sample	No ; Yes ; 0 ; 1
DEATH_FROM_DISEASE	Yellow	Bladder Cancer (MSK, Eur Urol 2014)	STRING	Death due to disease	Patient	
LYMPH_NODE_STATUS	Yellow	Bladder Cancer (MSK, Eur Urol 2014)	STRING	Lymph Node Status	Sample	Negative ; Positive ; 0 of 17 ; 0 of 9 ; 0 of 19 ; 12 of 18 ; 0 of 0 ; 0 of 23 ; 0 of 8 ; 0 of 29 ; 0 of 16 ; 0 of 2 ; 1 of 2 ; 1 of 31 ; 0 of 22 ; 3 of 20 ; 0 of 7 ; 1 of 23 ; 0 of 37 ; 13 of 15 ; 0 of 25 ; Node Positive ; Node Negative ; Unknown
SURGERY_PROCEDURE	Yellow	Bladder Cancer (MSK, Eur Urol 2014)	STRING	Surgery Procedure	Patient	
VARIANT_HISTOLOGY	Yellow	Bladder Cancer (MSK, Eur Urol 2014)	STRING	Variant Histology	Patient	
NUMBER_OF_TUMORS	Yellow	Nonmuscle Invasive Bladder Cancer (MSK Eur Urol 2017)	STRING	Number of Tumors	Patient	
YEAR_OF_SURGERY	Yellow	Bladder Cancer (MSK, Nat Genet 2016)	NUMBER	Year of surgery.	Sample	2005 ; 2007 ; 2011 ; 2000 ; 2006 ; 2010 ; 2003 ; 2013 ; 2004 ; 2012 ; 2002 ; 1994 ; 2008 ; 2095 ; 2099 ; 2001 ; 2009
BATCH_NUMBER	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Batch number.	Sample	86 ; 113 ; 207 ; 128 ; 150 ; 175 ; 199 ; 223 ; 249 ; 235 ; 170 ; 192
CLINICAL_ASSESSMENT	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Clinical Assessment	Patient	
COMPLETE_TCGA_ID	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Complete TCGA ID	Sample	TCGA-BL-A0C8 ; TCGA-BL-A13I ; TCGA-BL-A13J ; TCGA-BL-A3JM ; TCGA-BT-A0S7 ; TCGA-BT-A0YX ; TCGA-BT-A20J ; TCGA-BT-A20N ; TCGA-BT-A20O ; TCGA-BT-A20P ; TCGA-BT-A20Q ; TCGA-BT-A20R ; TCGA-BT-A20T ; TCGA-BT-A20U ; TCGA-BT-A20W ; TCGA-BT-A2LB ; TCGA-BT-A2LD ; TCGA-BT-A3PH ; TCGA-BT-A3PJ ; TCGA-BT-A3PK ; TCGA-BT-A42B ; TCGA-BT-A42C ; TCGA-C4-A0F0 ; TCGA-C4-A0F1 ; TCGA-C4-A0F6 ; TCGA-C4-A0F7 ; TCGA-CF-A1HR ; TCGA-CF-A1HS ; TCGA-CF-A27C ; TCGA-CF-A3MF ; TCGA-CF-A3MG ; TCGA-CF-A3MH ; TCGA-CF-A3MI ; TCGA-CU-A0YN ; TCGA-CU-A0YO ; TCGA-CU-A0YR ; TCGA-CU-A3KJ ; TCGA-CU-A3QU ; TCGA-CU-A3YL ; TCGA-DK-A1A3 ; TCGA-DK-A1A5 ; TCGA-DK-A1A6 ; TCGA-DK-A1A7 ; TCGA-DK-A1AA ; TCGA-DK-A1AB ; TCGA-DK-A1AC ; TCGA-DK-A1AD ; TCGA-DK-A1AE ; TCGA-DK-A1AF ; TCGA-DK-A1AG ; TCGA-DK-A2HX ; TCGA-DK-A2I1 ; TCGA-DK-A2I2 ; TCGA-DK-A2I4 ; TCGA-DK-A2I6 ; TCGA-DK-A3IK ; TCGA-DK-A3IL ; TCGA-DK-A3IM ; TCGA-DK-A3IN ; TCGA-DK-A3IQ ; TCGA-DK-A3IS ; TCGA-DK-A3IT ; TCGA-DK-A3IU ; TCGA-DK-A3IV ; TCGA-DK-A3WW ; TCGA-DK-A3WX ; TCGA-DK-A3WY ; TCGA-DK-A3X1 ; TCGA-DK-A3X2 ; TCGA-E5-A2PC ; TCGA-E7-A3X6 ; TCGA-E7-A3Y1 ; TCGA-FD-A3B3 ; TCGA-FD-A3B5 ; TCGA-FD-A3B6 ; TCGA-FD-A3B7 ; TCGA-FD-A3B8 ; TCGA-FD-A3N5 ; TCGA-FD-A3NA ; TCGA-FD-A3SJ ; TCGA-FD-A3SL ; TCGA-FD-A3SM ; TCGA-FD-A3SN ; TCGA-FD-A3SO ; TCGA-FD-A3SP ; TCGA-FD-A3SQ ; TCGA-FD-A3SR ; TCGA-FD-A3SS ; TCGA-FJ-A3Z7 ; TCGA-FJ-A3ZE ; TCGA-FJ-A3ZF ; TCGA-FT-A3EE ; TCGA-G2-A2EC ; TCGA-G2-A2EF ; TCGA-G2-A2EJ ; TCGA-G2-A2EK ; TCGA-G2-A2EO ; TCGA-G2-A2ES ; TCGA-G2-A3IB ; TCGA-G2-A3IE ; TCGA-G2-A3VY ; TCGA-GC-A3BM ; TCGA-GC-A3I6 ; TCGA-GC-A3OO ; TCGA-GC-A3RB ; TCGA-GC-A3RC ; TCGA-GC-A3RD ; TCGA-GC-A3WC ; TCGA-GC-A3YS ; TCGA-GD-A2C5 ; TCGA-GD-A3OP ; TCGA-GD-A3OQ ; TCGA-GD-A3OS ; TCGA-GU-A42R ; TCGA-GV-A3JV ; TCGA-GV-A3JW ; TCGA-GV-A3JX ; TCGA-GV-A3JZ ; TCGA-GV-A3QF ; TCGA-GV-A3QG ; TCGA-GV-A3QH ; TCGA-GV-A3QI ; TCGA-GV-A3QK ; TCGA-GV-A40E ; TCGA-GV-A40G ; TCGA-H4-A2HO ; TCGA-H4-A2HQ ; TCGA-HQ-A2OE ; TCGA-K4-A3WS ; TCGA-K4-A3WU ; TCGA-K4-A3WV
IF_EXTRACAPSULAR_SPREAD_PRESENT	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	If Extracapsular Spread Present 	Sample	Extensive ; Focal ; Unknown
INCIDENTAL_PROSTATE_CANCER	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Incidental Prostate Cancer Indicator	Sample ; Patient	No ; Yes ; Unknown
LOST_TO_FOLLOWUP	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Lost To Followup	Patient	
METHOD_OF_INITIAL_PATH_DIAGNOSIS	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Method Of Initial Pathologic Diagnosis	Patient	
METHOD_OF_INITIAL_PATH_DIAGNOSIS_OTHER	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Other Method Of Initial Pathological Diagnosis	Patient	
NEW_TUMOR_EVENT_OTHER_SITE	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Other Site of New Tumor Event 	Patient	
NEW_TUMOR_EVENT_SITE	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	New Tumor Event Site	Sample	Lung ; Liver ; Lymph Node Only ; Other (please specify)
NEW_TUMOR_EVENT_TYPE	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	New Tumor Event Type	Sample	Locoregional (Urothelial tumor event) ; Distant Metastasis
NODES_EX	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	NUMBER	Nodes Ex	Sample	0 ; 12 ; 11 ; 8 ; 24 ; 14 ; 17 ; 13 ; 4 ; 23 ; 9 ; 6 ; 7 ; 16 ; 28 ; 3 ; 54 ; 18 ; 27 ; 40 ; 22 ; 46 ; 35 ; 30 ; 5 ; 47 ; 2 ; 29 ; 19 ; 15 ; 25 ; 85 ; 48 ; 38 ; 37
PATHOLOGIC_DISTANT_SPREAD	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Pathologic Distant Spread	Patient	
PATHOLOGIC_SPREAD_INCIDENTAL_PROSTATE_CANCER	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Pathologic Spread Incidental Prostate Cancer	Patient	
PRIOR_TUMOR	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Prior Tumor	Sample	No ; Yes
REGIONAL_NODES_PATHOLOGIC_SPREAD	Yellow	Bladder Urothelial Carcinoma (TCGA, Nature 2014)	STRING	Regional Nodes Pathologic Spread	Sample	pNX ; pN0 ; pN2 ; pN1 ; pN3
INTRAVESICAL_TREATMENT	Yellow	Bladder Cancer (MSK, Cell Reports 2022)	STRING	Intravesical Treatment	Sample	0 ; 1 ; 3 ; 2 ; .
MET_LOCATION	Yellow	Bladder Cancer (MSK, Cell Reports 2022)	STRING	Met Location	Patient	
SPECIMEN_STAGE	Yellow	Bladder Cancer (MSK, Cell Reports 2022)	STRING	Specimen Stage	Sample	4 ; 3 ; 2 ; 1
TX_BET_PRI_MET_SAMPLE_COLLECTION	Yellow	Bladder Cancer (MSK, Cell Reports 2022)	STRING	Treatment between Pri-Met sample collection	Patient	
CIS	Yellow	Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)	STRING	CIS.	Patient	
DISTANT_RECURRENCE	Yellow	Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)	STRING	Distant recurrence.	Patient	
TIME_TO_DISTANT_RECURRENCE	Yellow	Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)	NUMBER	Time to distant recurrence	Patient	
TIME_TO_LOCAL_RECURRENCE_STATUS	Yellow	Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)	STRING	Time to local recurrence status	Patient	
UROTHELIAL_PRIMARY	Yellow	Upper Tract Urothelial Cancer (MSK, Eur Urol 2015)	STRING	Urothelial primary.	Patient	
AJCC_TUMOR_CLINICAL_CT	Yellow	Upper Tract Urothelial Carcinoma PDX (MSK, Nat Commun 2020)	STRING	Code of pathological T (primary tumor) to define the size or contiguous extension of the primary tumor (T), using staging criteria from the American Joint Committee on Cancer (AJCC).	Patient	
ETHINICITY	Yellow	Bladder Cancer (Columbia University/MSK, Cell 2018)	STRING	Ethinicity	Patient	
ORTHOTOPIC_XENOGRAFT_INFORMATION	Yellow	Bladder Cancer (Columbia University/MSK, Cell 2018)	STRING	Orthotopic Xenograft Information	Patient	
PATHOLOGICAL_CLASSIFICATION_OF_PARENTAL_TUMOR_SAMPLE	Yellow	Bladder Cancer (Columbia University/MSK, Cell 2018)	STRING	Pathological Classification of Parental Tumor Sample	Patient	
PRIOR_INTRAVESICAL_THERAPY	Yellow	Bladder Cancer (Columbia University/MSK, Cell 2018)	STRING	Prior Intravesical Therapy	Patient	
PRIMARY_VS_SECONDARY	Yellow	Bladder Cancer (MSK/TCGA, 2020)	STRING	Primary Vs Secondary	Sample	Primary MIBC ; Secondary MIBC
PRIOR_INTRAVESICAL_CHEMOTHERAPY	Yellow	Bladder Cancer (MSK/TCGA, 2020)	STRING	Prior Intravesical Chemotherapy	Sample	Bacillus Calmette-Guerin (BCG)
DISEASE_STATE	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	Disease State	Sample	Metastatic ; MIBC ; NMIBC ; Localized UTUC
ERDAFITINIB_TREATED	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	Erdafitinib Treated	Patient	
ERDAFITINIB_TX_OS_MONTHS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	NUMBER	Overall survival in months since date of Erdafitinib Treatment.	Patient	
ERDAFITINIB_TX_OS_STATUS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	The patient's survival status since Erdafitinib Tx	Patient	
ERDAFITINIB_TX_PFS_MONTHS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	NUMBER	Progress Free Survival (Months since Erdafitinib Tx)	Patient	
ERDAFITINIB_TX_PFS_STATUS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	Progression Free Status since Erdafitinib Tx	Patient	
SEQUENCING_OS_MONTHS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	NUMBER	Overall survival in months since date of sequencing. If patient died before sequencing overall survival in months is set to '0'. If patient is alive and last contact date is before date of sequencing, overall survival in months is set to 'NA'	Patient	
SEQUENCING_OS_STATUS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	The patient's survival status since sequencing; is the patient alive or deceased.	Patient	
SMOKIMG_STATUS	Yellow	Bladder Cancer (MSK, Clin Cancer Res 2023)	STRING	Smoking Status	Patient	
AJCC_INCIDENTAL_PROSTATE_CANCER	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	American Joint Committee on Cancer Code Incidental Prostate Cancer	Patient	
EXTRACAPSULAR_EXTENSION	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	The yes/no/unknown indicator that asks whether or not there is extracapsular extension.	Patient	
EXTRACAPSULAR_EXTENSION_PRESENT	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Text term to describe the extent of extracapsular extension present in a case of bladder carcinoma.	Patient	
NONINVASIVE_BLADDER_CA_TX_TYPE	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Noninvasive Bladder Cancer Treatment Type	Patient	
NONINVASIVE_BLADDER_HISTORY	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	History of Noninvasive Bladder Cancer	Patient	
OCCUPATION_CURRENT	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	The text that describes the type of business or industry associated with a person's job.	Patient	
OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	To specify an exposure to a substance with a defined atomic or molecular structure that results from, or takes part in, reactions involving changes in its structure, composition, or properties at work.	Patient	
OCCUPATION_PRIMARY_INDUSTRY	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Text to describe the industry in which a person's primary occupation time was spent.	Patient	
TIME_TO_COMPLETE_RESPONSE	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Time To Complete Response (months)	Patient	
TX_90DAYS_POST_RESECTION	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Treatment (90 Days Post Resection)	Patient	
TX_COMPLETE_RESPONSE	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Treatment (Complete Response)	Patient	
TX_INDUCTION_COURSES_INDICATOR	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Treatment (Induction Courses Indicator)	Patient	
TX_MAINTENANCE_COURSES_INDICATOR	Yellow	Bladder Urothelial Carcinoma (TCGA, Firehose Legacy)	STRING	Treatment (Maintenance Courses Indicator)	Patient	
TUMOR_TISSUE_SITE_PATIENT	Yellow	Bladder Cancer (TCGA, Cell 2017)	STRING	Text term that describes the anatomic site of the tumor or disease.	Patient	
AGE_AT_LAST_FOLLOWUP	Yellow	Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)	NUMBER	Age At Last Follow-Up	Patient	
BODY_SITE	Yellow	Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)	STRING	Body site where sample was collected	Sample	Renal pelvis primary ; Lung nodule ; Bladder primary ; LN from cystetcomy LND ; Retroperitoneal LN ; Peritoneal mass ; Liver metasatsis ; Left Inguinal LN ; Right para-aortic LN ; Right supra-clavicular LN ; Left supra-clavicular LN ; Inguinal LN ; Prostate bed ; Para-aortic LN ; Presacral mass ; Omental Metastasis ; Pelvic LN ; Para-esophageal LN ; Spinal mass ; Right pelvic mass ; Ureter and kideny
CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED	Yellow	Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)	STRING	Chemotherapy or intravesical therapy received prior to sample acquisition: None , Gemcitabine and Cisplati=Gemcitabine and Cisplatin , Bacillus Calmette-Guerin=Bacillus Calmette-Guerin , DR=Docetaxel and Ramucirumab , D=Docetaxel , MVAC , Gemcitabine and Carboplatin=Gemcitabine and Carboplatin , Mitomycin	Sample	Gemcitabine and Cisplatin ; Bacillus Calmette-Guerin ; Docetaxel and Ramucirumab ; Docetaxel ; MVAC ; MVAC, Docetaxel ; Bacillus Calmette-Guerin, Gemcitabine and Cisplatin ; Gemcitabine and Carboplatin ; Bacillus Calmette-Guerin,Mitomycin ,Gemcitabine and Cisplatin
HIGHEST_RECORDED_CLINICAL_TNM_STAGE	Yellow	Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)	STRING	The highest clinical TNM stage of the patient recorded	Patient	
HISTOPATOLOGY_PRIMARY_TUMOR	Yellow	Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)	STRING	Histopathology of the primary tumor of the patient: UC=Urothelial Carcinoma	Patient	
ADC+IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive ADC + Immunotherapy?	Patient	
ADC_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive ADC Therapy?	Patient	
ADJUVANT_RADIATION_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive adjuvant radiation therapy	Patient	
BASELINE_ECOG	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	NUMBER	ECOG Performance Status at trial entry	Patient	
BEST_RESPONSE_ADC	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to ADC Therapy	Patient	
BEST_RESPONSE_ADC_AND_IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to ADC + Immunotherapy	Patient	
BEST_RESPONSE_CHEMOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to Chemotherapy?	Patient	
BEST_RESPONSE_CHEMOTHERAPY_AND_IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to Chemotherapy + Immunotherapy?	Patient	
BEST_RESPONSE_IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to Immunotherapy?	Patient	
BEST_RESPONSE_TARGETED_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	What was the subject's best response to Targeted Therapy?	Patient	
CHEMOTHERAPY+IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive Chemotherapy + Immunotherapy?	Patient	
CHEMO_SURVIVAL	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	NUMBER	Survival time from the initation of chemotherapy	Patient	
CONCURRENT_CHEMOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject have concurrent chemoradiation for the primary tumor	Patient	
DEATH_REASON	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Reason for Death	Patient	
IMMUNOTHERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive Immunotherapy?	Patient	
IMMUNO_SURVIVAL	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	NUMBER	Survival time from the initation of immunotherapy	Patient	
METASTATIC_RADIATION_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive radiation therapy for metastatic disease?	Patient	
NEOADJUVANT_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive neoadjuvant therapy?	Patient	
NGS_PRIOR_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the patient recieve therapy prior to NGS? If so, what was given?	Patient	
PRIMARY_MET	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Was the sample collected for analysis a primary tumor or met	Patient	
PRIMARY_RADIATION_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject have radiation therapy for the primary tumor	Patient	
PRIMARY_SURGERY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Type of surgery for primary cancer	Patient	
PRIMARY_SURGERY_HISTOLOGY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Histology from primary cancer surgery	Patient	
PRIMARY_SURGERY_M_STAGE	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Primary surgery M Stage	Patient	
PRIMARY_SURGERY_N_STAGE	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Primary surgery N Stage	Patient	
PRIMARY_SURGERY_T_STAGE	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Primary surgery T Stage	Patient	
PRIMARY_SURGERY_VARIENT_HISTOLOGY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Variant hisotlogy from primary cancer surgery	Patient	
SURGERY_ADVANCED_DISEASE	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive surgery for advanced disease?	Patient	
SURVIVAL_TIME	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	NUMBER	Survival time in months from diagnosis of high grade or invasive disease to last contact or death	Patient	
SYSTEMIC_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive systemic therapy for metastatic disease?	Patient	
TARGETED_THERAPY	Yellow	Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)	STRING	Did the subject receive Targeted Therapy?	Patient	
ALLELE_FREQUENCY_CELLULARITY	Purple	Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)	NUMBER	Cllularity based on allele frequency	Sample	14 ; 5 ; 61 ; 17 ; 69 ; 67 ; 23 ; 26 ; 11 ; 54 ; 93 ; 73 ; 68 ; 4 ; 28 ; 53 ; 22 ; 32 ; 51 ; 83 ; 71 ; 36 ; 64 ; 21 ; 50 ; 60 ; 75 ; 24 ; 55 ; 45 ; 70 ; 34 ; 6 ; 19 ; 42 ; 31 ; 72 ; 79 ; 59 ; 37 ; 65 ; 49 ; 58 ; 62 ; 52 ; 46 ; 25 ; 12 ; 44 ; 80 ; 85 ; 84 ; 92 ; 30 ; 18 ; 41 ; 43 ; 74 ; 40 ; 77 ; 63 ; 35 ; 57 ; 8 ; 3 ; 29 ; 33 ; 47 ; 9 ; 20 ; 15 ; 87 ; 39
ASSOCIATED_ADENOMA	Purple	Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)	STRING	Associated Adenoma	Patient	
INTESTINAL_PERCENTAGE	Purple	Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)	NUMBER	% Intestinal	Sample	100 ; 0 ; 90 ; 10 ; 40 ; 30 ; 5 ; 20 ; 50 ; 70 ; 80 ; 75 ; 60
MORPHOLOGY_OTHER_FEATURES	Purple	Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)	STRING	Morphology Other Features	Sample	Mucinous ; Partly Mucinous ; Squamous ; Lynch Syndrome ; Signet Ring ; Adenoma With Intraepithelial Neoplasia And Dysplasia Components ; Medullary
MORPHOLOGY_SUBTYPE	Purple	Ampullary Carcinoma (Baylor College of Medicine, Cell Reports 2016)	STRING	Morphology Subtype	Sample	Intestinal ; Pancreatobiliary ; Mixed
IMMUNOHISTOCHEMISTRY	Purple	Acinar Cell Carcinoma of the Pancreas (JHU, J Pathol 2014)	STRING	Immunohistochemistry	Sample	Chymotrypsin +, Trypsin + ; Trypsin +, Lipase + ; Trypsin + ; Lipase +, Trypsin +, Chymotrypsin + ; Alpha-1-Antitrypsin +, Lipase + ; Alpha-1-Antitrypsin + ; Trypsin +, Chymotrypsin + ; Chymotrypsin +, Lipase +
NODAL_STATUS	Purple	Pancreatic Cancer (UTSW, Nat Commun 2015)	STRING	Nodal Status	Sample	1 ; 0
PATHOLOGICAL_DIAGNOSIS	Purple	Insulinoma (Shanghai, Nat Commun 2013)	STRING	Pathological Diagnosis	Patient	
CYST_SIZE	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	NUMBER	Cyst Size (cm)	Sample	5.5 ; 12 ; 2 ; 3.9 ; 8 ; 4.5 ; 3.4 ; 6.5 ; 6 ; 5 ; 4 ; 3 ; 16 ; 18 ; 13 ; 14 ; 15 ; 3.5 ; 10.5 ; 2.8 ; 2.5 ; 9
DYSPLASIA	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	STRING	Dysplasia	Sample	High grade ; Low grade
MAIN_VS_BRANCH_DUCT	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	STRING	Main vs Branch Duct	Sample	Main ; Mixed-type ; Branch
RELEVANT_MEDICAL_HISTORY	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	STRING	Relevant Medical History	Patient	
SCA_TYPE	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	STRING	Serous Cystadenomas (SCAs)	Sample	Microcystic ; Solid variant
TUMOR_FOCALITY	Purple	Cystic Tumor of the Pancreas (Johns Hopkins, PNAS 2011)	STRING	Primary neoplasm focus type	Patient	
ENETS_STAGING	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	ENETS Staging	Sample	IIb ; IIIb ; IIIa ; IIa ; IV ; I
ENETS_T_STAGING	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	ENETS T-Staging	Sample	3 ; 2 ; 4 ; 1
EXTRA_PANC_SPREAD	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	Extra-Panc Spread	Sample	Absent ; Present
FAMILIAL_SYNDROME	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	Familial Syndrome	Patient	
FUNCTIONAL	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	Functional	Sample	No ; Yes
PERSONAL_HISTORY	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	Personal History	Patient	
SURGICAL_MARGIN	Purple	Pancreatic Neuroendocrine Tumors (Multi-Institute, Nature 2017)	STRING	Surgical Margin	Patient	
ACINAR_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Acinar fraction	Sample	1 ; 0;0;0 ; 0 ; 5;10;5 ; 0;0 ; 5 ; 25;40 ; 12;0;NA ; 20;NA;50 ; 10 ; 1;1 ; 15 ; 0;5 ; 0;15 ; 20 ; 2;0 ; 5;5;8 ; 15;25;8 ; 24;52 ; 0;30 ; 35;70 ; 40;0 ; 45 ; 65;40 ; 58;15 ; 0;1 ; 8;2 ; 10;16 ; 8;20 ; 2 ; 3 ; 5;5 ; 0;15;0 ; 45;10 ; 3;0 ; 8;40;15 ; 30;20 ; 20;30 ; 5;0 ; 20;16 ; 30;15 ; 0;2 ; 25 ; 15;0 ; 5;4 ; 50;8 ; 0;35 ; 25;0 ; 6;8 ; 0;10 ; 3;20 ; 2;20 ; 0;4 ; 12;0 ; 35 ; 35;60 ; 4 ; 1;0
ADDITIONAL_PATHOLOGIC_FINDINGS	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Additional pathologic findings	Sample	None identified ; Pancreatic intraepithelial neoplasia : Highest grade - PanIN-3 ; Other : Gastric GIST ; Chronic pancreatitis ; Other : Pancreatic duct margin with intraductal papillary mucinous tumor with low grade dysplasia ; Other : Chronic Gastritis ; Other : Main duct intraductal papillary mucinous neoplasm gastric-type 1.2cm ; Pancreatic intraepithelial neoplasia : Highest grade - PanIN-2 ; Other : IPMN, Pancreatic atrophy ; Acute pancreatitis ; Other : necrosis ; Other : Microscopic tumor extension: tumor invades ampulla of Vater and invades peripancreatic soft tissue. ; Other : IPMN ; Other : atrophy ; Other : Duodenal mucosal suspicious for gluten sensitivity enteropathy ; Other : cholelithiasis ; Other : Patchy foveloar metaplasia of proximal duodenum, sugestive of peptic duodenitis; patchy fat necrosis in peripancreatic soft tissue ; Other : PanIN ; Other : Balser's necrosis. ; Other : NET G1 ; Other : gallbladder:CHRONIC CHOLECYSTITIS WITH CHOLESTEROLOSIS AND ADHESIONS
ALCOHOL_CONSUMPTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Alcohol consumption	Patient	
CLINICAL_STAGING_DISTANT_METASTASIS_CM	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Clinical staging distant metastasis (CM)	Sample	cM0 ; cMX ; cM1
FAT_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Fat fraction	Sample	4 ; 0;6;0 ; 0 ; 0;0;0 ; 0;0 ; 15 ; 10 ; 0;0;NA ; 5 ; 5;NA;2 ; 2 ; 1 ; 2;5 ; 20 ; 1;5 ; 40 ; 0;1 ; 1;0 ; 25 ; 5;0 ; 0;2 ; 0;8 ; 30 ; 8;0 ; 3 ; 12
FOLLOW_UP_DAYS	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	NUMBER	Follow-up days	Patient	
HISTOLOGY_DIAGNOSIS	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Histology Diagnosis	Patient	
INFLAMMATION_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Inflammation fraction	Sample	7 ; 7;30;25 ; 5 ; 10;13;5 ; 10;15 ; 15 ; 10;5 ; 10 ; 5;4;NA ; 3;NA;7 ; 5;5 ; 2;2 ; 3;5 ; 3;2 ; 2;10;5 ; 8;3;2 ; 8;6 ; 15;8 ; 3 ; 10;2 ; 8;15 ; 5;2 ; 1 ; 2 ; 9;18 ; 8;5 ; 4;4 ; 5;4 ; 6;8 ; 20 ; 5;10 ; 4;3 ; 6 ; 8;5;1 ; 15;10 ; 9 ; 4 ; 4;2 ; 5;10;5 ; 5;13 ; 15;5;3 ; 10;10 ; 7;5 ; 6;5 ; 10;8 ; 8 ; 30 ; 12;20 ; 3;15 ; 10;3 ; 10;4 ; 9;16 ; 5;8 ; 20;15 ; 5;3
ISLET_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Islet fraction	Sample	2 ; 1;3;2 ; 0 ; 2;2;3 ; 0;0 ; 1 ; 2;2 ; 2;0;NA ; 3;NA;5 ; 0;1 ; 0;2 ; 2;0 ; 1;1;1 ; 2;2;1 ; 1;3 ; 3 ; 5 ; 2;3 ; 4;2 ; 1;1 ; 0;0;0 ; 1;0 ; 1;2 ; 0;2;0 ; 5;5 ; 2;1 ; 0;3
IS_THIS_PATIENT_LOST_TO_FOLLOW_UP	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Is the patient lost to follow-up?	Patient	
LYMPH_VASCULAR_INVASION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Lymph vascular invasion	Sample	Present ; Not identified ; Indeterminate
MEDICAL_CONDITION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Medical condition	Patient	
MUSCLE_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Muscle fraction	Sample	0 ; 0;0;0 ; 0;1 ; 0;0 ; 0;0;NA ; 3 ; 1 ; 0;NA;0 ; 2;0 ; 2 ; 10 ; 15 ; 90;2 ; 0;2 ; 5 ; 0;16 ; 5;5 ; 1;5 ; 25 ; 0;3 ; 5;0 ; 2;1 ; 0;10 ; 1;1 ; 4
NEOPLASTIC_CELLULARITY	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Neoplastic cellularity	Sample	25 ; 15;5;20 ; 40 ; 45;35;45 ; 35;40 ; 30 ; 25;20 ; 75 ; 45;60;NA ; 65 ; 45 ; 40;NA;5 ; 38 ; 60 ; 20 ; 35;35 ; 5 ; 65;60 ; 35;10 ; 50 ; 34 ; 11;20 ; 86;81;65 ; 35 ; 1;35 ; 20;9;12 ; 25;15 ; 9;1 ; 16 ; 10;8 ; 8;2 ; 15;20 ; 16;55 ; 56 ; 1;1 ; 5;23 ; 23 ; 26;25 ; 40;60 ; 46 ; 70;70 ; 45;40 ; 12;12 ; 70 ; 13 ; 65;35;45 ; 20;0 ; 48 ; 60;60 ; 65;65 ; 35;20;25 ; 20;20 ; 65;35 ; 28 ; 15;8;20 ; 50;50 ; 10;20 ; 15;10 ; 10;10 ; 2;1 ; 40;45 ; 55 ; 5;4 ; 44 ; 10 ; 20;30 ; 27;40 ; 20;10 ; 18 ; 25;12 ; 4;10 ; 16;14 ; 16;16 ; 18;16 ; 13;12 ; 33;30 ; 20;16 ; 15 ; 54;55 ; 12 ; 15;5 ; 10;15 ; 19 ; 8 ; 36 ; 25;40 ; 30;65 ; 37 ; 58
NON_NEOPLASTIC_DUCT	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Non neoplastic duct	Sample	1 ; 2;1;0 ; 0 ; 3;10;10 ; 0;0 ; 1;1 ; 1;1;NA ; 1;NA;1 ; 0;1 ; 2 ; 2;2 ; 2;0 ; 1;1;1 ; 0;2 ; 1;2 ; 1;0 ; 0;0;0 ; 2;3 ; 0;0;2 ; 5;0 ; 2;4 ; 3;0
NUMBER_OF_LYMPH_NODES_EXAMINED	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	NUMBER	Number of lymph nodes examined	Sample	6 ; 13 ; 15 ; 40 ; 23 ; 20 ; 24 ; 11 ; 10 ; 12 ; 29 ; 17 ; 19 ; 21 ; 5 ; 26 ; 16 ; 27 ; 18 ; 3 ; 25 ; 2 ; 9 ; 31 ; 7 ; 36 ; 1 ; 4 ; 33 ; 8 ; 41 ; 42 ; 32 ; 22 ; 34 ; 14 ; 35 ; 43 ; 37 ; 46 ; 0 ; 47 ; 39
NUMBER_OF_LYMPH_NODES_POSITIVE_FOR_TUMOR	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	NUMBER	Number of lymph nodes positive for tumor	Sample	5 ; 2 ; 1 ; 3 ; 0 ; 11 ; 6 ; 12 ; 4 ; 10 ; 7 ; 13 ; 23 ; 20 ; 9 ; 16 ; 17 ; 8
PARTICIPANT_COUNTRY	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Country of participant	Patient	
PATHOLOGIC_STAGING_DISTANT_METASTASIS_PM	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Pathologic staging distant metastasis (PM)	Sample	pMX ; pM0 ; pM1
PATHOLOGIC_STAGING_PRIMARY_TUMOR_PT	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Pathologic staging primary tumor (PT)	Sample	pT2 ; pT3 ; pT1c ; pTX ; pT4 ; pT1a
PATHOLOGIC_STAGING_REGIONAL_LYMPH_NODES_PN	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Pathologic staging regional lymph nodes (PN)	Sample	pN2 ; pN1 ; pN0 ; pNX
STROMAL_FRACTION	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Stromal fraction	Sample	60 ; 75;55;53 ; 55 ; 35;30;32 ; 55;44 ; 23 ; 37;27 ; 45 ; 15 ; 35;35;NA ; 27 ; 30 ; 28;NA;30 ; 44 ; 18 ; 50 ; 75 ; 57;56 ; 33;31 ; 60;68 ; 52 ; 54 ; 20 ; 58;41 ; 80;78 ; 5;2;20 ; 38 ; 42 ; 2;58 ; 54;60;76 ; 65;72 ; 50;32 ; 71 ; 51 ; 80;56 ; 51;13 ; 77;65 ; 34;22 ; 83 ; 36 ; 82 ; 20;40 ; 26;54 ; 67;67 ; 54;34 ; 58 ; 10 ; 23;22 ; 53 ; 40;46 ; 72;57 ; 70 ; 59 ; 27;60;54 ; 55;67 ; 62 ; 48 ; 73 ; 17;19 ; 30;28 ; 60;53;68 ; 27;53 ; 26;55 ; 68 ; 22 ; 60;45;60 ; 43;45 ; 71;72 ; 78;88 ; 47;56 ; 68;60 ; 50;55 ; 50;50 ; 42;49 ; 31 ; 25;25 ; 39 ; 63;68 ; 40 ; 41;47 ; 73;74 ; 64 ; 32 ; 69;82 ; 74 ; 77 ; 57;68 ; 31;68 ; 60;33 ; 54;66 ; 71;69 ; 46 ; 72;67 ; 74;54 ; 59;44 ; 78;78 ; 79 ; 37 ; 14;23 ; 72 ; 61 ; 28 ; 78 ; 42;23 ; 67;70 ; 25 ; 65 ; 65;53 ; 65;32 ; 35
TOBACCO_SMOKING_HISTORY	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Tobacco smoking history	Patient	
TUMOR_NECROSIS	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Tumor necrosis	Patient	
TUMOR_STAGE_PATHOLOGICAL	Purple	Pancreatic Ductal Adenocarcinoma (CPTAC, Cell 2021)	STRING	Tumor stage pathological	Sample	Stage III ; Stage IIB ; Stage IB ; Stage IA ; Stage IIA ; Stage IV
GTF2I_MUTATION_STATUS	Purple	Thymic Epithelial Tumors (NCI, Nat Genet 2014)	STRING	GTF2I Mutation Status	Sample	WT ; MUT
ATYPICAL_MITOTIC_FIGURES	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Atypical Mitotic Figures	Patient	
CAPSULAR_INVASION	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	CAPSULAR INVASION	Patient	
CLINICAL_STATUS_WITHIN_3_MTHS_SURGERY	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Clinical Status Within 3 Mths Surgery	Patient	
CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Cytoplasm Presence Less Than Equal 25 Percent	Patient	
DIFFUSE_ARCHITECTURE	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Diffuse Architecture	Patient	
HISTORY_ADRENAL_HORMONE_EXCESS	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Excess Adrenal Hormone History Type	Patient	
HISTORY_BASIS_ADRENAL_HORMONE_DX	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Excess Adrenal Hormone Diagnosis Method Type	Patient	
METASTATIC_DX_CONFIRMED_BY	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic Neoplasm Confirmed Diagnosis Method Name	Patient	
METASTATIC_DX_CONFIRMED_BY_OTHER	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Metastatic Neoplasm Confirmed Diagnosis Method Text	Patient	
MITOSES_PER_50_HPF	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	NUMBER	Mitoses Count	Patient	
MITOTIC_RATE	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Mitotic Rate	Patient	
NUCLEAR_GRADE_III_IV	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Nuclear Grade III IV	Patient	
PHARM_TX_MITOTANE_ADJUVANT	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Mitotane Therapy Adjuvant Setting	Patient	
PHARM_TX_MITOTANE_FOR_MACRO_DISEASE	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Mitotane Therapy For Macroscopic Residual Disease	Patient	
PHARM_TX_MITOTANE_INDICATOR	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Mitotane Therapy	Patient	
PHARM_TX_MITOTANE_THERAPUTIC_AT_PROG	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Therapeutic Mitotane Lvl Progression	Patient	
PHARM_TX_MITOTANE_THERAPUTIC_AT_REC	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Therapeutic Mitotane Lvl Recurrence	Patient	
PHARM_TX_MITOTANE_THERAPUTIC_LEVELS	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Therapeutic Mitotane Levels Achieved	Patient	
PHARM_TX_MITOTANE_THERAPUTIC_MACRO	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Therapeutic Mitotane Lvl Macroscopic Residual	Patient	
RET	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	RET	Patient	
SDHA	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	SDHA	Patient	
SDHAF2_SDH5	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	SDHAF2 SDH5	Patient	
SDHB	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	SDHB	Patient	
SDHC	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	SDHC	Patient	
SDHD	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	SDHD	Patient	
SINUSOID_INVASION	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Sinusoid Invasion	Patient	
TMEM127	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Tmem127	Patient	
VHL	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Von Hippel-Lindau syndrome (VHL) is a hereditary condition associated with hemangioblastomas, which are blood vessel tumors of the brain, spinal cord, and eye.	Patient	
WEISS_SCORE_OVERALL	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Weiss Score Overall	Patient	
WEISS_VENOUS_INVASION	Purple	Adrenocortical Carcinoma (TCGA, Firehose Legacy)	STRING	Weiss Venous Invasion	Patient	
ALCOHOL_EXPOSURE_INTENSITY	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Alcohol Exposure Intensity	Patient	
DIABETES_DIAGNOSIS_DAYS_TO	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	The number of days from the date the patient was diagnosed with cancer to the date of the patient's diagnosis of diabetes.	Patient	
DIABETES_DIAGNOSIS_INDICATOR	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Participant medical history -diabetes mellitus: a metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization._A term that is used to indicate a question with permissible values of yes/no/unknown.	Patient	
GRADE_TIER_SYSTEM	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Term to describe the number of levels or 'tiers' in the system used to describe the cellular histologic grade in a tissue specimen.	Patient	
HISTORY_CHRONIC_PANCREATITIS	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Indicator to signify whether or not the patient has a history of clinical chronic pancreatitis.	Patient	
HISTORY_CHRONIC_PANCREATITIS_DAYS_TO	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	The number of days from the date the patient was diagnosed with cancer to the date of the patient's diagnosis of clinical chronic pancreatitis.	Patient	
INVASIVE_ADENOCARCINOMA_INDICATOR	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Text term to indicate a histologic diagnosis of invasive adenocarcinoma in a tissue specimen.	Patient	
TUMOR_RESECTED_MAX_DIMENSION	Purple	Pancreatic Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Tumor resected max dimension	Patient	
BX_EXTRAPROSTATIC_EXTENSION	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Extraprostatic extension status as reported in the pathology report	Sample	PRESENT ; ABSTRACTION_PENDING ; UNKNOWN ; ABSENT
BX_GLEASON_COMBO	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Combined Gleason score as reported in the pathology report	Sample	9 ; 8 ; 7
BX_GLEASON_PRIMARY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Primary Gleason score as reported in the pathology report	Sample	4 ; 5
BX_GLEASON_SECONDARY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Secondary Gleason score as reported in the pathology report	Sample	5 ; 4 ; 3
BX_LYMPHOVASCULAR	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Lymphovascular invasion status as reported in the pathology report	Sample	UNKNOWN ; ABSTRACTION_PENDING ; PRESENT ; ABSENT
BX_MARGIN	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Margin status as reported in the pathology report	Sample	POSITIVE ; ABSTRACTION_PENDING ; UNKNOWN ; NEGATIVE
BX_PERINEURAL_INVASION	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Perineural invasion status as reported in the pathology report	Sample	PRESENT ; ABSTRACTION_PENDING ; UNKNOWN ; ABSENT
BX_SEMINAL_VESICLES	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Seminal vesicle invasion status as reported in the pathology report	Sample	PRESENT ; ABSTRACTION_PENDING ; UNKNOWN ; ABSENT
CALC_TIME_TO_RALP	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Calculated elapsed time, in days, between patient's primary diagnosis with prostate cancer and date of their prostatectomy as reported in the medical record.	Patient	
DX_BX_GLEASON_COMBO	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Combined Gleason score for the diagnostic biopsy of primary prostate cancer as reported in medical record.	Patient	
DX_BX_GLEASON_PRI	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Primary Gleason score for the diagnostic biopsy of primary prostate cancer as reported in medical record.	Patient	
DX_BX_GLEASON_SEC	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Secondary Gleason score for the diagnostic biopsy of primary prostate cancer as reported in medical record.	Patient	
DX_BX_HISTOLOGY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Histology of diagnostic biopsy for primary prostate cancer.	Patient	
DX_BX_M_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	M Stage at diagnosis as reported in medical record.	Patient	
DX_BX_NUM_CORE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Number of cores with adenocarcinoma in the diagnostic biopsy for primary prostate cancer as reported in medical record.	Patient	
DX_BX_N_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	AJCC Regional Lymph Node (N) stage at diagnosis.	Patient	
DX_BX_PERC_CORE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Highest percent core involved in the diagnostic biopsy for primary prostate cancer as reported in medical record.	Patient	
DX_BX_TOT_CORES	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	NUMBER	Total cores obtained in the diagnostic biopsy for primary prostate cancer as reported in medical record.	Patient	
DX_BX_T_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	AJCC Primary Tumor (T) stage at diagnosis.	Patient	
METS_SITES_AT_METS_ABST_BLADDER	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Metastasis to bladder noted during the patient's course of treatment.	Patient	
METS_SITES_AT_METS_ABST_LYMPH_NODES	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Metastasis to lymph nodes noted during the patient's course of treatment.	Patient	
METS_SITES_AT_METS_ABST_OTHER	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Metastasis to other sites noted during the patient's course of treatment.	Patient	
METS_SITES_AT_METS_DX_ALL	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	All locations in the body where prostate cancer spread at the time of diagnosis with metastatic prostate cancer.	Patient	
METS_SITES_AT_METS_DX_BLADDER	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Metastasis to the bladder noted at time of diagnosis with metastatic prostate cancer.	Patient	
METS_SITES_AT_METS_DX_LYMPH	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Metastasis to lymph nodes noted at time of diagnosis with metastatic prostate cancer.	Patient	
METS_SITES_AT_METS_DX_OTHER	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Other metastatic sites reported at time of diagnosis with metastatic prostate cancer.	Patient	
PRD_CHEMOTHERAPY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: For your advanced prostate cancer (prostate cancer that is outside of the prostate), please check off all therapies that you have previously received or are currently receiving. Set to YES if patient reported receiving chemotherapy for advanced prostate cancer previously or currently.	Patient	
PRD_CURRENT_LOCATION	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Where is your prostate cancer currently located (select all that apply)?	Patient	
PRD_DIAGNOSIS_MET_ADV	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: When you were first diagnosed, were you diagnosed with advanced or metastatic prostate cancer (prostate cancer that has spread beyond the prostate, including biochemical recurrence)?	Patient	
PRD_EXP_CLINICAL_TRIAL	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: For your advanced prostate cancer (prostate cancer that is outside of the prostate), please check off all therapies that you have previously received or are currently receiving. Set to YES if patient reported receiving therapy through a clinical or experimental trial for advanced prostate cancer previously or currently.	Patient	
PRD_FAMILY_HISTORY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Do you have any family history of prostate and/or breast cancer?	Patient	
PRD_HISPANIC	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Do you consider yourself Hispanic, Latino/a or Spanish?	Patient	
PRD_HORMONE_THERAPY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: For your advanced prostate cancer (prostate cancer that is outside of the prostate), please check off all the hormone therapies that you have previously received or are currently receiving. Set to YES if patient reported receiving hormone therapy for advanced prostate cancer previously or currently.	Patient	
PRD_OTHER_CANCER	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Have you had any other types of cancer?	Patient	
PRD_OTHER_CANCER_TYPE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Have you had any other types of cancer? Free text was cleaned and grouped. If cancer type did not appear in 5 or more patient responses, it was categorized as OTHER CANCER.	Patient	
PRD_OTHER_THERAPY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: For your advanced prostate cancer (prostate cancer that is outside of the prostate), please check off all therapies that you have previously received or are currently receiving. Set to YES if patient reported receiving other therapies for advanced prostate cancer previously or currently.	Patient	
PRD_PROSTATECTOMY	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Have you had your entire prostate surgically removed (known as a prostatectomy)?	Patient	
PRD_RACE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: What is your race (select all that apply)? Infrequent responses have been categorized as Other for confidentiality.	Patient	
PRD_TREATED_AT_ENROLLMENT	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient reported response to the question: Did you receive local treatment to your prostate when you were first diagnosed (local treatment includes surgery, radiation, or cryotherapy)?	Patient	
RALP	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Patient received a prostatectomy as reported in the medical record.	Patient	
RALP_EXTRACAPSULAR_EXTENSION	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Extracapsular extension status of the prostatectomy as reported in the medical record.	Patient	
RALP_MARGIN	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Margin status of the prostatectomy as reported in the medical record.	Patient	
RALP_M_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	AJCC Metastasis (M) stage at prostatectomy as reported in medical record.	Patient	
RALP_NUMBER_POSITIVE_LN	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Number of lymph nodes involved with adenocarcinoma at time of prostatectomy as reported in the medical record.	Patient	
RALP_N_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	AJCC Regional Lymph Node (N) stage at prostatectomy.	Patient	
RALP_PERINEURAL_INVASION	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Perineural invasion status of the prostatectomy as reported in the medical record.	Patient	
RALP_POSITIVE_LN	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Lymph nodes involved with adenocarcinoma at time of prostatectomy as reported in the medical record.	Patient	
RALP_SEMINAL_VESICLES	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	Seminal vesicle invasion status of the prostatectomy as reported in the medical record.	Patient	
RALP_T_STAGE	Cyan	The Metastatic Prostate Cancer Project (Provisional, June 2021)	STRING	AJCC Primary Tumor (T) stage at prostatectomy.	Patient	
CLONET_PURITY	Cyan	Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)	NUMBER	CLONET Purity	Sample	0.99 ; 0.96 ; 0.97 ; 0.9 ; 0.92 ; 1 ; 0.43 ; 0.45 ; 0.5 ; 0.44 ; 0.87 ; 0.37 ; 0.55 ; 0.67 ; 0.51 ; 0.81 ; 0.8 ; 0.61 ; 0.94 ; 0.35 ; 0.7 ; 0.6 ; 0.69 ; 0.4 ; 0.2 ; 0.47 ; 0.38 ; 0.84 ; 0.41 ; 0.73 ; 0.48 ; 0.64 ; 0.82 ; 0.98 ; 0.53 ; 0.74 ; 0.62 ; 0.85 ; 0.42 ; 0.27 ; 0.63 ; 0.76 ; 0.56 ; 0.91 ; 0.57 ; 0.83 ; 0.79 ; 0.28 ; 0.86 ; 0.59 ; 0.75 ; 0.54 ; 0.58 ; 0.93 ; 0.66 ; 0.65 ; 0.52 ; 0.71 ; 0.49 ; 0.72 ; 0.68 ; 0.24 ; 0.36 ; 0.77 ; 0.33 ; 0.29 ; 0.39 ; 0.46 ; 0.78 ; 0.88 ; 0.89 ; 0.32 ; 0.31 ; 0.95
CONTROL_SITE	Cyan	Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)	STRING	Control Site	Sample	Blood ; Benign tissue ; Cerebellum
PATHOLOGY_CLASSIFICATION	Cyan	Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)	STRING	Pathology Classification	Sample	D ; A ; B ; C ; E ; Adenocarcinoma ; Inadequate for diagnosis ; Adenocarcinoma with NE features ; Small cell
ANDROGEN_DEPRIVATION_THERAPY	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	Androgen Deprivation Therapy (ADT)	Patient	
BLOCK_ID	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	BLOCK ID	Sample	00-010K ; 00-010L ; 00-010M ; 00-010N ; 00-029J2 ; 00-029N9 ; 00-029O6 ; 00-029P7 ; 00-029T2 ; 00-090B2 ; 00-090G2 ; 00-090T3 ; 00-140FF ; 00-140G ; 00-140H1 ; 00-140J9 ; 00-140K3 ; 00-140N ; 01-002G1 ; 01-087MM ; 01-087QQ1 ; 01-095C6 ; 01-095N1 ; 01-120A1 ; 01-120C1 ; 01-181AA ; 02-065M3 ; 02-065N1 ; 02-065P3 ; 02-065W2 ; 02-083D1 ; 02-083E1 ; 02-142II ; 03-027M1 ; 03-027P2 ; 03-081L ; 03-082H1 ; 03-082K2 ; 03-082OO ; 03-130L ; 03-130M4 ; 03-139E3 ; 03-139M9 ; 03-163S4 ; 03-192A1 ; 03-192B ; 03-192C2 ; 03-192D2 ; 03-192E3 ; 03-192F3 ; 03-192N2 ; 04-050G2 ; 04-050L1 ; 04-050N1 ; 04-050O2 ; 04-050R1 ; 04-050V1 ; 04-050W1 ; 04-101F2 ; 04-101H1 ; 04-101J1 ; 04-101L3 ; 04-101N1 ; 04-112G3 ; 04-112H3 ; 04-112I1 ; 04-112M1 ; 04-112N1 ; 04-149E2 ; 04-149J1 ; 05-011D2 ; 05-011G4 ; 05-092D1 ; 05-092E7 ; 05-092G2 ; 05-092H1 ; 05-092I1 ; 05-116F ; 05-116LL ; 05-123D1 ; 05-123E2 ; 05-144E1 ; 05-144EE1 ; 05-144H1 ; 05-144HH1 ; 05-144I1 ; 05-144K1 ; 05-144L1 ; 05-144M1 ; 05-144R1 ; 05-144U1 ; 05-144V1 ; 05-144W1 ; 05-144Z1 ; 05-148E3 ; 05-165K5 ; 05-165M1 ; 05-165O ; 05-187E1 ; 05-187I1 ; 05-187J3 ; 05-214BB2 ; 05-214E1 ; 05-214G1 ; 05-217F1 ; 05-217L3 ; 05-217N1 ; 05-217OO3 ; 05-221MM1 ; 06-047H1 ; 06-047QQ1 ; 06-081D3 ; 06-081E ; 06-081F2 ; 06-081H5 ; 06-081I1 ; 06-081J1 ; 06-081K2 ; 06-127H3 ; 06-131BB1 ; 06-134H1 ; 07-042EE1 ; 07-042H2 ; 07-044KK ; 07-050EE1 ; 07-050XX1 ; 07-062F2 ; 08-006H1 ; 08-006TT1 ; 08-020D1 ; 08-020HH1 ; 08-020N2 ; 08-020Y6 ; 08-037F1 ; 08-093J1 ; 09-006F1 ; 10-013F1 ; 10-013G1 ; 10-013J2 ; 10-039E3 ; 11-028G3 ; 11-028L1 ; 12-005I2 ; 12-005K1 ; 12-011D26 ; 12-011I7 ; 12-011J1 ; 12-021H4 ; 97-159H2 ; 97-201D ; 97-201H ; 97-201I ; 97-201J ; 97-201K ; 97-201M ; 98-328H ; 98-328J ; 98-328K ; 98-328O ; 98-362B1 ; 98-362K2 ; 98-372K2 ; 98-372L ; 99-064N ; 99-064O ; 99-069F ; 99-069G1 ; 99-069I ; 99-090A2 ; 99-091C ; 99-091I ; 99-091J ; 99-091K ; 99-091L ; 99-091N ; 99-091P
CGH	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	CGH	Sample	X
CGH_SAMPLE_ID	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	CGH Sample ID	Sample	00-010K_LIVER ; 00-010L_LN ; 00-010M_LN ; 00-010N_PROSTATE ; 00-029J2_LN ; 00-029N9_LN ; 00-029O6_LN ; 00-029P7_LUNG ; 00-029T2_PELVIC_MASS ; 00-090G2_LUNG ; 00-090T3_LN ; 00-140FF_BONE ; 00-140G_LIVER ; 00-140H1_LUNG ; 00-140J9_LN ; 00-140K3_BLADDER ; 00-140N_LN ; 01-002G1_LN ; 01-087MM_BONE ; 01-087QQ1_BONE ; 01-095C6_LIVER ; 01-095N1_LN ; 01-120A1_LIVER ; 01-120C1_LN ; 01-181AA_BONE ; 02-065N1_SKIN ; 02-065P3_PROSTATE ; 02-065W2_SCROTUM ; 02-083D1_LUNG ; 02-083E1_LN ; 02-142II_BONE ; 03-027M1_LUNG ; 03-027P2_LIVER ; 03-081L_LN ; 03-082H1_LIVER ; 03-082K2_LN ; 03-082OO_BONE ; 03-130L_RETROPERITONEAL ; 03-130M4_LIVER ; 03-139E3_RETROPERITONEAL ; 03-139M9_RETROPERITONEAL ; 03-163S4_LIVER ; 03-192A1_LIVER ; 03-192B_LUNG ; 03-192C2_LN ; 03-192D2_LN ; 03-192F3_LUNG ; 03-192N2_PROSTATE ; 04-050G2_LN ; 04-050L1_LN ; 04-050N1_PROSTATE ; 04-050O2_PROSTATE ; 04-050R1_LN ; 04-050V1_LN ; 04-050W1_LN ; 04-101F2_PROSTATE ; 04-101H1_PERITONEAL ; 04-101J1_LN ; 04-101L3_LN ; 04-101N1_LN ; 04-112G3_LN ; 04-112H3_LN ; 04-112I1_LN ; 04-112N1_BLADDER ; 04-149E2_LN ; 04-149J1_PROSTATE ; 05-011D2_LN ; 05-011G4_LUNG ; 05-092D1_BLADDER ; 05-092E7_LIVER ; 05-092G2_LUNG ; 05-092H1_LN ; 05-092I1_LN ; 05-116F_LUNG ; 05-116LL_BONE ; 05-123D1_PROSTATE ; 05-123E2_LN ; 05-144E1_LIVER ; 05-144EE1_BONE ; 05-144H1_LN ; 05-144HH1_BONE ; 05-144I1_LN ; 05-144K1_LUNG ; 05-144L1_LUNG ; 05-144M1_LN ; 05-144R1_PROSTATE ; 05-144U1_ADRENAL ; 05-144V1_ADRENAL ; 05-144W1_SPLEEN ; 05-144Z1_LN ; 05-148E3_LIVER ; 05-165K5_LUNG ; 05-165M1_LN ; 05-165O_ADRENAL ; 05-187E1_LIVER ; 05-187I1_PROSTATE ; 05-187J3_LN ; 05-214BB2_BONE ; 05-214E1_LN ; 05-214G1_LN ; 05-217F1_LN ; 05-217L3_LUNG ; 05-217N1_LN ; 05-217OO3_BONE ; 05-221MM1_BONE ; 06-047H1_LN ; 06-047QQ1_BONE ; 06-081D3_PROSTATE ; 06-081E_LIVER ; 06-081F2_LN ; 06-081H5_LN ; 06-081I1_LUNG ; 06-081J1_LN ; 06-081K2_LN ; 06-127H3_LN ; 06-131BB1_BONE ; 06-134H1_LN ; 07-042EE1_BONE ; 07-042H2_LN ; 07-044KK_BONE ; 07-050EE1_BONE ; 07-050XX1_BONE ; 07-062F2_LUNG ; 08-006H1_LN ; 08-006TT1_BONE ; 08-020D1_PROSTATE ; 08-020HH1_BONE ; 08-020N2_LN ; 08-020Y6_KIDNEY ; 08-037F1_LIVER ; 08-093J1_LN ; 09-006F1_RENAL ; 10-013F1_LN ; 10-013G1_RETROPERITONEAL ; 10-013J2_LN ; 10-039E3_LUNG ; 11-028G3_ADRENAL ; 11-028L1_LUNG ; 12-005I2_LIVER ; 12-005K1_LUNG ; 12-011D26_PROSTATE ; 12-011I7_LN ; 12-011J1_BLADDER ; 12-021H4_LIVER ; 97-159H2_LIVER ; 97-201D_LUNG ; 97-201H_BLADDER ; 97-201I_PROSTATE ; 97-201J_LN ; 97-201K_LN ; 97-201M_LN ; 98-328H_APPENDIX ; 98-328J_LN ; 98-328K_PERITONEUM ; 98-328O_LIVER ; 98-362B1_LN ; 98-362K2_LUNG ; 98-372K2_BLADDER_NECK ; 98-372L_LN ; 99-064N_LN ; 99-064O_LN ; 99-069F_LUNG ; 99-069G1_PERITONEUM ; 99-069I_BLADDER_NECK ; 99-090A2_LIVER ; 99-091C_LIVER ; 99-091I_LN ; 99-091J_LN ; 99-091K_LN ; 99-091L_LN ; 99-091N_LN
EXOME	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	Exome	Sample	X
EXOME_SAMPLE_ID	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	EXOME Sample ID	Sample	00-010K_LIVER ; 00-010L_LN ; 00-010M_LN ; 00-010N_PROSTATE ; 00-029J2_LN ; 00-029N9_LN ; 00-090B2_LN ; 00-090G2_LUNG ; 00-090T3_LN ; 00-140FF_BONE ; 00-140G_LIVER ; 00-140J9_LN ; 00-140N_LN ; 01-087MM_BONE ; 01-095C6_LIVER ; 01-095N1_LN ; 01-120A1_LIVER ; 01-120C1_LN ; 02-065M3_LN ; 02-065N1_SKIN ; 02-065P3_PROSTATE ; 02-065W2_SCROTUM ; 02-083D1_LUNG ; 02-083E1_LN ; 03-027M1_LUNG ; 03-027P2_LIVER ; 03-081L_LN ; 03-082H1_LIVER ; 03-130L_RETROPERITONEAL ; 03-130M4_LIVER ; 03-139E3_RETROPERITONEAL ; 03-139M9_RETROPERITONEAL ; 03-163S4_LIVER ; 03-192A1_LIVER ; 03-192B_LUNG ; 03-192C2_LN ; 03-192D2_LN ; 04-050G2_LN ; 04-050L1_LN ; 04-050N1_PROSTATE ; 04-050O2_PROSTATE ; 04-050V1_LN ; 04-050W1_LN ; 04-101F2_PROSTATE ; 04-101H1_PERITONEAL ; 04-101J1_LN ; 04-101L3_LN ; 04-112G3_LN ; 04-112H3_LN ; 04-112I1_LN ; 04-112M1_LN ; 04-112N1_BLADDER ; 04-149E2_LN ; 04-149J1_PROSTATE ; 05-011D2_LN ; 05-011G4_LUNG ; 05-092D1_BLADDER ; 05-092E7_LIVER ; 05-092I1_LN ; 05-116F_LUNG ; 05-123D1_PROSTATE ; 05-123E2_LN ; 05-144E1_LIVER ; 05-144EE1_BONE ; 05-144H1_LN ; 05-144HH1_BONE ; 05-144I1_LN ; 05-144M1_LN ; 05-144R1_PROSTATE ; 05-144U1_ADRENAL ; 05-144W1_SPLEEN ; 05-144Z1_LN ; 05-148E3_LIVER ; 05-165K5_LUNG ; 05-165M1_LN ; 05-165O_ADRENAL ; 05-187E1_LIVER ; 05-187I1_PROSTATE ; 05-187J3_LN ; 05-214BB2_BONE ; 05-214E1_LN ; 05-214G1_LN ; 05-217F1_LN ; 05-217L3_LUNG ; 05-217N1_LN ; 05-221MM1_BONE ; 06-081D3_PROSTATE ; 06-081E_LIVER ; 06-081F2_LN ; 06-081H5_LN ; 06-081I1_LUNG ; 06-081J1_LN ; 06-081K2_LN ; 06-134H1_LN ; 07-042H2_LN ; 07-050EE1_BONE ; 07-050XX1_BONE ; 07-062F2_LUNG ; 08-006H1_LN ; 08-006TT1_BONE ; 08-020D1_PROSTATE ; 08-020N2_LN ; 08-020Y6_KIDNEY ; 08-037F1_LIVER ; 08-093J1_LN ; 09-006F1_RENAL ; 10-013F1_LN ; 10-013G1_RETROPERITONEAL ; 10-013J2_LN ; 10-039E3_LUNG ; 11-028G3_ADRENAL ; 11-028L1_LUNG ; 12-005I2_LIVER ; 12-005K1_LUNG ; 12-011D26_PROSTATE ; 12-011I7_LN ; 12-011J1_BLADDER ; 12-021H4_LIVER ; 97-159H2_LIVER ; 97-201I_PROSTATE ; 97-201J_LN ; 97-201K_LN ; 97-201M_LN ; 98-328H_APPENDIX ; 98-328J_LN ; 98-328K_PERITONEUM ; 98-328O_LIVER ; 98-362B1_LN ; 98-372K2_BLADDER_NECK ; 98-372L_LN ; 99-064N_LN ; 99-064O_LN ; 99-069F_LUNG ; 99-069G1_PERITONEUM ; 99-069I_BLADDER_NECK ; 99-090A2_LIVER ; 99-091C_LIVER ; 99-091I_LN ; 99-091J_LN ; 99-091K_LN ; 99-091N_LN
EXP	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	EXP	Sample	X
EXP_SAMPLE_ID	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	EXP Sample ID	Sample	00-010K_LIVER ; 00-010L_LN ; 00-010M_LN ; 00-010N_PROSTATE ; 00-029J2_LN ; 00-029N9_LN ; 00-090B2_LN ; 00-090G2_LUNG ; 00-090T3_LN ; 00-140FF_BONE ; 00-140G_LIVER ; 00-140J9_LN ; 00-140N_LN ; 01-087MM_BONE ; 01-087QQ1_BONE ; 01-095C6_LIVER ; 01-095N1_LN ; 01-120A1_LIVER ; 01-120C1_LN ; 01-181AA_BONE ; 02-065M3_LN ; 02-065N1_SKIN ; 02-065P3_PROSTATE ; 02-065W2_SCROTUM ; 02-083E1_LN ; 02-142II_BONE ; 03-027M1_LUNG ; 03-027P2_LIVER ; 03-081L_LN ; 03-082K2_LN ; 03-082OO_BONE ; 03-130L_RETROPERITONEAL ; 03-130M4_LIVER ; 03-139E3_RETROPERITONEAL ; 03-139M9_RETROPERITONEAL ; 03-163S4_LIVER ; 03-192A1_LIVER ; 03-192B_LUNG ; 03-192C2_LN ; 03-192D2_LN ; 03-192E3_SPLEEN ; 04-050G2_LN ; 04-050L1_LN ; 04-050N1_PROSTATE ; 04-050O2_PROSTATE ; 04-050V1_LN ; 04-050W1_LN ; 04-101F2_PROSTATE ; 04-101H1_PERITONEAL ; 04-101J1_LN ; 04-101L3_LN ; 04-112G3_LN ; 04-112H3_LN ; 04-112I1_LN ; 04-112M1_LN ; 04-112N1_BLADDER ; 04-149E2_LN ; 04-149J1_PROSTATE ; 05-011D2_LN ; 05-011G4_LUNG ; 05-092D1_BLADDER ; 05-092E7_LIVER ; 05-092I1_LN ; 05-116F_LUNG ; 05-123D1_PROSTATE ; 05-123E2_LN ; 05-144E1_LIVER ; 05-144EE1_BONE ; 05-144H1_LN ; 05-144HH1_BONE ; 05-144I1_LN ; 05-144M1_LN ; 05-144R1_PROSTATE ; 05-144U1_ADRENAL ; 05-144W1_SPLEEN ; 05-144Z1_LN ; 05-148E3_LIVER ; 05-165K5_LUNG ; 05-165M1_LN ; 05-165O_ADRENAL ; 05-187E1_LIVER ; 05-187I1_PROSTATE ; 05-187J3_LN ; 05-214BB2_BONE ; 05-214E1_LN ; 05-214G1_LN ; 05-217F1_LN ; 05-217L3_LUNG ; 05-217N1_LN ; 06-047H1_LN ; 06-047QQ1_BONE ; 06-081D3_PROSTATE ; 06-081E_LIVER ; 06-081F2_LN ; 06-081H5_LN ; 06-081I1_LUNG ; 06-081J1_LN ; 06-081K2_LN ; 06-127H3_LN ; 06-134H1_LN ; 07-042H2_LN ; 07-044KK_BONE ; 07-050EE1_BONE ; 07-050XX1_BONE ; 07-062F2_LUNG ; 08-006H1_LN ; 08-020D1_PROSTATE ; 08-020N2_LN ; 08-037F1_LIVER ; 08-093J1_LN ; 09-006F1_RENAL ; 10-013F1_LN ; 10-013G1_RETROPERITONEAL ; 10-013J2_LN ; 10-039E3_LUNG ; 11-028G3_ADRENAL ; 11-028L1_LUNG ; 12-005I2_LIVER ; 12-005K1_LUNG ; 12-011D26_PROSTATE ; 12-011I7_LN ; 12-011J1_BLADDER ; 12-021H4_LIVER ; 97-159H2_LIVER ; 97-201H_BLADDER ; 97-201I_PROSTATE ; 97-201J_LN ; 97-201K_LN ; 97-201M_LN ; 98-328H_APPENDIX ; 98-328J_LN ; 98-328K_PERITONEUM ; 98-328O_LIVER ; 98-362B1_LN ; 98-372K2_BLADDER_NECK ; 98-372L_LN ; 99-064N_LN ; 99-064O_LN ; 99-069F_LUNG ; 99-069G1_PERITONEUM ; 99-069I_BLADDER_NECK ; 99-090A2_LIVER ; 99-091C_LIVER ; 99-091I_LN ; 99-091J_LN ; 99-091K_LN ; 99-091L_LN ; 99-091N_LN ; 99-091P_LN
NUM_SAMPLES_CAPTURE_MULTIPLEX	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	NUM SAMPLES CAPTURE MULTIPLEX	Sample	1 ; 2
PSA	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	Prostate-specific antigen (ng/ml)	Patient ; Sample	Positive ; Negative ; 1.57 ; 139.99 ; 1.36 ; 142.66 ; 1.17 ; 77.46 ; 0.22 ; 14 ; 2.2 ; 4.95 ; 1280 ; 5.01 ; 1436 ; 251 ; 24.3 ; 72 ; 1 ; 1868.17 ; 0.26 ; 395 ; 8.71 ; 0.08 ; 0.94 ; 0.18 ; 1.13 ; 0.01
SAMPLE_TYPE_DETAIL	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	Detailed Description of Sample Type	Sample	Localized
SEQCAP_EZ_EXOME_VERSION	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	SEQCAP EZ EXOME VERSION	Sample	v3 ; v2
SOURCE_LAB	Cyan	Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)	STRING	Source Lab	Sample	HUDSON ALPHA ; FHCRC ; UW
GLEASON_SCORE	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)	STRING	The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.	Sample ; Patient	4+3 ; 4+4 ; 3+4 ; 3+3 ; 4+5 ; 4+3;5 ; 4+5;3 ; 3+4;5 ; 3+5 ; 7 ; 8 ; 9 ; 6 ; Tx_Effects ; 9-10 ; <7 ; UNK ; 10 ; 11 ; 5+4 ; 5+5
GLEASON_SCORE_PERCENT_4_AND_5	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)	NUMBER	Gleason score percent 4 & 5.	Sample	80 ; 100 ; 95 ; 20 ; 2 ; 60 ; 30 ; 10 ; 0 ; 40 ; 75 ; 70 ; 82 ; 5 ; 90 ; 15 ; 50 ; 12 ; 62 ; 85 ; 22 ; 32
MODIFIED_CAPRA_S_SCORE_WITHOUT_INCLUDING_SURGICAL_MARGINS	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)	NUMBER	Modified Capra S Score Without Including Surgical Margins	Sample	4 ; 6 ; 5 ; 1 ; 2 ; 7 ; 3 ; 8 ; 0
SERUM_PSA	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)	NUMBER	Serum PSA.	Patient	
TMPRSS2_ERG_FUSION_STATUS	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)	STRING	TMPRESS2-ERG fusion status.	Sample	Positive with interstitial deletion ; Negative ; Positive
ERG_FISH_RESULT	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)	STRING	ERG Fish result.	Sample	Translocation ; Translocation with deletion
ETS_FUSION_SEQ	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)	STRING	ETS fusion seq	Sample	Intergenic fusion: ETV1, 736bp after exon 7 ; Protein fusion: in frame (TMPRSS2-ERG) ; Protein fusion: mid-exon (NRF1-BRAF) ; Protein fusion: out of frame (ERG-TMPRSS2) ; Protein fusion: out of frame (TMPRSS2-ERG) ; TMPRSS2-ERG Antisense fusion ; Transcript fusion (SLC45A3-ERG) ; Transcript fusion (TMPRSS2-ERG) ; No Data ; Positive ; Negative
EXOME_SEQUENCED_IN_BARBIERI_ET_AL_2012	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)	STRING	Exome sequenced in Barbieri et al.	Sample	YES ; NO
PERCENT_GLEASON_PATTERN_4_OR_5	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)	NUMBER	Gleason Score Percent 4 & 5.	Patient	
WGS_BASED_PURITY_ESTIMATION	Cyan	Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)	NUMBER	WGS based purity estimation	Sample	0.82 ; 0.68 ; 0.71 ; 0.55 ; 0.59 ; 0.52 ; 0.81 ; 0.47 ; 0.58 ; 0.66 ; 0.21 ; 0.57 ; 0.56 ; 0.22 ; 0.72 ; 0.63 ; 0.85 ; 0.77 ; 0.74 ; 0.76 ; 0.61 ; 0.2 ; 0.75 ; 0.49 ; 0.53 ; 0.5 ; 0.69 ; 0.78 ; 0.6 ; 0.73 ; 0.23 ; 0.87 ; 0.91 ; 0.93 ; 0.987485939 ; 0.98619574 ; 0.986770348 ; 0.987765515 ; 0.986101988 ; 0.989353818 ; 0.981220344 ; 0.955607185 ; 0.985668542 ; 0.963609215 ; 0.990340369 ; 0.985765359 ; 0.964023558 ; 0.978957198 ; 0.930986675 ; 0.984901504 ; 0.960558865 ; 0.989911686 ; 0.987697014 ; 0.958216265 ; 0.974849128 ; 0.957871969 ; 0.975636327 ; 0.963392074 ; 0.960175891 ; 0.969050287 ; 0.972622595 ; 0.989479567 ; 0.966497133 ; 0.974547807 ; 0.976035033 ; 0.951495212 ; 0.969215309 ; 0.969838148 ; 0.969288471 ; 0.990650525 ; 0.972743162 ; 0.968710776 ; 0.964072934 ; 0.951502599 ; 0.968681781 ; 0.970660308 ; 0.987248603 ; 0.96672836 ; 0.959928156 ; 0.970176001 ; 0.963001817 ; 0.974897413 ; 0.978959841 ; 0.986326992 ; 0.975341872 ; 0.972839378 ; 0.962038511 ; 0.990417872 ; 0.972489541 ; 0.971309404 ; 0.979102747 ; 0.983847878 ; 0.980818808 ; 0.990765697 ; 0.983479033 ; 0.985866772 ; 0.976779552 ; 0.985176883 ; 0.986054938 ; 0.98055776 ; 0.977198113 ; 0.97869518 ; 0.979809708 ; 0.968158014 ; 0.986421692 ; 0.987825091 ; 0.985316622 ; 0.979608287 ; 0.97946173 ; 0.977314743 ; 0.973242048 ; 0.979609124 ; 0.971595353 ; 0.979947426 ; 0.91582805 ; 0.982954278 ; 0.986674797 ; 0.970407057 ; 0.977928918 ; 0.970875165 ; 0.980102317 ; 0.975261265 ; 0.99150328 ; 0.968020809 ; 0.985980959 ; 0.988285887 ; 0.987846468 ; 0.988243779 ; 0.988142292 ; 0.988007487 ; 0.988080327 ; 0.987498845 ; 0.986994367 ; 0.98860832 ; 0.985267276 ; 0.988070026 ; 0.987208173 ; 0.98451186 ; 0.984424731 ; 0.981709127 ; 0.98792709 ; 0.984328887 ; 0.987236883 ; 0.988028018 ; 0.987566756 ; 0.987681825 ; 0.98759815 ; 0.987569438 ; 0.986707361 ; 0.986494452 ; 0.987465601 ; 0.98865668 ; 0.975767435 ; 0.982411358 ; 0.970591576 ; 0.986862317 ; 0.988731668 ; 0.987317177 ; 0.987269235 ; 0.987758228 ; 0.988061671 ; 0.987837467 ; 0.986660281 ; 0.987078312
ETS_RAF_SPINK1_STATUS	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	ETS RAF-SPINK1 status.	Sample	ERG+ ; RAF1+ ; ETV1+ ; No ETS ; ERG+ (small cell) ; (ERG+) ; SPINK1+
MATCHED_GE_ACGH	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	Matched GE acgh.	Sample	Yes ; No
SURVIVAL_FROM_FIRST_CHEMOTHERAPY	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	NUMBER	Survival from first chemotherapy.	Patient	
SURVIVAL_FROM_FIRST_HORMONE_THERAPY	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	NUMBER	Survival from first hormone therapy	Patient	
TREATMENT_HORMONE_THERAPY	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	Hormone therapy.	Patient	
TREATMENT_PALLIATIVE_RADIATION	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	Palliative radiation.	Patient	
TREATMENT_PROSTATECTOMY	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	Prostatectomy.	Patient	
TREATMENT_RADIATION	Cyan	Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)	STRING	Radiation.	Patient	
COPY_NUMBER_CLUSTER	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	Copy number cluster.	Patient	
ERG_FUSION_ACGH	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	ERG fusion acgh.	Sample	Not_Assessed ; Negative ; Positive ; Flat
ERG_FUSION_GEX	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	ERG fusion gex.	Sample	Not_Assessed ; Negative ; Positive
GLEASON_SCORE_1	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.	Sample	4 ; 5 ; 3 ; 7 ; >=8 ; 6
GLEASON_SCORE_2	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.	Sample	3 ; 4 ; 5
SEQUENCING	Cyan	Prostate Adenocarcinoma (MSK, Cancer Cell 2010)	STRING	Sequencing	Sample	Sanger and Sequenom ; No ; Sequenom
ADJUVANT_HORMONE_THERAPY	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Adjuvant Hormone Therapy	Patient	
BIOPSY_GLEASON_SCORE	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Biopsy Gleason Score	Sample	7 ; 8 ; 6 ; 9 ; 9-10 ; 4+3 ; 3+4 ; <7 ; 9-11
BIOPSY_GLEASON_SCORE_1	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Biopsy Gleason Score 1	Sample	3 ; 4
BIOPSY_GLEASON_SCORE_2	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Biopsy Gleason Score 2	Sample	4 ; 3 ; 5
CNA_DATA	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	NUMBER	CNA data.	Sample	2.9281013 ; 0.1623892 ; 0.0470761 ; 0.1817346 ; 0.3027872 ; 18.8553982 ; 15.6128556 ; 4.3548547 ; 25.3151406 ; 5.1307046 ; 0.2471087 ; 0.2084784 ; 0.1482648 ; 0.1125704 ; 4.3427755 ; 1.7288217 ; 8.6103081 ; 0.1535364 ; 8.1160663 ; 3.075491 ; 1.3324873 ; 3.6106016 ; 0.7207387 ; 0.1433115 ; 1.1026285 ; 0.1597745 ; 4.2634535 ; 15.1162827 ; 7.8168397 ; 1.6664467 ; 1.7786014 ; 0.2096433 ; 0.2999429 ; 0.2227074 ; 0.8118826 ; 5.5283051 ; 0.1888304 ; 2.699642 ; 1.0972583 ; 4.5894925 ; 11.5492863 ; 0.1423996 ; 1.202829 ; 1.0204494 ; 9.3844811 ; 0.2130048 ; 11.1580621 ; 5.8809542 ; 0.100582 ; 0.0822244 ; 7.414548 ; 0.1685721 ; 0.1076925 ; 2.9879377 ; 9.2169073 ; 0.2244728 ; 0.1770888 ; 4.8947718 ; 0.3021948 ; 0.1968243 ; 0.1717349 ; 0.0838745 ; 0.6825233 ; 0.1612004 ; 0.1937774 ; 0.162958 ; 0.1532693 ; 0.7360305 ; 13.8880551 ; 2.170759 ; 22.6107274 ; 0.1975106 ; 0.3828419 ; 0.269898 ; 0.2995935 ; 50.2723357 ; 0.1775899 ; 20.6694897 ; 0.1812303 ; 0.091057 ; 4.3218778 ; 0.1234781 ; 3.5736614 ; 7.1573125 ; 0.2399915 ; 0.2402256 ; 8.8809968 ; 2.8572903 ; 0.1573032 ; 3.2314659 ; 0.1821983 ; 9.0833369 ; 0.0427553 ; 0.0713592 ; 6.7263554 ; 0.2024286 ; 0.2057895 ; 12.0341886 ; 0.1756284 ; 0.00323 ; 8.3057509 ; 2.8239277 ; 0.1048549 ; 13.9304278
ECE	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	ECE	Sample	Focal ; Invades Capsule ; Established ; FOCAL
ECE_BINARY	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	ECE Binary	Sample	No ; Yes
METASTATIC_DISEASE	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Metastatic disease	Patient	
METS_FREE_TIME_MONTHS	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	NUMBER	MetsFreeTime_Months	Patient	
PATH_GLEASON_SCORE	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Path Gleason Score	Sample	7 ; 8 ; 9 ; 6
PATH_GLEASON_SCORE_1	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Path Gleason Score 1	Sample	3 ; 4 ; 5
PATH_GLEASON_SCORE_2	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	Path Gleason Score 2	Sample	4 ; 3 ; 5
RADIATION_TREATMENT_NEOADJUVANT	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	A yes/no indicator that asks whether the patient startedneoadjuvant preoperative radiotherapy?	Patient	
SMS	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	SMS	Sample	Negative ; Positive ; Tumor present at the apical margin. ; Free of tumor
STEPHANSON_5YR_NOMOGRAM	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	NUMBER	stephanson 5yr nomogram	Sample	97.00693488 ; 76.6892314 ; 95.89979649 ; 98.14146161 ; 60.24832726 ; 3.093795292 ; 96.57979012 ; 10.90684608 ; 70.13084888 ; 68.15625429 ; 96.49181962 ; 96.5955317 ; 98.18032384 ; 90.99119306 ; 89.97220993 ; 40.47600031 ; 65.11791945 ; 79.0270865 ; 82.50359297 ; 98.2073009 ; 87.78517246 ; 97.03099728 ; 98.10784459 ; 99.05759692 ; 29.50749099 ; 90.24220705 ; 96.83847427 ; 75.56040883 ; 93.85312796 ; 93.39342117 ; 88.37109804 ; 97.20457196 ; 85.41170955 ; 81.21763468 ; 95.96970677 ; 57.22625852 ; 97.58313894 ; 92.02321768 ; 83.29637051 ; 97.33707905 ; 93.01852584 ; 98.84128571 ; 96.97058201 ; 98.30427766 ; 17.67987609 ; 93.05775166 ; 92.69109964 ; 94.19718981 ; 98.62158895 ; 98.35467339 ; 92.76998639 ; 96.81456089 ; 73.91797304 ; 97.21837044 ; 76.4687717 ; 95.60980797 ; 98.54444265 ; 97.4514842 ; 92.77323484 ; 96.18577957 ; 97.16714621 ; 97.57310152 ; 93.99219155 ; 84.66464877 ; 91.8751657 ; 97.61633873 ; 93.14140677 ; 96.61492109 ; 96.94510102 ; 92.21696854 ; 87.08275557 ; 93.74825358 ; 98.8053143 ; 98.14499021 ; 96.7031002 ; 97.4486053 ; 7.688673586 ; 89.76866007 ; 96.98215723 ; 94.0261662 ; 97.14202285 ; 98.54280353 ; 96.61256075 ; 78.61270308 ; 97.21534252 ; 97.36996889 ; 87.84890175 ; 97.39425182 ; 94.19075847 ; 96.64462209 ; 97.59110808 ; 86.5231216 ; 94.1216588 ; 68.77686977 ; 62.26018071 ; 96.85177207 ; 93.64681244 ; 85.75083017 ; 98.05318117 ; 91.29773974 ; 93.95238757 ; 93.20688248 ; 97.93156981 ; 94.85135674
SVI	Cyan	Prostate Adenocarcinoma (MSK, PNAS 2014)	STRING	svi	Sample	Negative ; Positive
ABI_ENZA_EXPOSURE_STATUS	Cyan	Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)	STRING	Abiraterone (ABI) and Enzalutamide (ENZA) Exposure Status	Patient ; Sample	Naive ; On treatment ; Exposed ; UNK
ABSOLUTE_EXTRACT_PURITY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Absolute extract purity.	Sample	0.56 ; 0.48 ; 0.52 ; 0.84 ; 0.72 ; 0.47 ; 0.36 ; 0.66 ; 0.76 ; 0.64 ; 0.32 ; 0.44 ; 0.86 ; 0.85 ; 0.97 ; 0.4 ; 0.5 ; 0.68 ; 0.67 ; 0.81 ; 0.59 ; 0.3 ; 0.79 ; 0.63 ; 0.54 ; 0.75 ; 0.55 ; 0.71 ; 0.61 ; 0.57 ; 0.41 ; 0.49 ; 0.23 ; 0.35 ; 0.43 ; 0.6 ; 0.87 ; 0.58 ; 0.38 ; 0.29 ; 0.62 ; 0.2 ; 0.24 ; 0.33 ; 0.17 ; 0.69 ; 0.53 ; 0.45 ; 0.46 ; 0.91 ; 0.88 ; 0.77 ; 0.82 ; 0.73 ; 0.94 ; 0.83 ; 0.89 ; 0.99 ; 0.31 ; 0.39 ; 0.93 ; 0.22 ; 0.74 ; 0.34 ; 0.65 ; 0.16 ; 0.37 ; 0.92 ; 0.8 ; 0.27 ; 0.19 ; 0.7 ; 0.96 ; 0.9 ; 0.21 ; 0.78 ; 0.26 ; 0.25 ; 1 ; 0.51 ; 0.42 ; 0.95
ABSOLUTE_GENOME_DOUBLINGS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Absolute Genome Doublings	Sample	0 ; 1
AKT1_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	AKT1 Mutation	Sample	0 ; 1
AR_MRNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR mRNA	Sample	1021.46 ; 1159.89 ; 2584.41 ; 267.23 ; 215.08 ; 2750.37 ; 543.31 ; 830.78 ; 473.27 ; 734.63 ; 1291.5 ; 752.7 ; 702.92 ; 556.99 ; 997.85 ; 540.38 ; 348.44 ; 646.14 ; 273.78 ; 481.75 ; 548.02 ; 297.12 ; 1239.67 ; 486.88 ; 324.35 ; 415.6 ; 783.17 ; 859.87 ; 2359.45 ; 1272.79 ; 1306.75 ; 923.37 ; 952.02 ; 1004.4 ; 554.49 ; 1067.25 ; 911.74 ; 1042.31 ; 758.65 ; 1705.81 ; 1096.26 ; 1175.97 ; 1330.65 ; 935.87 ; 814.74 ; 666.04 ; 1460.64 ; 538.81 ; 1253.7 ; 422.27 ; 1167.24 ; 1082.36 ; 2177.65 ; 1170.67 ; 1393.32 ; 1824.9 ; 1113.55 ; 953.92 ; 891.62 ; 1771.1 ; 609.27 ; 2669.72 ; 1481.44 ; 1844.85 ; 1029.97 ; 745.02 ; 347.28 ; 300.12 ; 816.13 ; 252.79 ; 459.82 ; 440.29 ; 141.78 ; 206.4 ; 340.78 ; 234.4 ; 420.12 ; 456.79 ; 204.35 ; 130.52 ; 597.7 ; 192.34 ; 294.23 ; 1278.74 ; 460.01 ; 567.54 ; 2238.73 ; 2911.53 ; 1997.09 ; 498.93 ; 1260.58 ; 900.8 ; 1004.54 ; 1426.64 ; 300 ; 981.52 ; 841.04 ; 1410.03 ; 318.97 ; 598.51 ; 595.02 ; 192.43 ; 575.06 ; 285.8 ; 576.85 ; 540.46 ; 391.17 ; 197.76 ; 493.49 ; 744.7 ; 503.19 ; 206.92 ; 155.68 ; 267.99 ; 429.66 ; 231.89 ; 103.82 ; 785.84 ; 242.23 ; 400.83 ; 526.79 ; 560.09 ; 226.3 ; 400.39 ; 473.77 ; 544.43 ; 583.4 ; 196.92 ; 738.37 ; 378.38 ; 180.22 ; 419.35 ; 430.45 ; 804.85 ; 163.83 ; 417.19 ; 106.69 ; 356.71 ; 616.83 ; 880.57 ; 691.92 ; 521.27 ; 254.24 ; 638.29 ; 610.43 ; 781.75 ; 1293.38 ; 463.28 ; 383.96 ; 750.88 ; 1325.43 ; 347.49 ; 608.66 ; 448.57 ; 1022.08 ; 1353.51 ; 1176.4 ; 1370.88 ; 1903.17 ; 1022.06 ; 876.76 ; 998.14 ; 1567.22 ; 101.86 ; 1177.38 ; 341.6 ; 666.67 ; 392.28 ; 131.28 ; 635.62 ; 353.36 ; 673.5 ; 542.02 ; 526.28 ; 206.75 ; 173.44 ; 815.93 ; 1769.64 ; 592.04 ; 535.35 ; 1389.16 ; 1032.81 ; 766.09 ; 861.28 ; 254.79 ; 451.84 ; 1596.37 ; 549.83 ; 290.06 ; 516.7 ; 712.37 ; 159.03 ; 863.12 ; 4759.26 ; 1013.92 ; 902.86 ; 853.66 ; 406.1 ; 302.7 ; 367.4 ; 415.87 ; 304.32 ; 2163.8 ; 278.28 ; 675.93 ; 769.72 ; 221.52 ; 442.64 ; 366.17 ; 258.48 ; 147.15 ; 1730.88 ; 1177.14 ; 1500.11 ; 1406.64 ; 862.68 ; 1414.3 ; 2584.26 ; 1518.52 ; 1162.12 ; 456.32 ; 174.48 ; 567.03 ; 714.83 ; 375.87 ; 247.35 ; 344.68 ; 979.31 ; 522.13 ; 644.01 ; 1086.53 ; 281.18 ; 258.67 ; 252.65 ; 349.24 ; 2364.84 ; 848.55 ; 1498.5 ; 1611.61 ; 417.78 ; 320.19 ; 130.34 ; 469.46 ; 1301.03 ; 214.62 ; 1044.27 ; 1855.32 ; 943.98 ; 1066.56 ; 437.03 ; 1739.93 ; 649.29 ; 357.41 ; 997.78 ; 585.97 ; 246 ; 645.66 ; 903.06 ; 1582.12 ; 625.53 ; 251.67 ; 233.56 ; 346.93 ; 654.21 ; 262.17 ; 175.61 ; 270.43 ; 394.33 ; 364.79 ; 319.02 ; 2528.04 ; 2868.82 ; 1008.62 ; 881.67 ; 1784.45 ; 1057.76 ; 627.52 ; 1906.5 ; 1295.4 ; 583.52 ; 913.28 ; 2352.2 ; 1898.33 ; 1797.23 ; 1441.87 ; 986.26 ; 1613.14 ; 1100 ; 230.46 ; 846.29 ; 128.64 ; 524.47 ; 717.03 ; 458.29 ; 483.99 ; 276.66 ; 476.14 ; 551.31 ; 627.3 ; 175.91 ; 261.53 ; 1305.12 ; 808.75 ; 1268.35 ; 1241.45 ; 760.14 ; 760.23 ; 638.51 ; 293.98 ; 1283.5 ; 493.73 ; 306.07 ; 729.82 ; 466.48 ; 275.34 ; 246.41 ; 381.45 ; 675.51 ; 252.13 ; 524.6 ; 551.82 ; 127.01 ; 158.43 ; 411.32 ; 561.2 ; 557.23 ; 1034.66 ; 553.51 ; 305.89 ; 750 ; 521.34 ; 933.74 ; 186.32
AR_PROTEIN	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR Protein	Sample	-0.3 ; 0.58 ; -2.01 ; 0.3 ; 1.09 ; 0.31 ; -0.74 ; -1.37 ; -0.14 ; 0.97 ; 0.32 ; -0.65 ; -0.53 ; 1.82 ; 0.75 ; 1.29 ; 0.8 ; 1.07 ; 0.94 ; 0.91 ; 0.22 ; -0.96 ; 0.37 ; -0.05 ; 0.43 ; -1.27 ; 1.06 ; 0.12 ; 0.02 ; -0.01 ; 0.83 ; 0.71 ; 0.62 ; -0.61 ; 0 ; 0.08 ; -0.42 ; 1.35 ; 0.23 ; 0.16 ; -1.32 ; 1.01 ; 0.2 ; 1.45 ; 1.4 ; 0.47 ; 0.72 ; 0.25 ; -0.46 ; 0.33 ; -1.13 ; 1.68 ; 1.6 ; 0.89 ; -0.73 ; -1.07 ; -1.04 ; 0.11 ; 0.61 ; 1.65 ; -2.23 ; -0.94 ; -0.83 ; -0.29 ; 0.4 ; -0.03 ; 0.17 ; -0.08 ; -1.34 ; 1 ; 0.27 ; 1.22 ; -0.66 ; 1.84 ; 0.05 ; -0.56 ; -1.26 ; -0.5 ; 0.42 ; -0.77 ; -0.35 ; 2.17 ; -1.23 ; -0.22 ; 1.16 ; -0.8 ; 0.41 ; 1.85 ; 0.7 ; 1.83 ; -0.24 ; -1.16 ; 2.49 ; -0.4 ; 0.77 ; -1.97 ; 0.74 ; -0.31 ; -0.44 ; 0.06 ; -0.06 ; 1.05 ; 1.37 ; 0.53 ; -0.93 ; 0.46 ; -0.04 ; -0.07 ; 1.25 ; 0.29 ; 2.12 ; -0.28 ; -0.52 ; -0.9 ; 0.82 ; -0.45 ; 1.54 ; 0.65 ; -1.11 ; 0.18 ; -0.57 ; 0.19 ; 0.76 ; -1.69 ; -0.11 ; -1.48 ; 1.28 ; -0.36 ; 0.99 ; -1.18 ; -0.68 ; 0.78 ; 0.26 ; 0.54 ; -0.09 ; -1.35 ; -1.33 ; 0.57 ; 2.02 ; 0.48 ; -0.69 ; -0.98 ; 0.81 ; 1.21 ; 0.96 ; -1.67 ; -0.58 ; -0.02 ; -1.19 ; -0.15 ; 0.09 ; 1.97 ; 1.23 ; 0.04 ; 0.5 ; -1.02 ; 0.64 ; 0.51 ; 0.87 ; 0.36 ; 0.49 ; 1.03 ; -0.59 ; -1.49 ; -0.13 ; -1.38 ; -0.25 ; -0.39 ; -1.25 ; -0.99 ; -0.48 ; -0.49 ; -0.7 ; -0.26 ; -1.14
AR_SCORE	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR score	Sample	0.95 ; 2.84 ; 2.82 ; 3.8 ; 1.94 ; -7.5 ; -5.27 ; 0.04 ; -6.14 ; -1.47 ; 10.53 ; -2.72 ; 1.52 ; 6.97 ; -3.22 ; 7.86 ; -6.79 ; -0.55 ; -2.69 ; 11.94 ; -10.12 ; 9.17 ; 0.71 ; -0.5 ; 4.5 ; -14.11 ; 1.51 ; 1.95 ; 3.06 ; -2.68 ; -3.07 ; 1.36 ; -1.66 ; 0.17 ; -7.51 ; -0.09 ; 3.21 ; -6.54 ; -4.75 ; -7.26 ; 7.56 ; 10.77 ; -2.64 ; 1.71 ; -2.44 ; -7.09 ; 2.93 ; 1.14 ; 4.32 ; -5.74 ; 2.89 ; 1.17 ; 2.91 ; 5.68 ; -0.83 ; 4.05 ; 2.05 ; 1.43 ; -7.43 ; -4.81 ; -9.95 ; -2.56 ; 6.08 ; 1.23 ; 12.3 ; 4.68 ; -3.69 ; -3.31 ; -0.69 ; 1.35 ; -7.07 ; -3.23 ; -8.33 ; 0.29 ; -6.06 ; 9.93 ; 2.65 ; -10.25 ; -2.93 ; -2.43 ; -10.11 ; -10.39 ; 2.27 ; 4.58 ; 0.06 ; -0.54 ; -5.96 ; 7.21 ; 3.9 ; -4.25 ; 12.58 ; -2.46 ; -6.61 ; 1.62 ; 0.93 ; 1.04 ; 4.52 ; 9.01 ; 0.36 ; -2.79 ; -8.48 ; -1.72 ; 5.69 ; -11.74 ; -4.48 ; -4.96 ; 1.34 ; -7.19 ; 4.39 ; -3.27 ; -2.5 ; -11.51 ; -6.87 ; -9.99 ; -2.47 ; -3.77 ; -1.27 ; -8.86 ; -1.86 ; -0.23 ; -5.68 ; -7.1 ; 4.77 ; -8.55 ; -5.05 ; 2.28 ; -12.26 ; -0.07 ; -2.84 ; -0.95 ; -5 ; -8.03 ; -0.89 ; -3.1 ; 2.61 ; -12.48 ; -3.54 ; 2.64 ; 4.78 ; -14.06 ; -8.83 ; -4.47 ; -6.17 ; -5.11 ; -3.24 ; -9.14 ; -9.08 ; -8.05 ; 6.91 ; -7.67 ; 17.61 ; 1.93 ; 4.3 ; 8.86 ; -7.94 ; 0.03 ; -2.7 ; 9.87 ; 7.01 ; -0.43 ; -2.29 ; 2.22 ; -3.04 ; -2.89 ; 11.6 ; -1.98 ; 9.59 ; -1.59 ; -1.18 ; -8.85 ; -9.5 ; -5.55 ; -3.67 ; -7.54 ; -11.8 ; -0.32 ; -3.7 ; 0.14 ; -4.57 ; -15.03 ; 6.31 ; 1.82 ; -4.8 ; -6.8 ; 4.85 ; 2.4 ; -17.37 ; 6.18 ; -9.26 ; 6.85 ; -2.04 ; -13.3 ; -2.01 ; 14.45 ; 5.26 ; 15.32 ; 6.21 ; 9.96 ; 10.41 ; 5.85 ; -1.21 ; -0.67 ; 10.39 ; 9.42 ; 7.23 ; 21.68 ; 3.92 ; 5.53 ; 14.71 ; 4.14 ; 4.34 ; -2.71 ; 13.24 ; 1.75 ; 12.98 ; -0.48 ; 5.91 ; 1.81 ; 5.49 ; 22.75 ; -0.02 ; 3.33 ; -6 ; -1.41 ; 3.1 ; 6.7 ; 14.8 ; 15.9 ; -1.38 ; 2.63 ; -5.56 ; 0.49 ; -10.23 ; 12.81 ; 11.64 ; 9.51 ; 7.28 ; 2.54 ; 12.35 ; 2.16 ; 3.25 ; 6.38 ; -0.64 ; -9.16 ; 23.02 ; 3.37 ; 3.49 ; -13.84 ; 1.55 ; 0.43 ; -0.53 ; 1.07 ; -6.56 ; 3.56 ; -6.21 ; 0.69 ; 26.54 ; -4.69 ; -8.8 ; 13.87 ; 9.27 ; 3.73 ; 13.54 ; 16.14 ; 18.4 ; 6.79 ; 2.97 ; 11.13 ; 0.74 ; -7.88 ; 1.77 ; 1.6 ; 18.9 ; 12.7 ; -3.12 ; 8.99 ; -1.78 ; 10.22 ; -13.56 ; -1.14 ; 5.7 ; -6.32 ; 10.38 ; 4.65 ; 3.65 ; -4.01 ; -1.23 ; -4.09 ; -1.45 ; 7.34 ; 1.84 ; -6.59 ; -12.02 ; 17.56 ; 16.52 ; 3.7 ; -4.78 ; -6.3 ; 4.23 ; 5.46 ; -14.82 ; -18.17 ; 5.64 ; -1.15 ; 1.76 ; 7.45 ; 5.51 ; 2.57 ; -13.83 ; 10.78 ; 10.74 ; -9.71 ; 0.519533775 ; 0.530915311 ; -0.018700514 ; 0.368749179 ; 0.516237016 ; 0.034218454 ; 0.30720697 ; 0.504188448 ; 0.457715675 ; 0.433600463 ; 0.520369934 ; 0.47824925 ; -0.082116136 ; 0.398341808 ; 0.483086853 ; 0.424981972 ; 0.034240574 ; 0.45180833 ; 0.403902257 ; 0.448031519 ; 0.46352632 ; 0.574258284 ; 0.521441309 ; 0.359681776 ; 0.487832525 ; 0.551797418 ; 0.466526889 ; -0.012699584 ; 0.482821161 ; 0.463314534 ; 0.430181281 ; 0.529720098 ; 0.543851987 ; 0.413777451 ; 0.666384611 ; 0.329016067 ; 0.526799152 ; 0.656332271 ; 0.534210094 ; 0.47962937 ; 0.520546742 ; 0.163661679 ; 0.557017328 ; 0.225499884 ; 0.335186263 ; -0.264685716 ; 0.657344059 ; 0.042421885 ; -0.01056407 ; 0.472054725 ; 0.24979926 ; 0.568427315 ; 0.534309528 ; 0.450532772 ; 0.468634792 ; 0.438622636 ; 0.605639123 ; 0.656139266 ; 0.597548537 ; 0.484918132 ; 0.632644819 ; 0.480467073 ; 0.665633239 ; 0.501055916 ; 0.392856689 ; 0.001642294 ; 0.388261888 ; 0.513492618 ; 0.499631641 ; 0.241856644 ; 0.139053607 ; 0.460534586 ; 0.317585934 ; 0.406176684 ; 0.424063244 ; 0.587452328 ; 0.50855212 ; 0.359569353 ; 0.510387298 ; 0.399826263 ; 0.108947074 ; 0.495017731 ; 0.529449362 ; 0.598741441 ; 0.600831993 ; 0.348267508 ; 0.482979886 ; 0.610715124 ; 0.595065883 ; 0.555146218 ; 0.133678743 ; 0.301691124 ; 0.235027665 ; 0.515944715 ; 0.244096132 ; 0.055680391 ; -0.082331493 ; 0.025955171 ; 0.506730475 ; 0.379235879 ; 0.039532643 ; 0.413144313 ; 0.29973511 ; 0.492546574 ; 0.502621438 ; 0.565472844 ; 0.438254614 ; 0.574097721 ; 0.420475145 ; 0.398497343 ; 0.445073199 ; 0.501453638 ; 0.635018088 ; 0.603667298 ; 0.211875088 ; 0.50009976 ; 0.623256802 ; 0.549377836 ; 0.581982293 ; 0.400228893 ; 0.562280836 ; 0.313454683 ; 0.382202526 ; 0.588158629 ; 0.532440976 ; 0.447393238 ; 0.328911789 ; 0.543088471 ; 0.590437172 ; 0.455751366 ; 0.617909386 ; 0.489187635 ; 0.502720868 ; 0.524092729 ; 0.533963776 ; 0.523211487 ; 0.594907593 ; 0.227818772 ; 0.217075223 ; 0.556973446 ; 0.512147379 ; 0.534050775 ; -0.015928602 ; 0.449352021 ; 0.030781042 ; 0.47090501 ; 0.630237804 ; 0.575509076 ; 0.502722297 ; 0.56352672 ; 0.466571614 ; -0.12184595 ; 0.397584639 ; 0.427521803 ; 0.115746947 ; 0.562030345 ; 0.341486199 ; 0.299055536 ; 0.025212994 ; 0.451596818 ; 0.491469052 ; 0.304485025 ; 0.44854804 ; 0.463860362 ; 0.303105194 ; 0.409259251 ; 0.513986415 ; 0.401926036 ; 0.52069081 ; 0.40026185 ; 0.508643261 ; 0.66421692 ; 0.363666596 ; 0.295495166 ; 0.381136239 ; 0.524488554 ; 0.445731216 ; 0.376140155 ; 0.362043322 ; 0.613318493 ; 0.588466643 ; 0.029843709 ; 0.624217457 ; 0.427095913 ; 0.412105788 ; 0.559269536 ; 0.465386079 ; 0.572861618 ; 0.246841333 ; 0.490931116 ; 0.478393724 ; 0.513552186 ; 0.518940304 ; 0.525027434 ; 0.436892702 ; 0.431379099 ; 0.496068978 ; 0.595414924 ; 0.532595425 ; 0.590077486 ; 0.464784728 ; 0.531803148 ; 0.623168884 ; 0.533909242 ; 0.307022925 ; 0.567766782 ; 0.296045709 ; 0.539133735 ; 0.48669144 ; 0.473319663 ; 0.434474267 ; 0.513923726 ; 0.568899478 ; 0.303539965 ; 0.604623917 ; 0.546285356 ; 0.61008058 ; 0.468430955 ; 0.495507421 ; 0.520479307 ; 0.481939679 ; 0.320815037 ; 0.485265156 ; 0.384561266 ; 0.440457186 ; 0.602391782 ; 0.496046687 ; 0.517750339 ; 0.46380286 ; 0.541646452 ; 0.452825722 ; 0.499682534 ; 0.546252869 ; 0.596777346 ; 0.317903162 ; 0.33243211 ; 0.532529256 ; 0.440939076 ; 0.493880307 ; 0.564441623 ; 0.394849627 ; 0.505591017 ; 0.415889832 ; 0.528435007 ; 0.687895365 ; 0.140770511 ; 0.522809905 ; 0.622547817 ; 0.400294391 ; 0.46118062 ; 0.400252163 ; 0.429000784 ; 0.377742515 ; 0.452394683 ; 0.004218797 ; 0.406261917 ; 0.427918557 ; 0.158827409 ; 0.361019044 ; 0.693974469 ; 0.430924223 ; 0.471782261 ; 0.49613913 ; 0.588942046 ; 0.447750461 ; 0.473256177 ; 0.566639488 ; -0.111873001 ; 0.416196431 ; 0.59440319 ; 0.535748314 ; 0.462606648 ; 0.527461935 ; 0.490541098 ; 0.389617125 ; 0.525307398 ; 0.444699152 ; 0.533529851 ; 0.561439414 ; 0.579073112 ; 0.339972218 ; 0.649993462 ; 0.351563579 ; 0.637814551 ; 0.543654568 ; 0.303212001 ; 0.665953093 ; 0.557995567 ; 0.499763287 ; 0.5394665 ; 0.540542942 ; 0.64294423 ; 0.387284588 ; 0.589464574 ; 0.455834023 ; 0.479956229 ; 0.457496609 ; 0.480305509 ; 0.462358456 ; 0.477872987 ; 0.43694691 ; 0.484156596 ; 0.550640123 ; 0.539950892 ; 0.405015792 ; 0.330632561 ; 0.655057564 ; 0.435772982 ; 0.622175475 ; 0.595321383 ; 0.363739925 ; 0.489383541 ; 0.603596217 ; 0.605165783 ; 0.595326667 ; -0.175827934 ; 0.458817007 ; -0.026118384 ; 0.496380184 ; 0.370352377 ; 0.702217718 ; 0.371245161 ; 0.058879077 ; 0.042386212 ; 0.389603789 ; 0.630945504 ; 0.610480186
AR_V7_PRESENCE	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR V7 Presence	Sample	1 ; 0
AR_V7_RATIO	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR V7 Ratio	Sample	1.96 ; 3.08 ; 1.72 ; 11.11 ; 12.5 ; 16.35 ; 2.63 ; 0 ; 2.38 ; 3.23 ; 1.92 ; 11.63 ; 7.14 ; 3.8 ; 14.29 ; 8.22 ; 4 ; 3.92 ; 3.64 ; 2.78 ; 1.85 ; 1.39 ; 2.17 ; 4.55 ; 3.77 ; 1.49 ; 1.09 ; 10.17 ; 4.76 ; 0.53 ; 0.67 ; 8.33 ; 10 ; 7.41 ; 0.93 ; 2.7 ; 3.85 ; 1.82 ; 1.35 ; 2.44 ; 4.26 ; 9.09 ; 1.32 ; 5 ; 7.84 ; 10.34 ; 6.67 ; 16.67 ; 27.5 ; 11.9 ; 5.88 ; 4.17 ; 17.65 ; 3.33 ; 3.45 ; 6.25 ; 2.56 ; 1.1 ; 7.35 ; 1.06 ; 2.2 ; 28.57 ; 5.71 ; 8.7 ; 3.7 ; 0.95 ; 3.03 ; 14.81 ; 3.19 ; 1.56 ; 2.16 ; 60 ; 2.04 ; 33.33 ; 0.65 ; 1.89 ; 1.67 ; 25 ; 37.5 ; 0.84 ; 7.69 ; 17.24 ; 2.33 ; 1.79 ; 5.26 ; 1.64 ; 3.57 ; 2.08 ; 11.76 ; 20 ; 15.38 ; 16.2 ; 36.46 ; 8.47 ; 3.39 ; 2.67 ; 0.97 ; 0.63 ; 0.83 ; 1.37 ; 19.51 ; 2.86 ; 35.71 ; 2.13 ; 3.74 ; 1.27 ; 9.38 ; 22.22 ; 4.88 ; 4.35 ; 100
AR_V7_READS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	AR V7 Reads	Sample	2 ; 4 ; 1 ; 26 ; 0 ; 5 ; 3 ; 6 ; 11 ; 8 ; 10 ; 23 ; 66
ATM_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	ATM Mutation	Sample	0 ; 1
AVE_DNA_PURITY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Average DNA Purity	Sample	0.57 ; 0.5 ; 0.615 ; 0.835 ; 0.725 ; 0.48 ; 0.43 ; 0.665 ; 0.72 ; 0.79 ; 0.775 ; 0.735 ; 0.68 ; 0.32 ; 0.465 ; 0.855 ; 0.85 ; 0.98 ; 0.425 ; 0.51 ; 0.69 ; 0.685 ; 0.82 ; 0.6 ; 0.355 ; 0.645 ; 0.555 ; 0.755 ; 0.605 ; 0.7 ; 0.625 ; 0.81 ; 0.67 ; 0.58 ; 0.405 ; 0.485 ; 0.455 ; 0.235 ; 0.675 ; 0.385 ; 0.505 ; 0.54 ; 0.865 ; 0.53 ; 0.44 ; 0.765 ; 0.325 ; 0.38 ; 0.745 ; 0.2 ; 0.76 ; 0.285 ; 0.26 ; 0.34 ; 0.28 ; 0.71 ; 0.66 ; 0.845 ; 0.595 ; 0.815 ; 0.475 ; 0.86 ; 0.905 ; 0.695 ; 0.435 ; 0.415 ; 0.875 ; 0.45 ; 0.805 ; 0.64 ; 0.635 ; 0.655 ; 0.74 ; 0.87 ; 0.395 ; 0.93 ; 0.84 ; 0.62 ; 0.89 ; 0.49 ; 0.885 ; 0.36 ; 0.77 ; 0.945 ; 0.27 ; 0.31 ; 0.75 ; 0.825 ; 0.4 ; 0.445 ; 0.41 ; 0.92 ; 0.895 ; 0.59 ; 0.17 ; 0.8 ; 0.575 ; 0.78 ; 0.52 ; 0.96 ; 0.42 ; 0.795 ; 0.83 ; 0.535 ; 0.35 ; 0.37 ; 0.47 ; 0.335 ; 0.9 ; 0.515 ; 0.565 ; 0.955 ; 0.545 ; 0.25 ; 0.375 ; 0.29 ; 0.705 ; 0.56 ; 0.715 ; 0.275 ; 0.88 ; 0.585 ; 0.95 ; 0.525
AVE_RNA_PURITY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Average RNA Purity	Sample	0.36 ; 0.635 ; 0.46 ; 0.615 ; 0.65 ; 0.7 ; 0.56 ; 0.395 ; 0.62 ; 0.72 ; 0.775 ; 0.76 ; 0.675 ; 0.365 ; 0.535 ; 0.57 ; 0.825 ; 0.655 ; 0.845 ; 0.33 ; 0.39 ; 0.61 ; 0.115 ; 0.69 ; 0.52 ; 0.78 ; 0.55 ; 0.73 ; 0.53 ; 0.695 ; 0.59 ; 0.22 ; 0.71 ; 0.725 ; 0.685 ; 0.455 ; 0.645 ; 0.505 ; 0.275 ; 0.21 ; 0.335 ; 0.465 ; 0.405 ; 0.44 ; 0.58 ; 0.495 ; 0.565 ; 0.5 ; 0.545 ; 0.745 ; 0.435 ; 0.43 ; 0.75 ; 0.26 ; 0.235 ; 0.37 ; 0.35 ; 0.575 ; 0.38 ; 0.2 ; 0.45 ; 0.265 ; 0.41 ; 0.555 ; 0.765 ; 0.64 ; 0.755 ; 0.63 ; 0.785 ; 0.42 ; 0.47 ; 0.285 ; 0.51 ; 0.595 ; 0.48 ; 0.28 ; 0.77 ; 0.82 ; 0.49 ; 0.805 ; 0.525 ; 0.29 ; 0.375 ; 0.84 ; 0.475 ; 0.81 ; 0.665 ; 0.67 ; 0.585 ; 0.255 ; 0.68 ; 0.79 ; 0.855 ; 0.385 ; 0.305 ; 0.715 ; 0.865 ; 0.34 ; 0.625 ; 0.09 ; 0.485 ; 0.355 ; 0.85 ; 0.605 ; 0.175 ; 0.86 ; 0.345 ; 0.515 ; 0.425 ; 0.295 ; 0.315 ; 0.54 ; 0.215 ; 0.415 ; 0.325 ; 0.3 ; 0.12 ; 0.4 ; 0.195 ; 0.23 ; 0.14
BRCA1_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Brca1 cna	Patient	
BRCA1_GERMLINE_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	BRCA1 Germline Mutation	Sample	0 ; 1
BRCA1_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	BRCA1 Mutation is present	Sample	0 ; 1
BRCA2_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	BRCA2 CNA	Sample	diploid ; hetloss ; homdel
BRCA2_GERMLINE_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	BRCA2 Germline Mutation	Sample	0 ; 1
BRCA2_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	BRCA2 Mutation is present	Sample	0 ; 1
CDK12_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	CDK12 CNA	Sample	diploid ; hetloss ; homdel
CDK12_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	CDK12 Mutation	Sample	0 ; 1
CDKN1B_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	CDKN1B CNA	Sample	diploid ; hetloss ; homdel
CDKN1B_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Cdkn1b mut	Patient	
CHD1_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	CHD1 CNA	Sample	diploid ; hetloss ; homdel
CHD1_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	CHD1 Mutation is present	Sample	0 ; 1
CLINICAL_GLEASON	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Clinical Gleason	Sample	4+3 ; 3+3 ; 3+4 ; 4+5 ; 4+4 ; 2+4 ; 5+4 ; 5+3 ; 3+5 ; 5+5 ; 9 ; 7 ; 8 ; 10 ; 6
CLINICAL_GLEASON_CATEGORY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Clinical Gleason category	Sample	4+3 ; 3+3 ; 3+4 ; >=8 ; 3+5
CLINICAL_GLEASON_SUM	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Clinical Gleason Sum	Sample	7 ; 6 ; 9 ; 8 ; 10
CTNNB1_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	CTNNB1 Mutation is present	Sample	0 ; 1
DEMIX_PURITY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	DeMix Purity	Sample	0.44 ; 0.62 ; 0.47 ; 0.56 ; 0.65 ; 0.5 ; 0.4 ; 0.64 ; 0.68 ; 0.66 ; 0.42 ; 0.53 ; 0.71 ; 0.59 ; 0.74 ; 0.3 ; 0.49 ; 0.55 ; 0.6 ; 0.23 ; 0.7 ; 0.43 ; 0.61 ; 0.52 ; 0.63 ; 0.37 ; 0.67 ; 0.31 ; 0.36 ; 0.46 ; 0.58 ; 0.51 ; 0.48 ; 0.73 ; 0.33 ; 0.34 ; 0.35 ; 0.69 ; 0.72 ; 0.32 ; 0.57 ; 0.29 ; 0.45 ; 0.54 ; 0.27 ; 0.41 ; 0.28 ; 0.38 ; 0.79 ; 0.39 ; 0.76 ; 0.8 ; 0.18 ; 0.77 ; 0.78 ; 0.24 ; 0.2 ; 0.19 ; 0.26
ERG_STATUS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Erg status	Patient	
ETV1_STATUS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	ETV1 Status	Sample	none ; fusion ; high
ETV4_STATUS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	ETV4 Status	Sample	none ; fusion ; high
EXON_IMBALANCE_SCORE	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Exon Imbalance Score	Sample	1.29 ; 1.46 ; 1.09 ; 3.58 ; 2.96 ; 2.9 ; 1.5 ; 1.96 ; 1.91 ; 1.34 ; 1.78 ; 2.41 ; 2.03 ; 1.39 ; 2.31 ; 2.32 ; 1.72 ; 2.36 ; 1.99 ; 1.51 ; 3.85 ; 1.61 ; 3.25 ; 4.19 ; 2.68 ; 1.79 ; 1.6 ; 1.86 ; 1.8 ; 2.02 ; 2.29 ; 2.04 ; 1.82 ; 1.36 ; 2 ; 1.71 ; 1.81 ; 1.47 ; 2.5 ; 1.75 ; 2.43 ; 1.66 ; 1.87 ; 1.89 ; 1.77 ; 1.24 ; 1.85 ; 2.21 ; 1.16 ; 2.34 ; 1.26 ; 1.13 ; 2.05 ; 4.31 ; 2.63 ; 2.48 ; 3.68 ; 2.4 ; 5.41 ; 4.75 ; 3.36 ; 4.14 ; 3.22 ; 3.09 ; 3.9 ; 4.6 ; 5.08 ; 4.44 ; 3.14 ; 1.9 ; 1.19 ; 1.18 ; 1.31 ; 1.74 ; 1.76 ; 2.94 ; 1.62 ; 3.33 ; 2.2 ; 2.92 ; 3.28 ; 1.95 ; 2.55 ; 3.27 ; 3.16 ; 1.92 ; 1.68 ; 1.97 ; 5.31 ; 3.63 ; 2.59 ; 2.01 ; 3.05 ; 4.91 ; 2.38 ; 3.38 ; 3.15 ; 2.57 ; 2.25 ; 2.26 ; 2.51 ; 2.99 ; 2.06 ; 5.5 ; 2.33 ; 3.07 ; 2.1 ; 3.84 ; 2.49 ; 2.07 ; 2.87 ; 2.62 ; 1.35 ; 1.56 ; 2.3 ; 2.58 ; 1.69 ; 1.49 ; 2.35 ; 1.44 ; 6.03 ; 1.59 ; 2.79 ; 5.27 ; 2.27 ; 3.66 ; 2.17 ; 2.08 ; 4.54 ; 1.83 ; 1.94 ; 1.11 ; 2.09 ; 2.14 ; 2.75 ; 3.83 ; 4.1 ; 3.7 ; 2.54 ; 1.52 ; 3.53 ; 2.84 ; 2.73 ; 3.04 ; 1.28 ; 5.36 ; 6.22 ; 5.91 ; 5.17 ; 1.84 ; 1.48 ; 1.43 ; 1.42 ; 5.54 ; 2.7 ; 2.47 ; 4.9 ; 2.37 ; 2.67 ; 1.73 ; 4.18 ; 3.26 ; 1.58 ; 1.27 ; 3.37 ; 4.99 ; 2.39 ; 3.44 ; 2.15 ; 2.22 ; 4.93 ; 2.19 ; 3.94 ; 2.74 ; 3.59 ; 3.3 ; 3.79 ; 1.63 ; 1.45 ; 1.7 ; 2.46 ; 2.81 ; 1.14 ; 2.16 ; 1.32 ; 1.08 ; 1.54 ; 1.23 ; 4.84 ; 5.42 ; 4.01 ; 3.34 ; 3.45 ; 3 ; 6.4 ; 5.07 ; 1.38 ; 3.51 ; 2.12 ; 2.45 ; 2.64 ; 2.85 ; 3.8 ; 3.82 ; 2.76
FAM175A_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	FAM175A CNA	Sample	diploid ; hetloss
FANCC_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	FANCC CNA	Sample	diploid ; hetloss ; gain ; amp
FANCC_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	FANCC Mutation	Sample	1 ; 0
FANCD2_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	FANCD2 CNA	Sample	diploid ; hetloss ; homdel
FANCD2_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	FANCD2 Mutation	Sample	0 ; 1
FLI1_STATUS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	FLI1 Status	Sample	none ; high ; fusion
FOXA1_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	FOXA1 mutation is present	Sample	0 ; 1
HRAS_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	HRAS mutation is present	Sample	0 ; 1
ISOPURE_PURITY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	ISOpure Purity	Sample	0.28 ; 0.65 ; 0.45 ; 0.67 ; 0.78 ; 0.62 ; 0.39 ; 0.68 ; 0.8 ; 0.87 ; 0.86 ; 0.71 ; 0.31 ; 0.51 ; 0.61 ; 0.94 ; 0.72 ; 0.95 ; 0.36 ; 0.29 ; 0.75 ; 0.69 ; 0 ; 0.82 ; 0.54 ; 0.76 ; 0.66 ; 0.07 ; 0.49 ; 0.25 ; 0.11 ; 0.47 ; 0.41 ; 0.44 ; 0.58 ; 0.79 ; 0.52 ; 0.74 ; 0.56 ; 0.42 ; 0.83 ; 0.43 ; 0.73 ; 0.77 ; 0.21 ; 0.14 ; 0.27 ; 0.06 ; 0.5 ; 0.55 ; 0.4 ; 0.46 ; 0.18 ; 0.34 ; 0.6 ; 0.84 ; 0.33 ; 0.59 ; 0.85 ; 0.48 ; 0.91 ; 0.53 ; 0.81 ; 0.89 ; 0.9 ; 0.22 ; 0.92 ; 0.7 ; 0.19 ; 0.88 ; 0.93 ; 0.3 ; 0.57 ; 0.38 ; 0.35 ; 0.64 ; 0.17 ; 0.37 ; 0.26 ; 0.32 ; 0.24 ; 0.63 ; 0.03 ; 0.12 ; 0.16 ; 0.09
KDM6A_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	KDM6A mutation is present	Sample	0 ; 1
KMT2A_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	KMT2A mutation is present	Sample	0 ; 1
KMT2C_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	KMT2C Mutation	Sample	0 ; 1
KMT2D_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	KMT2D Mutation	Sample	0 ; 1
MED12_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	MED12 Mutation is present	Sample	0 ; 1
MRNA_EXPRESSION_CLUSTER	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	MRNA expression cluster.	Sample	1 ; 2 ; 3
MUTATIONS	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Mutations	Sample	11 ; 22 ; 28 ; 21 ; 15 ; 41 ; 38 ; 26 ; 35 ; 36 ; 63 ; 37 ; 13 ; 17 ; 29 ; 33 ; 24 ; 1019 ; 42 ; 2 ; 16 ; 60 ; 103 ; 39 ; 74 ; 19 ; 90 ; 45 ; 32 ; 49 ; 10 ; 20 ; 40 ; 51 ; 67 ; 150 ; 48 ; 46 ; 31 ; 14 ; 43 ; 81 ; 23 ; 3 ; 5 ; 30 ; 266 ; 298 ; 68 ; 44 ; 135 ; 12 ; 382 ; 34 ; 27 ; 25 ; 76 ; 4 ; 18 ; 7 ; 97 ; 50 ; 52 ; 110 ; 120 ; 47 ; 286 ; 189 ; 55 ; 102 ; 521 ; 54 ; 57 ; 62 ; 9 ; 130 ; 58 ; 122
PREOPERATIVE_PSA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Preop PSA	Patient	
PTEN_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	PTEN CNA	Sample	diploid ; homdel ; hetloss
PTEN_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	PTEN Mutation is present	Sample	0 ; 1
RAD51C_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	RAD51C CNA	Sample	diploid ; gain ; hetloss ; homdel
RB1_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	RB1 CNA	Sample	diploid ; hetloss ; homdel
RB1_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Rb1 mut	Patient	
REVIEWED_GLEASON	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Reviewed gleason	Sample	3+4 ; 3+3 ; 4+3 ; 4+5 ; 4+4 ; 5+4 ; 5+5 ; 3+5
REVIEWED_GLEASON_CATEGORY	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	Reviewed Gleason category	Sample	3+4 ; 3+3 ; 4+3 ; >=8 ; 5+4 ; 4+5 ; 3+5 ; 4+4 ; 5+3 ; 5+5
REVIEWED_GLEASON_SUM	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Reviewed Gleason Sum	Sample	7 ; 6 ; 9 ; 8 ; 10
SETD2_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	SETD2 Mutation	Sample	0 ; 1
SPINK1_HIGH	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	SPINK1 High	Sample	0 ; 1
SPOPL_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	SPOPL CNA	Sample	diploid ; hetloss ; homdel
SPOP_MUTATION	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	SPOP Mutation	Sample	0 ; 1
TP53_CNA	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	STRING	TP53 CNA	Sample	diploid ; hetloss ; homdel
ZMYM3_MUT	Cyan	Prostate Adenocarcinoma (TCGA, Cell 2015)	NUMBER	Zmym3 mut	Patient	
BIOCHEMICAL_RECURRENCE_INDICATOR	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Biochemical Recurrence Indicator	Patient	
BONE_SCAN_RESULT	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Bone scan result.	Patient	
CT_SCAN_AB_PELVIS_INDICATOR	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Diagnostic ct abd pelvis performed	Patient	
CT_SCAN_AB_PELVIS_RESULTS	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Diagnostic ct abd pelvis result	Patient	
DAYS_TO_BIOCHEMICAL_RECURRENCE_FIRST	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Days to first biochemical recurrence	Patient	
DAYS_TO_BONE_SCAN_PERFORMED	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Days to bone Scan performed	Patient	
DAYS_TO_CT_SCAN_AB_PELVIS	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Days to diagnostic computed tomography performed	Patient	
DAYS_TO_MRI	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Days to diagnostic mri performed	Patient	
DAYS_TO_PSA	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Days to Prostate-Specific Antigen (PSA) Test	Patient	
DIAGNOSTIC_MRI_RESULT	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Diagonostic MRI result.	Patient	
ETS	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	ETS	Sample	Negative ; TMPRSS2-ERG ; SLC45A3-ERG ; Positive
FAMILY_HISTORY_PRAD	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Family History of Prostate Adenocarcinoma	Patient	
GLEASON_PATTERN_PRIMARY	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Gleason pattern primary	Patient	
GLEASON_PATTERN_SECONDARY	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Gleason pattern secondary	Patient	
GLEASON_PATTERN_TERTIARY	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Gleason pattern tertiary	Patient	
MRI_RESULTS	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Diagnostic mri result	Patient	
PSA_MOST_RECENT_RESULTS	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	NUMBER	Psa most recent results	Patient	
TUMOR_LEVEL	Cyan	Prostate Adenocarcinoma (CPC-GENE, Nature 2017)	STRING	Tumor level.	Sample ; Patient	Apex|Middle|Base ; Apex|Middle ; Middle|Base ; Base ; Middle ; Apex|Base ; Apex
ALB_G_DL	Cyan	Prostate Adenocarcinoma Organoids (MSK, Cell 2014)	NUMBER	alb (g/dl)	Sample	4.8 ; 4 ; 4.5 ; 2.8 ; 3.9 ; 4.7
ALP_U_L	Cyan	Prostate Adenocarcinoma Organoids (MSK, Cell 2014)	NUMBER	alp (u/l)	Sample	56 ; 134 ; 112 ; 69 ; 2402 ; 67 ; 199
HGB_G_DL	Cyan	Prostate Adenocarcinoma Organoids (MSK, Cell 2014)	NUMBER	hgb (g/dl)	Sample	13.1 ; 10.4 ; 10.7 ; 9.4 ; 8.4 ; 12.3 ; 16.2
LDH_U_L	Cyan	Prostate Adenocarcinoma Organoids (MSK, Cell 2014)	NUMBER	ldh (u/l)	Sample	190 ; 175 ; 154 ; 222 ; 452 ; 249 ; 114
AGE_AT_SAMPLE_COLLECTION	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	NUMBER	Age at Sample Collection	Patient	
DENOVO_METASTATSIS	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	STRING	Timing of metastases	Sample	De-novo metastatic ; Metastatic recurrence
DZ_VOLUME	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	STRING	Disease volume	Patient	
IS_CRPC	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	STRING	Castration Resistance Event	Sample	Yes ; No
OS_SMP_MONTHS	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	NUMBER	Overall survival in months since sample collection.	Patient	
SMP_CRPC_MONTHS	Cyan	Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)	STRING	Time from sample to castration resistance [months]	Patient	
8Q_ARM	Cyan	Race Differences in Prostate Cancer (MSK, 2021)	STRING	8q arm	Sample	Neutral ; Gain ; Not called ; Loss
PIK3R1_LOSS_STATUS	Cyan	Prostate Adenocarcinoma (MSK, Clin Cancer Res. 2022)	STRING	PIK3R1 Loss Status	Sample	No ; Yes
PIK3R1_STATUS	Cyan	Prostate Adenocarcinoma (MSK, Clin Cancer Res. 2022)	STRING	PIK3R1 Status	Sample	Unaltered ; Loss ; Driver_Alteration
AREA	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	Code for independent intratumoral area	Sample	primary tumor 1 ; primary tumor 2 ; metastasis 1 ; metastasis 2 ; primary tumor 3 ; metastasis 3 ; metastasis 4
CGA	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	IHC Chromogranin-A expression	Sample	Positive ; Negative
ERG	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	IHC ERH expression	Sample	0 ; 1
ERG_FUS	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	ERG fusion present	Sample	No ; Yes
GLEASON_PR	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	NUMBER	Primary Gleason pattern	Sample	5 ; 4 ; 3
GLEASON_SE	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	NUMBER	Secondary Gleason pattern	Sample	5 ; 4 ; 3
GLEASON_SU	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	NUMBER	Gleason Score	Sample	10 ; 9 ; 8 ; 7 ; 6
HIST	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	Tumor subtype (histology)	Sample	Usual prostate adenocarcinoma with NE differentiation ; Carcinoid tumor ; Adenocarcinoma with Paneth cell NE differentiation ; Small cell carcinoma
IDC	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	Intraductal Carcinoma	Sample	No ; Yes
ISUP	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	NUMBER	ISUP-Grade group	Sample	5 ; 4 ; 2 ; 3 ; 1
PTEN_CYT	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	IHC expression PTEN cytoplasmic	Sample	Negative ; Positive
PTEN_NUC	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	IHC expression PTEN nuclear	Sample	Negative
SYP	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	IHC Synaptophysin expression	Sample	Positive ; Negative
TIME_POINT	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	NUMBER	Time point of tumor sampling	Sample	1 ; 2 ; 3 ; 4 ; 5
WES	Cyan	Prostate Cancer Brain Metastases (Bern, Nat Commun. 2022)	STRING	Availability of whole exome sequencing data	Sample	1
CLINICAL_STATE	Cyan	Prostate Cancer (MSK, JCO Precis Oncol 2017)	STRING	Clinical State	Sample	Metastatic castration-resistant ; Locoregional ; Metastatic non-castrate
MUTATIONS_PER_MEGABASE	Cyan	Prostate Cancer (MSK, JCO Precis Oncol 2017)	NUMBER	Mutations per megabase	Sample	37.5 ; 24.17 ; 8.33 ; 1.67 ; 5 ; 4.17 ; 3.33 ; 2.5 ; 5.83 ; 0.83 ; 0.72 ; 30.83 ; 1.45 ; 2.17 ; 7.5 ; 4.35 ; 0 ; 13.33 ; 16.67 ; 21.67 ; 26.09 ; 10 ; 2.9 ; 6.67 ; 28.99 ; 30.43 ; 18.84 ; 6.52 ; 5.8 ; 5.07 ; 3.62 ; 21.01 ; 7.25 ; 8.7 ; 9.42
BLADDER_NECK_INVASION	Cyan	Prostate Adenocarcinoma (SMMU, Eur Urol 2017)	STRING	Bladder neck invasion	Patient	
EXTRAPROSTATIC_EXTENSION	Cyan	Prostate Adenocarcinoma (SMMU, Eur Urol 2017)	STRING	Extraprostatic extension	Patient	
FPSA_PSA	Cyan	Prostate Adenocarcinoma (SMMU, Eur Urol 2017)	NUMBER	FPSA/PSA	Patient	
SEMINAL_VESICLE_INVASION	Cyan	Prostate Adenocarcinoma (SMMU, Eur Urol 2017)	STRING	Seminal vesicle invasion	Patient	
NORMAL_GENOME_COVERAGE	Cyan	Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)	NUMBER	Normal Genome Coverage	Sample	87.13 ; 171.94 ; 102.92 ; 111.26 ; 106.96 ; 83.62 ; 104.67 ; 213.52 ; 41.7 ; 40.91 ; 75.2 ; 84.2 ; 104.84 ; 53.59 ; 86.4 ; 98.54 ; 102.28 ; 88.1 ; 107.12 ; 106.47 ; 151.12 ; 92.12 ; 116.75 ; 113.06 ; 44.13 ; 98.88 ; 96.74 ; 96.98 ; 51.36 ; 102.03 ; 101.83 ; 120.53 ; 93.17 ; 126.2 ; 75.78 ; 89.34 ; 101.58 ; 100.55 ; 120.67 ; 54.49 ; 98.82 ; 51.42 ; 160.24 ; 103.88 ; 84.83 ; 111.69 ; 53.08 ; 103.86 ; 82.61 ; 101.77 ; 49.9 ; 103.14 ; 129.58 ; 80.86 ; 96.17 ; 76.17 ; 83.37 ; 119.94 ; 64.07 ; 88.28 ; 43.62 ; 94.41 ; 95.35 ; 96.9 ; 98.02 ; 122.25 ; 107.82 ; 66.59 ; 106.05 ; 116.51 ; 105.6 ; 110.25 ; 167 ; 54.02 ; 49.54 ; 96.6 ; 93.4 ; 82.34 ; 114.96 ; 99.15 ; 118.65 ; 103.7 ; 47.76 ; 86 ; 115.23 ; 50.82 ; 94.11 ; 79.51 ; 77.88 ; 103.16 ; 98.72 ; 117.83 ; 108.86 ; 50.16 ; 83.01 ; 62.61 ; 97.86 ; 86.3 ; 91.89 ; 173.92 ; 144.54 ; 156.5 ; 92.1 ; 207.4 ; 153.8 ; 87.65 ; 202.87 ; 103.73 ; 151.41 ; 174.14 ; 77.78 ; 84.25 ; 94.17 ; 166.71 ; 144.56 ; 194.44 ; 84.52 ; 105.71 ; 159.2 ; 151.77 ; 99.44 ; 92 ; 160.16 ; 94.28 ; 189.95 ; 188.14 ; 170.98 ; 175.56 ; 88.59 ; 107.08 ; 94.45 ; 161.44 ; 92.6 ; 154.47 ; 202.79 ; 151.13 ; 128.14 ; 150.52 ; 91.57 ; 156.81 ; 143.35 ; 104.1 ; 90.29 ; 95.95 ; 89.59 ; 95.68 ; 102.97 ; 153.47 ; 99.3 ; 100.89 ; 128.62 ; 93.63 ; 183.92 ; 153.12 ; 135.11 ; 181.51 ; 86.74 ; 91.42 ; 106.49 ; 207.02 ; 182.14 ; 153.48 ; 165.56 ; 131.74 ; 171.98 ; 67.82 ; 86.76 ; 93.43 ; 164.49 ; 122.38 ; 173.35 ; 107.72 ; 153.46 ; 152.41 ; 79 ; 110.09 ; 89.13 ; 150.88 ; 166.66 ; 164.35 ; 89.83 ; 98.52 ; 90.15 ; 146.86 ; 155.94 ; 143.14 ; 164.17 ; 176.81 ; 157.47 ; 148.43 ; 105.32 ; 95.25 ; 160.89 ; 85.53 ; 142.2 ; 142.89 ; 111.93 ; 133.22 ; 196.23 ; 161.04 ; 101.38 ; 84.62 ; 113.31 ; 201.62 ; 145.22 ; 75.73 ; 62.49 ; 80.2 ; 117.03 ; 154.42 ; 70.62 ; 140.99 ; 152.44 ; 134.3 ; 130.18 ; 55.73 ; 64.24 ; 69.98 ; 68.94 ; 82.3 ; 62.6 ; 76.85 ; 162.06 ; 156.25 ; 73.63 ; 77.53 ; 74.73 ; 84.42 ; 71.65 ; 71.66 ; 74.08 ; 140.6 ; 86.05 ; 147.21 ; 160.35 ; 82.64 ; 98.51 ; 71.9 ; 140 ; 163.7 ; 89.75 ; 70.05 ; 65.46 ; 122.9 ; 55.3 ; 104.11 ; 104.7 ; 87.93 ; 100.27 ; 37.93 ; 35.73 ; 20.13 ; 90.95 ; 85.57 ; 32.64 ; 89.89 ; 112.67 ; 87.15 ; 94.35 ; 75.66 ; 103.82 ; 82.52 ; 71.68 ; 109.58 ; 147.96 ; 213.2 ; 114.03 ; 145.38 ; 188.18 ; 280.43 ; 159.44 ; 177.53 ; 171.14 ; 179.84 ; 185.6 ; 191.82 ; 173.37 ; 186.89 ; 186.08 ; 201.31 ; 179.38 ; 151.11 ; 147.68 ; 165.78 ; 178.69 ; 176.48 ; 158.72 ; 176.09 ; 188.84 ; 149.16 ; 81.74 ; 99.88 ; 132.14 ; 122.86 ; 233.79 ; 149.47 ; 151.57 ; 252.27 ; 185.51 ; 205.3 ; 235.71 ; 239.21 ; 205.91 ; 195.7 ; 218.99 ; 154.41 ; 170.84 ; 178.27 ; 202.76 ; 189.48 ; 178.74 ; 171.29 ; 163.53 ; 151.44 ; 164.01 ; 167.7 ; 114.71 ; 134.51 ; 187.99 ; 188.41 ; 139.98 ; 146.06 ; 175.59 ; 141.43 ; 145.11 ; 132.28 ; 151.76 ; 152.42 ; 214.32 ; 251.06 ; 181.5 ; 219.56 ; 182.57 ; 301.61 ; 155.72 ; 210.39 ; 168.63 ; 190.56 ; 191.14 ; 202.81 ; 167.44 ; 168.05 ; 181.29 ; 150.39 ; 183.49 ; 185.26 ; 303.11 ; 105.09 ; 188.28 ; 130.78 ; 203.7 ; 141.61 ; 202.36 ; 187.21 ; 184.84 ; 173.12 ; 152.56 ; 211.05 ; 192.06 ; 315.28 ; 180.16 ; 195.45 ; 163.5 ; 192.12 ; 178.44 ; 155.58 ; 211.53 ; 168.32 ; 209.04 ; 173.73 ; 182.27 ; 165.25 ; 293.81 ; 131.85 ; 204.93 ; 97.17 ; 185.62 ; 198.5 ; 200.91 ; 113.58 ; 202.99 ; 197.44 ; 147 ; 167.84 ; 158.06 ; 185.28 ; 209.7 ; 74.61 ; 97.26 ; 275.87 ; 311.99 ; 211.87 ; 223.63 ; 185.47 ; 193.91 ; 197.45 ; 223.33 ; 180.67 ; 221.64 ; 192.58 ; 197.11 ; 157.33 ; 201.36 ; 204.38 ; 197.36 ; 171.87 ; 177.82 ; 159.4 ; 138.05 ; 164.13 ; 161.45 ; 107.75 ; 150.03 ; 204.23 ; 167.32 ; 178.96 ; 185.88 ; 217.93 ; 211.94 ; 196.12 ; 186.2 ; 169.41 ; 191.17 ; 155.61 ; 163.99 ; 173.56 ; 174.37 ; 184 ; 181.79 ; 183.2 ; 199.4 ; 152.5 ; 164.5 ; 172.33 ; 182.09 ; 179 ; 152.06 ; 199.88 ; 211.74 ; 85.98 ; 110.37 ; 99.25 ; 93.13 ; 79.59 ; 98.77 ; 131.75 ; 100.03 ; 109.07 ; 100.05 ; 100.1 ; 103.58 ; 115.15 ; 91.62 ; 100.08 ; 101.08 ; 100.78 ; 99.29 ; 105.01 ; 99.43 ; 92.2 ; 94.2 ; 183.98 ; 197.57 ; 95.53 ; 112.38 ; 119.51 ; 119.45 ; 125.82 ; 125.63 ; 120.05 ; 112.27 ; 100.61 ; 97.23 ; 102.83 ; 86.2 ; 115.22 ; 113.32 ; 108.78 ; 108.83 ; 128.03 ; 138.92 ; 117.35 ; 123.01 ; 146.04 ; 130.36 ; 109.98 ; 129.51 ; 127.72 ; 118.35 ; 132.94 ; 124.95 ; 126.68 ; 147.44 ; 123.78 ; 167.03 ; 131.62 ; 140.94 ; 132.41 ; 134.03 ; 154.61 ; 142.76 ; 126.39 ; 118.73 ; 117.72 ; 272.28 ; 129.29 ; 156.06 ; 146.31 ; 144.72 ; 132.58 ; 76.21 ; 145.88 ; 124.93 ; 160.92 ; 184.99 ; 152.19 ; 145.45 ; 153.94 ; 175.37 ; 158.07 ; 191.58 ; 168.86 ; 147.31 ; 129.55 ; 154.4 ; 204 ; 282.61 ; 283.45 ; 328.02 ; 318.43 ; 286.27 ; 254.02 ; 338.65 ; 307.53 ; 258.18 ; 193.78 ; 165.08 ; 186.8 ; 183.07 ; 210.57 ; 167.46 ; 133.13 ; 157.12 ; 229.88 ; 59.44 ; 217.64 ; 161.88 ; 239.68 ; 145.69 ; 56.4 ; 88 ; 114.91 ; 99.8 ; 184.95 ; 112.86 ; 83.77 ; 79.74 ; 101.97 ; 102.43 ; 102.98 ; 81.8 ; 104.91 ; 79.36 ; 155.23 ; 88.56 ; 75.89 ; 164 ; 123.55 ; 87.91 ; 125.76 ; 68.87 ; 101.64 ; 84.87 ; 155.19 ; 142.68 ; 86.9 ; 120.33 ; 192.45 ; 71.72 ; 79.26 ; 95.75 ; 180.42 ; 76.27 ; 87.42 ; 92.37 ; 73.55 ; 85.61 ; 91.82 ; 81.55 ; 89.78 ; 104.32 ; 107.93 ; 109.27 ; 108.49 ; 82.29 ; 83.48 ; 89.52 ; 91.07 ; 76.93 ; 96.26 ; 104.6 ; 94.44 ; 83.38 ; 109.92 ; 111.81 ; 69 ; 72.53 ; 96.94 ; 94.59 ; 91.63 ; 80.17 ; 69.16 ; 186.66 ; 113.82 ; 79.22 ; 101.47 ; 74.2 ; 97.24 ; 181.89 ; 150.3 ; 148.74 ; 167.01 ; 145.19 ; 85.26 ; 103.01 ; 86.28 ; 78.76 ; 116.27 ; 102.11 ; 86.87 ; 62.73 ; 89.9 ; 72.92 ; 112.54 ; 103.09 ; 64.29 ; 64.74 ; 80.6 ; 86.13 ; 81.14 ; 163.39 ; 74.07 ; 76.5 ; 78.59 ; 148.87 ; 156.48 ; 97.12 ; 148.06 ; 107.92 ; 64.36 ; 75.63 ; 69.05 ; 64.89 ; 71.12 ; 74.84 ; 74.98 ; 99.78 ; 101.17 ; 47.23 ; 103.44 ; 89.49 ; 131.06 ; 133.31 ; 189.53 ; 138.02 ; 96.83 ; 81.67 ; 182.4 ; 106.11 ; 102.71 ; 78.4 ; 66.86 ; 88.76 ; 57.8 ; 71 ; 77.8 ; 82.93 ; 170.97 ; 76.13 ; 82.68 ; 85.23 ; 78.7 ; 91.23 ; 64.08 ; 81.44 ; 131.86 ; 97.47 ; 109.24 ; 57.82 ; 60.12 ; 74.31 ; 167.82 ; 82.33 ; 114 ; 70.42 ; 78.97 ; 94.24 ; 77.24 ; 113.78 ; 86.23 ; 66.28 ; 89.98 ; 69.51 ; 91.9 ; 55.76 ; 65.39 ; 75.15 ; 95.16 ; 171.39 ; 166.48 ; 99.12 ; 98.28 ; 96.89 ; 128.15 ; 110.34 ; 96.57 ; 71.7 ; 87.77 ; 81.18 ; 78.01 ; 68.43 ; 97.29 ; 76.02 ; 61.48 ; 123.69 ; 180.77 ; 124.64 ; 101.22 ; 82.07 ; 101.62 ; 109.91 ; 108.91 ; 71.31 ; 109.13 ; 83.61 ; 114.63 ; 96.46 ; 89.99 ; 94.15 ; 60.59 ; 75.5 ; 179.23 ; 89.05 ; 83.44 ; 79.87 ; 102.47 ; 121.05 ; 113.04 ; 86.08 ; 108.39 ; 95.78 ; 77.22 ; 58.63 ; 63.55 ; 74.42 ; 91.28 ; 115.52 ; 77.52 ; 96.38 ; 58.38 ; 67.79 ; 103.27 ; 163.27 ; 82.32 ; 173.71 ; 103.22 ; 63.71 ; 104.65 ; 93.54 ; 103.26 ; 88.38 ; 68.75 ; 74.6 ; 63.61 ; 162.99 ; 143.94 ; 83.7 ; 76.75 ; 67.54 ; 67.92 ; 185.72 ; 172.39 ; 112.84 ; 67.24 ; 85.11 ; 113.1 ; 103.37 ; 106.4 ; 90.07 ; 60.91 ; 56.09 ; 55.91 ; 73.07 ; 147.28 ; 160.77 ; 55.6 ; 71.77 ; 118.34 ; 72.18 ; 78.07 ; 79.44 ; 77.21 ; 86.47 ; 78.38 ; 168.16 ; 107.81 ; 154.34 ; 179.45 ; 116.36 ; 101.78 ; 105.17 ; 77.99 ; 74.04 ; 66.13 ; 88.5 ; 169.88 ; 89.76 ; 67.83 ; 71.69 ; 65.84 ; 72.08 ; 82.16 ; 109.77 ; 104.05 ; 104.22 ; 141.84 ; 170.08 ; 181.63 ; 175.74 ; 111.68 ; 74.8 ; 96.44 ; 99.03 ; 125.05 ; 118.71 ; 102.49 ; 64.59 ; 78.77 ; 182.21 ; 136.14 ; 97.04 ; 101.31 ; 96.49 ; 64.37 ; 86.86 ; 88.45 ; 120.72 ; 82.18 ; 79.57 ; 105.2 ; 123.52 ; 68.81 ; 101.36 ; 113.13 ; 94.77 ; 63.98 ; 75.11 ; 85.07 ; 58.49 ; 173.69 ; 73.8 ; 90.7 ; 72.85 ; 75.41 ; 96.75 ; 94.23 ; 160.19 ; 119.06 ; 96.27 ; 117.92 ; 94.72 ; 73.61 ; 70.33 ; 185.7 ; 212.97 ; 109.72 ; 88.69 ; 76.72 ; 67.98 ; 86.79 ; 78.84 ; 177.98 ; 115.54 ; 74.94 ; 84.38 ; 71.16 ; 78.14 ; 184.96 ; 86.84 ; 59.85 ; 86.99 ; 102.48 ; 133.28 ; 61.71 ; 82.65 ; 164.73 ; 115.17 ; 87.74 ; 78.21 ; 89.94 ; 89.8 ; 93.31 ; 47.28 ; 81.7 ; 107.94 ; 86.65 ; 98.14 ; 169.11 ; 115.1 ; 156.9 ; 177.93 ; 83.83 ; 82.1 ; 94.33 ; 74.1 ; 77.45 ; 57.96 ; 107.45 ; 82.5 ; 75.54 ; 92.77 ; 94.14 ; 128.02 ; 64.85 ; 75.91 ; 75.05 ; 95.67 ; 68.9 ; 85.93 ; 86.57 ; 147.48 ; 77.89 ; 81.53 ; 69.86 ; 85.15 ; 68.28 ; 60.11 ; 73.24 ; 67.44 ; 73.47 ; 83.87 ; 74.55 ; 77.08 ; 86.68 ; 158.08 ; 79.18 ; 47.82 ; 81.22 ; 81.51 ; 90.86 ; 52.07 ; 71.06 ; 71.43 ; 79.38 ; 73.26 ; 85.39 ; 75.57 ; 85.44 ; 65.42 ; 62.15 ; 87.5 ; 66.37 ; 71.45 ; 63.56 ; 69.63 ; 77.96 ; 64.02 ; 74.82 ; 71.96 ; 69.45 ; 61.65 ; 68.2 ; 64.1 ; 69.4 ; 72.86 ; 60.93 ; 68.26
TUMOR_GENOME_COVERAGE	Cyan	Prostate Adenocarcinoma (MSK/DFCI, Nature Genetics 2018)	NUMBER	Tumor Genome Coverage	Sample	86.01 ; 129.16 ; 69.41 ; 89.49 ; 108.37 ; 90.76 ; 129.68 ; 100.16 ; 101 ; 52.37 ; 113.4 ; 82.28 ; 90.64 ; 84.39 ; 64.43 ; 117.59 ; 95.06 ; 103.86 ; 121.94 ; 115.71 ; 112.55 ; 115.63 ; 108.25 ; 121.27 ; 81.33 ; 97.11 ; 119.85 ; 71.52 ; 111.43 ; 106.7 ; 103.96 ; 106.04 ; 118.22 ; 91.2 ; 98.53 ; 117.28 ; 100.69 ; 94.65 ; 79.6 ; 103.58 ; 94.83 ; 93.71 ; 89.12 ; 108.9 ; 106.67 ; 103.67 ; 82.45 ; 128.43 ; 96.63 ; 108.42 ; 87.37 ; 102.27 ; 110.59 ; 94.3 ; 122.78 ; 98.6 ; 88.52 ; 110.15 ; 87.36 ; 92.81 ; 101.19 ; 105.3 ; 112.35 ; 97.65 ; 100.82 ; 99.84 ; 109.92 ; 86.4 ; 83.5 ; 110.84 ; 117.38 ; 102.97 ; 111.39 ; 91.35 ; 109.18 ; 102.71 ; 96.7 ; 95.54 ; 124.73 ; 114.76 ; 105.61 ; 119.83 ; 71.9 ; 84.12 ; 118.56 ; 104.05 ; 109.08 ; 84.61 ; 116.03 ; 98.37 ; 98.07 ; 92.67 ; 100.19 ; 90.83 ; 80.5 ; 93.42 ; 111.86 ; 116.94 ; 97.54 ; 149.41 ; 168.14 ; 167.01 ; 85.39 ; 159.24 ; 159.13 ; 103.19 ; 167.99 ; 103.73 ; 141.32 ; 188.09 ; 90.79 ; 100.72 ; 96.8 ; 161.8 ; 119.79 ; 192.1 ; 78.23 ; 103.23 ; 153.07 ; 162.13 ; 97.26 ; 88.77 ; 109.96 ; 93.87 ; 154.86 ; 166.34 ; 153.92 ; 261.05 ; 89.71 ; 96.13 ; 94.22 ; 165.54 ; 99.09 ; 152.6 ; 190.61 ; 201.35 ; 167.27 ; 171.53 ; 80.3 ; 164.19 ; 187.15 ; 90.5 ; 89.36 ; 84.52 ; 82.42 ; 84.87 ; 80.42 ; 143.49 ; 105.51 ; 87.5 ; 163.2 ; 86.76 ; 131.05 ; 139.63 ; 129.64 ; 143 ; 90.03 ; 79.03 ; 103.55 ; 169.59 ; 161.91 ; 153.3 ; 166.29 ; 195.95 ; 149.28 ; 99.7 ; 107.19 ; 91.87 ; 157.78 ; 150.3 ; 119.63 ; 106.97 ; 159.79 ; 152.84 ; 92.1 ; 85.96 ; 94.18 ; 150.65 ; 142.1 ; 160.54 ; 87.78 ; 96.54 ; 82.67 ; 140.68 ; 172.35 ; 152.63 ; 161.88 ; 137.39 ; 179.39 ; 181.25 ; 109.23 ; 74.14 ; 174.56 ; 91.27 ; 159.91 ; 151.5 ; 99.66 ; 217.28 ; 177.04 ; 156.66 ; 77.53 ; 94.32 ; 210.5 ; 140.12 ; 76.97 ; 64.93 ; 56.57 ; 73.43 ; 132.19 ; 157.39 ; 82.1 ; 130.02 ; 150.43 ; 176.68 ; 149.24 ; 178.27 ; 72.73 ; 66.13 ; 150.78 ; 65.84 ; 70.79 ; 68.51 ; 68.67 ; 143.5 ; 93.07 ; 75.49 ; 61.79 ; 80.6 ; 78.83 ; 75.8 ; 73.84 ; 143.53 ; 72.2 ; 228.85 ; 180.74 ; 72.33 ; 129.34 ; 74.08 ; 155.25 ; 152.48 ; 83.81 ; 96.43 ; 83.7 ; 83.66 ; 54.77 ; 104.64 ; 91.05 ; 56.23 ; 96.26 ; 51.29 ; 50.11 ; 66.19 ; 50.43 ; 97.02 ; 54.37 ; 77.4 ; 139.14 ; 124.16 ; 110.31 ; 67.4 ; 53.21 ; 106.66 ; 50.4 ; 134.13 ; 227.56 ; 136.35 ; 71.66 ; 81.6 ; 294.5 ; 228.34 ; 230.57 ; 246.23 ; 247.87 ; 274.14 ; 240.42 ; 245.49 ; 242.45 ; 249.38 ; 272.6 ; 334.65 ; 316.88 ; 160.51 ; 113.92 ; 178.46 ; 156.19 ; 113.17 ; 171.49 ; 93.67 ; 177.39 ; 119.6 ; 128.41 ; 167.72 ; 136.36 ; 144.63 ; 343.93 ; 259.79 ; 276.64 ; 123.91 ; 298.63 ; 282.93 ; 276.69 ; 293.53 ; 208.47 ; 297.49 ; 213.71 ; 247.08 ; 289.36 ; 252.04 ; 263.34 ; 261.34 ; 246.84 ; 236.48 ; 211.32 ; 243.62 ; 219.31 ; 205.61 ; 209.31 ; 231.14 ; 256.24 ; 208.14 ; 257.4 ; 188.75 ; 188.34 ; 276.84 ; 248.72 ; 187.47 ; 257.29 ; 277.45 ; 274.64 ; 324.38 ; 285.66 ; 266.89 ; 331.41 ; 287.82 ; 216.09 ; 244.65 ; 301.64 ; 300.21 ; 235.29 ; 255.25 ; 261.12 ; 207.23 ; 230.47 ; 253.14 ; 247.3 ; 216.73 ; 227.61 ; 423.38 ; 117.36 ; 247.54 ; 214.29 ; 286.08 ; 228.05 ; 260.86 ; 271.59 ; 242.06 ; 249.05 ; 126.27 ; 263.44 ; 262.96 ; 309.3 ; 224.19 ; 248.77 ; 264.53 ; 280.75 ; 255.58 ; 237.87 ; 289.27 ; 244.06 ; 262.78 ; 295.46 ; 272.17 ; 102.32 ; 208.94 ; 193.4 ; 179.16 ; 145.67 ; 213.09 ; 250.64 ; 130.14 ; 183.16 ; 297.01 ; 230.8 ; 236.36 ; 259.9 ; 231.74 ; 239.54 ; 316.02 ; 104.41 ; 124.96 ; 398.63 ; 277.74 ; 139.77 ; 261.65 ; 261.83 ; 314.53 ; 251.03 ; 228.84 ; 218.02 ; 273.57 ; 231.9 ; 279.3 ; 271.76 ; 291.32 ; 343.18 ; 260.42 ; 244.53 ; 262.93 ; 198.09 ; 239.44 ; 220.51 ; 234.16 ; 189.43 ; 238.04 ; 324.39 ; 219.64 ; 317.12 ; 248.15 ; 308.08 ; 288.69 ; 299.73 ; 294.81 ; 235.77 ; 284.11 ; 244.9 ; 245.96 ; 215.8 ; 300.38 ; 300.43 ; 270.02 ; 286.26 ; 266.09 ; 285.99 ; 236.4 ; 216.31 ; 215.16 ; 302.76 ; 243.71 ; 238.05 ; 310.15 ; 260.36 ; 91.78 ; 105.5 ; 98.57 ; 93.62 ; 83.62 ; 112.89 ; 129 ; 93.8 ; 110.61 ; 99.24 ; 96.1 ; 107.56 ; 122.62 ; 104.14 ; 100.79 ; 98.74 ; 108.83 ; 102.48 ; 94.97 ; 95.43 ; 105.75 ; 98.28 ; 146.16 ; 221.84 ; 260.83 ; 129.38 ; 207.5 ; 240.82 ; 241.11 ; 205.22 ; 270.28 ; 198.52 ; 185.71 ; 222.2 ; 207.1 ; 266.24 ; 217.32 ; 180.44 ; 200.94 ; 283.07 ; 245.81 ; 274.12 ; 281.37 ; 131.25 ; 141.82 ; 169.71 ; 158.43 ; 179.64 ; 168.04 ; 145.55 ; 141.63 ; 113.66 ; 144.44 ; 144.36 ; 162.83 ; 123.32 ; 137.15 ; 105.17 ; 126.06 ; 154.94 ; 107.5 ; 145.9 ; 167.06 ; 163.62 ; 157.81 ; 252.56 ; 124.55 ; 147.38 ; 163.32 ; 167.1 ; 133.33 ; 132.65 ; 104.93 ; 124.28 ; 125.79 ; 236.75 ; 181.47 ; 236.84 ; 221.62 ; 212.31 ; 195.07 ; 217.17 ; 209.06 ; 223.5 ; 232.99 ; 180.76 ; 263.27 ; 318.66 ; 263.18 ; 357.79 ; 297.76 ; 281.74 ; 239.69 ; 280.04 ; 274.17 ; 331.49 ; 231.82 ; 282.48 ; 254.04 ; 267.56 ; 267.73 ; 181.34 ; 229.69 ; 213.72 ; 69.22 ; 277.71 ; 213.97 ; 310.08 ; 179.63 ; 244.98 ; 66.5 ; 57.7 ; 103.09 ; 134.61 ; 175.32 ; 166.4 ; 105.78 ; 86.13 ; 57.99 ; 75.15 ; 94.99 ; 99.68 ; 82.9 ; 154.27 ; 93.4 ; 142.52 ; 81.08 ; 86.68 ; 173.69 ; 103.88 ; 138.79 ; 81.34 ; 118.97 ; 100.41 ; 148.5 ; 141.37 ; 87.58 ; 170.7 ; 261.93 ; 87.63 ; 59.87 ; 102.8 ; 169.21 ; 55.32 ; 88.3 ; 68.97 ; 106 ; 71.77 ; 57.63 ; 109.2 ; 94.33 ; 107.54 ; 107.88 ; 111.74 ; 87.55 ; 86.51 ; 92.52 ; 81.19 ; 128.16 ; 83.22 ; 96.19 ; 78.62 ; 88.92 ; 107.94 ; 92.48 ; 75.41 ; 98.89 ; 110.18 ; 53.82 ; 84.69 ; 116.38 ; 105.48 ; 79.24 ; 83.58 ; 69.76 ; 170.74 ; 104.39 ; 81.77 ; 99.83 ; 88.1 ; 164.74 ; 140.99 ; 111.2 ; 122.07 ; 190.43 ; 88.26 ; 81.97 ; 87.44 ; 95.77 ; 82.02 ; 104.73 ; 107.78 ; 95.23 ; 74.48 ; 110.47 ; 67.89 ; 84.51 ; 120.51 ; 86 ; 81.51 ; 72.15 ; 59.16 ; 163.24 ; 68.01 ; 83.07 ; 91.56 ; 169.53 ; 161.73 ; 88.45 ; 55.61 ; 98.36 ; 55.98 ; 70.31 ; 89.78 ; 73.21 ; 76.11 ; 80.85 ; 150.76 ; 99.49 ; 62.81 ; 101.87 ; 152.72 ; 170.4 ; 127.88 ; 100.32 ; 62.26 ; 164.46 ; 104.3 ; 94.64 ; 66.84 ; 59.49 ; 85.55 ; 71.59 ; 73.87 ; 72.05 ; 80.02 ; 159.34 ; 88.02 ; 80.86 ; 123.03 ; 95.11 ; 86.48 ; 92.2 ; 82.96 ; 107.92 ; 88.31 ; 60.65 ; 110.94 ; 68.61 ; 60.09 ; 81.29 ; 73.94 ; 162.65 ; 94.87 ; 91.59 ; 63.12 ; 96.3 ; 83.77 ; 114.2 ; 98.3 ; 86.28 ; 65.57 ; 76.81 ; 64.76 ; 55.54 ; 61.14 ; 86.71 ; 176.26 ; 98.01 ; 173.24 ; 90.01 ; 105.84 ; 112.25 ; 98.15 ; 89.08 ; 56.59 ; 79.1 ; 60.02 ; 71.93 ; 78.22 ; 80.33 ; 68.65 ; 77.56 ; 72.34 ; 131.21 ; 177.65 ; 142.85 ; 66.11 ; 76.79 ; 101.28 ; 101.33 ; 99.91 ; 115.06 ; 102.33 ; 91.93 ; 88.13 ; 106.69 ; 91.55 ; 74.04 ; 56.46 ; 82.56 ; 166.91 ; 80.89 ; 71.89 ; 65.09 ; 102.51 ; 133.45 ; 93.16 ; 65.14 ; 102.65 ; 99.02 ; 72.08 ; 80.82 ; 66.22 ; 81.03 ; 77.04 ; 61.84 ; 95.5 ; 72.53 ; 116.83 ; 95.31 ; 83.68 ; 87.56 ; 78.4 ; 77.88 ; 124.66 ; 68.98 ; 163.23 ; 123.74 ; 110.89 ; 105.59 ; 103.87 ; 80.24 ; 78.39 ; 97.38 ; 74.34 ; 157.37 ; 128.8 ; 144.91 ; 71.24 ; 71.02 ; 66.55 ; 82 ; 117 ; 131.12 ; 111.71 ; 81.79 ; 100.73 ; 91.25 ; 106.89 ; 109.45 ; 98.55 ; 78.37 ; 68.57 ; 81.64 ; 175.21 ; 135.95 ; 74.59 ; 74.13 ; 97.48 ; 78.99 ; 80.99 ; 72.79 ; 71.5 ; 85.67 ; 197.06 ; 142.53 ; 156.83 ; 177.99 ; 85.61 ; 113.82 ; 100.92 ; 161.09 ; 84.88 ; 64.82 ; 59.92 ; 173.8 ; 105.31 ; 54.41 ; 76.6 ; 73.3 ; 76.09 ; 74.27 ; 80.66 ; 87.52 ; 107.32 ; 84 ; 182.1 ; 159.93 ; 159.23 ; 143.46 ; 99.22 ; 95.71 ; 92.22 ; 116.31 ; 104.57 ; 107.55 ; 88.64 ; 57.41 ; 77.92 ; 170.11 ; 135.3 ; 101.52 ; 99.76 ; 67.95 ; 82.11 ; 61.81 ; 82.35 ; 65.43 ; 69 ; 79.49 ; 67.53 ; 89.33 ; 182.74 ; 100.03 ; 98.67 ; 97.78 ; 94.51 ; 108.4 ; 66.76 ; 58.14 ; 78.7 ; 77.19 ; 168.05 ; 73.76 ; 78.24 ; 69.32 ; 59.27 ; 173.87 ; 92.61 ; 157.16 ; 104.91 ; 64 ; 67.96 ; 150.35 ; 178.4 ; 101.91 ; 84.46 ; 94.56 ; 70.19 ; 76.28 ; 75.66 ; 59.72 ; 186.26 ; 115.85 ; 106.37 ; 67.43 ; 59.88 ; 55.85 ; 75.64 ; 177.07 ; 109.31 ; 79.68 ; 101.89 ; 84.43 ; 113.95 ; 97.63 ; 105.4 ; 100.39 ; 82.76 ; 177.93 ; 105.03 ; 74.69 ; 64.2 ; 70.89 ; 73.2 ; 110.96 ; 65.31 ; 98.62 ; 62.07 ; 71 ; 83.02 ; 73.66 ; 75.95 ; 186.03 ; 141.05 ; 90.22 ; 184.82 ; 149.37 ; 97.6 ; 89.89 ; 94.62 ; 70.59 ; 66.14 ; 69.35 ; 66.99 ; 104.99 ; 73.62 ; 72.52 ; 72.21 ; 88.81 ; 90.42 ; 68.17 ; 59.43 ; 68.11 ; 98.95 ; 94.1 ; 67.42 ; 65.83 ; 84.79 ; 131.15 ; 81.88 ; 85.63 ; 74.36 ; 57.24 ; 73.73 ; 53.54 ; 82.81 ; 80.53 ; 77.51 ; 54.98 ; 75.18 ; 79.07 ; 63.85 ; 65.22 ; 79.66 ; 68.1 ; 81.43 ; 96.46 ; 79.44 ; 75.78 ; 74.29 ; 77.97 ; 72.75 ; 75.59 ; 58.61 ; 58.5 ; 90.29 ; 54.4 ; 84.89 ; 55.29 ; 73.44 ; 66.71 ; 74.78 ; 82.57 ; 71.41 ; 65.42 ; 96.74 ; 71.64 ; 68.52 ; 72.77 ; 66.02 ; 71.39 ; 81.57
AR_CAPTURE_SCORE	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	AR Score (Capture)	Sample	0.530915311 ; 0.513758088 ; 0.543858752 ; 0.475205272 ; 0.396554391 ; 0.476629065 ; 0.590949287 ; -0.077035276 ; 0.423778615 ; 0.483086853 ; 0.444622815 ; 0.010512826 ; 0.420828496 ; 0.448031519 ; 0.429870729 ; 0.574258284 ; 0.56326612 ; 0.381326255 ; 0.428493676 ; 0.516667649 ; 0.449063707 ; -0.03614012 ; 0.495277626 ; 0.521590667 ; 0.423467566 ; 0.486335411 ; 0.518520874 ; 0.412465091 ; 0.63565987 ; 0.329016067 ; 0.507454262 ; 0.652815964 ; 0.609259265 ; 0.467225189 ; 0.508121123 ; 0.140104385 ; 0.566414237 ; 0.256528462 ; 0.335186263 ; -0.086674497 ; 0.644638412 ; -0.045219177 ; -0.071339543 ; 0.472054725 ; 0.137066211 ; 0.568427315 ; 0.518260817 ; 0.450532772 ; 0.472677435 ; 0.463072784 ; 0.59709931 ; 0.656139266 ; 0.597548537 ; 0.484918132 ; 0.632644819 ; 0.504681369 ; 0.025212994 ; 0.451596818 ; 0.491469052 ; 0.304485025 ; 0.399127314 ; 0.463860362 ; 0.236219511 ; 0.428486092 ; 0.453005251 ; 0.369422659 ; 0.489109679 ; 0.347739763 ; 0.508643261 ; 0.66421692 ; 0.336293135 ; 0.278661836 ; 0.381136239 ; 0.558044108 ; 0.450434141 ; 0.376140155 ; 0.326126493 ; 0.652461243 ; 0.598794733 ; 0.002926997 ; 0.631746134 ; 0.427095913 ; 0.367711606 ; 0.54129456 ; 0.465386079 ; 0.542703782 ; 0.214682053 ; 0.478393724 ; 0.519401127 ; 0.496286975 ; 0.5242512 ; 0.420517997 ; 0.410384405 ; 0.467127633 ; 0.579196804 ; 0.56826558 ; 0.600455985 ; 0.464784728 ; 0.551291499 ; 0.615513432 ; 0.544046305 ; 0.291389237 ; 0.550821556 ; 0.256449489 ; 0.509907834 ; 0.540618453 ; 0.473319663 ; 0.434474267 ; 0.55145549 ; 0.616301428 ; 0.345696608 ; 0.585260451 ; 0.551609149 ; 0.608437427 ; 0.468430955 ; 0.525359979 ; 0.52827165 ; 0.481939679 ; 0.343513898 ; 0.485265156 ; 0.41026465 ; 0.447946789 ; 0.602391782 ; 0.496046687 ; 0.513166643 ; 0.474494988 ; 0.601032862 ; 0.464880023 ; 0.499682534 ; 0.56680839 ; 0.599966019 ; 0.30920426 ; 0.33355941 ; 0.49760362 ; 0.387917873 ; 0.491622475 ; 0.554089123 ; 0.378113154 ; 0.505591017 ; 0.415889832 ; 0.52391495 ; 0.689517998 ; 0.130590985 ; 0.506868564 ; 0.631124274 ; 0.400294391 ; 0.479838743 ; 0.400252163 ; 0.417647838 ; 0.454374238 ; 0.452394683 ; 0.048908048 ; 0.406261917 ; 0.50471271 ; 0.167348987 ; 0.372620628 ; 0.693974469 ; 0.430924223 ; 0.471782261 ; 0.481195065 ; 0.566216352 ; 0.447750461 ; 0.449570044 ; 0.580090456 ; -0.142622218 ; 0.416196431 ; 0.59440319 ; 0.535748314 ; 0.462606648 ; 0.58059184 ; 0.531079067 ; 0.389617125 ; 0.513954706 ; 0.444699152 ; 0.561439414 ; 0.359608222 ; 0.670705835 ; 0.345307235 ; 0.661855908 ; 0.519765109 ; 0.381665746 ; 0.665953093 ; 0.589259931 ; 0.499763287 ; 0.5394665 ; 0.540542942 ; 0.64294423 ; 0.387284588 ; 0.589464574 ; 0.455834023 ; 0.479956229 ; 0.460459615 ; 0.513974179 ; 0.443765757 ; 0.473221604 ; 0.477459336 ; 0.528435158 ; 0.550640123 ; 0.533447987 ; 0.377120249 ; 0.336968689 ; 0.648067323 ; 0.518702764 ; 0.632123751 ; 0.609205399 ; 0.363739925 ; 0.559340521 ; 0.595606594 ; 0.631129565
AR_POLYA_SCORE	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	AR Score (PolyA)	Sample	0.519533775 ; -0.018700514 ; 0.368749179 ; 0.516237016 ; 0.034218454 ; 0.30720697 ; 0.504188448 ; 0.457715675 ; 0.433600463 ; 0.520369934 ; 0.47824925 ; -0.082116136 ; 0.398341808 ; 0.424981972 ; 0.034240574 ; 0.45180833 ; 0.403902257 ; 0.46352632 ; 0.521441309 ; 0.359681776 ; 0.487832525 ; 0.551797418 ; 0.466526889 ; -0.012699584 ; 0.482821161 ; 0.463314534 ; 0.430181281 ; 0.529720098 ; 0.543851987 ; 0.413777451 ; 0.666384611 ; 0.526799152 ; 0.656332271 ; 0.534210094 ; 0.47962937 ; 0.520546742 ; 0.163661679 ; 0.557017328 ; 0.225499884 ; -0.264685716 ; 0.657344059 ; 0.042421885 ; -0.01056407 ; 0.24979926 ; 0.534309528 ; 0.468634792 ; 0.438622636 ; 0.605639123 ; 0.480467073 ; 0.665633239 ; 0.501055916 ; 0.392856689 ; 0.001642294 ; 0.388261888 ; 0.513492618 ; 0.499631641 ; 0.241856644 ; 0.139053607 ; 0.460534586 ; 0.317585934 ; 0.406176684 ; 0.424063244 ; 0.587452328 ; 0.50855212 ; 0.359569353 ; 0.510387298 ; 0.399826263 ; 0.108947074 ; 0.495017731 ; 0.529449362 ; 0.598741441 ; 0.600831993 ; 0.348267508 ; 0.482979886 ; 0.610715124 ; 0.595065883 ; 0.555146218 ; 0.133678743 ; 0.301691124 ; 0.235027665 ; 0.515944715 ; 0.244096132 ; 0.055680391 ; -0.082331493 ; 0.025955171 ; 0.506730475 ; 0.379235879 ; 0.039532643 ; 0.413144313 ; 0.29973511 ; 0.492546574 ; 0.502621438 ; 0.565472844 ; 0.438254614 ; 0.574097721 ; 0.420475145 ; 0.398497343 ; 0.445073199 ; 0.501453638 ; 0.635018088 ; 0.603667298 ; 0.211875088 ; 0.50009976 ; 0.623256802 ; 0.549377836 ; 0.581982293 ; 0.400228893 ; 0.562280836 ; 0.313454683 ; 0.382202526 ; 0.588158629 ; 0.532440976 ; 0.447393238 ; 0.328911789 ; 0.543088471 ; 0.590437172 ; 0.455751366 ; 0.617909386 ; 0.489187635 ; 0.502720868 ; 0.524092729 ; 0.533963776 ; 0.523211487 ; 0.594907593 ; 0.227818772 ; 0.217075223 ; 0.556973446 ; 0.512147379 ; 0.534050775 ; -0.015928602 ; 0.449352021 ; 0.030781042 ; 0.47090501 ; 0.630237804 ; 0.575509076 ; 0.502722297 ; 0.56352672 ; 0.466571614 ; -0.12184595 ; 0.397584639 ; 0.427521803 ; 0.115746947 ; 0.562030345 ; 0.341486199 ; 0.299055536 ; 0.44854804 ; 0.303105194 ; 0.409259251 ; 0.513986415 ; 0.401926036 ; 0.52069081 ; 0.40026185 ; 0.363666596 ; 0.295495166 ; 0.524488554 ; 0.445731216 ; 0.362043322 ; 0.613318493 ; 0.588466643 ; 0.029843709 ; 0.624217457 ; 0.412105788 ; 0.559269536 ; 0.572861618 ; 0.246841333 ; 0.490931116 ; 0.513552186 ; 0.518940304 ; 0.525027434 ; 0.436892702 ; 0.431379099 ; 0.496068978 ; 0.595414924 ; 0.532595425 ; 0.590077486 ; 0.531803148 ; 0.623168884 ; 0.533909242 ; 0.307022925 ; 0.567766782 ; 0.296045709 ; 0.539133735 ; 0.48669144 ; 0.513923726 ; 0.568899478 ; 0.303539965 ; 0.604623917 ; 0.546285356 ; 0.61008058 ; 0.495507421 ; 0.520479307 ; 0.320815037 ; 0.384561266 ; 0.440457186 ; 0.517750339 ; 0.46380286 ; 0.541646452 ; 0.452825722 ; 0.546252869 ; 0.596777346 ; 0.317903162 ; 0.33243211 ; 0.532529256 ; 0.440939076 ; 0.493880307 ; 0.564441623 ; 0.394849627 ; 0.528435007 ; 0.687895365 ; 0.140770511 ; 0.522809905 ; 0.622547817 ; 0.46118062 ; 0.429000784 ; 0.377742515 ; 0.004218797 ; 0.427918557 ; 0.158827409 ; 0.361019044 ; 0.49613913 ; 0.588942046 ; 0.473256177 ; 0.566639488 ; -0.111873001 ; 0.527461935 ; 0.490541098 ; 0.525307398 ; 0.533529851 ; 0.579073112 ; 0.339972218 ; 0.649993462 ; 0.351563579 ; 0.637814551 ; 0.543654568 ; 0.303212001 ; 0.557995567 ; 0.457496609 ; 0.480305509 ; 0.462358456 ; 0.477872987 ; 0.43694691 ; 0.484156596 ; 0.539950892 ; 0.405015792 ; 0.330632561 ; 0.655057564 ; 0.435772982 ; 0.622175475 ; 0.595321383 ; 0.489383541 ; 0.603596217 ; 0.605165783 ; 0.595326667 ; -0.175827934 ; 0.458817007 ; -0.026118384 ; 0.496380184 ; 0.370352377 ; 0.702217718 ; 0.371245161 ; 0.058879077 ; 0.042386212 ; 0.389603789 ; 0.630945504 ; 0.610480186
CAPTURE_ARV7_SRPM	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	Capture ARV7 SRPM spliced reads per million	Sample	4.775563185 ; 0.415812207 ; 0.066105437 ; 0.280565907 ; 0.015423731 ; 6.294758145 ; 0.803078179 ; 0 ; 0.161611277 ; 1.287748811 ; 7.552762953 ; 1.436150163 ; 1.146481848 ; 5.602293477 ; 0.33221747 ; 1.125263593 ; 0.55068069 ; 0.036889517 ; 0.175395102 ; 0.248024508 ; 1.107165034 ; 3.543477666 ; 2.717231083 ; 4.106570469 ; 2.768043886 ; 4.465239855 ; 0.259502023 ; 1.721427805 ; 0.369191111 ; 0.38906225 ; 11.79147001 ; 0.086325048 ; 0.092856162 ; 0.078706301 ; 5.162714536 ; 0.80047883 ; 5.607161118 ; 0.759538474 ; 0.074744285 ; 11.31693036 ; 0.4003053 ; 2.250064605 ; 0.337514839 ; 3.858716989 ; 6.469037953 ; 0.083161856 ; 1.566593854 ; 0.71332427 ; 0.493122263 ; 0.093526349 ; 0.118633123 ; 1.948717593 ; 0.340101755 ; 2.902963447 ; 1.476917771 ; 0.744583747 ; 0.460033493 ; 0.583957718 ; 0.976893448 ; 4.240645126 ; 2.848301016 ; 0.096476458 ; 0.116646917 ; 0.341227626 ; 0.137828389 ; 0.429121951 ; 3.843231764 ; 3.897110984 ; 0.077570185 ; 5.024336822 ; 0.741924935 ; 0.907398511 ; 0.099102966 ; 0.069878432 ; 0.851358364 ; 0.806661832 ; 1.584114148 ; 0.888521404 ; 1.971237978 ; 1.798508748 ; 1.938783515 ; 1.321739038 ; 0.098752624 ; 0.03391126 ; 0.220458991 ; 2.300671041 ; 1.620747079 ; 0.025743684 ; 6.013833132 ; 0.779368811 ; 1.278270837 ; 0.044110176 ; 0.336538224 ; 0.404736582 ; 3.014170517 ; 0.44512322 ; 3.871268678 ; 7.744848252 ; 9.218735545 ; 1.470194583 ; 6.145940331 ; 0.258259021 ; 0.566205628 ; 5.985482238 ; 1.945725848 ; 0.098587198 ; 0.179972341 ; 5.762088148 ; 4.029647952 ; 1.253095685 ; 5.573787283 ; 5.786350278 ; 1.515216585 ; 3.339224282 ; 11.11523884 ; 9.636198467 ; 2.193795309 ; 0.656345208 ; 2.583267974 ; 0.345581324 ; 3.934924056 ; 0.630439727 ; 2.803914255 ; 7.710480136 ; 1.586589253 ; 1.680496174 ; 1.81458148 ; 0.020487937 ; 0.209921409 ; 5.86605625 ; 1.802941043 ; 1.314595653 ; 4.360028932 ; 0.713131741 ; 2.022640544 ; 2.298304422 ; 0.469522364 ; 0.151787961 ; 5.129161366 ; 0.669624435 ; 1.805397569 ; 0.456247936 ; 6.323305562 ; 3.770389808 ; 2.745107475 ; 3.162297756 ; 4.218918957 ; 0.292775028 ; 6.198044528 ; 0.258068525 ; 0.054696421 ; 0.359789541 ; 2.437613645 ; 0.042555834 ; 4.985299232 ; 0.741319435 ; 0.318702185 ; 1.028819311 ; 1.101414524 ; 9.834749736 ; 0.349423544 ; 1.031745786 ; 0.593686495 ; 7.818969395 ; 0.026050221 ; 7.450047367 ; 0.06206002 ; 0.915761818 ; 0.808831856 ; 6.561566262 ; 1.197375436 ; 2.214419459 ; 1.342987007 ; 1.37091699 ; 0.378761749 ; 0.264146882 ; 1.048082058 ; 1.058129991 ; 0.245294395 ; 0.139732415 ; 0.32677925 ; 2.525637536 ; 0.742204533 ; 0.628796938 ; 6.505290512 ; 0.977101623 ; 1.410428227 ; 3.655791312 ; 3.1427011
ETS_FUSION_DETAILS	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	ETS Fusion Details	Sample	TMPRSS2-ERG ; EIF4A2-ETV5 ; TMPRSS2-ETV4 ; CLTC-ETV1 ; TMPRSS2-ETV1 ; CCAR-ETV1 ; SLC45A3-ETV1 ; chr14_q21.1-ETV11 ; chr14_q21.1-ETV1 ; MSMB-ERG ; HNRNPH1-ETV4 ; TMPRSS2-ETV5 ; SLC45A3-ERG ; CANT1-ETV4 ; ACPP-ETV1 ; GRHL2-FLI1 ; RP11-356O9.1-ETV1 ; YWHAE-ETV1 ; AGR2-ETV1 ; ALOX15B-ETV1 ; HNRNPA2B1-ETV1 ; FASN-ETV4 ; TCAF-ETV1 ; GRHL2-ERG ; GPR179-ETV4
NEPC_CAPTURE_SCORE	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	NEPC Score (Capture)	Sample	-0.056371939 ; 0.095012166 ; -0.081487905 ; -0.024651844 ; -0.019347617 ; 0.137899261 ; 0.009038471 ; 0.246253731 ; -0.051822441 ; -0.033797467 ; -0.089122949 ; 0.712959776 ; 0.067795625 ; -0.061576331 ; 0.133399893 ; -0.015595529 ; 0.099745647 ; -0.001815554 ; 0.021885495 ; -0.052156988 ; 0.011468481 ; 0.726437205 ; 0.062777221 ; -0.073700834 ; -0.020417373 ; 0.112580599 ; 0.018064716 ; -0.005394134 ; -0.052870023 ; 0.012951549 ; -0.039657416 ; -0.004824668 ; -0.026399962 ; -0.00906459 ; 0.010474602 ; 0.237644507 ; -0.132916909 ; 0.039298259 ; 0.066050276 ; 0.341390399 ; -0.008138869 ; 0.817263904 ; 0.668608064 ; -0.078135403 ; 0.61108438 ; 0.03578815 ; -0.024007814 ; 0.039210968 ; -0.00074229 ; -0.002686046 ; 0.011042935 ; 0.008637365 ; -0.005359239 ; -0.022080452 ; 0.174771788 ; 0.004098977 ; 0.763776295 ; -0.023474839 ; -0.054581254 ; -0.046054504 ; 0.146565127 ; 0.009369075 ; 0.107510235 ; -0.068305825 ; -0.035395069 ; 0.07184772 ; -0.093919614 ; -0.059523479 ; -0.077623946 ; -0.034434432 ; -0.023230227 ; -0.062526961 ; -0.006208166 ; -0.022381722 ; -0.122781869 ; -0.11620073 ; 0.015612321 ; -0.109771611 ; -0.034351639 ; 0.663232038 ; -0.003638033 ; -0.145004311 ; 0.089863751 ; -0.038631313 ; -0.12185709 ; -0.052440577 ; 0.098586018 ; 0.030024108 ; -0.069896319 ; 0.050285436 ; -0.035378694 ; -0.058602206 ; 0.022580758 ; -0.088832904 ; 0.020095342 ; -0.086844944 ; 0.052786811 ; 0.005983076 ; -0.038442026 ; -0.050188018 ; 0.00484899 ; 0.109102534 ; -0.008552169 ; 0.072125721 ; -0.088992196 ; -0.008179724 ; -0.044365123 ; -0.045646626 ; -0.034624118 ; 0.037178454 ; -0.09959778 ; -0.081615942 ; 0.006570673 ; -0.028969009 ; -0.024298423 ; -0.004287663 ; 0.066828153 ; 0.020794457 ; -0.053687126 ; -0.055143233 ; -0.034182265 ; -0.039928811 ; 0.025887309 ; -0.013374758 ; -0.002363045 ; -0.069142258 ; -0.012552581 ; -0.083321245 ; -0.093058421 ; -0.080592344 ; -0.049335274 ; -0.056344855 ; -0.032412828 ; -0.093039546 ; 0.064117185 ; 0.114352768 ; -0.01657687 ; -0.035415161 ; -0.001306883 ; -0.026330762 ; -0.026255014 ; 0.013924012 ; 0.673420424 ; -0.058632157 ; -0.038984719 ; 0.048805442 ; -0.031197622 ; 0.092102768 ; 0.122915607 ; -0.02661211 ; -0.071843978 ; 0.216112468 ; -0.040947009 ; -0.029148069 ; 0.348117589 ; -0.071367333 ; -0.019956949 ; -0.093113984 ; -0.092095688 ; -0.013405599 ; -0.038953869 ; -0.05862272 ; 0.076469177 ; -0.004336037 ; 0.575969492 ; -0.072215559 ; -0.048304971 ; 0.051702349 ; -0.079038066 ; -0.094484862 ; -0.027370505 ; 0.050479522 ; 0.058879905 ; 0.027446969 ; -0.094395152 ; 0.075443025 ; 0.07133105 ; -0.028156601 ; -0.045192852 ; -0.075115182 ; 0.0080612 ; 0.011109401 ; -0.015675285 ; -0.057699784 ; 0.061938886 ; 0.011527461 ; 0.000958154 ; -0.004546812 ; 0.008015227 ; 0.036786382 ; -0.013790979 ; -0.054467175 ; 0.051266196 ; -0.048447021 ; -0.108992735 ; -0.000483278 ; 0.061033223 ; 0.087713712 ; 0.127634164 ; 0.10597279 ; -0.080456333 ; 0.075191778 ; 0.024312143 ; -0.093558296 ; -0.200871558 ; -0.038826601 ; 0.055384943 ; -0.010253788
NEPC_POLYA_SCORE	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	NEPC Score (PolyA)	Sample	-0.007932095 ; 0.41511208 ; -0.054222654 ; -0.070306754 ; 0.204482649 ; 0.099344602 ; -0.126507768 ; -0.113462122 ; -0.04686481 ; 0.080228614 ; -0.056330969 ; 0.187589536 ; -0.11281314 ; -0.097039865 ; 0.768063486 ; 0.024293058 ; -0.098525443 ; 0.096454341 ; 0.030728692 ; 0.004191354 ; 0.056300654 ; -0.092766196 ; -0.022196012 ; 0.775059287 ; 0.007118763 ; -0.073481193 ; -0.054542088 ; 0.09881756 ; -0.016712902 ; -0.038631592 ; -0.082216137 ; -0.075977373 ; -0.02914701 ; -0.059646876 ; -0.039651515 ; -0.004005571 ; 0.219306227 ; -0.123544865 ; 0.05011311 ; 0.509785455 ; -0.034016877 ; 0.8509693 ; 0.69959735 ; 0.579301944 ; -0.079006837 ; -0.030192324 ; -0.055803214 ; -0.022763714 ; -0.050456257 ; -0.106970848 ; -0.024349651 ; -0.023491161 ; 0.68475424 ; 0.115640611 ; -0.018610142 ; -0.074201158 ; 0.563035208 ; 0.297676142 ; 0.026698617 ; 0.100398227 ; 0.006992012 ; 0.059868325 ; -0.025292627 ; -0.105233854 ; 0.267031997 ; 0.007710543 ; 0.083089058 ; 0.262579771 ; 0.148364734 ; 0.080561541 ; 0.042372595 ; -0.078878488 ; 0.020079012 ; 0.015000331 ; -0.086508082 ; -0.118139941 ; -0.097299446 ; 0.717098363 ; 0.007624075 ; -0.019113835 ; 0.043429092 ; 0.091588813 ; 0.414385729 ; 0.549466827 ; 0.236199907 ; -0.073882765 ; 0.084871386 ; 0.778789006 ; 0.026361844 ; 0.338517732 ; -0.067177515 ; -0.025939312 ; -0.091970248 ; 0.094974436 ; 0.105405597 ; 0.036394984 ; -0.052830302 ; -0.061474392 ; -0.126476741 ; -0.045023632 ; -0.054380524 ; 0.252084019 ; -0.057787733 ; -0.038585971 ; -0.018149961 ; -0.053136336 ; -0.063247335 ; -0.075741968 ; 0.00037836 ; -0.028706079 ; 0.008051685 ; -0.104299535 ; -0.00787485 ; -0.002627626 ; -0.149875103 ; -0.045624467 ; 0.012708063 ; -0.093718645 ; 0.066537332 ; 0.045996668 ; -0.075079548 ; -0.050222425 ; -0.074711597 ; -0.065670597 ; -0.062274491 ; 0.574680919 ; -0.148904153 ; -0.052775994 ; -0.090910624 ; 0.376823241 ; -0.026881413 ; 0.369375652 ; -0.088903589 ; -0.029437377 ; 0.023035576 ; -0.00864238 ; -0.117297106 ; -0.085389958 ; 0.536270386 ; 0.009292444 ; -0.044722326 ; 0.236949892 ; -0.028265748 ; 0.037821969 ; -0.046866561 ; 0.079228185 ; 0.104518947 ; -0.104790907 ; 0.081827341 ; 0.087956815 ; -0.140342604 ; -0.080759406 ; -0.064505668 ; -0.05264051 ; -0.046421 ; -0.147209254 ; -0.064862417 ; -0.156136443 ; -0.074109448 ; 0.672070881 ; -0.050833998 ; 0.038057405 ; -0.045763314 ; -0.085321361 ; 0.024179541 ; -0.007256637 ; -0.094146618 ; -0.016637439 ; -0.099219113 ; -0.105444587 ; -0.018310276 ; -0.11483178 ; 0.004057742 ; -0.153091431 ; -0.002786257 ; -0.070200467 ; -0.092200345 ; -0.035714984 ; 0.058585327 ; -0.036836727 ; 0.051021568 ; -0.100173491 ; -0.036849275 ; -0.096511575 ; -0.013973623 ; -0.120237878 ; -0.108176796 ; -0.037153176 ; -0.078572918 ; -0.039322101 ; 0.043608722 ; -0.107675841 ; -0.09535639 ; -0.092745129 ; -0.017781921 ; -0.115279051 ; -0.088324158 ; -0.130310565 ; -0.118230435 ; -0.078528046 ; -0.110470308 ; -0.068930578 ; -0.138613752 ; 0.049700843 ; 0.088814369 ; -0.050479866 ; -0.022721533 ; -0.07174273 ; 0.010193505 ; 0.706545706 ; -0.098752127 ; -0.072335556 ; -0.077923446 ; 0.078729037 ; -0.101091791 ; 0.144374423 ; -0.024007665 ; 0.312823437 ; -0.129122902 ; -0.049323387 ; -0.084647633 ; 0.028498482 ; -0.059407174 ; 0.587379971 ; -0.146204081 ; -0.073358957 ; 0.012886455 ; -0.11678769 ; 0.038218287 ; 0.029979967 ; 0.038862601 ; -0.074252361 ; -0.106987503 ; -0.103633142 ; -0.027564371 ; -0.068877739 ; -0.129552793 ; 0.030772908 ; -0.072369264 ; -0.14438266 ; -0.036651943 ; 0.055504716 ; 0.077581456 ; 0.108223322 ; -0.12453455 ; 0.049116495 ; -0.012141693 ; -0.147280447 ; -0.083806699 ; 0.015479822 ; -0.070361171 ; -0.004480799 ; 0.814244306 ; 0.076471278 ; 0.914879087 ; -0.061600196 ; -0.038972724 ; -0.136660015 ; -0.043922587 ; 0.813584188 ; 0.808817896 ; 0.014346903 ; -0.062975315 ; -0.014648221
NEPC_SCORE	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	NEPC Score	Sample	-0.007932095 ; -0.056371939 ; 0.41511208 ; -0.054222654 ; -0.070306754 ; 0.204482649 ; 0.099344602 ; -0.126507768 ; -0.113462122 ; -0.04686481 ; 0.080228614 ; -0.056330969 ; 0.187589536 ; -0.11281314 ; -0.033797467 ; -0.097039865 ; 0.768063486 ; 0.024293058 ; -0.098525443 ; -0.061576331 ; 0.096454341 ; -0.015595529 ; 0.030728692 ; 0.004191354 ; 0.056300654 ; -0.092766196 ; -0.022196012 ; 0.775059287 ; 0.007118763 ; -0.073481193 ; -0.054542088 ; 0.09881756 ; -0.016712902 ; -0.038631592 ; -0.082216137 ; 0.012951549 ; -0.075977373 ; -0.02914701 ; -0.059646876 ; -0.039651515 ; -0.004005571 ; 0.219306227 ; -0.123544865 ; 0.05011311 ; 0.066050276 ; 0.509785455 ; -0.034016877 ; 0.8509693 ; 0.69959735 ; -0.078135403 ; 0.579301944 ; 0.03578815 ; -0.079006837 ; 0.039210968 ; -0.030192324 ; -0.055803214 ; -0.022763714 ; 0.008637365 ; -0.005359239 ; -0.022080452 ; 0.174771788 ; -0.050456257 ; -0.106970848 ; -0.024349651 ; -0.023491161 ; 0.68475424 ; 0.115640611 ; -0.018610142 ; -0.074201158 ; 0.563035208 ; 0.297676142 ; 0.026698617 ; 0.100398227 ; 0.006992012 ; 0.059868325 ; -0.025292627 ; -0.105233854 ; 0.267031997 ; 0.007710543 ; 0.083089058 ; 0.262579771 ; 0.148364734 ; 0.080561541 ; 0.042372595 ; -0.078878488 ; 0.020079012 ; 0.015000331 ; -0.086508082 ; -0.118139941 ; -0.097299446 ; 0.717098363 ; 0.007624075 ; -0.019113835 ; 0.043429092 ; 0.091588813 ; 0.414385729 ; 0.549466827 ; 0.236199907 ; -0.073882765 ; 0.084871386 ; 0.778789006 ; 0.026361844 ; 0.338517732 ; -0.067177515 ; -0.025939312 ; -0.091970248 ; 0.094974436 ; 0.105405597 ; 0.036394984 ; -0.052830302 ; -0.061474392 ; -0.126476741 ; -0.045023632 ; -0.054380524 ; 0.252084019 ; -0.057787733 ; -0.038585971 ; -0.018149961 ; -0.053136336 ; -0.063247335 ; -0.075741968 ; 0.00037836 ; -0.028706079 ; 0.008051685 ; -0.104299535 ; -0.00787485 ; -0.002627626 ; -0.149875103 ; -0.045624467 ; 0.012708063 ; -0.093718645 ; 0.066537332 ; 0.045996668 ; -0.075079548 ; -0.050222425 ; -0.074711597 ; -0.065670597 ; -0.062274491 ; 0.574680919 ; -0.148904153 ; -0.052775994 ; -0.090910624 ; 0.376823241 ; -0.026881413 ; 0.369375652 ; -0.088903589 ; -0.029437377 ; 0.023035576 ; -0.00864238 ; -0.117297106 ; -0.085389958 ; 0.536270386 ; 0.009292444 ; -0.044722326 ; 0.236949892 ; -0.028265748 ; 0.037821969 ; -0.046866561 ; 0.763776295 ; -0.023474839 ; -0.054581254 ; -0.046054504 ; 0.079228185 ; 0.009369075 ; 0.104518947 ; -0.104790907 ; 0.081827341 ; 0.087956815 ; -0.140342604 ; -0.080759406 ; -0.077623946 ; -0.034434432 ; -0.064505668 ; -0.05264051 ; -0.006208166 ; -0.046421 ; -0.147209254 ; -0.11620073 ; -0.064862417 ; -0.156136443 ; -0.074109448 ; 0.672070881 ; -0.050833998 ; -0.145004311 ; 0.038057405 ; -0.045763314 ; -0.12185709 ; -0.085321361 ; 0.024179541 ; -0.007256637 ; 0.030024108 ; -0.094146618 ; -0.016637439 ; -0.099219113 ; -0.105444587 ; -0.018310276 ; -0.11483178 ; 0.004057742 ; -0.153091431 ; -0.002786257 ; 0.005983076 ; -0.070200467 ; -0.092200345 ; -0.035714984 ; 0.058585327 ; -0.036836727 ; 0.051021568 ; -0.100173491 ; -0.036849275 ; -0.044365123 ; -0.045646626 ; -0.096511575 ; -0.013973623 ; -0.120237878 ; -0.108176796 ; -0.037153176 ; -0.078572918 ; -0.024298423 ; -0.039322101 ; 0.043608722 ; 0.020794457 ; -0.107675841 ; -0.055143233 ; -0.09535639 ; -0.092745129 ; 0.025887309 ; -0.013374758 ; -0.017781921 ; -0.115279051 ; -0.088324158 ; -0.130310565 ; -0.093058421 ; -0.118230435 ; -0.078528046 ; -0.110470308 ; -0.068930578 ; -0.138613752 ; 0.049700843 ; 0.088814369 ; -0.050479866 ; -0.022721533 ; -0.001306883 ; -0.026330762 ; -0.07174273 ; 0.010193505 ; 0.706545706 ; -0.098752127 ; -0.072335556 ; 0.048805442 ; -0.077923446 ; 0.092102768 ; 0.078729037 ; -0.101091791 ; -0.071843978 ; 0.144374423 ; -0.040947009 ; -0.024007665 ; 0.312823437 ; -0.129122902 ; -0.019956949 ; -0.093113984 ; -0.092095688 ; -0.049323387 ; -0.084647633 ; -0.05862272 ; 0.028498482 ; -0.059407174 ; 0.587379971 ; -0.072215559 ; -0.048304971 ; 0.051702349 ; -0.079038066 ; -0.146204081 ; -0.073358957 ; 0.050479522 ; 0.012886455 ; 0.027446969 ; -0.11678769 ; -0.094395152 ; 0.038218287 ; 0.029979967 ; 0.038862601 ; -0.074252361 ; -0.106987503 ; -0.103633142 ; -0.027564371 ; 0.011109401 ; -0.068877739 ; -0.057699784 ; 0.061938886 ; 0.011527461 ; 0.000958154 ; -0.004546812 ; 0.008015227 ; 0.036786382 ; -0.013790979 ; -0.129552793 ; 0.030772908 ; -0.072369264 ; -0.14438266 ; -0.036651943 ; 0.061033223 ; 0.055504716 ; 0.077581456 ; 0.108223322 ; -0.12453455 ; 0.049116495 ; -0.012141693 ; -0.147280447 ; -0.200871558 ; -0.083806699 ; 0.015479822 ; -0.070361171 ; -0.004480799 ; 0.814244306 ; 0.076471278 ; 0.914879087 ; -0.061600196 ; -0.038972724 ; -0.136660015 ; -0.043922587 ; 0.813584188 ; 0.808817896 ; 0.014346903 ; -0.062975315 ; -0.014648221
NEUROENDOCRINE_FEATURES	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	Neuroendocrine Features	Sample	No ; Yes
OFF_ARSI	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	Off ARSI?	Sample	1 ; 0
POLYA_ARV7_SRPM	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	NUMBER	polyA ARV7 SRPM spliced reads per million	Sample	0.359638588 ; 0 ; 2.967834462 ; 0.945580928 ; 0.295066818 ; 0.241376204 ; 0.046007026 ; 16.30142048 ; 0.293267022 ; 13.91813855 ; 0.031325275 ; 1.197904571 ; 3.090198952 ; 0.347693428 ; 1.931602066 ; 1.040041049 ; 0.108799384 ; 0.477997833 ; 1.915184493 ; 7.072234215 ; 3.432712479 ; 6.826120611 ; 7.623047328 ; 0.33562331 ; 1.390696345 ; 0.401384168 ; 0.56001697 ; 0.023185071 ; 4.103732135 ; 0.018257867 ; 0.321409637 ; 0.020762465 ; 5.464646933 ; 0.123115499 ; 11.35583685 ; 0.296774275 ; 0.064060929 ; 4.59847661 ; 1.213522426 ; 0.757742805 ; 0.154630141 ; 8.665337001 ; 0.151970303 ; 2.176258491 ; 2.216471625 ; 1.458866671 ; 0.076127104 ; 1.24528957 ; 0.266514666 ; 9.189845989 ; 0.073764544 ; 4.792273044 ; 1.941374 ; 0.321029086 ; 2.269797907 ; 0.887418584 ; 9.003858728 ; 0.265415264 ; 0.544955948 ; 1.308837952 ; 3.460551369 ; 0.017289236 ; 0.055154919 ; 0.049334862 ; 9.908761942 ; 0.138329921 ; 3.203520466 ; 0.040115338 ; 0.069097735 ; 6.789992366 ; 7.057091636 ; 0.446516951 ; 0.296709569 ; 2.003835843 ; 1.387273614 ; 1.866267773 ; 4.20933181 ; 6.095356519 ; 2.848021649 ; 0.152416359 ; 0.22766687 ; 7.474963313 ; 9.498678257 ; 3.482022566 ; 4.802169358 ; 1.339654817 ; 3.395090764 ; 0.520875089 ; 0.094451137 ; 0.033904947 ; 0.072803226 ; 2.934642209 ; 0.722322598 ; 5.208030908 ; 0.080204779 ; 0.615534039 ; 2.923690317 ; 0.041871584 ; 8.225638321 ; 1.048784218 ; 4.034351189 ; 0.697390496 ; 0.680098815 ; 0.61251658 ; 2.146114911 ; 1.253568103 ; 0.908079326 ; 1.292543605 ; 0.304408587 ; 0.844694955 ; 0.0939815 ; 12.86481469 ; 0.417700435 ; 2.083844433 ; 1.057285167 ; 0.137248121 ; 0.081166027 ; 0.053219631 ; 5.410177893 ; 0.028636346 ; 4.263883673 ; 0.472262972 ; 1.102097414 ; 0.535330514 ; 8.440507298 ; 2.508178955 ; 0.131195029 ; 0.19958259 ; 0.393961073 ; 6.678164317 ; 8.515932067 ; 8.477264195 ; 1.535620624 ; 0.074710528 ; 3.404308629 ; 2.129945057 ; 1.528960592 ; 3.008741862 ; 1.531360737 ; 3.81665004 ; 4.893897582 ; 2.259226015 ; 1.440820757 ; 0.017106909 ; 0.242352271 ; 3.251216101 ; 4.018135911 ; 0.05419819 ; 9.996190501 ; 2.086305681 ; 1.528938821 ; 0.024988266 ; 1.049750226 ; 2.929843942 ; 0.089573196 ; 5.454406391 ; 9.620818401 ; 13.91896634 ; 5.123133495 ; 0.312812761 ; 7.421005815 ; 0.043230773 ; 0.166775364 ; 0.43794369 ; 6.270221615 ; 4.763266829 ; 2.081095274 ; 10.755457 ; 14.61358344 ; 3.320255815 ; 0.877448108 ; 5.461869689 ; 0.265807124 ; 6.58791774 ; 1.003101087 ; 3.173810777 ; 2.85916853 ; 2.36025903 ; 0.040202249 ; 0.27681859 ; 7.107470444 ; 1.071395549 ; 1.000572706 ; 2.315823175 ; 0.197068349 ; 6.444414359 ; 9.283198106 ; 5.54833803 ; 3.651621931 ; 4.396061134 ; 0.336828988 ; 1.737331327 ; 0.048688001 ; 0.720245768 ; 0.075780107 ; 0.30566656 ; 1.366973071 ; 0.702520256 ; 9.444283084 ; 0.846957451 ; 1.174199913 ; 5.727578278 ; 1.864247638 ; 2.280689361 ; 0.139498575 ; 0.908095737 ; 1.348176866 ; 1.660506583 ; 0.028141704 ; 0.275150629 ; 3.025709682 ; 0.524037891 ; 0.720078424 ; 6.897242812 ; 0.681360472 ; 3.407283531 ; 2.650947868 ; 6.658004919 ; 0.634350877 ; 0.502206948 ; 1.160649434 ; 1.736397898 ; 2.200606655 ; 4.528489178
RAF1_BRAF_STATUS	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	RAF1/BRAF Alteration Status	Sample	KIAA1549-BRAF ; UBN2-BRAF ; GOLGA4-RAF1 ; LSM1-BRAF ; TMPRSS2-BRAF
TAXANE_EXPOSURE_STATUS	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	Taxane Exposure Status	Sample	Naive ; Exposed ; UNK
UNIQUE_PAPER_SAMPLES	Cyan	Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)	STRING	Unique Paper Samples	Sample	YES
ETS_STATUS	Cyan	Prostate Cancer (DKFZ, Cancer Cell 2018)	STRING	ETS Status	Sample	1 ; 0
LOCALIZED_TUMOR	Cyan	Prostate Cancer (DKFZ, Cancer Cell 2018)	STRING	Localized Tumor	Sample	TRUE ; FALSE
MEDIAN_PURITY	Cyan	Prostate Cancer (DKFZ, Cancer Cell 2018)	NUMBER	Median Purity	Sample	50 ; 40 ; 48 ; 57 ; 49 ; 54 ; 46 ; 58 ; 45 ; 53 ; 44 ; 51 ; 38 ; 42 ; 41 ; 55 ; 62 ; 43 ; 33 ; 36 ; 78 ; 47 ; 64 ; 37 ; 39 ; 66 ; 63 ; 68 ; 61 ; 59 ; 60 ; 56 ; 52 ; 29 ; 34 ; 35 ; 75 ; 32 ; 67
MONO_MULTIFOCAL	Cyan	Prostate Cancer (DKFZ, Cancer Cell 2018)	STRING	Mono or Multifocal Status	Sample	mono ; multi
TIME_FROM_SURGERY_TO_BCR_LASTFU	Cyan	Prostate Cancer (DKFZ, Cancer Cell 2018)	NUMBER	Time from Surgery to BCR/Last Follow Up	Patient	
HORMONE_THERAPY_STATUS	Cyan	Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024)	STRING	Hormone Therapy Status	Sample	CRPC ; Naive ; Neoadjuvant
LAST_TREATMENT_CATEGPORY	Cyan	Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024)	STRING	Last Treatment Category	Sample	Chemotherapy ; 1st Generation ADT ; Naive ; 2nd Generation ADT
PRIOR_TREATMENTS	Cyan	Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024)	STRING	Prior Treatments	Sample	1st Generation ADT ; 2nd Generation ADT
TUMOR_SITE_GROUP	Cyan	Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024)	STRING	Tumor Site Group	Sample	Primary ; Bone ; Other Metastasis
ALB	Cyan	Prostate Cancer (MSK, Science 2022)	NUMBER	ALB (g/dl)	Sample	4.5 ; 3.1 ; 4.3 ; 4.2 ; 4.8 ; 4 ; 2.9 ; 4.1 ; 3.8 ; 3.2 ; 3.6 ; 2.6 ; 3.5 ; 2.8
ALP	Cyan	Prostate Cancer (MSK, Science 2022)	NUMBER	ALP (U/l)	Sample	67 ; 1001 ; 1088 ; 373 ; 65 ; 74 ; 97 ; 134 ; 137 ; 108 ; 130 ; 104 ; 209 ; 486 ; 56 ; 109 ; 38 ; 93 ; 346 ; 239 ; 112 ; 69
HGB	Cyan	Prostate Cancer (MSK, Science 2022)	NUMBER	HGB (g/dl)	Sample	13.1 ; 9.8 ; 10 ; 12.2 ; 14.1 ; 15.6 ; 6.1 ; 14.6 ; 12.5 ; 12.3 ; 12 ; 8 ; 13.3 ; 11 ; 8.2 ; 9.4 ; 7.7 ; 10.4 ; 10.7
BCLC_STAGE	MediumSeaGreen	Hepatocellular Carcinomas (INSERM, Nat Genet 2015)	STRING	BCLC Stage	Patient	
DISEASE_STAGE	MediumSeaGreen	Hepatocellular Carcinomas (INSERM, Nat Genet 2015)	STRING	Disease Stage	Sample	Poor prognosis HCC ; Classic HCC ; Small HCC ; F0_F1 non cirrhotic HCC ; F2_F3 non cirrhotic HCC ; Early HCC ; HCC in Adenoma ; Hypermutated HCC ; Macronodule
ETIOLOGY	MediumSeaGreen	Hepatocellular Carcinomas (INSERM, Nat Genet 2015)	STRING	Etiology	Patient	
SERUM_ALPHA_FOETO_PROTEIN	MediumSeaGreen	Hepatocellular Carcinomas (INSERM, Nat Genet 2015)	STRING	Serum Alpha Foeto Protein (ng/ml)	Patient	
IO_RESPONSE	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	IO Response	Sample	PD ; SD ; PR ; NE ; CR
NON_VIRAL	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	If sample doesn't have HBV/HCV etc.	Sample	Yes ; No
OS_IO	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	NUMBER	Overall Survival on Immunotherapy (Months)	Patient	
OS_SORAFENIB	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	NUMBER	Overall Survival on Sorafenib	Patient	
OS_STATUS_IO	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	Overall Survival Status on Immunotherapy	Patient	
OS_STATUS_SORAFENIB	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	Overall Survival Status on Sorafenib	Patient	
PFS_IO	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	NUMBER	PFS Months on Immunotherapy	Patient	
PFS_SORAFENIB_TREATMENT	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	NUMBER	PFS on Sorafenib Treatment (Months)	Patient	
PFS_STATUS_IO	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	PFS Status on Immunotherapy	Patient	
PFS_STATUS_SORAFENIB_TREATMENT	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	PFS Status on Sorafenib Treatment	Patient	
SORAFENIB_TREATMENT	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	Sorafenib Treatment	Patient	
STAGE_AT_HCC_DIAGNOSIS	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	Stage of HCC at Diagnosis	Patient	
STAGE_OF_HCC_SYSTEMIC	MediumSeaGreen	Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)	STRING	Stage of HCC at Systemic	Patient	
AFP_UG_L	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	AFP (ug/L)	Patient	
ALLEN_AND_LISA_TYPE	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Allen and Lisa Subtype	Patient	
CA19_9_U_ML	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	CA19-9 (U/ml)	Patient	
HBEAG	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	HBeAg	Patient	
HBSAG	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	HBsAg	Patient	
HBV_DNA_IU_ML	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	HBV DNA (IU/ml)	Patient	
HEPATITIS	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Virus infection	Patient	
HISTOLOGY_COMPONENT	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Histology of component	Sample	HCC component ; ICC component ; Mixed component ; Combined component collected as a whole
LCM	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Laser Capture Microdissection (LCM)	Sample	No ; Yes
NESTIN_STAINING_SCORE	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Nestin staining score	Patient	
TERT_PROMOTER_MUT	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	TERT promoter mutations	Patient	
TUMOR_SAMPLES	MediumSeaGreen	Combined Hepatocellular and Intrahepatic Cholangiocarcinoma (Peking University, Cancer Cell 2019)	STRING	Tumor sample(s)	Patient	
AGE_D	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	NUMBER	Patient age at death	Patient	
BCLC	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	STRING	Barcelona Clinic Liver Cancer clinical stage	Sample	A ; B ; C ; 0 ; D
CENSORING	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	NUMBER	Days to censoring	Patient	
CHILD	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	STRING	Child-Pugh score for liver disease	Sample	6 ; B ; 7 ; 5 ; A ; 9 ; 8 ; 11 ; C
EDMONDSON	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	NUMBER	Edmondson histological grade	Sample	3 ; 2 ; 1 ; 4
IPT	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	STRING	Pathology-based assessment of immunophenotype (PMID:  28102259)	Sample	Inflamed ; Immune-Excluded ; Not-Classifiable ; Immune-Desert ; Nd
MELD	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	NUMBER	Model for End-stage Liver Disease	Sample	11 ; 8 ; 7 ; 19 ; 24 ; 13 ; 17 ; 12 ; 25 ; 14 ; 22 ; 15 ; 9 ; 6 ; 21 ; 20 ; 18 ; 10 ; 5
MVI	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	STRING	Presence of macrovascular invasion	Sample	No ; Yes
SURVIVAL	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	NUMBER	Days of survival	Patient	
ULD	MediumSeaGreen	Hepatocellular Carcinoma (MERiC/Basel, Nat Commun. 2022)	STRING	Underlying liver disease	Patient	
ALPHA_FETOPROTIEN_AT_PROCUREMENT	MediumSeaGreen	Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)	STRING	Alpha Fetoprotein At Procurement	Patient	
EDMONDSON_GRADE	MediumSeaGreen	Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)	STRING	Edmondson tumor grading	Sample	II ; III ; II-III ; I
LIVER_FIBROSIS	MediumSeaGreen	Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)	STRING	Fibrosis in non-cacerous liver tissue is determined according to the New Inuyama Classification.	Patient	
MUTIPLE_NODULES	MediumSeaGreen	Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)	STRING	Synchronous or metachronous nodules	Sample	synchronous ; metachronous
OTHER_DISEASES	MediumSeaGreen	Liver Hepatocellular Carcinoma (RIKEN, Nat Genet 2012)	STRING	Other diagnosed diseases	Patient	
ASSOCIATED_GENETIC_METABOLIC_DISEASE	MediumSeaGreen	Hepatocellular Adenoma (INSERM, Cancer Cell 2014)	STRING	Associated Genetic Metabolic Diseases	Patient	
NODULE_NUMBER	MediumSeaGreen	Hepatocellular Adenoma (INSERM, Cancer Cell 2014)	STRING	Number of Nodules	Patient	
NODULE_SIZE	MediumSeaGreen	Hepatocellular Adenoma (INSERM, Cancer Cell 2014)	NUMBER	Nodule Size (mm)	Sample	60 ; 50 ; 76 ; 110 ; 59 ; 40 ; 150 ; 130 ; 53 ; 75 ; 80 ; 200 ; 70 ; 47 ; 120 ; 90 ; 35 ; 30 ; 36 ; 95
ORAL_CONTRACEPTION	MediumSeaGreen	Hepatocellular Adenoma (INSERM, Cancer Cell 2014)	STRING	Oral Contraception 	Patient	
ANONYMIZED_PATIENT_ID	MediumSeaGreen	Hepatocellular Carcinoma (MSK, JCO Precis Oncol 2023)	STRING	Display Patient Id	Sample	8 ; 4 ; 11 ; 12 ; 7 ; 10 ; 20 ; 5 ; 9 ; 6 ; 22 ; 43 ; 3 ; 1 ; 21 ; 27 ; 13 ; 25 ; 38 ; 45 ; 15 ; 42 ; 17 ; 31 ; 47 ; 49 ; 44 ; 41 ; 26 ; 36 ; 19 ; 23 ; 35 ; 32 ; 29 ; 30 ; 39 ; 51 ; 16 ; 24 ; 48 ; 28 ; 14 ; 34 ; 18 ; 40 ; 46 ; 2 ; 37 ; 33 ; 50
HEPATIC_INFLAMMATION_ADJ_TISSUE	MediumSeaGreen	Liver Hepatocellular Carcinoma (TCGA, Firehose Legacy)	STRING	Adjacent hepatic tissue inflammation extent type	Patient	
ADJUVANT_SYSTEMIC_THERAPY	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient underwent adjuvant systemic therapy	Patient	
BILIARY_SCORE	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	NUMBER	Biliary score	Patient	
CHOLECYSTITIS	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient has cholecystisi	Patient	
CURATIVE_INTENT_SURGERY	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient underwent curative intent surgery	Patient	
C_N	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Presence of suspicious node on imaging (clinically +/-)	Patient	
DIABETES	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient has diabetes disease	Patient	
DIAGNOSIS_AGE	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	NUMBER	Patient age at diagnosis	Patient	
HISTO_SUBTYPE	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Histology subtype	Sample	INDET ; LD ; SD ; EXCLUDE, NO SLIDE ; INDET FAVOR LD ; INDET FAVOR SD
MAJOR_LIVER_RESECTION	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient underwent major liver resection	Patient	
MULTIFOCAL_DISEASE	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient has multifocal disease	Patient	
NEOADJUVANT_SYSTEMIC_THERAPY	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient underwent nejoadjuvant systemic therapy	Patient	
PALLIATIVE_SYSTEMIC_THERPAY	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient underwent palliative systemic therapy	Patient	
PRED_CATEGORY	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Pred category	Sample	Biliary-aligned ; HCC-aligned ; HCC class ; Biliary class
P_N	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Node status on pathology	Patient	
RESECTION_MARGIN	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Resection margin	Patient	
VIRAL_HEPATITIS	MediumSeaGreen	Hepatocellular Carcinoma (MSK, 2024)	STRING	Indicates whether patient has viral hepatitis	Patient	
CYTOLOGICAL_PHENOTYPE	Teal	Poorly-Differentiated and Anaplastic Thyroid Cancers (MSK, JCI 2016)	STRING	Cytological Phenotype	Sample	tall cell variant ; Hurthle ; follicular ; papillary ; mixed ; papillary, tall cell variant ; tall cell variant  phenotype (changed after consensus) upstaged T ; follicular, Hurthle ; follicular, papillary ; papillary, follicular ; follicular in met ; columnar
GROWTH_PATTERN	Teal	Poorly-Differentiated and Anaplastic Thyroid Cancers (MSK, JCI 2016)	STRING	Growth Pattern	Sample	solid ; solid 5% and remainder follicular ; papillary ; solid 5% and remainder papillary ; cribriform growth wit PTC nuclei photo ; solid and papillary
PDTC_DEFINITION	Teal	Poorly-Differentiated and Anaplastic Thyroid Cancers (MSK, JCI 2016)	STRING	PDTC Definition	Patient	
ARMDRIVER_CN	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	ArmDriver CN	Sample	19p:1.673 ; 11q:1.043,Xq:1.816 ; 22q:0.991 ; 22q:1.723 ; 5p:2.181 ; 22q:1.769 ; 22q:1.371 ; 2p:1.518,2q:1.518,3p:1.538,3q:1.538,4p:1.493,4q:1.493,5p:2.578,5q:2.578,7p:2.566,7q:2.566,8p:1.487,8q:1.487,10p:1.482,10q:1.482,11p:1.486,11q:1.486,12p:2.545,12q:2.545,21q:1.481,22q:1.461,Xq:1.853 ; 7q:2.763,16p:2.771 ; 1q:2.692,2q:2.66 ; 9p:1.884,9q:1.884 ; 5p:2.814,5q:2.814,7p:3.614,7q:3.614,12p:2.799,12q:2.799,16p:2.807,16q:2.807,Xq:2.143 ; 22q:1.158 ; 13q:1.299,15q:1.306 ; 22q:1.673 ; 22q:1.422 ; 7p:2.489,7q:2.489,13q:2.241,18p:2.243,18q:2.243,21q:2.237,22q:2.238 ; 22q:1.883 ; 5p:1.011 ; 13q:1.897 ; 22q:1.105 ; 21q:1.839 ; 22q:1.231 ; 22q:1.666 ; 1q:3.188,9q:1.426 ; 1q:2.732 ; 1q:2.834,11q:1.129 ; 22q:1.148 ; 13q:1.207 ; 22q:1.181 ; 1q:2.604 ; 22q:1.26 ; 13q:1.523,22q:1.482 ; 22q:1.877 ; 9q:2.328 ; 2p:1.59,2q:1.59,6p:2.399,6q:2.399,7p:2.461,7q:2.461,8p:1.558,8q:1.558,9p:1.565,9q:1.565,16p:2.399,16q:2.399,17p:2.383,17q:2.383,18p:1.572,18q:1.572,21q:1.565,22q:1.532 ; 13q:1.86 ; 22q:1.597 ; 22q:1.725 ; 22q:1.357 ; 22q:1.221 ; 22q:1.505 ; 22q:1.114 ; 22q:1.258 ; 15q:1.189,22q:1.195 ; 1p:2.105,1q:2.105,9p:1.869,9q:1.869 ; 22q:1.377 ; 22q:1.203 ; 1p:1.346,9p:1.57,9q:1.357,10p:1.606,10q:1.606,17p:1.661,17q:1.943,21q:1.849,22q:1.363 ; 22q:1.888 ; 22q:1.305 ; 22q:1.121 ; 22q:1.235 ; 22q:1.411 ; 17p:1.588,19p:1.347 ; 15q:1.2 ; 1q:2.599,9p:1.365,9q:1.365,11p:1.375,11q:1.375,16p:1.423,16q:1.423,22q:1.416 ; 1q:2.725,5p:2.754 ; 22q:1.262 ; 6q:1.233,19p:1.326 ; 1q:2.43,16q:1.531 ; 3p:2.476,9p:1.827,9q:1.827 ; 1q:2.563 ; 22q:1.119 ; 1q:2.544,5p:2.546,5q:2.546,7p:3.073,7q:3.073,8q:2.542,9q:1.41,16p:2.452,16q:2.452,20p:2.56,20q:2.56,Xq:2.111 ; 17p:2.662,17q:2.662 ; 9p:1.824,9q:1.824 ; 22q:1.083 ; 1q:2.654,5p:3.227,9p:1.405,9q:1.405 ; 11p:2.526,11q:2.526,14q:2.527,17p:2.521,17q:2.521,18p:2.528,18q:2.528,21q:2.519,22q:1.616 ; 22q:1.824 ; 1q:2.135 ; 9p:1.477,9q:1.477,11p:1.478,11q:1.478,17p:2.122,17q:2.122,22q:1.481 ; 9p:2.156,9q:2.156,22q:1.382 ; 5p:2.608,5q:2.608,9p:1.465,9q:1.465,10p:1.643,10q:1.643,11p:1.453,11q:1.453,13q:2.338,14q:2.513,17p:2.491,17q:2.491,18p:2.419,18q:2.419,19p:2.453,19q:2.453,20p:2.53,20q:2.53,22q:1.452 ; 22q:1.211 ; 9q:1.312,13q:1.324 ; 5p:2.685,5q:2.685,7p:3.316,7q:3.316,10p:2.658,10q:2.658,11p:2.613,11q:2.613,12p:2.65,12q:2.65,17p:2.596,17q:2.596,19p:2.559,19q:2.559,20p:3.244,20q:3.244,Xq:2.229 ; 4p:2.433,4q:2.433,5p:2.441,5q:2.441,7p:2.438,7q:2.438,9p:2.432,9q:2.432,12p:2.431,12q:2.431,13q:2.428,14q:2.446,16p:2.44,16q:2.44,17p:2.445,17q:2.445,20p:2.443,20q:2.443,Xq:2.166 ; 1p:1.647,1q:1.647,2p:1.667,2q:1.667,3q:1.658,6q:1.257,9p:1.645,9q:1.645,10p:0.707,15q:1.661,17p:1.64,18p:1.645,18q:1.645,Xq:1.839 ; 22q:1.17 ; 22q:1.257 ; 13q:1.631,22q:1.612 ; 2p:1.619,2q:1.619,3p:2.384,3q:2.384,4p:2.386,4q:2.386,5p:2.397,5q:2.397,7p:2.386,7q:2.386,10p:2.382,10q:2.382,11p:1.58,11q:1.58,12p:2.368,12q:2.368,14q:2.401,16p:2.376,16q:2.376,17p:2.361,17q:2.361,19p:2.313,19q:2.313,22q:2.34,Xq:2.103 ; 21q:1.655,22q:1.654 ; 13q:1.284 ; 7q:2.695,22q:1.228 ; 2p:1.735,2q:1.735,3p:2.243,3q:2.243,5p:2.261,5q:2.261,7p:2.27,7q:2.27,8p:2.269,8q:2.269,12p:2.241,12q:2.241,13q:2.237,14q:2.251,16p:2.269,16q:2.269,17p:2.265,17q:2.265,20p:2.237,20q:2.237 ; 2p:1.478,2q:1.478,5p:2.525,5q:2.525,7p:3.012,7q:3.012,9p:1.441,9q:1.441,12p:2.499,12q:2.499,13q:2.489,14q:2.531,15q:1.445,17p:2.506,17q:2.506,19p:2.449,19q:2.449,20p:2.533,20q:2.533,21q:1.437,22q:1.434 ; 11p:2.793 ; 5p:2.754,5q:2.754,7p:3.483,7q:3.483,12p:2.733,12q:2.733,14q:2.733,16p:2.718,16q:2.718,17p:2.697,17q:2.697,20p:2.711,20q:2.711,Xq:2.203 ; 22q:1.326 ; Xq:2.772 ; 22q:1.719 ; 1q:3.121,5p:3.157,9p:1.355,9q:1.355 ; 2p:1.701,2q:1.701,7p:2.318,7q:2.318,8p:1.677,8q:1.677,9p:1.677,9q:1.677,10p:1.68,10q:1.68,15q:1.681,16p:2.323,16q:2.323,17p:1.677,17q:1.677,19p:2.247,19q:2.247,20p:2.33,20q:2.33,22q:1.668 ; 17p:1.86,17q:1.86 ; 22q:1.426 ; 2p:1.538,2q:1.538,5p:2.455,5q:2.455,7p:2.439,7q:2.439,8p:1.522,8q:1.522,9p:1.518,9q:1.518,11p:2.426,11q:2.426,12p:2.424,12q:2.424,14q:1.532,16p:2.397,16q:2.397,17p:2.352,17q:2.352,18p:1.534,18q:1.534,19p:2.287,19q:2.287,20p:2.397,20q:2.397,21q:2.384 ; 22q:1.862 ; 22q:1.653 ; 22q:1.218 ; 22q:1.297 ; 22q:1.204 ; 22q:0.707 ; 17p:2.618,17q:2.618 ; 2p:2.127,5p:2.145,5q:2.145,7p:2.333,7q:2.333,8p:2.146,8q:2.146,11p:2.135,11q:2.135,12p:2.138,12q:2.138,16p:2.294,16q:2.294,17p:2.129,17q:2.129,18p:2.13,18q:2.13,20p:2.105,20q:2.105,21q:2.135 ; 22q:1.208 ; 22q:1.878 ; 22q:1.612 ; 2p:2.522,5p:2.531,5q:2.531,7p:3.044,7q:3.044,8p:2.523,8q:2.523,11p:2.505,11q:2.505,12p:2.511,12q:2.511,14q:2.382,16p:2.979,16q:2.979,17p:2.499,17q:2.499,18p:2.515,18q:2.515,20p:2.428,20q:2.428,21q:2.512,22q:2.137,Xq:2.259 ; 1q:2.754 ; 18p:1.25,18q:1.25,22q:1.252 ; 1p:2.139,1q:2.139 ; 6p:1.833,6q:1.833,8p:2.16,8q:2.16 ; 2p:1.185,12p:2.755,12q:2.755,16p:2.791,17q:2.779,22q:1.168 ; 22q:1.288 ; 13q:1.333,Xq:1.855 ; 22q:1.747 ; 17p:1.164 ; 1q:2.822,9q:1.092 ; 22q:1.742 ; 17p:1.661,17q:1.978 ; 4p:2.796,4q:2.796,5p:2.833,5q:2.833,6p:2.72,6q:1.801,11p:1.103,11q:1.103,13q:1.106,19q:3.421 ; 22q:1.873 ; 9p:1.594,9q:1.469 ; 1p:1.668,1q:1.668,2p:1.688,2q:1.688,3p:1.665,3q:1.665,4p:2.167,4q:2.167,5p:2.167,5q:2.167,6p:1.664,6q:1.664,7p:2.645,7q:2.645,8p:2.163,8q:2.163,9p:2.147,9q:2.147,10p:1.651,10q:1.651,11p:1.661,11q:1.661,12p:2.168,12q:2.168,13q:1.664,14q:2.169,15q:1.662,16p ; 1p:2.743,1q:2.743,4p:2.723,4q:2.723,5p:2.749,5q:2.749,7p:2.747,7q:2.747,12p:2.741,12q:2.741,14q:2.749,16p:2.776,16q:2.776,Xq:2.253 ; 22q:1.73 ; 13q:1.094,22q:1.067 ; 12p:1.834,12q:2.595,19p:1.221,19q:2.015,22q:1.163 ; 1q:2.504 ; 9p:1.845,9q:1.845 ; 1q:2.56,6p:1.783,6q:1.783,9p:1.767,9q:1.767,13q:1.272,19p:2.171,19q:2.171 ; 22q:1.864 ; 22q:1.45 ; 1q:2.446 ; 22q:1.766 ; 22q:1.835 ; 22q:1.256 ; 1q:2.753 ; 22q:1.778 ; 14q:2.107 ; 22q:1.808 ; 21q:1.622 ; 22q:1.282 ; 22q:1.487 ; 1q:2.829,22q:1.202 ; 8p:2.184,8q:2.184 ; 1q:2.618 ; 9q:1.545 ; 5p:2.803,5q:2.803,7p:2.802,7q:2.802,17p:1.441,17q:2.015
ARM_SCNA_CLUSTER	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Arm-level SCNA cluster assignment	Sample	SomeSCNA ; 22q ; Quiet ; Many SCNA
BRAFV600E_RAF_SCORE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	BRAFV600E RAF Score	Sample	0.533 ; 0.828 ; 0.946 ; -0.849 ; -0.831 ; 0.909 ; -0.872 ; 0.955 ; 0.859 ; 0.865 ; -0.757 ; -0.276 ; 0.697 ; -0.965 ; 0.464 ; 0.648 ; -0.86 ; 0.919 ; -0.107 ; 0.926 ; -0.858 ; -0.717 ; -0.719 ; 0.242 ; 0.143 ; 0.775 ; -0.974 ; 0.808 ; -0.884 ; 0.916 ; -0.526 ; 0.462 ; -0.943 ; 0.602 ; 0.929 ; 0.806 ; -0.973 ; -0.902 ; 0.927 ; -0.541 ; -0.33 ; -0.205 ; 0.062 ; -0.791 ; -0.485 ; 0.635 ; -0.591 ; -0.783 ; -0.762 ; -0.834 ; 0.549 ; -0.177 ; 0.588 ; 0.917 ; -0.531 ; -0.735 ; 0.448 ; 0.823 ; -0.76 ; -0.474 ; -0.989 ; 0.82 ; -0.693 ; -0.88 ; 0.833 ; -0.97 ; -0.91 ; 0.908 ; -0.395 ; -0.89 ; -0.827 ; -0.846 ; -0.803 ; -0.772 ; 0.936 ; -0.889 ; -0.83 ; -0.681 ; -0.935 ; -0.92 ; -0.782 ; -0.862 ; -0.436 ; -0.967 ; -0.843 ; 0.883 ; -0.641 ; 0.633 ; -0.784 ; -0.951 ; -0.893 ; -0.763 ; -0.602 ; -0.504 ; 0.864 ; -0.661 ; -0.701 ; -0.982 ; -0.506 ; -0.799 ; 0.717 ; -0.975 ; -0.728 ; 0.152 ; 0.967 ; -0.877 ; -0.904 ; -0.366 ; -0.63 ; -0.851 ; -0.96 ; -0.948 ; -0.956 ; -0.912 ; 0.685 ; 0.687 ; -0.837 ; -0.536 ; -0.636 ; 0.288 ; -0.957 ; -0.806 ; -0.839 ; -0.609 ; -0.928 ; -0.699 ; -0.874 ; 0.941 ; -0.471 ; -0.824 ; -0.882 ; -0.911 ; -0.627 ; -0.986 ; -0.787 ; -0.753 ; -0.695 ; 0.393 ; -0.854 ; -0.828 ; -0.9 ; -0.663 ; -0.34 ; -0.866 ; -0.938 ; 0.086 ; -0.507 ; -0.842 ; -0.981 ; -0.214 ; 0.169 ; -0.648 ; 0.847 ; -0.718 ; 0.816 ; 0.835 ; -0.273 ; -0.734 ; -0.777 ; -0.795 ; -0.949 ; 0.665 ; -0.992 ; -1 ; 0.887 ; -0.829 ; -0.894 ; -0.979 ; -0.988 ; -0.793 ; -0.527 ; -0.947 ; -0.936 ; -0.892 ; -0.903 ; -0.307 ; -0.959 ; 0.774 ; -0.958 ; -0.952 ; -0.868 ; -0.688 ; -0.553 ; -0.501 ; 0.875 ; -0.586 ; -0.739 ; 0.855 ; -0.81 ; 0.971 ; -0.686 ; -0.918 ; -0.707 ; 0.601 ; -0.923 ; 0.861 ; -0.078 ; 0.763 ; -0.732 ; -0.961 ; -0.66 ; 0.863 ; 0.876 ; 0.559 ; 0.776 ; 0.773 ; -0.966 ; 0.671 ; 0.965 ; 0.93 ; -0.665 ; -0.794 ; 0.907 ; 0.943 ; 0.974 ; 0.966 ; 0.683 ; 0.935 ; 0.558 ; 0.749 ; 0.572 ; 0.924 ; -0.164 ; 0.896 ; 0.928 ; -0.704 ; -0.726 ; -0.886 ; 0.638 ; -0.937 ; 0.92 ; 0.482 ; -0.759 ; -0.655 ; -0.312 ; 0.767 ; -0.518 ; 0.931 ; -0.891 ; -0.716 ; 0.874 ; -0.626 ; 0.888 ; 0.976 ; -0.727 ; 1 ; 0.613 ; 0.961 ; 0.894 ; -0.971 ; -0.494 ; -0.898 ; 0.314 ; -0.441 ; 0.509 ; 0.88 ; -0.672 ; -0.835 ; -0.697 ; -0.963 ; -0.696 ; -0.814 ; -0.698 ; -0.346 ; 0.906 ; -0.875 ; 0.043 ; -0.642 ; 0.508 ; -0.983 ; -0.466 ; -0.624 ; -0.664 ; -0.906 ; -0.524 ; -0.901 ; -0.79 ; -0.984 ; -0.888 ; -0.607 ; -0.917 ; -0.883 ; 0.172 ; -0.552 ; 0.881 ; -0.345 ; -0.653 ; -0.876 ; -0.708 ; -0.764 ; -0.969 ; -0.87 ; -0.26 ; -0.254 ; -0.852 ; 0.99 ; -0.651 ; -0.736 ; -0.804 ; -0.797 ; -0.633 ; 0.684 ; -0.658 ; -0.135 ; -0.498 ; -0.933 ; 0.933 ; 0.904 ; -0.856 ; -0.968 ; 0.381 ; -0.802 ; -0.927 ; -0.939 ; -0.922 ; 0.658 ; -0.343 ; -0.562 ; -0.615 ; -0.924 ; -0.945 ; -0.977 ; -0.512 ; -0.816 ; -0.896 ; -0.914 ; 0.526 ; -0.124 ; -0.864 ; -0.341 ; -0.09
BRAFV600E_RAS	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	BRAF600E mutation vs. RAS mutation sample	Sample	Ras-like ; Braf-like
DARK	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Primary exome sample with no driver found	Patient	
DIFFERENTIATION_SCORE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Differentiation Score	Sample	0.574 ; 2.072 ; 1.089 ; -0.309 ; -3.163 ; 1.894 ; -0.739 ; 1.917 ; 1.126 ; 1.914 ; -0.576 ; 0.834 ; 1.844 ; -0.606 ; -0.32 ; 0.937 ; -0.546 ; 0.708 ; 1.588 ; 1.944 ; -0.422 ; -0.719 ; -1.737 ; 1.142 ; 0.833 ; 1.659 ; -0.303 ; 1.116 ; -0.664 ; 2.23 ; -0.017 ; 1.334 ; -1.19 ; 1.039 ; 1.163 ; 1.797 ; -1.849 ; -0.648 ; 1.387 ; -1.284 ; -1.116 ; -0.23 ; 1.42 ; -0.072 ; -1.484 ; -0.785 ; 0.185 ; 0.246 ; -1.411 ; -0.48 ; -1.247 ; 1.6 ; 0.352 ; 1.239 ; 1.169 ; 0.95 ; -0.54 ; 0.782 ; 1.135 ; -1.223 ; 0.014 ; -1.125 ; 0.651 ; 0.82 ; -0.83 ; -0.535 ; -0.846 ; 0.318 ; -1.056 ; -0.927 ; 1.648 ; 2.22 ; -1.027 ; 0.152 ; 0.357 ; 0.088 ; -0.439 ; 1.327 ; -0.834 ; -1.112 ; 0.494 ; -1.522 ; -0.746 ; 0.227 ; -1.088 ; 0.223 ; -1.222 ; 0.275 ; 0.087 ; -2.265 ; 1.842 ; 0.22 ; -0.226 ; -0.84 ; -1.029 ; -0.294 ; -0.561 ; 0.626 ; 1.293 ; -0.874 ; -0.778 ; -0.358 ; 0.03 ; -0.34 ; 0.665 ; -0.156 ; -0.321 ; 1.367 ; 1.838 ; 0.586 ; -0.29 ; 1.134 ; 0.841 ; -0.847 ; -0.753 ; -0.947 ; -1.14 ; -1.703 ; -0.187 ; 1.189 ; 0.9 ; -0.972 ; -0.071 ; 0.712 ; 1.77 ; -0.39 ; 0.315 ; 0.312 ; -0.083 ; -0.547 ; -1.133 ; -0.498 ; 1.783 ; 0.583 ; 0.32 ; -0.266 ; -0.584 ; -0.704 ; -1.366 ; -0.502 ; 0.239 ; 0.787 ; 1.645 ; -1.159 ; -1.193 ; 0.086 ; 0.359 ; 0.296 ; -0.841 ; 0.749 ; -0.116 ; -1.136 ; -1.155 ; 1.151 ; -1.216 ; -0.633 ; -1.543 ; -0.811 ; -0.627 ; -1.278 ; 1.302 ; -4.084 ; -0.548 ; 2.043 ; -1.147 ; 0.835 ; -1.412 ; 0.642 ; -0.931 ; 1.008 ; 0.38 ; -0.507 ; -0.691 ; 0.036 ; 0.598 ; -1.695 ; -1.052 ; 1.49 ; 2.226 ; -0.63 ; -1.826 ; -1.766 ; -0.839 ; -0.66 ; -1.925 ; -2.059 ; -1.398 ; -1.129 ; -0.981 ; 1.232 ; -1.945 ; 1.235 ; -0.982 ; -0.505 ; -1.491 ; -0.391 ; -1.905 ; 0.803 ; 0.362 ; 2.048 ; -0.261 ; -1.637 ; 1.066 ; -0.416 ; 1.38 ; -0.365 ; -1.131 ; -0.854 ; 1.549 ; -2.018 ; 0.257 ; 1.155 ; -1.573 ; -0.379 ; 0.083 ; 0.003 ; -0.283 ; -0.674 ; -0.681 ; 1.576 ; 0.911 ; 0.405 ; 0.979 ; 2.203 ; 2.085 ; 1.063 ; 1.247 ; 2.152 ; 1.988 ; -1.09 ; -0.772 ; 1.515 ; 1.514 ; 1.353 ; 0.735 ; 1.52 ; 0.51 ; 1.516 ; 0.244 ; 0.852 ; 0.693 ; 1.795 ; 2.098 ; -0.506 ; 1.518 ; -0.734 ; -0.707 ; -0.244 ; -0.599 ; 1.869 ; 0.967 ; 0.136 ; 1.613 ; 0.161 ; 0.175 ; 0.843 ; -0.726 ; 1.634 ; 0.475 ; -0.542 ; 1.949 ; -1.69 ; 1.654 ; -0.951 ; 1.923 ; 0.888 ; -1.896 ; 1.712 ; 1.397 ; -0.491 ; 0.882 ; 1.657 ; -2.145 ; 0.924 ; -0.852 ; 1.274 ; 0.622 ; 0.301 ; -0.64 ; 1.747 ; -0.662 ; -0.5 ; -1.104 ; -0.932 ; -0.893 ; -0.353 ; -0.245 ; 1.17 ; 2.019 ; -0.386 ; -1.561 ; 0.636 ; -0.355 ; 0.481 ; -1.069 ; -0.61 ; -0.275 ; 1.094 ; -0.408 ; 0.146 ; -1.402 ; -1.277 ; -0.466 ; 0.127 ; -1.487 ; -0.204 ; 0.985 ; 2.588 ; -0.651 ; 1.183 ; -1.302 ; 0.032 ; -2.393 ; -1.414 ; -0.696 ; -0.752 ; -0.497 ; -1.348 ; -0.583 ; -0.862 ; -0.517 ; -1.089 ; -1.6 ; -0.447 ; 0.126 ; 0.049 ; -0.389 ; 1.806 ; 0.23 ; 0.045 ; -1.135 ; 1.798 ; -0.177 ; 1.156 ; 1.818 ; 2.533 ; -0.108 ; 1.958 ; -0.075 ; 0.575 ; 1.171 ; -1.536 ; 1.796 ; -1.031 ; 1.609 ; 2.131 ; -0.02 ; -0.286 ; -1.068 ; -1.316 ; 0.807 ; 0.681 ; -0.477 ; -0.377 ; -0.424 ; -1.403 ; -0.853 ; -1.515 ; 0.552 ; -2.175 ; -1.076 ; 0.353 ; -0.73 ; -0.758 ; -1.717 ; -1.092 ; -0.878 ; -1.418 ; -1.47 ; -1.481 ; -1.034 ; 0.609 ; 0.912 ; -0.8 ; -0.463 ; 0.21
ERK_SCORE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	ERK Score	Sample	-17.459 ; -33.967 ; -34.307 ; 11.636 ; 46.506 ; -5.677 ; 6.38 ; -61.525 ; -22.865 ; -24.457 ; 20.738 ; -6.458 ; -14.799 ; 13.053 ; -26.746 ; -29.446 ; 12.726 ; -29.298 ; -18.365 ; -22.241 ; 7.713 ; 18.52 ; 21.239 ; -7.43 ; 3.84 ; -51.68 ; 10.58 ; -1.897 ; 15.439 ; -22.675 ; 19.94 ; 3.106 ; 9.454 ; 6.041 ; -13.422 ; -2.132 ; 22.855 ; 42.551 ; -9.911 ; 21.314 ; -4.272 ; 35.464 ; 1.17 ; 12.75 ; 26.319 ; 21.136 ; 2.385 ; 23.922 ; 12.002 ; 21.947 ; 11.991 ; -16.057 ; 28.685 ; -18.343 ; 5.316 ; 11.305 ; -0.71 ; -32.349 ; -13.029 ; 26.617 ; 7.683 ; 16.435 ; -28.882 ; 16.712 ; 31.75 ; 25.764 ; 8.539 ; -11.251 ; 16.364 ; 21.679 ; -26.819 ; 0.296 ; 15.349 ; 14.575 ; 1.573 ; 16.42 ; -2.821 ; -11.454 ; 1.712 ; 11.936 ; 5.749 ; 40.425 ; 13.054 ; 19.747 ; 20.908 ; 1.317 ; 8.402 ; -0.836 ; -32.596 ; 44.541 ; -8.327 ; 10.432 ; 10.595 ; 16.257 ; 24.248 ; 4.639 ; 33.358 ; -12.064 ; -4.824 ; 16.194 ; 1.721 ; 11.538 ; -3.935 ; 17.405 ; -18.599 ; 14.177 ; -5.092 ; -2.76 ; 0.236 ; -4.538 ; 19.413 ; 3.119 ; 12.613 ; 21.73 ; 4.263 ; 20.412 ; 19.875 ; 33.115 ; 46.883 ; -15.666 ; 9.282 ; -9.745 ; 15.353 ; 23.07 ; -6.063 ; 24.017 ; 7.433 ; 27.128 ; 20.557 ; 11.199 ; 1.098 ; -0.576 ; 0.524 ; 14.614 ; 8.098 ; 9.166 ; 16.092 ; -2.731 ; 22.616 ; 19.955 ; 23.818 ; 10.952 ; -18.58 ; 28.246 ; 17.785 ; 16.363 ; 15.81 ; -0.552 ; 17.252 ; -1.51 ; 28.718 ; 18.504 ; 11.208 ; 42.767 ; 15.501 ; 21.81 ; 27.979 ; 7.727 ; 7.956 ; 36.446 ; 3.243 ; 3.603 ; 44.866 ; -13.759 ; 4.353 ; -13.493 ; 9.036 ; -6.494 ; 30.224 ; 4.433 ; 31.897 ; 12.381 ; 18.156 ; 21.5 ; 15.793 ; 19.241 ; 32.27 ; -6.711 ; -35.056 ; 4.982 ; 16.645 ; 21.89 ; 15.606 ; 11.791 ; 25.249 ; 41.33 ; 15.823 ; 17.16 ; 15.663 ; 43.049 ; 28.512 ; -3.978 ; 31.809 ; 16.582 ; 24.455 ; 24.088 ; 60.386 ; 12.061 ; 12.112 ; -9.832 ; 30.277 ; -0.378 ; -13.574 ; 16.354 ; -3.689 ; 51.797 ; 8.635 ; 19.438 ; 16.071 ; -5.109 ; 4.222 ; -25.657 ; 17.899 ; 29.643 ; 10.058 ; -7.518 ; 4.212 ; -8.948 ; 0.321 ; 0.226 ; -15.123 ; -26.429 ; 2.488 ; -36.566 ; -10.887 ; -32.378 ; 30.723 ; -36.378 ; -1.054 ; -5.213 ; -21.639 ; -3.046 ; 24.492 ; -35.353 ; -32.465 ; -23.131 ; -20.227 ; -8.759 ; -18.135 ; -21.015 ; -16.37 ; -14.129 ; -7.498 ; 16.153 ; -57.985 ; -31.595 ; 7.728 ; -54.985 ; 15.468 ; 13.765 ; 11.394 ; -7.735 ; 5.918 ; -27.705 ; 8.938 ; 13.389 ; -19.959 ; 19.01 ; 9.927 ; -1.793 ; 9.449 ; -10.258 ; 14.395 ; 17.986 ; -26.22 ; 6.492 ; -26.808 ; 30.618 ; -12.198 ; 28.081 ; -16.945 ; 37.298 ; -28.823 ; -0.154 ; -26.211 ; -10.16 ; -26.499 ; -12.373 ; -13.423 ; 14.891 ; 15.065 ; 2.155 ; -10.074 ; 9.353 ; -2.491 ; 23.363 ; -4.307 ; 16.353 ; 37.808 ; -7.114 ; 12.187 ; -0.358 ; 18.749 ; 9.706 ; 1.037 ; -7.841 ; -11.971 ; 26.431 ; 22.908 ; 21.578 ; 12.032 ; -1.565 ; 6.312 ; 5.518 ; 12.491 ; 25.224 ; 1.792 ; 26.863 ; 10.613 ; 8.485 ; 22.243 ; 1.557 ; 16.806 ; 16.816 ; 1.774 ; 19.596 ; 15.735 ; 23.543 ; 25.456 ; 11.944 ; -63.282 ; 4.381 ; -29.729 ; 8.783 ; 27.84 ; -43.083 ; 16.989 ; 7.947 ; -10.317 ; 23.247 ; 16.464 ; 44.713 ; 13.115 ; 25.274 ; 18.268 ; 17.846 ; 11.957 ; 28.929 ; 21.196 ; 11.335 ; -38.422 ; 30.648 ; 40.651 ; 4.396 ; -28.378 ; 0.721 ; 16.707 ; -5.729 ; -56.894 ; 7.216 ; -28.621 ; 8.58 ; 20.505 ; 4.568 ; 17.572 ; -5.863 ; 13.847 ; -14.842 ; -7.784 ; 8.266 ; 28.571 ; 12.119 ; 14.911 ; -19.636 ; 2.83 ; -3.14 ; 14.206 ; 18.995 ; 6.145 ; 12.408 ; 6.931 ; 16.263 ; -6.429 ; 37.012 ; 18.65 ; 6.071 ; 12.276 ; 35.395 ; 17.156 ; -1.5 ; 6.884 ; 17.422 ; 2.605 ; 10.146 ; 15.556 ; 23.609 ; -6.366 ; 26.303 ; 23.827 ; 28.862 ; 22.876
EXTRATHYROIDAL_EXTENSION	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Extrathyroidal Extension	Sample ; Patient	Minimal (T3) ; Moderate/Advanced (T4a) ; Very Advanced (T4b) ; [Unknown]
FOCAL_DRIVER_CN	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Gene with focal SCNA, CN level	Sample	PTEN:1.032 ; PTEN:1.426 ; PTEN:1.311 ; BRAF:1.823 ; BRAF:1.723 ; PTEN:1.506 ; BRAF:1.738 ; PTEN:1.608 ; BRAF:1.734
FOLLICULAR_COMPONENT_PERCENT	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Percentage of follicular component	Sample	100 ; 90 ; (>= 99%) ; 10 ; 80 ; 30 ; 70 ; 60 ; 20 ; 0 ; 50 ; 40
GERMLINE_MUT_GENES_VARIANT	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Germline nonsense or indels within a set of genes: variant type	Sample	FAM176A:In_Frame_Del ; BRCA2:Nonsense_Mutation ; SOX4:In_Frame_Del ; FANCM:Nonsense_Mutation ; GNA14:Nonsense_Mutation ; MSH6:Frame_Shift_Ins ; BRCA2:Frame_Shift_Del ; FANCM:In_Frame_Del ; FANCD2:Frame_Shift_Del,ATM:Nonsense_Mutation ; BRCA2:Nonsense_Mutation,PIK3CG:In_Frame_Del ; SPOCK2:In_Frame_Del ; PPL:In_Frame_Ins ; PPL:In_Frame_Del,BRCA2:Nonsense_Mutation ; LAMB3:Frame_Shift_Del ; MLEC:In_Frame_Del ; NQO1:Frame_Shift_Del ; ITGB8:Nonsense_Mutation ; MAP3K1:In_Frame_Del ; SLC35F2:Nonsense_Mutation ; SORBS2:Frame_Shift_Del ; SRCAP:In_Frame_Del,TMEM43:Nonsense_Mutation ; CHEK2:Frame_Shift_Del,FANCF:Nonsense_Mutation ; FANCM:Frame_Shift_Del ; CHEK2:Frame_Shift_Del ; ABTB2:Nonsense_Mutation ; RUNX2:In_Frame_Del ; TMEM43:In_Frame_Del ; BRCA2:In_Frame_Del ; BRCA1:Frame_Shift_Del ; FAM176A:In_Frame_Del,MAP3K1:In_Frame_Del ; PPL:In_Frame_Del ; FN1:In_Frame_Del ; TBC1D2:Frame_Shift_Del ; MAP3K1:In_Frame_Del,PPL:In_Frame_Ins
HISTOLOGICAL_TYPE_OTHER	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Text field to describe the tumor histological type (cancer type).	Sample	columnar cell variant ; encapsulated follicular ; Papillary carcinoma, diffuse sclerosing variant ; Papillary carcinoma: mixed papillary and follicular variant ; cribriform morular ; cribiform morular ; Diffuse sclerosing variant ; Diffuse Sclerosing Variant
HISTORY_RADIATION_EXPOSURE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Person lifetime risk radiation exposure indicator	Patient	
LOWPASS	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Lowpass WGS sequenced sample	Sample	No ; Yes
MACIS_SCORE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	MACIS Score	Patient	
MB_COV	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	MB Cov	Patient	
METHOD_PURITY	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Method for purity (ABSOLUTE SNP AC, or AF for mutation allele fraction only)	Sample	AF ; SNP ; AC
MRNA_CLUSTER	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	MRNA Cluster	Sample	1 ; 2 ; 3 ; 5 ; 4
MUT_CANCER_GENE_CENSUS_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Mutation Cancer Gene Census Protein Change	Sample	AXIN1:p.A330V:14 ; PTEN:p.L139*:20,PPP2R1A:p.M291K:4,FANCF:p.V273G:5 ; HRAS:p.Q61R:61 ; CTNNB1:p.P744T:6,CACNA1D:p.G674D:4,BRAF:p.V600E:26 ; BRAF:p.V600E:20 ; NRAS:p.Q61R:102,LPP:p.N477S:35 ; FANCD2:p.M507V:6,CSF3R:p.G415R:139,BRAF:p.V600E:38 ; MITF:p.N190S:41,MEN1:p.L173fs:21,KRAS:p.Q61R:34 ; SETD2:p.E1138D:12,BRCA2:p.H2932Y:9,BRAF:p.V600E:33 ; HRAS:p.Q61K:49 ; TPM3:p.Y163H:47,BRAF:p.V600E:36 ; BRAF:p.598_599insNIFLHEDLTVKIGDFGLA:35 ; ATM:p.L2452P:3 ; NSD1:p.I2394fs:44,JAK1:p.V764I:42 ; BRAF:p.V600E:29 ; IL7R:p.R291T:11,BRAF:p.V600E:23 ; NRAS:p.Q61R:56,ERG:p.E129Q:12 ; NRAS:p.Q61R:60 ; UBR5:p.A1768V:10 ; WHSC1L1:p.S138L:23,SLC34A2:p.T688M:20,NKX2-1:p.K25N:3,BRAF:p.V600E:18 ; HRAS:p.Q61R:33 ; PIK3CA:p.M1043I:40,BRAF:p.V600E:46 ; GNAS:p.Q870H:13 ; BRAF:p.V600E:6 ; NRAS:p.Q61R:85,CHEK2:p.Y390*:8 ; BRAF:p.V600E:38 ; HRAS:p.Q61R:32 ; NRAS:p.Q61R:31 ; NRAS:p.Q61R:52 ; BRAF:p.V600E:7 ; MET:p.E1378Q:11,LPP:p.E392Q:8,BRAF:p.V600E:24 ; BRAF:p.V600E:21 ; BRAF:p.V600E:30,AKT1:p.E133D:22 ; BRAF:p.V600E:35 ; TFE3:p.R412Q:8,CHEK2:p.N186S:6 ; KDR:p.E759K:4,BRAF:p.V600E:22 ; BRAF:p.V600E:58 ; MYC:p.L348P:3 ; KDR:p.M1285T:8 ; HRAS:p.Q61R:62 ; BRAF:p.V600E:14 ; MLL:p.D2718V:5,BRAF:p.V600E:49 ; NRAS:p.Q61R:124 ; NUMA1:p.H74R:63,BRAF:p.V600E:42,BCL9:p.R584I:6 ; BRAF:p.V600E:33 ; BRAF:p.V600E:34 ; BRAF:p.V600E:18 ; BRAF:p.V600E:32 ; BRAF:p.V600E:30 ; NRAS:p.Q61R:55,CHEK2:p.L391F:26,CDH11:p.D355Y:29 ; WRN:p.L1178P:21 ; BRAF:p.V600E:10 ; BRAF:p.V600E:36 ; MN1:p.533_534QQ>Q:4,BRAF:p.V600E:15 ; BRAF:p.V600E:25 ; BRAF:p.V600E:28 ; SETBP1:p.D61V:12,BRAF:p.V600E:41 ; NRAS:p.Q61R:72 ; BRAF:p.V600E:19 ; BRAF:p.V600E:23 ; SMARCA4:p.P930L:3,BRAF:p.V600E:35 ; BRAF:p.V600E:22 ; MLL3:p.Q3591*:5,HOOK3:p.S232C:34,BRAF:p.V600E:33 ; BRAF:p.V600E:24 ; DNMT3A:p.W313*:7,ATP1A1:p.V332G:12 ; BRAF:p.V600E:8 ; BRAF:p.V600E:27 ; FCGR2B:p.L62P:21,BRAF:p.V600E:27 ; CREBBP:p.L673*:7 ; BRAF:p.V600E:3 ; MLL3:p.S3213L:36,BRAF:p.V600E:22 ; HRAS:p.Q61R:15,CDKN2C:p.D67N:30 ; BRIP1:p.G509F:6,BRAF:p.V600E:19 ; BRAF:p.V600E:41 ; YWHAE:p.D157V:10,SYK:p.T283A:6,PLAG1:p.P457S:4,GMPS:p.V219M:3,BRAF:p.V600E:35 ; NRAS:p.Q61R:88 ; GNAS:p.G251R:15,BRAF:p.V600E:43 ; TSHR:p.I640V:5,NRAS:p.Q61R:96 ; BRAF:p.V600E:16 ; CACNA1D:p.W372C:6,BRAF:p.V600E:24 ; RB1:p.R798W:24,BRAF:p.V600E:48 ; TRRAP:p.G1498R:47,BRAF:p.V600E:34 ; BRAF:p.V600E:39 ; BRAF:p.V600E:44,AKT1:p.E17K:9 ; BRAF:p.PTPQQ490del:4 ; NSD1:p.N1488S:16,BRAF:p.V600E:23,APC:p.D1714Y:10 ; CLTCL1:p.A381T:3,CD74:p.S183fs:2,BRAF:p.V600E:26 ; MYST4:p.E999Q:5,BRAF:p.V600E:17 ; FBXO11:p.R593T:6,ERCC3:p.K557N:5,BRAF:p.V600E:2,ARID2:p.Q1031*:9 ; BRAF:p.V600E:45 ; NSD1:p.K513R:3,HRAS:p.Q61K:73 ; BCL11A:p.E611K:16 ; BRAF:p.V600E:42 ; KDM6A:p.K768E:26,BRAF:p.V600E:24 ; CTNNB1:p.Y716C:4,BRAF:p.V600E:42 ; BRAF:p.V600E:13 ; PDE4DIP:p.E2276K:23,BRAF:p.V600E:9 ; MLL:p.S3515V:58,BRAF:p.V600E:46,AKT1:p.E17K:17 ; MLL:p.Q3621H:4,BRAF:p.V600E:28 ; SF3B1:p.T7I:23,RARA:p.I258fs:17,BRAF:p.V600E:43 ; BRAF:p.V600E:5 ; FANCG:p.E48fs:2,BRAF:p.V600E:21 ; BRAF:p.V600E:17 ; NF2:p.V146I:3,BRAF:p.V600E:40 ; DNMT3A:p.Q402*:5,BRAF:p.V600E:28 ; EZR:p.L104F:30,CCDC6:p.Q24*:16,BRAF:p.V600E:28 ; PRDM16:p.P55L:24,BRAF:p.V600E:22 ; BRAF:p.V600E:12 ; APC:p.R213*:16 ; BRAF:p.V600E:65,BCOR:p.D1226fs:59 ; IL7R:p.S360G:28,BRAF:p.V600E:40 ; TP53:p.E343fs:26,DICER1:p.E1813G:117 ; TP53:p.Q375*:6,BRAF:p.V600E:32 ; DICER1:p.D1810H:92 ; USP6:p.Y1366*:44,BRAF:p.V600E:24 ; BRAF:p.V600E:37 ; SDC4:p.Q136R:41,BRAF:p.V600E:29 ; TTL:p.S151L:16,NIN:p.G2027R:19,BRAF:p.V600E:25,BCL9:p.K86N:20 ; NF1:p.K1568R:4,GOLGA5:p.I703M:11,BRAF:p.V600E:44,ATRX:p.K299E:6 ; NRAS:p.Q61R:80,FANCG:p.W16*:31 ; ETV1:p.P221A:5,BRAF:p.V600E:32,ABL1:p.E453K:5 ; STAT5B:p.E710_splice:9 ; BRCA2:p.A2738S:27,BRAF:p.V600E:25 ; SETBP1:p.E446D:6,BRAF:p.V600E:27 ; EBF1:p.R381G:4,BRAF:p.V600E:31 ; ETV5:p.R464C:28,BRAF:p.V600E:25 ; TERT:p.R470H:5,PPP2R1A:p.A273V:29,BRAF:p.V600E:39 ; CLTCL1:p.K1163R:3,BRAF:p.V600E:25 ; LCK:p.I17T:4 ; ROS1:p.P1020H:21,FH:p.Q376H:31,BRAF:p.V600E:40 ; WHSC1L1:p.P464L:34,STAG2:p.I910R:38,NRAS:p.Q61R:69 ; MLLT4:p.Q1446E:17,IRF4:p.S435N:3,ERBB2:p.K937R:4,BRAF:p.V600E:31 ; BRAF:p.V600E:31 ; NTRK3:p.N294T:33 ; RBM15:p.S212R:37 ; NRAS:p.Q61R:57,MLL:p.N1653T:5 ; HRAS:p.Q61R:80 ; TFE3:p.L120R:8,BRAF:p.V600E:49 ; HRAS:p.Q61R:29 ; BRAF:p.V600E:11 ; BRAF:p.V600E:19,AKT2:p.E17K:12 ; SSX1:p.F79I:62,BRAF:p.V600E:25 ; NRAS:p.Q61R:67,CHEK2:p.L462I:6 ; NRAS:p.Q61K:84 ; PDE4DIP:p.Q849R:10 ; MLL3:p.K3847N:27,BRAF:p.V600E:22,BCL6:p.S597C:19 ; RB1:p.P827S:24,NRAS:p.Q61R:95 ; BRAF:p.V600E:36,ATM:p.T1908fs:23 ; NF1:p.E244_splice:19 ; VTI1A:p.E143_splice:19,TP53:p.Q192*:9,RUNDC2A:p.A47V:27 ; ATM:p.W2845C:98 ; WT1:p.R443S:4 ; MYST4:p.L154R:3,MKL1:p.P451S:5 ; BRAF:p.V600E:9 ; NOTCH2:p.D1921A:3,HRAS:p.Q61K:47 ; NRAS:p.Q61K:64 ; BRAF:p.V600E:14,ATM:p.L2132V:29 ; NRAS:p.Q61K:55 ; TCF3:p.R105Q:9 ; PCM1:p.F1253C:6,HRAS:p.Q61R:52 ; NRAS:p.Q61R:116 ; KRAS:p.G12V:7,ELF4:p.T565N:41 ; NRAS:p.Q61R:62 ; NRAS:p.Q61R:55,DICER1:p.R1906S:59 ; TSHR:p.M453T:52 ; BRAF:p.V600E:15 ; PRDM16:p.DLDS624del:32,BRAF:p.V600E:23 ; KIAA1549:p.E968K:22,BRAF:p.TAPTP488del:19 ; BRCA2:p.C1820R:3,BRAF:p.V600E:26 ; ELL:p.V196M:25 ; NRAS:p.Q61K:90 ; KDM5A:p.K1162Q:28 ; NUP214:p.A187T:15,BRAF:p.V600E:25 ; PMS1:p.S803G:16 ; PTEN:p.D252V:33,PIK3R1:p.P617R:34,PDGFRB:p.G805S:34,BCOR:p.R1261G:3 ; BRAF:p.V600E:54 ; BRAF:p.K601E:43 ; CDK12:p.E1162K:12,BAP1:p.E31G:9 ; NRAS:p.Q61K:99 ; NRAS:p.Q61R:95 ; NRAS:p.Q61R:66 ; PCSK7:p.N334S:4,BRAF:p.V600E:23 ; BRAF:p.V600E:26 ; KRAS:p.Q61K:10,BRAF:p.V600E:5 ; NRAS:p.Q61R:36 ; NRAS:p.Q61K:56 ; JUN:p.S17L:15,BRAF:p.V600E:25,ABL2:p.S1080*:8 ; BRAF:p.V600E:63 ; SOX2:p.D39fs:19,HRAS:p.Q61R:38,ASXL1:p.G1299D:27 ; MLLT1:p.N115S:61,HRAS:p.Q61R:39 ; BRAF:p.V600E:51 ; IL7R:p.R267M:33,BRAF:p.V600E:23 ; C15orf55:p.R1108Q:5,BRAF:p.V600E:34 ; BRCA1:p.V412I:9 ; ZNF384:p.R337C:27,BRAF:p.V600E:24 ; TRIP11:p.E842K:5,BRAF:p.V600E:16 ; MLL3:p.S2184C:6,MLL3:p.H2006Y:15,MLL3:p.S1955F:12,MLL3:p.Q1791*:15,BRAF:p.V600E:19 ; NKX2-1:p.K163E:9,BRAF:p.V600E:37 ; TRRAP:p.I333T:3,BRAF:p.V600E:13 ; PHF6:p.G93C:15,BRAF:p.V600E:31 ; CHN1:p.I336T:21,BRAF:p.V600E:38 ; PIK3CA:p.G118D:11,BRAF:p.V600E:55,AKAP9:p.H2680R:3 ; MSI2:p.A268V:5,AKAP9:p.R3668G:3 ; ALK:p.P693S:3 ; PDE4DIP:p.Q2060K:8,MLL:p.K1574R:3,FBXO11:p.Q72*:5 ; TERT:p.S602L:5 ; COL1A1:p.P147fs:2 ; MLL:p.N3061S:31,BRAF:p.V600E:29 ; NUP214:p.N1350S:13,BRAF:p.V600E:15 ; ZNF521:p.V934M:22,HOOK3:p.A715T:4 ; DNMT3A:p.P195L:8 ; NRAS:p.Q61R:39,CLTCL1:p.L1376F:3 ; SUFU:p.Q212*:18,BRAF:p.V600E:49 ; NRAS:p.Q61K:83 ; BRAF:p.V600E:68 ; NRAS:p.Q61R:81 ; NRAS:p.Q61R:59 ; KRAS:p.Q61K:24 ; BRAF:p.V600E:43 ; SEPT6:p.Y298D:50,POU2AF1:p.P93L:3,GNAS:p.E52K:2,FANCD2:p.G713D:4,BRAF:p.V600E:52 ; CD74:p.E278K:4,BRAF:p.V600E:37 ; NRAS:p.Q61R:62,FANCD2:p.V670A:28 ; BRAF:p.V600E:36,ATM:p.T2228I:53 ; CHEK2:p.H143Q:39,BRAF:p.V600E:16 ; SF3B1:p.M876L:17,BRAF:p.V600E:20 ; MLL:p.K2779E:23,BRAF:p.V600E:27 ; FGFR2:p.K296N:8,BRAF:p.V600E:12 ; BRAF:p.598_599insKIGDFGLA:13 ; MSH2:p.R383L:37,BRAF:p.V600E:37
MUT_CLINDX_TX_GENE_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Clinicaly relevant gene non-silent mutations; protein-change, alt allele counts	Sample	MAP3K1:p.L1354V:3,PTEN:p.L139*:20 ; HRAS:p.Q61R:61 ; CTNNB1:p.P744T:6,BRAF:p.V600E:26 ; BRAF:p.V600E:20 ; NRAS:p.Q61R:102 ; ATR:p.R993_splice:3,BRAF:p.V600E:38 ; MITF:p.N190S:41,MEN1:p.L173fs:21,KRAS:p.Q61R:34 ; BRCA2:p.H2932Y:9,BRAF:p.V600E:33 ; HRAS:p.Q61K:49 ; BRAF:p.V600E:36 ; ATR:p.L1013V:27,BRAF:p.598_599insNIFLHEDLTVKIGDFGLA:35 ; ATM:p.L2452P:3 ; BRAF:p.V600E:29 ; BRAF:p.V600E:23 ; ERG:p.E129Q:12,NRAS:p.Q61R:56 ; NRAS:p.Q61R:60 ; NKX2-1:p.K25N:3,BRAF:p.V600E:18 ; HRAS:p.Q61R:33 ; PIK3CA:p.M1043I:40,BRAF:p.V600E:46 ; GNAS:p.Q870H:13 ; BRAF:p.V600E:6 ; PTCH1:p.T778M:4,NRAS:p.Q61R:85 ; BRAF:p.V600E:38 ; HRAS:p.Q61R:32 ; NRAS:p.Q61R:31 ; NRAS:p.Q61R:52 ; BRAF:p.V600E:7 ; MET:p.E1378Q:11,BRAF:p.V600E:24 ; BRAF:p.V600E:21 ; ERBB4:p.S1105C:37,BRAF:p.V600E:30,AKT1:p.E133D:22 ; BRAF:p.V600E:35 ; KDR:p.E759K:4,BRAF:p.V600E:22 ; BRAF:p.V600E:58 ; MYC:p.L348P:3 ; KDR:p.M1285T:8 ; HRAS:p.Q61R:62 ; BRAF:p.V600E:14 ; MLL:p.D2718V:5,BRAF:p.V600E:49 ; NRAS:p.Q61R:124 ; BRAF:p.V600E:42 ; BRAF:p.V600E:33 ; BRAF:p.V600E:34 ; BRAF:p.V600E:18 ; BRAF:p.V600E:32 ; BRAF:p.V600E:30 ; NRAS:p.Q61R:55 ; IGF1R:p.P327H:3,BRAF:p.V600E:33 ; BRAF:p.V600E:10 ; BRAF:p.V600E:15 ; BRAF:p.V600E:25 ; BRAF:p.V600E:28 ; BRAF:p.V600E:41 ; NRAS:p.Q61R:72 ; BRAF:p.V600E:19 ; SMARCA4:p.P930L:3,BRAF:p.V600E:35 ; BRAF:p.V600E:22 ; BRAF:p.V600E:24 ; DNMT3A:p.W313*:7 ; BRAF:p.V600E:8 ; BRAF:p.V600E:27 ; CREBBP:p.L673*:7 ; BRAF:p.V600E:3 ; HRAS:p.Q61R:15 ; SYK:p.T283A:6,BRAF:p.V600E:35 ; NRAS:p.Q61R:88 ; GNAS:p.G251R:15,BRAF:p.V600E:43 ; NRAS:p.Q61R:96 ; ESR1:p.W383*:3,BRAF:p.V600E:30 ; BRAF:p.V600E:16 ; RB1:p.R798W:24,BRAF:p.V600E:48 ; BRAF:p.V600E:39 ; BRAF:p.V600E:44,AKT1:p.E17K:9 ; BRAF:p.PTPQQ490del:4 ; APC:p.D1714Y:10,BRAF:p.V600E:23 ; ATR:p.Q1073*:16,BRAF:p.V600E:26 ; BRAF:p.V600E:17 ; BRAF:p.V600E:2 ; BRAF:p.V600E:45 ; HRAS:p.Q61K:73 ; CTNNB1:p.Y716C:4,BRAF:p.V600E:42 ; BRAF:p.V600E:13 ; BRAF:p.V600E:9 ; MLL:p.S3515V:58,BRAF:p.V600E:46,AKT1:p.E17K:17 ; MLL:p.Q3621H:4,BRAF:p.V600E:28 ; RARA:p.I258fs:17,BRAF:p.V600E:43 ; BRAF:p.V600E:5 ; NF2:p.V146I:3,BRAF:p.V600E:40 ; DNMT3A:p.Q402*:5,BRAF:p.V600E:28 ; ERBB3:p.H768R:16,PTCH1:p.A507V:9,BRAF:p.V600E:28 ; BRAF:p.V600E:12 ; APC:p.R213*:16 ; BRAF:p.V600E:65 ; BRAF:p.V600E:40 ; TP53:p.E343fs:26 ; TP53:p.Q375*:6,BRAF:p.V600E:32 ; BRAF:p.V600E:37 ; NF1:p.K1568R:4,BRAF:p.V600E:44 ; NRAS:p.Q61R:80 ; ETV1:p.P221A:5,ABL1:p.E453K:5,BRAF:p.V600E:32 ; ERBB4:p.V1307L:3 ; BRCA2:p.A2738S:27,BRAF:p.V600E:25 ; BRAF:p.V600E:31 ; ETV5:p.R464C:28,BRAF:p.V600E:25 ; ROS1:p.P1020H:21,BRAF:p.V600E:40 ; NRAS:p.Q61R:69 ; ERBB2:p.K937R:4,BRAF:p.V600E:31 ; NTRK3:p.N294T:33 ; MLL:p.N1653T:5,NRAS:p.Q61R:57 ; HRAS:p.Q61R:80 ; BRAF:p.V600E:49 ; HRAS:p.Q61R:29 ; BRAF:p.V600E:11 ; BRAF:p.V600E:19,AKT2:p.E17K:12 ; NRAS:p.Q61R:67 ; NRAS:p.Q61K:84 ; RB1:p.P827S:24,NRAS:p.Q61R:95 ; ATM:p.T1908fs:23,BRAF:p.V600E:36 ; NF1:p.E244_splice:19 ; TP53:p.Q192*:9 ; ATM:p.W2845C:98 ; WT1:p.R443S:4 ; NOTCH2:p.D1921A:3,HRAS:p.Q61K:47 ; NRAS:p.Q61K:64 ; ATM:p.L2132V:29,BRAF:p.V600E:14 ; NRAS:p.Q61K:55 ; HRAS:p.Q61R:52 ; NRAS:p.Q61R:116 ; KRAS:p.G12V:7 ; NRAS:p.Q61R:62 ; BRAF:p.TAPTP488del:19 ; BRCA2:p.C1820R:3,BRAF:p.V600E:26 ; NRAS:p.Q61K:90 ; PIK3R1:p.P617R:34,PTEN:p.D252V:33,PDGFRB:p.G805S:34 ; BRAF:p.V600E:54 ; BRAF:p.K601E:43 ; BAP1:p.E31G:9 ; NRAS:p.Q61K:99 ; NRAS:p.Q61R:95 ; NRAS:p.Q61R:66 ; BRAF:p.V600E:26 ; KRAS:p.Q61K:10,BRAF:p.V600E:5 ; NRAS:p.Q61R:36 ; NRAS:p.Q61K:56 ; BRAF:p.V600E:63 ; HRAS:p.Q61R:38,ASXL1:p.G1299D:27 ; HRAS:p.Q61R:39 ; BRAF:p.V600E:51 ; MAP3K1:p.G1311*:3 ; BRCA1:p.V412I:9 ; NKX2-1:p.K163E:9,BRAF:p.V600E:37 ; CDKN1A:p.R9P:7 ; PIK3CA:p.G118D:11,BRAF:p.V600E:55 ; ALK:p.P693S:3 ; MLL:p.K1574R:3 ; MLL:p.N3061S:31,BRAF:p.V600E:29 ; DNMT3A:p.P195L:8 ; NRAS:p.Q61R:39 ; NRAS:p.Q61K:83 ; BRAF:p.V600E:68 ; NRAS:p.Q61R:81 ; NRAS:p.Q61R:59 ; KRAS:p.Q61K:24 ; BRAF:p.V600E:43 ; GNAS:p.E52K:2,BRAF:p.V600E:52 ; ATM:p.T2228I:53,BRAF:p.V600E:36 ; MLL:p.K2779E:23,BRAF:p.V600E:27 ; FGFR2:p.K296N:8,BRAF:p.V600E:12 ; BRAF:p.598_599insKIGDFGLA:13 ; MSH2:p.R383L:37,BRAF:p.V600E:37
MUT_DNAREPAIR_GENE_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	DNA repair gene non-silent mutations ; protein-change, alt allele counts	Sample	FANCF:p.V273G:5 ; FANCD2:p.M507V:6,ATR:p.R993_splice:3 ; BRCA2:p.H2932Y:9 ; ATR:p.L1013V:27 ; ATM:p.L2452P:3 ; CHEK2:p.Y390*:8 ; CHEK2:p.N186S:6 ; CHEK2:p.L391F:26 ; PPM1D:p.C478fs:5 ; PPM1D:p.N574fs:22 ; ATR:p.Q1073*:16 ; PPM1D:p.L482fs:37 ; FANCG:p.E48fs:2 ; TP53:p.E343fs:26 ; TP53:p.Q375*:6 ; FANCG:p.W16*:31 ; BRCA2:p.A2738S:27 ; FANCM:p.M1561T:14 ; CHEK2:p.L462I:6 ; ATM:p.T1908fs:23 ; TP53:p.Q192*:9 ; ATM:p.W2845C:98 ; ATM:p.L2132V:29 ; BRCA2:p.C1820R:3 ; BRCA1:p.V412I:9 ; PPM1D:p.T406fs:34 ; PPM1D:p.D470N:3 ; FANCD2:p.G713D:4 ; FANCD2:p.V670A:28 ; ATM:p.T2228I:53 ; CHEK2:p.H143Q:39 ; MSH2:p.R383L:37
MUT_DRIVER_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Non-silent mutation protein change BRAF, HRAS, NRAS, KRAS, EIF1AX: number of alternate allele counts	Sample	HRAS:p.Q61R:61 ; BRAF:p.V600E:26 ; BRAF:p.V600E:20 ; NRAS:p.Q61R:102 ; BRAF:p.V600E:38 ; KRAS:p.Q61R:34 ; EIF1AX:p.G9D:63 ; BRAF:p.V600E:33 ; HRAS:p.Q61K:49 ; BRAF:p.V600E:36 ; BRAF:p.598_599insNIFLHEDLTVKIGDFGLA:35 ; BRAF:p.V600E:29 ; BRAF:p.V600E:23 ; NRAS:p.Q61R:56 ; NRAS:p.Q61R:60 ; BRAF:p.V600E:18 ; HRAS:p.Q61R:33 ; BRAF:p.V600E:46 ; BRAF:p.V600E:6 ; NRAS:p.Q61R:85 ; HRAS:p.Q61R:32 ; NRAS:p.Q61R:31 ; NRAS:p.Q61R:52 ; BRAF:p.V600E:7 ; BRAF:p.V600E:24 ; BRAF:p.V600E:21 ; BRAF:p.V600E:30 ; BRAF:p.V600E:35 ; BRAF:p.V600E:22 ; BRAF:p.V600E:58 ; HRAS:p.Q61R:62 ; BRAF:p.V600E:14 ; BRAF:p.V600E:49 ; NRAS:p.Q61R:124 ; BRAF:p.V600E:42 ; BRAF:p.V600E:34 ; BRAF:p.V600E:32 ; NRAS:p.Q61R:55 ; BRAF:p.V600E:10 ; BRAF:p.V600E:15 ; BRAF:p.V600E:25 ; BRAF:p.V600E:28 ; BRAF:p.V600E:41 ; NRAS:p.Q61R:72 ; BRAF:p.V600E:19 ; BRAF:p.V600E:8 ; BRAF:p.V600E:27 ; BRAF:p.V600E:3 ; HRAS:p.Q61R:15 ; NRAS:p.Q61R:88 ; BRAF:p.V600E:43 ; NRAS:p.Q61R:96 ; BRAF:p.V600E:16 ; BRAF:p.V600E:48 ; BRAF:p.V600E:39 ; BRAF:p.V600E:44 ; BRAF:p.PTPQQ490del:4 ; BRAF:p.V600E:17 ; BRAF:p.V600E:2 ; BRAF:p.V600E:45 ; HRAS:p.Q61K:73 ; BRAF:p.V600E:13 ; BRAF:p.V600E:9 ; BRAF:p.V600E:5 ; BRAF:p.V600E:40 ; EIF1AX:p.G9D:15 ; BRAF:p.V600E:12 ; BRAF:p.V600E:65 ; BRAF:p.V600E:37 ; NRAS:p.Q61R:80 ; BRAF:p.V600E:31 ; NRAS:p.Q61R:69 ; NRAS:p.Q61R:57 ; HRAS:p.Q61R:80 ; HRAS:p.Q61R:29 ; BRAF:p.V600E:11 ; NRAS:p.Q61R:67 ; NRAS:p.Q61K:84 ; NRAS:p.Q61R:95 ; EIF1AX:p.A113V:22,EIF1AX:p.A113_splice:21 ; HRAS:p.Q61K:47 ; NRAS:p.Q61K:64 ; NRAS:p.Q61K:55 ; HRAS:p.Q61R:52 ; EIF1AX:p.G9R:62 ; NRAS:p.Q61R:116 ; KRAS:p.G12V:7 ; NRAS:p.Q61R:62 ; BRAF:p.TAPTP488del:19 ; NRAS:p.Q61K:90 ; EIF1AX:p.G8R:30 ; BRAF:p.V600E:54 ; BRAF:p.K601E:43 ; NRAS:p.Q61K:99 ; NRAS:p.Q61R:66 ; EIF1AX:p.A113_splice:7,KRAS:p.Q61K:10,BRAF:p.V600E:5 ; NRAS:p.Q61R:36 ; NRAS:p.Q61K:56 ; BRAF:p.V600E:63 ; HRAS:p.Q61R:38 ; HRAS:p.Q61R:39 ; BRAF:p.V600E:51 ; BRAF:p.V600E:55 ; NRAS:p.Q61R:39 ; NRAS:p.Q61K:83 ; BRAF:p.V600E:68 ; NRAS:p.Q61R:81 ; NRAS:p.Q61R:59 ; KRAS:p.Q61K:24 ; BRAF:p.V600E:52 ; BRAF:p.598_599insKIGDFGLA:13
MUT_EPIGENETIC_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Epigenetic modifier gene with protein change and alt allel counts	Sample	SETD2:p.E1138D:12 ; ARID1B:p.Q1657K:6 ; NSD1:p.I2394fs:44 ; SMARCC2:p.L446V:7 ; KDM6B:p.S399T:4 ; CHD6:p.N2470S:29 ; EHMT2:p.R1188L:3 ; HDAC5:p.P322A:3 ; MLL:p.D2718V:5 ; SRCAP:p.G86D:9 ; MBD6:p.P245S:4 ; ARID1B:p.Q1382*:26 ; MBD5:p.S906P:3 ; SETD1A:p.P1126fs:2 ; SMARCA4:p.P930L:3 ; MLL3:p.Q3591*:5 ; EED:p.I251V:5 ; DNMT3A:p.W313*:7 ; CREBBP:p.L673*:7 ; MLL3:p.S3213L:36 ; SMARCA5:p.A823P:29 ; EZH1:p.M349L:6 ; NSD1:p.N1488S:16 ; MYST4:p.E999Q:5 ; CHD3:p.Q510H:8 ; NSD1:p.K513R:3,DNMT1:p.V1343M:5 ; DOT1L:p.G1054D:3 ; KDM6A:p.K768E:26,CHD2:p.W1529fs:19 ; KDM3A:p.I747V:11 ; MLL:p.S3515V:58,DNMT1:p.D706N:27,CHD2:p.S1812L:6 ; MLL:p.Q3621H:4 ; KAT2A:p.G505S:21 ; DNMT3A:p.Q402*:5 ; MBD1:p.P128S:70,EED:p.G35E:16 ; PRDM16:p.P55L:24 ; MBD6:p.T752A:3 ; HDAC8:p.H334Y:28 ; CHD4:p.V1492G:4,CHD3:p.K603N:36 ; MLL4:p.P621fs:4 ; GATAD2B:p.P537L:3 ; KDM2B:p.T1266N:15 ; RBBP4:p.E57K:6 ; KDM3B:p.P780fs:193 ; MLL:p.N1653T:5 ; NCOR2:p.L1651Q:3 ; MLL3:p.K3847N:27 ; PCGF2:p.G22E:10 ; SUV420H1:p.S744R:4,KDM6B:p.A884V:3 ; MYST4:p.L154R:3 ; ARID1B:p.D1723N:7 ; TET3:p.H710Y:3 ; TET1:p.I1429T:7,EZH1:p.Y642F:26 ; PRDM16:p.DLDS624del:32 ; MLL4:p.A1510T:7 ; PYGO1:p.H144Y:30 ; KDM5A:p.K1162Q:28 ; CHD3:p.R399H:7 ; PCGF2:p.R64W:32 ; RCOR1:p.L146_splice:3 ; BAP1:p.E31G:9 ; SETD1A:p.N1461S:9 ; RNF2:p.L58F:7,CHD7:p.E741G:3 ; ASXL1:p.G1299D:27 ; ARID1B:p.S355fs:2 ; SRCAP:p.G2122S:10 ; MLL5:p.D186_splice:66 ; MLL3:p.S2184C:6,MLL3:p.H2006Y:15,MLL3:p.S1955F:12,MLL3:p.Q1791*:15 ; SMARCD3:p.R425C:15 ; ASH1L:p.A93G:8 ; KDM4C:p.G302E:5 ; MLL:p.K1574R:3 ; MECP2:p.P127S:8 ; MLL:p.N3061S:31 ; DNMT3A:p.P195L:8 ; ASH1L:p.P100S:6 ; KDM2A:p.S348fs:70 ; SMARCAL1:p.F728L:4 ; SUV420H1:p.Y818H:62,SETDB1:p.E1204K:129,KDM2A:p.P536L:109,ASH1L:p.T2910A:34,ARID1B:p.R1935H:5 ; MLL:p.K2779E:23
MUT_OTHER_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Interesting gene with protein change and alt allel counts	Sample	ATR:p.R993_splice:3 ; ATR:p.L1013V:27 ; ATM:p.L2452P:3 ; DOK5:p.*307C:4 ; PIK3CA:p.M1043I:40 ; GNAS:p.Q870H:13 ; CHEK2:p.Y390*:8 ; TG:p.Q1246P:10 ; TG:p.C1306S:47 ; CHEK2:p.N186S:6 ; RASGRF2:p.V229M:15 ; TG:p.R950Q:4,DOK6:p.R25fs:18 ; INHBC:p.R245G:19,CHEK2:p.L391F:26 ; PPM1D:p.C478fs:5 ; TG:p.K1534E:6 ; PPM1D:p.N574fs:22 ; RASGRF2:p.R1070H:11 ; ZFHX3:p.G1022D:3 ; ZFHX3:p.Q2304R:3 ; GNAS:p.G251R:15 ; TSHR:p.I640V:5 ; BMP6:p.R379Q:8 ; APC:p.D1714Y:10 ; ATR:p.Q1073*:16 ; RAPGEF1:p.S148N:5 ; ZFHX3:p.H1571R:48 ; DLEC1:p.A163P:53,PPM1D:p.L482fs:37 ; ZFHX3:p.K2987fs:44 ; APC:p.R213*:16 ; DICER1:p.E1813G:117 ; DICER1:p.D1810H:92 ; TG:p.L1891fs:26 ; TG:p.M346fs:20 ; CHEK2:p.L462I:6 ; PIK3CG:p.H471Q:46,ATM:p.T1908fs:23 ; FNTB:p.E41fs:17 ; ATM:p.W2845C:98 ; ZFHX3:p.P1595A:21 ; ATM:p.L2132V:29 ; DICER1:p.R1906S:59 ; TSHR:p.M453T:52,IGSF1:p.P764R:7 ; ZFHX3:p.L2474R:4 ; TG:p.C164G:5 ; TG:p.C140G:27 ; TG:p.L510fs:35 ; TG:p.I821fs:20 ; TG:p.G1975fs:38 ; PPM1D:p.T406fs:34 ; ACVR2A:p.I458T:6 ; RAPGEF1:p.K1011R:7 ; PIK3CA:p.G118D:11 ; ZFHX3:p.A1214G:123 ; PAK3:p.E197D:4 ; PPM1D:p.D470N:3 ; GNAS:p.E52K:2,IGSF1:p.I314F:49 ; ATM:p.T2228I:53 ; CHEK2:p.H143Q:39
MUT_RARE_DRIVER_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Non-silent mutation protein change PP1MD, CHEK2, TSHR : number of alternate allele counts	Sample	CHEK2:p.Y390*:8 ; CHEK2:p.N186S:6 ; CHEK2:p.L391F:26 ; PPM1D:p.C478fs:5 ; PPM1D:p.N574fs:22 ; TSHR:p.I640V:5 ; PPM1D:p.L482fs:37 ; CHEK2:p.L462I:6 ; TSHR:p.M453T:52 ; PPM1D:p.T406fs:34 ; PPM1D:p.D470N:3 ; CHEK2:p.H143Q:39
MUT_TUMORPORTAL_GENE_PROTEIN_CHANGE	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	TumorPortal Gene Lawrence et. al. (2014) cancer genes non-silent mutations; protein-change, alt allele counts	Sample	PTEN:p.L139*:20,PPP2R1A:p.M291K:4,MAP3K1:p.L1354V:3 ; HRAS:p.Q61R:61 ; CTNNB1:p.P744T:6,BRAF:p.V600E:26 ; BRAF:p.V600E:20 ; ZRANB3:p.V440A:8,NRAS:p.Q61R:102 ; ELF3:p.S133F:4,BRAF:p.V600E:38 ; KRAS:p.Q61R:34 ; SETD2:p.E1138D:12,BRAF:p.V600E:33 ; HRAS:p.Q61K:49 ; KEAP1:p.G477S:12 ; BRAF:p.V600E:36 ; BRAF:p.598_599insNIFLHEDLTVKIGDFGLA:35 ; ATM:p.L2452P:3 ; NUP210L:p.S1557T:64,NSD1:p.I2394fs:44 ; BRAF:p.V600E:29 ; IL7R:p.R291T:11,BRAF:p.V600E:23 ; NRAS:p.Q61R:56 ; NRAS:p.Q61R:60 ; TCP11L2:p.V193L:3 ; BRAF:p.V600E:18 ; MUC17:p.A1590D:83,HRAS:p.Q61R:33 ; PIK3CA:p.M1043I:40,BRAF:p.V600E:46 ; BRAF:p.V600E:6 ; NRAS:p.Q61R:85 ; BRAF:p.V600E:38 ; HRAS:p.Q61R:32 ; NRAS:p.Q61R:31 ; NRAS:p.Q61R:52 ; BRAF:p.V600E:7 ; MET:p.E1378Q:11,BRAF:p.V600E:24 ; BRAF:p.V600E:21 ; BRAF:p.V600E:30,AKT1:p.E133D:22 ; BRAF:p.V600E:35 ; RSBN1L:p.V767A:4,BRAF:p.V600E:22 ; BRAF:p.V600E:58 ; HRAS:p.Q61R:62 ; BRAF:p.V600E:14 ; MLL:p.D2718V:5,BRAF:p.V600E:49 ; NRAS:p.Q61R:124 ; BRAF:p.V600E:42 ; BRAF:p.V600E:33 ; BRAF:p.V600E:34 ; BRAF:p.V600E:32 ; BRAF:p.V600E:30 ; NRAS:p.Q61R:55 ; PPM1D:p.C478fs:5 ; BRAF:p.V600E:10 ; BRAF:p.V600E:15 ; BRAF:p.V600E:25 ; BRAF:p.V600E:28 ; BRAF:p.V600E:41 ; NRAS:p.Q61R:72 ; BRAF:p.V600E:19 ; BRAF:p.V600E:20,AZGP1:p.I96M:6 ; BRAF:p.V600E:23 ; SMARCA4:p.P930L:3,BRAF:p.V600E:35 ; BRAF:p.V600E:22 ; PPM1D:p.N574fs:22,MLL3:p.Q3591*:5,BRAF:p.V600E:33 ; BRAF:p.V600E:24 ; DNMT3A:p.W313*:7 ; BRAF:p.V600E:8 ; BRAF:p.V600E:27 ; ZFHX3:p.G1022D:3,BRAF:p.V600E:27 ; CREBBP:p.L673*:7 ; ZFHX3:p.Q2304R:3,BRAF:p.V600E:3 ; MLL3:p.S3213L:36,BRAF:p.V600E:22 ; HRAS:p.Q61R:15 ; SOS1:p.C441Y:4,BRAF:p.V600E:19 ; BRE:p.I60L:3,BRAF:p.V600E:41 ; NRAS:p.Q61R:88 ; BRAF:p.V600E:43 ; NRAS:p.Q61R:96,EZH1:p.M349L:6 ; BRAF:p.V600E:16 ; RB1:p.R798W:24,BRAF:p.V600E:48 ; BRAF:p.V600E:39,APOL2:p.A238V:100 ; BRAF:p.V600E:44,AKT1:p.E17K:9 ; RASA1:p.G875A:21,BRAF:p.PTPQQ490del:4 ; NSD1:p.N1488S:16,BRAF:p.V600E:23,APC:p.D1714Y:10 ; BRAF:p.V600E:26 ; BRAF:p.V600E:17 ; TP53BP1:p.G976W:84 ; ZFHX3:p.H1571R:48,BRAF:p.V600E:41 ; CTCF:p.D581H:7,BRAF:p.V600E:2,ARID2:p.Q1031*:9 ; POLE:p.E1715Q:5,BRAF:p.V600E:45 ; NSD1:p.K513R:3,HRAS:p.Q61K:73 ; KDM6A:p.K768E:26,COL5A3:p.Q236E:4,BRAF:p.V600E:24 ; CTNNB1:p.Y716C:4,BRAF:p.V600E:42 ; BRAF:p.V600E:25,ALPK2:p.I2145V:5 ; BRAF:p.V600E:13 ; BRAF:p.V600E:9 ; PPM1D:p.L482fs:37,MLL:p.S3515V:58,BRAF:p.V600E:46,AKT1:p.E17K:17 ; MLL:p.Q3621H:4,BRAF:p.V600E:28 ; SF3B1:p.T7I:23,BRAF:p.V600E:43 ; BRAF:p.V600E:5 ; BRAF:p.V600E:13,ALPK2:p.L575P:30 ; ZFHX3:p.K2987fs:44,BRAF:p.V600E:25 ; BRAF:p.V600E:40,ALPK2:p.S164P:4 ; DNMT3A:p.Q402*:5,BRAF:p.V600E:28 ; MBD1:p.P128S:70,EZR:p.L104F:30,ERBB3:p.H768R:16,DIS3:p.D319N:22,CCDC6:p.Q24*:16,BRAF:p.V600E:28 ; BRAF:p.V600E:12 ; BRAF:p.V600E:3 ; APC:p.R213*:16 ; MED23:p.M525V:3,BRAF:p.V600E:65,BCOR:p.D1226fs:59 ; IL7R:p.S360G:28,BRAF:p.V600E:40 ; TP53:p.E343fs:26 ; TP53:p.Q375*:6,BRAF:p.V600E:32 ; BRAF:p.V600E:37 ; NF1:p.K1568R:4,BRAF:p.V600E:44 ; NRAS:p.Q61R:80 ; CHD4:p.V1492G:4 ; MLL4:p.P621fs:4,BRAF:p.V600E:27 ; BRAF:p.V600E:31 ; PPP2R1A:p.A273V:29,BRAF:p.V600E:39,ACVR2B:p.V359L:26 ; CUX1:p.E1065*:33,BRAF:p.V600E:40 ; STAG2:p.I910R:38,NRAS:p.Q61R:69 ; IRF4:p.S435N:3,ERBB2:p.K937R:4,BRAF:p.V600E:31 ; BRAF:p.V600E:45 ; COL5A1:p.E677*:4 ; NRAS:p.Q61R:57,MLL:p.N1653T:5 ; HRAS:p.Q61R:80 ; BRAF:p.V600E:49 ; HRAS:p.Q61R:29 ; BRAF:p.V600E:11 ; NRAS:p.Q61R:67 ; NRAS:p.Q61K:84 ; MLL3:p.K3847N:27,BRAF:p.V600E:22 ; RB1:p.P827S:24,NRAS:p.Q61R:95 ; BRAF:p.V600E:36,ATM:p.T1908fs:23 ; MUC17:p.P3155S:6,BRAF:p.V600E:34 ; NF1:p.E244_splice:19 ; TP53:p.Q192*:9,PPP6C:p.S208T:14 ; ATM:p.W2845C:98 ; WT1:p.R443S:4 ; ZFHX3:p.P1595A:21,BRAF:p.V600E:9 ; HRAS:p.Q61K:47 ; NRAS:p.Q61K:64 ; MUC17:p.A1703T:23,CNKSR1:p.Q44E:7,BRAF:p.V600E:14,ATM:p.L2132V:29 ; NRAS:p.Q61K:55 ; HRAS:p.Q61R:52 ; MPO:p.P545fs:98 ; NRAS:p.Q61R:116 ; KRAS:p.G12V:7 ; NRAS:p.Q61R:62 ; EZH1:p.Y642F:26 ; CTCF:p.K593N:4,BRAF:p.V600E:23 ; ZFHX3:p.L2474R:4,MUC17:p.N303S:11,BRAF:p.V600E:22 ; MLL4:p.A1510T:7,BRAF:p.TAPTP488del:19 ; FLG:p.G585E:26,BRAF:p.V600E:26 ; POU2F2:p.Q159H:14 ; NRAS:p.Q61K:90 ; COL5A3:p.R1644H:4 ; SMC3:p.I45V:17 ; SPOP:p.P94R:45 ; BRAF:p.V600E:17,AXIN2:p.R77W:4 ; PTEN:p.D252V:33,PIK3R1:p.P617R:34,BCOR:p.R1261G:3 ; BRAF:p.V600E:54 ; BRAF:p.K601E:43 ; CDK12:p.E1162K:12,BAP1:p.E31G:9 ; NRAS:p.Q61K:99 ; NRAS:p.Q61R:95,COL5A3:p.P276T:8 ; NRAS:p.Q61R:66 ; BRAF:p.V600E:16,BCLAF1:p.N221I:10 ; TGFBR2:p.D222G:17,BRAF:p.V600E:26 ; KRAS:p.Q61K:10,COL5A3:p.P1414L:15,BRAF:p.V600E:5 ; NRAS:p.Q61R:36 ; NRAS:p.Q61K:56 ; FAT1:p.V912I:16,BRAF:p.V600E:18 ; SACS:p.S2824L:12,BRAF:p.V600E:25 ; TBC1D12:p.A260fs:2 ; BRAF:p.V600E:63 ; HRAS:p.Q61R:38,ASXL1:p.G1299D:27 ; HRAS:p.Q61R:39 ; BRAF:p.V600E:39 ; BRAF:p.V600E:51 ; MAP3K1:p.G1311*:3 ; IL7R:p.R267M:33,BRAF:p.V600E:23 ; COL5A3:p.P137S:7 ; BRCA1:p.V412I:9 ; MXRA5:p.D438A:31,BRAF:p.V600E:37 ; PPM1D:p.T406fs:34,BRAF:p.V600E:41 ; MLL3:p.S2184C:6,MLL3:p.H2006Y:15,MLL3:p.S1955F:12,MLL3:p.Q1791*:15,BRAF:p.V600E:19 ; CDKN1A:p.R9P:7 ; COL5A1:p.P978S:6,BRAF:p.V600E:11 ; HIST1H1E:p.R25H:4,BRAF:p.V600E:15 ; EIF2S2:p.R325P:25,BRAF:p.V600E:27 ; PHF6:p.G93C:15,BRAF:p.V600E:31 ; PIK3CA:p.G118D:11,BRAF:p.V600E:55 ; ARID5B:p.K1027R:4 ; ALK:p.P693S:3 ; ZFHX3:p.A1214G:123,BRAF:p.V600E:29 ; MLL:p.K1574R:3 ; COL5A1:p.R1627Q:4,BRAF:p.V600E:38 ; MLL:p.N3061S:31,BRAF:p.V600E:29 ; DNMT3A:p.P195L:8 ; PPM1D:p.D470N:3,BRAF:p.V600E:28 ; NRAS:p.Q61R:39 ; SIRT4:p.R97Q:3 ; FLG:p.T550A:56,BRAF:p.V600E:24 ; NRAS:p.Q61K:83 ; BRAF:p.V600E:68 ; SACS:p.H4354L:40,NRAS:p.Q61R:81 ; NRAS:p.Q61R:59 ; KRAS:p.Q61K:24 ; SFRS2:p.S220C:3,BRAF:p.V600E:23 ; SETDB1:p.E1204K:129,POU2AF1:p.P93L:3,BRAF:p.V600E:52 ; BRAF:p.V600E:36,ATM:p.T2228I:53 ; CUX1:p.V1195L:30,BRAF:p.V600E:16 ; SF3B1:p.M876L:17,BRAF:p.V600E:20 ; KEL:p.Q357H:22,BRAF:p.V600E:24 ; MLL:p.K2779E:23,BRAF:p.V600E:27 ; FGFR2:p.K296N:8,BRAF:p.V600E:12 ; NTN4:p.D111E:4,BRAF:p.V600E:10 ; TBX3:p.Q115*:7,BRAF:p.V600E:10 ; BRAF:p.598_599insKIGDFGLA:13
NONSILENT_DENSITY_AGE_FIT	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Nonsilent Mutation Density Residual with Age Fit	Sample	0.3807 ; 0.4841 ; -0.0619 ; 0.1441 ; 0.1649 ; -0.0617 ; 1.0826 ; -0.0726 ; -0.1034 ; -0.1883 ; 0.4744 ; -0.2841 ; 0.1476 ; 0.1379 ; -0.2328 ; 0.1055 ; -0.2036 ; 0.0449 ; 0.3095 ; 0.1467 ; 0.0876 ; 0.3107 ; -0.1069 ; 0.3153 ; 0.2522 ; -0.2128 ; -0.3507 ; -0.1793 ; -0.1853 ; -0.242 ; -0.0574 ; -0.0092 ; -0.2889 ; 0.2501 ; -0.0098 ; 0.0108 ; 0.1152 ; -0.0505 ; -0.1516 ; 0.1678 ; -0.185 ; 0.2825 ; 0.3545 ; -0.1165 ; 0.0371 ; 0.195 ; -0.24 ; -0.0184 ; -0.0284 ; -0.3202 ; 0.0717 ; 0.0878 ; 0.1298 ; -0.0254 ; -0.0109 ; -0.0154 ; 0.0534 ; 0.2189 ; 0.1373 ; 0.0599 ; -0.3159 ; 0.0242 ; 0.1568 ; -0.155 ; 0.0048 ; -0.1156 ; -0.1178 ; -0.058 ; 0.0471 ; -0.4096 ; -0.0056 ; -0.0188 ; -0.0781 ; 0.0199 ; -0.2774 ; -0.11 ; -0.1494 ; -0.259 ; -0.0263 ; -0.2767 ; -0.1472 ; 0.0074 ; 0.4206 ; -0.1283 ; -0.1481 ; -0.0186 ; 0.0116 ; -0.1806 ; -0.0596 ; -0.1572 ; -0.0176 ; 0.0982 ; 0.0195 ; -0.1465 ; -0.0418 ; 0.0234 ; -0.2772 ; 0.5406 ; -0.0319 ; 0.404 ; 0.1922 ; -0.0211 ; 0.2482 ; 0.0689 ; 0.061 ; -0.1438 ; -0.1203 ; -0.1529 ; 0.0975 ; -0.1384 ; -0.1924 ; -0.1801 ; -0.3145 ; -0.0538 ; -0.2299 ; -0.1689 ; -0.3967 ; 0.7589 ; -0.0931 ; -0.1787 ; 0.1918 ; -0.3085 ; -0.1026 ; 1.6931 ; 0.0089 ; 0.2884 ; -0.0048 ; 0.1533 ; -0.0689 ; -0.0198 ; 0.1157 ; 0.088 ; 0.2856 ; -0.2639 ; -0.1016 ; -0.4199 ; 0.334 ; -0.1422 ; 0.0961 ; -0.1803 ; -0.0799 ; -0.1997 ; -0.1589 ; -0.3429 ; -0.1185 ; 0.3351 ; -0.4662 ; -0.3446 ; 0.2999 ; 0.0255 ; 1.5536 ; -0.0996 ; -0.1704 ; -0.4625 ; 0.0544 ; -0.1932 ; -0.1859 ; -0.2356 ; -0.3919 ; -0.0385 ; 0.3786 ; 0.1578 ; -0.0474 ; -0.1628 ; 0.0161 ; 0.1538 ; 0.208 ; 0.2356 ; -0.0185 ; -0.0512 ; 0.3499 ; 0.2937 ; 0.0734 ; 0.0247 ; 0.0394 ; 0.3852 ; 0.1252 ; -0.1447 ; -0.1135 ; 0.4399 ; 0.1339 ; -0.0029 ; 0.3871 ; 0.1393 ; 0.1308 ; 0.4335 ; -0.0305 ; 0.1412 ; 0.0563 ; 0.0617 ; -0.1496 ; 0.3199 ; -0.1544 ; -0.0446 ; -0.3331 ; -0.0529 ; -0.0716 ; -0.1759 ; -0.1244 ; -0.0409 ; -0.1983 ; -0.1986 ; -0.1234 ; 0.0637 ; 0.0302 ; 0.6876 ; 0.0648 ; -0.0443 ; -0.1116 ; 0.2348 ; -0.1147 ; 0.0393 ; -0.3339 ; 0.5674 ; -0.1765 ; -0.2599 ; -0.1861 ; 0.0273 ; 0.0844 ; 0.005 ; -0.3233 ; -0.3291 ; 0.5395 ; -0.1675 ; -0.1126 ; 0.0607 ; 0.0044 ; -0.1155 ; 0.0187 ; -0.1776 ; -0.0805 ; -0.178 ; -0.0181 ; 0.0936 ; -0.2134 ; 0.2611 ; 0.0425 ; -0.2477 ; 0.1147 ; -0.0973 ; -0.1969 ; 0.4161 ; -0.0237 ; 0.0014 ; -0.1349 ; -0.1575 ; 0.2932 ; 0.0493 ; -0.1877 ; 0.3033 ; 0.0505 ; -0.1487 ; -0.2354 ; 0.0214 ; 0.0363 ; 0.1309 ; 0.1544 ; 0.0249 ; -0.0012 ; 0.0668 ; 0.2556 ; 0.2798 ; 0.0309 ; 0.1272 ; -0.0271 ; 0.4628 ; -0.0089 ; 0.1749 ; -0.086 ; 0.0784 ; -0.149 ; -0.1501 ; -0.125 ; 0.1291 ; -0.1773 ; -0.2177 ; 0.1165 ; -0.1406 ; -0.0792 ; 0.0303 ; -0.1847 ; 1.3316 ; -0.2334 ; -0.0766 ; -0.0831 ; 0.3004 ; 0.02 ; -0.3266 ; -0.0205 ; -0.1929 ; -0.1392 ; 0.3563 ; 0.0751 ; -0.026 ; -0.1099 ; -0.0597 ; -0.1382 ; -0.0532 ; -0.2012 ; -0.1984 ; 0.2165 ; -0.1555 ; 0.0786 ; -0.0883 ; 0.3196 ; -0.2416 ; 0.0431 ; 0.2608 ; -0.0016 ; -0.3308 ; 0.0376 ; -0.088 ; -0.1941 ; 0.1934 ; -0.1347 ; -0.0239 ; -0.2603 ; -0.1089 ; 0.1056 ; -0.1053 ; -0.2406 ; -0.064 ; 0.0105 ; 0.1692 ; 0.1582 ; -0.0233 ; 0.0368 ; -0.0159 ; -0.1603 ; 0.6127 ; 0.3474 ; 0.0365 ; 0.0408 ; 0.3479 ; 0.0172 ; 0.1877 ; 0.1902 ; -0.3477 ; -0.1271 ; -0.1681 ; 0.0962 ; 0.3185 ; -0.0266 ; -0.1389 ; -0.0388 ; 0.0236 ; -0.071 ; 0.0465 ; -0.08 ; 0.051 ; -0.1888 ; -0.2501 ; -0.105 ; -0.2259 ; -0.2746 ; 0.169 ; 0.0194 ; -0.0337 ; 0.1621 ; 0.1128 ; -0.2313 ; 0.8475 ; 0.3635 ; 0.0436 ; -0.0431 ; 0.2192 ; -0.1174 ; -0.0816 ; -0.1957 ; -0.1308 ; -0.1775 ; 0.0965 ; 0.0132 ; -0.3036 ; 0.5885 ; -0.0999 ; 0.3163 ; -0.2131
NONSILENT_MUTATION_DENSITY	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Nonsilent Mutation Density	Sample	0.896 ; 0.931 ; 0.399 ; 0.441 ; 0.626 ; 0.468 ; 1.605 ; 0.375 ; 0.43 ; 0.901 ; 0.033 ; 0.417 ; 0.682 ; 0.544 ; 0.208 ; 0.437 ; 0.741 ; 0.1 ; 0.656 ; 0.6 ; 0.532 ; 0.637 ; 0.17 ; 0.407 ; 0.341 ; 0.908 ; 0.478 ; 0.636 ; 0.342 ; 0.436 ; 0.735 ; 0.679 ; 0.105 ; 0.035 ; 0.295 ; 0.214 ; 0.178 ; 0.281 ; 0.288 ; 0.104 ; 0.67 ; 0.267 ; 0.274 ; 0.398 ; 0.369 ; 0.492 ; 0.798 ; 0.631 ; 0.365 ; 0.409 ; 0.601 ; 0.248 ; 0.244 ; 0.234 ; 0.134 ; 0.498 ; 0.501 ; 0.331 ; 0.299 ; 0.471 ; 0.199 ; 0.432 ; 0.639 ; 0.345 ; 0.555 ; 0.172 ; 0.519 ; 0.625 ; 0.347 ; 0.243 ; 0.241 ; 0.485 ; 0.412 ; 0.14 ; 0.435 ; 0.374 ; 0.171 ; 0.276 ; 0.067 ; 0.44 ; 0.277 ; 0.175 ; 0.489 ; 0.239 ; 0.509 ; 0.882 ; 0.313 ; 0.476 ; 0.445 ; 0.271 ; 0.27 ; 0.614 ; 0.474 ; 0.287 ; 0.508 ; 0.334 ; 0.102 ; 0.961 ; 0.47 ; 0.571 ; 0.572 ; 0.434 ; 0.467 ; 0.269 ; 0.265 ; 0.137 ; 0.2 ; 0.233 ; 0.167 ; 0.168 ; 0.101 ; 0.367 ; 0.139 ; 1.049 ; 0.211 ; 0.591 ; 0.24 ; 0.174 ; 2.099 ; 0.333 ; 0.736 ; 0.539 ; 0.235 ; 0.386 ; 0.577 ; 0.542 ; 0.712 ; 0.236 ; 0 ; 0.918 ; 0.338 ; 0.253 ; 0.381 ; 0.213 ; 0.07 ; 0.207 ; 0.39 ; 0.728 ; 0.068 ; 0.904 ; 0.521 ; 2.158 ; 0.45 ; 0.203 ; 0.138 ; 0.602 ; 0.103 ; 0.799 ; 0.502 ; 0.401 ; 0.771 ; 0.751 ; 0.306 ; 0.3 ; 0.695 ; 0.816 ; 0.541 ; 0.41 ; 0.5 ; 0.703 ; 0.303 ; 0.877 ; 0.511 ; 0.962 ; 0.431 ; 0.766 ; 0.578 ; 0.935 ; 0.273 ; 0.534 ; 0.605 ; 0.209 ; 0.713 ; 0.204 ; 0.307 ; 0.176 ; 0.242 ; 0.249 ; 0.648 ; 0.382 ; 0.998 ; 0.567 ; 0.403 ; 0.479 ; 0.518 ; 0.377 ; 1.138 ; 0.38 ; 0.348 ; 0.481 ; 0.302 ; 1.123 ; 0.205 ; 0.514 ; 0.42 ; 0.169 ; 0.368 ; 0.179 ; 0.77 ; 0.52 ; 0.802 ; 0.537 ; 0.672 ; 0.301 ; 0.587 ; 0.298 ; 0.538 ; 0.592 ; 0.513 ; 0.37 ; 0.268 ; 0.808 ; 0.438 ; 0.472 ; 0.553 ; 0.414 ; 0.638 ; 0.072 ; 0.238 ; 1.895 ; 0.343 ; 0.309 ; 0.734 ; 0.406 ; 0.312 ; 0.069 ; 0.66 ; 0.46 ; 0.136 ; 0.56 ; 0.279 ; 0.558 ; 0.364 ; 0.034 ; 0.396 ; 0.408 ; 0.311 ; 0.594 ; 0.308 ; 0.418 ; 0.937 ; 0.535 ; 0.402 ; 0.836 ; 0.603 ; 0.141 ; 0.142 ; 0.718 ; 0.373 ; 0.404 ; 0.424 ; 0.569 ; 0.135 ; 0.573 ; 0.315 ; 0.071 ; 0.166 ; 0.411 ; 0.371 ; 0.466 ; 1.527 ; 0.811 ; 0.516 ; 0.393 ; 0.275 ; 0.448 ; 1.056 ; 0.524 ; 1.067 ; 0.444
NORMAL_EXOME_DEPTH	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Normal Exome Depth	Sample	132.9 ; 135.1 ; 130.4 ; 124.7 ; 137 ; 136.5 ; 141.3 ; 130 ; 140.9 ; 148.1 ; 123.8 ; 136.4 ; 114.4 ; 127.1 ; 129.9 ; 109.5 ; 116.1 ; 67.2 ; 99.7 ; 74.4 ; 87.8 ; 108.1 ; 69.4 ; 76.4 ; 79.1 ; 69.7 ; 73.8 ; 83.9 ; 104.1 ; 81.2 ; 122.2 ; 133 ; 53 ; 50.2 ; 48.6 ; 93.7 ; 53.2 ; 64 ; 53.3 ; 56.7 ; 134.6 ; 61.7 ; 134.1 ; 159.8 ; 66.5 ; 56.9 ; 55.1 ; 97.4 ; 140.5 ; 125.4 ; 79 ; 145.1 ; 65.5 ; 45.4 ; 143.2 ; 137.8 ; 147.4 ; 112.5 ; 125 ; 137.1 ; 114.3 ; 129.3 ; 148.4 ; 140.6 ; 80.1 ; 80.7 ; 82.5 ; 72.5 ; 82.3 ; 80.3 ; 88 ; 74.7 ; 87.4 ; 88.3 ; 78.2 ; 75.6 ; 82.1 ; 81.8 ; 75.1 ; 106.4 ; 81.1 ; 81.5 ; 73.2 ; 74.1 ; 77 ; 78 ; 78.5 ; 75.9 ; 70.1 ; 78.8 ; 85.3 ; 84.1 ; 74.8 ; 83.4 ; 78.1 ; 77.8 ; 75.3 ; 103.7 ; 112.4 ; 127.3 ; 87.2 ; 102.7 ; 98.9 ; 91.5 ; 105.9 ; 129.8 ; 123.6 ; 126.3 ; 116.2 ; 87.5 ; 94.4 ; 83.5 ; 78.7 ; 135.2 ; 76.5 ; 92.6 ; 41.1 ; 42 ; 46.3 ; 54 ; 56.1 ; 51.7 ; 52.3 ; 129.4 ; 134.8 ; 171.1 ; 182.1 ; 161.6 ; 120.5 ; 122.1 ; 124.6 ; 109.8 ; 77.7 ; 81.9 ; 116.3 ; 109.4 ; 97.2 ; 57.5 ; 66 ; 84 ; 69 ; 72.3 ; 70.4 ; 146.2 ; 90 ; 66.6 ; 94.7 ; 108.8 ; 67.1 ; 71.3 ; 84.5 ; 81.4 ; 75.2 ; 93 ; 110.4 ; 108.5 ; 108 ; 136.1 ; 117.5 ; 88.4 ; 94.1 ; 113.3 ; 107.6 ; 97.9 ; 160.9 ; 110 ; 121.6 ; 149.3 ; 117.7 ; 89.6 ; 95.2 ; 171.9 ; 120.2 ; 93.3 ; 74.3 ; 124.5 ; 98.3 ; 112 ; 110.2 ; 136.3 ; 98.2 ; 105.8 ; 141.9 ; 61.6 ; 95.8 ; 126.4 ; 116.9 ; 67.6 ; 50.7 ; 63.5 ; 55 ; 72.4 ; 60.6 ; 70.7 ; 50.9 ; 69.3 ; 65.3 ; 121.1 ; 130.9 ; 119.1 ; 99.6 ; 125.8 ; 76.2 ; 77.4 ; 86.2 ; 75 ; 101.2 ; 89.5 ; 66.8 ; 68.1 ; 69.6 ; 75.4 ; 81.7 ; 72.8 ; 73.1 ; 94.6 ; 67 ; 55.3 ; 86.6 ; 68.5 ; 65.9 ; 108.6 ; 109.9 ; 106.1 ; 110.3 ; 106.5 ; 111.4 ; 91.6 ; 114.2 ; 119.7 ; 101.8 ; 93.4 ; 108.4 ; 98.8 ; 165.2 ; 151.8 ; 107.1 ; 101.5 ; 105 ; 84.8 ; 115.3 ; 107.7 ; 112.9 ; 114.1 ; 115.5 ; 137.9 ; 135.3 ; 117.2 ; 131.4 ; 40 ; 57.6 ; 55.2 ; 60.5 ; 47.8 ; 102.5 ; 89.3 ; 106.6 ; 84.2 ; 69.2 ; 76 ; 80 ; 76.7 ; 70.5 ; 82.9 ; 70.3 ; 74 ; 69.8 ; 77.5 ; 78.4 ; 92.9 ; 70.6 ; 73.4 ; 88.1 ; 70.8 ; 112.2 ; 97.6 ; 79.3 ; 67.4 ; 72.9 ; 113.8 ; 136.8 ; 74.6 ; 87.6 ; 56.2 ; 75.5 ; 86.4 ; 73.7 ; 93.6 ; 96.6 ; 103.1 ; 122 ; 125.6 ; 109.1 ; 120.9 ; 111.7 ; 134.5 ; 124.2 ; 68.7 ; 83.2 ; 104.9 ; 118.2 ; 101.7 ; 124.3 ; 109.6 ; 81 ; 103.2 ; 63 ; 110.8 ; 101.3 ; 119.6 ; 107.8 ; 104.6 ; 132.2 ; 87.1 ; 97.1 ; 102.9 ; 89.7 ; 63.7 ; 57.7 ; 46.9 ; 27.3 ; 63.8 ; 54.2 ; 58.2 ; 54.6 ; 111.8 ; 84.9 ; 62.2 ; 332 ; 95.1 ; 100.5
NUM_MUT_APOBEC	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	APOBEC Mutation Number	Sample	2 ; 0 ; 1 ; 14 ; 6 ; 4 ; 3 ; 7 ; 9 ; 5 ; 8 ; 26 ; 18 ; 21 ; 12
NUM_MUT_CPGT	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	CpGT Mutation Number	Sample	3 ; 2 ; 4 ; 0 ; 5 ; 9 ; 1 ; 7 ; 14 ; 12 ; 6 ; 8 ; 10 ; 11 ; 22 ; 13 ; 15
NUM_MUT_DBSNP	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Number of mutations in dbSNP	Sample	1 ; 3 ; 2 ; 0 ; 5 ; 4 ; 8
NUM_SILENT_MUTATION	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Total Number of Silent Mutation	Sample	10 ; 4 ; 6 ; 3 ; 9 ; 5 ; 8 ; 1 ; 2 ; 0 ; 11 ; 12 ; 16 ; 7 ; 24 ; 27 ; 13 ; 17 ; 23 ; 14 ; 15
PRIMARY_EXOME	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Sample has exome passing QC	Sample	Yes ; No
TUMOR_EXOME_DEPTH	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	NUMBER	Tumor Exome Depth	Sample	133.6 ; 137.7 ; 121.9 ; 130.3 ; 66.9 ; 117.3 ; 117.7 ; 127.4 ; 134.2 ; 148.2 ; 130 ; 129.5 ; 107 ; 90.7 ; 122.5 ; 104.1 ; 99.2 ; 147.9 ; 115.7 ; 81.7 ; 143.7 ; 113.2 ; 94.2 ; 78.1 ; 82.3 ; 80 ; 75 ; 76.5 ; 109 ; 82 ; 132.7 ; 142.7 ; 109.9 ; 66.6 ; 60.1 ; 45.8 ; 54.7 ; 57.4 ; 63.9 ; 53.2 ; 74.9 ; 68.8 ; 127.6 ; 74.2 ; 154.2 ; 139.5 ; 70.5 ; 58.6 ; 94.5 ; 136.2 ; 146.6 ; 78.3 ; 138.3 ; 69.3 ; 72.4 ; 119.8 ; 119.2 ; 135.8 ; 135.4 ; 150 ; 136 ; 112.5 ; 132.8 ; 133.7 ; 115.1 ; 80.9 ; 80.4 ; 81.2 ; 77.8 ; 78.5 ; 78.4 ; 85.3 ; 83.9 ; 86 ; 78 ; 88.6 ; 69.9 ; 151.3 ; 90.9 ; 77.3 ; 81.5 ; 85.2 ; 84.6 ; 77.2 ; 83.3 ; 77.7 ; 92.3 ; 89.7 ; 76.9 ; 77.4 ; 80.6 ; 88.4 ; 76.2 ; 75.2 ; 85 ; 69 ; 81.3 ; 129.2 ; 98 ; 141.6 ; 130.1 ; 123.5 ; 120.5 ; 127 ; 117.8 ; 126.9 ; 122.8 ; 109.1 ; 129.6 ; 93.8 ; 118.6 ; 130.9 ; 143.9 ; 103.3 ; 98.4 ; 135.3 ; 77.9 ; 71.2 ; 65.9 ; 67.9 ; 72 ; 101.3 ; 92.1 ; 90.6 ; 151.5 ; 138.4 ; 146.1 ; 129.4 ; 116.9 ; 80.3 ; 117.9 ; 100.9 ; 91.1 ; 113.9 ; 83.4 ; 99.4 ; 133.8 ; 96.1 ; 111.6 ; 54.1 ; 72.9 ; 56.1 ; 78.7 ; 68.1 ; 165.3 ; 87.6 ; 69.2 ; 77.6 ; 111 ; 88.9 ; 112.4 ; 113.8 ; 91 ; 106.7 ; 116.4 ; 108.7 ; 117 ; 86.7 ; 104.6 ; 126.5 ; 76.4 ; 122.9 ; 79.1 ; 114 ; 134.5 ; 132.9 ; 122.7 ; 114.6 ; 108 ; 134.6 ; 158.6 ; 157 ; 130.4 ; 114.5 ; 106.1 ; 119.5 ; 111.3 ; 131.3 ; 117.2 ; 91.3 ; 102 ; 107.7 ; 71.4 ; 96.8 ; 98.2 ; 63.3 ; 70.6 ; 53.5 ; 71.9 ; 68.5 ; 64.1 ; 86.1 ; 73.3 ; 75.1 ; 63.5 ; 61.5 ; 105.3 ; 102.7 ; 67.5 ; 74.3 ; 85.1 ; 84.1 ; 74.1 ; 67.6 ; 89 ; 92.9 ; 72.1 ; 76.8 ; 93.2 ; 73.8 ; 98.3 ; 94.9 ; 80.7 ; 97.8 ; 74.8 ; 94.4 ; 99.1 ; 88 ; 49 ; 104.3 ; 71.7 ; 114.3 ; 115.4 ; 110.9 ; 101.5 ; 97.3 ; 91.8 ; 97.9 ; 110.2 ; 141.2 ; 116.3 ; 62.3 ; 106.9 ; 125.1 ; 84.7 ; 135.2 ; 79 ; 121 ; 105.6 ; 118.1 ; 123.2 ; 124.6 ; 125.6 ; 68.6 ; 72.2 ; 76.3 ; 78.2 ; 55.6 ; 47.5 ; 105.7 ; 92.5 ; 95.1 ; 84.2 ; 73.2 ; 74.7 ; 154.9 ; 82.5 ; 80.2 ; 87.7 ; 83 ; 195.4 ; 75.6 ; 73.1 ; 79.2 ; 99.8 ; 78.9 ; 86.6 ; 98.8 ; 75.5 ; 69.5 ; 87.8 ; 145.5 ; 76.6 ; 80.1 ; 83.6 ; 79.8 ; 70.2 ; 60.2 ; 88.7 ; 87 ; 91.6 ; 77 ; 102.9 ; 82.8 ; 99.5 ; 66.4 ; 92 ; 131.8 ; 119.3 ; 127.2 ; 116.2 ; 115 ; 122.3 ; 126.6 ; 116.7 ; 105.1 ; 62 ; 139.8 ; 136.9 ; 71.3 ; 128.5 ; 62.6 ; 54.3 ; 100 ; 123.7 ; 93.4 ; 110.7 ; 115.6 ; 99.6 ; 113.3 ; 48.4 ; 100.2 ; 70.7 ; 68.9 ; 58.4 ; 79.3 ; 68.3 ; 71.8 ; 154.5 ; 82.2 ; 91.2
WGS_STATUS	Teal	Papillary Thyroid Carcinoma (TCGA, Cell 2014)	STRING	Yes/No indicator for WGS data	Sample	No ; Yes
BRACHYTHERAPY_TYPE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Brachytherapy Type	Patient	
BRACHYTHERAPY_TYPE_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Brachytherapy Type Other	Patient	
CERVIX_SUV_RESULTS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Standardized uptake value cervix uteri assessment measurement	Patient	
CHEMO_CONCURRENT_COURSE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	The text that represents the planned dosage frequency for a agent.	Patient	
CHEMO_CONCURRENT_DOSE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Occurring or operating at the same time. The use of synthetic or naturally-occurring chemicals for the treatment of diseases.	Patient	
CHEMO_CONCURRENT_FRACTIONS_TOTAL	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	A total number of doses of a drug, vaccine or other agent administered to a patient.	Patient	
CHEMO_CONCURRENT_REASON_NOT_GIVEN	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Text term to capture the explanation for a chemotherapy not being given concurrent to radiation therapy.	Patient	
CHEMO_CONCURRENT_REASON_NOT_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Another reason that is not already specified or mentioned for why concurrent chemotherapy was not given.	Patient	
CHEMO_CONCURRENT_TYPE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	The chemotherapy regimen or schedule and agent in the therapy of patient	Patient	
CHEMO_CONCURRENT_TYPE_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Specify the other chemotherapy agent administered.	Patient	
CORPUS_INVOLVEMENT	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Cervical carcinoma corpus uteri involvement indicator	Patient	
DAYS_TO_DIAGNOSTIC_COMPUTED_TOMOGRAPHY_PERFORMED	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Days to diagnostic computed tomography performed	Patient	
DAYS_TO_DIAGNOSTIC_MRI_PERFORMED	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Days to diagnostic mri performed	Patient	
DAYS_TO_FDG_OR_CT_PET_PERFORMED	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Days to fdg or ct pet performed	Patient	
DAYS_TO_LABORATORY_PROCEDURE_TUMOR_MARKER_SQUAMOUS_CELL_CARCINOMA_ANTIGEN_RESULT	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Days to laboratory procedure tumor marker squamous cell carcinoma antigen result	Patient	
DAYS_TO_PERFORMANCE_STATUS_ASSESSMENT	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Days to performance status assessment	Patient	
FEDPET_OR_CT_RESULTS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Fdg or ct pet performed outcome	Patient	
HISTORY_HORMONAL_CONTRACEPTIVES_USE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	History hormonal contraceptives use	Patient	
HISTORY_IMMUNOSUPPRESIVE_DX	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior immunosuppressive therapy type	Patient	
HISTORY_IMMUNOSUPPRESIVE_DX_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior immunosuppressive therapy other	Patient	
HISTORY_IMMUNOSUPPRESSIVE_DISEASE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Patient history immune system and related disorders name	Patient	
HISTORY_IMMUNOSUPPRESSIVE_TX_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Prior infectious disease other	Patient	
HPV_TYPES_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Human papillomavirus other type text	Patient	
HPV_TYPES_POSITIVE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Human papillomavirus type	Patient	
HPV_TYPING_METHOD	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Human papillomavirus laboratory procedure performed name	Patient	
HPV_TYPING_METHOD_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Human papillomavirus laboratory procedure performed text	Patient	
HYSTERECTOMY_TYPE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Hysterectomy performed type	Patient	
KERATINIZATION_SQUAMOUS_CELL	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Keratinizing squamous cell carcinoma present indicator	Patient	
LYMPHOVASCULAR_INVOLVEMENT	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Lymphovascular invasion indicator	Patient	
LYMPH_NODES_SUPRACLAVICULAR	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Diagnostic mri result outcome	Patient	
MARGINS_INVOLVED_HYSTERECTOMY	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Cervical neoplasm pathologic margin involved type	Patient	
OTHER_HYSTERECTOMY_TYPE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Hysterectomy performed text	Patient	
OTHER_IMMUNOSUPPRESSIVE_DISEASE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Patient history immune system and related disorders text	Patient	
OTHER_INVOLVED_MARGINS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Cervical neoplasm pathologic margin involved text	Patient	
OTHER_POS_NODE_LOCATION	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Lymph node location positive pathology text	Patient	
PCR_PRIMER_PAIRS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Oligonucleotide primer pair laboratory procedure performed name	Patient	
PCR_PRIMER_PAIRS_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Oligonucleotide primer pair laboratory procedure performed text	Patient	
PELVIC_EXTENSION_COMMENT	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Cervical carcinoma pelvic extension text	Patient	
PREGNANCIES_COUNT_ECTOPIC	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Ectopic pregnancy count	Patient	
PREGNANCIES_COUNT_INDUCED_ABORTION	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Patient pregnancy therapeutic abortion count	Patient	
PREGNANCIES_COUNT_LIVE_BIRTH	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Number of successful pregnancies which resulted in at least 1 live birth	Patient	
PREGNANCIES_COUNT_MISCARRIAGE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Patient pregnancy spontaneous abortion count	Patient	
PREGNANCIES_COUNT_STILLBIRTH	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Pregnancy stillbirth count	Patient	
PREGNANCIES_COUNT_TOTAL	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	NUMBER	Total number of pregnancies	Patient	
PREGNANT_AT_DIAGNOSIS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Pregnant at diagnosis	Patient	
RADIATION_THERAPY_DOSE_PARAAORTIC_NODES	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	External beam radiation therapy administered paraaortic region lymph node dose	Patient	
RADIATION_THERAPY_XRT_TYPE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Rt administered type	Patient	
RADIATION_TYPE_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Radiation type notes	Patient	
RT_TX_REASON_NOT_COMPLETED	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Radiation therapy not administered reason	Patient	
RT_TX_REASON_NOT_COMPLETED_OTHER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Radiation therapy not administered specify	Patient	
RT_TX_TOTAL_DOSE_TO_PELVIS	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Rt pelvis administered total dose	Patient	
SCCA_TUMOR_MARKER	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Laboratory procedure tumor marker squamous cell carcinoma antigen result value	Patient	
TUMOR_RESPONSE	Teal	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Tumor response cdus type	Patient	
AGE_CATEGORY	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Age category at diagnosis	Patient	
DISTANT_METASTASIS	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Indicates if patient has distant metastasis	Patient	
LEUKOCYTOSIS	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Indicates if patient has leukocytosis	Patient	
NODAL_METASTASIS	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Indicates if patient has nodal metastasis	Patient	
TUMOR_CELLULARITY	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	NUMBER	Tumor cellularity	Sample	0.36 ; 0.53 ; 0.5 ; 1 ; 0.55 ; 0.54 ; 0.52 ; 0.32 ; 0.69 ; 0.33 ; 0.58 ; 0.31 ; 0.62 ; 0.3 ; 0.37 ; 0.85 ; 0.63 ; 0.42 ; 0.59 ; 0.45 ; 0.73 ; 0.44 ; 0.47 ; 0.4 ; 0.41 ; 0.67 ; 0.79 ; 0.35 ; 0.61 ; 0.49 ; 0.98 ; 0.88 ; 0.6 ; 0.83 ; 0.56 ; 0.29 ; 0.89 ; 0.81 ; 0.71 ; 0.38 ; 0.9 ; 0.7 ; 0.74 ; 0.21 ; 0.51 ; 0.57 ; 0.64
WGS	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Identifies samples that underwent whole genome sequencing	Sample	Absent ; Present
WXS	Teal	Anaplastic Thyroid Cancers (GATCI, Cell Reports 2024)	STRING	Identifies samples that underwent whole-exome sequencing	Sample	Present ; Absent
BX_EPITHELIOID	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Sample has epithelioid characteristics	Sample	NO ; YES ; YES; FOCAL
BX_NUCLEAR_GRADE	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Nuclear grade of the sample	Sample	LOW ; HIGH
BX_SPINDLE_CELL	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Sample has spindle cell characteristics	Sample	NO ; YES ; YES; FOCAL
BX_VASOFORMATIVE	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Sample has vasoformative characteristics	Sample	YES ; NO ; YES; FOCAL
DX_BIOPSY_LOCATION	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Location of first biopsy that showed presence of angiosarcoma	Patient	
PRD_DIAGNOSIS_LOC	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: When you were first diagnosed with angiosarcoma, where in your body was it found (select all that apply)?	Patient	
PRD_EVER_LOCATION	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Please select all of the places in your body that you have ever had angiosarcoma (select all that apply).	Patient	
PRD_LOCATION_AT_ENROLLMENT	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Please select all of the places in your body where you currently have angiosarcoma (select all that apply). If you don't have evidence of disease, please select No Evidence of Disease (NED).	Patient	
PRD_OTHER_CANCER_LIST	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Please list which cancer(s) and approximate year(s) of diagnosis.	Patient	
PRD_OTHER_CANCER_RADIATION	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Have you had radiation as a treatment for another cancer(s)?	Patient	
PRD_RADIATION	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Have you had radiation as a treatment for angiosarcoma? If you had radiation for other cancers, we will ask you about that later.	Patient	
PRD_RADIATION_SURGERY	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Was your radiation before or after surgery?	Patient	
PRD_SURGERY	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: Have you had surgery to remove angiosarcoma?	Patient	
PRD_SURGERY_CLEAN_MARGINS	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Patient reported response to the question: If [surgery], did the surgery remove all known cancer tissue (also known as clean margins)?	Patient	
PRIMARY_SITE_NOTES	LightYellow	The Angiosarcoma Project - Count Me In (Nature Medicine, 2020)	STRING	Notes regarding site of origin of angiosarcoma	Patient	
FIRST_TREATMENT_MIOTIC_RATE_50HPF	LightYellow	Gastrointestinal Stromal Tumors (MSK, Clin Cancer Res 2023)	NUMBER	First Treatment Miotic Rate 50Hpf	Patient	
FIRST_TREATMENT_TUMOR_SIZE_CM	LightYellow	Gastrointestinal Stromal Tumors (MSK, Clin Cancer Res 2023)	NUMBER	First Treatment Tumor Size Cm	Patient	
OS_ADJUVANTTHERAPY	LightYellow	Gastrointestinal Stromal Tumors (MSK, Clin Cancer Res 2023)	STRING	Did the patient receive imatinib therapy after surgical resection.	Patient	
PRE_THERAPY_GROUP	LightYellow	Gastrointestinal Stromal Tumors (MSK, Clin Cancer Res 2023)	STRING	Pre Therapy Group	Patient	
BIOCHEMICAL_TESTING	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Biochemical Testing Performed	Sample	Unknown ; Yes ; No
CLINICALLY_AGGRESSIVE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Clinically Aggressive (extensive invasion, local regional disease, local recurrence)	Patient	
CLINICALLY_AGRESSIVE_AND_OR_METASTATIC	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Clinically Aggressive and/or Metastatic	Patient	
DAYS_FROM_SURGERY_TO_LAST_FOLLOWUP	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	NUMBER	Days from surgery to last followup	Patient	
DAYS_TO_EVENT_AGGRESSIVE_DISEASE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	NUMBER	Event Free Days (Aggressive disease)	Patient	
DAYS_TO_EVENT_DISTANT_METASTASIS	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	NUMBER	Event Free Days (Distant Metastasis)	Patient	
DOPAMINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Dopamine Secreting	Sample	Yes
EPINEPHRINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Epinephrine Secreting	Sample	Yes
EXTENSIVE_LOCAL_INVASION	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Extensive Local Invasion	Patient	
LEUKOCYTE_INDEX_METHYLATION	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	NUMBER	Leukocyte Index Methylation	Sample	0.063507213 ; 0.149280741 ; 0.166017186 ; 0.134070872 ; 0.11073316 ; 0.047788116 ; 0.073169894 ; 0.078381684 ; 0.06593326 ; 0.114810597 ; 0.12898097 ; 0.107375481 ; 0.176773262 ; 0.062080894 ; 0.086247892 ; 0.060535734 ; 0.049006049 ; 0.095561638 ; 0.070872697 ; 0.077701264 ; 0.117229486 ; 0.082447897 ; 0.072864879 ; 0.136801628 ; 0.057716799 ; 0.079952063 ; 0.082337452 ; 0.050863241 ; 0.098960288 ; 0.083447984 ; 0.103225109 ; 0.059168235 ; 0.064184072 ; 0.06048959 ; 0.087795745 ; 0.084222579 ; 0.04842036 ; 0.160229105 ; 0.083478448 ; 0.10656879 ; 0.221159714 ; 0.056380241 ; 0.071991182 ; 0.114195624 ; 0.055019857 ; 0.047793153 ; 0.071422483 ; 0.045149084 ; 0.062245562 ; 0.037997153 ; 0.054125767 ; 0.253624327 ; 0.06936545 ; 0.047796865 ; 0.049125731 ; 0.162921494 ; 0.133836779 ; 0.249603836 ; 0.043974393 ; 0.076022386 ; 0.234458422 ; 0.108193972 ; 0.193440171 ; 0.087888465 ; 0.067440162 ; 0.139778295 ; 0.042584867 ; 0.123388216 ; 0.309773654 ; 0.029305719 ; 0.078797294 ; 0.027778126 ; 0.198564937 ; 0.180584994 ; 0.086587735 ; 0.097566167 ; 0.048744082 ; 0.109516192 ; 0.068356894 ; 0.046688854 ; 0.10956879 ; 0.064827879 ; 0.060440187 ; 0.07224372 ; 0.082019534 ; 0.253044867 ; 0.078872636 ; 0.098258145 ; 0.094848301 ; 0.115783773 ; 0.163736609 ; 0.167259388 ; 0.129616699 ; 0.159405991 ; 0.129234076 ; 0.309869577 ; 0.054734885 ; 0.570035691 ; 0.092262061 ; 0.167726309 ; 0.082293945 ; 0.112331112 ; 0.164101689 ; 0.046785097 ; 0.220244694 ; 0.065173177 ; 0.181296087 ; 0.058505056 ; 0.065224999 ; 0.070251514 ; 0.115670778 ; 0.103734722 ; 0.378436196 ; 0.067650153 ; 0.121535251 ; 0.106002168 ; 0.115774153 ; 0.090415842 ; 0.037917639 ; 0.084719609 ; 0.072357725 ; 0.059756751 ; 0.063577816 ; 0.068670319 ; 0.146599573 ; 0.226403825 ; 0.090865153 ; 0.040145574 ; 0.070305145 ; 0.078358756 ; 0.199100204 ; 0.120320018 ; 0.063117374 ; 0.103056367 ; 0.140157732 ; 0.059552275 ; 0.237181464 ; 0.059000922 ; 0.197181635 ; 0.043896898 ; 0.064024507 ; 0.104672424 ; 0.160184172 ; 0.07532094 ; 0.039387645 ; 0.127108219 ; 0.188615913 ; 0.078850246 ; 0.063781286 ; 0.059595233 ; 0.074754149 ; 0.080013912 ; 0.079232066 ; 0.122065275 ; 0.123402278 ; 0.13008261 ; 0.240124057 ; 0.031640896 ; 0.151232619 ; 0.101736901 ; 0.126445976 ; 0.083384154 ; 0.187977182 ; 0.04952206 ; 0.04606692 ; 0.157383858 ; 0.037768205 ; 0.104521 ; 0.108707013 ; 0.077509902 ; 0.089362098 ; 0.100524164 ; 0.140349295 ; 0.11614946 ; 0.102260746 ; 0.07275252 ; 0.199041128 ; 0.113887765
LOCAL_REGIONAL_DISEASE_AT_DIAGNOSIS	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Local Regional Disease at DiagNosis	Patient	
METANEPHRINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Metanephrine Secreting	Sample	Yes
METHOXYTYRAMINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Methoxytyramine Secreting	Sample	Yes
NOREPINEPHRINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Norepinephrine Secreting	Sample	Yes
NORMETANEPHRINE	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Normetanephrine secreting	Sample	Yes
PHEOCHROMOCYTOMA_OR_PARAGANGLIOMA	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Pheochromocytoma or Paraganglioma	Sample	pheochromocytoma ; paraganglioma
SPECIFIC_TUMOR_LOCATION	LightYellow	Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	STRING	Specific Tumor Location	Sample	Adrenal ; retrocaval retroperitoneum extra adrenal PGL ; peri-renal extra adrenal PGL ; thoracic paraspinal extra adrenal PGL ; intrapericardial para-aortic extra adrenal PGL ; retrocaval retroperitoneal extra adrenal PGL ; cardiac atrium extra adrenal PGL ; thoracic extra adrenal PGL ; aorto-caval peripancreatic presacral extra adrenal PGL ; peri-aortic retroperitoneal extra adrenal PGL ; aortocaval retroperitoneal extra adrenal PGL ; retroperitoneal extra adrenal PGL ; para-aortic extra adrenal PGL ; peri-adrenal extra adrenal PGL ; adrenal ; peri-adrenal retroperitoneal extra adrenal PGL ; minor pelvis extra adrenal PGL ; para-adrenal soft tissue extra adrenal PGL ; peri-aortic extra adrenal PGL above left renal vein ; porto-caval extra adrenal PGL ; throacic eipdural paraganglioma ; para-aortic/celiac artery extra adrenal PGL ; para-aortic /peri-caval retroperitoneal extra adrenal PGL ; para-aortic /peri-caval extra adrenal PGL ; thoracic mediastinal extra adrenal PGL
PAX_FUSION	LightYellow	Rhabdomyosarcoma (NIH, Cancer Discov 2014)	STRING	PAX Fusion	Sample	PAX7-FOX01 ; PAX7-FOXO1 ; PAX3-FOXO1 ; Fusion Negative (RNAseq) ; Fusion Negative (RT-PCR) ; PAX3-IN080D ; PAX3-NCOA1 (RNAseq)
AMP_12Q15_CDK4	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	AMP 12q15 CDK4	Sample	3.657 ; -0.034 ; -0.18 ; -0.016 ; 3.615 ; -0.005 ; -0.196 ; 0.008 ; -0.575 ; 0 ; -0.003 ; -0.614 ; 0.03 ; 0.001 ; -0.01 ; -0.653 ; -0.006 ; -0.022 ; -0.251 ; -0.051 ; 0.072 ; 0.02 ; -0.89 ; -0.416 ; -0.035 ; -0.207 ; -0.085 ; -0.083 ; -0.29 ; -0.837 ; 0.032 ; -0.461 ; -0.001 ; 0.022 ; -0.706 ; -0.523 ; 0.01 ; -0.14 ; 0.023 ; 0.009 ; 0.004 ; 0.019 ; 0.043 ; -0.78 ; -0.834 ; 0.504 ; -0.011 ; -0.008 ; -0.467 ; 0.035 ; 0.003 ; 0.005 ; -0.832 ; 0.014 ; -0.032 ; -0.031 ; -0.45 ; -0.563 ; -0.57 ; -0.456 ; 0.505 ; 0.002 ; 0.516 ; -0.914 ; 0.278 ; 0.686 ; -0.601 ; -0.355 ; -0.924 ; -0.121 ; -0.292 ; 0.173 ; 1.013 ; 0.021 ; -0.401 ; 0.103 ; -0.484 ; 0.161 ; 0.359 ; 0.436 ; -0.157 ; -0.269 ; -0.334 ; 0.843 ; -0.063 ; -0.371 ; -0.033 ; 0.287 ; 1.349 ; -0.105 ; -0.015 ; 0.176 ; -0.007 ; -0.262 ; -0.141 ; 2.292 ; -0.202 ; -0.049 ; -0.287 ; 0.099 ; 0.006 ; 0.012 ; 0.651 ; 0.049 ; -0.631 ; -0.252 ; 0.2 ; -0.045 ; -0.259 ; 0.024 ; 0.026 ; -0.025 ; -0.434 ; 0.185 ; -0.04 ; 0.135 ; -0.475 ; -0.472 ; 0.106 ; -0.078 ; 0.038 ; -0.047 ; 0.029 ; 0.503
AMP_12Q15_DDIT3	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	AMP 12q15 DDIT3	Sample	-0.189 ; -0.345 ; -0.173 ; -0.086 ; 3.657 ; -0.666 ; -0.034 ; 0.434 ; -0.328 ; -0.018 ; 0.001 ; -0.008 ; -0.181 ; 0.009 ; -0.187 ; -0.017 ; -0.879 ; 0.012 ; -0.063 ; 0.122 ; -0.249 ; -0.036 ; 3.463 ; -0.045 ; 3.431 ; -0.343 ; 0.057 ; -0.012 ; -0.478 ; 0.161 ; -0.016 ; -0.193 ; -0.009 ; 0.055 ; -0.049 ; 0.278 ; 3.486 ; -0.309 ; 0.011 ; -0.731 ; 0 ; -0.003 ; -0.969 ; 0.03 ; -0.928 ; -0.007 ; -0.022 ; -0.678 ; -0.057 ; 0.079 ; 0.023 ; -0.004 ; -0.95 ; -0.441 ; -0.038 ; -0.237 ; -0.095 ; -0.13 ; -0.315 ; -0.006 ; -0.862 ; 0.033 ; -0.502 ; -0.001 ; 0.029 ; -0.977 ; -0.621 ; 0.01 ; -0.152 ; 0.026 ; 0.004 ; 0.02 ; 0.449 ; -0.904 ; -1.009 ; 0.628 ; -0.594 ; 0.048 ; 0.003 ; 0.007 ; -0.996 ; 0.014 ; -0.04 ; -0.568 ; -0.644 ; -0.623 ; -0.511 ; 0.529 ; 0.002 ; -0.013 ; 0.578 ; 0.489 ; 0.768 ; -0.667 ; -0.416 ; -0.989 ; -0.971 ; -0.139 ; -0.314 ; 0.19 ; -0.005 ; 0.391 ; 1.013 ; 0.024 ; -0.525 ; 0.103 ; -0.549 ; 0.235 ; 0.667 ; 0.639 ; -0.24 ; -0.369 ; -0.425 ; 1.123 ; -0.072 ; -0.4 ; -0.046 ; 0.435 ; 0.005 ; 1.522 ; -0.154 ; 0.514 ; -0.306 ; -0.257 ; 1.393 ; -0.374 ; -0.376 ; 0.173 ; 0.013 ; 0.942 ; 0.066 ; -0.631 ; 0.345 ; -0.126 ; -0.056 ; -0.412 ; -0.292 ; 0.025 ; 0.034 ; -0.028 ; -0.588 ; 0.257 ; 0.378 ; -0.513 ; -0.518 ; 0.118 ; -0.253 ; 0.129 ; -0.066 ; 0.038 ; 0.589 ; -0.096
AMP_12Q15_FRS2	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	AMP 12q15 FRS2	Sample	3.657 ; 2.546 ; 0.002 ; 0.099 ; 2.331 ; -0.268 ; 0.678 ; 0.008 ; -0.575 ; 0 ; -0.003 ; -0.605 ; 0.599 ; 0.001 ; -0.01 ; -0.653 ; -0.006 ; -0.052 ; -0.251 ; -0.051 ; 0.072 ; 0.02 ; 0.019 ; -0.035 ; -0.207 ; -0.085 ; -0.083 ; -0.29 ; -0.005 ; -0.825 ; 0.024 ; -0.012 ; -0.461 ; -0.001 ; 0.022 ; -0.523 ; 0.011 ; -0.14 ; 0.023 ; 0.009 ; 0.004 ; 0.043 ; -0.78 ; -0.834 ; 0.504 ; -0.011 ; -0.008 ; -0.467 ; 0.005 ; 0.029 ; 0.003 ; -0.832 ; -0.032 ; -0.019 ; -0.45 ; -0.563 ; -0.57 ; -0.456 ; 0.505 ; 0.516 ; -0.914 ; 0.278 ; 0.686 ; -0.601 ; -0.355 ; -0.924 ; -0.121 ; -0.292 ; 0.173 ; 1.013 ; 0.021 ; -0.401 ; 0.103 ; 0.674 ; 0.161 ; 0.359 ; 0.436 ; -0.157 ; -0.269 ; -0.342 ; 0.843 ; -0.063 ; -0.371 ; 0.935 ; 0.287 ; 1.349 ; -0.105 ; -0.015 ; 0.176 ; -0.007 ; -0.226 ; -0.141 ; 0.881 ; -0.202 ; -0.106 ; -0.287 ; 0.14 ; 0.006 ; -0.013 ; 0.651 ; 0.049 ; -0.542 ; -0.252 ; 0.204 ; -0.045 ; 0.012 ; 0.137 ; 0.288 ; 0.026 ; -0.025 ; -0.434 ; 0.185 ; -0.04 ; 0.135 ; 0.78 ; 0.106 ; -0.078 ; 0.038 ; -0.047
AMP_12Q15_HMGA2	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	AMP 12q15 HMGA2	Sample	3.657 ; -0.098 ; -0.016 ; 1.738 ; -0.18 ; -0.021 ; 1.44 ; -0.492 ; -0.39 ; 0.012 ; 3.067 ; -0.032 ; -0.013 ; 1.519 ; 3.226 ; -0.003 ; 0.268 ; 0.017 ; 0.678 ; 0.008 ; -0.575 ; 0 ; -0.605 ; 0.071 ; 0.001 ; -0.01 ; -0.653 ; -0.006 ; -0.052 ; -0.251 ; -0.051 ; 0.072 ; 0.02 ; -0.424 ; -0.035 ; -0.207 ; -0.085 ; -0.083 ; -0.29 ; -0.005 ; -0.825 ; 0.024 ; -0.012 ; -0.461 ; -0.001 ; 0.022 ; -0.523 ; 0.011 ; -0.14 ; 0.023 ; 0.009 ; 0.004 ; 0.019 ; 0.043 ; -0.78 ; -0.834 ; 0.504 ; -0.011 ; -0.008 ; -0.467 ; 0.029 ; 0.003 ; 0.005 ; -0.832 ; -0.019 ; -0.45 ; -0.563 ; -0.57 ; -0.456 ; 0.505 ; 0.002 ; 0.516 ; -0.914 ; 0.278 ; 0.686 ; -0.601 ; -0.355 ; -0.924 ; -0.121 ; -0.292 ; 0.173 ; 1.013 ; 0.021 ; -0.401 ; 0.103 ; -0.484 ; 0.161 ; 0.359 ; 0.436 ; -0.157 ; -0.269 ; -0.342 ; 0.843 ; -0.063 ; -0.371 ; 0.377 ; 0.287 ; 1.349 ; -0.105 ; -0.015 ; 0.176 ; -0.007 ; -0.226 ; -0.141 ; 0.171 ; -0.202 ; -0.106 ; -0.287 ; 0.14 ; 0.006 ; 0.651 ; 0.049 ; -0.542 ; -0.252 ; 0.2 ; -0.045 ; 0.137 ; -0.71 ; 0.026 ; -0.025 ; -0.434 ; 0.185 ; -0.04 ; 0.135 ; -0.475 ; -0.52 ; 0.106 ; -0.078 ; 0.038 ; -0.047
AMP_12Q15_MDM2	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	AMP 12q15 MDM2	Sample	3.657 ; 2.948 ; 0.678 ; 0.008 ; -0.575 ; 0 ; -0.003 ; -0.605 ; 0.071 ; 0.001 ; -0.01 ; -0.653 ; -0.006 ; -0.052 ; -0.251 ; -0.051 ; 0.072 ; 0.02 ; 0.019 ; -0.035 ; -0.207 ; -0.085 ; -0.083 ; -0.29 ; -0.005 ; -0.825 ; 0.024 ; -0.012 ; -0.461 ; -0.001 ; 0.022 ; -0.523 ; 0.011 ; -0.14 ; 0.023 ; 0.009 ; 0.004 ; 0.043 ; -0.78 ; -0.834 ; 0.504 ; -0.011 ; -0.008 ; -0.467 ; 0.005 ; 0.029 ; 0.003 ; -0.832 ; -0.032 ; -0.019 ; -0.45 ; -0.563 ; -0.57 ; -0.456 ; 0.505 ; 0.002 ; 0.516 ; -0.914 ; 0.278 ; 0.686 ; -0.601 ; -0.355 ; -0.924 ; -0.121 ; -0.292 ; 0.173 ; 1.013 ; 0.021 ; -0.401 ; 0.103 ; 0.634 ; 0.161 ; 0.359 ; 0.436 ; -0.157 ; -0.269 ; -0.342 ; 0.843 ; -0.063 ; -0.371 ; 0.377 ; 0.287 ; 1.349 ; -0.105 ; -0.015 ; 0.176 ; -0.007 ; -0.226 ; -0.141 ; 0.142 ; -0.202 ; -0.106 ; -0.287 ; 0.14 ; 0.006 ; -0.013 ; 0.651 ; 0.049 ; -0.542 ; -0.252 ; 0.204 ; -0.045 ; 0.012 ; 0.137 ; 0.288 ; 0.026 ; -0.025 ; -0.434 ; 0.185 ; -0.04 ; 0.135 ; 0.78 ; -0.55 ; 0.106 ; -0.078 ; 0.038 ; -0.047
AVG_CN_12Q13_15	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	avg CN 12q13~15	Sample	25 ; 19 ; 8 ; 15 ; 13 ; 20 ; 23 ; 16 ; 3 ; 2 ; 1 ; 4 ; 5
CANCER_DNA_FRACTION	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	Cancer DNA Fraction	Sample	0.45 ; 0.68 ; 0.75 ; 0.57 ; 0.89 ; 0.66 ; 0.56 ; 0.61 ; 0.97 ; 0.44 ; 0.94 ; 0.92 ; 0.71 ; 0.4 ; 0.9 ; 0.73 ; 0.63 ; 1 ; 0.54 ; 0.27 ; 0.64 ; 0.93 ; 0.81 ; 0.99 ; 0.58 ; 0.88 ; 0.67 ; 0.96 ; 0.79 ; 0.78 ; 0.83 ; 0.69 ; 0.35 ; 0.91 ; 0.86 ; 0.95 ; 0.87 ; 0.98 ; 0.84 ; 0.8 ; 0.77 ; 0.72 ; 0.82 ; 0.38 ; 0.76 ; 0.85 ; 0.43 ; 0.53 ; 0.7 ; 0.65 ; 0.74 ; 0.34 ; 0.55 ; 0.37 ; 0.52 ; 0.42 ; 0.23 ; 0.62 ; 0.32
DAYS_TO_NEW_TUMOR_EVENT	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	Time interval from the date of new tumor event including progression, recurrence and new primary malignacies to the date of initial pathologic diagnosis, represented as a calculated number of days.	Patient	
DISEASE_MULTIFOCAL_INDICATOR	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Disease multifocal indicator	Patient	
DISTANT_RECURRENCE_SITE	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Distant Recurrence Site	Patient	
FNCLCC_GRADE	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	FNCLCC Grade	Sample	2 ; 3 ; 1
LEIOMYO_MAJOR_VESSEL_INVOLVEMENT	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Leiomyosarcoma major vessel involvement	Patient	
LEUKOCYTE_FRACTION	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	leukocyte_fraction	Sample	0.182637297 ; 0.483617791 ; 0.305910661 ; 0.169894503 ; 0.493090878 ; 0.098407784 ; 0.027675444 ; 0.339665347 ; 0.088691337 ; 0.464510751 ; 0.378329238 ; 0.679375286 ; 0.053580699 ; 0.645141824 ; 0.422456736 ; 0.338075655 ; 0.074588316 ; 0.055554853 ; 0.082191807 ; 0.589387758 ; 0.571234222 ; 0.372772701 ; 0.321057192 ; 0.443005207 ; 0.065996477 ; 0.270103936 ; 0.098334331 ; 0.359960129 ; 0.726627402 ; 0.057938787 ; 0.547557958 ; 0.296289534 ; 0.437185876 ; 0.191954905 ; 0.062584442 ; 0.483048209 ; 0.132330084 ; 0.24756068 ; 0.028125533 ; 0.794103913 ; 0.052872429 ; 0.102806277 ; 0.385340456 ; 0.05893163 ; 0.067129828 ; 0.168593368 ; 0.040703819 ; 0.27002485 ; 0.066362597 ; 0.29165922 ; 0.185409222 ; 0.173535108 ; 0.241127458 ; 0.019719217 ; 0.590875858 ; 0.363312094 ; 0.028491305 ; 0.348173733 ; 0.104016193 ; 0.324010992 ; 0.105440499 ; 0.032251225 ; 0.216892683 ; 0.043691669 ; 0.049590243 ; 0.106634167 ; 0.168745397 ; 0.06251683 ; 0.056495252 ; 0.025544344 ; 0.065221285 ; 0.060385989 ; 0.290820404 ; 0.038236115 ; 0.062701439 ; 0.089418993 ; 0.028139072 ; 0.035677364 ; 0.035328071 ; 0.062448188 ; 0.070583083 ; 0.056585815 ; 0.286449173 ; 0.287404969 ; 0.103627429 ; 0.019830549 ; 0.058842777 ; 0.119606099 ; 0.064890727 ; 0.058466907 ; 0.026763272 ; 0.041074484 ; 0.109631632 ; 0.124813141 ; 0.135011051 ; 0.118665365 ; 0.025302936 ; 0.022121793 ; 0.016903945 ; 0.186192199 ; 0.110094674 ; 0.312574468 ; 0.036128261 ; 0.182972984 ; 0.186027458 ; 0.03854779 ; 0.041155088 ; 0.421075875 ; 0.164985463 ; 0.014113615 ; 0.26443638 ; 0.097268466 ; 0.018770688 ; 0.050188173 ; 0.057177406 ; 0.048194595 ; 0.097281404 ; 0.154798086 ; 0.114911509 ; 0.05814924 ; 0.430051432 ; 0.100301041 ; 0.049636987 ; 0.118872806 ; 0.033922092 ; 0.011618332 ; 0.02911515 ; 0.090077349 ; 0.222437695 ; 0.030192461 ; 0.089223985 ; 0.407364936 ; 0.518926547 ; 0.04994695 ; 0.097256948 ; 0.25743788 ; 0.108401776 ; 0.36077993 ; 0.102097935 ; 0.228730696 ; 0.501107181 ; 0.285613987 ; 0.304423824 ; 0.143593754 ; 0.29562528 ; 0.228340073 ; 0.134046249 ; 0.145171865 ; 0.056031021 ; 0.292926832 ; 0.264766247 ; 0.347351638 ; 0.044842346 ; 0.088291052 ; 0.051651885 ; 0.060715317 ; 0.044684113 ; 0.049304373 ; 0.078745161 ; 0.040636902 ; 0.047982006 ; 0.055271184 ; 0.286521652 ; 0.215477866 ; 0.586281934 ; 0.598683358 ; 0.105498443 ; 0.440570368 ; 0.12678928 ; 0.410469453 ; 0.17671916 ; 0.2572005 ; 0.377537384 ; 0.221826044 ; 0.068167718 ; 0.2666446 ; 0.243464362 ; 0.062347785 ; 0.204618733 ; 0.155509825 ; 0.405935626 ; 0.61477606 ; 0.475585559 ; 0.099464701 ; 0.559988347 ; 0.324223236 ; 0.283386498 ; 0.04950557 ; 0.291595806 ; 0.72143242 ; 0.063791614 ; 0.215683679 ; 0.313261945 ; 0.351208527 ; 0.091812937 ; 0.553255222 ; 0.093542064 ; 0.095907168 ; 0.121974596 ; 0.555505931 ; 0.669294803 ; 0.054810616 ; 0.282531578 ; 0.254465936 ; 0.153271075 ; 0.13387455
MONTHS_TO_DISTANT_RECURRENCE	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	Months to distant recurrence.	Patient	
NEW_TUMOR_EVENT_DX_INDICATOR	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	New tumor event dx indicator	Patient	
PARADIGM_CLUSTER	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	PARADIGM CLUSTER	Sample	4 ; 1 ; 5 ; 2 ; 3
SHORT_HISTOLOGY	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Short Histology	Patient	
SUBCLONAL_GENOMIC_FRACTION	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	NUMBER	Subclone Genomic Fraction	Sample	0.07 ; 0.43 ; 0.33 ; 0.21 ; 0.11 ; 0.31 ; 0 ; 0.61 ; 0.01 ; 0.12 ; 0.02 ; 0.03 ; 0.48 ; 0.04 ; 0.1 ; 0.18 ; 0.14 ; 0.28 ; 0.27 ; 0.16 ; 0.51 ; 0.08 ; 0.06 ; 0.13 ; 0.09 ; 0.15 ; 0.25 ; 0.24 ; 0.37 ; 0.39 ; 0.2 ; 0.29 ; 0.34 ; 0.23 ; 0.36 ; 0.58 ; 0.32 ; 0.19 ; 0.4 ; 0.17 ; 0.05 ; 0.55 ; 0.22 ; 0.46 ; 0.38 ; 0.26 ; 0.52 ; 0.75 ; 0.65 ; 0.78 ; 0.3
SYNOVIAL_SS18SSX_FUSION_STATUS	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Synovial ss18ssx fusion status	Sample ; Patient	Unknown ; Positive - SS18-SSX2
TREATMENT_OUTCOME_AT_TCGA_FOLLOWUP	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	treatment outcome at tcga followup	Patient	
TUMOR_TOTAL_DEPTH	LightYellow	Adult Soft Tissue Sarcomas (TCGA, Cell 2017)	STRING	Tumor total depth	Sample ; Patient	Unknown ; Deep ; Superficial
FACETS_REVIEW	LightYellow	Sarcoma (MSK, Nat Commun. 2022)	STRING	FACETs Review	Sample	YES ; NO
FACETS_WGD	LightYellow	Sarcoma (MSK, Nat Commun. 2022)	STRING	FACETs WGD	Sample	FALSE ; TRUE
FGA_REPORTED	LightYellow	Sarcoma (MSK, Nat Commun. 2022)	NUMBER	FGA Reported	Sample	0.0793 ; 0.1107 ; 0.0574 ; 0.1414 ; 0.0038 ; 0.0959 ; 0.0199 ; 0.5637 ; 0.3129 ; 0.1997 ; 0.0026 ; 0.0712 ; 0.1986 ; 0.1156 ; 0.0169 ; 0.2961 ; 0.0091 ; 0.1484 ; 0.5365 ; 0.3504 ; 0.0149 ; 0.1064 ; 0.0036 ; 0.4975 ; 0.2363 ; 0.3336 ; 0.022 ; 0.3289 ; 0 ; 1.00E-04 ; 0.0583 ; 0.001 ; 0.0211 ; 0.0368 ; 0.1523 ; 0.1108 ; 0.0013 ; 0.0826 ; 4.00E-04 ; 0.0934 ; 0.2581 ; 0.2752 ; 0.1372 ; 0.0972 ; 0.1529 ; 0.1531 ; 0.0628 ; 0.0509 ; 0.1023 ; 0.0224 ; 0.0151 ; 0.004 ; 0.0791 ; 0.0663 ; 0.0727 ; 0.0061 ; 0.0044 ; 0.0071 ; 0.1433 ; 0.0033 ; 0.24 ; 0.1324 ; 0.2472 ; 0.0077 ; 0.1507 ; 0.0024 ; 0.3503 ; 0.2886 ; 0.3304 ; 0.1744 ; 0.1176 ; 0.2229 ; 0.5327 ; 0.1479 ; 0.0025 ; 0.3515 ; 0.1415 ; 0.0096 ; 0.053 ; 0.0045 ; 0.0018 ; 0.2388 ; 0.0266 ; 0.1212 ; 0.2414 ; 0.0582 ; 0.06 ; 0.0059 ; 0.2195 ; 0.1632 ; 0.0247 ; 0.0511 ; 0.0022 ; 0.0047 ; 0.1102 ; 0.1364 ; 5.00E-04 ; 0.2063 ; 0.0844 ; 0.0813 ; 0.1726 ; 0.0578 ; 0.0226 ; 0.1219 ; 0.3424 ; 0.4221 ; 0.5385 ; 0.003 ; 0.3136 ; 0.5477 ; 0.2742 ; 0.4122 ; 0.3416 ; 0.0384 ; 3.00E-04 ; 0.3521 ; 0.2613 ; 0.0889 ; 0.5867 ; 0.0402 ; 0.0052 ; 0.0736 ; 0.2084 ; 0.0168 ; 0.1911 ; 0.0631 ; 0.1764 ; 0.0608 ; 0.041 ; 0.0862 ; 0.0521 ; 0.1222 ; 0.1646 ; 0.0029 ; 0.2575 ; 0.0023 ; 0.0474 ; 0.0079 ; 0.0888 ; 0.1187 ; 0.0949 ; 0.2929 ; 0.1989 ; 0.226 ; 0.0592 ; 6.00E-04 ; 0.561 ; 0.9351 ; 0.2447 ; 0.1685 ; 0.2971 ; 0.0671 ; 0.1508 ; 0.1037 ; 0.3204 ; 0.064 ; 0.0316 ; 0.315 ; 0.0842 ; 0.045 ; 0.1205 ; 0.2525 ; 0.4839 ; 0.0054 ; 0.0142 ; 0.3858 ; 0.4721 ; 0.0166 ; 0.9887 ; 0.2284 ; 0.3151 ; 0.0111 ; 0.9771 ; 0.4488 ; 0.1428 ; 0.1847 ; 0.3377 ; 0.3574 ; 0.197 ; 0.0943 ; 0.0012 ; 0.7838 ; 0.4086 ; 0.6367 ; 8.00E-04 ; 0.0771 ; 0.9307 ; 0.4029 ; 0.1619 ; 0.054 ; 0.0049 ; 0.2012 ; 0.6256 ; 0.1559 ; 0.2524 ; 0.0174 ; 0.0499 ; 0.5181 ; 0.0503 ; 0.2254 ; 0.1435 ; 0.0099 ; 0.0223 ; 0.0377 ; 0.16 ; 0.2708 ; 0.15 ; 0.2533 ; 0.2288 ; 0.0115 ; 0.3588 ; 0.1859 ; 0.0444 ; 0.2391 ; 0.1251 ; 0.1838 ; 0.0145 ; 0.3736 ; 0.2319 ; 0.5876 ; 0.4658 ; 0.0232 ; 0.2029 ; 0.1272 ; 0.3216 ; 0.0242 ; 0.014 ; 0.011 ; 0.0046 ; 0.0417 ; 0.4387 ; 0.0227 ; 0.0027 ; 0.3853 ; 0.1084 ; 0.2586 ; 0.1688 ; 0.052 ; 0.1019 ; 0.0471 ; 0.4464 ; 0.1626 ; 0.3798 ; 0.1644 ; 0.2486 ; 0.2016 ; 0.1785 ; 0.0101 ; 0.0117 ; 0.0126 ; 0.1032 ; 0.406 ; 0.0135 ; 0.2642 ; 0.0412 ; 0.0221 ; 0.0345 ; 0.0156 ; 0.1311 ; 0.0016 ; 0.1751 ; 0.2809 ; 0.0901 ; 0.0076 ; 0.2845 ; 0.6156 ; 0.0095 ; 0.0209 ; 0.2049 ; 0.3095 ; 0.3086 ; 0.0183 ; 0.3082 ; 0.016 ; 0.2157 ; 0.1757 ; 0.0086 ; 0.4264 ; 0.0543 ; 0.0065 ; 0.2478 ; 0.0201 ; 0.2395 ; 0.1333 ; 0.202 ; 0.1363 ; 0.6391 ; 0.1834 ; 0.0369 ; 0.009 ; 0.0401 ; 0.0176 ; 0.1315 ; 0.3025 ; 0.0131 ; 0.1029 ; 0.2464 ; 0.2142 ; 0.0724 ; 0.0107 ; 0.2011 ; 0.3922 ; 0.0021 ; 0.0349 ; 0.0118 ; 0.156 ; 0.2558 ; 0.1965 ; 0.1063 ; 0.2017 ; 0.0776 ; 0.1945 ; 0.1405 ; 0.0125 ; 0.0116 ; 0.3741 ; 0.0225 ; 0.0112 ; 0.0068 ; 0.0214 ; 0.0157 ; 0.0875 ; 0.0568 ; 0.021 ; 0.0062 ; 0.3332 ; 0.0106 ; 0.2116 ; 0.0448 ; 0.3033 ; 0.0251 ; 0.0697 ; 0.093 ; 0.0757 ; 0.4031 ; 0.0035 ; 0.0102 ; 0.0087 ; 2.00E-04 ; 0.141 ; 0.0017 ; 0.0137 ; 0.0593 ; 0.4969 ; 0.3721 ; 0.0932 ; 0.0939 ; 0.1134 ; 0.1821 ; 0.1769 ; 0.1409 ; 0.1411 ; 0.0716 ; 0.1909 ; 0.2459 ; 0.1266 ; 0.1924 ; 0.1972 ; 0.0559 ; 0.0257 ; 9.00E-04 ; 0.0048 ; 0.0318 ; 0.5818 ; 0.1021 ; 0.0439 ; 0.21 ; 0.0752 ; 0.2303 ; 0.0363 ; 0.0089 ; 0.1596 ; 0.0693 ; 0.2498 ; 0.0652 ; 0.1546 ; 0.2377 ; 0.2442 ; 0.2048 ; 0.0987 ; 0.0353 ; 0.0927 ; 0.549 ; 0.1154 ; 0.0957 ; 0.2358 ; 0.2365 ; 0.0644 ; 0.0979 ; 0.0181 ; 0.111 ; 0.2511 ; 0.0041 ; 0.1241 ; 0.1839 ; 0.0464 ; 0.4435 ; 0.1576 ; 0.274 ; 0.2561 ; 0.103 ; 0.1341 ; 0.0269 ; 0.1213 ; 0.1197 ; 0.1207 ; 0.0141 ; 0.1518 ; 0.2208 ; 0.2227 ; 0.0134 ; 0.2452 ; 0.1866 ; 0.0152 ; 0.0015 ; 0.0482 ; 0.012 ; 0.1912 ; 0.1451 ; 0.0508 ; 0.5515 ; 0.2374 ; 0.4645 ; 0.2884 ; 0.5973 ; 0.2901 ; 0.363 ; 0.2323 ; 0.5188 ; 0.8814 ; 0.0589 ; 0.4124 ; 0.3974 ; 0.286 ; 0.0524 ; 0.5879 ; 0.6574 ; 0.5959 ; 0.0743 ; 0.6528 ; 0.1053 ; 0.4306 ; 0.2245 ; 0.137 ; 0.5527 ; 0.2557 ; 0.7398 ; 0.1223 ; 0.5259 ; 0.2904 ; 0.568 ; 0.0977 ; 0.5123 ; 0.6561 ; 0.0835 ; 0.6199 ; 0.7499 ; 0.2422 ; 0.0051 ; 0.0615 ; 0.1167 ; 0.2234 ; 0.3856 ; 0.4075 ; 0.0249 ; 0.1305 ; 0.0407 ; 0.126 ; 0.0744 ; 0.2045 ; 0.0612 ; 0.0019 ; 0.0032 ; 0.0332 ; 0.0371 ; 0.0759 ; 0.1119 ; 0.187 ; 0.0506 ; 0.1893 ; 0.3387 ; 0.18 ; 0.1631 ; 0.5785 ; 0.2877 ; 0.0505 ; 0.1307 ; 0.2196 ; 0.2621 ; 0.061 ; 0.3697 ; 0.0649 ; 0.1105 ; 0.0028 ; 0.0837 ; 0.1419 ; 0.0128 ; 0.1124 ; 0.2483 ; 0.738 ; 0.1421 ; 0.0996 ; 0.0397 ; 0.0258 ; 0.0958 ; 0.1228 ; 0.0075 ; 0.1232 ; 0.0362 ; 0.1845 ; 0.3509 ; 0.6139 ; 0.1114 ; 0.0677 ; 0.0978 ; 0.1466 ; 0.0923 ; 0.2891 ; 0.0994 ; 0.2878 ; 0.1575 ; 0.0083 ; 0.365 ; 0.7855 ; 0.0597 ; 0.125 ; 0.2788 ; 0.0039 ; 0.3537 ; 0.3311 ; 0.2409 ; 0.0178 ; 0.3527 ; 0.2798 ; 0.4294 ; 0.3705 ; 0.2269 ; 0.383 ; 0.4272 ; 0.6023 ; 0.4704 ; 0.6079 ; 0.4034 ; 0.1704 ; 0.5197 ; 0.0541 ; 0.1214 ; 0.4657 ; 0.2354 ; 0.4348 ; 0.37 ; 0.2807 ; 0.2777 ; 0.4237 ; 0.1844 ; 0.773 ; 0.394 ; 0.2722 ; 0.6426 ; 0.3538 ; 0.1101 ; 0.1557 ; 0.2902 ; 0.2908 ; 0.2958 ; 0.2666 ; 0.2212 ; 0.2178 ; 0.0887 ; 0.0121 ; 0.0573 ; 0.1403 ; 0.0778 ; 0.2559 ; 0.1916 ; 0.0926 ; 0.2382 ; 0.0783 ; 0.127 ; 0.0256 ; 0.3674 ; 0.3137 ; 0.6165 ; 0.654 ; 0.3664 ; 0.4152 ; 0.1384 ; 0.0365 ; 0.05 ; 0.1569 ; 0.6065 ; 0.0173 ; 0.3062 ; 0.191 ; 0.4011 ; 0.1375 ; 0.2441 ; 0.4138 ; 0.0758 ; 0.3098 ; 0.0154 ; 0.2805 ; 0.1264 ; 0.1399 ; 0.0998 ; 0.034 ; 0.2124 ; 0.1737 ; 0.1189 ; 0.3775 ; 0.6319 ; 0.8423 ; 0.5047 ; 0.2025 ; 0.2098 ; 0.3061 ; 0.03 ; 0.0298 ; 0.1832 ; 0.1865 ; 0.0576 ; 0.3679 ; 0.0547 ; 0.1267 ; 0.2783 ; 0.0531 ; 0.3955 ; 0.2547 ; 0.0785 ; 0.2597 ; 0.1776 ; 0.2871 ; 0.5579 ; 0.1566 ; 0.1321 ; 0.1787 ; 0.5487 ; 0.1937 ; 0.204 ; 0.3411 ; 0.2221 ; 0.1779 ; 0.4041 ; 0.1901 ; 0.1209 ; 0.2903 ; 0.254 ; 0.243 ; 0.1236 ; 0.2977 ; 0.1545 ; 0.2694 ; 0.129 ; 0.1875 ; 0.0386 ; 0.0718 ; 0.317 ; 0.0966 ; 0.0319 ; 0.1424 ; 0.2678 ; 0.5552 ; 0.2746 ; 0.1727 ; 0.0831 ; 0.3013 ; 0.1383 ; 0.2787 ; 0.3606 ; 0.2111 ; 0.2021 ; 0.2346 ; 0.2362 ; 0.4252 ; 0.2258 ; 0.0938 ; 0.0413 ; 0.1922 ; 0.4794 ; 0.0486 ; 0.2463 ; 0.1957 ; 0.1038 ; 0.3284 ; 0.1182 ; 0.2823 ; 0.206 ; 0.1492 ; 0.3465 ; 0.0805 ; 0.3517 ; 0.6598 ; 0.3707 ; 0.2825 ; 0.2243 ; 0.2162 ; 0.2013 ; 0.1729 ; 0.2505 ; 0.1309 ; 0.6259 ; 0.1955 ; 0.4889 ; 0.3708 ; 0.2485 ; 0.104 ; 0.4824 ; 0.3556 ; 0.2075 ; 0.3822 ; 0.1563 ; 0.0098 ; 0.5783 ; 0.8001 ; 0.5082 ; 0.0336 ; 0.2959 ; 0.8063 ; 0.7885 ; 0.1668 ; 0.0944 ; 0.1639 ; 0.1163 ; 0.1836 ; 0.0055 ; 0.4486 ; 0.1952 ; 0.316 ; 0.3334 ; 0.2952 ; 0.5521 ; 0.4099 ; 0.0415 ; 0.031 ; 0.0348 ; 0.115 ; 0.2758 ; 0.6228 ; 0.0031 ; 0.0292 ; 0.556 ; 0.2811 ; 0.3482 ; 0.1564 ; 0.3121 ; 0.3709 ; 0.029 ; 0.4974 ; 0.2469 ; 0.2747 ; 0.0114 ; 0.2467 ; 0.1455 ; 0.6117 ; 0.1585 ; 0.0416 ; 0.5498 ; 0.2082 ; 0.1033 ; 0.3193 ; 0.1628 ; 0.0874 ; 0.1687 ; 0.2988 ; 0.1709 ; 0.1051 ; 0.1852 ; 0.0877 ; 0.1195 ; 0.2681 ; 0.3371 ; 0.9484 ; 0.1876 ; 0.821 ; 0.0775 ; 0.0385 ; 0.609 ; 0.5392 ; 0.6134 ; 0.04 ; 0.0538 ; 0.1337 ; 0.0403 ; 0.2061 ; 0.2583 ; 0.2857 ; 0.1291 ; 0.1323 ; 0.1853 ; 0.2853 ; 0.0699 ; 0.2629 ; 0.1218 ; 0.0398 ; 0.3029 ; 0.3585 ; 0.2863 ; 0.3854 ; 0.797 ; 0.185 ; 0.071 ; 0.3687 ; 0.1565 ; 0.292 ; 0.1297 ; 0.3655 ; 0.0523 ; 0.2831 ; 0.1498 ; 0.3432 ; 0.0302 ; 0.5787 ; 0.2539 ; 0.1106 ; 0.0285 ; 0.4287 ; 0.5794 ; 0.4526 ; 0.1616 ; 0.2861 ; 0.0475 ; 0.0034 ; 0.0375 ; 0.2443 ; 0.2237 ; 0.4717 ; 0.3092 ; 0.0296 ; 0.1334 ; 0.1843 ; 0.0981 ; 0.4759 ; 0.0915 ; 0.1946 ; 0.1643 ; 0.0405 ; 0.1116 ; 0.002 ; 0.2676 ; 0.182 ; 0.0561 ; 0.1081 ; 0.1524 ; 0.0745 ; 0.1723 ; 0.1874 ; 0.1434 ; 0.0462 ; 0.1245 ; 0.5039 ; 0.6893 ; 0.6153 ; 0.1975 ; 0.0175 ; 0.7042 ; 0.1006 ; 0.2847 ; 0.1732 ; 0.1795 ; 0.1472 ; 0.166 ; 0.0301 ; 0.0423 ; 0.916 ; 0.0941 ; 0.0358 ; 0.1513 ; 0.1758 ; 0.1235 ; 0.0344 ; 0.0189 ; 0.0195 ; 0.0953 ; 0.2216 ; 0.079 ; 0.2495 ; 0.1777 ; 0.0042 ; 0.5504 ; 0.3591 ; 0.4961 ; 0.4812 ; 0.3992 ; 0.5535 ; 0.5092 ; 0.4493 ; 0.5597 ; 0.4833 ; 0.5026 ; 0.4675 ; 0.5063 ; 0.4784 ; 0.0264 ; 0.0204 ; 0.0342 ; 0.0153 ; 0.0687 ; 0.0434 ; 0.1339 ; 0.1281 ; 0.0667 ; 0.0252 ; 0.7897 ; 0.1244 ; 0.2725 ; 0.2569 ; 0.5695 ; 0.5187 ; 0.2786 ; 0.092 ; 0.4566 ; 0.7372 ; 0.3047 ; 0.4096 ; 0.5135 ; 0.4724 ; 0.2804 ; 0.7288 ; 0.587 ; 0.3283 ; 0.0094 ; 0.489 ; 0.2733 ; 0.653 ; 0.4342 ; 0.6239 ; 0.4411 ; 0.3815 ; 0.1357 ; 0.2113 ; 0.167 ; 0.1356 ; 0.7496 ; 0.4799 ; 0.146 ; 0.5987 ; 0.3533 ; 0.2639 ; 0.0989 ; 0.2145 ; 0.2966 ; 0.2789 ; 0.4521 ; 0.2981 ; 0.1558 ; 0.459 ; 0.4573 ; 0.2399 ; 0.2962 ; 0.3675 ; 0.5105 ; 0.3067 ; 0.3649 ; 0.2125 ; 0.4265 ; 0.2713 ; 0.8269 ; 0.5377 ; 0.2419 ; 0.3648 ; 0.6751 ; 0.3566 ; 0.511 ; 0.9197 ; 0.706 ; 0.0851 ; 0.6627 ; 0.1895 ; 0.0123 ; 0.3241 ; 0.2235 ; 0.3471 ; 0.1191 ; 0.1477 ; 0.5242 ; 0.5246 ; 0.4169 ; 0.6371 ; 0.0648 ; 0.6809 ; 0.6428 ; 0.2236 ; 0.1578 ; 0.1514 ; 0.5721 ; 0.3863 ; 0.3949 ; 0.2875 ; 0.3628 ; 0.4552 ; 0.4959 ; 0.4613 ; 0.231 ; 0.4217 ; 0.5247 ; 0.3215 ; 0.5236 ; 0.4925 ; 0.5716 ; 0.2426 ; 0.1275 ; 0.4014 ; 0.1974 ; 0.6772 ; 0.1592 ; 0.3788 ; 0.5621 ; 0.4095 ; 0.6038 ; 0.2625 ; 0.0177 ; 0.5871 ; 0.3261 ; 0.6133 ; 0.2174 ; 0.5983 ; 0.4697 ; 0.1345 ; 0.0419 ; 0.64 ; 0.6107 ; 0.6401 ; 0.2659 ; 0.2515 ; 0.1469 ; 0.6909 ; 0.3514 ; 0.3689 ; 0.1854 ; 0.1537 ; 0.5938 ; 0.5478 ; 0.3231 ; 0.3382 ; 0.6786 ; 0.4369 ; 0.4374 ; 0.2023 ; 0.5601 ; 0.4547 ; 0.7385 ; 0.149 ; 0.0182 ; 0.2041 ; 0.2421 ; 0.0601 ; 0.5344 ; 0.0859 ; 0.5013 ; 0.1655 ; 0.4992 ; 0.41 ; 0.3399 ; 0.2544 ; 0.1942 ; 0.5763 ; 0.656 ; 0.3191 ; 0.2342 ; 0.19 ; 0.545 ; 0.3821 ; 0.5433 ; 0.3346 ; 0.8522 ; 0.1886 ; 0.2953 ; 0.4434 ; 0.2148 ; 0.5607 ; 0.49 ; 0.2457 ; 0.0848 ; 0.1597 ; 0.7417 ; 0.1016 ; 0.6082 ; 0.376 ; 0.2928 ; 0.7049 ; 0.4753 ; 0.3852 ; 0.4027 ; 0.3038 ; 0.2669 ; 0.2088 ; 0.0289 ; 0.2128 ; 0.055 ; 0.1008 ; 0.006 ; 0.1256 ; 0.3945 ; 0.4755 ; 0.0376 ; 0.113 ; 0.1028 ; 0.0346 ; 0.028 ; 0.0623 ; 7.00E-04 ; 0.0591 ; 0.107 ; 0.1211 ; 0.109 ; 0.0653 ; 0.02 ; 0.173 ; 0.0265 ; 0.0163 ; 0.3558 ; 0.6224 ; 0.0056 ; 0.0952 ; 0.0904 ; 0.142 ; 0.4575 ; 0.5034 ; 0.521 ; 0.1661 ; 0.1801 ; 0.5529 ; 0.1719 ; 0.3959 ; 0.0638 ; 0.0327 ; 0.4888 ; 0.4148 ; 0.6679 ; 0.5476 ; 0.0308 ; 0.1057 ; 0.4853 ; 0.4698 ; 0.539 ; 0.1135 ; 0.3659 ; 0.4772 ; 0.1482 ; 0.0057 ; 0.4705 ; 0.3094 ; 0.0124 ; 0.3564 ; 0.2672 ; 0.6067 ; 0.2565 ; 0.3172 ; 0.499 ; 0.4998 ; 0.5792 ; 0.3495 ; 0.2627 ; 0.5167 ; 0.3901 ; 0.3599 ; 0.205 ; 0.5027 ; 0.519 ; 0.0229 ; 0.0544 ; 0.6795 ; 0.644 ; 0.2028 ; 0.2149 ; 0.2994 ; 0.1443 ; 0.3684 ; 0.2701 ; 0.4599 ; 0.4206 ; 0.6088 ; 0.0909 ; 0.3437 ; 0.1998 ; 0.0388 ; 0.4739 ; 0.2369 ; 0.4763 ; 0.4481 ; 0.6085 ; 0.0731 ; 0.4131 ; 0.4139 ; 0.0072 ; 0.0372 ; 0.5325 ; 0.1122 ; 0.0203 ; 0.2955 ; 0.3046 ; 0.2181 ; 0.3802 ; 0.0335 ; 0.8304 ; 0.3597 ; 0.3242 ; 0.1445 ; 0.4572 ; 0.5596 ; 0.6057 ; 0.0119 ; 0.0207 ; 0.2623 ; 0.3101 ; 0.1968 ; 0.4156 ; 0.5883 ; 0.5272 ; 0.6602 ; 0.6651 ; 0.2827 ; 0.2631 ; 0.4226 ; 0.1287 ; 0.6616 ; 0.1504 ; 0.2905 ; 0.1462 ; 0.4605 ; 0.1298 ; 0.5152 ; 0.2281 ; 0.5252 ; 0.3367 ; 0.4477 ; 0.6045 ; 0.5402 ; 0.3998 ; 0.5251 ; 0.0967 ; 0.1549 ; 0.2139 ; 0.0715 ; 0.1984 ; 0.0184 ; 0.7111 ; 0.9365 ; 0.7803 ; 0.6127 ; 0.359 ; 0.2305 ; 0.3117 ; 0.0786 ; 0.3726 ; 0.7533 ; 0.4816 ; 0.7162 ; 0.3995 ; 0.5942 ; 0.421 ; 0.0092 ; 0.0011 ; 0.3691 ; 0.0647 ; 0.0497 ; 0.1343 ; 0.2614 ; 0.036 ; 0.0014 ; 0.0067 ; 0.0676 ; 0.2201 ; 0.7569 ; 0.1265 ; 0.0634 ; 0.1342 ; 0.1367 ; 0.1026 ; 0.1234 ; 0.0138 ; 0.1438 ; 0.0945 ; 0.1872 ; 0.5028 ; 0.048 ; 0.1417 ; 0.1756 ; 0.0493 ; 0.2001 ; 0.2552 ; 0.1544 ; 0.1833 ; 0.0881 ; 0.0723 ; 0.0383 ; 0.3887 ; 0.3496 ; 0.3742 ; 0.2301 ; 0.2156 ; 0.5927 ; 0.4569 ; 0.0869 ; 0.0717 ; 0.0146 ; 0.0569 ; 0.0729 ; 0.1318 ; 0.0929 ; 0.2438 ; 0.344 ; 0.1055 ; 0.0053 ; 0.1571 ; 0.0172 ; 0.0641 ; 0.1652 ; 0.0058 ; 0.0378 ; 0.0622 ; 0.2209 ; 0.2489 ; 0.6556 ; 0.2279 ; 0.3037 ; 0.1654 ; 0.1824 ; 0.257 ; 0.0084 ; 0.1035 ; 0.5725 ; 0.0341 ; 0.0073 ; 0.1774 ; 0.8047 ; 0.1085 ; 0.0515 ; 0.291 ; 0.0968 ; 0.0259 ; 0.2058 ; 0.7514 ; 0.2057 ; 0.177 ; 0.3271 ; 0.1695 ; 0.0698 ; 0.1276 ; 0.2267 ; 0.2002 ; 0.0343 ; 0.2186 ; 0.22 ; 0.4965 ; 0.0399 ; 0.1752 ; 0.0248 ; 0.0984 ; 0.5737 ; 0.1987 ; 0.0127 ; 0.2619 ; 0.0317 ; 0.0452 ; 0.2389 ; 0.3545 ; 0.114 ; 0.0254 ; 0.1394 ; 0.3232 ; 0.0734 ; 0.0409 ; 0.2592 ; 0.1115 ; 0.0674 ; 0.8553 ; 0.9915 ; 0.0427 ; 0.0234 ; 0.0263 ; 0.1453 ; 0.3369 ; 0.4412 ; 0.3059 ; 0.1296 ; 0.0159 ; 0.3446 ; 0.2644 ; 0.235 ; 0.2239 ; 0.2132 ; 0.1707 ; 0.216 ; 0.3769 ; 0.4413 ; 0.1932 ; 0.7565 ; 0.3309 ; 0.267 ; 0.6521 ; 0.7016 ; 0.2085 ; 0.2144 ; 0.6257 ; 0.1288 ; 0.6364 ; 0.3003 ; 0.1493 ; 0.0691 ; 0.566 ; 0.4667 ; 0.3147 ; 0.2757 ; 0.0133 ; 0.1369 ; 0.6096 ; 0.1694 ; 0.1999 ; 0.4419 ; 0.6808 ; 0.0238 ; 0.2654 ; 0.581 ; 0.8101 ; 0.5443 ; 0.5165 ; 0.1567 ; 0.2408 ; 0.5218 ; 0.6456 ; 0.5354 ; 0.1991 ; 0.6654 ; 0.4002 ; 0.3146 ; 0.5934 ; 0.5204 ; 0.2843 ; 0.4789 ; 0.1148 ; 0.3084 ; 0.2381 ; 0.7058 ; 0.2151 ; 0.4768 ; 0.665 ; 0.6345 ; 0.3468 ; 0.5162 ; 0.1141 ; 0.1092 ; 0.4545 ; 0.6652 ; 0.3 ; 0.5574 ; 0.4905 ; 0.2385 ; 0.8919 ; 0.6445 ; 0.3053 ; 0.345 ; 0.768 ; 0.554 ; 0.5508 ; 0.1771 ; 0.2735 ; 0.4088 ; 0.5831 ; 0.2784 ; 0.305 ; 0.4425 ; 0.6182 ; 0.1742 ; 0.2602 ; 0.2579 ; 0.1755 ; 0.1355 ; 0.564 ; 0.5686 ; 0.3718 ; 0.6286 ; 0.2604 ; 0.6281 ; 0.5873 ; 0.0632 ; 0.246 ; 0.0109 ; 0.9628 ; 0.5619 ; 0.3906 ; 0.455 ; 0.3425 ; 0.7315 ; 0.1857 ; 0.2889 ; 0.3202 ; 0.2692 ; 0.3396 ; 0.3476 ; 0.0284 ; 0.4589 ; 0.4696 ; 0.8315 ; 0.3395 ; 0.2428 ; 0.4307 ; 0.6301 ; 0.2675 ; 0.7175 ; 0.3299 ; 0.3035 ; 0.577 ; 0.0546 ; 0.3529 ; 0.1602 ; 0.2031 ; 0.2521 ; 0.2036 ; 0.2224 ; 0.7572 ; 0.207 ; 0.6899 ; 0.0755 ; 0.55 ; 0.3942 ; 0.1883 ; 0.7163 ; 0.0165 ; 0.3057 ; 0.4324 ; 0.1354 ; 0.0136 ; 0.47 ; 0.5386 ; 0.3486 ; 0.5349 ; 0.3488 ; 0.4127 ; 0.3796 ; 0.462 ; 0.6114 ; 0.3948 ; 0.8211 ; 0.6148 ; 0.1268 ; 0.049 ; 0.5809 ; 0.7602 ; 0.2841 ; 0.3263 ; 0.6676 ; 0.4362 ; 0.2683 ; 0.2638 ; 0.1953 ; 0.4322 ; 0.7522 ; 0.4669 ; 0.5741 ; 0.1962 ; 0.2415 ; 0.3519 ; 0.1052 ; 0.5701 ; 0.212 ; 0.1269 ; 0.4238 ; 0.4836 ; 0.722 ; 0.1377 ; 0.2343 ; 0.5445 ; 0.4288 ; 0.431 ; 0.0627 ; 0.3518 ; 0.429 ; 0.0519 ; 0.6299 ; 0.2278 ; 0.0832 ; 0.3123 ; 0.4125 ; 0.2387 ; 0.0194 ; 0.677 ; 0.0554 ; 0.4383 ; 0.2607 ; 0.3805 ; 0.057 ; 0.6022 ; 0.3715 ; 0.7079 ; 0.2948 ; 0.5635 ; 0.3985 ; 0.0599 ; 0.4563 ; 0.215 ; 0.525 ; 0.5233 ; 0.4903 ; 0.4314 ; 0.5846 ; 0.5533 ; 0.5093 ; 0.1071 ; 0.3422 ; 0.467 ; 0.3076 ; 0.3023 ; 0.1351 ; 0.0359 ; 0.5335 ; 0.2969 ; 0.1553 ; 0.1169 ; 0.2636 ; 0.1066 ; 0.0458 ; 0.327 ; 0.1714 ; 0.3188 ; 0.5972 ; 0.065 ; 0.307 ; 0.2748 ; 0.2348 ; 0.6202 ; 0.2347 ; 0.1448 ; 0.448 ; 0.1079 ; 0.1164 ; 0.181 ; 0.1204 ; 0.0291 ; 0.0825 ; 0.0395 ; 0.056 ; 0.1133 ; 0.4862 ; 0.4161 ; 0.0392 ; 0.059 ; 0.0799 ; 0.0529 ; 0.0307 ; 0.1416 ; 0.0469 ; 0.0501 ; 0.0536 ; 0.0233 ; 0.0937 ; 0.0144 ; 0.4292 ; 0.0558 ; 0.2032
MSI_YN	LightYellow	Sarcoma (MSK, Nat Commun. 2022)	STRING	MSI YN	Patient	
TUMOR_LOCATION_DETAILED	LightYellow	Myoepithelial Carcinomas of Soft Tissue (WCM, CSH Molecular Case Studies 2022)	STRING	Specific Tumor Location	Sample	Left inguinal ; Para-aortic ; Left shoulder ; Axillary ; Left chest wall ; Supra-clavicular
WCMID	LightYellow	Myoepithelial Carcinomas of Soft Tissue (WCM, CSH Molecular Case Studies 2022)	STRING	WCMID	Patient	
FUSION_TYPE	LightYellow	Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)	STRING	Fusion type	Patient	
METASTATIC_SITES_OF_DISEASE_AT_DIAGNOSIS	LightYellow	Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)	STRING	Metastatic Sites of Disease at Diagnosis	Sample	none ; Osseous (Spine, Left Humerus, Left Iliac Bone, Sternum), Subpectoral mass, Bone marrow ; Bone, Bone Marrow, Pancreatic ; Distant Nodes (Abdominopelvic, Thoracic), Bone, Bone Marrow ; Bone, Bone Marrow, Distant LNs (Thoracic) ; Bone Marrow, Nodes, Paravertebral Soft Tissue, Skull Base, Orbit R, Bone (Multiple Vertebral Bodies) ; Bone Marrow ; Pulmonary, Femur ; Bone Marrow, Bones (Femur Bilateral, Ilium and Sacrum, Mutiple Vertebrae from C7-L4).
MEDR_PRIMARY_SITE	LightYellow	The Angiosarcoma Project (Provisional, July 2020)	STRING	Site of origin of disease	Patient	
CONTIGUOUS_ORGAN_INVADED	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Contiguous organ invaded	Patient	
CONTIGUOUS_ORGAN_RESECTION	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Contiguous organ resection site	Patient	
CONTIGUOUS_ORGAN_RESECTION_OTHER	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Other contiguous organ resection site	Patient	
DISCONTINUOUS_LESIONS_COUNT	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Discontiguous lesion count	Patient	
LEIOMYOSARCOMA_UTERINE_INVOLVEMENT	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Primary tumor lower uterus segment	Patient	
LOCOREGIONAL_RECURRENCE_INDICATOR	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Local disease recurrence	Patient	
METASTATIC_DISEASE_CONFIRMED	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Metastatic neoplasm confirmed	Patient	
MPNST_NF1_GENETIC_TESTING_INDICATOR	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Mpnst nf1 genetic testing	Patient	
MPNST_NF1_MUTATIONS_IDENTIFIED	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Mpnst specific mutations	Patient	
MPNST_NF_FAMILIAL_OR_SPORADIC	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Mpnst neurofibromatosis heredity	Patient	
MPNST_NF_INDICATOR	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Mpnst neurofibromatosis	Patient	
MPNST_PLEXIFORM_NEUROFIBROMA_SITE	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Mpnst exisiting plexiform neurofibroma	Patient	
NTE_LESION_PATHOLOGIC_DEPTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Nte lesion pathologic depth	Patient	
NTE_LESION_PATHOLOGIC_LENGTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Nte lesion pathologic length	Patient	
NTE_LESION_PATHOLOGIC_WIDTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Nte lesion pathologic width	Patient	
NTE_LESION_RADIOLOGIC_DEPTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Nte lesion radiologic depth	Patient	
NTE_LESION_RADIOLOGIC_LENGTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Nte lesion radiologic length	Patient	
NTE_LESION_RADIOLOGIC_WIDTH	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Nte lesion radiologic width	Patient	
SYNOVIAL_SS18SSX_TESTING_METHOD	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Synovial ss18ssx testing method	Patient	
TUMOR_BURDEN_PATHOLOGIC	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Tumor burden pathologic	Patient	
TUMOR_BURDEN_RADIOLOGIC	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Tumor burden radiologic	Patient	
TUMOR_TOTAL_NECROSIS	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Tumor total necrosis	Patient	
WELL_DIFF_LIPOSARC_PRIOR_DX_DAYS_TO	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Days to well differentiated liposarcoma primary dx	Patient	
WELL_DIFF_LIPOSARC_PRIOR_DX_INDICATOR	LightYellow	Sarcoma (TCGA, Firehose Legacy)	STRING	Well differentiated liposarcoma primary dx	Patient	
WELL_DIFF_LIPOSARC_RESECTION_DAYS_TO	LightYellow	Sarcoma (TCGA, Firehose Legacy)	NUMBER	Days to well differentiated liposarcoma resection	Patient	
LEUKEMIA_TYPE	LimeGreen	Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2015)	STRING	Leukemia Type	Sample	Pre-B ; T-ALL ; Early Pre-B ; MixedPreB-M5 ; ALL ; AML/ALL ; MATURE-B ; Pro-B ; B-lin: NOS ; Transitional Pre-B ; AUL ; AML M0 ; AML M5 ; AML M1 ; Mature-B
MLL_STATUS	LimeGreen	Acute Lymphoblastic Leukemia (St Jude, Nat Genet 2015)	STRING	MLL status.	Sample	INF_MLLr ; INF_NON_MLLr ; NON_INF_MLLr ; Negative ; Unknown ; Positive
EPIGENETIC	LimeGreen	Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)	STRING	Epigenetic	Patient	
EXOME_CAPTURE	LimeGreen	Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)	STRING	Exome Capture	Sample	SureSelect Human All Exon ; 0 ; SureSelect XT Human All Exon 50 Mb ; SureSelect XT2 Human All Exon v4+UTRs ; SureSelect XT Human All Exon v4+UTRs
IGHV_GENE	LimeGreen	Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)	STRING	IGHV Gene	Sample	IGHV1-3 ; IGHV4-39 ; IGHV4-61 ; IGHV5-10-1 ; IGHV1-69 ; IGHV3-23 ; IGHV1-24 ; IGHV3-21 ; IGHV1-2 ; IGHV4-34 ; IGHV2-70 ; IGHV3-30 ; IGHV4-31 ; IGHV3-9 ; IGHV3-7 ; IGHV3-53 ; IGHV3-48 ; IGHV4-30-4 ; IGHV1-8 ; IGHV1-18 ; IGHV3-74 ; IGHV3-15 ; IGHV4-4 ; IGHV3-33 ; IGHV4-59 ; IGHV3-66 ; IGHV3-64 ; IGHV3-73 ; IGHV3-11 ; IGHV4-38-2 ; IGHV3-49 ; IGHV3-72 ; IGHV5-51 ; IGHV7-4-1 ; IGHV1-45 ; IGHV1-46 ; IGHV2-5 ; IGHV6-1 ; IGHV4 34 ; IGHV3-20 ; IGHV4-60 ; IGHV3-30-3 ; IGHV2-70D ; IGHV4-30-2 ; IGHV3 ; IGHV3-43 ; IGHV7-4 ; IGHV2-26 ; mutated ; unmutated ; unknown
IGHV_IDENTITY	LimeGreen	Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)	NUMBER	IGHV Identity (%)	Sample	100 ; 97.25 ; 93.05 ; 99.18 ; 96.52 ; 98.26 ; 99.6 ; 99.19 ; 90.97 ; 96.18 ; 91.66 ; 93.2 ; 96.69 ; 94.44 ; 93.33 ; 93 ; 98.48 ; 97.58 ; 91.09 ; 99.65 ; 0 ; 98.95 ; 85.48 ; 85.98 ; 91.31 ; 92.36 ; 93.41 ; 92.7 ; 97.91 ; 96 ; 90.65 ; 88.19 ; 87.84 ; 93.4 ; 89.58 ; 90.73 ; 98.61 ; 95.83 ; 93.68 ; 91.23 ; 90.62 ; 98.22 ; 92.27 ; 97.94 ; 95.48 ; 92.41 ; 90.23 ; 88.13 ; 96.01 ; 94.09 ; 97.02 ; 96.59 ; 88.76 ; 99.43 ; 89.81 ; 88.7 ; 99.08 ; 96.51 ; 99.59 ; 97.06 ; 98.05 ; 93.87 ; 95.28 ; 95.79 ; 89.26 ; 97.56 ; 91.8 ; 97.19 ; 94.58 ; 96.83 ; 86.94 ; 99.3 ; 90.87 ; 98.8 ; 90.81 ; 96.49 ; 93.54 ; 93.01 ; 88.88 ; 84.91 ; 94.79 ; 91.43 ; 92.73 ; 90.44 ; 92.37 ; 95.91 ; 98.25 ; 88.41 ; 95.23 ; 95.13 ; 92.98 ; 95.87 ; 87.85 ; 91.67 ; 94.39 ; 94.64 ; 92.51 ; 99.66 ; 89.64 ; 91.82 ; 95.58 ; 95.2 ; 91.93 ; 92.62 ; 91.7 ; 94.16 ; 90.52 ; 92.01 ; 93.3 ; 91.29 ; 95.08 ; 96.77 ; 88.54 ; 89.69 ; 97.54 ; 97.1 ; 94.47 ; 96.13 ; 96.26 ; 93.97 ; 95.66 ; 89.93 ; 98.9 ; 90.27 ; 96.91 ; 90.18 ; 94.84 ; 95.27 ; 98.41 ; 96.74 ; 96.94 ; 93.75 ; 91.58 ; 93.26 ; 93.95 ; 91.9 ; 96.62 ; 94.04 ; 89.45 ; 96.37 ; 94.19 ; 88.89 ; 92.09 ; 97.95 ; 94.5 ; 94.74 ; 85.76 ; 91.75 ; 98.3 ; 96.88 ; 90.53 ; 92.44 ; 95.9 ; 92.18 ; 96.06 ; 95.61 ; 96.22 ; 93.47 ; 99.58 ; 94.61 ; 90.48 ; 90.41 ; 90.09 ; 90.07 ; 96.55 ; 87.5 ; 92.28 ; 90.84 ; 86.46 ; 93.8 ; 95.62 ; 87.72 ; 89.43 ; 89 ; 95.55 ; 92.88 ; 92.5 ; 91.76 ; 99.61 ; 96.87 ; 92.71 ; 87.4 ; 89.51 ; 94.73 ; 86.45
IGHV_MUTATED	LimeGreen	Chronic Lymphocytic Leukemia (IUOPA, Nature 2015)	STRING	IGHV Mutated	Sample	UNMUT ; MUT ; Undetermined ; BICLONAL
CAPTURE_BAIT_SET	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature 2015)	STRING	Bait Set used in capture	Sample	whole_exome_agilent_1.1_refseq_plus_3_boosters ; whole_exome_agilent_designed_120 ; whole_exome_agilent_sureselect_50mb
TUMOR_SUBTYPE	LimeGreen	Cutaneous T Cell Lymphoma (Columbia U, Nat Genet 2015)	STRING	Tumor Subtype	Sample	Folliculotropic Mycosis Fungoides ; CTCL, NOS with Large cell morphology (CD30) ; CTCL, NOS ; Intravascular gamma delta T cell lymphoma ; CTCL, NOS with Large cell transformation (CD30) ; CD30+ LPD (ALCL type) ; CD30+ LPD (Lymphomatoid papulosis vs. ALCL, borderline) ; CD30+ LPD (Type D Lymphomatoid papulosis)
BCL2_FISH_STATUS	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	BCL2 Fish Status	Sample	Positive ; Negative
BCL6_FISH_STATUS	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	BCL6 Fish Status	Sample	Positive ; Negative
B_SYMPTOMS_AT_DIAGNOSIS	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	Presence of B Symptoms at Diagnosis?	Patient	
CNS_RELAPSE	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	CNS Relapse	Patient	
INITIAL_TX_RESPONSE	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	Initial Treatment Response	Patient	
IPI	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	International Prognostic Index (IPI)	Patient	
IPI_AGE	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	IPI factor age; 1 = age > 60 years; 0 = age <=60 years	Patient	
IPI_ANNARBOR_STAGE	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	Ann Arbor staging as an IPI Factor	Patient	
IPI_ECOG	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	IPI factor ECOG; 0 = ECOG <= 1; 1 = ECOG > 1	Patient	
IPI_EXTRANODAL_SITES	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	IPI factor Extranodal; 1 = Extranodal sites > 1; 0 = Extranodal sites <= 1	Patient	
IPI_LDH	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	NUMBER	IPI factor LDH; LDH > normal reference, 1;  LDH <= normal reference, 0	Patient	
MYC_FISH	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	MYC Fish Status	Sample	Positive ; Negative
PROGNOSTIC_MODEL	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	Genomic Risk Model Classification	Sample	Medium risk ; High risk ; Low risk
TESTICULAR_INVOLVEMENT	LimeGreen	Diffuse Large B-Cell Lymphoma (Duke, Cell 2017)	STRING	Yes or No indicator for testicular involvement	Patient	
ANY_COO	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Cell of origin by gene expression profiling or nanostring	Sample	Unclassified ; ABC ; GCB
CCC	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Consensus Clustering Category	Sample	OxPhos ; BCR ; HR
CLUSTER	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Cluster	Sample	2 ; 4 ; 3 ; 0 ; 5 ; 1
CNS_INVOLVEMENT	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Yes or No indicator for CNS involvement	Patient	
COO_GEP	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Cell of origin category by Gene Expression Profiling (Affy)	Sample	Unclassified ; ABC ; GCB
COO_LYMPH2CX	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Cell of origin category by Lymph2CX (nanostring)	Sample	Unclassified ; ABC ; GCB
DBSNP_MUTATION_DENSITY	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	dbSNP Mutation Density	Sample	0.307 ; 0.762 ; 0.334 ; 0.154 ; 0.53 ; 0.268 ; 0.15 ; 0.772 ; 0.505 ; 0.236 ; 0.708 ; 0.741 ; 0.554 ; 0.149 ; 0.296 ; 0.409 ; 0.445 ; 0.0298 ; 0.394 ; 0.297 ; 0.205 ; 0.485 ; 0.452 ; 0.155 ; 0.35 ; 0.443 ; 0.845 ; 0.855 ; 0.502 ; 0.793 ; 1.01 ; 0.46 ; 0.49 ; 0.54 ; 0.742 ; 0.389 ; 0.565 ; 0.447 ; 0.474 ; 0.627 ; 0.386 ; 0.206 ; 0.177 ; 0.264 ; 0.361 ; 0.325 ; 0.0592 ; 1.07 ; 0.663 ; 0 ; 0.804 ; 0.528 ; 0.324 ; 0.207 ; 0.392 ; 0.178 ; 0.303 ; 0.841 ; 0.314 ; 0.639 ; 0.308 ; 0.748 ; 0.886 ; 0.279 ; 0.378 ; 0.254 ; 0.85 ; 0.603 ; 1.14 ; 0.801 ; 0.312 ; 0.449 ; 0.602 ; 0.342 ; 0.541 ; 0.438 ; 0.246 ; 0.522 ; 0.276 ; 1.1 ; 0.461 ; 1.09 ; 0.401 ; 0.653 ; 1.22 ; 0.503 ; 0.359 ; 0.181 ; 0.837 ; 0.878 ; 0.41 ; 0.477 ; 0.856 ; 0.767 ; 0.806 ; 0.385 ; 0.969 ; 0.632 ; 0.725 ; 0.482 ; 0.791 ; 0.354 ; 27.9 ; 0.333 ; 0.471 ; 0.736 ; 0.486 ; 0.473 ; 0.212 ; 0.448 ; 0.88 ; 0.582 ; 0.444 ; 0.265 ; 0.832 ; 0.693 ; 0.258 ; 0.283 ; 0.669 ; 0.615 ; 1.87 ; 0.634
DRIVER_MUTATION_DENSITY	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Driver mutations per megabase	Sample	0.154 ; 0.427 ; 0.182 ; 0.0307 ; 0.383 ; 0.178 ; 0.0897 ; 0.416 ; 0.327 ; 0.118 ; 0.324 ; 0.321 ; 0.0595 ; 0.207 ; 0.263 ; 0.148 ; 0 ; 0.243 ; 0.0585 ; 0.334 ; 0.0603 ; 0.0931 ; 0.159 ; 0.285 ; 0.26 ; 0.143 ; 0.386 ; 0.297 ; 0.461 ; 0.167 ; 0.204 ; 0.072 ; 0.419 ; 0.21 ; 0.314 ; 0.0894 ; 0.126 ; 0.251 ; 0.238 ; 0.0882 ; 0.059 ; 0.177 ; 0.147 ; 0.12 ; 0.0297 ; 0.0296 ; 0.385 ; 0.181 ; 0.328 ; 0.089 ; 0.322 ; 0.294 ; 0.121 ; 0.0594 ; 0.151 ; 0.323 ; 0.0314 ; 0.339 ; 0.152 ; 0.0606 ; 0.187 ; 0.317 ; 0.186 ; 0.0636 ; 0.031 ; 0.315 ; 0.25 ; 0.224 ; 0.331 ; 0.155 ; 0.188 ; 0.141 ; 0.241 ; 0.0614 ; 0.491 ; 0.123 ; 0.278 ; 0.356 ; 0.145 ; 0.266 ; 0.239 ; 0.329 ; 0.325 ; 0.264 ; 0.119 ; 0.242 ; 0.649 ; 0.149 ; 0.0889 ; 0.235 ; 0.348 ; 0.122 ; 0.511 ; 0.0908 ; 0.399 ; 0.236 ; 0.195 ; 0.212 ; 0.128 ; 0.425 ; 0.129 ; 0.19 ; 0.0332 ; 0.366 ; 0.271 ; 0.0315 ; 0.396 ; 0.362 ; 0.214
IPI_EXBM	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	IPI factor Extralymphatic Involvement; 0 = E <= 1; 1 = E > 1	Patient	
IPI_STAGE	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	IPI factor stage; 0 = stage I/II or 1 = stage III/IV	Patient	
MUTATION_DENSITY	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Mutations per megabase	Sample	1.198632 ; 5.152426 ; 2.791399 ; 1.967947 ; 6.86424 ; 1.874168 ; 2.004043 ; 4.219 ; 3.745556 ; 1.766626 ; 4.835482 ; 4.743075 ; 3.933557 ; 0.684328 ; 1.832312 ; 2.920554 ; 3.412618 ; 0.119004 ; 3.032015 ; 3.147916 ; 1.1414 ; 4.24614 ; 3.950216 ; 0.992649 ; 4.65025 ; 1.994209 ; 3.966225 ; 3.099608 ; 4.05112 ; 4.491633 ; 5.503688 ; 2.3419 ; 2.614313 ; 2.590993 ; 5.904855 ; 1.826615 ; 2.917789 ; 1.729035 ; 1.673164 ; 5.426305 ; 3.327865 ; 0.705438 ; 1.534913 ; 2.06525 ; 2.462802 ; 1.805627 ; 1.723677 ; 0.975828 ; 0.739657 ; 5.511803 ; 2.801707 ; 0.148638 ; 5.330008 ; 0.356495 ; 2.046338 ; 0.178699 ; 6.038721 ; 2.296919 ; 1.391533 ; 2.308706 ; 2.200658 ; 1.069971 ; 2.211551 ; 4.56007 ; 1.446359 ; 2.924609 ; 3.166466 ; 1.356867 ; 1.849588 ; 4.116746 ; 3.67236 ; 1.331818 ; 3.085831 ; 1.239948 ; 1.301688 ; 4.472015 ; 3.048301 ; 4.88543 ; 3.511143 ; 2.714669 ; 2.597281 ; 3.068825 ; 1.459616 ; 1.713036 ; 2.943828 ; 1.406185 ; 3.531571 ; 2.300859 ; 6.162744 ; 1.228213 ; 5.439132 ; 2.745332 ; 6.823137 ; 10.527212 ; 6.267394 ; 3.139899 ; 2.200325 ; 7.171629 ; 4.777879 ; 3.194797 ; 5.006701 ; 4.133531 ; 6.660292 ; 7.844452 ; 5.937472 ; 1.741096 ; 1.836467 ; 7.781009 ; 4.233956 ; 5.923697 ; 3.491686 ; 5.016806 ; 3.425694 ; 179.058458 ; 1.937404 ; 2.796884 ; 4.510924 ; 3.402646 ; 3.917273 ; 1.982077 ; 2.191384 ; 3.326807 ; 5.069874 ; 3.105009 ; 3.015902 ; 0.895561 ; 6.389384 ; 3.734878 ; 4.55349 ; 1.887354 ; 4.533294 ; 3.415283 ; 8.599562 ; 3.110665 ; 5.010039
NUM_DBSNP_MUTATIONS	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	dbSNP mutations per megabase	Sample	10 ; 25 ; 11 ; 5 ; 18 ; 9 ; 26 ; 17 ; 8 ; 24 ; 19 ; 14 ; 15 ; 1 ; 13 ; 7 ; 16 ; 33 ; 12 ; 23 ; 20 ; 6 ; 2 ; 36 ; 22 ; 0 ; 27 ; 21 ; 28 ; 37 ; 42 ; 29 ; 929 ; 59
NUM_DRIVER_SCNA	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Number of Driver SCNAs	Sample	11 ; 1 ; 3 ; 0 ; 9 ; 6 ; 22 ; 7 ; 16 ; 18 ; 8 ; 2 ; 26 ; 20 ; 23 ; 17 ; 14 ; 10 ; 15 ; 13 ; 12 ; 4 ; 25 ; 21 ; 19 ; 5 ; 28 ; 24 ; 27 ; 33
NUM_DRIVER_SV	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Number of Driver Structural Variants	Sample	0 ; 1 ; 2 ; 3
PLOIDY_ABSOLUTE	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Absolute Ploidy	Sample	2.23 ; 2.03 ; 2.11 ; 2 ; 2.2 ; 1.98 ; 2.02 ; 1.95 ; 2.18 ; 1.88 ; 1.99 ; 2.05 ; 3.64 ; 2.06 ; 3.31 ; 2.09 ; 2.01 ; 2.39 ; 2.24 ; 2.19 ; 2.17 ; 2.12 ; 1.96 ; 2.04 ; 3.95 ; 1.97 ; 2.13 ; 2.22 ; 2.25 ; 2.1 ; 2.32 ; 2.15 ; 2.16 ; 2.07 ; 3 ; 1.86 ; 1.84 ; 2.08 ; 3.9 ; 2.14 ; 3.74 ; 2.33 ; 2.3 ; 4.18 ; 1.76 ; 1.93 ; 1.9 ; 2.26 ; 3.47 ; 3.37 ; 3.94 ; 3.2 ; 2.21 ; 2.73 ; 3.29 ; 2.6 ; 3.66
R_CHOP_LIKE_CHEMO	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	STRING	Patient received R-CHOP-like chemo; yes,no	Patient	
SILENT_MUTATION_DENSITY	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Silent mutations per megabase	Sample	0.338 ; 1.34 ; 0.85 ; 0.584 ; 1.65 ; 0.476 ; 0.479 ; 0.98 ; 0.832 ; 0.412 ; 1.39 ; 0.919 ; 0.845 ; 0.149 ; 0.414 ; 0.759 ; 0.979 ; 0.0298 ; 0.576 ; 0.772 ; 0.322 ; 0.94 ; 1.18 ; 0.248 ; 0.892 ; 0.57 ; 1.33 ; 0.784 ; 0.656 ; 0.991 ; 1.54 ; 0.669 ; 0.49 ; 0.684 ; 1.36 ; 0.389 ; 0.753 ; 0.596 ; 0.568 ; 1.22 ; 0.773 ; 0.206 ; 0.266 ; 0.561 ; 0.44 ; 0.632 ; 0.386 ; 0.237 ; 0.148 ; 1.51 ; 0.844 ; 0.0595 ; 1.07 ; 0.119 ; 0.415 ; 0.0596 ; 1.47 ; 0.53 ; 0.503 ; 0.681 ; 0.573 ; 0.515 ; 1.42 ; 0.22 ; 0.862 ; 0.7 ; 0.401 ; 0.637 ; 1.25 ; 0.823 ; 0.31 ; 0.724 ; 0.286 ; 0.341 ; 1.2 ; 1.02 ; 1.29 ; 0.801 ; 0.468 ; 0.513 ; 0.722 ; 0.652 ; 0.481 ; 0.814 ; 0.457 ; 0.843 ; 0.552 ; 1.59 ; 1.48 ; 0.586 ; 2.76 ; 0.957 ; 0.452 ; 1.79 ; 0.674 ; 1.16 ; 1.24 ; 1.73 ; 1.8 ; 1.58 ; 0.444 ; 1.97 ; 1.14 ; 0.993 ; 1.52 ; 0.65 ; 50.4 ; 0.605 ; 0.848 ; 0.82 ; 0.585 ; 0.742 ; 0.776 ; 1.21 ; 0.166 ; 1.4 ; 0.873 ; 0.969 ; 1.06 ; 2.22 ; 0.755
TOTAL_REARRANGEMENT	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Total Rearrangement	Sample	0 ; 3 ; 2 ; 1 ; 5 ; 4 ; 6
TUMOR_IN_NORMAL_ESTIMATE	LimeGreen	Diffuse Large B cell Lymphoma (DFCI, Nat Med 2018)	NUMBER	Fraction of tumor cells in normal sample estimated by deTIN	Sample	0.005 ; 0 ; 0.025 ; 0.01 ; 0.015 ; 0.04
FISH_TRANSLOCATION	LimeGreen	Multiple Myeloma (Broad, Cancer Cell 2014)	STRING	FISH translocation.	Sample	t(4;14) ; t(11;14) ; t(14;16) ; (-17p13)
HEAVY_CHAIN	LimeGreen	Multiple Myeloma (Broad, Cancer Cell 2014)	STRING	HEAVY CHAIN	Sample	G ; A ; ND ; M
LIGHT_CHAIN	LimeGreen	Multiple Myeloma (Broad, Cancer Cell 2014)	STRING	Light chain.	Sample	Kappa ; Lambda ; Biphenotypic ; ND
PRIOR_MGUS	LimeGreen	Multiple Myeloma (Broad, Cancer Cell 2014)	STRING	Prior MGUS.	Patient	
BCL2_BA	LimeGreen	Non-Hodgkin Lymphoma (BCGSC, Nature 2011)	STRING	BCL2 Break Apart	Patient	
BCL6_BA	LimeGreen	Non-Hodgkin Lymphoma (BCGSC, Nature 2011)	STRING	BCL6 Break Apart	Patient	
MYC_BA	LimeGreen	Non-Hodgkin Lymphoma (BCGSC, Nature 2011)	STRING	Myc ba	Patient	
NUM_EXTRANODAL_SITES	LimeGreen	Non-Hodgkin Lymphoma (BCGSC, Nature 2011)	STRING	Number of Extranodal Sites of Disease	Patient	
TREATMENT_DETAILS	LimeGreen	Non-Hodgkin Lymphoma (BCGSC, Nature 2011)	STRING	Treatment Details	Patient	
NORMAL_GENOME_LIBRARY	LimeGreen	Diffuse Large B-cell Lymphoma (BCGSC, Blood 2013)	STRING	Normal Genome Library	Sample	A01449 ; HS2703 ; A06420 ; A01446 ; A01454 ; HS2975 ; A06422 ; A01448 ; HS2973 ; HS2705 ; A06721 ; A01432 ; A01677 ; A01459 ; A01433 ; A01441 ; A01438 ; A01451 ; A01440 ; A02011 ; A01452 ; A01447 ; A01973 ; A01436 ; A03291 ; A01439 ; A01442 ; A01443 ; A01445 ; A01437 ; A01455 ; A06421 ; A01444 ; A01974 ; HS2707 ; A01453 ; A01458 ; A03586 ; HS2971 ; A01450
TUMOR_GENOME_LIBRARY	LimeGreen	Diffuse Large B-cell Lymphoma (BCGSC, Blood 2013)	STRING	Tumor Genome Library	Sample	A01427 ; HS2702 ; A06417 ; A01423 ; A01428 ; HS2974 ; A06419 ; A01431 ; HS2972 ; HS2704 ; A06720 ; A01429 ; A01676 ; A01457 ; A01430 ; A01420 ; A01462 ; A01435 ; A01419 ; A02010 ; A01416 ; A01418 ; A01972 ; A01434 ; A03290 ; A01415 ; A01421 ; A01414 ; A01424 ; A01413 ; A01422 ; A06418 ; A01417 ; A01971 ; HS2706 ; A01426 ; A01456 ; A03561 ; HS2970 ; A01425 ; A12437 ; A12438 ; A12439 ; A12440 ; A12441 ; A12442 ; A12443 ; A12445 ; A12449 ; A12444 ; A12446 ; A12447 ; A14217
FIRST_PRESENTING_SYMPTOM	LimeGreen	Primary Central Nervous System Lymphoma (Mayo Clinic, Clin Cancer Res 2015)	STRING	First presenting symptom.	Patient	
IMAGING	LimeGreen	Primary Central Nervous System Lymphoma (Mayo Clinic, Clin Cancer Res 2015)	STRING	Imaging	Patient	
INITIAL_RX	LimeGreen	Primary Central Nervous System Lymphoma (Mayo Clinic, Clin Cancer Res 2015)	STRING	Initial Rx	Patient	
SUBSEQUENT_RX	LimeGreen	Primary Central Nervous System Lymphoma (Mayo Clinic, Clin Cancer Res 2015)	STRING	Subsequent Rx	Patient	
ALTERNATE_THERAPY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	Alternative Therapy Given	Patient	
BCR_ABL1_STATUS	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	BCR ABL1 status	Sample	Negative ; Positive ; Unknown
BM_DAY_15	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	Bone Marrow Blasts Day 15	Patient	
BM_DAY_29	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	Bone Marrow Blasts Day 29	Patient	
BM_DAY_43	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	Bone Marrow Blasts Day 43	Patient	
BM_DAY_8	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	Bone Marrow Blasts Day 8	Patient	
CELL_OF_ORIGIN	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	Cell of tumor origin	Sample	B-Precursor ; B Cell ALL ; T Cell ALL
CONGENITAL_ABNORMALITY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	Congentital abnormality.	Patient	
ETV6_RUNX1_FUSION_STATUS	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	ETV6-RUNX1 Fusion Status	Sample	Positive ; Negative ; Unknown
MRD_END_CONSOLIDATION	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at end of consolidation	Patient	
MRD_END_CONSOLIDATION_SENSITIVITY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at end of consolidation Sensitivity	Patient	
MRD_PERCENT_DAY_29	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 29.	Patient	
MRD_PERCENT_DAY_29_SENSITIVITY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 29 Sensitivity	Patient	
MRD_PERCENT_DAY_43	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 43	Patient	
MRD_PERCENT_DAY_43_SENSITIVITY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 43 Sensitivity	Patient	
MRD_PERCENT_DAY_8	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 8	Patient	
MRD_PERCENT_DAY_8_SENSITIVITY	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	NUMBER	MRD percentage at day 8 Sensitivity	Patient	
TCF3_PBX1_STATUS	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	TCF3-PBX1 Status	Sample	Negative ; Unknown ; Positive
TESTES_SITE_OF_RELAPSE	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	Testes Site of Relapse	Sample	No ; Yes
TRISOMY_4_10	LimeGreen	Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)	STRING	Trisomy 4_10.	Sample	Negative ; Unknown ; Positive
BONE_MARROW_BIOPSY_PERFORMED	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Bone Marrow Biopsy Performed	Patient	
BONE_MARROW_INVOLVEMENT	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Bone Marrow Involvement	Patient	
BONE_MARROW_SAMPLE_HISTOLOGY	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Bone Marrow Sample Histology	Patient	
B_CELL_GENOTYPE_METHOD	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	B Cell Genotype Method	Patient	
EBV_POSITIVE_MALIGNANT_CELLS_PERCENT	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	NUMBER	EBV Positive Malignant Cells Percent	Patient	
EBV_STATUS	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Epstein-Barr Virus (EBV) Status	Patient	
EBV_STATUS_MALIGNANT_CELLS_METHOD	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	EBV Status Malignant Cells Method	Patient	
EXTRANODAL_INVOLVMENT_OTHER	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Extranodal disease involvement site	Patient	
EXTRANODAL_LYMPHOMATOUS_INVOLVEMENT	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Extranodal involvement	Patient	
GENETIC_ABNORMALITY_METHOD_OTHER	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Abnormality tested methodology	Patient	
GENETIC_ABNORMALITY_RESULTS	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Abnormality tested results	Patient	
GENETIC_ABNORMALITY_TESTED	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Genetic abnormality tested	Patient	
GENETIC_ABNORMALITY_TESTED_OTHER	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Other genetic abnormality tested	Patient	
IGH_GENOTYPE_RESULT	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Igh genotype results	Patient	
IGK_GENOTYPE_RESULT	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Igk genotype results	Patient	
IMMUNOPHENOTYPIC_ANALYSIS_METHOD	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Immunophenotypic analysis methodology	Patient	
IMMUNOPHENOTYPIC_ANALYSIS_RESULTS	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Result of immunophenotypic analysis	Patient	
IMMUNOPHENOTYPIC_ANALYSIS_TESTED	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Immunophenotypic analysis test	Patient	
LDH_NORM_RANGE_UPPER	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Ldh upper limit	Patient	
LYMPH_NODE_INVOLVEMENT_SITE	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Nodal anatomic site	Patient	
MAXIMUM_TUMOR_BULK_ANATOMIC_SITE	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Maximum tumor bulk anatomic location	Patient	
MIB_1_POSITIVE_PERCENT_RANGE	LimeGreen	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA, Firehose Legacy)	STRING	Mib1 positive percentage range	Patient	
ADMIXTURE_LABEL	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	Continental-level genetic ancestry label for the patient. The patient is assigned European (EUR), African (AFR), East Asian (EAS), South Asian (SAS) or Native American (NAM) ancestry label if the inferred contribution of that population to their ancestry is at least 80%, otherwise they are labeled as admixed/other (ADM)	Patient	
ADRENAL_GLANDS	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of Adrenal Gland as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
AFR	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Estimated proportion of African ancestry	Patient	
ANCESTRY_LABEL	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	Final genetic ancestry label assigned to the patient based on ANCESTRY_CONTINENTAL_LABEL and ANCESTRY_ASJ. EUR = European (excluding Ashkenazi Jewish), ASJ = Ashkenazi Jewish European, AFR = African, EAS = East Asian, SAS = South Asian, NAM = Native American, ADM = Admixed/Other	Patient	
ASJ	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	Genetically inferred Ashkenazi Jewish ancestry. If ANCESTRY_NUM_NONREF_ASJ_MARKERS is at least 3, the patient is considered to be of Ashkenazi Jewish ancestry.	Patient	
CNS_BRAIN	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of CNS/Brain as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
CURRENT_AGE_DEID	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	---DESCRIPTION: Current age (limit 89). Derived from Birthdate (RMS) ---MISSING DATA: Contact RMS Database Maintainers ---SOURCE:CDM Generated (Via IDB/RMS dates)	Patient	
EAS	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Estimated proportion of East Asian ancestry	Patient	
EUR	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Estimated proportion of European ancestry	Patient	
GLEASON_FIRST_REPORTED	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	"---DESCRIPTION: Patient level summary of the 1st reported Gleason score from pathology reports. NLP used to derive ---MISSING DATA: No reported Gleason Score for patient. Rule-based NLP did not sense the word ""gleason"" any pathology reports. ---SOURCE:CDM Generated (NLP)"	Patient	
GLEASON_HIGHEST_REPORTED	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	"---DESCRIPTION: Patient level summary of the highest reported Gleason score from pathology reports. NLP used to derive ---MISSING DATA: No reported Gleason Score for patient. Rule-based NLP did not sense the word ""gleason"" any pathology reports. ---SOURCE:CDM Generated (NLP)"	Patient	
GLEASON_SAMPLE_LEVEL	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	"---DESCRIPTION: Sample summary of the Gleason score reported on the specified sample ID at the time of surgery or biopsy ---MISSING DATA: No reported Gleason Score for patient. Rule-based NLP did not sense the word ""gleason"" any pathology reports. ---SOURCE:CDM Generated (NLP)"	Sample	
HISTORY_OF_PDL1	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History if patient ever had a pathology specimen annotated as PD-L1 positive ---MISSING DATA: Patient not tested for PD-L1 ---SOURCE:CDM Generated (NLP)	Patient	
INTRA_ABDOMINAL	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	Intra Abdominal	Patient	
LIVER	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of Liver as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
LYMPH_NODES	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of LN as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
NAM	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Estimated proportion of Native American ancestry	Patient	
NUM_ICDO_DX	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	---DESCRIPTION: Number of Tumor Registry Entries for patient ---MISSING DATA: No tumor registry data entered for patient ---SOURCE:CDM Generated (Via IDB/RMS dates)	Patient	
NUM_NONREF_ASJ_MARKERS	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Number of ASJ informative markers with alternate alleles seen in the patient.	Patient	
OTHER	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of another site as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
PDL1_POSITIVE	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: Indication if specimen was labeled as PD-L1 positive in surgical pathology report ---MISSING DATA: Patient not tested for PD-L1 ---SOURCE:CDM Generated (NLP)	Sample	Yes ; No
PLEURA	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of Pleura as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
PRIOR_MED_TO_MSK	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: Binary indication if patient recieve anti-cancer medication prior to MSK ---MISSING DATA: Initial consult (IC) notes need to be (1) within a list of acceptable note types, (2) be within 90 days of first MSK dates if patients have multiple primaries. Note types consist of medical oncologists, radiation oncologists, surgery, inpatient services and others, as they are most likely to contain information about external treatments prior to MSK. ---SOURCE:CDM Generated (NLP)	Patient	
REPRODUCTIVE_ORGANS	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: History of Reproductive Organs as a tumor site as indicated in radiology report impression ---MISSING DATA: No CT/PET/MRI radiology report available for patient. Impression section missing from report. ---SOURCE:CDM Generated (NLP)	Patient	
SAS	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	NUMBER	Estimated proportion of South Asian ancestry	Patient	
SMOKING_PREDICTIONS_3_CLASSES	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	---DESCRIPTION: Inferred smoking history. Classes: Current/Former, Never, Unknown ---MISSING DATA: The patient might not have had a 'Smoking Status' section in their Clindoc note. Potential factor for older notes, if the formatting of the section has changed; majority are from 2015-->present. ---SOURCE:CDM Generated (NLP)	Patient	
STAGE_HIGHEST_RECORDED	LimeGreen	Diffuse Large B-Cell Lymphoma (MSK, 2024)	STRING	"---DESCRIPTION: Highest recorded stage in tumor registry (ICD-O). Data has been aggregated from the CDM derived stage information, which bins stage in ""stage 1-3"" and ""stage 4"". ---MISSING DATA: Stage data not entered by admins in tumor registry ---SOURCE:CDM Generated (Via IDB/RMS dates)"	Patient	
ASCT_CONSOLIDATION	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	ASCT Consolidation in 1st Remisison	Sample	No ; Yes
BONE_MARROW_POS	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	Bone Marrow Positive by Morphological Assessment	Sample	No ; Yes
ECOG_GT_2	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	ECOG greater than or equal to 2	Sample	No ; Yes ; Unknown
EXTRANODAL_DISEASE	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	Extranodal Disease other than Bone Marrow	Sample	No ; Yes
FIRST_LINE_TREATMENT	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	First-line Treatment	Patient	
MAINTENANCE_TX	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	Maintenance Treatment	Sample	Yes ; No
MISSING_FROM_BASELINE_CLINICAL	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	Missing from Baseline Clinical Data	Sample	BMB and LDH ; LDH ; BMB
MSK_IMPACT_BEYOND_FIRST_RELAPSE_BIOPSY	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	MSK-IMPACT Orderded beyond First Relapse Biopsy	Patient	
MSK_IMPACT_ON_DIAGNOSTIC_BIOPSY	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	MSK-IMPACT on Diagnostic Biopsy	Patient	
MSK_IMPACT_ON_FIRST_RELAPSE_BIOPSY	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	MSK-IMPACT Ordered on First Relapse Biopsy	Patient	
MSK_IMPACT_PANEL	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	MSK-IMPACT Panel	Sample	IMPACT410 ; IMPACT468 ; IMPACT-HEME-400 ; RDTB49
PROSPECTIVE_COHORT	LimeGreen	Mature T and NK Neoplasms (MSK, Blood Adv 2023)	STRING	Prospective Cohort	Sample	Yes ; No
EBV_GENOME_STATUS	LimeGreen	Mature B-Cell Neoplasms (Simon Fraser University, Blood 2023)	STRING	EBV genome status	Patient	
ONCOTREE	LimeGreen	Mature B-Cell Neoplasms (Simon Fraser University, Blood 2023)	STRING	Oncotree	Sample	BL ; DLBCLNOS
PATIENT_SUBGROUP	LimeGreen	Mature B-Cell Neoplasms (Simon Fraser University, Blood 2023)	STRING	Patient subgroup	Patient	
TUMOR_BIOPSY	LimeGreen	Mature B-Cell Neoplasms (Simon Fraser University, Blood 2023)	STRING	Tumor biopsy	Sample	Frozen ; FFPE
AGE_SAMPLING	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Age at sampling	Patient	
ARRAY450K	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in 450K methylation array 	Sample	No ; Yes
CLL_EPITYPE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	CLL epitype: naive-like (n-CLL), intermediate (i-CLL) and memory-like (m-CLL)	Sample	n-CLL ; m-CLL ; unclassified ; 0 ; i-CLL ; Chemo + no Ab
DEATH_DAYS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Death (days) from the date of sampling	Patient	
DISEASE_TYPE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Disease type	Sample	CLL ; MBL
EC_DISCOVERY	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in expression cluster discovery set (1=yes, 0=no)	Sample	Yes ; No
EC_EXTENSION	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Sample included in expression cluster extension set (1=yes, 0=no)	Sample	No ; Yes
EXPRESSION_CLUSTER	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Expression cluster	Patient	
FFS_MONTHS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Failure-free survival (months)	Patient	
FFS_STATUS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Failure-free survival status	Patient	
IGHV_IDENTITY_PERCENTAGE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Immunoglobulin genes mutation identity percentage	Patient	
IGHV_MUTATION_STATUS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Immunoglobulin genes mutation status	Patient	
IGLV3_21_R110	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	IGLV3-21 R110 mutation status	Sample	No ; Yes
M-CLL_WES	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in M-CLL WES genetic candidate driver discovery cohort (1=yes, 0=no)	Sample	No ; Yes
NORMAL_MEAN_COVERAGE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Normal Mean Coverage (WES)	Sample	63 ; 70.1 ; 77.2 ; 60.2 ; 106.5 ; 158.3 ; 68.5 ; 70.2 ; 62 ; 86.1 ; 142.4 ; 60.3 ; 74.5 ; 65.9 ; 77.9 ; 73.7 ; 60.5 ; 69 ; 92.6 ; 89.4 ; 114.3 ; 85.2 ; 75 ; 83.8 ; 70.5 ; 109.3 ; 98.1 ; 137 ; 111.8 ; 107.9 ; 77.3 ; 206 ; 136.3 ; 143.8 ; 100.6 ; 114.7 ; 137.1 ; 228.9 ; 118.7 ; 157.5 ; 165.8 ; 80.4 ; 119.7 ; 129.4 ; 106.7 ; 109.6 ; 197.4 ; 74.7 ; 146.5 ; 360.7 ; 109.7 ; 121 ; 93.1 ; 143.2 ; 82.1 ; 130.7 ; 116.1 ; 81.6 ; 78.2 ; 83.3 ; 79.1 ; 73.1 ; 176.4 ; 65.7 ; 80.8 ; 84.1 ; 80.9 ; 28.5 ; 126.8 ; 89 ; 78.9 ; 58.4 ; 80.7 ; 70.8 ; 137.6 ; 73.6 ; 75.1 ; 83.1 ; 71.8 ; 64.4 ; 135.4 ; 64.5 ; 65.2 ; 115.3 ; 136 ; 101.6 ; 66.3 ; 107.8 ; 61.6 ; 329.4 ; 261.1 ; 59.5 ; 62.1 ; 76 ; 71.6 ; 79.4 ; 62.8 ; 71.7 ; 67.2 ; 75.6 ; 81.5 ; 52.2 ; 107.3 ; 132.8 ; 128.9 ; 96.2 ; 62.4 ; 110.6 ; 103.1 ; 72.1 ; 113.8 ; 103.6 ; 85 ; 139.8 ; 126.3 ; 86.4 ; 66.8 ; 77.8 ; 77.4 ; 69.4 ; 85.7 ; 81.4 ; 84.6 ; 86.9 ; 90.3 ; 74.6 ; 86.8 ; 84.3 ; 92.7 ; 98.2 ; 94.5 ; 90.2 ; 100.9 ; 91.3 ; 79.5 ; 79.7 ; 83.4 ; 96.7 ; 70.3 ; 85.9 ; 99 ; 77.1 ; 90 ; 95.7 ; 91.4 ; 82.8 ; 66 ; 61.1 ; 115.8 ; 66.9 ; 75.7 ; 105.3 ; 138.6 ; 100.1 ; 121.3 ; 85.8 ; 87.6 ; 88.1 ; 92.5 ; 57.2 ; 63.5 ; 61.7 ; 88.5 ; 83.6 ; 93 ; 99.8 ; 121.6 ; 61.4 ; 68.6 ; 71.5 ; 82.3 ; 79 ; 84.5 ; 78.5 ; 51.9 ; 67.5 ; 55.4 ; 93.9 ; 57.9 ; 64 ; 69.3 ; 72.8 ; 57.8 ; 68.8 ; 68.2 ; 54.5 ; 60.4 ; 56.4 ; 60.6 ; 63.3 ; 52.5 ; 89.7 ; 58.5 ; 75.2 ; 67.7 ; 64.2 ; 69.6 ; 69.7 ; 58.8 ; 70.7 ; 65.8 ; 54.3 ; 58.2 ; 66.6 ; 60.7 ; 72.4 ; 68.3 ; 59.7 ; 69.2 ; 81.9 ; 63.4 ; 71.4 ; 67 ; 93.5 ; 87.4 ; 86.5 ; 75.9 ; 77 ; 88.7 ; 82.2 ; 79.3 ; 86 ; 81.1 ; 86.3 ; 87.1 ; 74.8 ; 80.5 ; 91.7 ; 85.1 ; 78.4 ; 84 ; 94.9 ; 98.9 ; 77.6 ; 76.6 ; 95.3 ; 89.8 ; 55.5 ; 105.5 ; 101.1 ; 61 ; 74.9 ; 96.4 ; 92.9 ; 104.7 ; 97.3 ; 103.8 ; 108.5 ; 92.1 ; 124.7 ; 110.4 ; 84.8 ; 100.4 ; 66.7 ; 100.8 ; 91.9 ; 100.3 ; 102.4 ; 72.3 ; 90.1 ; 99.5 ; 102.9 ; 87.9 ; 62.2 ; 82 ; 89.2 ; 58.3 ; 95.4 ; 72.5 ; 64.3 ; 107.1 ; 95.8 ; 72 ; 76.8 ; 61.9 ; 80 ; 73.9 ; 81.7 ; 76.9 ; 74.4 ; 56.6 ; 71.2 ; 57.6 ; 79.8 ; 69.5 ; 67.9 ; 76.7 ; 59.8 ; 89.6 ; 68 ; 84.4 ; 72.7 ; 68.9 ; 94.8 ; 61.8 ; 70 ; 75.3 ; 122.3 ; 64.8 ; 105 ; 96.6 ; 82.5 ; 63.1 ; 81.2 ; 86.2 ; 85.4 ; 92.8 ; 115.5 ; 75.4 ; 85.6 ; 72.9 ; 67.6 ; 237.4 ; 167.2 ; 141.6 ; 150.3 ; 175.9 ; 142 ; 179.8 ; 153.4 ; 152.7 ; 156.1 ; 167.4 ; 143.9 ; 135.9 ; 167.6 ; 164.4 ; 144.9 ; 200.5 ; 170.5 ; 112.4 ; 96 ; 232.8 ; 247.3 ; 162.7 ; 231.9 ; 292 ; 234.6 ; 137.8 ; 153.9 ; 127.1 ; 126.4 ; 145.3 ; 82.4 ; 65.5 ; 60.8 ; 105.1 ; 147.8 ; 65.1 ; 77.7 ; 52.9 ; 47 ; 50.5 ; 48.9 ; 50.3 ; 60.1 ; 56 ; 47.6 ; 54.7 ; 58.7 ; 74.1 ; 53.2 ; 44.9 ; 50.1 ; 53.5 ; 50.9 ; 73.2 ; 47.5 ; 80.2 ; 68.4 ; 50.6 ; 56.3 ; 49.4 ; 52.1 ; 59.2 ; 49.6 ; 123.3 ; 128.1 ; 147.1 ; 151.5 ; 158.7 ; 167.5 ; 167.8 ; 169.6 ; 165.4 ; 148.2 ; 141.5 ; 141.2 ; 166.1 ; 189.4 ; 171.7 ; 38.5 ; 143.4 ; 57.5 ; 45.2 ; 47.7 ; 48.5 ; 50.8 ; 108.9 ; 136.9 ; 125.9 ; 51.2 ; 90.7 ; 112 ; 41.9 ; 46.6 ; 49.1 ; 51.7 ; 49 ; 49.2 ; 54 ; 43.8 ; 44.6 ; 50.2 ; 51.4 ; 53.6 ; 49.3 ; 52.3 ; 48.8 ; 47.1 ; 48 ; 104.1 ; 35.3 ; 51 ; 73 ; 44.4 ; 45.5 ; 48.6 ; 45.7 ; 32.6 ; 21.7 ; 40.9 ; 86.7 ; 87.3 ; 49.8 ; 37.5 ; 32.8 ; 26.8 ; 89.3 ; 52.7 ; 25.4 ; 24.2 ; 44.2 ; 55.1 ; 29.8 ; 33 ; 30 ; 33.3 ; 37.1 ; 42.5 ; 45 ; 33.1 ; 29.2 ; 56.7 ; 54.2 ; 68.7 ; 29.7 ; 65 ; 63.6 ; 76.4 ; 26.3 ; 53.8 ; 35.1 ; 31.7 ; 16.1 ; 25.9 ; 19.9 ; 52 ; 26.4 ; 28.3 ; 51.6 ; 38.8 ; 22.7 ; 30.2 ; 50.4 ; 50 ; 45.3 ; 43.1 ; 48.3 ; 59.1 ; 53 ; 32.5 ; 24 ; 62.5 ; 21.4 ; 33.6 ; 37.7 ; 28 ; 42.2 ; 34.7 ; 56.1 ; 41 ; 103.2 ; 31.3 ; 94.1 ; 32.3 ; 20.1 ; 49.9 ; 40.4 ; 22.9 ; 34.9 ; 43.9 ; 35.4 ; 25.2 ; 57.7 ; 42.4 ; 21.5 ; 37.8 ; 40 ; 33.7 ; 36.4 ; 47.8 ; 36.1 ; 32.2 ; 31.6 ; 46.8 ; 44.7 ; 35 ; 34.2 ; 64.7 ; 42.8 ; 43.4 ; 44.3 ; 40.8 ; 45.9 ; 101.5 ; 45.1 ; 56.8 ; 48.7 ; 60.9 ; 44 ; 62.3 ; 53.1 ; 65.4 ; 41.1 ; 84.7 ; 97.9 ; 78.6 ; 135.1 ; 111.3 ; 112.6 ; 41.4 ; 97.8 ; 116.9 ; 111 ; 122.7 ; 43.5 ; 40.1 ; 39.3 ; 109.8 ; 122.6 ; 73.5 ; 112.7 ; 116.5 ; 127.7 ; 116.2 ; 127.6 ; 107.5 ; 89.5 ; 109.5 ; 113.6 ; 64.6 ; 73.4 ; 94 ; 41.7 ; 33.8 ; 93.8 ; 66.2 ; 85.3 ; 146.3 ; 67.1 ; 114.5 ; 65.6 ; 33.2 ; 98.4 ; 23.1 ; 27.1 ; 87.8 ; 80.6 ; 78.7 ; 67.3 ; 216.1 ; 62.6 ; 83.5 ; 84.9 ; 101.3 ; 99.6 ; 71.9 ; 55.6 ; 48.1 ; 87.2 ; 39.9 ; 47.4 ; 57 ; 77.5 ; 86.6 ; 32.7 ; 69.8 ; 40.3 ; 88.4 ; 94.4 ; 46.3 ; 98.3 ; 74.2 ; 72.2 ; 88.6 ; 83 ; 84.2 ; 63.9 ; 47.9 ; 76.3 ; 38.2 ; 78.1 ; 28.2 ; 24.4 ; 55 ; 88 ; 54.4
PRIOR_TREATMENT_CATEGORY	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Prior treatment category	Patient	
RNA_SEQUENCING	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in RNA-Sequencing	Sample	Yes ; No
RRBS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in reduced representation bisulfite sequencing 	Sample	Yes ; No
TREATMENT_AFTER_SAMPLING	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	First treatment after sampling	Patient	
TUMOR_MEAN_COVERAGE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Tumor mean coverage (WES)	Sample	79.7 ; 135.5 ; 141.1 ; 146 ; 82.1 ; 68 ; 96.7 ; 84.5 ; 60 ; 63.8 ; 54.3 ; 68.8 ; 139 ; 88.9 ; 89 ; 64.3 ; 69.2 ; 55.8 ; 65.7 ; 62.4 ; 114.1 ; 78.2 ; 72.7 ; 100.9 ; 78.8 ; 109.8 ; 103.4 ; 133.4 ; 145.4 ; 227.9 ; 69.6 ; 310 ; 137.6 ; 135.4 ; 103.5 ; 138.4 ; 114.5 ; 219.1 ; 97.7 ; 146.4 ; 247.9 ; 77.1 ; 108.7 ; 243.7 ; 115.1 ; 237.8 ; 227.3 ; 62.7 ; 131.6 ; 121.3 ; 121.9 ; 114.4 ; 109 ; 79.1 ; 127.7 ; 124.6 ; 79.3 ; 76.7 ; 152 ; 60.6 ; 50.5 ; 157.2 ; 71.8 ; 74.4 ; 80.7 ; 84.1 ; 11.4 ; 209.2 ; 78.9 ; 111.3 ; 91.7 ; 76.9 ; 73.8 ; 119.5 ; 73.6 ; 65.3 ; 152.7 ; 64.1 ; 93.2 ; 73.1 ; 68.2 ; 61.8 ; 116.9 ; 59.8 ; 87.4 ; 66.1 ; 406.9 ; 262.7 ; 63 ; 64.4 ; 138.1 ; 63.3 ; 63.5 ; 82.3 ; 123.5 ; 67.4 ; 65.1 ; 102.8 ; 109.1 ; 126.5 ; 109.6 ; 112.7 ; 113.3 ; 96.8 ; 104.4 ; 142 ; 124.4 ; 132.9 ; 123.1 ; 142.3 ; 135 ; 76.2 ; 87 ; 83.4 ; 77.4 ; 78.4 ; 89.8 ; 70.3 ; 77.6 ; 80.1 ; 89.3 ; 86.1 ; 57.2 ; 74.3 ; 85 ; 79.4 ; 56.7 ; 73.9 ; 90.4 ; 79 ; 91.4 ; 80.4 ; 79.8 ; 74.7 ; 78.3 ; 79.9 ; 88.2 ; 106.4 ; 106.3 ; 101.7 ; 85.9 ; 87.1 ; 89.2 ; 81 ; 64 ; 62.8 ; 77.7 ; 99.1 ; 76.5 ; 108.4 ; 60.7 ; 108.6 ; 113.6 ; 102.1 ; 52.9 ; 94.8 ; 81.6 ; 75.6 ; 84.3 ; 107.2 ; 94.2 ; 102.6 ; 54.5 ; 83.8 ; 53.9 ; 90.5 ; 68.9 ; 93.6 ; 75.8 ; 85.4 ; 82.2 ; 66.2 ; 61.4 ; 96.4 ; 76 ; 67.8 ; 60.3 ; 58 ; 74.9 ; 58.7 ; 82.9 ; 53.6 ; 64.8 ; 93.5 ; 69.7 ; 65.2 ; 60.9 ; 65.4 ; 57.3 ; 61.6 ; 63.9 ; 110.3 ; 59.9 ; 58.3 ; 58.5 ; 69.3 ; 70.5 ; 68.7 ; 67.7 ; 60.2 ; 62.2 ; 65.8 ; 70 ; 66.8 ; 54.7 ; 61 ; 56 ; 57.7 ; 81.2 ; 90 ; 78.1 ; 90.6 ; 70.2 ; 71.9 ; 81.1 ; 100.6 ; 79.6 ; 87.8 ; 78.6 ; 73.4 ; 89.5 ; 83 ; 73.3 ; 87.9 ; 102.2 ; 88 ; 77.3 ; 82 ; 78 ; 85.8 ; 85.5 ; 88.4 ; 99.2 ; 92.2 ; 93 ; 74.8 ; 82.6 ; 95.6 ; 107.7 ; 97 ; 107.4 ; 84.9 ; 101.9 ; 116 ; 80.3 ; 95.1 ; 63.6 ; 102 ; 96.5 ; 98 ; 86.7 ; 90.8 ; 86.4 ; 72.4 ; 72.6 ; 117.1 ; 109.7 ; 75.5 ; 245.2 ; 112.5 ; 95.3 ; 82.4 ; 88.5 ; 89.7 ; 87.7 ; 102.3 ; 103.2 ; 74.1 ; 86.9 ; 95.9 ; 71.6 ; 80.8 ; 89.1 ; 76.6 ; 76.1 ; 91.3 ; 104 ; 115 ; 88.7 ; 85.6 ; 62.9 ; 75.1 ; 87.3 ; 71.7 ; 96.1 ; 66.6 ; 71.2 ; 75.2 ; 82.8 ; 91.1 ; 56.5 ; 68.6 ; 66.4 ; 66.5 ; 74 ; 64.9 ; 86.2 ; 91.5 ; 72.3 ; 59.7 ; 72 ; 72.9 ; 71 ; 60.8 ; 69.4 ; 77.2 ; 75 ; 74.6 ; 83.2 ; 92.5 ; 70.4 ; 83.3 ; 98.8 ; 69.8 ; 70.9 ; 67.9 ; 74.5 ; 60.4 ; 69.5 ; 155.2 ; 152.8 ; 177.8 ; 140.4 ; 147.4 ; 157.3 ; 147 ; 137.8 ; 112 ; 115.5 ; 153.8 ; 141.2 ; 144.8 ; 128 ; 120.7 ; 147.5 ; 134.5 ; 137.7 ; 163.3 ; 186.6 ; 184 ; 181.9 ; 189.2 ; 179.6 ; 187.5 ; 203.4 ; 198.8 ; 173.5 ; 168 ; 185.1 ; 78.7 ; 75.9 ; 93.8 ; 80.6 ; 62 ; 114.3 ; 151.1 ; 91 ; 142.8 ; 148.7 ; 144 ; 134.9 ; 151.2 ; 175.9 ; 145 ; 69 ; 137.9 ; 159.6 ; 124.5 ; 150.1 ; 152.6 ; 133.6 ; 151.4 ; 143.4 ; 145.2 ; 149.8 ; 156.1 ; 141.6 ; 139.4 ; 127.4 ; 126.6 ; 143.5 ; 128.4 ; 142.1 ; 134.6 ; 130.4 ; 140.2 ; 119.3 ; 133.3 ; 157.1 ; 145.8 ; 137.1 ; 127.6 ; 127.8 ; 139.9 ; 136.1 ; 146.5 ; 128.7 ; 148.9 ; 110.7 ; 149.9 ; 135.2 ; 163.1 ; 158.8 ; 183.2 ; 160.5 ; 168.6 ; 148.4 ; 164.5 ; 176.1 ; 139.3 ; 161.3 ; 185.7 ; 81.7 ; 80.5 ; 50.8 ; 48 ; 48.3 ; 48.9 ; 48.5 ; 72.5 ; 24.8 ; 128.8 ; 52.4 ; 105.4 ; 108.2 ; 51.2 ; 49.4 ; 49.6 ; 45.5 ; 52.7 ; 52 ; 51.6 ; 33.3 ; 55.9 ; 53.1 ; 48.2 ; 53 ; 46.1 ; 49.8 ; 51.8 ; 45 ; 51.9 ; 56.1 ; 36.1 ; 44.4 ; 44.7 ; 47.2 ; 45.2 ; 48.6 ; 30.7 ; 33.9 ; 52.2 ; 44.3 ; 76.3 ; 28.9 ; 66.9 ; 35.8 ; 63.4 ; 47.5 ; 28.5 ; 20.2 ; 51.5 ; 20.3 ; 84.4 ; 26 ; 38.8 ; 62.6 ; 23.8 ; 39.4 ; 26.7 ; 35 ; 92.9 ; 33.1 ; 36.6 ; 32.5 ; 32.3 ; 62.5 ; 68.1 ; 25.3 ; 66.3 ; 87.2 ; 26.3 ; 55 ; 25.8 ; 31 ; 46.9 ; 51 ; 31.6 ; 27.9 ; 19.7 ; 23.6 ; 29.7 ; 50 ; 20.7 ; 37.4 ; 30.3 ; 35.3 ; 46.7 ; 32.1 ; 47.4 ; 42.2 ; 40.7 ; 41.5 ; 44.9 ; 22.6 ; 53.2 ; 41.3 ; 48.7 ; 53.3 ; 28 ; 38.7 ; 50.9 ; 41.8 ; 32.9 ; 22.1 ; 27.8 ; 90.2 ; 50.4 ; 67.1 ; 50.1 ; 98.2 ; 29.6 ; 88.1 ; 38.5 ; 18 ; 47.6 ; 25.9 ; 16.9 ; 30.1 ; 40.5 ; 51.3 ; 62.3 ; 39.6 ; 21.9 ; 25.7 ; 25.2 ; 32.4 ; 23.9 ; 40.8 ; 43.4 ; 49 ; 32.7 ; 32.2 ; 42.8 ; 34.4 ; 38 ; 19.6 ; 21.7 ; 29.5 ; 27.2 ; 37.2 ; 45.9 ; 34.3 ; 44.6 ; 39 ; 50.7 ; 33.5 ; 54.8 ; 51.4 ; 48.8 ; 41.6 ; 44.8 ; 42.5 ; 53.5 ; 52.6 ; 41.7 ; 42 ; 52.8 ; 33.6 ; 46.5 ; 64.7 ; 42.1 ; 69.9 ; 59 ; 42.3 ; 49.7 ; 59.6 ; 50.3 ; 59.1 ; 58.1 ; 63.2 ; 54 ; 46.6 ; 39.2 ; 90.1 ; 88.3 ; 94.4 ; 97.1 ; 41.1 ; 47.9 ; 50.2 ; 35.1 ; 43.9 ; 147.2 ; 98.7 ; 101 ; 129.8 ; 124.8 ; 154.5 ; 101.4 ; 72.1 ; 51.1 ; 105.2 ; 88.6 ; 112.2 ; 24.2 ; 82.5 ; 83.1 ; 116.6 ; 81.4 ; 110.8 ; 81.8 ; 87.5 ; 43.8 ; 57.6 ; 83.6 ; 80.9 ; 89.9 ; 70.1 ; 85.3 ; 76.8 ; 67 ; 58.8 ; 55.4 ; 63.7 ; 31.3 ; 120.2 ; 67.3 ; 50.6 ; 49.5 ; 41 ; 64.5 ; 59.2 ; 82.7 ; 96 ; 73 ; 43.2 ; 57.9 ; 35.2 ; 91.9 ; 69.1 ; 71.5 ; 47.3 ; 60.1 ; 92.6 ; 54.9 ; 71.3 ; 84 ; 80.2 ; 72.2 ; 75.4 ; 66 ; 27.4 ; 57.5 ; 83.7 ; 86.8 ; 97.2 ; 48.4 ; 65.9
TUMOR_MOLECULAR_SUBTYPE	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Tumor molecular subtype: mutated IGHV (M-CLLs), unmutated IGHV (U-CLLs)	Sample	U-CLL ; M-CLL
TUMOR_SAMPLE_PLOIDY	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Tumor sample ploidy (WES)	Sample	2 ; 2.03 ; 2.05 ; 1.95 ; 1.98 ; 2.01 ; 2.04 ; 2.02 ; 1.99 ; 1.97 ; 1.96 ; 2.07 ; 2.1 ; 1.92 ; 2.13 ; 1.93 ; 2.06 ; 1.94 ; 2.08
TUMOR_SAMPLE_PURITY	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	NUMBER	Tumor sample purity (WES)	Sample	0.92 ; 0.94 ; 0.83 ; 0.87 ; 0.93 ; 0.86 ; 1 ; 0.77 ; 0.96 ; 0.82 ; 0.98 ; 0.85 ; 0.99 ; 0.89 ; 0.91 ; 0.66 ; 0.8 ; 0.58 ; 0.5 ; 0.63 ; 0.74 ; 0.9 ; 0.72 ; 0.67 ; 0.6 ; 0.88 ; 0.95 ; 0.59 ; 0.45 ; 0.75 ; 0.78 ; 0.64 ; 0.68 ; 0.81 ; 0.69 ; 0.97 ; 0.49 ; 0.54 ; 0.73 ; 0.84 ; 0.76 ; 0.71 ; 0.62 ; 0.65 ; 0.7 ; 0.39 ; 0.47 ; 0.48 ; 0.52 ; 0.57 ; 0.79 ; 0.55 ; 0.33
U-CLL_WES	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Sample included in U-CLL WES genetic candidate driver discovery cohort (1=yes, 0=no)	Sample	Yes ; No
U1_STATUS	LimeGreen	Chronic Lymphocytic Leukemia (Broad, Nature Genetics 2022)	STRING	Final U1 mutational status	Sample	WT ; MUT
CNA_CLUSTER_K4	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	CNA cluster K4.	Sample	3 ; 2 ; 1 ; 4
DATA_CORE_SAMPLE	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	Data core sample.	Sample	Y ; N
MAF_DATA	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	MAF Data.	Sample	Y ; N
MICRO_RNA_CLUSTER	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	MicroRNA cluster.	Sample	6 ; 4 ; 1 ; 2 ; 5 ; 3
MICRO_RNA_SCORE	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	NUMBER	MicroRNA score.	Sample	0.936182815 ; 0.923555802 ; 0.795833159 ; 0.8681518 ; 0.953263868 ; 0.869799717 ; 0.888897494 ; 0.769037046 ; 0.751790929 ; 0.86844934 ; 0.932869329 ; 0.79763473 ; 0.877287726 ; 0.71082576 ; 0.70262485 ; 0.874537804 ; 0.890025216 ; 0.908260689 ; 0.897648505 ; 0.918650794 ; 0.790575691 ; 0.877755907 ; 0.460983716 ; 0.80219575 ; 0.898513296 ; 0.909932648 ; 0.842435138 ; 0.914765853 ; 0.828806248 ; 0.843520432 ; 0.912165907 ; 0.876855817 ; 0.390770931 ; 0.911154351 ; 0.802482844 ; 0.596528 ; 0.894790354 ; 0.829517277 ; 0.842998833 ; 0.930343034 ; 0.78035969 ; 0.756697585 ; 0.913841183 ; 0.480973374 ; 0.820773525 ; 0.879877208 ; 0.366698565 ; 0.762721706 ; 0.921320947 ; 0.886489497 ; 0.396873131 ; 0.190161319 ; 0.900667706 ; 0.576051552 ; 0.739984154 ; 0.798974359 ; 0.867965161 ; 0.900509523 ; 0.875250932 ; 0.918013002 ; 0.807377395 ; 0.45957569 ; 0.822827613 ; 0.909680147 ; 0.840372671 ; 0.869465256 ; 0.920652251 ; -0.14185334 ; 0.928732873 ; 0.81473312 ; 0.936305291 ; 0.677581832 ; 0.770817643 ; 0.9151894 ; 0.887382298 ; 0.877018213 ; 0.88209171 ; 0.93181747 ; 0.788513777 ; 0.905982296 ; 0.519368529 ; 0.891829399 ; 0.819387387 ; 0.667510536 ; 0.837571802 ; -0.102733132 ; 0.594277483 ; 0.85566506 ; 0.837730267 ; 0.888581036 ; 0.807152783 ; 0.706422825 ; 0.883397264 ; 0.900244534 ; 0.934636502 ; 0.757451043 ; 0.811767884 ; 0.872298235 ; 0.77520147 ; 0.858645969 ; 0.641019608 ; 0.694269048 ; 0.435212832 ; 0.32464941 ; 0.907347869 ; 0.875629713 ; 0.910202499 ; 0.866569291 ; -0.164556962 ; 0.739874405 ; -0.061109725 ; 0.736696762 ; 0.921856623 ; 0.853878533 ; 0.891767554 ; 0.882469449 ; 0.836740624 ; 0.835714286 ; 0.652238476 ; 0.452596592 ; 0.877057267 ; 0.891243726 ; 0.871917175 ; 0.784111389 ; 0.469920802 ; 0.777473716 ; 0.774263515
MSI_STATUS_5_MARKER_CALL	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	MSI status 5 marker call.	Sample	MSI-H ; MSS ; MSI-L ; Indeterminant
MSI_STATUS_7_MARKER_CALL	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	MSI status 7 marker call.	Sample	MSI-H ; MSS ; MSI-L ; Indeterminant
MUTATION_RATE_CLUSTER	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)	STRING	Mutation rate cluster	Sample	2_HIGH ; 1_LOW ; 3_HIGHEST
IHC_DETAIL	PeachPuff	Endometrial Cancer (MSK, 2018)	STRING	IHC Detail	Patient	
MMRD_IHC	PeachPuff	Endometrial Cancer (MSK, 2018)	STRING	MMR-D by IHC	Sample	N ; not done ; Y ; inconclusive
PFS_MONTHS_FIRST_LINE_TX	PeachPuff	Endometrial Cancer (MSK, 2018)	NUMBER	First-Line Therapy PFS (months)	Patient	
POLE_IMPACT	PeachPuff	Endometrial Cancer (MSK, 2018)	STRING	POLE ultra-mutated by IMPACT	Patient	
PROGRESSION_STATUS	PeachPuff	Endometrial Cancer (MSK, 2018)	STRING	Progression Status	Patient	
COVERAGE_NORMAL	PeachPuff	Uterine Clear Cell Carcinoma (NIH, Cancer 2017)	NUMBER	Normal Sample Coverage(fold)	Sample	103 ; 71 ; 89 ; 78 ; 80 ; 85 ; 57 ; 140 ; 154 ; 46 ; 60 ; 61 ; 119 ; 97 ; 72
SECONDARY_PATHOLOGICAL_REVIEW	PeachPuff	Uterine Clear Cell Carcinoma (NIH, Cancer 2017)	STRING	Tumor subject to Secondary Pathological review?	Sample	No ; Yes
CANCER_TYPE_DETAILED_CODE	PeachPuff	Uterine Sarcoma/Mesenchymal (MSK, Clin Cancer Res 2020)	STRING	Cancer Type Detailed Code	Sample	LMS ; USTUMP ; HGNonLMS ; LGESS
INITIAL_FIGO_STAGE	PeachPuff	Uterine Sarcoma/Mesenchymal (MSK, Clin Cancer Res 2020)	STRING	Initial FIGO Stage	Sample	IIIA ; I ; IB ; IVA ; IVB ; IA ; IIB ; IIIC ; IIIB ; IIC
METASTASIS_SITE_CODE	PeachPuff	Uterine Sarcoma/Mesenchymal (MSK, Clin Cancer Res 2020)	STRING	Metastasis Site Code	Sample	Others ; Lung ; Abdomen ; Omentum ; Pelvis ; Liver
SMP_OS_MOS	PeachPuff	Uterine Sarcoma/Mesenchymal (MSK, Clin Cancer Res 2020)	NUMBER	Overall survival from sample [months]	Patient	
CIBERSORT_ABSOLUTE _SCORE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Absolute Score	Sample	0.37 ; 0.15 ; 0.78 ; 0.39 ; 0.43 ; 0.9 ; 0.44 ; 0.53 ; 1.36 ; 0.72 ; 0.67 ; 0.91 ; 0.86 ; 0.3 ; 0.61 ; 0.41 ; 0.93 ; 0.64 ; 0.62 ; 0.49 ; 0.83 ; 0.95 ; 0.35 ; 0.87 ; 0.97 ; 0.47 ; 0.8 ; 1.14 ; 0.81 ; 0.45 ; 0.65 ; 1.02 ; 0.77 ; 0.98 ; 0.74 ; 0.42 ; 0.84 ; 0.6 ; 1.12 ; 0.2 ; 0.71 ; 1.35 ; 0.52 ; 0.79 ; 0.55 ; 0.7 ; 0.34 ; 0.99 ; 0.76 ; 0.58 ; 2.5 ; 0.5 ; 0.75 ; 0.51 ; 1.63 ; 0.92 ; 0.46 ; 0.59 ; 1.49 ; 1.21 ; 1.19
CIBERSORT_B _CELLS _MEMORY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT B Cells Memory	Sample	0 ; 0.019078676 ; 0.015477154 ; 0.014642819 ; 0.002332159 ; 0.002365816 ; 0.007246349 ; 0.001 ; 0.014150682 ; 0.028690669 ; 0.003299952 ; 0.008617884 ; 0.014679488 ; 0.019373833 ; 0.006524058 ; 0.016317124 ; 0.009631275 ; 0.013644085 ; 0.017101616 ; 0.009145218 ; 0.0019259 ; 0.040723911 ; 0.00180072
CIBERSORT_B _CELLS _NAIVE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT B cells naive	Sample	0.010443511 ; 0.004411131 ; 0.039852399 ; 0 ; 0.005773262 ; 0.001059623 ; 0.052107498 ; 0.005885269 ; 0.0002 ; 0.005639499 ; 0.028168355 ; 0.012463677 ; 0.011222617 ; 0.023552518 ; 0.031297567 ; 0.009964698 ; 0.001468636 ; 0.017468027 ; 0.0008 ; 0.022073223 ; 0.030621947 ; 0.007473998 ; 0.026238122 ; 0.015676172 ; 0.0004 ; 0.029244357 ; 0.014017651 ; 0.010868604 ; 0.03118917 ; 0.014830874 ; 0.010769803 ; 0.015292295 ; 0.0006 ; 0.019563355 ; 0.008889822 ; 0.005798878 ; 0.016955087 ; 0.00669145 ; 0.030012721 ; 0.124378981 ; 0.042572483 ; 0.038086734 ; 0.008844079 ; 0.01866044 ; 0.003230715 ; 0.016298314 ; 0.045750101 ; 0.037397016 ; 0.010986849 ; 0.0009 ; 0.011563794 ; 0.00168362 ; 0.010998418 ; 0.04942716 ; 0.021980571 ; 0.00875642 ; 0.022408764 ; 0.003670969 ; 0.01763236 ; 0.045215956 ; 0.003029268 ; 0.058010582
CIBERSORT_DENDRITIC _CELLS _ACTIVATED	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Dendritic Cells Activated	Sample	0.00612096 ; 0.007160341 ; 0.039683645 ; 0.0041831 ; 0 ; 0.012429489 ; 0.015480802 ; 0.009007116 ; 0.022078706 ; 0.009461798 ; 0.032192268 ; 0.042889981 ; 0.028793179 ; 0.004345187 ; 0.036799065 ; 0.009009601 ; 0.001379743 ; 0.008867171 ; 0.023599304 ; 0.00170767 ; 0.041396454 ; 0.048482686 ; 0.024126845 ; 0.006704016 ; 0.003705692 ; 0.002002463 ; 0.014442484 ; 0.005438661 ; 0.006207267 ; 0.060779007 ; 0.07376121 ; 0.02101373 ; 0.055190295 ; 0.006758145 ; 0.008110889 ; 0.002996522 ; 0.003833063 ; 0.003921947 ; 0.007310619 ; 0.009959128 ; 0.005009947 ; 0.007935982 ; 0.049617216 ; 0.021351223 ; 0.022602173 ; 0.009914774 ; 0.081958621 ; 0.032505502 ; 0.023606374 ; 0.0015387 ; 0.010619227 ; 0.016131815 ; 0.004934959 ; 0.015000539 ; 0.015563506 ; 0.007590874 ; 0.009602334 ; 0.017862528 ; 0.01803284 ; 0.013967784 ; 0.009557828 ; 0.00602792 ; 0.029581456 ; 0.012682978 ; 0.043358278
CIBERSORT_DENDRITIC _CELLS _RESTING	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Dendritic Cells Resting	Sample	0 ; 0.010407182 ; 0.021836951 ; 0.00817583 ; 0.061026835 ; 0.033059137 ; 0.012365358 ; 0.0001 ; 0.030543531 ; 0.011092339 ; 0.001049951 ; 0.004780403 ; 0.004461257 ; 0.010183766 ; 0.002742905 ; 0.002732616 ; 0.018233193 ; 0.012153007 ; 0.003669428 ; 0.030006631 ; 0.030731553 ; 0.012869295 ; 0.00363144 ; 0.005772881 ; 0.01803949 ; 0.014219009 ; 0.005672928 ; 0.017781494 ; 0.004972786 ; 0.02868622 ; 0.059757333 ; 0.006471643 ; 0.016770321 ; 0.003387154 ; 0.007996144 ; 0.0007 ; 0.046680774 ; 0.002492303 ; 0.065752505 ; 0.011314816 ; 0.004733789 ; 0.01672796 ; 0.049886437 ; 0.001005253 ; 0.017311522 ; 0.00618781 ; 0.086513328 ; 0.005855964 ; 0.025064852 ; 0.011178091 ; 0.009838939 ; 0.0002 ; 0.001366269 ; 0.017629382 ; 0.002885581 ; 0.0004 ; 0.021208229 ; 0.019213128 ; 0.00549566
CIBERSORT_EOSINOPHILS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Eosinophils	Sample	0 ; 0.011681456 ; 0.027104312 ; 0.0009 ; 0.006304285 ; 0.024383635 ; 0.010748036 ; 0.010365772 ; 0.0003 ; 0.0007 ; 0.018264584 ; 0.007794239 ; 0.001638531 ; 0.008152597 ; 0.040648716 ; 0.019763217 ; 0.006576348 ; 0.012958822 ; 0.017523387 ; 0.02579255 ; 0.00128331 ; 0.015382924 ; 0.016382998 ; 0.011223627 ; 0.010695738 ; 0.001495829 ; 0.0008 ; 0.0004 ; 0.023100596 ; 0.007938323 ; 0.025684679 ; 0.0006 ; 0.001268082 ; 0.007400155 ; 0.016439373 ; 0.002005813 ; 0.021394706
CIBERSORT_MACROPHAGES _M0	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Macrophages M0	Sample	0.024896194 ; 0.016040522 ; 0.122233997 ; 0 ; 0.054263627 ; 0.027346769 ; 0.074245364 ; 0.079259476 ; 0.063456552 ; 0.128991522 ; 0.062962959 ; 0.102629415 ; 0.007085054 ; 0.052890205 ; 0.048188695 ; 0.027789143 ; 0.043837507 ; 0.036327449 ; 0.026942536 ; 0.006640164 ; 0.017816682 ; 0.015333559 ; 0.062493983 ; 0.04413059 ; 0.064232161 ; 0.026623532 ; 0.160223537 ; 0.037066542 ; 0.015992922 ; 0.095737426 ; 0.051160224 ; 0.00770542 ; 0.083275431 ; 0.008591921 ; 0.106226948 ; 0.145158987 ; 0.11382124 ; 0.027204716 ; 0.02503175 ; 0.141429525 ; 0.031163318 ; 0.043674035 ; 0.059535132 ; 0.007519195 ; 0.184708541 ; 0.045221132 ; 0.087850691 ; 0.063637704 ; 0.093244702 ; 0.036097355 ; 0.042293294 ; 0.016427891 ; 0.052651407 ; 0.083981574 ; 0.087639399 ; 0.01902837 ; 0.017185208 ; 0.058283669 ; 0.157369678 ; 0.304649896 ; 0.011028416 ; 0.013521662 ; 0.175928867 ; 0.170651046 ; 0.037858222 ; 0.095029079 ; 0.099516789 ; 0.046756746 ; 0.062999837 ; 0.074846217 ; 0.181109898 ; 0.101667828 ; 0.207247911 ; 0.01575249 ; 0.063996724 ; 0.063638898 ; 0.166271953 ; 0.056808071 ; 0.430658443
CIBERSORT_MACROPHAGES _M1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Macrophages M1	Sample	0.047057934 ; 0.00394293 ; 0.020499422 ; 0.018807855 ; 0.064099852 ; 0.012830509 ; 0.006238274 ; 0.053001228 ; 0.091911576 ; 0.023867009 ; 0.006664382 ; 0.056281696 ; 0.092353708 ; 0.01282946 ; 0 ; 0.052425878 ; 0.012564144 ; 0.05725825 ; 0.029796878 ; 0.013094056 ; 0.003920914 ; 0.023880414 ; 0.011079146 ; 0.006318375 ; 0.012991405 ; 0.047401521 ; 0.0002 ; 0.063111119 ; 0.02439787 ; 0.016122823 ; 0.041096529 ; 0.040816315 ; 0.032144626 ; 0.004253386 ; 0.064399209 ; 0.050662903 ; 0.060980028 ; 0.016167916 ; 0.018306136 ; 0.015098039 ; 0.00987097 ; 0.070700628 ; 0.019701249 ; 0.070048837 ; 0.077019546 ; 0.016577828 ; 0.076748995 ; 0.024328606 ; 0.029584537 ; 0.018902943 ; 0.079014882 ; 0.099611915 ; 0.0009 ; 0.037899661 ; 0.019022007 ; 0.002384896 ; 0.194001873 ; 0.008736583 ; 0.013020446 ; 0.077466078 ; 0.004766039 ; 0.023516134 ; 0.065229078 ; 0.004394117 ; 0.023567338 ; 0.019426868 ; 0.024603135 ; 0.0433648 ; 0.007387838 ; 0.306262844 ; 0.007473355 ; 0.011451255 ; 0.066989651 ; 0.009653509 ; 0.039194685 ; 0.003210075 ; 0.03294438 ; 0.034536967 ; 0.004096005 ; 0.20547773 ; 0.007875625 ; 0.088930214 ; 0.052855743 ; 0.00889596 ; 0.059493274 ; 0.042764415 ; 0.207608597 ; 0.099728201 ; 0.064693237
CIBERSORT_MACROPHAGES _M2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Macrophages M2	Sample	0.072523873 ; 0.027211297 ; 0.049193367 ; 0.122544366 ; 0.140338468 ; 0.145650337 ; 0.066621604 ; 0.035774299 ; 0.352506586 ; 0.122295409 ; 0.151204409 ; 0.117348345 ; 0.213796665 ; 0.058647987 ; 0.06641301 ; 0.022231967 ; 0.154422067 ; 0.0008 ; 0.110485885 ; 0.075305468 ; 0.147629049 ; 0.110666462 ; 0.139210676 ; 0.053857024 ; 0.105220232 ; 0.253723841 ; 0.10620711 ; 0.010375886 ; 0.113943164 ; 0.229949042 ; 0.120844083 ; 0.124492647 ; 0.174904075 ; 0.208800355 ; 0.130015737 ; 0.179213063 ; 0.152417514 ; 0.0947925 ; 0.123462338 ; 0.213574815 ; 0.248352302 ; 0.165327623 ; 0.279895555 ; 0.18378076 ; 0.168158407 ; 0.202442392 ; 0.154202848 ; 0.104517526 ; 0.208602464 ; 0.137049713 ; 0.090333965 ; 0.08291912 ; 0.189955698 ; 0.207091546 ; 0.047962606 ; 0.153705136 ; 0.182363781 ; 0.053377612 ; 0.285098088 ; 0.090772415 ; 0.127467118 ; 0.174081384 ; 0.092418353 ; 0.088148927 ; 0.180950468 ; 0.028277497 ; 0.151485066 ; 0.083600371 ; 0.129435366 ; 0.112311231 ; 0.219421538 ; 0.124292888 ; 0.097929766 ; 0.03309009 ; 0.443728427 ; 0 ; 0.099516218 ; 0.174223788 ; 0.094545911 ; 0.254847613 ; 0.184924122 ; 0.157008808 ; 0.138981912 ; 0.060843228 ; 0.193189949 ; 0.307954382 ; 0.162633253 ; 0.26555035 ; 0.176413766 ; 0.137475272 ; 0.158603661 ; 0.095607114 ; 0.390061502 ; 0.145488511 ; 0.22904602
CIBERSORT_MAST _CELLS _ACTIVATED	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Mast Cells Activated	Sample	0 ; 0.015087431 ; 0.033824616 ; 0.049418849 ; 0.018873801 ; 0.07237302 ; 0.018753335 ; 0.001126745 ; 0.035334153 ; 0.019248281 ; 0.031426484 ; 0.046995801 ; 0.045033677 ; 0.056142168 ; 0.014757236 ; 0.002601277 ; 0.005498505 ; 0.129636775 ; 0.008075333 ; 0.005250649 ; 0.030856792 ; 0.019894683 ; 0.013628498 ; 0.024953588 ; 0.013023059 ; 0.036358248 ; 0.095529589 ; 0.073013728 ; 0.109393005 ; 0.039742974 ; 0.061907521 ; 0.128791658 ; 0.034636055 ; 0.006719297 ; 0.01372593 ; 0.108706228 ; 0.00227769 ; 0.01149725 ; 0.037907652 ; 0.049773167 ; 0.058770763 ; 0.005492839
CIBERSORT_MAST _CELLS _RESTING	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Mast Cells Resting	Sample	0 ; 0.065981557 ; 0.21207275 ; 0.099926731 ; 0.021773803 ; 0.042382678 ; 0.106293289 ; 0.027745052 ; 0.034316037 ; 0.047224779 ; 0.016645745 ; 0.018269735 ; 0.092315548 ; 0.072599294 ; 0.130442357 ; 0.02840326 ; 0.011250673 ; 0.076648017 ; 0.05073331 ; 0.046598774 ; 0.028764852 ; 0.034147031 ; 0.052446093 ; 0.05178604 ; 0.097073479 ; 0.032160254 ; 0.051687953 ; 0.079300673 ; 0.071131317 ; 0.026757166 ; 0.017436486 ; 0.00596616 ; 0.018592465 ; 0.024691718 ; 0.033777368 ; 0.032059529 ; 0.045550741 ; 0.002898656 ; 0.050744634 ; 0.003860163 ; 0.013040807 ; 0.026044313 ; 0.041334208 ; 0.010357642 ; 0.020993106 ; 0.032382459 ; 0.020947178 ; 0.047959996 ; 0.01460814 ; 0.071758177 ; 0.026629608 ; 0.014877105 ; 0.036807022 ; 0.012959135 ; 0.083143647 ; 0.004351604 ; 0.042631692
CIBERSORT_MONOCYTES	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Monocytes	Sample	0 ; 0.00385161 ; 0.002542568 ; 0.041004139 ; 0.019246682 ; 0.012905363 ; 0.045689566 ; 0.0003 ; 0.021205627 ; 0.004718605 ; 0.046614126 ; 0.033466742 ; 0.018172299 ; 0.057276039 ; 0.009198579 ; 0.015500241 ; 0.027223716 ; 0.027796018 ; 0.013321546 ; 0.015968111 ; 0.005956481 ; 0.030148189 ; 0.054421936 ; 0.010850501 ; 0.002564539 ; 0.041579984 ; 0.02840839 ; 0.051242322 ; 0.023889679 ; 0.015489192 ; 0.02761867 ; 0.003605974 ; 0.030101489 ; 0.013078051 ; 0.051333479 ; 0.009016892 ; 0.0004 ; 0.011103314 ; 0.006634182 ; 0.026199623 ; 0.014863803 ; 0.011249512 ; 0.020732476 ; 0.009388966 ; 0.002629565 ; 0.029366632 ; 0.002181305 ; 0.012636839 ; 0.039610944 ; 0.006748859 ; 0.015829072 ; 0.003415035 ; 0.011821109 ; 0.023056066
CIBERSORT_NEUTROPHILS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Neutrophils	Sample	0.00967535 ; 0 ; 0.094933366 ; 0.006120479 ; 0.024388609 ; 0.020368787 ; 0.006842302 ; 0.018422424 ; 0.01725032 ; 0.137670181 ; 0.006247294 ; 0.0226248 ; 0.007693776 ; 0.010198554 ; 0.048423841 ; 0.002556199 ; 0.157403077 ; 0.028471817 ; 0.035778439 ; 0.013000122 ; 0.239323207 ; 0.004399126 ; 0.074511355 ; 0.045830018 ; 0.105643912 ; 0.266741893 ; 0.027284937 ; 0.042566719 ; 0.042736941 ; 0.009127693 ; 0.030273428 ; 0.031272954 ; 0.045348883 ; 0.01927318 ; 0.0009 ; 0.001940573 ; 0.009113625 ; 0.015226148 ; 0.0284594 ; 0.008671362 ; 0.1185783 ; 0.011317526 ; 0.059587641 ; 0.072578025 ; 0.031045659 ; 0.002014424 ; 0.028468981 ; 0.005992563 ; 0.005406991 ; 0.041876884 ; 0.044460701 ; 0.022511308 ; 0.008455565 ; 0.019512128 ; 0.047270477 ; 0.022128812
CIBERSORT_NK _CELLS _ACTIVATED	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT NK Cells Activated	Sample	0.020942068 ; 0.004934448 ; 0 ; 0.014684549 ; 0.02318389 ; 0.014546171 ; 0.027957379 ; 0.010194706 ; 0.017594418 ; 0.060977392 ; 0.014532283 ; 0.081825121 ; 0.002681846 ; 0.018869097 ; 0.009243439 ; 0.016213555 ; 0.013514406 ; 0.02793142 ; 0.054924606 ; 0.042554994 ; 0.051867091 ; 0.021782958 ; 0.031367877 ; 0.002789135 ; 0.029367134 ; 0.074014313 ; 0.02872328 ; 0.04054915 ; 0.105500717 ; 0.050743363 ; 0.00110555 ; 0.03239514 ; 0.10639045 ; 0.024890194 ; 0.054248224 ; 0.00418142 ; 0.033949534 ; 0.029434116 ; 0.027640251 ; 0.02729506 ; 0.05385969 ; 0.037878075 ; 0.054539991 ; 0.079006224 ; 0.002045284 ; 0.036534493 ; 0.052652388 ; 0.073224264 ; 0.010084213 ; 0.018403697 ; 0.020033554 ; 0.009842251 ; 0.035347052 ; 0.026200573 ; 0.095799524 ; 0.008723851 ; 0.02064572 ; 0.011322581 ; 0.017937373 ; 0.002314538 ; 0.014971624 ; 0.019284594 ; 0.069134349 ; 0.009230714 ; 0.054696075 ; 0.055392899 ; 0.048861303 ; 0.028120711 ; 0.034249071 ; 0.038248608 ; 0.024638292 ; 0.05131453 ; 0.019183604 ; 0.036010774 ; 0.02334588 ; 0.029795527 ; 0.066840911 ; 0.002659192 ; 0.027449986 ; 0.008318946 ; 0.047962053 ; 0.003258252
CIBERSORT_NK _CELLS _RESTING	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT NK Cells Resting	Sample	0 ; 0.018425297 ; 0.084425262 ; 0.033211036 ; 0.067142743 ; 0.0001 ; 0.029287744 ; 0.020821045 ; 0.019629883 ; 0.073868667 ; 0.016716326 ; 0.019629646 ; 0.0003 ; 0.02209679 ; 0.037773189 ; 0.017253413 ; 0.034001026 ; 0.080428803 ; 0.019796059 ; 0.01531505 ; 0.02417088 ; 0.001813999 ; 0.026913005 ; 0.030943857 ; 0.033115855 ; 0.056594181 ; 0.008729727 ; 0.034585703 ; 0.0008 ; 0.011965047 ; 0.003062666 ; 0.034393768 ; 0.065210688
CIBERSORT_PLASMA _CELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT Plasma Cells	Sample	0.017867521 ; 0.00176099 ; 0.050305497 ; 0.007199854 ; 0.027627049 ; 0.012292451 ; 0.006136476 ; 0.00615282 ; 0.034349671 ; 0.0006 ; 0.050717552 ; 0.029774138 ; 0.087616998 ; 0.022842137 ; 0.008908075 ; 0.001624051 ; 0.051383493 ; 0.028840788 ; 0.047689147 ; 0.053445267 ; 0.055385291 ; 0.003981782 ; 0.011671998 ; 0.006063698 ; 0.031251803 ; 0.021648923 ; 0.057724868 ; 0.0007 ; 0.013975788 ; 0.0001 ; 0.003502029 ; 0 ; 0.00172655 ; 0.089815096 ; 0.006541175 ; 0.007948338 ; 0.046343582 ; 0.058490698 ; 0.041585333 ; 0.050302654 ; 0.039919707 ; 0.055970953 ; 0.022069207 ; 0.024427266 ; 0.01279678 ; 0.011458756 ; 0.041497227 ; 0.00647704 ; 0.043384893 ; 0.029447879 ; 0.029467374 ; 0.001911367 ; 0.024248712 ; 0.091752351 ; 0.00704365 ; 0.040284527 ; 0.016467675 ; 0.043745649 ; 0.019515459 ; 0.010129747 ; 0.007937663 ; 0.004338932 ; 0.015359593 ; 0.002019326 ; 0.030300705 ; 0.070557933 ; 0.033097091 ; 0.038080912 ; 0.031350984 ; 0.010732175 ; 0.078532432 ; 0.055544593 ; 0.039926845 ; 0.012116224 ; 0.029239852 ; 0.00339234 ; 0.059210761 ; 0.049541359 ; 0.014336444 ; 0.012271592 ; 0.029677669 ; 0.026971786 ; 0.019304946 ; 0.058648319 ; 0.007080589 ; 0.024315518 ; 0.038323966 ; 0.064580904
CIBERSORT_T _CELLS _CD4 _MEMORY _ACTIVATED	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells CD4 Memory Activated	Sample	0 ; 0.026119631 ; 0.002504556 ; 0.009782414 ; 0.007532985 ; 0.035281171 ; 0.007105428 ; 0.017896475 ; 0.0003 ; 0.062742251 ; 0.025389225 ; 0.032685341 ; 0.016912327 ; 0.263662345 ; 0.097293058 ; 0.053681598 ; 0.503309554 ; 0.001489306 ; 0.031665751 ; 0.002679818 ; 0.065220541 ; 0.049980042 ; 0.275833718
CIBERSORT_T _CELLS _CD4 _MEMORY _RESTING	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells CD4 Memory Resting	Sample	0.088247615 ; 0.026435753 ; 0.217047308 ; 0.06169803 ; 0.015101252 ; 0.218447078 ; 0.096159419 ; 0.101975277 ; 0.257694874 ; 0.215617674 ; 0.180804762 ; 0.072129432 ; 0.136319654 ; 0.095277213 ; 0.158299126 ; 0.104674412 ; 0.284732939 ; 0.107587815 ; 0.176219029 ; 0.079296814 ; 0.049639616 ; 0.082865548 ; 0.176943387 ; 0.124472718 ; 0.139556902 ; 0.221950913 ; 0.359625849 ; 0.053273559 ; 0.247713667 ; 0.414372638 ; 0.095558177 ; 0.20566446 ; 0.167282206 ; 0.15312548 ; 0.172918892 ; 0.36866113 ; 0.190698911 ; 0.079155671 ; 0.124923504 ; 0.186223789 ; 0.222912019 ; 0.192326822 ; 0.155098137 ; 0.117139625 ; 0.151125497 ; 0.145822992 ; 0.143980157 ; 0.077021852 ; 0.22358277 ; 0.060144906 ; 0.115811487 ; 0.178005848 ; 0.157712493 ; 0.303072564 ; 0.034506425 ; 0.140721701 ; 0.292386957 ; 0.113361734 ; 0.103577841 ; 0.069356038 ; 0.207054009 ; 0.094326881 ; 0.111390552 ; 0.151782648 ; 0.135062253 ; 0.09073604 ; 0.218420192 ; 0.096250531 ; 0.21779436 ; 0.164865609 ; 0.124816275 ; 0.081380422 ; 0.136729657 ; 0.160050801 ; 0.003827364 ; 0.081197741 ; 0.141768576 ; 0.098042625 ; 0.058394539 ; 0.141971235 ; 0.080097796 ; 0.125676207 ; 0.141429748 ; 0.134138183 ; 0.113462274 ; 0.173192267 ; 0.208514252 ; 0.14099011 ; 0.031092652 ; 0.074485955 ; 0.098306727 ; 0.071179987 ; 0.239386292 ; 0.125632435 ; 0.187681071
CIBERSORT_T _CELLS _CD4 _NAIVE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells CD4 Naive	Sample	0
CIBERSORT_T _CELLS _CD8	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells CD8	Sample	0.036816257 ; 0.002130758 ; 0.043745478 ; 0.047075193 ; 0.050190166 ; 0.089036423 ; 0.01781162 ; 0.017771978 ; 0.305302969 ; 0.016694075 ; 0.0004 ; 0.23977877 ; 0.048920734 ; 0.029908963 ; 0.05901444 ; 0 ; 0.061136375 ; 0.087713967 ; 0.018563104 ; 0.072290433 ; 0.067875939 ; 0.019412424 ; 0.060441238 ; 0.057224851 ; 0.051264159 ; 0.022225746 ; 0.128965836 ; 0.011836886 ; 0.006103286 ; 0.064132247 ; 0.082780907 ; 0.123466351 ; 0.049229317 ; 0.089063113 ; 0.065985323 ; 0.109885559 ; 0.078174173 ; 0.015260895 ; 0.047550012 ; 0.036872541 ; 0.108651861 ; 0.109470307 ; 0.029312715 ; 0.145274304 ; 0.093416052 ; 0.057892742 ; 0.109550741 ; 0.092732909 ; 0.162358545 ; 0.008603041 ; 0.086170937 ; 0.074472037 ; 0.098087625 ; 0.024497424 ; 0.068410488 ; 0.040886712 ; 0.16848275 ; 0.01497689 ; 0.01546921 ; 0.129747623 ; 0.016943114 ; 0.008406152 ; 0.119573197 ; 0.071564429 ; 0.039137254 ; 0.077080519 ; 0.021893216 ; 0.149854695 ; 0.020138707 ; 0.016723849 ; 0.046626728 ; 0.63289952 ; 0.053007557 ; 0.061654733 ; 0.191800595 ; 0.055865002 ; 0.163010063 ; 0.03888996 ; 0.039094717 ; 0.03011827 ; 0.090537458 ; 0.038721394 ; 0.264904483 ; 0.034484496 ; 0.085321157 ; 0.063511306 ; 0.073887376 ; 0.066290344 ; 0.06592389 ; 0.143705494 ; 0.24395747 ; 0.030642108
CIBERSORT_T _CELLS _FOLLICULAR _HELPER	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells Follicular Helper	Sample	0.035408717 ; 0.014944149 ; 0.001314347 ; 0 ; 0.011140644 ; 0.014378883 ; 0.058437763 ; 0.060458172 ; 0.10551234 ; 0.072989693 ; 0.010317116 ; 0.077566594 ; 0.016860233 ; 0.006606719 ; 0.027016898 ; 0.060904492 ; 0.052863572 ; 0.083529995 ; 0.083814428 ; 0.069693176 ; 0.012846689 ; 0.015331903 ; 0.002192122 ; 0.027238232 ; 0.006965088 ; 0.096956018 ; 0.029154427 ; 0.047263698 ; 0.045841298 ; 0.070066347 ; 0.073904574 ; 0.044134912 ; 0.023992102 ; 0.061050076 ; 0.034617457 ; 0.01494661 ; 0.081580939 ; 0.033005898 ; 0.073799185 ; 0.021802422 ; 0.021676235 ; 0.079008992 ; 0.010177208 ; 0.084212413 ; 0.045137299 ; 0.096795497 ; 0.013428672 ; 0.120657123 ; 0.001711434 ; 0.014451686 ; 0.001274594 ; 0.083597209 ; 0.009639726 ; 0.02143719 ; 0.024431161 ; 0.007989276 ; 0.018158207 ; 0.052257959 ; 0.019611349 ; 0.00995094 ; 0.0026438 ; 0.075026311 ; 0.027823669 ; 0.108819909 ; 0.020752246 ; 0.014417241 ; 0.024640361 ; 0.159976185 ; 0.030498309 ; 0.05726203 ; 0.010287635 ; 0.016325308 ; 0.011367262 ; 0.025906813 ; 0.053233302 ; 0.069264334 ; 0.104941128 ; 0.081837455 ; 0.036809347 ; 0.045953357 ; 0.063741986 ; 0.139580503 ; 0.05056075
CIBERSORT_T _CELLS _GAMMA _DELTA	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells Gamma Delta	Sample	0 ; 0.002598418 ; 0.012162159 ; 0.021748457 ; 0.030562897 ; 0.052661005 ; 0.009010017 ; 0.003992697 ; 0.0128425 ; 0.040490228 ; 0.022112668 ; 0.023439594 ; 0.037699444 ; 0.044567053 ; 0.054679848 ; 0.004897877 ; 0.047553185 ; 0.004284004 ; 0.004320911 ; 0.265176591 ; 0.004317008 ; 0.070019705 ; 0.029759765 ; 0.0006
CIBERSORT_T _CELLS _REGULATORY _(TREGS)	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CIBERSORT T Cells Regulatory (Tregs)	Sample	0 ; 0.022737675 ; 0.016090453 ; 0.011980289 ; 0.026782261 ; 0.015668239 ; 0.028332406 ; 0.006352148 ; 0.04120487 ; 0.009822934 ; 0.0004 ; 0.010235752 ; 0.00687843 ; 0.00442106 ; 0.00906967 ; 0.021983045 ; 0.009819622 ; 0.015350342 ; 0.001645347 ; 0.011763169 ; 0.002204626 ; 0.004202812 ; 0.017933064 ; 0.0094154 ; 0.01092673 ; 0.006463702 ; 0.001303502 ; 0.013355372 ; 0.056220642 ; 0.0262358 ; 0.028484946 ; 0.005921685 ; 0.020834183 ; 0.019249438 ; 0.012461263 ; 0.025438194 ; 0.017676251 ; 0.02562487
CLIN_STAGE_DIST_METS-CM	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Clinical Stage Distribution Metastasis â€“ cM	Patient	
CNV_1Q_AMP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV 1q AMP	Sample	0.005761569 ; 0.000978501 ; 0.003805798 ; 0.00313913 ; 0.131950499 ; 0.588337381 ; 0.009886273 ; 0.335791813 ; 0.554316666 ; 0.032914497 ; 0.002757972 ; 0 ; 0.26160588 ; 0.810292168 ; 0.224806047 ; 3.80E-05 ; 8.84E-05 ; 0.713144091 ; 0.01153052 ; 0.002878658 ; 0.001724522 ; 0.000816684 ; 0.000277034 ; 0.016533914 ; 0.131320241 ; 0.001422013 ; 0.008340476 ; 0.124562884 ; 0.426543057 ; 0.284680929 ; 0.003398339 ; 0.020039557 ; 0.028202121 ; 0.000652912 ; 0.007044113 ; 0.001938268 ; 0.000879966 ; 0.566440807 ; 0.014794003 ; 0.089327755 ; 0.002070001 ; 0.008267534 ; 0.240745792 ; 0.004694148 ; 0.003746224 ; 0.142891225 ; 0.274251993 ; 0.190078055 ; 0.027806684 ; 0.000899662 ; 0.166020994 ; 0.253917096 ; 0.016728619 ; 0.002870901 ; 0.458642624 ; 0.098145517 ; 0.045136978 ; 0.430309377 ; 0.004475428 ; 0.266096258 ; 0.000595152 ; 0.010595091 ; 0.043401406 ; 0.215849759 ; 0.62144095 ; 0.001100237 ; 0.348272487 ; 0.000333665 ; 0.410300448 ; 0.092649243 ; 0.151209284 ; 0.260744145 ; 0.141450915 ; 0.118123338 ; 0.025331244
CNV_1Q_DEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV 1q DEL	Sample	-0.016886191 ; 0 ; -0.001375124 ; -0.043811447 ; -0.01420399 ; -0.00468552 ; -0.000726575 ; -0.000310868 ; -0.00100262 ; -9.85E-05 ; -0.000490928 ; -0.000537474 ; -0.091810653 ; -0.010880178 ; -0.000633572 ; -2.55E-05 ; -0.028557583 ; -0.017919344 ; -0.02658492 ; -0.017869153 ; -0.041422012 ; -1.54E-05 ; -0.007832131 ; -0.00506506 ; -0.043062122 ; -0.000648148 ; -0.000222039 ; -0.001213574 ; -0.014771766 ; -0.008686236 ; -0.003401977 ; -0.025528506 ; -0.002417106 ; -0.001843017 ; -0.002370195 ; -0.006828509 ; -0.005789059 ; -0.00225703 ; -0.003600071 ; -0.002380017 ; -0.001479407 ; -0.01793059 ; -0.016165776 ; -0.016802222 ; -0.001048497 ; -0.001605586 ; -0.001714734 ; -0.00977493 ; -0.001916029 ; -0.004193273 ; -0.012304598 ; -0.006951058 ; -0.003293513 ; -0.000660581 ; -0.047929426 ; -0.000224265 ; -0.013677414 ; -0.001757162 ; -0.031026014 ; -0.001862026 ; -0.000303572 ; -0.002837097 ; -0.003798404 ; -0.007844061 ; -0.016228174 ; -0.095116164 ; -0.013058781 ; -0.0229681 ; -0.001486725 ; -0.002030269 ; -0.015766433 ; -0.003782297 ; -0.001980205 ; -0.016427767 ; -0.009007688 ; -0.019652702 ; -0.021722017 ; -0.068690488
CNV_3Q_AMP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV 3q AMP	Sample	0.009796749 ; 0 ; 0.003557554 ; 0.268048184 ; 0.013221618 ; 0.405527663 ; 0.002000249 ; 0.326433728 ; 0.010537265 ; 0.000125954 ; 0.000349225 ; 0.00090885 ; 3.93E-05 ; 0.022152841 ; 0.112848771 ; 0.002063857 ; 0.000435609 ; 0.01139247 ; 0.002129629 ; 0.162623864 ; 0.203619111 ; 0.001237317 ; 0.004247474 ; 0.003173341 ; 0.003380363 ; 0.013065794 ; 0.089442964 ; 0.005535154 ; 0.012597006 ; 0.187988723 ; 0.002273465 ; 0.000747792 ; 0.028710501 ; 0.051347771 ; 0.034279747 ; 0.002372009 ; 0.000231892 ; 0.017922255 ; 0.17615102 ; 0.090120448 ; 0.376787468 ; 0.004470598 ; 0.006028132 ; 0.002272731 ; 0.136186586 ; 0.000266397 ; 0.011390353 ; 0.100474431 ; 0.030893769 ; 0.000255572 ; 0.001173413 ; 0.000405656 ; 0.00034245 ; 0.426536847 ; 0.176426135 ; 0.001213689 ; 0.242258634 ; 0.083155192 ; 0.163937849 ; 0.075747549
CNV_3Q_DEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CNV 3q DEL	Sample	-0.023339852 ; -0.002698584 ; -0.003122768 ; -0.073670939 ; -0.000856205 ; -0.110063016 ; -0.007950328 ; -0.000207719 ; -0.023866202 ; -0.005465167 ; 0 ; -0.005212673 ; -0.021353659 ; -0.038363057 ; -0.210417756 ; -0.097520363 ; -0.011242408 ; -0.052457471 ; -0.000868323 ; -0.003489469 ; -0.019029565 ; -0.021106253 ; -0.001245513 ; -0.015028621 ; -0.044486227 ; -0.000658373 ; -0.000201005 ; -0.008649932 ; -0.045147436 ; -0.002843947 ; -0.008244015 ; -0.007665712 ; -0.004589812 ; -0.000550972 ; -0.000334779 ; -0.002387141 ; -0.008578778 ; -0.002305824 ; -0.006350382 ; -0.044166784 ; -0.001064044 ; -0.015521278 ; -0.004861285 ; -0.005103458 ; -0.004818201 ; -0.004272987 ; -0.002022706 ; -0.041093192 ; -0.002163191 ; -0.015025716 ; -0.033351905 ; -0.012053628 ; -0.004209591 ; -0.000582126 ; -0.000856933 ; -0.014711711 ; -0.013714462 ; -0.03162148 ; -0.013557086 ; -0.004178351 ; -0.000574442 ; -0.008377274 ; -0.031027797 ; -0.117524875 ; -0.012890698 ; -0.02685752 ; -0.016362319 ; -0.011803866 ; -0.000473355 ; -0.002169021 ; -0.079315575 ; -0.001974315 ; -0.004073222 ; -0.00690175 ; -0.021330753 ; -0.000314798 ; -0.015492594
CNV_4Q_AMP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV 4q AMP	Sample	0.014250962 ; 0 ; 0.002393507 ; 0.000109284 ; 0.064997832 ; 0.019164116 ; 2.79E-06 ; 0.007941129 ; 0.015115205 ; 7.34E-05 ; 0.000650063 ; 0.000973227 ; 0.000754789 ; 0.000446531 ; 0.021908213 ; 0.004073356 ; 0.001831731 ; 2.15E-05 ; 0.046533793 ; 0.002579581 ; 0.00079462 ; 0.004817637 ; 0.004985567 ; 0.012025851 ; 0.036590969 ; 0.01129473 ; 0.007949318 ; 0.000426944 ; 0.037680011 ; 0.001905127 ; 0.00016282 ; 0.010002796 ; 1.68E-05 ; 0.044860534 ; 0.000282338 ; 0.005030412 ; 0.006610292 ; 0.005374178 ; 0.011912057 ; 0.000444979 ; 0.000672214 ; 0.002322995 ; 0.011365024 ; 0.001457121 ; 0.01483176 ; 0.001175305
CNV_4Q_DEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV 4q DEL	Sample	-0.023494917 ; -0.01112554 ; -0.005361581 ; -0.050230318 ; -0.381597562 ; -0.119590154 ; -0.005928216 ; -0.485607019 ; -0.025598317 ; -0.006784099 ; -0.003059389 ; -0.005595477 ; -0.278804664 ; -0.043604925 ; -0.165150754 ; -0.103711441 ; -0.013211994 ; -0.055272951 ; -0.005118486 ; -0.010103645 ; -0.021835922 ; -0.019964098 ; -0.004003871 ; 0 ; -0.012660904 ; -0.047764927 ; -0.000764994 ; -0.215851256 ; -0.011127615 ; -0.04007455 ; -0.007270925 ; -0.018111091 ; -0.017806263 ; -0.012735819 ; -0.000740079 ; -0.011154762 ; -0.160785654 ; -0.003088754 ; -0.005517554 ; -0.019031371 ; -0.005376077 ; -0.013075595 ; -2.98E-05 ; -0.050706515 ; -0.000937405 ; -0.206222747 ; -0.016593224 ; -0.01133029 ; -0.225720624 ; -0.008060267 ; -0.003167805 ; -0.007245738 ; -0.014190813 ; -0.007796096 ; -0.001009317 ; -0.02175412 ; -0.026722719 ; -0.023956429 ; -0.015606792 ; -0.234033494 ; -0.164517995 ; -0.060733953 ; -0.01966535 ; -0.010118216 ; -0.030961733 ; -0.001173457 ; -0.000253125 ; -0.034077111 ; -0.001532753 ; -0.007956516 ; -0.079583915 ; -0.031655005 ; -0.116987117 ; -0.031470962 ; -0.116374872 ; -0.017694369 ; -0.028388489 ; -0.01415543 ; -0.022462196 ; -0.009191827 ; -0.00619722 ; -0.081189645 ; -0.31732797 ; -0.028878096 ; -0.00851741 ; -0.018841793 ; -0.076203323 ; -0.027478768 ; -0.246613392 ; -0.004088097
CNV_AMP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV AMP	Sample	0.038877665 ; 1.17E-05 ; 0.000243818 ; 0.098113801 ; 0.24420711 ; 0.219721966 ; 0 ; 0.274666466 ; 0.0418212 ; 0.00015084 ; 0.017465096 ; 0.269313888 ; 0.041329089 ; 0.128758751 ; 0.167850707 ; 0.044998681 ; 0.065467984 ; 0.052014371 ; 0.045314014 ; 0.045375442 ; 0.019047801 ; 2.00E-07 ; 0.044799188 ; 0.167869834 ; 0.000146769 ; 0.138666321 ; 3.33E-08 ; 0.167332085 ; 0.035198403 ; 0.041968396 ; 0.035134947 ; 3.50E-05 ; 0.04828426 ; 0.064640447 ; 0.095571936 ; 0.323246107 ; 0.062727583 ; 4.15E-05 ; 0.018025661 ; 0.047402035 ; 0.014393735 ; 0.000348114 ; 0.085416885 ; 0.000147956 ; 0.009184245 ; 0.063228516 ; 0.000115682 ; 0.385955474 ; 0.000813962 ; 0.035379732 ; 0.073526732 ; 0.224999076 ; 0.000158276 ; 0.000119261 ; 0.051935749 ; 0.15183888 ; 0.000740447 ; 0.045518077 ; 0.116898431 ; 0.045922162 ; 0.259260859 ; 0.041772051 ; 0.044645537 ; 0.018125898 ; 0.089007713 ; 0.000609382 ; 0.000785674 ; 0.10927099 ; 0.017915723 ; 0.174486818 ; 0.000178777 ; 0.195425536 ; 0.042450766 ; 0.194728454 ; 0.048341817 ; 0.048335778 ; 0.805695672 ; 0.036117392 ; 0.044778387 ; 7.33E-05 ; 0.021422303 ; 0.251575936 ; 0.073642226 ; 0.126832043 ; 0.000132588 ; 0.075011161 ; 0.329561071 ; 0.085911472 ; 0.111791982 ; 0.131671202
CNV_CLASS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV class	Sample	CNV_LOW ; CNV_HIGH
CNV_DEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	CNV DEL	Sample	1.43E-05 ; 9.31E-06 ; 5.93E-05 ; 0.002260223 ; 0.330703347 ; 0.018445972 ; 0.012181118 ; 0.331737971 ; 0.000232878 ; 0 ; 0.0006768 ; 0.372287041 ; 1.11E-05 ; 0.348704409 ; 0.001083995 ; 0.018199062 ; 0.020352993 ; 0.018033471 ; 2.22E-05 ; 0.017682543 ; 0.002211541 ; 1.55E-05 ; 0.052006459 ; 0.491688464 ; 0.018025661 ; 0.075161896 ; 3.76E-05 ; 1.40E-06 ; 0.001969706 ; 0.248423835 ; 0.299821411 ; 0.02005336 ; 0.003030803 ; 0.017570882 ; 0.020458729 ; 0.001338495 ; 0.023242954 ; 7.60E-05 ; 0.281230088 ; 0.019980775 ; 0.000224702 ; 0.01749751 ; 0.491125051 ; 3.63E-05 ; 0.012143202 ; 0.078502133 ; 0.035623529 ; 0.018708803 ; 0.030018893 ; 0.026753086 ; 7.14E-05 ; 0.083306514 ; 0.516647281 ; 0.293548454 ; 0.409118908 ; 2.31E-06 ; 9.62E-05 ; 0.018033776 ; 0.024296112 ; 8.99E-06 ; 0.005207401 ; 0.30040734 ; 0.018864037 ; 0.009800931 ; 3.67E-06 ; 4.98E-05 ; 0.018712496 ; 0.018027094 ; 0.200347839 ; 0.018529704 ; 4.76E-05 ; 0.018036765 ; 0.018047975 ; 0.273023239 ; 0.199043404 ; 3.64E-06 ; 0.289753048 ; 0.171819961 ; 0.188981339 ; 0.156151631
CNV_IDX	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	CNV idx	Sample	1.292639933 ; 0.118480401 ; 0.174427719 ; 1.750745835 ; 7.062483444 ; 3.206485284 ; 0.610544403 ; 5.846872142 ; 0.825469308 ; 0.23259562 ; 0.103538746 ; 0.175460897 ; 6.264013781 ; 1.300911329 ; 4.16601537 ; 2.92410267 ; 0.448567224 ; 1.827783368 ; 0.117984612 ; 0.36400443 ; 0.743913927 ; 0.968385832 ; 0.037652558 ; 0.10422179 ; 0.629254484 ; 1.257412782 ; 0.400215642 ; 5.92206939 ; 0.380049798 ; 2.04679354 ; 0.215064437 ; 0.730471136 ; 0.459632928 ; 0.067541355 ; 0.557054701 ; 0.321551621 ; 2.73147802 ; 2.835751595 ; 0.112300954 ; 0.108108442 ; 0.506601471 ; 0.274624621 ; 0.56063435 ; 0.081096258 ; 1.542454073 ; 0.658740375 ; 2.928653664 ; 0.18174419 ; 0.563707282 ; 0.402217982 ; 5.48245768 ; 0.138302686 ; 0.172992111 ; 0.723440323 ; 0.700120616 ; 1.624050731 ; 0.816261462 ; 0.046244824 ; 0.759519858 ; 1.51025813 ; 0.623689582 ; 0.635283831 ; 4.872899162 ; 3.855353468 ; 4.403322524 ; 0.688823904 ; 0.668276245 ; 0.095221818 ; 1.21580133 ; 0.099159025 ; 0.034407469 ; 1.268069804 ; 0.033533736 ; 0.585354783 ; 1.578135012 ; 0.372169582 ; 2.887210768 ; 1.144517018 ; 3.281137801 ; 0.556900161 ; 0.923181545 ; 0.104003783 ; 0.542297565 ; 0.631934059 ; 0.030015236 ; 0.39358965 ; 2.141732857 ; 3.902728214 ; 3.377673268 ; 0.332383257 ; 0.91735067 ; 5.501272687 ; 1.556572742 ; 3.07327003 ; 0.771704727
EPIC_BCELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC Bcells	Sample	0.004595748 ; 0.005666428 ; 0.006418323 ; 0.005577885 ; 0.003088213 ; 0.001629109 ; 0.004052783 ; 0.003577571 ; 0.004179295 ; 0.004218625 ; 0.005791063 ; 0.005614163 ; 0.005182084 ; 0.005114234 ; 0.00332298 ; 0.002976646 ; 0.005195016 ; 0.005543654 ; 0.006596366 ; 0.005166918 ; 0.004118258 ; 0.005662834 ; 0.005557191 ; 0.005909312 ; 0.005200559 ; 0.004075369 ; 0.005420698 ; 0.004029459 ; 0.004322812 ; 0.006487549 ; 0.004444401 ; 0.005177041 ; 0.004359049 ; 0.004528554 ; 0.005098513 ; 0.004460847 ; 0.005209019 ; 0.002196903 ; 0.004866398 ; 0.005506597 ; 0.006402477 ; 0.006931651 ; 0.007955392 ; 0.005730778 ; 0.006071288 ; 0.00208603 ; 0.012745927 ; 0.004215926 ; 0.005863154 ; 0.007891409 ; 0.003108123 ; 0.016229609 ; 0.003404556 ; 0.007932213 ; 0.004036411 ; 0.006382884 ; 0.004926435 ; 0.004979518 ; 0.014894189 ; 0.002296699 ; 0.005235246 ; 0.009399873 ; 0.005483621 ; 0.008953555 ; 0.0067689 ; 0.004000451 ; 0.003503154 ; 0.005384921 ; 0.003464145 ; 0.004485592 ; 0.012965305 ; 0.006626794 ; 0.005026187 ; 0.004039392 ; 0.018025928 ; 0.005454982 ; 0.006741019 ; 0.005502748 ; 0.008642722 ; 0.006343461 ; 0.006020275 ; 0.003476539 ; 0.002510216 ; 0.00437853 ; 0.005318682 ; 0.007294917 ; 0.003797846 ; 0.006765475 ; 0.009739342 ; 0.004837211 ; 0.007382878 ; 0.004994598 ; 0.014872008 ; 0.009022295 ; 0.004767503
EPIC_CAFS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC CAFs	Sample	0.045125791 ; 0.056677626 ; 0.067375618 ; 0.060593928 ; 0.014328871 ; 0.064998151 ; 0.09190801 ; 0.067769323 ; 0.075393304 ; 0.159679699 ; 0.028713248 ; 0.097078048 ; 0.022440994 ; 0.025807817 ; 0.200220933 ; 0.032530637 ; 0.103207263 ; 0.017993074 ; 0.064384568 ; 0.022602285 ; 0.064685078 ; 0.078699134 ; 0.115973086 ; 0.036781095 ; 0.065950716 ; 0.217301757 ; 0.189251581 ; 0.052128545 ; 0.101417864 ; 0.065319095 ; 0.141805626 ; 0.12990102 ; 0.102365644 ; 0.039355715 ; 0.118553064 ; 0.138551785 ; 0.06407184 ; 0.171428644 ; 0.396427238 ; 0.082586753 ; 0.137741651 ; 0.10085879 ; 0.030422016 ; 0.109255916 ; 0.051567513 ; 0.045042235 ; 0.069778323 ; 0.109470974 ; 0.146545755 ; 0.030381439 ; 0.245624092 ; 0.066982605 ; 0.437720749 ; 0.076065268 ; 0.022281501 ; 0.061490059 ; 0.040904304 ; 0.065285664 ; 0.031289689 ; 0.118953119 ; 0.058682364 ; 0.073173287 ; 0.054561115 ; 0.084386617 ; 0.068433718 ; 0.018259117 ; 0.245873229 ; 0.094470153 ; 0.124031449 ; 0.052902816 ; 0.07740866 ; 0.072052749 ; 0.061861318 ; 0.168628647 ; 0.039861707 ; 0.040036596 ; 0.046914004 ; 0.082280026 ; 0.014995028 ; 0.020465846 ; 0.03431866 ; 0.388840022 ; 0.094950229 ; 0.057148988 ; 0.104628581 ; 0.035342991 ; 0.077860922 ; 0.12302872 ; 0.037214567 ; 0.024165291 ; 0.035083294 ; 0.035242686 ; 0.036505622 ; 0.056699664 ; 0.237164751
EPIC_CD4_TCELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC CD4 Tcells	Sample	0.075643165 ; 0.100222966 ; 0.127155905 ; 0.112090146 ; 0.063531838 ; 0.174134279 ; 0.07002453 ; 0.065130682 ; 0.175829124 ; 0.096748688 ; 0.122822159 ; 0.113625405 ; 0.105618133 ; 0.092134705 ; 0.095114204 ; 0.072912978 ; 0.13687414 ; 0.086076324 ; 0.126116005 ; 0.116480361 ; 0.091412586 ; 0.10828337 ; 0.094754968 ; 0.10856077 ; 0.10865991 ; 0.12764772 ; 0.194236095 ; 0.12915044 ; 0.102821213 ; 0.13841229 ; 0.085956044 ; 0.131887618 ; 0.094506407 ; 0.085921464 ; 0.118607577 ; 0.109482646 ; 0.101627765 ; 0.062381378 ; 0.07116207 ; 0.128255657 ; 0.158318728 ; 0.117115467 ; 0.136826018 ; 0.119170745 ; 0.116252847 ; 0.101301135 ; 0.190886091 ; 0.101517641 ; 0.114493109 ; 0.131031212 ; 0.052792773 ; 0.117841991 ; 0.069614216 ; 0.137075172 ; 0.093054629 ; 0.148799843 ; 0.123258586 ; 0.097412193 ; 0.135733147 ; 0.098801088 ; 0.120915156 ; 0.133402048 ; 0.117235002 ; 0.20409367 ; 0.130744929 ; 0.068455696 ; 0.08983858 ; 0.097992123 ; 0.106148283 ; 0.105776981 ; 0.127668486 ; 0.099153436 ; 0.105775791 ; 0.078980272 ; 0.163024583 ; 0.091207189 ; 0.132741322 ; 0.105293495 ; 0.127639879 ; 0.105062707 ; 0.112556539 ; 0.065617035 ; 0.072331793 ; 0.113720547 ; 0.090943407 ; 0.160684601 ; 0.091939368 ; 0.108917746 ; 0.111071052 ; 0.089824854 ; 0.133624962 ; 0.085099802 ; 0.194267542 ; 0.22202567 ; 0.089595072
EPIC_CD8_TCELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	EPIC CD8 Tcells	Sample	0.034381469 ; 0.041562969 ; 0.031354942 ; 0.044365306 ; 0.031658353 ; 0.006508822 ; 0.042667198 ; 0.032434667 ; 0.034775754 ; 0.042677677 ; 0.035670588 ; 0.034682381 ; 0.018651113 ; 0.037330484 ; 0.040712363 ; 0.076101921 ; 0.035558676 ; 0.050296678 ; 0.0421249 ; 0.038409552 ; 0.035879255 ; 0.046021406 ; 0.06307061 ; 0.052156669 ; 0.049383477 ; 0.010845963 ; 0.019354278 ; 0.04469791 ; 0.033989272 ; 0.039595057 ; 0.04509666 ; 0.033872945 ; 0.032133044 ; 0.044274755 ; 0.047321103 ; 0.040021967 ; 0.035251651 ; 0.031593671 ; 0.041579539 ; 0.022851227 ; 0.038989869 ; 0.045018409 ; 0.035453503 ; 0.027176374 ; 0.03522931 ; 0.169993489 ; 0.06036526 ; 0.06007514 ; 0.045626743 ; 0.044015107 ; 0.013339386 ; 0.037353248 ; 0.034985182 ; 0.043301072 ; 0.03878787 ; 0.050010993 ; 0.039417667 ; 0.041874395 ; 0.043499463 ; 0.03362146 ; 0.034217712 ; 0.01668522 ; 0.03552117 ; 0.039508302 ; 0.010548701 ; 0.026465241 ; 0.031302276 ; 0.055027196 ; 0.053395146 ; 0.032607874 ; 0.038402581 ; 0.013685766 ; 0.027766592 ; 0.035878962 ; 0.045724267 ; 0.053361059 ; 0.04025961 ; 0.041651211 ; 0.040554232 ; 0.043460088 ; 0.049057793 ; 0.038687944 ; 0.025750294 ; 0.023855996 ; 0.063668402 ; 0.052033662 ; 0.035186068 ; 0.031112939 ; 0.026449078 ; 0.043054277 ; 0.04943904 ; 0.031691155 ; 0.033524424 ; 5.12E-08 ; 0.028463459
EPIC_ENDOTHELIAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC Endothelial	Sample	0.047247678 ; 0.056081262 ; 0.050682921 ; 0.058249827 ; 0.063943075 ; 0.114858814 ; 0.056644142 ; 0.067883558 ; 0.044993308 ; 0.110137007 ; 0.047452551 ; 0.105438711 ; 0.04257597 ; 0.062030244 ; 0.07238533 ; 0.074618826 ; 0.132518871 ; 0.087109023 ; 0.104962403 ; 0.063408919 ; 0.073710586 ; 0.077628328 ; 0.100176584 ; 0.067570639 ; 0.267129768 ; 0.147513616 ; 0.076433938 ; 0.0968925 ; 0.103538262 ; 0.052963288 ; 0.117913805 ; 0.080990031 ; 0.094765293 ; 0.13572922 ; 0.091623186 ; 0.080876696 ; 0.115537488 ; 0.114757023 ; 0.133829893 ; 0.133562549 ; 0.12208323 ; 0.091572847 ; 0.063623215 ; 0.148295618 ; 0.095754957 ; 0.109129131 ; 0.131387928 ; 0.143556921 ; 0.103001166 ; 0.054719455 ; 0.100179506 ; 0.110029945 ; 0.080478688 ; 0.081580986 ; 0.038672923 ; 0.12871576 ; 0.046900078 ; 0.044211258 ; 0.041931867 ; 0.111089441 ; 0.062289497 ; 0.060392349 ; 0.105357622 ; 0.065979471 ; 0.078487444 ; 0.050668927 ; 0.140659271 ; 0.132889331 ; 0.075680425 ; 0.061969134 ; 0.065170953 ; 0.108277744 ; 0.131855933 ; 0.149448996 ; 0.114536976 ; 0.06545845 ; 0.059487435 ; 0.079296536 ; 0.07255053 ; 0.074407637 ; 0.044698224 ; 0.171853539 ; 0.085395952 ; 0.084042172 ; 0.084442983 ; 0.076176778 ; 0.178905676 ; 0.085797165 ; 0.084138822 ; 0.06940191 ; 0.077794978 ; 0.098499307 ; 0.064904537 ; 0.069009999 ; 0.184282336
EPIC_MACROPHAGES	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC Macrophages	Sample	0.002878929 ; 0.001627258 ; 0.004971567 ; 0.003754992 ; 0.007304327 ; 0.003170654 ; 0.001135568 ; 0.001420519 ; 0.009247814 ; 0.003454382 ; 0.00692925 ; 0.002562586 ; 0.00569926 ; 0.000940909 ; 0.00133655 ; 0.00116644 ; 0.003291385 ; 0.001089022 ; 0.005944262 ; 0.002075369 ; 0.004558948 ; 0.002766177 ; 0.004079595 ; 0.003399076 ; 0.003655548 ; 0.004932524 ; 0.003331587 ; 0.00140797 ; 0.004822916 ; 0.002937646 ; 0.001916371 ; 0.003407333 ; 0.003602011 ; 0.004577919 ; 0.002330233 ; 0.003183905 ; 0.003356582 ; 0.003184432 ; 0.003523899 ; 0.011554706 ; 0.005223646 ; 0.005441517 ; 0.007146413 ; 0.005005061 ; 0.004295623 ; 0.00481661 ; 0.003685652 ; 0.006587758 ; 0.005458865 ; 0.003346583 ; 0.001663694 ; 0.003059245 ; 0.003404118 ; 0.003773438 ; 0.001245467 ; 0.002939082 ; 0.006079859 ; 0.001658171 ; 0.012644167 ; 0.00527552 ; 0.003675535 ; 0.008031966 ; 0.001150593 ; 0.003261892 ; 0.006156781 ; 0.001646215 ; 0.003490464 ; 0.001412001 ; 0.002052767 ; 0.002609858 ; 0.005576804 ; 0.008524373 ; 0.003653403 ; 0.000433903 ; 0.011478385 ; 0.000828178 ; 0.00231511 ; 0.004117287 ; 0.002238438 ; 0.003497833 ; 0.004422598 ; 0.003535598 ; 0.002150148 ; 0.003461457 ; 0.002557199 ; 0.009797105 ; 0.002576266 ; 0.00826782 ; 0.010901218 ; 0.002293855 ; 0.003529352 ; 0.005015088 ; 0.010912287 ; 0.008491865 ; 0.004165019
EPIC_NKCELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	EPIC NKcells	Sample	6.39E-10 ; 4.15E-09 ; 2.10E-10 ; 9.84E-10 ; 8.69E-09 ; 9.76E-10 ; 8.13E-09 ; 4.04E-09 ; 3.74E-07 ; 4.99E-09 ; 5.28E-09 ; 3.03E-09 ; 1.49E-10 ; 6.77E-10 ; 2.86E-09 ; 1.17E-09 ; 3.95E-09 ; 1.95E-10 ; 5.66E-12 ; 1.70E-10 ; 3.50E-09 ; 3.70E-09 ; 8.81E-10 ; 1.44E-08 ; 1.99E-09 ; 5.10E-07 ; 1.25E-09 ; 9.64E-09 ; 2.43E-08 ; 1.74E-09 ; 4.10E-08 ; 8.38E-09 ; 1.35E-08 ; 2.73E-09 ; 2.78E-09 ; 1.18E-09 ; 8.60E-09 ; 4.37E-08 ; 5.71E-09 ; 2.99E-09 ; 4.85E-09 ; 2.80E-09 ; 2.25E-09 ; 1.60E-09 ; 4.92E-10 ; 3.73E-09 ; 4.74E-09 ; 1.02E-09 ; 7.56E-11 ; 1.86E-09 ; 8.19E-09 ; 1.24E-08 ; 1.06E-09 ; 2.01E-09 ; 4.63E-09 ; 6.37E-09 ; 5.17E-10 ; 6.15E-10 ; 1.15E-09 ; 6.69E-07 ; 1.04E-10 ; 5.75E-10 ; 5.75E-08 ; 2.45E-09 ; 4.65E-10 ; 1.45E-08 ; 7.50E-09 ; 4.21E-09 ; 3.06E-09 ; 1.44E-09 ; 3.78E-09 ; 4.41E-09 ; 6.88E-09 ; 2.09E-09 ; 2.07E-09 ; 1.58E-09 ; 1.08E-09 ; 1.53E-10 ; 4.41E-10 ; 5.54E-09 ; 1.10E-07 ; 6.72E-10 ; 7.00E-10 ; 1.81E-09 ; 2.82E-08 ; 1.90E-08 ; 7.83E-09 ; 8.09E-10 ; 3.05E-09 ; 9.11E-08 ; 2.82E-07 ; 1.49E-09 ; 4.80E-09 ; 7.00E-09
EPIC_OTHERCELLS	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	EPIC other cells	Sample	0.79012722 ; 0.738161488 ; 0.712040724 ; 0.715367914 ; 0.816145315 ; 0.634700169 ; 0.73356776 ; 0.761783675 ; 0.655581026 ; 0.583083916 ; 0.752621136 ; 0.640998702 ; 0.799832446 ; 0.776641607 ; 0.586907637 ; 0.739692551 ; 0.583354645 ; 0.751892225 ; 0.649871496 ; 0.751856594 ; 0.725635286 ; 0.680938746 ; 0.616387965 ; 0.725622424 ; 0.500020021 ; 0.487682541 ; 0.511971821 ; 0.671693166 ; 0.649087637 ; 0.694285073 ; 0.602867088 ; 0.61476397 ; 0.668268543 ; 0.685612359 ; 0.616466321 ; 0.623422151 ; 0.674945653 ; 0.614457941 ; 0.348610921 ; 0.615682507 ; 0.531240397 ; 0.633061315 ; 0.71857344 ; 0.585365506 ; 0.69082846 ; 0.567631369 ; 0.531150815 ; 0.574575636 ; 0.579011207 ; 0.728614796 ; 0.583292424 ; 0.648503347 ; 0.370392479 ; 0.650271851 ; 0.801921196 ; 0.601661375 ; 0.738513065 ; 0.7445788 ; 0.720007478 ; 0.629962672 ; 0.714983821 ; 0.698915258 ; 0.680690877 ; 0.593816436 ; 0.698859525 ; 0.830504353 ; 0.485333012 ; 0.612824268 ; 0.635227781 ; 0.739647742 ; 0.67280721 ; 0.691679134 ; 0.66406077 ; 0.56258982 ; 0.607348151 ; 0.743653544 ; 0.711541498 ; 0.681858696 ; 0.733379171 ; 0.746762428 ; 0.748925904 ; 0.327989213 ; 0.716911368 ; 0.713392309 ; 0.648440744 ; 0.658669918 ; 0.609733834 ; 0.636110127 ; 0.720485921 ; 0.766422598 ; 0.693145404 ; 0.739457081 ; 0.645013579 ; 0.63475045 ; 0.451561854
ER_ESR1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	ER ESR1	Sample	0.769 ; -0.302 ; -0.1 ; 0.129 ; -2.18 ; -0.892 ; 1.06 ; -0.997 ; -0.729 ; 0.0794 ; 0.75 ; -0.995 ; -0.67 ; 0.443 ; -0.153 ; -1.63 ; -0.23 ; 0.616 ; -0.715 ; 0.372 ; -0.103 ; -0.066 ; 0.241 ; 0.135 ; 0.205 ; -0.818 ; -0.437 ; -0.134 ; -0.434 ; 0.35 ; 0.696 ; 0.569 ; -0.284 ; -0.304 ; 0.667 ; 0.203 ; -0.94 ; -1.06 ; -0.768 ; -0.546 ; 1.1 ; 0.321 ; 0.0343 ; -0.0349 ; 0.209 ; -0.0754 ; -0.0648 ; -0.296 ; 0.19 ; -0.473 ; -1.46 ; -0.0747 ; 0.0985 ; 0.456 ; 0.548 ; 0.755 ; -0.0921 ; -0.846 ; -0.188 ; -0.126 ; 0.459 ; -1.76 ; -0.282 ; -0.81 ; -1.62 ; -0.108 ; -0.055 ; 0.515 ; 0.184 ; -0.167 ; -0.0707 ; -0.329 ; -0.0713 ; -0.378 ; -0.914 ; 0.624 ; 0.628 ; 0.983 ; -0.00667 ; 0.853 ; 0.638 ; 1.39 ; -1.31 ; -0.718 ; 0.736 ; 0.583 ; -0.248 ; -0.246 ; -0.808 ; -0.0498 ; -0.155 ; -0.37 ; -0.318 ; -0.403 ; -0.867
ESTIMATE_ESTIMATESCORE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	ESTIMATE ESTIMATE Score	Sample	7706.69731 ; 6346.448091 ; 10459.4136 ; 7475.466867 ; 8263.691016 ; 9036.558917 ; 5237.500804 ; 5354.097739 ; 12645.03712 ; 9939.42943 ; 8155.228634 ; 8125.463586 ; 8454.043409 ; 3549.96715 ; 6878.815598 ; 4880.388642 ; 11875.73099 ; 4387.604155 ; 10516.52542 ; 6556.938081 ; 7984.832197 ; 6458.248576 ; 9611.601525 ; 7510.723965 ; 11829.61469 ; 10595.79412 ; 11389.03605 ; 6427.968547 ; 10184.09709 ; 9818.551954 ; 8858.125394 ; 9967.070206 ; 9882.110241 ; 8382.33106 ; 9184.59418 ; 10871.31612 ; 10036.59592 ; 10691.29492 ; 12373.7375 ; 12103.71789 ; 11399.93018 ; 11846.78763 ; 11152.01933 ; 11303.23332 ; 9463.638986 ; 10245.50774 ; 9746.458422 ; 10948.54419 ; 10647.97878 ; 7272.429584 ; 7419.10209 ; 9645.742029 ; 9523.426913 ; 9856.873041 ; 6240.560516 ; 8986.72648 ; 9882.280246 ; 5636.797597 ; 14081.62084 ; 11534.48275 ; 8279.071556 ; 13528.27318 ; 5869.797912 ; 9794.840535 ; 12539.84535 ; 5628.770775 ; 10247.47059 ; 6563.290264 ; 9155.605519 ; 7462.471572 ; 10104.54327 ; 11077.53838 ; 8535.497339 ; 5486.734429 ; 14902.69135 ; 3483.874446 ; 7008.788984 ; 8947.304105 ; 7166.95192 ; 5714.583545 ; 7556.329167 ; 9768.219013 ; 7426.420402 ; 8097.585593 ; 8423.391107 ; 11854.49227 ; 9017.046099 ; 12343.51419 ; 11094.70219 ; 5819.638871 ; 8764.865538 ; 8585.387077 ; 13450.41388 ; 13390.7734 ; 12015.36641
ESTROGEN_RECEPTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Estrogen Receptor	Sample	Cannot be determined ; Positive ; Negative ; Unknown
ESTROGEN_RECEPTOR_%	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Estrogen Receptor %	Sample	75 ; -1 ; 5 ; 80 ; 85 ; 90 ; 95 ; 70 ; 35 ; 40 ; 60 ; 86 ; 50 ; 45
FIGO_STAGE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	FIGO stage	Patient	
GENOMICS_SUBTYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Genomics subtype	Sample	MSI-H ; CNV_low ; CNV_high ; POLE
HISTOLOGIC_GRADE_FIGO	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Histologic FIGO grade	Patient	
HISTOLOGIC_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Histologic type	Patient	
HRD_BRCA1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	HRD BRCA1	Sample	0 ; 1
HRD_BRCA1_OR_BRCA2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	HRD BRCA1 or BRCA2	Sample	0 ; 1
HRD_BRCA2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	HRD BRCA2	Sample	0 ; 1
JAK1_MS_INDEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	JAK1 MS INDEL	Sample	WT ; MS_indel
JAK1_MUTATION	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	JAK1 Mutation	Sample	WT ; Missense_Mutation ; Frame_Shift_Del ; Nonsense_Mutation ; Frame_Shift_Del_Nonsense_Mutation ; Frame_Shift_Del_Frame_Shift_Ins ; Frame_Shift_Ins_Nonsense_Mutation
LOG2_INDEL_PER_MBP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 INDEL per Mbp	Sample	1.450879273 ; 2.440219926 ; 0.319245674 ; 0.207641466 ; 0.282995148 ; 0.168435383 ; 2.581235568 ; 3.34540868 ; 0.455772534 ; 2.512450001 ; 0.043988012 ; 1.417826394 ; 0.801600757 ; 0.354607617 ; 0.245810227 ; 0.42283286 ; 3.694931928 ; 2.274711708 ; 1.2211157 ; 3.187681472 ; 0.086674411 ; 2.364182099 ; 2.618078608 ; 3.59866904 ; 0.580489024 ; 3.24062152 ; 3.371537285 ; 0.389123498 ; 0.128134019 ; 0.667424661 ; 2.218238939 ; 3.447198405 ; 2.456586466 ; 2.18915136 ; 2.919047794 ; 1.955780345 ; 2.293055185 ; 0.519478029 ; 3.043446359 ; 2.198912528 ; 2.907188335 ; 2.883172881 ; 3.207157908
LOG2_INDEL_TOTAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 INDEL total	Sample	5.832890014 ; 7.169925001 ; 3.169925001 ; 2.584962501 ; 3 ; 2.321928095 ; 7.339850003 ; 8.214319121 ; 3.700439718 ; 7.257387843 ; 1 ; 5.781359714 ; 4.64385619 ; 3.321928095 ; 2.807354922 ; 3.584962501 ; 8.596189756 ; 6.965784285 ; 5.459431619 ; 8.038918989 ; 1.584962501 ; 7.076815597 ; 7.383704292 ; 8.491853096 ; 4.087462841 ; 8.098032083 ; 8.243173983 ; 3.459431619 ; 2 ; 4.321928095 ; 6.894817763 ; 8.326429487 ; 7.189824559 ; 6.857980995 ; 7.73470962 ; 6.554588852 ; 6.988684687 ; 3.906890596 ; 7.876516947 ; 6.87036472 ; 7.721099189 ; 7.693486957 ; 8.060695932
LOG2_SNP_PER_MBP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 SNP per Mbp	Sample	5.014858245 ; 3.451287679 ; 0.970671335 ; 1.258934249 ; 1.530342916 ; 1.101321187 ; 1.2211157 ; 1.634715536 ; 3.961812528 ; 1.037474705 ; 5.60519854 ; 4.335929558 ; 1.93256673 ; 4.056121768 ; 0.775745316 ; 1.434447489 ; 1.331721187 ; 8.7318234 ; 6.998568599 ; 1.560942049 ; 1.401011577 ; 1.080351414 ; 5.016239079 ; 1.771826721 ; 1.417826394 ; 4.80079975 ; 1.349358266 ; 3.1479216 ; 2.246751627 ; 1.967248569 ; 4.333716157 ; 1.383998466 ; 1.313865823 ; 1.201828046 ; 1.499080695 ; 0.207641466 ; 1.05907234 ; 3.542277219 ; 3.576376116 ; 4.570184685 ; 4.530149616 ; 1.182279033 ; 6.465459001 ; 1.142367912 ; 5.055718949 ; 8.31441313 ; 4.572063684 ; 1.663200075 ; 1.514796483 ; 1.576001633 ; 0.610053482 ; 7.567338041 ; 3.211986209 ; 4.843430085 ; 1.015548827 ; 1.240148892 ; 3.667073084 ; 0.993284573 ; 0.722601368 ; 3.426576341 ; 3.932859217 ; 1.59090564 ; 0.695276782 ; 2.954052221 ; 1.605657252 ; 3.572626906 ; 1.691133088 ; 1.620259553 ; 4.15721395 ; 1.162461482 ; 3.197452556 ; 3.839223293 ; 0.947697998 ; 3.915204152 ; 2.023260846 ; 3.2871191 ; 6.7573255 ; 0.924352909
LOG2_SNP_TOTAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 SNP total	Sample	9.984418459 ; 8.330916878 ; 5 ; 5.523561956 ; 5.95419631 ; 5.247927513 ; 5.459431619 ; 6.108524457 ; 8.882643049 ; 5.129283017 ; 10.58965115 ; 9.278449458 ; 6.523561956 ; 8.982993575 ; 4.584962501 ; 5.807354922 ; 5.64385619 ; 13.74199358 ; 12.00105627 ; 6 ; 5.754887502 ; 5.209453366 ; 9.985841937 ; 6.303780748 ; 5.781359714 ; 9.763212367 ; 5.672425342 ; 7.994353437 ; 6.930737338 ; 6.569855608 ; 9.276124405 ; 5.727920455 ; 5.614709844 ; 5.426264755 ; 5.906890596 ; 2.584962501 ; 5.169925001 ; 8.430452552 ; 8.46760555 ; 9.523561956 ; 9.481799432 ; 5.392317423 ; 11.46301341 ; 5.321928095 ; 10.02652344 ; 13.32347703 ; 9.525520809 ; 6.14974712 ; 5.930737338 ; 6.022367813 ; 4.169925001 ; 12.57341051 ; 8.06608919 ; 9.807354922 ; 5.087462841 ; 5.491853096 ; 8.566054038 ; 5.044394119 ; 4.459431619 ; 8.303780748 ; 8.851749041 ; 6.044394119 ; 4.392317423 ; 7.77478706 ; 6.06608919 ; 8.463524373 ; 6.189824559 ; 6.087462841 ; 9.09011242 ; 5.357552005 ; 8.049848549 ; 8.751544059 ; 4.95419631 ; 8.832890014 ; 6.64385619 ; 8.14974712 ; 11.75780667 ; 4.906890596
LOG2_VARIANT_PER_MBP	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 variant per Mbp	Sample	5.090218957 ; 3.941606385 ; 1.142367912 ; 1.349358266 ; 1.634715536 ; 1.182279033 ; 1.691133088 ; 4.362228844 ; 5.612520487 ; 4.875737466 ; 2.066555769 ; 4.415525945 ; 0.801600757 ; 1.331721187 ; 1.560942049 ; 1.401011577 ; 8.737485435 ; 7.006927428 ; 1.499080695 ; 1.201828046 ; 5.025868086 ; 1.860596943 ; 1.59090564 ; 5.315549182 ; 1.434447489 ; 3.667073084 ; 1.295786701 ; 2.603454103 ; 2.218238939 ; 4.821482763 ; 1.46712601 ; 1.483191823 ; 1.417826394 ; 1.277478143 ; 1.530342916 ; 0.42283286 ; 3.981739572 ; 1.121990524 ; 4.093231531 ; 5.123913178 ; 4.964246973 ; 6.473523558 ; 5.382393153 ; 1.162461482 ; 8.317776613 ; 5.050337259 ; 1.797751858 ; 1.732044006 ; 7.571805466 ; 3.691478851 ; 5.271130528 ; 4.103661326 ; 1.037474705 ; 0.775745316 ; 3.839223293 ; 4.44863097 ; 0.924352909 ; 3.409863787 ; 1.450879273 ; 1.545723606 ; 1.872844004 ; 1.704899366 ; 4.648850071 ; 1.383998466 ; 3.674088391 ; 4.37949908 ; 4.42387369 ; 0.993284573 ; 1.258934249 ; 3.341007532 ; 6.863169791 ; 1.05907234 ; 1.576001633
LOG2_VARIANT_TOTAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Log2 variant total	Sample	10.06204614 ; 8.861086906 ; 5.321928095 ; 5.672425342 ; 6.108524457 ; 5.392317423 ; 6.189824559 ; 9.306061689 ; 10.59712143 ; 9.840777924 ; 6.700439718 ; 9.361943774 ; 4.64385619 ; 5.64385619 ; 6 ; 5.754887502 ; 13.74766852 ; 12.00947875 ; 5.906890596 ; 5.426264755 ; 9.995767151 ; 6.426264755 ; 6.044394119 ; 10.29347165 ; 5.807354922 ; 8.566054038 ; 5.584962501 ; 7.366322214 ; 6.894817763 ; 9.784634846 ; 5.857980995 ; 5.882643049 ; 5.781359714 ; 5.554588852 ; 5.95419631 ; 3.584962501 ; 8.903881846 ; 5.285402219 ; 9.022367813 ; 10.09671515 ; 9.932214752 ; 11.47116713 ; 10.36194377 ; 5.357552005 ; 13.32685077 ; 10.02097994 ; 6.339850003 ; 6.247927513 ; 12.57790084 ; 8.592457037 ; 10.24792751 ; 9.033423002 ; 5.129283017 ; 4.584962501 ; 8.751544059 ; 9.396604781 ; 4.906890596 ; 8.285402219 ; 5.832890014 ; 5.977279923 ; 6.442943496 ; 6.209453366 ; 9.605479518 ; 5.727920455 ; 8.573647187 ; 9.324180547 ; 9.370687407 ; 5.044394119 ; 5.523561956 ; 8.209453366 ; 11.86457308 ; 5.169925001 ; 6.022367813
LVSI	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Lymphovascular space invasion	Patient ; Sample	No ; Present ; NP
METHYLATION_AVAILABLE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Methylation available	Sample	YES
METHYLATION_QUALITY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Methylation quality	Sample	PASS
MIRNASEQ_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	miRNAseq sample type	Sample	Tumor
MLH1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	MLH1	Sample	Intact nuclear expression ; Loss of nuclear expression ; Cannot be determined ; Unknown
MLH1_PROMOTER_HYPERMETHYLATION	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	MLH1 Promoter Hypermethylation	Sample	Cannot be determined ; Absent ; Present
MLH2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	MLH2	Sample	Intact nuclear expression ; Cannot be determined ; Loss of nuclear expression ; Unknown
MSH6	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	MSH6	Sample	Loss of nuclear expression ; Intact nuclear expression ; Cannot be determined ; Unknown
MUTATION_SIGNATURE_C>A	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature C>A	Sample	8.300395257 ; 14.64174455 ; 16.12903226 ; 17.77777778 ; 9.836065574 ; 16.21621622 ; 27.90697674 ; 7.352941176 ; 21.86836518 ; 17.64705882 ; 23.24675325 ; 15.64516129 ; 10.98901099 ; 19.00990099 ; 30.43478261 ; 15.55555556 ; 12.72727273 ; 6.12244898 ; 42.00729927 ; 44.28989751 ; 14.28571429 ; 20.75471698 ; 13.88888889 ; 33.36623889 ; 10.25641026 ; 12.96296296 ; 12.21198157 ; 20 ; 15.7480315 ; 13.95348837 ; 16.52892562 ; 14.89361702 ; 20.03231018 ; 27.27272727 ; 21.15384615 ; 10.41666667 ; 26.19047619 ; 13.55932203 ; 12.79069767 ; 20.58823529 ; 12.18130312 ; 13.19727891 ; 15.96638655 ; 29.26829268 ; 5.882352941 ; 33.98299079 ; 20.51282051 ; 12.18809981 ; 22.22222222 ; 35.05365854 ; 19.44444444 ; 13.85869565 ; 15 ; 18.75 ; 29.41176471 ; 45.14276337 ; 14.58333333 ; 16.10486891 ; 18.32402235 ; 20.83333333 ; 12.12121212 ; 22.72727273 ; 13.22751323 ; 28.125 ; 23.80952381 ; 15.87301587 ; 13.23210412 ; 13.84615385 ; 16.05504587 ; 16.66666667 ; 19.31818182 ; 13.43283582 ; 17.83088235 ; 10 ; 17.42424242 ; 16.04651163 ; 9.677419355 ; 13.13131313 ; 2.473498233 ; 23.22357019 ; 6.666666667 ; 17.24137931 ; 24.07407407 ; 23.52941176
MUTATION_SIGNATURE_C>G	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature C>G	Sample	1.482213439 ; 2.803738318 ; 3.225806452 ; 8.888888889 ; 13.1147541 ; 13.51351351 ; 11.62790698 ; 33.82352941 ; 1.6985138 ; 14.70588235 ; 1.168831169 ; 1.612903226 ; 36.26373626 ; 2.772277228 ; 13.04347826 ; 3.636363636 ; 6.12244898 ; 0.270072993 ; 0.268423621 ; 9.523809524 ; 7.547169811 ; 13.88888889 ; 0.493583416 ; 3.846153846 ; 7.407407407 ; 2.304147465 ; 12 ; 2.755905512 ; 6.976744186 ; 5.785123967 ; 3.191489362 ; 2.423263328 ; 12.72727273 ; 9.615384615 ; 2.083333333 ; 14.28571429 ; 22.03389831 ; 20 ; 5.714285714 ; 1.453488372 ; 2.941176471 ; 5.949008499 ; 2.176870748 ; 1.820728291 ; 0 ; 26.47058824 ; 0.212615167 ; 2.564102564 ; 1.535508637 ; 19.44444444 ; 0.253658537 ; 8.333333333 ; 1.222826087 ; 2.857142857 ; 5 ; 6.25 ; 5.882352941 ; 0.393829997 ; 0.74906367 ; 2.458100559 ; 12.12121212 ; 27.27272727 ; 3.968253968 ; 25 ; 4.444444444 ; 19.04761905 ; 1.904761905 ; 3.036876356 ; 7.692307692 ; 10 ; 2.293577982 ; 23.07692308 ; 7.272727273 ; 7.575757576 ; 1.136363636 ; 6.944444444 ; 7.462686567 ; 3.125 ; 7.5 ; 1.893939394 ; 2.558139535 ; 3.333333333 ; 3.516483516 ; 12.90322581 ; 14.14141414 ; 1.413427562 ; 2.253032929 ; 16.66666667 ; 13.79310345 ; 5.555555556
MUTATION_SIGNATURE_C>T	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature C>T	Sample	72.52964427 ; 64.48598131 ; 70.96774194 ; 62.22222222 ; 62.29508197 ; 51.35135135 ; 48.8372093 ; 36.76470588 ; 42.46284501 ; 52.94117647 ; 51.94805195 ; 61.4516129 ; 36.26373626 ; 48.31683168 ; 39.13043478 ; 57.77777778 ; 61.81818182 ; 63.26530612 ; 38.64963504 ; 39.97071742 ; 61.9047619 ; 52.83018868 ; 58.33333333 ; 42.34945706 ; 73.07692308 ; 61.11111111 ; 60.59907834 ; 42 ; 56.2992126 ; 62.79069767 ; 60.33057851 ; 58.5106383 ; 55.25040388 ; 40 ; 50 ; 75 ; 47.61904762 ; 40.6779661 ; 62.85714286 ; 68.89534884 ; 58.82352941 ; 63.45609065 ; 58.0952381 ; 47.75910364 ; 53.65853659 ; 35.29411765 ; 44.22395464 ; 53.84615385 ; 60.84452975 ; 36.11111111 ; 29.45365854 ; 38.88888889 ; 60.73369565 ; 66.66666667 ; 54.6875 ; 47.05882353 ; 35.28060387 ; 60.41666667 ; 62.54681648 ; 46.70391061 ; 52.08333333 ; 48.48484848 ; 31.81818182 ; 65.07936508 ; 43.75 ; 55.55555556 ; 57.14285714 ; 59.86984816 ; 56.92307692 ; 55 ; 55.50458716 ; 34.61538462 ; 72.72727273 ; 60.60606061 ; 48.01136364 ; 63.88888889 ; 58.20895522 ; 59.00735294 ; 62.5 ; 54.54545455 ; 56.74418605 ; 60 ; 58.68131868 ; 51.61290323 ; 32.5 ; 94.34628975 ; 53.43731947 ; 58.62068966 ; 57.40740741
MUTATION_SIGNATURE_T>A	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature T>A	Sample	1.383399209 ; 0.934579439 ; 3.225806452 ; 2.222222222 ; 8.196721311 ; 8.108108108 ; 2.325581395 ; 4.411764706 ; 6.157112527 ; 5.882352941 ; 0.454545455 ; 2.580645161 ; 2.197802198 ; 8.316831683 ; 8.695652174 ; 4.444444444 ; 5.454545455 ; 6.12244898 ; 1.102189781 ; 1.171303075 ; 0 ; 5.660377358 ; 5.555555556 ; 0.592300099 ; 6.41025641 ; 3.703703704 ; 3.456221198 ; 8 ; 3.149606299 ; 4.958677686 ; 3.191489362 ; 4.36187399 ; 9.090909091 ; 3.846153846 ; 2.083333333 ; 7.142857143 ; 1.694915254 ; 2.857142857 ; 4.651162791 ; 2.941176471 ; 1.416430595 ; 2.993197279 ; 5.322128852 ; 7.317073171 ; 14.70588235 ; 1.240255138 ; 5.128205128 ; 4.510556622 ; 2.777777778 ; 0.917073171 ; 3.260869565 ; 4.285714286 ; 6.666666667 ; 3.125 ; 0.918936659 ; 8.333333333 ; 3.745318352 ; 3.463687151 ; 4.166666667 ; 6.060606061 ; 3.439153439 ; 1.301518438 ; 3.076923077 ; 5 ; 2.752293578 ; 9.615384615 ; 3.636363636 ; 1.515151515 ; 7.386363636 ; 6.944444444 ; 5.970149254 ; 1.654411765 ; 2.5 ; 3.787878788 ; 2.558139535 ; 3.296703297 ; 10 ; 8.080808081 ; 0.706713781 ; 1.964182553 ; 3.448275862 ; 1.851851852
MUTATION_SIGNATURE_T>C	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature T>C	Sample	14.42687747 ; 15.26479751 ; 3.225806452 ; 8.888888889 ; 3.278688525 ; 8.108108108 ; 4.651162791 ; 8.823529412 ; 22.71762208 ; 8.896103896 ; 17.25806452 ; 7.692307692 ; 18.01980198 ; 4.347826087 ; 7.272727273 ; 14.28571429 ; 8.686131387 ; 7.637872133 ; 9.523809524 ; 11.32075472 ; 8.333333333 ; 6.614017769 ; 5.128205128 ; 7.407407407 ; 19.93087558 ; 14 ; 17.71653543 ; 2.325581395 ; 10.74380165 ; 15.95744681 ; 14.70113086 ; 13.46153846 ; 10.41666667 ; 4.761904762 ; 8.474576271 ; 20 ; 5.714285714 ; 9.593023256 ; 5.882352941 ; 15.01416431 ; 21.36054422 ; 24.92997199 ; 9.756097561 ; 11.76470588 ; 6.236711552 ; 12.82051282 ; 19.00191939 ; 13.88888889 ; 11.22926829 ; 22.22222222 ; 19.29347826 ; 7.142857143 ; 3.333333333 ; 14.0625 ; 5.562848704 ; 6.25 ; 14.98127341 ; 22.79329609 ; 15.15151515 ; 4.545454545 ; 12.43386243 ; 0 ; 6.666666667 ; 19.36507937 ; 20.60737527 ; 15.38461538 ; 10 ; 19.26605505 ; 1.923076923 ; 1.818181818 ; 7.575757576 ; 18.75 ; 6.944444444 ; 11.94029851 ; 15.99264706 ; 12.5 ; 18.93939394 ; 19.06976744 ; 13.33333333 ; 18.46153846 ; 16.12903226 ; 9.090909091 ; 0.706713781 ; 16.926632 ; 3.448275862 ; 5.555555556
MUTATION_SIGNATURE_T>G	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Mutation signature T>G	Sample	1.877470356 ; 1.869158879 ; 3.225806452 ; 0 ; 3.278688525 ; 2.702702703 ; 4.651162791 ; 8.823529412 ; 5.095541401 ; 14.28571429 ; 1.451612903 ; 6.593406593 ; 3.564356436 ; 4.347826087 ; 4.444444444 ; 9.090909091 ; 4.081632653 ; 9.284671533 ; 6.661786237 ; 4.761904762 ; 1.886792453 ; 16.58440276 ; 1.282051282 ; 7.407407407 ; 1.497695853 ; 4 ; 4.330708661 ; 13.95348837 ; 1.652892562 ; 4.255319149 ; 3.231017771 ; 3.636363636 ; 1.923076923 ; 13.55932203 ; 2.857142857 ; 2.61627907 ; 1.983002833 ; 2.176870748 ; 4.201680672 ; 5.882352941 ; 14.10347271 ; 5.128205128 ; 1.919385797 ; 5.555555556 ; 23.09268293 ; 11.11111111 ; 1.630434783 ; 3.333333333 ; 3.125 ; 12.70101739 ; 4.166666667 ; 1.872659176 ; 6.25698324 ; 8.333333333 ; 6.060606061 ; 4.545454545 ; 1.851851852 ; 8.888888889 ; 5.079365079 ; 1.952277657 ; 3.076923077 ; 5 ; 4.128440367 ; 9.615384615 ; 1.818181818 ; 5.397727273 ; 1.388888889 ; 2.985074627 ; 2.389705882 ; 3.409090909 ; 3.023255814 ; 6.666666667 ; 1.758241758 ; 9.677419355 ; 10 ; 7.070707071 ; 0.35335689 ; 2.195262854 ; 3.448275862
MYOMETRIAL_INVASION_SPECIFY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Myometrial invasion Specify	Patient	
NUM_FULL_TERM_PREGNANCIES	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Num full term pregnancies	Sample	1 ; 4 or more ; 2 ; 3 ; Unknown
OTHER_IHC_SPECIFY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Other IHC specify	Sample	CD10 is negative. CD56 and Synaptophysin stains highlight the neuroendocrine component, while chromogranin stain is largely negative. ; P16 and BCL2 positive ; Vimentin Negative HNF 1 Beta Negative WT 1 Focally positive ; Ki-67, 57% ; positive for p16 (strong and diffuse), focally positive for CK5/6 and p40 ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ negative ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ positive ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ positive in myometrium ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive. Vimentin (Vim3B4) ï¿½ï¿½ï¿½ positive. ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ focally positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ positive ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ positive; ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ negative; ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ focally positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ focally positive; ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½Positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ Negative ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ Focal positivity; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ Positive ; CK7 - positive; Vimentin - positive; ; Cytokeratin 7 (OV-TL 12/30) ï¿½ï¿½ï¿½ Positive; Vimentin (Vim3B4) ï¿½ï¿½ï¿½ Focal positivity ; CK7 - focal positivity; Vimentin - focal positivity; ; Cytokeratin 7 (OV-TL 12/30) - Positive; Vimentin (Vim3B4) - Negative; ; CK7 - positive; Vimentin - focal positivity; ; see comment below ; CK7 - positive; Vimentin - negative; ; CK - positive; Vimentin - positive; ; CK7 - patchy positivity; Vimentin - positive; ; CK7 - patchy positive; Vimentin - negative; ; Ki67 positive 90%, Vimentin positive - 5%, SMA negative, CD10 - negative, miogenine - negative, desmine - negative, S-100 - negative ; CK7 - positive; Vimentin - patchy positive; ; CK7 - negative; Vimentin - patchy positive; ; Cytokeratin 7 - positive; Vimentin - negative; ; CK7 - positive; Vimentine - negative;
PATHWAY_ACTIVITY_EGFR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity EGFR	Sample	-1.17 ; 0.17 ; -0.02 ; -1.14 ; -0.98 ; 1.34 ; 0.16 ; -0.59 ; -1.35 ; 0.43 ; -1.11 ; 2.12 ; -1.32 ; -1.16 ; 0.68 ; 1.78 ; 1.57 ; -0.57 ; 1.82 ; 0.31 ; 0.6 ; 0.08 ; -0.06 ; -0.83 ; 0.71 ; 1.18 ; 0.47 ; 0.97 ; 1.59 ; -1.3 ; -1.33 ; -1 ; 1.47 ; 0.67 ; -1.04 ; -1.02 ; 0.02 ; 0.23 ; 0.58 ; 1.66 ; 0.27 ; -0.99 ; -0.75 ; 2.14 ; -0.31 ; -0.17 ; -0.11 ; 0.89 ; 0.25 ; -1.39 ; 0.88 ; 1.36 ; -1.37 ; -0.41 ; -2.32 ; -0.46 ; -0.35 ; 0.06 ; 0.7 ; -0.87 ; 0.99 ; 0.59 ; -0.43 ; -0.18 ; 0.03 ; 0.2 ; -0.37 ; -0.08 ; -0.34 ; 0.85 ; 0.3 ; 0.37 ; -0.7 ; 0.39 ; -0.33 ; -1.03 ; -0.84 ; 1.72 ; -0.54 ; -0.44 ; -0.03 ; -0.61 ; 2.45 ; -0.51
PATHWAY_ACTIVITY_HYPOXIA	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity Hypoxia	Sample	0.09 ; -0.32 ; 0.24 ; 0.7 ; -0.61 ; -1.18 ; 0.41 ; -1.37 ; -1.4 ; -0.3 ; 0.72 ; 0.42 ; -1.66 ; -1.31 ; 1.11 ; -0.12 ; -0.19 ; 1.38 ; 0.47 ; 0.17 ; -0.66 ; 1.84 ; -0.21 ; 0.51 ; 1.46 ; 0.55 ; 0.67 ; -0.31 ; -0.46 ; -0.91 ; 0.78 ; 0.33 ; -0.47 ; -0.52 ; -1.54 ; -0.82 ; -0.02 ; 0.31 ; -1.26 ; -0.88 ; 0.83 ; 0.35 ; -1.64 ; -1.19 ; -0.37 ; -1.73 ; -0.35 ; 0.03 ; 1.98 ; -0.7 ; 0.22 ; -0.05 ; 0.64 ; 0.1 ; 0.49 ; -0.49 ; -0.43 ; 0.36 ; 0.99 ; 0.44 ; -0.36 ; -0.26 ; 2.52 ; -0.99 ; -0.62 ; -1.43 ; 1.32 ; 0.79 ; -0.25 ; -0.6 ; -0.03 ; 0.29 ; 0.16 ; -1.09 ; -1.01 ; 0.56 ; 1.96 ; -1.21 ; -0.56 ; 0.62 ; 1.41 ; 3.42 ; 0.6 ; 0.87 ; -0.97 ; 0.88 ; -0.72
PATHWAY_ACTIVITY_JAK.STAT	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity JAK.STAT	Sample	0.93 ; -0.91 ; 0.4 ; 1.85 ; 0.08 ; -0.66 ; 0.33 ; 0.97 ; 1.02 ; -0.64 ; 0.83 ; 0.1 ; -0.53 ; -1.4 ; 1.93 ; -1.02 ; 1.49 ; -1.63 ; -0.51 ; -1.75 ; -0.14 ; 0.3 ; -0.02 ; -0.09 ; -0.81 ; 1.57 ; 1.11 ; -1.23 ; -0.7 ; -0.35 ; 1.33 ; -0.44 ; 0.98 ; 1.14 ; -0.03 ; -0.65 ; 0.44 ; -0.83 ; -0.57 ; 1.01 ; 0.72 ; 0.34 ; -0.76 ; -0.88 ; -0.21 ; 0.73 ; -1.21 ; 0.24 ; 1.52 ; -0.41 ; 2.4 ; -0.32 ; -0.77 ; 0.15 ; 0.54 ; 0.89 ; -1.47 ; -0.54 ; -1.16 ; 0.68 ; -0.89 ; -0.62 ; -0.68 ; -1.97 ; 1.79 ; -1.8 ; 0.07 ; -0.56 ; -0.48 ; 0.82 ; -0.36 ; -1.34 ; -0.49 ; -0.61 ; -1.1 ; 1.98 ; -0.9 ; 2.7 ; 2.09 ; 0.41 ; 0.28
PATHWAY_ACTIVITY_MAPK	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity MAPK	Sample	-0.7 ; 0.65 ; -0.25 ; -1.85 ; -2.14 ; 1.32 ; -0.28 ; -0.19 ; -0.4 ; 0.26 ; -1.36 ; 1.83 ; -0.07 ; 1.52 ; 1.54 ; 0.75 ; -0.1 ; 1.31 ; 0.82 ; 0.54 ; -0.02 ; -0.87 ; 0.11 ; 1.19 ; -0.26 ; 0.36 ; -0.89 ; -0.2 ; 1.35 ; 1.01 ; -1.05 ; -0.79 ; 0.42 ; 0.62 ; -0.03 ; 1.23 ; -0.88 ; 0.34 ; 2.01 ; -0.22 ; -0.29 ; -1.69 ; 0.73 ; -0.17 ; -1.06 ; 1.27 ; 1.69 ; -0.78 ; -0.34 ; -1.34 ; -0.62 ; -0.8 ; 0.63 ; -0.18 ; 0.24 ; 0.91 ; -0.11 ; 0.7 ; 1.96 ; 0.92 ; -0.58 ; 0.06 ; 0.33 ; 0.57 ; -0.43 ; 0.14 ; 0.78 ; -1.02 ; 0.53 ; -0.41 ; -2.47 ; -1.63 ; -1.66 ; -0.37 ; 1.51 ; 1.34 ; -0.96 ; -0.24 ; -0.32 ; -1.4 ; -0.27 ; 1.15 ; -0.82 ; 1.7
PATHWAY_ACTIVITY_NFKB	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity NFkB	Sample	0.04 ; -0.54 ; 1.25 ; -0.73 ; 0.89 ; -0.24 ; -0.26 ; -1.09 ; 0.58 ; -0.02 ; 0 ; 0.21 ; 0.79 ; -1.97 ; -0.82 ; -0.23 ; 0.77 ; -1.4 ; 0.56 ; -0.49 ; -0.29 ; -1.2 ; -0.4 ; 0.31 ; 0.17 ; 0.81 ; 0.3 ; -0.47 ; 1.14 ; -0.45 ; -1.29 ; 0.05 ; 1.13 ; -0.25 ; -1.1 ; 0.25 ; 0.48 ; -0.69 ; 1.37 ; 0.66 ; 0.34 ; 0.83 ; 1.36 ; -0.06 ; -0.66 ; 0.08 ; 0.16 ; 0.4 ; -0.36 ; -1.49 ; 1.29 ; -1.54 ; -0.19 ; -1.93 ; 1.04 ; 0.19 ; -0.14 ; 2.15 ; -0.71 ; 0.62 ; 1.83 ; -0.21 ; -1.74 ; -0.63 ; 0.46 ; 0.12 ; 1.54 ; 0.64 ; -1.99 ; 2.03 ; -2.51 ; -0.48 ; -0.97 ; -0.83 ; -0.34 ; -1.28 ; 1.31 ; 0.26 ; -1.16 ; -0.05 ; 1.42 ; 0.59 ; 0.27 ; 1.33 ; 3.31
PATHWAY_ACTIVITY_P53	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity p53	Sample	-0.67 ; -0.53 ; 0.43 ; 0.15 ; -1.98 ; 0.56 ; -1.05 ; -1.6 ; -1.39 ; 0.95 ; 0.47 ; 1.2 ; -2.19 ; -1.69 ; 2.14 ; 1.64 ; 1.65 ; 0.67 ; -0.44 ; 1.95 ; -0.57 ; 1.12 ; -0.85 ; 0.41 ; 1.61 ; -0.42 ; -0.99 ; 1.32 ; -0.04 ; -0.47 ; 0.2 ; 1.02 ; 0.84 ; -0.31 ; 0.09 ; 1.15 ; -2.16 ; 1.14 ; 2.05 ; 1.29 ; 0.25 ; -0.58 ; 0.92 ; -0.24 ; 0.26 ; -0.49 ; -0.4 ; 1.49 ; -0.52 ; -1.4 ; 0.44 ; -0.6 ; 0.39 ; 1.31 ; 0.22 ; -1.03 ; 2.01 ; -0.39 ; -0.25 ; -0.18 ; -1.33 ; -0.91 ; -1.34 ; 0.69 ; 1.1 ; 1.01 ; -0.62 ; -0.89 ; 0.38 ; -1.42 ; -0.65 ; 0.34 ; -0.35 ; -0.69 ; 1.3 ; 1.41 ; 1.22 ; -0.32 ; -0.5 ; 0.55 ; -1.36 ; -0.64 ; 0.63 ; 0.57 ; -0.73 ; 0.64
PATHWAY_ACTIVITY_PI3K	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity PI3K	Sample	1.67 ; 2.41 ; 0.16 ; -0.39 ; -0.54 ; 1.04 ; 0.42 ; 0.36 ; -0.88 ; -0.02 ; 1.46 ; -0.04 ; 0.25 ; 0.39 ; 0.64 ; 1.19 ; 0.27 ; -0.28 ; 0.57 ; 0.81 ; 0.33 ; -0.69 ; -1.69 ; 0.11 ; -1.3 ; -0.73 ; 1.2 ; 0.06 ; 1.32 ; -2.22 ; -1.52 ; 1.12 ; 0.3 ; -0.25 ; 0.47 ; 0.58 ; -0.35 ; 0.66 ; -2.38 ; -0.53 ; -0.48 ; -0.7 ; -0.14 ; 0.88 ; -1.32 ; 0.9 ; 0.4 ; -1.05 ; -1.06 ; -1.48 ; 0.55 ; 0.38 ; 1.58 ; 1.36 ; -1.31 ; 0.54 ; 2.39 ; -0.47 ; 2.01 ; -0.16 ; 0.51 ; -0.24 ; 0.72 ; -0.6 ; 0.31 ; -0.1 ; -0.31 ; 0.8 ; -0.61 ; 1.21 ; 1.47 ; -1.57 ; 0.83 ; -1.14 ; -1.01 ; -0.67 ; -0.68 ; -0.34 ; -0.4 ; 1.26 ; -0.07 ; -0.51 ; -0.44 ; -1
PATHWAY_ACTIVITY_TGFB	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity TGFb	Sample	-0.75 ; -0.87 ; -0.61 ; -0.53 ; -2.51 ; 0.78 ; 1.01 ; 0.55 ; -0.66 ; 1.46 ; -1.41 ; 0.12 ; -0.98 ; -2.33 ; 0.67 ; 0.57 ; 1.1 ; -0.41 ; -0.8 ; -0.17 ; 0.2 ; -0.46 ; 0.94 ; -1.18 ; 2.19 ; 0.25 ; 0.46 ; -0.13 ; 0.33 ; 0.4 ; 0.29 ; 0.37 ; 0.61 ; 0.71 ; 0.31 ; 0.14 ; 1.08 ; 1.68 ; 0.72 ; 0.74 ; 0.89 ; -1.44 ; 0.96 ; -0.1 ; -0.39 ; -0.08 ; -0.06 ; -1.93 ; 1.67 ; -0.18 ; 1.24 ; -0.9 ; 0.15 ; -0.91 ; -1.73 ; -1.47 ; 1.61 ; -0.71 ; -1.35 ; 0.6 ; -1.79 ; 0.62 ; -0.11 ; -0.88 ; 0.54 ; -0.28 ; 0.21 ; 0.03 ; -1.24 ; -1.28 ; 0.84 ; 1.39 ; 0.34 ; 0.05 ; -0.19 ; 1.33 ; -0.34 ; -0.15 ; -1.17 ; 1.75
PATHWAY_ACTIVITY_TNFA	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity TNFa	Sample	-0.01 ; -0.07 ; 1.63 ; -1.06 ; -0.02 ; -0.27 ; 0.18 ; -1.18 ; 0.51 ; 0.47 ; 0.22 ; 0.69 ; -1.78 ; -0.6 ; 0 ; 1.31 ; -1.52 ; 0.29 ; -1.01 ; 0.24 ; -0.99 ; -0.46 ; 0.96 ; 1.23 ; -0.38 ; -0.05 ; 1.21 ; 0.07 ; -1.34 ; -0.26 ; 1.3 ; -0.44 ; -0.59 ; 0.16 ; 0.9 ; -0.45 ; 0.71 ; 1.72 ; 0.65 ; 0.54 ; 1.68 ; -0.55 ; -1.09 ; -0.42 ; 0.43 ; -1.22 ; 1.2 ; -1.6 ; -0.7 ; -1.42 ; -0.78 ; 0.73 ; 0.66 ; 1.4 ; -0.33 ; 0.45 ; 1.69 ; 1.71 ; -0.06 ; -1.65 ; -0.87 ; 1.09 ; -0.66 ; 1.96 ; 0.91 ; -1.66 ; 1.14 ; -2.21 ; -0.28 ; -0.69 ; -0.75 ; -0.57 ; -0.41 ; -1.31 ; 1.52 ; -1.03 ; -0.91 ; -0.9 ; 1.38 ; 1.06 ; -0.43 ; -0.11 ; 0.53 ; 2.82 ; 0.63
PATHWAY_ACTIVITY_TRAIL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity Trail	Sample	-1.09 ; -1.6 ; 1.67 ; -0.07 ; 0.96 ; 0.04 ; -2 ; -1.55 ; 1.19 ; -0.61 ; 0.77 ; -0.02 ; -2.3 ; -1.08 ; -1.02 ; 1.03 ; -1.39 ; 0.34 ; -0.78 ; -0.94 ; -0.88 ; 0.01 ; -0.42 ; 0.29 ; 0.39 ; -0.11 ; -0.41 ; 0.41 ; 0.28 ; -0.6 ; 0.46 ; -0.67 ; -0.27 ; -0.31 ; 0.08 ; -0.99 ; -0.8 ; 1.47 ; 0.03 ; 1.14 ; 0.33 ; 0.09 ; -0.63 ; 0.11 ; -0.13 ; 0.82 ; -0.58 ; -1.29 ; 0.93 ; -0.18 ; -0.51 ; 0.99 ; 0.86 ; -1.1 ; 2.12 ; 0.06 ; 1.96 ; -1.81 ; 1.53 ; -2.22 ; -0.01 ; 0.3 ; -0.35 ; 0.73 ; 0.42 ; -1.7 ; 1.57 ; -2.31 ; -0.24 ; -0.23 ; 0.67 ; -1.35 ; 0.02 ; 0.17 ; 1.17 ; -0.97 ; -0.1 ; 1.91 ; -0.93 ; 1.81 ; 2.03 ; 0.31
PATHWAY_ACTIVITY_VEGF	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Pathway Activity VEGF	Sample	1.14 ; 2.14 ; -0.9 ; 0.39 ; 2.1 ; -0.76 ; 0.58 ; -1.16 ; 0.52 ; -0.13 ; 1.05 ; 0.35 ; -0.33 ; 1.56 ; -0.65 ; 2.24 ; 0.09 ; 0.33 ; -0.07 ; 0.41 ; -0.38 ; 1.33 ; -0.72 ; -0.31 ; 0.05 ; 1.49 ; 0.19 ; -0.28 ; -0.78 ; -0.98 ; 1.52 ; -0.96 ; -1.13 ; -0.58 ; 0.2 ; -1.07 ; -0.94 ; -1.64 ; -0.39 ; 0.07 ; -0.51 ; -0.57 ; -0.24 ; -0.11 ; -0.73 ; 1.69 ; 0.04 ; -0.14 ; -1.5 ; -0.29 ; 0.17 ; 0.69 ; -0.82 ; 0.36 ; 1.42 ; 0.51 ; 1.02 ; -1.66 ; 2.28 ; -1.06 ; -0.4 ; -0.48 ; 1.01 ; 0.57 ; -0.01 ; 1.54 ; 0.01 ; -1.1 ; -0.3 ; 0.16 ; 1.68 ; 0.81 ; -1.29 ; 1.03 ; 1.06 ; -0.56 ; 0.5 ; -1.52 ; 1.48 ; -0.04 ; -1.75 ; 1.53 ; -1.65
PATH_STAGE_DIST_METS-PM	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Pathological Stage Distribution Metastasis-pM	Patient	
PATH_STAGE_PRIMARY_TUMOR-PT	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Path Stage Primary Tumor-pT	Patient	
PATH_STAGE_REG_LYMPH_NODES-PN	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Path Stage Reg Lymph Nodes-pN	Patient	
PI3K_AKT1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K AKT1	Sample	0 ; 1
PI3K_AKT2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K AKT2	Sample	0 ; 1
PI3K_AKT3	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K AKT3	Sample	0 ; 1
PI3K_DEPDC5	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K DEPDC5	Sample	0 ; 1
PI3K_DEPTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K DEPTOR	Sample	0 ; 1
PI3K_INPP4B	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K INPP4B	Sample	0 ; 1
PI3K_MAPKAP1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K MAPKAP1	Sample	0 ; 1
PI3K_MLST8	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K MLST8	Sample	0 ; 1
PI3K_MTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K MTOR	Sample	0 ; 1
PI3K_NPRL2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K NPRL2	Sample	0 ; 1
PI3K_NPRL3	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K NPRL3	Sample	0 ; 1
PI3K_PATHWAY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K Pathway	Sample	1 ; 0
PI3K_PDK1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PDK1	Sample	0 ; 1
PI3K_PIK3CA	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PIK3CA	Sample	1 ; 0
PI3K_PIK3CB	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PIK3CB	Sample	0 ; 1
PI3K_PIK3R1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PIK3R1	Sample	0 ; 1
PI3K_PIK3R2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PIK3R2	Sample	0 ; 1
PI3K_PPP2R1A	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PPP2R1A	Sample	1 ; 0
PI3K_PTEN	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K PTEN	Sample	1 ; 0
PI3K_RHEB	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K RHEB	Sample	0 ; 1
PI3K_RICTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K RICTOR	Sample	0 ; 1
PI3K_RPS6	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K RPS6	Sample	0 ; 1
PI3K_RPS6KB1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K RPS6KB1	Sample	0 ; 1
PI3K_RPTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K RPTOR	Sample	0 ; 1
PI3K_STK11	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K STK11	Sample	0 ; 1
PI3K_TSC1	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K TSC1	Sample	1 ; 0
PI3K_TSC2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PI3K TSC2	Sample	0 ; 1
PMS2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	PMS2	Sample	Intact nuclear expression ; Loss of nuclear expression ; Cannot be determined ; Unknown
POLE_SUBTYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	POLE subtype	Sample	No ; Yes
PROGESTERONE_RECEPTOR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Progesterone Receptor	Sample	Cannot be determined ; Positive ; Negative ; Unknown
PROGESTERONE_RECEPTOR_%	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Progesterone Receptor %	Sample	5 ; -1 ; 30 ; 50 ; 20 ; 70 ; 90 ; 80 ; 7 ; 40 ; 60 ; 92 ; 95 ; 85 ; 10 ; 65
PROTEOMICS_OCT	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Tandem Mass Tag batch for proteomics measurement	Sample	No ; Yes
PROTEOMICS_TMT_BATCH	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Tandem Mass Tag batch for proteomics measurement	Sample	2 ; 4 ; 1 ; 3
PROTEOMICS_TMT_CHANNEL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Tandem Mass Tag channel for proteomics measurement	Sample	128N ; 130N ; 131 ; 129C ; 129N ; 130C ; 127C ; 127N ; 128C
PROTEOMICS_TMT_PLEX	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Tandem Mass Tag plex for proteomics measurement	Sample	5 ; 16 ; 2 ; 12 ; 14 ; 15 ; 11 ; 9 ; 13 ; 3 ; 6 ; 7 ; 10 ; 8 ; 4 ; 1
PROTEOMICS_TUMOR_NORMAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Tandem Mass Tag batch for proteomics measurement	Sample	Tumor
PR_PGR	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	PR PGR	Sample	0.253 ; -0.0242 ; 0.0767 ; 0.0696 ; -2.8 ; -0.983 ; -0.745 ; -1.72 ; -1.79 ; 0.771 ; -0.422 ; -2.4 ; -2 ; 0.75 ; 0.604 ; -2.57 ; -0.407 ; 1.47 ; -0.336 ; -1.03 ; 0.108 ; 0.667 ; 0.951 ; 0.243 ; -0.912 ; -0.696 ; -0.387 ; -0.145 ; -0.122 ; -0.0653 ; 1.28 ; 0.8 ; -0.184 ; 0.0228 ; 0.864 ; 0.661 ; -0.601 ; -0.484 ; 0.428 ; -0.936 ; 0.316 ; 0.622 ; 0.758 ; -0.34 ; -0.0404 ; 0.608 ; -0.344 ; 0.383 ; 0.314 ; -1.08 ; -2.6 ; -1.93 ; 0.924 ; -1.67 ; 0.371 ; -1.15 ; 0.0846 ; 0.474 ; -0.643 ; -0.129 ; 0.454 ; -0.609 ; -1.09 ; 0.538 ; -2.11 ; -0.888 ; 0.863 ; 0.054 ; 0.288 ; -1.76 ; -0.604 ; -1.1 ; -0.0363 ; -0.105 ; -1.34 ; -0.61 ; 0.41 ; 1.5 ; -0.179 ; -0.197 ; 0.784 ; 0.837 ; -2.06 ; -0.65 ; 1.06 ; -0.458 ; -0.48 ; -3.06 ; -2.1 ; -1.21 ; 0.856 ; -0.451 ; -1.64 ; -2.9 ; -1.42
PURITY_CANCER	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Purity Cancer	Sample	0.730880164 ; 0.715223373 ; 0.365434419 ; 0.571299524 ; 0.623745319 ; 0.554177035 ; 0.642431399 ; 0.487728614 ; 0.516615598 ; 0.3855902 ; 0.694163579 ; 0.643834137 ; 0.53935279 ; 0.848208592 ; 0.514841368 ; 0.632079059 ; 0.330364549 ; 0.713908354 ; 0.582138542 ; 0.651375137 ; 0.607380774 ; 0.669628949 ; 0.28695343 ; 0.610413148 ; 0.298756785 ; 0.449105173 ; 0.482803588 ; 0.647566516 ; 0.476333232 ; 0.428986832 ; 0.250955331 ; 0.404198571 ; 0.510604207 ; 0.608515395 ; 0.417360147 ; 0.22946024 ; 0.279277989 ; 0.209490344 ; 0.100259031 ; 0.293810101 ; 0.39622699 ; 0.144692723 ; 0.570248414 ; 0.38263115 ; 0.502674298 ; 0.453568112 ; 0.423044883 ; 0.59072105 ; 0.426011719 ; 0.77235307 ; 0.560807043 ; 0.322261222 ; 0.529494006 ; 0.397792557 ; 0.356328585 ; 0.418050437 ; 0.595569786 ; 0.36724791 ; 0.370659592 ; 0.534767631 ; 0.330014565 ; 0.682222746 ; 0.472159908 ; 0.403135805 ; 0.763208662 ; 0.305268446 ; 0.360835808 ; 0.433965799 ; 0.526925007 ; 0.556850798 ; 0.541519478 ; 0.578781362 ; 0.24094175 ; 0.717091014 ; 0.594726783 ; 0.564237797 ; 0.763673461 ; 0.639515552 ; 0.732064691 ; 0.314292946 ; 0.592598499 ; 0.658231952 ; 0.337676312 ; 0.57498839 ; 0.359083985 ; 0.753031126 ; 0.714476676 ; 0.544443077 ; 0.330951988 ; 0.443528669 ; 0.16252204
PURITY_IMMUNE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Purity Immune	Sample	0.060494906 ; 0.082629765 ; 0.260963289 ; 0.076005374 ; 0.26273407 ; 0.189781135 ; 2.27E-18 ; 0.074969712 ; 0.314749855 ; 0.100674478 ; 0.147902919 ; 0.142389668 ; 0.223339079 ; 0.046460963 ; 0.130018403 ; 0.158828136 ; 0.237359854 ; 0.085761394 ; 0.205001063 ; 0.141321035 ; 0.086578499 ; 0.030069605 ; 0.055775942 ; 0.202506396 ; 0.069933635 ; 0.346200922 ; 0.26933117 ; 0.133461604 ; 0.172595657 ; 0.107124413 ; 0.034227034 ; 0.142267913 ; 0.154403781 ; 0.168378061 ; 0.045648765 ; 0.113551357 ; 0.221445079 ; 0.11312731 ; 0.164944633 ; 0.413698802 ; 0.164304785 ; 0.138124857 ; 0.305938879 ; 0.178791861 ; 0.153605478 ; 0.220275126 ; 0.224253983 ; 0.111994798 ; 0.158812029 ; 0.148952464 ; 0.227748077 ; 0.025074678 ; 0.198948242 ; 0.035279107 ; 0.210719013 ; 0.212727517 ; 0.12367529 ; 0.490438133 ; 0.136843014 ; 0.150426081 ; 0.393045827 ; 0.090842904 ; 0.297638094 ; 0.281868662 ; 0.168580861 ; 0.090616832 ; 0.054325363 ; 0.118997554 ; 0.233208597 ; 0.253958448 ; 0.254109924 ; 0.0632497 ; 0.413790787 ; 0.002630944 ; 0.160723734 ; 0.199052848 ; 0.121613963 ; 0.097312578 ; 0.097162309 ; 0.030460134 ; 0.140145736 ; 0.199829128 ; 0.046631214 ; 0.312899462 ; 0.096244666 ; 0.092486411 ; 0.200823898 ; 0.248159781 ; 0.335899561 ; 0.365215471 ; 0.250298316
PURITY_STROMA	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	Purity Stroma	Sample	0.208624931 ; 0.202146861 ; 0.373602292 ; 0.352695102 ; 0.113520611 ; 0.25604183 ; 0.357568601 ; 0.437301675 ; 0.168634547 ; 0.513735322 ; 0.157933501 ; 0.213776195 ; 0.237308131 ; 0.105330444 ; 0.355140229 ; 0.209092805 ; 0.432275597 ; 0.200330252 ; 0.212860395 ; 0.207303827 ; 0.306040727 ; 0.300301446 ; 0.657270628 ; 0.187080456 ; 0.63130958 ; 0.204693905 ; 0.247865242 ; 0.21897188 ; 0.351071112 ; 0.463888755 ; 0.714817635 ; 0.453533516 ; 0.334992012 ; 0.223106544 ; 0.536991088 ; 0.656988404 ; 0.499276932 ; 0.677382346 ; 0.734796336 ; 0.292491097 ; 0.439468225 ; 0.71718242 ; 0.123812708 ; 0.438576989 ; 0.343720225 ; 0.326156762 ; 0.352701134 ; 0.297284152 ; 0.415176252 ; 0.078694467 ; 0.21144488 ; 0.6526641 ; 0.271557752 ; 0.566928335 ; 0.432952402 ; 0.369222046 ; 0.280754924 ; 0.142313957 ; 0.492497394 ; 0.314806288 ; 0.276939607 ; 0.22693435 ; 0.230201998 ; 0.314995532 ; 0.068210478 ; 0.604114722 ; 0.584838829 ; 0.447036647 ; 0.239866397 ; 0.189190754 ; 0.204370598 ; 0.357968938 ; 0.345267463 ; 0.280278042 ; 0.244549483 ; 0.236709354 ; 0.114712575 ; 0.26317187 ; 0.170773 ; 0.65524692 ; 0.267255766 ; 0.14193892 ; 0.615692473 ; 0.112112148 ; 0.544671348 ; 0.154482463 ; 0.084699426 ; 0.207397142 ; 0.333148452 ; 0.19125586 ; 0.587179644
RNASEQ_R1_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	RNAseq R1 Sample Type	Sample	Tumor
RNASEQ_R2_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	RNAseq R2 Sample Type	Sample	Tumor
TP53_ATM	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 ATM	Sample	0 ; 1
TP53_CHEK2	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 CHEK2	Sample	0 ; 1
TP53_MDM4	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 MDM4	Sample	0 ; 1
TP53_PATHWAY	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 Pathway	Sample	1 ; 0
TP53_RPS6KA3	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 RPS6KA3	Sample	0 ; 1
TP53_TP53	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	NUMBER	TP53 TP53	Sample	1 ; 0
TREATMENT_NAIVE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Treatment naive	Patient	
TUMOR_SITE_OTHER	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Tumor Site Other	Patient	
TUMOR_STAGE-PATHOLOGICAL	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	Tumor stage	Patient	
WGS_NORMAL_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	WGS normal sample type	Sample	Blood_normal
WGS_TUMOR_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	WGS tumor sample type	Sample	Tumor
WXS_NORMAL_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	WXS normal sample type	Sample	Blood_normal
WXS_TUMOR_SAMPLE_TYPE	PeachPuff	Endometrial Carcinoma (CPTAC, Cell 2020)	STRING	WXS tumor sample type	Sample	Tumor
MMRD_MECHANISM	PeachPuff	Endometrial Carcinoma MSI (MSK, Clin Cancer Res 2022)	STRING	MMR-D Mechanism	Sample	Germline ; MLH1 methylation ; Somatic
HISTOLOGIC_SUBTYPE	PeachPuff	Endometrial Carcinoma cfDNA (MSK, Clin Cancer Res 2022)	STRING	Histologic Subtype	Sample	Endometrioid ; Serous ; Carcinosarcoma ; De-differentiated ; HG Carcinoma ; Mixed ; Adenosarcoma
SURGIVAL_STAGE	PeachPuff	Endometrial Carcinoma cfDNA (MSK, Clin Cancer Res 2022)	STRING	Surgical Stage	Sample	IA ; IB + ITC ; IIIB ; IIIC2 ; IVB ; IVB* ; IB ; IIIC1 ; IA + ITC ; IIIA
HISTORY_COLORECTAL_CANCER	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	History colorectal cancer	Patient	
HISTORY_MENOPAUSAL_HORMONE_THERAPY	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	History menopausal hormone therapy	Patient	
HISTORY_TAMOXIFEN_USE	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	History tamoxifen use	Patient	
LYMPH_NODES_AORTIC_EXAMINED_COUNT	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes aortic examined count	Patient	
LYMPH_NODES_AORTIC_POS_BY_HE	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes aortic pos by he	Patient	
LYMPH_NODES_AORTIC_POS_BY_IHC	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes aortic pos by ihc	Patient	
LYMPH_NODES_AORTIC_POS_TOTAL	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes aortic pos total	Patient	
LYMPH_NODES_PELVIC_EXAMINED_COUNT	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes pelvic examined count	Patient	
LYMPH_NODES_PELVIC_POS_BY_HE	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes pelvic pos by he	Patient	
LYMPH_NODES_PELVIC_POS_BY_IHC	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes pelvic pos by ihc	Patient	
LYMPH_NODES_PELVIC_POS_TOTAL	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Lymph nodes pelvic pos total	Patient	
PERITONEAL_WASHING	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	Peritoneal washing	Patient	
PREGNANCIES_FULL_TERM_COUNT	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	Pregnancies full term count	Patient	
SURGICAL_APPROACH_AT_DIAGNOSIS	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	STRING	Surgical approach at diagnosis	Patient	
TUMOR_INVASION_PERCENT	PeachPuff	Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)	NUMBER	Tumor invasion percent	Patient	
ARID1A_MUTATION	LightSkyBlue	Gastric Adenocarcinoma (TMUCIH, PNAS 2015)	STRING	ARID1A mutation is present.	Sample	Wt ; Mut ; 1 ; 0
CDH1_STATUS	LightSkyBlue	Gastric Adenocarcinoma (TMUCIH, PNAS 2015)	STRING	CDH1 Status	Sample	CDH1_mut ; CDH1_wt
CLONAL_LABEL	LightSkyBlue	Gastric Adenocarcinoma (TMUCIH, PNAS 2015)	STRING	Clonal Label	Sample	Non-Ultraclonal ; Ultraclonal
DNA_REPAIR_STATUS	LightSkyBlue	Gastric Adenocarcinoma (TMUCIH, PNAS 2015)	STRING	DNA Repair Status	Sample	NonDef ; Def
EBV_PRESENT	LightSkyBlue	Gastric Adenocarcinoma (TMUCIH, PNAS 2015)	NUMBER	EBV present.	Patient	
BIOPSY_OBTAINED	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Biopsy Obtained at MSK or OSH	Sample	MSK ; OSH
CLINICAL_TRIAL_1L	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Clinical Trial 1L	Patient	
CLINICAL_TRIAL_2L	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Clinical Trial 2L	Patient	
CLINICAL_TRIAL_3L	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Clinical Trial 3L	Patient	
DETAILS_FIRST_LINE_COMMENTS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Details on First Line & Comments	Patient	
EBV_TESTED	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	EBV Tested	Patient	
ECOG_AT_STAGE_4_DX	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	ECOG Score Recorded at Stage IV Diagnosis	Patient	
HER2_IHC_OR_FISH	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	HER2 IHC or FISH	Sample	POS ; NEG
HER2_IMPACT	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	HER2 IMPACT	Sample	AMP ; DIPLOID
HER2_IMPACT_LR	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	HER2 IMPACT LR	Sample	1.6343 ; 3.5492 ; 2.5047 ; -0.0064 ; 0.2218 ; 2.1365741 ; 0.8577704 ; 2.1711148 ; 0.0033 ; 4.0635 ; -0.0283 ; -0.0278 ; 0.0849 ; 1.0801 ; -0.0058 ; 0.0207 ; 2.6923 ; 1.9729 ; 0.0098 ; -0.0924 ; -0.0405 ; 0.1684 ; 1.0232 ; 4.8681 ; 4.5226 ; 0.0955 ; 0.1249 ; -0.0703 ; -0.0029 ; 0.0038 ; 3.9188 ; 0.1355 ; -0.0587 ; 1.2571 ; 0.0157 ; 0.0095 ; 2.4781 ; 1.4303 ; 0.5217 ; 0.0945 ; -0.1145 ; 0.0394 ; 0.0578 ; 0.737 ; 0.1015 ; 0.0557 ; -0.0051 ; 0.0273 ; 0.1339 ; 0.0514 ; 0.0974 ; 3.9227 ; 0.0446 ; 0.0376 ; 0.2676 ; 0.1484 ; 0.2811 ; 0.1089 ; 2.4911 ; 3.93413903 ; 0.0601 ; 0.0166 ; -0.0379 ; -0.0149 ; -0.031 ; 0.9811 ; -0.0581 ; 0.3988593 ; 0.0946 ; -0.0591 ; 0.0865 ; 1.8917 ; 2.7649 ; 2.5678 ; 2.7631 ; 0.141 ; 0.1003 ; -0.0516 ; -0.0218 ; -0.053 ; 5.1654 ; -0.0456 ; 0.0751 ; 0.1951 ; -0.0433 ; 0.3577 ; 0.1552 ; -0.0918 ; 3.5751 ; 1.8071 ; 0.6844 ; 0.005 ; 0.6416 ; 3.3777 ; 0.1243 ; -0.0147 ; 0.2188 ; 0.1837 ; 0.0046 ; -0.0037 ; 2.6839 ; 3.858 ; 3.8087 ; -0.0858 ; 0.0731 ; 0.5131 ; 0.3164 ; 0.2312 ; -0.0307 ; 0.01 ; -0.0478 ; 0.0105 ; 0.7639 ; -0.0195 ; -0.0225 ; 0.0565 ; 3.4775 ; 0.1139 ; 3.9633 ; 0.0215 ; 0.1142 ; 0.0199 ; 0.0102 ; 0.0054 ; -0.0627 ; 4.3585 ; 0.2086 ; 0.4541 ; 2.495 ; 4.3658 ; 0.0932 ; 0.2111 ; 0.0107 ; -0.0237 ; 3.9367 ; -0.0008 ; -0.0382 ; 0.3739 ; 0.0582 ; -0.1033 ; -0.0694 ; 0.3060556 ; 1.1959 ; 1.246712101 ; 1.2095 ; 0.6603 ; 0.8726 ; 4.452 ; 2.0107 ; 3.5871 ; -0.0563 ; 0.1399 ; 3.988 ; -0.0032 ; -0.0644 ; -0.0343 ; -0.0166 ; -0.0181 ; 2.6426 ; 0.0429 ; 0.0178 ; 0.0312 ; 1.2654 ; 1.7896593 ; 0.1274 ; 0.3802 ; 2.37 ; 3.1228 ; 0.0183 ; -0.0755 ; 0.138 ; 3.4756 ; 1.9004556 ; 2.026 ; 0.0036 ; -0.007 ; 4.5928 ; 0.2509 ; 0.0473 ; 0.9224 ; 0.0739 ; 1.6362 ; -0.1317 ; -0.0661 ; 0.0658 ; 0.9923 ; -0.0727 ; 0.0003 ; 0.1167 ; -0.0758 ; 0.3282 ; 0.5385 ; 0.0431 ; 4.8119 ; 2.5704 ; -0.0012 ; 0.0972 ; 0.0526 ; 3.9735926 ; 2.4022 ; -0.0127 ; 0.2208 ; 0.2297 ; 3.251 ; 0.0111 ; 0.1816 ; -0.1287 ; 0.1595 ; 0.4198 ; 0.0479 ; 0.3535 ; -0.0692 ; 0.2873 ; 0.0062 ; 0.9512 ; 0.0279 ; 0.1327 ; 0.0931 ; 0.2768 ; 0.0646 ; 0.0025 ; 0.0142 ; -0.0221 ; 0.0362 ; 2.7704 ; -0.0116 ; 0.0511 ; -0.0003 ; 0.119 ; 1.1414 ; -0.0011 ; 0.0237 ; -0.0351 ; 0.0242 ; -0.1535 ; 0.0013 ; -0.0524 ; 0.1422 ; 0.0218 ; 0.3969 ; -0.2022 ; 0.0892 ; 0.0527 ; 0.0068 ; 0.0841 ; 0.0109 ; 0.3466 ; -0.0267 ; 0.0191 ; 3.2626 ; 3.4072 ; 0.0448 ; -0.1611 ; 0.0518 ; 0.0198 ; -0.0148 ; -0.025 ; 0.0766 ; -0.0098 ; 0.1585 ; 0.041 ; -0.09 ; -0.0257 ; 0.1573 ; 3.7006 ; 0.106 ; 4.1988778 ; 2.2954 ; 3.4038 ; 0.0546 ; -0.0572 ; 1.0565 ; 0.0336 ; 0.2083 ; 0.0669 ; 4.0773 ; 0.0351 ; 0.0903 ; -0.0209 ; 0.0764 ; -0.17 ; 0.65 ; 0.2449 ; -0.1064 ; 0.0639 ; 3.0364 ; -0.0551 ; 0.0754 ; 0.0513 ; 1.1254 ; 0.7475 ; 0.0064 ; 3.1549 ; 0.0228 ; 0.0347 ; 0.2727 ; 0.309 ; 0.0462 ; 0.356 ; 5.2225 ; -0.0626 ; -0.0784 ; 0.107 ; 0.086 ; 0.3701 ; 0.0814 ; 0.1359 ; 0.1106 ; -0.0183 ; 0.1949 ; -0.0108 ; 1.6894407 ; -0.0336 ; 0.0571 ; -0.1377 ; 4.3421 ; 3.9242 ; 1.1208 ; 0.4903 ; 5.0873 ; 0.6017 ; 2.4743 ; 0.229 ; 3.9111 ; 2.1651 ; 0.8474 ; 1.2867 ; 5.1823 ; 5.2069 ; 2.416839742 ; 4.33778244 ; 1.884011738 ; 1.71501475 ; 3.435495252 ; 2.263635404
HER2_RESPONSE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	HER2 Response	Sample	CR ; SD ; PR ; POD
HER2_TTP_ON_1ST_LINE_MONTHS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	HER2 Total Time Period on First Line (Months)	Sample	5.23 ; 7.63 ; 25.67 ; 14.57 ; 17.43 ; 12.13 ; 23.3 ; 24.27 ; 25.43 ; 37.3 ; 7.07 ; 5.6 ; 14 ; 24.73 ; 30.03 ; 12.17 ; 7.3 ; 15.67 ; 8.77 ; 26.23 ; 6.5 ; 34.8 ; 29.77 ; 6.13 ; 11.37 ; 10 ; 2.5 ; 8.4 ; 8.07 ; 15.7 ; 10.03 ; 23.37 ; 23.8 ; 16.33 ; 7.87 ; 16.57 ; 2.8 ; 9.87 ; 19.97 ; 9.13 ; 18.93 ; 8.83 ; 16.27 ; 13.2 ; 12.9 ; 12.97 ; 17.1 ; 7.13 ; 6.03 ; 5.9 ; 13 ; 3.53 ; 3.7 ; 18.27 ; 6.6 ; 18.83
HER2_TX_STATUS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	HER2 Treatment Status	Sample	OFF TREATMENT ; ON TREATMENT
HER2_VITAL_STATUS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	HER2 Vital Status	Sample	NED ; DOD ; AWD ; LTF
H_PYLORI	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	H-PYLORI.	Sample	NEGATIVE ; POSITIVE ; UNKNOWN
IMPACT_PRE_POST	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IMPACT pre/post	Sample	POST-TX ; PRE-TX
IO_EBV_TESTED	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IO EBV Tested	Sample	NEGATIVE ; INSUFFICIENT TISSUE ; NOT TESTED ; POSITIVE
IO_EGC_SURVIVAL_OS_MONTHS_START_OF_IO_TO_DATE_OF_DEATH_LAST_FOLLOW_UP	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	EGC Overall Survival from start of IO to date of death/follow up/POD	Sample	DOD ; LTF ; AWD
IO_MUT_GROUPS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IO Mutation Group	Sample	0 ; 1
IO_OS_MONTHS_START_OF_IO	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	IO OS Months From Start of IO	Patient	
IO_PDL1_TESTED	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IO PDL1 Tested	Sample	not tested ; not evaluable ; negative ; positive ; BMS tested?
IO_PFS_MONTHS_START_OF_IO_TO_POD	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	IO PFS from Start of IO to POD	Patient	
IO_PFS_STATUS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IO Progression Free Status	Patient	
IO_REGIMEN_MONOTHERAPY_VS_COMBINATION	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	IO Regimen Monotherapy Vs Combination	Sample	Monotherapy ; Combination
LAUREN_CLASS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Lauren class.	Patient	
MET_LIVER	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Liver Metastasis	Sample	YES ; NO
MET_LUNG	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Lung Metastasis	Sample	NO ; YES
MET_PERITONEUM	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Peritoneum Metastasis	Sample	YES ; NO
NUMBER_OF_LINES_OF_TREATMENT_FOR_MET_DISEASE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Number of Lines of Treatment For Met Disease	Patient	
OS_MONTHS_STAGE_IV	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Overall survival in months since stage IV diagonosis	Patient	
PLATINUM_BEST_RESPONSE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Platinum Best Response	Patient	
PLATINUM_GERMLINE_TESTED	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Platinum Germline Tested	Patient	
PLATINUM_HRD_MUTATION	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Platinum HRD Mutation	Patient	
PLATINUM_LST_SCORE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Platinum LST Score	Patient	
PLATINUM_OS_MONTHS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Platinum Overall Survival Months	Patient	
PLATINUM_OS_STATUS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Platinum Overall Survival Status	Patient	
PLATINUM_PFS_MONTHS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Platinum Progression Free Months	Patient	
PLATINUM_PFS_STATUS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Platinum Progression Free Status	Patient	
RECEIVED_IO_AFTER_1ST_LINE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Did the patient receive IO after first line therapy	Patient	
RETROSPECTIVE_OR_PROSPECTIVE	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Is the sample retrospective or prospective	Sample	PROSPECTIVE ; RETROSPECTIVE
SITE_OF_TISSUE_BIOPSY	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	STRING	Site of Tissue Biopsy	Sample	GEJ ; Body ; Liver ; Lymph Nodes ; Distal ; Peritoneum ; Fallopian Tube/Ovary ; Colon ; Occipital ; Upper ; Cardia ; Adrenal ; Pelvic peritoneal ; Lung ; Omental nodule ; Breast ; Peritoneal nodule ; Omentum ; not sure ; Peritoneal fluid ; Lesser curvature ; Brain ; Uterus, cervix, tubes and ovaries ; Esophagus ; Femoral head and curettings ; 34 cm ; Remnant ; Manubrium ; Mid ; Falciform ; Falciform ligament ; Ovary ; Pleural fluid ; Upper quadrant washings ; Retroperitoneum ; distal ; Pleural nodule ; Stomach ; body ; Adrenal mass ; wall ; lower third ; Lung nodule ; Adhesions ; Neck soft tissue ; Esophageal lesion ; Antrum ; LN ; 35 ; thoracic ; Umbilical nodule ; Perietal lesion ; Cerebellum
TOTAL_TIME_PERIOD_MONTHS	LightSkyBlue	Metastatic Esophagogastric Cancer (MSK, Cancer Discovery 2017)	NUMBER	Total Time Period in Months	Patient	
AGE_AT_SAMPLING	LightSkyBlue	Esophageal/Stomach Cancer (MSK, 2020)	NUMBER	Age at Sampling	Sample	78 ; 46 ; 57 ; 59 ; 33 ; 69 ; 51 ; 73 ; 62 ; 79 ; 71 ; 37 ; 23 ; 54 ; 65 ; 58 ; 53 ; 61 ; 64 ; 40 ; 87 ; 41 ; 42 ; 47 ; 48 ; 72 ; 63 ; 36 ; 83 ; 55 ; 70 ; 56 ; 68 ; 67 ; 45 ; 50 ; 77 ; 80 ; 66 ; 74 ; 76 ; 49 ; 60 ; 44 ; 52 ; 38 ; 81 ; 24 ; 25 ; 31 ; 92 ; 28 ; 43 ; 82 ; 22 ; 94 ; 39 ; 86 ; 35 ; 75 ; 21 ; 34 ; 88
CSTAGE_CATEGORY	LightSkyBlue	Esophageal/Stomach Cancer (MSK, 2020)	STRING	cStage Category	Patient ; Sample	III ; IV ; II
PSTAGE_CATEGORY	LightSkyBlue	Esophageal/Stomach Cancer (MSK, 2020)	STRING	pStage Category	Patient ; Sample	IV ; I ; III ; II
CN_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	cN Category	Sample	1 ; 0 ; 2 ; 3
CT_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	cT Category	Sample	3 ; 4 ; 2 ; 1
IMPACT_TMB_SCORE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	NUMBER	IMPACT TMB Score	Patient	
NT_RESPONDER	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	nT Responder	Sample	No ; Yes
PATHOLOGIC_DOWNSTAGING	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	Pathologic Downstaging	Sample	No ; Yes
PET_RESPONDER	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	PET Responder	Sample	Yes ; No ; Unknown
PN_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	pN Category	Sample	0 ; 1 ; 3 ; 2
PT_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	pT Category	Sample	2 ; 3 ; 1 ; 0 ; 4
RESIDUAL_NODAL_DISEASE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	Residual Nodal Disease	Sample	Yes ; No
TP53_BIALLELIC_GROUPS	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	TP53 Biallelic Groups	Sample	Other ; WT ; MDM2 ; Truncating Biallelic
TREATMENT_EFFECT	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	NUMBER	Treatment Effect	Patient	
TRG_SCORE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2022)	STRING	TRG Score	Sample	4 ; 1 ; 3 ; 2 ; 0
BARRETTS_ESOPHAGUS	LightSkyBlue	Esophageal Adenocarcinoma (DFCI, Nat Genet 2013)	STRING	Barretts esophagus.	Patient ; Sample	No ; Yes
2L_TREATMENT	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	2L Treatment	Patient	
3L_TREATMENT	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	3L Treatment	Patient	
ACHIEVED_6_MONTHS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Achieved 6-month PFS	Patient	
BASELINE_ERBB2_ANY_NGS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline ERBB2 any NGS	Patient	
BASELINE_ERBB2_PLASMA_NGS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline ERBB2 plasma NGS	Patient	
BASELINE_ERBB2_TISSUE_NGS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline ERBB2 tissue NGS	Patient	
BASELINE_EXTERNAL_HER2_IHC_FISH	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline external HER2 IHC/FISH	Patient	
BASELINE_INTERNAL_HER2_IHC_FISH	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline internal HER2 IHC/FISH	Patient	
BASELINE_MSK_ERBB2_STATUS_IHC_FISH_OR_TISSUE_PLASMA_NGS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline MSK ERBB2 status (IHC, FISH, or tissue/plasma NGS)	Patient	
BASELINE_PD_L1_STATUS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline PD-L1 status	Patient	
BASELINE_RTK_RAS_ALTERED	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Baseline RTK-RAS altered	Patient	
BEST_RESPONSE_PERCENTAGE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Best response (%) (NA is not measured)	Patient	
BINDING_NEOANTIGENS_PER_MB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Binding neoantigens per mb	Sample	2.105263158 ; 3.842105263 ; 2.052631579 ; 0.184210526 ; 1.184210526 ; 2.5 ; 3.421052632 ; 2.368421053 ; 2.763157895 ; 1.105263158 ; 4.342105263 ; 1.078947368 ; 2.078947368 ; 3.5 ; 1.552631579 ; 3.052631579 ; 3.236842105 ; 2.394736842 ; 1.868421053 ; 2.947368421 ; 2.684210526 ; 2.605263158 ; 2.184210526 ; 0.578947368 ; 3.473684211 ; 3.894736842 ; 6.210526316 ; 1.894736842
CLONAL_STRONG_BINDING_NEOANTIGENS_PER_MB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Clonal strong binding neoantigens per mb	Sample	0.894736842 ; 1.736842105 ; 0.394736842 ; 0 ; 0.078947368 ; 0.947368421 ; 1.289473684 ; 0.526315789 ; 0.5 ; 1.921052632 ; 1.210526316 ; 0.447368421 ; 1.315789474 ; 1.184210526 ; 1.526315789 ; 0.421052632 ; 0.789473684 ; 0.815789474 ; 0.921052632 ; 1 ; 0.973684211 ; 1.763157895 ; 1.710526316 ; 0.763157895
CTDNA_INDUCTION_RESPONSE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	ctDNA induction response	Patient	
CURRENT_CYCLE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Current cycle	Patient	
ERBB2_AMP_MSKIMPACT	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	ERBB2 amplification by MSKIMPACT	Sample	Amplified ; Not detected ; Not amplified
FRACTION_OF_CLONAL_MUTATIONS_WITH_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Fraction of clonal mutations with binding neoantigens	Sample	0.386363636 ; 0.388235294 ; 0.138888889 ; 0 ; 0.05 ; 0.164835165 ; 0.315789474 ; 0.41509434 ; 0.260638298 ; 0.148148148 ; 0.25 ; 0.327586207 ; 0.366834171 ; 0.380165289 ; 0.314814815 ; 0.144230769 ; 0.303030303 ; 0.223684211 ; 0.292207792 ; 0.351515152 ; 0.306306306 ; 0.192771084 ; 0.20979021 ; 0.236641221 ; 0.269230769 ; 0.348623853 ; 0.201086957 ; 0.370165746 ; 0.225694444 ; 0.292929293
FRACTION_OF_GENOME_ALTERED_ON_WES	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Fraction of genome altered on WES 	Sample	0.399161884 ; 0.908199462 ; 0.884230747 ; 0.098477225 ; 0.084958974 ; 0.841994373 ; 0.311129339 ; 0.486645976 ; 0.929143294 ; 0.479653412 ; 0.349789971 ; 0.427671492 ; 0.905077557 ; 0.373032455 ; 0.935727264 ; 0.438809597 ; 0.568650491 ; 0.702157762 ; 0.590534635 ; 0.257968268 ; 0.574392331 ; 0.412554373 ; 0.527135273 ; 0.922653415 ; 0.264409975 ; 0.865974467 ; 0.789765176 ; 0.794599345 ; 0.285964444
FRACTION_OF_MUTATIONS_WITH_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Fraction of mutations with binding neoantigens	Sample	0.909090909 ; 0.858823529 ; 0.722222222 ; 0.7 ; 0.75 ; 0.857142857 ; 0.833333333 ; 0.817610063 ; 0.776595745 ; 0.666666667 ; 0.772058824 ; 0.724137931 ; 0.829145729 ; 0.867768595 ; 0.759259259 ; 0.759615385 ; 0.806060606 ; 0.776315789 ; 0.753246753 ; 0.745454545 ; 0.81981982 ; 0.855421687 ; 0.783216783 ; 0.778625954 ; 0.761538462 ; 0.76146789 ; 0.709677419 ; 0.717391304 ; 0.817679558 ; 0.819444444 ; 0.727272727
FRACTION_OF_MUTATIONS_WITH_STRONG_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Fraction of mutations with strong binding neoantigens	Sample	0.556818182 ; 0.511764706 ; 0.351851852 ; 0.5 ; 0.416666667 ; 0.527472527 ; 0.561403509 ; 0.566037736 ; 0.462765957 ; 0.407407407 ; 0.536764706 ; 0.413793103 ; 0.512562814 ; 0.537190083 ; 0.481481481 ; 0.442307692 ; 0.503030303 ; 0.513157895 ; 0.480519481 ; 0.527272727 ; 0.441441441 ; 0.421686747 ; 0.51048951 ; 0.458015267 ; 0.476923077 ; 0.486238532 ; 0.387096774 ; 0.391304348 ; 0.491712707 ; 0.444444444 ; 0.404040404
FRACTION_OF_MUTATIONS_WITH_WEAK_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Fraction of mutations with weak binding neoantigens	Sample	0.352272727 ; 0.347058824 ; 0.37037037 ; 0.2 ; 0.333333333 ; 0.32967033 ; 0.271929825 ; 0.251572327 ; 0.313829787 ; 0.259259259 ; 0.235294118 ; 0.310344828 ; 0.316582915 ; 0.330578512 ; 0.277777778 ; 0.317307692 ; 0.303030303 ; 0.263157895 ; 0.272727273 ; 0.218181818 ; 0.378378378 ; 0.43373494 ; 0.320610687 ; 0.284615385 ; 0.275229358 ; 0.322580645 ; 0.326086957 ; 0.325966851 ; 0.375 ; 0.323232323
HER2_IMPACT_FOLD_CHANGE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	HER2 IMPACT fold change	Sample	2.4 ; 8.3 ; 20.4 ; 4.4 ; 18.1 ; 8.9 ; 41.9 ; 8.4 ; 3.2 ; 17.6 ; 4.1 ; 6.9 ; 22.9 ; 3.3 ; 42.3 ; 2.7 ; 4.3 ; 25.6 ; 2.8
HIGHEST_CPS_SCORE_AT_BASELINE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Highest CPS score at baseline	Patient	
INVESTIGATOR_PATIENT_ID	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Investigator Patient ID	Patient	
LOSS_OF_HETEROZYOSITY_PERCENTAGE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Loss of heterozyosity (%)	Sample	0.45804981 ; 0.269218801 ; 0.39619168 ; 0.00895229 ; 0.004686838 ; 0.328435234 ; 0.242375601 ; 0.437049986 ; 0.204619543 ; 0.161831635 ; 0.282913644 ; 0.232417104 ; 0.284058849 ; 0.350258383 ; 0.228153926 ; 0.25207293 ; 0.079344881 ; 0.310511672 ; 0.03020279 ; 0.289961005 ; 0.643225687 ; 0.378495741 ; 0.430479259 ; 0.509141477 ; 0.184179735 ; 0.020734693 ; 0.192502645 ; 0.324484552 ; 0.204376363
MATH_SCORE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	MATH Score	Sample	29.27711017 ; 10.30684492 ; 33.22569381 ; 37.16824513 ; 30.65796446 ; 16.84022272 ; 11.50293103 ; 25.34655738 ; 79.88652932 ; 32.32465286 ; 10.1374359 ; 16.65657397 ; 0 ; 12.28141852 ; 33.95267176 ; 23.93512195 ; 50.29857778 ; 30.36650602 ; 20.60104784 ; 23.65152142 ; 54.83589041 ; 56.53728195 ; 59.8167147 ; 12.7171987 ; 34.18616505 ; 18.1373064 ; 66.64153485 ; 36.37262765
NON_TARGET_PROG_ONLY	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Non-target progression only	Patient	
NO_OF_MUTATIONS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	No. of mutations	Sample	156 ; 280 ; 177 ; 21 ; 102 ; 153 ; 180 ; 244 ; 332 ; 218 ; 217 ; 111 ; 295 ; 188 ; 95 ; 162 ; 108 ; 234 ; 179 ; 145 ; 222 ; 163 ; 191 ; 168 ; 54 ; 291 ; 261 ; 437 ; 158
NO_OF_MUTATIONS_WITH_STRONG_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	No. of mutations with strong binding neoantigens	Sample	49 ; 87 ; 38 ; 5 ; 25 ; 48 ; 64 ; 90 ; 55 ; 73 ; 24 ; 102 ; 65 ; 26 ; 46 ; 83 ; 39 ; 74 ; 35 ; 60 ; 62 ; 53 ; 12 ; 72 ; 89 ; 128 ; 40
NUMBER_OF_CLONAL_MUTATIONS_WITH_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of clonal mutations with binding neoantigens	Sample	34 ; 66 ; 15 ; 0 ; 3 ; 36 ; 49 ; 20 ; 19 ; 73 ; 46 ; 17 ; 50 ; 45 ; 58 ; 16 ; 30 ; 31 ; 35 ; 38 ; 37 ; 67 ; 65 ; 29
NUMBER_OF_CYCLES_FLUORO-PYRIMIDINE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of cycles  fluoro-pyrimidine	Patient	
NUMBER_OF_CYCLES_PEMBROLIZUMAB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of cycles pembrolizumab	Patient	
NUMBER_OF_CYCLES_PLATINUM	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of cycles platinum 	Patient	
NUMBER_OF_CYCLES_TRASTUZUMAB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of cycles trastuzumab	Patient	
NUMBER_OF_MUTATIONS_WITH_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of mutations with binding neoantigens	Sample	80 ; 146 ; 78 ; 7 ; 45 ; 95 ; 130 ; 90 ; 105 ; 42 ; 165 ; 41 ; 79 ; 133 ; 59 ; 116 ; 123 ; 91 ; 71 ; 112 ; 102 ; 99 ; 83 ; 22 ; 132 ; 148 ; 236 ; 72
NUMBER_OF_MUTATIONS_WITH_WEAK_BINDING_NEOANTIGENS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Number of mutations with weak binding neoantigens	Sample	31 ; 59 ; 40 ; 2 ; 20 ; 30 ; 35 ; 32 ; 18 ; 63 ; 15 ; 33 ; 50 ; 42 ; 36 ; 39 ; 37 ; 10 ; 60 ; 108
OFF_TREATMENT	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Patient off treatment	Patient	
RATIO_OF_CLONAL_TO_ALL_MUTATIONS	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Ratio of clonal to all mutations	Sample	0.693181818 ; 0.770588235 ; 0.398148148 ; 0 ; 0.083333333 ; 0.230769231 ; 0.605263158 ; 0.729559748 ; 0.590425532 ; 0.42962963 ; 0.5 ; 0.620689655 ; 0.693467337 ; 0.760330579 ; 0.759259259 ; 0.240384615 ; 0.587878788 ; 0.460526316 ; 0.564935065 ; 0.642424242 ; 0.684684685 ; 0.457831325 ; 0.384615385 ; 0.511450382 ; 0.607692308 ; 0.669724771 ; 0.494565217 ; 0.70718232 ; 0.565656566
RATIO_OF_CLONAL_TO_CLONAL_AND_SUBCLONAL	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Ratio of clonal to clonal and subclonal	Sample	1 ; 0.97761194 ; 0.87755102 ; 0.166666667 ; 0.954545455 ; 0.802325581 ; 0.920634921 ; 0.787234043 ; 0.753246753 ; 0.660194175 ; 0.765957447 ; 0.93877551 ; 0.828828829 ; 0.961538462 ; 0.763779528 ; 0.972477064 ; 0.863636364 ; 0.419847328 ; 0.779069767 ; 0.759615385 ; 0.760416667 ; 0.923076923 ; 0.933333333
RESPONSE_AT_3_WEEKS_PERCENTAGE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Response at 3 weeks (%)	Patient	
SAMPLE_CPS_SCORE	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Sample CPS score	Sample	5 ; 1 ; 0 ; 2 ; 10
STRONG_BINDING_NEOANTIGENS_PER_MB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Strong binding neoantigens per mb	Sample	1.289473684 ; 2.289473684 ; 1 ; 0.131578947 ; 0.657894737 ; 1.263157895 ; 1.684210526 ; 2.368421053 ; 1.447368421 ; 1.921052632 ; 0.631578947 ; 2.684210526 ; 1.710526316 ; 0.684210526 ; 1.210526316 ; 2.184210526 ; 1.026315789 ; 1.947368421 ; 0.921052632 ; 1.578947368 ; 1.631578947 ; 1.394736842 ; 0.315789474 ; 1.894736842 ; 2.342105263 ; 3.368421053 ; 1.052631579
TUMOR_MATCHED_CTDNA	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Tumor-matched ctDNA 	Patient	
WEAK_BINDING_NEOANTIGENS_PER_MB	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	NUMBER	Weak binding neoantigens per mb	Sample	0.815789474 ; 1.552631579 ; 1.052631579 ; 0.052631579 ; 0.526315789 ; 0.789473684 ; 0.921052632 ; 0.842105263 ; 0.473684211 ; 1.657894737 ; 0.394736842 ; 0.868421053 ; 1.315789474 ; 1.105263158 ; 0.947368421 ; 1.026315789 ; 0.973684211 ; 0.263157895 ; 1.578947368 ; 2.842105263
WHOLE_GENOME_DOUBLING	LightSkyBlue	Esophageal Cancer-TRAP Project (MSK, Lancet Oncol 2020)	STRING	Whole genome doubling	Sample	no ; yes
H_PYLORI_INFECTION	LightSkyBlue	Stomach Adenocarcinoma (Pfizer and UHK, Nat Genet 2014)	STRING	H-PYLORI infection.	Patient	
PATHOLOGY_LAUREN	LightSkyBlue	Stomach Adenocarcinoma (Pfizer and UHK, Nat Genet 2014)	STRING	Pathology Lauren.	Patient	
ARHGAP26_ARHGAP6_CLDN18_REARRANGEMENT	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	ARHGAP26-ARHGAP6-CLDN18 Rearrangement.	Sample	1 ; 0
CDKN2A_SILENCING	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	Epigenetic silencing status of CDKN2A.	Sample	FALSE ; TRUE
ESTIMATED_LEUKOCYTE_PERCENTAGE	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	NUMBER	Estimated leukocyte percentage.	Sample	0.357 ; 0.175 ; 0.329 ; 0.181 ; 0.425 ; 0.308 ; 0.263 ; 0.395 ; 0.393 ; 0.285 ; 0.416 ; 0.225 ; 0.13 ; 0.241 ; 0.095 ; 0.151 ; 0.024 ; 0.275 ; 0.204 ; 0.279 ; 0.174 ; 0.088 ; 0.265 ; 0.339 ; 0.193 ; 0.3 ; 0.025 ; 0.15 ; 0.529 ; 0.312 ; 0.14 ; 0.167 ; 0.291 ; 0.148 ; 0.264 ; 0.201 ; 0.2 ; 0.315 ; 0.304 ; 0.409 ; 0.255 ; 0.154 ; 0.108 ; 0.428 ; 0.31 ; 0.449 ; 0.461 ; 0.073 ; 0.094 ; 0.237 ; 0.057 ; 0.295 ; 0.166 ; 0.07 ; 0.138 ; 0.16 ; 0.162 ; 0.259 ; 0.398 ; 0.254 ; 0.074 ; 0.132 ; 0.282 ; 0.365 ; 0.268 ; 0.422 ; 0.115 ; 0.089 ; 0.316 ; 0.354 ; 0.1 ; 0.243 ; 0.149 ; 0.377 ; 0.177 ; 0.101 ; 0.215 ; 0.099 ; 0.353 ; 0.414 ; 0.223 ; 0.022 ; 0.251 ; 0.142 ; 0.049 ; 0.457 ; 0.21 ; 0.342 ; 0.221 ; 0.284 ; 0.362 ; 0.066 ; 0.083 ; 0.157 ; 0.232 ; 0.216 ; 0.084 ; 0.314 ; 0.569 ; 0.161 ; 0.287 ; 0.036 ; 0.06 ; 0.356 ; 0.26 ; 0.252 ; 0.311 ; 0.383 ; 0.061 ; 0.229 ; 0.121 ; 0.296 ; 0.118 ; 0.05 ; 0.224 ; 0.172 ; 0.211 ; 0.327 ; 0.309 ; 0.202 ; 0.325 ; 0.368 ; 0.363 ; 0.064 ; 0.188 ; 0.012 ; 0.234 ; 0.189 ; 0.051 ; 0.045 ; 0.158 ; 0.441 ; 0.107 ; 0.18 ; 0.155 ; 0.272 ; 0.125 ; 0.286 ; 0.165 ; 0.137 ; 0.028 ; 0.198 ; 0.185 ; 0.257 ; 0.492 ; 0.163 ; 0.027 ; 0.196 ; 0.277 ; 0.305 ; 0.238 ; 0.208 ; 0.173 ; 0.344 ; 0.145 ; 0.053 ; 0.24 ; 0.379 ; 0.079 ; 0.199 ; 0.346 ; 0.183 ; 0.435 ; 0.478 ; 0.122 ; 0.127 ; 0.113 ; 0.046 ; 0.239 ; 0.352 ; 0.248 ; 0.152 ; 0.493 ; 0.102 ; 0.109 ; 0.321 ; 0.067 ; 0.326 ; 0.178 ; 0.45 ; 0.085 ; 0.12 ; 0.056 ; 0.037 ; 0.28 ; 0.023 ; 0.065 ; 0.369 ; 0.299 ; 0.219 ; 0.04 ; 0.244 ; 0.288 ; 0.042 ; 0.39 ; 0.55 ; 0.097 ; 0.035 ; 0.044 ; 0.071 ; 0.08 ; 0.333 ; 0.075 ; 0.116 ; 0.445 ; 0.135 ; 0.233 ; 0.117 ; 0.129 ; 0.029 ; 0.087 ; 0.267 ; 0.104 ; 0.105 ; 0.378 ; 0.059 ; 0.289 ; 0.335 ; 0.502 ; 0.293 ; 0.588 ; 0.423 ; 0.442 ; 0.318 ; 0.319 ; 0.401 ; 0.465 ; 0.541 ; 0.508 ; 0.471 ; 0.438 ; 0.227 ; 0.273 ; 0.278 ; 0.334 ; 0.406 ; 0.203 ; 0.516 ; 0.144 ; 0.371 ; 0.231 ; 0.36 ; 0.512 ; 0.347 ; 0.483 ; 0.534 ; 0.034 ; 0.292 ; 0.506 ; 0.349 ; 0.436 ; 0.341 ; 0.402 ; 0.124 ; 0.147 ; 0.27 ; 0.317 ; 0.692 ; 0.212 ; 0.258 ; 0.328 ; 0.403 ; 0.427 ; 0.062 ; 0.553 ; 0.355 ; 0.391 ; 0.38 ; 0.103 ; 0.337 ; 0.176 ; 0.475 ; 0.466 ; 0.262 ; 0.48 ; 0.367 ; 0.947 ; 0.197 ; 0.399 ; 0.082 ; 0.246 ; 0.503 ; 0.373 ; 0.486 ; 0.396 ; 0.374 ; 0.424 ; 0.131 ; 0.376 ; 0.65 ; 0.207 ; 0.136 ; 0.195 ; 0.437 ; 0.653 ; 0.242 ; 0.462 ; 0.394 ; 0.467 ; 0.236 ; 0.513 ; 0.114 ; 0.038 ; 0.524 ; 0.447 ; 0.324 ; 0.404 ; 0.077 ; 0.476 ; 0.5 ; 0.433 ; 0.603 ; 0.297 ; 0.218 ; 0.594 ; 0.182 ; 0.464 ; 0.09 ; 0.256 ; 0.076 ; 0.283 ; 0.522 ; 0.41 ; 0.413 ; 0.322 ; 0.192 ; 0.217 ; 0.228 ; 0.043 ; 0.419 ; 0.168 ; 0.372 ; 0.159 ; 0.119 ; 0.389 ; 0.338 ; 0.213 ; 0.361 ; 0.364 ; 0.497 ; 0.247 ; 0.351 ; 0.555 ; 0.266 ; 0.332 ; 0.039 ; 0.111 ; 0.235 ; 0.033 ; 0.302 ; 0.191 ; 0.169 ; 0.186 ; 0.055 ; 0.477 ; 0.032 ; 0.269 ; 0.29 ; 0.405 ; 0.086 ; 0.514 ; 0.253 ; 0.507 ; 0.222 ; 0.343 ; 0.386 ; 0.143 ; 0.019 ; 0.382 ; 0.472 ; 0.443 ; 0.531 ; 0.261 ; 0.632 ; 0.307 ; 0.19 ; 0.184 ; 0.206 ; 0.047 ; 0.281 ; 0.432 ; 0.271 ; 0.554 ; 0.687 ; 0.381 ; 0.245 ; 0.306 ; 0.146 ; 0.078 ; 0.345 ; 0.366 ; 0.274 ; 0.126 ; 0.276 ; 0.093 ; 0.46 ; 0.479 ; 0.081 ; 0.485 ; 0.179 ; 0.499 ; 0.22 ; 0.128 ; 0.112 ; 0.091
INTESTINAL_TYPE_SUBCLASS	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	Intestinal type subclass.	Patient	
MET_SKIPPED_EXONS_18_AND_19	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	MET skipped exons 18 and 19.	Sample	0 ; 1
MET_SKIPPED_EXON_2	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	MET skipped exon 2.	Sample	0 ; 1
MICRORNA_EXPRESSION_CLUSTER	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	MicroRNA expression cluster.	Sample	C1 ; C2 ; C3 ; C4 ; C5
PERCENT_LYMPHOCYTE_INFILTRATION	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	NUMBER	Numeric value to represent the percentage of infiltration by lymphocytes in a tumor sample or specimen.	Patient	
PERCENT_TUMOR_CELLS	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	NUMBER	Numeric value to represent the percentage of malignant cell tumor nuclei content in a tumor sample or specimen.	Patient	
PERCENT_TUMOR_NUCLEI	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	NUMBER	Numeric value to represent the percentage of tumor nuclei in a malignant neoplasm sample or specimen.	Patient	
RHOA_MUTATION	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	RHOA mutation is present.	Sample	0 ; 1 ; Y42C ; L22R ; R5W ; Y74D ; R5Q
SIGNET_RING	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Nature 2014)	STRING	Signet ring.	Patient	
ARID1A_PROTEIN_CODING	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	ARID1A Protein Coding	Sample	1 ; 0
CDKN2A_MET	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	CDKN2A Methylation	Sample	FALSE ; TRUE
DAYS_FROM_SURGERY_TO_RECURRENCE	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	NUMBER	Days from surgery to recurrence	Patient	
DNA_METHYLATION_CLUSTER_EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	DNA Methylation Cluster - EC	Sample	C1 ; C2
DNA_METHYLATION_CLUSTER_GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	DNA Methylation Cluster - GEA	Sample	C1 ; C2 ; C3
DNA_METHYLATION_CLUSTER_GEA_CIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	DNA Methylation Cluster - GEA-CIN	Sample	C1 ; C2 ; C3
DNA_METHYLATION_CLUSTER_SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	DNA Methylation Cluster - SCC	Sample	C1 ; C2 ; C3
EBV_POSITIVE	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	EBV Positive	Patient	
EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	EC	Patient	
ECSMG	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	EC-SMG	Patient	
ESOPHAGEAL_TUMOR_LOCATION_CENTERED	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Esophageal tumor cental location	Sample ; Patient	distal ; mid ; proximal ; mid-distal
GASTRIC_CLASSIFICATION	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Gastric Classification	Sample	CIN ; MSI ; EBV ; GS
GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA	Patient	
GEACIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA-CIN	Patient	
GEACINSMG	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA-CIN-SMG	Patient	
GEAGEJ	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA-GEJ	Patient	
GEASMG	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA-SMG	Patient	
GEA_CIN_INTEGRATED_CLUSTER_COCA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster COCA	Sample	C1 ; C2 ; C3
GEA_CIN_INTEGRATED_CLUSTER_CONSENSUS	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster Consensus	Sample	C1 ; C2 ; C3
GEA_CIN_INTEGRATED_CLUSTER_ICLUSTER	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster iCluster	Sample	C1 ; C2 ; C4 ; C3
GEA_CIN_INTEGRATED_CLUSTER_MKL_KNN_4	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster MKL KNN 4	Sample	C4 ; C3 ; C2 ; C1
GEA_CIN_INTEGRATED_CLUSTER_MKL_KNN_7	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster MKL KNN 7	Sample	C2 ; C7 ; C5 ; C4 ; C1 ; C6 ; C3
GEA_CIN_INTEGRATED_CLUSTER_SUPERCLUSTER	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster SuperCluster	Sample	C1 ; C2 ; C3
GEA_CIN_INTEGRATED_CLUSTER_VOTING	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEA CIN Integrated Cluster Voting	Sample	C1 ; C2 ; C3
GEJ_CATEGORY	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	GEJ Category	Patient	
GENE_EXPRESSION_CLUSTER_GEA_CIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Gene Expression Cluster - GEA-CIN	Sample	C3 ; C1 ; C2
KRAS_PROTEIN_CODING	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	KRAS Protein Coding	Sample	0 ; 1
MAJOR_ANATOMIC_SITE	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Major Anatomic Site	Sample	fundus_body ; antrum ; GEJ_cardia
MIRNA_EXPRESSION_CLUSTER_EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	miRNA Expression Cluster - EC	Sample	C1 ; C3 ; C2
MIRNA_EXPRESSION_CLUSTER_GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	miRNA Expression Cluster - GEA	Sample	C1 ; C4 ; C2 ; C3
MIRNA_EXPRESSION_CLUSTER_GEA_CIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	miRNA Expression Cluster - GEA-CIN	Sample	C3 ; C1 ; C2
MIRNA_EXPRESSION_CLUSTER_SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	miRNA Expression Cluster - SCC	Sample	C1 ; C2
MLH1_METHYLATION	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	MLH1 methylation.	Sample	FALSE ; TRUE
MRNA_EXPRESSION_CLUSTER_EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	MRNA Expression Cluster EC	Sample	C1 ; C3 ; C2
MRNA_EXPRESSION_CLUSTER_GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	MRNA Expression Cluster GEA	Sample	C5 ; C3 ; C2 ; C1 ; C4
MRNA_EXPRESSION_CLUSTER_SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	MRNA Expression Cluster SCC	Sample	C2 ; C3 ; C1
PIK3CA_PROTEIN_CODING	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	PIK3CA Protein Coding	Sample	0 ; 1
PROTEIN_CODING_RHOA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	RHOA Protein Coding	Sample	0 ; 1
REFLUX_HISTORY	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	History of reflux.	Patient	
REGIONAL_LYMPH_NODES	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Regional Lymph Nodes	Patient	
RPPA_CLUSTER_EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	RPPA Cluster - EC	Sample	C1 ; C2 ; C3
RPPA_CLUSTER_GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	RPPA Cluster - GEA	Sample	C1 ; C2 ; C3
RPPA_CLUSTER_GEA_CIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	RPPA Cluster - GEA-CIN	Sample	C1 ; C2 ; C3
RPPA_CLUSTER_SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	RPPA Cluster - SCC	Sample	C1 ; C2
SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCC	Patient	
SCCSMG	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCC-SMG	Patient	
SCC_CLUSTER_ICLUSTER_AND_SMARCA4	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCC Cluster iCluster and SMARCA4	Sample	C1 ; C2 ; C3
SCNA_CLUSTER_EC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCNA Cluster EC	Sample	C1 ; C2 ; C3 ; C4
SCNA_CLUSTER_GEA	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCNA Cluster GEA	Sample	C1 ; C2
SCNA_CLUSTER_GEA_CIN	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCNA Cluster GEA CIN	Sample	C1 ; C2 ; C3
SCNA_CLUSTER_SCC	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	SCNA Cluster SCC	Sample	C1 ; C2
TP53_PROTEIN_CODING	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	TP53 Protein Coding	Sample	0 ; 1
TUMOR_EXTENT	LightSkyBlue	Esophageal Carcinoma (TCGA, Nature 2017)	STRING	Tumor extent	Patient	
3_WEEK_CT_OVERALL_RESPONSE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	3 Week CT Overall Response	Patient	
3_WEEK_CT_RESPONSE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	3 Week CT Response(Mixed vs Uniform)	Patient	
9_WEEK_MATCHED_CTDNA_RECURRENCE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	9 Week Matched ctDNA Recurrence	Patient	
9_WEEK_MAXIMAL_LESION_DECLINE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	NUMBER	9 Week Maximal Lesion Decline(%)	Patient	
9_WEEK_MINIMAL_LESION_DECLINE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	NUMBER	9 Week Minimal Lesion Decline(%)	Patient	
9_WEEK_MIXED_RESPONSE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	9 Week Mixed Response	Patient	
9_WEEK_RECIST_RESPONSE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	9 Week RECIST Response	Patient	
BEST_RESPONSE_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Best Response Category	Patient	
BRAIN_METASTASIS	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Brain Metastasis	Patient	
CTDNA_ERBB2_AT_PROGRESSION	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	ctDNA ERBB2 At Progression	Patient	
ESCAPE_LESION	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Escape Lesion	Patient	
ESCAPE_LESION_SITE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Escape Lesion Site	Patient	
MATCHED_CTDNA_MUTATION_3_WEEK_CHANGE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Matched ctDNA Mutation 3 week Change	Patient	
ON_POST_TREATMENT_ERBB2_AMP_BY_WES	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	On/Post Treatment ERBB2 Amp by WES	Patient	
ON_TREATMENT_POST_PROGRESSION_SIMPLIFIED_HER2_STATUS	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	On Treatment/Post Progression Simplified HER2 Status	Patient	
POD_6_MONTHS	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	POD 6 Months	Patient	
POST_PROGRESSION_SIMPLIFIED_HER2_STATUS	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Post Progression Simplified HER2 Status	Patient	
PRE_OR_POST_TREATMENT	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Pre or Post Treatment	Sample	Post ; Pre ; On
PRE_TREATMENT_ERBB2_CTDNA	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Pre Treatment ERBB2 ctDNA	Patient	
PRE_TREATMENT_ERBB2_TUMOR_WES	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Pre Treatment ERBB2 Tumor WES	Patient	
PRE_TREATMENT_HER2_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Pre Treatment HER2 Category	Patient	
PRE_TREATMENT_PD_L1_CPS_CATEGORY	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Pre Treatment PD-L1 CPS Category	Patient	
RECEIVED_INDUCTION	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Received Induction	Patient	
TISSUE_COLLECTION_SITE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Tissue Collection Site	Sample	Adrenal ; GEJ ; Scalp ; Lymph Node, retroperitoneum ; Esophagus ; Brain ; Liver ; Lung ; Stomach ; Psoas ; Left Temporal Mass ; Para-Esophageal ; L3 ; Lymph Node ; Right Neck ; Abdominal wall ; spine ; Left Gluteus Maximus ; Left neck ; Peritoneum
TUMOR_MATCHED_CTDNA_RECURRENCE	LightSkyBlue	Esophagogastric Cancer (MSK, Clin Cancer Res 2023)	STRING	Tumor Matched ctDNA Recurrence	Patient	
BIRTH_COUNTRY	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Birth Country	Patient	
CANCER_PROCUREMENT_STATE_PROVINCE	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Cancer Procurement State Province	Patient	
CITY_OF_PROCUREMENT	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	City of procurement.	Patient	
COLUMNAR_METAPLASIA_GOBLET_CELL_INDICATOR	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Columnar mucosa goblet cell present	Patient	
ESOPHAGEAL_TUMOR_LOCATION_INVOLVED	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Esophageal tumor involvement site	Patient	
ESOPH_COLUMNAR_METAPLASIA_INDICATOR	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Columnar metaplasia present	Patient	
ESOPH_NON_CA_DEGREE_OF_DYSPLASIA	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Columnar mucosa dysplasia	Patient	
FAMILY_HISTORY_ESOPH_GASTIC_CANCER	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	History of esophageal cancer	Patient	
HISTORY_BARRETTS_ESOPHAGEAL_INDICATOR	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Barretts esophagus	Patient	
HISTORY_IF_BARRETTS_GOBLET_CELL_INDICATOR	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Goblet cells present	Patient	
HISTORY_REFLUX_DISEASE_TREATMENT	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Antireflux treatment type	Patient	
INITIAL_DIAGNOSIS_ESOPHAGEAL_CA_TYPE	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Initial diagnosis by	Patient	
LYMPH_NODE_SPRD_RADIOGRAPH_EVIDENCE	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Lymph node metastasis radiographic evidence	Patient	
NUMBER_OF_RELATIVES_DIAGNOSED	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	NUMBER	Number of relatives diagnosed	Patient	
PATIENT_TO_UNDERGO_SURGERY	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Planned surgery status	Patient	
TUMOR_SAMPLE_PROCUREMENT_COUNTRY	LightSkyBlue	Esophageal Carcinoma (TCGA, Firehose Legacy)	STRING	Tumor sample procurement country	Patient	
ABDONIMAL_PAIN	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Abdominal Pain(Yes/No)	Sample	Yes ; No
ADRENAL_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Adrenal Metatstasis(Yes/No)	Sample	No ; Yes
AFIB	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	AFIB(Yes/No)	Sample	No ; Yes
ALTERNATIVE_DX_BINARY	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Alternativa Diagnosis Binary(Yes/No)	Sample	No ; Yes
ANEMIA_COMORBIDITIES	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Anemia(Yes/No)	Sample	No ; Yes
ANEMIA_SYMPTOMS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Anemia Symptoms(Yes/No)	Sample	No ; Yes
ANXIETY_DEPRESSION_PTSD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Anxiety/Depression/PTSD(Yes/No)	Sample	No ; Yes
ASTHMA	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Asthma(Yes/No)	Sample	No ; Yes
AUTOIMMUNE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Autoimmune(Yes/No)	Sample	No ; Yes
B12_DEFICIENCY	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	B12 Deficiency(Yes/No)	Sample	No ; Yes
BELCHING	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Belching(Yes/No)	Sample	No ; Yes
BLOATING	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Bloating(Yes/No)	Sample	Yes ; No
BONE_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Bone Metatstasis(Yes/No)	Sample	No ; Yes
BOWEL_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Bowel Metatstasis(Yes/No)	Sample	No ; Yes
CAD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Coronary Artery Disease(Yes/No)	Sample	No ; Yes
CELIAC	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Celiac(Yes/No)	Sample	No ; Yes
CHEST_PAIN	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Chest Pain(Yes/No)	Sample	No ; Yes
CKD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	CKD(Yes/No)	Sample	No ; Yes
COLONIC_POLYPS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Colonic Polyps(Yes/No)	Sample	No ; Yes
COPD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	COPD(Yes/No)	Sample	No ; Yes
DECR_APPETITE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Decr Appetite(Yes/No)	Sample	No ; Yes
DENOVO_PRIMARY_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Denovo Primary Metastasis(Yes/No)	Sample	No
DM	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	DM(Yes/No)	Sample	No ; Yes
DVT_PE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Venous Thrombosis or Pulmonary Embolism(Yes/No)	Sample	No ; Yes
DYSPHAGIA	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Dysphagia(Yes/No)	Sample	No ; Yes
EARLY_SATIETY	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Early Satiety(Yes/No)	Sample	Yes ; No
ECOG_PS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	ECOG performance status	Patient	
EPIDURNALMASS_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Epidurnal Mass Metastasis(Yes/No)	Sample	No
EYE_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Eye Metastasis(Yes/No)	Sample	No
GALLBLADDER_DISEASE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Galbladder Disease(Yes/No)	Sample	No ; Yes
GENITO_URINARY_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	)Genito Urinary Metastasis(Yes/No)	Sample	No ; Yes
GERD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	GERD(Yes/No)	Sample	Yes ; No
GOUT	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	GOUT(Yes/No)	Sample	No ; Yes
HEMATEMESIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Hematemesis(Yes/No)	Sample	No ; Yes
HEMOCHROMATOSIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Hemochromatosis(Yes/No)	Sample	No ; Yes
HEPATOBILARY_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Hepatobilary Metastasis(Yes/No)	Sample	No ; Yes
HIV	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	HIV Status(Yes/No)	Sample	No ; Yes
HLD	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	HLD(Yes/No)	Sample	No ; Yes
HTN	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	HTN Status(Yes/No)	Sample	Yes ; No
IBS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	IBS	Sample	No ; Yes
INCIDENTAL	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Incidental(Yes/No)	Sample	No ; Yes
IRON_DEFICENCY	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Iron Deficiency(Yes/No)	Sample	No ; Yes
LEPTOMENINGES_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Leptomeninges Metastasis(Yes/No)	Sample	No ; Yes
LOCALRECURRENCE_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Localrecurrence Metastasis(Yes/No)	Sample	No ; Yes
LUNG_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Lung Metastasis(Yes/No)	Sample	No ; Yes
LYMPHNODE_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Lymph Node Metastasis(Yes/No)	Sample	Yes ; No
MELENA	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Melena(Yes/No)	Sample	No ; Yes
MET_NONMET_STATUS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Metastatic/Non-Metastatic	Patient	
MSI_HYPERMUTANT	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	MSI Hypermutant(Yes/No)	Sample	No ; Yes
MULTIPLE_CANCERS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Multiple Cancers(Yes/No)	Sample	No ; Yes
NAUSEA_VOMITING	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Nausea/Vomiting(Yes/No)	Sample	No ; Yes
NEPHROLITHIASIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Nephrolithiasis(Yes/No)	Sample	No ; Yes
ODYNOPHAGIA	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Odynophagia(Yes/No)	Sample	No ; Yes
OSTEOARTHRITIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Osteoarthritis(Yes/No)	Sample	No ; Yes
OSTEOPOROSIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Osteoporosis(Yes/No)	Sample	No ; Yes
OTHER_DX	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Other Diagnosis	Sample	Bacteremia ; Crohn's ; Abdominal Ultrasound ; Delayed Gastric Emptying ; Constipation ; Dvt ; Ent Pathology ; Esophageal Dysmotility Or Achalasia ; Fever Unknown Origin ; Diverticulitis ; Gallbladder Pathology ; Esophagitis Or Gastritis ; Abdominal Pain Nos ; Gluten Allergy ; Colitis ; Gastrointestinal Infection ; Food Impaction ; Ileus ; Infectious Lymphangitis ; Negative Biopsy ; Anemia ; Antibiotics ; Hiatal Hernia ; Pain Unknown Etiology ; Paracentesis ; Lyme Disease Or Other Tick-Borne Illness ; Superior Mesenteric Artery Syndrome ; Unknown ; Thyroid Pathology ; Bowel Obstruction ; Medication Side Effect ; H. Pylori ; Pancreatitis ; Reflux ; Ppi Or H2 Blocker ; Irritable Bowel Syndrome ; Thrush ; Cardiac ; Genitourinary Tract Pathology ; Pulmonary Pathology
OTHER_SYMPTOMS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Other Symptoms(Yes/No)	Sample	Loose Stool, Abdominal Distention ; Sore Throat ; Diarrhea, Sour Taste In Mouth ; Provider Recommended Egd At Time Of Colonoscopy Without Specific Indication ; Diarrhea ; Cough, Allergic Symptoms To Hamster ; Fatigue ; Weakness ; Fatigue, Thirst, Polyuria, Hypercalcemia ; Hematochezia, Back Pain ; Fatigue, Back Discomfort ; Elevated Alk Phos On Routine Labs ; Abdominal Swelling (Ascites) ; Long History Peptic Ulcer Diease ; Syncope With Car Accident, Workup Showed Mass ; Trying To Conceive, Thought Abdominal Pain Was Pregnancy But Test Was Negative ; Pulmonary Embolism ; Weakness, Dyspnea ; Shortness Of Breath, Lightheadedness (Symptomatic Anemia) ; Phlegm ; Iron Deficiency ; Periodic Cough ; Upper Gi Bleed In Setting Of Anticoagulation For Dvt ; Back Pain ; Diarrhea, Hematochezia, Hospitalization For Infectious Diarrhea 7/2014, Workup For Crohn's; Long Hx Gerd ; Constipation ; Abdominal Distention ; Syncope ; Palpitations ; Weakness, Dizziness (Symptomatic Anemia) ; Shortness Of Breath (Anemia And Underlying Copd) ; Family History Surveillance ; Constipation, Abdominal Distention, Backk Pain,  Biliary Obstruction ; Lost Ability To Belch ; Shortness Of Breath Walking Up Stairs ; Diaphoresis, Back Pain ; Diarrhea And Constipation Alternating ; Presyncope ; Weakness Due To Iron Deficiency ; Emotional Distress ; Syncope (Symptomatic Anemia) ; Diarrhea With Eating ; Fatigue (Likely Symptomatic Anemia) ; Cough ; Syncope, Hypotension (2/2 Anemia) ; Diarrhea Then Constipation, Hiccups, Dyspnea On Exertion ; History Of Ulcers, Intestinal Metaplasia ; Fatigue (Symptomatic Anemia) ; Mild Dyspnea On Exertion, Occasional Regurgitation ; Fatigue, Dyspnea, Chest Tightness ; Hiccups, Gastric Outlet Obstruction ; Ascites, Fatigue ; Right Scapular Pain, Fatigue ; Shortness Of Breath With Activity, Chronic Constipation ; Weight Loss X2 Years ; Constipation, Shortness Of Breath ; History Of Gastric Polyps With High Grade Dysplasia, Surveillance Endoscopy ; Screening Egd Due To Hx Barrett's, Also Lynch Syndrome Hx Multiple Malignancies ; Fatigue, Presyncope ; Heartburn, Fatigue ; Difficulty Swallowing, , Generalized Weakness ; Watery Bowel Movements ; Food Backing Up, Heartburn ; Routine Screening In Another Country ; Heartburn, Stretching Sensation Across His Upper Abdomen, Especiially After Eating, Constipation, Nausea ; Positive Guaiac, Fatigue ; Heartburn, Cough, Constipation, Fatigue ; Diarrhea, Back Pain ; Sensation Of Food Sticking In The Back Of Her Throat After Large Meals, Post Menopausal Bleeding, A Lot Of Gas ; Hematochezia ; Hiccups ; Weakness, Fatigue ; Fatigue, Constipation, Rectal Bleeding, Syncope ; Dyspepsia ; Constipation, 3 Weeks Of Drooling And Right Arm Weakness, Poor Sleep ; Heartburn ; Difficulty Eating Large Quantities Of Food, Constipation ; Fatigue, Hematochezia, Constipation ; Shortnesness Of Breath, Dyspnea, Fatigue ; Known Barrett's ; Occasional Emesis ; Diaphoresis With Ambulation ; Pale, Cough, Lethargy, Shortness Of Breath On Exertion ; Diagnosed On Screening ; Lynch, Iron Deficiency Anemia ; Heartburn, Gas Sensations ; Regurgitation ; Worsening Constipation, Anxiety ; Unable To Lie Flat Bend Forward Or Lie Sideways ; Regurgitation Of Phlegm ; Constipation (1 Year) ; Diabetic Neuropathy, Dyspnea ; Increased Phlegm ; Shortness Of Breath ; Fatigue, Anxiety Related To Diagnosis ; Heartburn, Constipation, Pain While Swallowing ; Fatigue, Low Back Pain ; Dyspnea On Exertion, Tachycardia, Weakness ; Fatigue, Bloody Phlegm ; Fatigue, Shortness Of Breath ; Flu-Like Symptoms, Decreased Energy ; Ascites ; Dizziness ; Followed For Bladder Cancer, Found On Cystoscopy To Have Signet Ring Cell Adeno ; Constipation, Fatigue, Doe ; Symptomatic Met = Ascites S/P Paracentesis ; Fatigue, Dyspnea ; Fatigue, Nasal Congestion ; Flatulence ; Dyspepsia, Ruq Pain, Constipation ; Acute Onset Weakness And Fatigue ; Weakness, Constipation ; Lightheadedness (Symptomatic Anemia) ; Patient's Son Encouraged Him To Get Egd ; Anorexia ; Intermittent Diarrhea, Poor Oral Intake, Back Pain, Difficulty Swallowing Foods ; Dyspepsia, Eosinophilic Esophagitis, ; Heartburn,  Coffee-Ground Emesis ; Dry Heaves ; Note History Of Rt To Thymus As An Infant ; Fatigue, Palpitations, Tachycardia (Symptomatic Anemia) ; Fatigue, Weakness, Malaise, Constipation ; Dyspepsia, Increased Abdominal Girth ; Dizziness, Black Stool, Vomiting Blood ; Stomach Upset After Eating ; Hemoptysis X1 ; Constipation, Fatigued, Dizzy ; Malaise ; Back ; Abdominal Distension, Fatigue, Constipation, Shortness Of Breath ; Screening Egd Due To Hx Barrett's ; Dyspnea, Melanotic Stool, Fatigue ; Choking Sensation, Occasional Night Sweats ; Constipation, Cramps ; Fever ; Lower Back Pain ; Coughing With Eating And Drinking ; Dyspnea On Exertion ; Heartburn, Fatigue, Mucositis, Nasal Sores, Coryzal Symptoms, Sore Throat, ; Recurrent Bleeding From Gastric Polyp, Noted On Routine Egd/Colo Screening (Gerd, Hx Gastric Polyp Since 2013) ; Change In Vision, Fatigue ; Neck Swelling Due To Dvt ; Choking, Coughing Up, Heartburn ; Discomfort Under Ribs, Sleeping Poorly, Fatigue ; Syncope, Shortness Of Breath (Both Symptomatic Anemia); Sensation Of Lump In Chest ; Dysgeusia ; Choking, Sore Throat ; Annual Egd And Colo Due To History Of Colon Cancer
OVARY_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Ovary Metastasis(Yes/No)	Sample	No ; Yes
PAROTID_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Parotid Metsstasis(Yes/No)	Sample	No
PELVICWALL_FLOOR_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Pelvicwall Floor Metastasis(Yes/No)	Sample	No ; Yes
PERICARDIUM_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Pericardium Metastasis(Yes/No)	Sample	No ; Yes
PERITONEUM_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Pericardium Metastasis(Yes/No)	Sample	No ; Yes
PLEURA_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Pleura Metastasis(Yes/No)	Sample	No ; Yes
PRE-DM	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Pre DM(Yes/No)	Sample	No ; Yes
PRIMARY_SITE_TRI	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Primary Site Tri	Patient	
REFLUX	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Reflux(Yes/No)	Sample	No ; Yes
SARCOIDOSIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Sarcoidosis(Yes/No)	Sample	No ; Yes
SEASONAL ALLERGIES	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Seasonal Allergies(Yes/No)	Sample	No ; Yes
SEIZURE DISORDER	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Seizure Disorder(Yes/No)	Sample	No ; Yes
SKIN_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Skin Metastasis(Yes/No)	Sample	No ; Yes
SLEEP APNEA	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Sleep Apnea(Yes/No)	Sample	No ; Yes
SOFTTISSUE_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Soft Tissue Metastasis(Yes/No)	Sample	No ; Yes
SPLEEN_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Spleen Metastasis(Yes/No)	Sample	No ; Yes
STOMACH_ESOPHAGUS_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Stoamch Esopagus Metastasis(Yes/No)	Sample	No ; Yes
STROKE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Stroke(Yes/No)	Sample	No ; Yes
SYMPTOMATIC_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Symptomatic Metastasis(Yes/No)	Sample	No ; Yes
THYROID_DISEASE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Thyroid Disease(Yes/No)	Sample	No ; Yes
THYROID_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Thyroid Metastasis(Yes/No)	Sample	No
TIME_SX_DX_MONTHS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	NUMBER	Time Symptom Dx  (Months)	Patient	
TRACHEA_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Trachea Metastasis(Yes/No)	Sample	No ; Yes
ULCER	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Ulcer(Yes/No)	Sample	No ; Yes
UPDATED_TUMOR_SUBTYPE	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Updated Tumor Subtype	Sample	CIN ; GS ; Instable ; Unknown ; EBV
USED_FOR_GENOMICS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Used For Genomics(Yes/No)	Sample	Yes
USED_FOR_SURVIVAL	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Used For Survival(Yes/No)	Sample	Yes ; No
USE_FOR_SYMPTOM_ANALYSIS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Use For Symptom Analysis(Yes/No)	Sample	No ; Yes
UTERUS_METS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Uterus Metastasis(Yes/No)	Sample	No
WEIGHT_LOSS	LightSkyBlue	Esophagogastric Cancer (MSK, J Natl Cancer Inst 2023)	STRING	Weight Loss(Yes/No)	Sample	No ; Yes
FAMILY_HISTORY_OF_STOMACH_CANCER	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Family history of stomach cancer.	Patient	
NUMBER_OF_RELATIVES_WITH_STOMACH_CANCER	LightSkyBlue	Stomach Adenocarcinoma (TCGA, Firehose Legacy)	STRING	Number of relatives with stomach cancer.	Patient	
LAURENS_CLASSIFICATION	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	STRING	Laurens classification	Patient	
STAGE_M	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	STRING	Stage M	Patient	
STAGE_N	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	STRING	Stage N	Patient	
STAGE_T	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	STRING	Stage T	Patient	
XCELL_ADC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell ADC	Sample	0 ; 37.86 ; 12.67 ; 14.87 ; 15.82 ; 13.17 ; 21.73 ; 18.02 ; 9.54
XCELL_ADIPOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell ADIPOCYTES	Sample	0 ; 0.86 ; 0.63
XCELL_ASTROCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell ASTROCYTES	Sample	0 ; 1.51 ; 3.53 ; 2.62
XCELL_B-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell B-CELLS	Sample	0.63 ; 0 ; 17.4 ; 0.47 ; 5.38
XCELL_BASOPHILS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell BASOPHILS	Sample	12.04 ; 9.94 ; 15.69 ; 0 ; 3.4 ; 0.94 ; 0.9 ; 10.4
XCELL_CD4+ MEMORY T-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD4+ MEMORY T-CELLS	Sample	0.39 ; 2.23 ; 9.35 ; 1.59 ; 1.45 ; 2.71 ; 1.27 ; 3.29 ; 2.83 ; 2.26 ; 0
XCELL_CD4+ NAIVE T-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD4+ NAIVE T-CELLS	Sample	0 ; 0.65
XCELL_CD4+ T-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD4+ T-CELLS	Sample	0
XCELL_CD4+ TCM	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD4+ TCM	Sample	0 ; 0.78
XCELL_CD4+ TEM	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD4+ TEM	Sample	0 ; 5.71 ; 1.22 ; 0.17 ; 0.76
XCELL_CD8+ NAIVE T-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD8+ NAIVE T-CELLS	Sample	4.61 ; 3.78 ; 6.9 ; 4.2 ; 5.49 ; 5.67 ; 5.33 ; 5.16 ; 4.02 ; 2.88 ; 4.43
XCELL_CD8+ T-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD8+ T-CELLS	Sample	0 ; 1.69 ; 9.16 ; 5.76 ; 0.16
XCELL_CD8+ TCM	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD8+ TCM	Sample	0 ; 0.26 ; 21.6 ; 1.51 ; 1.56 ; 0.78 ; 4.41 ; 1.46
XCELL_CD8+ TEM	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CD8+ TEM	Sample	0 ; 1.3
XCELL_CDC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CDC	Sample	0 ; 0.55 ; 6.1 ; 0.18 ; 1.49 ; 2.32 ; 1.32 ; 0.16
XCELL_CHONDROCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CHONDROCYTES	Sample	0 ; 0.82 ; 4.57 ; 0.38
XCELL_CLASS-SWITCHED MEMORY B-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CLASS-SWITCHED MEMORY B-CELLS	Sample	0 ; 5.14 ; 0.93
XCELL_CLP	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CLP	Sample	7.6 ; 20.55 ; 10.26 ; 10.49 ; 13.73 ; 9.72 ; 6.12 ; 12.34 ; 11 ; 8.12 ; 5.44
XCELL_CMP	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell CMP	Sample	0 ; 1.08 ; 0.4
XCELL_DC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell DC	Sample	0 ; 4.72 ; 0.4 ; 0.48 ; 0.71 ; 0.39
XCELL_ENDOTHELIAL CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell ENDOTHELIAL CELLS	Sample	0 ; 0.72 ; 0.01 ; 4.78 ; 3.84 ; 3.31 ; 1.98
XCELL_EOSINOPHILS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell EOSINOPHILS	Sample	0
XCELL_EPITHELIAL CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell EPITHELIAL CELLS	Sample	0 ; 26.37 ; 50.31 ; 67.71 ; 58.91 ; 44.29 ; 1.33 ; 36.38 ; 63.59 ; 47.83 ; 0.15
XCELL_ERYTHROCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell ERYTHROCYTES	Sample	0
XCELL_FIBROBLASTS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell FIBROBLASTS	Sample	0 ; 15.97 ; 47.58 ; 11.05 ; 6.46
XCELL_GMP	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell GMP	Sample	0
XCELL_HEPATOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell HEPATOCYTES	Sample	0
XCELL_HSC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell HSC	Sample	0 ; 1.51 ; 7.06 ; 7.16 ; 26.54 ; 37.3 ; 15.36 ; 6.31 ; 17.51 ; 15.9
XCELL_IDC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell IDC	Sample	0 ; 14.08 ; 29.09 ; 3.2 ; 4.26 ; 7.18 ; 6.94 ; 3.18
XCELL_KERATINOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell KERATINOCYTES	Sample	0 ; 2.1 ; 7.09 ; 9.62 ; 7.97 ; 3.58 ; 2.51 ; 6.15 ; 3.47
XCELL_LY ENDOTHELIAL CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell LY ENDOTHELIAL CELLS	Sample	0 ; 0.47 ; 1.29 ; 0.27 ; 0.06
XCELL_MACROPHAGES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MACROPHAGES	Sample	0 ; 0.19 ; 11.1 ; 5.42 ; 0.36 ; 1.11 ; 0.92 ; 3.26 ; 4.83 ; 2.72
XCELL_MACROPHAGES M1	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MACROPHAGES M1	Sample	0 ; 0.53 ; 8.52 ; 3.59 ; 0.01 ; 1.95 ; 1.36 ; 2.37 ; 4.41 ; 2.82 ; 0.4
XCELL_MACROPHAGES M2	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MACROPHAGES M2	Sample	0 ; 0.78 ; 6.43 ; 4.89 ; 1.61 ; 2.08 ; 1.47 ; 2.6 ; 4.57 ; 2.17 ; 1.5
XCELL_MAST CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MAST CELLS	Sample	0 ; 0.3 ; 0.42
XCELL_MEGAKARYOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MEGAKARYOCYTES	Sample	0 ; 0.5 ; 0.37 ; 1.08 ; 1.33 ; 0.55 ; 0.61 ; 0.42
XCELL_MELANOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MELANOCYTES	Sample	0.1 ; 1.25 ; 0.93 ; 0.18 ; 0.13 ; 0.56 ; 0.98 ; 0.53 ; 1.29 ; 1.04
XCELL_MEMORY B-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MEMORY B-CELLS	Sample	0 ; 0.88 ; 0.56
XCELL_MEP	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MEP	Sample	13.57 ; 11.89 ; 5.98 ; 4.42 ; 11.42 ; 4.67 ; 0 ; 7.24 ; 5.96 ; 7.49 ; 5.82
XCELL_MESANGIAL CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MESANGIAL CELLS	Sample	0 ; 0.51 ; 2.28
XCELL_MONOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MONOCYTES	Sample	0 ; 5.43 ; 0.14 ; 1.59 ; 1.83 ; 1.09
XCELL_MPP	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MPP	Sample	0
XCELL_MSC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MSC	Sample	16.77 ; 16.24 ; 13.75 ; 31.66 ; 10.59 ; 28.23 ; 11.33 ; 24.47 ; 7.85 ; 15.98 ; 30.42
XCELL_MV ENDOTHELIAL CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MV ENDOTHELIAL CELLS	Sample	0 ; 0.35 ; 0.79 ; 0.94 ; 0.65 ; 0.19
XCELL_MYOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell MYOCYTES	Sample	2.58 ; 0.53 ; 0 ; 0.87 ; 2.33 ; 0.01 ; 0.14 ; 0.03
XCELL_NAIVE B-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell NAIVE B-CELLS	Sample	0 ; 0.1 ; 0.7
XCELL_NEURONS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell NEURONS	Sample	14.3 ; 0.86 ; 0.01 ; 0.14 ; 0.27 ; 0.67 ; 1.49 ; 0.17 ; 0.38 ; 10.91
XCELL_NEUTROPHILS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell NEUTROPHILS	Sample	0 ; 0.83 ; 0.07 ; 0.13
XCELL_NK CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell NK CELLS	Sample	0 ; 2.41 ; 1.3
XCELL_NKT	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell NKT	Sample	0 ; 0.21 ; 7.79 ; 1.9 ; 0.94 ; 5.36 ; 1.98 ; 0.67 ; 0.39
XCELL_OSTEOBLAST	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell OSTEOBLAST	Sample	16.58 ; 9.68 ; 2.9 ; 0 ; 9.82 ; 1.7 ; 2.7 ; 3.46
XCELL_PDC	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PDC	Sample	0 ; 0.97 ; 16.49 ; 1.03 ; 1.16 ; 0.34 ; 0.52 ; 4.08 ; 1.18 ; 4.1
XCELL_PERICYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PERICYTES	Sample	0 ; 0.43
XCELL_PLASMA CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PLASMA CELLS	Sample	1.53 ; 2.84 ; 9.47 ; 1.43 ; 2.6 ; 1 ; 0.13 ; 1.35 ; 3.31 ; 1.36 ; 1.72
XCELL_PLATELETS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PLATELETS	Sample	0
XCELL_PREADIPOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PREADIPOCYTES	Sample	0 ; 0.24
XCELL_PRO B-CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell PRO B-CELLS	Sample	3.31 ; 1.34 ; 0.02 ; 0 ; 2.2
XCELL_SEBOCYTES	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell SEBOCYTES	Sample	0 ; 3.28 ; 3.91 ; 5.11 ; 4.65 ; 2.27 ; 3.22 ; 3.77 ; 5.08
XCELL_SKELETAL MUSCLE	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell SKELETAL MUSCLE	Sample	0
XCELL_SMOOTH MUSCLE	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell SMOOTH MUSCLE	Sample	29.05 ; 25.98 ; 1.92 ; 25.7 ; 15.32 ; 31.82 ; 48.26 ; 28.36 ; 21.67 ; 23.32 ; 15.57
XCELL_TGD CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell TGD CELLS	Sample	0 ; 1.27 ; 0.63
XCELL_TH1 CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell TH1 CELLS	Sample	41.21 ; 29.23 ; 28.41 ; 6.69 ; 25.18 ; 10.81 ; 4.21 ; 11.49 ; 7.19 ; 25.89
XCELL_TH2 CELLS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell TH2 CELLS	Sample	8.17 ; 10.7 ; 21.64 ; 4.58 ; 6.81 ; 19.57 ; 6.7 ; 13.63 ; 13.8 ; 13.75 ; 0
XCELL_TREGS	LightSkyBlue	Gastric Cancer (OncoSG, 2018)	NUMBER	xcell TREGS	Sample	0 ; 1.78 ; 0.49 ; 0.46 ; 0.2
